[{"article": "Cancer is the No.\n\"You don\u2019t want to go screening people for hallmark (cancer) mutations unless you absolutely know that when you find it, that there is a tumor there and that it is a tumor that needs to be treated,\" said Wyndham, who was not involved in the study.\nThe first goal would be to try it in people at high risk of cancer but no symptoms yet \u2013 such as smokers, or people with cancer-causing gene mutations like BRCA mutations, Velculescu said.\nThe agency has chastised a company called Pathway Genomics over its \"liquid biopsy\" test , saying the company had not shown the $699 test worked as advertised.\n\u201dThe survival difference between late stage and early stage disease in these cancers would account for more than a million lives each year worldwide,\u201d Velculescu said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story includes the following: \u201cSeveral different liquid biopsies are already on the market, used to help track whether cancer treatments are working. But there\u2019s nothing yet that can detect cancer in someone who has not yet been diagnosed.\u201d\u00a0 It also includes the following:\n\u201cCurrently, colon cancer can be detected very early with colonoscopies, and even stopped before pre-cancerous growths get out of control. But colonoscopies are uncomfortable and carry a small risk of injury.\n\u201cMammograms can detect early breast cancer, Pap smears can detect cervical cancer or pre-cancerous changes and a type of specialized chest x-ray called a spiral CT can detect lung cancer. There\u2019s a debate over the usefulness of screening for prostate cancer but blood tests and physical exams can indicate some men at high risk.\u201d\nThis is sufficient to list early methods to find cancer, but the story could have also mentioned that early screening or testing doesn\u2019t always equate to saving lives, just more medical care. We just covered this issue as it relates to lung cancer, \u201cImbalanced \u2018Saved by the Scan\u2019 campaign neglects big concerns over lung cancer screening.\u201c", "answer": 1}, {"article": "Jan. 6, 2010 -- A new imaging technique that measures the random motion of water within the brain may prove useful for detecting early signs of Alzheimer's disease.\n\"This might help doctors when trying to differentiate between normal aging and diseases like Alzheimer's.\"\nIn a study published in the Jan. 19 issue of Neurology, Carlesimo and colleagues found that DTI scanning predicted declines in memory performance with more accuracy than traditional MRI.\n\"This type of brain scan appears to be a better way to measure how healthy the brain is in people who are experiencing memory loss,\" Carlesimo says in a news release.\nThe technique, known as diffusion tensor imaging (DTI) or diffusion MRI, is used to assess changes in the white matter regions of the brain.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0The story mentioned that the testing procedure reported on \u2018shows evidence of being more sensitive\u2019 than other tests, while acknowledging that \u2018a good clinical evaluation is still the best tool\u2019.", "answer": 1}, {"article": "Eight months later, none of the tumors had come back.\nThe procedure, which costs about $2,000, takes about an hour, and the patient is typically kept overnight in the hospital for observation.\nIn a preliminary study, the technique, called microwave ablation, eliminated lung tumors in 19 of 28 patients.\nAn electromagnetic wave then agitates water molecules in the surrounding tumor tissue, producing friction and heat that eventually destroy the tumor.\nBut more patients have to be followed for far longer to see if they stay in remission, they say.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story spells out both the current treatment options and potential new therapies. It says, \u201cStandard treatment options include surgery, chemotherapy, and radiation. Researchers are looking at a number of ways of destroying tumors with heat from radiofrequency waves or by freezing it, for example.\u201d But the story could have given even a little information about how the tumor reduction rates in this preliminary study stack up against chemotherapy and radiation.", "answer": 1}, {"article": "\"In 2012, scientists took that particular frog and wanted to know why is it, why do these frogs keep milk fresh?\nThe urumin peptide could be a novel treatment since it targets the hemagglutinin, unlike current drugs on the market which target other parts of the virus, resulting in less impact, Jacob said.\n\"The peptide described in the Immunity report is somewhat unusual because of the apparent specificity,\" Rollins-Smith said about how urumin specifically targets H1 viruses.\n\"This peptide works by directly killing the virus, and it is specific for all influenza viruses that have a H1 type of hemagglutinin,\" Jacob said.\n\"I need to come up with a strategy to deliver it systemically as well; maybe an injectable, which goes in the bloodstream and kills influenza viruses,\" Jacob mused.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story would have benefited from information about how this possible antiviral treatment might fit in with other types of treatment. For example, the researchers note in the abstract of their report that vaccines may take too long to produce in pandemic situations, making antiviral treatments relevant.", "answer": 0}, {"article": "CHICAGO (Reuters) - The hallucinogen psilocybin \u2014 known by the street name magic mushrooms \u2014 may help ease the anxiety that often accompanies late-stage cancer, U.S. researchers said on Monday.\nEverything had to be shut down,\u201d Grob said in a telephone interview.\n\u201cIt was something of a public health crisis.\n\u201cForty to 45 years ago, the culture was going through tremendous upheaval.\nThe treatments were given in random order and neither the doctors nor the patients were told which compound was administered.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 0}, {"article": "Accordingly, the 28-day \u201chealing\u201d diet he suggests consists almost entirely of natural, unprocessed foods, especially lean protein foods like light-meat poultry, fish, egg whites and low-fat dairy, beans (combined with whole grains), and nonacidic vegetables and fruits.\nIf adopting the above measures fails to fully control acid reflux, taking a proton pump inhibitor may also be needed.\nSomeone with a body mass index in the overweight range is almost twice as likely to have GERD as a person of normal weight.\nFor further protection, the head of the bed can be raised by six inches or more.\nBut while certain common foods \u2014 like raw onions, garlic, citrus juices, coffee and chocolate \u2014 are likely to cause reflux in most people with the condition, Dr. Aviv and other experts emphasize that everyone is different, and trial and error is the most effective way to determine an individual\u2019s trigger foods and drinks.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not address several other available treatments for acid reflux or GERD. For example, over-the-counter antacids can be useful tools for addressing heartburn in patients with infrequent acid reflux. Prescription strength and over-the-counter H2 receptor blockers are also often used to address acid reflux and GERD. The story also doesn\u2019t discuss surgical options for GERD.", "answer": 0}, {"article": "The article is available free on the JACM website until July 19, 2017.\nThe study design and results, which suggest further controlled studies of this intervention approach in ASD, are published in the Journal of Alternative and Complementary Medicine (JACM), a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.\nCoauthors Lana Warren, EdD, OT/L and Patricia Rao, PhD, Kennedy Krieger Institute, Baltimore, MD, and David Paton, DAc, LAc, Starting Point Acupuncture and Health Services, Catonsville, MD, identified the most positive outcome of the study as the high compliance rate, with all parents of the children ages 3-10 completing the intervention.\nNew Rochelle, NY, June 19, 2017-A pilot feasibility study to determine if young children with autism spectrum disorder (ASD) and their parents would tolerate and adhere to an office- and home-based acupuncture/acupressure intervention showed completion of all 16 biweekly sessions and measurements of their effects before, during, and after the protocol.\nIn the article entitled \"A Pilot Observational Study of an Acupressure/Acupuncture Intervention in Children with Autism Spectrum Disorder,\" most parents reported that the intervention had a positive impact on their relationship with their child.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release doesn\u2019t describe potential benefits for ASD patients, so it\u2019s not clear what alternatives are relevant in this context. Alternatives to what? Ergo, we\u2019ll rank this as not applicable.", "answer": 2}, {"article": "The Alzheimer's Society has more about cannabis and Alzheimer's disease.\nTUESDAY, July 24, 2018 (HealthDay News) -- The active ingredient in pot that gets you high can calm agitation in people with advanced Alzheimer's disease, a small new study suggests.\n\"We would love to see this study done in a larger group of people, to see if it continues to be effective in a larger group, and how worried we need to be about this sedation side effect,\" Fargo said.\n\"This is the first clinical trial to show that a cannabinoid can decrease agitation,\" said lead researcher Krista Lanctot, a senior scientist at Sunnybrook Health Sciences Center in Toronto.\nFor example, only one person out of five to 14 treated with antipsychotics actually experiences a decrease in agitation, Lanctot said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "It\u2019s clearly explained that a major rationale for this study is that the existing pharmaceutical approaches in treating agitated Alzheimer\u2019s patients \u2013 mainly off label use of antipsychotics and anti-seizure meds \u2014 don\u2019t work very well and have significant side effects.\nThere are behavioral approaches to agitation but, given the topic of this article, not including them seems reasonable.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070225/5disease.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions Avastin, laser treatment, and phototherapy as alternatives. The story could have provided more information on the advantages and disadvantages of the different approaches. The story should have also\u00a0mentioned that Avastin isn't approved for this indication.", "answer": 1}, {"article": "Their editorial accompanies the Marban report in the Feb. 14 advance online issue of The Lancet.\n\"We have been trying as doctors for centuries to find a treatment that actually reverses heart injury,\" Eduardo Marban, MD, PhD, tells WebMD.\n\"These findings suggest that this therapeutic approach is feasible and has the potential to provide a treatment strategy for cardiac regeneration after [heart attack],\" write University of Hong Kong researchers Chung-Wah Siu and Hung-Fat Tse.\n\"That is what we seem to have been able to achieve in this small number of patients.\nThe finding, just in time for Valentine's Day, is the clearest evidence yet that literally broken hearts can heal.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no comparison to alternative treatments. What do patients typically do after suffering a heart attack? Given what modern medicine has achieved so far with heart care, how long can someone expect to live after having a heart attack? Are there surgical options, pharmaceutical treatments or lifestyle changes that could make a difference? Even in a short, 511-word story, some of the space devoted to the lead researcher\u2019s quotes could have been given to even one sentence about alternatives.\n\u00a0\n\u00a0", "answer": 0}, {"article": "Antidepressants frequently prescribed to help treat bipolar depression do little to help patients recover, according to a new study that adds fuel to a long-running debate over how to best treat an affliction that affects an estimated eight million Americans.\n\nBipolar disorder, also known as manic depression, is a serious mental illness that involves dramatic swings in mood, including frequent and lengthy periods of depression. Along with mood-stabilizing drugs like lithium, many physicians also treat the disorder with common...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u00a0notes, in\u00a0passing, that mood stabilizing drugs are used.\u00a0 It doesn't say anthing about other options (such as psychosocial treatments) and whether any of these treatments work.\u00a0 ", "answer": 0}, {"article": "ZURICH (Reuters) - An experimental cancer drug that Novartis hopes will raise the profile of its oncology portfolio cut the risk of death or disease progression by more than a third in breast cancer patients with a hard-to-target gene mutation.\nEven though PIK3CA mutations are the most common genetic change in hormone-receptor positive breast cancer, trials of agents seeking to put a brake on this pathway to tumor growth have largely disappointed including on safety issues.\n\u201cThe results of SOLAR-1 are the most encouraging observed to date from a trial evaluating a PI3K inhibitor\u201d for patients with this kind of breast cancer, said Fabrice Andre, a professor at France\u2019s Institut Gustave Roussy.\n\u201cThese data have the potential to allow physicians to address an unmet need in this patient population by using a biomarker-driven treatment to inform their sequencing decisions,\u201d Andre added.\nLike other companies, Novartis is seeking to personalize treatment for cancer patients by using biomarkers like those showing PIK3CA gene mutations to help guide treatment.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study is comparing the combination of Faslodex and\u00a0BYL719/alpelisib to Faslodex alone. It\u2019s not clear if there are other treatment options for this patient population or if Faslodex alone would be the standard of care for these patients at this point in their treatment.", "answer": 0}, {"article": "PROVIDENCE, R.I. [Brown University] -- New results from a clinical trial involving more than 900 military veterans at high risk for keratinocyte carcinoma skin cancer provides evidence that using the generic skin cream fluorouacil 5 percent for two to four weeks may reduce the risk of a squamous cell carcinoma (SCC) needing surgery by 75 percent within a year.\nThe finding that less than one month's use of fluorouacil 5% (5-FU) appeared to prevent cancer for up to a year is encouraging, said lead author Dr. Martin A. Weinstock, a professor of dermatology in the Warren Alpert Medical School of Brown University and chief of dermatology at the Providence Veterans Affairs Medical Center.\nBut in the new study, 5-FU appeared to provide prolonged protection after discontinuation and could be combined with sunscreen, Weinstock said.\nAfter the first year, 20 of the 464 veterans in the control group developed a squamous cell carcinoma that required surgery, but only five of the 468 veterans who got 5-FU did, a statistically significant 75 percent reduction in the risk, according to the study.\nThe cream does have common side effects including reddened, more sensitive and often crusty skin, effects that resolve when the application of the cream stops, Weinstock acknowledged.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The study mentions that surgery is the normal response to these skin cancers and that Mohs surgery is the procedure of choice in many cases. It also points out that \u201ccurrent means for preventing new carcinomas in high-risk patients \u2014 sunscreen or oral medications\u201d \u2014 are available.", "answer": 1}, {"article": "Immunotherapy, as it\u2019s called, has yet to prove itself with solid tumors like breast, prostate, lung, colon and brain cancers.\nThe patient is one of nine in the trial, and so far, many of the other people are having similar experiences on the therapy.\nThe tumors in the first patient remained under control for almost eight months, but the cancer returned after that in new parts of the brain.\nThe man did not develop such serious complications, however, and after about four months, these tumors too started to shrink.\nBut most of the success so far has been with blood cancers like lymphomas and leukemias.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does a pretty good job of describing the standard therapies available and, in this case, delivered to the patient. \u00a0\u00a0", "answer": 1}, {"article": "The study, conducted at the University of Texas M.D.\nThe findings, published in today's Journal of the American Medical Association, are a setback to the hope that better diets can prevent breast cancer recurrence.\nThe study focused on more than 3,000 women \u2014 average age 53 \u2014 who had been treated successfully for early-stage breast cancer.\n\"I went into the study expecting to see a difference between the two groups,\" he said.\n\"We always assumed we're not eating enough fruits and vegetables and that the more we ate, the better,\" Jones said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story failed to mention other breast cancer recurrence strategies (avoiding weight gain, medications, etc.).\u00a0 Especially as the outcome of the study reported on was to show no benefit, other options that have demonstrated efficacy for decreasing risk recurrence could have been mentioned.", "answer": 0}, {"article": "About 10 percent of the students had an abnormal EKG.\nThe American Heart Association suggests that athletes who are identified as at risk for heart problems as a result of a family history or physical exam be referred for further cardiovascular examination, which could include an electrocardiogram.\nThere's no official policy from the American College of Cardiology, but officials say most members support screening student athletes.\nThe severity of this and the other two problems that turned up as a result of the abnormal EKGs are reason enough, Debauche says, to screen all school athletes nationwide.\nIn severe cases, asthma can cause the heart to thicken and put kids at risk of cardiomyopathy and sudden death.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0     \n\n \nThe story makes no attempt to compare the standard approach of screening based on family history, medical exam and personal history to the proposed method of routine screening for all. \u00a0The story suggests that existing recommendations are inadequate. However, there is no evidence provided to validate the approach of routine screening.\u00a0 \n ", "answer": 0}, {"article": "Greenwood says he'd like to see many more patients try diabetes prevention programs.\nA recent pilot study with Utah-based Intermountain Healthcare that included about 200 people, all of whom were at high risk of Type 2 diabetes, found that 75 percent of the participants completed the Omada program and lost at least 5 percent of their body weight.\nAfter all, pulling off these changes is difficult\n\n\"I'm still on the journey to get to more optimal, health\" says Lonny Northrup, who lives in Utah.\nSince last May, he has lost about 50 pounds (52, to be exact, but it fluctuates a bit) and his blood sugar has returned to the normal range.\n\"I got really good, specific recommendations that worked for me and my lifestyle,\" Northrup says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article very briefly mentions that other technology-based programs for improving diet and exercise exist, but does not go into much detail, especially on outcomes. We think it would be useful to have included outcomes from a well-studied program, such as Weight Watchers, or even Virta Health, which recently published some (more) impressive one year results with a similar sounding app.", "answer": 0}, {"article": "The trial was funded by Mayo Clinic.\nIn this group, the rate of heart attack, stroke and revascularization and death was 3.7 percent among those with a low ceramide score, but 16.4 percent in people with the highest ceramide levels.\nThe study found that individuals with the highest levels of blood ceramides were found to have a 3- to 4-times greater risk of having a cardiovascular event compared with those with the lowest ceramide score, regardless of their LDL cholesterol level or the presence of a blockage in the heart\u2019s arteries.\nBut the risk of having an event became higher as ceramide level increased; for each 1-point increase in the ceramide risk score, the risk rose by 9 percent.\n\u201cOur research suggests that evaluating ceramide levels in patients who are not at immediate risk for coronary artery disease events may help cardiologists decide who could benefit from proactive and preventive treatment, such as statins, or lifestyle changes to prevent a serious cardiac event down the road,\u201d says Jeff Meeusen, Ph.D., a clinical chemist, co-director of Cardiovascular Laboratory Medicine at Mayo Clinic and the study\u2019s lead author.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release doesn\u2019t mention that over the past few years many new blood tests for refining cardiac risk have been researched. Independent expert guidelines do not endorse their use. How well ceramides compare to these blood tests will have to be determined by future studies.", "answer": 0}, {"article": "The current study compared the use of traditional medical options -- tranexamic acid pills, mefenamic acid (Ponstel), combined estrogen-progestogen and progesterone alone -- to the use of the levonorgestrel intrauterine system.\nBritish researchers found that the treated IUD was more effective at reducing the effects of heavy menstrual bleeding (also called menorrhagia) on quality of life compared to other treatments.\nFor women who do want to get pregnant, Gupta said, taking the blood-clotting drug tranexamic acid during periods is an alternate method of treating heavy periods.\nFor women who may be hesitant to use an IUD because of pelvic infections linked to an early version called the Dalkon Shield, Gupta said that as long as women are screened for sexually transmitted diseases before getting an intrauterine system, the risk of infection is low.\nWomen in the IUD group reported much greater improvement -- 32.7 points on the symptom scale versus 21.4 points in the standard treatment group.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study discussed the usual treatment for heavy menstrual bleeding, but what is not clear is if the side effects from using Mirena are different from the current medications. Inadequate discussion of alternatives and comparisons overall.", "answer": 0}, {"article": "In a new clinical trial, scientists show that a daily dose of probiotic Lactobacillus and Bifidobacterium bacteria taken over a period of just 12 weeks is enough to yield a moderate but significant improvement in the score of elderly Alzheimer's patients on the Mini-Mental State Examination (MMSE) scale, a standard measure of cognitive impairment.\nAt the beginning and the end of the 12-week experimental period, the scientists took blood samples for biochemical analyses and tested the cognitive function of the subjects with the MMSE questionnaire, which includes tasks like giving the current date, counting backwards from 100 by sevens, naming objects, repeating a phrase, and copying a picture.\nEven though this increase is moderate, and all patients remained severely cognitively impaired, these results are important because they are the first to show that probiotics can improve human cognition.\nWalter Lukiw, Professor of Neurology, Neuroscience and Ophthalmology and Bollinger Professor of Alzheimer's disease at Louisiana State University, who reviewed the study but was not involved in the research, said: \"This early study is interesting and important because it provides evidence for gastrointestinal (GI) tract microbiome components playing a role in neurological function, and indicates that probiotics can in principle improve human cognition.\nBut scientists have long hypothesized that probiotics might also boost cognition, as there is continuous two-way communication between the intestinal microflora, the gastrointestinal tract, and the brain through the nervous system, the immune system, and hormones (along the so-called \"microbiota-gut-brain axis\").\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Although there is no cure for Alzheimer\u2019s, several drug and non-drug options are available to treat symptoms of the disease, including medications for memory loss and treatments for behavioral and sleep changes associated with this condition. None of these are addressed in the news release.", "answer": 0}, {"article": "WEDNESDAY, Sept. 21, 2016 (HealthDay News) -- New guidelines issued by three leading cancer organizations suggest that more breast cancer patients should consider radiation therapy after a mastectomy.\n\"The guideline is timely,\" said Dr. Janna Andrews, an attending physician in radiation medicine at Norwell Health Cancer Institute, in Lake Success, N.Y. \"The field of post-mastectomy radiation is changing.\n\"In the past, if a woman had a small tumor, less than 5 centimeters, and not more than three or four positive lymph nodes, many doctors would say she does not need [post-mastectomy radiation therapy],\" she said.\nFor instance, he explained, ''a woman 65 who has microscopic involvement in a single lymph node and an estrogen-receptor positive cancer would be very different from a 38-year-old who has three lymph nodes involved and so-called triple-negative breast cancer.\"\n\"The new guidelines say there is clear evidence that the benefit of [post-mastectomy radiation therapy] extends to women with limited lymph node involvement,\" said Dr. Stephen Edge.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story essentially compares getting radiation therapy to not getting radiation therapy (but, as noted above, doesn\u2019t really offer much detail on the benefits of radiation therapy).\nDepending on the\u00a0circumstances, patients who receive post-mastectomy radiation may also be treated with chemotherapy, and we wished that had been discussed, too, since the combination can potentially increase health risks.\n\u00a0", "answer": 1}, {"article": "Chattoo also offers patients a nutritionist and trainer with the procedure.\nShe told FoxNews.com that the balloon \u201cmakes you feel full all the time to the point where you\u2019re not angry about having to lose things like chocolate and cake.\u201d\n\nBrown said that the balloon acted like a \u201crestart button\u201d and retrained her body to adapt to a new lifestyle of healthy eating and exercise.\nNow, there is a new solution for people with a body mass index (BMI) between 30 and 40 that want to lose weight called the Orbera gastric balloon.\n\u201cThe beauty of the procedure is that it is a nonsurgical procedure,\u201d Chattoo said.\nThe balloon remains in the patient\u2019s stomach for six months and is then removed the same way it was inserted, through the mouth.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The only time alternative treatments are mentioned is when the story refers to gastric bypass and stomach stapling as \u201cinvasive surgeries\u201d in the first sentence. There is no discussion of exercise and diet, other than in conjunction with Orbera. There is no discussion of how Orbera\u2019s benefits compare to gastric bypass or stomach stapling. There is also no discussion of how Orbera differs from other gastric balloon procedures (more on that under \u201cNovelty\u201d).\nAlso, the way these other surgical alternatives are characterized in the story is misleading. Yes, they\u2019re \u201cinvasive,\u201d but they\u2019re also clinically proven to help obese patients lose weight, keep it off, and live longer. We\u2019re not sure if the same is true for Obrera, because this piece includes no discussion of clinically tested benefits. And, it should be noted that Obrera is invasive, too \u2014 after all, it involves placing a large foreign body in a person\u2019s stomach.", "answer": 0}, {"article": "\u201cEczema can cause significant skin irritation and discomfort for patients, so it is important to have a variety of treatment options available to patients, including those patients whose disease is not controlled by topical therapies.\u201d\n\nAtopic dermatitis, a chronic inflammatory skin disease, is often referred to as \u201ceczema,\u201d which is a general term for several types of inflammation of the skin.\nDupixent\u2019s active ingredient is an antibody (dupilumab) that binds to a protein [interleukin-4 (IL-4) receptor alpha subunit (IL-4R )], that causes inflammation.\nThe Agency also is responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nBy binding to this protein, Dupixent is able to inhibit the inflammatory response that plays a role in the development of atopic dermatitis.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release gets a borderline satisfactory for mentioning topical corticosteroids as an alternative treatment for eczema but neglects to mention that other pharmaceuticals are also now available for treating it.", "answer": 1}, {"article": "In fact, Dr. Weinstein's findings, released today in the Journal of the American Medical Association, conclude that surgery is only slightly more effective in some cases than a non-surgical approach.\nHe says he thinks that sometimes people are too quick with surgery.\n\"I think that it be important for people to have good information,\" he adds.\nHis back pain was excrutiating,reports.\nThe operation was a success and she's been pain-free for four years.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions various kinds of non-operative care, including physical therapy, medications and steroid injections, as the alternative to surgery.", "answer": 1}, {"article": "Then the N.Y.U.\nIf the time is slower, even by a small amount, he or she probably has a concussion, according to neurologists.\nThat situation prompted researchers at New York University\u2019s Langone Concussion Center to begin wondering recently whether there might be other, easier diagnostic tools to check young players for concussions.\nThe King-Devick test did much better, correctly assessing concussion in 75 percent of the young injured players and inaccurately identifying it in only one.\nThose of us who coach or care for young athletes know by now that an athlete who falls or collides with something during play or seems dazed, dizzy, loses consciousness or complains of head pain should be tested for a concussion, which occurs when the brain is physically jostled within the skull.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The most commonly used testing method \u2014 the\u00a0Standardized Assessment of Concussion \u2014 which measures cognition and a timed tandem gait test of balance were part of the research being reported and were described in the story.", "answer": 1}, {"article": "A controller the size of a cellphone enables her to set her Esteem to different environments, such as \"home,\" \"restaurant\" or \"school.\"\nIt contains a battery that must be replaced in about seven years.\n\"This really fills a need for adults with moderate to severe sensorineural hearing loss,\" Marzo said.\nIn March, she plans to have one put in her right ear.\nI nodded a lot because I couldn't hear them.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story briefly mentions hearing aids, but the article does not go into detail about other alternatives to surgery.", "answer": 0}, {"article": "Advanced online publication: http://www.\nThe published results showed a gene-dose effect at the high dose of tramiprosate (150 mg, twice daily), with patients with two APOE4 alleles (APOE4/4 homozygotes) showing the largest clinical benefit, those with one APOE4 allele (APOE4 heterozygotes) showing an intermediate benefit, while APOE4 non-carriers showed no benefit from tramiprosate.\nEfficacy Results in APOE4/4 Homozygous Patients from the JPAD Phase 3 Analyses\n\nThe published results showed the largest clinical benefit in the Alzheimer's APOE4/4 homozygous AD patients, who represent approximately 15 percent of patients in the study.3 APOE4/4 homozygous patients who received the high dose of tramiprosate showed efficacy benefit compared to placebo on both cognitive and functional measures in the Phase 3 analyses.\nData published by Alzheon in the Journal of the Prevention of Alzheimer's Disease is the first report to associate efficacy of an amyloid-targeted drug with the number of APOE4 alleles\n\nFRAMINGHAM, Mass., October 24, 2016 - Results published today in The Journal of the Prevention of Alzheimer's Disease (JPAD) describe analyses of Phase 3 data for the investigational amyloid-targeted drug, tramiprosate, in patients with Mild to Moderate Alzheimer's disease (AD).\nIn these new subgroup analyses, the high dose of tramiprosate showed promising clinical effects in APOE4/4 homozygous AD patients already receiving maximal standard of care, and this dose was not associated with any events of vasogenic edema,\" said Susan Abushakra, MD, Chief Medical Officer of Alzheon and lead author on the JPAD publication.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This release summarizing the research study did not include comparisons with existing drugs \u2014 but we won\u2019t fault them for that. There are no known therapies that \u201ctreat\u201d Alzheimer\u2019s, only those that relieve some of its underlying symptoms.\nBut a\u00a0 mention of preventative strategies would have been welcomed here.\nMany researchers are pointing out that Alzheimer\u2019s is not a disease simply due to overload of amyloid but its causes may be multifactorial, with, for example, blood vessel disease (narrowing of small arteries) and high blood pressure being significant risk factors. Lifestyle changes, including regular exercise, may do more to help prevent Alzheimer\u2019s than any drug now available, and a discussion of that is included in a HealthNewsReview.org blog post from earlier this year.", "answer": 2}, {"article": "That\u2019s called secondary prevention.\nIt is important to keep in mind that other therapies, such as statins, have also been proven to decrease the risk of cardiovascular events.\nBy Charles H. Hennekens: After more than 25 years of research on aspirin for primary prevention, we are not much further along than we were after the landmark findings from the Physicians Health Study in 1988.\nIt is important to note that this draft recommendation applies to people who are not at increased risk for bleeding, have at least a 10-year life expectancy, and are willing to take low-dose aspirin daily.\nIf there was a foolproof way to identify individuals at high risk for a future heart attack or stroke, as well as those at high risk for developing complications, we would know who should be taking aspirin for primary prevention and who should not.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Alternatives are mentioned (smoking cessation, eating a balanced diet, getting sufficient exercise), and that\u2019s sufficient to rate as Satisfactory. The piece would be strengthened by comparing the relative benefits of the other options.", "answer": 1}, {"article": "Newswise \u2014 An international team led by researchers at the Austrian Institute of Molecular Biotechnology (IMBA) in Vienna and the University of Maryland School of Medicine in Baltimore discovered that genetically determined breast cancer can be largely prevented by blocking a bone gene.\nIn 2010, Josef Penninger, the scientific director of IMBA in Vienna and his team have shown that sex hormones can trigger breast cancer (Schramek et al., Nature) through proteins called RANKL and its receptor RANK, which are key factors in bone metabolism.\nMoreover, the scientists \u2013 together with colleagues in Barcelona and from the CIMBA* consortium mapping more than 23,000 women \u2013 showed that genetic variants in the RANK gene are associated with a higher risk of developing breast cancer in women who carry BRCA1 and also BRCA2 mutations.\nUntil now, prophylactic surgery is the only procedure which significantly reduces the breast cancer risk, but which is also often associated with postoperative complications.\nBased on our discovery, the already approved drug Denosumab or other future drugs that will block RANKL/RANK, could be used for breast cancer prevention in BRCA mutation carriers,\" explains Verena Sigl.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions prophylactic surgery as the only current method for reducing breast cancer risk. It doesn\u2019t compare denosumab to mastectomy nor to bisphosphonates, which are other drugs that interfere with RANKL proteins and RANK receptors.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Testing women for human papillomavirus (HPV) may catch more pre-cancerous growths than standard cervical cancer screening does \u2014 but more evidence is needed before the newer tests become routine, a study published Monday concludes.\nIt has not been clear exactly how HPV testing, or liquid-based Pap tests, measure up against standard Pap tests.\nSeveral other clinical trials in the review looked at HPV testing.\nIf more women received the screening that already exists, \u201cthat would be a huge step forward,\u201d Whitlock said.\nIt may not even be the doctor\u2019s \u2014 but may instead depend on whatever health system he or she is part of.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was great detail in comparing the liquid test and HPV testing with traditional cervical cancer screening.", "answer": 1}, {"article": "The study was divided into three parts.\nThe researchers recruited a total of 12 patients with Alzheimer's disease, seven younger healthy controls (ages 25-38 years old) and five older healthy controls (age 50 or older) for brain-only PET scans.\nIn total, the researchers looked at 80 different regions in the brain to evaluate how well the tracers were taken up by the brain, how well they penetrated through the tissue and how specifically they bound to the tau protein rather than just sticking indiscriminately to anything.\nRegions of the brain that typically contain accumulated tau protein include the temporal lobe, parietal lobe and occipital lobe, among others; grey matter in the cerebellum is thought to contain low or no tau in patients with Alzheimer's.\nThey found that healthy brains retained little to no tracer, whereas the brains of those with Alzheimer's showed tau to be in regions of the brain consistent with previously reported postmortem data on filamentous tangles.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release accurately notes that there is no definitive diagnostic tool for Alzheimer\u2019s disease other than an autopsy of the brain. It also refers to a \u201ccurrently used\u201d tau tracer.\nWe wish it had been clearer that the research being described is not the only work being done in this area. For example, this 2015 paper in the journal Alzheimer\u2019s and Dementia describes a number of innovative approaches being explored in this field.", "answer": 1}, {"article": "For more information about NIH and its programs, visit http://www.\nThe study shows that for adults aged 75 years and older with high blood pressure, a systolic blood pressure goal of less than 120 mm Hg reduced rates of cardiovascular events, such as heart attack and heart failure, as well as stroke, by 33 percent.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\nThe new analysis singles out adults aged 75 and older and confirms that those with high blood pressure also benefit from the lower pressure target similar to the larger group studied in the earlier research: non-diabetic adults aged 50 and older.\nWhile study participants with the lower blood pressure goal appeared to have better cardiovascular outcomes overall, the researchers caution all other hypertension patients to talk to their doctor to determine whether this lower goal is best for their individual care.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Again, the release explains a trial which presumably used different medications and/or different doses to reach the targeted systolic blood pressure levels (although none are identified). It offers no information on alternative mechanisms for reaching those goals and without more information on what approaches were used, it would be hard to cite alternatives.", "answer": 0}, {"article": "Another sensor, just approved by the F.D.A.\nIt has to be placed above the hip or the buttocks, which makes reaching it awkward, and then the wire leading from the sensor has to be connected to a transmitter that wirelessly sends the information to the pump.\nThe device, made by Medtronic MiniMed, is called the Paradigm Real-Time, a combination insulin pump and continuous glucose sensor.\nThe main problem was that the sensor was simply not as accurate as a blood-glucose tester.\nThat night, however, the sensor kept beeping me awake, nearly every hour, warning that my glucose level was too high.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story describes alternative options, including traditional blood glucose monitoring devices and insulin pumps (minus the glucose sensors). The story also describes other similar devices that may be on the market soon. ", "answer": 1}, {"article": "May 4, 2010 (New York) -- An experimental weight loss/blood pressure pill may pack a one-two punch against hunger and high blood pressure, one of the main health consequences of obesity, according to new research presented at the American Society of Hypertension\u2019s 25th annual meeting in New York.\nThe higher the dose, the more substantial the weight loss, and the more likely it was to be maintained over time, the study shows.\nThe new analysis of three separate studies included more than 4,500 people.\nData on this drug are slated to be reviewed this summer by an FDA advisory panel.\nAt six months, people who took the full dose of Qnexa once daily lost nearly 10% of their body weight; by one year, it was up to 10.4%.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0There was no information about how well this product works in comparison with other approaches to weight loss.", "answer": 0}, {"article": "That's the tantalizing premise behind Deplin, a prescription form of the B-vitamin folate. Although it has been on the market since 2006, Deplin is generating growing buzz at psychiatric conferences and among clinicians and patients, particularly those who haven't responded to antidepressants or did for a while only to have their depression return.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions cognitive-behavioral therapy, aerobic exercise and substance-abuse programs as effective alternatives for individuals with treatment-resistant depression. It should also have mentioned electroconvulsive therapy (commonly referred to as \u201cshock therapy\u201d), which is highly effective\u00a0for depression and should be considered by patients with severe symptoms or when symptoms\u00a0do not respond to other therapies.", "answer": 1}, {"article": "Pryor believes balloons are a better option for patients who are candidates for weight loss surgery but don't want surgery.\nThe study lasted a year, but \"we don't know what happens after that,\" Pryor said.\nThe balloon treatment will be available starting in January, but the cost hasn't been announced, Pryor said.\n\"While there is potentially easier insertion that does not require sedation, I still doubt after removal there will be weight loss,\" he said.\nAn advantage of the balloons is that patients have no downtime and can go back to work the same day, the researchers said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story includes discussion of weight loss surgery and lifestyle interventions. It includes a quote noting that the Obalon device does not require patients to be sedated during insertion, which implies there are other similar balloon devices, though the story would have been better if it specifically noted that there are already two very similar devices available in the U.S. as well as other balloon devices that are for sale in other countries. It also could have pointed out that these results don\u2019t appear more effective than an intensive\u00a0behavioral program.", "answer": 1}, {"article": "Sharif said the excellent short-term outcomes and 100 percent cure rate of HCV in organ recipients should prompt transplant centers to rethink use of HCV-infected kidneys.\nIn a study of 20 uninfected patients, researchers found that transplanting infected kidneys and then treating recipients for HCV resulted in a 100 percent cure rate.\nThough some patients might not want to take the risk associated with an infected kidney, others might consider it a good option, given the high death rates for dialysis patients awaiting transplants, the researchers suggested.\nBut the cost effectiveness of using these kidneys versus remaining on dialysis would be significant, he noted.\n\"There is a tremendous lack of kidneys for transplant,\" he explained.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story made it clear that the alternative to receiving an infected kidney is waiting more than a year on average for a healthy kidney or remaining on dialysis.", "answer": 1}, {"article": "MONDAY, June 6, 2011 (HealthDay News) -- There's too little evidence to say definitively whether treating early, localized prostate cancer with radiation is a better option than \"watchful waiting,\" new research finds.\nThey should also consider age and overall health status, including whether or not the patient has other conditions more likely to cause death than the prostate cancer.\nMen and their doctors need to consider what the tumor looks like under the microscope, which can help gauge how aggressive it may be.\n\"Men need to learn as much as they can about the possible outcomes and benefits of the various treatments and the potential side effects, and choose which direction they are most comfortable with,\" Brooks said.\nIn part, that's because researchers found no randomized controlled trials -- considered the gold standard of research -- that compared radiation therapy with watching waiting, Ip said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The entire story was about a systematic review of studies comparing different doses of radiation and different types of radiation therapy \u2013 and whether any has been shown to be a better option than \u201cwatchful waiting.\u201d", "answer": 1}, {"article": "Restless legs syndrome causes a person to feel a powerful urge to move his or her legs.\n\"Treatments for restless legs syndrome is now frequently advertised direct-to-consumer, and thus while this may enhance awareness it may result in patients seeking treatment for milder or other conditions not well-studied,\" he explained.\n\"Physicians and patients now have better information on the effectiveness and harms of two types of drug treatments for patients with at least moderately severe restless legs symptoms in which to guide treatment choices,\" said review author Dr. Timothy Wilt, core investigator at the Minneapolis VA Health Care System.\n\"Up to 25 to 50 percent with even moderate to severe and longstanding symptoms stop taking these medications after more than a year due to either side effects or lack of benefit,\" he noted.\nThe medications, which include Requip (ropinirole), levodopa, Neurontin (gabapentin) and Lyrica (pregabalin), appear to reduce symptoms of the syndrome in more than 60 percent of patients, researchers report.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story notes that drugs may not be appropriate for individuals with milder symptoms, it didn\u2019t discuss what approaches might be useful.\u00a0Recommendations from the National Institute of Neurological Disorders include:\nThe key point is that for many individuals with mild symptoms, the cost, side effects and unclear longer term benefits and harms of these medications indicate that many patients will seek other options including options that are low risk but potentially of limited benefit.\n ", "answer": 0}, {"article": "Overall, research is suggesting that CT scans of people at risk of lung cancer might make a dent in cancer mortality, and it\u2019s possible that more frequent screening might make an even bigger dent, Hanley noted.\nThe three groups of people had some important differences, such as in average age and how long and heavily they had smoked, so the researchers had to use mathematical tools to try to eliminate the influence of those differences, said Hanley.\nIt is not clear when or how guidelines for lung cancer screening could be drawn up, and until they are, insurers including government programs such as Medicare are unlikely to pay the average $300 cost of a scan.\nFor instance, to compare death rates, the researchers tracked how many people died among those who were screened, then pulled out all the people with similar underlying characteristics in the other two groups and looked at their death rates, Hanley explained.\nA total of 64 people died in the screened population, the authors report \u2014 but applying the death rate among people with the same underlying characteristics in one of the unscreened populations, they estimated that the number of deaths would have been 100.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe story does not discuss alternatives. It would require only another sentence to at least note the reduction in the risk of lung cancer, heart disease and other ailments that come from quitting smoking.", "answer": 0}, {"article": "So, should we be referring to physical therapists, osteopaths or chiropractors from the ER?\"\n\"This study shows that basically neck pain will get better on its own,\" said Dr. Victor Khabie, chief of the departments of surgery and sports medicine at Northern Westchester Hospital in Mount Kisco, N.Y. \"It would've been good if they had a no-treatment group, too,\" he added.\nAll are probably still viable treatment options, but what we don't know is what each particular patient will need,\" Bronfort said, adding that it's possible a combination of treatments might be helpful, too.\nThis is especially true if you've been in a car accident, or if you have any neurological symptoms, such as repeatedly dropping things, or if you have pain radiating down your arm.\nThere are different pathways to healing, and whether you feel you're better off with chiropractic, home exercises or medications, this study shows that all three are basically just as effective.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The trial was set up as a direct comparison of popular treatments for neck pain, and that is just how the story presents it. It even includes a comment from an independent source that this sort of neck pain tends to improve on its own. As mentioned above, the story could have provided more details about the potential harms of the various treatment options.", "answer": 1}, {"article": "The human collagen used to develop the corneas was provided by biotechnology company FibroGen Inc.\n\u201cWe are still in the prototype stage, but this shows that regenerating a human cornea is possible.\u201d\n\nTwo years after having the corneas implanted, six of the 10 patients had improved vision .\nA shortage of human donor tissue coupled with the threat of graft rejection from donor corneal transplants has driven the search for other ways of treating corneal damage.\n\u201cThis is the first time we have been able to regenerate a cornea in humans,\u201d researcher May Griffith, PhD, of the Ottawa Hospital Research Institute and the University of Ottawa tells WebMD.\nIt has been 10 years since Griffith and colleagues first reported the development of a material with the potential to grow healthy new tissue in people with damaged corneas.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compares the biosynthetic corneas both to human corneas and to plastic corneas. It is the only story of the three to even mention plastic corneas. Other alternatives could have been explored.", "answer": 1}, {"article": "Multigene testing is not more expensive than testing for the BRCA mutations alone, he said.\n\u201cThe interpretation of these tests is not a simple color-by-numbers thing.\u201d The vast majority of uncertain genes will be benign, but a misinterpretation could lead a patient to a drastic, unnecessary surgical procedure, he said.\n(Reuters Health) - When the results of a test wouldn\u2019t change how doctors manage a patient\u2019s care, most say it\u2019s not worth doing.\nBut new tests for breast cancer risk mutations beyond the well-known BRCA genes would offer actionable information for many women and their doctors, a new study finds.\nEarlier this year, 17 genetic experts argued against testing for a wider panel of breast cancer-related gene mutations until they are proven to be valid and useful in clinical practice (see Reuters story of May 27, 2015 here: reut.rs/1TvOoDf).\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The piece in itself is about an investigation of the clinical usefulness of additional (alternative) genetic panels to the \u201croutine\u201d BRCA1/2 tests. So the story meets our standard here. But as mentioned before, there are serious concerns about the use and availability of genetic test panels and it would have been great to add some context.", "answer": 1}, {"article": "The answer?\nDuring the scans, each person performed tasks related to vision, memory, reading or motor skills, or rested quietly.\nThere are no laboratory tests to diagnose migraines, depression, bipolar disorder and many other ailments of the brain.\nWe show here that it's not measuring what you're thinking, but how your brain is organized.\nFurther, the researchers found that the technique was powerful enough to distinguish people who were extraordinarily alike.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Brief mention is made of self-reporting and behavior as current options for diagnosing illnesses like migraines, depression, and bipolar disorder but there\u2019s no mention of their limitations or how a new diagnostic test might compare.", "answer": 0}, {"article": "The Menlo Park, California-based company\u2019s shares were up 3 percent at $33.00 in extended trading on Wednesday.\nBased on the most recent estimates, about 7.8 million Americans have some form of excessive sweating including palms, feet, underarms or head, and about half of this population suffer from the underarm form, said Dermira spokeswoman Erica Jefferson, in an interview ahead of the data readout.\nFor instance, a class of drugs called anticholinergics are commonly used off-label for this purpose, but they are linked with the risk of dementia.\nIn the first trial, a significant improvement in the severity of sweating was seen in 52.8 percent of the patients treated with the drug, compared with 28.3 percent patients in the control group, on a scale designed by the company.\nIn the second trial, a significant improvement was seen in 66.1 percent of the drug-treated patients, compared with 26.9 percent in the control group.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Many alternatives are mentioned, and that\u2019s enough to skirt by as Satisfactory.\nHowever, the discussion of alternatives (such as antiperspirants and Botox injections) seems mostly to revolve around pointing out how problematic they are, without any discussion of actual comparative effectiveness, which is a disservice to readers.", "answer": 1}, {"article": "Sandoval is alive today because of an experimental form of immunotherapy called CAR-T.\nThe FDA will review these results and could make a decision on approval by the end of the year.\nBeing around for my daughter, my son, my wife.\nWith CAR-T, a patient\u2019s own immune cells are removed from the body, reprogrammed to find and destroy cancer cells, then put back into the bloodstream.\nSide effects included flu-like symptoms and confusion, and there were three treatment-related deaths.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not report anything about existing treatment alternatives, such as various types of chemotherapy and stem cell transplants, including typical outcomes for lymphoma patients.", "answer": 0}, {"article": "As a nicotine-gum addict, Mike Metzger used to worry about the warning on its label: \"Stop using the nicotine gum at the end of 12 weeks.\"\n\nBut that was before a prominent smoking-cessation scientist, K. Michael Cummings, told him to keep chewing the gum as long as it helped him stay off cigarettes. So 15 years after quitting smoking, Mr. Metzger, a 63-year old retired New York telephone worker, still chews 16 pieces of nicotine gum a day.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not do a good job comparing nicotine gum to going cold turkey, counseling or other therapies. Some of the studies mentioned talk about a combination of therapies that include gum and counseling. We would have liked to have seen a better comparison to give readers the best sense of what choice they should make if considering quitting smoking.", "answer": 0}, {"article": "CHICAGO (Reuters) - A new analysis of evidence used by a U.S. advisory panel to roll back breast cancer screening guidelines suggests it may have ignored evidence that more frequent mammograms save more lives, U.S. researchers said on Tuesday.\nBut Helvie and colleague Edward Hendrick of the University of Colorado wrote that \u201cthe USPSTF chose to ignore the science available to them and overemphasized the potential harms of screening mammography, to the serious detriment of U.S. women who follow their flawed recommendations.\u201d\n\nDr. Carol Lee who chairs the American College of Radiology\u2019s Breast Imaging Commission said the new study highlights the risk of setting policy based on the conclusions of one group of scientists.\nWhen they were issued, the task force\u2019s guidelines contradicted years of messages about the need for routine breast cancer screening starting at age 40, kicking off a fury of protest among breast cancer experts and advocacy groups who argued the recommendation of fewer screenings would confuse women and result in more deaths from breast cancer.\nMany groups, including the American Cancer Society, have stuck by their long-standing recommendations of a yearly breast exam for women starting at age 40, stressing that the breast X-rays have been proven to save lives by spotting tumors early, when they are most easily treated.\nShe said breast mammograms have contributed significantly to reducing deaths from breast cancer, a fact that should not be ignored in favor of mathematical models.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article fails to mention the disadvantages of annual mammography screening beginning at age 40.\u00a0 By not including balanced information, the article may lead readers to believe this new analysis is totally accurate.\u00a0 The choice of declining screening was not presented as a reasonable option.", "answer": 0}, {"article": "The rate for 413 volunteers given placebo treatment was 7.7 percent.\nThe 504 patients treated with the antibiotic nose gel mupirocin, also known as Bactroban, and washed with chlorhexidine, a common ingredient in mouthwash, developed an S. aureus infection 3.4 percent of the time.\nThe new study, published in the New England Journal of Medicine, used a rapid test to identify which patients, most of whom were scheduled to undergo surgery, had the bacteria in at least one nostril.\nIn a commentary, Dr. Richard Wenzel of the Virginia Commonwealth University in Richmond said the chlorhexidine-alcohol mixture should replace the older disinfectant when scrubbing people for surgery, and the nasal disinfection technique should primarily be used for people undergoing cardiac surgery, receiving an implant, or whose immune system is likely to be affected.\nA second infection study, also reported in the journal, found that a chlorhexidine-alcohol combination produced 41 percent fewer surgical-site infections as the commonly used mixture of povidone and iodine, which gives a yellow-orange tinge to the skin.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This question was not addressed in the story. The reality is that there is no routinely applied standard of practice related to routine surgery. While antibiotics are routinely administered early during a surgical procedure, patient preparation is not standardized.\u00a0 ", "answer": 0}, {"article": "I\u2019d rather have done 10 rounds with Mike Tyson.\u201d\n\nRichard Burt of Northwestern University in Chicago, who carried out the first HSCT for MS in 1995 and is coordinating the international trials, told the BBC: \u201cThere has been resistance to this in the pharma[ceutical] and academic world.\nI got my life and my independence back and the future is bright again in terms of being a mum and doing everything with Isla.\u201d\n\nTwo years after the treatment, she has had no relapses and there was no evidence of active disease on her scans.\nAt one point, I couldn\u2019t even hold a spoon and feed myself.\u201d\n\nWithin a few days of the transplant, he was able to move his toes, and after four months could stand unaided, although he still needs a wheelchair.\n\u201cI couldn\u2019t dress or wash myself; I didn\u2019t even have the strength to carry my daughter.\u201d\n\nShe had needed a wheelchair before her transplant, but after the treatment she walked out of hospital.\nThe treatment has traditionally been used to treat bone and blood cancers.\u201d\n\nBasil Sharrack, a consultant neurologist at Sheffield teaching hospitals NHS foundation trust, said: \u201cThe new treatment is showing some remarkable results in the small number of patients we have treated so far.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Aside from noting that there is no cure for this type of MS, the story offers no information about existing treatments such as drugs to lessen relapses and steroid treatments to cope with flare-ups. More detail could be provided about how this form of MS is currently treated. It also isn\u2019t clear whether the bone marrow treatment will affect long-term disability or not.", "answer": 0}, {"article": "Benign prostate hyperplasia, also known as enlarged prostate, is a non-cancerous condition familiar to millions of aging males.\nHowever, the authors did not see as great an improvement in \"urodynamic\" results, such as improved flow rate of the urine, which would indicate how well the bladder and urethra are performing; in this area, the patients did not improve as much as those who underwent TURP surgery, they noted.\nAnother drawback is that few doctors are trained in PAE so far, said Pisco, chair of radiology at Hospital Pulido Valente and professor in the Faculty of Medical Sciences at New University of Lisbon in Portugal.\nThe treatment -- called prostatic artery embolization, or PAE -- is ready to be used in certain patients, namely those with a prostate larger than 60 cubic centimeters, \"with severe lower urinary tract symptoms and a weakened urinary stream,\" said Dr. Joao Martins Pisco, lead author of a study slated to be presented March 29 at the annual meeting of the Society of Interventional Radiology in Chicago.\nMeanwhile, there is no size limitation for PAE, which requires only local anesthesia and also lowers the risk of other side effects, such as blood loss and retrograde ejaculation, which occurs when semen leaks into the bladder, researchers said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story provided some insight about how this new minimally invasive treatment for benign prostatic hyperplasia compared with TURP. \u00a0However it neglected to mention that there are number of surgical techniques and minimally invasive techniques available for which there is comparable effectiveness and fewer complications than TURP. \u00a0And while the study authors claim the new procedure has value because it didn\u2019t have the higher risk for the need for re-operation, the 9-month follow-up was too short to actually be able to lay claim to this benefit.\nThe oddest part of the story was the line that other minimally invasive treatments \u201care less effective and have a greater risk of a need for reoperation according to background materials that accompanied the study. (emphasis added)\u00a0 Does that mean according to marketing materials provided?\u00a0 What was that source of that material?\u00a0 What a silly, unsubstantiated, unsourced thing to include!", "answer": 0}, {"article": "But Himpens tells WebMD he's skeptical either would make much difference.\nBut some, including the manufacturer of the Lap-Band -- used in a technique called laparoscopic adjustable gastric banding -- take exception to the study, criticizing the small sample size and the number of patients lost to follow-up.\nThe critics also point out that both the device itself and the expertise of surgeons placing it have improved greatly since the patients in the study had their bands placed, in the years 1994 through 1997.\nNearly half of the 82 patients followed for 12 years or longer required removal of the bands and about 40% had major complications, the researchers found.\nDespite that degree of satisfaction, \"I think people have exaggerated expectations from the band procedure,\" says researcher Jacques Himpens, MD, an attending surgeon at St. Pierre University Hospital in Brussels.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While the story did mention at the very end how the pace of weight loss with the product reported on compared with weight loss following gastric bypass surgery, the story ought to have provided better insight about the long-term outcomes in those who have gastric bypass and those who chose not to have surgery to help manage their excess weight. \u00a0That way, readers could compare the two commonly utilized surgical options and understand the differences between them. The story hints at this by paraphrasing a study author saying that Lap-Band patients, \u201cmay have less weight loss and more complications than those who choose other weight loss surgeries.\u201d But it never provides any evidence to back that claim. We also would have liked to have seen some comment about diet and exercise.", "answer": 0}, {"article": "\"We have pioneered the development of a closed-loop artificial pancreas because we believe it will significantly impact the lives of individuals with both type 1 and type 2 diabetes, by providing exquisite control of blood sugar,\" Dr. Richard A. Insel, executive vice president for research at the Juvenile Diabetes Research Foundation (JDRF), said during a noon teleconference Saturday.\nUsing this technology is still seen as a stopgap, however, while a biological solution to diabetes is sought.\nHowever, teenagers did not see a benefit, probably because they were less likely to wear the device, Tamborlane said.\nThese results were similar to findings in children where the system extended the amount of time spent at target blood sugar levels, he added.\n\"This will help keep people healthy while we drive toward a biological approach, which will take longer,\" he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The artificial pancreas approach isn\u2019t compared to any other alternatives, if only because the article never identifies the comparator group as those using the insulin pump.", "answer": 0}, {"article": "The team recruited 45 healthy participants aged 21-70 years who were either obese or overweight.\nThe researchers, including senior author Penny M. Kris-Etherton, PhD, distinguished professor of nutrition at Pennsylvania State University, publish their findings in the Journal of the American Heart Association.\nModerate-fat diet with one avocado a day lowered 'bad' cholesterol by 13.5 mg/dL\n\nThe researchers found that participants' levels of low-density lipoprotein (LDL) - referred to as the \"bad\" cholesterol - were an average of 8.3 milligrams per deciliter (mg/dL) lower after following the lower-fat diet without an avocado and 7.4 mg/dL lower after following the moderate-fat diet without an avocado, compared with their baseline average.\nIt is well known that avocados are high in fat, but the majority of an avocado's fat is monounsaturated, which is deemed a \"good\" type of fat.\nWhat is more, the team found that a number of additional blood measurements - such as total cholesterol, small dense LDL, triglycerides and non-HDL (high-density lipoprotein) - were better after participants followed the moderate-fat diet with one avocado a day, compared with the other two diets.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We would have liked to have seen a brief listing of other foods that provide healthier fats somewhere in the story to provide a bit of balance. The story does note: \u201cStill, the team believes their findings indicate that people should consider replacing saturated fatty acids in their diet with healthier fats from avocados and other sources. Kris-Etherton adds:\u201cWe need to focus on getting people to eat a heart-healthy diet that includes avocados and other nutrient-rich food sources of better fats.\u201d\u00a0However, other stories we reviewed about this study mentioned specific foods that are high in monounsaturated fats.\nMore importantly, given the ubiquity of statin drugs, we would have liked to have seen some comparison of the effects seen in this study with those attained via statin therapy. An independent expert could have easily provided that information, had the story consulted one.", "answer": 0}, {"article": "Is that a big difference?\nSo the new data may be the best that doctors and patients in this situation can expect for the foreseeable future.\nAnd while such a study is being done, the technology (especially stenting technology) changes.\nThey had blockages in either two or three coronary arteries but did not require emergency procedures.\nThat can call into question the ultimate relevance of the findings.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study itself was a comparison between two treatment paths, and the story explains that. A mention of drug treatment as an option would have been welcome.", "answer": 1}, {"article": "Plenary sessions feature the latest research on the use of and testing for cannabis, combating premature death due to preventable causes such as tobacco and alcohol, the development of an \"intelligent\" surgical knife, programmable bio-nano-chips, and the epigenetic causes of disease.\nTo verify the accuracy of the biochip test, 384 samples were analyzed and results compared to those from a standard molecular diagnostic test.\nThis test detects the presence of a protein in the blood produced by a specific variation of the apolipoprotein gene (ApoE4), which is associated with increased risk of developing Alzheimer's disease.\n\"Pairing this test with medical and family history for risk of Alzheimer's disease has the real potential to advance personalized medicine,\" said Harte.\nAs biochip tests allow clinicians and researchers to quickly run multiple tests on one sample of blood, this new test is also faster and more affordable than the standard DNA test, producing results in only three hours.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release makes it very clear that the new test was being compared with standard DNA testing.", "answer": 1}, {"article": "He presented the findings here at the annual meeting of the American Academy of Dermatology.\nResearchers used a ''microfocused\" ultrasound to target the sweat glands in 14 men and women, aged 18 to 75, says Mark Nestor, MD, PhD, a dermatologist and voluntary associate professor of dermatology at the University of Miami Miller School of Medicine.\n\"Microfocused ultrasound appears to be effective and safe in the treatment of hyperhidrosis,\" Nestor says.\nMarch 19, 2012 (San Diego) -- Ultrasound treatment can reduce excessive sweating in the underarms by nearly 80%, according to a new study.\nThe sweating can occur even when the temperature is cool and the person is at rest.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story added a list of other treatment alternatives at the end of the story.\u00a0 We wish it had also provided some comparison of effectiveness.\u00a0 Oddly, it listed the cost of a competing technology but not the cost of the ultrasound which was the focus of the story.\nBut most odd \u2013 and the reason we give this an unsatisfactory score \u2013 is that at the same dermatology meeting, data were presented on the use of a competing microwave device for hyperhidrosis \u2013 with longer term results and in more patients!", "answer": 0}, {"article": "Finzi notes previous studies show between 50 to 60 percent of patients may benefit from the treatment.\n\u201cI had less problems with depression.\u201d\n\nEven though the study she took part in is now over, she said she will continue to get Botox injections.\n\u201cWe don\u2019t believe it has anything to do with looks,\u201d says researcher Dr. Eric Finzi of Chevy Chase Cosmetic Center.\nCosts vary widely, but the American Society for Aesthetic Plastic Surgery said the average price for a Botox treatment in 2016 was $376.\n\u201cI found overall my mood was better on a day-to-day basis,\u201d she said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article\u00a0makes no comparison between botox and\u00a0current treatments for depression so we\u2019re left wondering: what does botox bring to the table? How do its benefits compare with medication? Does botox have fewer side effects?\u00a0Does it cost less than other therapies? All we get is anecdotal evidence from the one patient who had unsuccessfully \u201ctried alternative therapies and medication to cope with her symptoms.\u201d", "answer": 0}, {"article": "\u201cKangaroo mother care is care of preterm infants carried skin-to-skin with the mother.\n\u201cKangaroo mother care may change the behavior of less well-educated mothers by increasing their sensitivity to the needs of their children, thus making them equivalent to mothers in more favorable environments.\u201d\n\nTwenty million babies are born at a low birth weight every year around the globe, the World Health Organization reports.\nRelated: More U.S. Moms are Breastfeeding Their Babies\n\n\u201cThe effects of kangaroo mother care at one year on IQ and home environment were still present 20 years later in the most fragile individuals, and kangaroo mother care parents were more protective and nurturing,\u201d Dr. Nathalie Charpak and colleagues at the Kangaroo Foundation in Bogota, Colombia, wrote in their report.\nIts key features are: early, continuous and prolonged skin-to-skin contact between the mother and the baby; exclusive breastfeeding (ideally); it is initiated in hospital and can be continued at home; small babies can be discharged early; mothers at home require adequate support and follow-up,\u201d WHO said.\n\u201cIt is a gentle, effective method that avoids the agitation routinely experienced in a busy ward with preterm infants.\u201d\n\nAnd it\u2019s safe, WHO added.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The purpose of the study was to compare the KMC approach with a neonatal intensive care. There are no other viable alternatives to infant care that we know of.", "answer": 1}, {"article": "The biggest variable is patients themselves.\nIn the past, many doctors assumed implants would wear out in about 10 or 15 years, and they urged young patients to put off surgery as long as possible to minimize the risk of needing a costly and difficult revision surgery\u2014or even two.\n\"I was in the best shape of my life before I went in for the surgery,\" says Mr. Jeffries, the money manager, who trained twice a day for six months before his hip-resurfacing surgery in 2008.\n\"If your goal is a 30-year knee, you need to avoid high-impact sports,\" says John Wright, an orthopedic surgeon at Brigham and Women's Hospital in Boston.\n\"If you have a brand new sports car and leave it in the garage, it will last forever and you won't have any fun,\" says Thomas Schmalzried, an orthopedic surgeon at St. Vincent Medical Center in Los Angeles.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\nThe article did not discuss potential alternative treatments. This is a key question, since joint replacement has not traditionally been employed in this age group. Alternative therapies might include weight loss and other lifestyle interventions, exercise programs, activity modification, various medications, and other forms of surgery.\nThis is where the article could have been much tougher. Are these younger individuals exchanging short-term benefits for long-term problems with failed joint replacements? Some tough questioning of the patients would have been interesting. Were they even aware that they had other treatment options? Many individuals employ lifestyle changes and exercise to cope with knee problems for many years\u2014and preserve a reasonable quality of life. They might not experience the level of athletic performance demanded by the patients in this article. But in delaying joint replacement they may have better long-term treatment results.", "answer": 0}, {"article": "WASHINGTON (Reuters) - A new, longer-lasting \u201cmorning-after\u201d pill to prevent unwanted pregnancy appears to work with no unexpected side effects, U.S. health regulatory staff said in documents released on Tuesday.\nThe drugmaker has said its pill, also known by its chemical name ulipristal, works primarily by preventing ovulation of a woman\u2019s egg.\nAt the meeting, an FDA panel of outside experts will decide whether to recommend the agency approve the emergency contraceptive for the U.S. market.\nEfforts in 2001 to make it available without a prescription stirred fierce opposition from conservatives, and the bid stalled under the George W. Bush administration.\nBoth versions of Plan B, which are available over the counter for women at least 17 years of age, have only been proven to work for up to 72 hours after intercourse.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story mentions other emergency contraceptive options, it does not really describe the pluses and minuses of the new approach compared to the most important alternatives, Plan B or Mifeprex.1clip_filelist.xml\"/>1clip_themedata.thmx\"/>1clip_colorschememapping.xml\"/>\n\n\n\n", "answer": 0}, {"article": "For more information, visitwww.asmbs.org.\nThetreatment involves patients swallowing a capsule that quicklydissolves in the stomach to reveal a deflated gastric balloon inside.With a thin catheter attached to the device, but long enough toremain outside the patient\u2019s mouth, a physician fills the balloonwith fluid (550 mL) to about the size of a grapefruit.\n\u201cFor many struggling with theirweight, procedureless gastric balloon devices may serve as atreatment option that bridges the gap between weight-loss drugs andsurgery.\u201d\n\nTheU.S.\n\u201cOur findings demonstrate that Elipseprovides individuals and their caregivers with a safe, effective, andnon-invasive weight loss intervention that does not require surgery,endoscopy, or anesthesia.\u201d\n\nResearcherspresented interim results for the first 34 patients of a multi-centerstudy that showed individuals lost an average of 22 pounds after fourmonths or 37 percent of their excess weight.\nInaddition to Dr. Chuttani, study authors of the abstract entitled,\u201cThe First Procedureless Gastric Balloon: A Prospective StudyEvaluating Safety, Weight Loss, Metabolic Parameters and Quality ofLife,\u201d include, Evzen Machytka MD, PhD, Martina Bojkova MD, TomasKupka MD, and Marek Buzga MSc, PhD from the University of Ostrava,Ioannis Raftopoulos MD, Andreas Giannakou MD, and Kandiliotis IoannisMD from the Iatriko Medical Center, and Kathy Stecco MD, Samuel LevyMD, and Shantanu Gaur MD, from Allurion Technologies.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release makes several mentions of alternative therapies including traditional gastric balloon surgery, other newly approved gastric balloon devices, bariatric surgery, weight-loss drugs and diet and exercise.\nThe release also suggests the gastric balloon pill would be an option filling a treatment gap between weight-loss drugs and surgery.\nWhile the release doesn\u2019t offer data on how the gastric balloon pill compared with all these alternative methods, we\u2019ll give it a pass for the frequent mentions of alternatives.", "answer": 1}, {"article": "What if you could lose weight and reduce your risk of life-threatening disease without any changes in what you eat -- other than a five-day special diet once every few months?\nThe next step for researchers is a large, FDA phase III clinical trial to test the FMD on patients diagnosed with age-related diseases or at high risk for them.\nThe diet, which was designed to mimic the results of a water-only fast, allowed for participants to consume between 750 and 1,100 calories per day.\nThe researchers also noted that participants considered \"at risk\" because they had risk factors such as high IGF-1, cholesterol, blood pressure or blood sugar levels, made significant progress toward better health.\nThe diet reduced cardiovascular risk factors including blood pressure, signs of inflammation (measured by C-reactive protein levels), as well as fasting glucose and reduced levels of IGF-1, a hormone that affects metabolism.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not include any discussion on how people can manage long-term health risks through many other kinds of diets, exercise or medications to lower blood pressure. Even one line on such alternatives would have satisfied this criterion.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Monitoring high-risk pregnancies with ultrasound tests may help prevent some fetal and newborn deaths, a new research review finds.\nIn some cases, early delivery may be the best course, but it is unclear whether other options \u2014 such as bed rest or tighter blood pressure control in a woman with high blood pressure \u2014 are effective.\nSome had flaws in their design, while in other cases the researchers failed to provide details on key elements of the study design.\nIn practice, Doppler ultrasound may also be recommended for women who have diabetes or are having a prolonged pregnancy (beyond 42 weeks).\nAbnormal findings indicate that the fetus may be under stress.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n \nThe story says other types of testing, including electronic fetal-heart monitoring, may also be done during high-risk pregnancies. \n", "answer": 1}, {"article": "Seventy-four subjects with type 2 diabetes were randomly assigned to follow either a vegetarian diet or a conventional anti-diabetic diet.\nThe vegetarian diet was found to be almost twice as effective in reducing body weight, resulting in an average loss of 6.2kg compared to 3.2kg for the conventional diet.\nThe vegetarian diet consisted of vegetables, grains, legumes, fruits and nuts, with animal products limited to a maximum of one portion of low-fat yoghurt per day; the conventional diabetic diet followed the official recommendations of the European Association for the Study of Diabetes (EASD).\nThis is important as increased subfascial fat in patients with type 2 diabetes has been associated with insulin resistance, so reducing it could have a beneficial effect on glucose metabolism.\nDr. Kahleov\u00e1 said: \"Vegetarian diets proved to be the most effective diets for weight loss.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does mention one alternative to the vegetarian diet \u2014 the\u00a0anti-diabetic conventional diet which\u00a0adheres to\u00a0official recommendations of the European Association for the Study of Diabetes.\u00a0 ", "answer": 1}, {"article": "Timothy Hardy, Mujdat Zeybel, Christopher P. Day, Christian Dipper, Steven Masson, Stuart McPherson, Elsbeth Henderson, Dina Tiniakos, Steve White, Jeremy French, Derek A. Mann, Quentin M. Anstee and Jelena Mann.\nCirrhosis - the most severe stage, occurring after years of inflammation, where the liver shrinks and becomes scarred and lumpy; this damage is permanent and can lead to liver failure (where the liver stops working properly) and liver cancer\n\nIt can take years for fibrosis or cirrhosis to develop and the presence of this scarring predicts those people with the worse prognosis.\nIt is the first time an epigenetic signature in blood has been discovered which is diagnostic of the severity of fibrosis for people with Non-alcoholic Fatty Liver Disease (NAFLD).\nSteatosis (\"fatty liver\") - a build-up of fat in the liver cells that is often picked up as an incidental finding during tests carried out for another reason \n\n2.\nSenior author Dr Jelena Mann of Newcastle University's Institute for Cellular Medicine added: \"This is the first time that a DNA methylation 'signature' from the blood has been shown to match the severity of a liver disease.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release discusses the new technique and liver biopsies. It doesn\u2019t discuss other techniques, such as the use of MREs or other noninvasive diagnostics (like those discussed here or here or here). How does the proof-of-concept approach discussed in this news release compare to any of these other techniques? It\u2019s not clear.\nImaging tests including ultrasound, CT and MRI can detect fatty changes in the liver, although not necessarily fibrosis. The NAFLD fibrosis score used by the investigators as a comparison test is probably the most useful for detecting fibrosis.", "answer": 0}, {"article": "While the proton therapy market is expected to more than double by 2018, with an estimated 300 proton therapy rooms, Jongen's Brussels-based company IBA is working on a smaller and cheaper model they hope will make proton therapy more accessible.\n\"There are a number of cancers which are not localized,\" he said.\n\"It would be much less expensive making it more possible for a hospital to afford it -- a smaller system can already treat a relatively large number of patients per year.\"\nAt the moment, fewer than 1% of cancer patients are treated with proton therapy, but Jongen is hopeful that smaller and cheaper machines will be the game changer.\nOnce the proton beam has been generated, it's piped into a treatment room where patients receive a powerful dose of targeted radiation that kills only those cancerous cells.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Let\u2019s take a look a the alternatives mentioned:\nThere is no mention of other forms of targeted radiation therapy and importantly, their relative merit in cancer treatment as compared to proton beam therapy.", "answer": 0}, {"article": "(Reuters) - Merck & Co\u2019s blockbuster drug Keytruda met the main goal of a late-stage trial testing the treatment in patients with cancers of the digestive tract, the U.S. drugmaker said on Wednesday.\n\u201cThis marks the sixth tumor type where Keytruda has demonstrated a survival benefit, and represents the first time an anti-PD-1 therapy has achieved overall survival for this patient population,\u201d said Roy Baynes, chief medical officer of Merck Research Laboratories.\nKeytruda, among a class of medicines called PD-1 inhibitors, is Merck\u2019s top selling drug and has already been approved to treat several forms of cancer including skin and lung cancer.\nEsophageal cancer is the seventh most commonly diagnosed cancer in the world, the company said.\nKeytruda, when compared to chemotherapy, enabled certain patients with esophageal cancer to live longer, helping the drug meet the main goal of the late-stage study, Merck said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story simply stated that \u201cKeytruda, when compared to chemotherapy, enabled certain patients to live longer.\u201d \u00a0No basis for that comparison was provided.\nA review of this class of drugs pointed out that another PD-1 inhibitor, Bristol-Myers Squibb\u2019s Opdivo (nivolumab), has also shown to improve survival (albeit marginally) in gastric cancers.\nIn addition, Endpoints News noted that another PD-1 drug is being tested by Celgene and BeiGene to treat esophageal and esophagogastric cancers.", "answer": 0}, {"article": "For more information or to obtain a PDF of any study, please contact:\n\nDawn Peters (US) +1 781-388-8408 \n\nsciencenewsroom@wiley.com \n\nFollow us on Twitter @WileyNews\n\nFull Citation: \"Dietary Isoflavone Intake and All-Cause Mortality in Breast Cancer Survivors: the Breast Cancer Family Registry.\"\n\"Whether lifestyle factors can improve survival after diagnosis is an important question for women diagnosed with this more aggressive type of breast cancer.\nFor more than 200 years, we have delivered consistent performance to our stakeholders.\n\"Because of this disparity, it remains unknown whether isoflavone consumption should be encouraged or avoided for breast cancer patients.\"\nA free abstract of this article will be available via the Cancer News Room upon online publication.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There other dietary and lifestyle factors that affect cancer risk and survival. The release doesn\u2019t mention any of them.", "answer": 0}, {"article": "A new study raised questions about the benefits of a relatively common procedure for heart patients\u2014implanting tiny devices that prop open clogged arteries to relieve chest pain.\n\nThe 200-patient study conducted by U.K. researchers found that patients with stable chest pain, or angina, who received stent devices experienced no significant improvement in exercise time on a treadmill, compared with similar patients who received no stents during sham procedures.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story, in describing the study, makes clear that management of angina pain with medication is equally effective in these kinds of patients.", "answer": 1}, {"article": "Until more research is in, what should a woman with a personal history of breast cancer do?\nCurrently, the American Cancer Society recommends annual breast MRI plus mammography for women at very high risk for breast cancer, such as those with a known genetic mutation known as BRCA or those with a very strong family history.\nStudying the effectiveness of MRI screening on all three groups of women, Dr. Wendy DeMartini, an assistant professor of radiology at the University of Washington Medical School, said MRI imaging found proportionally more cancers in women who had been treated for breast cancer than in the women considered at very high risk.\n\"There are some tumors that don't show up on mammography as well as they do on MRI,\" he explained.\nWhile the society recommends neither for nor against MRI imaging for those with a personal history of breast cancer, he said it regularly reviews study findings to determine if the guidelines need updating.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nAlthough the story does say that MRI scanning would be used in conjunction with conventional mammography, it does not include any discussion of the relative merits. Indeed, the study did not appear to include any comparison of MRI scans to conventional mammography that would provide any insight to whether the combination of scanning methods might be superior to conventional mammography alone.\n", "answer": 0}, {"article": "After replacement surgery and months of physical therapy, patients can lift no more than 15 or 20 pounds, he said.\n\"The last time I had an injection in my wrist, it was so painful, I thought I was going to have to pull over coming home and have someone else come and drive,\" she recalled.\n\"The cost is that you don't have the ability to lift heavy objects,\" Collins said.\nMore than a dozen bones lie beneath the skin and muscles of the hand and wrist, compared with two or three for those larger joints.\n\"Some of the newer implant designs save a lot of the bone stock,\" said Collins, who performs about 10 wrist replacements a year.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article outlines some alternatives to wrist replacement surgery (e.g. medications, physical therapy, and fusion)\u2014and briefly sketches their advantages and disadvantages. There are other surgical treatments for wrist arthritis as well, though the evidence to support them is also sparse.", "answer": 1}, {"article": "Acupuncture designed to treat depression appears to improve symptoms in pregnant women, suggesting it as an alternative to antidepressant medication during pregnancy, a study found.\n\nThe study, published Monday in the journal Obstetrics & Gynecology, is the largest to date examining the effectiveness of acupuncture to treat depression in pregnant women. It was funded by a grant from the government's Agency for Healthcare Research and Quality. \"Acupuncture that we have tested works for pregnant, depressed women,\"...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions other established, safe and effective treatments for depression such as psychotherapy and antidepressant medications.", "answer": 1}, {"article": "Clinical trials are needed to investigate whether these beverages do indeed help prevent diabetes, the researchers say.\nIf the benefits turn out to be real, they add, health care providers might begin advising patients at risk for diabetes not only to exercise and lose weight, but to drink more tea and coffee, too.\nThe current analysis could have overestimated the effect of these beverages on diabetes risk due to statistical issues with the smaller studies, Huxley and her colleagues note.\nIn the years since then, they add, the amount of research on coffee and diabetes risk \u201chas more than doubled,\u201d while other studies have suggested that tea and decaf coffee may also be preventive.\nIt\u2019s also not possible to say from the current evidence that heavy coffee drinkers (and tea and decaf drinkers) don\u2019t have other characteristics that might protect them against developing diabetes, they add, such as eating a healthier diet.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0While the last line of the story mentioned exercise and diet, there was no context for readers to evaluate how coffee and tea consumption compared to these strategies for reducing the chance of developing type II diabetes.", "answer": 0}, {"article": "They also put tested at against petroleum jelly and regular moisturizer on 22 people with dry, flaky legs.\nThe cream\u2019s effects are detailed in a scientific report in the journal Nature Materials, but as part of the school\u2019s close association with the companies, it\u2019s being patented and produced at almost the same time.\n\u201cFor now, there is no magical cream that can make you look younger.\u201d\n\nOlivo will work first to develop the product to deliver drugs to the skin \u2013perhaps allergy or eczema medication, or long-lasting sunscreen, MIT said.\nA team at the Massachusetts Institute of Technology has developed the cream and licensed it to two companies with close ties to the lab \u2014 one called Living Proof, best known for spinning out MIT inventions to the hair care market, and a second one called Olivo Labs, which will develop it for medical uses, perhaps to deliver drugs to the skin.\n\u201cRubber alone would not be that strong.\u201d\n\nIn this case, the catalyst is platinum-based and it turns the gel into a thin, stretchy sheet.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll give a Satisfactory in this category since the story states that the problem of undereye bags\u2013which the story seems to focus on\u2013is normally addressed by surgery, and clearly a topical product is preferable to an invasive approach. \u00a0Another obvious alternative, with no risks or costs, is\u00a0leaving the normally aging skin alone, but that\u2019s not discussed.", "answer": 1}, {"article": "Gonzalez said the new trial addressed a serious medical need.\nThe trial, led by Nestor R. Gonzalez, MD, professor of Neurosurgery and director of the Neurovascular Laboratory at Cedars-Sinai, enrolled 52 patients with severe brain atherosclerosis, also known as intracranial atherosclerotic disease, or ICAD, who showed symptoms of either a recent stroke or a mini-stroke, called a transient ischemic attack.\n\"This clinical trial moves us significantly closer to preventing strokes and death in high-risk populations,\" said Keith Black, MD, professor and chair of the Department of Neurosurgery.\n\"Even under the best current treatments, ICAD carries high rates of recurrent stroke and death, compared with other causes of stroke,\" he said.\nLOS ANGELES (Embargoed Until Oct. 18, 2018 @ 10:05AM ET) -- A surgical technique called EDAS (encephaloduroarteriosynangiosis) significantly decreases the rate of stroke recurrence and death for patients with severe atherosclerosis of the brain arteries, according to findings of a Phase IIa clinical trial presented today at the World Stroke Congress in Montreal.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release covers alternatives to the EDAS surgery with the following:\u00a0 \u201cCurrent ICAD therapies \u2014 in addition to intensive medical management \u2014 include bypass surgery to connect a blood vessel from outside the brain to a vessel inside the brain, as well as angioplasty with stenting, which involves inflating a tiny balloon inside a cerebral artery to open it up and placing a stent device inside the artery. Despite advances in medical care, annual rates of recurrent stroke and death remain high, at 15 percent or more for ICAD patients, according to published research.\u201d\nSince the therapy was compared to intensive medical therapy\u00a0only, it is not clear how this procedure compares to other vascular surgical therapies (such as bypass surgery or angioplasty with stenting, both named in the release).\u00a0 If 52 patients with 9.6% recurrent stroke (5 patients) were compared to 52 hypothetical patients with a 15% recurrent stroke rate (8 patients), the results would\u00a0not be statistically significant and would have a significantly high likelihood that they occurred by chance alone. This kind of statistics manipulation can mislead readers into believing there is a big difference between this new therapy and older vascular surgical therapies.", "answer": 1}, {"article": "Surgery isn't the answer for all older lung cancer patients, according to Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society.\nLike many patients his age, he didn't expect there would be any effective treatment.\nSo they are referred for supportive care to control symptoms, rather than surgery to remove the cancer.\nOne year after surgery, more people had died from other causes than died from lung cancer.\nPatients with heart or other health problems may not be candidates.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "For early stage lung cancer elderly patients who may be presented with a spectrum of choices from surgery to hospice, the article provides little evidence-based advice.", "answer": 0}, {"article": "Researchers from Nemours and UCF found that nanoparticles can be used to deliver curcumin to tumor sites.\n\"This shows that nanoparticles can be an effective delivery vehicle for cancer drugs,\" said Professor Sudipta Seal, who directs of UCF's NanoScience Technology Center and Advanced Materials Processing Analysis Center, and is a collaborator on the study.\nThis research demonstrates a novel method of treating this tumor without the toxicity of aggressive therapy that can also have late effects on the patient's health,\" said Tamarah J. Westmoreland, MD, PhD, a pediatric surgeon at Nemours Children's Health System and senior author of the study.\nAttaching curcumin, a component of the common spice turmeric, to nanoparticles can be used to target and destroy treatment-resistant neuroblastoma tumor cells, according to a new study published in Nanoscale.\nThe study, conducted in partnership by researchers at Nemours Children's Hospital and the University of Central Florida, demonstrates a potentially novel treatment for neuroblastoma, the most common cancer in infants.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does not discuss any existing alternatives to treat neuroblastoma. Conventional therapy includes chemotherapy for those with advanced-stage neuroblastoma. Commonly used agents include cisplatin, doxorubicin, cyclophosphamide and epipodophyllotoxins. For those with early-stage neuroblastoma, surgery is often an option.\nSome patients are also given adrenocortical hormone to treat their symptoms.\nWe give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": "The game, \u201cWizard\u201d, is designed to help so-called episodic memory \u2014 the type of memory needed to remember where you left your keys several hours ago, or to remember a few hours later where you parked your car in a multi-storey car park.\n\u201cWe need a way of treating the cognitive symptoms of schizophrenia, such as problems with episodic memory, but slow progress is being made toward developing a drug treatment,\u201d said Barbara Sahakian from the department of psychiatry at Cambridge University.\nThis study, published in the journal Philosophical Transactions of the Royal Society B, found that 22 patients who played the memory game made significantly fewer errors and needed significantly fewer attempts to remember the location of different patterns specific tests.\nThere is increasing evidence that computer-assisted training can help people with schizophrenia overcome some of their symptoms, with better outcomes in their daily lives.\nImportantly, the patients also said they enjoyed the game and were motivated to play it across the eight hours of cognitive training.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says \u201cThere is increasing evidence that computer-assisted training can help people with schizophrenia overcome some of their symptoms,\u201d but doesn\u2019t tell us which symptoms or which types of training are relevant. The story also doesn\u2019t tell readers whether there are other possible pharmaceutical, lifestyle, or cognitive training interventions that may help schizophrenia patients retain or improve episodic memory. Indeed, other computer systems are being explored as well as stimulation of brain regions using electro-magnetic fields. And options being used in clinical practice\u00a0are skills training explained on the National Alliance on Mental Illness\u00a0website.", "answer": 0}, {"article": "nutritional guidelines, which I\u2019ve discussed before, says that coffee is not only O.K.\nIf any other modifiable risk factor had these kind of positive associations across the board, the media would be all over it.\nMost of us are worrying that it might be hurting us.\nI\u2019m not suggesting that we start serving coffee to little kids.\n\u2014 it agrees that it might be good for you.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Not really applicable in this setting, though tea research might have been used as a comparison.", "answer": 2}, {"article": "The folks who carried out this egg industry-funded research were from the Pennington Biomedical Research Center in Baton Rouge, La.\nThis place conducts some serious research on diet and weight.\nThey could have just asked people if they liked eating eggs for breakfast.\nInstead, they recruited 20 volunteers who were overweight or obese and assigned them to a week of either egg breakfasts or ready-to-eat cereal breakfasts.\nBoth types of breakfasts had the same number of calories, but the egg breakfasts contained \u201chigher protein quality,\u201d according to an abstract for the study, posted online here.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Even a sentence about the effectiveness of other weight loss approaches, such as behavioral weight loss programs, would have been enough to satisfy this criterion.", "answer": 0}, {"article": "Kris-Etherton and colleagues did an intensive study with 45 typical Americans \u2013 all overweight or obese, but with healthy cholesterol and blood pressure levels.\nSo that was the only difference between the two diets, which then tells us that it's the avocado that has additional benefits which are beyond the unsaturated fat.\u201d\n\nThe findings are similar to a batch of studies that showed people who were given olive oil and nuts and told to add them to their diets ended up healthier.\n\u201cI love guacamole and with my recipe, I'll use avocados, cilantro, lime juice and garlic... and then sometimes I'll put salsa in, or red pepper flakes.\u201d\n\nBut like anything, too much of a good thing can be harmful.\n\u201cIn the past, we used to substitute carbohydrate for saturated fat, and that would result in a low-fat diet,\u201d said Penny Kris-Etherton, chair of the American Heart Association\u2019s Nutrition Committee and distinguished professor of nutrition at Pennsylvania State University.\nSaturated fat \u2013 the kind found in meat and butter \u2013 has a different chemical structure from the unsaturated fats found in plant products.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes it clear that there are multiple ways that people can change their diet to improve cardiovascular health \u2014 avocados are not the only way to go. For example, the story points to studies which found that consuming other foods high in monounsaturated fatty acids (such as olive oil) were linked to reduced risk of heart disease and stroke. The story also notes that saturated fats increase heart disease risk. Ergo, another way to reduce risk is to lower consumption of meat and butter, rather than eating avocados. The story does not mention additional ways to lower LDL cholesterol, such as taking statin drugs, increasing exercise, quitting smoking, or limiting alcohol intake.", "answer": 1}, {"article": "The National Marrow Donor Program has more on Wiskott-Aldrich syndrome.\n\"This is a very good first step, but it's a little scary and we need to move to safer vectors,\" said Dr. Mary Ellen Conley, director of the Program in Genetic Immunodeficiencies at St. Jude Children's Research Hospital in Memphis, Tenn.\n\n\"The study shows proof-of-principle that gene therapy with stem cells in a genetic disorder like this has strong potential,\" added Paul Sanberg, a stem cell specialist who is director of the University of South Florida Center of Excellence for Aging and Brain Repair in Tampa.\n\"One of the long-lasting complications is the kids couldn't do this, they couldn't do that, they see themselves as different,\" Conley said.\nIn this study, the researchers inserted a healthy gene capable of producing WAS protein into hematopoietic stem cells (the \"granddaddy\" cells that give rise to different blood cells), then transferred these stem cells back into the patient using a viral vector.\n\"This is a first step that says you can correct the disease but I think most people would look at it and say the risk of leukemia is something, and that, let's see if we can avoid that,\" said Conley, whose team at St. Jude is working on a therapy involving a different type of vector.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u00a0discusses one of the primary\u00a0existing treatments for\u00a0Wiskott-Aldrich syndrome: bone marrow transplants.\u00a0The story\u2019s muddled overview\u00a0of this treatment is likely to leave readers confused, however. The story starts off its description by\u00a0saying that such\u00a0transplants, if they succeed, \u201cbasically cure the\u00a0disease.\u201d\u00a0It then goes on to list a number of\u00a0serious complications that can\u00a0plague even apparently successful\u00a0transplants. So the children\u00a0treated via transplant\u00a0sound like they probably aren\u2019t \u201ccured\u201d\u00a0as the story initially states. We\u2019ll call it satisfactory, but we wish the story was a bit clearer on this point.", "answer": 1}, {"article": "\u201cWomen will know pretty quickly if acupuncture will work for them.\nWomen who had a reduction in their hot flashes saw a benefit beginning after about three to four weeks of weekly treatments.\u201d\n\nThe National Institutes of Health-funded study was designed to examine different patterns of responses to acupuncture.\n\u201cWe had hoped to identify some of the characteristics of the women who benefitted from acupuncture, but like so many treatments, we could not really tell ahead of time who would benefit,\u201d Avis said.\n\u201cWomen bothered by hot flashes and night sweats may want to give acupuncture a try as a relatively low-cost, low-risk treatment,\u201d said Nancy Avis, Ph.D., lead author of the study and professor of Public Health Sciences at Wake Forest School of Medicine, a part of Wake Forest Baptist.\nHowever, 37 percent showed only a minimal reduction of 9.6 percent in frequency of hot flashes, while 4 percent reported a 100 percent increase in hot flashes.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are a number of pharmaceutical options that are used to provide patients with some relief from hot flashes, and these are not mentioned at all. A release needs to note what a given treatment option (acupuncture in this case) brings to the table that other treatment options do not. How is it different? How might it be better? Or worse? That sort of context is invaluable for readers.", "answer": 0}, {"article": "The study found none.\nIn the new study, Ellen Freeman of the University of Pennsylvania School of Medicine in Philadelphia and colleagues gave 205 women who were either starting to go through menopause who had already gone through menopause either Lexapro or a placebo for eight weeks.\nThe number of hot flashes among the women taking Lexapro, which is also known as escitalopram, dropped to about five on average after eight weeks--a 47 percent decrease or about 4.6 fewer hot flashes per day, the researchers reported.\nBut hormone use plummeted after the federal government's massive Women's Health Initiative shocked women and doctors by concluding the risks of the medication outweighed its benefits.\nAlthough the benefit was modest, it appeared to be significant enough that women might consider trying it, the researchers said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story mentions hormone replacement, it gives readers the impression that this approach is no longer used for the treatment of hot flashes because the risks outweigh the benefits. In fact,\u00a0women with more bothersome menopausal symptoms may still use\u00a0hormones for short-term relief, concluding that the benefits for them individually still outweigh the risks. This story should have spent some more time putting the benefits and risks of antidepressants in context with those of hormone replacement. Also, many women try complementary and alternative medicine treatments.", "answer": 0}, {"article": "The signature was found in the cerebrospinal fluid (CSF) of 90% of people with a diagnosis of Alzheimer's disease and 72% of people with mild cognitive impairment (MCI) -- a disorder that often progresses to Alzheimer's.\nLow levels of the amyloid protein amyloid-beta 1-42, along with high levels of total tau and elevated phospho tau 181 (P-tau 181), identified Alzheimer's disease in three independent study groups, Hugo Vanderstichele, PhD, of the Belgian biotech company Innogenetics, tells WebMD.\nAug. 9, 2010 -- Researchers have identified a protein \"signature\" in the spinal fluid of patients with Alzheimer's disease, which could represent an important advance in its diagnosis.\nIn one study, this protein signature was also seen in spinal fluid samples from all patients with mild cognitive impairment who progressed to Alzheimer's disease within five years.\n\"Using this approach, which was totally independent of diagnosis, we were able to identify patients with Alzheimer's disease,\" Vanderstichele says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story does not tell readers either that other researchers are working on similar tests that use spinal fluid or that brain scans are also being developed that may be able to detect changes associated with Alzheimer\u2019s Disease.", "answer": 0}, {"article": "He agreed that quicker diagnosis could mean better treatment and outcomes for patients.\nCurrently, it's recommended that a blood test focused on elevated fasting levels of blood sugar (glucose) or a blood component called glycated hemoglobin (HbA1c) be confirmed with a second blood test at a follow-up visit.\n\"By diagnosing diabetes quicker, we can improve outcomes,\" said Courgi, an endocrinologist at Northwell Health's Southside Hospital in Bay Shore, N.Y. \"The current standard is to delay diagnosis with repeat office visits and blood work.\n\"It's just that the guidelines don't clearly let you use the tests from that one blood sample to make the initial diabetes diagnosis,\" she explained.\n\"I'm hoping that these results will lead to a change in the clinical guidelines when they are revised in early 2019, which could make identifying diabetes a lot more efficient in many cases,\" Selvin said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story made it clear that doing tests one at a time is called for in the current guideline.\nBut the story doesn\u2019t mention the fasting plasma glucose test and the oral glucose tolerance test, which along with the glucose blood test, can be used if A1C test results aren\u2019t consistent, the A1C test isn\u2019t available, or you have a condition such as pregnancy that might render the A1C test inaccurate.", "answer": 0}, {"article": "Article reference: R.M.\nThis study suggests that IV fluids could help women maintain hydration at appropriate levels, reduce the likelihood of c-section, and decrease length of labor,\" says Dr. Berghella.\nThe higher fluid rate also reduced the overall time of labor by an average of 64 minutes, and shortened the pushing phase by nearly 3 minutes, on average.\nOf those, about half (or 593 women) received IV fluids at a rate of 250 milliliters per hour, and the other half (622 women) received fluids at the lower rate of 125 milliliters per hour.\nWomen getting the faster fluid rate (250 milliliters per hour) were less likely to get a cesarean section.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The analysis compared increased levels of hydration during labor with levels used in \u201cgeneral practice in the United States.\u201d That\u2019s explained in the release.", "answer": 1}, {"article": "Iron is essential to the developing brain, he said, and deficiencies during early months \u2014 perhaps linked to early clamping \u2014 could affect nerve and muscle control, making it harder for the child to later control a pen or interact comfortably with peers.\nThen, moments after birth, that cord is severed.\nFor nine months, the developing fetus is attached to its mother by the umbilical cord.\nBabies who are anemic often appear tired and pale.\nCutting the cord is a momentous event in a baby's life.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There\u2019s either early or late clamping, and the article describes both methods", "answer": 1}, {"article": "But some pain experts defend the value of the diagnostic tests.\nPatients don't care much about the finer points of diagnostic accuracy.\nSkipping the diagnostic nerve blocks can save $10,000 in medical costs.\nCoping with an aching back isn't easy.\nOf about 150 patients, the group that got radiofrequency treatment immediately had more people who felt better.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No discussion of alternatives \u2013 not for diagnostic testing nor for treatment of the underlying back pain. ", "answer": 0}, {"article": "Israel is director of the respiratory therapy department at Brigham and Women's Hospital in Boston.\nTwo generic versions of the drug were launched last year, which could make it less pricey than new-wave asthma drugs headed for the market, Israel added.\nOne person dropped out because of a sharp decline in white blood cells, which bounced back after the drug was discontinued.\n\"It will take years of study to determine the usefulness of this drug in treatment.\"\nIf proven effective, Gleevec might provide a relatively inexpensive new treatment for asthma patients.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We would have liked to see more discussion of the options for treating severe asthma besides the story\u2019s fleeting mention of \u201cnew-wave asthma drugs headed for the market.\u201d", "answer": 0}, {"article": "NEW YORK (Reuters Health) - A fresh look at the medical evidence shows women who eat more fiber are less likely to get breast cancer.\nOf more than 710,000 women, 2.4 percent ended up with breast cancer.\nAnd those in the top fifth of fiber intake were 11 percent less likely to do so than women in the bottom fifth.\nIf it turns out to cut cancer risk as well, that would be an extra bonus, Clarke said.\nFruits, vegetables, beans, and whole grains are all high in fiber.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did touch on other risk factors:\u00a0 \u201calcohol drinking, weight, hormone replacement therapy and family history\u201d", "answer": 1}, {"article": "Doctors who have turned surgery into a popular treatment for obesity are setting their sights on a burgeoning new market: diabetes patients.\n\nA growing amount of research suggests that bariatric surgery, which shrinks the stomach and sometimes reroutes the intestines, has a lasting effect on the most common form of diabetes, and not just because patients lose weight. Studies have found that more than 75% of patients with this type of diabetes who undergo the surgery see their disease disappear. They can go on to live diabetes-free...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article\u00a0would have been stronger if it had\u00a0described\u00a0the range of treatments for Type 2 now in use,\u00a0from diet and exercise to medications and insulin. This would have helped readers understand the choices diabetics face\u2013a challenging lifetime regimen that is not always successful, or a somewhat risky surgery that might provide permanent relief.\u00a0\u00a0\u00a0", "answer": 0}, {"article": "Adding small amounts of powdered ginger to food may help take the edge off seasonal allergy symptoms, according to an animal study published online in the Journal of Nutritional Biochemistry. Daily intake of dried ginger significantly reduced sneezing and other signs of allergy in rodents with induced allergic rhinitis, or hay fever.\n\nA major component in ginger, 6-gingerol, suppresses the activation of T lymphocytes, or T cells, a type of white blood cell that plays an important role in sensitizing people to specific allergens,...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not talk about existing ways to reduce symptoms of allergies. One could argue that such discussion would be propagating the idea the study might apply to humans \u2014 not necessarily a good thing. But then again, the whole underlying point of the story is that there\u2019s some relevance here to people. On balance, we\u2019d rather see the story include this information, which might be more useful for readers than the sneezing rates of mice anyway.", "answer": 0}, {"article": "Millions of Americans suffer from pet allergies that prevent them from enjoying the benefits of owning a dog or a cat.\n\u201cBut now I don\u2019t really feel allergy symptoms anymore.\u201d\n\nTo find a prescribing doctor for Allerdent in your area or to find more information, visit Allovate.com.\n\u201cThe patients who came in were treated for the very things that they were sensitive to, and that included indoor allergens, like dustmite and pet dander, as well as outdoor allergens such as tree pollen, grass pollen, ragweed pollen,\u201d Dr. William Reisacher, an associate professor of otolaryngology and director of allergy services at Weill Cornell Medicine/New York-Presbyterian Hospital, told FoxNews.com.\nI was really uncomfortable and miserable.\u201d\n\nJoyce tried over-the-counter medications but couldn\u2019t find relief.\nThe toothpaste, called Allerdent, works to keep breath fresh and fight cavities while also offering the same benefits as an allergy shot or drops.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that normal treatments incorporate shots or drops of allergen extracts as a way of sensitizing patients.It also mentions medications.\nWe\u2019ll award a minimal Satisfactory on that basis, but we\u2019d note that it\u2019s not clear how long the participants used the toothpaste before they started to see a decrease in their symptoms. Usually allergy medication works anywhere from 30 minutes to a few hours to a few days. We saw no comparison on this factor between the toothpaste and regular allergy medication.", "answer": 1}, {"article": "It left some doctors at the conference incredulous and uncertain how to treat their patients.\nThe fact that this uncertainty is occurring so long after the 1998 approval of Herceptin \u2014 the paragon of \u201cpersonalized medicine\u201d \u2014 suggests that it will not be so easy to tailor other drugs to patients based on gene or protein tests.\nDr. Soonmyung Paik, who presented the second study at the cancer conference, said the problem might lie not in sloppy testing but rather in the cutoff used to determine which women get Herceptin.\n\u201cTo me, the take-home message is that we don\u2019t have a perfect test, unfortunately,\u201d Dr. Paik said.\nDr. Paik, who is with the National Surgical Adjuvant Breast and Bowel Project, said that about 40 percent of women had intermediate levels of Her2.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions Herceptin as a promising drug in the arsenal of breast cancer treatments; however, the story does not mention that Herceptin is given along with chemotherapy.\u00a0 We are also not told that women take Herceptin by infusion (IV), sometimes for up to a year.\u00a0 This may be play into the cost/benefit decision-making process of whether to retest formerly Her2/neu negative women, or whether it makes sense for Her2/neu women to now take the drug. ", "answer": 0}, {"article": "The U.S. Centers for Disease Control and Prevention has more about healthy eating for a healthy weight.\nWhen it comes to speedy weight loss, the HMR program and Biggest Loser diet shared the top ranking, followed by the Atkins diet in second place and Weight Watchers in third.\nOn the opposite end of the list, the Whole30 diet -- a 30-day program that bans processed foods, legumes, grains, dairy, alcohol and added sugar -- ranked as the worst overall diet on the list, the new report said.\nThe MIND diet ranked first in the \"Easiest Diet to Follow\" category in a three-way tie with Weight Watchers and the Fertility diet, which asserts that certain dietary changes can boost fertility.\nThe panel of experts -- including nutritionists and doctors specializing in diabetes, heart health and weight loss -- scored each diet for short-term and long-term weight loss.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story (and the release it\u2019s based on) focus on the comparative rankings of different diets. Besides DASH, the MIND Diet, Mediterranean Diet, Fertility Diet, Biggest Loser, Weight Watchers and Atkins Diet are also very briefly compared and contrasted in different categories including weight loss, ease of following, safety and nutritional value.\nThe original news release does provide ranking numbers which could have improved our understanding of the comparisons.", "answer": 1}, {"article": "And 90 percent reported satisfaction with the device overall.\nThe SYNCHRONY EAS implant best assists people whose hearing loss is referred to as \u201cski-slope\u201d hearing loss, based on the steeply sloping image that appears on an audiogram when a patient has more trouble hearing higher-frequency sounds.\nBut a hearing implant system that just received FDA approval will now meet that previously unmet need and benefit those patients, according to Harold C. Pillsbury, MD, chair of the Department of Otolaryngology/Head and Neck Surgery at the UNC School of Medicine.\nThe EAS System FDA approval is for candidates who are 18 years old and older who have normal to moderate sensorineural hearing loss in the low frequencies, sloping to a severe-to-profound hearing loss in the high frequencies.\n\u201cThe technology is remarkable and so were the results.\u201d\n\nThe implant relies on two auditory technologies \u2013 the SYNCHRONY cochlear implant that stimulates the auditory nerve for high-frequency hearing loss and the EAS audio processor, which has a built-in acoustic amplification for low-frequency hearing loss.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Although the release makes some distinction between the type of hearing loss most likely to benefit from this FDA approved device; and it explains in some detail how the device is an improvement over other cochlear implants, it isn\u2019t clear about the overlapping benefits of newer digital hearing aids and the implants for people in the \u201cmoderate\u201d sensorineural hearing loss category.", "answer": 0}, {"article": "If there really was such a big difference between the medications, why didn't it show up in these types of studies?\nACE inhibitors are poorly tolerated by many patients because they can produce a bothersome dry cough, and some end up stopping medication as a result.\nBut some doctors and researchers were puzzled by the fact that in head-to-head comparisons between the two classes of drugs they appeared to equally safe and effective.\nMost significantly, research showed a significant effect in reducing the risk of death with ACE inhibitors but not with ARBS.\nIf your risk is lower it's harder to show a benefit.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Since the story involves the comparison of two classes of drugs for treating cardiovascular disease, there are obviously treatment options available.", "answer": 1}, {"article": "NEW YORK (Reuters) - An insomnia drug being developed by Merck & Co was significantly better at improving sleep than a placebo in a mid-stage study, according to data presented on Wednesday.\nThe drug, MK-4305, helped patients sleep for a larger percentage of eight hours spent in bed at one night and at the end of four weeks of treatment, Merck said.\nThe most common side effects included upper respiratory tract infection, urinary tract infection, dizziness, drowsiness on waking, headache and vivid dreams.\nThe improvement was 11.6 percent at 40 mg, 6.6 percent at 20 mg and 6.2 percent at the lowest dose.\n\u201cWe are encouraged by these Phase II results showing positive effects of MK-4305 in patients with primary insomnia,\u201d Michelson said in a statement.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No. See comments above under \"novelty.\" Also, there is no sense in this story that drugs aren\u2019t the only solution to this problem. MayoClinic.com\u00a0 ticks through a number of alternatives to drug therapy, including \"Going to bed only when sleepy, Using the bedroom only for sleeping and sexual intimacy (as opposed to reading, writing, studying, watching TV, or other activities), Going to another room when unable to sleep and engaging in another activity until sleepy.\" You can find more here: http://www.mayoclinic.org/insomnia/treatment.html. ", "answer": 0}, {"article": "This news release is available in French.\n\"The issue of exercise-induced bronchospasm is real -- but if you use your releaver medication, blue puffer, before you exercise, and then take the time to cool down afterwards, you should be okay,\" he says.\nIn a study recently published in BMJ Open Respiratory Research, experts from Concordia University, the H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al and several other institutions* analyzed the exercise habits of 643 participants who had been diagnosed with asthma.\n\"It would be great to see physicians recommending physical activity to patients with asthma, alongside traditional pharmacological treatments,\" he says.\n\"Our study shows that those who were able to engage in physical activity on a regular basis year-round benefit most,\" says Bacon.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "A bit of context was missing here. The news release quotes the study\u2019s lead author saying, \u201cIt would be great to see physicians recommending physical activity to patients with asthma, alongside traditional pharmacological treatments,\u201d but the news release doesn\u2019t detail what those drugs are. According to the National Heart, Lung and Blood Institute, asthma is treated with two types of medicines: long-term control and quick-relief medicines. Long-term control medicines,\u00a0like inhaled corticosteroids, help reduce airway inflammation and prevent asthma symptoms. Quick-relief inhalers, or \u201crescue,\u201d medicines relieve asthma symptoms that may flare up.\nAnother problem here is that this study really doesn\u2019t provide anything to support the author\u2019s desire to see physicians recommending more exercise. Should we simply tell patients with severe asthma to exercise? Or do we need to treat them in a way that permits them to exercise safely? This study isn\u2019t designed to answer these questions, so it really can\u2019t compare alternatives. We would have given credit if the release had simply said that \u201conly interventional studies designed to examine the combination of physical activity and medication recommendations can determine how best to see if this observation can lead to better patient outcomes.\u201d", "answer": 0}, {"article": "\u2022 Available multimedia located on the right column of the release link: https:/\n\u2022 After February 26, view the manuscript and editorial online\n\u2022 For updates and new science from the Circulation journal follow @CircAHA\n\nStatements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position.\nMost participants were able to stay on both diets.\nThe association makes no representation or guarantee as to their accuracy or reliability.\nThis research received no specific grant from any funding agency, commercial or not-for-profit sectors.\nAuthors said they did find two differences between the diets that may be noteworthy.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This study was designed to strictly compare just two types of diets. So not bringing up other dietary options seems appropriate.", "answer": 1}, {"article": "An experimental drug has proved effective at treating an aggressive form of breast cancer in patients who aren't responding to the widely used drug Herceptin, giving hope to women with otherwise limited treatment options, said drug maker GlaxoSmithKline PLC, presenting the results Saturday at the American Society of Clinical Oncology meeting in Atlanta.\n\nWhen taken with a standard chemotherapy treatment in a clinical study, the new drug, Tykerb nearly doubled the time to 8.5 months before the average patient's breast cancer...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions Herceptin (generic name trastuzumab) and chemotherapy (here, Xeloda) as other treatments for HER-2 positive breast cancer. ", "answer": 1}, {"article": "I'll Be Me ,\" Saturday, November 7, at 8 p.m.\nThe only small concern they found was that patients taking resveratrol lost about two pounds during the one-year study, and weight loss is already a problem with Alzheimer's, Turner said.\nThe main goal of the current study, which included 119 patients, was to find out whether high doses of resveratrol could be safe.\nAntioxidant may be most effective in combination\n\nThis is one of the first studies to look not only at these biomarkers, but also the metabolites of resveratrol in spinal fluid, to show that resveratrol is probably getting into the brain, said Dr. Giulio M. Pasinetti, who is the Saunders Family Chair and professor in neurology at the Icahn School of Medicine at Mount Sinai.\n\"There could be 500 milligrams, which is what they advertise [researchers gave participants in the study four 500 milligram pills a day] or there could be zero,\" he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions both drugs used in Alzheimer\u2019s treatment and lifestyle factors \u2014 such as diet and exercise \u2014 that may help slow mental decline in Alzheimer\u2019s patients.\nHowever, we thought one of the comments from Dr. Turner on this subject was confusing and not backed by evidence.\nOne glass of red wine a day could help those with mild Alzheimer\u2019s, \u201cbut no more than that,\u201d Turner said.", "answer": 1}, {"article": "Autism has always been a tricky disorder to diagnose.\nThe images of the children in the study -- MRIs of the brain -- were taken at 12 to 29 months while their language was assessed one to two years later at 30 to 48 months.\nThere\u2019s no such thing as a blood test, cheek swab or other accepted biological marker so specialists must depend on parent and teacher reports, observations and play assessments.\nBrain imaging has become a popular subject of research in recent years as the technology to be able to scan, store and analyze the terabytes of information in the pictures has become more affordable.\nThe spectrum is wide and some are destined to be on the mild end and be very talkative, sometimes almost indistinguishable from those without the disorder in some settings, while others will suffer from a more severe form and have trouble being able to speak basic words.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While noting that there are currently no blood tests or biological markers available to autism specialists, the story shares that specialists who treat children with autism currently rely on \u201cparent and teacher reports, observations and play assessment\u201d to make a diagnosis.", "answer": 1}, {"article": "Erin M. Schumer, MD, MPH, Victor van Berkel, MD, PhD, and colleagues from the University of Louisville analyzed breath samples collected before and after surgery from 31 lung cancer patients and compared their carbonyl VOCs levels with samples from 187 healthy patients.\nThe pump is reusable; the balloon, microchip, and lab test together cost around $20, all supporting the increasing acceptance of breath tests as a cost-effective, easy-to-perform, non-invasive, and rapid option for the diagnosis of lung cancer.\nThe American Cancer Society (ACS) estimates that more than 224,000 Americans will be diagnosed with lung cancer this year, and more than 158,000 lung cancer patients will die\u2014that translates to 433 lung cancer deaths per day in the United States.\n\u201cThe great potential with breath analysis is detecting lung cancer at any point, both as a primary screening tool and to follow patients after disease has been treated,\u201d said Dr. van Berkel.\nIt has a 5-year impact factor of 4.104, the highest of any cardiothoracic surgery journal worldwide.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This release effectively points out that current practice uses periodic CT scans as the method of monitoring the potential recurrence of lung cancer in patients. It states that the breath analysis might be a substitute for the more expensive imaging procedure.", "answer": 1}, {"article": "This showed that they \u201cvalue the relationship more than being right,\u201d Williams said.\nA relationship is obviously so much more than that.\u201d\n\nMembers of Williams\u2019s research team visited 15 couples in their home once a week for 10 weeks.\nIn analyzing the recordings, Williams identified 10 communication patterns that caregiving spouses used to connect with their partners and show affection.\nThey included sharing news about friends or relatives or plans for the day as a way to involve their spouse in day-to-day events; waiting patiently and keeping eye contact while spouses searched for words; and finding alternate ways to communicate \u2014 for example, singing songs together when attempts to engage the spouse in certain topics failed.\nPrevious research has found that communication decline among people with dementia is a significant source of stress to caregivers, and most say they need education about communication.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There have been a number of studies on different approaches to enhancing communication for individuals who interact with dementia patients. The story does mention the fact that previous studies have been done, but it doesn\u2019t really describe them or their results in any meaningful way. We give credit for the mention of previous research below under the Novelty criterion, but we\u2019ll dock a point here for the lack of any real discussion of alternatives.", "answer": 0}, {"article": "Of 18 patients in the open-label series, 11 patients achieved satisfactory-to-excellent pain relief.\nNewswise \u2014 MONTREAL June 8, 2015 \u2013 Weekly sessions of non-invasive repetitive transcranial magnetic stimulation provided sufficient long-term pain relief in 61 percent of patients with central post-stroke pain, and delivered long-term relief for patients who continued for one year, according to a study presented at the International Neuromodulation Society 12th World Congress by Masahito Kobayashi, MD, PhD, of the Department of Neurosurgery, Saitama Medical University \u2013 Department of Neurology, Institute of Brain and Blood Vessels, Mihara Memorial Hospital in Saitama, Japan.\nThe study reported at the INS 12th World Congress builds on observations that electrical motor cortex stimulation\u2019s effectiveness in relieving central post-stroke pain can be predicted by rTMS, suggesting the techniques share similar pain-relief mechanisms.\nHe added that the remaining question to answer is whether the level of the patients\u2019 severe uncontrollable pain would continue to decrease if rTMS continued for several years.\nSince the 1990s, Japan has been an active center of research into the study of electrical motor cortex stimulation (EMCS) to treat post-stroke pain using surgically implanted devices.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Although a similar but more invasive therapy (electrical motor cortex stimulation) was noted in passing, we think that some additional comments should have been included about alternative treatments, Stroke.org list a host of therapies for post-stroke pain including physical therapy, NSAIDs, narcotics, and antiepilesy drugs.", "answer": 0}, {"article": "\"The next questions are, 'how do we increase the number of patients who respond?'\nA number of targeted therapies have been approved in recent years for the treatment of advanced RCC, with five antiangiogenic and two mTOR inhibitors (including everolimus; these drugs block a protein that regulates cell growth, proliferation, survival, etc.\nBased on the CheckMate-025 findings, earlier this month (September 16) the FDA granted Breakthrough Therapy Designation to nivolumab for the potential indication of metastatic RCC.\nThe median duration of treatment was 5.5 months with nivolumab and 3.7 months with everolimus.\nThe study included 821 patients with advanced RCC across 151 sites in 24 countries in North America, Europe, Australia, South America and Asia.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Although not named specifically, other therapies are mentioned: \u201d\u00a0A number of targeted therapies have been approved in recent years for the treatment of advanced RCC, with five antiangiogenic and two mTOR inhibitors (including everolimus; these drugs block a protein that regulates cell growth, proliferation, survival, etc.), showing benefits in pivotal phase III trials\u201d\nTo be sure, this is not really a true comparison of options, just a listing. But since the main alternative is the treatment used in the trial, this may be a moot point. We\u2019ll give the benefit of the doubt on the rating.", "answer": 1}, {"article": "For those at high risk, doctors recommend blood pressure medicine, quitting smoking, exercising more and eating a healthier diet \u2014 but so far chocolate isn\u2019t on the list.\nOver the next decade, there were 1,549 strokes, and the more chocolate women ate, the lower their risk.\nThe women ranged in age from 49 to 83 years.\nSOURCE: bit.ly/qhsaZ0 Journal of the American College of Cardiology, October 10, 2011.\nNearly 800,000 Americans suffer a stroke every year, with about a sixth of them dying of it and many more left disabled.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 1}, {"article": "D'Amico stressed that men should not start taking vitamin D supplements in hopes of slowing or curing prostate cancer.\nThe findings also need to be replicated in a much larger number of patients, D'Amico said.\nWhen the prostate gland was examined after their surgery, researchers found that many who received vitamin D had improvements in their prostate tumors, while the tumors in the placebo group remained the same or got worse.\nHowever, the study was small, and results from a larger trial aren't expected for several years, he added.\n\"In greater than 60 percent of those taking it, vitamin D actually made the cancer better,\" said Hollis.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are options other than surgery or watchful waiting for prostate cancer (e.g. radiation). The story did not mention them.", "answer": 0}, {"article": "The median survival of those getting surgery and Hipec, plus intravenous chemotherapy, was 22.3 months, almost double the 12.6 months for those getting only the intravenous chemotherapy.\nBut Dr. Alan Venook, a colon cancer specialist at the , said that a couple of patients referred by him had \u201cdied miserable deaths.\nOne lost much of her abdominal wall to infection and just died in misery.\u201d\n\nAnother risk is that the surgery may be done unnecessarily.\nBy contrast, said Dr. Paul Sugarbaker, a surgeon at Washington Hospital Center and the leading proponent of Hipec, \u201cthere are no long-term survivors with systemic chemotherapy \u2014 zero.\u201d\n\nDr. Sugarbaker, who opposed Dr. Ryan in the debate, said that it has long been known that cancerous cells are unable to withstand as much heat as healthy cells.\n\u201cI\u2019ve had to say my goodbyes to everybody,\u201d Mr. S. said the day before the operation.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Various comparisons were made \u2013 on both sides of the debate.\nA proponent of the new method said:\u00a0 \u201c\u201cthere are no long-term survivors with systemic chemotherapy \u2014 zero.\u201d\nBut the story also said:\u00a0\u201ccritics say that \u2026new drugs have come to market that allow patients with metastatic colorectal cancer to live two years with intravenous chemotherapy alone\u201d", "answer": 1}, {"article": "So far, while Diamond has noted an immune response in patients given the combination treatment in clinical trials, he has not seen a clinical benefit.\nI think the prognosis is going to be good now.\u201d\n\nThe most frequent mutation across all cancers occurs in a gene called p53, which contributes to cells becoming oncogenic when they produce a mutant form of the p53 protein (p53 gene mutations are present in about 50% of malignancies).\n\u201cEven the marks where it was climbing up my neck are all gone.\u201dFurther study needed\n\nWhat Diamond is hoping for now is funding for a full clinical trial so that he can test the combination in advanced triple-negative breast cancer patients who test positive for p53.\nBut we\u2019ve got to get these patients in.\u201d\n\nFollowing the success in Young, the formula has recently been given to two other triple negative breast cancer patients at City of Hope.\nThe researchers tested this vaccine, known as p53MVA, in a 2013 clinical trial and found it to be safe in patients with advanced gastrointestinal cancers.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The only alternative mentioned in this release was hospice. Because this type of cancer is considered a terminal, non-curable disease if the patient has not responded to surgery, radiation and standard chemotherapy, that may be appropriate. However, the vaccine described here isn\u2019t the only\u00a0experimental treatment in development.\u00a0There have been mixed results in studies of iniparib combined with\u00a0chemotherapy, and immunotherapy.\u00a0Some other experimental treatments\u00a0could have been mentioned, along with palliative care.", "answer": 0}, {"article": "\u201cBut this is a small study, a proof of concept.\n\u201cWe can\u2019t yet say that this study means that DHEA is a viable alternative to HRT, but ... we should be looking to do larger studies to confirm these initial results.\u201d\n\nDHEA, or dehydroepiandrosterone, is a natural steroid hormone mostly made in the adrenal glands and has a variety of therapeutic uses.\nItalian researchers writing in the journal of the International Menopause Society, Climacteric, said they had found the first robust evidence that low doses of DHEA can help sexual function and menopausal symptoms, suggesting it may one day become an alternative to hormone replacement therapy (HRT).\nAt the start of the trial, all groups had similar sexual activity, but after the year, those taking calcium and vitamin D scored an average of 34.9 on the questionnaire scale, while those taking DHEA had a score of 48.6, showing that those on DHEA had more sexual interest and activity.\nAmerican researchers said in January that the antidepressant Lexapro, made by drugmaker Forest Laboratories, significantly cut the number and severity of hot flushes in menopausal women, and other antidepressants including GlaxoSmithKline\u2019s Paxil and the Pfizer drugs Prozac and Effexor also have been found to be effective.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions several alternative treatments to hormones. It says, \u201cAmerican researchers said in January that the antidepressant Lexapro, made by drugmaker Forest Laboratories, significantly cut the number and severity of hot flushes in menopausal women, and other antidepressants including GlaxoSmithKline\u2019s Paxil and the Pfizer drugs Prozac and Effexor also have been found to be effective.\u201d\nBut it seems strange that the story refers only to these brand name products and does not mention any of the generic medications such as fluoxetine and citalopram that have also been proven to reduce hot flashes.\nThis issue, and the lack of cost information, make this story less helpful to consumers than it might have been.", "answer": 0}, {"article": "\u2022 If you have any question or request regarding interview opportunities, please contact:\n\u2022 For full details of a session, have a look at the Scientific Programme & Planner: http://spo.\nThe findings from this PROOF study were confirmed in a meta-analysis preformed by the same group and reported at this same EuroPRevent congress.3 This analysis, drawing on data involving almost 120,000 subjects, found that \"low-dose\" moderate-to-vigorous physical activity - of, say, 75 minutes per week or 15 minutes per day - significantly reduced mortality in the elderly.\nNow, a study in a French cohort of more than 1000 elderly subjects (the PROOF study) has found a negative correlation between their level of physical activity and risk of all-cause death, suggesting that in the elderly (as in other population groups) the risk of death decreases with greater and more regular exercise.\nIndeed, most physical activity guidelines are the same for the middle-aged adults as for the elderly, even though it is estimated that over 60% of the elderly are unable to achieve this same level of exercise.\nDuring that follow-up their level of physical activity was monitored and categorised according to five levels of MET-h values per week: <1; 1-3.74; 3-75-7.49 (equivalent to brisk walking for up to 150 minutes per week, and the recommended activity level); 7.5-15; and >15 MET-h per week.2 Mortality and cardiovascular events were recorded over the follow-up period and associated with exercise levels.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions various forms of exercise and physical activity, and\u00a0the comparison of very active to inactive (and various levels within these extremes) is made clear. But there is no attempt to broaden the discussion to related factors that might also impact longevity in old age, including diet, body weight, alcohol consumption, and social engagement.\u00a0This could have been accomplished in a broad sweep with just a few additional words.", "answer": 0}, {"article": "ISNES, Belgium, Aug. 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (\"Volition\") today announced preliminary data from a prospective, multi-centered Proof of Concept Study of 84 men into the utility of Volition's Nu.Q\u2122 assays to diagnose men with high-grade prostate cancer.\nThe tests are based on the technology platform of Nucleosomics\u00ae, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.\nCommenting on the results, Principal Investigator, Professor Thierry Roumeguere, Head of Urological Services, Erasme Hospital, Brussels, Belgium said \"A non-invasive test to help in the risk stratification of men with suspected or actual prostate cancer will be a major step forward in the management of this disease.\nOther risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic products Volition might develop; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission.\nBased on this data, we believe that this test could assist clinicians in more accurate patient selection for prostate biopsy and treatment and substantially reduce the amount of unnecessary procedures in men with low-grade tumors or no tumor.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release directly compares this experimental blood test to current practice employing the PSA blood test, but there aren\u2019t enough details about how the comparison was made for readers to get a sense of whether the claim of superiority has a reasonable basis. There is no justification for stating it is 94% accurate compared to PSA testing being 33% accurate at identifying high-grade tumors at this preliminary stage.\nIt is well known that the PSA is not a very accurate screening test. There are other attempts to improve upon it., including using MRIs to determine whether someone has a lesion that corresponds to the elevated PSA or not.", "answer": 0}, {"article": "A majority of states have adopted national guidelines that prohibit basic EMS staff from administering the drug as an injection.\nHaving trained EMS staff to administer naloxone in rural areas will save lives.\u201d\n\nTo reduce opioid overdose deaths, particularly in rural areas, CDC recommends expanding training on the administration of naloxone to all emergency service staff, and helping basic EMS personnel meet the advanced certification requirements.\nThe findings indicate naloxone was most likely to be administered to women, people between the ages of 20 and 29, and people living in suburban areas.\nAs of 2014, only 12 states allowed basic EMS staff to administer naloxone for a suspected opioid overdose; all 50 states allow advanced EMS staff to administer the overdose reversal treatment.\nThe use of naloxone by rural EMS staff, however, was only 22.5 percent higher when compared with urban EMS naloxone use.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "We\u2019re giving the release points here because it does something that most releases never do. It actually gives a nod to alternatives. In a quote from CDC Director Tom Frieden, it says,\u00a0\u201cMany of these deaths can be prevented by improving prescribing practices to prevent opioid addiction, expanding the use of medication-assisted treatment, and increasing use of naloxone for suspected overdoses.\u201d", "answer": 1}, {"article": "\"We estimate that use of [Brilinta] instead of [Plavix] for one year in 1,000 patients with acute coronary syndromes and who are planning to undergo an invasive strategy at the start of drug treatment would lead to 11 fewer deaths, 13 fewer myocardial infarctions, and six fewer cases of stent [clotting] without an increase in the rates of major bleeding or transfusion,\" conclude study researcher Christopher P. Cannon, MD, and colleagues.\nAnd since the drugs irreversibly bind to blood-clotting platelets, a patient has to stop taking these drugs for five to seven days before the body can make enough new platelets.\nThat's probably why the 6,732 study patients who got Brilinta were 16% less likely to die, or have a heart attack or stroke, than were the 6,676 patients who got Plavix.\nThe new kid on the block is AstraZeneca's ticagrelor, to be named Brilinta if the experimental drug gets FDA approval.\nStone has in the past received honoraria from the makers of both Plavix and Brilinta and serves on the advisory boards of Boston Scientific and Abbott Vascular.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0The story indicated that the drug reported on was more effective than the currently available treatments at reducing death, heart attack, and stent clotting. \u00a0The story would have been greatly improved had it provided absolute data on the occurrence of these events.", "answer": 1}, {"article": "Scientists have developed a simple three-in-one blood test they believe could transform treatment of advanced prostate cancer, helping to extend or save lives.\nThey are cheap and simple to use, but most importantly, because they aren\u2019t invasive, they can be employed or applied to routinely monitor patients to spot early if treatment is failing \u2013 offering patients the best chance of surviving their disease.\u201d\n\nThe research was funded by the Prostate Cancer Foundation, Prostate Cancer UK, Movember, Cancer Research UK and the National Institute for Health Research.\n\u201cNot only could the test have a major impact on treatment of prostate cancer, but it could also be adapted to open up the possibility of precision medicine to patients with other types of cancer as well.\u201d\n\nBy testing cancer DNA in the bloodstream, the researchers found they could pick out which men with advanced prostate cancer were likely to benefit from treatment with the drug.\nProf Johann de Bono, Regius professor of cancer research at the ICR, and consultant medical oncologist at the Royal Marsden NHS foundation trust, said: \u201cOur study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaparib.\nThe liquid biopsy, less invasive than a tissue biopsy, also detects early signs of resistance to olaparib and monitors the cancer\u2019s evolution over time, according to the paper, published in Cancer Discovery on Monday.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article makes no mention about alternatives. It doesn\u2019t make clear what current standard therapy is for prostate cancer or how patients are currently selected for treatment with the targeted cancer drug.\nIt also didn\u2019t discuss that the drug itself\u2013olaparib\u2013is still being researched for effectiveness.", "answer": 0}, {"article": "Patients played the role of cab drivers who picked up passengers and delivered them to one of six requested shops in the city.\nAlthough the results are still preliminary, the method may potentially hold promise for boosting memory in patients with early Alzheimer's disease, the researchers said.\nHaber noted that the brain damage that occurs with epilepsy, which can produce memory problems, is different than that resulting from Alzheimer's disease, in which the formation of amyloid plaques and neurofibrillary tangles are believed to contribute to nerve cell deterioration.\nSo it's difficult to generalize this study's results to other diseases that affect memory, she said, and the research didn't show if effects of temporary deep brain stimulation last beyond the study period.\nUsing electrical impulses to stimulate a part of the brain critical for memory function significantly improved patients' navigational ability, reflecting improved spatial memory, the small study from the University of California, Los Angeles (UCLA) suggests.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story should have made some mention of the drugs currently available to improve memory function of people with Alzheimer\u2019s disease. Although these drugs do not alter the progression of the disease, a comparison of their memory-enhancing effects to the level of improvement seen in this test would have given readers a useful way to better understand the size and duration of the effect these researchers saw.", "answer": 0}, {"article": "TUESDAY, Jan. 19, 2010 (HealthDay News) -- DNA testing for the human papillomavirus should replace the Pap smear as the main way to screen women for cervical cancer, according to Italian researchers.\nThe HPV test works a step further back in the process, looking to see if women are infected with HPV.\nThe U.S. Centers for Disease Control and Prevention has more on cervical cancer screening.\nThis is happening in single-payer health systems which have national screening.\nThe HPV test should become the screening tool of choice for women 35 and older, the researchers said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job of describing the pros and cons of HPV DNA testing to pap smears, even indicating how HPV could be particularly useful in resource-poor countries.", "answer": 1}, {"article": "About UABKnown for its innovative and interdisciplinary approach to education at both the graduate and undergraduate levels, the University of Alabama at Birmingham is the state of Alabama\u2019s largest employer and an internationally renowned research university and academic medical center; its professional schools and specialty patient-care programs are consistently ranked among the nation\u2019s top 50.\nThere is hope for dry eye patients worldwide.\u201d\n\nDiagnosis of dry eye is identified by an eye care professional based on careful evaluation of signs and symptoms, including dryness, discomfort, vision changes and damage to the surface of the eye.\n\u201cIt is critical for eye care professionals to have a dialogue with patients who report symptoms because dry eye can be a progressive ocular surface disease.\u201d\n\nThe twice-daily eye drop solution of 5 percent lifitegrast ophthalmic solution is the only prescription eye drop indicated for the treatment of both signs and symptoms of dry eye, and it is the first new dry eye prescription drop approved in the last 13 years.\n\u201cDry eye is a common complaint to eye care professionals, with millions of U.S. adults experiencing the symptoms of this often chronic disease,\u201d Nichols said.\nFocusing her research on all aspects of the eye, Nichols discussed the mechanics of the three layers of the tear film and the importance of each from the cornea outward:\n\u2022 Mucin layer: helps tears adhere to the eye\n\u2022 Aqueous layer or water layer: nourishes and protects the cornea\n\u2022 Lipid or oil layer: lubricates and prevents evaporation and provides smooth refractive surface needed for optimal vision\n\n\u201cWe are unsure which of the 200-plus different lipids and 500-plus unique proteins are most important for protecting and lubricating the eye, and the absence or insufficiency of which results in dry eye,\u201d Nichols said.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release notes that researchers are working to find new treatments for dry eye, with more than 30 studies under way. But it makes no mention of the currently available treatments or how this product compares with them.\nOther available treatments including artificial tears; Restasis, a drop that that induces tear production; and there are many other eye drops on the market that treat some of the side effects of eye dryness.", "answer": 0}, {"article": "Viagra is one of three licensed drugs to treat erectile dysfunction, Davies explained. The other two are Cialis and Levitra. They can take from half an hour to several hours to work, and they're not for everyone: Men who've had a stroke or heart attack are told to use the drugs with caution, reports the Daily Mail. Even those without medical issues simply don't like the wait.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned three anti-impotence drugs now on the market and talked about how the new cream might be better. But there is simply no evidence base upon which to compare three approved drugs with a cream that has only been tested in 10 rats.\u00a0", "answer": 0}, {"article": "People with painfully damaged knees and hips have increasingly turned to \"minimally invasive\" joint-replacement surgery. But these relatively new procedures, though they promise shorter recuperation times, are raising concerns about potential complications.\n\nMany surgeons in recent years have performed joint replacements with ever smaller incisions. In minimally invasive surgery, the incision is typically about three to four inches long, roughly half that of traditional surgery. By cutting less of the surrounding tissue...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\nThe article compares the new surgical techniques to traditional total joint replacement, and explains why it may be better or worse than longstanding approaches.", "answer": 1}, {"article": "The Ache: Nearly 5,000 people a year die from choking in the U.S., according to the nonprofit National Safety Council.\n\nThe Claim: Two new easy-to-use devices work like plungers to suck out obstructions in the airway, providing another option if standard treatment\u2014such as abdominal thrusts developed in 1974 by Henry Heimlich\u2014fail to clear the airway, say the companies who sell them.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The standard treatment for choking is the Heimlich maneuver. Representatives from Dechoker want to present the device as a fail-safe to the Heimlich maneuver.", "answer": 1}, {"article": "Type 1 diabetes is an autoimmune disease in which the body's immune system mistakenly attacks the insulin-producing beta cells in the pancreas.\nThe hope is that an artificial pancreas will closely mimic the way the human pancreas normally releases insulin in response to food or stress.\n\"For the eating-in scenario, overnight closed loop delivery increased the time plasma glucose levels were in target by a median 15 percent,\" said Hovorka.\nPrevious research suggests that in a 24-hour period, the average person with type 1 diabetes spends about 10 hours with blood sugar levels too high, and about an hour a day with blood sugar levels too low, according to Aaron Kowalski, assistant vice president for treatment therapies at the Juvenile Diabetes Research Foundation.\nFor the eating-in portion of the randomized study, 12 of the study volunteers were assigned to consume a medium-sized meal (60 grams of carbohydrates) at 7 p.m., and then another half were placed on the artificial pancreas program during the night, while the other half maintained their standard insulin pump therapy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was nothing in the story about current treatment approaches for reducing the risk of renal failure. This leads readers to believe that there is nothing they can do to prevent a renal injury or death other than take statins.", "answer": 0}, {"article": "The paper \"Real-time imaging of the resection bed using a handheld probe to reduce incidence of microscopic positive margins in cancer surgery\" is available online at http://cancerres.\nBecause of this, excess tissue surrounding the tumor is typically removed, but the question lingers of whether any cancer cells remain to re-emerge later as tumors.\nThe interdisciplinary research team led by Stephen Boppart, a University of Illinois professor of electrical and computer engineering and of bioengineering, performed the study on 35 patients with breast cancers at the Carle Foundation Hospital in Urbana, Illinois.\nIn the clinical study, surgeons treated patients according to the standard surgical procedure, but OCT data were collected from the margin of the tumor cavity and the margin of the removed tissue mass during surgery so that the results could be compared later.\n\"It is likely better to check to see if any residual tumor cells might be left behind, rather than checking the tissue mass that was taken out.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release goes into some detail about the current methods used by surgeons and pathologists to assess the extent of a tumor and the likely outer border of margins.\nWe\u2019ll rate this Satisfactory, although there is no discussion of an existing device \u2014 the Dune Medical Margin Probe \u2014 that uses different technology but is used for the same purpose. The new device is meant to be used in-vivo (on the lumpectomy or mastectomy bed) versus on the tumor specimen removed during surgery.", "answer": 1}, {"article": "Frank Ruschitzka, MD, of Zurich University Hospital, tells WebMD that ideas that at first seem \"crazy\" can turn out to be lifesaving.\n\"We saw two distinct patterns, one of which correlated with heart failure,\" says study leader Vasileios Kechagias, a PhD candidate at the University Hospital Jena.\nSpecially developed software divides patients into groups depending on the pattern of molecules detected.\nThe new study involved 27 people with heart failure so severe that they were comfortable only at rest, 25 people with less severe heart failure, and 28 healthy people.\nAug. 30, 2011 (Paris) -- German researchers say they\u2019re a step closer to developing an electronic nose that can distinguish between people who have heart failure and those who don't.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no comparison with existing alternatives, which leaves readers a bit confused. How is heart failure detected now and why would the world need this device? There are numerous diagnostic tests used in the diagnosis of heart failure, many of them as simple as a blood test or ultrasound.", "answer": 0}, {"article": "Dr. Howard N. Hodis, a preventive cardiologist at the University of Southern California, said the billion-dollar W.H.I.\n\u201cWomen today have so many options \u2014 a wide array of doses, from low to traditional, and ways to use them.\u201d In addition to pills, there are patches, gels and sprays applied to the skin.\nThe most common symptom \u2014 hot flashes \u2014 can leave some women dripping with sweat for minutes at a time several times a day and especially during the night.\nFor women without a history of cancer, blood clots or heart disease, most professional medical societies concerned with women\u2019s health now recommend treatment for menopausal symptoms for up to five years using therapy that combines estrogen and progesterone and even longer for those who take estrogen alone.\nVaginal and urinary symptoms can be treated with vaginal inserts containing very small amounts of estrogen that do not enter the bloodstream and thus are safe for women who have had breast cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story tried to cover so much ground in revisiting old ideas and explaining new ideas, it did not take the time to set up a comprehensive list of alternative ways for women to deal with menopausal symptoms. It listed the traditional hormone replacement and then discussed what it labeled \u201ccustom compounded\u201d products without much explaining of what they are.\nRegular exercise, for example, is among many non-drug approaches listed routinely for menopausal symptoms.", "answer": 0}, {"article": "TUESDAY, Aug. 25, 2015 (HealthDay News) -- Needles beat pills for treating hot flashes in breast cancer survivors, according to a new trial that compared acupuncture, \"sham\" acupuncture, the medication gabapentin and a placebo pill.\nAt 24 weeks, 16 weeks after treatments ended, acupuncture was still associated with the greatest reduction in hot flashes.\nInterestingly, sham acupuncture came in second place for effectiveness, the researchers said.\nThe drug is typically used to treat seizures and nerve pain.\n\"Breast cancer survivors have hot flashes because of hormonal repression,\" he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study was all about comparing alternatives so by that means, rates a satisfactory score.", "answer": 1}, {"article": "Dr. Warren was puzzling over how to recreate that synaptic traffic cop when, because of a scheduling conflict, he showed up in 2001 at the wrong scientific conference and happened to sit next to Mark F. Bear, a neuroscience professor at M.I.T.\nBut the company and outside researchers believe that such compounds may prove most effective in young children, whose brains are far more likely to respond rapidly when barriers to learning are removed.\nThose with 55 to 200 repeats are considered carriers, and recent research shows they can have severe neurological declines late in life that mimic Alzheimer\u2019s and Parkinson\u2019s.\nIf authenticated in further, larger trials, the results could also become a landmark in the field of autism research, since scientists speculated that the drug may help some patients with autism not caused by fragile X, perhaps becoming the first medicine to address autism\u2019s core symptoms.\n\u201cBut I\u2019m not going to have kids for at least 10 years anyway, and they\u2019ll have a cure for by then.\u201d\n\nShe paused, looked at her mother and said: \u201cYou\u2019ve got 10 years.\u201d\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The treatment approach appears to be genuinely novel.\u00a0An expert source comments that\u00a0fragile X syndrome, up until recently, was viewed as \"disability needing rehab, not a disorder needing medication.\"", "answer": 1}, {"article": "With statins you get toxicity \u2013 with these drugs we don\u2019t see any side effects with the antibody.\u201d\n\nIn an accompanying editorial, authors Dr. Stephen G. Young, and Loren G. Fong, Ph.D. write: \u201cAt this point, the status of PCSK9 therapeutics appears to be full speed ahead.\nTwo arms used 72 healthy volunteers who were either injected with a single dose of the drug in increasing amounts to test for side effects, which is the purpose of a phase one clinical trial.\nThe cost of this drug will also play a role in determining which patients might use it, Fong and Young say.\nNone of the subjects who received REGN727 discontinued the study because of adverse effects, and the subjects who received REGN727 had a striking reduction of 60 to 65% in LDL cholesterol, according to Stein.\nStein called the trial results \u201ca very important breakthrough,\" while being careful to note that they represent early science which should be confirmed through larger and longer studies.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Superficial comparisons were included:\nAgain, we\u2019ll give the story the benefit of the doubt on this but it is too early to even suggest that the antibody won\u2019t have any side effects.", "answer": 1}, {"article": "What if doctors had a pill that prevents breast cancer and nobody wanted to take it? That has pretty much been the situation with tamoxifen, an estrogen-like drug that was proved in 1998 to cut in half the chance of developing breast cancer if taken for five years by women with increased risk of the malignancy. The trouble is, tamoxifen also triggers menopausal symptoms like hot flashes and slightly increases the chances that a woman will develop blood clots and uterine cancer. As a result, women haven't been too eager to take the medication--nor have many doctors been all that enthusiastic...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention another chemoprevention hormone drug, tamoxifen. It also mentioned aromatase inhibitors as options being investigated for chemoprevention. Does not mention need for mammograms (screening as early detection shown to improve outcomes) in post-menopausal women at a higher risk of breast cancer. It should be noted that the results presented in this story are initial findings after 4 years of raloxifene. Tamoxifen is usually taken for 5 years and there is much more long-term clinical data on safety and efficacy for this drug. The study was unblinded early due to the improved side effect profile for raloxifene, which was not statistically significant. ", "answer": 1}, {"article": "Fear of doctors, the prospect of being poked and prodded in strange places, a lack of insurance to cover the costly test -- or a combination of all three -- are to blame for as many as half of the over-50 crowd putting off or avoiding the screening test altogether.\nThat test, which looks at two different DNA markers (instead of the one marker used by PreGen-Plus), is the one with which Markowitz is more familiar.\nCompared to more invasive procedures, the test still might miss some polyps and cancers and may need to be repeated more often.\nNot since 1998, when the FDA approved the PSA test for early detection of prostate cancer, had new technology been created in early cancer detection until the stool DNA test.\nSince 2003, the PreGen-Plus kit could be ordered through a physician or other licensed health care provider for $800, although some insurance and health plans covered the cost partially or in full.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions other screening alternatives, including colonoscopy and CT colonography (or virtual colonoscopy). But it does not mention traditional fecal occult blood testing, the mainstay stool test for decades. And it provides only a cursory comparison of the advantages/disadvantages of the new test compared with existing approaches.", "answer": 0}, {"article": "Lauren Pestikas sits as she receives an infusion of the drug ketamine during a 45-minute session at an outpatient clinic in Chicago on July 25, 2018.\nFor now, ketamine has not received approval from the U.S. Food and Drug Administration for treating depression, though doctors can use it for that purpose.\n\u201cIt truly has revolutionized the field,\u201d changing scientists\u2019 views on how depression affects the brain and showing that rapid relief is possible, said Yale University psychiatrist Dr. Gerard Sanacora, who has done research for or consulted with companies seeking to develop ketamine-based drugs.\nIts potential effects on depression were discovered in animal experiments in the late 1980s and early 1990s showing that glutamate, a brain chemical messenger, might play a role in depression, and that drugs including ketamine that target the glutamate pathway might work as antidepressants.\nExactly how ketamine works is unclear, but one idea is that by elevating glutamate levels, ketamine helps nerve cells re-establish connections that were disabled by depression, said ketamine expert Dr. Carlos Zarate, chief of experimental therapies at the National Institute of Mental Health.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned conventional antidepressants that \u201ctarget serotonin, a different chemical messenger, and typically take weeks to months to kick in \u2014 a lag that can cause severely depressed patients to sink deeper into despair.\u201d\nIt also quoted an expert who said \u201cketamine should be a last-resort treatment for depression after other methods have failed.\u201d\nThe story could have mentioned other medications to treat depression as well as psychotherapy.", "answer": 1}, {"article": "\"Great.\n\"So before we activated the device, we have all sorts of problems\u2026 This is basically your brain saying, 'I'm not breathing.'\nAn estimated 22 million Americans suffer from sleep apnea, putting them at greater risk for diabetes, heart disease, stroke and memory loss.\nA study published in the New England Journal of Medicine found that 68 percent of patients experienced less sleep apnea after getting the implant.\nIt's been a game changer,\" Dr. Maurits Boon said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does tell readers that CPAP, a widely used treatment for sleep apnea, did not work for the patient being profiled. However, the story doesn\u2019t let us know how often CPAP is ineffective, whether there is any difference in effectiveness between CPAP and Inspire for most patients, or what other treatment options are available.", "answer": 0}, {"article": "People with Type 2 diabetes get an earful of grim lectures about their health prospects and endure much hardship to manage their condition well. But new research offers those who do so a rare reward. A glass of wine every day not only won't hurt, says a new study: It can actually improve cardiac health, help manage cholesterol and foster better sleep.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no discussion of how the effects seen in this study compare with other methods of improving cardiac health, managing cholesterol or sleeping better, including lifestyle or medications.\nModerate exercise, for example, also raises HDL levels, lowers blood pressure, and reduces waist circumference. \u00a0And yes, it also improves sleep and mood, and reduces fall risk.", "answer": 0}, {"article": "Feb. 7, 2011 -- Giving your sweetie chocolate for Valentine's Day may show you care for their health as well as their heart.\nAntioxidants are a group of compounds known to fight the damaging effects of oxidative stress on cells within the body and are increasingly thought to have many heart-healthy properties.\nTwo groups of antioxidants in particular, polyphenols and flavonols, which are found in various fruits and seeds, have been the focus of much research due to their potentially healthy effects.\nResearchers found the antioxidant activity of dark chocolate and cocoa powder was equivalent to or higher than that found in some other so-called \u201csuper fruit\" powders or juices, including acai berry, blueberry, cranberry, and pomegranate.\n\"When looking for a sweet snack, a square of dark chocolate might, in fact, be your healthiest choice!\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story never pointed out that everyday fruits and vegetables can be good sources of antioxidants.\u00a0They are usually less expensive than antioxidant \u201csuperfruits\u201d and have less fat and sugar than chocolate. In addition, drinks such as coffee, green tea, and red wine are also rich in antioxidants.\u00a0And clearly, eating a variety of different foods is the best approach to overall health.", "answer": 0}, {"article": "In 2008 Sciencewatch (Thomson Reuters http://sciencewatch.com/ana/st/hpv/08julHPVWheler/) ranked her global citation contributions over the past decade, 7th in human papillomavirus contributions and in the top 1% in the field of clinical medicine.\nWhenThe paper, \u201cEfficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study,\u201d was published in the June 28, 2016 online edition of The Lancet (www.thelancet.com/infection).\nThey found that the vaccine protected the women against HPV infections during the follow-up period and that the women were protected from many types of HPV across a broad age range.\nThrough its partnership with the New Mexico Cancer Care Alliance, an \u201cexemplary national model for cancer health care delivery,\u201d the UNM CCC offers access to more than 175 clinical trials to New Mexicans in every part of the state.\nNewswise \u2014 WhatA research paper published in The Lancet Infectious Diseases reported that the human papillomavirus (HPV) vaccine is safe and efficacious across a wide age range of women.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "It is difficult to gather from the news release what alternatives were considered in the study.\u00a0Clearly one group of women received HPV vaccinations. We can only assume the other group did not.\nAlternatives to this vaccine strategy include achieving higher rates of vaccination in younger women and expanding cervical cancer screening services.\u00a0", "answer": 0}, {"article": "Study participants were enrolled in the Women's Health Initiative, which \"represents a large and well-characterized cohort [group] of postmenopausal women, and the medication data collected in this cohort made it possible for us to investigate multiple types, durations and strengths of NSAID use,\" Coghill explained.\nWhile the study found an association between NSAID use and a reduced risk of colorectal cancer, it did not prove a cause-and-effect.\nThe findings were slated for presentation on Sunday at the AACR International Conference on Frontiers in Cancer Prevention Research, in Boston.\nExperts say that for studies presented at medical meetings, data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nIn the study, researchers examined the use of aspirin and non-aspirin NSAIDs among more than 160,000 postmenopausal women in relation to deaths from colorectal cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story failed to detail any existing alternatives for colorectal cancer, such as targeted drug therapies for people with advanced colon cancer.", "answer": 0}, {"article": "Still, this group stressed the risk was very small, resulting in 2 cases of throat cancer in 1,000 people ages 60 to 79, compared with the normal rate of 1 per 1,000.\nBut in September, a different group of scientists used the same database and concluded in an article in the British Medical Journal that bisphosphonates appeared to double the risk of esophageal cancer after about 5 years of use.\nThe task force offers no advice for women younger than 60 or for men of any age, though men account for at least 20 percent of US patients with osteoporosis.\nThe US Preventive Services Task Force, which sets standards on disease prevention and primary care, suggests that all women get a bone density screening by age 65, or by 60 if a patient might be at high risk for fractures.\nIn a statement, the FDA said it is reviewing the data and is considering changing the labeling on bisphosphonates.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article discussed multiple treatments: bisphosphonates, calcium, and vitamin D. It would have been useful to at least mention some other drug treatments that were discussed in the recent report of the US Preventive Services Task Force: estrogen replacement therapy, parathyroid hormone, and raloxifene.\n\u00a0\n ", "answer": 0}, {"article": "But he also sees a lot of patients who cannot be candidates.\nThat's why Orr saw blank spots where people's noses and eyes should be in their faces, sort of like \"holes in the film,\" says Colby.\n\"In order to implant this device, we need to remove the natural lens, or the cataract, and then use a portion of the natural lens to position and support the telescope,\" says Williams.\nSo the take-home message: If you're over 60 and you begin to experience visual loss, get yourself to an eye specialist as soon as possible to see if you can be treated with medication to stabilize and even reverse the vision loss you've experienced.\nAs a result, the Food and Drug Administration plans to monitor safety for at least five years for the next set of patients who receive the telescope.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Again, this could be a model for other stories. It places the new surgery in the context of existing surgeries and compares it to drug treatments, even explaining how those treatments and surgeries are performed, all in just a few sentences. Every story should have a section like this: \n\"Cataract surgery removes the natural lens and, in most cases, replaces it with an artificial lens, which means there is no foundation for the telescope. And for patients who are in the early stages of macular degeneration, Williams says that medications approved just six years ago are effective and a lot less invasive than the telescope. The drugs are injected directly into the eye on a monthly basis. And with this treatment, doctors are able to prevent severe visual loss in over 90 percent of patients. In nearly half of all patients, visual improvement is significant.\"\u00a0\nThe only thing that would have made this better is if the reporter had asked at least one more source besides Williams for comments and context.", "answer": 1}, {"article": "However, the treatment failed to improve secondary goals of the trial, such as heart-pumping efficiency and six-minute walking distance, and Vericel shares fell more than 31 percent by afternoon trading on Monday.\nIf the disease worsens despite all available medicinal and interventional therapies, the only options are heart transplant or a pumping assist device.\nWith advanced heart failure, a leading cause of hospitalizations, blood-pumping ability is diminished as the heart\u2019s left ventricle becomes enlarged and weakened.\n\u201cThe idea is to find a treatment for this group of people before they get to that stage,\u201d Henry said.\n(Reuters) - A stem cell therapy developed by Vericel Corp helped reduce deaths and hospitalizations in advanced heart failure patients, according to data from a midstage study, potentially providing a treatment that could delay the need for heart transplants.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story points out alternatives by stating \u201cdespite all available medicinal and interventional therapies, the only options are heart transplant or a pumping assist device.\u201d", "answer": 1}, {"article": "The latest health and science updates, breakthroughs, research, and the best in investigative and informative journalism.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned means, other than the featured products, for obtaining recommended levels of vitamin B-6 and B-12.", "answer": 1}, {"article": "Their study was presented at the 26th annual meeting of the European Society of Human Reproduction and Embryology in Rome, Italy.\nAs many as 80% of all women have uterine fibroids (noncancerous growths in the uterus), according to the nonprofit National Uterine Fibroids Foundation.\nAs of now, EllaOne is used in Europe as a morning-after pill because it blocks the effects of key hormones -- namely progesterone -- involved in ovulation.\nThe hormone progesterone also feeds uterine fibroids, so blocking its effects may help treat painful fibroids.\nEnter EllaOne, a member of a new class of drugs called selective progesterone receptor modulators.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions Lupron and Uterine Artery Embolization as alternatives to EllaOne but fails to mention many other safe and effective options that are currently available. For example, oral contraceptives (which are not approved for fibroids but are commonly used for that indication) can help reduce bleeding and cramping associated with fibroids. Likewise, the Mirena IUD often stops bleeding altogether. NSAIDs can also be used for pain. Myomectomy, surgery to remove fibroids, preserves fertility. By not mentioning these options, the story leaves the reader with the impression that there are few viable alternatives.", "answer": 0}, {"article": "It was funded by the government of France.\nAfter six months, only 31% of patients on FOLFIRINOX reported a decent quality of life, compared with 66% of those on gemcitabine.\nResearchers found that even though people on the FOLFIRINOX had a longer average survival rate of 11.1 months, versus the gemcitabine group with 6.8 months, the quality of life for patients on FOLFIRINOX was not as good.\nThe other patients were given a combination of four chemotherapy drugs, (oxaliplatin, irinotecan, fluorouracil and leucovorin) known as FOLFIRINOX.\nInvestigators concluded that although the FOLFIRINOX did improve survival rates over gemcitabine, the toxicity of the drug combination caused numerous negative side effects.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We thought USA Today did a much better job, ending their story with this independent expert perspective:\n\u201c\u2026doctors are testing other drug combinations to treat pancreatic cancer. She\u2019s hopeful that these combinations will work as well or better than Folfirinox, with fewer serious side effects. Folfirinox \u201cis going to be one of a host of options\u201d for patients, Azad says \u201d\nThere was no independent perspective in this story and no such comparison with other approaches being researched for pancreatic cancer.", "answer": 0}, {"article": "Records covered the use of both low- and high-dose aspirin (ranging from 75 milligrams to 500 milligrams), so-called \"nonselective\" NSAIDs (such as ibuprofen [Advil] and naproxen [Aleve]), and both older and newer types of COX-2 inhibitors.\nThe study appears in the May 29 online issue of the journal Cancer.\nFor more on NSAIDs and cancer, visit the U.S. National Cancer Institute.\nIn turn, prescription histories were gathered for both the cancer patient group and almost 179,000 healthy Danes.\nTing also advised that people consult with their doctor before starting on any blood thinner.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions sun protection as a key method of preventing skin cancer.", "answer": 1}, {"article": "Weiss advises women with advanced breast cancer to have genetic testing.\nThe trial results are preliminary, as talazoparib has not yet been approved by the U.S. Food and Drug Administration.\nThe drug, talazoparib, works by blocking an enzyme called poly ADP ribose polymerase (PARP), thus preventing cancer cells from killing healthy ones.\nIn addition, several ongoing studies are looking at combinations with PARP inhibitors \"to try to expand who may benefit or lengthen how long they may work,\" Litton said.\nIn the current trial, the women who were randomly selected to receive talazoparib had a higher response rate to treatment than women who received standard chemotherapy: 63 percent versus 27 percent, the researchers found.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions another drug that has a similar mechanism of action, and is approved for BRCA-mutated breast cancer and ovarian cancer.\nThere is no discussion of how the drugs may differ with regard to harms or benefits\u2013which we\u2019ll address in novelty, below.", "answer": 1}, {"article": "Her team reviewed MRI images from 130 patients treated for clot-caused strokes at Sainte-Anne Hospital in Paris between May 2006 and October 2008.\n\"This concerns as many as a quarter of all stroke patients who cannot be given tPA because they wake up with stroke symptoms or are unable to say when their stroke began.\"\n\"A tool that can estimate the age of stroke would be of great value in cases of unknown stroke onset time,\" said lead researcher Dr. Catherine Oppenheim, professor of radiology at Universite Paris Descartes in France.\nWith the MRI data, radiologists could predict with more than 90 percent accuracy which patients had experienced stroke symptoms for longer than three hours.\nResearchers found that MRI data could accurately determine if patients had experienced stroke symptoms within a three-hour period or less, which would allow the use of a clot-busting drug that works best if administered within that window of time.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story provided insight about a couple of situations in which it wasn\u2019t possible to determine the time of stroke onset. \u00a0The study reported on whether MRI could be used in these sorts of situations when the patient isn\u2019t able to provide information about the time of stroke onset.", "answer": 1}, {"article": "A rare form of blindness inched closer to a cure, after two groups published preliminary studies on replacing the bad gene that causes the condition. The results are likely to boost the prospects of gene therapy, a technique that shows promise but has yet to prove it can be used to cure many diseases.\n\nAbout 2,000 people in the U.S. have Leber's congenital amaurosis No. 2, caused when a child inherits a certain flawed gene from both parents. Patients with the bad gene can't make a protein that is supposed to nourish the eye's...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This article presents a truly novel technique and potential treatment.\u00a0 There\u00a0are no treatments options currently available for this condition.", "answer": 1}, {"article": "Australian researchers have discovered that an existing medication could have promise in preventing breast cancer in women carrying a faulty BRCA1 gene.\nBy pinpointing the cells that give rise to breast cancers in women who have inherited a faulty version of the BRCA1 gene, Walter and Eliza Hall Institute researchers have identified that the drug denosumab may have potential to prevent breast cancer from developing.\n\"We therefore investigated what effect RANK inhibition had on the cancer precursor cells in BRCA1-mutant breast tissue.\"\nProfessor Lindeman, who is also a medical oncologist at The Royal Melbourne Hospital, said the discovery of RANK as a marker of cancer precursors was an important breakthrough, because inhibitors of the RANK signalling pathway were already in clinical use.\n\"By thoroughly dissecting how normal breast tissue develops, we have been able to pinpoint the precise cells that are the culprits in cancer formation,\" she said.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes that: \u201cThis is potentially a very important discovery for women who carry a faulty BRCA1 gene, who have few other options. Current cancer prevention strategies for these women include surgical removal of the breasts and/or ovaries.\u201d That\u2019s enough to merit a satisfactory rating. However, the release would have been much stronger if it had mentioned other options for women with the BRCA1 mutation, such as enhanced screening or chemo-preventive drugs (such as tamoxifen), which may also reduce risk.", "answer": 1}, {"article": "Many people have never heard of rotavirus, but it is one of the most common causes of childhood illness -- many ailments that parents or pediatricians describe as \"stomach flu\" are caused by rotavirus infection.\nVirtually every child in the world contracts the virus repeatedly by age 5, gradually building immunity.\nThe problem occurs naturally, albeit rarely; it showed up at a sharply elevated rate in babies who received RotaShield.\nThe vaccine won approval from the Food and Drug Administration on Feb. 3, and some doctors have received supplies of it.\nRotaTeq contains live, but weakened, strains of rotavirus designed to build immunity without causing illness.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No mention of alternatives.", "answer": 0}, {"article": "\u201cYou can say, \u2018O.K., let\u2019s dismiss the observational studies because they have all these problems.\u2019 \u201d But, he said, despite the virtues of a randomized controlled clinical trial, such a study \u201cwill never ever be done.\u201d It would be impossible to keep people on a low-sodium diet for years with so much sodium added to prepared foods.\nBut that study, others say, will never happen.\n\u201cDiet is a complicated business,\u201d he said.\nLowering salt consumption, Dr. Alderman said, has consequences beyond blood pressure.\nDr. Alderman said that he once was an unpaid consultant for the Salt Institute but that he now did no consulting for it or for the food industry and did not receive any support or take any money from industry groups.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This criterion does not apply with this story.", "answer": 2}, {"article": "\n\u2022 Study addresses key U.S. Food and Drug Administration (FDA) requirement, keeping SHP465 on track for potential 2017 U.S. launch\n\u2022 Key secondary endpoint also met, showing higher proportion of patients were rated improved (p<0.001)\n\u2022 Data add to overall robust clinical development program for SHP465\n\nShire plc (LSE: SHP,NASDAQ: SHPG) today announces positive topline results from a four-week Phase 3, randomized, double-blind, multi-center, placebo-controlled, dose-optimization, safety and efficacy study, SHP465-305, in children and adolescents aged 6-17 years with Attention-Deficit/Hyperactivity Disorder (ADHD).\nThe CGI-I is a standardized assessment tool that allows clinicians to rate the severity of ADHD illness, change over time and efficacy of medication.\nI'm excited about these positive data from SHP465-305 because of the benefit that this potential new treatment option may provide for patients with ADHD.\"\nAdverse events were generally mild to moderate in severity and similar to those observed in previous SHP465 studies and with other amphetamine compounds.\nWe focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "While the news release mentions the existence of other drugs, this new drug is not compared to any of them but to placebo and a symptoms standardization tool.", "answer": 0}, {"article": "So he fears that fat injections for breast enlargement could increase unnecessary biopsies.\nThat hasn\u2019t stopped Dr. Todd Malan, a board-certified ob-gyn in , Ariz., who is the surgeon in the ABC news clip, from anointing himself the \u201cFirst in U.S. to perform Stem Cell Enhanced Breast Augmentation!\u201d on his Web site.\nThe study, which Dr. Khouri plans to publish in a peer-reviewed journal, found that the procedure does not impede the reading of mammograms and that on average, 85 percent of transplanted fat survived to give patients natural-feeling larger breasts.\nBut Dr. Michael F. McGuire, the president of the American Society of Plastic Surgeons, cautioned: \u201cHow you take the fat, how you process it, how you inject it are all factors in how successful fat survival is going to be.\u201d\n\nIn some cases, radiologists can distinguish between innocuous and suspicious calcifications, said Dr. Sameer A. Patel, a plastic and reconstructive surgeon at Fox Chase Center in .\n\u201cAnyone can take fat and inject it into the breast, and the patient will look good immediately afterwards,\u201d Dr. Khouri said, but a few months later, the fat injected by a doctor with sub-par skills may result in \u201coil cysts, masses, and scarring.\u201d\n\nTo some, this kind of fat recycling seems simple.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nThe story mentions breast implants as an alternative to fat grafting. However, except for lower cost, implants are portrayed as inferior to fat grafting in all of the comparisons. Here again, the story should have noted that there are no published studies that directly compare the experiences of women who received fat grafts with those who got implants, so as the task force report noted, no one can yet say with any confidence how the options compare.\nAlso, the story did not mention other alternatives that were noted in the task force report: \u201cAlternative forms of nonsurgical and surgical management consist of injections of man-made substances to improve tissue volume (such as hyanuronic acid, polylactic acid, etc.), use of man-made implants, or other surgical procedures that transfer fat from the body (flaps).\u201d\n", "answer": 0}, {"article": "\"Although there appear to be some benefit of an overall lower death rate in both groups, the [special panel] recommended stopping the trial,\" Nabel said.\nThe study involves 10,251 patients ages 40 to 82 at 77 sites in the United States and Canada at high risk for heart disease for any reason, such as high blood pressure, high cholesterol or obesity.\nNabel stressed that while the death rate was higher in the intensive group, the rate in both groups was still lower than would be expected in patients at high risk receiving standard treatment.\nAbout half were placed on a regimen combining diet and exercise with commonly used drugs designed to lower their blood sugar levels to those of the average person with diabetes, while the other half were put on a more intensive regimen designed to drive levels closer to those of someone without diabetes.\n\"\n\nAn estimated 21 million Americans suffer from Type 2 diabetes, the most common form of the disease, and the number has been increasing because of the obesity epidemic.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While the story stated that the blood sugar levels of those in the group attempting more intensive management were lower than those of typical patients, the story did not provide context for readers to know how their treatment actually would compare to those in the study.\u00a0 ", "answer": 0}, {"article": "Driscoll and her research colleagues used data from 6,467 community-dwelling, postmenopausal women aged 65 and older who reported some level of caffeine consumption.\n\"The mounting evidence of caffeine consumption as a potentially protective factor against cognitive impairment is exciting given that caffeine is also an easily modifiable dietary factor with very few contraindications,\" said Ira Driscoll, PhD, the study's lead author and a professor of psychology at the University of Wisconsin-Milwaukee.\nThe findings come from participants in the Women's Health Initiative Memory Study, which is funded by the National Heart, Lung, and Blood Institute.\n\"What is unique about this study is that we had an unprecedented opportunity to examine the relationships between caffeine intake and dementia incidence in a large and well-defined, prospectively-studied cohort of women.\"\nThe paper \"Relationships Between Caffeine Intake and Risk for Probable Dementia or Global Cognitive Impairment: The Women's Health Initiative Memory Study\" is available at: http://biomedgerontology.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Our expectation is that the release would at least\u00a0share some basic alternatives. For example, this National Institute on Aging education page states regular aerobic exercise is associated with reduced risk of cognitive decline, and that many other lifestyle and dietary factors (such as a plant-based diet) are believed to reduce risk.", "answer": 0}, {"article": "The full picture of the knock-on effects of exposing your gut flora to antibiotics is still coming into focus, said Ramanan Laxminarayan, director of the Center for Disease Dynamics, Economics, and Policy and a leading voice on the dangers of mounting antibiotic resistance.\nThe rate of infection increased in every age group over the age of 15, in both men and women, and in all ethnic groups.\nA commentary published with the study argued that reducing infection rates in men who have sex with men and who are highly sexually active might lower STI infection rates more generally in a community.\nIn reality, the median use among the men was about 6.8 pills per month.\nThe authors noted, however, that the study length was short and they can\u2019t tell if the strategy would work as well over the long term.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story should have noted that this study did not compare the approach of routinely taking a pill after sex to a more conventional approach of regular testing followed by treatment when an infection is found.", "answer": 0}, {"article": "But the scientific evidence has been slim.\nWhat was lacking was clear evidence that taking melatonin in supplement form had the same sleep-inducing effect.\nDo melatonin supplements really help people sleep?\nThat's why there's so much interest in a study in the current issue of the journal Sleep.\nMillions of jet-lagged and sleep-deprived Americans--citing countless self-help articles--insist they do.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article mentioned that melatonin was as effective as the prescription medications Ambien or Lunesta.", "answer": 1}, {"article": "Imperial Health Charity (formerly Imperial College Healthcare Charity) raises funds for five London hospitals within Imperial College Healthcare NHS Trust: Charing Cross, Hammersmith, Queen Charlotte's & Chelsea, St Mary's and Western Eye hospitals.\nBethan Hughes, from Wellcome's Innovation team said: \"This innovation has the potential to transform lives for those who suffer loss of sight through glaucoma, and offers hope of a breakthrough in early diagnosis of other neurodegenerative diseases.\nThe test also has potential for early diagnosis of other degenerative neurological conditions, including Parkinson's, Alzheimer's and multiple sclerosis.\nIn clinical trials, the pioneering diagnostic -- developed by researchers at University College London (UCL) and the Western Eye Hospital -- allowed doctors to see individual nerve cell death in the back of the eye.\nNow, for the first time, we have been able to show individual cell death and detect the earliest signs of glaucoma.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are no mentions of alternative methods to screen for early signs of glaucoma.\nAccording to the American Academy of Ophthalmology, the test for glaucoma is not one test but several including measuring eye pressure and cornea thickness, examining the optic nerve and testing peripheral vision, among other steps.", "answer": 0}, {"article": "Walnuts, that is.\nAnd a study of men attending a fertility clinic, published in May by the journal Human Reproduction, found that high intake of omega-3 fats was linked to more normal sperm size and shape, while high intake of saturated fats was related to lower sperm concentration.\nWalnuts are the only nuts with appreciable levels of omega-3 fatty acids, which some studies of male infertility have linked to better sperm quality, says researcher Wendie Robbins, PhD, of the UCLA Fielding School of Public Health.\nAug. 15, 2012 -- If you aspire to fatherhood, it might not hurt to go a little nuts.\nAnimal and human studies have shown that omega-3 fats and other polyunsaturated fatty acids \u201cplay critical roles in sperm maturation and membrane function,\u201d Robbins\u2019 team writes.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that fish oil is also a source of omega-3 fats that are thought to be beneficial for fertility. It could have mentioned that the\u00a0major omega-3 found in walnuts is\u00a0alpha-linolenic acid (ALA), which is\u00a0a precursor\u00a0to the two long-chain omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), that\u00a0are most consistently associated with health benefits. Only a small amount of ALA gets converted by the human body to these\u00a0beneficial forms, whereas fatty fish is naturally rich in the active long-chain\u00a0fatty\u00a0acids. Therefore, eating fish might theoretically be as good or a better choice for improving fertility.", "answer": 1}, {"article": "Sudden cardiac arrest is a leading cause of death in the United States.\nIn addition, studies show that bystanders are often reluctant to perform mouth-to-mouth resuscitation on strangers, but are more likely to try rapid chest compression.\nThat hesitation is rooted not only in reluctance to lock lips with a stranger, but by anxiety over how to perform conventional CPR, in which the rescuer breathes into the victim twice after every 30 chest compressions.\nStudies show that either mouth-to-mouth or hands-only CPR may double the survival rate from cardiac arrest, but bystanders typically step in to provide the potentially life-saving intervention in only about one-third of cases.\n\"If you have access to an AED (Automated External Defibrillator), you want to apply that as early as possible,\" advised San Francisco General's Barton.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article discusses hands-only and mouth-to-mouth resuscitation, and explains that these are used while bystanders await other options\u2014usually treatment by emergency medical personnel and/or automated external defibrillator and, ultimately, hospital medical staff.", "answer": 1}, {"article": "Many smokers already had sought out spiral CTs, even though the American Cancer Society hasn't recommended the test - citing a lack of clear evidence that they work - and most insurance doesn't cover the $300 to $400 cost.\nNor is it clear if the study results are applicable to all smokers.\nThe trial enrolled people ages 55 to 74 who were or had been very heavy smokers and gave them one scan a year for three years.\nLetters being mailed to study participants advise them to discuss with their doctors whether they should have additional scans or not.\nAbout 200,000 new lung cancers are diagnosed in the U.S. each year, and the disease kills about 159,000 people annually.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThis story highlights advice that quitting is the best way for smokers to avoid lung cancer.\n", "answer": 1}, {"article": "NEW YORK (Reuters Health) - A less common form of obesity surgery may spur more weight loss than its far more popular cousin, gastric bypass \u2014 but at the price of greater long-term risks, researchers reported Tuesday.\nThe study involved 850 U.S. veterans who underwent some form of weight-loss surgery, at an average age of about 50, and more than 41,000 vets who had only non-surgical care.\nThe surgeon removes part of the stomach, and the remaining \u201csleeve\u201d-like stomach is attached to the final section of the small intestine; that puts even greater limits on the body\u2019s absorption of calories and nutrients.\nIn a 2008 study, it accounted for just 1 percent of weight-loss, or bariatric, surgeries done in the U.S., and 5 percent in Europe.\nThe average weight loss seen with either gastric bypass or duodenal switch will improve or reverse obesity-related ills like diabetes, sleep apnea and knee arthritis, according to Livingston, who wrote an editorial published with the study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story concentrates on patients receiving weight-loss surgery, and does not discuss non-surgical alternatives at much length. It does mention the study by Livingston questioning the value of surgery over medical management. Behavior coaching, diet and exercise are all potential treatments for obesity.", "answer": 1}, {"article": "Researchers acknowledge immunotherapy's promise is furthest from realization for bulky solid tumors, perhaps too advanced for the immune system to beat.\nMore are on the way.\nAnderson professor of blood and marrow transplantation.\nThe cancer, glioblastoma, typically kills within that time.\nBy the mid-90s, textbooks had grown to 1,000 pages.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions chemotherapy and radiation as alternatives.", "answer": 1}, {"article": "Her report is the latest warning from researchers who suspect that stents are being overused and may even be causing heart attacks and deaths.\nThey were in stable condition and free of chest pain, and were picked at random to receive either heart medicines only or balloon treatment and stents with heart medicines.\nThe study did not address the use of angioplasty and stents in people who have not had heart attacks.\nThe people who generally do best are those who arrive at the hospital and have angioplasty within 90 minutes of the heart attack.\nThe devices, which came into widespread use in the 1990s, are made of either bare metal or metal coated with a drug meant to help keep the artery from closing again.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story presented the treatment options following a heart attack as a balloon treatment (angioplasty) and stent along with optimal medical management OR optimal medical management alone that were discussed in the study outlined.", "answer": 1}, {"article": "The key asset Pfizer wanted?\nBut the data it presented at the European conference showed that the drug may not actually be more effective than Lynparza, the PARP inhibitor that\u2019s been marketed by AstraZeneca since 2014.\nA few weeks ago, the Food and Drug Administration granted Tesaro\u2019s drug fast-track approval status \u2014 and this new data will support its registration applications to both the FDA and the European Medicines Agency, Tesaro CEO Lonnie Moulder said.\n\u201cAt this time, there\u2019s nothing available that has been approved by regulatory agencies for these women who have recurrence to their ovarian cancer.\u201d\n\nThe company aims to use its PARP inhibitor, rucaparib, to treat only patients with BRCA mutations who have had two or more chemotherapies.\nAt the European conference this weekend, Tesaro added a few more details to that data:\n\nThe study looked at 553 patients whose cancer responds to a certain type of chemotherapy, known as platinum chemo.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention that an existing drug of this type, Lynparza, is being used to treat advanced ovarian cancer in women who have undergone chemo. The story attempts to compare the three drugs under development, but we do wish more data and commentary had been included so readers get a better sense of where each drug stands, and what makes them unique (or not).", "answer": 1}, {"article": "Nezhat advises women to look for a surgeon experienced in doing minimally invasive surgery.\nThe researchers found that the two advanced minimally invasive techniques led to similar results, and both appeared to be generally superior to the traditional open procedure.\nAt the same time, lymph nodes are often removed to determine the stage of the cancer and whether further treatment is necessary.\nOn the other hand, the newness of the technology could have deterred surgeons from using it for difficult cases, potentially biasing the results in a positive way for the robotic technique.\nNo differences between the three methods were seen in the numbers of complications, report the researchers in the journal Obstetrics & Gynecology.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The entire story was based on a systematic review of studies of three surgical approaches to endometrial cancer. The story did a nice job briefly explaining the differences in the surgical techniques and the differences seen in the study.", "answer": 1}, {"article": "For more information about Hebrew SeniorLife, visit http://www.\n\"Our study highlights the fact that having a bone density test not only tells women about their risk of fracture, but also their long term risk for cardiovascular disease.\nBased in Boston, the non-profit, non-sectarian organization has provided communities and health care for seniors, research into aging, and education for geriatric care providers since 1903.\n\"We found that that the presence of calcifications increased the likelihood of having cardiovascular disease such as heart attacks, and even the likelihood of cardiovascular deaths and mortality in general.\"\nThe Institute carries out rigorous studies that discover the mechanisms of age-related disease and disability; lead to the prevention, treatment and cure of disease; advance the standard of care for older people; and inform public decision-making.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "As we noted previously, the Framingham Cardiovascular Risk Calculator is commonly used to assess the 10-year risk of a cardiovascular event and guide related treatment. The release does not mention this tool or how the results of bone density scanning would compare or improve upon it.", "answer": 0}, {"article": "MILAN (Reuters) - An established targeted therapy for bowel cancer may also help women with an aggressive form of breast cancer, a mid-stage clinical study revealed on Monday, opening up a potential new market for the medicine.\nNo question,\u201d he said.\nSales last year were $1.7 billion.\n\u201cThis study clearly opens the field ...\n\u201cWe are very excited by these results,\u201d lead researcher Jose Baselga of the Massachusetts General Hospital Cancer Center in Boston told the European Society for Medical Oncology (ESMO) \u2014 Europe\u2019s biggest cancer meeting.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 2}, {"article": "For more information about deep brain stimulation, visit the American Association of Neurological Surgeons\n\"This is a case report, and not a treatment for anything,\" he said, adding, \"There are risks to this procedure and one has to really look at the tradeoffs.\"\nThe finding introduces the possibility that deep brain stimulation -- a surgical implant that delivers electrical pulses to the brain -- might one day become a treatment for drug-resistant hypertension or lead to clues about the brain's role in regulating blood pressure.\nMONDAY, Jan. 24, 2011 (HealthDay News) -- Doctors administering deep brain stimulation to control a patient's severe pain report that they discovered the treatment consistently lowered the man's hard-to-control high blood pressure.\nThe man's blood pressure gradually decreased enough for him to stop taking all blood pressure medications, though the deep brain stimulation failed to control his pain long-term.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story mentions that multiple drugs may be needed to control blood pressure in individuals with treatment-resistant hypertension, it never mentions the lifestyle factors that contribute to the problem and can help alleviate it if addressed. These include\u00a0obesity, high sodium intake, and heavy alcohol use.", "answer": 0}, {"article": "The Merck drug boceprevir and Vertex Pharmaceutical\u2019s similar drug telaprevir are expected to win FDA approval within months, following phase III trials showing that both drugs boosted cure rates to around 70% when used with standard therapy.\nResults from two phase III boceprevir trials are published in the New England Journal of Medicine.\n\u201cTriple-drug therapy represents a major advance in the treatment of hepatitis C for patients,\u201d he says.\nThe drugs will be used in patients with HCV genotype 1 -- the hardest to treat form of the viral infection.\nAdding one of the drugs to the current two-drug regimen of peginterferon and ribavirin will make the treatment of hepatitis C more complex, but it will also cure a lot more people, hepatitis C specialist Donald M. Jensen, MD, of the University of Chicago Medical Center, tells WebMD.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compares the new drugs to the standard therapy for chronic hepatitis C. \n", "answer": 1}, {"article": "\"But isn't there some benefit to getting tested earlier, like needing fewer lymph nodes removed and not needing chemotherapy?\nAlso, because of the nature of the study and the small sample size in the young age group sub-analysis, Lichtenfeld said that \"this cannot be interpreted as a study telling us what age to start mammograms.\"\nStill, \"the observations are consistent with what we have seen with the value of early detection.\nThey were also 32 percent more likely to need surgery to remove the whole breast (mastectomy), and 66 percent more likely to need lymph nodes removed.\nI think it's safe to say that most women, if they could be assured the same survival, would choose not to get more aggressive therapies,\" she said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes clear that different advisory groups have differing guidelines for what age to start getting mammograms (40 or 50 years old).\nIt would have been nice if the story had included examples of what makes someone higher risk or not (personal cancer history, family history, history of radiation), but we think this was satisfactory.", "answer": 1}, {"article": "That study was funded by the device\u2019s manufacturer, Neuronetics, a company based in Malvern, Pa.\nMagnetic stimulation is aimed at patients with such \u201ctreatment-resistant depression.\u201d\n\nSupporters say rTMS is worth the cost \u2014 between $6,000 and $12,000 for the four-to-six-week treatment \u2014 because it enables people such as Curtis to resume productive lives.\nThe costs of ECT \u2014 typically about $3,300 for four weeks of thrice-weekly treatments, according to AHRQ data \u2014 are covered by most private insurers as well as by Medicare and Medicaid.\nThe procedure, which is more widely used than rTMS, requires two to three treatments a week for three to four weeks and is effective for many patients.\nThe technique has been shown to work better than a placebo, but the proportion of patients who show complete relief ranges widely, from as few as 10 percent to as many as 57 percent, according to various studies.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job comparing rTMS with the major treatment alternative for patients who do not respond to antidepressant medication: electroconvulsive therapy. ECT has a much longer track record of use and is more effective, but has more risks and side effects and may not be feasible for patients who are not good candidates for anesthesia.\nThe story could have compared rTMS to FDA approved vagal nerve stimulation (also evaluated in the AHRQ report) \u2013 which has even weaker evidence for benefit.", "answer": 1}, {"article": "The U.S. Food and Drug Administration today approved Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis.\nThe most common adverse reactions reported with the use of Siliq include joint pain (arthralgia), headache, fatigue, diarrhea, throat pain (oropharyngeal pain), nausea, muscle pain (myalgia), injection site reactions, influenza, low white blood cell count (neutropenia) and fungal (tinea) infections.\n\"Moderate-to-severe plaque psoriasis can cause significant skin irritation and discomfort for patients, and today\u2019s approval provides patients with another treatment option for their psoriasis,\" said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nSiliq is also approved with a Medication Guide to inform patients of the risk of suicidal ideation and behavior, and that because Siliq is a medication that affects the immune system, patients may have a greater risk of getting an infection, or an allergic or autoimmune condition.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Since Siliq is recommended as a last resort drug of sorts, the news release hints there are other alternatives available. These include other topical treatments like anti-inflammatory drugs, light therapy and oral/injected medications, such as immunosuppressants.\nAlthough we would have liked more elaboration on other treatment options, we feel the news release did just enough for a Satisfactory rating here.", "answer": 1}, {"article": "Professor Tony Barrett, from the Department of Chemistry, said: \"This work is the result of extensive collaboration between chemists, biologists and clinicians, which has helped to bring a new treatment from discovery to clinical testing in record time, streamlining the process.\"\nThe trial is still ongoing, so results are not available yet.\nWe hope that this promising new class of drug will offer more options to patients who have few left available to them, and help more people survive their cancer.\"\nThe drug may not become available to patients for a number of years yet, but researchers believe that if clinical trials are successful, it could be used to tackle a variety of treatment-resistant cancers.\nParticular cancers, such as treatment-resistant breast cancers, have a unique dependence on transcription, meaning targeting CDK7 may be particularly effective.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There\u2019s no mention of competing projects to develop better therapies for hard-to-treat cancers.", "answer": 0}, {"article": "The current study sets the stage for clinical trials in humans.\n\"This work is very exciting and promising,\" said Nichols, who added, \"The FVII-deficient dogs tolerated the initial gene therapy infusions very well and have had no adverse side effects over several years of follow up.\nBoth Nichols and Margaritis agreed: \"The table is now set to propose clinical trials that would treat people who suffer from FVII deficiency.\"\n\"These dogs have the type of mutation found in the majority of patients with this disorder, so this approach could lead to a sustained gene therapy in people.\"\n\"We developed a unique animal model of this disease after identifying dogs with naturally occurring factor VII deficiency,\" said Margaritis.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release tells us that this rare clotting disorder is currently treated by infusions of clotting factors. The release could have done a better job of explaining how difficult that therapy is for patients. Is the disorder regulated well by that method? We aren\u2019t given any information or what those costs are vs. what a one-time gene therapy might cost.", "answer": 1}, {"article": "On The Early Show Friday, Family Circle magazine Editor in Chief Linda Fears discussed everyday lessons that can make a big difference.\nIt's a tremendous challenge for parents to teach their teenagers and \"tweens\" everything they ought to know.\nFor more information on this subject, see these two articles on WebMD: Weight Loss: How To Read Food Labels and Cracking the Code.\nTo watch the segment,\n\nFor much more on folic acid, from the federal Centers for Disease Control and Prevention, click here.\nNow, there's new information showing how important folic acid is.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Recommendations of adequate folic acid intake were presented.\u00a0 The treatment options, obtaining folic acid from dietary sources or from supplements were both presented.", "answer": 1}, {"article": "Omalu found traces of the disease in the brain of legendary Pittsburgh Steelers player and pro Hall of Famer Mike Webster in 2002.\nWhen compared to the brains without CTE, researchers found those brains with CTE had significantly higher amounts of CCL11, even when compared to those brains with Alzheimer's, another degenerative brain disease.\nHowever, contrary to the popularly held belief that a greater number of concussions are linked to CTE , no connection was found between levels of CCL11 and reported number of concussions.\nIn this new study, researchers found an increased amount of the protein CCL11 in patients previously diagnosed with CTE.\nAlthough there are different stages of the disease that indicate how far it has progressed, this study was unable to determine any connections between levels of CCL11 and severity of CTE.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes it clear that there is no method for diagnosing this brain disorder in living people, and it mentions that other biomarkers are being tested.\nHowever, the information was relayed in a somewhat confusing way. The story notes that a diagnostic approach focusing on CCL11 may only be \u201cone part of a larger process.\u201d It then quotes a researcher from the study as saying: \u201cThis may be one of the abnormalities [of the disease], but it may take 2-3 to be useful to diagnose CTE.\u201d The story then refers to other studies that have attempted to identify other means of diagnosing CTE in living patients. However, it offers little information on those other diagnostic tools. Presumably, they have significant limitations since we are still unable to diagnose CTE in the living. But perhaps other biomarkers have been found, but not yet incorporated into a reliable diagnostic tool. Either way, we wish that had been more clear \u2014 as well as the relevance of these previous studies to the CCL11 research.", "answer": 1}, {"article": "To find out more about mercury in seafood, go to the Got Mercury?\nThe point is that you should have a variety of types of seafood and not limit yourself to one type, and variety includes canned tuna.\u201d\n\nAlice Lichtenstein, senior scientist and director of the Cardiovascular Nutrition Laboratory at Tufts University said the panel hasn\u2019t suggested that pregnant women eat more tuna.\nIn the report, the panel argues that albacore tuna is a \u201cspecial case.\u201d They noted that even when women ate double the recommended weekly amount of tuna, the benefits far outweighed the risks.\nFish is rich in omega-3 fatty acids, B vitamins, iodine, selenium and vitamin D. And numerous studies show that the nutrients in fish are particularly important for brain development in fetuses and nursing infants.\n\u201cIt may be that the issue is re-evaluated and there is no change.\u201d\n\nMercury levels in our oceans are on the rise due to an increase in industrial mercury emissions.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that health officials recommend fish that \u201care lower on the food chain and have accumulated less mercury in their tissue,\u201d such as sardines and salmon. The story also states that salmon contains significantly less mercury than tuna, and lists other types of seafood that are recommended by Consumer Reports as being low in mercury. We\u2019ll call that good enough for a satisfactory rating. The story could have mentioned other factors \u2014 for example, reading aloud to your child \u2014 that are also associated with improved childhood brain development.", "answer": 1}, {"article": "People with cluster headaches can have as many as eight per day in bouts that last for weeks or months.\nThe study found that 78 percent of patients reported being pain-free or having adequate relief within 15 minutes of receiving high-flow oxygen, compared with 20 percent of patients after they received high-flow air.\n\"This work paves the way for further studies to optimize the administration of oxygen and its more widespread use as an acute attack treatment in cluster headache, offering an evidence-based alternative to those who cannot take triptan agents,\" they concluded.\nThe current treatment is injection with the drug sumatriptan, but frequent use of the drug isn't recommended because of the risk of adverse effects.\n\"To our knowledge, this is the first adequately powered trial of high-flow oxygen compared with placebo, and it confirms clinical experience and current guidelines that inhaled oxygen can be used as an acute attack therapy for episodic and chronic cluster headache,\" wrote Anna S. Cohen, of the National Hospital for Neurology and Neurosurgery in London, and colleagues.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story fails to compare pain relief from the standard drug treatment with that of high-flow oxygen. The study itself failed to do this, but a diligent reporter would have dug to find outcomes data on the drug treatment. ", "answer": 0}, {"article": "Cigarette smoking is responsible for 90 percent of all lung cancer cases in the United States.\nIt turned out that gene activity in the PI3K pathway was \"off the chart\" in smokers with lung cancer versus those without the disease.\nAnd when treated with the compound myo-inositol, the gene pathway activity declined along with improvement in the troublesome lesions, the researcher noted.\nMaybe one day, screening could be done using an even simpler nasal or sputum test, the researchers said.\n\"It's incredibly, incredibly exciting,\" said Dr. Patrick Nana-Sinkam, a lung cancer expert with the Ohio State University Comprehensive Cancer Center, who was not involved with the new study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Not only was the other genetic signature research not mentioned, there was no discussion of other means of detecting early lung cancer such as chest CT \u2013 albeit controversial. ", "answer": 0}, {"article": "After her mother unexpectedly died from a tear in the wall of her heart at age 63, Patricia Walters talked to her doctor, Leslie Cho, about how to better monitor her own heart health.\n\nPregnant at the time with her own daughter, Ms. Walters, now 46, says she was \"a nervous wreck\" worrying that she, too, might face serious cardiac risk.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Because of the imbalance in its framing, the story doesn\u2019t even discuss the option of not having the test \u2013 which can be a rational choice.\u00a0 The framing \u2013 \u201csimple blood test\u2026easily done at the same time as a cholesterol screening, and covered by most insurance\u201d \u2013 is promotional.\u00a0 Why don\u2019t some experts think this test adds much?\u00a0 What is the evidence for that perspective?\u00a0 That alternative viewpoint is clearly downplayed.", "answer": 0}, {"article": "The Ache: In the digital age, many people spend hours daily bent over computers, phones and tablets\u2014our necks craned forward. Some scientists say this unnatural position can lead to pain, headaches and other symptoms, sometimes collectively called \u201ctext neck.\u201d\n\nThe Claim: Technology itself comes to the rescue. An Android app called the Text Neck Indicator measures the angle of your phone and lets you know when you\u2019re holding it in a favorable viewing position. And a new wearable device, Alex, monitors the angle of your neck...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does cite a physical therapy expert about steps that can be taken to prevent or minimize neck pain. For example, the story says, \u201cWhen you\u2019re working on a computer or using a device, try to take a break every 15 or 20 minutes and stretch or change position.\u201d That\u2019s good, but for many people experiencing neck pain, it may not be enough. There are a wide array of treatment options for neck pain, depending on the diagnosis of what is causing the pain, including medication (such as NSAIDs like ibuprofen) and physical therapy.", "answer": 1}, {"article": "They\u2019re also studying the cost difference.\n\u201cWe are actually not surprised that there isn\u2019t a big difference between the two because both therapies are effective at relaxing the overactive bladder muscles.\u201d\n\nWomen can choose between a surgical procedure, which is more expensive at first, versus regular Botox injections, which are less costly and less invasive but which could add up over time, Amundsen said.\n\u201cPregnancy, childbirth, menopause, and the structure of the female urinary tract account for this difference.\u201d\n\nThe researchers at nine medical centers did a head to head comparison of a single Botox injection to the implanted medical device, assigning 381 women to randomly get one or the other treatment.\nThe Botox injections freed 20 percent of the women in the study of incontinence, compared to 4 percent who had a nerve stimulator implant, Amundesen and colleagues reported in the Journal of the American Medical Association.\nOn average, both treatments cut the number of \u201caccidents\u201d \u2013 Botox by almost four times a day and the nerve stimulator by about three times a day.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We not only see a comparison to the medical device that the study focused on, but also methods that require no overt treatment, \u201csuch as weight loss, drinking less caffeine and alcohol, and avoiding lifting heavy objects.\u201d The story also notes that \u201c[e]xercises to strengthen the pelvic floor muscles can help, as can \u2018bladder training\u2019 to accustom the body to urinating at regular times.\u201d\nThe story could have been more clear that these treatments aren\u2019t likely to work for the women in this study who had a specific type of severe urge incontinence that is usually not responsive to exercise and other less invasive measures.", "answer": 1}, {"article": "Rosenfeld says it's never wrong to prescribe an antibiotic for a well-diagnosed ear infection.\nThese 2 new studies were designed to provide the research to fill the gap, and clarify treatment recommendations for babies and toddlers.\nThe foundation for the \"watchful waiting\" treatment recommendation instead of taking drugs is based on this and previous studies that did not have very many children under age 2 in the clinical trials.\nThe study authors caution about the overuse of these drugs and the risk of antibiotic resistance.\nIn the United States study, 80% of the children on antibiotics felt better on the seventh day of treatment; 74% of the children taking a placebo also felt better on the seventh day.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story adequately describes the rationale supporting watchful waiting, which is the primary alternative to antibiotics for an acute ear infection.", "answer": 1}, {"article": "The Mount Sinai Hospital is in the \"Honor Roll\" of best hospitals in America, ranked No.\nDr. Wanna and a team of researchers from Vanderbilt University examined roughly 230 patients with every type of cochlear implant, including three FDA-approved implants that use different types of electrodes to stimulate the auditory nerve.\nDr. Wanna and the researchers also looked at the impact of two major surgical approaches used to insert the electrodes in the inner ear: \"round window\" (where surgeons open the membrane without bone removal or drilling in the inner ear) and \"cochleostomy\" (which requires drilling into the bone to get inside the inner ear).\nMore specifically, the non-wire electrodes were less traumatic, causing less injury and minimizing fractures inside the inner ear.\nThey found that electrodes designed with no wire (called lateral wall electrodes) performed the best in maintaining residual hearing in the inner ear, compared to electrodes made with wire.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are a variety of ways to treat hearing loss besides cochlear implants but, outside of the mention of oral steroids (with no detail given), none are mentioned.", "answer": 0}, {"article": "When treating a patient suffering from depression, Brent Forester considers which anti-depressant to prescribe\u2014ideally, one that will ease psychic pain without side effects.\n\nIt can be a tough call.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although quantification is mostly missing, the article properly points out that clinical judgment-based treatment alone misses the mark a lot of the time, and is essentially educated guesswork. The article might have been strengthened even more had it given information about alternatives or adjuncts to drugs, such as behavioral therapy and electroshock therapy.", "answer": 1}, {"article": "However, they say these findings \u201craise questions that warrant investigation\u201d and call for verification in randomised studies \u201cbefore recommending a change to current practice.\u201d\n\nNotes to Editors\n\n Research: Antenatal nutritional supplementation and autism spectrum disorders in the Stockholm youth cohort: population based cohort study\n\n Journal: The BMJ\nResearch indicates that ASD most likely develops in the womb and that a mother\u2019s diet during pregnancy could have an influence.\nThere was no consistent evidence that either iron or folic acid use were associated with a reduced risk of ASD.\nThe researchers stress that their findings cannot establish cause and effect, but say they raise questions about a possible association that warrant further investigation.\nSo an international research team set out to assess whether nutrient supplementation during pregnancy is associated with reduced risk of ASD, with and without intellectual disability.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does not discuss that pregnant woman might achieve recommended vitamin intake via the food they eat.", "answer": 0}, {"article": "Pre-implantation genetic screening doesn\u2019t necessarily get patients pregnant unless they have good embryos, Robbins noted.\n\u201cThey\u2019ve lost family members generation after generation after generation, or they\u2019ve had family members who\u2019ve suffered from chronic disease that\u2019s totally preventable.\u201d\n\nThese procedures not only help limit the passing on of diseases\u2014 they may also help couples get pregnant faster.\n\u201cWe can\u2019t fix the embryos yet, but we can determine which embryos are affected by the disease and which aren\u2019t and only transfer back those that are not affected,\u201d Robbins, who is also a fertility doctor at Northwestern Memorial Hospital, said.\n\u201cWe have the technology and ability to eradicate diseases that have ravaged families for decades,\u201d Dr. Kaylen Silverberg, of Texas Fertility Center, told Fox News.\nSpecialists now have a way to test the parents-to-be that may not only increase their chances of getting pregnant but also reduce the risk of them passing on certain genetic diseases.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternative to screening before implantation is not screening before implantation. That\u2019s sufficiently clear that we\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "Tumor cells make PD-L1 turn on PD-1 when immune cells approach.\nLung cancer is the top cancer killer in the U.S. It\u2019s diagnosed in more than 220,000 people a year and it killed nearly 160,000 people last year, according to the National Cancer Institute.\n\"I suspect the findings were significant enough that this will be a practice-changing finding,\" Dr. Pasi Janne, lung cancer specialist at Harvard Medical School and the Dana-Farber Cancer Institute, told NBC News.\nRelated: Keytruda Keeps Some Patients Alive For Three Years\n\n\"Immunotherapy is a whole new way of treating cancer, including lung cancer,\" said Janne, who was not involved in the study.\nThe drug, Keytruda, is the same drug that former president Jimmy Carter says helped stall advanced melanoma that had spread to his brain.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does talk about the alternatives to this drug, and the \u201cso-called standard of care.\u201d But it does not provide any numbers to back these comparisons up. There\u2019s a dilemma here because Merck did not release the details of the study. We would have been happy, though, even if the story made mention of some of the comparison findings from other studies. The drug is approved for treatment in lung cancer, so there must have been previous trials that could be referenced.", "answer": 0}, {"article": "Fleischman, the March of Dimes official, says there's no such risk from 17-HP, partly because it's not used before the 16th week of pregnancy, when fetal organs have already formed.\nThe drug is not for women whose prior premature births were of twins or other multiple births, or who are carrying more than one fetus in their current pregnancy.\nEveryone in this field is mindful of the long-running tragedy of vaginal and other cancers and male urinary disorders that resulted from the last drug thought to prevent premature birth \u2013 a synthetic estrogen called diethylstilbesterol, or DES.\nThe study showed that 37 percent of women who got weekly injections of it delivered prematurely, compared to 55 percent of women who got injections of a placebo.\nNor is it for women who have other conditions that raise their risk of preterm birth, such as high blood pressure or infection.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was at least the historical perspective on \u201cthe last drug thought to prevent premature birth \u2013 a synthetic estrogen called diethylstilbesterol, or DES.\u201d", "answer": 1}, {"article": "But in a new study the kids who consumed the fermented dairy product did no better, based on number of stools produced, than youngsters in a comparison group.\nThe study examined 159 children with constipation for at least two months with a defecation rate of less than three times per week.\nThe finding is significant, the researchers say, because probiotics have helped some adults with constipation.\nIt seemed logical that probiotics, live microorganisms that are often called \u201cfriendly\u201d or \u201cgood\u201d bacteria, might work for children.\nAbout half were given the probiotic product twice daily for three weeks; children in the comparison group were given a dairy product without the probiotic.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll give the story the benefit of the doubt on this criterion. The story indicated that a regular diet supplemented with probiotics was not better for relief of constipation in children than supplementation with dairy products.\nAt the end of the piece, there was mention of treatment which consists of education, dietary advice, behavioral modification and then if these were unsuccessful, the use of laxatives. Because in this context \u2018dietary advice\u2019 often refers to fiber content and fluid consumption in the diet, it is not clear how probiotics compared to these other approaches.", "answer": 1}, {"article": "New research by scientists at the University of Maryland School of Medicine has found that esophageal cancer patients treated with proton therapy experienced significantly less toxic side effects than patients treated with older radiation therapies.\nThe results have particular relevance for the University of Maryland School of Medicine; this fall the school will open the Maryland Proton Treatment Center (MPTC).\nWhile most cancer patients are well served with today's state-of-the-art radiation therapy technology, up to 30 percent are expected to have a greater benefit from the new form of targeted proton beam therapy.\nOthers include:\n\u2022 Selective Internal Radiation Therapy, a precision modality for treating patients with particularly difficult-to-remove tumors involving the liver such as those from colorectal cancers;\n\u2022 Thermal Therapies, the use of \"heat\" in treating a broad spectrum of malignancies.\n\"This evidence underscores the precision of proton therapy, and how it can really make a difference in cancer patients' lives,\" said Dr. Chuong.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does discuss alternative cancer therapies, such as Gammapod and selective internal radiation therapy \u2014 but neither of those therapies is used on esophageal cancer. In fact, the list of therapies included in the release muddies the water for readers: it\u2019s not clear why it\u2019s there. However, the release does not discuss longstanding treatment options for esophageal cancer, such as surgery and chemotherapy. This is particularly problematic because esophageal cancer treatment often involves chemotherapy and radiation therapy, or chemotherapy, radiation therapy and surgery. Discussing radiation therapy in isolation may give readers a skewed picture of treatment options \u2014 particularly for Stage II, III, and IV esophageal cancer.", "answer": 0}, {"article": "The Johns Hopkins researchers also calculated the effects of surgery on health costs for the patients.\nWhile mortality in the hospital was 0.3 percent, some 21 percent of patients had to be admitted to the hospital again for one reason or another within a year of their operations.\nThe ultimate savings case requires some extrapolation, though.\nFinally, surgery isn't without risk.\nThe cost of the surgery was about $30,000, which exceeds the savings observed directly.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThere is no information about alternative approaches. Even in a brief blog post, just a line about alternatives would satisfy this criterion. ", "answer": 0}, {"article": "In Manhattan some raw-milk drinkers hire a mule to bring the white stuff to an agreed-upon location in...\nCarol Peterson, an IT manager at Xerox, drives almost two hours each month to her favorite farm in upstate New York for her unpasteurized supply.\nAnd they consider themselves lucky.\nNo biggie--just zip to your local supermarket and pick up a carton.\nNow that's trickier.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Beyond mention of raw milk and pasteurized milk, the story mentioned that two states (Washington and Maine) which permit raw milk to be sold but hold it to the same standard for bacteria counts as pasteurized milk.", "answer": 1}, {"article": "Doctors say bronchial thermoplasty has given them a new weapon in the battle against severe asthma, and many patients call it life-changing.\nAvoiding allergens and using inhaled medications are enough to keep asthma under control in most patients.\nAfter the procedure, the airways no longer are so prone to constricting, studies show.\nIt takes place in three steps, each separated by about three weeks.\nAsthma patients suffer fewer attacks and need fewer hospital visits.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that avoiding allergens and using inhaled medications are enough to keep asthma under control in most patients.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Fast food outlets should hand out free cholesterol-lowering statin drugs to their customers to \u201cneutralize\u201d the heart risks of eating fatty foods like burgers and fries, British scientists suggested on Thursday.\n\u201cThey are not a magic bullet.\u201d\n\nA study in June in the Archives of Internal Medicine suggested, in fact, that statins do not save lives in patients without heart disease, although they may prevent some non-fatal heart attacks.\nTaking a statin is a rational way of lowering some of the risks of eating a fatty meal.\u201d\n\nStill, Peter Weissberg, medical director at the British Heart Foundation (BHF) health charity, said Francis\u2019 idea should not be taken too literally.\nWhile statins might combat some of the toll that fatty foods take on cholesterol, there\u2019s a lot they can\u2019t negate: \u201csodium content is high, fibres are absent, and caloric load gargantuan,\u201d Messerli said of the fast food the authors looked at.\nIn a study published in the American Journal of Cardiology, scientists from the National Heart and Lung Institute at Imperial College London calculated that the reduction in heart disease risk offered by a statin could offset the increase in risk from eating a cheeseburger and a milkshake.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The first quote in the story says \"It\u2019s better to avoid fatty foods altogether.\" And the story goes on to make that point in several ways. The story quotes directly from the editorial, too, saying that there is \"no substitute for systematic lifestyle improvements, including healthy diet, regular exercise, weight loss, and smoking cessation\".", "answer": 1}, {"article": "A common heart drug called a beta blocker was associated with a striking increase in survival for women with ovarian cancer in a study that suggests a possible new strategy for treating a variety of tumors.\n\nResearchers analyzing a database of 1,425 women with the tough-to-treat cancer found those who had taken a certain type of beta blocker lived more than four years longer on average than those who hadn\u2019t been prescribed the drug. The women were taking the medicine to treat high blood pressure or another heart problem, not...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The relevant research is based on evaluating the use of beta blockers in conjunction with conventional chemotherapy, not as an alternative to chemotherapy or other courses of treatment. As such, we\u2019ll rate \u201cCompare Alternatives\u201d as Not Applicable.", "answer": 2}, {"article": "\"Apixaban is now the first oral anticoagulant [blood thinner] to show a statistically significant improvement in survival over warfarin in atrial fibrillation patients,\" Fonarow said.\n\"The three of them together showed that the risk of bleeding was just too high and there was no real benefit in that population.\nFor the trial, more than 18,000 patients with atrial fibrillation and a heightened risk for stroke were randomly assigned to receive either apixaban or warfarin.\nHowever, \"in that case, apixaban was given to patients with coronary artery disease who were also taking two other blood thinners,\" Ansell noted.\nThe major effect on stroke was preventing hemorrhagic stroke, which is caused by bleeding in the brain and is the most serious type of stroke.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compared the outcome measure of apixabane to warafarin; in addition, it indicated that there is another medication in the same category that has been recently approved by the FDA.", "answer": 1}, {"article": "At the recommended doses, evidence of the desired drug effect in tumors has been obtained using novel PET imaging at Penn.\nIn addition to inhibiting the cell cycle, palbociclib has been shown, for example to alter several recently described non-cell cycle functions of CDK4/6, a finding expected to expand its therapeutic role, O'Dwyer added.\nPalbociclib targets the rapid division of tumor cells by inhibiting the activity of the enzymes CDK4 and CDK6, which propel cell division and increase in number in most cancers.\nAlso, combining palbociclib with other anti-cancer agents is feasible, and early results in myeloma and some solid tumors have led to more definitive studies.\n\"All living cells undergo cell division and palbociclib's unique capacity to halt the cell division process (also known as the 'cell cycle') therefore has potentially broad applicability,\" said the study's lead author Amy S. Clark, MD, MSCE, an assistant professor of Hematology/Oncology at Penn's Perelman School of Medicine and ACC.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Since there is no comparison to standard therapy it\u2019s hard for the reader to come away knowing what the pros and cons are for the drug and how advantageous a tumor cell inhibitor might be to a patient\u2019s specific cancer.  ", "answer": 0}, {"article": "While Roche did not provide specific overall survival data, the headline result helps its bid to catch up to better-established immunotherapies from Merck and Bristol-Myers Squibb and its shares rose about 1 percent in early trading.\nThe Basel-based company, which had previously announced Tecentriq, Avastin and chemotherapy had reduced the risk of disease progression or death, said on Monday it hopes for a quick approval from authorities for the cocktail.\nThis could help Roche make the case that its cocktail is suitable for broad patients groups, not just those with specific biomarkers.\n\u201cWe are pleased the IMpower150 study demonstrated a clinically meaningful survival benefit for people receiving their initial treatment for this type of advanced lung cancer,\u201d said Sandra Horning, Roche\u2019s chief medical officer.\nShe also said the survival benefit was observed across key subgroups, including those with varying levels of a protein called PD-L1 that can help tumors avoid detection.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story contains some information about the nature of the new clinical trial and that it was designed to compare the \u201cnewer\u201d cocktail to older ones, including one with a drug made by Roche. It\u2019s also open that this is meant to boost sales of a drug to help offset the loss associated with other drugs going generic or facing biosimilar competition.\nThat wasn\u2019t enough, though. Readers are not given enough information to know if this cocktail is better than cheaper and more tested alternatives. For example: What about the outcomes of lung cancer patients treated with the combination of drugs without immunotherapy?", "answer": 0}, {"article": "Reiman wrote a commentary that accompanies the study in Nature.\nThe results are encouraging for pharmaceutical companies that have spent billions of dollars on efforts to come up with the first drug to treat the underlying cause of Alzheimer's.\n\"It was surprising, encouraging and thought-provoking to see such a striking reduction of existing plaques,\" Reiman says.\n\"If that hint of a clinical benefit is confirmed, it would be a game changer in the fight against Alzheimer's disease,\" says Dr. Eric Reiman, executive director of the Banner Alzheimer's Institute in Phoenix.\nResults from a small number of patients who received a high dose of the drug, called aducanumab, hint that it may also be able to slow the loss of memory and thinking.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is clear that there are no drugs that treat the underlying cause of Alzheimer\u2019s. It links to a story about a competing amyloid-reducing drug that failed to produce any benefit in a large clinical trial.\nWe did want to know: Are there any older drugs that have been tried for this? Were they equally optimistic when they were first introduced?\u00a0 Putting them into perspective would help as it seems there were prior drugs that were hyped to prevent or slow the progression of AD\u2013but subsequently didn\u2019t pan out.", "answer": 1}, {"article": "For more industry information, health research and recipe ideas, visit =.\nColorectal cancer is the third most common type of cancer worldwide and is second to only lung cancer as the leading cause of death in Western Countries.1 Diet has been shown to be a modifiable risk factor in preventing many types of cancer, including colorectal cancer.\nIt is estimated that 30-50 percent of colorectal cancer in men and 20 percent in women can be prevented by diet and other lifestyle changes.2\n\nAn article detailing these findings, \"Dietary Walnut Suppression of Colorectal Cancer in mice: mediation by miRNA patterns and fatty acid incorporation\" has been published in the Journal of Nutritional Biochemistry.3\n\nThis study was supported from a grant by the American Institute for Cancer Research and the California Walnut Commission.\nThis is the first study that evaluates whether walnut consumption can cause changes to micro-ribonucleic acids (miRNA), the nucleotides that are involved in altering gene expression.\nThe study results found that a smaller tumor size was associated with greater percentage of omega-3s in tumor tissues, suggesting that ALA may provide a protective benefit.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release discusses the chemistry of inflammation and the growth of tumors in the mice. It briefly mentions \u201cdiet and lifestyle changes\u201d as means to reduce risk, but does not discuss what specific changes are shown to be helpful. It also does not discuss screening and polyp removal, arguably the best-supported intervention for catching colon cancer before it spreads.", "answer": 0}, {"article": "MONDAY, Jan. 11, 2010 (HealthDay News) -- As a major organization of pediatricians considers revising its recommendations on circumcision of newborn boys, two new reviews of existing research offer conflicting conclusions about the bitterly debated procedure.\n\"There are some clear benefits to circumcision,\" he said.\n\"These may be considered unacceptable for an elective procedure,\" she said.\n\"There are some risks to circumcision, although the significant ones appear to be rare.\"\nTwo studies involved neonatal circumcision, and six involved older males, roughly 14 to 49 years old.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 0}, {"article": "Even if they are promising, however, the company will have to conduct a final trial before it can apply for F.D.A.\nThis lack of positive physiological reinforcement for smoking is believed to reduce the nicotine craving that causes smokers to fail in their efforts to quit.\nThe multishot sequences being tested are designed to extend the antibody response for many months, although eventually the body will stop producing the anti-nicotine antibodies, he said.\nAn effective vaccine could play a major role in reducing smoking around the world, said Dr. Vocci, who estimated that current rates of smoking would lead to one billion deaths in the 21st century.\nBecause the compound is too big to cross the blood-brain barrier, the vaccine is expected to diminish or eliminate the pleasure associated with puffing a cigarette.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does a good job covering existing drug therapies, but misses behavioral therapies (of proven benefit) entirely.", "answer": 1}, {"article": "\"It's kind of an extreme makeover of a cell,\" said Douglas A. Melton, co-director of the Harvard Stem Cell Institute, who led the research.\n\"The goal is to create cells that are missing or defective in people.\n\"It introduces a whole new paradigm for treating disease.\"\nResearchers in the field, who have become accustomed to rapid advances, said they, too, were surprised by the advance.\nAlthough the experiment involved mice, Melton and other researchers were optimistic that the approach would work in people.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no discussion of treatment options; however this story was not actually about a treatment but a highly-experimental approach in mice.", "answer": 2}, {"article": "Newly postmenopausal women who received estrogen via a skin patch had reduced beta-amyloid deposits, the sticky plaques found in the brains of people with Alzheimer\u2019s disease, a Mayo Clinic study published this month in the Journal of Alzheimer\u2019s Disease found.\n\u201cIt also may have a significant impact on women making the decision to use hormone therapy in the early postmenopausal years.\u201d\n\nStudy co-authors are Val Lowe, M.D.\n\u201cThis study showed, for the first time, that the brain amyloid deposition \u2500 a hallmark of Alzheimer\u2019s disease \u2500 is reduced in newly postmenopausal women who received 17beta-Estradiol patch form of hormone therapy,\u201d says lead author Kejal Kantarci, M.D., a Mayo Clinic radiologist.\nThe authors are seeking funding to perform amyloid PET imaging at eight more Kronos Early Estrogen Prevention study sites around the U.S.\n\n\u201cIf our results are confirmed in the larger group of women, this finding has the potential to change the concepts for preventive interventions that drive the Alzheimer\u2019s disease field today,\u201d Dr. Kantarci says.\n\u201cWomen with APOE e4, who have a greater genetic risk for Alzheimer\u2019s disease, particularly benefited from this therapy.\u201d\n\nMenopause is defined as occurring 12 months after a woman\u2019s last menstrual period and marks the end of menstrual cycles.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release offers no other approaches available to postmenopausal women for reducing Alzheimer\u2019s disease risk and that\u2019s appropriate in this case. It would be an over-reach to try and name the many other Alzheimer\u2019s disease prevention options being studied.\nIn addition, the findings\u00a0address an intermediate endpoint, i.e. amyloid deposition as a disease marker, not the disease itself.", "answer": 1}, {"article": "Sadly, disappointment is part of it, according to Pharr, who typically hears the frustration of people who go through a study that worked for another person but not for them.\nThe ethics of human experimentation were thoroughly examined before the study began.\nThe results of the study: Most participants fared well.\nNeither his primary care physician nor his neurologist could identify the cause of his deterioration.\nIn fact, they first believed he had suffered a stroke.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that there are no effective treatments available.", "answer": 1}, {"article": "Examining more than 500,000 Facebook posts from both groups, researchers determined which words, post lengths, frequency of posting and timing of posts were most associated with a depression diagnosis. They found people with depression used the words \"I, my, and me,\" as well as such words as \"hurt, tired, and hospital,\" more often than others in the months preceding their diagnosis. Using indicators such as these, they built a computer model that could predict which people would receive a depression diagnosis with comparable accuracy to commonly used clinical surveys.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job of articulating how the social media model might differ from conventional depression diagnostic tools, as well as how these approaches could potentially be used to support each other (rather than using one in place of the other).", "answer": 1}, {"article": "Further,Dr.\n\u201cIf you take the core patients who are at highest risk, it makes you appreciate how important this drug class is,\u201d said Dr. Amit Khera, Director of the Preventive Cardiology Program and Associate Professor of Internal Medicine at UT Southwestern.\nFrank Brown of Dallas, grandfather of six and the owner of Frank\u2019s Wrecker Service in Dallas, has familial hypercholesterolemia, an inherited condition that causes high levels of cholesterol, especially low-density lipoprotein (LDL) cholesterol or \u201cbad cholesterol.\u201d High levels of LDL cholesterol are strongly associated with heart disease.\nUsing data from the Dallas Heart Study, a population-based study that gathered extensive medical data on 6,000 Dallas residents, the two researchers showed that certain mutations to the gene that codes for the protein PCSK9 lead to low levels of cholesterol in the blood.\n\u201cIn the world of cholesterol patients, most are well-controlled with statins, and they should stay on those,\u201d said Dr. Khera.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does mention three other drugs that are designed to reduce cholesterol levels. However, the release would have been stronger if it had also mentioned the importance of diet, exercise and other lifestyle factors that can significantly influence cholesterol levels.", "answer": 1}, {"article": "The new test \"helps push the envelope further,\" he said.\nThe issue with available troponin testing has been that they must be repeated two more times over the next 12 to 16 hours for accurate readings.\nResearchers led by Dr. Till Keller at the University Heart Center in Hamburg, Germany, compared the new highly sensitive troponin I test with the current test and other blood markers for heart attack among 1,818 people who showed symptoms of a possible heart attack.\nTUESDAY, Dec. 27, 2011 (HealthDay News) -- A new test measuring levels of troponin I in the blood may help determine whether someone is really having a heart attack earlier than is currently possible.\n\"We need a blood test that can tell people when they walk in or soon thereafter that they are having a heart attack because the sooner you make the diagnosis, the sooner you can start the right therapy.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The only comparisons are very broad and lack substantiation with actual data. The study compared the existing test for troponin l and a more specific test and examined the data using different break points and time.\u00a0 Here\u2019s the authors conclusions, \u201cAmong patients with suspected acute coronary syndrome, hsTnl (the new test) or cTnl (the existing test) determination 3 hours after admission may facilitate early rule out of MI (heart attack).\u00a0 A serial change in hsTnl or cTnl levels form admission (using the 99th percentile cut off value) to 3 hours after admission may facilitate early diagnosis of AMI.\u201d\u00a0 The story conclusions don\u2019t seem to match those of the authors.", "answer": 0}, {"article": "Lipton directs the Montefiore Headache Center at the Albert Einstein College of Medicine in the Bronx.\nAbout 35 million Americans have migraines, according to the American Headache Society, and about 20% to 30% of these patients have headaches that are preceded by visual or other sensory warning signs.\nDrugs commonly used in the treatment of severe headaches are generally not considered effective in the aura phase of migraine attacks, and many patients want to treat their migraines without using drugs, neurologist and headache specialist Richard B. Lipton, MD, tells WebMD.\n\"There is a lot of unmet medical need out there in the treatment of migraine,\" he says.\n\"Some people don't tolerate the drug treatments very well and others just want to avoid them.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story states that \"Drugs commonly used in the treatment of severe headaches are generally not considered effective in the aura phase of migraine attacks.\"\u00a0 In fact inexpensive drugs\u00a0(such as nonsteroidals) or others, such as triptans, \u00a0are effective in the aura phase.  So we think the discussion of alternative options is incomplete. \n\u00a0", "answer": 0}, {"article": "Within one month of the emergency department visits, 727 heart attacks or death in patients occurred.\n\"Adoption of the clinical chemistry score algorithm would standardize reporting of high-sensitivity cardiac troponin test results, how the tests are interpreted in the normal range, and represent an option less susceptible to both analytical and preanalytical errors.\n\"We have developed a simple lab score that is superior to using cardiac troponin alone for the identification of patients at low and high risk for heart attack or death at emergency department presentation,\" say Dr. Peter Kavsak, McMaster University, Hamilton, Ontario.\nAccording to Professor Andrew Worster, also from McMaster University, \"This lab score may reduce both the number of blood tests and time spent in the emergency department for chest pain patients.\"\n\"Clinical chemistry score versus high-sensitivity cardiac troponin I and T tests alone to identify patients at low or high risk for myocardial infarction or death at presentation to the emergency department\" is published August 20, 2018.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The text mentions two alternatives: a single blood test, called a cardiac troponin test, and \u201cmultiple blood tests over several hours.\u201d\u00a0 It makes the case that the proposed laboratory score is superior to both.\nThe release omits discussion of other strategies such as electrocardiograms, exams and patient history typically used in acute treatment facilities. Stress tests are not as readily available. It does raise the question of the timing of the troponin test that was used to calculate the score \u2014 ideally, we\u2019d like to know that results were quickly available if we\u2019re seeing this as a way to shorten emergency room stays.", "answer": 1}, {"article": "The current study, she added, shows that \u201chigh quality (stroke) care is available in hospitals on the weekends and weekdays.\u201d In fact, care might even be more aggressive on weekends.\nOf these, 20,279 were admitted on weekends and 58,378 during the week.\n\u201cAnyone who thinks they are having a stroke should seek care at a hospital immediately.\nA total of 543 weekend stroke sufferers got the drug versus only 229 weekday stroke patients.\nIndividuals should not wait to seek care for stroke,\u201d Kazley told Reuters Health by email.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As with the HealthDay report, this criterion is not applicable for this story.", "answer": 2}, {"article": "Although colon cancer is the second leading cause of cancer death for men and women in the U.S., many adults don't undergo the screenings once they reach age 50 (or earlier for those with a family history), Ahlquist told a news conference.\nPatients must often take time off work and need transportation home from the procedure.\n\"We were pleased by the results of this first clinical study,\" he says.\nOne screening test, the colonoscopy, in which a flexible, lighted tube with a video camera is inserted to examine the colon, requires dietary restriction and preparation of the colon.\nAt the meeting, Ahlquist presented the results of the first clinical evaluation study, which enrolled 1,100 patients.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No meaningful comparison with existing colon cancer screening tests and no acknowledgement that there are other new tests now in development.", "answer": 0}, {"article": "The process can take several years.\nTUESDAY, Dec. 27, 2016 (HealthDay News) -- Heart failure patients have weakened hearts, but researchers say an experimental drug used for the first time in humans may repair heart cells and improve heart function.\n\"It's a remarkable thing that you could give a drug once and have it affect heart function three months later -- it's really extraordinary,\" she said.\nEven with all these options, the death rate among these patients is \"unacceptably high,\" Lenihan said.\nThe study was funded by Acorda Therapeutics, the maker of cimaglermin, and the report was published online Dec. 26 in the journal JACC: Basic to Translational Science.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention alternatives for dealing with weakened left ventricular function, primarily through this paragraph:\n\u201cPeople with heart failure often take a combination of drugs, Lenihan said. These include medications to lower blood pressure and diuretics to help remove excess fluid that builds up as a result of the heart\u2019s labored pumping ability. In addition, some people have implanted defibrillators or pacemakers.\u201d", "answer": 1}, {"article": "Psoriasis is an immune-mediated disease that causes itchy, dry and red skin.\nIn the study, published in the New England Journal of Medicine, investigators compared guselkumab to adalimumab, the most common medication currently used to treat psoriasis.\nThe disease affects nearly 3 percent of the world's population, according to the World Psoriasis Day consortium, but about half of all patients with psoriasis do not get any treatment, Dr. Gordon said.\n\"Research like this study is leading to a series of new medications that promise high levels of response for an increasing number of patients,\" said first author Kenneth Gordon, MD, professor in Dermatology.\nAt week 40, for example, 81 percent of patients taking a 200-mg dose of guselkumab had a score of 0 or 1, compared to 49 percent of patients taking adalimumab.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release discusses only two potential treatments: the drugs guselkumab and adalimumab. There are many additional options. Other medications include methotrexate, cyclosporine, and retinoids, among others. There are also a number of topical treatments and several forms of light therapy. The release would have been stronger if it had explained why guselkumab (or adalimumab, for that matter) are important treatment options or when physicians may incorporate medications like these into their treatment plans.", "answer": 0}, {"article": "Researchers have found that delivering a fecal microbiota transplant (FMT) in a pill\u2014a poop pill, basically\u2014is no worse than a similar procedure done with a colonoscopy.\nThough the procedures were done in a Canadian hospital, the FMTs delivered by colonoscopy cost nearly $500 USD more than the capsules, which cost about $300.\nThe transplants work by replacing those \u201chealthy\u201d bacteria.\nTwo-thirds of the 57 patients who got the pills said their experiences were \u201cnot at all unpleasant,\u201d while just 44 percent of the 59 patients who received the FMT via a colonoscopy could say the same.\nOther efforts to take the \u201cpoop\u201d out of the poop pills\u2014to just include the bacteria thought to be behind the benefits\u2014have failed.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Standard treatment for C. diff is antibiotics. This should have been mentioned.", "answer": 0}, {"article": "Biologics are genetically engineered proteins derived from human genes.\nThe result: The thick, red, flaking skin lesions that are characteristic of psoriasis cleared up in about three times as many patients who got briakinumab as those who got methotrexate.\n\"This is the single most effective drug we've had in psoriasis, ever,\" says Kenneth B. Gordon, MD, a dermatologist and clinical associate professor at the University of Chicago's Pritzker School of Medicine.\n\"This drug has had, in this trial, the highest efficacy we have ever seen with any biologic in psoriasis before,\" says study researcher Kristian Reich, MD.\nAt that time, the company said it wanted to evaluate the \"next steps\" for briakinumab and might try for approval again at a later date.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While mentioning the similar drug Stelara, the story didn\u2019t wrap the new research into the context of other approaches to psoriasis \u2013 including some non-drug therapies.\u00a0 It would take only another sentence to give some broader context about other therapeutic approaches.", "answer": 0}, {"article": "Do not ignore or delay obtaining professional medical advice because of information accessed through ASN.\n\u201cIn the absence of randomized trials and large individual cohort studies, this study is the best available evidence to drive clinical decision-making by patients and doctors on whole dietary approaches in chronic kidney disease.\u201d\n\nDisclosures: The authors reported no financial disclosures.\nThe findings appear in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).\nThe article, entitled \u201cHealthy Dietary Patterns, Mortality and End-Stage Kidney Disease in CKD: A Meta-Analysis of Cohort Studies,\u201d will appear online at http://cjasn.asnjournals.org/ on December 8, 2016, doi: 10.2215/CJN.\nThe content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN).\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release alludes to the standard dietary recommendations for people with chronic kidney disease and how hard those recommendations are to follow. But it does not provide us enough information to feel like a true comparison, nor does it discuss the controversies surrounding those recommendations.", "answer": 0}, {"article": "Newswise \u2014 Women who need breast surgery to remove an abnormality that cannot be felt, also known as a non-palpable breast lesion, now may benefit from the convenience and comfort provided by an advanced new tissue locating technology offered at Rush University Medical Center.\nThe SAVI SCOUT Radar Localization System helps to decrease the time a woman is in the operating room, increase the success rates of lesion removal and reduce the amount of healthy breast tissue that is removed during the procedure.\n\u201cUltimately, this wireless technology has the potential to reduce surgical delays, and more importantly will benefit patients by increasing comfort and satisfaction during a stressful time,\u201d Madrigrano said.\n\u201cWhen there is an abnormality that we can\u2019t feel and are unable to biopsy, we have to find that lesion in surgery,\u201d said Dr. Andrea Madrigrano, assistant professor of surgery at Rush University Medical Center.\nWire localization requires a high degree of coordination between radiology and surgical scheduling, which can lead to delays between placement of the wire and surgery, often requiring a woman to wait long periods of time with the wire in her breast.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does provide comments on the current standard of care and places the Savi Scout in a positive light in comparison.\u00a0 But since no clinical trials have been conducted comparing the two,\u00a0 readers should be reminded that the advantages stated are theoretical.", "answer": 1}, {"article": "For more industry information, health research and recipe ideas, visit http://www.\nWalnuts are the only nut that provide a significant amount (2.5 grams per one ounce serving) of alpha-linolenic acid (ALA), the plant-based form of omega-3s.\"\nIn addition to providing omega-3s, walnuts also deliver a convenient source of fiber (2 grams per ounce) and protein (4 grams per ounce).\nFolsom, Calif., (Nov. 19, 2015) - A new study published in the American Journal of Clinical Nutrition found that consuming tree nuts, such as walnuts, may lower the risk of cardiovascular disease.1 After conducting a systematic review and meta-analysis of 61 controlled trials, one of the authors, Michael Falk, PhD, Life Sciences Research Organization, found that consuming tree nuts lowers total cholesterol, triglycerides, LDL cholesterol, and ApoB, the primary protein found in LDL cholesterol.\nBeyond finding that tree nuts lower total cholesterol, triglycerides, LDL cholesterol and ApoB, researchers also found that consuming at least two servings (two ounces) per day of tree nuts, such as walnuts, has stronger effects on total cholesterol and LDL.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "No alternatives are mentioned such as exercise, medications, lifestyle changes and so on. In fact, other research points to olive oil, for example, as being helpful in modifying cholesterol and risk for cardiovascular disease. A brief mention of this would have been appropriate.", "answer": 0}, {"article": "This suggested the test could be used to tell the conditions apart.\nChanges in cytokine levels of cerebrospinal fluid offer a very early measurable sign of infection.\u201d\n\nDr. Curtis and colleagues decided to see if they could detect patterns within the cytokines that might differentiate infections from other brain diseases or disorders.\n\u201cOnce confirmed with additional research, our test could provide a first, rapid and less invasive way to look at what\u2019s happening in the brain and guide treatment or further testing.\u201d\n\nThe results were published in the journal PLOS ONE on October 31st.\n\u201cMoving forward, our goal is to formally validate our findings with a larger sample size that includes both adults and children for future use in the clinical arena.\u201d\n\nArticle reference: Danielle Fortuna, D Craig Hooper, Amity L Roberts, Larry A Harshyne, Michelle Nagurney, Mark T Curtis, \u201cPotential role of CSF cytokine profiles in discriminating infectious from non-infectious CNS disorders,\u201d PLOS ONE, DOI: 10.1371/journal.pone.0205501, 2018.\n\u201cBeing able to rapidly identify a central nervous system disorder as infectious can be crucial in rapid response.\u201d\n\n\u201cIn addition, the test could distinguish viral from non-viral infections, a distinction that could spare a child with a viral infection from an unnecessary course of antibiotics, and tailor the care toward antiviral and supportive measures as needed,\u201d said Dr. Curtis.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This was perhaps the weakest points of the release, since many alternatives do exist and which also use CNF.\u00a0 For example, the color and clarity of CNF can indicate an infection, and the presence of free-floating cancer cells typically indicate some kind of tumor.\nThe release would have been stronger had it brought up these and other standard-of-care procedures, noted how they work, and explained how this particular test may be better or cover a blind spot.", "answer": 0}, {"article": "For more information, visit http://www.\nAlong with discovering that the use of laparoscopy for the surgical treatment of GERD has increased significantly in the last decade, the researchers also found that, on average, the minimally invasive approach reduced length of hospital stay by approximately two days, and open operations were more than $9,000 more expensive than minimally invasive procedures.\n\"Surprisingly, in 2003, 12 years after the first laparoscopic anti-reflux operation was reported, only 25 percent of all the anti-reflux operations were performed laparoscopically in the U.S.,\" Dr. Schlottmann said.\nCHICAGO (January 26, 2017): Patients with gastroesophageal reflux disease, known as GERD, who undergo laparoscopic anti-reflux operations compared with traditional \"open\" operations suffer fewer postoperative complications, experience faster recovery, and incur lower health care costs, according to study results published online as an \"article in press\" on the Journal of the American College of Surgeons website, ahead of print publication.\n\"Anti-reflux surgery should be considered in patients who do not achieve complete control of their symptoms [regurgitation or cough] with medications; who do not want to take medications for the rest of their lives; or who experience complications of medical therapy.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does a good job here. It compares different surgical methods and it also names alternatives for treating GERD such as medications and changes in the diet.\nIt also states which group of patients the surgery is aimed at: \u201cAnti-reflux surgery should be considered in patients who do not achieve complete control of their symptoms [regurgitation or cough] with medications; who do not want to take medications for the rest of their lives; or who experience complications of medical therapy.\u201d", "answer": 1}, {"article": "But there are still a lot of unanswered questions about immune therapy.\n\"We as a lung cancer community are incredibly excited about the activity of immunotherapy in various aspects of the disease,\" said Pasi Janne, director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute in Boston.\nThere have been no other recent treatment breakthroughs in squamous cancer, which most commonly occurs in smokers or former smokers, so this advance is particularly welcome, said Janne.\nIn addition to melanoma and lung cancer, this brake-release approach has been shown effective in early trials against bladder, kidney, head and neck cancers, and some blood cancers.\n\"It is early days for the successes of immune therapy,\" said Mark Fishman, president of the Novartis Institutes for BioMedical Research, a research arm of drug company Novartis, which is taking a different approach to turning the immune system against cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that \u201cchemotherapy, radiation, surgery and so-called targeted therapies \u2013 can help beat back tumors, but once cancer has spread, it almost always returns.\u201d We\u2019ll rate this sufficient for a satisfactory, although it would have been useful to have some actual data as to how\u00a0Opdivo compares to these other approaches.", "answer": 1}, {"article": "BMI loss was between 7.1 and 14.7 kg/m2.\nLed by University of Adelaide researchers, in collaboration with Flinders Medical Centre, and published in the journal Obesity Surgery, the study is the first to show medium to long-term follow-up (3-5 years) of lap band surgery in Australian adolescents.\n\u201cWe are talking about a group of adolescents with severe obesity and significant health and psychological problems related to their increased weight \u2013 this is not for everyone,\u201d says corresponding author and Paediatric Endocrinologist Dr Alexia Pe\u00f1a, who is a Senior Lecturer with the University of Adelaide\u2019s Robinson Research Institute.\nThe study found that weight and BMI improved significantly at all follow-up times following surgery from three months through to 45 months and, in some cases, as long as five years.\n\u201cOur findings support lap band surgery as a safe and effective option for management of adolescents with severe obesity \u2013 provided it is performed by an experienced surgeon and managed afterwards in a paediatric multidisciplinary environment with regular follow-up until adulthood.\u201d\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release states through a quote from the lead author of the study that the lap band procedure \u201cis a good result when compared to BMI reduction using the few medications available or lifestyle measures,\u201d but offers no actual comparisons with any non-surgical approaches to weight loss.", "answer": 0}, {"article": "For further information, please contact:\n\nThis information was brought to you by Cision http://news.cision.com\n\nThe following files are available for download:\nThe results of our study clearly support the use of SBRT for elderly patients, especially those who may not be able to tolerate longer courses of radiotherapy or more invasive treatment options,\" says Meredith Giuliani, MBBS, FRCPC, MEd, a radiation oncologist in the Cancer Clinical Research Unit at Princess Margaret Cancer Centre, University Health Network in Toronto and lead study author.\n\"This study is the largest series of its type to evaluate SBRT outcomes in patients aged 80 years and older,\" says Joel Goldwein, MD, Senior Vice President, Medical Affairs for Elekta.\n\"In addition to providing important support for using SBRT to treat early-stage lung cancer in elderly patients, these findings highlight the value of multi-institutional collaborations and large data sets that can provide statistically meaningful answers to critical questions about treatment outcome and guide clinical decision making.\"\nThe results, which were based on data from more than 1,000 patients across five institutions that comprise the Elekta Lung Research Group, are available online and will be published in the July 15 print issue of International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release makes no meaningful comparison to alternatives. The closest the release comes to mentioning any alternative is in a quote by the lead author, \u201cThe results of our study clearly support the use of SBRT for elderly patients, especially those who may not be able to tolerate longer courses of radiotherapy or more invasive treatment options.\u201d However, this is not sufficient to give them credit here.", "answer": 0}, {"article": "event of the year.\u201d\n\n\u201cIf everything checks out,\u201d Jami Rubin of Goldman Sachs said in an interview, \u201cthat will confirm in our minds that Eliquis has potential to take a majority share of the $10 billion anticoagulation market.\u201d\n\nMore than 2.6 million people have atrial fibrillation in the United States, according to the Centers for Disease Control and Prevention.\nAnd Eliquis and Pradaxa require two pills a day, one in the morning and one in the evening, instead of the once-daily warfarin.\nAs many as 12 million people will have it by 2020 because of an aging population with longer life expectancy.\nThe drug acts on an enzyme that leads to blood clots.\nThere is great appeal and demand for new drugs that do not vary so much and deliver the same stroke-preventing benefits.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compared the study drug with the long time treatment, warfarin, as well as mentioning a newly approved medication and another medication in the approval process.", "answer": 1}, {"article": "Thanks to members Drs.\nThis is different than studies recently published that say the average response differs.\u201d The full report, published ahead of print in the Clinical Journal of Sport Medicince (CJSM) and will appear in the (British Journal of Sports Medicine) BJSM, entitled, AMSSM Scientific Statement Concerning Viscosupplementation Injections for Knee Osteoarthritis Importance for Individual Patient Outcomes, includes the following notable AMSSM recommendations and one suggestion:\n\u2022 AMSSM RECOMMENDS viscosupplementation injections for Kellgren and Lawrence (KL) grade II-III knee osteoarthritis in those patients above the age of 60 based on HIGH quality evidence demonstrating benefit using OMERACT-OARSI Responder Rating but the evidence should be downgraded due to indirectness for those under 60 years of age.\nThe lifetime risk of suffering symptomatic knee OA is estimated to be 44.7% and approximately 1 in 11 of the US population is diagnosed with symptomatic knee OA by age 60.\nNewswise \u2014 LEAWOOD, KS \u2014 Osteoarthritis (OA) is one of the leading causes of disability in adults in the United States and knee OA specifically is ranked within the top 10 non-communicable diseases for global disability-adjusted life years.\nWith this knowledge, the American Medical Society for Sports Medicine (AMSSM) has released a new scientific statement that provides guidance for physicians and healthcare professionals who provide care for those patients with knee osteoarthritis.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release states that \u201cpeople are more likely to show clinical improvement with viscosupplementation over placebo (saline) and intra-articular steroids. This is different than studies recently published that say the average response differs.\u201d Unfortunately, the release doesn\u2019t provide any data supporting that claim.\nReviewers agreed that most every credible source of information on the management of osteoarthritis of the knee suggest a step-wise progression of treatments including weight reduction, braces, analgesics, and the like. \u00a0While the release does mention steroid injections it does so dismissively.\nWeight loss and strengthening exercises are also mentioned as initial management recommendations, but are quickly glazed over because of \u201ccontroversial\u201d treatment aspects. What is controversial about current OA treatment?", "answer": 0}, {"article": "Reiki, a therapy in which hands are placed lightly on the body or just above it, is increasingly being used to reduce cancer-related fatigue, anxiety, nausea and pain. Several studies suggest a benefit to patients, but scientists say more large, rigorous studies are needed.\n\nCancer patients\u2014due to the disease and to side effects of chemotherapy\u2014often suffer from severe mental and physical fatigue, doctors say. Anxiety, nausea and pain are also common. In recent years, many cancer centers have been offering Reiki, a form of...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The column does not compare Reiki to any other alternatives. It mentions one study that looked at other massage techniques, but doesn\u2019t explain how/if those approaches differ from Reiki. \u201cA 2004 study of 1,290 cancer patients at Memorial Sloan-Kettering found a light-touch massage, standard Swedish massage and foot massage all helped symptoms including pain, depression anxiety, nausea and fatigue; the study didn\u2019t have a control group.\u201d", "answer": 0}, {"article": "When I began training last year for my first marathon, my running partner Dave Freedholm, an experienced amateur distance runner, impressed on me the need to vigilantly avoid dehydration. His drink of choice was Accelerade. Like Gatorade, the original sports drink, it's packed with sugars and sodium to provide energy and replace the electrolytes depleted in sweat. But it also contains protein, which he said would help my muscles repair themselves more quickly after the punishing training runs he took me on.\n\nSure enough, I never felt much pain until after the marathon itself, and even then I recovered within a couple of days...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention the different sports drinks for athletes and water for the rest of us.", "answer": 1}, {"article": "(Reuters) - Johnson & Johnson said on Tuesday its blockbuster drug Stelara was found to be effective in treating a chronic bowel disease in a late-stage trial.\nBoth 6 mg/kg and 130 mg doses of the intravenous treatment showed clinical remission in significantly more patients, compared with those on placebo, after eight weeks, the company said.\nThe patient had no prior history of high blood pressure or cirrhosis, the drugmaker said.\nThe treatment and the placebo arms reported similar proportion of side effects, with one patient on the 6 mg/kg dose dying following excessive bleeding, J&J said.\nCurrent treatments include Pfizer Inc\u2019s Xelijanz, an oral treatment for adults patients with moderate-to-severe UC, and Merck & Co\u2019s Renflexis.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does note other UC treatment options, and notes that the patients in the study had not responded to those treatments.", "answer": 1}, {"article": "Strokes had a higher impact on the patient\u2019s quality of life, the study reported.\nThe European trial, which included 1,713 patients randomly assigned to either stent or endarterectomy, found that stent patients were at much higher risk of stroke, death or heart attack in the first 30 days after surgery, with 7.4 percent suffering one of these adverse events, compared with 4 percent of the surgery group.\nThe most important message is that the overall death rate was extremely low, 0.6 percent, said one of the study\u2019s principal investigators, Dr. Gary S. Roubin, the chairman of cardiovascular medicine at Lenox Hill Hospital in New York.\nAmong the possible explanations offered for the disparities are that the European study included only symptomatic patients, who may have had more advanced disease, and that the North American trial carefully screened the doctors doing the stenting procedure, including only highly skilled physicians with a lot of experience.\nLong-term follow-up of patients, which was two and a half years on average but is continuing, found both groups at equal risk of suffering a stroke that should have been prevented by the procedure: 2 percent of those in the stent group compared with 2.4 percent of the surgical patients.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story doesn\u2019t give enough attention to the question of whether one should intervene at all in asymptomatic patients.\u00a0 It states that surgery\u00a0\"has\u00a0been shown to be more effective than medical therapy alone\" for preventing strokes, but it is not\u00a0clear that this is true for asymptomatic patients. \u00a0", "answer": 0}, {"article": "CDC To Doctors: Anti-HIV Pill No Magic Bullet Against Virus\n\nIn November, researchers revealed a encouraging finding: taking a pill can greatly reduce the risk of getting HIV.\nBut the landmark study, involving 2,500 men who have sex with men, showed that taking Truvada faithfully can reduce the risk of infection by as much as 92 percent.\nIt's the first time anybody's shown that taking a pill can prevent HIV \u2013 and it was the first new weapon against HIV unveiled in many years.\nWhen researchers tested the blood of patients for traces of Truvada, they found many who claimed to have taken the pill regularly weren't telling the truth.\nBut those who said they took the drug at least 9 out of every 10 day had a 73 percent lower risk.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Not applicable.\u00a0 Because of the nature of this drug, no comparison is really necessary.\u00a0 As the story stated, \u201cIt\u2019s the first time anybody\u2019s shown that taking a pill can prevent HIV \u2013 and it was the first new weapon against HIV unveiled in many years.\u201d", "answer": 1}, {"article": "The researchers focused on 16 studies that recorded the effects of practicing yoga on mental-health issues ranging from depression, schizophrenia, ADHD, sleep complaints and eating disorders to cognitive problems.\nFor instance, yoga may influence brain chemicals known as neurotransmitters (boosting levels of feel-good agents like serotonin), lower inflammation, reduce oxidative stress and produce a healthier balance of lipids and growth factors \u2014 just as other forms of exercise do.\n\u201cWhat we are saying is that we still need to do further, large-scale studies before we are ready to conclude that people with mental illnesses can turn to yoga as a first-line treatment,\u201d says Doraiswamy.\nThe Huffington Post reported that many troops use yoga as a form of treatment for PTSD, for example, with companies like Warriors at Ease training instructors in yoga techniques specifically catered to those in the military.\nIndividually, people feel better after doing the physical exercise,\u201d says lead study author Dr. P. Murali Doraiswamy, a professor of psychiatry and medicine at Duke University Medical Center.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u00a0suggests that yoga would be an attractive alternative to psychiatric medications, but it doesn\u2019t mention that psychotherapy is a well-validated and effective\u00a0nonpharmacologic treatment for many of the disorders discussed in the story. And other major categories of treatment for people with some of the disorders discussed include a range of medications, a range of self-help strategies, and for some conditions, somatic treatments such as transcranial magnetic stimulation.", "answer": 0}, {"article": "He reviewed the findings for WebMD.\nAlthough approved by the FDA, the femtosecond laser procedure is not widely used in the U.S., according to the American Academy of Ophthalmology.\n\"There certainly seems to be a benefit to using the laser,\" says American Academy of Ophthalmology (AAO) spokesman James Salz, MD, clinical professor of ophthalmology at the University of Southern California in Los Angeles.\n\"The idea is that all the surgeon will have to do is remove the pieces with a vacuum,\" says researcher Mark Packer, MD, of Oregon Health and Sciences University in Portland.\n\"If you have a technique to soften the cataract, there appears to be less chance of damage [to the eye ],\" Salz says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story suggests numerous times that laser surgery is likely to be safer and lead to better outcomes compared with traditional surgery. Again, these statements are based on very brief presentations and with limited information. While it may in fact be true, there is no reason to believe that the femtolaser is superior in any way to conventional surgery at this time. But it would have helped to have some idea of the outcomes currently seen with traditional surgery and how frequently complications occur. This information would have helped us judge how much we stand to gain from the new technology. Unfortunately, these details are not provided.", "answer": 0}, {"article": "\"If your immune system has been educated by the vaccine to recognize the tumor cells, we think it will allow the immune system to take care of any individual [cancer] cells trying to set up shop,\" explained Dr. Elizabeth Mittendorf, a surgical oncologist at the University of Texas M.D.\n\"Whether it actually has an increase in survival remains to be seen,\" he said.\nDon Diamond, director of translational vaccine research and a professor of virology at the City of Hope Comprehensive Cancer Center in Duarte, Calif., reviewed the findings and said, \"Their approach is well thought out and makes sense.\"\nPhase 3 studies are needed before the vaccine could be approved.\nThe women received monthly injections for six months.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Barely satisfactory \u2013 the story at least mentioned that \u201cNumerous vaccines to prevent breast cancer recurrence are currently under study.\u201d", "answer": 1}, {"article": "Each carries problems.\n\u201cWith an average of one man dying every 45 minutes from prostate cancer in the UK, the need for a more reliable test that can identify dangerous forms of the disease earlier is greater than ever.\u201d\n\nIn the past few years, a number of celebrities have revealed that they had been diagnosed with prostate cancer and have joined campaigns to raise awareness of the disease, including Michael Parkinson, Ian McKellen and most recently Stephen Fry, the comedian and former rector of Dundee University, who this year described how he had surgery to deal with a prostate tumour.\n\u201cOur new method is far more accurate and also allows us to identify the difference between cancerous and benign tissue in the prostate without the need for invasive surgery.\u201d\n\nThe prostate is a small gland in the male reproductive system and is normally about the shape and size of a walnut.\n\u201cThe technique now needs to be tested in a much larger number of men to confirm just how well it can detect the aggressive cancers, while also ruling out those who do not have prostate cancer,\u201d said Simon Grieveson, head of research funding at Prostate Cancer UK, which funded the Dundee project (with support from the Movember Foundation).\n\u201cThis breakthrough comes at a time when prostate cancer is being pushed to the forefront of our consciousness in the UK, not least because of the disturbing upward trend in its prevalence,\u201d said Fry.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention several current methods of detecting and diagnosing prostate cancer \u2014 the PSA (prostate-specific antigen) test, a digital rectal exam (DRE),\u00a0the use of MRI imaging, and an invasive biopsy, which are all alternatives to this new test.\u00a0 The story also points out the shortcomings of each of those approaches. However, this is a just-passing Satisfactory, since all of this information was taken directly from the university\u2019s news release (see below).", "answer": 1}, {"article": "We are excited to announce that FibromyalgiaTreating.com is now part of RedOrbit.com. All of the same great people, writers and editors but now with more firepower. We now have access to an enormous amount of additional research information from doctors and scientists. We can now extend to other conditions that may be part of your everyday lives and help you on a broad level if that is what you need. We are here for you and now, better than ever so sit back and enjoy the new Fibromyalgia Treating by RedOrbit!", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses the continued benefit of mammography for early detection of breast cancer. The story highlights that computer-assisted screening does not replace human judgment in interpretation of radiological films. ", "answer": 1}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\n\"The nerve root is a sensitive structure that when pinched becomes inflamed and causes pain,\" said lead investigator Alessandro Napoli M.D., Ph.D., an interventional radiologist at Sapienza University of Rome.\nThe single-center prospective study included 80 patients experiencing at least three months of low back pain due to a herniated disk that had not responded to conservative treatments including exercise and medication.\nMost back pain is short-term, but about 20 percent of people affected by acute low back pain go on to develop chronic low back pain lasting a year or more.\n\"The body reacts with muscle constriction, which decreases the distance between vertebrae, and a vicious cycle is created.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions that the study included 80 patients \u201cexperiencing at least three months of low back pain due to a herniated disk that had not responded to conservative treatments including exercise and medication.\u201d But that\u2019s an inadequate description of accepted alternatives. Patients with persistent pain due to a disc herniation have a number of well accepted alternative treatments including epidural steroid injections, surgical discectomy as well as other minimally invasive procedures.", "answer": 0}, {"article": "I would lose my place,\" said Abby, 13, of Lexington, Massachusetts.\nThis was another small study -- 20 dyslexic volunteers and 21 participants without the condition -- testing how people identify shapes, navigate a virtual environment, and do other tasks involving spatial reasoning.\nThe most important intervention is a direct, explicit teaching of phonics, or how symbols correspond with sounds, Branstetter said.\n\"If they can create projects -- instead of drawing a picture of a room, if they can make a model of a room -- they will generally do it pretty much to scale because they can visualize things very clearly,\" she said.\nHere's another insight about dyslexia: men with the condition may have enhanced visual-spatial abilities, according to a study in the journal Learning and Individual Differences.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\n\nThe study authors wrote that although standardized tests did not accurately predict changes in reading ability during the study period, \u201cit is possible that there are behavioral measures not included here that may predict outcome.\u201d Indeed, their journal article specifically referred to other research into clinical testing that did appear to predict how children with poor reading skills responded to teaching. The story fails to make clear that the study reported here did not attempt to make a comprehensive comparison of the predictive power of scans and other methods of assessing children with reading problems. ", "answer": 0}, {"article": "\"Results lend support to current national initiatives from the National Academies, White House, and bipartisan legislation requesting that the U.S. Food and Drug Administration create a new regulatory classification for hearing devices meeting appropriate specifications to be available over the counter,\" the authors write.\nPresently, hearing aids can only be purchased in the United States through a licensed professional, with an average cost of $4,700 for two hearing aids (uncovered by Medicare).\nFor more details and to read the full study, please visit the For The Media website.\nAccording to nationally representative estimates, less than 20 percent of adults with hearing loss report hearing aid use.\nEditor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The entire release is about an alternative\u00a0comparison, which is refreshing. On the other hand,\u00a0it is hard to compare alternatives in highly controlled settings. Real life is a lot different.", "answer": 1}, {"article": "Behind that common piece of advice is a complex series of physiological processes that calm the body, slow the heart and help control pain.\n\nBreathing and controlling your breath is one of the easiest ways to improve mental and physical health, doctors and psychologists say. Slow, deep and consistent breathing...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "To its credit, the story does point out that people can take classes as well as use a device that monitors breathing to change their breathing habits. However, since the story is about ways to reduce stress and improve health, we think it had an obligation to discuss other evidence-based approaches for reaching this goal, including regular physical activity, certain types of psychotherapy, or even self-taught breathing exercises that don\u2019t require buying a device or paying for a class. And certainly the makers of the many competitors to the Spire device may well wonder why the article did not mention that other such devices are on the market.", "answer": 0}, {"article": "There is also another issue.\nThe chemotherapy question starts with American and European guidelines that say almost every woman with breast cancer that has gone beyond its earliest stages, when it is confined to the milk duct, should have the treatment.\nNow Dr. Berry, the M. D. Anderson statistician, and a group of leading cancer researchers have found that the chemotherapy benefits in those clinical trials were concentrated almost exclusively in women whose cancers were impervious to estrogen.\nAnd while some, including Dr. Winer, predict that the use of chemotherapy will almost certainly decline in the years ahead, for now most doctors are sticking with the current guidelines, waiting for expert advice from national panels on what to do.\nAnd the recent data indicating that some women can skip chemotherapy are based on an after-the-fact analysis of selected clinical trials.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Excellent discussion of chemotherapy treatment decision process, including discussion that no treatment is also an option. Certain chemotherapy treatments may carry serious risks and only small benefit for some women. For other women the benefit is greater, though this must still be weighed against the risks of treatment. ", "answer": 1}, {"article": "\"In this particular activation mechanism, the cells develop a subtle mutation within the functional part of the HER2 gene that activates the enzyme,\" said Ellis, professor and director of the Lester and Sue Smith Breast Center, part of the National Cancer Institute-designated Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine.\nIn addition to bringing to the table a novel treatment for metastatic breast cancer carrying a HER2 mutation, the researchers have tested the value of the circulating tumor DNA as a disease-monitoring marker.\nTo identify the patients in this study who carried the new HER2 mutation, the researchers required tissue from the tumor, a biopsy, from which they could extract and sequence the genetic material to determine the presence of the HER2 mutation.\nHER2 has been established as a therapeutic target in breast cancer, and breast cancers in which the HER2 gene is not amplified do not, in general, respond to HER2-directed therapeutic approaches.\nEllis and his colleagues developed a preclinical model to study this new HER2 mutation and discovered that the enhanced enzymatic activity could trigger tumor formation.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "No alternatives were compared in this study although the study authors mentioned that this drug was aimed at those women who did not respond to conventional therapies to treat HER2+ cancers.", "answer": 0}, {"article": "This can put people off, says the statement.\nWhile around 60 million people play golf at least twice every year, the participant profile is quite narrow: players tend to be middle aged to older, male, of white European heritage, relatively well off, and living in North America, Europe, and Australasia.\nThese set out what is currently known about golf's associations with health; the factors that may help or hinder take-up of the sport; and a series of recommendations for golfers, industry leaders, and policy makers on how best to maximise its health benefits, promote sustainability, and widen participation.\nAnd the sport can do its bit for sustainability by \"practices that prioritise diversity, healthy societies, connection with, and care of, the environment, environmental integrity and health and wellbeing,\" the statement suggests.\nEvidence suggests it may not only be good for mind and body, but also for a long life\n\nThe consensus--one of the first of its kind--comes on the eve of the Ryder Cup, the biennial golf tournament between Europe and the US.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Golf is often referred to as \u201ca good walk spoiled.\u201d\nCommon sense would suggest many of the benefits touted in this news release might also hold for a good walk or hike; unfortunately, no alternatives are mentioned.", "answer": 0}, {"article": "The number could double by 2050.\nMore: The hidden side of dementia: Families fight over care, end-of-life decisions, finances, estates\n\nDementia is a term used to broadly describe symptoms of cognitive decline; Alzheimer's disease is the most common cause of dementia.\nThe vaccine works by prompting the body to produce antibodies inhibiting the buildup of amyloid and tau, two proteins that are hallmarks of the degenerative brain disease.\n\u201cIf the onset of the disease could be delayed by even five years, that would be enormous for the patients and their families,\u201d Lambracht-Washington said in a statement.\nAn experimental vaccine that could hold off Alzheimer's disease showed promising results in animal testing, according to researchers at the University of Texas Southwestern Medical Center.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says the vaccine is among \u201cseveral promising treatments\u201d aimed at reducing the buildup of proteins associated with Alzheimer\u2019s. It could have also mentioned that another Alzheimer\u2019s vaccine is undergoing clinical trials.\nIt could have also mentioned current available medicines that have a very modest, short-term effect. Drugs called cholinesterase inhibitors have been approved by the FDA to lessen symptoms from Alzheimer\u2019s, but none is curative.", "answer": 1}, {"article": "Adverse reactions associated with UroLift System treatment were comparable to other minimally invasive surgical therapies as well as standard cystoscopy.\nWhile current surgical options, such as the 'gold standard' surgery, Transurethral Resection of the Prostate (TURP), can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation (dry orgasm).\nThe most common adverse events reported during the study included pain or burning with urination, blood in the urine, pelvic pain, urgent need to urinate, and the inability to control urine because of an urgent need to urinate.\n\"We are committed to providing patients with the highest quality, most effective options to address their urology needs,\" said Matthias Hofer, MD , urologist at Northwestern Memorial Hospital.\nPerformed through the urethra, an urologist uses the UroLift System to push aside the obstructive prostate lobes and positions small, tailored permanent UroLift implants to hold the prostate lobes in the retracted position.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "We learn that there are some alternatives (drugs and surgery), but we aren\u2019t told that there are numerous other minimally invasive procedures available\u2013laser treatments, microwave thermotherapy, radiofrequency ablation, vaporization, etc. \u00a0The release is overly dismissive of drug therapy, which has been shown to be effective, well tolerated, and safe. Pushing this treatment as a first line treatment is inappropriate\u2013and the absence of data from head-to-head trials with either other minimally invasive procedures or the gold standard (transurethral resection of the prostate or TURP) means that the relative value of the new technology is quite uncertain.", "answer": 0}, {"article": "\"In this study, by using an elegant adult-inducible SIRT1 knock-out mouse model, the authors now provide compelling evidence that SIRT1 is required in vivo [in the animal] for the effect of resveratrol on AMPK activation and on mitochondrial function,\" Marambaud said.\nThe study is in the May 1 issue of Cell Metabolism.\nWe should be very careful about claiming the importance of resveratrol for medical purposes.\nThe U.S. Centers for Disease Control and Prevention has more on healthy aging.\nBut don't go reaching for that Chianti yet.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story could have included even a line about other research in the prevention of cell aging.", "answer": 0}, {"article": "Neurontin causes sleepiness, and soy extracts can produce gastrointestinal troubles.\nNone of the drugs or extracts are approved by the Food and Drug Administration to treat hot flashes \u2014 only hormones are approved for that purpose \u2014 but doctors are free to prescribe medicines for any use they see fit, and many recommend the drugs or plant products for hot flashes, based on study findings and their patients' experiences.\n\"There's a lot of hype around trying things that we haven't proven effective and, sadly, we haven't proven they're safe,\" said Dr. Heidi D. Nelson, the first author of the journal article and an internist and professor at the Oregon Health and Science University.\nThe drugs include the antidepressants Paxil (paroxetine), Effexor (venlafaxine), Prozac (fluoxetine) and Celexa (citalopram), the blood pressure drug Catapres (clonidine), and the seizure drug Neurontin (gabapentin).\nThough hormones cause small increases in the risks for breast cancer and heart disease, a short course may still be the best choice for women with very severe symptoms, she said, though she added that women who have had breast cancer should definitely not take hormones.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Satisfactorily presents several non-hormonal options for treatment. However, lifestyle related non-hormonal treatment (e.g. cool, layered clothing, exercise, not smoking) is either not mentioned or presented as ineffective options for women with hot flashes. ", "answer": 1}, {"article": "A new generation of treatments for severe eczema is on the horizon, which doctors say could help millions more patients gain relief from chronic outbreaks of the oozing, itchy and sometimes debilitating rashes that come with the disease.\n\nAt least two new eczema medicines could be approved by the U.S. Food and Drug Administration in 2017, and a half-dozen more drugs are being tested in clinical trials.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Steroid treatments are mentioned and their numerous side effects emphasized.\nIt would have been helpful for the story to emphasize the role of non-medical treatment ( water avoidance, moisturizer, etc) since these are mainstays for many people.", "answer": 1}, {"article": "I would say a quarter of my patients fall asleep.\u201d\n\nThe decompression therapy is used to treat herniated discs, ruptured discs, sciatica, bulging discs, degenerative discs, posterior facet syndrome and spinal stenosis/arthritis.\nThe space agency noticed astronauts, who did not have gravity compressing their spines in space, reporting the disappearance of neck and back pain.\nThat same visit, the lightning pain going down his back went away, and he got up and walked out.\nSome of them returned to Earth 1 inch to 2 inches taller.\nThere is a group in Iowa that doesn\u2019t do surgery anymore because they have found more success with this,\u201d Fuh said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story mentions surgery and painkillers, this is not sufficient information on alternative options.", "answer": 0}, {"article": "But the supplement has largely failed to show benefits in human athletes.\n\u201cIt can be speculated that the training frequency could be higher (with shorter breaks after vigorous training sessions)\u201d in those drinking beer, he wrote in an e-mail response.\nThey also showed significantly less evidence of inflammation, as measured by various markers in their blood, and lower counts of white blood cells than the placebo group, an indication of overall better immune system health.\nFor the next two weeks, the men continued to dutifully swallow their nonalcoholic beer or other brew.\nThe beer was effective only if it was nonalcoholic.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does not mention potential alternatives that might aid marathon recovery, including any other dietary alterations, and does not discuss the advantages and disadvantages compared with any other approaches.", "answer": 0}, {"article": "The U.S. Food and Drug Administration said Tuesday it has approved Cotellic, a drug produced by Swiss biotech company Roche, for use in combination with the vemurafenib medication as a treatment for advanced melanoma.\n\nThe drugs are intended to target the illness after it has spread to other parts of the body or can\u2019t be removed by surgery.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No alternative therapies are discussed in the story. There is a lot of new drug development for melanoma; none mentioned.", "answer": 0}, {"article": "MONDAY, Feb. 7, 2011 (HealthDay News) -- Feeding children lots of fatty, sugary and processed foods may lower their IQ, while a diet rich in vitamins and nutrients appears to boost it, British researchers say.\nThe key seemed to be the diet at age 3, since diet at 4 and 7 seemed to have no effect on IQ, the research team noted.\nFor more information on healthful eating for kids, visit the U.S. Department of Agriculture.\nThis is particularly true during the first three years of life when the brain is developing rapidly, the study authors explained.\nChildren should be encouraged to eat healthy foods from an early age, she said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story should have mentioned\u00a0other techniques that can encourage better neurodevelopment. Most notably, time spent\u00a0talking to and interacting with children in early childhood has been\u00a0associated with striking differences in later IQ.", "answer": 0}, {"article": "On the surface, this seems to contradict a U.S. trend toward holding off on surgery and monitoring men who have low-risk cancers with what's called \"active surveillance.\"\nAnd it applied to men with tumors considered low-risk, meaning they have a relatively low Gleason score, a marker of tumor aggressiveness.\n\"There will always be questions, and an ongoing need to individualize therapy,\" he says.\n\"Active surveillance means observing the patient in a proactive way, with regularly scheduled biopsies,\" he adds.\nLike every new study of prostate cancer, the results need to be carefully parsed.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned the use of newer surgical techniques than those used to treat the men in the study who underwent prostatectomy. It also mentioned newer radiation therapies. \u00a0 In addition, the story concluded:", "answer": 1}, {"article": "Funding: National Cancer Institute grants P50 CA097248 and P30 CA046592, and the Sinabaldo and Diane Tozzi Research Fund\nThe study did find lower functional preservation of the larynx in the induction chemotherapy group compared to those who elected chemoradiation.\nMany patients can spare their voice box by having chemotherapy and radiation.\n\"This adds ammunition to the idea that we need to pick individual therapies more carefully.\nAnd it wasn't just those who responded to the chemotherapy.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Our main take-away from the release is that there are many treatment alternatives and room for patient and physician joint decision-making. ", "answer": 1}, {"article": "Sonata uses a probe that is inserted through the cervix into the uterus. The probe not only allows the doctor to see the fibroid using ultrasound, but it also has a radio-frequency device at the tip. The doctor hits a foot pedal to send energy through the probe to heat the fibroid, shrinking it over time. The body absorbs the dead tissue, so it does not have to be surgically removed.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This is a real strong point for the story. The story not only describes multiple other surgical options, as well as hormone treatments, but notes that many patients can wait until menopause, when changing hormone levels can mitigate problems associated with fibroids.", "answer": 1}, {"article": "(Boston) -- To date, there are no methods that can quickly and accurately detect pathogens in blood to allow the diagnosis of systemic bloodstream infections that can lead to life-threatening sepsis.\nThe diagnostic assay is built on FcMBL, a genetically engineered pathogen-binding protein previously developed by Ingber and Michael Super, a Wyss Senior Staff Scientist who co-leads the Institute's pathogen-detecting effort.\nThe standard of care for detecting such blood-borne infections is blood culture, but this takes days to complete, only identifies pathogens in less than 30% of patients with fulminant infections, and it is not able to detect toxic fragments of dead pathogens that also drive the exaggerated inflammatory reactions leading to sepsis.\nWe are currently working to ready it for high-throughput use in clinical and point of care situations and to accelerate it even further,\" said Mark Cartwright, Ph.D., a Staff Scientist at the Wyss Institute and a lead-author on the study.\nBiomarkers that report elevated inflammation are used clinically in the treatment of patients with sepsis; however, they fail to distinguish inflammation triggered by infectious pathogens from that induced by non-infectious causes, such as burns, traumas and surgeries.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes some alternatives to this new technology. It describes briefly that current blood cultures are often not adequate, both from a timing and sensitivity perspective. It would have been even more thorough to note that there are other diagnostic tools in the research pipeline.", "answer": 1}, {"article": "Kite Pharma is racing to get the first FDA approval of an experimental gene therapy to fight cancer.\n\nAn experimental gene therapy that turns a patient\u2019s own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday.\n\nIn all, 82 percent of patients had their cancer shrink at least by half at some point in the study.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is passing mention of chemotherapy, as well as stem cell transplant, and the story does note that these patients have exhausted all other available options. However, there is no mention of what the current accepted treatments for these specific lymphomas are. Furthermore, a clear understanding of treatment alternatives is compromised because\u00a0the story\u00a0does not clearly state that CAR-T therapy is currently only being tested for Acute Lymphocytic Leukemia (ALL) in children and young adults, as well as some B-cell lymphomas and leukemias. Without knowing this the reader can not answer\u00a0the obvious: \u201cwhat exactly does CAR-T treat and what are the alternatives?\u201d", "answer": 0}, {"article": "The study's primary endpoint was OS.\nThe technique uses an intricate network of magnets to aim a narrow proton beam at a tumor and \"paint\" the radiation dose onto it layer by layer.\nThey deposit the bulk of their cancer-fighting energy right at the tumor, thereby reducing the dose to cardiopulmonary structures, which impacts the toxicity, functional status, quality of life and even survival for patients, explained Chang.\nAlso, delivery of both the conventional intensity-modulated radiation therapy (IMRT) and proton therapy (IMPT), have improved, thereby reducing side effects for both treatment modalities.\"\nAt five years, the median OS was 26.5 months, and the corresponding five-year OS was 29 percent.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release states that results were compared to historical controls, but then goes on to detail all of the limitations with this comparison. The release does mention\u00a0intensity-modulated radiation therapy (IMRT) at the end and states the historical control was chemotherapy with conventional radiation.\nThe alternatives could have been presented in a more straight-forward way.  ", "answer": 1}, {"article": "The main side effects, Vertex said, were headache, upper respiratory tract infections, nasal congestion, rash and dizziness.\nIt can take years of research to determine how a mutation actually causes a disease and then to design a drug that corrects the problem.\nThe trial involved 161 people age 12 and older, all with at least one copy of the particular mutation, known as G551D.\nThe results were announced by a press release and have not been peer reviewed by experts.\nThe saltiness of their sweat \u2014 a measure used to diagnose the disease \u2014 was markedly reduced, suggesting that the drug was having an effect on chloride ion transport.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "It summarizes the alternative treatments for CF. It would\u2019ve been interesting to note what other therapies subjects in this study received.", "answer": 1}, {"article": "It was published Tuesday in JAMA, the journal of the American Medical Association.\nThe study, which was conducted by researchers from Leuphana University in Lueneburg, Germany, recruited 406 people with subthreshold depression, which is defined as having some symptoms of depression but not enough to be diagnosed with major depressive disorder.\nFor the problem-solving therapy, people were asked to create a list of the things that matter most to them in their lives and brainstorm on how to incorporate those things into daily life.\nIt took the trainers about 30 minutes to provide feedback for each session, and they also stayed in touch with participants via instant messaging, Buntrock says.\nIn this experiment, half of the participants were asked to do six half-hour-long exercises that were based on cognitive behavioral therapy and problem-solving therapy, which are techniques commonly used for in-person therapy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study compared online self-help interventions to an online education course about depression, and the story reflects that. The story doesn\u2019t discuss the use of in-person therapy for preventing the onset of MDD, nor does it discuss the use of pharmaceutical interventions.", "answer": 0}, {"article": "Microsoft stresses that Emma Watch is not a cure for the disease, which afflicts 10 million people.\nAfter a speech that both heralded and warned about coming leaps in technological power, Nadella screened a video that told the story of two British Microsoft Research employees, Haiyan Zhang and Nicolas Villa, who developed the tremor-interrupting device for a BBC documentary, The Big Life Fix.\n\"Once these symptoms can be identified and measured, it\u2019s possible to develop technology and devices that help humans manage their symptoms.\nThe goal of further research is to determine whether Emma Watch could help other people with similar Parkinson\u2019s symptoms.\"\nWatson erupts in tears as she calls her mother to say this is the first time she's been able to write her name in ages.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The Microsoft video embedded in the story states that there is no cure, and the story notes how the watch is not a cure. However, there\u2019s no mention of any alternative treatments, and many exist. Some of the first-line medications (levodopa, dopamine agonists, anticholinergics) are very effective in controlling tremor. For patients with\u00a0resistant symptoms, treatment with second-line medications (clozapine, amantadine, clonazepam, propranolol, neurontin) can be used. In patients with disabling\u00a0refractory\u00a0tremor, neurosurgical treatments including thermocoagulation and deep brain stimulation offer tremor control.", "answer": 0}, {"article": "As part of the research for the World Journal of Surgery study, 108 patients with early-stage breast cancer were prospectively implanted with the marker during \"reconstructive lumpectomy,\" a method of oncoplastic surgery to remove the cancer while reconstructing the remaining breast to improve cosmetic outcomes.\nIt is the first and only device that identifies in a reliable way the 3-D region where the tumor was removed.\nThe tiny marker clips stay in place so the surgical site can be viewed for long-term monitoring such as mammograms.\nIt is particularly effective because by suturing the implant to the tumor bed, the surgeon can more precisely indicate to the radiation oncologist where the cancer was located.\nThe average age of women in the study was 63 years.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This is a novel device and there aren\u2019t any similar devices it can be compared with.", "answer": 2}, {"article": "Not the smells of their colognes or perfumes, not of the laundry detergents they use \u2014 the smells of them?\nThe breath of diabetics sometimes smells of rotten apples, experts report; the skin of typhoid patients, like baking bread.\nModern medical research, too, confirms that the smell of someone\u2019s skin, breath and bodily fluids can be suggestive of illness.\nThese molecules offer a whiff of who we are, revealing age, genetics, lifestyle, hometown \u2014 even metabolic processes that underlie our health.\nBut not every physician\u2019s nose is a precision instrument, and dogs, while adept at sniffing out cancer, get distracted.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are currently ways to detect colon, lung, breast and ovarian cancers, all with some major benefits and some troublesome harms. \u00a0If this odor-sensing\u00a0technology is to succeed, we need to know if it is able to detect early signs of the disease\u00a0more accurately than current technologies\u00a0that are in use. The story should have discussed that.", "answer": 0}, {"article": "Bathing-suit season is here and with it, anxiety over cellulite. A new laser device that burrows under the skin is getting praise from some doctors who say it gives more dramatic and longer-lasting results than previous treatments, but others caution that more research is needed.\n\nCellulite is a dimpled, uneven appearance of skin caused by fat underneath. It affects some 85% of women and about 5% of men. Until recently, the main treatments to battle cellulite have been external treatments such as creams and radio-frequency and...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "In a practice that is far too common in such stories, this one mentioned alternatives but waved them off as ineffective without citing any data.\nUntil recently, the main treatments to battle cellulite have been external treatments such as creams and radio-frequency and massage devices. The creams are largely ineffective and the devices have a modest effect that typically lasts about six months, doctors say.\nMeantime, this entire story was based on two company-funded studies \u2013 one tiny and one unpublished!!!", "answer": 0}, {"article": "\"I expected the weight loss to be considerable with both therapies but we were surprised to see blood pressure improve so much more with the low-carbohydrate diet than with orlistat,\" researcher William S. Yancy, Jr., MD, an associate professor of medicine at Duke University Medical Center, says in a news release.\nA new study shows that a low-carbohydrate diet was equally good as the weight loss drug orlistat (the active ingredient in Alli and Xenical) at helping overweight and obese people lose weight, but people who followed the low-carb diet also experienced a healthy drop in their blood pressure levels.\n\"If people have high blood pressure and a weight problem, a low-carbohydrate diet might be a better option than a weight loss medication.\"\nResearchers say studies have already shown that the two weight loss methods are effective at promoting weight loss, but it's the first time the health effects of each have been compared head to head.\n\"It's important to know you can try a diet instead of medication and get the same weight loss results with fewer costs and potentially fewer side effects,\" Yancy says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Given the story\u2019s focus on blood pressure, it\u00a0should have mentioned how the results of this study might compare to treatment with blood pressure medication.", "answer": 0}, {"article": "Experts are still divided as to whether raising HDL levels will actually result in any meaningful improvements in clinical outcomes.\n\"There are a lot of people in the prevention/lipid field that are simultaneously excited and leery,\" said Dr. Howard Weintraub, clinical director of the Center for the Prevention of Cardiovascular Disease at NYU Langone Medical Center in New York City.\n\"I would be more excited [about anacetrapib] if I hadn't seen what happened to its cousin torcetrapib,\" Weintraub said.\n\"We have 94 percent confidence that this drug doesn't have the harmful effect that torcetrapib had, but we didn't prove a reduction in events,\" said Brigham and Women's Cannon.\nTo assess the safety of the trial, investigators randomly chose 1,623 adults with coronary heart disease who were taking cholesterol-lowering statins to receive either anacetrapib or a placebo for 18 months.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story does note that niacin (spelled incorrectly by the way) is the only drug that reliably increases HDL, we would have liked to have seen a bit more information about the role of diet and exercise and how researchers think a CETP inhibitor like anacetrapib (if approved) might fit into the context of other approaches. ", "answer": 0}, {"article": "The U.S. Food and Drug Administration approved the vaccine for girls in 2008 and for boys aged 9 through 26 in 2009.\nThe researchers also saw some reduction in the number of precancerous penile lesions, although at this point they said it's impossible to know whether this will result in a lower rate of penile cancers.\nHPV is almost ubiquitous in males and females, but experts note that most people will clear the virus naturally so that it does not result in any harm.\nAccording to a study presented last year by researchers at the University of Maryland, just one-third of teen girls and young women who start the three-dose series actually finish, and almost three-quarters don't start it at all.\n\"It's a similar efficacy to what we've seen in females,\" said Giuliano, who is chair of cancer epidemiology and genetics at the H. Lee Moffitt Cancer Center in Tampa.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not explain the existing treatment (or lack of treatment) for HPV infections in young men. Although far from perfect as a preventive, the use of condoms could have been given some space in the story along with limiting the number of sexual partners or abstinence. ", "answer": 0}, {"article": "Geier published a 2006 study contending that 11 autistic children taking Lupron did better on tests of awareness, sociability and behavior.\n\"We were basically under seige in this house,\" Badillo said.\nIt's what happens when you have high testosterone,\" Badillo said.\n\"These people are preying on the fears of parents.\nGeier could not be reached for comment despite several attempts by phone.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Good job on this as well.\u00a0 The story states that \"untested autism treatments have flourished.\"\u00a0 And it ends with: \n       \n \n ", "answer": 1}, {"article": "The oral drug targets an enzyme called Syk.\n\"Inhibition of the Syk pathway offers a new drug target for rheumatoid arthritis,\" Weinblatt and colleagues conclude.\nWeinblatt reports receiving grants, fees, or honoraria from a number of drug and biomedical companies, including Rigel.\nNobody is exactly sure of the role Syk plays in rheumatoid arthritis.\nIt's not clear whether long-term use of R788 will increase cancer risk; longer-term clinical trials will have to evaluate this risk.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story drops readers into this supposed battle between this new drug and methotrexate, but it does not explain why these two drugs are being compared. Nor does it explain, as HealthDay does, that this drug is part of a new class of drugs in various stages of development.", "answer": 0}, {"article": "When considering where to give birth, most parents-to-be and doctors in Western nations believe a hospital is the best place.\n\nNot so Jean Stevens, 32, who chose to deliver two children at home in the U.K. She says her two labors were nearly pain-free.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is, by its nature, about comparing alternatives. The story looks explicitly at home births compared to births in medical centers; and, among medical centers, the story explains the difference between hospitals and birth centers.", "answer": 1}, {"article": "Buck scientists strive to discover new ways of detecting, preventing and treating age-related diseases such as Alzheimer's and Parkinson's, cancer, cardiovascular disease, macular degeneration, osteoporosis, diabetes and stroke.\nWhile the medication remains the single most effective agent in the management of PD symptoms, long-term use causes its own side effects, among them abnormal involuntary movements or AIMS.\nIn earlier studies, Andersen's team found that low-dose lithium was protective in two different mouse models of PD.\nThis study, published online in Brain Research, involved Parkinsonian mice that were given Carbidopa/Levodopa (sold as Sinemet\u00ae), a drug used to boost levels of the neurotransmitter dopamine, which is lost in PD.\nThis work was supported by grants from National Institutes of Health 5P20GM103653-02; RL!\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Although levodopa/carbidopa is the main approach to treatment, other drugs are available that are not mentioned. In addition to medical therapy, deep brain stimulation is also available at most academic medical centers.", "answer": 0}, {"article": "Still, the big questions surrounding sauna bathing\u2019s safety have always centered on its occupant\u2019s (and her heart\u2019s) ability to withstand the heat.\n\u201cAs infrared heat penetrates more deeply than warmed air, users develop a more vigorous sweat at a lower temperature than they would in traditional saunas,\u201d says Dr. Richard Beever, a clinical assistant professor of family medicine at the University of British Columbia.\nFrom the Jewish to Mesoamerican \u201chouses of heat,\u201d people all over the world have long associated a good sweat with a wide assortment of health benefits.\nBut if you\u2019re wondering whether an infrared sauna is worth a try, the evidence suggests you have little to lose and possibly something to gain by checking one out.\n\u201cSauna bathing leads to a significant increase in heart rate and reduction in total vascular resistance, thereby decreasing blood pressure,\u201d says Dr. Ernst van der Wall, chief of cardiology at the Netherlands Leiden University Medical Centre.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Alternatives are not discussed, especially for the health claims mentioned like sleep improvement or better heart health.\u00a0How do infrared saunas compare, for example, to exercise, diet modifications or other alternatives? Also, can the effects of a sauna be replicated by going out in hot weather and/or working up a sweat? What makes saunas unique and worth the time, effort and cost?", "answer": 0}, {"article": "\u201cThere\u2019s been a longstanding fear of skin testing, and it turns off a lot of allergy sufferers from getting help,\u201d said Dr. Mitchell, the author of \u201cAllergy and Asthma Solution\u201d (Marlowe, 2006), which advocates oral immunotherapy, or allergy drops, instead of shots.\nThe lab sends the physician a report with these figures and the patient\u2019s risk of a reaction.\nThe size of the wheal and the diameter of the redness help determine if the patient is allergic.\nBecause they were not considered very sensitive, physicians were left with a lasting impression that blood testing was inferior to skin testing.\nIf an allergist does an in-office skin-prick test, he gets the fees for those tests.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions the skin testing and talking with their primary care doctors about their symptoms as alternatives to the blood test.", "answer": 1}, {"article": "A study believed to be the largest of its kind suggests that the physical aspects of yoga are effective at relieving low back pain, but it didn't find any evidence that yoga provided broader mental benefits.\n\nThe study, funded by the National Institutes of Health's National Center for Complementary and Alternative Medicine, was published online Monday in the Archives of Internal Medicine. It was lead by researchers at Seattle's Group Health Research Institute.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The clinical trial trial itself involved multiple alternatives: yoga, aerobic exercise and stretching, and a self-care educational intervention involving activity and lifetyle modification.\nSo that probably fulfills this criterion.\n \n", "answer": 1}, {"article": "Kerry Aldrich, 15, suffered a concussion playing varsity soccer for The Potomac School in McLean, Va., three weeks ago when she did a face-first dive and violent somersault.\n\"The brain, in its development, while it is actively developing, seems to be less able to take these forces and to really rebound from these forces,\" Dr. Gioia observed.\n\u2026 It's like a sophisticated video game, but the numbers that are generated from the report are critical in helping to better identify the severity and recovery from the injury.\"\nBut, Regan adds, diagnosing them can be daunting: While there are some physical symptoms such as headaches, nausea, dizziness and blurred vision, concussions don't cause bleeding or swelling in the brain and don't show up on X-rays.\nBut for students such as Aldrich, who don't know their baseline, extra caution is the doctor's order.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\nThe broadcast fails to note alternative methods of determining when an athlete can safely return to play after a concussion, including inexpensive low-tech aids and clinical judgment. There is considerable debate in the sports medicine community on this point. The broadcast also does not elaborate on the potential disadvantages of the Impact system or on the potential advantages of its alternatives (traditional and electronic).\n", "answer": 0}, {"article": "Dr Ishwar Singh, a specialist in novel drug design and development from the University of Lincoln's School of Pharmacy, is leading the research team.\nWith this new knowledge, synthesised versions of teixobactin can be more easily developed, taking the process from up to 30 hours to just ten minutes for a single coupling step - a significant step towards turning teixobactin into a viable new drug.\nThe development of new antibiotics which can be used as a last resort when other drugs are ineffective is therefore a crucial area of study for healthcare researchers around the world.\nThey are also 16 times more potent than a clinically-used antibiotic in killing the superbug MRSA, and they were also highly potent against other antibiotic-resistant infections, such as vancomycin resistant enterococci, and tuberculosis.\"\nEach amino acid sits at a specific place in teixobactin's structure, and the Lincoln team has now successfully replaced enduracididine - which holds position ten - with two alternative amino acids which are not positively charged.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "It appears that the release compares teixobactin to existing antibiotics, but it does not tell readers that the comparison is laboratory studies versus real world experience, which is not a fair comparison.", "answer": 0}, {"article": "Jaffe said the study focused on time to treatment failure because delaying or preventing inflammation is the key to successful treatment.\n\u201cSince each of these signs can be associated with different types of uveitis, the study\u2019s results broaden the applicability of treatment for patients.\u201d\n\nThe study authors note, however, that patients in the adalimumab group reported serious adverse effects, such as respiratory tract infections and allergic reactions, more frequently than those in the placebo group.\nThe studies also looked at whether an alternative would be better tolerated or more effective, yet still safe.\u201d\n\nThe study consisted of 217 adults who had active, non-infectious intermediate or posterior uveitis, or panuveitis.\n\u201cThe hope is that by delaying or eliminating recurrences, the symptoms will be minimized or eliminated.\u201d\n\nThe researchers found that median time to treatment failure was 24 weeks in the adalimumab group and 13 weeks in the placebo group.\nIn addition to Jaffe, co-authors include Andrew D. Dick, Antoine P. Br\u00e9zin, Quan Dong Nguyen, Jennifer E. Thorne, Philippe Kestelyn, Talin Barisani-Asenbauer, Pablo Franco, Arnd Heiligenhaus, David Scales, David S. Chu, Anne Camez, Nisha V. Kwatra, Alexandra P. Song, Martina Kron, Samir Tari, and Eric B. Suhler.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Although the release mentions the weakness of corticosteroids in uveitis treatment, it doesn\u2019t go far enough in explaining how steroids compare with adalimumab, even though steroids were given to the patients concurrently with adalimumab in \u201cdiminishing doses\u201d throughout the trial.\nIt\u2019s worth noting, especially for comparison with adalimumab, how the long-term use of corticosteroid drugs work against uveitis symptoms by suppressing the body\u2019s entire immune system \u2014 and, as a side effect, metabolism \u2014 not just one specific target of inflammation. Humira also suppresses the body\u2019s immune system although through a different mechanism.", "answer": 0}, {"article": "\u201cShould he take a statin?\nBut the reality is that people are being operated on.\u201d\n\n\u201cWe are trying to avoid a diagnosis to avoid a prevention whose value is disputed,\u201d he said.\nThe drug, finasteride, is available as a generic for about $2.00 a day, and millions of men safely take it now to shrink their prostates, its approved use.\n\u201cFinasteride has to be recognized as the first clearly demonstrated way to prevent prostate cancer with any medication or any oral agent at all.\u201d\n\nFinasteride has had its ups and downs.\nThe amount of benefit he\u2019ll get is not much, but his risk reduction still is 25 or 30 percent.\u201d\n\nDr. Thompson knows what he will do about finasteride.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not adequately describe the option of not taking this drug as a preventive measure.\u00a0 A lot of space was given to the arguments for prescribing a drug without mentioning the possibility of the clinician having a shared decision-making discussion with the man about not taking the drug \u2013 and about the potential tradeoffs of this or any other prostate cancer treatment.\u00a0 ", "answer": 0}, {"article": "Four hundred international units of vitamin D are also recommended each day to help the body absorb calcium.\nIt's important to note that calcium intakes on food labels are based on adult requirements of 1,000 milligrams per day.\nThe message here, Senay says, is that calcium supplements are useful for bone health \u2014 but you should only take them if you do so regularly, as directed by a doctor.\nResearchers studied the effect of 600-milligram calcium supplements twice a day on women over 70 and found that only those women who took 80 percent or more of their pills were less likely to experience fractures.\nOther ways women can protect their bones as they age include weight-bearing exercise, and osteoporosis drugs for women at high risk for fractures.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention diet and weight bearing exercise as alternatives to calcium supplementation. However, more information about the advantages and disadvantages of the alternatives should have been provided. Other options, such as exercises to improve stability and interventions to prevent falls, could also have been mentioned.", "answer": 1}, {"article": "\u201cThings are moving forward, but it is still a work in progress.\u201d\n\nMedical guidelines in the U.S. already urge people to take low doses of aspirin to prevent heart disease if the predicted benefits outweigh the risk of side effects, or if they have already suffered a heart attack.\nEarlier this year, Ray\u2019s team published an analysis of previous aspirin trials showing the medication did not prevent deaths from heart disease or cancer, and was likely to cause more harm than good.\nAs a result, doctors may find and remove tumors or precancerous polyps, which could prolong the patient\u2019s life - the idea behind colon cancer screening.\nEarlier this year, an analysis of previous clinical trials showed that people on aspirin were less likely to die of cancer than those not on the medication, with a 37-percent drop in cancer deaths observed from five years onwards.\nDr. Kausik Ray of St. George\u2019s University of London, who has studied aspirin, said the new study did not look at overall death rates or side effects such as serious stomach bleeds.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The WebMD story did a better job on this simply by including one line about \u201cother strategies will also reduce the risk of cancer\u201d \u2013 regular physical activity, healthy weight, not smoking.", "answer": 0}, {"article": "LONDON (Reuters) - British scientists have discovered a \u201crogue gene\u201d which helps cancer spread around the body and say blocking it with the right kind of drugs could stop many types of the disease in their tracks.\nSurinder Soond, who worked on the study, said it was a \u201cnovel and exciting approach to treating cancer and the spread of tumors which holds great potential.\u201d\n\n\u201cThe challenge now is to identify a potent drug that will get inside cancer cells and destroy the activity of the rogue gene,\u201d said Andrew Chantry of UEA\u2019s school of biological sciences, who led the research.\nIf a drug was developed that deactivated WWP2, he said, conventional therapies such as chemotherapy and radiotherapy could be used on primary tumors with no risk of the disease taking hold elsewhere.\nThe culprit gene, called WWP2, is an enzymic bonding agent found inside cancer cells, the researchers explained in their study, published in the journal Oncogene Monday.\nChantry said in a telephone interview the findings mean drugs could be developed in the next 10 years that could be used to halt the aggressive spread of many forms of cancer, including breast cancer, brain, colon and skin cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes no comparisons with alternatives. It mentions chemotherapy and radiotherapy in passing. Reading the story carefully, one might believe that any treatment developed from this finding would work only in conjunction with these other treatments. But we can\u2019t be sure.\u00a0The story should have mentioned other proposed interventions intended to disrupt the spread of cancer cells, including some drugs that are already in clinical trials.", "answer": 0}, {"article": "Oct. 17, 2010 -- Women aged 65 and older are advised to undergo bone mineral density (BMD) screening every two years, but those with normal results at age 67 may be able to wait 10 years before their next screening test, a new study suggests.\nTheir findings are based on the women's T-score, which is a measure of bone density.\nThat was longer than we expected, and it's great news for this group of women.\"\nResearchers say the 10-year interval is OK because the women\u2019s risk of developing the brittle bone disease osteoporosis in that time is low.\n\"Our study found it would take about 16 years for 10 percent of women in the highest bone density ranges to develop osteoporosis.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The entire story is about different intervals for bone density screening.", "answer": 1}, {"article": "MORE: A Cheaper Way to Quit Smoking?\nThe research was funded by the National Institute on Aging, but some of the authors also receive pharmaceutical industry funding and one reported funding from Philip Morris.\nThe randomized controlled trial included 74 people, mainly in their late 70\u2019s, with mild cognitive impairment (MCI).\nHowever, patients on nicotine did lose a few pounds, which is a known side effect.\nYou can also continue the discussion on TIME Healthland\u2019s Facebook page and on Twitter at @TIMEHealthland.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no mention of alternative strategies to either improve or slow down the degradation of cognitive function in people with mild cognitive impairment.", "answer": 0}, {"article": "Indiana University researchers have found that magnesium intake may be beneficial in preventing pancreatic cancer.\nThe study also found that the effects of magnesium on pancreatic cancer did not appear to be modified by age, gender, body mass index or non-steroidal anti-inflammatory drug use, but was limited to those taking magnesium supplements either from a multivitamin or individual supplement.\n\"Pancreatic cancer is really unique and different from other cancers,\" said study co-author Ka He, chair of the Department of Epidemiology and Biostatistics at the IU School of Public Health-Bloomington.\nUsing information from the VITamins and Lifestyle study, Dibaba and the other co-authors analyzed an enormous trove of data on over 66,000 men and women, ages 50 to 76, looking at the direct association between magnesium and pancreatic cancer and whether age, gender, body mass index, non-steroidal anti-inflammatory drugs use and magnesium supplementation play a role.\nBut few studies have explored the direct association of magnesium with pancreatic cancer; of those that did, their findings were inconclusive, said Daniel Dibaba, a Ph.D. student at the School of Public Health-Bloomington, who led the IU study.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The focus of this release is on a study that tries to compare the effect of meeting RDAs of magnesium and not meeting that daily target.\nBut the release doesn\u2019t mention any other suspected risk factors for pancreatic cancer such as obesity, smoking, alcohol abuse, inactivity, genetics, and so on, which might have been helpful.", "answer": 0}, {"article": "Contrary to earlier reports, giving acetaminophen (Tylenol, etc.)\n\u2022 The percentage of days with full asthma control were virtually the same for acetaminophen and ibuprofen: 85.8 and 86.8 percent, respectively.\n\"We found no matter how you slice it, there was absolutely no difference between Tylenol and Motrin,\" says senior investigator and corresponding author Wanda Phipatanakul, MD, MS, of Boston Children's Hospital's Division of Allergy and Immunology.\n\u2022 At least one asthma exacerbation occurred in 49 percent of the acetaminophen group, vs. 47 percent of the ibuprofen group.\nThe 18-site study should settle a debate that originated when several retrospective studies seemed to indicate that children had exacerbations of their asthma when receiving Tylenol for pain and/or fever.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The study was designed to compare the safety of two drugs \u2013 acetaminophen and ibuprofen \u2013 in children with mild, persistent asthma, since previous observational studies had correlated acetaminophen with increased asthma symptoms.\nSince the drugs themselves are already alternatives in treating pain and fever, we rate this one Not Applicable.", "answer": 2}, {"article": "A minimally invasive procedure designed to shrink prostate tissue with a series of nine-second blasts of steam offers men a new treatment for urinary symptoms commonly associated with enlarged prostates.\n\nThe procedure, called Rez\u016bm (pronounced \u201cresume\u201d) and developed by NxThera Inc. of Maple Grove, Minn., became widely available in the U.S. in the second half of 2016. Thermal energy in the form of steam is applied to the prostate with a needle. As it cools it releases heat energy into the tissue, killing cells and shrinking...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are numerous other minimally invasive treatments (laser, thermotherapy, radio frequency ablation) that are not mentioned.", "answer": 0}, {"article": "Researchers said they had identified a family of retroviruses in patients with chronic fatigue syndrome, opening up a potentially promising new avenue of treatment for a debilitating disease that afflicts as many as four million Americans and 17 million people world-wide.\n\nThe finding will likely spur patients with the condition to seek treatment with drugs used to fight HIV, the virus that causes AIDS. Although HIV and the newly identified virus group are different, they are both retroviruses.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 0}, {"article": "\"We found that the current practice of feeding children in an early stage does not contribute to their recovery\", says lead author Professor Greet Van den Berghe from KU Leuven / University Hospitals Leuven.\nThis common practice is based on the assumption that it will help them recover more quickly.\nThe current standard of care for such children is based mostly on the assumption that they need to eat to regain their strength.\nThe artificial nutrition is infused directly into the bloodstream.\nThe researchers examined whether fasting or receiving very small amounts of feeding during the first week in the paediatric intensive care unit was better for the children than full feeding through an IV.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This release is about a comparative study between early and late parenteral feeding upon admittance to an ICU.", "answer": 1}, {"article": "Medical device makers have been working for years to develop a so-called artificial pancreas to deliver insulin to patients with type 1 diabetes, an autoimmune disease in which the body destroys its own ability to make insulin.\n\u201cThese devices could transform the management of type 1 diabetes, but it is likely to be a gradual process,\u201d Roman Hovorka of Cambridge, who led the research, said in a telephone interview.\nThe ultimate goal is to create a device that can check patients blood day and night, during and between meals, and deliver insulin as required.\nThe new system, which involves patients wearing a matchbox-sized monitor and a similar-sized pump with a tube to deliver insulin into the body, also halved the amount of time blood sugar dropped to worrying or dangerous levels, they said.\nWhen we started, the technology wasn\u2019t very good and the functionality was limited, and it took a number of generations to move to the device that we have now.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t describe how type 1 diabetes is currently managed and why new automated systems might be an improvement.\u00a0An important benefit would be\u00a0the prevention of nighttime episodes of hypoglycemia. The\u00a0story doesn\u2019t\u00a0make this clear.\u00a0\u00a0", "answer": 0}, {"article": "The boxes are a new idea for many Americans.\n\u2018\u2018They do it because they want to be nurturing and they are, but it\u2019s not safe.\u2019\u2019\n\nTo get the boxes, prospective moms can register through babyboxuniversity.com, watch a handful of videos on sleep safety and pass a quiz.\nThe idea for baby boxes started in Finland in the 1930s, and is tied to a sharp drop in sudden infant deaths, according to Dr. Kathryn McCans, a pediatrician who chairs New Jersey\u2019s Child Fatality and Near Fatality Review Board.\nBut when they\u2019re linked to a practice that started in Finland decades ago to help babies sleep safely, they\u2019re taking on a new purpose as so-called baby boxes make their way to the U.S.\n\nParents are beginning to take baby boxes home from hospitals along with their newborns.\nThe boxes aren\u2019t the only option for safe sleeping, of course, but health officials say they\u2019re a useful part of a broader safe-sleep education program.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We think the headline and most of the story makes the boxes seem very important.\nThis is the only sentence that hints there are alternatives. \u201cThe boxes aren\u2019t the only option for safe sleeping, of course, but health officials say they\u2019re a useful part of a broader safe-sleep education program.\u201d (Italics by reviewers.)\nIf the boxes are just part of a broader education, then perhaps it isn\u2019t \u201cditching the crib\u201d as the headline says that leads to safer infant sleep but parent training that advises a firm mattress, bumper-free cribs and absence of clutter that are keys to a safer sleeping environment.", "answer": 0}, {"article": "Hoberman is chief of the general academic pediatrics division at Children's Hospital of Pittsburgh of UPMC.\n\"Though we should be rightly concerned about the emergence of resistance overall for this condition, the benefits of the 10-day regimen greatly outweigh the risks,\" he added.\nWhat's more, the children in the five-day group didn't have a lower risk of antibiotic resistance or of side effects such as diarrhea or diaper rash.\n\"Given significant concerns regarding overuse of antibiotics and increased antibiotic resistance, we conducted this trial to see if reducing the duration of antibiotic treatment would be equally effective along with decreased antibiotic resistance and fewer adverse reactions,\" Dr. Alejandro Hoberman said in a university news release.\n\"The results of this study clearly show that for treating ear infections in children between 9 and 23 months of age, a five-day course of antibiotic offers no benefit in terms of adverse events or antibiotic resistance,\" Hoberman said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This rates not satisfactory by virtue of the fact it didn\u2019t mention the one alternative that the evidence suggests might be best, at least for older kids: Doing nothing except treating the pain.", "answer": 0}, {"article": "However, common side effects included headache, dizziness and nausea.\n\"In this long-term study of lorcaserin for treating patients for obesity, there was good weight loss, outstanding safety profile and the drug was extremely well-tolerated,\" said lead researcher Dr. Steven Smith from the Translational Research Institute for Metabolism and Diabetes in Winter Park, Fla.\n\n\"As patients are looking for additional options and physicians are looking for new tools, [lorcaserin] provides us with a look into the future for what's going to be available for helping patients lose weight,\" he added.\n\"This close look at lorcaserin reaffirms that better daily use of feet and forks holds far greater promise for meaningful, sustainable and affordable weight control than pharmacotherapy,\" Katz said.\nAlso, it does not have the same problems as the previous weight-loss drugs, Fen-Phen (Phentermine), Acomplia (rimonabant) or Meridia (sibutramine), which had been associated with heart problems, he said.\n\"If weight-loss drugs are tailor-made to hit only the right receptor, based on physiological knowledge, it seems to be possible to develop weight-loss medications that do not possess any serious adverse effects,\" Astrup added.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Like the other two pieces, it ignores the idea that drugs might not work better than exercise or diet. It took one year on a drug for people to lose 13 pounds on average. That\u2019s a little more than 1 pound a month, and that number dropped considerably the second year. As Katz points out, \"Among those who remained, lorcaserin produced relatively modest weight loss when combined with diet and exercise counseling, and that weight loss was maintained in over half of the participants only so long as they kept taking the drug\u2026This close look at lorcaserin reaffirms that better daily use of feet and forks holds far greater promise for meaningful, sustainable and affordable weight control than pharmacotherapy.\" That is something that merited more than just a comment from Katz.", "answer": 0}, {"article": "To him, diet underpins longevity.\nThe idea of caloric control improving your health, and therefore your lifespan, is nothing new, but researchers are now hoping to accurately determine the type of diet that could make you live longer.\nThe pathways he refers to are known as TOR, PKA and IGF pathways, which when controlled can switch on certain reactions inside the body causing immune cells to die and organs to shrink.\n\"It can reprogram your body and put it on a path to live longer,\" says Longo.\nUnlike the 5-2 diet, which requires two days of low calories at any point in the week, Longo's diet involves fasting for five consecutive days, which requires much more willpower.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story makes no mention of other ways to achieve similar benefits. How does this dieting approach compare, for example, to regular exercise as a means to age healthier?", "answer": 0}, {"article": "DOI: 10.4172/2155-6105.1000290 \n\nhttp://www.\nThe results, published in the Journal of Addiction Research & Therapy, show that 66 per cent of respondents reported an improvement in respiratory symptoms, 29 per cent reported no change and 5 per cent reported worsening.\nSenior author Professor Peter Hajek from QMUL said: \"There is no doubt that e-cigarettes are much safer than conventional cigarettes, but smokers are still led to believe that they're dangerous.\nFor more information, please contact: \n\nJoel Winston \n\nPublic Relations Manager (School of Medicine and Dentistry) \n\nQueen Mary University of London \n\nj.winston@qmul.ac.uk \n\nTel: +44 (0)20 7882 7943 / +44 (0)7970 096 188\n\n* Research paper: 'Changes in the Frequency of Airway Infections in Smokers who Switched to Vaping: Results of an Online Survey'.\nThe on-line survey of 941 respondents assessed subjective changes in respiratory symptoms in smokers who switched to vaping for at least two months.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Smoking cessation programs that incorporate counseling, nicotine replacement therapy such as patches or gum, and antidepressants are considered to be cost-effective and relatively safe. The news release does not mention this.\nThe healthiest and most cost-effective strategy is to avoid both smoking and e-cigarettes.", "answer": 0}, {"article": "Newswise \u2014 CHAPEL HILL, NC \u2013 UNC researchers say the results from the multi-site phase 2 and 3 trials of brexanolone injection are not only promising, but could change the way postpartum depression (PPD) is treated.\nThe first statistically significant reduction in depression severity with brexanolone injection relative to placebo was observed as early as 24 hours after dosing.\nA unique dose group of brexanolone 60 \u00b5g/kg/hr in one of the studies was not included in the integrated efficacy analysis, but was included in integrated analyses of safety.\n\u201cHaving a drug developed specifically for postpartum depression is a game-changer for women\u2019s health,\u201d said Meltzer-Brody.\nThe most common (\u226510% of subjects) adverse events following during brexanolone injection administration were headache, dizziness and somnolence.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions that women currently can receive antidepressants for postpartum depression, but that the new drug being studied goes to work relieving symptoms faster than traditional antidepressants \u2014 days rather than weeks.", "answer": 1}, {"article": "But stimulating the vagus nerve requires surgery to implant a device near the collarbone.\nThe approach, which is not yet approved by the FDA, could offer an alternative or enhancement to treatment with drugs, says Christopher DeGiorgio, the neurologist at UCLA who invented the new approach.\nThe trigeminal nerve stimulator, in contrast, never penetrates the skin and is powered by an external device about the size of a large cell phone, DeGiorgio says.\n\"For me it's extremely effective,\" says Jennifer Rees, 49, who lives in the Los Angeles area and has been using the nerve stimulator for six years.\nThe device is appealing because it doesn't require surgery, doesn't have side effects and is very easy to use, Rees says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not adequately compare the device to alternatives and gives the impression that this is the best treatment choice. It says for example, \u201cAbout 3 million Americans have epilepsy, and for about one-third of them, drugs alone do not control their seizures.\u201d It does not say what the one-third referenced do to supplement the drugs.\u00a0It tends to leave readers with the idea that for at least that subset of the patient population, this device is the only alternative.", "answer": 0}, {"article": "Actually, nitrous is making a comeback in U.S. maternity circles. It has remained a staple of childbirth in Canada, Australia, and Britain \u2014 Catherine, Duchess of Cambridge (the former Kate Middleton), who welcomed her third royal baby, Louis Arthur Charles, last month, reportedly has used it. But it basically disappeared in the United States in the 1970s. American women preferred to be numbed below the waist with epidural anesthesia, or at least that became the gold standard for pain relief.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does well to provide relevant historical and cultural context; namely, that the traditional approach to labor pain in the US is biased toward epidural anesthesia, despite the fact that nitrous oxide is a common alternative in other countries.\nGiven the current opioid epidemic in this country, it may have been timely to mention the extensive use of narcotics in managing labor pain in the US.", "answer": 1}, {"article": "Greek researchers offered fresh evidence of the health benefits of the Mediterranean diet, reporting in a large study that it helps improve several risk factors linked to diabetes, obesity and heart disease.\n\nThe Mediterranean diet is high in monounsaturated fats such as olive oil and also relies heavily on whole-grain cereals, fruits and vegetables, fish and low consumption of animal fats. It has been shown in numerous studies and clinical trials to reduce mortality from such causes as cardiovascular disease and cancer.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not provide any insight about how this dietary intervention compares with other approaches (exercise or drugs) for attaining the benefits suggested from the \u201dMediterranean diet\u2019.\u00a0 Even a line would have helped readers think about this context.", "answer": 0}, {"article": "He was fascinated by certain powerful cells of the immune system \u2014 T cells.\n\"It used to be there were three basic treatment options for cancer \u2014 surgery, radiation and chemotherapy \u2014 or some combination of those three.\nSharon Belvin's nightmare with cancer began in 2004, when she was just 22.\nShe had about a 50-50 chance of surviving the next six months.\nWe were letting the T cells kill the cancer cells.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story refers to other treatment options, including surgery, radiation and chemotherapy.", "answer": 1}, {"article": "The findings are published in the Nov. 28 online edition of Arthritis & Rheumatism.\nFor the study, the investigators analyzed the findings of 40 studies published between January 1990 and December 2011.\nThe study team found no differences between the two groups of arthritis patients in rates of follow-up surgery, or 90-day blood clot or death risk.\nIn addition, rheumatoid arthritis patients have a higher infection risk after total knee replacement than osteoarthritis patients, the study authors found.\nThe studies included arthritis patients aged 18 or older who had hip or knee replacements.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story was just about comparing joint replacement outcomes in different groups of patients, so it is understandable that it did not delve into alternative treatment.\n\u00a0", "answer": 2}, {"article": "In one of his own studies, Wong found no effect on soy germ isoflavones among women who took the supplements for two years.\n\u201cConsuming soy is not bad for them,\u201d Wong noted, \u201cbut it might be a waste of money if you don\u2019t see any benefit.\u201d\n\u201cIt is something they need to gauge, is it worth the risk?\u201d Wong told Reuters Health.\n\u201cThere is a major cultural difference in how we deal with menopause symptoms,\u201d he mused.\nThey all kept diaries of their hot flashes and filled out questionnaires about various problems tied to menopause, including hot flashes, sweating, insomnia, tiredness and headache.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story states that \u201cThe standard drug treatment for stubborn menopause symptoms is hormone replacement therapy. But doctors and women have become increasingly wary of that option because of serious side effects such as increased risk for heart attack, stroke and breast cancer.\u201d", "answer": 1}, {"article": "CHICAGO \u2014 Insulin pumps are used by tens of thousands of teenagers worldwide with Type 1 diabetes, but they can be risky and have been linked to injuries and even deaths, a review by federal regulators finds.\nAt times, the devices malfunctioned, but other times, teens were careless or took risks, the study authors wrote.\nThey didn\u2019t advise against using the devices.\nThe pumps are popular because they allow young people to live more normal lives, giving themselves insulin discreetly in public.\n\u201cWithout appropriate glucose monitoring, the pumps can increase the risk of getting sick more quickly compared to injections,\u201d Luedke said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Multiple daily insulin injections, the standard most widely used treatment option for Type I diabetes, is appropriately referenced. ", "answer": 1}, {"article": "\"The DTI approach is a powerful tool for breast reconstruction in elderly patients,\" comments ASPS Member Surgeon Andrea Moreira, MD, of the Cleveland Clinic.\nThe researchers believe the DTI technique may expand the options for older women, who are less likely to undergo breast reconstruction.\nThe researchers emphasize that DTI isn't an option for every patient, depending on breast shape and other factors.\nSo far, however, most studies of DTI have focused on younger women.\nhas been the one consistently excellent reference for every specialist who uses plastic surgery techniques or works in conjunction with a plastic surgeon.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The point of the study was comparing two options for breast reconstruction.", "answer": 1}, {"article": "Another group did high intensity exercise on the treadmill but in short interval bouts.\nWhile it\u2019s not entirely clear why, part of the reason may have to do with the fact that extreme exercise generates body heat, which can be detrimental to sperm health; for marathoners and people training at intense levels, finding ways to dissipate body heat is a major concern.\n\u201cBut this is a much better done study than almost anything that\u2019s been done before on the subject.\u201d He notes that most previous studies did not randomly assign people to exercise groups and compare the outcome on sperm quality, but rather recorded sperm measures among men who reported their exercise habits after the fact.\nIn the study, Behzad Maleki at Justus-Liebig University in Germany and his colleagues recruited 280 sedentary, middle-aged men and randomly assigned them to one of three exercise regimens, or to no exercise, and followed them for six months.\n\u201cThis fits reasonably well with what we thought about the effects of exercise,\u201d says Dr. Peter Schlegel, vice president of the American Society of Reproductive Medicine and chairman of urology at New York Presbyterian/Weill Cornell Medical Center.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does suggest in the first paragraph other approaches to improving semen quality.\u00a0 \u201cAmong the most (advice) dispensed: eat a healthy diet, keep a healthy weight, avoid alcohol and tobacco and stay away from certain medications, such as blood pressure and depression drugs.\u201d", "answer": 1}, {"article": "JACKSONVILLE, Fla. \u2014 Researchers at Mayo Clinic\u2019s campus in Florida have conducted the world\u2019s first prospective, blinded and placebo-controlled clinical study to test the benefit of using bone marrow stem cells, a regenerative medicine therapy, to reduce arthritic pain and disability in knees.\nThe findings in The American Journal of Sports Medicine include an anomalous finding \u2014 patients not only had a dramatic improvement in the knee that received stem cells, but also in their other knee, which also had painful arthritis but received only a saline control injection.\nBut, depending on how they are processed and used, stem cells can, in fact, be regulated by the U.S. Food and Drug Administration as biological products or drugs requiring rigorous safety and efficacy approval processes.\n\u201cThis is just a theory that can explain our results, so it needs further testing.\u201d\n\nAnother explanation is that merely injecting any substance into a knee offered relief from pain.\nGiven that the stem cell-treated knee was no better than the control-treated knee \u2014 both were significantly better than before the study began \u2014 the researchers say the stem cells\u2019 effectiveness remains somewhat uninterpretable.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "As noted earlier in this review, other treatments \u2014 tested and untested \u2014 exist, including Platelet\u00a0Rich Plasma presumed to carry biological growth factors to arthritic joints; steroid injections; exercise; surgery; and analgesics. None were mentioned.", "answer": 0}, {"article": "Kudrow is one of hundreds of doctors investigating a new class of drugs that block calcitonin gene-related peptide (CGRP), a molecule that spikes during a migraine attack.\n\u201cIt's not a pill, it's an injection that stays in the system for a long period of time and is continuously blocking that CGRP mechanism of migraine.\u201d\n\nResults from several pharmaceutical trials are expected either later this year or in early 2018.\nMy entire head throbbed and stung.\u201d\n\nKaufman, who lives in Los Angeles, visited dozens of doctors, trying every option, including pain clinics, holistic remedies, Botox shots, and even hypnotherapy.\nShe feels like a different person who no longer has to shy away from social commitments.\n\u201cIf we can block CGRP, then we can abort a migraine attack,\u201d says Kudrow.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions some alternatives, but only to discuss how they don\u2019t work and/or carry side effects. This is a particularly important shortcoming. There are several medications that can be used effectively for patients with chronic migraine to prevent their occurrence, including beta blockers, calcium channel blockers, and some medications used in seizure disorder. \u00a0Some patients are also able to prevent migraine by careful lifestyle changes, like avoiding changes in caffeine consumption, alcohol (particularly wines), foods, and irregular sleeping habits.", "answer": 0}, {"article": "But Dr.\n\u201cIt creates these huge ethical quandaries about trying a drug that has a modest benefit for the average patient at enormous expense.\u201d\n\nFolotyn is given by a rapid intravenous procedure once a week for six weeks out of every seven.\nIn the prospectus for that offering, the company said that one of the risks for investors was \u201cthe relative price of Folotyn as compared to alternate treatment options.\u201d It said there was a risk it might have to lower the price or offer discounts to successfully market Folotyn.\nMr. Schimmer\u2019s note was entitled \u201cFolotyn Prices High, Reiterate Outperform.\u201d He estimated annual sales of the drug in the United States reaching about $300 million by 2014.\nAnd because a patient\u2019s out-of-pocket co-payments alone \u2014 Medicare\u2019s is 20 percent \u2014 could be thousands of dollars a month for Folotyn, Allos is financing a co-payment assistance program run by the National Organization for Rare Disorders, a patient advocacy group.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story clearly states that there are no alternatives to Folotyn for this particular indications, but compares the price of the drug to several other expensive cancer drugs. The story should have emphasized that Folotyn was studied in patients who have relapsed and a comparison with currently used regimens is not available.", "answer": 1}, {"article": "For more information, please visit www.alzheimersprevention.org.\n\"We've been studying the impact of meditation on memory for more than 20 years, and are as encouraged as we've ever been on its powerful role in maximizing brain health,\" said Khalsa, president and medical director of the Alzheimer's Research and Prevention Foundation and a clinical associate professor of integrative medicine at the University of New Mexico School of Medicine.\nThe article reviews decades of research into the impact that various meditation techniques have had on the prevention of Alzheimer's disease, focusing on one evidence-based practice that Khalsa says can be a powerful part of any Alzheimer's prevention and spiritual fitness program, Kirtan Kriya (KK), a meditation technique which has been successfully used to improve memory in studies of people with subjective cognitive decline and mild cognitive impairment.\nWhile preliminary studies have suggested a link between meditation, a sense of spirituality or faith and the risk of Alzheimer's disease, the article's author, Dharma Singh Khalsa, M.D., states that a cultivation of higher levels of psycho-social well-being, such as independence, resilience and life purpose represents \"an important new frontier that deserves further research as it is freely available to anyone, anytime, anywhere.\"\nTUCSON, Ariz., July 15, 2015 /PRNewswire/ -- Meditation and spiritual fitness are key components in reducing the risk of Alzheimer's disease according to a new article, \"Stress, Meditation, and Alzheimer's Prevention: Where the Evidence Stands\", published in an early online version of the Journal of Alzheimer's Disease 48(1).\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release focuses on only one technique \u2014 the Kriya Kirtan. However, the news release could have provided more context, as given in the article, on the importance of other lifestyle factors including diet, physical activity, cognitive training, and social engagement. The combination of these lifestyle factors actually does have some randomized controlled trial evidence supporting it now, with recent publication of the FINGER study.", "answer": 0}, {"article": "(R) Anthony L. Asher, MD, FACS, medical director at Carolinas HealthCare System's Neurosciences Institute and the senior author on the report, and (L) Stuart H. Burri, MD, chairman, department of radiation oncology at Levine Cancer Institute, spearheaded an international, multi-institutional, randomized trial that will ultimately improve the standard of care for patients with a specific type of brain tumor, brain metastases, by reducing the toxicity of their treatment without reducing the effectiveness.Video - http://origin-qps.onstreammedia.com/origin/multivu_archive/PRNA/ENR/CarolinasHealthCareSystem.mp4Photo - http://photos.prnewswire.com/prnh/20160726/392955\nThe study, released on July 26, 2016, shows that patients with the most common form of brain tumor can be treated in an effective and substantially less toxic way by omitting a widely used portion of radiation therapy.\nThe technique was pioneered at Levine Cancer Institute and they are looking to expand and further validate the approach with the National Cancer Institute.\nIn this study, although whole brain radiation decreased the number of new brain tumors over time, its addition to focused radiation interestingly did not result in a survival benefit over focused radiation alone.\nThese results will allow tens of thousands of patients with brain tumors to experience a better quality of life while maintaining the same length of life.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release is clear that the point of the study was a direct comparison of two commonly-used treatments. The release also points out that surgery is a treatment option for these patients.", "answer": 1}, {"article": "\u201cAlthough the randomized controlled trial is the gold-standard methodology in comparing between conditions,\u201d said Thomas G. Brown, an assistant professor of psychiatry at McGill University, \u201cit washes out a factor that may be important in potentiating A.A.\u2019s benefits, namely patient choice and preference.\u201d In other words, having a patient choose the form of treatment, rather than being assigned to it as in most studies, could be an important factor.\nNone of the studies compared A.A. with no treatment at all, and the researchers said that made it more difficult to draw conclusions about effectiveness.\nhas helped a lot of people,\u201d Dr. Nunes said.\nBut Sarah Zemore, of the Alcohol Research Group of the National Alcohol Research Center, said studies that observed the results of a treatment without setting up randomized control groups could also be informative.\nThe paper was published last week in The Cochrane Library, a journal devoted to systematic reviews of health care interventions.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions several treatment options compared with, on in conjunction to 12-step groups.", "answer": 1}, {"article": "Oct. 18, 2010 -- Vitamin B12 may help protect the brain against Alzheimer's disease, according to new evidence that suggests the vitamin and an amino acid called homocysteine may both be involved in the development of Alzheimer\u2019s.\nDuring the study, published in Neurology, 17 people developed Alzheimer\u2019s disease.\n\u201cLow levels of vitamin B12 are surprisingly common in the elderly.\"\nThe seven-year study followed 271 Finnish people ages 65 to 79 who did not have any symptoms of Alzheimer's disease at the start of the study.\n\u201cOur findings show the need for further research on the role of vitamin B12 as a marker for identifying people who are at increased risk of Alzheimer\u2019s disease,\u201d says researcher Babak Hooshmand, MD, MSc, with Karolinska Institutet in Stockholm, Sweden, in a news release.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 0}, {"article": "The first CT scan was OK.\nA chest X-ray showed nothing suspicious.\nIf Lazarus hadn't had any studies, says Dr. Harvey Pass of the NYU Medical Center in New York, the tumor would have grown causing pain, cough bleeding and maybe not have been able to be surgically removed.\nBut over time, periodic scans revealed a small growth in Burton's lungs.\n\"So I don't need any chemotherapy, I don't need any radiation.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention chest x-rays and stopping smoking as alternatives to CT screening.", "answer": 1}, {"article": "Pregnant women are generally advised to limit their consumption of certain types of fish like swordfish and tuna because they contain mercury.\nBut many other types are considered safe, especially smaller fish like sardines that are not at the top of the food chain and therefore not likely to accumulate mercury and other contaminants from eating other fish.\nMore than six million children in the United States have asthma, according to the Centers for Disease Control and Prevention, as do more than 330 million children and adults worldwide, according to the Global Asthma Network.\nThe research was paid for by the Danish government and private foundations.\nThe author of that editorial, Dr. Christopher E. Ramsden, from the National Institutes of Health, said the findings would help doctors develop a \u201cprecision medicine\u201d approach in which fish-oil treatment could be tailored to women who are most likely to benefit.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Aside from avoidance of maternal smoking, there are no known ways to reduce the risk of developing asthma in childhood. The story explains this is why doctors are testing this method, and excited by the findings.", "answer": 1}, {"article": "FDA approves first drug aimed at women with inherited breast cancer\n\nU.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.\n\nThe Food and Drug Administration on Friday approved AstraZeneca PLC\u2019s Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story just briefly mentions the alternatives\u2013chemotherapy.", "answer": 1}, {"article": "The back of the Snooz'n bottle says the beverage will \"combat stress, energy drinks and sleeplessness\" and takes about 30 minutes to take effect.\nIt's typically released by the pineal gland around 10 p.m.; secretion stops around 4 or 5 a.m., helping to trigger the body to wake up, Scharf says.\nIn a statement, Drank inventor Peter Bianchi says \"the safety of Drank's consumers remains a top priority\" and the company is working to modify the product's packaging and marketing \"to reflect its classification as a dietary supplement.\"\n\"The issue is this: Some of them probably have some biologic effect, but they haven't been as well studied as you'd like,\" Scharf says.\nThe number of nonalcoholic beverages making relaxation claims continues to rise; 40 new ones came on the market in 2010, according to Mintel.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This is the most important shortcoming of the story. While prescription sleep aids are mentioned briefly, the story really should have delved deeper into discussion of\u00a0the effectiveness of sleep medications. It also didn\u2019t mention behavioral treatments for insomnia, which may be just as effective as drugs and produce a more enduring benefit.\u00a0The public should\u00a0understand that behavior change will nearly always trump a pill (or supplement, etc.) for long-term efficacy and health effects.", "answer": 0}, {"article": "The Foundation was established in 2007 with the support of the Queensland Government.\n\"Kidney stones are a bit of a mystery, occur frequently in the community and generally affect young, healthy adults,\" Dr Furyk said.\n\"It can be extremely painful to pass these jagged little crystallized minerals and it's very common for sufferers to go to an emergency department for treatment.\nUp to 15 per cent of the Australian adult population and 1 in 11 people in the United States suffer from kidney stones, which range in size from a grain of sand to a pearl or even larger, and can be excruciating to pass through the urinary tract.\n\"It may also have implications for patients living in rural and regional areas, where access to urologists - the specialist doctors who treat this condition - can be limited.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "While the study leader states that patients using this drug \u201cmight not need more complicated treatments including surgeries,\u201d that doesn\u2019t meet our criteria for comparing alternatives. Are there other drugs similar in function to tamsulosin that might also benefit patients?\u00a0 Alpha blockers which relax the ureter muscles have helped some pass stones with less pain. Some patients with larger stones are treated with lithotripsy which employs sound waves that break stones into smaller pieces.", "answer": 0}, {"article": "Lozano acknowledges that retrieving childhood memories, which he says has occurred in about one-third of his patents \u2014 requires lofty voltages that he would be uncomfortable sending patients home on.\nPatients with Alzheimer's typically have reduced glucose activity in their brains, as well as, again, shrinking memory circuits.\nThe degree to which glucose is burned is a commonly used measure of brain activity.\nIn half the patients the stimulation was turned on right away.\nTo the researcher's surprise, following stimulation the patient reported a sensation of deja vu.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Are there alternatives to deep brain stimulation for treating Alzheimer\u2019s? This story doesn\u2019t say.", "answer": 0}, {"article": "Dr. Michael Rosenbaum, the lead investigator, said the 10-week study was too short and too small to determine whether continuous leptin treatments could allow dieters to keep off their weight permanently and effortlessly.\nEveryone who has dieted knows that losing weight is the easy part.\nThey also usually stop losing weight and often gain back what they have already lost.\nThe leptin would then serve as a sort of virtual fat.\nThey also measured thyroid hormone concentrations in the blood and found that leptin reversed the declines in those levels that occurred with weight loss.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No mention of any other weight loss maintenance methods.", "answer": 0}, {"article": "A growing body of evidence suggests that weight-loss surgery is more effective than diet and exercise at getting rid of Type 2 diabetes.\n\nA small but rigorous randomized trial published Wednesday in JAMA Surgery provides the latest evidence showing the superiority of bariatric surgery over lifestyle changes in resolving the chronic condition involving high blood sugar.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This is a tough call. The study in question was designed to compare bariatric surgery against specific lifestyle therapies. And the story capably provides that comparison. But while it\u2019s a splendid thing to be able to \u201ccure\u201d diabetes in some obese patients who have weight loss surgery, it\u2019s also important to mention the role of medication and diet in maintaining good management of the disease and preventing complications. The story doesn\u2019t really address this. A word about strategies for preventing diabetes in the first place would also have been welcome here.", "answer": 0}, {"article": "Neuronix received European approval several months ago and has installations in the UK and Germany.\nThe device, which consists of a chair containing an electronic system and software in the back and a coil placed at the head, has been tested on mild to moderate Alzheimer\u2019s patients who suffer from dementia but are not totally dependent.\n\u201cIf out of 10 years the patients have left to live we can keep them at home in a relatively mild state of the disease for three, four, five years, it\u2019s a lot.\u201d\n\nAccording to Alvaro Pascual-Leone, director of the hospital\u2019s Berenson-Allen Centre for Non-invasive Brain Stimulation, brain stimulation - or transcranial magnetic stimulation - involves a very low current applied to a specific part of the brain and is approved by the FDA for treatment of a variety of ailments and diagnostic applications.\nThe study\u2019s results will be submitted for publication in the coming weeks and a follow-up study on 30 patients is planned.\nThe device, which combines electromagnetic stimulation with computer-based cognitive training, is already approved for use in Europe, Israel and several Asian countries such as Singapore.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no comparison with any other approach for Alzheimer\u2019s disease.\nApart from telling us, \u201cTheir improvement was significantly more than the average seen in patients taking just medication,\u201d we are not provided with any meaningful comparison to other approaches.", "answer": 0}, {"article": "Biomarkers of inflammation were measured at the beginning and end of the study.\nResults of the randomized, controlled clinical trial -- which involved more than 200 overweight, postmenopausal women who had insufficient levels of vitamin D at the beginning of the study -- are published online ahead of the July print issue of Cancer Prevention Research, a journal of the American Association for Cancer Research.\nEditor's note: To obtain a copy of the Cancer Prevention Research paper, \"Effect of vitamin D3 supplementation in combination with weight loss on inflammatory biomarkers in postmenopausal women: a randomized controlled trial,\" or to arrange an interview with corresponding author Catherine Duggan, please contact: Kristen Woodward in Fred Hutch media relations, kwoodwar@fredhutch.org or 206-667-5095.\n\"We know from our previous studies that by losing weight, people can reduce their overall levels of inflammation, and there is some evidence suggesting that taking vitamin D supplements can have a similar effect if one has insufficient levels of the nutrient,\" said lead and corresponding author Catherine Duggan, Ph.D., a principal staff scientist in the Public Health Sciences Division at Fred Hutch.\nAt the end of the study, all of the participants had reduced levels of inflammation, regardless of whether they took vitamin D, \"which highlights the importance of weight loss in reducing inflammation,\" Duggan said.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The study didn\u2019t discuss alternative preventive measures or genetic causes of increased cancer risks. But this is such a broad and expansive topic that we don\u2019t think the release should have been expected to address those myriad issues. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "They were then followed till they were about 10 years old, according to the study.\nWEDNESDAY, Nov. 10, 2010 (HealthDay News) -- Offering your baby a special formula when weaning off breastfeeding may offer some protection against the development of the antibodies associated with type 1 diabetes, if you have a family history of the disease, new research suggests.\n\"The data in this study is not sufficiently strong to support recommending any changes for parents,\" said the author of an accompanying editorial, Dr. David Harlan, co-director of the Diabetes Center of Excellence at the University of Massachusetts Memorial Medical Center in Worcester.\n\"I think this is an important study because we need to understand what causes type 1 diabetes,\" said Harlan, who added the caveat: \"In this study, while there is an apparent signal, there are also some causes for withholding complete faith in the conclusion that the formula caused diabetes.\"\n\"We observed that early dietary intervention [with extensively hydrolyzed formula] decreased the frequency of diabetes-associated autoantibodies, which are markers of an ongoing disease process, by about 50 percent by the age of 10 years,\" said the study's lead author, Dr. Michael Knip, a professor of pediatrics at the Hospital for Children and Adolescents in Helsinki, Finland.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are many options when weaning an infant from breast milk.\u00a0 The story discusses the NEJM study which compared extensively hydrolyzed formula with regular infant formula.\u00a0 While the more expensive hydrolyzed forumula was associated with fewer cases of Type 1 diabetes antibodies in at-risk children, the story notes that there is not definitive evidence that cow\u2019s milk formula will increase the risk of Type 1 Diabetes compared to other types of formular or breast feeding.", "answer": 1}, {"article": "That\u2019s Stage IV cancer and it\u2019s almost always deadly at that stage.\nThe drug works far better in patients whose tumors express more PD-1, meaning they have a lot of PD-1 activity, so the drug will optimally be used jointly with a test for PD-1.\n\u201cWhen this study was started the average life expectancy of someone with advanced melanoma was 11 months and now we're seeing that a large percentage of people are living at least three years.\u201d\n\nKeytruda \u2014 known generically as pembrolizumab \u2014 targets the activity of genes called PD-1 (anti-programmed-death-receptor-1) and PD-L1.\n\"These are patients whose disease cannot be surgically removed, cannot be cured by surgery and usually the majority of these patients have disease that involved vital organs,\" said Dr. Stephen Hodi, a melanoma specialist at the Dana-Farber Cancer Institute who worked on the study.\nThat compares to about 5 percent of patients given the standard therapy, interleukin, the American Society for Clinical Oncology (ASCO) says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says the\u00a0majority of participants in the study had Stage IV disease and had limited treatment options. It also briefly discusses the other alternative treatment, i.e. ipilimumab.\nWhile this is Satisfactory for this criterion, we would have liked to see more general information about how melanoma is treated,\u00a0including surgery, chemotherapy, and radiation therapy.", "answer": 1}, {"article": "The Ache: The bathroom scale shows how much you\u2019ve gained or lost in pounds, but gives no information about whether the change is fat or muscle.\n\nThe Claim: A whole-body scan, called Dual-Energy X-ray Absorptiometry, or DXA for short, gives a detailed snapshot of your body composition, including how your body weight breaks down into fat, bone and lean tissue.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story addresses four other techniques used for assessing body fat: BMI, water weighing, bioimpedance and pinching folded skin with calipers. The story would\u2019ve been more useful had\u00a0it mentioned that there appear to be no comparative effectiveness studies on long term outcomes using these different methods.", "answer": 1}, {"article": "Toni Weiser is a veteran of skin-cancer removals. The 75-year-old retired teacher in Santa Fe, N.M., says she\u2019s had at least eight basal and squamous cell cancers scraped, frozen and surgically excised from her arms, face and shoulders.\n\nWhen a basal-cell cancer reappeared on Mrs. Weiser\u2019s nose last year, her dermatologist suggested a new, painless, nonsurgical treatment and she eagerly agreed. After 16 treatments with a small radiation device held millimeters from her nose, the tumor was gone. \u201cI felt nothing\u2014just some mild...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes it clear that eBx is being positioned as an alternative to longstanding treatments such as topical creams, freezing and surgery. It doesn\u2019t compare effectiveness outcomes between these competing approaches in a meaningful way, but we think the story does enough to clear the bar here.", "answer": 1}, {"article": "But the F.D.A.\nDr. Min said in an e-mail message that foam sclerotherapy was \u201cvery safe,\u201d but that \u201cit is associated with higher risks than liquid sclerotherapy.\u201d Foam injections have been blamed as the cause of blood clots in leg veins, he wrote, adding that one known stroke \u201cmay have been caused by foam sclerotherapy.\u201d\n\nBut foam sclerotherapy has been a big relief for some patients.\nYet, he said both are \u201cvery safe and effective, and a heck of a lot better than surgery.\u201d (It entailed ripping out the groin-to-ankle vein with a wire via an incision.)\nThat said, polidocanol was the \u201csecond most commonly used sclerosing agent\u201d because, he said, \u201cmost physicians want to give their patients the best available treatment.\u201d\n\nF.D.A.\nThe other, polidocanol, had not been legal, although some doctors used it, importing it from abroad or obtaining it from pharmacies that make drug compounds.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses surgery for varicose veins in the past tense, suggesting that it is no longer used. (\"It entailed ripping out the groin-to-ankle vein with a wire via an incision.\") In fact,\u00a0as discussed above, the supposed long-term superiority of newer techniques over surgery has not yet been proven, and surgery still has a place in the treatment of certain types of varicose veins, especially larger veins.\u00a0The story also failed to mention\u00a0lifestyle changes, such as weight loss or\u00a0avoiding standing or sitting for long periods, which are typically the first line treatment for this condition.\u00a0\u00a0As the story was in the fashion section,\u00a0they should have also mentioned makeup, hosiery, etc, in addition to therapeutic interventions that a doctor might recommend. ", "answer": 0}, {"article": "Why use the traditional approach if the laparoscopic technique is better in some ways?\nThe study \"confirms what a lot of surgeons who do both procedures know already,\" Brunt said.\nThe traditional approach may be appropriate when it's too risky to place patients under general anesthesia, Brunt said, such as in elderly patients and those with multiple health problems.\nThe procedures are designed to reduce the bulge of the hernia and make a patch so it doesn't protrude again.\n\"It's as if you had a leak in a tire that's ballooned out,\" Brunt said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study compared two major surgical approaches and the story mentioned the existence of a third approach that wasn\u2019t tested.\u00a0 However, it didn\u2019t mention nonsurgical management or \u201cwatchful waiting,\u201d which may be an appropriate strategy for patients with minimal symptoms or who are asymptomatic. Since almost all hernia repairs are elective \u2013 meaning that they are designed to minimize pain and bulging\u00a0rather than preventing a potentially serious medical problem (such as bowel obstruction or incarceration in the hernia) \u2013 it is appropriate to mention that for many patients part of\u00a0the decision making process is whether to have surgery or not. Once one decides to have surgery, then the question of what is the best procedure becomes relevant. Some patients make the decision about whether to have surgery on not based upon the risks and benefits of the procedure, so that is why mentioning not having surgery is part of the comparison of treatment options.", "answer": 0}, {"article": "This has major implications for how we now investigate and manage patients with suspected heart disease.\"\nThe number of patients undergoing additional procedures increased within the first year but had levelled out by the end of the five-year period.\nThe research is published in the New England Journal of Medicine and is being presented at the European Society of Cardiology Annual Congress in Munich.\nAfter receiving the scan, the number of patients suffering a heart attack within five years dropped by 40 per cent, the study found.\nThis is the first study to look at the impact of the scans on long-term survival rates.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "No mention is made of other non-invasive tests used to screen for coronary artery disease, such as calcium scans, exercise ECG\u2019s, echocardiography, and nuclear heart scans to name a few.\u00a0 These alternatives are named in the published study.", "answer": 0}, {"article": "\"I think people should consider it [TXA] following trauma on the basis of this study,\" he said.\nThe researchers believe that TXA could have even wider uses, such as reducing brain bleeds after brain injury.\nAlthough there was some worry that TXA might lead to more heart attacks, strokes or clots in the lungs, the researchers observed no such increase among patients getting the drug.\nThe drug, tranexamic acid (TXA) is cheap, widely available around the world and easily administered, experts said.\nAmong patients receiving TXA, the rate of death from any cause was cut by 10 percent compared to patients receiving placebo, the researchers found.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Unlike the\u00a0competing coverage from the AP and NPR, this story\u00a0mentions the fact that there are other drugs\u00a0which help promote clotting and might be useful\u00a0for trauma patients. The story correctly warns that the benefits of TXA\u00a0can\u2019t be generalized to other drugs without additional research. \u00a0", "answer": 1}, {"article": "\u201cThe most salient message is that the [Gardasil] vaccine can prevent HPV infection on the external genital region, which means that we can now prevent most cases of genital warts if the boy is vaccinated at a sufficiently early age,\u201d says study researcher Joel Palefsky, MD, a professor of medicine at the University of California, San Francisco.\nThe vaccine is recommended for optional use in boys and men.\nOf 4,065 boys and men aged 16 to 26 from 18 countries, vaccination with an HPV vaccine that targets four types of HPV infection -- HPV-6, HPV-11, HPV-16, and HPV-18 -- protects against infection with these types of HPV and potentially the development of related external genital warts or lesions.\nThe vaccine is used in girls and boys and young adults ages 9 to 26 for prevention of genital warts caused by HPV types 6 and 11.\nHPV, a sexually transmitted disease, can be transmitted through vaginal, anal, and oral sex and has been linked to genital warts as well as cervical, vaginal, vulvar, oral, penile, and anal cancers.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Althought far from perfect as a preventive, the use of condoms should have been given some space in the story; along with limiting the number of sexual partners or abstinence.", "answer": 0}, {"article": "We want to outline health-care pathways that provide the best care for patients.\u201d\n\nThe analysis demonstrated an average cost of $13,389 for the wrist approach with same-day discharge, compared with $17,076 for the groin approach with at least one night of hospitalization, resulting in a cost savings of about $3,700 for outpatients who get the wrist-access procedure.\nIn contrast, the wrist artery is small and is associated with fewer complications.\n\u201cThe traditional way has been to go through the bigger femoral artery that is a straight pathway to the heart,\u201d Amin said.\nIndependent of the length of stay, the wrist approach costs about $900 less than the groin approach, on average.\n\u201cWe have seen that it is very safe to send these patients home the same day,\u201d said Amin, who treats patients at Barnes-Jewish Hospital.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The point of the study was to compare variants on angioplasty method, and the release does that clearly.", "answer": 1}, {"article": "TUESDAY, May 4, 2010 (HealthDay News) -- Noninvasive stool DNA testing can detect two types of colorectal precancers and could play a larger role in colon cancer prevention, say two new studies.\nSome of the study authors and the Mayo Clinic have a financial interest related to technology used with this research.\nThe U.S. National Cancer Institute has more about colorectal cancer screening.\nIt's important for people with IBD because they are at much higher risk for colorectal cancer than the general population.\nUnlike common polyps, they tend to be flat and the same color as the colon lining.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No comparison with colonoscopy or flexible sigmoidoscopy or with iFOBT or immunochemical fecal occult blood tests. ", "answer": 0}, {"article": "WEDNESDAY, Feb. 15, 2012 (HealthDay News) -- The quit-smoking drug Chantix may also help problem drinkers cut their alcohol consumption, a small new study suggests.\n\"We are not currently performing any studies with Chantix, although other groups are actively pursuing this line of research with a view to developing Chantix as an aid to people wanting to quit or cut down their drinking,\" Childs said.\nExactly how this drug curbs drinking is not fully understood, but its use may increase blood pressure, heart rate and feelings of sadness and nausea, thereby blunting the pleasurable effects of alcohol, the researchers said.\nThe results of the new study were released online in Alcoholism: Clinical & Experimental Research prior to publication in the May print issue.\nRecently, the drug was linked to a small but significant risk of heart attack and stroke among people with pre-existing heart disease.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no reference to alternatives other than comments from one source that \u201cthat new ways of treating alcoholism are much needed.\u201d It could have told readers about naltrexone, acamprosate, or disulfiram, which are already approved by the FDA for the treatment of alcohol dependence (alcoholism). There is no mention of the role of behavioral and psychiatric treatments as alternative or adjunctive care for alcoholics.", "answer": 0}, {"article": "Copyright 2012 The Associated Press.\nYet no government agency recommends their routine use \"regardless of the quality of a person's diet,\" says a fact sheet from the federal Office of Dietary Supplements.\nThe main reason to take a multivitamin is to correct or prevent a deficiency, \"but there may be a modest benefit in reducing the risk of cancer in older men,\" Gaziano said.\nThere also was a trend toward fewer cancer deaths among multivitamin users, but the difference was so small it could have occurred by chance alone.\n\"It's a very mild effect and personally I'm not sure it's significant enough to recommend to anyone\" although it is promising, said Dr. Ernest Hawk, vice president of cancer prevention at the University of Texas MD Anderson Cancer Center and formerly of the National Cancer Institute.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says that multivitamins are\u00a0\u201cless effective than a good diet, exercise and not smoking, each of which can lower cancer risk by 20% to 30%, cancer experts say.\u201d We\u2019ll call this good enough for a satisfactory, but we do quibble with the story\u2019s broad assertions regarding the effectiveness of these lifestyle recommendations. With the exception of smoking cessation, which is certainly effective for preventing cancer, it\u2019s never been conclusively proven\u00a0that dietary changes or exercise can reduce cancer risk. In fact, recent research suggests that fruits and vegetables \u2014 long thought to be strong cancer fighters \u2014 actually have little or no effect on cancer risk. Obesity is emerging\u00a0as the main diet-related culprit when it comes to cancer, something the story could have\u00a0been more precise about.", "answer": 1}, {"article": "WASHINGTON (Reuters) - Screening smokers and former smokers for lung tumors using three-dimensional X-rays reduced their risk of dying from lung cancer by 20 percent, researchers said on Thursday.\nThe researchers said their findings could save thousands of lives.\n\u201cThis screening does not prevent lung cancer and it does not protect the large majority of subjects from death by lung cancer,\u201d Varmus said.\nHer ideas were controversial to start with and widely disregarded when other researchers found her work had been paid for by a tobacco company.\n\u201cWe will have what breast cancer has now, which is a lot of survivors.\u201d\n\nThe researchers have some caveats.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study compared spiral CT scanning to chest X-rays and did mention smoking cessation.", "answer": 1}, {"article": "AMD, the No.\nThese provocative results were then confirmed in a much larger data set of 87 million patients where similar results were observed and the study expanded to include prevention and delay of \"wet\" AMD, the most devastating form of the disease.\nThe next step in this research is to perform a clinical trial to determine the ability of this drug to prevent AMD.\n\"In the end, L-DOPA may not be the drug that ends the disease but the pathway identified is likely to be a key observation as the search for a cure continues.\"\n\"Research points to this as a pathway to regulate and prevent this most common cause of blindness in adults,\" said Murray Brilliant, Ph.D., director, Marshfield Clinic Research Foundation Center for Human Genetics, Marshfield, Wisconsin.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "No alternatives are mentioned. While there is no known effective cure for AMD, there are treatments available to slow the progression of the disease or prevent severe vision loss including drug injection, laser therapy and vitamin supplementation.", "answer": 0}, {"article": "TUESDAY, Nov. 27, 2018 (HealthDay News) --What if a simple zap to the spine could relieve the debilitating lower back and leg pain brought on by a herniated disk?\nStill, Park noted that diagnostic uncertainty can undermine the ability of surgery to get at the true source of a patient's pain, given that \"the problem with low back pain is that there are many causes of it, and physicians have trouble identifying the cause of pain.\"\nSuch is the promise of \"pulse radiofrequency\" therapy (pRF), which sends inflammation-reducing pulses of energy to nerve roots in the spine, a new study claims.\nHe noted that because \"the majority of people with back pain improve with time and exercise alone,\" it remains an open question as to whether the pRF procedure really cured the condition.\n\"Without inflammation the pain fades, and the body starts a self-healing process that allows for complete resolution of the disk herniation in a large proportion of patients.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions interventions that are commonly recommended for low back pain, including waiting it out. Generally speaking, there\u2019s no standard treatment for most back pain, and often no treatment is recommended.", "answer": 1}, {"article": "\"At age 11, I developed this condition, called alopecia areata, where I lost my hair,\" says Velasquez-Manoff, a science writer in Berkeley, Calif. \"It started in patches, but eventually I lost it all.\"\nHe talked to many people who were using an unlikely tool to treat their problems: parasitic worms that live in your gut \u2014 permanently.\nThe first study to finish was a big one in Europe that looked to see if pig whipworms helped with Crohn's disease.\nHe says the benefits of the worms definitely didn't outweigh the bad side effects.\nA few years ago Velasquez-Manoff was working on a book about autoimmune diseases, like allergies, asthma, Crohn's disease and alopecia.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention how parasites compare to existing treatments for autoimmune diseases in terms of safety, efficacy or cost.", "answer": 0}, {"article": "It's the first study to specifically examine...\nNow, it may be good for the brain as well.\nNow, it may be good for the brain as well.\nWe've long known that the Mediterranean diet is good for the heart.\nWe've long known that the Mediterranean diet is good for the heart.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story didn\u2019t even include a line about other stroke prevention research \u2013 dietary or otherwise.", "answer": 0}, {"article": "Doctors said Thursday that the increased risk did not outweigh the benefits of the drugs.\nThe drugs, which include Depakote, Lamictal, Topamax, Keppra, Lyrica and Neurontin, are sometimes prescribed for chronic pain and headaches, as well.\n\u201cWhat\u2019s really important to say is that bipolar disorder is very difficult to treat, the burden is enormous, and these medications help keep people free of mood and anxiety symptoms and allow them to function,\u201d said Andrew A. Nierenberg, medical director of the bipolar clinic and research program at Massachusetts General Hospital.\nThe Food and Drug Administration undertook a combined analysis of 199 clinical trials with 43,892 patients and found 4 suicides and 105 reports of suicidal symptoms among the 27,863 patients who were given the drugs compared to no suicides and 35 reports of suicidal symptoms among the 16,029 patients treated with placebos.\nDrugs for epilepsy, bipolar illness and mood problems double the risks of suicidal thoughts and behavior, and patients taking them should be watched for sudden behavioral changes, drug regulators have said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes some pharmacological treatments available for patients with epilepsy.\u00a0 No other treatments are discussed.\u00a0 The story\u00a0might have been enhanced by giving more info on alternative treatments along with some pros/cons.\u00a0\u00a0 \nOther available drug treaments include: phenobarbital, phenytoin, carbamazepine, valproate, gabapentin, lamotrigine, topiramate, levetriacetam, oxcarbazepine, zonisamide, felbamate. ", "answer": 0}, {"article": "But scientists at Stanford University say there may be a way to prevent jet lag without medication or adjusting your sleep schedule.\nThis study builds on previous research published in 2014, which found that light therapy works best at night because the body's circadian rhythms are more sensitive to light at night, even through closed eyelids.\nIt will enable us to have more potent countermeasures to jet lag than continuous light, which is the current prescribed light therapy treatment,\" Zeitzer said.\nThrough light therapy, the technique Zeitzer is experimenting with, a person's brain can be tricked into adjusting more quickly to disturbances in sleep cycles by increasing how long he or she is exposed to light prior to traveling to a new time zone.\nA team of researchers led by neurobiologist Jamie Zeitzer is working on a technique that exposes people to short flashes of light while they sleep to help them adjust more quickly to time zone changes.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Jet lag has been studied with other therapies, most notably with caffeine and melatonin. Neither of these other therapies are mentioned in the context of describing this study. Cochrane systematic reviews on jet lag therapies can be found here and here.\nThis report doesn\u2019t suggest any comparison between the light therapy and these other therapies.", "answer": 0}, {"article": "Dec. 20, 2010 -- Scientists using brain scanning technologies say they have been able to predict with 90% accuracy which children with dyslexia will be able to improve reading skills over a period of a few years.\n\nResearchers say their findings reveal activity in specific brain regions during reading that could eventually lead to new treatments for people with dyslexia.\n\n\u201cAt this time, we cannot say which treatment type will each child benefit from,\u201d study researcher Fumiko Hoeft, MD, PhD, an imaging expert at Stanford University, tells WebMD in an email. \u201cBut with more research, and if researchers combine it with intervention studies, then we should be able to identify brain patterns that are predictive of responding to one type of intervention or another.\u201d\n\nShe says in a news release that the study \u201cgives us hope that we can identify which children might get better over time\u201d and that the findings represent \u201ca huge step forward.\u201d\n\nThe discovery of brain regions involved in the learning disorder \u201cmay provide a mechanism for enduring improvement that promotes relatively successful reading development,\u201d according to the study, published in the Dec. 20 issue of the Proceedings of the National Academy of Sciences.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story provided even less background than other stories about current methods for assessing dyslexia and responses to interventions.", "answer": 0}, {"article": "For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email mediarelations@jamanetwork.org.\nThe many potential preventive health benefits of breastfeeding should also be communicated openly to the general public, not only to mothers, so breastfeeding can be more socially accepted and facilitated.\nThe authors suggest several biological mechanisms of breast milk may explain their results, including that breast milk contains many immunologically active components and anti-inflammatory defense mechanisms that influence the development of an infant\u2019s immune system.\nIn addition, more high-quality studies are needed to clarify the biological mechanisms underlying this association between breastfeeding and lower childhood leukemia morbidity,\u201d the study concludes.\nIn a review of all 18 studies, the authors found breastfeeding for six months or longer was associated with a 19 percent lower risk compared with no breastfeeding or breastfeeding for a shorter period of time.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Perhaps it goes without saying that the alternative to breast milk is infant formula, but the release could have stated this explicitly, which would have provided an opportunity to point out the other potential health advantages of breastmilk as well as the financial advantages. Not doing so provides a rather incomplete narrative.", "answer": 0}, {"article": "(CNN) A saliva test may someday be able to diagnose a concussion and predict how long symptoms last, according to a study published Monday in the JAMA Pediatrics.\nThe saliva biomarker may be showing that neurons experienced force and not that a there is a concussion, with which the brain cannot perform its typical functions within a normal range, he said: \"I would hesitate to assign too much potential groundbreaking science.\"\n'Way too early to know'\n\nHowever, the editorial authors, Dr. William P. Meehan III of Micheli Center for Sports Injury Prevention at Boston Children's Hospital in Massachusetts and Dr. Rebekah Mannix of Brain Injury Center at Boston Children's Hospital, noted that \"the relatively small sample size in this study requires larger-scale studies to determine the reliability\" of the results.\nStill, \"the findings are promising, representing potential biomarkers for the diagnosis, recovery, and prognostic assessment of a sport-related concussion.\"\n\"Fortunately, the technology required to measure saliva RNA is already employed in medicine; we use it to check patients for upper respiratory viruses in our hospitals and clinics every day,\" Hicks said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As noted earlier, the story explicitly compared accuracy rates for the saliva test versus the survey tool doctors currently use. In addition, the story mentioned that researchers also are testing for concussion-related biomarkers in blood, using EEG records and \u201cexploring functional MRI techniques to look at the metabolic function of different areas of the brain.\u201d The story discusses all of these approaches as preliminary investigations.", "answer": 1}, {"article": "Beaumont's center is one of just 28 proton therapy centers in the U.S.\nThe facilities are impressive, clean and welcoming, but the difference is the people \u2013 best hospital staff I've ever encountered.\nThe results supported the use of high-dose definitive radiation therapy, via proton beam therapy, for selected patients with unresected spine and sacral chordomas.\"\nIn his study published in the International Journal of Radiation Oncology, Biology, Physics, he and his colleagues found, \"in circumstances where surgery may result in significant neurologic or organ dysfunction, patients can be treated definitively with radiation therapy alone.\nSaid Tracy, \"We were told that I should prepare myself for the loss of functionality below the waist \u2013 including bowel, bladder and sexual functions.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release discusses, in brief terms, the risks and challenges associated with surgical treatment options and with other forms of radiation therapy but it makes no effort to compare treatment outcomes.\u00a0The release could have been much more clear that treatment options are surgery vs. \u201ctraditional radiation\u201d vs. proton beam radiation.", "answer": 0}, {"article": "Dr. Bremner said he typically suggests a trial of therapy for up to a year to see if sexual function or other symptoms improve.\nCurrently, we\u2019re in limbo as to how to advise patients.\u201d\n\nHe acknowledged that the need for such a study for men is \u201cless compelling\u201d because, in contrast to women, who experience an abrupt drop in estrogen at menopause, often with disruptive symptoms, hormone decline in aging men is far more gradual, and symptoms, when they occur, are commonly viewed as normal signs of aging, not hormone deficiency.\nThe most common reason men seek testosterone therapy is waning sexual desire or performance, although the ability of the hormone to relieve sexual symptoms is unpredictable.\nAlthough low hormone levels are widely thought to increase a man\u2019s risk of depression, the researchers found that \u201cpsychological symptoms had little or no association with the testosterone level.\u201d\n\nThere are four main approaches to testosterone therapy available in this country: intramuscular injections every one to three weeks; skin applications through a patch or gel; and pellets implanted under the skin that last for months.\nThe researchers, who published their findings in The New England Journal of Medicine, noted that the deck might have been stacked in favor of a hazardous outcome because study participants, especially the group that received testosterone, had high rates of high blood pressure, diabetes, obesity and elevated blood lipids.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article\u00a0could have mentioned \u00a0lifestyle changes, such as getting more exercise and\u00a0quitting smoking, that may improve libido,\u00a0combat fatigue,\u00a0and increase sexual function.\u00a0But since there\u2019s not much evidence that these or other approaches are effective,\u00a0we don\u2019t think the article should be dinged for failing to mention them. We\u2019ll rule it Not Applicable in this case. ", "answer": 2}, {"article": "Dr. Pan\u2019s co-authors were Zhong Ping Duan at Beijing Youan Hospital, Capital Medical University, in Beijing; Er Hei Dai and Bao Shen Zhu at Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang; Shu Qing Zhang and Wen Jing Zhao at Hepatobiliary Disease Hospital of Ji Lin Province, Changchun; Guo-Rong Han and Hong-Xiu Jiang at Second Affiliated Hospital of Southeast University, Nanjing; Yuming Wang at Institute for Infectious Diseases, Southwest Hospital, Third Military Medical University, Chongqing; Huai Bin Zou at Youan Hospital, Capital Medical University, Beijing; and Huai Hong Zhang at Nanyang Center Hospital, Nanyang, Henan, all for the China Study Group for the Mother-to-Child Transmission of Hepatitis B.\nThe study focused on the most common way that children become infected with hepatitis B, an incurable viral infection that causes liver disease and cancer, which is through infection during the perinatal period.\nThose with a high viral load should receive tenofovir treatment starting at gestational week 30 until delivery to reduce the risk of transmission to their infants.\nIn terms of safety, researchers found that tenofovir was well tolerated; only one participant treated with tenofovir voluntarily withdrew from the study due to nausea.\nBased on the findings, the investigators recommend that women be tested for HBV viral load at week 28 of pregnancy.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release is comparing the use of an antiviral drug given to pregnant women versus the normal procedure of giving both a vaccine and immune globulin.", "answer": 1}, {"article": "\"Multicentric Cancer Detected at Breast MR Imaging and Not at Mammography: Important or Not?\"\n\"The results show that multicentric cancer detected on breast MRI after mammography appears to represent a larger tumor burden in approximately a quarter of patients and can result in potential changes to cancer grade and treatment,\" Dr. Iacconi said.\nIn 73 of those 285 patients, or 25.6 percent, MRI identified at least one additional cancer in a different quadrant of the breast than the index cancer, or the cancer detected by mammography and/or breast palpation.\n\"In general, it is accepted that radiation can likely treat invasive cancer less than 1 centimeter, but lesions larger than 1 centimeter, especially invasive carcinomas, may not be reliably treated with conservation.\"\nBreast MRI is the most sensitive technique for the detection of breast cancer, with widespread application in the screening of high-risk patients and pre-surgical planning.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "As noted above, the release does not mention other studies that have indicated that cancers found on preoperative MRI scans don\u2019t affect at least short-term patient outcomes. It also does not discuss using ultrasound to check the breasts of patients prior to surgery for a breast tumor discovered through mammography.", "answer": 0}, {"article": "Yet the study suggests the opposite has happened.\nThe study found that among all opioid users, concurrent use of benzodiazepines more than doubled the risk of an emergency room or inpatient visit for a drug overdose.\nThe study also found that eliminating concurrent benzodiazepine and opioid use could reduce the risk for an opioid overdose\u2013related emergency room or inpatient visit by 15 percent.\nFinally, since the study looked at correlation (not causation), it\u2019s possible that it missed some other factor driving up overdose deaths among concurrent benzodiazepine and opioid users \u2014 perhaps, for whatever reason, these users may be more likely to misuse their drugs.\nThe drugs are benzodiazepines, which are widely known by their brand names Xanax and Valium and commonly prescribed to help treat anxiety.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The headline states that reducing simultaneous opioid/benzodiazepine use is \u201cnot the only answer\u201d to opioid overdoses. But the story doesn\u2019t provide discussion of other strategies, such as social services and behavioral healthcare to assist recovering addicts, regulation of pain management clinics, prescription drug monitoring laws, access to naloxone, and a host of others.\nThe article also does not address a critical point: That benzodiazepines are not\u00a0the right treatment for chronic anxiety and there is little reason to prescribe them long-term (one issue is that patients may have been started\u00a0on them years or decades ago and it\u2019s very hard to get them off of them despite what we know now).\nOther treatments such as antidepressants (eg. sertraline, fluoxetine) and therapy are much more effective and safer for chronic anxiety. The article does mention that opioids are, similarly, not the right treatment for most chronic pain, but this was buried toward the end of the article and should have been given more prominence.", "answer": 0}, {"article": "Learn more about brain health at http://www.\nThe study found that people whose diets adhered more closely to the Dietary Approaches to Stop Hypertension (DASH) diet were less likely to develop depression than people who did not closely follow the diet.\nThe odds of becoming depressed over time was 11 percent lower among the top group of DASH adherers versus the lowest group.\nOn the other hand, the more closely people followed a Western diet--a diet that is high in saturated fats and red meats and low in fruits and vegetables--the more likely they were to develop depression.\nThey also filled out questionnaires about how often they ate various foods, and the researchers looked at how closely the participants' diets followed diets such as the DASH diet, Mediterranean diet and the traditional Western diet.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "One alternative raised in the release is the Mediterranean diet. But the release doesn\u2019t describe the Mediterranean diet or quantify how adherence to that diet was associated with a decreased risk of depression symptoms. Other factors that can contribute to reduced risk of depression aren\u2019t discussed.", "answer": 0}, {"article": "The games are based on the work of Japanese neuroscientist Ryuta Kawashima, M.D.\n\"Functional MRI allows you to study which brain areas are simultaneously active and gives information on the participation of certain areas with specific brain circuits,\" Dr. De Giglio said.\nAt follow-up, the 12 patients in the video-game group had significant increases in thalamic functional connectivity in brain areas corresponding to the posterior component of the default mode network, which is one of the most important brain networks involved in cognition.\n\"This increased connectivity reflects the fact that video gaming experience changed the mode of operation of certain brain structures,\" Dr. De Giglio said.\nThe modifications in functional connectivity shown in the video game group after training corresponded to significant improvements in test scores assessing sustained attention and executive function, the higher-level cognitive skills that help organize our lives and regulate our behavior.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release fails to mention any alternatives to the use of the video game/training program which might produce equivalent improvement in connectivity within this region of the brain. As previously mentioned, there are other forms of therapy for patients with MS and it isn\u2019t clear how this new therapy compares. At least a mention of this would have been appropriate. The last line of the release says this new treatment could be combined with existing rehabilitation therapy, but we think this is too little, too late.", "answer": 0}, {"article": "reconstructions\u201d currently being conducted on injured knees \u201ccould be avoided without adversely affecting outcomes.\u201d\n\nThis possibility should reverberate across playing fields nationwide, where, at the moment, preseason high school, collegiate and adult-league sports practices are under way, with a concomitant surge in A.C.L.\nPart of the reason for A.C.L.\nWhy, then, undergo A.C.L.\n\u201cWe definitely know only parts of the long-term outcome\u201d after different A.C.L.\n(For those fortunate enough not to be personally familiar with A.C.L.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 1}, {"article": "Varicose veins are one of the more unsightly signs of aging. But new, less-invasive treatments are making it easier to remove them painlessly, bypassing a difficult surgical procedure that was often the only option in the past.\n\nAs many as 25% of women and 15% of men suffer from varicose veins; over the age of 50, one out of two people are affected. Heredity plays a part, but obesity, prolonged standing on the job and hormone therapy increase the risks. Sometimes, varicose veins have no signs or symptoms and require no treatment,...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story balances the different approaches well. Again, we would have liked to have seen some numbers used in the comparisons, though.", "answer": 1}, {"article": "We're sorry, but Newspapers.com doesn't work properly without JavaScript enabled. You will need to enable Javascript by changing your browser settings. Learn how to enable it.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article states that Biaxin is the current standard of treatment for community acquired pneumonia; in fact, there are many others. ", "answer": 0}, {"article": "SIR Annual Scientific Meeting, March 17-22, 2018.\nThis abstract can be found at sirmeeting.org\n\nThe Society of Interventional Radiology is a nonprofit, professional medical society representing more than 7,500 practicing interventional radiology physicians, trainees, students, scientists and clinical associates, dedicated to improving patient care through the limitless potential of image-guided therapies.\n\"Advanced stage liver tumors, including ones that have spread from other locations, have limited treatment options because the patients can be in poor health; further, the complex structure of the organ can make it difficult to target with standard approaches,\" said Steven S. Raman, M.D., professor of radiology, surgery and urology at the David Geffen School of Medicine, University of California, Los Angeles, and lead author of the study.\nLOS ANGELES (March 21, 2018)--Advanced stage liver tumors may be safely treated through image-guided injections of an immunotherapy approved for melanoma, according to a study presented today at the Society of Interventional Radiology's Annual Scientific Meeting.\n\"This is an exciting way to look to the future, but patients living with advanced liver cancer should understand that this treatment will not be available for several years, except through clinical trials.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release rightly quotes the study\u2019s lead author saying that there are \u201climited treatment options\u201d for patients with advanced liver cancer. It notes researcher\u2019s future plans to combine the\u00a0 therapy with a checkpoint inhibitor to activate a stronger immune response.\nThere\u2019s no cure for advanced liver cancer, although chemotherapy and low-dose radiation may be used to slow its spread and relieve pain. The drug sorafenib (Nexavaris) has been shown to improve survival.\nRadiofrequency ablation (RFA), transarterial chemoembolization (TACE), and the targeted therapy sorafenib (Nexavar) may be other options for select patients with liver cancer. For patients whose cancer originated elsewhere and spread to the liver, chemotherapy specific to the primary cancer may be appropriate.", "answer": 1}, {"article": "(Reuters) - Johnson & Johnson said its drug, Tremfya, was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderate-to-severe plaque psoriasis in a late-stage study.\nAbout 7.5 million Americans live with plaque psoriasis, of which 20 percent have moderate-to-severe form of the disease, J&J said.\nTremfya, first approved in July 2017 as a plaque psoriasis treatment in the United States, is also being tested as a for psoriatic arthritis and Crohn\u2019s disease.\nThat market is expected to double to $21.11 billion by 2022, according to U.S. consultant Grand View Research.\nWith $2.1 billion in sales in 2017, Cosentyx has become one of the top revenue earners for Novartis and is expected to make up for falling revenue from its blood cancer treatment, Gleevec, whose patent expired two years ago.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Another weakness of this story is that alternatives are not mentioned. In addition to a multitude of other immunosuppressant drugs, there are a host of treatments available for adults with moderate to severe plaque psoriasis, including:\nLight therapy, Vitamin A & D derivatives, as well as other medications that don\u2019t work via immune system suppression.\nAlso, bear in mind, these are symptomatic treatments only, since there is no known cure for psoriasis.", "answer": 0}, {"article": "The average age of children in the study was 7.\nBut the most immediate question for Sobel is \"whether an olfactory impairment is at the heart of the social impairment in autism.\"\nThe findings suggest that non-verbal tests related to smell might serve as useful early indicators of ASD, the researchers say.\nThe researchers now plan to test whether the sniff-response pattern they've observed is specific to autism or whether it might show up also in people with other neurodevelopmental conditions.\n\"This raises the hope that these findings could form the base for development of a diagnostic tool that can be applied very early on, such as in toddlers only a few months old.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release infers that a new tool for early diagnosis of ASD in children would be valuable, but it doesn\u2019t tell readers why. Readers would be better able to appreciate the significance of the new work if it had addressed \u2014 even in broad terms \u2014 the challenges involved in current approaches to diagnosing ASD. What do ASD screening and diagnostic techniques look like for infants? Toddlers? Older children? That information would be valuable context for understanding the potential importance of the new study.", "answer": 0}, {"article": "\u201cAdding more might not strengthen the wall, but you have to take enough to keep the wall strong.\nOtherwise it might fall apart.\u201d\n\nSOURCE: bit.ly/i4tDqs The Journal of Clinical Endocrinology and Metabolism, online January 5, 2011.\nA 6-month supply of vitamin D supplements can be bought for less than $10, and many multivitamins contain the recommended daily dose of vitamin D.\n\nAs for calcium, the NIH advises 1,000 mg per day for men ages19-70, and then 1,200 mg per day for men older than 70.\nThe recommended daily intake of vitamin D is 600 IU in adults up to age 70, and 800 IU for older people, according to the National Institutes of Health (NIH).\n\u201cIt\u2019s like the four legs of the stool: vitamin D and calcium, exercise, medications if a person is losing bone, and the fourth leg is telling people how to prevent fractures,\u201d Zaidi said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "At least the story gave some broad contex about other approaches to prevent bone-thinning:\n\u201cTo build bone density, weight-bearing exercise is needed, such as running or weight-lifting, according to the NIH.\nTo reduce the risk of bone weakening, the NIH recommends not smoking, drinking less alcohol and exercising more.\nZaidi said that both vitamin D and calcium are extremely important for human health, so people should follow the previous vitamin D and calcium recommendations.\u201d", "answer": 1}, {"article": "Michael Burk found walking increasingly painful last year. Crossing the street and tying his shoes became challenges, and colleagues noticed he was limping at work.\n\nOn a recent morning, Mr. Burk reported to the Hospital for Joint Diseases, part of NYU Langone Medical Center in New York City, for hip-replacement surgery. His surgeon had promised him a better quality of life, and said both the operation and recovery would be quick.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This is one of the biggest shortcomings of the story. Before considering a total hip replacement, a patient may be advised to try alternatives that might delay or avoid surgery, such as exercise to strengthen the muscles around the hip joint, the use of canes or walkers, and medication. The vast majority of patients with hip pain, and most even with hip arthritis, do not need a hip replacement. Conservative care can be highly effective at a fraction of the cost and risk. The story did not mention those possibilities.", "answer": 0}, {"article": "The study started in August 2010.\nDr Emmanuel Hanon, Senior Vice President, Vaccines Research and Development, GSK, said: \"This is the first time that such high efficacy has been demonstrated in a vaccine candidate for older people and it is remarkable, as we know that these people frequently have an age-related weakening of their immune system.\nAnthony Cunningham, Executive Director of the Westmead Institute for Medical Research in Australia and Principal Investigator of the ZOE-70 study said: \"These data show that this investigational vaccine maintains high efficacy against herpes zoster in people over 70 and 80 years of age, the age groups who are most affected by the disease.\nIn addition to older adults, the candidate vaccine is being evaluated in immunocompromised patient populations, including solid and haematological cancer patients, haematopoietic stem cell and renal transplant recipients and HIV-infected people.\nThe high efficacy is in line with the results of the ZOE-50 trial, a study in people over 50 years old which was presented and published last year showing a 97% efficacy (95% confidence interval: 93-99%)2.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does not acknowledge that another shingles vaccine has been in use in the United States since 2006. Although the study results do suggest that GSK\u2019s vaccine is likely to be more effective than the currently used vaccine, the release could easily give a casual reader the impression that no other vaccine exists.", "answer": 0}, {"article": "A three-year-old Silicon Valley start-up, Counsyl Inc., won the Bronze Innovation Award for its simple, low-cost genetic test that can alert prospective parents who might be carrying genes that could cause hereditary diseases in their children.\n\nCounsyl's technology promises a \"high quality-of-life impact for families at risk for conceiving children with familial diseases,\" says Larry Bock, an Innovation Awards judge and special limited partner at venture firm Lux Capital. \"This technology bundles previously...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0The story does a good job of comparing the status quo to benefits offered by Counsyl\u2019s new test. Another alternative to this test is to wait until pregnancy to screen. The Counsyl test would be best where one parent having a single copy of the defective gene would be enough to cause problems.", "answer": 1}, {"article": "\u201cThe findings published today substantially increase our optimism for the potential for the development of a Zika vaccine for humans.\u201d\n\nBeyond that, \u201cthis is a promising [vaccine] candidate that can be easily produced in large quantities,\u201d said coauthor, Col. Nelson Michael, an Army doctor who specializes in flaviviruses, such as Zika and dengue.\nBoth of these vaccines depend on new technology in which scientists learn the exact DNA of proteins on the surface of the virus and then create copies to be put in a vaccine.\nRight now, just one of those three vaccines will be progressing to clinical trials.\nThe urgency for a vaccine to protect against Zika infection has intensified as the virus spreads rapidly across Latin America and the Caribbean.\nThen the monkeys were exposed to active forms of the virus.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job of noting other vaccine types and the clinical testing of a competing vaccine.", "answer": 0}, {"article": "More than half of patients ultimately die specifically from progressive lung cancer with observation, and 2-year survival is less than 40 percent with either approach,\" write researcher Robert Timmerman, MD, of the University of Texas Southwestern Medical Center, Dallas, and colleagues in the Journal of the American Medical Association.\nOverall, the rate of complete plus partial response after therapy was 89%.\nIn these situations, the lung cancer tumor is deemed inoperable and conventional radiation therapy or observation without cancer treatment is offered.\nThe next step is a clinical trial to evaluate the therapy in a larger number of patients and determine the proper dosage for maximum benefit and minimal risk.\nNeither option is considered ideal.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story describes surgery and conventional radiation as possible alternatives to SBRT.", "answer": 1}, {"article": "\u201cIf surgeons aim to use partial knees in a quarter or more of their knee replacements this will substantially improve the results of knee replacement and will save money.\nIn addition, more partial knee replacements will be done and more patients will benefit from this procedure.\u201d\n\nEd Burn, first author of the paper, said they needed to get surgeons on board.\n\u201cThis has allowed us to provide strong proof that partial knee replacements are both better for patients and cheaper for the NHS.\u201d\n\nWhether people had a partial or total replacement varied by surgeon, as did the success of the operation, the researchers discovered.\nThe NHS, however, needs to get the support of surgeons, many of whom rarely carry out the less invasive procedure.\nMany more people facing surgery for knee problems would be better off with a partial rather than total knee replacement, which should allow them to recover faster, say experts.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "If, as we noted under \u201cDisease Mongering,\u201d the story is focused only on patients that require either partial or total knee replacement, then the only alternatives are, well, partial or total knee replacement. And the story refers explicitly to both.\nBut there are nuances missing. The partial procedure is thought to be a simpler one. As such, it may lead patients to undergo surgery at an earlier stage than they may otherwise have if they had the full replacement. As such, an alternative of waiting would be reasonable. This really is the challenge. There are few things between conservative measures and surgery for patients with knee arthritis.", "answer": 1}, {"article": "All were enrolled in the CHARGE study (CHildhood Autism Risks from Genetics and Environment) from 2003 to 2009.\nThe risk rose if the mothers or the children had a high-risk gene form.\nIt may be that the vitamins contribute to high levels of folate.\nExactly why the prenatal vitamins may protect against autism is not clear, she says.\nThe groups included:\n\nMothers reported their use of prenatal vitamins or other supplements before, during, and after pregnancy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story should have mentioned a healthful diet as a means to ensure adequate intake of folate and other nutrients that are important for fetal development.", "answer": 0}, {"article": "(With HIV, 50 to 60 percent is about the efficacy range researchers hope for.)\nDeveloping a vaccine to stop HIV is thought to be among the most daunting challenges in medicine for one big reason: The virus is extraordinarily genetically diverse, even more so than the flu.\nWe need more human studies of this HIV vaccine\n\nBut we still don\u2019t know if the vaccine will protect humans from the virus, since the studies so far have only looked at safety and immune responses, not efficacy.\nThis led to a massive concentration of resources into HIV/AIDS research, and triggered global and coordinated efforts to stem the disease.\nThe mosaic approach seems promising in very early clinical research\n\nIn the 35 years of the HIV epidemic, only four HIV vaccine concepts have been tested in humans.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article mentions many of the other important public health measures to control HIV (education, public awareness campaigns, condom use, etc) and other vaccines in trials.", "answer": 1}, {"article": "For advice, information and support, visit http://www.\nThe research, published today in The Lancet Neurology (1), shows people with Parkinson's who were given the oral drug rivastigmine were 45% less likely to fall and were considerably steadier when walking, compared to those on the placebo.\nAs part of the condition, they also have lower levels of acetylcholine, a chemical which helps us to concentrate - making it extremely difficult to pay attention to walking.\nDr Arthur Roach, Director of Research at Parkinson's UK, which funded the study said:\n\n\"People affected by Parkinson's, their carers, and health and social care professionals have said that preventing falls and improving balance is the biggest unmet need for people living with the condition, other than finding a cure.\nParkinson's UK Research Fellow Dr Emily Henderson and principal researcher on the study, based at the University of Bristol, said:\n\n\"With the degeneration of dopamine producing nerve cells, people with Parkinson's often have issues with unsteadiness when walking.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "While there do not appear to be any pharmacological treatments specifically for preventing falls in Parkinson\u2019s patients, there are non-pharmacological approaches to fall prevention including certain exercises, making adjustments to home environments, modification of medications and multi-pharmacy, walking aids, and more. The release does not mention these. In addition, the drug amantadine (aka Symmetrel) has been used to address muscle rigidity (which can lead to falls) in Parkinson\u2019s disease patients.", "answer": 0}, {"article": "Obesity-related health conditions include high blood pressure, type 2 diabetes and high cholesterol.\nIt takes about eight minutes to place the balloons, and about 14 minutes to remove them, according to Dr. Jaime Ponce, medical director of the bariatric surgery program at Hamilton Medical Center in Dalton, Ga. Ponce was the principal investigator of the clinical trial on the ReShape system.\nBut the device can only be used for six months at a time, and it is not likely to be an alternative for people who require lap-band surgery, stomach stapling or other forms of bariatric surgery, said Dr. Mitchell Roslin, chief of obesity surgery for Lenox Hill Hospital in New York City.\nThe people who initially will use the ReShape are people who can afford to pay for it out-of-pocket and need to drop some pounds quickly, Roslin said.\nThe balloons have been available in Europe since 2011, where their average price is about $6,200, according to the manufacturer, ReShape Medical Inc. in California.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story skates very quickly by the notion that diet and exercise are alternatives to the ReShape device, as well as alternatives to bariatric surgery.\u00a0 It would have helped to quote a psychologist or other expert on behavior change about what permanent value may or may not come from such a short-term weight loss.\nTo have a medical device, with very real risks, temporarily placed in someone\u2019s stomach in the name of temporarily losing 7 more pounds than matched controls (whose weight losses may well be longer lived given they were fueled by behavior change) is not good medicine. \u00a0The story \u2013 perhaps through the input of an independent expert \u2013 could have made the point that\u00a0well-supported behavior modification may have achieved the same result as the balloon intervention did.", "answer": 0}, {"article": "TUESDAY, May 25, 2010 (HealthDay News) --Giving certain breast cancer patients estrogen-lowering drugs before surgery enhances their chances of being able to choose a breast-conserving lumpectomy instead of a full mastectomy, new research suggests.\nAfter the four months of estrogen-lowering therapy, the research team found that 82 percent of those women in the marginal group were, in fact, able to undergo successful breast-conservation surgery.\nThe women were classified into three groups as the study began: \"marginal\", meaning that the women were eligible for a lumpectomy to conserve the breast, but that it would be disfiguring or require several operations; \"mastectomy-only\", meaning a lumpectomy was not considered possible; and \"inoperable\", meaning that doctors believed that even a mastectomy would not completely remove the cancer.\nIt focused on postmenopausal women who had been diagnosed with estrogen receptor-positive (ER+) breast cancer that was either at stage II or stage III -- that is, tumors that were around an inch or greater in size and might have spread to the lymph nodes under the arm.\nThe 352 women who participated were monitored for tumor growth before and after being placed on a 16-week regimen of aromatase inhibitors -- estrogen-lowering agents -- before any surgery.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Chemotherapy also is sometimes used presurgically to\u00a0shrink tumors and allow\u00a0for\u00a0less invasive surgery instead of mastectomy. The story should at least have pointed this out and could have attempted to provide some comparison of the two approaches.", "answer": 0}, {"article": "\"The study by Schwartz and colleagues in this issue of JAMA Pediatrics adds to a growing body of evidence supporting the importance of providing drinking water access in schools.\nThe large, clear, electrically cooled jugs with a push lever for fast dispensing were placed in 483 school cafeterias, about 40 percent of schools during the 2008-2009 and the 2012-2013 school years.\nThe study, published in JAMA Pediatrics, analyzed data collected from 1,227 elementary and middle schools across New York City - some with and some without \"water jets.\"\n\"We associated these water dispensers with almost a one percentage point reduction in the likelihood of being overweight for boys and a little over a half a percentage point reduction for girls,\" said lead researcher Brian Elbel, an associate professor of population health and health policy at NYU School of Medicine.\nThe editorial, entitled \"Power of a Simple Intervention to Improve Student Health: Just Add Water,\" said the study's findings are significant.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explains how water jets may be more effective than old-fashioned water fountains, due to concerns over water quality and fountain cleanliness. Drinking fountains also are less efficient at serving large numbers of children, the article adds.", "answer": 1}, {"article": "NEW YORK (Reuters Life!)\nThe study, led by Hung Fu Tseng, a research scientist at Kaiser Permanente in Southern California, compared about 75,000 vaccinated members of the Kaiser Permanente Health plan with about 225,000 similarly aged members who weren\u2019t vaccinated.\n- The herpes zoster vaccine could prevent tens of thousands of cases of shingles each year if it was offered to everyone who is eligible, with vaccinated adults half as likely to develop shingles, a study said.\n\u201cThe human cost of shingles is enormous,\u201d said Michael Oxman, who studies infectious diseases at the University of California, San Diego, and was involved in a previous study of the vaccine.\nMost shingles patients are older adults, but people with a weak immune system or those under stress may also develop it.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\n\nWhile there are reports of links between stress and shingles outbreaks, there is no alternative that has been studied to the extent that vaccination has. However, given the high cost of the vaccine (for people without generous insurance coverage) and other practical hurdles to vaccination, and then the relatively small risk of an attack (about 1 percent per year in unvaccinated people), it would have been helpful to see some discussion of the relative priority of shingles vaccination for most older people.\nOverall, as noted above, there is still a valid choice NOT to get this vaccine, yet that perspective did not appear in the story as an alternative.", "answer": 0}, {"article": "\"As the kids with cystic fibrosis are living longer and longer, a lot of these ancillary problems are become more apparent,\" said C. Michael White, director of the Evidence-based Practice Center and lead author of the study.\nBut with antibiotics and other medical advances, the median age for people with the disease increased to 37 by 2008.\nLungs are clogged with a thick mucus, which can lead to lung infections.\nIn the 1950s, children with cystic fibrosis generally died before age 8.\nCaused by defective genes, cystic fibrosis affects multiple organs.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 0}, {"article": "She also recommended he try naltrexone, a prescription drug.\nThe analysis also found that another drug, acamprosate, is effective at helping people who have already stopped drinking to maintain abstinence, perhaps partly by easing the physical and emotional cravings experienced by heavy drinkers who quit.\nBut there's good evidence that the combination of counseling and drugs such as naltrexone can help people cut back on drinking, or move toward abstinence.\nHis institute is stepping up efforts to work with the medical community on that front, he says, and is also touting Rethinking Drinking, a website aimed at consumers that offers the latest research-based information on a range of treatment options.\nPart of the challenge, researchers say, is that many drinkers don't realize that a medicine long used to help people addicted to opioids quit their drug habit can help alcoholics and other heavy drinkers cut back, too.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This was a tricky one\u2013the story briefly\u00a0discusses a variety of other methods that can help treat alcohol dependence, but it doesn\u2019t compare them head-to-head. That said, we do get a sense of the options available.", "answer": 1}, {"article": "\u201cHospitalization is often necessary when patients start to retain fluid, develop congestion and experience shortness of breath.\nThis is a big game-changer.\u201d\n\nFunded by the Ted Rogers Centre for Heart Research, the device called CardioMEMS\u2122 HF System was successfully implanted by interventional cardiologists at the Peter Munk Cardiac Centre in March 2017.\nWith this device, we can see warning signs days in advance, and adjust treatment accordingly.\u201d\n\nThe most rapidly rising cardiovascular disease in Canada, heart failure affects close to one million Canadians, and an estimated 26 million people globally.\nEach year, approximately 55,000 patients receive innovative and compassionate care from multidisciplinary teams in the Peter Munk Cardiac Centre, and the Centre trains more cardiologists, cardiovascular surgeons and vascular surgeons than any other hospital in Canada.\nProduced by Abbott, the CardioMEMS\u00d4 HF System is approved in the United States by the Food & Drug Administration (FDA) and is currently awaiting approval by Health Canada.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Heart failure is treated in a variety of ways and depends on the type and severity. Clinicians first treat its underlying cause, whether it be high blood pressure, coronary heart disease or diabetes. This may include lifestyle changes, such as increasing physical activity, reducing weight, quitting smoking and eating more heart-healthy foods.\nPhysicians may prescribe medications, such as ACE inhibitors, beta blockers and diuretics, so that the heart won\u2019t work as hard and that fluid won\u2019t build up in the lungs.\nIn severe cases, heart failure is treated with surgery, such as a heart transplant, or with the implantation of a device, such as a pacemaker, a left ventricular assist device or an implantable cardioverter defibrillator.\nSince the news release doesn\u2019t touch upon any of these alternatives, we give it a Not Satisfactory here.", "answer": 0}, {"article": "SOURCE: bit.ly/AhalBY\nBut the authors of the study, published in the American Journal of Clinical Nutrition, stopped short of recommending people take a daily magnesium supplement because their analysis focused on magnesium in food \u2014 and it may be another aspect of the food that is responsible for their finding.\nFor every extra 100 milligrams of magnesium a person ate per day, their risk of an ischemic stroke \u2014 the most common kind, typically caused by a blood clot \u2014 fell by nine percent.\nThe results suggest that people eat a healthy diet with \u201cmagnesium-rich foods such as green leafy vegetables, nuts, beans and whole grains,\u201d she added.\nIn seven studies published in the past 14 years, about 250,000 people in the United States, Europe and Asia were followed for an average of 11.5 years.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll give the story a satisfactory grade for emphasizing that this study could not address whether other aspects of peoples\u2019 diets affected the findings \u2013 and that the results were consistent with dietary recommendations.\nThe story would have been stronger if it had mentioned the importance of hypertension control in stroke reduction \u2013 and that it may be the favorable dietary pattern that is working with these people through improved blood pressure control.", "answer": 1}, {"article": "Ho's implant was inspired by previous research involving sex workers in Kenya.\n\"What we don't know yet is if this can be a stand-alone option for preventing HIV transmission or if it might be best used in conjunction with other prevention strategies.\nThe tool, a vaginal implant, decreases the number of cells that the HIV virus can target in a woman's genital tract.\n\"We know that some drugs taken orally never make it to the vaginal tract, so this implant could provide a more reliable way to encourage T cells not to respond to infection and therefore more reliably and cheaply prevent transmission,\" said Emmanuel Ho, a professor in the School of Pharmacy at Waterloo.\nUnlike conventional methods of HIV prevention, such as condoms or anti-HIV drugs, the implant takes advantage of some people's natural immunity to the virus.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release briefly mentions \u201cconventional methods of HIV prevention, such as condoms or anti-HIV drugs.\u201d\nGiven the preliminary nature of this experimental device it\u2019s unlikely the authors can conclude how effective this vaginal implant is in comparison to these well-studied, conventional approaches. But mentioning how effective condoms and anti-HIV medications are might have been helpful context.", "answer": 1}, {"article": "Mr. McCourry came home from war unable to escape scenes of an explosion that nearly killed him, and haunted by the memory of two young girls he accidentally killed in a fire fight.\nIt was a turning point, and for the next year I continued to get better.\u201d\nThe drug floods the brain with hormones and neurotransmitters that evoke feelings of trust and well-being, users report.\nA handful of medications meant to help left him feeling like a zombie, and he gave them up.\nI realized I had viewed myself as a monster, and I was able to start to have some compassion for myself.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The answer is revealing; essentially current interventions \u2014 mostly psychotherapy and/or drugs \u2014 have been mostly ineffective.", "answer": 1}, {"article": "In the Swiss research, animals took a drug that dissolved a barrier around the part of the brain where mammals store their fear memories. Afterward, they stopped being afraid of noises that were linked to electric shocks, which meant their bad memories had been erased, according to the Mail. Human brains, explains NYU neuroscience Prof. Joseph LeDoux, could actually \"overwrite\" memories with happier thoughts if the medication is developed for people, according to the Daily Mail.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story does not discuss current psychological practices to treat fear and anxiety disorders or how this new research might be relevant. \u00a0", "answer": 0}, {"article": "2 Barnes DE, Yaffe K (2011) The projected effect of risk factor reduction on Alzheimer's disease prevalence.\nIt is estimated that as many as 3 million cases of Alzheimer's dementia worldwide can be prevented with as little as a 10% reduction in the burden of preventable lifestyle.\n\"I believe neuroradiology, and especially quantitative MRI technology, will have a huge impact in the future of diagnosis and treatment of Alzheimer's disease, since there is compelling evidence for the baseline size of hippocampus as a key determinant of risk for future cognitive decline, and since many lifestyle factors can cause atrophy or expansion in the volume of this critical brain structure,\" says neurologist Majid Fotuhi, M.D., Ph.D., of Johns Hopkins University.\nThe American Journal of Neuroradiology (AJNR) is published monthly by the American Society of Neuroradiology (ASNR), a professional association of more than 5,000 members who specialize in diagnostic radiology of the central nervous system, brain, head and neck through the use of X-ray, MRI, CT and angiography.\n\"We are working closely with neuroradiologists to redefine how we can reduce risk for Alzheimer's with quantitative neuroimaging that helps us pinpoint symptom-relevant volume loss in the brain and subsequent targets for tracking our lifestyle-based interventions,\" says Dr. David Merrill, a geriatric psychiatrist at UCLA Medical Center.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The main premise of the news release is that MRI imaging can help people lower their risks for cognitive decline by encouraging them to make lifestyle and behavioral changes. It states that risk factors include obesity, diet, sleep, hypertension, diabetes, depression and smoking. However, the release does not address any alternatives \u2014 besides brain imaging \u2014 that might help people make the desired changes. Behavioral change counseling, which is an established approach to reducing problematic behaviors, is not discussed.", "answer": 0}, {"article": "Drug list (formulary): To see a list of covered drugs for the plan you\u2019re considering, use the drop-down menus below.\n\nIf your employer is offering coverage, contact HR for the pharmacy plan name.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Mentions other \nadjuvant drug treatment, tamoxifen, as well as some side effects of both of the aromatase inhibitor drugs (Femara and \nArimide) studied as well as Tamoxifen.", "answer": 1}, {"article": "TUESDAY, Feb. 2, 2010 (HealthDay News) --When a doctor wants to assess the condition of heart arteries without putting a gadget into those blood vessels, the X-ray technology called computed tomography -- more commonly called a CT scan -- is better than magnetic resonance imaging, or MRI, a German review of studies has found.\nIndeed, CT and MRI are not contenders in clinical practice but are used for different reasons to make different assessments, Schoepf said.\nIndeed, CT appears to be better for assessment of coronary artery disease, matched against not only MRI but other methods, such as echocardiography, he said.\nBut doctors do not always want to run the risks that can be associated with that technique, and the leading candidates for less invasive assessment are CT and MRI.\n\"It is a question of what specific question you are looking to answer,\" he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that CT and MRI are each used for different reasons, but it implies\u00a0erroneously\u00a0that either is an all-around alternative to catheterization, and thus the \"best\" way to detect coronary artery disease.", "answer": 0}, {"article": "CBS News correspondent Kelly Wallace reports Kate Miller's 15-year-old son Cody killed himself just 17 days after starting the drug.\nShe's now writing letters to every patient who takes Singulair, urging them not to over-react.\n\"But because suicide is a life-threatening event we thought it was important to provide this information in the product label.\"\nMichelis said, \"They should not stop taking their medication unless they are experiencing a major change in their moods.\"\nIn clinical trials of asthma patients, the most common side effects were headache, flu, abdominal pain and cough.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The perspective of the clinician who prescribes Singulair and other drugs for asthma and allergies provides an adequate, if brief, discussion of treatment options. ", "answer": 1}, {"article": "The lower the amount of free PSA, the more likely cancer is the cause and the more likely the disease is aggressive, requiring treatment, according to Dr. Patrick C. Walsh, a Johns Hopkins urologist and the author of \u201cDr.\nOn the Way: New Guidelines\n\nBased on recent studies, the American Urological Association will soon release revised guidelines that, experts hope, will reduce unnecessary biopsies and prostate surgeries, which even in the best hands can leave a man impotent and incontinent.\nThat means that 2.25 percent of the total number of men with a PSA less than 4 had life-threatening cancers.\n\u201cWe need at least 1 \u00bd to 2 years\u2019 worth of data\u201d to make a meaningful judgment about how to proceed, Dr. Carter said.\nThis approach has resulted in many biopsies in men who did not have cancer \u2014 about 70 percent of those with elevated PSAs are cancer free \u2014 and debilitating prostate surgery in men with cancers that would never have become a threat in their remaining years of life.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does not describe the option of no screening, nor does it describe all treatment options if prostate cancer is diagnosed, such as watchful waiting or radiation (in addition to surgery that it does breifly mention).\u00a0 ", "answer": 0}, {"article": "The Lung EpiCheck blood test detects changes in DNA methylation in 6 markers in cfDNA associated with lung cancer.\nThe reason for the high mortality rate is that currently most cases are detected when the patient becomes symptomatic, which is usually at late stages of the disease.\nIt is estimated that there are about 1.8 million new cases of lung cancer annually worldwide and about 1.55 million die from the disease each year.\nThe results will be presented in a poster presentation titled Lung EpiCheck \u2122 - Results of the Training and Test Sets of a Methylation-Based Blood Test for Early Detection of Lung Cancer at the IASLC 19th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, to take place on September 22-26, 2018 in Toronto, Canada.\nSuch promising results combined with the simplicity of the test, could allow us to detect lung cancer at the early stages and hence improve 5-year survival from about 15% to about 50-70%.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes alternatives to the blood test include the standard CT scan.\nCurrently, early stage lung cancer can be detected either accidentally, when testing for other conditions, or by using low-dose CT scans, which are costly, carry associated risks such as high radiation, and are employed only for a very high-risk population.", "answer": 1}, {"article": "NEW YORK (Reuters) - Johnson & Johnson\u2019s Stelara helped a significantly higher percentage of Crohn\u2019s disease sufferers than those who received a placebo, according to a study of patients who had not been helped by other commonly used drugs.\n\u201cThey\u2019ll feel measurably better.\u201d\n\n\u201cThe patient population was really quite ill and had very high disease activity, and despite that we saw nice response rates,\u201d Sandborn said.\nIn addition, nearly 70 percent of patients who stayed on Stelara beyond the initial six weeks of the mid-stage study continued to respond to the drug and there was a significantly higher rate of remission at 22 weeks than in a placebo group.\nAfter 22 weeks, 69.4 percent of the Stelara patients maintained a clinical response and 41.7 percent were deemed to be in clinical remission.\n\u201cIt\u2019s effective in the patient population that has the greatest unmet need at this point in time,\u201d Sandborn said of patients who do not respond to anti-TNF drugs.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story gets a check here for telling us that subjects in this study had tried TNF antagonists but didn\u2019t benefit or couldn\u2019t tolerate them. It gets another check when it mentions that when medicines for Crohn\u2019s disease stop working, many patients require surgery.\nThere was room for more details here, too, or an outline of what\u2019s unknown. The article states the trial was placebo-controlled in individuals who \u201cfailed\u201d other approved meds, but that doesn\u2019t mean we know how it compares to other meds commonly used, like prednisone.", "answer": 1}, {"article": "July 7, 2011 -- An experimental therapy involving stem cell injections from the patient's own blood is showing promise in the treatment of people with chest pain that is not responsive to drugs, angioplasty, or surgery.\nThe approach also showed promise in a 2007 pilot study involving fewer than 30 patients.\nThe newly reported study included 167 patients with severe angina treated at 26 medical centers across the country.\nAbout 850,000 Americans have angina that persists despite available treatments.\nPatients with untreatable angina who received the injections of CD34+ stem cells in key areas of the heart had significantly fewer chest pain episodes and significantly better performance on exercise tests than patients who got placebo injections.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story puts this approach into the context of attempts to help people who have angina despite available treatments.", "answer": 1}, {"article": "Bolstered by stories like Ham's, doctors are experimenting with marijuana as an addiction treatment in Massachusetts and California.\nPeople are dying and, as a result, we ought to use things that are proven to be effective,\" said Dr. Richard Saitz, chair of the Department of Community Health Sciences at the Boston University School of Public Health.\nBut supporters point to doctors like Dr. Gary Witman, of Canna Care Docs, who has treated addicts with cannabis at his offices in Fall River, Stoughton and Worcester, Massachusetts.\n\"I don't think it's a cure for everybody,\" said Maine Rep. Diane Russell, a Portland Democrat and a leader in the state effort to legalize marijuana.\nThe findings in the Journal of Pain study that found chronic pain sufferers reduced their opioid use when using medical pot were limited because participants self-reported the data.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Alternatives were not adequately discussed. There are a wide range of alternatives for pain control other than\u00a0opioids and marijuana treatment options, such as\u00a0non-opioid analgesics and physical therapy. Also, the prescription drug\u00a0Marinol is a medicine with the active ingredient of marijuana (THC) that\u2019s approved to treat the nausea of chemotherapy and for appetite stimulation in HIV patients, and the dosing can be better controlled.", "answer": 0}, {"article": "# # #\nGiven the prevalence of chronic pain, high frequency SCS is an exciting advance for our patients.\u201d\n\n\n\nSCS is an increasingly common therapy that delivers electric pulses to the spinal cord, through a small device implanted under the skin, for difficult to treat chronic pain in the trunk and limbs.\nAccording to a study published in the Online First edition of Anesthesiology, the official medical journal of the American Society of Anesthesiologists\u00ae (ASA\u00ae), patients who received a novel high frequency form of spinal cord stimulation (SCS) therapy experienced significantly greater, long-term relief for both chronic back and leg pain, when compared to a traditional low frequency form of SCS therapy.\u201cThis is the first long-term study to compare the safety and effectiveness of high frequency and traditional SCS therapy for back and leg pain,\u201d said Leonardo Kapural, M.D., lead study author and professor of anesthesiology at Wake Forest University School of Medicine and clinical director at Carolinas Pain Institute at Brookstown in Winston-Salem, N.C. \u201cChronic back and leg pain have long been considered difficult to treat and current pain relief options such as opioids have limited effectiveness and commonly known side effects.\nThe new treatment, called HF10\u2122 therapy, uses proprietary high frequency pulses of 10,000 Hz, compared to traditional SCS which uses frequencies of 40 to 60 Hz.\nHF10 therapy also provides pain relief without paresthesia \u2013 a stimulation-induced sensation commonly perceived as tingling or buzzing, which masks a patient\u2019s perception of pain \u2013 typical of traditional SCS.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions traditional SCS, opioids, and back surgery as other approaches to back pain, and notes that they have \u201climited effectiveness and\u00a0commonly known side effects.\u201d But we don\u2019t think this is enough for a Satisfactory grade here. The options for treatment of back pain are much more diverse than just surgery, narcotics, and an implanted spinal cord stimulator, and so in a sense the release is offering a false choice. Other less invasive components of multimodal pain management strategy include exercise, physical therapy, yoga, NSAIDS (e.g. ibuprofen), and behavioral counseling.", "answer": 0}, {"article": "Further tests are required before this latest method can be used within a clinical setting.\nThe researchers concluded: \u201cThe opportunity to one day readily understand the health of a patient\u2019s blood vessels, key to cardiovascular health, with a simple retinal image could lower the barrier to engage in critical conversations on preventive measures to protect against a cardiovascular event.\u201d\nThe risk factors include the person\u2019s gender, smoking status, blood pressure and age\u2014estimated to within four years of the patient\u2019s actual age.\n\u201cHowever, some of these parameters may be unavailable\u2026We therefore explored whether additional signals for cardiovascular risk can be extracted from retinal images, which can be obtained quickly, cheaply and non-invasively in an outpatient setting.\u201d\n\nRead more: Can smartphones replace your GP?\nTraining deep-learning models on data from more than a quarter of a million patients, the scientists were able to predict the cardiovascular risk factors that were not previously thought to be present in retinal fundus images.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions cardiovascular risk calculators, which use parameters such as a person\u2019s gender, smoking status, blood pressure, and age.\n\u201cMost cardiovascular risk calculators use some combination of these parameters to identify patients at risk of experiencing either a major cardiovascular event or cardiac-related mortality within a pre-specified time period, such as 10 years,\u201d the  paper states.\n\u201cHowever, some of these parameters may be unavailable\u2026We therefore explored whether additional signals for cardiovascular risk can be extracted from retinal images, which can be obtained quickly, cheaply and non-invasively in an outpatient setting.\u201d", "answer": 1}, {"article": "When the researchers used the longer Tao brush, they were able to detect endometrial cancer in all but 7% of the women who had the disease, and close to half of the ovarian cancers. Combined with the fact that these tests were performed with a mere swipe of the uterine wall, these measures of \u201csensitivity\u201d \u2014 the ability to detect cancers that are actually there \u2014 represent a major improvement over the screening tests currently available.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story describes standard Pap smear tests, adding that they do a \u201cpoor job\u201d of detecting endometrial and ovarian cancer. Blood testing for cancer-related biomarkers, such as CA-125, is also noted as well as ultrasound tests of the uterus. The story also notes these are most commonly late-stage tests.", "answer": 1}, {"article": "Nov. 18, 2012 -- Researchers say they've been able to use nanoparticles to stop multiple sclerosis (MS) in mice that are bred to have the disease.\nWhat remains to be seen is whether the researchers have picked the right proteins that might turn off the disease in humans, he says.\nThey are made from the same material that's used to create dissolving stitches.\nThe particles are about 200 times smaller than the thickness of a human hair.\nIt\u2019s rational, but we won\u2019t know until we get it into people,\u201d says Coetzee, who was not involved in the research.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not discuss the many alternative approaches under study and in clinical practice spoken to in the journal article itself.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061015/23addict.b.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story did not include mention of any other approaches to obesity treatment though there certainly are other options.", "answer": 0}, {"article": "Still, the failure rate was similar to the failure rate of the IUD when used during the five-year period (which is under 1%).\nThe women were informed of the pregnancy risk associated with using their device longer than recommended, and the researchers called them for followup every 6 months for 36 months or until the women had their device removed.\nThe benefit of being able to use the implant and IUD for a longer period of time is that it could reduce costs for individuals and insurance.\nThough the data is preliminary, the researchers say they believe that the hormonal IUD and the implant can both be used for an additional year longer than the FDA recommends.\nIn a new study published in the journal Obstetrics & Gynecology, researchers discovered that the hormonal IUD and the implant are highly effective a year after they are currently approved for use.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The authors might have briefly mentioned the pros and cons of different methods other than implants and IUDs \u2014 such as birth control pills and condoms.", "answer": 0}, {"article": "The liquid is called silver diamine fluoride, or S.D.F.\nIt\u2019s been used for decades in Japan, but it\u2019s been available in the United States, under the brand name Advantage Arrest, for just about a year.\nBut studies show it can halt the progression of cavities and prevent them, and dentists are increasingly using it off-label for those purposes.\nNow there\u2019s an alternative: an antimicrobial liquid that can be brushed on cavities to stop tooth decay \u2014 painlessly.\nNobody looks forward to having a cavity drilled and filled by a dentist.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is effectively a comparison between the use of SDF and the use of drilling and filling to treat cavities. The story does not address the use of laser technology, in lieu of drilling, but that technique still requires the use of fillings \u2014 and would still require the patient to be still during potentially lengthy treatment (which is one reason for the use of general anesthesia in young patients).\u00a0 Alternatives of using nitrous oxide in the office or procedural sedation with the proper safeguards were not\u00a0discussed, either.", "answer": 1}, {"article": "USUALLY NOT THE FIRST STEP\n\n\u201cI have a long list of chronic pain patients coming to seek acupuncture,\u201d said Jongbae Park, head of Asian Medicine & Acupuncture Research at the University of North Carolina at Chapel Hill School of Medicine.\nBut, he added, \u201cI would sincerely say more than 75 percent of my patients will see improvement.\u201d\n\nVickers said people who are considering acupuncture should first make sure their acupuncturist is appropriately qualified and licensed.\nIt\u2019s usually \u201cnot their first approach to address the condition,\u201d he said - rather people seek acupuncture when traditional care fails to stop their pain.\n\u201cI am a biased clinician,\u201d Park told Reuters Health.\n\u201cA doctor who has a patient in pain has a lot of options,\u201d such as medications and physical or talk therapy, said lead author Andrew Vickers, from Memorial Sloan-Kettering Cancer Center in New York.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions medications, physical, and talk therapy as potential options for chronic pain.\u00a0 A complete story however might also have included some information about the standard treatments and how they compare to placebo.\u00a0 When you look at physical therapy for chronic low back and NSAIDs the results are not all that impressive", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070225/5laser.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story provides an excellent overview of some of the newer procedures and techniques for laser eye surgery to correct\u00a0 vision problems related to the size and shape of the cornea. The story mentions the potential pros and cons of LASIK and PRK surgery, and how a surgeon and a patient might decide which procedure is right, if appropriate at all. \nThe story provides an excellent service by encouraging people to be educated consumers when making a decision about this heavily promoted eye surgery", "answer": 1}, {"article": "Even participants who had normal-range blood pressure, triglycerides or cholesterol levels before surgery saw improved measures.\n\"The potential impact of such risk reduction translates into a reduced likelihood of developing significant heart disease later in life, including atherosclerosis, heart failure and stroke,\" says study author Marc Michalsky, surgical director of the Center for Healthy Weight and Nutrition at Nationwide Children's Hospital in Columbus, Ohio, in an email.\nBefore surgery, only 3 percent of the teens had no cardiac risk factors at all, but three years later, just over half of them (52 percent) had no risk factors.\nThe findings are important because many of the participants in this study likely already had some level of cardiac damage, such as thickened arteries or heart walls, says Geetha Raghuveer, a pediatric cardiologist at Children's Mercy Kansas City in Missouri who was not involved in the study.\n\"If you have very high blood pressure or lipids [cholesterol] or diabetes, you do see cardiovascular changes even at a very young age,\" Raghuveer says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job here, quoting Geetha Raghuveer, a pediatric cardiologist at Children\u2019s Mercy Kansas City in Missouri who, it reports, was not involved in the study. Raghuveer is quoted saying surgery \u201cwould be considered for the highly obese and those not responding to any behavioral modifications, physical activity or calorie restriction.\u201d Further, the story says, Raghuveer endorses public health efforts that \u201caim for better obesity prevention, including parent education and interventions when children are toddlers and preschoolers.\u201d\n\u201cThe big question is, how do we prevent obese kids from getting to this point where they would need an invasive surgical procedure?\u201d Raghuveer says in the story.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061008/16organ.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story describes the primary treatment option for people with kidney failure, that is dialysis. However, the article doesn\u2019t describe it any more than naming it. There is no assessment of effectiveness of dialysis and, indeed, it is painted in a very negative manner \u2013 \u201c\u2026slowly dying on dialysis.\u201d While dialysis is by no means a cure, it does allow people to live who would otherwise die due to kidney failure. ", "answer": 0}, {"article": "The men in the trial received the ADT drugs for two years.\n\u201cIt really builds on some prior data and combines prior findings to ask and answer a new question that is quite relevant for men affected by prostate cancer.\u201d\n\nSome patients benefitted from adding the drugs more than others.\nThe findings should trickle down to clinical settings \u201cpretty quickly,\u201d said Dr. William Shipley, chair of the genitourinary oncology unit at Massachusetts General Hospital and one of the researchers behind the study, which was published Wednesday in the New England Journal of Medicine.\nThe specific ADT drug used in the study, bicalutamide, has since been largely replaced by another kind of drug that decreases the amount of testosterone the body produces.\nThe drug, a type of androgen-depleting therapy, is a frontline treatment for men who opt not to have surgery for the cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Readers get a solid description of the standard of care, including typical procedures in the first occurrence, and how radiation therapy is typically used after a recurrence. Hormone blockers are not oversold as some revolutionary new advancement, but an existing treatment that needed long-term study to determine if they were beneficial.", "answer": 1}, {"article": "Arena then hopes to file its request for market approval with the Food and Drug Administration by the end of 2009.\nThe drug also proved to be highly selective, meaning it hit the intended targets inside the body and did not cause troubling side effects.\nThose people taking the drug also saw reduced cholesterol levels and waist size, changes that have been linked to lessening cardiovascular risk factors such as blood pressure.\nThe experimental drug stimulates the 5-HT2C serotonin receptor, which is located in the hypothalamus, an area of the brain associated with regulation of food intake and metabolism.\nPeople taking the Arena pill experienced significantly more weight loss, at least 5 percent of their weight over 12 weeks, than people taking a placebo, according to the report filed in the journal Obesity.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not provide any information about other treatment options (currently available medications, lifestyle changes, and surgical interventions) that provide similar or superior weight loss results.", "answer": 0}, {"article": "The Food and Drug Administration has approved DBS therapy for movement disorders such as Parkinson's disease, tremor and dystonia \u2014 usually in people who haven't responded well to medications.\nThe intermittent system controlled overeating much better than the continuous or random protocols \u2014 and nearly as well as in a separate group of mice that got zapped manually by a researcher watching their behavior on video.\nSo it seems like a nice opportunity,\" says Halpern, noting that addictive disorders haven't had new therapies for decades.\nTrouble is, the moderation wore off in a few days, and the DBS also interfered with the animals' social behavior.\nThat got Halpern thinking about a newer system \u2014 one that doesn't stimulate continuously, like DBS, but switches on briefly only after sensing a trouble signal, much like a pacemaker monitors and responds to abnormal heart rhythms.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are treatments for addictive or impulsive behaviors, although arguably they all have less than stellar records of success, and many that involve medications come with a host of side effects. Some mention of these should have been made, though.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070805/13knee.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that other manufacturers make implants that may be just as good as or better than the Gender Knee for women. We wish the story had included an additional sentence on nonsurgical alternatives to remind readers that surgery is a matter of patient preference\u2014and many patients choose to opt out.", "answer": 1}, {"article": "\"I think this may be changing in health care,\" said Spears, \"but because migraine affects women more than men, there is a stigma around the stereotype of a patient who comes in with multiple complaints, calls frequently and wants to see the doctor frequently.\" Men, on the other hand, have been stereotyped as going to the doctor \"only when something he has is real.\"", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention other current drugs and alternate approaches to treating patients with migraines so it gets a satisfactory in this category.\nHowever, most of these remedies are supported by poor or medium quality evidence and the article does not separate those that\u00a0have more robust evidence and those that have been supported by tenuous or flawed evidence only.", "answer": 1}, {"article": "Researchers reintroduced the drug to 32 patients who were initially treated as part of a study of 634 patients.\nThe team found that in patients whose cancer initially progressed while on ipilimumab, whose who were reintroduced to the drug had a disease control rate of 65 to 75 percent, compared to zero in the patient who got the vaccine only.\nThe study is the first to test ipilimumab in patients whose skin cancer had spread to the brain, and the findings, released in an abstract or brief summary, support its potential use in these patients, the researchers said.\n\u201cThese findings may have implications for the use of ipilimumab therapy in the long-term management of advanced melanoma,\u201d the researchers reported in the abstract.\nIpilimumab is a monoclonal antibody, an engineered human immune system protein that boosts the body\u2019s immune response by interfering with another immune compound called CTLA-4, which acts as a sort of brake on immune system cells.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story does not mention existing treatments, nor does it mention other experimental treatments for advanced melanoma that are also being presented at this same meeting.", "answer": 0}, {"article": "\"Guidelines changed based on this study,\" Jolly noted.\n\"These findings will likely have important implications for clinical practice,\" Fonarow said.\n\"There has been some controversy about removing blood clots during the treatment of heart attacks,\" said lead researcher Dr. Sanjit Jolly, an associate professor of cardiology at McMaster University in Hamilton, Ontario.\n\"This is an unexpected finding, and we want to confirm this in other studies,\" Jolly said.\nThe results of the study were published online March 16 in the New England Journal of Medicine to coincide with a planned presentation of the findings at the American College of Cardiology's annual meeting in San Diego.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternative here is clearly to do the angioplasty without clot removal. That is satisfactorily established. We wish the story had been a bit clearer about the different techniques available for clot removal, however. The story talks about \u201cmanual\u201d vs. \u201cmechanical\u201d removal, but never explains what that means. The press release notes that with \u201cmanual\u201d clot removal,\u201dthe surgeon uses a syringe to create suction to remove clots,\u201d whereas mechanical removal \u201cuses machinery to create the suction.\u201d", "answer": 1}, {"article": "If you are interested in enrolling in a clinical trial, you can find one at clinicaltrials.gov.\nThe study shows the results of a six-month follow-up with patients in 2007, and researchers are presently working with data from the two-year follow-up.\nThe particular kind of cells used in this research are called mesenchymal stem cells, and come from adults, not embryos.\nThe study is a step forward in a field in which a lot of approaches have been tried in animals and preliminary human trials, but none has been approved for widespread clinical use for heart patients.\nThe new results are a milestone in stem cell research, and for patients, said Jeffrey Karp, a researcher at Brigham and Women's Hospital in Boston, Massachusetts, who runs a stem cell biology lab at Harvard University.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compares this process, which involves infusing the patient with a donor\u2019s bone marrow stem cells, with both use of the patient\u2019s own stem cells and with surgical introduction of the cells. \nThe story does not specify conventional treatments for heart failure, which would have provided useful context. Still, the story earns a satsifactory rating. ", "answer": 1}, {"article": "\u201cIt was like how can I make it through this day because I am so tired?\n\u201cAnd then the doctors looked piece by piece, and realized that what I have is sleep apnea.\u201d\n\nTurner\u2019s nightly interrupted breathing increased her chances of heart attack or stroke by three to four times, according to Dr. Robson Capasso, associate professor of Otolaryngology Head and Neck Surgery at Stanford University.\nI thought since I'm older so that's what it is.\u201d\n\nIt wasn\u2019t until a mother-daughter vacation that Turner\u2019s daughter noticed something interesting when her mother slept.\nWhat's more, a recent study in the New England Journal of Medicine found that the bulky CPAP machines \u2014 standard treatment for many patients with sleep apnea \u2014 doesn't help prevent heart attacks or stroke, although it does help patients sleep better and improve mood.\n\u2022 should be over the age of 22\n\u2022 have a diagnosis of moderate to severe obstructive sleep apnea\n\u2022 be unable to use or get consistent benefit from CPAP\n\nDr. Sanjeev Kothare, professor of neurology at NYU Langone Medical Center, cautions about using Inspire unless sleep apnea patients meet the requirements for the procedure.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We are only told that the usual alternative\u2013an external continuous positive airway pressure (CPAP) machine\u2013\u201cproved too cumbersome\u201d for this one patient\u2019s continued use. Also, according to a NEJM study, we are told that CPAP machines don\u2019t \u201chelp prevent heart attacks or stroke, although it does help patients sleep better and improve mood.\u201d How does the implantable device fare in terms of heart attacks or stroke? The story doesn\u2019t tell us.\nBottom line:\u00a0There is much more evidence showing CPAP is proven to improve the very same outcomes for which the new device is touted. This point should have been included.", "answer": 0}, {"article": "Straiton didn\u2019t respond to emails seeking comment.\nSurgeons may also perform what\u2019s known as angioplasty, which uses a catheter to insert a tiny balloon and inflate it to open the valve; sometimes surgeons will also insert a stent, or tiny wire mesh cage, to keep the artery propped open.\nThis procedure, known as a transcatheter aortic valve replacement, is done by threading a catheter to the heart through a small incision in the chest or from the large artery in the groin - it doesn\u2019t require cutting open the chest.\n\u201cThese symptoms lead to reduced functional capacity (inability to perform physical exertion) and also impact a patient\u2019s overall sense of wellbeing and quality of life,\u201d Cohen, who wasn\u2019t involved in the study, said by email.\nThe analysis focused on people with what\u2019s known as aortic stenosis, which occurs when the large blood vessels leading away from the heart narrow, forcing it to work much harder to pump blood.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses alternatives this way:\nPeople who don\u2019t get this type of minimally invasive surgery may instead get a more invasive procedure that involves surgeons cutting open the chest to repair a damaged valve.\nSurgeons may also perform what\u2019s known as angioplasty, which uses a catheter to insert a tiny balloon and inflate it to open the valve; sometimes surgeons will also insert a stent, or tiny wire mesh cage, to keep the artery propped open.\nWhile this is an attempt to explain the other type of surgery, it uses terms that apply to heart vessel surgery, not valve surgery (\u201cangioplasty,\u201d and \u201ckeep the artery propped open.\u201d)", "answer": 0}, {"article": "Antioxidants neutralize unstable forms of oxygen called reactive oxygen species that can damage cells throughout the body.\nBut the finding is in line with a previous study of U.S. adults that found that a higher intake of vitamin E, but not vitamin C or beta-carotene, was related to a lower risk of developing Alzheimer\u2019s over two years.\nResearchers found that among 5,400 Dutch adults age 55 and older, the one-third who reported the highest vitamin E intake from food were 25 percent less likely to develop dementia, including Alzheimer\u2019s disease, over the next decade than the third with the lowest intakes.\nReactive oxygen species are produced naturally in the body, as byproducts of metabolism; because the brain is an area of high metabolic activity, it is thought to be particularly vulnerable to accumulating oxidative damage over a lifetime.\nNEW YORK (Reuters Health) - Older adults who get plenty of vitamin E in their diets may have a somewhat lower risk of developing dementia than those who consume less of the nutrient, a study published Monday suggests.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is currently no proven method for preventing age-related dementia. We might have wished that this story had mentioned some other diet and\u00a0lifestyle choices that are\u00a0associated with reduced risk in observational studies. These include staying physically active, not smoking, eating a Mediterranean-style diet (rich\u00a0in\u00a0fruits and vegetables and omega-3 fatty acids), and keeping\u00a0your mind engaged in intellectually challenging pursuits.\u00a0 But since the evidence is kind of squishy for all of this, we rule this satisfactory. ", "answer": 1}, {"article": "So far, however, there is little scientific proof of their effectiveness\u2014many studies of probiotics have involved less-than-rigorous...\nBut some researchers are investigating the beneficial bugs for conditions that have nothing to do with the digestive tract.\nThey are live microorganisms\u2014or \"good\" bacteria\u2014that when consumed in capsules or yogurt are said to confer a health benefit.\nOne of the fastest-growing dietary supplements, probiotics are now prominent on drug and big-box store shelves.\nProbiotics are widely used to aid digestion and help restore gut bacterial balance after antibiotics.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story discussed the use of probiotics for multiple conditions. We don\u2019t think the story could be expected to compare alternatives for all of these conditions, so we\u2019ll rate it not applicable.", "answer": 2}, {"article": "\"However, there are gaps in knowledge about what is the best way to alleviate pain during vaccination.\"\n\"We found that, when used consistently during vaccine injections in the first year of life, only liposomal lidocaine combined with parental video instruction and orally administered sucrose showed a benefit on acute pain when compared with placebo, video alone, and video and sucrose together,\" wrote the authors.\n\"The effects of consistent pain management on the development of preprocedural anxiety (fear), hypersensitivity to pain and compliance with future vaccination warrant future investigation,\" they recommend.\n\"Vaccinations cause acute distress for both infants and their parents, contributing to vaccination avoidance,\" states Dr. Anna Taddio, a pharmacist and senior associate scientist at The Hospital for Sick Children (SickKids) and professor, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario.\nFor babies under age 1 year, lidocaine cream, combined with a small amount of sugar given by mouth and infant soothing, can help relieve pain from routine vaccinations, according to a study in CMAJ (Canadian Medical Association Journal).\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release compares a range of methods for alleviating vaccination pain in infants \u2014 training parents on how to soothe a child, giving the child sugar water, and applying lidocaine cream. We\u2019re not told the contents of the training video but presumably it focused on holding, verbal soothing and nursing. In its practice guidelines, the CMAJ recommends breastfeeding during a vaccine injection to mitigate pain in infants.", "answer": 1}, {"article": "\"For high-risk people, those with heart disease or [who] have had a stroke who are taking a standard dose of a statin, further reduction in LDL cholesterol will give them extra benefit,\" said Dr. Colin Baigent of the Clinical Trial Service Unit and Epidemiological Studies Unit at University of Oxford in the United Kingdom, who was involved in both studies.\nThe researchers found that in trials comparing statin doses, taking high-dose statins reduced the odds of having a stroke by an additional 15 percent, compared to the usual doses of statins.\n\"But if you are at risk from those diseases, you would need intensive treatment to lower LDL cholesterol, even if your LDL cholesterol level is not very high,\" he added.\n\"If you are at risk from a heart attack or stroke, either because you have had these conditions before or because you have the risk factors for them, you should be considered for intensive treatment to lower the LDL cholesterol,\" Cheung said.\n\"If your blood cholesterol is raised but you do not have other risk factors for heart disease and stroke, then your doctor may well decide that you do not need to take any drugs to lower cholesterol,\" he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The main comparison with the higher doses of statins studied is to lower doses of this class of medication, and this was covered in this story. We would have liked to have seen at least some discussion of how statin use compared to diet and exercise in reducing risk for heart attacks and stroke.", "answer": 1}, {"article": "An experimental Alzheimer\u2019s drug showed positive results and raised hopes anew that pharmaceutical companies were moving closer to a medicine that could finally disrupt the disease\u2019s memory-robbing course, though a string of failures shadow the efforts.\n\nAlzheimer\u2019s has proved an especially tough drug target. Approved therapies only relieve symptoms temporarily, and one experimental treatment after another promising to stymie the neurodegeneration has ultimately failed to work. Some pharmaceutical companies, after costly failures,...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned there are 126 therapies in clinical development, according to\u00a0 the Alzheimer\u2019s Drug Discovery Foundation, with beta amyloid being the most common drug target being tested in human trials. It also mentioned approved therapies that \u201conly relieve symptoms temporarily.\u201d\nThere is also evidence that a healthy lifestyle can be of benefit to people at risk for Alzheimer\u2019s and those with early symptoms.", "answer": 1}, {"article": "The key to making the therapy work?\nThe patients were children who had inherited a mutated gene causing a rare disorder, adrenoleukodystrophy, or ALD.\nThe only treatment is a bone-marrow transplant \u2014 if a compatible donor can be found \u2014 or a transplant with cord blood, if it was saved at birth.\nFor the first time, doctors have used gene therapy to stave off a fatal degenerative brain disease, an achievement that some experts had thought impossible.\nThey become unable to eat without a feeding tube, to see, hear or think.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did a good job of describing other treatment options \u2014 including bone marrow and cord blood transplants \u2014 as well as the associated risks.", "answer": 1}, {"article": "THURSDAY, Oct. 12, 2017 (HealthDay News) -- Breast cancer is the second leading cause of cancer death among women in the United States, and routine screenings remain the most reliable way to detect the disease early, a breast cancer expert says.\n\"Having one risk factor or even several doesn't mean a woman will definitely develop breast cancer,\" she said in a Fox Chase news release.\nIts effectiveness depends on the size of a breast tumor and the density of breast tissue.\n\"I advise women to speak with their physician to determine what is right for them,\" Evers said.\nThis is an important part of breast health,\" she said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll will give the story credit for noting that there are several screening methods, and for pointing out that not all women who have symptoms get breast cancer.", "answer": 1}, {"article": "New investigation advises doctors to recommend cranberry products as first line of defense against repeated urinary tract infections (UTIs)\n\nCARVER, Mass., September 19, 2017 - A thorough review of dozens of studies led scientists to conclude that healthcare professionals should be telling their patients to have cranberry products as a first step in reducing recurrent UTIs.\nHowever, patients with recurrent UTIs who ingested cranberry products and had undergone gynecological surgery, experienced a significant reduction in UTIs.\n\"Our investigation supports that cranberry products can be a powerful tool to fight off frequent UTIs,\" explains lead author, Dr. \u00c2ngelo Lu\u00eds.\nLuis A, Domingues F and Pereira, L. Can cranberries contribute to reduce the incidence of urinary tract infections?\nThe review explains that the medicinal properties of cranberries may be attributed to their unique polyphenol, proanthocyanidins - or PACs, for short.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are a number of lifestyle changes, in addition to modifying one\u2019s cranberry consumption, that can reduce the risk of UTIs. For example, increasing one\u2019s water intake or changing one\u2019s form of birth control.\nIn addition, there are medical interventions such as use of vaginal estrogen preparations (for post-menopausal women) and taking an antibiotic preventively after intercourse.", "answer": 0}, {"article": "In one of two related studies published Monday, Anderson and his colleagues described in the journal Nature Biotechnology how they had tested 774 variations of alginate in rodents and monkeys and identified a handful that elicited a greatly reduced foreign body response.\n\u201cOur goal is to bring that kind of biological cure across the spectrum of type 1 diabetes.\u201d\n\nThe potential of the approach has attracted interest from both small startups and large biopharmaceutical companies that are looking at stem cell-based therapies for diabetes.\nThe problem with existing alginates is that the body eventually catches on to the material as a foreign substance, suffocating the implant in a layer of scar tissue.\nAnd whereas the Massachusetts researchers examined beta cells exclusively for their study, the ViaCyte team is exploring using less mature cells that, once implanted, differentiate into both insulin-producing beta cells and those that secrete another hormone called glucagon that\u2019s deficient in the disease.\n\u201cThis is really the first demonstration of the ability of these novel materials in combination with a stem-cell derived beta cell to reverse diabetes in an animal model,\u201d said Julia Greenstein, vice president of discovery research at JDRF, an organization trying to end type 1 diabetes that provided some funding for the studies.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does contrast this research with other research into treating diabetes. The story might have provided\u00a0a bit of context about other work on developing an artificial pancreas for Type 1 Diabetes patients (there\u2019s a lot on this).", "answer": 1}, {"article": "Switching to AstraZeneca PLC's breast-cancer drug Arimidex after treatment with older drug tamoxifen not only helps women live longer, but also increases their chances of staying cancer-free after initial therapy for breast cancer, according to a study in the online edition of the Lancet Oncology medical journal.\n\nThe data, which come from more than 4,000 patients in three clinical trials, have shown that switching treatment from tamoxifen to Arimidex reduces the risk of dying by 29%.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that this hormone therapy to prevent breast cancer recurrence is in addition to surgery. Tamoxifen, another hormone therapy, is also mentioned. ", "answer": 1}, {"article": "Investigators in the Netherlands report the results of a three-year follow-up of a randomized controlled trial that compared three noninvasive treatments that included imiquimod and fluorouracil cream.\n\"Throughout the last two decades there has been a growing interest in these non-surgical therapies, which offer the possibility of avoiding surgery and reducing demands on busy medical practices.\"\nThe prognosis is excellent, but it can cause significant disfigurement by invading surrounding tissues.\nWhile most types of BCC require surgery, superficial BCC can be treated topically with noninvasive treatments such as PDT, imiquimod cream, fluorouracil cream, cryosurgery or electrodessication and curettage.\nThe three study groups had a similar distribution of baseline characteristics, with the exception of tumor size.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The study notes that several topical agents are available in addition to surgery. It might also have mentioned that surgery can be done as a one time thing and probably has better outcomes.", "answer": 1}, {"article": "Chicago (CNN) -- For the first time, patients with the deadliest form of skin cancer have two new treatment options that prolong survival, according to new research presented at a cancer conference in Chicago on Sunday.\nYervoy takes a while to work, and some patients may not have that time, study author Chapman said.\nThose taking vemurafenib had a 63% reduced risk of death compared to those on chemo.\nPatients with and without the BRAF mutation were eligible to participate.\n\"I've been doing this for 25 years, and we've not had drugs that extended survival.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Adequate job reporting the comparisons seen in the trials of the two drugs.", "answer": 1}, {"article": "We\u2019ve tested them in our polymers with very good results, we\u2019ve been able to get increased loadings of drugs in the polymer and we\u2019ve shown almost across the board that we can get a steady release rate of that drug from the polymer as well.\u201d\n\nThe team says TEPI patches could go on sale within three years, and Medherant is working with some large, unnamed, pharmaceutical companies to get them ready for market.\n\u201cWhat we do is dissolve the active ibuprofen, for example, into the adhesive so we can have quite a high loading - so up to 30 percent of the adhesive will be the ibuprofen,\u201d said Haddleton.\n\u201cWhen that\u2019s placed on the skin just like an elastoplast then the drug will actually diffuse across the skin into the body at the site of the pain and then relieve the pain in the same way as current gels and creams.\nAlthough TEPI patch remains highly tacky and adheres well to skin, it is not uncomfortable to peel off, unlike many traditional plasters.\nThe team says that popular ibuprofen gels make it difficult to control dosage and can be easily rubbed off.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was a decent amount of discussion about alternatives like ibuprofen administered orally or topically as a gel.", "answer": 1}, {"article": "LaCroix says her new study refutes that research and shows that older adults can still benefit at levels below the moderate-to-vigorous guidelines.\n\u201cBut what we have here is solid evidence that light physical activity reduces a woman\u2019s risk of dying over the next three to four years\u2014and we see the benefits are substantial and independent of moderate-to-vigorous physical activity.\u201d\n\nThe study could not show a cause-and-effect relationship between activity level and risk of death, only an association.\n\u201cIt\u2019s not one size fits all.\u201d\n\nBut national guidelines still recommend that adults over age 65 follow the same guidelines as younger people: to get at least 150 minutes of moderate-to-vigorous physical activity per week.\n\u201cThey throw up their hands and think, \u2018that\u2019s not for me.\u2019 But everyone does light physical activity, and the idea that doing more of it can have substantial health benefits should be welcome news.\u201d\nAnd recent analyses, compiled from studies in which adults self-reported their levels of physical activity, have suggested that older adults have to log moderate-to-vigorous exercise in order to reduce their risk of early death.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study compared different levels of physical activity. As such, it was comparative. However, there are other important lifestyle habits that affect mortality (cigarette smoking or drinking alcohol, for instance), and it would be interesting to know how helpful light activity is compared to these other lifestyle modifications.", "answer": 0}, {"article": "The Kelly study appears in the Oct. 5 online issue of the Journal of Epidemiology and Community Health.\nIn the U.K., women are advised not to drink at all during the first trimester of their pregnancy and to drink no more than a drink or two a week after that.\nMothers were first asked about their alcohol use when the kids were 9 months old.\nIndeed, many of the women included in the \"light drinkers\" group had no more than a drink or two during their entire pregnancy.\nThe children were last given a battery of behavioral and cognitive tests when they were 5 years of age.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story outlines the choices women make\u2026 stopping all drinking during pregnancy, reducing drinking, or continuing to drink as usual.", "answer": 1}, {"article": "A number of new multiple-sclerosis medications are beginning to hit the market that promise to make it easier for patients to control flare-ups of the disease and slow its progression.\n\nThe drugs, designed to be taken orally, represent a new generation of treatment for MS. Currently, people with the disease can choose from a range of drugs that are administered by injection.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe story gives us the existing alternatives (shots) and puts the new oral drug in perspective. The comment from neurologist Mark Keegan about why a patient might choose not to switch is very telling and might have been put higher in the story.\n\n", "answer": 1}, {"article": "Besides M.D.\nIn the last decade, hopeful of finding a better test, ovarian cancer researchers have invested much time in the investigation of other biomarkers and technologies.\nAnd if I can be saved, so can other people.\u201d\n\nThe study results were unveiled Thursday in advance of a major cancer conference next month.\nThe protein, known as CA-125, has not been good at identifying new early-stage ovarian cancer because it can become elevated for other reasons, leading to false positives.\nOvarian cancer, though rare, is the fourth-leading cancer killer among U.S. women.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is clear to say that there is no good existing screening method and that using CA-125 alone has been proven inneffective.", "answer": 1}, {"article": "The F.D.A.\nTimothy Anderson, pharmaceutical analyst at Sanford C. Bernstein & Company, said in a recent note that Entresto was \u201clikely to become a mega-brand over time\u201d but that the initial uptake was \u201clikely to be on the slower side given the entrenched nature of off-patent ACE inhibitors.\u201d He said it was highly unusual that there were no major competitors for Entresto on the way, giving it a \u201clong runway.\u201d\n\nIn a clinical trial with more than 8,400 participants, patients were randomly assigned to take either Entresto or enalapril, an ACE inhibitor.\nAfter about 27 months, 21.8 percent of those taking Entresto had either died from cardiovascular causes or had been hospitalized for worsening heart failure, compared with 26.5 percent for those taking enalapril.\nThe other ingredient, sacubitril, inhibits an enzyme known as neprilysin, a new mechanism of action for a heart failure drug.\nIt said there were also cases of angioedema, an allergic reaction that usually results in swelling of the lips or face but can be life threatening if swelling interferes with breathing.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does say that Entresto will be competing with generic versions of drugs called \u201cangiotensin-converting enzyme (ACE) inhibitors or somewhat similar angiotensin II receptor blockers.\u201d We\u2019ll award a Satisfactory on that basis. The story could have added value by making it clear that these drugs \u2014 or Entresto \u2014 would be used as part of a suite of treatments for heart failure. For example, depending on the cause of low, or reduced, heart ejection fraction (meaning your heart is not pumping out blood efficiently), treatment options may include surgically implanting a defibrillator, changes in diet and physical activity, or the prescription of other drugs (including betablockers or inotropes).", "answer": 1}, {"article": "Plum said that Epigenomics did not see its test as being necessarily in competition with the Exact Sciences test, because the blood-based test would be good alternative for people put off by stool testing.\nThere\u2019s a lot of hope for getting a stool-based test.\u201d\n\nPromising results for the blood-based tests were reported this week at a meeting in Barcelona, Spain.\nThe company reported Thursday at a meeting of the American Association for Cancer Research that in a trial of 1,100 patients, the test had detected 64 percent of adenomas, or polyps, larger than one centimeter in diameter, and 85 percent of cancers, as judged by the colonoscopies also given to the patients.\nBut the blood-based test may have a similar problem, since a positive signal could come from cancers anywhere in the body.\nThe specificity of the Exact Sciences test is 88 percent, meaning that 12 percent of the time the patient will be given a false alarm.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As noted in the \u201cbenefits\u201d criterion above, this story did not even discuss other stool tests like fecal immunochemical testing or other fecal occult blood tests that are currently available and have been shown to perform well in appropriate samples.\u00a0 It did a decent job in comparing two new technologies, but got hung up on this comparison while forgetting existing tests.\u00a0 In so doing, the end of the story devolves a bit into a \u201cmy product is better than your product\u201d tit for tat. Which is what can happen when your only quoted sources all have connections to the companies involved.", "answer": 0}, {"article": "\"Our concern is there are so many CT scans being done right now that we should really be starting to think: Do we need to all of these CT scans?\"\nMore than 4 million were in children.\nMake sure your doctor explains why you need a CT scan and gives you the lowest possible dose, reports LaPook.\nBut they put out a lot of radiation.\nSome experts say that estimate is overly alarming.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Two other scanning methods -MRI and ultrasound \u2013 were briefly mentioned.\u00a0 ", "answer": 1}, {"article": "That aching back is hard to fix, but here are a few things to try\n\nThese real-life cyborgs hack their bodies with chips, magnets and other tech\nSo it makes sense that Jay jumped at the chance to experience long-term pain relief with the help of a spinal-cord stimulator.\nAccording to the National Center for Health Statistics, an estimated 25.3 million Americans, or 11.2 percent of U.S. adults, experience chronic pain.\nShe also describes her path to spinal stimulation, how the device works with the body to short-circuit pain, and the many roadblocks to relief that patients face.\nBut the pain is far more controlled, and I can function much better at my current level of discomfort.\u201d\n\nAs the human and financial costs of the opioid crisis rise, spinal stimulation may become more popular, even though it\u2019s expensive.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story referenced Jay\u2019s use of \u201cpainkillers\u201d and states that spinal stimulation \u201cmay become more popular\u201d due to the opioid crisis. But it didn\u2019t compare the effectiveness, safety, or cost of spinal stimulation with the array of treatments available for back pain. Those treatments include not just opioids but over-the-counter medications, movement, cognitive behavioral therapy, acupuncture, spinal manipulation, and steroid injections.\nIn general, patients contemplating this procedure have already undergone many other treatments. Moreover, there as other treatments that could be done as alternatives. These would include non-invasive treatments such as interdisciplinary rehab, yoga, non-opioid pain meds and invasive treatments such as surgery and injections. More on the range of treatment Jay tried and other she considered would have been helpful.", "answer": 0}, {"article": "By comparison, the only approved long-term prescription weight loss medication available on the market today, Xenical, is associated with a seven-pound weight loss when combined with diet and exercise.\nTopamax is commonly used to treat migraines and seizures.\nAccording to the manufacturer's study, the two drugs, when taken together, and at controlled-release doses, were very safe.\nTwo existing drugs, in combination, have shown significant promise in promoting weight loss, according to a new report.\nAmong the 2,487 study participants, nine became pregnant, and none of their children were born with cleft palates, the report said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Adequate.\u00a0 The story stated:", "answer": 1}, {"article": "New clinical research published today in PLoS One shows that over-the-counter magnesium appears safe and effective to treat mild to moderate depression.\nIn addition, these positive effects were shown quickly, at two weeks, and the supplements were well tolerated and similarly effective regardless of age, sex, or use of antidepressants, among other factors.\nThe study participants, who were currently experiencing mild-to-moderate depression, had a mean age of 52, with 38 percent of them male.\nDepression presents an enormous disease burden, with a reported 350 million people worldwide suffering from the disease, but traditional SSRI treatments carry a burden of their own - in dollars and side effects.\n\"This is the first randomized clinical trial looking at the effect of magnesium supplementation on symptoms of depression in U.S. adults,\" says Tarleton.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release makes some statements suggesting magnesium supplements are as effective as SSRI anti-depressants and offer lower cost and fewer side effects. No evidence is offered for this and the study was far too small and too brief to demonstrate magnesium effectiveness.\u00a0\nThe release should have delved into this area more,\u00a0especially\u00a0because there are so many current treatments for depression. For example, the release offered no mention of other classes of anti-depressant medications or non-drug interventions like cognitive behavioral therapy.\u00a0\u00a0", "answer": 0}, {"article": "The other co-authors were from the CDC.\n\"This seems like a no-brainer to screen patients who have any of these additional risk factors,\" said lead author Dr. Matthew O'Brien, assistant professor of medicine at Northwestern University Feinberg School of Medicine.\nThe study showed that screening patients using an expanded set of risk factors, which the USPSTF suggests but does not formally recommend, would identify most cases of prediabetes and type 2 diabetes.\n\"This could be a particular problem for people of low socioeconomic status who are at high risk of developing diabetes and may be unable to pay for a screening test,\" O'Brien said.\nThe study was conducted collaboratively with the United States Centers for Disease Control and Prevention (CDC), using data collected every year from a nationally representative sample of U.S. adults.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Are there alternatives to \u201cscreening?\u201d That might be a philosophical question, but one has to ask if there is an overall health benefit to more intensive screening. We\u2019re told that \u201clifestyle programs and some medications have been proven to prevent or delay type 2 diabetes among adults with prediabetes,\u201d though that\u2019s a topic under debate by experts. We also learn that \u201ca large volume of research over the last three decades has demonstrated that treating type 2 diabetes prevents life-threatening complications such as heart attacks, strokes and kidney failure.\u201d But some experts argue that the only proven action that prevents complications are lifestyle changes. The majority of drug and insulin interventions come from trials showing that they can alter sugar levels, but there is very little evidence they prevent complications in type 2 diabetics.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - The inexpensive tests that look for hidden blood in a person\u2019s stool are effective for colon cancer screening, a study out Tuesday confirms.\nAdvances in the stool tests in recent years have made them more effective.\nIn this study, about 10 percent of all participants had a false-positive finding on the stool test.\nImmunochemical FOBT is now largely replacing the older test.\nPositive results on the screen prompt a follow-up colonoscopy to investigate the source of the blood.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Good comparisons between the newer FOBT test, the older stool test, and colonoscopy.", "answer": 1}, {"article": "This test might help.\nIn a subgroup of women, the test accurately classified 4 of 5 preterm deliveries as being at-risk, and incorrectly suggested that 3 of 18 women who had a full-term pregnancy were at risk for early labor.\nHowever, a new blood test \u2014 which is still experimental and not yet available outside of a research lab \u2014 can pick up on gene activity in the body that suggests a pregnancy is at risk for preterm delivery, according to a study published Thursday in the journal Science .\n\"Those molecules will circulate in the blood for some time, they can be measured, and you can see the contributions from essentially every tissue in the body,\" senior investigator Stephen Quake told BuzzFeed News.\nThe study was funded by the March of Dimes and other nonprofit sources, although Quake and his colleagues have filed for a patent on the test.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "BuzzFeed\u2019s story establishes early on that ultrasound tests are the go-to method for determining pregnancies that are at-risk for preterm delivery, among other complications. It also gives the accuracy of that test as a measure (48%) and compares it to the experimental test\u2019s accuracy (45%).", "answer": 1}, {"article": "(Reuters Health) - Leaving a bedroom door or window open may help people sleep better, a study from the Netherlands suggests.\nThe study participants were asked not to drink alcoholic beverages or caffeinated drinks, which could influence sleep.\nClosed environments tended to have less background noise \u2013 but they also had significantly higher carbon dioxide levels, which indicated lower ventilation levels.\nOverall, skin temperature and the bed temperature were higher in closed conditions than open conditions.\nThey also wore a sensor that tracked their movements at night, including indications of restlessness.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t provide alternative treatments known to improve sleep quality, such as establishing good sleep hygiene.", "answer": 0}, {"article": "This barrier works to protect the brain from toxins.\n\"GBM is one of the most aggressive of all cancers and it affects people of all ages,\" said Catherine (Bracken) Ivy, founder and president of The Ben & Catherine Ivy Foundation.\nIn addition, TGen laboratory research also found that PPF increases the effectiveness of a standard-of-care chemotherapy drug called temozolomide (TMZ), and radiation, to treat glioblastoma.\n\"Our data suggests that PPF, working in combination with TMZ and radiation, could limit glioblastoma invasion and improve the clinical outcome for brain tumor patients,\" said Dr. Tran, the study's senior author.\nOne of the fundamental challenges in treating brain cancer with drugs is what is known as the blood-brain barrier that separates circulating blood from the brain extracellular fluid in the central nervous system.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "While there are no truly effective treatments for glioblastoma multiforme, in this case it would have been helpful to compare this experimental approach to others being studied. In particular, the release could have noted that gene therapy, therapeutic vaccines, radio-labeled drugs and antibodies are also being tested, including tests in patients, an important contrast to this study, which was just a cell culture test.", "answer": 0}, {"article": "The website for LipoFuze says that the supplement \"increases the metabolic mechanism in your body.\" The site also says the green tea and caffeine will \"rev up your metabolism\" and \"increase energy, focus and physical performance.\" The site features testimonials it says are from users who claim they have lost huge amounts of weight with the help of LipoFuze. One man says he dropped more than 100 pounds, although it's unclear how long that took. A woman says she lost 40 pounds in less than a year, including 20 pounds in her first month.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "An independent expert says in the story:\n\u201c\u2026patients often ask about caffeine as a weight-loss aid. \u201cI tell them it\u2019s definitely not going to be as helpful as 30 minutes of exercise.\u201d (He) says a little caffeine before a workout might help a person exercise harder and longer, which could theoretically help them control their weight. But the real credit would go to the exercise, not the caffeine.", "answer": 1}, {"article": "Still, some researchers not involved in the study said the topic required more work.\nWe need more studies, funded by someone other than the company that makes the product.\u201d\n\nSmoking is the largest cause of preventable death in the United States, killing more than 480,000 Americans a year.\nThe smoking rate has declined substantially since the 1960s, but the pace of decline has slowed in recent years and health experts are trying to figure out how to get more smokers to quit.\n\u201cThe approach taken here is a very reasonable one that appears to have been successful,\u201d said Gary A. Giovino, a professor of health behavior at the State University of New York at Buffalo.\nThe practice is common for smoking cessation therapies, said Robert West, director of tobacco studies at University College London, who was among the study\u2019s authors.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We give the story credit for noting\u00a0that the \u201crates of quitting for smokers in this study who received the treatment and did not want to quit right away were about the same as those in previous studies of patients who wanted to quit abruptly.\u201d That\u2019s good context. However, the story does not mention that the competing drug bupropion (sold as Zyban and Wellbutrin) has also been shown to offer some benefit\u00a0in smokers who prefer to gradually reduce cigarette consumption over abrupt discontinuation. That\u2019s an important omission.", "answer": 0}, {"article": "Revenues from pharmaceutical and device corporations are available at http://www.\nThe international DAWN trial previously demonstrated that patients with a small area of irreversible brain damage and a large area of brain at jeopardy of being lost if the clot remains are more likely to recover with minimal disability if the clot is removed up to 24 hours after symptoms begin or were noticed.\nIt is already well-established that the benefit of clot removal declines each hour during the first 6 hours after symptoms are detected.\nThe current results demonstrate the importance of prompt imaging and treatment of patients with clot-caused stroke, even in those who wake up having experienced a stroke or who for other reasons are not identified in the first few hours after the onset of symptoms.\n\u2022 Available downloadable B-roll, animation and images to this news tip are on the right column of the tip link https:/\n\u2022 For more news at AHA International Stroke Conference 2018, follow us on Twitter @HeartNews #ISC18.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does a good job of explaining the comparison of doing the procedure between 6 and 24 hours after a stroke and not doing it. Theoretically, they could have compared the procedure to clot-busting medication which is sometimes used in these settings, but that would have been a different study altogether.", "answer": 1}, {"article": "But scientists also realized it could have other uses.\nAnd the population that could be most benefited by this could be post-menopausal women.\u201d\n\nCommenting on the research, Tim Speckor, Professor of Genetic Epidemiology at King\u2019s College London, U.K., says: \u201cIt\u2019s a nice mouse study that seems to work\u2014whether it works in humans is another matter.\u201d\nIt\u2019s a fairly dramatic effect.\u201d Mice also showed increased oxygen consumption, higher levels of physical activity and more heat production in beige fat (which dissipates energy around the body).\nAs a result, they started considering it as a potential treatment for osteoporosis, particularly in post-menopausal women\u2014a period when women lose bone mass fairly quickly.\nIn trials on mice, the antibody was found to increase bone mass and reduce adipose tissue (fat)\u2014and while human studies are some way off, the findings could lead to new treatments for weight loss and osteoporosis.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Given how far removed this is from clinical trials, much less a clearly defined treatment, it\u2019s very difficult to determine what the alternatives would be. For example, would we expect the story to list alternatives for osteoporosis treatment? Or for weight loss? Both? As such, we\u2019ll rate this not applicable.", "answer": 2}, {"article": "Although tenecteplase appears to be more effective for stroke patients, it's not approved for that use in the United States, according to Dr. Rohan Arora, director of stroke at Long Island Jewish Hospital in Forest Hills, N.Y.\nThe investigators found that 22 percent of the patients treated with tenecteplase had more than 50 percent of blood flow return to the brain, compared with 10 percent of those treated with alteplase.\nTHURSDAY, April 26, 2018 (HealthDay News) -- After a stroke, many patients are given the clot-busting intravenous drug alteplase, but another drug may be more effective, Australian researchers report.\nFor the new study, which did not receive drug company funding, Campbell and his colleagues randomly assigned 202 stroke patients to either alteplase or tenecteplase before surgery to remove clots.\nIn addition, tenecteplase is easier to give, requiring only a single injection, while alteplase requires an injection and an IV drip, he added.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story said tenecteplase is \u201ceasier to give, requiring only a single injection, while alteplase requires an injection and an IV drip.\u201d\nThat\u2019s sufficient but the story would have been stronger had it mentioned the option of simply proceeding with surgical removal of a clot, called a thrombectomy, without first giving either medication. All patients in this trial went on to receive mechanical thrombectomy regardless of which medication they received.", "answer": 1}, {"article": "The study was presented Monday at the annual meeting of the American College of Cardiology in Orlando, Fla.\n\"Based on our findings, we conclude that this new method of using blood pressure-lowering drugs was more effective and just as safe as current approaches,\" lead author Ruth Webster said in a news release from the American College of Cardiology.\nThe pill contains low doses of the three medications -- telmisartan, amlodipine and chlorthalidone.\nAmong those who took the so-called \"triple pill\" for six months, 70 percent had achieved their blood pressure targets, compared with 55 percent of those who received their usual care.\nTUESDAY, March 13, 2018 (HealthDay News) -- A pill that combines three blood pressure-lowering drugs improves people's chances of lowering their high blood pressure, researchers report.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As the story noted, the study compared the combination pill to \u201cusual care.\u201d However, the story doesn\u2019t state what \u201cusual care\u201d means.\nThe story should have explained what \u201cusual care\u201d meant and whether there were differences in the intensity of therapy between the groups. Maybe the intensity of usual care just needs to be increased.", "answer": 0}, {"article": "But, lead author Dr. Giacomo Koch said, \u201cWhat we found is that the improvement was more marked in those patients that were more impaired.\u201d\n\nKoch, from the Santa Lucia Foundation in Rome, told Reuters Health he thinks those patients with more severe problems would likely see a benefit outside of just test results.\nThe \u201creal\u201d magnetic stimulation group improved by about 16 percent right after the treatment and 23 percent at the later time point, while there was no significant benefit seen in patients given the fake stimulation.\nThe ideal option might end up being a combination treatment that involves stimulation in certain patients and other therapies that address a range of skills important for regaining function, Barrett added.\nBefore treatment, right after and another two weeks later, stroke patients were given tests to measure their visual-spatial skills, as well as attention and concentration.\nFor those with neglect, doctors typically prescribe cognitive rehabilitation, in which therapists teach skills and help the patient become more aware of the affected side of the body.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says that doctors typically prescribe cognitive rehabilitation for patients with post-stroke \u201cneglect\u201d symptoms, but that progress is often slow and the associated hospital stays costly.", "answer": 1}, {"article": "The scientists then ran each volunteer through a large array of physical and cognitive tests.\nBut science has not been able to establish definitively whether such changes result primarily from the passage of time \u2014 in which case they are inevitable for anyone with birthdays \u2014 or result at least in part from lifestyle, meaning that they are mutable.\n\u201cWe wanted to understand what happens to the functioning of our bodies as we get older if we take the best-case scenario,\u201d said Stephen Harridge, senior author of the study and director of the Centre of Human and Aerospace Physiological Sciences at King\u2019s College London.\nThe findings suggest that many of our expectations about the inevitability of physical decline with advancing years may be incorrect and that how we age is, to a large degree, up to us.\nOlder people tend to be quite sedentary nowadays, and being sedentary affects health, making it difficult to separate the effects of not moving from those of getting older.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story implies that the fountain of youth may be vigorous exercise in the amount described. But there is no attempt to say whether lesser amounts, or other types of physical activity, may have similar results or not. A reader may then say, \u201cWhat\u2019s the point? If I can\u2019t do that much, I shouldn\u2019t bother to get off the couch at all.\u201d Exercise is not an all-or-nothing activity. The authors could have provided a brief statement that it isn\u2019t clear whether lesser amounts of exercise may have similar or different results.", "answer": 0}, {"article": "http://jama.\nThere were no significant differences in other secondary outcomes: quality of life, pain, ankle motion, mobility, and patient satisfaction.\n\"Close contact casting was delivered successfully for most participants, substantially reducing the number of patients requiring invasive surgical procedures at the outset and additional operations during a 6-month period,\" the authors write.\nEditor's Note: The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.\nAmong older adults with an unstable ankle fracture, the use of a modified casting technique known as close contact casting (a molded below-knee cast with minimal padding) resulted in similar functional outcomes at 6 months compared with surgery, and with fewer wound complications and reduced intervention costs, according to a study appearing in the October 11 issue of JAMA.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release aptly compares this new treatment with traditional surgery, which has largely been abandoned due to high rates of malunion resulting in functional deficits in displaced ankle fractures. The release also briefly mentions traditional \u201chard\u201d casting.", "answer": 1}, {"article": "While studies have highlighted the short-term benefits of CBT, until now question marks have been raised about whether it can have long-term effects.\n\u201cThese findings on the longer-term benefits at seven years post-treatment are really exciting,\u201d Bhalotra said.\nReturning to the women and their children seven years later, researchers found that the treated mothers were still significantly less likely to be depressed than the control group.\nMore than 400 million people worldwide report episodes of depression, at a global cost of around \u00a3600bn in 2010.\nBetween 12% and 20% of women in the 35 countries in the Organisation for Economic Co-operation and Development suffer from perinatal depression, and 20-35% in poorer countries.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that people are often prescribed drugs for depression, and that CBT may be a better alternative.", "answer": 1}, {"article": "\"While reductions in [cardiovascular] death still trump these bleeding events, if rivaroxaban is approved, we should expect a number of bleeding events that will require medical attention,\" Hicks wrote.\nThe review came in briefing documents that were filed Monday in advance of an FDA advisory panel meeting Wednesday, at which the panel is to vote on whether to recommend approval of Xarelto for treating people with acute coronary syndrome (a group of conditions brought on by sudden reduced blood flow to the heart).\n\"While it is true that these bleeding events typically do not lead to death or irreversible harm, these events may represent the biggest problem for both patients and health care providers if rivaroxaban is approved.\"\nXarelto (rivaroxaban) is one of a new class of blood thinners that have been developed to overcome some of the problems that exist with the standard treatment, warfarin (Coumadin), which requires constant dose monitoring.\nPeople who took Xarelto -- and suffered from the most common type of atrial fibrillation and didn't have heart valve damage -- were about one-third less likely to experience bleeding in the brain than those who took warfarin, the investigators found.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Warfarin (Coumadin) is mentioned but no meaningful comparison is provided.\nAs we noted previously, the comments are out of context, not in the advisory document and relate to the use of the drugs in patients with stroke and not acute coronary syndrome.", "answer": 0}, {"article": "Wong acknowledged that the study's design had limitations, making it important that the findings be confirmed by additional research.\nThe research, published in today's Journal of the American Medical Association, is the first to directly examine what has become conventional wisdom: that many older men need not treat early prostate cancer because it tends to grow so slowly that they will probably die of something else first.\nThe findings prompted debate among specialists, who said the results could have potentially far-reaching implications because they address one of the central quandaries about prostate cancer and because the disease is so common.\nThe study of more than 44,000 American men ages 65 to 80 found that those who chose to aggressively treat their prostate cancer with surgery or radiation were about 30 percent less likely to die than those who waited, indicating that treatment offered a clear advantage.\n\"This debunks the idea that older men do not benefit from treatment,\" said Christopher L. Amling of the University of Alabama in Birmingham.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study does describe the three main treatment options for early prostate cancer: surgery, radiation, and observation.\u00a0 While more information about surgery or radiation may have been helpful, overall, the article does describe the main choices and especially provides context about where observation may fit into the list of choices.\u00a0 ", "answer": 1}, {"article": "The comparison groups in the experiments varied as well.\nThe medicine, though never approved for use in the United States, led to birth defects in some 10,000 kids in Europe and Canada.\nUnfortunately, medicines to relieve morning sickness have a checkered history.\nAlso, inconsistencies in methodology from study to study made it difficult to pool the results and draw firm conclusions.\nMost focused on the symptoms of nausea and vomiting, but they measured the symptoms at different times, she says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses many different treatments for morning sickness and\u00a0reports that they all lack good-quality evidence to support their use.", "answer": 1}, {"article": "See the Cartoons of the Week.\nFurther, Neal says, the findings apply not only to heart-disease risk but also to the risk of diabetes, since high cholesterol at a young age is a strong predictor of prediabetes and diabetes.\nBut because West Virginia has one of the nation's highest rates of death from heart disease, since 2000, the state has offered free, universal cholesterol screening to all fifth-graders enrolled in public schools.\n\"The weight of the child, his waist circumference and whether he has siblings who are overweight would help to select a group that is at greater risk of having high cholesterol,\" he says.\nThe question of how soon children should be screened for high cholesterol is becoming increasingly important in the U.S., with its rate of child obesity topping 20%.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story includes comments from an independent expert suggesting alternatives to universal cholesterol testing to identify children who may have elevated cholesterol levels. For children who are found to have high cholesterol, the story says doctors may advise lifestyle changes or drug treatment. However, the story fails to mention the lack of evidence that identifying elevated cholesterol in children is more effective at preventing the development of heart disease or other health problems than helping all children to maintain a healthy lifestyle and then waiting until adulthood to test cholesterol levels.", "answer": 0}, {"article": "Publicity in recent years about emotional, cognitive, and memory problems in aging football and hockey players who suffered multiple concussions during their careers has raised the anxiety level around the topic. A lawsuit by thousands of NFL players who claim the league did not keep them well enough informed about the long-term risks of concussion - dementia is one of them - is based in Philadelphia and has raised even higher the profile of what doctors call mild traumatic brain injury.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The treatment is put in context with other treatments.", "answer": 1}, {"article": "But tests of the concept since the late 1980s have been overwhelmingly disappointing.\nThe new report, however, is believed to be the first time that genetically engineered immune system cells -- specifically, T lymphocytes -- have produced the same effect.\nIn the study, Rosenberg and his colleagues took lymphocytes from the blood and inserted into them genes for a receptor capable of \"recognizing\" a protein on melanoma cells called MART-1.\nThe report, published online by the journal Science, is the latest result of a three-decade effort by surgeon Steven A. Rosenberg to find ways to manipulate the human immune system to fight cancer.\nFour years ago, Rosenberg and his colleagues treated a group of melanoma patients with naturally occurring anti-cancer cells extracted from their tumors, and some of those patients also have had long-term disappearance of their cancers.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no mention of the use of autologous tumor infiltrating lymphocyte treatment which, although effective in roughly half the patients for whom it is an option, is not a possibility for all patients. There was no mention of the surgery, chemotherapy, radiation therapy, and biologic therapy that are currently used in the treatment of melanoma. The story did not mention that at least some of these treatments were used in conjunction with the experimental treatment.", "answer": 0}, {"article": "Over the 12 month period, systolic blood pressure of people in the Web-based lifestyle counseling group decreased by 10 mmHg, while it decreased by 6 mmHg for the other group.\nYou don\u2019t need to go to a doctor in person for lifestyle counseling that can lower your blood pressure.\n\u201cNo one should die of hypertension.\n\u201cI am so happy to see this on the agenda for three main reasons.\nOne of the caveats of the study was that participants were highly motivated people looking for ways to cope with and decrease their blood pressure.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Because the participants were already taking high blood pressure medication, which would be the typical alternative to compare this non-drug intervention against, we\u2019ll rate this N/A.", "answer": 2}, {"article": "EMBARGOED UNTIL AUG. 14, 2017, AT 10 A.M. EDT\n\"They secrete tiny vesicles that are chock-full of signaling molecules such as RNA and proteins.\nOther laboratory rats from the same age group were assigned to receive placebo treatment, saline injections instead of stem cells.\nFrom cardiac imaging and advanced diagnostics to surgical repair of complex heart problems to the training of the heart specialists of tomorrow and research that is deepening medical knowledge and practice, the Cedars-Sinai Heart Institute is known around the world for excellence and innovations.\n\"Now we find that these specialized stem cells could turn out to reverse problems associated with aging of the heart.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Who\u2019s to say that lifestyle factors such as a good diet and robust exercise wouldn\u2019t do a good job of staving off the harms of aging more reliably than a costly stem cell procedure? That\u2019s not mentioned.", "answer": 0}, {"article": "Hare was not involved in the study.\nIt's the first time tissue-specific stem cells, other than bone-marrow cells, have been tested in humans, Hare says.\nIt's early -- results are in for only the first 16 patients -- but the results already are drawing praise from experts not easily impressed by first reports.\n\"This is a groundbreaking study of extreme importance,\" Joshua Hare, MD, director of the University of Miami's Interdisciplinary Stem Cell Institute, tells WebMD via email.\nThese adult stem cells already are committed to becoming heart cells, but they can transform into any of the three different kinds of heart tissues.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The experimental approach is not compared to existing alternatives. There is \n\n\n\na passing reference to \u201clifestyle changes and medical management\u201d. Were all of these patients taking the same medications and following the same diet and exercise routines prior to the study and during the study? What is currently the best course for the types of heart conditions these patients have? These are among the many questions not answered in the story.\n", "answer": 0}, {"article": "To learn more, visit njhealth.org.\nIt may seem strange to fight bacteria with more bacteria, but it could lead to a long-term solution for eczema patients\n\nEczema is the most common skin disease worldwide.\nThe next steps involve testing those different combinations, ensuring they're safe and conducting a longer trial to see if the benefits of bacterial cream can truly provide a permanent solution for eczema patients.\nExperts say there is more research to be done, but that the goal of the trial is to discover the best combination of bacteria to clear eczema from the skin and then make it available to patients as a prescription cream.\n\"What the cream does is help the skin gain back its natural balance and create that barrier needed to keep it healthy.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The article does well in mentioning two alternative treatments for eczema that can often prove problematic: antibiotics and corticosteroids.\nThere are a host of other treatment options as listed here.", "answer": 1}, {"article": "Bishop says the benefit of the FlexBar, which costs between $16 and $33, over traditional hand weights is that it helps people strengthen without recreating the symptoms.\nAnd he didn't want to give it all up due to a \"spot of pain\" in his elbow.\nAnd the FlexBar makes it simple to do this kind of stretch.\nHe says weights can overwork the muscle and sometimes leads to more pain.\nWhen Holzman came to Sport & Spine for help, Bishop put him through a series of traditional treatments including ultrasound, strengthening and stretching exercises, cross-friction massage, heat and ice.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions other treatment approaches to tennis elbow, including ultrasound, strengthening and stretching exercises, cross-friction massage, heat and ice.", "answer": 1}, {"article": "Autism is a group of complex brain developmental disorders characterized by impairments in social interaction, communication, and stereotypical and repetitive behaviours.\nThe next step in the research is to understand exactly how oxytocin changes brain circuitry to improve social behavior, and to document how related treatments might be used to boost established social learning interventions.\nThe diagnosed incidence is estimated to be one in 68 children and effective interventions remain limited.\nIt is also the first clinical trial investigating the efficacy, tolerability and safety of intranasal-administered oxytocin in young children with autism.\nThis is the first time a medical treatment has shown this type of benefit for children with autism and findings reinforce outcomes from a longer sustained program of research by this team.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release correctly states that behavioral therapies, the standard treatment for autism, are time-intensive, costly and sometimes offer minimal benefits.", "answer": 1}, {"article": "\"What we've had available the last 16, 17 years has made a big difference,\" Richert says, \"and what we have coming onboard now, these are going to make even a larger difference.\nHe has been free of MS relapses for several years now, an improvement that may be attributed to the drug Copaxone, one of a half-dozen drugs on the market now that can slow the course of MS.\n\nBabin says he is grateful for the drug \u2014 but he has to go through the painful process of injecting it every day.\n\"In reality, these are extremely potent pills that have the potential to cause a variety of serious side effects,\" he says.\nThat drug, called fampridine, does not prevent the nerve damage of MS, but in about a third of patients, it improves their damaged nerves, so they can walk better.\nEasier To Take, More Impact\n\nThis week's issue of The New England Journal of Medicine reports on two new drugs that can be taken orally to slow the progress of MS.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "For a short radio and web piece, the story did a good job of comparing the new drugs with injections (through the story of a patient\u2019s experience) and mentioning the problems with another MS drug Tysbari and mentioning another new oral MS drug that may be approved soon. ", "answer": 1}, {"article": "MONDAY, Dec. 17, 2012 (HealthDay News) -- For patients whose high blood pressure cannot be controlled despite taking several medications, a short burst of radio waves at the nerves around the kidneys may do the trick, a small new study says.\nThe procedure is safe as well as effective, the study authors said.\nThe findings could be a significant step in treating people with resistant hypertension, which is a major risk factor for heart attack and stroke, the researchers said.\nIf it is applicable, it could mean patients need not take blood-pressure drugs, Esler suggested.\nThe treatment was effective for at least six months.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The independent expert quoted provided important reminders about \u201cso many things that go into getting blood pressure under control\u201d \u2013 lifestyle, medications, adherence, etc.", "answer": 1}, {"article": "And now, a real pill for your unreal illness.\nBefore the trial, one 40-year-old, who said he had fears starting at age 10 that he was going to die in his sleep, rated his certainty that he was suffering from a serious illness as an 8 on a scale of 1 to 10.\nThe study found that hypochondriacs who got cognitive behavior therapy, which encourages people to challenge the validity of their disabling beliefs, also improved -- as much as those given the drug.\nAccording to the standard manual of mental disorders, hypochondriasis is a potentially serious condition that can prompt people to go doctor shopping, abuse sick time at work and become complete invalids.\nIn the first controlled study that compared a group of hypochondriacs given the drug with a group that got psychological talk therapy and another group that received sugar pills, the medication significantly reduced people's fears about imaginary illnesses.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The only options one could glean from the story were the use of cognitive behavioral therapy or the drug Paxil for management of hypochondria.\u00a0 There was no discussion of other medications that are used for this purpose, nor any other psychological approaches that are used.\nThe story mentioned \"a combination of this talk therapy and medication might be especially effective\" though the study on which this story was written contained no data on this combination and so this is pure speculation.", "answer": 0}, {"article": "There was still a benefit four weeks later.\n\"The amount of additional sleep was not tremendous,\" said Dr. Carl Bazil, director of the division of epilepsy and sleep at New York-Presbyterian Hospital/Columbia University Medical Center.\nThe most common side effects were sleepiness (reported by about 10 percent of patients on the two higher doses of suvorexant), headache (reported by about 5 percent), dizziness and abnormal dreams (5 percent).\nBut, he said, suvorexant is seen as a potentially important development in the world of sleep medicine, because the drug blocks specific brain chemicals called orexins, which help keep people awake.\nThe study, published online Nov. 28 and in the Dec. 4 print issue of the journal Neurology, included 254 healthy adults with primary insomnia, which means it wasn't caused by an underlying physical or mental health problem.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Strong ending that addressed this criterion:\nAnother sleep specialist said the findings show \u201csome potential benefit\u201d from suvorexant, but he cautioned insomnia sufferers against relying completely on any drug.\n\u201cMedication can be important,\u201d said Dr. William Kohler, who directs the Florida Sleep Institute in Spring Hill. \u201cBut in the long run, the best methods for treating insomnia are behavioral techniques.\u201d\nKohler said cognitive behavioral therapy \u2014 where people learn to change the thoughts and habits that affect their sleep quality \u2014 is a proven way to manage insomnia. For most people, he said, medication should be a temporary treatment; behavior change is the long-term fix.\nBazil agreed: \u201cI look at most people with insomnia as someone who developed bad sleep habits.\u201d\nA drug, ideally used for a short time, may help encourage sleep and get people on the right track, Bazil said. \u201cBut those bad sleep habits \u2014 you\u2019ve got to address them too,\u201d he added.\n\u201cThe problem,\u201d Kohler noted, \u201cis that we don\u2019t want to make behavior changes. We want to pop a pill.\u201d", "answer": 1}, {"article": "In a study suggesting that red wine might be the next big thing in breast cancer prevention, a study has found that women who drank just under two servings of red wine daily experienced hormonal changes that mimic the effects of a drug used to prevent malignant breast tumors from coming back.\n\nThe study, published Friday in the Journal of Women's Health, found that consuming the same amount of white wine did not have the same effect in premenopausal women participating in the study.\n\nWomen intent on warding off breast cancer have been warned about alcohol consumption: as recently as November, a study found that women who consumed as few as three servings of alcohol a week increased their risk of developing the disease, which strikes one in eight American women at some point in life.\n\nWhite wine and other alcoholic beverages are believed to promote the conversion of androgens--\"male hormones\" such as testosterone, which circulate in all women's blood--into estrogen. And the greater a woman's lifetime exposure to estrogen--whether her own or estrogen that comes from medication or environmental sources--the higher her risk of developing breast cancer.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compares red wine with the class of drugs called aromatase inhibitors.\nBut that class of drugs has a long track record.\nThis was a tiny, very short-term study of red wine.\nYet the story allowed the researchers to assert that \u201cthis this was the first rigorous study to find that red wine is a \u2018nutritional aromatase inhibitor in healthy premenopausal women.\u2019\u00a0 \u201d\nThat\u2019s a pretty bold comparison after such a preliminary finding.\u00a0 An independent expert probably would have challenged that, but the story didn\u2019t provide any such challenge.", "answer": 0}, {"article": "\"What we found was a very coherent pattern of less cervical cancer among people who\u2019ve used the IUD based on thousands of women \u2014 and the pattern wasn't subtle at all, it was stunning,\" Dr. Victoria Cortessis, the study's lead author and associate professor of clinical preventive medicine at the Keck School of Medicine at the University of Southern California, told BuzzFeed Health.\n\nIUDs are small, T-shaped devices that are placed in the uterus to prevent sperm from reaching an egg. They are a highly effective form of birth control and they can offer protection against pregnancy for up to three, five, or ten years.\n\nThe study is the first of its kind to combine and analyze data from multiple studies to look at the issue. \"We went through all of the relevant human epidemiological data on this topic and narrowed it down to 16 high-quality observational studies of over 12,000 women from all over the world,\" Cortessis says.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did a good job of comparing IUDs to vaccines and regular screening, even going into the details of when and how often each of those should occur, and making it clear that IUDs are not yet a proven option for cervical cancer prevention.", "answer": 1}, {"article": "People seemed to have mental health benefits from physical activity regardless of whether they reported working out to the point of exhaustion or barely breaking a sweat.\n\u201cGiven that the intensity of exercise does not appear to be important,\u201d the authors wrote in their paper, \u201cit may be that the most effective public health measures are those that encourage and facilitate increased levels of everyday activities, such as walking or cycling.\u201d\n\nOf course, there are other benefits to more frequent and more intense bouts of exercise.\nThe study could not prove a cause-and-effect relationship between exercise and the risk of depression, but the authors say it strongly suggests one\u2014especially because they controlled for other potential factors, including age, gender, social support, smoking, drinking and body mass index.\nThe paper, published in the , followed more than 22,000 healthy Norwegian adults without symptoms of anxiety or depression for an average of 11 years, asking them about their exercise habits and symptoms of depression and anxiety at the beginning and end of the study.\nIt\u2019s also possible, they add, that exercise may trigger changes in self-esteem, the release of mood-boosting endorphins and the production of certain proteins.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study does mention that exercise, if it is proven to have a positive effect on depression, should be used along with medications and counseling in people who already have been diagnosed.\nHowever, it does not discuss methods for preventing depression. Are there any? Even if there are none, that should be mentioned.", "answer": 1}, {"article": "WASHINGTON (Reuters) - It may be possible to predict which women will develop a dangerous complication of pregnancy called pre-eclampsia weeks before they ever show the first symptoms, an international team of researchers reported Monday.\nThere is currently no test to predict which women will develop pre-eclampsia, which is marked by high blood pressure and high protein levels in urine.\nWriting in the journal Hypertension, the researchers said they did a simple study, testing the blood of 60 women who developed pre-eclampsia later in pregnancy and 60 women who did not.\nThey found a series of 45 different compounds linked with metabolism that were different in the women destined to develop the condition, and said that could form the basis of a test.\nThe babies are usually born prematurely and suffer complications all their lives.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0The article made it clear there are no validated diagnostic tests for preeclampsia early in pregnancy. ", "answer": 1}, {"article": "To learn more about NAMS, visit http://www.\nThe study was completed in Tehran, Iran, where the average age of women at menopause is younger than in the United States: 48.2 years versus 51 years, respectively.\n\"This small pilot study found that, on the basis of a menopause-rating scale, twice-daily consumption of fennel as a phytoestrogen improved menopause symptoms compared with an unusual minimal effect of placebo,\" says Dr. JoAnn Pinkerton, executive director of NAMS.\nIts multidisciplinary membership of 2,000 leaders in the field--including clinical and basic science experts from medicine, nursing, sociology, psychology, nutrition, anthropology, epidemiology, pharmacy, and education--makes NAMS uniquely qualified to serve as the definitive resource for health professionals and the public for accurate, unbiased information about menopause and healthy aging.\n(fennel) on menopausal symptoms in postmenopausal women: a randomized, triple-blind, placebo-controlled trial\" is one of the first clinical studies to examine the benefits of fennel for managing menopause symptoms, even though it had been previously studied and confirmed to manage premenopause symptoms.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release cites hormone therapy (HT) as the most effective treatment for symptoms, while noting concerns about HT\u2019s potential side effects.\nA broader discussion about managing hot flashes (the most bothersome symptom for most women) by avoiding alcohol and spicy foods, wearing layers, and other interventions would have been helpful.", "answer": 1}, {"article": "Alzheimer's disease is the most common age-associated neurodegenerative disorder that has no cure.\n\"Taken together, our findings from these people confirm the data obtained with animal models and support, for the first time in human subjects, our notion that calcineurin inhibition has a protective effect on the development and possible progression and even reversal of Alzheimer's disease,\" said senior author Giulio Taglialatela, Professor and Vice Chair for Research in the department of neurology and director of UTMB's Mitchell Center for Neurodegenerative Diseases.\nThe UTMB research team and others have shown previously that this enzyme plays a central role in the harmful effects of the A\u03b2 oligomers and that elevated calcineurin is found in the nervous system of Alzheimer's patients.\n\"These data clearly show that the prevalence of dementia and Alzheimer's in our transplant patient group is significantly lower, in fact almost absent, when compared to national data from the general population,\" said senior author Luca Cicalese, professor in the department of surgery.\nAs part of the medical care for transplant recipients, any evidence of memory impairment or dementia is immediately noted and monitored, as it can limit treatment compliance among these patients.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The Alzheimer\u2019s association lists a host of strategies that may lower risk of developing dementia. \u00a0These include exercise, socialization, blood pressure control and the like. In addition, there is an ongoing randomized clinical trial of anti-amyloid drugs in high risk patients.", "answer": 0}, {"article": "Most minimally invasive prostate operations are robot assisted.\n\u201cThis paper,\u201d Dr. Hu said, \u201cdemonstrates that there are hidden risks for patients who opt for laparoscopic or robotic surgery.\u201d\n\nIn laparoscopy, a surgeon inserts instruments through small cuts in the skin instead of making large incisions to expose the organs.\nThe study, published on May 10 in The Journal of Clinical Oncology, examined a sample of 2,702 Medicare patients undergoing radical prostatectomy, the complete removal of the prostate, from 2003 to 2005.\nLaparoscopic operations for prostate cancer, a minimally invasive surgery that is in rising demand, result in fewer immediate complications and quicker recovery than the more common open procedure, a new study reports.\nThe widely advertised procedure is becoming more popular, said Dr. Jim C. Hu, the lead author of the study and an instructor in surgery at Harvard.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article, like the study upon which it is based, compares only two treatment options\u2013miniminally invasive laparoscopic surgery and traditional \"open\" surgery to remove the prostate.\nIt would have been helpful, but not necessary, to place these two approaches in the context of the many choices men with prostate cancer face based on age, severity, co-morbidities, personal preference and other factors.\u00a0 ", "answer": 1}, {"article": "\u201cThe findings were exciting,\u201d she said.\nIn coherent breathing, the goal is to breathe at a rate of five breaths per minute, which generally translates into inhaling and exhaling to the count of six.\n\u201cThey show that a behavioral intervention can have effects of similar magnitude as an antidepressant.\u201d\n\nControlled breathing may also affect the immune system.\nWhile the study was small and lacked a control group, Dr. Streeter and her colleagues are planning a randomized controlled trial to further test the intervention.\nIf you have never practiced breathing exercises before, you may have to work up to this practice slowly, starting with inhaling and exhaling to the count of three and working your way up to six.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No mention is made of other approaches to manage stress. Exercise, laughter, social support, meditation and mindful prayer, and stepping away from the problem have all been shown through research to reduce stress, according to the American Psychological Association, which notes that not every strategy works for every person.", "answer": 0}, {"article": "Dr. Senay said another study done in Stockholm, Sweden observed that the decline of patients with a very mild form of Alzheimer's Disease after they began taking supplements that contained two Omega-3 fatty acids.\n\"Those who moderately adhered to the diet had a 53 percent reduction in risk of developing Alzheimer's disease,\" The Early Show medical contributor Dr. Emily Senay.\n\"Those who most closely adhered to the Mediterranean diet had a 68 percent reduction in the risk of Alzheimer's disease.\nThe Mediterranean diet can vary from country to country but the foods consumed from Greece to Spain tend to be high in fruits, vegetables, fish, legumes, nuts, bread, pasta, cereals, potatoes and unsaturated fats like olive oil.\nHowever, it's probably not too soon to incorporate a lot of these thing we know are so healthful, lots of fresh fruits and veggies, olive oil.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is not advocating a treatment, per se, but a change in diet aimed at prevention of disease. Other prevention options for those at risk for Alzheimer\u2019s were not discussed. ", "answer": 0}, {"article": "Ulcerative colitis is a chronic inflammatory bowel disease.\nWEDNESDAY, May 3, 2017 (HealthDay News) -- A new study finds that people with moderate to severe ulcerative colitis who haven't done well on other treatments may find relief with Xeljanz (tofacitinib), a drug currently used to treat arthritis.\nThe first two trials looked at more than 1,100 patients with moderate to severe ulcerative colitis who had failed with conventional treatment or treatment with newer \"tumor necrosis factor antagonist\" drugs, such as Remicade (infliximab).\n\"Treatment with oral tofacitinib is potentially a new treatment option for patients with moderate to severe ulcerative colitis, pending review by the [U.S. Food and Drug Administration],\" Sandborn said.\n\"I am not going out on a limb and say this should be the first choice, because we don't have enough data to say that's the way it should be positioned.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This one is a close call. The story makes clear that Xeljanz is given in pill form, as opposed to infusion or injection, which is a point worth making. It also notes that the trials only involved patients for whom existing pharmaceutical treatments had failed. In addition, the story tells readers that patients don\u2019t develop antibodies to Xeljanz, as they do with other pharmaceuticals in the same class of so-called \u201cbiologic\u201d drugs.\nThe story does not, however, explain to readers why antibodies are important or relevant to the treatment process. The story\u00a0also doesn\u2019t mention surgical treatment options, which involve removing the colon and rectum. Ultimately, however, the story does a very good job of placing the drug\u2019s potential use in context. One source, for example, notes that there is still far too much uncertainty to recommend making Xeljanz the first line of treatment, while another describes it as a potential \u201crescue therapy\u201d when other options fail. Altogether, the story is more good than bad on addressing alternatives.", "answer": 1}, {"article": "Texas rep expects Trump to make case for a border wall at State of the Union\n\n\"We're going to keep working to secure the border, and not blink until we either get it done or the voters get to speak in 2020\"", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Tamoxifen is mentioned as the alternative to raloxifene.", "answer": 1}, {"article": "For more information, visit http://www.\nToday, the University, with an annual economic impact of $6.3 billion, serves more than 30,000 undergraduate and graduate students at sites throughout its six-county service region in southeast Florida.\nIn a new study published in the American Journal of Medicine, Charles H. Hennekens, M.D., senior author and first Sir Richard Doll Professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University, indicates that black and white women ages 75 to 84 years who had an annual mammogram had lower 10-year breast cancer mortality than corresponding women who had biennial or no/irregular mammograms.\nHennekens notes that further research is needed, but that in the future, the use of regular claims-based surveillance for mammography as a source of data may offer some unique advantages over self-reports.\nFrom 1995 to 2005, according to Science Watch, Hennekens was the third most widely cited medical researcher in the world and five of the top 20 were his former fellows and/or trainees.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The main alternatives to extending mammograms to this age group are: 1) no mammogram after age 74 or 2) patients/physicians deciding together to have mammograms based on the patient\u2019s history and risk factors.\u00a0The release should have urged women older than 74 to talk with their healthcare provider about continuing or ending screening. Instead, the first paragraph seems likely to frighten older readers into thinking they definitely need to continue mammograms.", "answer": 0}, {"article": "With this new approach, SD-101 is the match that starts the fire.\"\nThe research showed that using the immunotherapy drug pembrolizumab and the experimental agent SD-101, a sequence of nucleic acids that mimics a bacterial infection, altered the microenvironment around the tumor in a way that enabled the immune system to more effectively attack the cancer.\n\"We have found that the reason patients with metastatic melanoma do not initially respond to immunotherapy with an anti-PD-1 is that their immune system was not ready,\" said Dr. Antoni Ribas, the study's lead author, a professor of medicine at the David Geffen School of Medicine at UCLA and director of the UCLA Jonsson Comprehensive Cancer Center Tumor Immunology Program.\nThe results of the study suggest that the combination of pembrolizumab and SD-101 could provide an alternative treatment for people with melanoma whose tumors have not responded or would be unlikely to respond to other therapies.\nIn UCLA-led study, new treatment is more effective in people receiving immunotherapy for the first time\n\nA UCLA-led study has found that a treatment that uses a bacteria-like agent in combination with an immunotherapy drug could help some people with advanced melanoma, an aggressive form of skin cancer, live longer.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release describes a phase Ib study using a combination of Keytruda an experimental agent. The presumed alternative is Keytruda alone, and that\u2019s made relatively clear in the release. However, this was not a head-to-head trial of the two.", "answer": 1}, {"article": "Many older adults prefer psychotherapy to medication for the treatment of anxiety.\nThese two trends are inextricably linked in the area of geriatric mental health and our search for better, more effective treatments with greater reach.\u201d\n\nThe author made conflict of interest disclosure.\nEditorial: Solving the Geriatric Mental Health Crisis in the 21st Century\n\nIn a related editorial, Eric J. Lenze, M.D., of the Washington University School of Medicine, St. Louis, writes: \u201cTherefore, we are in the midst of the following two unprecedented trends: the aging of the population and the transformation of everything in our lives by mobile technology.\nTo place an electronic embedded link to this study in your story Links will be live at the embargo time: http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/jamapsychiatry.2015.1154 and http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/jamapsychiatry.2015.1306\n\nTelephone-based cognitive behavioral therapy was better at reducing worry, generalized anxiety disorder symptoms and depressive symptoms in older adults who live in rural areas, where access to mental health treatment may be limited, according to an article published online by JAMA Psychiatry.\nGeneralized anxiety disorder (GAD) is one of the most common anxiety disorders in older adults and is associated with poor quality of life, increased health care utilization and impaired memory.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release points out that the study focuses on older adults living in rural settings where psychotherapy may be unavailable.\u00a0 It also points out that older adults may prefer psychotherapy over medications. \u00a0We wonder about other approaches to address loneliness in the elderly, especially in rural areas, that could improve a person\u2019s quality of life.\n\u00a0", "answer": 1}, {"article": "\u201cIf used perfectly, how much HIV protection could there be?\nBut 1 in 3 infections were prevented overall \u2014 and that\u2019s huge.\u201d\n\nWarren noted that other rings with antiretrovirals are also being developed, as well as rings that could offer multipurpose protection, against not only HIV but pregnancy.\n\u201cThat individual control of prevention is so powerful.\u201d\n\nThe dapivirine ring has been in development for more than a decade, and the the new studies are the first to show that it prevents HIV transmission.\nBut it\u2019s now known that, when taken properly, Truvada cuts new cases of HIV by at least 92%.\nMuch like the contraceptive NuvaRing, the dapivirine ring should be kept in every day and replaced once a month for maximum effectiveness.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "A discussion of the alternatives is a real strength in the article. It mentions\u00a0other rings in development as well as the Truvada pill which offers some protection against HIV, and examines some pros and cons of the different methods.", "answer": 1}, {"article": "Still, with an infection that currently has no good treatment and leads to an estimated 275 million lost work days a year in the U.S., well, what a difference a day makes.\n\u201cBut giving zinc over a long period of time for prevention should be done very carefully,\u201d she told Reuters Health.\nThe bottom line: After seven days of treatment, those taking the supplements had less than half the chance of still being sick.\nAlthough the precise estimate is still uncertain, researchers found that people who started taking zinc-loaded lozenges or syrups within 24 hours of showing symptoms \u2014 a sore throat, say, or runny nose \u2014 shortened their cold by one day.\n\u201cI think one can give it a try,\u201d said Dr. Meenu Singh, a pediatrician at the Post Graduate Institute of Medical Education and Research in Chandigarh, India, who led the new work.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story didn\u2019t compare zinc to alternatives, which is a shame. People take many different drugs, supplements and home remedies to fight colds. We wish that even a few words had been given to the evidence for those treatments as well.\u00a0We would have liked to have seen some comment on the best ways to protect yourself and your family from getting a cold besides zinc products. A few words about hand hygiene and keeping your hands away from your eyes, mouth and nose would have been helpful to the readers", "answer": 0}, {"article": "Before undergoing surgery, cancer patients could be given the Zika vaccine to \"let the viruses hunt down the GSCs [glioblastoma stem cells] and eliminate them,\u201d said virologist Dr. Cheng-Feng Qin of the Chinese Academy of Military Medical Sciences in Beijing, who worked on the study.\nA vaccine against the Zika virus could one day be used to fight the deadly brain cancer that claimed the life of Senator John McCain, according to a study in mice.\nAs both the Zika virus and glioblastoma can affect the brain, the team hypothesized that the former could be harnessed to treat the latter.\n\u201cWe still need to further improve the specificity of the cancer-killing ability, while retain the safety of the vaccine strain,\u201d Shi explained.\nCurrently, most people diagnosed with the condition die within two years.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Normal cancer treatments such as radiation, surgery, and chemotherapy are mentioned, and described as not successful in the long run against\u00a0human glioblastoma brain cancer.", "answer": 1}, {"article": "Griebling said the American Geriatrics Society includes desmopressin in the Beers Criteria for potentially inappropriate medications for older adults, primarily because of concerns about resulting low blood sodium levels.\nThe researchers also found that those in the higher-dose spray group experienced a \"significant improvement\" in overall quality of life, compared with the untreated group.\n\"Nocturia is very common in patients over 50 years old, and can cause significant problems by causing loss of sleep, and injury due to falls,\" said study lead author Dr. Jed Kaminetsky.\n\"Other researchers have examined the utility and safety of desmopressin for the treatment of nocturia in the past,\" he said.\nThe new drug, while promising, is of concern because of its potential to lower blood sodium levels in the elderly, one doctor said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No other treatments for nocturia are mentioned in the story, although it says there are no drugs approved for its treatment.\u00a0 However, there are a number of behavioral approaches to treating nocturia that are not considered at all in this story, except for a passing reference to another paper on exercise.", "answer": 0}, {"article": "\"While ENDS may have the potential to benefit established adult smokers ... [they] should not be used by youth and adult non-tobacco users because of the harmful effects of nicotine and other risk exposures,\" says Tim McAfee, director the Office on Smoking and Health at the U.S. Centers for Disease Control and Prevention.\nThey do, however, provide nicotine more effectively than aids such as patches or gums, according to Bauld.\nBut as it seems e-cigarettes are here to stay, most calls are for informed regulation rather than prohibition.\nThat craving is caused by smoking tobacco but is now being increasingly satisfied by e-cigarettes and the trend to \"vape\" instead of smoke.\nHowever, further evidence on the long-term health effects of e-cigarettes or nicotine is needed.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not describe the efficacy of alternative smoking cessation methods (e.g. nicotine gum and patches), but it did at least mention some.", "answer": 1}, {"article": "\"Although alemtuzumab [Lemtrada] treatment is associated with safety risks, those risks are manageable in most patients,\" Miskin said.\nMoreover, patients receiving Lemtrada were 2.5 times more likely to have their thinking skills improve compared to those given interferon.\nAnd they were more than twice as likely to see improvement in their ability to move without tremor or clumsiness, the findings showed.\nBy the study's end, nearly 28 percent of those given Lemtrada had improved by at least one point on a 10-point disability test, versus about 15 percent of those receiving interferon, the researchers found.\nDuring the time when the immune system is depleted, there is a risk of infection over eight to 12 weeks, including herpes infections, he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This study was comparing the new drug against interferon beta-1a, though we don\u2019t get any sense of how it might have fared against the whole range of MS drugs currently being used.", "answer": 0}, {"article": "Five patients were previously diagnosed with colorectal cancer and one with cholangiocarcinoma.\nThe single-color digital PCR test offers several advantages over other methods of circulating tumor DNA analysis, compared to next-generation targeted sequencing and fluorescent probe-based digital PCR assays.\nThe main advantage is that the new technique does not rely on pre-amplification, which can introduce errors and biases.\nMoreover, the test's rapid turnaround and relatively low cost, especially compared to next-generation DNA sequencing, provide a potential opportunity for universal monitoring of more patients than is currently done,\" explained lead investigator Hanlee P. Ji, MD, Associate Professor in the Department of Medicine at Stanford University and Senior Associate Director of the Stanford Genome Technology Center.\nThe test, which is called single color digital PCR, requires only a fraction of a tube of blood and can detect as few as three mutation-bearing molecules in a single reaction.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release makes a glancing reference to \u201cother methods.\u201d It says, \u201cThe single-color digital PCR test offers several advantages over other methods of circulating tumor DNA analysis, compared to next-generation targeted sequencing and fluorescent probe-based digital PCR assays. The main advantage is that the new technique does not rely on pre-amplification, which can introduce errors and biases.\u201d This is not an adequate comparison.\nIt would have been helpful to mention specific blood tests for the tumor types looked at even in this small sample size\u2013this would have given context and why this work is important.", "answer": 0}, {"article": "Other side effects include a potentially fatal fluid build-up in certain areas of the brain.\nIn the United States alone, there are 5.4 million people with Alzheimer's disease, and the numbers are expected to increase to 13 million by 2050, when approximately three of every five people over the age of 85 will have Alzheimer's disease, she said.\nIf any of these drugs make it through the pipeline, it also needs to be determined who will get them, including whether the drugs will be given to prevent Alzheimer's in patients at high-risk of the disease or to treat it once it's started.\n\"This is problematic in that use of these treatments may carry a very high risk for neurologic complications, thus necessitating heightened monitoring, and diminishing its applicability as a treatment for a larger patient population such as the Alzheimer's disease population,\" she said.\nThe new study, which appears online Oct. 10 in the Archives of Neurology, is among the first to show the effects of an anti-amyloid drug in humans with Alzheimer's disease, but experts caution that while promising, more research is needed before this drug can be deemed safe or effective.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explained that \u201cThere are approximately one dozen therapies, including vaccines, for Alzheimer\u2019s disease that are currently in the pipeline\u201d \u2026and \u201cnone are ready for prime time.\u201d\nNice touch.", "answer": 1}, {"article": "The electronic nose detected nearly 90 percent of people with asthma compared to about 70 percent who were accurately diagnosed in the traditional way with lung function tests, according to new research published in the April issue of the journal Chest.\nEach test is non-invasive, requiring only the use of exhaled air.\nThese VOCs produce a unique smell print for each individual and specific patterns are seen in people with asthma.\nThose with asthma had a history of allergies, and none had been treated with corticosteroids for at least four weeks prior to the start of the study.\nWhen combined with another test, called the fractional exhaled nitric oxide (FENO) test, the electronic nose did an even better job at detecting asthma, the study found.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses current methods for diagnosing asthma including the physical exam, spirometry, and nitric oxide tests.", "answer": 1}, {"article": "(Reuters) - Shares of Evofem Biosciences Inc jumped as much as 38 percent on Monday after its birth control gel showed effectiveness in a late-stage study, bringing the first hormone-free contraceptive close to approval.\n\u201cOur research and current understanding of women suggests the time is now for there to be a new non-hormonal category in contraception,\u201d Chief Executive Saundra Pelletier said on a conference call with analysts.\nThe rate stands at about 91 percent for oral pills and intrauterine devices, according to brokerage Roth Capital Partners.\nCondoms, the most common non-hormonal method of contraception, have an efficacy rate of 82 percent.\nAn estimated 16.5 million women in the United States do not use any method of contraception, according to the company, on fear of side effects, leaving them highly susceptible to unwanted pregnancies and sexually transmitted diseases.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions other birth control products, such as male condoms and birth control pills.\nHowever, the story sharply misleads readers by claiming that the positive results with the gel brings: \u201cthe first hormone-free contraceptive close to approval.\u201d That\u2019s simply wrong. Current hormone-free products include male condoms, copper IUDs, diaphragms, and cervical caps.", "answer": 0}, {"article": "A compound in raspberries is being touted as the next new fat burner. But people looking to lose a few pounds may not want to go running to the produce aisle just yet. Scientists say there are no major human studies to support the idea that a berry holds the secret to weight loss.\n\nRaspberry ketones, the organic compounds that give raspberries their aroma, raised hopes as a weight-loss aid after a 2005 study by Japanese researchers found the ketones boosted fat-burning processes in rat cells in a laboratory as long as those...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There\u2019s no mention of any\u00a0evidence-based strategies\u00a0for\u00a0achieving and maintaining weight loss \u2014 a significant gap considering how useless these\u00a0ketones are likely to be.", "answer": 0}, {"article": "The Food and Drug Administration approved a new drug on Tuesday to treat serious cases of eczema.\n\u201cScratching leads to swelling, cracking, weeping clear fluid, and finally, coarsening and thickening of the skin.\u201d\n\nThere are many treatments out there now, from simple skin lotions to steroid creams and immune suppressant drugs like tacrolimus.\n\u201cThe most common side effects include injection site reactions; cold sores in the mouth or on the lips; and eye and eyelid inflammation, including redness, swelling and itching,\u201d the FDA notes.\nIt\u2019ll cost $37,000 a year but the drug\u2019s makers, Regeneron Pharmaceuticals and Sanofi, have stressed that\u2019s the wholesale price and make a point of saying there will be programs to help people pay for it.\nBut none of these works for everybody, and the immune suppressant drugs can raise the risk of cancers such as lymphoma.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story states:\nThere are many treatments out there now, from simple skin lotions to steroid creams and immune suppressant drugs like tacrolimus. But none of these works for everybody, and the immune suppressant drugs can raise the risk of cancers such as lymphoma.", "answer": 1}, {"article": "There are no previously approved therapies for TRAPS or HIDS/MKD.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe new indications are for rare and serious auto-inflammatory diseases in adult and pediatric patients:\n\nAll three syndromes are hereditary diseases that are characterized by periodic attacks of fever and inflammation, as well as severe muscle pain.\n\u201cFor the first time, patients with TRAPS and HIDS/MKD, two painful and life altering diseases, have access to a treatment that may help improve their quality of life,\u201d said Badrul Chowdhury, M.D., Ph.D, director of the Division of Pulmonary, Allergy and Rheumatology Products in FDA\u2019s Center for Drug Evaluation and Research.\nThe agency is also responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Even if there are no approved drugs for these indications, surely there is some sort of therapy that patients suffering from them are prescribed, even if it\u2019s limited to palliative care. To leave out details on how patients with these rare disorders are currently treated does a disservice to the readers.", "answer": 0}, {"article": "Surgical removal of cancerous tissue also can spur the spread of cancer in the body.\nWhile there are drugs given to patients after surgery to prevent cancer cells from adhering to each other or other tissues, these drugs do not rid the body of cancer cells or collect them to allow an assessment of the patient\u2019s status.\n\u201cThis method is effective for both diagnosing and treating metastasis cancer and can be used in combination with traditional chemotherapy and radiation therapy,\u201d he added.\n\u201cWe have made a nano-sized device that we can put under the skin using an injection needle to recruit the cancer cells into a small area where we can treat them with less overall side effects to the whole body,\u201d Tang said.\nCurrently, there are many treatments for primary tumors but they do little to prevent metastasis and stray cancer cells from relocating to another part of the body.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release offers only the broadest possible language regarding diagnosis and treatment of metastasizing cancers. We appreciate that it would be impossible to provide a detailed overview of the existing diagnosis and treatment options in a news release. However, we would expect some discussion of how the \u201ccancer trap\u201d would compare to existing techniques and technologies. This is missing.", "answer": 0}, {"article": "Did I feel guilty for potentially contributing to the development of a superbug?\nThe studies also noted that the use of antibiotics must be weighed against the risk of antimicrobial resistance, to which prescriptions for childhood maladies such as ear infections are thought to contribute mightily, and against antibiotics' side effects, which can include diarrhea and eczema.\nNow two new studies (bolstered by an accompanying editorial) in the New England Journal of Medicine demonstrate what we parents have suspected for years: When it comes to ear infections, antibiotics are in order.\nCurrent practice guidelines for treating kids' mild middle-ear infections -- or acute otitis media -- call for watchful waiting, to be followed by antibiotics only if symptoms worsen or don't cease.\nBoth show that antibiotics are more effective than placebos in relieving ear-infection symptoms such as fever, poor appetite, decreased activity and irritability and suggested that their benefits warrant their being administered early on, regardless of the seeming severity of a child's symptoms.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story does note that more than half of children got better in one of the studies even though they didn\u2019t receive antibiotics, the story doesn\u2019t give a fair hearing to \u201cwatchful waiting\u201d or explain why it is recommended as an option for\u00a0some children with ear infections. According to data presented in these guidelines,\u00a0\u00a0antibiotics\u00a0shorten ear infections\u00a0by one day in 5% to 14% of children,\u00a0but the\u00a0majority of children will\u00a0get better without them. Antibiotics also lead to side effects in 5% to 10% of children, infrequent serious side effects, and\u00a0may contribute to antibacterial resistance. Provided with this full information,\u00a0different parents may make different choices about whether to treat their children immediately with\u00a0antibiotics for an ear infection.\nCNN, by comparison, ended its piece with a strong take-home message about the shared decision-making conversation parents should now have with their pediatricians. ", "answer": 0}, {"article": "But, she adds, epidemiological studies consistently show positive health effects from fish consumption on mortality, cardiovascular risk factors and, now, dementia.\nThe finding that DHA alone reduces risk, the authors write, is consistent with earlier data showing high levels of DHA in healthy brain tissue and low levels in the brains of people with Alzheimer\u2019s disease.\nThe average level of DHA among all the participants was 3.6 percent of all fatty acids, and the top 25 percent of the population had values above 4.2 percent.\nIn fact, fish intake accounted for less than half of the variability in DHA levels.\nThe study was financed in part by Martek, a concern that manufactures DHA, and one author received a grant from Pfizer, France.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story did not mention the lack of evidence-based measures to prevent Alzheimer disease.\u00a0 A brief statement about lack of strong evidence would help guide readers in this regard.", "answer": 0}, {"article": "Funding for the study was provided by F. Hoffmann-La Roche and Biogen Idec.\nThe result: at week 24, all of the patients receiving either dose of ocrelizumab fared better in terms of lesion count than either the placebo or standard treatment groups.\nThat said, Dr. Moses Rodriguez, a professor of neurology and immunology at the Mayo Clinic in Rochester, Minn., disputed the premise that ocrelizumab is shaping up as anything new and innovative.\nThe investigators further noted that even eight months after treatment launch, no serious adverse effects were directly attributable to the new drug.\nThe number of active lesions had dropped 89 percent more among the 600-mg group compared with those getting a placebo.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We only had the Mayo expert\u2019s broad comments comparing ocrelizumab and rituximab \u2013 but no comparative data on benefits and harms were provided.", "answer": 0}, {"article": "It affects cells that play important roles in helping the immune system battle bacteria, viruses and fungi that can cause infections.\nThat means an actual cure for the disease, said Kohn, who is also director of the Human Gene Medicine Program at UCLA.\nSo far, the treatment has restored immune systems in all 23 patients in the most recent clinical trials, including Evangelina.\nThe Vaccaros turned to Dr. Donald Kohn at the Broad Stem Cell Research Center at UCLA, where Kohn focuses on the development of new methods to treat genetic diseases of blood cells.\n\"Those stem cells are given back to the patient where they can go back to the bone marrow and make the blood cells for the rest of the patient's life,\" Kohn said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Most children with SCID receive a bone marrow transplant or receive weekly injections of ADA. This fact was not noted in the story. In addition a quick check of ClinicalTrials.Gov uncovered several new approaches that are technically different from that of the story. In addition, drug companies are working on the development of other approaches to this form of SCID.", "answer": 0}, {"article": "\"The protection started at more than 45 grams [about 1.5 ounces] a week,\" says researcher Susanna C. Larsson, PhD, of the Karolinska Institutet in Stockholm, Sweden.\nThe group eating the most chocolate got the most benefit, reducing stroke intake by 20%.\nIn this group, the median intake (half ate more, half less) was about 2.3 ounces a week.\nThose who ate the most chocolate were protected a bit more from strokes caused by hemorrhage than strokes caused by obstruction such as blood clots.\nLarsson isn't sure why.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story could have included a line about other, more established methods of preventing cardiovascular disease, but didn\u2019t.", "answer": 0}, {"article": "She tried decongestants, antihistamines and steroid nasal sprays.\nIt comes from the fiber-optic tip of Metson's endoscope, which also holds a high-res camera lens.\nShe rinsed out her sinuses faithfully with saltwater.\nBut they can't stop the inflammation some people are prone to, and that inflammation can cause new obstructions.\nBecause I think it's made enough of a difference that I'm glad I did it,\" Foreman says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u2019s sidebar\u00a0gives detailed descriptions of alternatives to surgery, including nasal irrigation and corticosteroid nasal sprays.", "answer": 1}, {"article": "Thousands of heart-failure patients die each year because they aren't able to get a transplanted organ. Now, many medical experts are touting the benefits of a new mechanical pump that gives a patient's own heart a new lease on life.\n\nPatients surgically implanted with the new pump, known as a left-ventricular assist device, or LVAD, had a survival rate of 58% after two years, according to a recent study. That's not as good as a heart transplant, which offers a survival rate of about 70% after 10 years. But it surpasses the...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compares the Heartmate II with earlier versions of the same device and with heart transplantation. \nBecause the story is about seriously ill patients for whom other treatments have failed, there is no need to describe the drug and lifestyle interventions used to manage heart failure. \nIt would have been useful, but not necessary, to mention other experimental surgeries and devices for advanced heart failure. ", "answer": 1}, {"article": "Dr. Neu said the broad-spectrum antibiotics prescribed to the mother before a surgical delivery were another concern; the antibiotics can be transmitted to the baby through breast milk if not before birth, decreasing the diversity of natural bacteria.\nThe theory is that maternal microbes \u201ctrain\u201d the infant\u2019s immune system, so it doesn\u2019t overreact or become destructive and precipitate autoimmune disorders like Type 1 diabetes.\nDuring labor, a newborn absorbs maternal microbes into its mouth and gastrointestinal tract, said Dr. Josef Neu, a neonatologist at the University of Florida who has written about C-section babies and the hygiene hypothesis.\nThe research looked at all full-term, firstborn births in Scotland over a 15-year period and tracked the babies\u2019 long-term health.\nThe biggest difference between babies born by scheduled and unscheduled C-section appeared in risk for Type 1 diabetes.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did a careful job of comparing the different delivery methods.\u00a0There could have been perhaps a little exploration about recovery time and adverse events in the moms who have c-section.", "answer": 1}, {"article": "Quantity surveyor Alex Laws was part of the Newcastle University clinical trial and is delighted with the results of the study.\nHowever, for the first time, a clinical trial has revealed metformin can promote a patient's ability to repair their own damaged blood vessels by increasing vascular stem cells.\n\"The results, which indicate that metformin, a drug commonly used in the treatment of Type 2 diabetes, could also have a powerful effect in people with Type 1 diabetes is unexpected.\nAlex said: \"I was keen to be part of the clinical trial as I know how important research is into helping people with the condition - I previously worked in the medical research field.\n\"For the first time, this study has shown metformin has additional benefit beyond improving diabetes control when given to patients with relatively well controlled Type 1 diabetes.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are no mentions in the release of possible alternatives to metformin as a means to reduce the risk of cardiovascular disease in type 1 diabetes patients. It would be of interest to patients to know if intensive dietary and exercise counseling had been studied and what the results were.", "answer": 0}, {"article": "But he also emphasized the structured nature of the program tested in his study.\nThe problem, Spira said, is that behavioral therapy for sleep problems is not always easily found -- and even when it's available, the process takes some effort.\nBy the end of the study, the mindfulness group was showing a significant improvement -- shaving about three points, on average, from their scores on the sleep-problem scale.\nOn average, the effects of the mindfulness program were comparable to what's been seen in studies of sleep medications and \"talk therapy,\" said study leader David Black, an assistant professor of preventive medicine at the University of Southern California, in Los Angeles.\nIn general, \"mindfulness\" practices encourage people to focus their attention on the present moment, instead of the past or future, and to take an objective look at their thoughts and emotions.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This aspect of the story was great.\u00a0In the fifth sentence, the story makes a comparison to alternatives, saying, that on \u201caverage, the effects of the mindfulness program were comparable to what\u2019s been seen in studies of sleep medications and \u2018talk therapy.\u2019\u201d it makes the same comparison in more detail later in the story and in discussing the availability of different therapies.", "answer": 1}, {"article": "Orchard and her colleagues found a correlation only between high-inflammatory diets and fracture in younger white women in the study.\n\"This suggests that a high-quality, less-inflammatory diet may be especially important in reducing hip fracture risk in younger women,\" the researchers wrote.\n\"By looking at the full diet rather than individual nutrients, these data provide a foundation for studying how components of the diet might interact to provide benefit and better inform women's health and lifestyle choices,\" said Jackson, who is national chair of the Women's Health Initiative steering committee.\nWomen with the least-inflammatory diets (based on a scoring system called the Dietary Inflammatory Index) lost less bone density during the six-year follow-up period than their peers with the most-inflammatory diets.\nBut in the study group overall, more-inflammatory diets were not linked to fracture and - in fact - the researchers found a modestly lower risk of lower-arm and total fracture in women with the highest dietary inflammation scores.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not go into any depth about the different diets being studied, but it does explain that different diets with different levels of inflammatory components had different degrees of impacts on bone density.\nIt states early in the release that \u201cvegetables, fruits, fish and whole grains\u201d are beneficial but it would be nice to see more focus on specific foods and even specific diets considered to be pro- or anti-inflammatory so that readers could compare and contrast different diet patterns.\nThese different food types were not described in the research publication either, but in these cases, we encourage PR staff to seek clarification from the investigators.", "answer": 1}, {"article": "CHICAGO -- The diabetes drug Actos was able to slow the progression of plaque buildup in artery walls, while an older diabetes drug failed to stop the progression in patients with diabetes and coronary-artery disease, according to a study released Monday.\n\nUntil now, no diabetes-therapy regimen has been shown to reduce the progression of coronary atherosclerosis within the arterial walls among patients with Type 2 diabetes, a disease characterized by high blood-glucose levels that result from the body's inability to use insulin.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the study mentions glimepiride as an alternative to Actos, it does not mention other options nor does it discuss the pros and cons of the alternatives. In particular, it would have been nice to know if any of the other classes of medications used to control glycemia are associated with reductions in plaque formation.\u00a0 ", "answer": 0}, {"article": "A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, brain injury, Parkinson's disease and epilepsy.\n\"While such changes may be detected with MRI, we believe there may be a less expensive and portable way to measure these changes with a transcranial Doppler (TCD) device.\"\n\"This important work provides insight into a tool that may yet prove useful in the recognition and management of concussion,\" said Jeffrey Kutcher, MD, FAAN, with the The Sports Neurology Clinic in Brighton, Michigan.\nThis is in contrast to traditional TCD ultrasound measurements like change in cerebral blood flow reactivity which differentiated between the two 60 percent of the time, average blood flow speed which differentiated 55 percent of the time and blood flow resistance which differentiated 53 percent of the time.\nVANCOUVER, British Columbia, April 13, 2016 /PRNewswire-USNewswire/ -- Mapping blood flow in the brain of athletes using an advanced form of ultrasound may make it easier to more accurately recognize concussions, according to a study released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Existing strategies to detect changes in blood flow in the brain\u2014magnetic resonance imaging (MRI) and \u201ctraditional\u201d transcranial Doppler devices\u2014are compared to the advanced version of TCD ultrasound tested here.\nHowever, we think the criteria here was just marginally met. An alternative for diagnosing concussion not discussed is evaluating clinical signs and symptoms, the typical method for classifying a head trauma as a concussion or not. We do not know whether doppler ultrasound is a better predictor of long-term problems than clinical signs and symptoms.", "answer": 1}, {"article": "Contact Professor Ole G. Mouritsen, head of Centre for Biomembrane Physics (MEMPHYS) at University of Southern Denmark, head of center Taste For Life, President of the Danish Academy of Gastronomy.\nWe think this knowledge should be available for society and also be put to use\", says Mouritsen.\nDespite these warnings, you can buy dried hijiki in many stores.\nThe men's reaction was that the bread tasted acceptable as long as the seaweed content was kept under 4%.\nNovember 16, 2015.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "No alternatives are discussed. In fact, why not simply talk about less salt instead of salt substitutes. The seaweed being added is at such a marginal percentage as to beg the question: why bother?", "answer": 0}, {"article": "Abagyan says it's still possible, though unlikely, the effect could be due to a still unidentified confounding factor.\nThe study, published May 3 in Scientific Reports, also uncovered antidepressant effects for three other drugs typically used for other purposes -- Botox, the pain reliever diclofenac and the antibiotic minocycline.\nThe researchers hypothesize that the antidepressant effects of diclofenac and minocycline may be due, at least in part, to their abilities to reduce inflammation.\nThe team found that the incidence of depression symptoms in patients who took ketamine in addition to other pain therapeutics dropped by 50 percent (with an error margin less than 2 percent) compared to the patients who took any other drug or drug combination for pain.\nAccording to Abagyan, it is possible that another factor common to patients taking ketamine was driving the antidepressant effect, such as the fact that ketamine also relieves pain.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes that depression is currently treated with \u201cfive classes of antidepressants, most commonly serotonin uptake inhibitors.\u201d\nThe release could also have included psychotherapy and other common non-pharmaceutical therapies for depression.", "answer": 1}, {"article": "MORE: You Asked: Should I Take Probiotics?\n\u201cThey seem credible to me, and they might hint that there are other mechanisms, besides just inflammation, linking the GI tract to the brain,\u201d he says.\nThe study\u2019s findings need to be confirmed in larger independent trials, and McIntyre says he wouldn\u2019t yet recommend taking a probiotic for symptoms associated with mental disorders like depression or anxiety.\nThat\u2019s why Dr. Roger McIntyre, professor of psychiatry and pharmacology at the University of Toronto, thinks the fMRI findings are the most interesting and important aspect of the new study: they signal that the probiotics may really be working on the brain itself.\nWhen people in the study were given functional MRI scans, the researchers found that improved depression scores were associated with changes in activity of several brain areas involved in mood regulation.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does address another type of probiotic,\u00a0lactobacilli,\u00a0noting that previous research has found the type of probiotic used in the current research,\u00a0bifidobacteria,\u00a0to be better at improving gastrointestinal symptoms.", "answer": 1}, {"article": "Repatha, with a list price of more than $14,000 a year, was approved based on its ability to dramatically lower \u201cbad\u201d LDL cholesterol in patients who require more intensive therapy on top of widely-used statins, such as Lipitor, or who are unable to tolerate statins.\nThe trial was widely expected to be positive, especially after a smaller study presented in November showed Repatha therapy led to regression of artery-clogging plaque, an underlying cause of heart disease.\nAt the heart meeting in March, researchers will also provide details on risk reduction for each of the components, such as non-fatal heart attack, non-fatal stroke, and heart-related death.\nThe data should pave the way for greater acceptance by health insurers and pharmacy benefit managers, who have been rejecting about 75 percent of prescriptions written for the expensive medicine despite multiple appeals by physicians.\n\u201cThese results show unequivocally the connection between lowering LDL cholesterol with Repatha and cardiovascular risk reduction, even in a population already treated with optimized statin therapy,\u201d Amgen research chief Sean Harper said in a statement.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are no alternatives to the use of Repatha mentioned in the story although it does mention that patients in the clinical trial already were being treated with \u201coptimized statin therapy.\u201d \u00a0That\u2019s not enough to give readers any firm sense of what the alternatives are and how well they work. There is no mention of diet or exercise or any other treatment approach.", "answer": 0}, {"article": "The other 10 received a fake treatment.\nDuring transcranial magnetic stimulation (TMS), a doctor places a large magnetic coil against the patient\u2019s scalp, which creates electric currents to stimulate nerve cells.\nThe tests also measured activities of daily living affected by neglect, such as dialing numbers on a phone, reading a menu, and sorting coins.\nResearcher Giacomo Koch, MD, PhD, of the Santa Lucia Foundation in Rome, Italy, and colleagues point out that the changes could be the combined effects of the mental tasks and the TMS.\nThis condition often occurs after a stroke on the right side of the brain and is typically treated with a combination of physical therapy and brain retraining or mental tasks using a pen and paper or computer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says that \u201cneglect\u201d symptoms after stroke are usually treated with\u00a0cognitive and physical therapy,\u00a0but that this is \u201coften not enough to make a meaningful improvement.\u201d Later, however, it quotes an expert who says that this kind of rehab alone \u201ccould and should be enough to treat this kind of stroke.\u201d Well, which one is it? We\u2019ll give the story credit for addressing this criterion, but wish there had been a bit more clarity on the effectiveness of standard rehab.", "answer": 1}, {"article": "COPENHAGEN (Reuters) - Merck & Co scored a double hit on Sunday with new clinical data showing its Keytruda immunotherapy offered big benefits in previously untreated lung cancer patients, either when given on its own or with chemotherapy.\nThe various findings suggest that treating lung cancer - the biggest cancer killer globally - with powerful new immune system-boosting medicines is going to involve more permutations than some experts originally expected.\nIn the event, researchers reported that Merck\u2019s combination cut the risk of disease progression or death by 47 percent compared to chemotherapy alone after 10.6 months, while 55 percent of patients saw their tumors shrink versus 29 percent.\nAn editorial in the New England Journal of Medicine, where the Merck monotherapy results were published, said Keytruda could become \u201ca new standard of care\u201d.\nIt was a major setback for Bristol, wiping out around a quarter of the company\u2019s market value, and it has caused investors to rethink prospects for immunotherapy treatments.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The primary message of this story is that Keytruda is superior to standard chemotherapy, as well as to another immunotherapy drug, marketed by Bristol-Myers Squibb, which was also approved by the FDA in 2015.", "answer": 1}, {"article": "Nov. 22, 2010 -- Exercising to piano music may help improve balance and prevent falls among the elderly.\n\nA new study shows older men and women who participated in a piano-music-based exercise program were less likely to suffer a fall than those who didn't. Those who exercised to piano music also showed improvements in balance and the manner or style of walking.\n\n\u201cEach year, one-third of the population 65 years and older experiences at least one fall, and half of those fall repeatedly,\u201d write researcher Andrea Trombetti, MD, of University Hospitals and Faculty of Medicine of Geneva, Switzerland, and colleagues in the Archives of Internal Medicine. \u201cExercise can counteract key risk factors for falls, such as poor balance, and consequently reduce risk of falling in elderly community-dwelling individuals.\u201d\n\nResearchers say a large proportion of falls in elderly people occur while walking, so improving gait and balance can have a major impact on fall prevention.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not put this trial in any context with the existing evidence on other types of physical activity or other methods of reducing the risk of falls by older people. \n", "answer": 0}, {"article": "\"LaVonne has had Alzheimer's disease longer than anybody I know, and that sounds negative, but it's really a positive thing because it shows that we're doing something right,\" Moore said.\nDeep brain stimulation is already used to treat some cases of Parkinson's disease and certain other brain disorders.\nWhen she entered the study, she was not preparing any meals.\nAnd those issues have a huge impact on daily life, for patients and their caregivers, Scharre added.\nThat patient was LaVonne Moore, 85, of Delaware, Ohio.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that \u201cmedications for Alzheimer\u2019s target brain chemicals involved in memory.\u201d", "answer": 1}, {"article": "SILVER SPRING, Md., May 18, 2016 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma.\nThis is the first product in its class (PD-1/PD-L1 inhibitors) approved to treat this type of cancer.\nThe safety and efficacy of Tecentriq were studied in a single-arm clinical trial involving 310 patients with locally advanced or metastatic urothelial carcinoma.\nIn all patients, 14.8 percent of participants experienced at least a partial shrinkage of their tumors, an effect that lasted from more than 2.1 to more than 13.8 months at the time of the response analysis.\n\"Tecentriq provides these patients with a new therapy targeting the PD-L1 pathway,\" said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not give us very much information about alternatives. These patients had already received other therapy and their cancer had recurred, so it is implied that they had no other alternatives. But this isn\u2019t stated very clearly. We can assume (and it seems evident) that the platinum-based therapy that the patients didn\u2019t respond to initially is the usual treatment.", "answer": 1}, {"article": "An expert who wasn\u2019t involved in the research echoed the cautions.\n\u201cThey wanted to know where they could get (the hormone) after the study was over.\u201d\n\nBut that\u2019s jumping the gun, she warned, because the treatment is still experimental and GHRH is not approved to treat mental decline.\nStill, she said, \u201cThere are things we can all do to postpone (mental) decline.\u201d Keeping medical conditions such as diabetes under control and getting regular exercise are two examples.\nBut recent work by one of Baker\u2019s co-authors hints that nasal sprays with the hormone insulin may have a positive impact on memory in people with Alzheimer\u2019s disease - although that\u2019s far from conclusive yet.\nBaker added that it\u2019s too early to say whether the hormone could play a role in thwarting the development of Alzheimer\u2019s, which may affect as many as five million Americans.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Here\u2019s the relevant adequate section of the story:\n\u201cBaker said researchers have failed so far to come up with effective drugs to treat mild cognitive impairment, just as there is no known treatment to stave off the normal memory decline that comes with age.\nBut recent work by one of Baker\u2019s co-authors hints that nasal sprays with the hormone insulin may have a positive impact on memory in people with Alzheimer\u2019s disease \u2013 although that\u2019s far from conclusive yet.\u201d", "answer": 1}, {"article": "A diet that includes tomatoes could lower the chance of having a stroke.\n\nA new study shows that men who had the highest levels of lycopene\u2014an antioxidant found in tomatoes\u2014had fewer strokes than men who had the lowest level of lycopene in their blood. Overall, the risk of strokes was reduced by 55%.\n\nThe study, based in Finland, will be published...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Diet, exercise, and not smoking are all mentioned as important factors for stroke prevention.", "answer": 1}, {"article": "\u201cThere is a great deal of interest in developing other uses of bimatoprost,\u201d Heather Katt, a spokeswoman for Allergan, wrote in an e-mail message, \u201cand Allergan is exploring ways to pursue that pathway through the F.D.A.\napproval process.\u201d\n\nFor those too impatient to wait, there is also the bold and fashionable solution of shaving one\u2019s head.\n\u201cWe keep on moving back that time, but I think there\u2019s absolutely no doubt that it\u2019s going to be done.\u201d\n\nHe believes hair cloning will be commercially available within 10 years.\nThough the claim was met with some skepticism by other clinicians, the idea that ACell\u2019s powder, which has been approved by the government, could facilitate new hair growth has breathed new life into the race to clone hair.\n\u201cIt was a noticeable difference.\u201d\n\nBut Latisse does not appear to be a silver bullet for hair loss.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses a number of alternatives, and even provides price information for some. It says, for example, \u201cFor those too impatient to wait, there is also the bold and fashionable solution of shaving one\u2019s head.\u201d We do wish, though, that some comparative effectiveness information had been given.", "answer": 1}, {"article": "\u201cWe are just feeding off of this cancer phobia.\u201d\n\nWhat is needed, and what the new test does not provide, is a way to decide which cancers are dangerous and which are not, Dr. Isaacs said.\nThe next step was to ask whether those variants really could predict who had prostate cancer.\nIn fact, no one knows what their effect is.\nBut the men in this study had an average age of about 65, when the disease is less common and more likely to kill.\nThere is already too much prostate-cancer screening, they say, resulting in too much treatment.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story never mentioned that it is an option to decline screening. ", "answer": 0}, {"article": "(CNN) -- Taking dietary supplements containing essential fatty acids can help reduce the symptoms of premenstrual syndrome, according to the results of study by researchers at a Brazilian university.\nAccording to the study, women who took the supplements for six months saw a bigger benefit than those who took them for three months.\nThe study, published Monday in the journal Reproductive Health, found that taking capsules containing about 1 gram of a blend of three essential fatty acids produced a significant reduction in PMS symptoms.\nThe supplements taken by women in the study contained 210 mg of gamma linolenic acid, 175 mg of oleic acid, 345 mg of linoleic acid, 250 mg of other polyunsaturated acids and 20 mg of vitamin E, according to researchers.\nThe researchers do not make any recommendation in their study about whether women who suffer from PMS should increase their intake of essential fatty acids or, instead, consult with their doctor.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story only gave half of the picture of alternative approaches; it mentions other supplements that have been studied for PMS, but fails to note that there are also prescription medications for PMS such as SSRIs.", "answer": 0}, {"article": "Participants had an average starting cholesterol of about 230 milligrams per deciliter of blood.\n\u201cIn a population like the U.S. where selenium levels are adequate, there\u2019s no reason to take extra selenium in supplements.\u201d\n\nThe question of the link between selenium and health outcomes, Guallar said, \u201cis a very interesting story that\u2019s still developing.\u201d\n\u201cIn a sense it\u2019s a necessary micronutrient and we need it, but we might be (in) a situation where we have enough \u2014 we might even have too much.\u201d\n\nSelenium is found in meat, bread, and some nuts.\nStill, the finding is \u201creassuring\u201d because previous research had linked high selenium with higher cholesterol levels, said study author Dr. Eliseo Guallar, from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\nLast week, a review of prior studies suggested that selenium probably doesn\u2019t help prevent cancer, but might be linked to an increased diabetes risk at high doses (see Reuters Health story of May 11, 2011.)\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions several foods that are rich in selenium and can help boost dietary intake.\u00a0It\u00a0didn\u2019t\u00a0discuss how the effects of selenium supplements compare with those of statin drugs or other cholesterol-lowering interventions, but it does make it clear that supplements are not necessary and not recommended in the U.S.\u00a0We\u2019ll rule it satisfactory.", "answer": 1}, {"article": "Anderson estimates Jardiance could boost Lilly\u2019s earnings per share by 8 percent on average across 2016 to 2020.\nThe vast majority of those patients could be candidates for Jardiance, which costs over $4,000 per year, Morningstar analyst Damien Conover said.\nIn calculating the combined number of cardiac deaths, non-fatal heart attacks and non-fatal strokes, 14 percent fewer events were seen in patients taking Jardiance in combination with standard treatments, compared with patients who took standard treatments alone, meeting the study\u2019s main goal.\nThat has not been the case with all things in diabetes,\u201d said David Marrero, president of health care and education at the American Diabetes Association.\nThe benefits were especially impressive because they added to protection that patients received from taking cholesterol fighters and other life-saving heart drugs, Zinman said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This is a novel preventative therapy and designated as an add-on, not a replacement, to standard therapy which include statins to lower cholesterol, and blood pressure drugs. The story mentions\u00a0Invokana, another drug in the same class as\u00a0empagliflozin, and it talks about\u00a0cholesterol-lowering drugs and blood pressure medication.", "answer": 1}, {"article": "Dr Jonas Zimmerman, a neuroscientist at Brown University in the US, who was also not involved with the study, echoed Jackson's point.\n\"Brain signals change from day to day (even hour to hour), the signals may be different depending on context (am I trying to lift a full or an empty glass, do I watch someone draw or do I want to draw myself), and brain signals change while we learn a new task,\" he told BuzzFeed news.\nIt was a struggle at first, but by the end of the trial he was able to complete the action three out of five times in a 10-minute period.\n\"This technology is possible because there's about 50 years of basic neuroscience that has been looking at how signals in the brain encode information about movement,\" Dr Andrew Jackson, a neuroscientist at Newcastle University who was not involved with the work, told BuzzFeed News.\n\"We have to be realistic about this, there's still quite a long way towards turning this into something that would be feasible for widespread use in large numbers of people,\" Jackson said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This experimental device does appear to allow this patient to do things that no other treatment can. However, the main achievement is a proof of concept. Unfortunately, the story makes the difference between his baseline function and his movements in the laboratory appear bigger than it is.", "answer": 2}, {"article": "LONDON -- AstraZeneca PLC said Monday its experimental heart pill Brilinta was more effective at preventing heart attacks and strokes in a large clinical trial than the blockbuster pill Plavix, boosting commercial prospects for the U.K. drug maker's still unmarketed treatment.\n\nPlavix, which is marketed by Sanofi-Aventis SA and Bristol-Myers Squibb Co., was the second-biggest-selling drug in the world last year, with global revenue of $8.6 billion, according to IMS Health. Any competitor to it could have a shot at big sales.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story takes the viewpoint of the study, which is a head-to-head trial comparing Brilinta against Plavix. \nReaders should know how these expensive drugs perform relative to the cheaper, older alternatives, which include aspirin and warfarin. \nIt should also describe results for those who use non-drug treatments after getting stents or experiencing other conditions for which anti-platelet medications are used. ", "answer": 0}, {"article": "\"The issue is, can you detect these in patients that don't have advanced cancer?\" Venook said. \"The answer is, we don't know.\" The numbers tested by the MD Anderson researchers -- 251 patients with pancreatic cancer (five of whom had very early lesions), 32 with chronic pancreatitis and 120 healthy controls -- aren't nearly large enough to draw such conclusions. And getting a clear answer, Venook said, would probably require lengthy and expensive studies on very large populations.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t mention how pancreatic cancer is currently diagnosed. Tests to identify pancreatic cancer in patients include, but aren\u2019t limited to, physical exams to look for the presence of jaundice, blood tests, imaging tests and biopsy.", "answer": 0}, {"article": "This page either does not exist or is currently unavailable.\n\nFrom here you can either hit the \"back\" button on your browser to return to the previous page, or visit the ABCNews.com Home Page. You can also search for something on our site below.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Did not mention other options for \nreducing cancer risks. ", "answer": 0}, {"article": "Asthma has complicated Todd Anderson's life ever since he was 3 years old. Doing sports\u2014even stairs\u2014had been difficult. Cigarette smoke, pollen, disinfectants or a passing whiff of perfume could set off a severe asthma attack. \"It feels like your chest is clenching up like a fist,\" says Mr. Anderson, a 29-year-old music teacher in the New York City schools.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\n\nThe story does refer to standard treatments; however, it portrays standard treatment as often inadequate for the type of patient featured in the story. The editorial accompanying the key research article on this treatment says that the fact that most of the control group participants in the trial reported doing better while they were in the trial may indicate that they had not been getting optimal standard treatment beforehand. The editorial author says bronchial thermoplasty should not be considered unless a patient has first been \u201csubmitted to a rigorous treatment protocol.\u201d In other words, when people with asthma say that standard treatment isn\u2019t working, the real problem may be that they haven\u2019t actually been treated properly.", "answer": 0}, {"article": "(Reuters Health) - Taking one or two baby aspirins a day for at least five years was tied to a lower risk of colorectal cancer in a study from Denmark.\n\u201cUnless low-dose aspirin is taken continuously, there is little protection against colorectal cancer,\u201d Dr. Soren Friis from the Danish Cancer Society Research Center in Copenhagen told Reuters Health.\nIn general, the risk of developing colorectal cancer varies with age, race, ethnicity and lifestyle.\nFor an average black or white male of the same age, the corresponding risks would be about 1.4 percent and 5.8 percent.\nNonaspirin NSAIDs were also protective against colorectal cancer with consistent long-term use, \u201cand there was some indication that even non-continuous use of these agents may be (marginally) effective for the prevention of colorectal cancer,\u201d Dr. Friis said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes no reference to colonoscopy as a means of identifying and removing polyps before they become cancerous. Other screening approaches that could have been mentioned include\u00a0sigmoidoscopy and fecal blood tests.", "answer": 0}, {"article": "Eli Lilly announced promising data on its efforts to have its Cymbalta depression treatment also used as pain medicine, saying a study showed the drug \"significantly\" reduced chronic lower-back pain.\n\nLilly has been looking at the potential of Cymbalta for relieving the discomfort of fibromyalgia and osteoarthritis pain as well as back pain. The company's results of late have been boosted by the antidepressant, whose second-quarter sales jumped 26% to $654.4 million.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No other options for treating chronic low back pain were mentioned. ", "answer": 0}, {"article": "In humans and many animals the lateral sleeping position is the most common one.\nIn the paper, \u201cThe Effect of Body Posture on Brain Glymphatic Transport,\u201d Dr. Benveniste and colleagues used a dynamic contrast MRI method along with kinetic modeling to quantify the CSF-ISF exchange rates in anesthetized rodents\u2019 brains in three positions \u2013 lateral (side), prone (down), and supine (up).\nBy using dynamic contrast magnetic resonance imaging (MRI) to image the brain\u2019s glymphatic pathway, a complex system that clears wastes and other harmful chemical solutes from the brain, Stony Brook University researchers Hedok Lee, PhD, Helene Benveniste, MD, PhD, and colleagues, discovered that a lateral sleeping position is the best position to most efficiently remove waste from the brain.\n\u201cIt is interesting that the lateral sleep position is already the most popular in human and most animals \u2013 even in the wild \u2013 and it appears that we have adapted the lateral sleep position to most efficiently clear our brain of the metabolic waste products that built up while we are awake,\u201d says Dr. Nedergaard.\n\u201cBecause of this finding, we propose that the body posture and sleep quality should be considered when standardizing future diagnostic imaging procedures to assess CSF-ISF transport in humans and therefore the assessment of the clearance of damaging brain proteins that may contribute to or cause brain diseases.\u201d\n\nDr. Benveniste and first-author Dr. Hedok Lee, Assistant Professor in the Departments of Anesthesiology and Radiology at Stony Brook developed the safe posture positions for the experiments.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release compared the potential benefit of sleeping on one\u2019s side and on the stomach or back. But there are many other potentially modifiable risk factors for Alzheimer\u2019s and other neurodegenerative diseases that weren\u2019t mentioned. Things like exercise, a healthy diet. maintaining social connections, etc have been more thoroughly studied than sleep positions.", "answer": 0}, {"article": "The researchers, led by Dr. Gabriele Di Lorenzo of the University of Palermo, describe the benefits as \u201cmodest.\u201d\n\nIn an email, Di Lorenzo told Reuters Health that the findings suggest that sublingual immunotherapy is \u201chighly effective in many, but not in all patients.\u201d He said that more work is needed to identify which patients might be most likely to benefit.\nAllergy shots may be used for hay fever when antihistamines and other allergy medications do not control a person\u2019s symptoms adequately, or for people who want to reduce their reliance on medication.\nA study published earlier this year \u2014 and not included in the current analysis \u2014 found that during that post-treatment year, Grazax patients had one-quarter fewer hay fever symptoms than those who had been given a placebo for comparison.\nThe most common side effects include itchiness and irritation in the mouth, ears and eyes, swelling of the mouth or tongue, headache and gastrointestinal problems like stomach pain and heartburn.\nKnown as sublingual immunotherapy, the treatment relies on the same principles as traditional allergy shots, but is delivered by tablets or drops that dissolve under the tongue.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\"/>1clip_themedata.thmx\"/>1clip_colorschememapping.xml\"/>\n\n\n\n \nThe story discusses alternative approaches for treating grass-pollen allergies, specifically antihistamines and allergy shots.\u00a0 \n", "answer": 1}, {"article": "Probabilities may not grab all patients by the collar. But telling someone he or she has a better than 1-in-3 chance of dying before the next decade's out (or even a better than 1-in-10 chance) would probably be a sobering reminder to hit the gym. The authors said the metric \"can be used to communicate fitness-related risk and motivate behavioral change after exercise stress testing.\"", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story at least mentions the existence of other alternatives for risk assessment, such as the\u00a0Framingham Risk Score.\u00a0But it doesn\u2019t really explain how this test differs from those other risk measures. We\u2019ll give the story the benefit of the doubt here.", "answer": 1}, {"article": "\"Shireen had the idea, 'Why can't I just test my food and figure out what's in it?'\nThe company, 6SensorLabs, has started taking pre-orders for the device it calls Nima, which can test food for gluten and get rapid results, said co-founder and chief technology officer Scott Sundvor.\nThe National Institute of Diabetes and Digestive and Kidney Diseases estimates that about 1 in 141 Americans has celiac disease, but many people don't know they have the condition.\nIt costs $179 to pre-order a tester plus three one-time-use pods, and $47.95 for a refill pack of 12 pods; prices will increase later this month, according to the company's website.\nMarilyn Grunzweig Geller, chief executive officer of the Celiac Disease Foundation, said she is not familiar with the new gluten-sensing device and was unable to comment on it directly.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article would be stronger if it mentioned not only the availability of other tests on the market, but also ways that those with celiac disease can reduce their risk of harm when they travel, eat out, or go to parties.\u00a0There is increasing availability of restaurants with the \u201cGF\u201d notation on the menu, indicating gluten free choices.", "answer": 0}, {"article": "Dr. Papas, an adviser to Novalar and an investigator in its clinical trials, said she thought the drug would appeal especially to those receiving cosmetic dentistry \u201cwho like to look good when they leave the dentist\u2019s office.\u201d\n\nNovalar said its surveys showed great interest in the product among consumers and among dentists, some of whom said they would mark up the price of the drug as a source of profit.\nIn two trials of 484 patients in total, people were given either OraVerse or a sham injection.\nThose patients would be expected to have lingering pain, and should not get Oraverse, Dr. Moore said.\nThe drug, however, is not approved for children younger than 6 or weighing less than 33 pounds.\nThat keeps the blood from carrying away the anesthetic from the mouth too quickly.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does not seriously explore the treatment \"option\" of not having the injection. ", "answer": 0}, {"article": "Dr. John Wagner, the director of pediatric blood and marrow transplantation at the , called the Pennsylvania results \u201cphenomenal\u201d and said they were \u201cwhat we\u2019ve all been working and hoping for but not seeing to this extent.\u201d\n\nA major drug company, , is betting on the Pennsylvania team and has committed $20 million to building a research center on the university\u2019s campus to bring the treatment to market.\nSimilar approaches are also being tried at other centers, including the and in New York.\nThe storm can also flood the lungs and cause perilous drops in \u2014 effects that nearly killed Emma.\nIt can cost more than $5,000 a month, depending on the dosage.\nFour adults improved but did not have full remissions, and one was treated too recently to evaluate.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions chemotherapy and bone marrow transplants as other treatment options for leukemia.", "answer": 1}, {"article": "Developed in the laboratory of UHN transplant surgeon Dr. Markus Selzner, with the help of UHN transplant surgeons Drs.\n\u201cThis new technology can help us answer the critical question, \u2018What\u2019s the best way to improve function and recover and repair the kidney before transplantation to get the best results for our patients?\u2019\u201d\n\nDr. Grant, who is also Professor of Surgery at the University of Toronto, emphasized that high-impact research projects such as this require strong collaborative teams \u2013 including researchers, surgical residents, nurses, Canadian Blood Services, perfusionists, colleagues at SickKids - working together on experimental and clinical trials.\n\u201cIt behaved like a normal kidney, despite it being an extended criteria donor kidney.\u201d\n\nHe points out blood tests within 48 hours showed that the kidney was removing wastes and excess fluid from the blood normally.\n\u201cThis can make a difference to other patients, so I am glad to be the first one helping them with my experience.\u201d\n\nAs soon as the donor kidney was reattached to the patient, it turned ruby-red and started to pour out urine, indicating that it was functioning well.\nNewswise \u2014 Toronto, ON (February 5, 2018) -- A deceased donor kidney has been preserved and kept healthy outside the body in a device that mimics the body\u2019s physiological functions and successfully transplanted into a human, for the first time in North America.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Here\u2019s how the release handles the issue: \u201cThis technology has advantages over the usual cold storage method in which a deceased donor kidney is cooled on ice to about four degrees Celsius, with no oxygen, slowing down its metabolism, and inhibiting the repair process. The kidney cannot survive longer than 30 hours in cold preservation. The new warm preservation technique avoids the damage of cold storage and instead allows the donor organ to improve and repair itself, potentially leading to better outcomes for patients.\u201d\nThis is a direct comparison, which is good, but raises some questions. For example, how long can a kidney survive using the new technique? More than 30 hours? There\u2019s a reference to \u201cthe damage of cold storage,\u201d but it doesn\u2019t tell readers what that damage is \u2014 or what it means when they say a kidney can \u201cimprove and repair itself.\u201d", "answer": 1}, {"article": "For more information visit http://www.\nIt also proves the principle that we can detect prostate cancers with specific targetable mutations using genomic sequencing to deliver more precise cancer care by matching treatment to those men most likely to benefit.\nThe development of olaparib, which is now owned by AstraZeneca, was underpinned by scientific research carried out with funding from Cancer Research UK at The Institute of Cancer Research (ICR) and the University of Cambridge, and clinical trials led by the ICR and The Royal Marsden, and other institutions in the UK and overseas.\nThe results have led on to the start of TOPARP-B, a second part of this trial in which only men whose prostate cancers have detectable DNA repair mutations will receive olaparib.\nThe drug, a type of treatment called a PARP inhibitor, was licensed last year for women with ovarian cancer and inherited BRCA mutations, but so far has not been approved for use on the NHS by NICE or the Cancer Drugs Fund.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This criteria doesn\u2019t apply since all the gene-specified patients were given the same treatment. The release implies that the study enrolled patients whose alternative treatments had failed, but it doesn\u2019t say what those treatments were. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "But Gee believes reimbursing patients to play games could cut other health costs \u2014 by promoting exercise and preventing disease, for example, or even reducing the amount of expensive drugs people take.\nIf it becomes proprietary, the only people who can do unfettered research on it are the people who own the procedure,\" he says.\nThe worst fear is that the technology will become outdated by the time the FDA process is complete.\nBut this kind of goal requires a totally different business model; before they can deliver their game to players, they first have to go through the Food and Drug Administration \u2014 the FDA.\n\"I'd like to think we could cut down standard clinical trials, in size and length of time, by half or more,\" he says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story includes a claim that video game therapy might replace drug treatment, but there is no clear comparison made between the approaches. Behavioral therapy is mentioned only indirectly. Such comparisons would have welcome even in a story whose main objective is describing\u00a0the approval process.", "answer": 0}, {"article": "Co-authors on the paper, all from Boston University, are T.A.\nRayVio's 293nm LED showed the most significant potential for vitamin D3 production in the shortest amount of time,\" said Dr. Holick, a Professor of Medicine, Physiology and Biophysics at Boston University School of Medicine, and endocrinologist at Boston Medical Center.\n\"The potential of digital UV technology for phototherapy is enormous,\" said Dr. Robert C. Walker, RayVio's CEO.\n\"This study will lead to a new generation of technology that can be labeled as photopharmacology in which the use of LEDs with targeted wavelengths can cause specific biologic effects in human skin to help treat and prevent chronic illnesses.\"\nThanks to the work of the research team and the pioneering work of the Boston University Photonics Center on UV LEDs, we may soon see innovative treatment options like simple integration with a wearable device could aid millions of people.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Natural sunlight is the main alternative discussed in the news release, since skin samples exposed to sunlight needed much more time to produce comparable levels of vitamin D3 than those exposed to RayVio\u2019s UV LED. The news release also mentions diet, pointing out that vitamin D is also found in plants, yeast and mushrooms. Other foods containing vitamin D include oily fish \u2014 like salmon, mackerel, and blue fish \u2014 as well as fortified milk and other dairy products.\nAnother alternative to treat vitamin D deficiency is oral supplementation.\nWe feel the news release\u2019s comparison to natural sunlight is enough for a Satisfactory rating here.", "answer": 1}, {"article": "The findings don't confirm that the ancient Chinese discipline relieves hot flashes, and only 14 men participated in the study, which was conducted by researchers at New York Methodist Hospital and Weill Cornell Medical College of Cornell University.\nIt's also possible, he said, that the symptoms went away on their own, which commonly happens to men on hormone therapy.\nThe question is whether the acupuncture reduced the hot flashes or a placebo effect played a role, said Freedland, who's familiar with the study findings.\nHormone therapy designed to reduce levels of testosterone in the body is one of the standard treatments for prostate cancer.\nFor more about prostate cancer, visit the U.S. National Library of Medicine.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There wasn\u2019t any comparison given between what acupuncture did in this tiny study and what else is now done or is being investigated for hot flashes in such men.\nOther hormone therapies and antidepressants are currently used.", "answer": 0}, {"article": "The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about colonoscopy.\nResearchers set out to determine if this phenomenon, called the \"Mozart Effect,\" played a role in the detection rates of precancerous polyps during colonoscopies.\n\"Both endoscopists had higher adenoma detection rates listening to music when compared with their baseline rates,\" lead researcher Dr. Catherine Noelle O'Shea, of the University of Texas Health Science Center at Houston, said in an American College of Gastroenterology news release.\nThe study authors suggested that the findings could help reduce the number of people affected by invasive colorectal cancer -- the third most common cancer diagnosed in men and women in the United States, according to background information in the news release.\nThe study was slated for presentation Monday at the American College of Gastroenterology's annual meeting in Washington, D.C. Because this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Was music the only option for improving detection?\u00a0 Experience of the physician is probably closely related to detection rate, as well as number of procedures done per year. Let\u2019s give Mozart his due, but let\u2019s analyze the evidence on other alternative explanations as well.", "answer": 0}, {"article": "Links will be live at the embargo time http://jamanetwork.\nWho and When: More than 140,000 U.S. women who had DCIS between 1998 and 2014; this study compared lumpectomy plus radiation vs. lumpectomy alone, lumpectomy vs. mastectomy, and lumpectomy plus radiation vs. mastectomy\n\nWhat (Study Measures and Outcomes): Use of radiation and/or extent of surgery (exposures); breast cancer mortality rates within 15 years (outcomes)\n\nHow (Study Design): This was an observational study.\nStudy Limitations: Some data were missing; investigators didn't have information on tamoxifen use; treatments in the study population weren't randomly assigned; and the possibility remains that the decision to undergo radiotherapy was associated with other favorable prognostic factors.\nAuthors: Steven A. Narod, M.D., of Women's College Research Institute, in Ontario, Canada, and co-authors\n\nResults: A small improvement in breast cancer survival was associated with radiation plus lumpectomy for DCIS.\nBottom Line: Lumpectomy plus radiation was associated with a small clinical benefit in reduced risk of breast cancer death compared with lumpectomy or mastectomy alone in women with ductal carcinoma in situ (DCIS), a noninvasive early form of breast cancer.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release let readers down in providing the broader context about controversies over appropriate treatment \u2014 if any \u2014 for women diagnosed with DCIS.", "answer": 0}, {"article": "Fried said the findings suggest stimulating the brain just as memories are forming is key.\n\u201cAlthough the current evidence is preliminary, is based on small samples and requires replication, the potential application of deep-brain stimulation in amnestic disorders is enticing,\u201d Black wrote.\nThe current study was done at the University of California at Los Angeles in seven epileptic patients awaiting surgery who had electrodes implanted deep in their brains to help pinpoint the source of their seizures.\nDespite costly efforts, no drug has been found that can keep Alzheimer\u2019s from progressing, and policymakers are growing increasingly worried about the swelling ranks of dementia patients as the population ages.\n\u201cThe question would be whether this can help memory in patients with memory impairments,\u201d he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story offers a bit more information about existing treatments than the other story we reviewed, but all it says is that available drugs cannot prevent Alzheimer\u2019s disease from progressing. The story would have been better if it had given readers some sense of how the memory-enhancing effects of available drugs compare to the size and duration of the effects seen in this test of brain stimulation.", "answer": 0}, {"article": "Note: Around 220,000 people have been diagnosed as having schizophrenia in England and Wales (https:/ )\nThe researchers found that 34.6% of the patients being treated by TMS showed a significant response, whereas only 9.1% of patients in the sham group responded ('significant response' was defined as a more than 30% decrease in the Total Auditory Hallucinations Rating Scale score).\nUsing magnetic resonance imaging (MRI), the pulses were targeted at a specific brain area in the temporal lobe, which is associated with language (the exact area is the crossing of the projection of the ascending branch of the left lateral sulcus and the left superior temporal sulcus)\n\nAfter 2 weeks, the patients were re-evaluated.\n\"This is the first controlled trial to precisely determine an anatomically defined brain area where high frequency magnetic pulses can improve the hearing of voices\", said lead researcher, Professor Sonia Dollfus (University of Caen, CHU, France).\nOne of the best-known is hearing voices, also known as Auditory Verbal Hallucination (AVH), which around 70% of people with schizophrenia experience at some point.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This is a close one. The release includes a quote from an independent researcher who was not associated with the study. In that quote, the researcher says, \u201cWhile response rates were moderate, TMS is a welcome addition to the therapeutic repertoire especially for patients who do not respond to medication.\u201d That\u2019s useful information. However, the release would have been far stronger if it had offered even one or two sentences about other treatment options, including medication. For example, do AVHs persist for many patients on medication for schizophrenia?\nOther non-drug techniques such as cognitive behavioral techniques are being used for auditory hallucinations as well.  ", "answer": 0}, {"article": "Scientists have used a form of stem-cell therapy to improve survival rates for the most severely sick lupus patients, a group that usually has no remaining treatment options.\n\nLupus is an autoimmune disease that attacks an individual's own organs, causing symptoms that range from swollen joints and skin rashes to severe damage to kidneys, lungs and other parts of the body.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Article mentioned that \nlupus patients are usually treated with immunosuppressive drugs and that for 5-10% of patients, these drugs are ineffective. \nWhile the original article was clear in presenting that HSCT was used as a treatment for this population for whom the \nstandard approach was no longer effective, this was not explicit in the article.", "answer": 0}, {"article": "When it comes to health, I\u2019m skeptical of willpower. Sure, I talk to my students about personal responsibility, but when it comes to the health of populations, I look for big fixes more than for small acts of will.\n\nThat\u2019s why my ears perked up when I heard that two old physician friends had decided to start taking, as a preventive measure, some of the medications often included in what the field has dubbed the \u201cpolypill.\u201d My friends are both top doctors in their 60s, with good diet and lifestyle, and this is now part of their...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no comparison with other approaches, except the implication that behavioral approaches like exercise are not necessarily easily followed,\u00a0and so taking a pill is an easier choice. Granted, when you depend on human compliance and behavior change for public health benefits, the results will be limited. But, the story overlooks the fact that taking a pill every day also requires long-term compliance, limiting the results, too.", "answer": 0}, {"article": "Obesity puts children at greater risk of developing preventable conditions like heart disease and diabetes at a younger age, and suffering poor health later in life.\nVitamin D is most commonly associated with the development and maintenance of strong bones as the body needs it to absorb calcium.\nThe team measured participants' vitamin D levels, body fat percentage, as well as their markers of liver and heart function at the start of the study, and again 12 months later.\nChildren who took vitamin D had a significantly lower BMI, the researchers found.\nIt's encouraging that a simple intervention could have these effects and this certainly merits further investigation to consider its potential impacts on vitamin D supplementation for children with obesity.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Alternatives to taking vitamin D to head off some of the symptoms of obesity are noticeably absent. Why aren\u2019t diet or exercise mentioned, at a minimum?", "answer": 0}, {"article": "There has never been a safe and effective treatment.\nMost patients who got the active drug, dupilumab, instead of a placebo reported that the itching began to wane within two weeks and was gone in a few months, as their skin began to clear.\nOn Saturday, the results of two large clinical trials of a new drug offered hope to the estimated 1.6 million adult Americans with an uncontrolled, moderate-to-severe form of the disease, atopic dermatitis, which is a type of eczema.\nThe constant itch, to say nothing of the disfigurement, can be so unbearable that many patients consider suicide.\n\u201cI knew immediately I was on the drug\u201d and not the placebo, said Daniela Velasco, an event planner in Playa del Carmen, Mexico.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that many creams and lotions fail to provide relief to people with moderate to severe eczema. It also reports that many patients try off-label treatment with immunosuppressive drugs or steroids, which can have serious side effects.\nThe story would have been stronger is it had pointed out that any patient who went to any other course of therapy would be taken out of the study, discouraging any\u00a0patient from using another therapy if they are still symptomatic.", "answer": 1}, {"article": "Lustig and his colleagues think they\u2019ve produced the \u201chard and fast data that sugar is toxic irrespective of its calories and irrespective of weight.\u201d\n\nMORE: FDA Wants Nutrition Labels to Include More Detail on Added Sugars\n\nLustig\u2019s confidence comes from the unique study, described in , of 43 Hispanic or African-American children aged eight to 18 years old.\n\u201cWe know that a healthy diet and weight loss cause good metabolic changes, and although this study tries to attribute its effects to low fructose, in fact it is impossible to do that because of the study design.\u201d\n\nSome experts are concerned for other reasons.\nThe only difference in the nine-day diet was that most of the sugar the children ate was replaced by starch \u2014 the overall number of calories remained the same.\nHe collected detailed food questionnaires from each of the adolescents to get an idea of the average amount of calories they ate per day, then designed a special menu for each of them for nine days that matched the total numbers of calories they would normally eat.\nBut I worry that people are going to hang everything on this when we still need to reduce consumption.\u201d\n\nLustig hopes that won\u2019t happen as more data emerges that details how sugar is altering the body in unhealthy ways outside of its caloric contribution.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article did a fairly good job of describing the limitations of previous dietary studies, compared to this one, especially as it relates to the effects of cutting sugar vs. losing weight.\u00a0It would have also been helpful to mention the role of exercise in controlling metabolic disease.", "answer": 1}, {"article": "A California company has developed a genetic test that can predict whether patients treated for early-stage colon cancer are likely to suffer a recurrence of the disease, the third leading cause of cancer deaths in the U.S.\n\nThe results of the test, based on an analysis of seven different genes found in colon-cancer tumors, yield a score that tells whether patients are at low, intermediate or high risk of having the disease come back after it is removed through surgery.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explains that the current alternative option to the genetic test is to assess risk of recurrence based on a patient\u2019s age, other illnesses and tumor characteristics\u2013a method that results in a clear recommendation for or against chemo in only 30 percent of patients.\n\u00a0", "answer": 1}, {"article": "Since amniocentesis carries a small risk of spontaneous miscarriage \u2014 Patsalis put it at around one or two percent \u2014 scientists have been looking for new less invasive ways to test for Down\u2019s and other potential genetic problems.\nIt involves taking a small amount of blood from the mother when she is between the 11th and 13th week of her pregnancy and detecting extra copies chromosome 21 in the fetus by analyzing the maternal blood.\n\u201cWe believe we can modify this test and make it much easier and simple... (and then) we can have something ready to be introduced into the clinic,\u201d he told Reuters in Nicosia.\n\u201cSuch a non-invasive approach will avoid the risk of miscarriages of normal pregnancies caused by current, more invasive procedures,\u201d the scientists wrote in their paper.\nIn a study in the Nature Medicine journal researchers from Cyprus said a trial on 40 pregnancies using the test, which involves analyzing the woman\u2019s blood to detect DNA differences between the mother and the fetus, showed it accurately predicted which fetuses were at risk of developing the syndrome.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story didn\u2019t even mention any of the other research being done in this field to improve prenatal diagnosis.", "answer": 0}, {"article": "So why does acupuncture seem to work?\nThe result: by the end of the treatment period, those in the acupuncture group were found to have hot flash scores that were 50 percent lower than those in the non-acupuncture group.\n\"Anyone who treats breast cancer struggles with this problem in their practice, because the hot flashes that some women experience with anti-hormonal treatment can be profound,\" she said.\nAnd because hormone treatment for breast cancer typically makes the hot flash experience even worse, Razzini added, acupuncture could be a useful tool for helping such patients \"stay on their therapy and improve their quality of life.\"\nWhich, in the end, may help to encourage insurance companies to their expand coverage so this can become an affordable option for all patients in need.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "NIH lists a number of approaches to dealing with hot flashes in cancer patients, ranging from pharmaceutical interventions to hypnosis. The story mentions only those discussed in the study. We would like to see at least a mention of other techniques. And going a step further, it would be useful to compare the side effects of acupuncture to pharmaceutical solutions and other non-traditional approaches.", "answer": 0}, {"article": "Researchers used CAR-T to treat a man with brain cancer to some success\n\nGlioblastoma is one of the deadliest cancers \u2014 an illness that responds to few treatment options, and often poorly. But a single case study that uses an experimental immunotherapy to treat these brain tumors might give oncologists a new way to approach the disease.\n\nThe therapy, called CAR-T, is controversial and has faced hurdles in clinical trials. It has shown great promise in treating blood cancers like leukemia and lymphoma \u2014 but has proven challenging in treating other forms of the disease, including solid tumors.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Very few details of conventional alternative treatments are included, but the story points out that glioblastoma is resistant to most treatment options. Still, the story should have noted that alternatives include surgery, radiation and chemotherapy.", "answer": 0}, {"article": "Attorney James Tuffin followed his usual daily routine last week: He ran five miles and drove to his office on suburban Long Island. In between, he stopped at Advanced Radiation Centers in North Hills, N.Y. There, he drank a quart of water, lay down on a treatment table and watched as a high-tech linear accelerator rotated around him for 90 seconds, blasting his cancerous prostate with radiation.\n\n\"On a good day, I'm in and out in a half-hour,\" says Mr. Tuffin, 54 years old, who was midway through his scheduled 45...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story stated that the radiation provided by the RapicArc is much greater than that of 40 years ago. \u00a0That said, the story provided the reader with no information about the treatment options available to those diagnosed with prostate cancer beyond radiation.\u00a0", "answer": 0}, {"article": "In a 2014 CDC report, the U.S. infant mortality rate (6.1 per 1,000 births) put it in 26th place among a selection of developed countries.\nThe question was presented in May at the yearly ACOG meeting in Washington: \u201cWhy not induce everyone at 39 weeks?\u201d Two doctors had been asked to debate: Errol Norwitz, chairman of obstetrics and gynecology at Tufts University School of Medicine, and Charles Lockwood, dean of the Morsani College of Medicine at the University of South Florida.\n\u201cI would personally recommend that any woman with a favorable cervix at 39 weeks be encouraged to get induced.\u201d\n\nOf course, Lockwood said, women should be heard.\nAlso, the drug can cause the placenta to detach from the uterine wall too early, and it can cause the uterine wall to tear.\nBut the question has some doctors reconsidering their assumptions about induction and has sparked criticism by women who contend there is already too much interference with uncomplicated pregnancies.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We will give the story a Satisfactory rating on this criterion because it clearly spells out that the subject is a debate between inducing labor 39 weeks into a normal pregnancy or waiting longer. However, the story mentions only one method of inducing labor.", "answer": 1}, {"article": "For the study, Lumeng's team collected data on more than 43,700 Michigan preschool-age children between 2005 and 2013.\n\"Even though children in the Head Start group began the observation period more obese, equally overweight, and moreunderweight than children in the comparison groups, at the end of the observation period the initially obese and overweight Head Start children were substantially less obese andoverweight than the children in the comparison groups,\" the authors wrote.\nThe program is designed to build stable family relationships, improve children's physical and emotional well-being and develop strong learning skills.\n\"Perhaps the program fosters better mental health in the children, which in turn leads to better eating,\" he said.\nAlmost one-quarter of preschool-aged children in the United States are overweight or obese, and obesity rates within Head Start populations are higher than national estimates, the study authors noted.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not place these findings in context with other obesity prevention and treatment initiatives for children. This is an area that has been studied extensively.", "answer": 0}, {"article": "\u2022 Surgery should be followed by intraperitoneal, or localized, chemotherapy delivered to the abdomen.\nThe goal is to have no cancer visible to the naked eye of the surgeon after the surgery.\nLocalized chemotherapy works best if there's no residual cancer after the initial surgery.\nIt is the combined effect of surgery and chemotherapy that works best.\n\"We should offer all women the possibility of a cure.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release discusses several other conventional treatment options for advanced-stage ovarian cancer.", "answer": 1}, {"article": "News releases can also be found at http://www.\nNot only does the tailored anti-gravity treadmill programme provide a great environment for healing, it also helps the person restore their belief that they can make a successful return to the sport they love.\nThe air pressure in the treadmill can be adjusted to take the patient from 100 per cent of their body weight to only 20 per cent, the same feeling as walking on the moon, and reducing the impact and pressure on joints during the run.\nThe Sports Ready clinic is student-led under supervision of experienced practitioners, with patients self-referring or sent by private clinics and NHS orthopaedic consultants.\nIn a report titled Return to running following knee osteochondral repair using an anti-gravity treadmill, published in the journal Physical Therapy in Sport, Dr Hambly demonstrates how a graduated return to running using an anti-gravity treadmill can help to reduce fears about re-injury and increase self-belief in being able to run on the injured knee.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release doesn\u2019t mention any alternatives to the treadmill for people needing rehabilitation after knee surgery. \nThe release is about a study of a single patient who pursued a single rehab journey following surgery. Besides that limitation, the news release also missed an opportunity to mention that there are non-surgical approaches to treating cartilage damage in the knee.", "answer": 0}, {"article": "People who were given Flublok Quadrivalent were over 40% less likely to develop culture-confirmed influenza.\n\"This study shows that Flublok\u00ae Quadrivalent, produced with modern recombinant technology can provide better protection against confirmed influenza-like illness among older adults than standard-dose quadrivalent influenza vaccine produced with traditional technology,\" said Lisa Dunkle MD, Chief Medical Officer of Protein Sciences.\nFlublok is highly purified and does not contain any preservatives (e.g., thimerosal - a form of mercury), egg proteins, gelatin or latex.\nFDA approved the quadrivalent formulation (\"Flublok Quadrivalent\") in October 2016 that will be commercially available for everyone over 18 years for the 2017/18 influenza season.\nFlublok contains three times more active ingredients than traditional vaccines and produced significantly higher immune responses to the A strains of influenza (especially H3N2) in the Flublok Quadrivalent study.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not list other flu vaccines by name, but does clearly describe the conventional vaccine that was compared to Flublok Quadrivalent in this study. The release also articulates what distinguishes Flublok from conventional vaccines in terms of its manufacturing and components (e.g., Flublok is made without using eggs, etc.).", "answer": 1}, {"article": "The findings were released at the American Society of Clinical Oncology meeting in Chicago.\nThe text messages were most effective at reducing distress at the 2- and 4-month marks, according to the data presented by chief author Kuang-Yi Wen, an assistant professor in the Cancer Prevention and Control program at Fox Chase.\nAt the fourth month mark, \u201cthe gap was huge\u201d between the texting and control groups, she told Reuters Health in a telephone interview.\nEveryone has different information-seeking behavior\u201d and the system can respond to that, Dr. Wen said.\nCompared to 52 women who only received an American Cancer Society pamphlet on chemotherapy, the 48 women in the texting group reported an overall lower level of distress and a higher quality of life during their therapy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned a control group that received pamphlets about chemotherapy. It wasn\u2019t clear if that was the current standard method of helping women cope. Also, the story could have explored existing options such as such as online support groups or regular check-ins with a doctor\u2019s office, or\u00a0already existing ask-a-nurse lines that are open all the time for patients.", "answer": 0}, {"article": "Wall Street sees denosumab as a potential blockbuster crucial to Amgen.\nHowever, based on some prior studies, independent experts say denosumab appears more effective at preventing spine fractures than three older pills \u2014 Fosamax, Actonel and Boniva \u2014 and calcitonin nasal sprays, which all use various pathways to slow down cells called osteoclasts that break down bone.\nThe second study included 1,468 men with prostate cancer at increased fracture risk due to cancer hormone therapy, although 556 dropped out for reasons from side effects and cancer progression to the study being extended from two to three years.\nThe studies found denosumab caused eczema in some patients, and a dozen of the women got a serious skin infection, cellulitis, that sometimes required hospitalization for intravenous antibiotics.\nExperts think denosumab prevents spine fractures about as well as Reclast, an intravenously injected drug that slows bone breakdown, and daily just below the skin injections of Forteo, the only drug that stimulates bone-building cells called osteoblasts.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story discusses several alternative drug options for treating osteoporosis, including vitamins, pills, patches, nasal sprays, and intravenously and subcutaneously injected drugs.\u00a0 Comparisons in efficacy between denosumab and some of these alternatives are provided.\u00a0 More information comparing the absolute risk reduction for spine fractures would have been a nice addition, as well.\u00a0\u00a0 ", "answer": 1}, {"article": "New research is helping Pfizer Inc. build a case for getting an important drug in its portfolio approved to treat a mysterious pain condition that could offer a big additional source of sales.\n\nThe New York drug maker said Tuesday that Lyrica, already on the market to treat certain types of pain, reduced painful symptoms among sufferers of fibromyalgia, a chronic and controversial condition that may affect as many as six million Americans. And today, it will unveil results from another study that it says shows Lyrica has a lasting...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While the story did mention that fibromyalgia is traditionally treated with a 'cocktail of off-label drugs including antidepressants and painkillers', this is really not an adequate description of the the treatment options.\u00a0 In fact, one of the drugs that may be included in this 'cocktail' is the very drug that is being reported on.", "answer": 0}, {"article": "Ramsden acknowledged that the Sydney study had been narrowly focused on a specific group of people: middle-aged men with a history of heart disease, who were asked to consume linoleic acid in quantities far exceeding both AHA guidelines and the dietary habits of most Americans.\nBut in the ensuing years, researchers have come to understand that not all PUFAs are alike, with key biochemical differences -- and perhaps varying cardiovascular impacts -- observed among multiple types of omega-3s (found in fish oils) and omega-6 linoleic acids.\nWhile omega-3 consumption was not affected, the men were also asked to lower their saturated fat intake so that it made up less than 10 percent of their diets.\nThe original \"Sydney Diet Heart Study,\" was initially conducted between 1966 and 1973, at a time when the cholesterol-lowering benefits of all polyunsaturated vegetable acids (PUFAs) were touted with a broad brush.\nDespite the fact the American Heart Association (AHA) currently recommends that 5 percent to 10 percent of all calories come from polyunsaturated fat (principally from omega-6), the NIH team found no evidence to support the notion that linoleic acid confers health benefits.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no mention of other approaches to reduce cardiovascular risk, either in the general population or men with a history of heart disease. Options include other lifestyle changes, drug therapy, surgery, and quitting\u00a0smoking. This could have been accomplished in just a few more words.", "answer": 0}, {"article": "First a drug must get F.D.A.\nWhile Medicare generally pays for drugs that are approved by the Food and Drug Administration, its debate over paying for Provenge has raised concerns among some cancer patients, doctors and investors who say the government is sending a warning shot that it will not automatically pay for high-priced medicines.\nThe analysis is part of a controversial review by the Centers for Medicare and Medicaid Services to determine whether to pay for Provenge, which costs $93,000 per patient and extended lives by about four months in clinical trials.\nThere is only \u201cmoderate\u2019\u2019 evidence that the newly approved prostate cancer drug Provenge helps patients, according to an analysis done for Medicare that was made public on Wednesday.\nBut the analysis for Medicare said that there were issues in how the trials were designed that made it difficult to assess how effective Provenge really was.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nAlthough the available treatments for men with advanced prostate cancer are limited, there are other approaches that could have been mentioned.  The omission is of particular importance because the analysis done for Medicare specifically highlighted questions about whether other treatments, including chemotherapy, that were given to patients in the Provenge trials might have influenced the outcomes.", "answer": 0}, {"article": "D'Onofrio is also a co-author of several studies based on patient data from Sweden that found similarly lower risk for substance abuse and transport accidents in people with ADHD who used medication.\nThe risk of substance use problems during periods of medication use was 35 percent lower in men and 31 percent lower in women in the study.\nThey then calculated the odds of the visits occurring during the person's use of ADHD medication versus the same person's non-use of ADHD medication.\nA significantly smaller number used nonstimulant ADHD medication such as Strattera, or atomoxetine.\nAnother study from this group recently reported in JAMA Psychiatry found that the use of ADHD medication was associated with lower risk of motor vehicle accidents in men and women.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release did not mention any alternatives for treating ADHD such as non-stimulant medications or cognitive behavioral therapy.", "answer": 0}, {"article": "Unlike traditional stents that remain in place after implantation, Absorb is designed to disappear fully within three years of the procedure.\n\u201cNo metal may also reduce the potential of future blockages that occur with permanent metallic stents.\u201d\n\nData released in October concluded Absorb was comparable to Abbott\u2019s own Xience drug-coated metal stent in safety and effectiveness but showed a higher risk of heart attacks and blood clots.\nThe stent, called Absorb, is made of a plastic similar to dissolving sutures and offers patients an alternative to metal stents currently used to prop open arteries cleared of blockages.\n\u201cNo metal means the treated artery can pulse and flex naturally as demands on the heart change with everyday activities,\u201d said Gregg Stone of Columbia University Medical Center, who led clinical trials for Absorb.\nAnalysts have predicted Absorb will gain a market niche but not surpass drug-dispensing metal stents such as Xience in share until longer-term data show more favorable clinical results.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The clinical trial summarized in the story compared the dissolvable stent with a metal stent coated with a drug to minimize future blood clots.\nThe story would have been stronger if it also had\u00a0mentioned traditional metal stents (with no drug coating) and the use of drugs to manage heart disease.", "answer": 1}, {"article": "Melatonin ws effective in synchronizing disrupted circadian rhythms of BP, heart rate and body temperature, making these circadian rhythms smoother and less irregular.\nThe maximum systolic BP lowering effect of melatonin falls between 3:00 and 8:00 in the morning, the time of the highest risk of heart attacks and strokes.\nMoreover, the higher the mean systolic BP was during the first week, the more it dropped on the second week of melatonin administration.\nNone of these effects was found in 34 placebo treated seniors, thus ruling out the possibility that rhythms could be improved just because of regular schedule and presence of medical personal who took measurements.\nIn conclusion, melatonin can be of great value for aged people suffering from hypertension as an adjuvant substance complementing basic medication as it is able to stabilize circadian BP, heart rate profiles and their phase relationships.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The only mention of alternatives occurs in the last sentence, which mentions \u201cbasic medication\u201d for hypertension sufferers and offers up circadian pacemakers as \u201ca new strategy in the treatment of hypertension.\u201d\nThere are established treatments for people with hypertension and for those with insomnia.  The former may range from changes in diet and the addition of exercise to a variety of medications to manage blood pressure. When insomnia becomes a regular occurrence, some people get help from behavioral changes (including diet, exercise and stress reduction) or a variety of prescription or over-the-counter sleep aids that are available.\u00a0", "answer": 0}, {"article": "Other Northwestern authors include Kate Tomasino, Emily Lattie, Hannah Palac, Mary J Kwasny, Kenneth Weingardt, Leland R Bardsley, Lauren Caccamo, Colleen Stiles-Shields and Stephen Schueller.\nThe preliminary study did not include a control arm, so it's possible that some people who enrolled in the trial would have improved anyway, partly because they may have been motivated to try something new, Mohr said.\n\"We designed these apps so they fit easily into people's lives and could be used as simply as apps to find a restaurant or directions,\" said lead study author David Mohr, professor of preventive medicine and director of the Center for Behavioral Intervention Technologies at Northwestern University Feinberg School of Medicine.\n\"Some of the participants kept using them after the study because they felt that the apps helped them feel better,\" Mohr said.\nThe study was supported by grant R01 MH100482 from the National Institute of Mental Health of the National Institutes of Health.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release states that over the course of 8 weeks, participants experienced improvements similar to what people with depression or anxiety would find through psychotherapy or medication. But again,how can such a comparison be made when\u00a064% of participants were already taking antidepressant medication, and 22% were receiving psychotherapy, when they enrolled in the study?", "answer": 0}, {"article": "The Site is down for maintenance.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no comparison made between work on this drug and any other research in this active field of research.", "answer": 0}, {"article": "A sticky mucus clogs organs, particularly the lungs and liver.\n\u201cEven thought it only affects a small percentage (of patients) the hope is there that we can finally do something about this disease.\u201d\n\nThe study, published in the New England Journal of Medicine Wednesday, looked at 84 people who got the drug.\nIn an editorial accompanying the study, Dr. Pamela Davis, of Case Western University paraphrased Winston Churchill, \u201cThis study is also a great victory in the war against genetic diseases and marks the end of the beginning for the treatment of the cystic fibrosis defect.\u201d\n\nIvacaftor has been submitted to the FDA for approval, and could be available next year, according to Konstan.\nThat trial is ongoing and the treatment is at least four or five years away from approval, but if it works, Beall says, it could help 90% of the people with cystic fibrosis.\nDrug recipients could blow out more than 10% more air from their lungs compared with patients who were not taking the drug, and were about half as likely to have a \u201cpulmonary exacerbation\u201d or a worsening of their lung disease that often requires hospitalization.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe story should have noted that advances in managing cystic fibrosis have dramatically increased the life span of people with the disease. Indeed, the editorial accompanying the journal article notes that the health of CF patients declines so gradually now that it will require following many patients for many years to find out if this new drug actually helps them live longer than the treatments already available.", "answer": 0}, {"article": "A birth-control pill that eliminates women's monthly periods could hit pharmacy shelves later this year, marking the latest effort by a drug company to expand a contraceptive's features beyond preventing pregnancy.\n\nSince \"The Pill\" was introduced nearly a half-century ago, most regimens have mimicked a woman's cycle by having a pill-free week each month when women can have bleeding and other symptoms.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article noted that some doctors may prescribe continous use of traditional pills, which can eliminate monthly periods; however, it doesn\u2019t mention whether any other reversible birth control methods may have similar effects. ", "answer": 1}, {"article": "For information on mammography visit Mammography Saves Lives or the Society of Breast Imaging website.\nI encourage women to speak with their providers about mammography benefits and limitations and create a schedule to get their annual mammograms,\" said Debra Monticciolo, MD, FACR, chair of the American College of Radiology Breast Imaging Commission.\n\"Mammography screening is not perfect but has been shown to markedly reduce the number of women each year who die from breast cancer,\" said Elizabeth Morris, MD, FACR, president of the Society of Breast Imaging.\nThis approach saves many more lives than screening started at a later age or with less frequent exams.\nThe ACR and SBI believe women 40 and older should have access to mammograms and that Medicare and private insurers should be required to cover them for these exams.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "A few options are mentioned, i.e. mammography screening only for high-risk groups, later-age screening, and less-than-annual mammograms. Other approaches that could have been discussed include regular physical exams of the breast by a clinician (without mammography) as well as breast self-exams.\u00a0", "answer": 1}, {"article": "\u201cThere are still lots of patients in need of transplants that are not getting them because of lack of matched donors, and that is unacceptable in the year 2016.\u201d\n\nJones estimates that about 7,500 transplants of donated stem cells were done in 2014 \u2014 primarily for leukemia and lymphoma but also for nonmalignant blood disorders such as sickle cell and aplastic anemia \u2014 but that more than 15,000 could easily be done annually if more doctors embraced the new methods now available.\nThe process is dangerous because it leaves a patient vulnerable to life-threatening infection for months before the reconstituted immune system begins to work.\nThis reduces the risk of damaging organs or causing a rejection of the donated marrow.\nA larger trial using umbilical cord blood that had been expanded in a lab is underway.\nIn fact, when she and her doctors scoured the registry for a match for her, only one name came up: her own.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions chemotherapy and radiation but no true comparison to standard cancer therapies or even emerging cancer therapies \u2014 like immunotherapy \u2014 is done in the piece.", "answer": 0}, {"article": "That accounts for a small percentage of people.\nThe prescription-free test is the first to report on three specific BRCA1 and BRCA2 breast cancer gene mutations, according to the FDA.\nMore: Breast cancer: Study finds tumor risk increased by use of oral contraceptives\n\nBut \u201cit has a lot of caveats,\u201d warned Donald St. Pierre, acting director of the FDA's Office of In Vitro Diagnostics and Radiological Health.\nStill, the company, which already tests DNA for other health risks as well as ancestry, said this cancer test is \"a step in the right direction.\"\nThe test detects only three out of more than 1,000 known BRCA mutations.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story may actually confuse readers on this count. The story says: \u201cThe prescription-free test is the first to report on three specific BRCA1 and BRCA2 breast cancer gene mutations, according to the FDA.\u201d That\u2019s awkwardly phrased. It would be more accurate to say that this is the first test you can get without a prescription that reports on these three mutations. 23andMe is not the only company that provides genetic testing for BRCA mutations, and the story does not make sufficiently clear to readers that there are other genetic tests available that evaluate a broader range of potential mutations. It\u2019s just that these other tests aren\u2019t made available directly to consumers.", "answer": 0}, {"article": "So, is kiwi the new \"wonder\" fruit?\n\"There is biological plausibility, but I would not go and grab three kiwis a day,\" said Dr. Nehal Mehta, a preventive cardiologist at the Hospital of the University of Pennsylvania in Philadelphia.\nThey are rich in lutein, a potent antioxidant, and this may be what is responsible for their blood pressure-lowering powers, said researchers who were led by Mette Svendsen of Oslo University Hospital in Norway.\nThe study was to be presented Tuesday at the American Heart Association's annual meeting in Orlando, Fla.\n\nCardiologists were quick to caution that there is no single magic food or ingredient that is the key to heart health, but they all agreed that kiwi may have a place in the five daily servings of fruit and vegetables that are currently recommended as part of a heart-healthy diet.\nResearchers measured blood pressure via 24-hour ambulatory monitoring, which is thought to be more precise than measuring it during a single point in time.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll give the story the benefit of the doubt because it at least mentioned the DASH diet, which is the main dietary intervention recommended in primary care for prehypertension and mild hypertension. The DASH diet is only a little more efficacious than the reported kiwi intervention. (for nonhypertensive patients, the DASH diet lowers the systolic BP 7.1 mm Hg).", "answer": 1}, {"article": "Two studies published Tuesday lend support to controversial new cholesterol guidelines that could vastly increase the number of Americans advised to take cholesterol-lowering drugs called statins.\nOne study suggests that the new guidelines are better at identifying who is truly at risk of a heart attack and should be given statins than the older guidelines are.\nBut they could help dispel some of the criticism of the new guidelines and strengthen the position of those who contend treatment should be extended to more people.\nThe new studies are not large clinical trials that will definitively settle the matter of whether to expand drug treatment to millions more people in hopes of preventing cardiovascular disease, the leading killer of Americans.\n\u201cThere is no longer any question as to whether to offer treatment with statins for patients for primary prevention, and there should now be fewer questions about how to treat and in whom,\u201d said an editorial that accompanied the publication of the studies in JAMA, a journal of the American Medical Association.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u00a0did not make any reference to dietary changes, lifestyle changes, or exercise.", "answer": 0}, {"article": "Previous surgical treatment was performed on 31 of 38 knees in the study group and 37 of the 42 knees in the control group.\nThe American Orthopaedic Society for Sports Medicine (AOSSM) is the premier global, sports medicine organization representing the interests of orthopaedic surgeons and other professionals who provide comprehensive health services for the care of athletes and active people of all ages and levels.\nThe study group consisted of 38 patients, 10 women and 28 men who were at least 40 years of age and a control group with 42 patients (27 men and 15 women) who were 39 years of age or younger.\n\"Our findings note that patients older than 40 may benefit from using a fresh osteochondral allograft transplantation to treat focal cartilage defects, a common cause of knee pain in adults,\" said lead author, Dennis Crawford, MD, PhD from the Oregon Health and Science University in Portland, Oregon.\n\"This type of osteochondral allograft transplantation has traditionally been used in younger active patients with cartilage disorders.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Other techniques for addressing knee pain, including oral medications, injectable medications, physical therapy, and other surgical treatment options, are not mentioned. It is not clear from the release how or why osteochondral allograft transplantation may be more advantageous than other options.", "answer": 0}, {"article": "Why are so few women being treated?\n\u201cThe management of menopause has been relatively similar in the UK, the USA and in Australia.\u201d\n\nUp to half of women in menopause experience so-called vasomotor symptoms, such as hot flashes and night sweats.\n\u201cWomen and doctors simply are not aware that symptoms can last this long.\u201d\n\nFinally, many women don\u2019t realize that non hormonal options can be safe and effective, she added.\nBut after the initial findings of the Women\u2019s Health Initiative study showed that HRT can increase the risk of breast cancer, stroke and other serious problems, many women stopped using it.\n\u201cExtrapolating our findings to 3.7 million Australian women aged 40 to 64 years, we found that 455,000 women are likely to have moderate to severe vasomotor symptoms, with most women (385,000) remaining untreated,\u201d they write.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll give the benefit of the doubt here. The story mentions systemic estrogen therapies, topical creams, and non-hormonal treatments. As noted above, we wish there had been more detailed comparisons of these treatments. Even some links telling people where to get more information would have been helpful.", "answer": 1}, {"article": "Two small prospective studies have suggested no survival difference among women with Stage 4 breast cancer who have surgery and those who don't, he said.\nHere's how he survived]\n\nPrevious research has reached the same conclusion, but a significant problem with this study and others like it is that they rely on retrospective data, looking back over any number of years, said Michael S. Sabel, the chief of surgical oncology at the University of Michigan, who was not involved in the newly published study.\n\"It's premature to suggest, and it\u2019s a difficult conversation to have with patients, that removing the breast will help them live longer in the face of Stage 4 disease,\" Sabel said.\nWith $45 billion pledge to charity, Mark Zuckerberg and wife imagine \u2018a world without suffering from disease\u2019\n\nThe myth of sugar-free drinks, candy: Study shows they can wreak havoc on teeth, too\n\nModern men tend to overeat like cavemen as a way of showing off to women\n\nFor more health news, you can sign up for our weekly newsletter here.\nBut with better therapies to control the cancer systemically and improved imaging that finds ever-smaller deposits of cancer in other parts of the body, it may be time to see whether surgery also can help increase the length of survival times, they said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article hints at \u201cmore sophisticated treatments and better imaging techniques\u201d that have developed over time, but it doesn\u2019t explicit state what those are. We would have liked to have seen a sentence or two describing some existing breast cancer treatments, in the case the patient chooses not to opt for surgery.\nHowever, since the story mentions radiation as a possible therapy, we give it a Satisfactory rating here.", "answer": 1}, {"article": "\"In health as elsewhere, if something looks too good to be true, it should be treated with great caution,\" says an editorial published this week in the medical journal BMJ.\n\"I cannot prove and I don't think anyone can prove that alcohol consumption can prevent anyone from dying or prevent heart attacks,\" says Kenneth Mukamal, an associate professor of medicine at Harvard Medical School, Boston.\nOne theory, backed by the new British study: the results are skewed by the fact that some non-drinkers are former drinkers with health problems.\n\"At those ages, any benefit we get from moderate drinking is only to the extent that someone who is moderately drinking is not heavily drinking,\" Mukamal says.\nBut that's not the only reason, says Lori Mosca, a professor of medicine at Columbia University Medical Center and a spokesperson for the American Heart Association.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The reporter interviewed two physicians who were knowledgeable about heart health \u2013 the cardiologist and the spokesperson for the American Heart Association (AHA). It was a missed opportunity to briefly explain some adjustments one can make to diet and lifestyle to fight heart disease as an alternative to a glass of red wine a day. For example, the AHA recommends 30 minutes of moderate exercise every day and a diet rich in fruits and vegetables to help control weight, blood pressure and cholesterol. An additional sentence along those lines would\u2019ve satisfied this criterion and, we think, improved the message for readers.", "answer": 0}, {"article": "\"It is important to conduct these trials before widespread adoption of technology, as has been the case with robotic prostatectomy (removal of the prostate),\" he said.\nLoyola Medicine offers both open and robotic radical cystectomy and all three bladder replacement techniques.\nA robotic system allows a surgeon to perform operations through a few small incisions.\nMovements by the surgeon's hand or wrist are translated into highly precise movements of the surgical instruments.\nAfter two years, there was no significant difference between the two groups in survival without disease progression.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The comparison of robot-assisted to open surgery was the main point of the release.", "answer": 1}, {"article": "Researchers said challenges in measuring the effectiveness of mammography screenings include increases in breast-cancer awareness and advances in treatment.\n\"Among women in the screening group, there was a 28 percent reduction in mortality from breast cancer during the same period.\nThus, the relative reduction in mortality that was causally related to the screening program alone was 10 percent.\"\nThe study, published in the New England Journal of Medicine, analyzed data from more than 40,000 women with breast cancer.\nResearchers from Norway and Harvard University compared the death rates from breast cancer in four groups: one group of women from 1996 through 2005 who were living in Norwegian counties with screening; another group in the same time period who were living in counties without screening; and two similar groups from 1986 through 1995.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 0}, {"article": "According to Kramer, \"This randomized study concludes that [aspirin's] use is not only effective for reducing the incidence of preeclampsia at term, but also preterm.\nThe reduction in risk was even greater for early deliveries.\nPreeclampsia is a serious high blood pressure disorder.\nA baby aspirin dose is 81 milligrams.\nThe women came from 13 different maternity hospitals across Europe and Israel.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are no known treatment alternatives to preventing preeclampsia.", "answer": 2}, {"article": "All of these study participants \u2014 largely people in their 70s, all with a diagnosis of either \"mild cognitive impairment\" or atypical dementia \u2014 are living with the unconfirmed suspicion that they have Alzheimer's. The study is underwritten by the Centers for Medicare & Medicaid Services and the Alzheimer's Assn. It set out to find out whether knowing \u2014 getting the costly test that would offer either confirmation or reprieve \u2014 would change the way that patients with cognitive troubles are treated, or the way that they plan their lives.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses the rise of imaging technology in diagnosing Alzheimer\u2019s disease, which used to be only definitively diagnosed post-mortem. It also mentions another new experimental technique \u2014 transcranial magnetic stimulation. We think the story could have better discussed the\u00a0relative accuracy of each option, though.", "answer": 1}, {"article": "Jan. 5, 2011 -- A two-week course of the antibiotic rifaximin (Xifaxan) helps to relieve the symptoms of irritable bowel syndrome (IBS), and the relief lasts up to 10 weeks after stopping the medication, according to new research.\nThe drug is approved by the FDA only for traveler's diarrhea and hepatic encephalopathy, a brain disorder caused by chronic liver failure.\n''The major finding was that all IBS symptoms improved,\" says Mark Pimentel, MD, director of the GI Motility Program at Cedars-Sinai Medical Center, Los Angeles, who led the clinical trial of the drug at Cedars.\nWith the drug treatment, Pimentel says, those with the IBS ''can enjoy social outings without the worry of having to run to the bathroom and having diarrhea.\"\nWith the new antibiotic treatment, Pimentel tells WebMD, many participants ''say they are 80% improved, 90% improved, that kind of results.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not compare the antibiotic approach to existing alternatives. It says only, \u201cExisting treatment options \u2014 diet and lifestyle modification, psychological therapy, and other drugs \u2014 do not help all people with the condition.\u201d Well, neither did the drug being studied!\u00a0 And the story didn\u2019t give any details about past research into antibiotic therapy for IBS.", "answer": 0}, {"article": "The study was funded by the Veterans Health Administration's Health Services Research and Development Service\nIn the meantime, he notes, people struggling with addiction who want to seek relief from pain should explore the full range of treatment options that have been shown to work in non-addicted patients, including physical therapy, exercise and psychotherapy as well as antidepressant medications.\nThe sharp rise in opioid addiction in recent years - often among people who started taking the painkillers as treatment for acute or chronic pain -- has made the search for effective non-drug pain treatment options even more urgent, Ilgen notes.\nThe newly published study did show that one in five veterans randomly assigned to ImPAT or the comparison approach did not actually attend any sessions - likely because of delays in getting the sessions going.\nThe low-cost approach, grounded in psychological theories of pain, could help address the nation's epidemic of addictions to opioid painkillers and illicit drugs.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release both addresses why some alternative treatment options are not available for chronic pain patients who suffer from addiction, and explicitly states that \u201cpeople struggling with addiction who want to seek relief from pain should explore the full range of treatment options that have been shown to work in non-addicted patients, including physical therapy, exercise and psychotherapy as well as antidepressant medications.\u201d", "answer": 1}, {"article": "Has he had any use of prescription painkillers since he started the study?\n\"They make you feel great; I'm not going to lie, you take a couple pills, you feel relaxed, you don't feel nervous, you have the weight of the world off your shoulders,\" said one young man named Brian who would not letreveal his identity.\nSuboxone works by taking the place of the opioids in the receptor - not only shutting off withdrawal symptoms but also blocking the effects of any new drugs.\nThe hope is one day that Suboxone can do for painkiller addiction that drugs like Prozac did for depression: convince the public that addiction is a brain disease, not a character flaw.\n\"It can be quite powerful when people begin to use it.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The segment refers to methadone early on. But it does not mention counseling as a stand-alone option for addiction to painkillers, or other drug- or non-drug options. ", "answer": 0}, {"article": "Doctors currently diagnose colds and flus through a patchwork of testing, observation and process of elimination.\nThe downside is that the test is expensive, about $300 to $400, but is covered by most insurers.\nThe test is expected to be used mainly in hospitals and emergency rooms, but doctors can send the swab to a local lab.\nThe new test, called the xTAG respiratory panel, approved earlier this year by the U.S. Food and Drug Administration, is the most comprehensive FDA-approved virus-panel to date.\nAccording to manufacturer Luminex Corp. , Austin, Texas, the viruses in the panel are expected to account for about 85% of the viral illnesses in the U.S. this year.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This article covers all of the bases on treatment diagnosis and treatment option.\u00a0 The flu can be diagnosed based upon clinical observations of signs and symptoms or by other available\u00a0flu tests.\u00a0 Treatment options, flu medicine, antibiotics or no treatment, are clearly indicated.\n\u00a0", "answer": 1}, {"article": "The treatments that were compared and ranked included acetaminophen; ibuprofen; intra-articular (IA) or joint injections of cortisone; platelet-rich plasma (PRP); hyaluronic acid (HA); several NSAIDs, such as naproxen, celecoxib, and diclofenac; and both oral and IA placebo.\nAn analysis of 12 articles also found that results with HA are not significantly different from those with IA placebo for treatment of knee OA.\nThis new research analyzed data from multiple trials to determine the relative effectiveness of various nonsurgical treatments for knee OA.\n\"Because knee OA has both a high disease burden and high treatment costs, additional prospective studies using similar outcomes, timelines, and measures of clinically important changes are needed,\" explained Dr. Jevsevar.\n\u2022 HA injections did not achieve a rank in the top five treatments for pain, function, or combined pain and function.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "A comparison of existing alternatives is the point of the journal article. The news release highlights the comparisons in clear language.", "answer": 1}, {"article": "Both the control diet and the pecan-rich diet were low in fruits, vegetables and fiber.\nA new study published in Nutrients shows that eating just 1.5 ounces of pecans - one small handful - every day may protect adults at risk for developing cardiovascular disease (CVD) and type 2 diabetes (T2D).\nThe study entitled \"A Pecan-Rich Diet Improves Cardiometabolic Risk Factors in Overweight and Obese Adults: A Randomized Controlled Trial\" is available online and will be presented at the American Society for Nutrition Annual Conference, Nutrition 2018 held in Boston this June.\n\"Pecans are naturally high in monounsaturated and polyunsaturated fats, so replacing a portion of the saturated fat in the diet with these healthier fats can explain some of the cardio-protective effects we observed,\" said lead researcher, Diane McKay, Ph.D. \"But pecans also contain a number of bioactive plant compounds as well as vitamins and essential minerals that all likely contributed to this benefit.\nWhat's really interesting is that just one small change - eating a handful of pecans daily - may have a large impact on the health of these at-risk adults.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are many different dietary recommendations that could lower a person\u2019s risk of heart disease and type 2 diabetes. This release does not discuss any other strategies for lowering the risk of type 2 diabetes or heart disease.", "answer": 0}, {"article": "(Editing by Pravin Char)\n\u201cNow we urgently need to see if it works like lithium in people.\u201d\n\nSome 60 years after it was first discovered, lithium - a mood stabiliser that can protect against both depression and mania, and reduce the risk of suicide - remains the most effective long-term treatment.\nScientists say the drug, ebselen, may be a swift answer to long-sought after better medications for patients with the manic depressive disorder, since it is already known to be safe.\nBut it is very toxic - at only twice the right dose it could kill a patient, Churchill said - and its adverse side-effects mean many people stop taking the drug and relapse into episodes of mania and depression.\n\u201cThis is one of the first handful of examples of drug repurposing, where a new use has been found for an existing drug,\u201d Vasudevan said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story describes lithium as the dominant treatment for bipolar disorder. \u201cSome 60 years after it was first discovered, lithium \u2013 a mood stabiliser that can protect against both depression and mania, and reduce the risk of suicide \u2013 remains the most effective long-term treatment.\u201d", "answer": 1}, {"article": "Other expert groups have made similar statements.\nAlso important to remember: While medications can be helpful, the first rule of allergy control is to avoid the substances that make you sniffle and sneeze.\nIt's a myth, he adds, that older, sedating antihistamines, such as Benadryl, are extra effective against nasal allergies.\nOver-the-counter treatments should not take the place of professional care \u2014 especially if you have never been formally diagnosed with allergies, if you have additional medical problems or if your symptoms persist or worsen, Eghrari-Sabet and Sublett say.\nAnd they both sit on store shelves next to antihistamines such as Claritin, Allegra and Zyrtec that were prescription drugs just a few years ago.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article did a great job comparing the various over-the-counter alternatives out there, from steroid nasal sprays like Flonase to antihistamines like Claritin to decongestants like Sudafed.", "answer": 1}, {"article": "MEMPHIS, Tenn., Oct. 26, 2015 /PRNewswire/ -- Imagine.\nIts effectiveness in breast cancer has been proven in a number of smaller studies, including a recent American College of Surgeons Oncology Group (ACOSOG) trial and extensive long-term ongoing, unpublished studies in Japan.\nDeveloped by IceCure Medical (Caesarea, Israel/Memphis, TN), specifically for breast applications, the IceSense3 Cryoablation System\u2122, has a long history of successful treatment of benign breast fibroadenomas.\n\"For women with certain types of breast cancer, cryoablation is showing promise as an alternative to surgery, particularly for patients over age 65,\" says Susan K. Boolbol, MD, Chief of the Appel-Venet Comprehensive Breast Service, Mount Sinai Beth Israel, who is participating in the trial.\nAs a market leader in cryoablation treatment of breast disease, IceCure will utilize its resources to provide clinical and technological support to sites in the cancer trial.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "ICE3 is compared extensively to surgery, which is the leading treatment for breast cancer. However, it would have helped to put the treatment into context with preceding and follow-up treatments, including radiation and chemotherapy.", "answer": 1}, {"article": "Locke said about 13 percent of patients in the trial had a severe side effect known as cytokine release syndrome, which produces high fevers, low blood pressure and other flulike symptoms.\n\u201cIt raises the potential that a cure can be possible.\u201d Some of the first patients who underwent treatment now have been in remission for three to five years, he said, although he cautioned that it's still too early to know whether those patients are cured.\n\u201cToday, marks another milestone in the development of a whole new scientific paradigm for the treatment of serious diseases,\u201d FDA Commissioner Scott Gottlieb said in a statement, adding that the approval demonstrates \u201cthe continued momentum of this promising new area of medicine.\u201d\n\nA CAR T-cell therapy involves a complicated and customized procedure in which T cells \u2014 sometimes called the foot soldiers of the immune system \u2014 are removed from the patient.\nThe one-time infusion, known as CAR T-cell therapy, is made by Kite Pharma, which is based in Santa Monica, Calif., and recently was bought by Gilead Sciences for $11.9 billion.\nThe FDA approval is the latest step forward for the fast-moving field of immunotherapy, which aims to bolster the immune system to attack malignancies.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses other drugs on the market. The implication is that the patient has failed all other available treatments. For insurers this will be a major point. Given the cost of the treatment, insurers may require additional standard therapies that may be less effective but significantly less costly. Moreover, how this new therapy compares to others has not been directly tested. It doesn\u2019t appear that any such head to head comparisons are in the near-term future.", "answer": 1}, {"article": "But the results do merit further research.\nIn the study, published in the Annals of Internal Medicine, researchers randomly assigned 108 people with type 2 diabetes to receive 3, 3.5, or 4 grams per day of salsalate or a placebo in addition to their current diabetes therapy for 14 weeks.\nDue to the small size of the study and short follow-up time, researchers say it's too soon to recommend use of salsalate for the treatment of type 2 diabetes.\n\"Because of salsalate's anti-inflammatory effects, our results suggest that inflammation plays a role in the pathogenesis of type 2 diabetes and that anti-inflammatory therapy may be useful for treating diabetes,\" write researchers Allison B. Goldfine, MD, of the Joslin Diabetes Center in Boston, and colleagues.\nThe results showed those who took salsalate at each of the dosage levels experienced a beneficial decrease in blood sugar A1c levels of 0.5% or more.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While it didn\u2019t compare the drug to existing alternatives, it really couldn\u2019t because at present no head-to-head data exists about this drug compared to other antidiabetic therapies, just data comparing different doses to each other and placebo.\nComparing the drug\u2019s bleeding risks to that of aspirin is not directly relevant to this criterion because aspirin is not currently used to treat\u00a0hyperglycemia.", "answer": 2}, {"article": "Weight training or cardio?\nThe findings, \"Effect of Exercise Type During Intentional Weight Loss on Body Composition in Older Adults with Obesity,\" appear in the November issue of the journal Obesity.\nThese results may be even more important for older adults who gain and lose weight with frequency, because seniors typically don't regain muscle - they regain fat mass - which is \"all the more reason for older adults to try and preserve muscle mass during weight loss,\" Beavers said.\nThe participants were randomly assigned to one of three groups: a weight-loss-only group, who followed a calorie-restricted diet with no exercise regimen; a weight loss plus cardio (i.e., walking) group; and a weight loss plus weight-training group.\nPut another way, the percentage of weight loss coming from muscle mass was 20% in the weight loss plus walking group, 16% in the weight loss alone group, and 10% in the weight loss plus weight training group.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The way that this study was designed compared the intervention of weight training and a weight loss diet (calorie-restricted dieting), diet and walking, and diet alone. Both walking and weight training were much more successful for weight loss than dieting alone. However, the release could have made the distinction in benefits a bit more clear. While seniors lost similar amounts of weight when walking and participating in weight training, the study showed that much of the weight lost from walking was coming from muscle mass, while the weight loss from lifting was from fat.", "answer": 1}, {"article": "Johnson, who runs the Institute of Endocrinology and Preventive Medicine in Dallas, says she only trusts the quality-controlled, safety-tested formulations that are made by pharmaceutical companies and approved by the Food and Drug Administration, whether the hormones come from plants or equine sources.\nFor one thing, the conclusions of the study have been discredited by subsequent studies.\nSuch custom compounds are not FDA-approved.\nOnce a woman is educated, then she knows what to go in and ask for.\n\u201cWe also learned that we see fewer strokes and heart attacks from non-oral methods like a patch or a cream,\u201d she says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article was only focused on HRT and did not discuss any alternatives.", "answer": 0}, {"article": "368 infants from the Basel-Bern Infant Lung Development birth cohort in Switzerland were included in the study.\nIt is already known that environmental factors have a modifying effect on specific genetic risk, so the aim of this new study was to find out whether this could also be true for breastfeeding and this specific gene related to asthma with the respect to respiratory symptoms in early infancy.\nThis is the first time that we were able to show the effect of the 17q21 variants on respiratory symptoms during the 1st year of life, depending on breastfeeding status.\n\"Our study is the first to show that breastfeeding can modify the effect of asthma-related genetic profiles on respiratory symptoms in the first year of life\", commented Dr Olga Gorlanova, from the University Children's Hospital Basel (UKBB), and the University of Basel, Basel, Switzerland.\nFindings revealed that during the weeks that infants were breastfed, those carrying the asthma risk genotypes, had a 27% decreased relative risk of developing respiratory symptoms.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There was no information provided pertaining to possible alternatives to breastfeeding that also might lead to a reduced risk of asthma among infants, even though there is a wealth of information linking numerous environmental factors to the exacerbation of asthma. A recent review article names more than 100 genetic variants have been associated with the development of asthma along with a host of environmental factors.", "answer": 0}, {"article": "Sixty percent of the people who considered pets to be a part of their social networks placed them in the central, most important circle \u2014 the same place many people put close family and social workers.\nThe scientists asked who they went to when they needed help or advice, where they gained emotional support and encouragement and how they spent their days.\nThe interviews with participants are poignant, and reveal the struggle and isolation that can come with mental illness.\nAs one person in the study said, \"When he comes up and sits beside you on a night, it's different, you know.\nPatients with pets often say the animals help keep them from following through on suicidal thinking, because they know their pets depend on them.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t mention other elements of treatment for schizophrenia or bipolar disorder, such as therapy groups that encourage peer support, pharmaceutical or psychosocial interventions.", "answer": 0}, {"article": "KVK is a leader in the development and manufacture of high-quality, FDA-approved medicines that address unmet patient needs.\nIt has not been established that the primary action of such drugs in treating obesity is one of appetite suppression since other central nervous system actions, or metabolic effects, may also be involved.\nLosing five to 10 percent of total body weight is likely to produce health benefits, such as improvements in blood pressure, blood cholesterol, and blood sugars.3\n\nSome side effects of phentermine that have been reported include pulmonary hypertension, valvular heart disease, palpitations, increased heart rate or blood pressure, insomnia, restlessness, dry mouth, diarrhea, constipation and changes in sexual drive.\nThe limited usefulness of agents of this drug class (anorectics), including Lomaira, should be measured against possible risk factors inherent in their use.\nThe possible role of phentermine has not been established, therefore the possibility of an association between heart valve disease and the use of phentermine alone cannot be ruled out.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release makes no mention of other drugs or methods of weight control. Nor does it compare its efficacy with the multitude of dietary approaches available today. It does say that Lomaira \u201cshould be used together with regular exercise and a reduced-calorie diet.\u201d", "answer": 0}, {"article": "This data can be sent to a mobile phone.\n\"The rate of false positive and false negative diagnosis that breath tests give is a real problem in gastroenterology,\" Berean, who is also Chief Technology Officer at Atmo Bioscience, said.\n\"This gives us confidence that our new technology could potentially solve many mysteries of the gut and help the large portion of the population who have not been able to find a useful diagnosis or treatment for their symptoms,\" Kalantar-zadeh said.\nThe vitamin pill-sized capsule, currently being commercialised by Atmo Biosciences, provides real time detection and measurement of hydrogen, carbon dioxides and oxygen in the gut.\n\"Importantly this test is non-invasive and allows the patient to continue with their daily life as normal.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release makes it clear that the capsule is being developed as (hopefully) a more sensitive measure of intestinal gases than currently used breath tests. It\u2019s also made clear such testing is used to diagnose conditions like small intestinal bacterial overgrowth (SIBO) and carbohydrate malabsorption.", "answer": 1}, {"article": "ASTRO publishes three medical journals, International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment.\n\u201cWe found that patients generally can resume normal activities the following day with typical side effects.\u201d\n\nThe study, which appeared in the Red Journal\u2019s January 2017 issue, presented the results of a nonrandomized, prospective clinical trial of 58 patients with low- or intermediate-risk (non-metastatic) prostate cancer, with a median follow-up period of 2.9 years.\n\u201cIt is becoming apparent that patients may be treated definitively for their prostate cancer in as little as a single day with a minimally invasive outpatient procedure,\u201d said lead study author Daniel J. Krauss, MD, a radiation oncologist at Oakland University\u2019s William Beaumont School of Medicine in Royal Oak, Michigan.\nIn contrast to low-dose-rate (LDR) brachytherapy, where radioactive seed implants are placed permanently in the body and gradually deposit low levels of radiation over a period of months, HDR treatments deposit the dose in one treatment, after which the radioactive implant is removed from the patient.\nWithin the six months following HDR therapy, seven patients (12.1%) experienced grade 2 urinary side effects, most commonly frequency/urgency (6.9%).\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release says the study compared safety and effectiveness of single high-dose-rate (HDR) brachytherapy to longer courses of HDR treatment and that this alternative \u201cmay or may not be sufficient to result in cure rates comparable to historical standards.\u201d\nThis sounds inconclusive. Just what are the \u201chistorical standards?\u201d And why talk about \u201ccure\u201d rates?\nA recently published randomized trial (PROTECT, Hamdy et al. NEJM, September 2016) of active monitoring, radiotherapy, and surgery for men with localized cancer found a 99% prostate-cancer specific survival for all treatment arms through 10 years of follow up. \u00a0Speaking of a \u201ccure\u201d rate for low-risk\u00a0disease that does not need to be cured is very misleading. H. Gilbert Welch, MD, MPH. professor of medicine at the Dartmouth Institute, has described these low risk diseases as \u201cpseudo disease.\u201d", "answer": 0}, {"article": "Claudia Kawas, a geriatric neurologist at the University of California, Irvine, said a patient strode into her office soon after the FDA approved the procedure and asked for the \"Alzheimer's test.\" In one hand, he held an article about the approval of Amyvid. In the other, he had a document from a right-to-die group. If the test was positive, he told her, he would get his affairs in order and kill himself within 60 days.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did a solid job of reporting on some of the landscape of research into other tests and other biomarkers for Alzheimer\u2019s disease.", "answer": 1}, {"article": "Dubbed Stop-af, the Medtronic trial showed that almost 70 percent of patients who had cryoablation remained free of the condition after one year, compared with just 7 percent of patients who received drug therapy, according to data presented at the American College of Cardiology meeting in Atlanta.\nA clinical trial of Medtronic Inc\u2019s (MDT.N) cryoablation system looked at 245 patients with paroxysmal atrial fibrillation, a condition marked by intermittent episodes of abnormal heart rhythm that causes the upper chambers of the heart to quiver.\nDuring the follow-up period, 97 percent of patients who got the procedure and 92 percent of the drug therapy patients did not suffer heart attack, stroke or death.\nPatients in the pilot study had advanced atrial fibrillation and tended to have other medical problems, such as high blood pressure, diabetes or coronary artery disease,\n\nPacker, who also led the pilot study, dubbed Cabana, acknowledged that the main limitation of this study was its small size, but said it lays the foundation for a larger one.\nThe Medtronic device, which the company added to its portfolio with the 2008 acquisition of CryoCath, has been approved in Europe and Australia.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0While mentioning that Johnson and Johnson had an ablation device approved for use in the treatment of atrial fibrillation, there was no discussion about how the results obtained with the Medtronic device compared.", "answer": 0}, {"article": "ABOUT CLEARPOP\n\nClearPop for Rapid Earache Relief represents a simple, safe, pediatrician recommended, clinically effective and fun way to treat earaches.\nDue to increasing concern about antibiotic overuse and its links to obesity, celiac disease, and Superbugs, the American Academy of Pediatrics now recommends against the use of antibiotics to treat routine ear infections in children over 2.\nFull study report at http://clearpop.com \n\n\n\nEAR INFECTION AND ANTIBIOTICS\n\nEar infections are the Number One reason kids aged 5 and under receive oral antibiotics.\n-is increasingly used by frequent flyers to deal with ear pain that afflicts children disproportionately during air travel.\nClearPop is made by Try This First, Inc. a physician-funded \"small pharma\" organization aimed at reducing the estimated 30 million antibiotics prescriptions written to children yearly for ear infection.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release\u00a0makes no comparisons between this product and the efficacy of antibiotics or other pain relief drugs such as Tylenol, Motrin, aspirin and others that come in pediatric formulations.", "answer": 0}, {"article": "\u2022 4.9 million babies are born with a serious birth defect worldwide every year\n\u2022 3.3 million children under five die from serious birth defects annually\n\u2022 Congenital heart disease is the most common form of birth defect, affecting 1 in 100 babies\n\u2022 42 babies are born with a heart defect in Australia every week\n\u2022 30 babies will undergo heart surgery in Australia every week\n\u2022 Heart defects account for 30% of deaths in children under five\n\n[1] Baker H, DeAngelis B, Holland B, Gittens-Williams L, Barrett T Jr. Vitamin Profile of 563 Gravidas during Trimesters of Pregnancy.\nThis will enable doctors to identify those women who are at greatest risk of having a baby with a birth defect, and ensure they are getting sufficient vitamin B3.\nIt\u2019s extremely rare to discover the problem and provide a preventive solution at the same time.\nBefore vitamin B3 was introduced into the mother\u2019s diet, embryos were either lost through miscarriage or the offspring were born with a range of severe birth defects.\nEvery year 4.9 million babies are born with a birth defect worldwide and one in four pregnant women suffer a miscarriage in Australia.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release doesn\u2019t mention any other strategies for preventing miscarriage beyond vitamin B3 supplements.", "answer": 0}, {"article": "This post has been updated.\nBut the patch costs less and has fewer side-effects than varenicline (including nausea, difficulty sleeping and abnormal dreams), so the researchers concluded that slow metabolizers should be put on the patch.\nThe ratio of two metabolites, or byproducts, of the body's processing of nicotine allows easy identification of the two groups.\nThe researchers, led by Caryn Lerman, a professort of psychiatry, divided 1,246 subjects into slow metabolizers of nicotine and normal metabolizers of the addictive chemical, based on the length of time it took for them to rid their bodies of the drug.\nThe results of the comparison showed that slow metabolizers did just as well on a nicotine patch or the drug varenicline (marketed as Chantix), a drug that works on the nicotine receptors in the brain.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study being reported on was a comparison of two popular smoking cessation aids, and the story also mentions nicotine gum. We\u2019ll award a satisfactory, but wish that the story had mentioned counseling as an approach that\u2019s also supported by strong evidence.", "answer": 1}, {"article": "Liao feared that cutting open Holmes\u2019 chest and sternum for an open bypass surgery would disrupt his rehabilitation from the cardiac arrest and delay his plans to return to athletics.\nThe learning curve for cardiac surgeons was too steep, though, and the system\u2019s tools weren\u2019t as useful for heart surgeries as they were for other procedures, said Dr. Goya Raikar, a cardiothoracic surgeon at Regions Hospital in St. Paul.\nIt\u2019s roughly the 50th coronary artery bypass Liao has performed using the robotic system at the University of Minnesota Medical Center, Fairview, and the surgeon said he\u2019s seen enough cases to believe it\u2019s making a difference.\nThe robotic systems come with million-dollar price tags and are used for a limited number of surgeries \u2014 mostly the removal of cancerous prostates in men or uteruses in women.\nThe number of da Vinci robots has doubled in Minnesota in less than two years, with two at the university and four at the Mayo Clinic in Rochester.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "In the two cases cited, the article at least briefly describes what treatment without the machines would have been like. In each case, it\u2019s open-heart surgery, which carries higher risks in the patients described. \nBut it would have been valuable to know where robot-assisted surgery falls among treatment choices\u2013including non-robot-assisted minimally invasive surgeries and non-surgical options\u2013for someone found with clogged coronary arteries, for instance. \u00a0", "answer": 0}, {"article": "No more than a few days later, the samples were transported to labs at the university, where they remained frozen until they were processed by researchers. This ensured that none of the bacteria had a chance to grow or change from the time the sample was collected. Also, it guaranteed that all samples were treated the same way.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Given the context of the research, this is not relevant.", "answer": 2}, {"article": "It's a \"close call,\" says H. Gilbert Welch, MD, MPH, of the Dartmouth Institute in Lebanon, N.H.\n\n\"This is a test that women who want it should be able to have,\" Welch tells WebMD.\nHow many lives?\n\"Because we don't know which cancers these are, all cancers are treated.\n\"Some will benefit in a very large way.\n\"The vast majority will turn out not to have cancer, but all of them will worry.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 1}, {"article": "Australian drug maker CSL Ltd. published results of a study that found 75 percent to 96 percent of vaccinated people should be protected with a single dose \u2013 the same degree of effectiveness as the regular winter flu shot.\nThe winter flu vaccine is widely available now, and U.S. health authorities urged people to get it out of the way now before swine flu shots start arriving in mid-October.\nBut scientists had feared that people of all ages would need two shots about a month apart because the new H1N1 strain is so genetically different from normally circulating flu strains that most of the population has little if any immunity.\nWaiting to get the first inoculation out of the way \"is not in anybody's best interest,\" added Dr. Nancy Nielsen, past president of the American Medical Association.\nThe report from the Centers for Disease Control and Prevention Friday also came with good news: Testing of vaccines for swine flu show that they work with a single dose and take effect rapidly.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe focus of this story is on the effectiveness of different immunization schedules and doses. However, as part of the background information, it could have noted that even after receiving a flu shot, public health officials are urging people to minimize close contact with other people, use good hygiene, and stay home when sick in order to reduce the likelihood of spreading or catching flu viruses.", "answer": 0}, {"article": "Commenting on the Nature Medicine study, he tells Newsweek the paper is \u201cvery interesting on a number of levels.\u201d\n\n\u201cFirst of all there\u2019s clearly growing interest in the potential therapeutic role of cannabinoids and in this particular case THC on various human conditions,\u201d he says.\nIn humans it could be years before an effect is noticed.\u201d\n\n\u201cFinally, there is the issue surrounding safety.\nIn a study published in Nature Medicine on Monday, researchers led by Andreas Zimmer, from the University of Bonn, Germany, have shown how THC can provide significant benefits to mice when it comes to age-related cognitive decline.\nTo study what effect THC has on the aging brain, scientists gave low doses of THC to mice at three different life stages\u2014two months, 12 months and 18 months.\nIn the U.K., Oxford University recently launched a \u00a310 million ($13 million) program to \u201cidentify new medical therapies through research into the molecular, cellular and systems mechanisms of cannabinoids.\u201d Meanwhile, the U.S. Food and Drug Administration has now approved several medications derived from THC.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Alternatives were not discussed. There are prescription medications for memory decline, as well as exercise and stimulation (eg, games).", "answer": 0}, {"article": "That's when they learned cocoa compounds named epicatechin monomers enhanced beta cells' ability to secrete insulin.\n\"The epicatechin monomers are making the mitochondria in the beta cells stronger, which produces more ATP (a cell's energy source), which then results in more insulin being released.\"\nThey found that by adding it to the high-fat diet, the compound would decrease the level of obesity in the animals and would increase their ability to deal with increased blood glucose levels.\nThe new study, published in the Journal of Nutritional Biochemistry, finds beta cells work better and remain stronger with an increased presence of epicatechin monomers, compounds found naturally in cocoa.\n\"What happens is it's protecting the cells, it's increasing their ability to deal with oxidative stress,\" Tessem said.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not put this potential treatment into context with available treatments. However, the research is far too preliminary to even begin making comparisons to alternatives.", "answer": 2}, {"article": "But they can be deadly in the modern era.\n\u201cThat hypothetically decreases the risk for adverse events.\u201d\n\nFor all the research on allergies, none of the drugs in the pipeline is a sure thing.\nIt\u2019ll be interesting to see how this translates into making it into a pharmacy, and into the hands of patients.\u201d\n\nCorrection: A previous version of the story misstated some aspects of Aimunne\u2019s work on peanut allergies.\n\u201cThere\u2019s really no doubt that there have been cold feet in the industry about this issue.\u201d\n\nBut investigators around the world have shown they can carry out these \u201cfood challenge\u201d trials safely \u2014 which could help hasten the development of new drugs.\nIt was approved by the FDA in 2003 to treat a form of asthma often triggered by allergens, but Stanford researchers are now testing it on patients with food allergies \u2014 and finding that it might help speed along classic allergy desensitization therapy, in which patients are slowly introduced to escalating quantities of the allergen, via allergy shots or those \u201chome brew\u201d concoctions.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is acknowledgment of the possibility that the new treatments may not work any better than older ones for many patients. The story would have been stronger if it had done more head-to-head comparisons of effectiveness.", "answer": 1}, {"article": "Cooper and his colleagues looked at 29,507 births to women covered by Medicaid in Tennessee between 1985 and 2000.\nThe alternatives that clinicians might want to consider are diuretics, alpha-methyldopa, some beta-blockers, and the calcium-channel blocker nifedipine, according to the FDA officials and an editorial accompanying the study.\nThe fraction of babies with defects was 7.1 percent in the ACE-inhibitor group; 1.7 percent in the other anti-hypertensive group; and 2.6 percent in the group taking no blood-pressure medication.\n\"It would be important for a pregnant woman and her health-care provider to be aware of this, so they can identify an alternative medicine to treat her hypertension,\" said William O. Cooper, a pediatrician at Vanderbilt Children's Hospital who headed the study, published in today's New England Journal of Medicine.\n\"I think it is safe to say that not a lot is known about the options for women in pregnancy,\" said Sandra L. Kweder of the FDA's Center for Drug Evaluation and Research.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article included a list of other medications that may be used to to lower blood pressure. However these suffer from the same lack of clinical testing of their safety for use in pregnant women. The story discussed the impact of pregnancy on blood pressure \u2013 lowering it for some women and raising it in others.", "answer": 1}, {"article": "[3] Analysis only included cases occurring 10 days after receiving the vaccine to account for the incubation period of the Ebola virus.\n\"This both historical and innovative trial was made possible thanks to exemplary international collaboration and coordination, the contribution of many experts worldwide, and strong local involvement,\" said Dr John-Arne R\u00f8ttingen, Specialist Director at the Norwegian Institute of Public Health, and the chairman of the study steering group [4].\nIn addition to showing high efficacy among those vaccinated, the trial also shows that unvaccinated people in the rings were indirectly protected from Ebola virus through the ring vaccination approach (so-called \"herd immunity\").\nAlso published in The Lancet (embargo as above), is a phase 2 trial of a different Ebola vaccine candidate, the recombinant adenovirus type-5 Ebola vaccine.\nThe vaccine's manufacturer, Merck, Sharpe & Dohme, this year received Breakthrough Therapy Designation from the United States Food and Drug Administration and PRIME status from the European Medicines Agency, enabling faster regulatory review of the vaccine once it is submitted.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release also briefly summarizes a study of a different Ebola vaccine candidate being developed by a Chinese organization. This study, also published in the same issue of The Lancet, was much smaller, involving only 500 participants, and suggested that the effectiveness of this vaccine declined during the first six months after the initial injection.\nTo be even more thorough, the release\u00a0might have\u00a0acknowledged that still other vaccines are under development by GlaxoSmithKline, Johnson & Johnson and at least one other pharmaceutical company.", "answer": 1}, {"article": "The body naturally synthesizes vitamin D when the skin is exposed to sunlight.\nBut whether vitamin D is the reason for the excess risks \u2014 and whether taking supplements can curb those risks \u2014 has yet to be shown.\nAt the end of the study, the researchers found no clear difference between the two groups in the average number of days missed from duty due to a respiratory infection \u2014 which included bronchitis, sinus infections, pneumonia, ear infections and sore throat.\nNEW YORK (Reuters Health) - A daily vitamin D supplement may help young men enjoy more sick-free days during cold and flu season, a small study suggests.\nOn the other hand, a recent study of 162 adults found that those who took 2,000 IU of vitamin D everyday for 12 weeks were no less likely to develop respiratory infections than those given placebo pills.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story points out that experts generally recommend supplements only when people aren\u2019t getting enough vitamin D from their diet or sunlight. And as noted above, the story points out that supplements expose people to some risks of vitamin D toxicity.", "answer": 1}, {"article": "If media wish to link to the paper once it's published, they can use the following link, which will go live when the embargo lifts: http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(16)30179-5/abstract\nThe research was funded by Novartis Pharmaceuticals, National Institute for Health Research (NIHR) and the EU (AirPROM), and is described by the lead researcher as \"a game changer for future treatment of asthma.\"\nWhen a person with asthma comes into contact with something that irritates their sensitive airways it causes the body to react in several ways which can include wheezing, coughing and can make breathing more difficult.\nThe rate in people with moderate-to-severe asthma taking the medication was reduced from an average of 5.4 percent to 1.1 percent over 12 weeks, according to the study published today in the prestigious The Lancet Respiratory Medicine journal.\nThe study was designed primarily to examine the effects on inflammation in the airway by measuring the sputum eosinophil count.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release makes no mention of alternative treatments for asthma. There is no comparison with current approaches such as inhalers and corticosteroids or any other approaches regarding this illness.\nThere are a variety of established treatments that are used according to standard protocols depending on asthma severity.  ", "answer": 0}, {"article": "Information on breast cancer is available at cancer.gov.\nThose who take a daily low-dose aspirin, also called a baby aspirin, usually do so to prevent cardiovascular disease, the leading cause of death for women older than 25.\nHowever, aspirin can increase the risk for internal bleeding, so women should talk with their doctors before starting a low-dose aspirin regimen, for any reason.\nAbout 23 percent of the women reported taking a low-dose aspirin (81 milligrams), 18 percent took ibuprofen, 11 percent took full-strength aspirin (325 mg) and about 10 percent took a COX-2 inhibitor or another nonsteroidal anti-inflammatory drug (NSAID).\nThe study did not find similar links between regular-dose aspirin or other NSAIDs and the risk for breast cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are a host of things that women can do to reduce their risk of breast cancer, though all of it\u2019s based on observational data, and aren\u2019t powered to prove that reducing the behavior actually reduces breast cancer.\u00a0There should have been at least some discussion about these factors.", "answer": 0}, {"article": "In a new study published Tuesday in the journal BMC Medicine, scientists studied 79 infants.\nOverall, the biggest differences in brain activity were seen at 9 months \u2013 which is much earlier than when a child typically shows behavioral problems associated with autism.\nThe EEG technique is much easier to use because the baby can be awake and moving and wiggling around, says Dr. Geraldine Dawson, chief science officer for the advocacy group Autism Speaks, which partially funded this research.\nBut he says by using an electroencephalogram and new, sophisticated computer programs to analyze the EEGs, he and his co-authors were able to correctly identify with 80% accuracy, which babies were at higher risk for autism and which were not.\nThis will now allow the researchers to evaluate them for autism and then look back at the brain activity patterns of the children who do fit the clinical criteria for autism.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story failed to compare this diagnostic approach to existing approaches, saying only that \u201cBosl says the first children enrolled in his study are now at 2 and 3 years old, which is the age when\u00a0\u00a0autism usually is diagnosed. This will now allow the researchers to evaluate them for autism and then look back at the brain activity patterns of the children who do fit the clinical criteria for autism.\u201d How they are going to be evaluated for autism remains a big question. One presumes that they will be given a battery of behavioral tests, which, for now, are the gold standard. This should have been explained and the reasons why children younger than 2 cannot be accurately screened should have been explored.", "answer": 0}, {"article": "A government panel of experts released updated guidelines today spelling out who should be taking a daily low-dose aspirin for heart health, which also offers the added benefit of protection against colorectal cancer.\n\"The benefits of aspirin outweigh the harms for most people in their 50's who are at risk of cardiovascular disease but not at increased risk of bleeding.\nAccording to the Centers for Disease Control and Prevention, about 610,000 Americans die of heart disease each year, accounting for 1 in 4 deaths.\nSpecifically, the group recommends that adults 50 to 59 years old who have a 10 percent or greater 10-year cardiovascular disease risk, are not at an increased risk for bleeding, and have a life expectancy of at least 10 years take a daily low-dose aspirin to prevent heart attack, stroke, and colorectal cancer.\nWhile taking low-dose aspirin daily can help prevent heart troubles, doctors note that it also increases the risk of bleeding in the stomach and intestines, and strokes caused by bleeding in the brain.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are other ways\u00a0to reduce cardiovascular risk, (exercise, diet modification, quitting smoking, other medications) and those would deserve at least a mention in a story like this, and how they compare in terms of benefits and harms.", "answer": 0}, {"article": "Then President Richard Nixon declared drugs \u201cpublic enemy No.\n\u201cThose kinds of changes are not delusional, because blinded interviews with family members, friends and work colleagues [confirm these reports].\u201d\n\nSimilar work has shown psilocybin can help treat anxiety associated with cancer, at UCLA and New York University.\nBut at the same time, many of these substances were taken in uncontrolled settings by large numbers of people, and certain proselytizers (like Timothy Leary) advocated their widespread use.\nThe idea that you can take a medicine one or a few times and become \u201ccured,\u201d or at least significantly helped, conflicts with current standard practices, which often involve taking medications every day for years, or life.\nIn the past 20 years or so, a small amount of research has once again begun to focus on these chemicals, showing that they have promise for treating a range of conditions, from addiction to depression and anxiety, says Evan Wood, a psychiatric researcher at the University of British Columbia.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although it mentions that mental health problems are often treated with\u00a0drugs like serotonin-specific reuptake inhibitors, it doesn\u2019t discuss how the psychedelic drugs compare to those drugs or each other, or other types of non-drug therapy. We\u2019ll give the benefit of the doubt here, though we wished for more detail.", "answer": 1}, {"article": "Jan. 18, 2011 -- Low doses of the antidepressant Lexapro (escitalopram) cooled off hot flashes better than placebo in about 200 menopausal women, according to a new study.\n''We believe escitalopram provides an option for treating moderate to severe hot flashes that are disrupting people's lives and quality of life,\" says study researcher Ellen Freeman, PhD, a research professor in the department of obstetrics-gynecology and psychiatry at the University of Pennsylvania School of Medicine, Philadelphia.\nThe new study findings suggest Lexapro can provide an option for women reluctant to take hormone therapy.\nThe findings are published in TheJournal of the American Medical Association.\nPrevious studies of other antidepressants have yielded mixed results, according to Freeman.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that hormone therapy is another treatment option for hot flashes, but it doesn\u2019t provide enough information\u00a0to allow the reader to compare the two approaches. The story should have mentioned that hormone therapy seems to be more effective than antidepressants at reducing hot flash symptoms, although the risks may also be greater. It also could have mentioned that complementary and alternative medicine approaches are often used for hot flashes.", "answer": 0}, {"article": "Researchers agreed that until there\u2019s clearer evidence for benefit, men with healthy hearts shouldn\u2019t seek out statin prescriptions for the purpose of lowering their prostate cancer risks.\n\u201cIf a person\u2019s on the fence about taking a statin medication for their heart, this is another potential benefit they may have by taking one of these,\u201d he told Reuters Health.\nTo prove that statins protect against aggressive cancer would require a large study in which cancer-free men, or those with early-stage disease, are randomly assigned to take statins or not and then tracked for years to see how many of them die from cancer.\nThe drugs run anywhere from $11 to more than $200 per month, and sometimes cause side effects including muscle pain, nausea and gas and liver dysfunction.\nHe said that cholesterol is a \u201ckey nutrient\u201d for cancer cells, so lower cholesterol levels in the body could prevent more aggressive forms of cancer from developing.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Final line of the story quotes an independent expert saying \u201cthat other strategies for lowering cholesterol \u2014 such as eating better and exercising regularly \u2014 are ways almost everyone can lower their disease risks in the meantime.\u201d", "answer": 1}, {"article": "A new asthma drug being developed by Sanofi and Regeneron Pharmaceuticals may help patients whose condition is not well controlled by existing medicines, according to the results of a small clinical trial released Tuesday.\n\nIn the 12-week study, the number of asthma attacks or other outbreaks of symptoms decreased by 87 percent in those getting the drug, dupilumab, compared with those getting a placebo.\n\nOther measures of lung function and disease control also improved, according to the study results, which were published online Tuesday in The New England Journal of Medicine and presented at the annual meeting of the American Thoracic Society in Philadelphia.\n\nDupilumab blocks the action of interleukin-4 and interleukin-13, two inflammatory chemicals made by the body that are believed to contribute to asthma. Sanofi and Regeneron say there are also preliminary signs dupilumab works against the skin condition atopic dermatitis, suggesting it can be blocking a biological pathway that contributes to multiple allergic conditions.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not provide a clear comparison between this drug and existing therapies. Olamizumab (Xolair), for example, has been available for a number of years to treat severe allergy and asthma.\u00a0 The story does note, helpfully, that the \u201cIn the first few weeks of the trial, when patients were still taking their existing drugs, there was no significant difference in the number of worsenings of asthma between dupilumab and the placebo\u201d.", "answer": 0}, {"article": "The ChemMedChem study is available at http://dx.\nThe best inhibitor in this group, SCA-50, showed strong activity against MRSA Mu50 strain and an inhibitory effect on MRSA Mu50 that was two-to-60 times more potent than all commonly used antibiotics, including vancomycin, the last resort option for treating MRSA-related infections.\nCommunity-acquired MRSA often begins as a skin boil and is spread by skin-to-skin contact.\nBecause of the widespread resistance of bacteria to antibiotics on the market, there is an urgent need for the development of new antimicrobials.\nTheir findings indicate that targeting SecA is an attractive antimicrobial strategy against MRSA and may be several times more effective than the antibiotics now available for treating the infection.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions that there are antibiotics currently used to treat MRSA infections. More detail regarding the effectiveness of these antibiotics and rates of antibiotic resistance would have been welcome.", "answer": 1}, {"article": "The new findings add to other evidence showing that medical testing is on the rise across the U.S., although in many cases the impact on overall health remains unclear.\nAfter 1998, that number rose to 112 per 100,000.\nThe condition usually occurs when a blood clot travels from the legs to the lungs, sometimes with fatal results.\n\u201cRight now, it is a difficult place for the patient to be in,\u201d Wiener said.\nIn the years before 1998, when the technique was introduced, 62 per 100,000 Americans were diagnosed with a pulmonary embolism annually.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The dilemma was framed appropriately at the end:", "answer": 1}, {"article": "\"Some cases of SIPE appear to have been the result of cardiac problems,\" said Moon, who was lead author of the study published online February 16 in Circulation: Journal of the American Heart Association.\nOften the symptoms dissipate over 24 hours, but the condition can be serious and even fatal and medical attention is recommended.\nMany don't know they are prone to the problem until they are in the water and quickly develop symptoms.\n\"This is a small study, but also very intensive with direct, accurate pressure measurements,\" Moon said.\nAfterward, she consulted her cardiologist and was prescribed a low dose of sildenafil that she takes shortly before competitions.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Information about possible treatment alternatives (for example, diuretics or oxygen) is not provided.", "answer": 0}, {"article": "Some 68% of the country is either overweight or obese, but there\u2019s not much clinical evidence on the best way to lose weight, outside of research on bariatric surgery. (True, \u201cEat less and exercise more\u201d is great advice if you can manage to follow it, but public-health authorities have repeated that line until they\u2019re blue in the face and as a population we\u2019ve only gotten fatter.)\n\nResearch presented over the weekend at the annual meeting of the Obesity Society and published online in the Journal of the American Medical Association suggests a few specific strategies that may help \u2026", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says up high that \"there\u2019s not much clinical evidence on the best way to lose weight, outside of research on bariatric surgery. (True, \u201cEat less and exercise more\u201d is great advice if you can manage to follow it, but public-health authorities have repeated that line until they\u2019re blue in the face and as a population we\u2019ve only gotten fatter.)\" The study itself compared three different approaches, and the story also makes this important note:\u00a0\"The countervailing theory is that people value things more when they pay for them, and that the mere act of ponying up $1,600 for three months of a diet program may make you take it more seriously.\"", "answer": 1}, {"article": "In this case, the study addressed a tricky problem.\nThe women on low-fat diets had a 9 percent lower rate of breast cancer; the incidence was 42 per thousand per year in women in the low-fat diet group, compared with 45 per thousand per year in women consuming their regular diet.\nThe most recent study follows a smaller one, reported last year, on low-fat diets for women who had breast cancer.\nBut the current study, asking if a low-fat diet could protect women from breast cancer in the first place, had findings that fell short of statistical significance, meaning they could have occurred by chance.\nThe idea is that a high-carbohydrate, low-fat diet leads to weight gain, higher insulin and blood glucose levels, and more diabetes, even if the calories are the same as in a higher-fat diet.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This article failed to provide context for the study diet in terms of typical diet, intended study diet, and actual study diet. Mention is made that there is more recent evidence suggesting that not all fats contribute equally to cardiovascular disease risk. Failed to mention caloric intake limitation for managing weight as an alternative to solely targeting fat consumption.", "answer": 0}, {"article": "\"It's known that EPA and DHA can inhibit breast tumour growth, but no one has looked directly at how effective these omega-3s are compared to ALA.\"\n\nMa found overall exposure to marine-based omega-3s reduced the size of the tumours by 60 to 70 per cent and the number of tumours by 30 per cent.\nThe next step is to investigate the effects of omega-3s on other forms of breast cancer.\nHowever, higher doses of the plant-based fatty acid were required to deliver the same impact as the marine-based omega-3s.\nIn North America, we don't get enough omega-3s from seafood, so there lies an opportunity to improve our diet and help prevent the risk of breast cancer.\"\nALA is plant-based and found in such edible seeds as flaxseed and in oils, such as soy, canola and hemp oil.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release doesn\u2019t mention evidence-backed strategies to reduce breast cancer risk such as limiting alcohol consumption and getting exercise.", "answer": 0}, {"article": "The original form of vancomycin is an ideal starting place for developing better antibiotics.\nEven if they found a solution to one of those, the organisms would still be killed by the other two.\u201d\n\nTested against Enterococci bacteria, the new version of vancomycin killed both vancomycin-resistant Enterococci and the original forms of Enterococci.\nThe researchers, led by Dale Boger, co-chair of TSRI\u2019s Department of Chemistry, discovered a way to structurally modify vancomycin to make an already-powerful version of the antibiotic even more potent.\nCombined with the previous modifications, this alteration gives vancomycin a 1,000-fold increase in activity, meaning doctors would need to use less of the antibiotic to fight infection.\nBoger called vancomycin \u201cmagical\u201d for its proven strength against infections, and previous studies by Boger and his colleagues at TSRI had shown that it is possible to add two modifications to vancomycin to make it even more potent.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release doesn\u2019t discuss the other areas of research into developing new drugs that may be useful in addressing antibiotic resistance \u2014 and it\u2019s a large field. We would not expect a news release to provide an exhaustive overview of other approaches being taken, but providing a sentence or two about other approaches would be extremely valuable in helping readers to place the new work in context.", "answer": 0}, {"article": "Franks says thalidomide can help an additional 75% of patients achieve remission.\nAll the other patients showed improvement, and the rash cleared up in 86%.\nOne patient withdrew from the study after one week due to digestive system side effects.\nThe lenalidomide study included 15 women with lupus skin conditions; six had lupus in other areas of the body, too.\nBut side effects are common and some, including nerve damage in the hands and feet, can be permanent.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "To be clear,\u00a0 the study did not compare lenalidomide to anything. The story discusses alternatives outside of these study results.", "answer": 1}, {"article": "Taylor said he thought it did not find any evidence of big benefits because the numbers of people studied and the salt intake reductions were relatively small.\nFrancesco Cappuccio, head of the World Health Organization\u2019s collaborating center for nutrition at Warwick University, said it was \u201ca surprisingly poor piece of work.\u201d\n\n\u201cThis study does not change the priorities outlined worldwide for a population reduction in salt intake to prevent heart attacks and strokes, the greatest killers in the world,\u201d he said in an emailed comment.\nIn Britain, the National Institute of Health and Clinical Guidance (NICE) has called for an acceleration of the reduction in salt in the general population from a maximum intake of 6 grams(g) a day for adults by 2015 to 3 g by 2025.\nElaine Rush, a professor of nutrition at Auckland University of Technology in Australia, said that putting a spotlight on single trials and generalizing dietary advice for a single nutrient such as salt was \u201cnot helpful.\u201d\n\n\u201cWhat is helpful is for the food industry to reformulate products to reduce sodium and increase the nutrient quality of foods by using real ingredients,\u201d she said in an emailed comment.\n\u201cThe people in the trials we analyzed only reduced their salt intake by a moderate amount, so the effect on blood pressure and heart disease was not large,\u201d he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no mention in this story about what is known about other means of reducing the risk of developing or dying of heart disease. \u00a0A brief mention \u2013 even one additional sentence \u2013 about the importance of smoking cessation, exercise, and other dietary changes would have provided perspective.", "answer": 0}, {"article": "SATURDAY, Sept. 29, 2012 (HealthDay News) -- Researchers say they've discovered a two-drug combination that delays treatment resistance in patients with advanced melanoma.\nAfter one year of treatment, 41 percent of patients receiving the full-dose combination treatment had no progression of their melanoma, compared with 9 percent of those receiving dabrafenib alone.\nAmong patients receiving the combination treatment, the development of side effects such as skin rash and a less dangerous type of skin cancer called squamous cell carcinoma was similar to that typically seen in patients taking only one of the drugs.\nPatients who received dabrafenib alone were able to receive the full-dose combination treatment if their cancer resumed progression.\nMelanoma is the most serious, and often deadly, form of skin cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Other new drugs have recently been approved for the treatment of advanced melanoma. The story did not mention these or compare results.", "answer": 0}, {"article": "For more information, go to UHhospitals.org.\nA new investigational delivery method for localized vaginal estrogen therapy that utilizes an applicator free softgel to alleviate moderate-to-severe vaginal pain during intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), received high rates of patient satisfaction among post-menopausal women, according to post-trial survey results published in the journal Menopause.\n\"These survey results show that something as simple as a change to a more elegant delivery system that is easier to use and not messy might empower more post-menopausal women to seek prescription treatment for VVA, and perhaps help them stay with the application guidelines for longer,\" said study first author Sheryl Kingsberg, PhD, Division Chief, OB/GYN Behavioral Medicine, UH Cleveland Medical Center; Professor of Obstetrics and Gynecology and Psychiatry, Case Western Reserve University School of Medicine; and first author of the survey analysis.\n\"We still have to find better ways to educate the millions of women suffering with VVA about the symptoms, however, so that more of them know it is common, decide to discuss treatment with their healthcare professional, and seek symptom relief with appropriate treatment.\"\nThe majority of women taking either TX004HR or placebo (85.4 - 92.1 percent) found the product easy to use.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release mentions several other over-the-counter and prescription products used to treat symptoms of VVA, including creams, moisturizers, tablets, vaginal rings and oral drugs. However, it does not explicitly compare the softgels to these products but mentions that women preferred the softgels to them. The only reference to this comparison comes in a quote from the first author, who described the softgels as \u201ca more elegant delivery system that is easier to use and not messy.\u201d\nIt would have been nice to see the data on how those women who had previously used another product felt the softgels compared.", "answer": 0}, {"article": "So when the government advisory panel \u2014 the U.S. Preventive Services Task Force \u2014 recommends against routine PSA testing, it\u2019s making a judgment call.\nThe rate of new diagnoses of all cancer types combined has been falling consistently in recent years.\nIn the U.S., a large randomized trial found no mortality benefit of screening.\nOne is how well screening can actually work to prevent cancer deaths; the other is what kind of negative effects screening brings along with its benefits.\nIn its latest results published this spring, the European study team said that men who undergo routine testing have significantly lower risk of prostate-cancer death after 11 years.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternative to PSA screening is the choice to decline screening, which is implicit in the discussion.", "answer": 1}, {"article": "'This is not the end': Using immunotherapy and a genetic glitch to give cancer patients hope\nBleeding episodes \u2014 which can result from injury or occur spontaneously \u2014 can cause extensive damage and be life threatening.\n\u201cPeople were planning their lives around hemophilia, and now they are doing activities that they weren't before,\u201d George said.\nAnd its effects lasted; after a year and a half, the longest patient follow-up, the therapy was continuing to work.\nJay Konduros used to rush home several times a year after accidentally cutting or bumping himself.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Individuals coping with hemophilia B have few options, and the story describes the main one: injections of blood-clotting factor to stem runaway bleeding.", "answer": 1}, {"article": "\u2022 3 diet shakes per day and 240 grams of non-starchy vegetables taking in between 600 and 700kcal a day for 8 weeks\n\u2022 volunteers then gradually returned to eating normal food over the next two weeks with very careful instruction on how much to eat\n\u2022 volunteers were seen once a month and supported with an individualized weight maintenance programme over the next 6 months\n\u2022 to keep weight steady after the weight loss, they were eating around one third less than before the study\n\nAllan Tutty, 57, from Sunderland, transformed his health by taking part in the study.\nIf a person gains more weight than they personally can tolerate, then diabetes is triggered, but if they then lose that amount of weight then they go back to normal.\nThough the volunteers lost weight they remained overweight or obese but they had lost enough weight to remove the fat out of the pancreas and allow normal insulin production.\nThe team were able to identify in advance participants who would not respond to adequate weight loss by reversing their diabetes as at the start they had almost absent insulin production from the pancreas.\nThis will examine how successfully people can reverse their diabetes through weight loss simply under the care of their family doctor and nurse.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are alternatives to this diet that have been shown to correct blood sugar results in large studies \u2014 specifically weight loss surgery. This should have been mentioned.", "answer": 0}, {"article": "Ultrasound waves applied to the whole brain improve cognitive dysfunction in mice with conditions simulating vascular dementia and Alzheimer's disease.\nBut there are currently no curative treatments available for vascular dementia or Alzheimer's disease, the most common causes of dementia.\nThe researchers conclude that their study, recently published in the journal Brain Stimulation, provides the first experimental evidence that whole-brain LIPUS therapy markedly improves cognitive dysfunctions without serious side effects by enhancing specific cells related to dementia's pathology.\nAlso, the cells lining the brain's blood vessels are tightly packed, forming a blood-brain barrier that prevents large molecules from crossing into the brain tissue.\nThe team, led by cardiologist Hiroaki Shimokawa, found that applying low-intensity pulsed ultrasound (LIPUS) to the whole brain of the mice improved blood vessel formation and nerve cell regeneration without having obvious side effects.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release states that \u201cthere are currently no curative treatments available for vascular dementia or Alzheimer\u2019s disease, the most common causes of dementia.\u201d", "answer": 1}, {"article": "Sha says it\u2019s not clear what might be found in plasma from young people that might help the symptoms of Alzheimer\u2019s.\nAnd a few of the patients seemed to do a little better in the skills of everyday living, although memory and thinking skills were not affected.\nThe work made headlines and launched a company, Alkahest, that\u2019s working to develop young human plasma into treatments for aging-related diseases.\nThere\u2019s no cure, and treatments that have looked promising have flopped in big trials.\nAt first they did what\u2019s called a blinded trial --- treating half the patients with real plasma, and giving half the patients a sham infusion, with no one knowing which patient got the real treatment.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does state flatly that, \u201cThere\u2019s no cure (for Alzheimer\u2019s), and treatments that have looked promising have flopped in big trials.\u201d", "answer": 1}, {"article": "As bariatric surgery has grown more common (some 144,000 such procedures were performed in the United States in 2004, more than double the number in 2002), D'Amico says, patients seeking body contouring have \"started to show up in plastic surgeons' offices in large numbers.\"\nSeven weeks after surgery, Baez concluded the pain and effort had been worth the result: an end to the recurrent skin infections in her thighs and abdominal folds.\nTo manage pain and prevent long periods under anesthesia, most patients have the procedures done in stages over a series of weeks or months.\nThere are no guidelines requiring bariatric surgeons to warn their patients, although recently professional societies of plastic surgeons and bariatric surgeons have begun holding seminars to discuss the idea.\nA small study published in January in the Annals of Plastic Surgery showed 27 percent of patients in one practice had complications including wound infections, fluid collections called seromas, collections of blood under the skin called hematomas and death of fat cells.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While presenting quite an unpleasant picture of what excess skin following the loss of a large amount of weight might be like, the article failed to provide any other options that consumers might choose to manage excess skin.", "answer": 0}, {"article": "Fish-oil supplements don't appear to help pregnant women prevent post-partum depression or boost the baby's brain development as previously believed, according to a large trial published Tuesday in the Journal of the American Medical Association.\n\nThe 2,400-woman, randomized study complicates the advice for pregnant women. It adds to a body of mixed research on some potential benefits of the popular omega-3 fatty acid known as DHA, or docosahexaenoic acid. DHA, which can move from the mother to the baby during pregnancy, accumulates...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Again, barely adequate in that the story at least discussed a bit about both DHA supplements and fish consumption \u2013 but wrapped this into broader healthy alternatives such as \"all pregnant women should strive for balance and eat a variety of foods, including fish.\"\u00a0\u00a0", "answer": 1}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\n\u201cThe recurrence rates of some forms of breast cancer and the consequence of metastatic cancer make these efforts urgent and important,\u201d said Lu, adding that his research team also hopes to advance the approach for prostate cancer detection.\nMore importantly, the fibronectin part of the complex is expressed during a cell\u2019s transition to cancer and plays a role in cell growth, migration and differentiation.\nThey chose the peptide \u2014 a chain of just five amino acids \u2014 for its inclination to bind to protein matrix structures around cancer cells, called fibrin-fibronectin complexes.\n\u201cWe showed with this technique that we can detect very tiny tumors of just a few hundred cells,\u201d Lu said, adding that the study pushed imaging boundaries, revealing smaller cancers than can be detected with current clinical imaging modalities.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "As noted earlier, the release had some information about alternatives, but it was somewhat disjointed and the reader would have a hard time understanding that there are indeed alternatives to this approach without reading the original paper.", "answer": 0}, {"article": "MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.\nEvery year, 1.3 million men in the U.S. undergo a prostate biopsy.i Although a biopsy is the only way to diagnose prostate cancer, the procedure is invasive and results in complications in 18 percent of patients, with 3 percent hospitalized for infection within 30 days.ii,iii,iv Common complications from a prostate biopsy may include bleeding, infection, sepsis/bacteremia, urinary symptoms/retention, and sexual dysfunction.\n\"While biopsy is the only path to prostate cancer diagnosis, no man wants to, nor should have to, go through the uncomfortable, costly procedure if it can be avoided,\" said Dr. Jan Groen, Chief Executive Officer of MDxHealth.\n\"This study demonstrated that routine use of SelectMDx to guide biopsy decision-making improves health outcomes and lowers healthcare costs associated with prostate cancer risk assessment in a population of U.S. men,\" said Dr. Matthew Resnick from the departments of Urologic Surgery and Health Policy at Vanderbilt University Medical Center, Nashville, TN.\n\"We believe that this strategy improves the value of conventional risk assessment strategies through improvements in both quality and cost, the numerator and denominator of the health care value equation.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Although the text does a good job of explaining the risks of a prostate biopsy, it does not make clear that the gains found in the study stem from a comparison of employing the SelectMDx test to determine if a particular prostate cancer warrants further diagnostic efforts versus using a PSA test or ultrasound to make such a judgment.\nThe traditional alternative is actually to make biopsy decisions based on PSA alone\u2013not ultrasound (which is used for the biopsy). \u00a0However, MRI is increasingly being used to identify potential high-risk tumors and guide guide biopsy decisions: MRI-targeted or standard biopsy for prostate-cancer diagnosis. \u00a0Kasivsisvanathan V, et al. N Engl J Med 2018; 378:1767.", "answer": 0}, {"article": "Studies in 2007 and 2008 suggested that stented arteries faced a higher risk of blood clots, potentially triggering heart attack a year or more down the road.\nExperts describe Abbott's device as an important step in finding a better approach to treating the leading cause of death in the U.S.\n\n\"This is presumably a better technology going forward, at least that's the theory, but it will take years to prove,\" said Dr. George Vetrovec, professor emeritus at Virginia Commonwealth University.\n\"We have good theoretical reasons to believe that by getting rid of the stent, and allowing the coronary artery to restore its normal shape, that will prevent many of those late events,\" said Dr. Gregg Stone, of Columbia University Medical Center, who helped conduct the pivotal trial of Absorb.\nThe Food and Drug Administration approved the device Tuesday for patients with coronary artery disease, the artery-narrowing condition that causes about 370,000 U.S. deaths each year, according to government figures.\nThe Absorb stent, already sold in Europe and Asia, is made of a degradable material that's designed to stay intact for one year then break down over the next two years.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The reporter\u2019s efforts to emphasize the long-term safety questions of\u00a0this new stent lead her/him to make clear comparisons between the dissolvable stent and both metal stents and drugs.\u00a0 For example, at one point the story notes that recent research showed that treating chest pain with drugs leads to outcomes similar to those that result from use of stents. \u00a0Missing from this comparative information are the efficacy of metal stents with polymer coatings that deliver a drug to prevent arterial re-clogging.", "answer": 1}, {"article": "Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.\nGood Pain Relief and Other Outcomes with Implant Treatment for SIJ Dysfunction\n\nThe study included 148 patients with low back pain caused by confirmed SIJ dysfunction, treated at 19 US spine surgery clinics.\nAfter one year, subjects assigned to SIJ fusion still had significant reductions in pain and disability, as well as improved quality of life.\nThe study is the first randomized controlled trial to directly compare the results of surgical and nonsurgical treatment for SIJ dysfunction.\nSeventy-three percent of subjects undergoing the implant procedure had \"clinically significant\" reduction in disability scores, compared to just 14 percent in the nonsurgical group.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release lists alternative therapies for SJD which include \u201cphysical therapy, steroid injections and/or radiofrequency ablation of sacral nerve root lateral branches\u201d as well as the therapy compared in the trial.", "answer": 1}, {"article": "Give these a click:\n\nPersonalized cancer vaccines have already helped treat three patients\n\nSmartwatches might cause cancer, says article based on \u2018expert\u2019 who pushes holistic breast cancer treatments\n\nSun damage keeps happening even after you go inside, new study says\nWhen the latest trial was started, Harrington explained, there was no standard of treatment for melanoma -- so it's compared to a treatment that no one expected to outpace T-VEC.\nNow that other therapies -- ones that target specific mutations in patients' cancer cells -- are showing more success than what was available when the trial was formed, researchers will have to see how T-VEC compares.\nA modified version of the Herpes Simplex 1 virus (known for causing cold sores and some cases of genital herpes) called T-Vec has successfully been used to treat melanoma in a phase III clinical trial.\nSo in addition to the destructive power of the T-VEC cells themselves, the therapy summons the immune system right to where it's needed -- the tumor.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While the story does not compare the treatment with current standard treatments, it does explain that those comparisons were not done in the paper and that they need to be done now. Ideally this would have been communicated much higher up in the story, as this isn\u2019t an afterthought\u2013it is the key information to determine how this agent should be used. Otherwise, one is left with the impression that everyone with melanoma will be getting this treatment if and when it is approved by the FDA. That is far from the truth.", "answer": 1}, {"article": "Tasimelteon received orphan drug status \u2014 which offers several years of marketing exclusivity for drugs developed for rare conditions \u2014 from the FDA in 2010 and from the European Commission in 2011.\nThe study, named Reset, was a 20-patient trial designed to test the maintenance effect of a 20 mg dose of the drug, tasimelteon.\nThe condition, in which a person\u2019s body clock does not automatically set to the 24-hour day, affects a majority of blind people.\nThe drug is being tested for \u2018non-24-hour disorder\u2019 that has no approved treatment.\nThe second trial showed that patients treated by the drug maintained their clinical benefits while placebo-treated patients showed significant deterioration in measures of night-time sleep, daytime naps and timing of sleep.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story may have used company-supplied language when it reported that the condition \u201chas no approved treatment.\u201d\nThere is no approved prescription drug treatment.\nBut there are non-prescription-drug options that the story never mentioned:\u00a0 light therapy, hypnosis, stimulants, melatonin, to name a few.", "answer": 0}, {"article": "The U.S. Food and Drug Administration today approved Trulance (plecanatide) for the treatment of Chronic Idiopathic Constipation (CIC) in adult patients.\nParticipants were randomly assigned to receive a placebo or Trulance, once daily.\nIf severe diarrhea occurs, patients should stop taking Trulance and contact their health care provider.\nTrulance should be avoided in patients six years of age to 18 years of age.\nThe most common and serious side effects of Trulance was diarrhea.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "A mention that there are numerous other prescription medications, over-the-counter drugs and lifestyle treatments available for this condition would have been beneficial here.", "answer": 0}, {"article": "Gerdes has published 32 animal studies showing a link between improvements in thyroid hormone levels and heart health in rats and mice.\n\"What we have tried to do here is show the effect of safe doses of thyroid hormones and we're seeing amazing results in multiple studies, with dramatic improvements in heart function, gene expression, and collagen levels, just by restoring depressed thyroid levels in the heart,\" said Gerdes.\nIn the study entitled \"Long-term physiological T3 supplementation in hypertensive heart disease in rats,\" aging female rats with hypertension progressing to heart failure were treated for one year (half their lifetime) with a low oral dose of the active form of thyroid hormone, T3.\n\"This low dose of thyroid hormone safely restored depressed cardiac tissue T3 levels to normal while largely preventing the accumulation of collagen, or scar tissue, resulting from sustained high blood pressure,\" said Gerdes.\nThyroid hormones administered to female rats with high blood pressure led to encouraging cardiac improvements, according to a study in the American Journal of Physiology led by NYIT College of Osteopathic Medicine researcher Martin Gerdes.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are many heart failure treatment options, from surgery to drugs. But most of those treatment options, such as angiotensin-converting enzyme (ACE) inhibitors, target systolic heart failure specifically. There are currently no effective treatments for diastolic heart failure, and the release tells readers this.(Diastolic heart failure happens when the left ventricle doesn\u2019t let in enough blood; systolic heart failure occurs when the left ventricle doesn\u2019t squeeze hard enough to push out sufficient blood.)", "answer": 1}, {"article": "Higher grade tumors correlate with higher restricted water volume in the cancer cells\u2019 large nuclei.\n\u201cDoctors at UC San Diego and UCLA now have a non-invasive imaging method to more accurately assess the local extent of the tumor and possibly predict the grade of the tumor, which can help them more precisely and effectively determine appropriate treatment.\u201d\n\nThe current standard of care for detecting and diagnosing prostate cancer is contrast enhanced magnetic resonance imaging (MRI), which involves intravenously injecting patients with a contrast agent to highlight blood flow.\n\u201cIf by imaging we could predict the tumor grade,\u201d added Robert Reiter, MD, professor of urology at UCLA, \u201cwe may be able to spare some patients from prostate resection and monitor their cancer with imaging.\u201d\n\nCo-authors include senior author Anders M. Dale, Hyung W. Choi, Joshua M. Kuperman, Natalie M. Schenker-Ahmed, Hauke Bartsch, Robert F. Mattrey and William G. Bradley, Department of Radiology, UCSD; J. Kellogg Parsons and Michael A. Liss, Department of Urology, UCSD; Ahmed Shabaik, Department of Pathology, UCSD; Jiaoti Huang, Department of Pathology, UCLA; Daniel J. Margolis and Steven S. Raman, Department of Radiology, UCLA; Leonard S. Marks, Department of Urology, UCLA.\nThe new approach described in today\u2019s published paper is called restriction spectrum imaging-MRI or RSI-MRI.\nBy doing both, the ability of imaging to accurately plot a tumor\u2019s location is increased and there is a more refined sense of the tumor\u2019s extent, said Nathan White, PhD, assistant project scientist at UC San Diego, study co-author and co-inventor of the RSI-MRI technique.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "We don\u2019t think the story discusses the relevant comparison techniques. It talks mainly about the new technique\u2019s performance compared with other types of MRI. But as noted above, many prostatic cancers, especially those with low PSA and Gleason scores, are not imaged at all (other than by ultrasound during biopsy). For us, the meaningful comparison of the new MRI technology would be with clinical staging, not another MRI technology. Unfortunately, such a comparison is never made or discussed.", "answer": 0}, {"article": "\u201cThe length of statin use, both greater than six months and greater than five years of use was associated with reduction in colorectal cancer risk.\u201d\n\nThe group of statins that showed the greatest effect in reducing risk are classified as lipophilic: atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Altocor, Altoprev, Mevacor), pitavastatin (Livalo), and simvastatin (Zocor),\n\nColorectal cancer is the third most common type of cancer in the U.S.; 102,900 new cases of colon cancer are diagnosed in men and women every year, and about 39,670 new cases of rectal cancer are diagnosed annually.\n\u201cThis effect was largely consistent across study design with both case control and cohort studies showing a strong correlation,\u201d he says in a news release.\nAlso, the longer patients used statin drugs, the greater their reduction in risk for colorectal cancer.\n\u201cOur findings suggest that randomized controlled trials designed to test the hypothesis that statins reduce the risk of colorectal cancer are warranted.\u201d\n\nThis study was presented at a medical conference.\n\u201cObservational studies have suggested that long-term use of statins is associated with reduced risk of several cancers, including breast, prostate, lung, pancreas and liver,\u201d says Samadder in the news release.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0There was no discussion of other factors that influence risk of colon cancer. It would require only a line in the story to do so. ", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070902/10healthwatch.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not discuss alternatives to oophorectomy.", "answer": 0}, {"article": "GeneSight's test is covered by Medicare for patients under the care of psychiatrists and who have failed to achieve satisfactory results with at least one antidepressant. The company has coverage with some commercial payers and is working to widen that coverage, said Myriad Genetics spokesman Ron Rogers. The Genomind Genecept Assay is partly covered by Medicare and Medicaid. If the out-of-pocket cost for people with commercial plans is more than $300, Genomind will contact the client before processing the test. The company also has a financial assistance program for uninsured patients.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "An independent source is included who mentions transcranial magnetic stimulation (TMS) and electroconvulsivetherapy (ECT)\u00a0as alternatives to antidepressants in the treatment of resistant depression.\nOne alternative that is not mentioned is cognitive behavioral therapy.", "answer": 1}, {"article": "Moffitt researchers compared the overall survival and the time to diagnosis of a second tumor, if any, of 250,195 breast cancer patients who received either neoadjuvant or adjuvant radiation therapy.\nSurgery is commonly followed by radiation therapy, which has been shown to increase relapse-free survival.\nThe majority of patients who have early stage breast cancer have surgery to remove their tumor or a complete mastectomy.\nThey included female patients in the analysis who were diagnosed between 1973 and 2011 with early-stage breast cancer.\nThis was true for patients who underwent both partial and complete mastectomies.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release briefly referenced chemotherapy and endocrine therapy as alternatives to pre- and post-surgical radiation but offered no comparison data.", "answer": 0}, {"article": "By using image processing and machine learning to teach computers how to spot signs of precancerous and cancerous cells, Asiedu hopes to remove the need for a trained physician at any point in the screening process and shift the task to midwives, community health workers and even the women themselves.\nWhile the Pap smear can be performed by a non-specialist, colposcopy requires visualization of the cervix, relying on highly trained professionals and expensive equipment that is not easily accessible to underserved populations.\nThe colposcope is a magnified telescopic device and camera designed to allow medical professionals to look through the speculum to see the cervix, which is located three to six inches inside the vagina.\n\"The mortality rate of cervical cancer should absolutely be zero percent because we have all the tools to see and treat it,\" said Nimmi Ramanujam, the Robert W. Carr, Jr., Professor of Biomedical Engineering at Duke.\nBy using both methods to visualize the cervix, the researchers will be able to make a direct comparison.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There is some description of current standard screening practices, and several failed attempts at lower-cost alternatives to traditional practice are briefly mentioned.\u00a0However, we are rating this Not Satisfactory for several reasons. First, there is confusion about the role of colposcopy; it is not a primary screening tool, but rather a method for further evaluation of women with an abnormal screening test for cervical cancer. Colposcopy is an essential part of any screening program, to be sure, but it is not generally seen as feasible or effective as a primary screening test. Second, cervical cancer screening methods in resource-poor settings have been actively studied and several alternatives to standard Pap smears exist. These include HPV testing (a rapid HPV test is under development using a self-collected sample) and visual inspection after acetic acid application.", "answer": 0}, {"article": "The study, \"Efficacy and Safety of an Injectable Combination Hormonal Contraceptive for Men,\" will be published online at http://press.\nOther authors of the study include: Hermann M. Behre of Martin Luther University of Halle-Wittenberg in Halle, Germany; Michael Zitzmann of the University of M\u00fcnster in M\u00fcnster, Germany; Richard A. Anderson of The University of Edinburgh in Edinburgh, United Kingdom; David J. Handelsman of the University of Sydney and Concord Hospital in Sydney, Australia; Silvia W. Lestari of the University of Indonesia in Jakarta, Indonesia; Robert I. McLachlan of Monash Medical Centre in Melbourne, Australia; M. Cristina Meriggiola of the University of Bologna in Bologna, Italy; Man Mohan Misro of the National Institute of Health & Family Welfare in New Dehli, India; Gabriela Noe of the Instituto Chileno de Medicina Reproductiva in Santiago, Chile; Frederick C. W. Wu of Manchester Royal Infirmary in Manchester, U.K.; Ndema A. Habib and Kirsten M. Vogelsong of the World Health Organization of Geneva, Switzerland; and Marianne M. Callahan, Kim A. Linton and Doug S. Colvard of CONRAD, East Virginia Medical School, a reproductive health organization based in Arlington, VA.\n\"More research is needed to advance this concept to the point that it can be made widely available to men as a method of contraception,\" Festin said.\n\"The study found it is possible to have a hormonal contraceptive for men that reduces the risk of unplanned pregnancies in the partners of men who use it,\" said one of the study's authors, Mario Philip Reyes Festin, MD, of the World Health Organization in Geneva, Switzerland.\nThe hormones were effective in reducing the sperm count to 1 million/ml or less within 24 weeks in 274 of the participants.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release mentions other available birth control methods for men including condoms, vasectomies and withdrawal. However, it should have given readers an idea of how the efficacy rate of injectable hormones compares with other available methods of birth control. According to the study, the efficacy of male injectible hormones is high when compared with other reversible methods available for men, and is comparable with the efficacy of female oral contraceptives.\nAlso, the news release did not mention other approaches to male birth control under study, which include hormone-containing gels applied to the skin and the synthetic hormones that could be formulated into a pill as well as non-hormonal mechanisms to prevent sperm development, according to the Eunice Kennedy Shriver National Institute of Child Health and Human Development.", "answer": 0}, {"article": "With a cure rate approaching 90 percent, acute lymphoblastic leukemia (ALL) - the most common type of childhood cancer - is often hailed as one of the \"success stories\" of modern cancer treatment.\nThe current study showed that an alternative schedule of high-dose methotrexate was superior.\nThey found that patients 10 years and older saw no benefit from decadron, and, in fact, were at much higher risk for a debilitating bone condition called osteonecrosis.\nDuring this clinical trial, the investigators decreased the duration of decadron from 28 days to 14 to determine if patients could avoid the side effect of increased infection while still benefiting from the steroid's anti-leukemic effects.\nPrevious studies by the Children's Oncology Group showed that in standard risk ALL patients--those with low white blood cell counts or under 10 years of age--decadron prevented relapse in both the spinal fluid and in the bone marrow.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release is comparing the efficacy of treatment regimens using different drugs so alternative treatments\u00a0for B-acute lymphoblastic leukemia are noted.", "answer": 1}, {"article": "The study was to be presented Sunday at the Alzheimer's Association International Conference in Washington, D.C.\nFor that reason, \"larger studies are needed to corroborate and validate their findings,\" Wright said.\nIn the study, Sapkota's team tested the saliva of 22 people with Alzheimer's disease, 25 people with what's known as mild cognitive impairment (a decline in memory and thinking that's sometimes a precursor to dementia), as well as 35 people whose mental skills were normal for their age.\nThey found that the saliva of people with Alzheimer's had different levels of certain substances compared to the saliva of healthy people or those with mild cognitive impairment.\nStill, Dr. Paul Wright, chair of neurology at North Shore University Hospital in Manhasset, N.Y., said the research \"is still in its infancy but very promising.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story is about screening for Alzheimer\u2019s, so it would have been useful to talk about other efforts to develop screening tools (and the lack of effective ones) or methods currently used to diagnose the condition.", "answer": 0}, {"article": "An international team of scientists found that Montmorency tart cherries helped to positively impact the gut microbiome - a collection of trillions of bacteria and other microbes that live in the intestinal tract.\nThe microbiome has been the focus of multiple studies in recent years due to its potential role in maintaining digestive health, as well as its impact on immunity, heart health, blood sugar control, weight management and even brain health.\nThe laboratory experiments were set up to mimic the conditions within the human digestive system, specifically the stomach, small intestine and three regions of the colon, to study how polyphenols are broken down and absorbed.\nThe Cherry Marketing Institute, a not-for-profit organization funded by U.S. tart cherry growers and processors, provided financial support for the study.\nHowever, when concentrated juices were fermented, this bifidogenic effect appeared to be leveled out by the larger increase of polysaccharides utilizing bacteria.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "What\u2019s not made clear to readers is that dozens (perhaps hundreds) of foods and beverages are rich sources of polyphenols.", "answer": 0}, {"article": "The other three people served as the control group.\nThe treatment, which combines a patient's immune system cells with stem cells from a donor's cord blood, even worked in people with long-standing diabetes who were believed to have no insulin-producing ability.\nWEDNESDAY, Jan. 11, 2012 (HealthDay News) -- A new type of stem cell treatment for people with type 1 diabetes appears to help re-educate rogue immune system cells, which allows cells in the pancreas to start producing insulin again.\n\"That means if you stop the autoimmune reaction, you may see beta cell regeneration, or there might be other precursor cells in the pancreas.\nThe average daily dose of insulin dropped almost 39 percent after 12 weeks for the group with some beta cell function and 25 percent in those with no beta cell function, suggesting that the group with no beta cell function now produced insulin.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does of course mention insulin treatment. However, it tells readers that by reducing blood sugar levels this new treatment would reduce complications from diabetes. This trial did not look at complication rates. Until there is evidence developed about complication rates in patients using this new type of treatment it is impossible to claim it is superior to standard therapy. After all, even if patients use less insulin, that fact alone does not guarantee that they will have better long-term health outcomes.", "answer": 0}, {"article": "DALLAS - March 29, 2018 - A first-of-its-kind drug targeting a fused gene found in many types of cancer was effective in 93 percent of pediatric patients tested, researchers at UT Southwestern's Simmons Cancer Center announced.\nThe TRK-fusion mutation can be present in many types of cancers, including lung, colon, thyroid, and breast cancer, as well as certain pediatric tumors.\nThe results of the larotrectinib trial in adult patients - a 75 percent response rate - were published last month in the New England Journal of Medicine.\nWhen this occurs, it leads to the TRK gene being turned on when it's not supposed to be and that causes the cells to grow uncontrollably.\nTRK, short for tropomyosin receptor kinase, is a gene that plays a key role in brain and nervous system development and has a limited role in nervous system functions such as regulating pain in later life.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The case study of the responsive patient includes mention of surgical management of her tumor prior to larotrectinib. The release does not include mention of the chemotherapy agents that are considered first-line therapy for many pediatric cancers.", "answer": 0}, {"article": "Those studies are expected to launch later this year, including two at Penn.\nThere are multiple studies going on right now to confirm these findings, which the authors note is a necessary step before the drug can become a standard second-line therapy.\n\"There have been a lot of studies looking at different drugs, but researchers have not seen positive results,\" said the study's lead author Evan Alley, MD, PhD, chief of Hematology and Medical Oncology at Penn Presbyterian Hospital.\nThe study evaluated 25 patients with pleural mesothelioma, all of whom were over the age of 18 and had either already been treated with chemotherapy or were unable to receive it.\n\"But we've found this new class of drugs, checkpoint inhibitors, seems to be more effective than what's been available in the past.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions that chemotherapy is a first-line treatment for these types of mesotheliomas and it alludes to other standard therapies without naming them. We are not told of the potential of other therapies to treat this disease and the prognosis of those patients, nor the effectiveness or safety of competing therapies. We\u2019ll give the benefit of the doubt but that additional information would have been helpful.", "answer": 1}, {"article": "And the study had one particularly unexpected outcome.\nThe devices also showed that resting heart rate spiked shortly before ovulation began, according to the Berlin company, which presented data from the small, preliminary study at the European Society of Human Reproduction and Embryology's annual meeting this month.\nThe advantage of a passive sensor is \"these things are done kind of autonomously so you don't need to do much except check when the resting heart rate starts coming up,\" Clue's head of scientific research, Dr. Vedrana H\u00f6gqvist Tabor, told BuzzFeed News.\nBy monitoring these multiple biomarkers while a woman is asleep, Ava\u2019s wearable and app can notify her during the five days she\u2019s most fertile, ending in ovulation, according to von Bidder, who says Ava has conducted studies on about 60 people.\nAnd while resting heart rate can be a tell-tale sign of ovulation, Lea von Bidder, CEO of Ava, says consumers shouldn\u2019t rely on that measurement alone if they\u2019re serious about getting pregnant.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compares the use of the Fitbit to manually tracking one\u2019s cycle (i.e. taking daily temperature and tracking consistency of cervical mucus). It also mentions some other gadgets that track body temperature. We\u2019ll award a Satisfactory on that basis, but there are a host of other options available for women who are seeking help in becoming pregnant. The story doesn\u2019t address any of them.", "answer": 1}, {"article": ".\nThe authors say capsaicin also possesses antimicrobial properties that \u201cmay indirectly affect the host by altering the gut microbiota.\u201d\n\nThe research corroborates a 2015 study conducted in China and published in the BMJ that found regular consumption of spicy food is associated with a lower risk of death.\nThe researchers note that people who ate hot red chili peppers tended to be \u201cyounger, male, white, Mexican-American, married, and to smoke cigarettes, drink alcohol, and consume more vegetables and meats .\nThough the mechanism by which chili peppers could help delay death is not well understood, there are some theories.\nIf so, science has some good news for you: Eating hot chili peppers may help you live longer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Of all the things people might do to live a longer, healthier, life, how does eating red hot chili peppers stack up? The reader of this story has no help evaluating how\u00a013% decrease risk of death compares to other dietary factors, such as the fruit and vegetable recommendations included in USDA dietary guidelines.", "answer": 0}, {"article": "\"The risk of MS among daughters whose mothers consumed four glasses of milk per day was 56% lower than daughters whose mothers consumed less than three glasses of milk per month,\" Harvard researcher Fariba Mirzaei, MD, says in a news release.\nThe study involved more than 35,000 female nurses whose mothers answered questions about their diet habits during pregnancy.\nIt revealed that women born to mothers who had the highest intake of vitamin D had a much lower risk of developing MS as an adult.\n\"We also found the risk of MS among daughters whose mothers were in the top 20% of vitamin D intake during pregnancy was 45% lower than daughters whose mothers were in the bottom 20% for vitamin D intake during pregnancy.\"\nThe disease most often strikes adults after age 20, but it can develop in children.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no mention of vitamin D supplements, but the story discussed main sources of the vitamin, including milk, fish, fortified foods, and sunlight.\u00a0\u00a0 ", "answer": 1}, {"article": "If you need a reason to become a dog lover, how about their ability to help protect kids from allergies and obesity?\nThe study also showed that the immunity-boosting exchange occurred even in three birth scenarios known for reducing immunity, as shown in Kozyrskyj's previous work: C-section versus vaginal delivery, antibiotics during birth and lack of breastfeeding.\nThe theory is that exposure to dirt and bacteria early in life--for example, in a dog's fur and on its paws--can create early immunity, though researchers aren't sure whether the effect occurs from bacteria on the furry friends or from human transfer by touching the pets, said Kozyrskyj.\n\"The abundance of these two bacteria were increased twofold when there was a pet in the house,\" said Kozyrskyj, adding that the pet exposure was shown to affect the gut microbiome indirectly--from dog to mother to unborn baby--during pregnancy as well as during the first three months of the baby's life.\n\"There's definitely a critical window of time when gut immunity and microbes co-develop, and when disruptions to the process result in changes to gut immunity,\" said Anita Kozyrskyj, a U of A pediatric epidemiologist and one of the world's leading researchers on gut microbes--microorganisms or bacteria that live in the digestive tracts of humans and animals.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This study is focused on describing the association between allergies and pets that were observed over a long-term study. But since the ultimate goal seems to be reducing allergies and asthma there are alternatives to exposing your baby to a dog to prevent them, such as incremental exposure and allergy screening tests. These alternatives were worth a brief mention.  ", "answer": 0}, {"article": "\"Mindfulness-based therapeutic interventions promote the use of meditative practices to increase present-moment awareness of conscious thoughts, feelings, and body sensations in an effort to manage negative experiences more effectively.\u201d\n\nChildren who are at a high risk for bipolar disorder or other anxiety disorders, such as the participants, often have poor coping skills when confronted by stress, and only a lucky few get help.\n\"The path from understanding the effects of psychotherapy on brain activity to the identification of treatment response is a challenging one, and will require additional studies of emotional processing circuits.\u201d\n\nSource: Strawn JR, Cotton S, Luberto CM, et al.\n\"This raises the possibility that treatment-related increases in brain activity during emotional processing may improve emotional processing in anxious youth who are at risk for developing bipolar disorder,\u201d said fellow co-author Dr. Jeffrey Strawn, a professor in UC's Department of Psychiatry and Behavioral Neuroscience, as well as director of the Anxiety Disorders Research Program, in a statement.\nSome mental health professionals have suggested that mindfulness exercises can help bridge the treatment gap, and there is some encouraging, if early, evidence showing that these techniques can be used to prevent relapses of depression or anxiety.\nAccording to the Anxiety and Depression Association of America, 80 percent of children with a diagnosed anxiety disorder and 60 percent of those diagnosed with depression do not receive treatment.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions pharmaceutical interventions, but doesn\u2019t actually offer a comparison. How might mindfulness-based cognitive therapy be better or worse? And how does mindfulness-based cognitive therapy compare to (or differ from) other forms of cognitive therapy for children with anxiety disorders?", "answer": 0}, {"article": "Previous reports22,23 of the overall randomized clinical trial found locoregional control and survival advantages associated with the addition of cetuximab to radiotherapy.\nIn a recent trial from France, 269 patients were queried about the treatment choices they might make if they faced the diagnosis of advanced laryngeal cancer.30 Only 29% stated that they would not consider options with a lower chance of cure if told that the best option, with respect to survival, was total laryngectomy.\nHistorically, locoregionally advanced squamous cell cancers of the larynx or hypopharynx have been treated with surgical resection, usually involving laryngectomy with or without postoperative radiotherapy.1 Although laryngectomy is an effective treatment, investigators have sought therapeutic strategies that result in voice preservation.\nFurthermore, there were greater severe acute toxic effects from the chemoradiotherapy treatments compared with radiotherapy alone,13 but no significant differences in severe late toxic effects were noted in the comparison of the 3 treatment arms.14 Unfortunately, the concomitant chemoradiotherapy arm had an increase in deaths not attributable to cancer compared with the other 2 arms; this finding needs to be explored further to determine whether undetected fatal late treatment toxic effects are greater with concomitant regimens.\nThe duration of locoregional control was defined as the absence of locoregional disease progression at the scheduled follow-up visits and was determined through a masked review of the investigator-generated data by an independent committee of experts.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The focus here is on laryngeal cancer treatments that don\u2019t require surgical intervention, so we can leave surgical interventions out of the picture. However, there are a range of other chemotherapy treatments that can be used in conjunction with radiation therapy, such as cisplatin. The release doesn\u2019t mention these \u201cchemoradiation\u201d options, much less offer any sort of comparison.", "answer": 0}, {"article": "Some people do need supplements.\n\u201cThe public has been receiving very confusing and alarming messages about calcium supplements,\u201d says JoAnn Manson, a professor of medicine at Harvard Medical School and chief of preventive medicine at Brigham and Women\u2019s Hospital, Boston.\nAmong others who might need a boost: Vegans, people with lactose intolerance and anyone who, for whatever reason, does not consume enough calcium, says Taylor Wallace, an affiliate professor of nutrition at George Mason University in Fairfax, Va., and a co-author of the new cardiovascular statement.\nMost recently, researchers at Johns Hopkins University tracked nearly 3,000 adults and found that those who took calcium supplements at the study outset were 22% more likely to show artery calcification 10 years later.\nAbout 35% of U.S. adults take calcium supplements, alone or in multivitamins, according to a recent report in the medical journal JAMA.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "On its face, the story deals with two options: taking calcium supplements or not taking them. Both options are addressed here, so it earns a \u201csatisfactory\u201d rating. But this story also goes a step further, highlighting other factors in supporting bone health, including vitamin D consumption and exercise.", "answer": 1}, {"article": "DALLAS, Oct. 20, 2015 -- Botox -- known for reducing facial wrinkles -- may also prevent irregular heart rhythms when injected into fat surrounding the heart after bypass surgery, according to research in the American Heart Association journal Circulation: Arrhythmia and Electrophysiology.\nAtrial fibrillation (also called AFib or AF) is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications.\n\"About a third of all patients undergoing bypass surgery will develop atrial fibrillation, putting them at higher risk for cardiovascular complications,\" said Jonathan S. Steinberg, M.D., senior study author and Adjunct Professor of Medicine at the University of Rochester and Director of the Arrhythmia Institute in the Valley Health System in Ridgewood, New Jersey.\nThe Russian State Research Institute of Circulation Pathology and the Siberian Division of Russian Academy of Medical Sciences funded the study.\nBut complications from the bypass surgery were similar in both groups, including time in intensive care and on a breathing machine, and infection rate.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Given the impact of post-operative atrial fibrillation, it is reasonable to assume that other attempts have been made to reduce its incidence in this population.\u00a0 A variety of antiarrhythmic drugs and beta adrenergic blockers have been studied with variable results. It would have been very helpful to add a few words about the alternative pharmalogical agents.", "answer": 0}, {"article": "This press release contains forward-looking statements.\nAs featured in the ASTRO Scientific Session poster titled \"High Dose Adaptive MRI Guided Radiation Therapy Improves Overall Survival of Inoperable Pancreatic Cancer,\" key data points and findings from the presentation include the following:\n\u2022 The study detailed a retrospective review of 42 locally-advanced pancreatic cancer patients treated with MRIdian at four institutions (University of California Los Angeles, University of Wisconsin, VU University Medical Center, Washington University).\nThe early results highlighted above, along with other data obtained using MRIdian will be tested in a multi-center, prospective, single-arm clinical trial for inoperable, locally advanced or borderline resectable pancreatic cancer.\nFurther studies, including the planned prospective multi-institutional study referenced in this press release, as well as patient data covering longer periods of time post-treatment, could lead to different or contrary results from those expressed during ASTRO or in the poster presentation.\nAs a result, MRIdian's on-table adaptive radiation therapy allows doctors to respond to subtle anatomical changes observed on a day-to-day basis and reshape the dose to better match the current contours of the tumor.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This study was all about comparing alternatives, so it scores Satisfactory on that criterion. It would have helped readers if alternatives would have been described more in laymen\u2019s terms.", "answer": 1}, {"article": "WEDNESDAY, Sept. 8, 2010 (HealthDay News) -- Statins, lauded for their ability to lower cholesterol and prevent heart attacks and strokes, may also reduce the risk of developing rheumatoid arthritis, Israeli researchers report.\nThe researchers looked for connections between statin use and the development of both rheumatoid arthritis and osteoarthritis, a degenerative joint disease that is unlikely to be affected by statins, the researchers noted.\nFor example, compared with patients who took statins less than 20 percent of the time, patients who took statins for 40 percent to 59 percent of the time had a 23 percent lower risk of developing rheumatoid arthritis, he said.\n\"We found that statin users who purchased their medication persistently were less likely to develop rheumatoid arthritis over a long follow-up period,\" said lead researcher Gabriel Chodick, from Maccabi Healthcare Services in Tel Aviv.\nDr. Robert Myerburg, a professor of medicine and physiology at the University of Miami Miller School of Medicine, stressed that \"this is a study looking for an association, and it doesn't prove that starting statins early in life will prevent or delay the onset of rheumatoid arthritis.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe story provides no background information about rheumatoid arthritis, its prevention or its treatments. There are four known risk factors for RA; gender (women develop RA about twice as frequently as men), family history, age (most people with RA develop symptoms between age 40 and 50 years) and smoking. A complete story would have included a few words on other preventive approaches. ", "answer": 0}, {"article": "You know, they go to rehab and there\u2019s not much more [more] they can recover usually.\u201d\n\nFor the study, Steinberg and his team recruited 18 patients who had suffered their first and only stroke six months to three years prior to the trial.\nResults showed that the implanted stem cells didn\u2019t survive very long in the brain, disappearing about one to two months after injections; however, patients still showed significant motor recovery at six and 12 months post-surgery.\nIn Steinberg's study, it did not \u201ccause problems by differentiating into unwanted tissues or forming tumors.\u201d And even when the stem cells came from an unrelated donor, the participants did not experience a strong immune reaction.\nIn addition to setting the stage for an expanded trial of the procedure, the promising results also change \u201cour notion of what happens after a stroke,\u201d Steinberg explained.\nIn other words, they are the precursors to muscle, fat, bone, and tendon tissue.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the article mentions there are \u201ctherapies\u201d that help\u00a0after a stroke, it does not mention what these are, how often they succeed, how often they fail, or their costs.", "answer": 0}, {"article": "Researchers analyzed the men\u2019s hormones and cholesterol with blood tests at the start and end of the study.\nPage has high hopes for the results, calling them \u201cunprecedented in the development of a prototype male pill.\u201d Longer-term studies are the next step toward a once-daily male contraceptive pill, she said.\nMore attractive to many men than a long-acting injection or topical gel\u2014both of which are in development\u2014the prototype pill offers a \u201cmajor step forward\u201d in male contraception, Stephanie Page, a professor at the University of Washington in Seattle and senior investigator on the study, said in a statement.\nThe prototype pill\u2014dimethandrolone undecanoate (DMAU)\u2014is somewhat similar to the combined female pill, which contains estrogen and a steroid hormone.\nRead more: Male birth control pill could be made from heart-stopping poison in ancient African arrows\n\nThe once-daily prototype pill suppressed certain hormones to the low levels you'd expect to see with effective longer-term contraceptives, results from an ENDO 2018, the Endocrine Society\u2019s annual meeting in Chicago, abstract show.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does refer to other medical treatments aimed at male birth control that are under development, namely \u201ca long-lasting injection or topical gel.\u201d So we\u2019ll give it credit here. We wish it had offered slightly more information here (e.g., are both of those technologies also hormone-based?).", "answer": 1}, {"article": "'This is not the end': Using immunotherapy and a genetic glitch to give cancer patients hope\n\nNew shingles vaccine is highly effective \u2014 and in short supply\n\nResearchers use immune-cell 'army' to battle another tough cancer\nFDA Commissioner Scott Gottlieb said the approval was \u201ca reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies.\u201d The medication, tested in three randomized, placebo-controlled trials with more than 500 patients, was effective in reducing seizures, the FDA said.\nHowever, it isn\u2019t clear whether such a reclassification would involve CBD products in general, the CBD formulation used specifically in Epidiolex or something else.\nFor those who have long argued that cannabis offers medical benefits, the FDA approval represents a milestone, \u201ca recognition that the plant is a rich source of compounds which have potential therapeutic activity,\u201d Justin Gover, chief executive of GW Pharmaceuticals, the London-based company that developed the drug, said in an interview last week.\nThe disorders afflict fewer than 45,000 people in the United States, but experts expect Epidiolex to be prescribed for other types of epilepsy as well.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does note that parents are giving their affected children \u201cunregulated\u201d CBD formulations, and although there are also other drug treatments and (although of unproven value) some efforts at surgery to abate the seizures, these offer less than good solutions, as the article notes.", "answer": 1}, {"article": "Naomi Wolf, author of \"Misconceptions: Truth, Lies, and the Unexpected on the Journey to Motherhood,\" blames insurance companies and hospitals, who she says deny women information about their choices.\nIf something does go wrong, in the eyes of the courts \"a normal birth is a risk.\nThe drug can cause painful contractions, which doctors treat with an epidural painkiller.\nSome doctors say the increased rate of Caesareans is partially attributable to maternal demand: busy mothers may want to schedule their deliveries.\nThe epidural can then retard contractions and lead to more drugs, fetal stress and the doctor's recommendation of a Caesarean.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story clearly mentions vaginal birth as the alternative to C-section.", "answer": 1}, {"article": "John Anderson, president of medicine and science for the American Diabetes Association, says \u201cIt\u2019s very promising and opens up new avenues of research, but we are a long way from replacing insulin, or a cure, or even knowing how this [hormone] will work in human tissue.\u201d\n\nThose concerns aren\u2019t lost on Melton, who also recognizes that more research is needed to confirm that betatrophin may benefit patients.\nEventually, the overwhelmed system leaves these sugars, in the form of glucose, to build up in the blood, which can lead to obesity, damage the heart, and cause other metabolic problems.\nIt\u2019s also possible that diabetics could lower their dependence on insulin and might even be able to wean themselves off of the injection altogether if their beta cell production is robust enough to provide the insulin they need.\n\u201cI was impressed by the fact that the number of beta cells in the mice doubled in one week with one injection,\u201d says Melton.\n\u201cNo one doubts that\u2019s not a good idea.\u201d\n\nMORE: Should You Take Statins?\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are a number of oral medications that can help make up for lagging insulin production, either by stimulating beta cells to produce more insulin or\u00a0making tissues more sensitive to\u00a0the insulin that is being produced. The story didn\u2019t mention any of these.", "answer": 0}, {"article": "Pain patches have a number of benefits, Rosenquist and Dombrowski said, not the least of which is convenience.\nBefore the FDA action, pain-relieving patches were available in the United States only by prescription, said Dr. John Dombrowski, director of the Washington Pain Center in Washington, D.C. Their active ingredients include such medications as lidocaine, capsaicin and non-steroidal anti-inflammatory drugs, or NSAIDs.\nThe active ingredients in Salonpas are methyl salicylate and menthol, common components of pain-relieving gels and creams, such as Bengay.\nThe U.S. Food and Drug Administration approved the country's first over-the-counter, pain-relieving transdermal patches in 2008.\n\"Salonpas is the Western world catching up with Asia,\" said Dr. Rick Rosenquist, a professor of anesthesia and director of pain medicine at the University of Iowa Carver College of Medicine and chairman of the American Society of Anesthesiologists' committee on pain medicine.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Alternatives are barely mentioned, and no non-pharmaceutical alternatives are mentioned. \u201cBoth doctors said that they expect more over-the-counter pain patches to hit the market if the popularity of Salonpas continues to grow. Future over-the-counter options, they predicted, could include reduced-dosage versions of the NSAID-delivering patches now available through prescription.\u00a0\u201cSuccess begets success,\u201d Dombrowski said. \u201cIf this does very well, other drug companies will say, \u2018I want a piece of this action.'\u201d\u201d\u00a0\u00a0Readers are left with the message that people are running out to buy these pain patches because they work, and that more companies are going to be making these patches because they are so beneficial. But there is no proof provided in this story of their success or their benefits.\u00a0There is no evidence conveyed that the patch is better than nothing, let alone existing, accepted treatments.\u00a0From a business story standpoint, this story fails. From a medical story standpoint, the story is incredibly misleading.", "answer": 0}, {"article": "In the largest population-based retrospective study to date, Dr. Lu-Yao and colleagues examined the records of 13,856 men in the Medicare-SEER registry diagnosed with locally advanced prostate cancer -- cancer growth that had not yet metastasized to distant sites in the body.\nA complete list of potential conflict interest disclosures can be found in the manuscript.\nAnother interesting finding from the research was that slightly more than half of men diagnosed with the disease did not receive combination therapies for their prostate cancer.\nThe risks of prostate removal, or prostatectomy, are well known and include higher chance of developing incontinence and erectile dysfunction.\nThe research was published September 25th in the journal Cancer.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The point of the study was to compare two common treatment options, and both are adequately described in the release.", "answer": 1}, {"article": "Without strong evidence for its efficacy, the American Congress of Obstetricians and Gynecologists does not include the treatment in its Practice Bulletin for Urinary Incontinence in Women. L. Elaine Waetjen, professor of obstetrics and gynecology at the University of California, Davis Medical Center, who has spent more than 15 years treating women for this problem, said that there is \"no scientific evidence that the O-Shot works for incontinence and there is also no clear biological mechanism for why it should treat this condition.\"", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story briefly discusses treatments that are supported by clinical studies and professional societies.\nWe do wish the evidence for and\u00a0success rates of the alternatives were described much more thoroughly.", "answer": 1}, {"article": "Spinal fluid can also reveal the disease but that can be a difficult and painful test.\nIn a study of 259 blood samples, the test identified early markers for Alzheimer's with 90 percent accuracy, reports CBS News correspondent John Blackstone.\nThere is still plenty of lab work to be done, more rigorous research before it's proven a simple blood test can diagnose Alzheimer's, but those working on the test are hopeful it can be approved for use by 2009, adds Blackstone.\nAccording to a paper published in the online edition of the British journal Nature Medicine, preliminary studies by a team of scientists led by a Stanford neurology professor show the test is yielding promising results in predicting which patients with mild memory loss are at high risk of developing Alzheimer's disease.\nBrain scans and spinal taps are helpful but they're not certain.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story states that \"only an autopsy can establish for sure whether a patient had Alzheimer\u2019s. Brain scans and spinal taps are helpful, but they\u2019re not certain.\u00a0 But the story did not provide insight about treatment options and what one could and couldn\u2019t do with advance information about pending development of Alzheimer\u2019s disease.", "answer": 1}, {"article": "The researchers are continuing the treatments and compiling data.\nCollaborating with Dr. Pisco were Marisa Duarte, M.D., Tiago Bilhim, M.D., Ph.D., Jorge Branco, M.D., Ph.D., Fernando Cirurgi\u00e3o, M.D., Marcela Forjaz, M.D., L\u00facia Fernandes, M.D., Jos\u00e9 Pereira, M.D., Nuno Costa, M.D., Joana B. M. Pisco, M.D., and Ant\u00f3nio G. Oliveira, M.D., Ph.D.\n\nRadiology is edited by Herbert Y. Kressel, M.D., Harvard Medical School, Boston, Mass., and owned and published by the Radiological Society of North America, Inc. (http://pubs. )\nHowever, myomectomy is not always possible or effective and can result in major complications including hysterectomy, according to study co-author Jo\u00e3o Martins Pisco, M.D., Ph.D., from the Department of Interventional Radiology at Saint Louis Hospital in Lisbon, Portugal.\nThe procedure was repeated in 28 patients whose fibroids had not been fully treated, as shown by MRI, and 11 of those patients subsequently got pregnant.\nFor the new study, Dr. Pisco and colleagues assessed pregnancy rates in 359 women with uterine fibroids who were unable to conceive and who underwent either conventional or partial UFE.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release discusses the different alternatives for treating uterine fibroids. It at first leads the reader to anticipate a study comparing UFE to myomectomy, but it turns out that the study is\u00a0much more about comparing conventional UFE to\u00a0partial UFE. The hypothesis that partial UFE may help reduce the risks of infertility compared to conventional UFE could have been given\u00a0more discussion.\nIt is not clear why the lack of difference between conventional and partial UFE is not highlighted in the study abstract or the release.", "answer": 1}, {"article": "\"Weight loss was similar but substantial in both groups we studied, but blood pressure improved more in the low-carb dieters,\" said study author Dr. William Yancy Jr., an associate professor of medicine at Duke University Medical Center and a staff physician at the Department of Veterans Affairs Medical Center in Durham, N.C.\n\n\"There are options out there.\nTwo other studies in the same issue of the journal looked at the effects of the DASH diet and a physician-supervised plan.\nThe third study compared an Internet weight-management program with a physician-managed program for extremely obese people that included a liquid diet component, followed by a structured diet, behavioral counseling and diet medications.\nYancy said the blood pressure and cholesterol drops might have been even more impressive if people had stayed on their medications, but as they lost weight and normalized these readings, the doctors took them off blood-pressure and cholesterol drugs.\nThe more intensive intervention was more successful with 31 percent losing more than 5 percent of their body weight, compared to just 9 percent of the Internet group.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Given the story\u2019s focus on blood pressure, it\u00a0should have\u00a0mentioned how the results of this study might compare to treatment with blood pressure medication.", "answer": 0}, {"article": "Dr. Bried, who implanted Mr. Mueller\u2019s hip last year, said he was concerned that squeaking might be \u201ca harbinger of something similar.\u201d\n\nMr. Mueller said Dr. Bried had told him to consider getting the hip replaced \u201csooner rather than later.\u201d\n\nStryker says such fears are overblown.\nWhatever the actual frequency, some investigators who have looked at the problem say the squeaking seems to be associated with extreme flexing of the ceramic implants, but exactly how is unclear.\nWhile there have been no reported cases of serious mishaps, some surgeons fear that the ceramic material might shatter at some point, leaving a patient with so many inflammatory shards in the hip that a doctor could never find them all.\n\u201cThere is no evidence that the wear associated with squeaking would lead systems to fail,\u201d said Dr. James A. D\u2019Antonio, an orthopedic surgeon outside Pittsburgh, who was a chief investigator on the clinical trials that led to regulatory approval for Stryker\u2019s Trident.\nBut durability tests have suggested that even those extracted hips would have outlasted conventional metal-and-plastic replacement joints, according to researchers.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story points out that the alternatives to a ceramic total hip replacement include hip replacements with implants made from metal and plastic. It doesn\u2019t mention whether there are nonsurgical alternatives to hip replacement, but this is beyond the scope of the story.", "answer": 1}, {"article": "CHICAGO (Reuters) - Measuring certain proteins in spinal fluid can accurately diagnose Alzheimer\u2019s and predict which patients with memory problems will develop the fatal brain-wasting disease, Belgian researchers said on Monday.\nWhen they looked to see how accurate these signatures were at spotting the disease, they found 90 percent of those with Alzheimer\u2019s had the disease pattern in their spinal fluid.\nAnd they may also help identify early signs of the disease in healthy people, the team reported in the Archives of Neurology.\nThey said measuring traces of beta amyloid and tau \u2014 two proteins associated with the telltale plaques and tangles that form in the brains of patients with Alzheimer\u2019s \u2014 accurately detected Alzheimer\u2019s in 90 percent of patients with the disease.\nBut biomarkers \u2014 proteins and imaging techniques \u2014 are helping to identify the disease much earlier.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThis story does not mention that brain scans are also being tested for their ability to aid in the diagnosis of Alzheimer\u2019s Disease.", "answer": 0}, {"article": "For participants with more severe vision loss (20/50 or worse), aflibercept improved vision on average nearly four lines, bevacizumab about 2.5 lines, and ranibizumab almost three lines.\nThose with mild vision loss (20/32 to 20/40) at baseline in all three treatment groups gained on average almost two lines on an eye chart.\nOver the past few years, drugs that target VEGF have become a standard treatment for DME, providing a preferred alternative or adjunct to laser treatment.\nThe DRCR.net had complete control over the design of the study, data ownership and content of presentations and publications related to this study.\nAt the start of the trial, 660 adults with DME were enrolled: their average age was 61 years and 90 percent had type 2 diabetes.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release discusses three competing drug therapies, but there should have been some mention of the alternative to drugs \u2014 laser treatment. How do these results compare with laser outcomes?", "answer": 0}, {"article": "And while the percentage of American adults who smoke is at the lowest level since the CDC began tracking such data, there are still an estimated 40 million adult smokers in the U.S.\n\u201cThe Tips campaign is an important counter measure to the $1 million that the tobacco industry spends each hour on cigarette advertising and promotion,\u201d said Corinne Graffunder, Dr.P.H., director of CDC\u2019s Office on Smoking and Health.\nWith a year-round campaign we could save even more lives and money.\u201d\n\nTips, the first federally funded anti-smoking paid media campaign, features former smokers talking about their smoking-related illnesses.\nAbout 80 percent of U.S. adult cigarette smokers who were surveyed reported seeing at least one television ad from Phase 2 of the 2014 campaign.\nUnlike the 2012 campaign, which aired for 12 consecutive weeks, the 2014 campaign aired in two phases, from February 3 to April 6 and from July 7 to September 7.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are a number of other campaigns out there that aim to help smokers kick the habit, such as the FDA\u2019s \u201cThe Real Cost\u201d campaign. How effective have those other campaigns been? How does that compare to the 2014 Tips campaign? The release offers no information related to those questions.", "answer": 0}, {"article": "(March 23, 2017)\u2014Statin drugs are widely used to manage high cholesterol and reduce the risk of cardiovascular disease.\nThe researchers acknowledge that statin drugs can contribute to liver damage in some people, but for people with advanced liver disease, \u201c[s]tatins are cost-effective, generally well-tolerated by patients and the benefits of statin treatment in most patients outweigh their potential hepatotoxic risk.\u201d\n\nRead the full article, \u201cRationale for the use of statins in liver disease\u201d published ahead of print in the American Journal of Physiology\u2014Gastrointestinal and Liver Physiology.\nIn some studies, the research team found that statins reduced inflammatory molecules that are typically elevated with liver disease and improved inflammation in the endothelium (cells that line the blood vessels).\nEstablished in 1887, the American Physiological Society (APS) was the first U.S. society in the biomedical sciences field.\nThe Society represents more than 10,500 members and publishes 15 peer-reviewed journals with a worldwide readership.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Other than the mention of organ transplantation, there was no mention of other treatments or preventative measures to prevent liver failure.\nFor a number of liver conditions, there are specific treatments. Whether statins are effective and how they compare to existing treatments is an unanswered question.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Taking multivitamins may help women without cardiovascular disease to ward off a heart attack, new research shows.\nAmong the women with heart disease, 13 percent of the non-supplement-users had heart attacks, compared to 14 percent of women who took multivitamins only, which wasn\u2019t a statistically significant difference (meaning it could have been due to chance).\nFor the women without heart disease at the study\u2019s outset, taking a multivitamin for less than five years reduced heart attack risk by 18 percent compared with non-users of supplements.\nTo investigate the relationship between vitamin use and heart disease in women, Rautiainen and her team followed 31,671 women with no history of heart disease and 2,262 women who did have cardiovascular disease for about 10 years.\nThe results don\u2019t settle the question of whether it\u2019s actually the vitamin pills that are protective, Rautiainen told Reuters Health via e-mail.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0There was no discussion of the impact of other lifestyle choices beyond consumption of multivitamins that have demonstrate effect on reducing the risk of heart attack. \u00a0Adopting other risk reduction behaviors is a more powerful way to reduce risk of heart attack.", "answer": 0}, {"article": "The researchers split the participants into two groups, one that received drug treatment and one that took placebo pills.\n\"Unfortunately, the study's numbers are so small that it cannot be decisive on the key issue, which is whether it's prudent to treat people early when there are uncertainties about the diagnosis and given the effect of stigma and adverse effects,\" said Dr. William Carpenter, director of the Psychiatric Research Center at the University of Maryland, who was not involved in the study.\nIn the first year of a two-year trial, 5 of the 31 of those on medication developed full-blown psychosis, compared with 11 of 29 of those who were taking dummy pills.\n\"It's a pessimistic trade-off, the weight gain and other side effects for what looks like a modest delay in the acute psychotic episode,\" said Dr. Steven Hyman, a professor of neurobiology at Harvard.\n\"This might discourage people, and legitimately so, from using this drug for prevention because of the weight gain, but hopefully it won't discourage study\" of other drugs.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no mention of other treatment options for patients who show signs of psychosis or who develop schizophrenia. Psychotherapy (including cognitive behavioral therapy) in conjunction with medication has been tried with some success in other studies to help patients manage symptoms (i.e. delusions, hallucinations) and improving functioning. ", "answer": 0}, {"article": "Autism is characterized by difficulties in social interaction, communication, and understanding other people\u2019s emotions and behavior.\nBy measuring six aspects of the brain\u2019s circuitry, the test was able to correctly pick out people who had been diagnosed with autism with 94 percent accuracy.\nThe test, which uses conventional magnetic resonance imaging or MRI machines, detected 94 percent of individuals with a high-functioning form of autism, they reported on Thursday.\nCHICAGO (Reuters) - U.S. researchers are closing in on an accurate test for autism, a finding that could lead to earlier diagnosis and treatment.\n\u201cThese results are the best yet in the search for a biological basis in terms of being able to distinguish those with and without the disease,\u201d said Nicholas Lange of Harvard Medical School, who directs the Neurostatistics Laboratory at McLean Hospital in Belmont, Massachusetts.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "At the present time there are no biologically based tests for autism. The diagnosis is made on the basis of subjective signs and symptoms. Unlike the CNN story we reviewed, this story makes no attempts to provide information on existing diagnostic testing.", "answer": 0}, {"article": "Washington, DC - September 18, 2018 - An international team of researchers has successfully deployed a Zika virus vaccine to target and kill human glioblastoma brain cancer stem cells, which had been transplanted into mice.\nWhen the team injected this ZIKV-LAV into the brains of mice, they saw no health effects on the mice, no weight loss, and no behavioral abnormalities such as loss of appetite, depression, lethargy, or self-injury.\nFor example, Man explains, the researchers could add an immune modulator as a 'cargo' in the viral genome.\nIn a study published this week in mBio\u00ae, an open-access journal of the American Society for Microbiology, the team shows that a live, attenuated version of the Zika virus could form the basis of a new treatment option for this fatal brain cancer.\nComparing those profiles, the team found that in the treated cells, the virus triggered a strong antiviral response in the cells, which induced inflammation and eventually cell death.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release states that normal cancer treatments such as radiation, surgery, and chemotherapy are not successful in the long run against\u00a0human glioblastoma brain cancer.", "answer": 1}, {"article": "SUNDAY, March 6, 2011 (HealthDay News) -- A simple blood test may one day offer a safe way to detect Down syndrome during pregnancy, researchers say.\nAlthough Down syndrome varies in severity, it usually causes some intellectual impairment and distinguishing facial features.\nOlder mothers are more likely to give birth to Down syndrome babies.\n\"We estimate we can introduce this to clinical practice in a couple of years.\"\n\"So they will be able to make a very personal decision without anyone realizing it,\" he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No discussion of how this compares with any of the other approaches being studied in this field.", "answer": 0}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\nThe trial results \u201cprovide crucial evidence for a safe and effective alternative to laser therapy against PDR,\u201d said NEI Director Paul A. Sieving, M.D., Ph.D.\n\n\u201cPatients who received Lucentis showed a little bit better central vision, much less loss of their side vision, and substantially less risk for surgery than patients who received laser treatment,\u201d said Lloyd Paul Aiello, M.D., Ph.D., director of the Beetham Eye Institute at Joslin Diabetes Center and Professor of Ophthalmology at Harvard Medical School.\nThe use of anti-VEGF treatment rather than laser for PDR could help prevent these symptoms.\u201d\n\nAdditionally, the need for vitrectomy surgery was lower in the Lucentis group (8 of 191 eyes) than in the laser group (30 of 203 eyes).\n\u201cLaser still has a role in the treatment of PDR for some patients, but anti-VEGF therapy gives us another tool in our search for better vision outcomes in our patients with diabetes.\u201d\n\nFounded in 1898, Joslin Diabetes Center is world-renowned for its deep expertise in diabetes treatment and research.\nBecause Lucentis is commonly injected to treat diabetic macular edema (DME)\u2014a build-up of fluid in the center of the retina\u2014the study permitted the use of Lucentis for DME in the laser group, if necessary.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does a good job of comparing Lucentis to conventional laser treatment for PDR and we\u2019ll award a Satisfactory rating on that basis.\nHowever, we\u2019d note that these are not necessarily the only two options. Lucentis is classed as an \u201canti-VEGF\u201d (anti- vascular endothelial growth factor) drug \u2014 by blocking a protein called VEGF, the drug can reverse abnormal blood vessel growth and decrease fluid in the retina. Other drugs in this category include Avastin and Eylea. Are those drugs under consideration for trials related to PDR treatment? If so, it\u2019s worth mentioning \u2014 particularly since Avastin costs around $60 per dose, as compared to Lucentis\u2019s $2,000 per dose.", "answer": 1}, {"article": "\u201cThis collaborative venue enabled two then-residents [Drs.\n\u201cSestamibi SPECT/CT offers an inexpensive and widely available means of better characterizing kidney tumors, and the identical test is now being performed as part of a large trial in Sweden, for which the first results have just recently been published and appear to confirm our conclusions.\u201d\n\nAlthough further study is needed to validate the accuracy of sestamibi SPECT/CT, this test appears to be a less expensive, faster, noninvasive alternative to surgery, says Michael A. Gorin, M.D., the other resident involved in developing this approach and now chief resident with The James Buchanan Brady Urological Institute of the Johns Hopkins University School of Medicine.\nThese results are hugely encouraging, but we need to do more studies.\u201d\n\nFor this study, 48 patients who were diagnosed with a kidney tumor on conventional CT or MRI were imaged with sestamibi SPECT/CT at Johns Hopkins prior to surgery.\nRadiologists, who were not allowed to talk to each other or know the results of the surgeries, graded the conventional and sestamibi SPECT/CT images benign or malignant using a 5-point scale (1 = definitely benign, 5 = definitely cancerous).\n\u201cIn the absence of diagnostic certainty, surgeons tend to remove kidney tumors in an abundance of caution, leading to an estimated 5,600 surgically removed benign kidney tumors each year in the United States.\u201d\n\nOther authors on this paper include, Sara Sheikhbahaei, Christopher S. Jones, Kristin K. Porter, Alex S. Baras, Phillip M. Pierorazio, Mark W. Ball, Lilja B. Solnes, Jonathan I. Epstein, and Mehrbod S. Javadi, all of the Johns Hopkins University School of Medicine, and Takahiro Higuchi of Wurzburg University in Germany.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release describes the results of comparing the diagnostic accuracy of regular CT or MRI scans alone or with the addition of sestamibi SPECT/CT\u00a0imaging. The release also states that the alternative to diagnostic certainty is surgery, even when it is unknown whether the tumor is malignant or non-cancerous.", "answer": 1}, {"article": "Maia Szalavitz is a health writer at TIME.com.\nResponding to the research, Yale Child Study Center director Fred Volkmar told WebMD: \u201cThe question remains, \u2018Is fluoxetine better than risperidone for this symptom?\u2019 It would be interesting to see studies comparing these two drugs head to head.\u201d\n\nHollander has previously received funding from pharmaceutical companies, but the current study was paid for by a grant from the Food and Drug Administration\u2019s \u201corphan\u201d drug program.\nThe only drugs approved to treat irritability and repetitive behaviors in autistic children are the atypical antipsychotics Risperdal (risperidone) and Abilify (aripiprazole), which tend to have more severe side effects than Prozac does.\nFor example, they like to line up their toys and they get very bent out of shape if there is any deviation.\u201d\n\nMORE: What Does a 400% Increase in Antidepressant Use Really Mean?\n\u201cThe clinicians could tell that people were doing better not only in terms of OCD symptoms but overall distress and ability to function.\u201d\n\nMORE: Why Are So Many Foster Care Children Taking Antipsychotics?\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Here\u2019s where the story both excels and disappoints. It takes note of prior research on antidepressants and notes that the \u201conly drugs approved to treat irritability and repetitive behaviors in autistic children are the atypical antipsychotics Risperdal (risperidone) and Abilify (aripiprazole), which tend to have more severe side effects than Prozac does.\u201d What the story does not explain, though, is that Hollander himself has researched this exact topic and arrived at very similar conclusions, which may bolster his case in some ways and weaken it in others. In 2005, he found in the journal Neuropsychopharmacology that \u201cLiquid fluoxetine in low doses is more effective than placebo in the treatment of repetitive behaviors and that \u201cLimitations include small sample size\u201d.\nThere was also no mention of the possibility of behavioral treatments.\n\u00a0\n\u00a0", "answer": 1}, {"article": "We could not find the requested page.\n\nPlease visit our home page to explore our services.", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release says \u201cthe ability of the test to correctly diagnose normal moles was 36 percent, approaching the levels achieved by expert dermatologists performing visual examinations of suspect moles under the microscope.\u201d\nThat differs from what\u2019s in the study, which reports \u201cthe visual examination of pigmented lesions by expert dermatologists using dermoscopy and following criteria such as the Menzies (or CASH[3]) method has yielded diagnostic accuracy as high as 98% sensitivity and 68% specificity in some studies.\u201d\nSixty-eight percent specificity is much more accurate than 36%, so we\u2019re not sure how that can be defined as \u201capproaching the levels\u201d of accuracy of visual exams by expert dermatologist.", "answer": 0}, {"article": "New stretch marks were also softer and smoother in 54 women who used the cream for three months, says Zoe Draelos, MD, a consulting professor of dermatology at Duke University Medical Center in Durham, N.C. \"The stretch marks did not go away,\" she tells WebMD.\nThe new product also contains pennywort, a plant found in Asia, Africa, and the Americas that has anti-inflammatory properties and is widely used in Indian naturopathic medicine for ulcer healing, she says.\nAs a result, doctors have been looking for a product to make new stretch marks look and feel better, Draelos says.\nAnd it has sulfur, which fights bacteria and infection, and a moisturizing cream to help rehydrate the skin, Draelos says.\nAny insult to the skin -- be it a cut or wound or the rapid stretching that drives the formation of stretch marks -- is accompanied by inflammation.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story fails to mention the existence of the many other moisturizing creams that purport to treat stretch marks. It also did not mention that plastic surgery is sometimes used to treat stretch marks.", "answer": 0}, {"article": "Software engineer Ben Wallace underwent subchondroplasty in November to help shore up a damaged hip.\nThe best candidates for the procedure are patients who still have some cartilage protecting their joint, but have somehow \"overloaded\" and injured the bone, causing swelling and pain, Hepinstall said.\n\"But there's a very narrow window of patients who are good ideal candidates for this, who basically have a real overload of their bone causing severe enough pain to warrant a surgical procedure, but also have healthy enough cartilage that doing something about the bone swelling is going to alleviate the majority of their pain,\" he stressed.\nThe calcium phosphate cement flows into the spongy inside portion of the bone, filling in microfractures and other damaged areas, and it hardens in about 10 minutes' time, said Dr. Kelton Vasileff, an orthopedic surgeon at the university's Wexner Medical Center.\n\"We don't want to send the message to people who have bone-on-bone, with big bone spurs and limited range of motion that they're all of a sudden going to get relief from injecting a little bit of cement into their bone,\" Hepinstall said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story introduces two approaches to managing arthritic pain for patients: joint replacement surgery and the bone cement outpatient procedure. The story mentions that the procedure is not appropriate for people with severe (\u201cbone-on-bone\u201d)\u00a0arthritis, but is directed at people with thin cartilage and mild arthritis. In standard clinical practice, joint replacement surgery is reserved for end-stage, debilitating arthritis. More appropriate comparison treatments for mild arthritis would include physical therapy and over-the-counter medicines. We do not learn from this story how the pain relief or functional improvements of bone cement compare to these typical conservative therapies. It\u2019s unclear whether or not this procedure has any place compared to standard treatment.", "answer": 0}, {"article": "Prescribing testosterone for age-related deficiency \u2014 which is only vaguely defined \u2014 took off in 2000. The trend was driven not by solid scientific evidence, but by the introduction of convenient, rub-on testosterone products, the first being Androgel. Many men are put on testosterone with no tests of their levels or despite tests showing normal levels, a study of Medicare claims found.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story takes a broad view, and looks at the evidence for using testosterone for a number of conditions. Given that, it would be tedious to try and discuss all the alternatives.", "answer": 2}, {"article": "\"The treatment I received on the trial changed my life.\n\"The fact that the treatment was performed so successfully by non-specialist centres in various health systems is really remarkable,\" says Professor Emberton, who is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre.\nThe research, published in The Lancet Oncology, found that around half (49%) of patients treated with VTP went into complete remission compared with 13.5% in the control group.\nThe chances of cancer progressing to a more dangerous stage were three times lower for patients on VTP, and the treatment doubled the average time to progression from 14 months to 28 months.\nThe VTP treatment is currently being reviewed by the European Medicines Agency (EMA), so it is likely to be a number of years before it can be offered to patients more widely.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "In some cases, the news release accurately compares VTP with the control, active surveillance. However, it also misleads readers by comparing VTP with aggressive treatment for higher-risk prostate cancer. For example, it states:\nRadical therapy causes lifelong erectile problems and around one in five patients also suffer from incontinence. By contrast, VTP only caused short-term urinary and erectile problems which resolved within three months, and no significant side-effects remained after two years.\nMoreover, the wording used by the release is misleading\u2013radical therapy does not always cause lifelong erectile problems as suggested. Nerve-sparing procedures can preserve potency for a substantial proportion of patients.\nBut with respect to VTP, even short-term problems are unacceptable if the treatment is not actually necessary.", "answer": 0}, {"article": "Hair changes about as fast as grass grows, which is to say it\u2019s extraordinarily slow and not visible to anyone checking impatiently in the mirror every day.\n\u201cThere aren\u2019t a lot of options, and I\u2019d love to be able to say to my patients, \u2018This is something you can try that is worth the money.\u2019 But I can\u2019t do that yet.\u201d\n\nHarklinikken\u2019s formula, refined over 20 years, is derived from plants and cow\u2019s milk.\nFor now, Maryanne Senna, a dermatologist and the director of the Hair Academic Innovative Research Unit at Massachusetts General Hospital in Boston, said the best she can tell patients who ask \u2014 and a lot of them do \u2014 is that Harklinikken won\u2019t do any harm.\nBut during regular follow-up appointments, Harklinikken uses high-tech equipment to photograph and magnify the scalp and count new hairs and active follicles, which motivates users to adhere to the regimen.\nIn the 1990s, clients mixed it with Rogaine, Mr. Skjoth said, \u201cand then we took the Rogaine part away and started focusing on the actual liquid.\u201d\n\nSmall studies have shown the efficacy of various plant-derived ingredients, mostly in mice.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t directly compare this product with other hair loss treatments such as minoxidil, laser treatments, and finasteride, a prescription-only medication marketed as Propecia. It mentions Rogaine (minoxidil) and a hair thickening shampoo as things one woman tried without success before turning to Harklinikken. The story does mention that for many women the hair will regrow on its own, which is a strength of the piece.", "answer": 0}, {"article": "Children have requested colorful designs inspired by superheroes, Disney's \"Frozen,\" and in Wyatt's case, the blue-skinned men from \"Blue Man Group.\"\nHer premature baby had been born with his right arm tangled in amniotic bands.\nHe expects to get fitted with his new arm later this month.\nHis mom, Cynthia, was most excited about seeing Wyatt being celebrated for who he is.\nThey gave it to Alex for free.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Other than the appearance, there are no comparisons with other types of prosthetic arms.", "answer": 0}, {"article": "For more information about NIH and its programs, visit http://www.\nIn addition to NHBLI, the study received funding from the NIH's National Institute of Diabetes and Digestive and Kidney Disease, the National Institute of Aging, and the National Eye Institute.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\nThe findings suggest that fenofibrate therapy may be beneficial in the way the researchers hoped: by reducing cardiovascular events in patients with type 2 diabetes who take statins but still have especially high triglycerides levels and low HDL cholesterol levels.\nBut the researchers wanted to know if the drug, when combined with statin treatment, could also reduce the risk of heart disease in people with type 2 diabetes.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release makes no mention of alternatives. Not only are there many statins on the market, but there are other approaches to managing high cholesterol levels and triglycerides. While statins are clearly the standard of care for patients with specific characteristics, the release should at least make mention of alternatives.There have been a number of medicines used in patients with diabetes to examine their role in decreasing cardiovascular events. The fact that there are many alternatives \u2014 from changes in diet and exercise to supplements (niacin) and medications (such as those derived from Omega-3 fish oils and fibrate drugs which lower triglycerides) \u2014 should have been mentioned.", "answer": 0}, {"article": "DURHAM, N.C. - Most high-risk lung cancer patients might not need annual low-dose computed tomography (LDCT) screenings if they are cleared of disease in their initial test, according to a study led by a Duke Cancer Institute researcher.\nThe researchers found that even former heavy smokers appear to have a reduced incidence of lung cancer if their initial LDCT screening is negative, suggesting that less frequent screening might be warranted.\nThe incidence of lung cancer at the first screen among those who were initially negative was 0.34 percent, compared to 1 percent of patients who were diagnosed during the baseline screening.\nIn the first year after a negative screen and before the scheduled first annual screen, 17 patients (0.09 percent of all initial negative LDCT participants) were diagnosed with lung cancer.\nThey then compared those patients to other CT-scan recipients whose screenings detected an abnormality to assess any differences in lung cancer incidence and lung cancer-specific deaths.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions alternatives in two different contexts. Chest radiography was an alternative test to CT scans. The study set out to analyze the most beneficial frequency of screenings and concluded that less frequency is a better alternative for smokers with an initial negative screen.", "answer": 1}, {"article": "LONDON (Reuters) - The first new asthma pill in decades has produced promising results in a small clinical trial, potentially paving the way for another treatment option for patients by the end of the decade.\nThe latest research, published in the journal Lancet Respiratory Medicine, comes at a time of considerable innovation in asthma care, with the recent launch of new injectable drugs for severe asthma that also target eosinophils.\nLarger and longer studies are now needed to prove that the twice-daily pill can also reduce severe asthma attacks, known as exacerbations.\nAt the same time, many drugmakers are developing improved asthma inhalers, including \u201csmart\u201d devices with sensors that monitor use.\nNovartis believes the medicine could be filed for regulatory approval in around 2019.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a great job here. It mentions that pills were standard treatment for asthma decades ago, but were replaced with inhalers that deliver drugs directly into the lungs. It also mentions that drugmakers recently launched injectable drugs for severe asthma that also target eosinophils and \u201care developing improved asthma inhalers, including \u2018smart\u2019 devices with sensors that monitor use.\u201d The story could have elaborated on how inhalers might compare to pills in terms of safety and efficacy, and mentioned there are other\u00a0new drugs (known as leukotrene receptor antagonists) that are also available as pills.", "answer": 1}, {"article": "SUNDAY, Jan. 17, 2010 (HealthDay News) -- Giving a vaccine through a scratch on the skin (scarification) triggers a stronger immune response than injected vaccines, say U.S. researchers, who also found that scarification requires 100 times less vaccine to prompt an immune response.\nAfter all, our immune system evolved over millions of years to respond to infections of injured skin, not vaccines delivered by hypodermic syringe into muscle,\" he noted.\nT-cells are located in lymph nodes and blood, as well as in peripheral tissues such as skin and lung.\nNearly all modern vaccines are given via injection, according to background information in a news release about the study, which is published in the Jan. 17 issue of Nature Medicine.\nIn their experiments, Kupper and colleagues found that scarification with the vaccinia virus offered much greater protection against smallpox than injecting the vaccine.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no meaningful, data-driven comparison of scarification delivery of vaccine versus injection. ", "answer": 0}, {"article": "TUESDAY, Dec. 29, 2009 (HealthDay News) -- Many older adults consume ginkgo biloba, hoping to keep their minds sharp, but a new study finds that the herbal product doesn't stave off cognitive decline.\nAlso, the age of the subjects is quite advanced, at an average of 79 years at the beginning of the trial.\nDr. Lon S. Schneider, director of the state of California's Alzheimer's Disease Research and Clinical Center at the University of Southern California, Los Angeles, said that these findings were \"straightforward and expected.\"\n\"If you are older and thinking 'I'll try ginkgo to preserve brain health,' we have no evidence that it is useful,\" he said.\nThese results remained the same regardless of sex, age, race or education, the researchers noted.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "In a story based on a study that pokes holes in some peoples\u2019 beliefs about a product to prevent cognitive decline, there could have been at least one line about other research into cognitive decline.\u00a0 ", "answer": 0}, {"article": "\"One of the concerns about taking aspirin remains the potential for intestinal bleeding.\nProfessor Elwood said: \"Our review, based on the available evidence, suggests that low-dose aspirin taken by patients with bowel, breast or prostate cancer, in addition to other treatments, is associated with a reduction in deaths of about 15-20%, together with a reduction in the spread of the cancer.\nThe team's review looked at all of the available data including five randomised trials and forty two observational studies of colorectal, breast and prostate cancers.\nThe study identified five healthy behaviours as being integral to having the best chance of leading a disease-free lifestyle: taking regular exercise, non-smoking, a healthy bodyweight, a healthy diet and a low alcohol intake.\nProfessor Elwood added: \"While there is a desperate need for more detailed research to verify our review and to obtain evidence on less common cancers, we'd urge patients diagnosed with cancer to speak to their doctor about our findings so they can make an informed decision as to whether or not they should take a low-dose aspirin as part of their cancer treatment.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The alternative approach to going on a low-dose regimen of aspirin \u2014 i.e. not doing so \u2014 is assumed but not made clear. But we\u2019ll award points to the release for smartly quoting one of the study authors on seeking out the advice of a doctor before taking aspirin regularly.", "answer": 1}, {"article": "\u201cFollowing a 'healthy diet' emerges as an important strategy for prevention of neurological disease, but remains to be proved.\u201d\n\nCathy A. Sila, MD, the George M. Humphrey II Professor of Neurology and the director of the Stroke & Cerebrovascular Center at the Neurological Institute Case Medical Center of Case Western Reserve University School of Medicine in Cleveland, Ohio, says the benefits of diet and lifestyle choices in disease prevention are more important than ever, given the rising costs of health care.\n\u201cMaybe olive oil improves vascular risk factors such as hypertension, dyslipidemia, diabetes, heart disease, obesity, which may in turn reduce stroke risk, or it may be that olive oil is anti-inflammatory or an antioxidant.\u201d Scarmeas writes an accompanying editorial.\n\u201cOlive oil is a healthy fat and it can reduce cholesterol and inflammation, and has been shown to help reduce the incidence of heart disease,\u201d she says.\n\u201cWe do not know for sure, and we do not know which particular aspect of olive oil is the most relevant to stroke,\u201d he says.\nThis is one of very few studies that looks at olive oil intake and risk for neurologic diseases, including stroke, Nikolaos Scarmeas, MD, of Columbia University in New York City, says in an email.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story ends, appropriately, with this: \u201cKeeping blood pressure controlled, not smoking, exercising regularly, and eating a healthy diet that is low in salt and rich in fruits and vegetables can also help reduce stroke risk.\u201d", "answer": 1}, {"article": "Visit redrazz.org for more information, and follow us on our social media channels:\nIn a mouse model, red raspberry supplementation of 5% dry feed weight was found to suppress inflammation and facilitate epithelium repair compared to mice with induced colitis (inflammation of the colon) and fed a standard chow diet.\nIn a secondary objective of the blood sugar control study, researchers found that subjects in the PreDM group who reported the highest level of hunger at baseline experienced greater satiety after the control meal compared to raspberry containing meals (p<0.05).\nWhile additional research, particularly in humans, is warranted, preliminary evidence from these studies suggests that the actions of essential nutrients, fiber, and polyphenolic phytochemicals found in red raspberries may play a role in supporting key metabolic functions, including anti-inflammatory, anti-oxidative and metabolic stabilizing activity.\nThese observations are not conclusive, and further research is needed to determine if red raspberry supplementation supports epithelial function in humans.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release was focused on raspberries, and raspberries alone. It would have been useful to know if other related berries (maybe blackberries, elderberries or lingonberries) have been found to have similar benefits.\u00a0", "answer": 0}, {"article": "The drug used in the study was manufactured by Organix Inc. in Woburn, Mass.\nHe also says \u201cPsilocybin therapy may not work for everyone, and some groups, such as people with schizophrenia, as well as adolescents, should not be treated with it.\u201d\n\nBoth the NYU Langone and Johns Hopkins studies were principally funded by the Heffter Research Institute, a non-profit, scientific institution with the principal mission of helping to design, review and fund studies on the use of psilocybin for a wide range of ailments (Ross previously served as a board member).\n\u201cAnd if it\u2019s true for cancer care, then it could apply to other stressful medical conditions.\u201d\n\nBossis cautions that patients should not consume psilocybin on their own or without supervision by a physician and a trained counselor.\n\u201cOur results represent the strongest evidence to date of a clinical benefit from psilocybin therapy, with the potential to transform care for patients with cancer-related psychological distress,\u201d says study lead investigator Stephen Ross, MD, director of substance abuse services in the Department of Psychiatry at NYU Langone.\nFor the study, half of the participants were randomly assigned to receive a 0.3 milligrams per kilogram dose of psilocybin while the rest received a vitamin placebo (250 milligrams of niacin) known to produce a \u201crush\u201d that mimics a hallucinogenic drug experience.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes that study participants received counseling in addition to the psilocybin treatment \u2014 which is an important point to make. However, the release doesn\u2019t discuss the use of counseling as a stand-alone treatment option for anxiety or depression, nor does the release address other pharmaceutical treatment options that can be used to treat mental health problems. The release would have been much stronger if it had compared the pros and cons of this treatment method with other treatment methods.", "answer": 0}, {"article": "But his thoughts were out of control.\n\"My wife took a summer off to be with me because she was scared of what was going to happen to me,\" he says.\nFrom Chaos To Calm: A Life Changed By Ketamine\n\nFor six years now, life has been really good for James.\nIt typically appears in childhood and often doesn't respond to traditional psychiatric drugs.\nThen they didn't, no matter how many he took.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes numerous claims about ketamine helping people when other treatments did not, but it does not provide specific comparisons about the pros and cons of ketamine compared to approved treatments.", "answer": 0}, {"article": "Error code 404. Something went\n\nwrong and we can't seem to find\n\nthe page you're looking for.\n\n Report a broken link.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are a range of treatment options for lymphedema. The article mentions a few:\nThe main treatment consists of wearing compression bandages and massage to bring down swelling. A lymphedema specialist initially prescribed a large pump that massaged (patient) Wolfe-Tank\u2019s arm for an hour a night, temporarily relieving some of the pain.\nIt also says lymph node transfer is \u201cnot the only option. A technique called lymphovenous bypass reroutes lymph-carrying channels, going around damaged or missing nodes to drain into veins instead.\u201d\nThe story laudably conveys a recommendation that patients be \u201cevaluated in a comprehensive lymphedema program to determine their best options.\u201d Information on what a \u201ccomprehensive lymphedema program\u201d is and how to find one would have been useful.", "answer": 1}, {"article": "Inside the brightly lit storefront in Brooklyn, N.Y., business was brisk as employees combed, washed and blow-dried little heads.\n\n\u201cDo I have a lot of lice?\u201d a boy asks the woman combing his hair slathered in Pantene conditioner.\n\nIt\u2019s the busiest time of the year for companies like Lice Busters, a family-run business Dalya Harel started in...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explored alternatives.", "answer": 1}, {"article": "The National Cancer Institute has more on prostate cancer.\n\"A low PSA, particularly those in men who have less than 1.0, and probably those less than 2.0, certainly could be considered for substantially longer intervals of PSA screening... Personalization of PSA screening is clearly underway.\"\n\"This gives us some confidence that annual PSA screening is going to soon become a thing of the past,\" said Dr. Nicholas J. Vogelzang, chair of the Developmental Therapeutics Committee of US Oncology, who moderated the teleconference.\nBut the maker of Avodart (dutasteride), GlaxoSmithKline, is unlikely to apply for new approval to market the drug for what is essentially prevention, meaning it would be used off-label in this context, he added.\nFor this study, about 20,000 men aged 55 to 74 in the Rotterdam area were screened, with those having PSA scores at or above the cut-off of 3.0 sent for biopsies and additional screenings every four years.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story didn\u2019t give any context on a number of points regarding alternatives. Each could have been addressed easily with a little re-wording or a few extra words.", "answer": 0}, {"article": "(Reuters) - The U.S. Food and Drug Administration (FDA) said it had approved Adamas Pharmaceuticals Inc\u2019s treatment for a side effect caused by a commonly prescribed Parkinson\u2019s drug, sending the shares of the drugmaker soaring in after-market trading.\nThe long-acting therapy is taken once-daily at bedtime.\nAn estimated 90 percent of levodopa-treated patients, about 200,000 people in the United States, suffer from LID, the company said.\nThe company said the drug is expected to be available in the fourth quarter, and formally launched in January 2018.\nThese patients have little recourse, other than opting for deep brain stimulation, a surgical procedure that involves blocking electrical signals from targeted areas in the brain.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that deep brain stimulation is a treatment option for those with severe symptoms.", "answer": 1}, {"article": "The researchers believe that adding probiotics to the peanut allergens may be important in improving the children\u2019s tolerance to the food, but Dr. Anna Nowak-Wegrzyn, an associate professor of pediatrics at Icahn School of Medicine at Mt.\nThe study, published in the journal , follows up on children enrolled in an earlier study of an immunotherapy treatment, which combined probiotics with small doses of peanuts that were designed to gradually train the children\u2019s immune systems to accept the peanut allergen rather than treat it as something foreign.\nIt makes sense that the probiotics may enhance the immunotherapy\u2019s effect, since probiotics are beneficial bacteria in the gut, where food allergens are processed.\nBut the new findings provide even more evidence that using peanuts to treat peanut allergy, and to re-train the immune system to be less allergic, can be effective.\n\u201cI think there is certainly a suggestion, but not hard proof, that the probiotics make a difference,\u201d says Nowak-Wegrzyn.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As noted above, the story notes that it is not clear whether the combination therapy works better than treatment that uses only immunotherapy. And the story does refer, briefly, to earlier immunotherapy studies. That\u2019s enough to earn a satisfactory rating here. However, a little more information on standard treatments and up-and-coming immunotherapy research would have made the story much stronger.", "answer": 1}, {"article": "But such evidence often does not pan out in human studies.\n\u201cIf we can even slightly lower their average blood sugar with metformin,\u201d Wilkin said, \u201cI believe we can have a big benefit on their risk of developing Type 1.\u201d\n\nDespite all these potential benefits of metformin \u2014 and despite a recommendation from the American Diabetes Association that it be tried before any other drug for newly diagnosed Type 2 diabetics \u2014 a recent study found that only about half of all such people get metformin as their first prescribed medication.\n\u201cPlain old metformin given in the same dose as we do for Type 2 diabetes doesn\u2019t seem to be a breakthrough for cancer, at least for pancreatic cancer.\u201d\n\nMany other metformin clinical trials are underway for breast, colorectal, endometrial and other cancers.\nThere needs to be more work in this area with all drugs for diabetes.\u201d\n\nFor Type 1 diabetes, researchers at the University of Colorado Denver School of Medicine published a study in May in which they added either a low dose of metformin or placebo pills to the insulin regimen of 74 adolescents.\nThe question is whether the rate-of-living theory is operational in mammals.\u201d\n\nPollak says that none of the most exciting possible benefits for the drug have yet been proved in randomized clinical trials of non-diabetics.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019re on the fence with this one. The start of the story focuses on new uses for metformin \u2014 uses that the story goes on to show are speculative and so far unproven (or disproven). It ends by highlighting that where the evidence for benefit exists \u2014 in patients with type 2 diabetes \u2014 metformin is underutilized compared to other diabetes medicines. However, the true comparison is for the potential new uses, and here the article should have stated clearly that until more evidence is available, metformin is unproven for these indications and that standard treatments should be the focus for the present. The story does warn that type 1 diabetics should never replace their insulin with metformin, but it doesn\u2019t highlight the importance of maintaining standard treatments for the other conditions that are discussed. Again, we\u2019ll err on the side of the story here.", "answer": 1}, {"article": "Three of them found that zinc acetate in daily doses of more than 75 milligrams (mg) shortened colds' duration by 42 percent, on average.\n\"In the evidence-based medicine framework, we are primarily interested in the question whether there is an effect, and how great, whereas the mechanism of the effect is a secondary issue,\" he said.\n\"Much of the variation in the published study findings can be explained by the daily dose of zinc administered in the zinc lozenges,\" said Hemila, who funded the research himself.\n\"When focusing on those studies which have used large daily doses of zinc, there is strong evidence that zinc lozenges shorten the duration of colds.\"\nbut I don't think the evidence is strong enough, nor do I think the author is suggesting, that we can base clinical practice on it,\" said Winston, also an associate professor in the University of California-San Francisco Department of Medicine.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not talk about existing strategies to relieve cold symptoms, and so, does not satisfactorily place the new research into context. A quick look at the National Institute for Allergies and Infectious Diseases website includes these: resting in bed, drinking plenty of fluids, gargling with warm salt water, using a decongestant or saline nasal spray, among others.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/060723/31robot.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While the article does mention cryo, seeds, and other forms of surgery for prostate cancer, the article doesn\u2019t mention other treatments, which could include active monitoring or radiation. Viewers are left with the impression that surgery is needed and is really the only option for treating prostate cancer. ", "answer": 0}, {"article": "To me, it was monumental.\"\n\"Both guys were taking steps the first time we turned the systems on,\" said Ron Triolo, a professor of orthopaedics and biomedical engineering at Case Western Reserve and executive director of the Advanced Platform Technology (APT) Center.\n\"In both cases, there is a disconnect between the brain and muscles,\" said Stephen Selkirk, MD, a neurologist at the VA's Spinal Cord Injury Division and assistant professor of neurology at Case Western Reserve School of Medicine.\nIn each patient, \"the pulses are sent in a pattern that is close to how normal muscles work,\" said Rudi Kobetic, a principal investigator at the Stokes Cleveland VA and APT Center.\n\"I went in there and I could barely take two steps,\" said Bush, 42, who researchers believe is the world's first MS patient to \"test-drive\" an implanted FES system.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There\u2019s scant reference to existing treatments, with just one quote that briefly mentions physical therapy:\nIn each patient, \u201cthe pulses are sent in a pattern that is close to how normal muscles work,\u201d said Rudi Kobetic, a principal investigator at the Stokes Cleveland VA and APT Center. \u201cWe try to time the pattern to stimulation so that it\u2019s integrated with their ability. Similar to regular physical therapy, we can see results.\u201d", "answer": 0}, {"article": "In a statement, she said the trial would help address how the procedure, if approved by federal regulators, \u201cshould be appropriately managed to minimize complications.\u201d\n\nSome experts have speculated that the adverse effects were dose-related.\nAlthough doctors are free to use any product on the market for whatever purposes they choose, companies may promote them only for their federally approved uses.\nThe use of a bioengineered protein should be \u201cdiscontinued either permanently or until further information becomes available regarding how to use it safely,\u201d said Dr. Thomas A. Einhorn, chairman of orthopedic surgery at Boston University.\nWhile use of the products in such operations has since fallen, one expert said the new report should convince doctors to stop using them in anterior cervical fusions, as the procedure is known.\nThe study published Tuesday found that patients who had received the bioengineered proteins during spinal fusions for lower or middle back pain did not have increased complications when compared with those who did not get the product.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe treatment of back and neck pain is hotly debated, but this story does not mention any of the non-surgical approaches nor does it provide any context about the outcomes of spinal fusion procedures.\n\u00a0", "answer": 0}, {"article": "ZURICH (Reuters) - Novartis will seek regulatory approval this year for a new kind of anti-inflammatory heart drug, though some experts fear fatal infection risks and a high price may overshadow the medicine\u2019s limited benefits.\nNovartis had said in June that the drug met its goal in the study but details were only unveiled at European Society of Cardiology meeting in Barcelona.\nThere was no significant difference in the rate of deaths from all causes between the placebo group and those on canakinumab.\n\u201cIn view of the additional oncology findings, we don\u2019t think you should just think about this as a cardiovascular drug,\u201d Narasimhan said.\n\u201cSome have wondered whether a particularly high-risk subgroup could be identified where canakinumab\u2019s current price can be justified,\u201d he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Both this story and the TIME story don\u2019t mention that there are\u00a0many effective and less expensive alternatives to secondary cardiac disease prevention, such as smoking cessation, aspirin, statins, blood pressure control, etc.", "answer": 0}, {"article": "Santarelli describes gantenerumab as a drug engineered to bind itself to plaques known as amyloid-betas, which accumulate as Alzheimer's progresses.\nIn the study, patients who received monthly gantenerumab injections showed reductions in such brain plaques.\nTherefore, it's not known if reducing the amount of them will slow or stop the disease.\nWhat is not entirely known at this point, though, is if these plaques cause Alzheimer's or are by-products of the disease.\nOct. 10, 2011 -- A small study shows that a new drug being tested for the treatment of Alzheimer's disease reduces the buildup of plaques in the brain associated with the fatal disease.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We preferred how HealthDay explained:\u00a0 \u201cThere are approximately one dozen therapies, including vaccines, that are currently in the pipeline\u2026.none are ready for prime time.\u201d", "answer": 0}, {"article": "This practice isn't totally harmless.\nYou should consume modest amounts in your diet, if possible (and for most people that is quite possible), or in the form of supplements if you can't get enough via food and drink.\nBut somehow we've arrived at a point when some physicians are prescribing large doses of Vitamin D supplements for their patients in the hope of preventing cancer, cardiovascular disease, diabetes, autoimmune disorders and other maladies, despite a lack of evidence that this works, according to a new commentary in the Journal of the American Medical Association.\nYou should be consuming 600 international units daily if you're between the ages of 1 and 70, and 800 IU each day if you're 71 or older, according to the Institute of Medicine, the health arm of the National Academcy of Sciences.\n(For a chart with a little more detail, see here.)\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story lays out what constitutes a healthy amount of vitamin D, how people can get that amount of vitamin D through their diet (or sunlight), and that some supplements may be needed.", "answer": 1}, {"article": "For more information about the symposium, visit www.thoracicsymposium.org.\nFor these patients, the best curative option is SBRT, a specialized type of external beam RT that uses advanced imaging techniques to deliver extremely targeted radiation to a tumor.\nThe advanced form of radiation therapy (RT) was well tolerated among this relatively understudied elderly population, indicating that SBRT is a viable option for patients who may otherwise be offered no curative treatment.\n\u201cElderly patients, who are otherwise doing well, should not have treatment withheld based solely on concerns about side effects and age.\u201d\n\nThe abstract, \u201cStereotactic body radiotherapy for early stage non-small cell lung cancer in patients 80 years and older: A multi-center analysis,\u201d will be presented in detail during the poster session at the 2017 Multidisciplinary Thoracic Cancers Symposium in San Francisco (full details below).\nWhile the primary treatment for early stage lung cancer is surgical removal of the tumor, some patients may not be able to tolerate surgery due to health status, advanced age or other factors.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release claims that SBRT is effective, without mentioning other types of radiation therapy or other options for lung cancer patients who are not candidates for surgery. It is unclear to the reader what this \u201cnew\u201d treatment is meant to replace.", "answer": 0}, {"article": "\"Wow!\"\nUltimately, the drug might be used by around 3,000 patients worldwide, if approved, and Schoenebaum expects it would be command a very high price, perhaps $250,000 a year.\nAnd the drug hasn't been submitted for review by the Food and Drug Administration, though Vertex expects to do that later this year.\nBut a key takeaway is that the medicine gets at a root cause of cystic fibrosis in some people rather than just relieving their symptoms.\nNow there are some promising results from a study in 161 people with a specific genetic mutation that affects about four percent of cystic fibrosis patients.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Nothing on existing alternatives.\u00a0 We wish the story had included even one line as the NY Times did: \u201cTwo inhaled antibiotics and one drug that loosens mucus are approved to treat cystic fibrosis, but nothing that directly improves chloride ion transport.\u201d", "answer": 0}, {"article": "Among randomized controlled trials (RCTs), there was a statistically significant reduction in CHD risk in higher risk populations, including:\n\u2022 16 percent in those with high triglycerides and 14 percent in those with high LDL cholesterol.\n\"It's also important that the observed risk reductions were even stronger in patient populations with elevated triglycerides and LDL cholesterol levels, two risk factors that affect more than one quarter of the American population.\"\n\"The meta-analyses of Alexander and colleagues suggests that omega-3 fatty acid intake may reduce risk of adverse CHD events, especially among people with elevated levels of TGs or LDL-C....omega-3 fatty acid intake of at least 1 gram of EPA+DHA per day, either from seafood or supplementation (as recommended by the American Heart Association), continues to be a reasonable strategy,\" said the authors.\nThe study was supported by a grant from GOED, which played no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.\n\"The 6 percent reduced risk among RCTs, coupled with an 18 percent risk reduction in prospective cohort studies -- which tend to include more real-life dietary scenarios over longer periods -- tell a compelling story about the importance of EPA and DHA omega-3s for cardiovascular health.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are many actions that invididuals can take to reduce their risk of coronary heart disease, including losing weight, exercising regularly, and managing stress. The release doesn\u2019t mention any of them. This is particularly problematic given that these are actions which are not mutually exclusive: one could lose weight, exercise regularly, manage stress and eat more fish (for example).", "answer": 0}, {"article": "For example, over 6 years of follow-up, no ovarian cancer cases were seen among BRCA2 mutation carriers who underwent salpingo-oophorectomy, compared with 3 percent of carriers who did not undergo the procedure, the researchers report.\nRoughly half of the women in the study had undergone either mastectomies (surgery to remove their breasts) or salpingo-oophorectomies (surgery to remove the ovaries and fallopian tubes) between 1974 and 2008, in order to proactively lower their risk of cancer.\nThe surgery in question is drastic: removal of the breasts or ovaries before any signs of cancer have arisen.\n\"There really isn't anything else that can reduce a woman's risk by this much.\"\nHe said the surgery today is often done in an outpatient setting, with the use of laparoscopes, which limits scarring and shortens a patient's recovery time.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nAlthough the story says the decision to undergo preventive surgery is complex, it does not describe the alternative approaches that women may choose.", "answer": 0}, {"article": "Krahn said the rate of complications from surgical removal will surprise doctors, because replacing a defibrillator is considered a minor procedure.\nIt can correct a heart that beats too fast, as in ventricular tachycardia, or quivers chaotically, a condition known as ventricular fibrillation.\nA total of 270,000 defibrillators have been recalled since January 2005, though it is unclear how many were inside patients and how many were on the shelf, according to the Food and Drug Administration.\nAbout 80,000 patients received the implantable devices in 2004.\n\"That risk is much higher than we initially thought,\" said study co-author Dr. Andrew Krahn of the London Health Sciences Center in Ontario.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "It is clear from the article that leaving a \u2018recalled\u2019 device in place is an option. Other options for treating heart rhythm problems are not noted. However, there are often not good options.", "answer": 1}, {"article": "This data is clinically significant.\n\"The migraine brain is hyperexcitable, and basic science studies have demonstrated modulation of neuronal excitability with this treatment modality,\" says Amaal Starling, M.D., a Mayo Clinic neurologist, who is first author of the study.\nWhile there is no cure, a new study published in Cephalalgia in March shows single-pulse transcranial magnetic stimulation is a new way to prevent migraine attacks.\nThe eNeura SpringTMS Post-Market Observational U.S. Study of Migraine study, also known as ESPOUSE, instructed participants to self-administer four pulses with the device in the morning and four pulses at night over three months to prevent and treat migraine attacks as needed.\nMigraine symptoms, which can be debilitating for many people, are the sixth leading cause of disability, according to the World Health Organization.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The lead author is quoted as saying:\nFor certain patients, treatment options for migraines, such as oral medications, are not effective, well-tolerated, or preferred.\nSome context would have been helpful here. It would help readers to know that the treatment of migraines is usually dictated by which of the several types of migraine the patient has (ie. episodic, chronic, environmentally triggered, and with or without an aura), and whether the goal is preventing an attack or treating an ongoing attack.\nTMS is a relative newcomer to a vast menu of treatment options for migraine.\nIt would have been helpful to state that there a large number of different treatments available for migraines including over-the-counter and prescription medications. Some are FDA approved and some are not. They include treatments for both acute symptoms of a migraine as well as preventing migraines from happening. There are also non-medication based treatments such as laying down in a darkened room and relaxation techniques. The use of preventive therapies for migraines is considered when the frequency is enough that focusing on the acute episode alone is not enough. This is something that patients decide, but is often considered if there are more than one attack per week. As noted, this study shows benefit, but it was not blinded and it doesn\u2019t compare itself to other available treatments.", "answer": 0}, {"article": "\u201cThe journal knew it.\u201d\n\n\u201cThe question for the journal, given that the authors worked for the company, is, \u2018Do we publish something like that?\u2019\u201d\n\nJohnston said there was an ongoing debate about whether or not scientists who review studies should know about potential industry interests.\nWhile there had been some concerns about the methods, \u201con balance there was enough interest to publish it,\u201d she told Reuters Health.\nWhile some people will want to see and feel an impact, he said, for many the clinical claim alone suffices.\nHe pointed out it was hard to draw any conclusions from this part of the study because it didn\u2019t include any data.\n\u201cScientifically there are no data there,\u201d he said about one of the company\u2019s experiments.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No need to compare this with other alternatives.\u00a0 This story was all about unsubstantiated claims made for one product.\u00a0 ", "answer": 2}, {"article": "Kuten and his colleagues studied the breath of 177 people \u2014 some healthy and some with various types of cancer \u2014 to detect the different chemicals emitted from the surface of cancer cells as they grow.\nWhile more work is needed to develop the technology, the early success could lead to the development of a cheap, easy-to-use and portable test to help diagnose cancer earlier.\nUsing the sensor to pinpoint chemical variations, the team found they could not only distinguish between healthy and malignant breath but also identify the four different common tumor types.\nLONDON (Reuters) - An \u201celectronic nose\u201d could be used as a simple breath test to detect lung, breast, bowel and prostate cancers, Israeli scientists said Wednesday.\n\u201cIf we can confirm these initial results in large-scale studies, this new technology could become a simple tool for early diagnosis of cancer along with imaging,\u201d said Abraham Kuten of Technion Israel Institute of Technology.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Even without detailing how the hypothetical tool might compare to existing alternatives, or fill a need, the story at least could\u2019ve told us that the reason further testing is needed is not just to repeat the research on a larger scale but also in order TO COMPARE the approach with what we\u2019re currently doing.", "answer": 0}, {"article": "Even More Evidence for the Health Benefits of Drinking\n\nPhotos: What Booze Looks like Under a Microscope\nThe study did find negative effects in children whose mothers drank moderately: this was defined as not having more than 3 to 6 British units of alcohol per week or more than 3 to 5 units on a single occasion.\nThe authors had earlier published similar results looking at the data for children in the study when they were 3, finding those whose mothers who didn\u2019t drink had slightly more behavior problems and slightly poorer performance on mental tests than kids born to light drinkers; the results also showed increasingly negative effects of alcohol going from moderate to heavy drinking.\nWhatever the case, American health authorities remain united in their advice that no amount of alcohol is safe for the fetus during pregnancy \u2014 and anyone who is familiar with fetal alcohol syndrome knows why.\n(More on Time.com: If I\u2019m Drunk, Then You Stepped On My Toes On Purpose)\n\nInterestingly, the new study parallels the effects of alcohol on health more generally; lighter drinkers tend to do better than teetotalers while the heaviest drinkers do worse.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that some women who usually drink decide to abstain either when planning to become pregnant, while others stop drinking after they learn they are pregnant, and still others continue to drink during pregnancy.", "answer": 1}, {"article": "The potential use of psilocybin in patients diagnosed with life-threatening diseases comes at a moment when medical care at the end of life is a subject of growing concern among patients and physicians. Research finds it's still common for dying patients to get painful and futile procedures. Palliative and hospice care, both aimed at easing the discomfort of the seriously ill, are growing specialties in American hospitals. An increasing number of patients, meanwhile, are demanding the right to die with a physician's help.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not address other treatment options for anxiety or depression, such as talk therapy or other pharmaceutical interventions.", "answer": 0}, {"article": "Barrow Neurological Institute is part of Dignity Health St. Joseph's Hospital in Phoenix.\nAdverse effects such as headache and infection occurred in 11.9% (5 of 42) of the patients in this study, consistent with rates reported in other DBS trials.\nThe ADvance Trial, using a device from Functional Neuromodulation, Inc., is aimed at evaluating the safety, efficacy and tolerability of DBS in this patient population.\nWhereas in Parkinson's disease and essential tremor, the target for the electrodes are nodes within the motor circuits, the Alzheimer's study targeted the fornix, which is part of the memory pathway.\nA neurosurgical procedure in which an implanted neurostimulator delivers electrical signals to specific areas of the brain to help regulate abnormal signals, DBS is currently only approved in the U.S. for the treatment of Parkinson's disease and essential tremor.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release briefly mentions the fact that there are \u201cfew promising pharmacologic treatment options,\u201d but there is little discussion of their use or\u00a0efficacy. Except for that, there is no mention of other treatment. Based on growing\u00a0evidence, there\u2019s increasing support for the idea that prevention may be the best bet to impact Alzheimer\u2019s and other forms of dementia.", "answer": 0}, {"article": ".\n\u201cWe thought we\u2019d be young forever,\u201d said Francis, who co-anchors a radio news program in Washington, D.C. \u201cThe big wake-up call is when our bodies wear down.\u201d\n\nBaby boomers, determined to keep moving no matter what wear and tear and arthritis have wrought, are fueling a surge in joint replacements.\nThe vast majority of joint-surgery patients report much less pain and greater mobility afterward, with success rates topping 95 percent, according to the American Academy of Orthopedic Surgeons, a physicians organization.\nThe procedures can cost up to $50,000 for knees and $40,000 for hips, though the prices vary widely among Medicare and private insurers, which typically bear the bulk of the cost.\nBaby boomers expect to be more active as they get older and have higher expectations about quality of life in their later years.\u201d\n\nStephanie Donvan, 60, of Arlington, who received a ConforMIS knee replacement in May, recalled feeling like she was \u201ccarrying a dead tree trunk\u201d before the surgery.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no mention of alternatives such as cartilage restoration procedures to stabilize joints, losing weight to ease joint strain, and managing activity to avoid injury.\nTreatment of hip and knee osteoarthritis is a classic example of a \u201cshared decision\u201d that should be made based on patient preference because there is no \u201cright\u201d answer \u2013 joint replacement is often no better than physical therapy, for example, but this did not come across at all in the piece.\nHere\u2019s an example of a decision aid for hip and knee osteoarthritis.", "answer": 0}, {"article": "CHICAGO (Reuters) - The common diabetes drug metformin may hold promise as a way to keep smokers from developing lung cancer, U.S. researchers said on Wednesday.\nOther studies have shown that metformin can cut diabetics\u2019 risk of pancreatic and breast cancers, and the latest finding now suggests it may defend the body against smoking-induced lung tumors.\nA team led by Dr. Philip Dennis of the National Cancer Institute, part of the National Institutes of Health, studied metformin in mice exposed to a potent, cancer-causing agent in tobacco called nicotine-derived nitrosamine ketone or NNK.\nMice that got the drug orally had 40 to 50 percent fewer tumors, while those injected with the drug had 72 percent fewer tumors.\n\u201cThis important laboratory study, together with prior laboratory and epidemiology research, suggests that metformin may be useful in cancer prevention and treatment,\u201d said Dr. Michael Pollak of McGill University in Montreal, who wrote a review on metformin research in the same journal.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No meaningful comparison with other lung cancer prevention approaches and not even with parallel human research in this field \u2013 as the HealthDay story did in at least mentioning a small human study of metformin in colorectal cancer patients. ", "answer": 0}, {"article": "Otto tracked 755 patients who died from breast cancer from 1995 to 2003 and another 3,739 control patients matched by age and other measures.\nThe risk reduction in younger women, aged 50 to 69, was smaller, at 39 percent, but still considered substantial.\nIt's not clear, for instance, whether the women who died of cancer got less aggressive treatment or refused treatment.\n\"But there is no way to figure out which cancers will be a problem or not,\" she said.\nNearly 36 percent of these women had never had a mammogram.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no discussion of alternatives to \u201croutine mammograms\u201d although the article does mention the debate as to the best schedule and age to begin. The clear alternative is not to be screened.\n\u00a0\n\u00a0", "answer": 0}, {"article": "Fleming and Dilger's co-authors include Supida Monaikul, Alexander Patsavas, Rosaline Waworuntu, and Brian Berg.\nThe article, \"Dietary polydextrose and galactooligosaccharide increase exploratory behavior, improve recognition memory, and alter neurochemistry in the young pig,\" is published in Nutritional Neuroscience.\n\"We found that, yes, VFAs are absorbed in the blood of pigs that were fed PDX/GOS.\nThe preference for novel objects, an indication of natural curiosity, is a sign of healthy brain development and points towards positive development of learning and memory.\nAlthough more work is needed to tackle remaining questions, the study adds to the growing body of research suggesting a strong and potentially modifiable link between the gut and the brain: a link that makers of infant formula should strongly consider.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There was a clear need to discuss the alternative to infant formula which is, of course, breast milk of the mother mammal. It is curious to know if the control piglets were able to suckle with their mother, and thus gain other socio-emotional benefits of that bonding (plus probably other important developmental constituents of breast milk) denied to the formula-fed pigs.", "answer": 0}, {"article": "TUESDAY, Aug. 17, 2010 (HealthDay News) -- Less invasive biopsies done with the help of imaging to guide the needle now make up the majority of biopsies being done, a new study finds.\nThat's an annual growth of 3 percent in number of biopsies, the researchers noted.\nIn addition, image-guided biopsies are more accurate, Quencer said.\nThis increase in less-invasive biopsies went along with a decrease in the number of more-invasive biopsies and through-the-skin biopsies where no imaging was used, the researchers found.\n\"This is a trend throughout the whole country.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No evidence-based comparison of biopsy techniques was provided \u2013 only the vague testimonials on behalf of the less invasive approach mentioned above.\u00a0 ", "answer": 0}, {"article": "Why so few?\n\"You have a lot of gun-shy patients because of a lot of bad experiences,\" says Michael John Coleman, founder of the patient group MAGNUM, also known as the National Migraine Association.\nMedicines backed by the strongest evidence include anti-seizure drugs (divalproex sodium, sodium valproate and topiramate), blood pressure drugs (metoprolol, propranolol and timolol) and, for menstrual-related migraines, a medicine called frovatriptan, the guidelines say.\nOne reason is that it's hard to persuade people to take medicines on days when they feel fine, says Elizabeth Loder, a neurologist at Brigham and Women's Hospital in Boston.\n\"The life toll that poorly controlled headaches take is really underappreciated,\" she says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is mainly about medications, but it does note that avoidable triggers can play a role in promoting migraines in some people.\u00a0 It also quotes a patient who says she\u2019s getting better results with diet, yoga and other lifestyle changes than with medications. We\u2019ll call it satisfactory.", "answer": 1}, {"article": "\u201cAnd Amgen\u2019s not a company that likes to price gouge.\u201d\n\nSchmidt said Imlygic\u2019s market potential as a standalone drug is \u201cvery, very modest.\nIt is genetically altered to replicate only in tumor cells while also producing a protein that activates T-cells, the search-and-destroy specialists of the immune system.\nIn many of the newer experiments, researchers are combining cancer-killing viruses like Imlygic with other immune-activating agents known as checkpoint inhibitors.\n\u201cAfter that, there were no side effects.\u201d\n\nSuch muted side effects point to a major benefit of this new approach, doctors and patients said.\n\u201cThey\u2019re old and easily upset, and I can\u2019t look sick.\u201d\n\nEarlier this month, a new scan revealed shadows that could be signs of melanoma.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions another drug called Yervoy and also mentions conventional treatments. It also describes other virus-based treatments that are under development.", "answer": 1}, {"article": "\"Experimental studies suggest that fructans may be beneficial in diabetes, obesity, stimulating the immune system of the body, decreasing levels of disease-causing bacteria in the intestine, relieving constipation and reducing the risk of colon cancer,\" Mercedes Lopez, of the National Polytechnic Institute in Guanajuato, said in the news release.\nThe fructans turn into alcohol when agave is processed into tequila, they said.\nBut drinking tequila won't help, the study authors noted.\nThe National Osteoporosis Foundation has more about osteoporosis prevention.\n\"They can be used in many products for children and infants to help prevent various diseases, and can even be used in ice cream as a sugar substitute.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No such comparisons provided. ", "answer": 0}, {"article": "One of the top research universities in the world, MSU focuses its vast resources on creating solutions to some of the world's most pressing challenges, while providing life-changing opportunities to a diverse and inclusive academic community through more than 200 programs of study in 17 degree-granting colleges.\nIn a proof-of-concept study, published in the journal Neurobiology of Disease, the drug nortriptyline, which has been used to treat depression and nerve pain, stopped the growth of abnormal proteins that can build up in the brain and lead to the development of the disease.\nThe idea that this clustering effect is controlled by how fast or slow a protein reconfigures itself is typically not a standard way of thinking in research on proteins, but our work has been able to show these changes.\"\nThis protein, known as alpha-synuclein, can cause the brain's nerve cells to die when in a clustered state and is a hallmark sign of the disease.\n\"We found that those on a certain class of antidepressant, called tricyclics, didn't need the levodopa therapy until much later compared to those who weren't on that type of antidepressant medication,\" Collier said.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Parkinson\u2019s disease is complex, unfolds over many years, and has many dimensions. It is often misdiagnosed. The release should have included some description of treatments available. Besides the drug levadopa, surgery and other therapies have been used to ease symptoms.", "answer": 0}, {"article": "So mystery and grief hung heavy when he collapsed from a cardiac arrest Jan. 6 inside the Teutonia M??\n\"We believe the people who do go home have fewer neurological problems that impair the quality of life,\" Dr. Callaway said.\nThe heart quits pumping blood, leaving vital organs depleted of oxygen -- a situation that can cause significant damage to the brain, kidneys and other organs, or death if quick emergency action is not taken.\nFor 24 hours, his body temperature was kept at 91 degrees Fahrenheit, which put him in a state of hibernation.\nA heart attack can prompt cardiac arrest -- a situation in which the heart rhythm goes chaotic, making it quiver rather than beat, Dr. Granato said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The sequence of when this treatment would be used \u2013 and the decisions about how and when it would be used \u2013 are unclear.\u00a0 So, too, then is any discussion about what the options are.\u00a0 ", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070311/19clot.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "MRI was presented alongside the traditional echocardiography test. But there was no discussion of other methods of treating massive deep vein clots in the legs other than the Angiojet device.\u00a0 ", "answer": 0}, {"article": "Dr. Gregg C. Fonarow, a professor of cardiology at the University of California, Los Angeles, agreed.\nDuring the study, the patients consumed an average of 18.8 grams of margarine per day, which meant ingestion of an average of 226 milligrams of EPA combined with 150 milligrams of DHA omega-3 fatty acids and/or 1.9 grams of ALA.\n\nBy the study's end, almost 14 percent of the heart attack patients had experienced another \"major cardiovascular event,\" with some cases ending in death.\nOne exception appeared to be among women ingesting ALA; researchers saw a 27 percent reduction in the risk for further cardiac complications, although that reduction did not quite reach statistical significance.\nIn fact, neither low doses of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which are found in fish oil, nor of alpha-linolenic acid (ALA), derived from nuts and several vegetable oils, provided any benefit to the vast majority of heart patients, the study showed.\nSUNDAY, Aug. 29, 2010 (HealthDay News) -- Most heart patients who take low-dose omega-3 fatty acid supplements don't appear to gain any additional protection against further cardiac trouble, new Dutch research cautions.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story addressed some other approaches albeit indirectly: \"The scientists focused on patients who were already taking medications to control blood pressure, cholesterol and potential clotting. So, the researchers theorized that the poor performance of the supplements may simply reflect the overwhelming power of the medications.\"\nThere was no discussion of other things that have been shown to lower the risk of future coronary events in those who have had a heart attack beyond taking medications. Even one line offering such context would have been helpful. ", "answer": 1}, {"article": "One recent analysis of previous studies found that people who took a low dose of aspirin every day for several years reduced their risk of developing Alzheimer\u2019s by 13 percent.\nIt\u2019s believed that aspirin, and possibly other nonsteroidal anti-inflammatory drugs, may reduce or head off that process.\nAnother study in 2003 in The European Journal of Clinical Pharmacology found a similarly beneficial effect for aspirin and other nonsteroidal anti-inflammatory drugs.\nOne of the most prominent followed more than 6,000 older women for nearly a decade and found that those who regularly took 100 milligrams of aspirin did no better on cognitive tests, over time, than those who were given a placebo.\nThe claim that aspirin can prevent the disease stems from the notion that Alzheimer\u2019s is caused by inflammation that disrupts proteins in the brain.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no discussion of any other approaches under investigation for prevention or delay of Alzheimer\u2019s disease.", "answer": 0}, {"article": "Doctors delivered Owen at 32 weeks so she could begin chemotherapy and radiation.\n\"If there is cancer, the tumor is shedding DNA into the mother's blood as well and that is what is accounting for this imbalance,\" study author Dr. Diana Bianchi, who serves on an advisory panel for the company, told CBS News.\nWhile prenatal testing is widely used for pregnant women at risk of having babies with chromosome disorders such as Down syndrome, new research shows certain types of tests may also reveal markers of cancer in mothers.\n\"I refuse to believe that there's going to be any other outcome than 'it's all going to be okay' because the alternative is unfortunately not something I want to think about.\"\nThe study, funded by Illumina, a maker of one non-invasive prenatal test, looked at eight women with abnormal test results.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No alternatives to the blood tests were mentioned in any context. The WSJ story, by contrast, notes that the blood tests are now used in place of more invasive amniocentesis or chorionic villus sampling to identify fetuses at risk. The WSJ also underscores the importance of having a positive blood test confirmed with one of these more invasive tests.\nNot undergoing testing at all might also be an option, but the story does not address this.", "answer": 0}, {"article": "To study the relationship between berry consumption and heart disease, Cassidy and her collaborators at the Harvard School of Public Health analyzed findings from the Nurses Health Study 2 which includes more than 90,000 nurses in the U.S.\n\"Even when we adjusted for things like fat intake, fiber intake, medication use, or body size, and for example, exercise, we still got these strong reductions in risk,\" Cassidy says.\n\"But nonetheless, for the first time I think we have some evidence that the intake of theses anthocyanins may have a protective effect.\"\nWomen With A Berry-Snacking Habit May Have Healthier Hearts\n\nWhen it comes to supernutritious foods, the blueberry has long had a health halo floating over it.\nAnd if they're out of season, like now, studies show frozen berries have similar levels of beneficial compounds.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No alternatives are mentioned. To prevent heart attacks, patients can either take medications, such as blood-thinning and cholesterol-lowering drugs, or make lifestyle changes, like maintaining a healthy weight, exercising and not smoking.", "answer": 0}, {"article": "Excellent/Good/Fair/Poor.\nThe results allow researchers to compare the predictive ability of a large number of health-related risk factors which were formerly studied separately and using different populations, although the predictive ability of risk factors does not necessarily imply they are causally related to the risk of dying.\nThe score, which uses measures that can be obtained by simple questionnaires without any need for physical examination, such as self-rated health and usual walking speed, could be used by individuals to improve awareness of their health status, and by doctors to identify high-risk individuals for further treatment, say the authors.\n\"The Ubble website allows anybody in the UK between forty and seventy years old to calculate their 'Ubble age' and their risk of dying within the next five years compared to the general population, using a simple set of a dozen or so questions,\" says study co-author Professor Erik Ingelsson from Uppsala University, Sweden.\nUsing these findings, the researchers then developed an easy-to-calculate risk score for an individual's risk of dying in the next 5 years, based on the most predictive self-reported information, including 13 questions for men and 11 for women.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The study and its press release make much of the potential advantage of predicting death via self-report questions rather than biological tests. So the text makes an overt comparison, admittedly without data.\nThe release could also have included the comparison to doing nothing. Whether providing any risk information (this version or another) or no risk information makes a difference is a legitimate question.", "answer": 1}, {"article": "By the end of the study, 27 of the 183 people, or 15 percent, who took Topamax had quit drinking entirely for seven weeks or more.\nThe drug works by inhibiting dopamine, the brain's \"feel-good\" neurotransmitters that are involved in all addictions, said Stephen Dewey, a neuroscientist at the Brookhaven National Laboratory.\n\"The size of the treatment effect is larger than in most of the other medications we've seen,\" said Dr. Mark Willenbring of the National Institute on Alcohol Abuse and Alcoholism.\nThe study, published in today's Journal of the American Medical Association, was funded by the maker of the drug, Johnson & Johnson Inc.'s Ortho-McNeil Neurologics.\n\"You can come in drinking a bottle of scotch a day and get treatment without detox,\" said Dr. Bankole Johnson of the University of Virginia, who led the study, which was conducted at 17 U.S. sites from 2004-2006.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story did not name names, it did mention that there were three other medications currently approved for use in the treatment of alcoholism.\u00a0 The story couched one benefit for use of the study drug as something for people who want to see their \"own doctors, rather than enter a rehab clinic to dry out.\"\u00a0\u00a0This is misleading as it makes it seem as though for the other medications currently approved for the treatment of alcoholism,\u00a0it is necessary to attend a specialized alcohol treatment program. \n\u00a0The story did not mention any 12-step programs that some use for treating alcoholism.", "answer": 0}, {"article": "CHICAGO \u2013 Initial findings from a randomized phase III clinical trial show that patients with advanced squamous non-small-cell lung cancer (NSCLC) benefit more from initial treatment with PD-L1 targeted immunotherapy atezolizumab (Tecentriq\u00ae) and chemotherapy than from chemotherapy alone -- 29% had a reduced risk of disease worsening or death compared with those who received chemotherapy alone.\nOutcomes for only two of the groups, however, are being reported in this presentation:\n\nOutcome data for the third treatment group, which received atezolizumab with a slightly different chemotherapy regimen (carboplatin and paclitaxel), are not yet available.\nAlthough the difference between treatment groups is modest, a statistically significant improvement shows that, overall, people with advanced squamous lung cancer can benefit when immunotherapy is added to standard treatment, according to the authors.\nAlthough the rate of severe side effects was higher with the combined modality treatment than with chemotherapy alone (68% vs. 57%), it had a manageable safety profile, consistent with known safety risks of the individual therapies.\nThe researchers will explore tumor PD-L1 expression and other molecular markers, such as tumor mutational burden (TMB), that may predict whether a patient will benefit from this treatment regimen.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This trial is a direct comparison with existing treatment.\nAs it turns out, a similar trial involving squamous cell lung cancer patients, also presented at ASCO, that used a different immunotherapy drug, did report improved overall survival, but those results were not public when this release was written.", "answer": 1}, {"article": "\"Here in the U.S., we do things differently,\" he said.\nEven though the ephedra-containing herbal is not readily available in the United States, the M-Y herbal formula is available in many countries besides China, including Korea, Japan, India and Germany, the study authors noted.\nCao and Wang, who specialize in infectious diseases and clinical microbiology, said the herbal recipe -- known as maxingshigan-yinqiaosan (M-Y) -- is easily accessible throughout China and much less expensive than Tamiflu (oseltamivir).\nThe results: Both M-Y and Tamiflu were effective at eliminating fever, whether administered on their own or in combination.\nThe M-Y flu preparation is composed of 12 herbs: ephedrae, zhimu, qinghao, shigao, yinhua, huangqin, chaoxingren, lianqiao, bohe, zhebeimu, niubangzi and gancao.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story never mentions vaccines, which of course can prevent the H1N1\u00a0flu from developing in the first place. Also, existing medications such as acetaminophen and ibuprofen can ease fever and other flu symptoms.", "answer": 0}, {"article": "The last update, in 2005, put more emphasis on chest pushes by alternating 30 presses with two quick breaths; those \"unable or unwilling\" to do the breaths could do presses alone.\nThis action should be taken only for adults who unexpectedly collapse, stop breathing and are unresponsive.\nNow the heart association has given equal standing to hands-only CPR.\nOnly about 6 percent of those who are stricken outside a hospital survive, although rates vary by location.\nThe CPR guidelines had been inching toward compression-only.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The segment makes clear that the two treatment options for observed adult cardiac arrest are conventional CPR and compression-only CPR. ", "answer": 1}, {"article": "WEDNESDAY, Aug. 17, 2011 (HealthDay News) -- People who have narrowed carotid arteries in the neck and show no symptoms may be at risk for stroke and not know it, but a simple ultrasound test can identify the problem, a new study suggests.\n\"If they are too sick or frail for surgery, it makes no sense to do the ultrasound,\" he said.\nAnother expert, Dr. Larry B. Goldstein, director of the Duke University Stroke Center, said that \"what remains uncertain is whether surgical intervention would result in an overall improvement in stroke-free survival.\"\nWhen treating asymptomatic carotid stenosis, Marquardt doesn't think the case has been made for distinguishing between high- and low-risk patients.\n\"This test could be a good tool to identify the right patients for surgery,\" Topakian said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Sorting throught the quotes from experts, it would seem that the combination of ultrasound tests could be used to better predict those individuals at lower risk who would be best off managed with medical therapy; and to better predict which individuals stand to benefit the most from surgery because their risk was higher.", "answer": 1}, {"article": "One of the top research universities in the world, MSU focuses its vast resources on creating solutions to some of the world\u2019s most pressing challenges, while providing life-changing opportunities to a diverse and inclusive academic community through more than 200 programs of study in 17 degree-granting colleges.\nYet, even with this therapy, certain white blood cells can still be overly stimulated and eventually become inflammatory.\nWith antiretroviral therapy \u2013 a standard form of treatment that includes a cocktail of drugs to ward off the virus \u2013 these cells have a better chance of staying intact.\n\u201cIt might not be people smoking marijuana,\u201d Kaminski said.\nUp until then, it was unclear how these compounds, also known as cannabinoids, affected the immune system.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There is no mention of any alternatives in the release.", "answer": 0}, {"article": "In the new study, Zick's team randomly assigned 30 people to take pills containing 2 grams of ground ginger root extract or a \"dummy\" placebo pill each day for 28 days.\nResearch has supported its use to treat stomach problems such as nausea and vomiting; the U.S. National Library of Medicine says it's \"likely safe,\" although some people may develop mild side effects.\nTUESDAY, Oct. 11, 2011 (HealthDay News) -- A small, preliminary study finds that ginger root supplements seem to reduce inflammation in the intestines -- a potential sign that the pills might reduce the risk of colon cancer.\nThe study, funded by the U.S. National Cancer Institute, was published online Oct. 11 in Cancer Prevention Research.\nIt's already clear that people with inflammatory conditions such as inflammatory bowel disease are at higher risk of colon cancer, he noted.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No context was given about any other research in the field of the inflammation \u2013 colon cancer link.\nIs this the only research in the field?\nThe relevant comparison may be the relative reduction in colorectal cancer risk (or inflammatory markers) with aspirin, the most common anti-inflammatory product most people are exposed to.", "answer": 0}, {"article": "What does that mean for men today?\nStill, growing numbers of doctors are using the method already to help decide when to order a biopsy, and \"I think the study does raise the question as to whether PSA velocity may at some point be a helpful factor in determining prognosis,\" he said.\nThose with a higher PSA velocity \u2014 the level rose more than a count of 0.35 a year \u2014 had a 54 percent survival rate, while those whose PSA rose more slowly had a 92 percent survival rate.\nWASHINGTON \u2014 Prostate cancer is more likely to be life-threatening if the man's PSA level rose rapidly during the years before he was diagnosed, says a new study that may help change how PSA tests are used.\nThe work is \"another step on the road to more sophisticated\" prostate cancer screening and treatment, Dr. Timothy Church of the University of Minnesota wrote in an editorial accompanying the work.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not adequately talk about options, whether that's treatment options once cancer is diagnosed or\u00a0alternatives to screening.\u00a0 For instance, the story doesn't mention the typical screening scenario (how often is it done, what does it involve?) nor does it mention the alternative of not screening, which is reasonable given that\u00a0experts don't know if screening or even early treatment saves lives.\u00a0 \u00a0 ", "answer": 0}, {"article": "\"Gardasil has the potential to meet an unmet medical need as the first vaccine to prevent cervical cancer,\" Merck's Dr. Patrick Brill-Edwards told the Vaccine and Related Biological Products advisory committee.\nHowever, this vaccine should not be considered a replacement for the standard screening test: the pap smear, adds Kaledin.\nHPV is the most common sexually transmitted disease.\nAlso, the drug does not protect against infection from the many other virus strains not included in the vaccine.\nThe drug protects against the two types of human papillomavirus (HPV) believed responsible for about 70 percent of cervical cancer cases.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention that the alternative is a pap smear and this vaccine is not a replacement for the pap smear. ", "answer": 1}, {"article": "Next time you order takeout wonton soup and a spicy Number 82, you might want to make sure it comes with brown rice.\nThe researchers tried to control for the fact that Americans who eat brown rice tend to be more healthy overall \u2014 they eat more fruits and vegetables and less red meat and trans fats, and they also tend to be thinner, more active and less likely to smoke than those who don\u2019t eat brown rice.\nBut the Harvard study is one of the first to distinguish between brown rice and white rice consumption in the United States, where rice is not a staple food and relatively little is eaten overall, said Dr. Qi Sun, an instructor in medicine at Brigham and Women\u2019s Hospital, which is affiliated with Harvard Medical School.\n\u201cIt\u2019s really recommended to replace white rice with the same amount of brown rice or other whole grains.\u201d\n\nThe researchers who did the study analyzed rice consumption among 39,765 men and 57,463 women who participated in the Health Professionals Follow-up Study and the Nurses\u2019 Health Study I and II; participants in the three groups ranged in age from 26 to 87.\nAnd correlation does not necessarily mean a cause-and-effect relationship, since factors other than brown rice consumption may have accounted for the decreased diabetes risk that was observed.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0Although the study came up with a suggestion derived from a statistical analysis about replacing some of one\u2019s white rice with brown rice, there was no discussion of other methods (i.e. maintaining adult body weight within the normal range or engaging in aerobic exercise) for reducing one\u2019s risk of type II diabetes. Even a short line could have been dedicated to this important context. ", "answer": 0}, {"article": "Surgery for a painful, common back condition known as spinal stenosis resulted in significantly reduced back pain and better physical function than treatment with drugs and physical therapy, according to the latest findings from a large federally funded research effort.\n\nThe results from the Spine Patient Outcomes Research Trial, or Sport, echo findings it reported last April involving degenerative spondylolisthesis, another common spinal problem. A separate, earlier report from the same study found nonsurgical treatment for...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article notes some of the common alternatives to surgery\u2014drugs and physical therapy\u2014although it does not mention another very common treatment, epidural steroid injections. ", "answer": 1}, {"article": "Aug. 17, 2011 -- German researchers say that highly trained dogs are able to reliably sniff out lung cancer in human breath.\n\"The whole field is focused on using something that's readily available that does not involve an expensive surgery or scan that would allow us to find early cancers,\" says Ramalingam, who is developing technology that aims to replicate the ability of dogs to smell trace amount of chemicals produced by cancerous tumors.\nBut that test has caused controversy because it falsely detects cancer in about one out of four people, leading to further invasive procedures.\nRecently a large, government-funded study found that longtime smokers at high risk for lung cancer who received annual rapid computed tomography (CT) scans of their lungs cut their risk of dying of the disease by 20%.\n\"This is the holy grail,\" says Suresh S. Ramalingam, MD, associate professor and director of the lung program at Emory University's Winship Cancer Institute in Atlanta.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job of explaining how lung cancer is detected by existing CT scan and bronchoscopy, and discusses the exposure of the patients to some risk during these procedures.\u00a0Where it fails is in giving us numbers for how the earlier detection might show an increase in survival for patients.", "answer": 1}, {"article": "Both drugs could win approval from the Food and Drug Administration by this summer.\nThe study of Amgen\u2019s evolocumab involved 4,465 patients with various degrees of risk, two-thirds of whom were randomly chosen to get the drug in addition to the medication they were already taking.\nThe drugs, evolocumab from Amgen and alirocumab from Sanofi and Regeneron, inhibit a protein in the body called PCSK9 that helps regulate cholesterol.\n(However, the PCSK9 drugs are taken by injection every two weeks or four weeks, which could deter some users.)\nStill, the findings could help smooth the way for regulatory approval, wider use of the drugs by doctors and possibly reimbursement by insurers.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article briefly compared PCSK9 inhibitors to statins, or other lipid-lowering drugs like Lipitor, stating that this new class of cholesterol drugs reduced bad cholesterol to lower levels than statins. It also mentioned the drug niacin, which did not protect against heart attacks and strokes, despite it raising good cholesterol levels and moderately lowering bad cholesterol.\nHowever, a more thorough discussion on traditional treatments would have been welcome. For example, why are other lipid-lowering medications needed if there are already quite a few out on the market? The AP story addressed this question, explaining many people cannot tolerate statins or get enough help from them.", "answer": 1}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nHowever, HbA1c levels increased in the final third of pregnancy, which is consistent with the decrease in sensitivity to insulin that often occurs during this time period.\nIn the current study, researchers evaluated whether the HbA1c test (also called the A1C test), commonly used to diagnose type 2 diabetes, could identify signs of gestational diabetes in the first trimester of pregnancy.\nAccording to the authors, comparatively few studies have examined whether the HbA1c test could help identify the risk for gestational diabetes, and these studies have been limited to women already at high risk for the condition.\nThe researchers analyzed records from the NICHD Fetal Growth Study, a large observational study that recruited more than 2,000 low-risk pregnant women from 12 U.S. clinical sites between 2009 and 2013.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There currently is no standardized screening test for identifying gestational diabetes in the first trimester. Earlier research into the usefulness of HbA1c testing for gestational diabetes in early pregnancy have been limited to high risk groups.", "answer": 1}, {"article": "MONDAY, Nov. 16, 2015 (HealthDay News) -- Breast-feeding a premature infant may help reduce the risk of a serious eye problem known as retinopathy of prematurity (ROP), new research suggests.\nThe studies included more than 2,200 preterm infants, comparing how often babies had been fed human milk or formula, and whether or not they developed ROP.\nIn re-evaluating the studies, Chen's team found that breast-feeding in any amount appeared to reduce the risk of ROP.\nThe takeaway from this study, Llanos said, is to breast-feed as long as possible, if possible.\n\"Human milk feeding potentially plays a strong role in protecting very preterm newborns from any-stage ROP and severe ROP,\" the international team of study authors wrote.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does not mention other preventative measures to take against ROP besides breast milk and formula. But neither does the original study, so we\u2019ll leave this criterion as not applicable.", "answer": 2}, {"article": "U.S. News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual \"America's Best Hospitals\" survey.\nThe former indication is potentially useful for using IsoPSA for screening by primary care physicians, while the second is helpful for urologists in identifying patients who would benefit from curative intent therapy and other applications.\nBy identifying molecular changes in the prostate specific antigen (PSA) protein, the findings, published online last month by European Urology, suggest that once validated, use of IsoPSA may substantially reduce the need for biopsy, and may thus lower the likelihood of overdetection and overtreatment of nonlethal prostate cancer.\n\"Due to its inherent simplicity, requiring only a blood draw and presenting information to the physician in familiar context using a single number - just like PSA itself - we are quite hopeful in IsoPSA's future utility after further validation studies,\" said Mark Stovsky, M.D., co-author and staff member, Cleveland Clinic Glickman Urological & Kidney Institute.\nThe study directly compared the clinical performance of a new test based on PSA, called IsoPSA, to PSA itself with patients already scheduled for prostate biopsy.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release compares IsoPSA to the current PSA blood test. IsoPSA detects molecular changes in the protein, it states. According to the journal article, IsoPSA is a structure-based assay encompassing the entire spectrum of the protein\u2019s structural changes.\nConventional tests are based on PSA concentrations in the blood or other bodily fluids.\nAlthough the news release doesn\u2019t go into much detail about current tests, we feel it does a good enough job for a Satisfactory rating here.\nHowever, it would have been good for the release to highlight that the current test is not uniformly recommended. No testing is a reasonable option according to the USPSTF\u2019s draft screening recommendations.", "answer": 1}, {"article": "What's more, he added, there are already several good ways to catch colon cancer -- or, even better, precancerous growths called polyps, which can then be removed before a tumor develops.\nThe idea of using a breath test to catch cancer is not new: Researchers are looking into breath tests for detecting a number of cancers, including lung and breast tumors.\nIt's still unclear which breath chemicals should be measured, or what statistical method is best for weeding out cases of colon cancer.\nThe study, of 78 people with and without colon cancer, found that those with the disease tended to have a distinct pattern of chemicals in their breath.\nIn the end, the researchers were able to correctly identify the cancer patients 76 percent of the time.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u00a0discusses existing options for\u00a0colon cancer screening, and what some experts think are the appropriate ages and intervals at which these tests should be done.", "answer": 1}, {"article": "They wrote up a plan to test what they called \u201csuperselective intra-arterial cerebral infusion\u201d of Avastin in 30 patients with glioblastomas that had recurred after standard treatment.\nEach patient would receive just one treatment directed into the brain, followed weeks later by a series of intravenous treatments with Avastin.\nIt consists mainly of cells that line the walls of capillaries in the brain and are so tightly packed that many molecules in the bloodstream cannot slip out between cells to reach the brain tissue itself.\nBut certain drugs, like mannitol, will temporarily open the barrier and were first used more than 20 years ago to help other medicines reach the brain.\nThe new technique refines the art of opening the barrier: it uses microcatheters \u2014 fine, highly flexible tubes that are inserted into an artery in the groin and then threaded up into tiny blood vessels nearly anywhere in the brain \u2014 to spray chemotherapy directly onto tumors or areas from which they have been removed.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story describes the conventional treatments for glioblastoma\u2013surgery, radiation and/or chemotherapy via pill or IV. ", "answer": 1}, {"article": "\"The whole process was overwhelming, because you have your 12-year-old who's wanting to end her life,\" Rick says.\n\"It reduced the odds of suicidal behavior by half,\" says Barbara Stanley, a psychologist at Columbia University and the lead author of the study.\nThis is the first large-scale study of the Safety Planning Intervention, which Stanley and her group developed in 2008 and which has been adopted at hospitals and clinics around the country.\nThe next step is for the patient \u2014 with help from the clinician \u2014 to come up with a set of coping strategies to help get through moments of intense suicidal ideation.\nAmong the nearly 1,200 people who received the intervention, half as many people had made suicide attempts (or had come very close) as those in the control group.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t adequately explain what the alternatives are\u2013if a hospital doesn\u2019t have this protocol in place, what normally happens with suicidal patients?\nThere\u2019s some history of alternative approaches that could have put this intervention into context. Up until 10 years ago \u201cno-suicide contracts\u201d were commonly used after emergency department visits, but they were repeatedly shown to be ineffective. Around that time, safety plans were recommended as an alternative, and clinical trials among active duty military found them to lower suicide risks. Post-discharge follow-up by in-person visit or phone calls was also shown to lower suicidal behavior by up to 30%. The authors of this study, then, developed and evaluated a combination of the two approaches.", "answer": 0}, {"article": "This study was presented at a medical conference.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\nThe study involved 5,275 men with localized cancer whose disease had not spread beyond the prostate gland; 1,982 of the men were taking anticlotting medications: aspirin, Lovenox, Plavix, and/or warfarin.\nBut if the findings are confirmed, \"patients who are taking aspirin for other reasons may see an added benefit,\" says study head Kevin Choe, MD, a radiation oncologist at the University of Texas Southwestern Medical School in Dallas.\nThe risk that cancer spread was also reduced by anticlotting medications, from 7% to 3%.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe researchers say it would be premature to recommend the use of anticoagulants in prostate cancer patients, because the benefits and risks have yet to be clearly identified\u2026 and so it is also premature to expect comparisons to alternatives.", "answer": 2}, {"article": "The positive results surprised even Stagl.\n\u201cWhile I certainly wouldn\u2019t say that anyone could take a 10-week course and be set for life, I think anyone could take a 10-week course and be much better at coping with stress.\u201d\n\nNext, the study team, led by Michael Antoni of the University of Miami, hopes to show that an easier-to-manage five-week group class works as well as the 10-week one.\nThe women who took the 10-week stress-management class shortly after surgery reported feeling better and having fewer depressive symptoms such as anxiety than those who took a one-day, breast-cancer education session.\n\u201cThis is really a teachable moment.\u201d\n\nThe skills taught in the course are useful at many stressful moments, Porter said, not just when cancer is diagnosed.\nIf a woman\u2019s stress level remains high indefinitely after diagnosis, she may have a worse outcome than if she can bring it back down, Stagl said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses stress management in broad terms, referring to it as teaching patients \u201crelaxation techniques and coping strategies.\u201d It does not discuss other possible treatment options for dealing with stress or depression following serious illness, such as professional counseling or medications.", "answer": 0}, {"article": "The U.S. Food and Drug Administration approved the first therapy to treat an underlying cause of cystic fibrosis, a pill that targets a genetic mutation affecting a small minority of patients suffering from the life-threatening breathing disorder.\n\nThe drug, Kalydeco, from Vertex Pharmaceuticals Inc., will be among the most expensive therapies on the market, costing $294,000 a year.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story at least mentioned that until now patients took \u201cmedicines that only tackled the symptoms of the disease, such as antibiotics to treat the infections. Patients typically spent a few hours each day wearing vibrating vests to dislodge mucus build-up.\u201d\u00a0 But there was no comparison of the effectiveness of the new drug with this past approaches.", "answer": 0}, {"article": "Sabourin Lussier, born with spina bifida, faced the possibility of kidney failure when she was just 19 years old. Her bladder, damaged by the devastating birth disorder, leaked uncontrollably and often backed urine up into her kidneys.\n\nA conventional surgery to reconstruct her bladder with intestinal tissue threatened further health complications. So in May 2000, Ms. Lussier and her mother, Gail Johnston, agreed to an experiment under which she and eight other patients with spina bifida would receive partial, laboratory-built...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is discussion that conventional surgery\u2013intestinal tissue used to reconstruct the bladder\u2013 \"threatens further health complications\". These are briefly discussed, and include clogging of intestinal mucus or formation of kidney stones. There is no mention of disadvantages and potential health problems of the surgery with a reconstructed organ, or the possibility of the patient rejecting this organ. ", "answer": 0}, {"article": "A lot changed in between the births of my second and third daughters. For one thing, this time around I really am getting no sleep; for another, the pediatrician recommended something for our 1-month-old that is different from what had been suggested for our other children. She said we needed to pick up a liquid multivitamin that contains 400 international units (IUs) of vitamin D. It was a little confusing, because with our first daughter, now almost 4, the doctor told us to simply get her out in the sun from time to time to let her body produce vitamin D,...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "In addition to vitamin D supplements, the story mentioned food, supplemented foods, and functional foods (cod liver oil) as well as sun light exposure as options for obtaining vitamin D.\nThe story would have been improved with some explanation of why sunlight exposure is most often inadequate due to latitude and cloud cover in addition to the discussion in this piece about the impact of sunscreen use.\u00a0\n\u00a0", "answer": 1}, {"article": "The U.K.\u2019s new at-home HIV test won\u2019t reach all the undiagnosed or guarantee that the people who test positive wind up receiving the care they need from a doctor, but letting people check their status quickly and accurately is likely to produce cascading positive effects, as HIV-positive people find it easier to seek care for themselves, warn past partners about exposure, and reduce risk for future partners.\nWhen asked if any test similar to BioSure\u2019s new take-home test was in development, Tara Goodin, a press officer for the Food and Drug Administration, said: \u201cThe FDA cannot confirm the existence of or comment on any current/pending product applications.\u201d\n\nThe FDA has approved two take-home HIV tests, but neither has all the strengths of the BioSure test.\nIn a 2012 study, researchers estimated that in 2008, approximately 20 percent of all HIV-positive people in the United State were undiagnosed.\nAnd because the incidence of other sexually transmitted infections declined for these men, after the diagnosis, the scientists had reason to believe the self-reports of condom usage were accurate.\nIn the United States, the Affordable Care Act designates HIV testing as a preventive service, meaning that all insurers must cover it without charging a co-pay.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This point is an important problem with the story. Without providing any evidence, the story pushes the assumption that self-testing at home offers the same benefits as testing that is coupled with counseling. While the story does provide some comparisons with at-home HIV tests currently available in the US, the comparisons are incomplete. It notes that users of one test have to send their blood sample to a lab and then call for results, without noting that this call provides an opportunity to explain the meaning of the test result and encourage follow-up counseling or treatment. The comparison with another test mentions only the false negative rate, without also reporting the false positive rates.", "answer": 0}, {"article": "(Reuters) - A combination of two Bristol-Myers Squibb drugs that help the immune system fight melanoma led to significantly greater tumor shrinkage than treatment with one of the medicines, according to a midstage study presented on Monday.\n\u201cLonger follow-up will be helpful to see the durability of these responses and what happens to patients who had complete responses,\u201d said Hodi, who presented data from the Checkpoint-069 study at the American Association for Cancer Research meeting in Philadelphia.\n\u201cThe response rates and the depth of responses are quite impressive,\u201d Dr. Stephen Hodi, director of the Melanoma Center at Dana-Farber Cancer Institute and co-lead author of the study, said in an interview.\nThe overall response rate, defined as tumors that shrank by at least 30 percent, was 61 percent for the 72 patients who received the combination versus 11 percent among the 27 who got Yervoy alone.\n\u201cMost of the patients who stopped for toxicity continued to benefit,\u201d said Fouad Namouni, Bristol\u2019s head of development for Yervoy and Opdivo.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story focuses solely on immunotherapy, and does not address surgery, chemotherapy, radiation therapy or other treatment techniques at all.\u00a0The story would have been stronger if it had touched on, at least briefly, a\u00a0fundamental question for readers: how is immunotherapy\u00a0potentially better than other treatment techniques?\u00a0We also think that a word about prevention would have been helpful to the reader.", "answer": 0}, {"article": "CHICAGO (Reuters) - A study in rats and monkeys suggests an experimental Merck & Co sleep drug may help induce sleep without causing the memory loss and attention problems sometimes seen in the commonly used drugs Ambien and Lunesta, company researchers said on Wednesday.\nThe most common side effects from Suvorexant have been headache and sleepiness.\nLevels of this compound rise during the day and fall at night.\nIn the study, rats given GABA blockers were less likely to recall the objects than those given DORA-22.\n\u201cHow impaired would they be?\u201d Renger said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no mention of the many non-drug strategies for dealing with insomnia.", "answer": 0}, {"article": "Called solanezumab, the drug attaches to a protein called beta-amyloid that builds up and clumps together to form sticky plaques that riddle Alzheimer's patients' brains.\nI would be happy with a sustained cognitive benefit for my mother-in-law.\"\nThere was even a hint that the drug helped to slow the decline in functioning.\nLarger studies in many more patients are needed before the drug will be available, though, she says.\nThe drug is designed to prevent those clumps from forming.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story does not include background on existing treatments.", "answer": 0}, {"article": "Long-standing American Heart Association guidelines recommend a diet primarily consisting of fruits, vegetables, fish, and other whole foods, with limited amounts of sodium, sugar, saturated fats, and refined carbohydrates.\nLooking at their answers, researchers gave them points in either the Mediterranean diet or Western diet category.\nThose who ate more foods in the Mediterranean diet category were 3.5 times less likely to experience one of these three events than people whose diets more closely resembled the Western standard.\nThey answered questions about their diet and reported how many times a week they consumed servings from separate food groups.\nOver nearly four years, 1,588 (about 10 percent) of the study participants suffered either a heart attack or stroke, or died.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did an adequate job of explaining the two diets, and it mentioned medication, which is another approach to preventing heart disease.", "answer": 1}, {"article": "Jordan says the new findings will quickly change care for some patients.\nAfter 2\u00bd years, Staley and her doctor stopped the drug \"to regain a measure of quality of life.\"\nHowever, because this cancer is very treatable, death rates were low: 0.4% of those on tamoxifen for 10 years died of endometrial cancer, compared to 0.2% of those taking it for five years.\nThe study involved an estrogen-blocking pill called tamoxifen, a standard therapy for the roughly two-thirds of breast cancer patients whose tumors are sensitive to estrogen.\nBreast cancer patients who double the length of time that they take a common medication can sharply reduce their risk of death, according to a new study that's predicted to influence medical practice.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The two women with breast cancer who reviewed this story found one good point, one weak point in the story on this criterion:", "answer": 0}, {"article": "Although the company selling Xiaflex will be Auxilium Pharmaceuticals of Malvern, Pa., the F.D.A.\nAuxilium was interested because of Peyronie\u2019s disease.\nIt now has only five employees and a business of collecting a roughly 11 to 12 percent royalty on sales of Xiaflex.\nThe ailments are named for French surgeons who described the conditions in the 18th and 19th centuries.\nSome people treated with Xiaflex in clinical trials for the Dupuytren\u2019s hand condition said it had made a big difference in their lives, and had allowed them to avoid painful surgery.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compares costs and outcomes for Xiaflex with open surgery and needle aponeurotomy.", "answer": 1}, {"article": "Any HIV in the sample triggers an acidity change, which the chip transforms into an electrical signal.\n\u201cWe have taken the job done by this equipment, which is the size of a large photocopier, and shrunk it down to a USB chip.\u201d\n\nThe test, which uses a mobile phone chip, requires a drop of blood to be placed onto a spot on the USB stick.\nThe researchers say the technology, although still in the early stages, could allow patients to regularly monitor their virus levels in a similar way to diabetes patients checking their blood sugar levels.\nBut in some cases the drugs stop working - sometimes because virus has developed resistance to them - and the first sign of that would be a rise in a patient\u2019s so-called \u201cviral load\u201d.\nLONDON (Reuters) - Scientists in Britain have developed a type of HIV test using a USB stick that can give a fast and highly accurate reading of how much virus is in a patient\u2019s blood.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Readers are told \u201ccurrent tests to detect virus levels take at least three days and involve sending a blood sample to a laboratory,\u201d which is basic but we\u2019ll mark this one satisfactory. However, knowing how often the WHO recommends viral-load tests be taken, and how sensitive and specific they are, would have made this story stronger.", "answer": 1}, {"article": "But the mind is a powerful thing.\nWhen gluten was reintroduced to her diet as a test, the symptoms returned, only to disappear when the gluten was again removed.\nAnother possibility is simply that given how small the studies were, the differences occurred by chance.\nBut only about 1 percent of the population has an autoimmune response to gluten.\nThe earliest report on whether gluten could muck with some digestive tracts comes from the late 1970s.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The main options here seem to be a diet with or without gluten. We\u2019ll rate this not applicable.", "answer": 2}, {"article": "Sometimes patients get stents when they have no pain at all, just blockages.\nTheir study focused on the insertion of stents, tiny wire cages, to open blocked arteries.\nThe devices are lifesaving when used to open arteries in patients in the throes of a heart attack.\nMore than 500,000 heart patients worldwide have stents inserted each year to relieve chest pain, according to the researchers.\nA procedure used to relieve chest pain in hundreds of thousands of heart patients each year is useless for many of them, researchers reported on Wednesday.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story (and the study) suggest that medication can manage pain from blocked arteries.", "answer": 1}, {"article": "The study is published in the journal BMJ.\n\"Dark chocolate may be a pleasant and effective way of delivering important dietary components that can provide health benefits to the ever increasing numbers of people at increased risk of cardiovascular disease,\" says researcher Christopher M. Reid, PhD, professor of cardiovascular epidemiology and preventive medicine at Monash University in Australia.\nThey did not study actual people eating actual chocolate.\nSeveral studies have found that dark chocolate, with its heart-healthy flavonols, can lower blood pressure and improve cholesterol.\nThe researchers also computed whether it would be cost-effective to spend money on a public education campaign about dark chocolate's benefits.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "At least the story quoted the Harvard expert:\nThose at risk of heart attack and stroke should first focus on lifestyle, Ding says. That includes weight loss if needed, exercising regularly, and not smoking.", "answer": 1}, {"article": "\"CCSVI equals hope and a lot of MS patients just are completely devoid of hope,\" Stecker says.\nZamboni calls it \"the liberation procedure\" but it is actually a common technique known as angioplasty when it's used to open clogged arteries \u2014 not veins.\nIt's been thought that multiple sclerosis is caused by a misguided immune system that attacks the nerves of the brain and spinal cord and can lead to muscle weakness, paralysis and death.\nIt's so seductive, in fact, that Canadians and Americans with MS have been flocking overseas to get the \"liberation procedure.\"\nSeveral patients have even died as a result.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study focuses exclusively on this novel surgical procedure. It should have at least mentioned that there are FDA-approved drug treatments for MS.", "answer": 0}, {"article": "Many people currently take fish oil supplements to decrease their risk for heart disease.\nOther supplements were not linked to breast cancer risk in the new study, including black cohosh, dong quai, soy, and St. John's wort, which are often taken to relieve some of the symptoms of menopause.\n\"There is some limited evidence from my study and others that fish oil may be good for preventing breast cancer, but there is not sufficient evidence to make a public health recommendation right now,\" cautions study researcher Emily White, PhD, an epidemiologist at the Fred Hutchinson Cancer Research Center in Seattle.\nOther studies have not found a link between eating more fatty fish and breast cancer risk, but it may be that the amount of omega-3 fatty acids in fish oil supplements is much higher than what is typically found in the diet.\n\"If you are taking fish oil now for other reasons, this is reassuring that it may have beneficial effects beside what you are taking it for,\" she says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "At the very least, the story included the fact that \"Other supplements were not linked to breast cancer risk in the new study, including black cohosh, dong quai, soy, and St. John\u2019s wort, which are often taken to relieve some of the symptoms of menopause.\" ", "answer": 1}, {"article": "\"Right then, I thought, \u2018Oh, why did I do this?\nThe implant uses those signals to stimulate hearing nerves in the inner ear and replicate the sound.\n\"I wasn't even really worried about the deafness because it was hurting so bad.\n\"I am most happy to hear my music,\u201d he said.\nIt is then that the patient will either hear sounds or not.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions no other treatment options. Is there anything short of surgery that might help?", "answer": 0}, {"article": "The compound WAY-316606 could therefore be used to treat baldness, without patients suffering the same side effects as they would on CsA.\n\u201cIt is also important to realize that this is being proposed as a treatment for hair loss, not a cure as such.\u201d\n\nThis piece has been updated with a comment from the British Association of Dermatologists.\nDr. Hawkshaw said in a statement: \u201cThe fact this new agent, which had never even been considered in a hair-loss context, promotes human hair growth is exciting because of its translational potential: It could one day make a real difference to people who suffer from hair loss.\u201d\n\n\u201cClearly though, a clinical trial is required next to tell us whether this drug or similar compounds are both effective and safe in hair-loss patients.\u201d\n\nA British Association of Dermatologists spokesperson said in a statement the results were interesting.\nAn existing drug used to treat a common bone disorder could hold the key to the cure for baldness, according to a new study.\nThe scientists were then able to identify that WAY-316606, a compound used to treat osteoporosis, has a similar effect on how SFRP1 is expressed.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story said current treatments for hair loss \u201care limited to two FDA-approved drugs, mioxidil and finasteride, which have mixed results. The other option is minimally invasive hair transplant surgery.\u201d", "answer": 1}, {"article": "In effect, those guidelines say there's no particular benefit from working out harder, other than saving time.\n(It's unclear whether the 9 percent improvement seen will be enough to cut their risk of heart disease, though.)\nThe result makes sense, since there's some previous evidence suggesting that higher-intensity exercise is tied to improving how the body processes sugar, said Neal Pire, an exercise physiologist who puts together medically based training programs at HNH Fitness in Oradell, N.J., a program of Holy Name Medical Center.\n\"The take-home message here is that if you're consuming a healthful diet and engaging with exercise consistent with the guidelines, you're going to see a benefit in your waistline and on the bathroom scale,\" said Ross.\nNow we have some answers: You may want to go just a tad longer and harder than you'd thought.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses the benefits of aerobic exercise on obesity and cardiovascular outcomes. It also mentions strength training, which we\u2019ll consider good enough for a satisfactory rating. A mention of other approaches \u2014 calorie-restricted diet, medications, even surgery in some cases \u2014 would also have earned the story a pass on this one.\n[Editor\u2019s note: this story was originally graded Not Satisfactory on this criterion, but has been change to Satisfactory for the reasons discussed below in the comments.]\u00a0", "answer": 1}, {"article": "Former smokers who had accumulated 30 pack-years were included only if they had stopped smoking within the previous 15 years.\nThe day the government announced the study results, Westside Medical Imaging of Beverly Hills, Calif., issued a press release saying that the study \u201cshould once and for all settle the controversy\u201d about whether CT lung scans save lives.\nTo take a trial that involves people at high risk for lung cancer and to extrapolate it and say it\u2019s good for people with intermediate or low risk is not appropriate.\u201d\n\nThe study, called the National Lung Screening Trial, focused on a specific high-risk group: 53,000 current and former heavy smokers, aged 55 to 74, who had smoked for at least 30 pack-years.\n\u201cI\u2019m concerned that some radiologists might be early in that learning curve and some patients may be harmed because of it.\u201d\n\nWhile the study found a benefit to scanning a specific group of high-risk smokers, that doesn\u2019t mean other groups will get the same benefit, says Dr. Peter B. Bach, a pulmonologist at Memorial Sloan-Kettering Cancer Center in New York.\nIn an interview, Dr. Lepor said that he only offers lung scans to those at high risk, and that he turns people away who are at low risk but want the scan anyway because \u201cthey just want to know.\u201d\n\nDr. Lepor said it would be \u201cimprudent\u201d not to incorporate the latest study data into his practice right away.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The one comparison was the synopsis of the key study finding:\u00a0\u201cThe smokers and former smokers were given either annual CT lung scans or chest X-rays. Compared with conventional X-rays, the CT, or computed tomography, scans create a detailed three-dimensional image of the lungs. The study was stopped when it was found that the scanning group had a 20 percent lower risk of dying from lung cancer than those being screened with X-rays.\u201d", "answer": 1}, {"article": "WEDNESDAY, April 28, 2010 (HealthDay News) -- A new drug may be the first new treatment in 25 years for a common diabetes-linked eye condition called diabetic macular edema (DME), researchers report.\n\"First and most importantly, it provides patients an improved therapy for diabetic macular edema.\nThe American Academy of Ophthalmology will review the study findings and make recommendations on whether Lucentis plus laser treatment should be the preferred treatment for a large number of patients with DME.\nFor 25 years, laser treatment has been the standard of care for DME, the main cause of vision loss in people with diabetes.\nBut researchers say it can also improve vision in people with DME, a common form of diabetic retinopathy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No comparison with the cheaper alternative \u2013 part of the important controversy raised in the NYT story. ", "answer": 0}, {"article": "\u201cWe believe the benefits increase with age.\nBut there are harms, and particularly in their 40s, women have to make a decision for themselves.\u201d\n\nOne potential harm is false positives, in which a suspicious mammogram finding leads to more tests, sometimes even biopsies, but turns out to be harmless.\n\u201cThe science supports mammography as an important tool in the fight against breast cancer,\u201d said Dr. Michael LeFevre, a former chairman of the task force and a professor of medicine at the University of Missouri.\nFor every 10,000 women screened repeatedly over 10 years, four lives are saved in women 40 to 49; eight in women 50 to 59; 21 in women 60 to 69; and 13 in women 70 to 74, the task force found.\nThe task force said it concluded \u201cwith moderate certainty\u201d that the benefit was moderate in women 50 to 74 and small in women 40 to 49.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternatives in a story like this one are the recommendations from other organizations, and the story does a good job of explaining the varying recommendations from the USPSTF and three other groups: the National Comprehensive Cancer Network, the American College of Obstetricians and Gynecologists, and the American Cancer Society. Well done.", "answer": 1}, {"article": "Drinking cow\u2019s milk produced at night may be a treatment for anxiety and insomnia, suggests an animal study in the Journal of Medicinal Food.\n\nA glass of milk at bedtime has long been touted as a sleep aid. But the study found that milk collected at night, or night milk, had enhanced sedative effects in mice compared with milk produced during the day. Night milk significantly decreased the rodents\u2019 physical activity, balance and coordination and increased sleep time compared with day milk, the research showed.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article states\nMice fed night milk were more inclined to explore open spaces, an indication of reduced anxiety that was comparable to the effects from consuming diazepam\u2026\nThe design of the study, however, does not support this claim\u00a0because a direct\u00a0comparison is never made between night milk and diazepam. Since we\u2019ve already addressed this issue above, however, we\u2019ll give the story credit here.", "answer": 1}, {"article": "\u201cThe goal is to develop a blood test, such as this one, that can accurately identify cancers in their earliest stages.\u201d\n\nKlein added: \u201cIt is several steps away and more research is needed, but it could be given to healthy adults of a certain age, such as those over 40, to see if they have early signs of cancer.\u201d\n\u201cWe hope this test could save many lives.\u201d\n\nThe study, by a research team that also included scientists from Stanford University, was presented at the annual conference of the American Society of Clinical Oncologists in Chicago.\nThe test, called a liquid biopsy, screens for cancer by detecting tiny bits of DNA released by cancer cells into blood.\nThe test had particularly good results for ovarian and pancreatic cancers, though the number of cancers detected was small.\n\u201cNow, as the NHS marks its 70th anniversary, we stand on the cusp of a new era of personalised medicine that will dramatically transform care for cancer and for inherited and rare diseases,\u201d said Stevens.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The current gold standard for confirming the diagnosis of most cancers is a tissue sample. This is not addressed in the article and should have been. It also could have been clearer that for some cancers there are no approved screening tests.", "answer": 0}, {"article": "So the researchers are hoping the Del Sontro family\u2019s heart disease is caused by a mutated gene.\nHis doctor told him absolutely not, saying, \u201cYou are the kind of guy we will read about who dies during the race of a massive heart attack.\u201d Mr. Del Sontro could still exercise, his cardiologist said, but no more than 45 minutes a day.\nTo keep the focus on truly rare mutations, the researchers are excluding those that are present in both members of the Del Sontro family and 3 percent or more of the other study participants.\nOr the change might be in a poorly understood region of DNA that controls genes rather than in a gene itself.\n\u201cOur main job is to find the gene,\u201d Dr. Biesecker said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Dozens of novel\u00a0risk factors, such as C-reactive protein, have been\u00a0proposed to more accurately identify individuals\u00a0whose cardiovascular risk is not appropriately predicted\u00a0by traditional risk\u00a0factors.\u00a0The use of these novel risk factors\u00a0is controversial. The story should have addressed this evidence. What about the Framingham risk score?", "answer": 0}, {"article": "WASHINGTON\u2014People with mild Alzheimer\u2019s disease who started taking an experimental Eli Lilly & Co. drug earlier in the course of their disease fared better than patients who started later in a clinical trial.\n\nThe outcome may bolster the company\u2019s case that the drug, solanezumab, can slow the decline of memory and function in mild Alzheimer\u2019s patients, despite prior studies with negative results. But the new data aren\u2019t final proof of the drug\u2019s benefit\u2014a separate, continuing study due to end in late 2016 is designed to...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does note that existing medications on the market \u201ccan alleviate symptoms but don\u2019t slow underlying disease progression.\u201d We\u2019ll rate this Satisfactory, although these medications are really only\u00a0marginally effective in a minority of patients.", "answer": 1}, {"article": "George said he believes the approach works by \u201cresetting\u201d electrical activity and restoring normal mood regulation.\nBased on the results, George and his team say, it would be necessary to treat 12 depressed patients with TMS in order to have one patient recover.\nNEW YORK (Reuters Health) - A daily dose of electricity delivered to a specific part of the brain can lift depression, new research confirms, even for people who\u2019ve already tried multiple antidepressants to no avail.\nAfter three weeks, 14 percent of patients in the real TMS group had recovered from their depression, compared to 5 percent of the sham TMS group; people who had the real treatment were four times as likely to get better as those who got the fake treatment.\nIn the May issue of the Archives of General Psychiatry, George and his colleagues report the results of their 190-patient study, the most rigorous investigation of TMS for depression so far.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story doesn\u2019t do enough to describe the\u00a0treatment options for a patient with major depression who fails the first treatment: These options include a\u00a0change in medication or combinations of medication, psychotherapy with or without medication, and neurostimulation such as TMS or ECT. \u00a0This type of information could have been obtained from an independent expert. ", "answer": 0}, {"article": "You know your cholesterol, your blood pressure ... your heart gene score?\nOther scientists and companies have long sought ways to measure risk from multiple, additive gene effects \u2014 the \"poly\" in polygenic \u2014 and Myriad Genetics has begun selling a type of polygenic test for breast cancer risk.\nIf the approach pans out and doctors adopt it, a bad score wouldn't mean that you'd get a disease, just that your genetic makeup increases the chance \u2014 one more piece of information in deciding on care.\n\"This is the first time polygenic scores have really been shown to reach the level of precision where they can have an impact\" on patient health.\n\"What I foresee is in five years, each person will know this risk number, this 'polygenic risk score,' similar to the way each person knows his or her cholesterol,\" said Dr. Sekar Kathiresan, who led the research team from the Broad Institute, Massachusetts General Hospital and Harvard Medical School.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does offer the following: \u201cOther scientists and companies have long sought ways to measure risk from multiple, additive gene effects \u2014 the \u201cpoly\u201d in polygenic \u2014 and Myriad Genetics has begun selling a type of polygenic test for breast cancer risk.\u201d\u00a0 And there are multiple\u00a0other methods for assessing the risk of a person developing specific diseases, although the story doesn\u2019t offer any comparison between those methods and the new one it touts.", "answer": 1}, {"article": "Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others: the ability of HETIOZ\u00ae to provide significant benefit in the treatment of the symptoms of jet lag disorder; Vanda's ability to obtain marketing approval for the use of HETLIOZ\u00ae in the treatment of jet lag disorder; and other factors that are described in the \"Risk Factors\" and \"Management's Discussion and Analysis of Financial Condition and Results of Operations\" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2017, which is on file with the SEC and available on the SEC's website at www.sec.gov.\nThere are no adequate and well-controlled studies of HETLIOZ\u00ae in pregnant women.\nThis clinical design allowed for the study of HETLIOZ\u00ae without the confounding effects of sleep deprivation and variable light conditions.\nHETLIOZ\u00ae has not been studied in patients with severe hepatic impairment and is not recommended in these patients.\nHETLIOZ\u00ae should be used during pregnancy only if the potential benefit justifies the potential risks.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are lots of ways to deal with this problem beyond taking an expensive pill, none of which are mentioned.", "answer": 0}, {"article": "\"Off-label\" refers to the practice of prescribing medicines to treat conditions not been specifically approved by the FDA.\nCyclobenzaprine, marketed in higher doses by others as Amrix, Fexmid, and Flexeril, is already widely used ''off-label'' for patients with fibromyalgia, Lederman says.\nAbout 5 million Americans have fibromyalgia.\n\"Bedtime treatment of fibromyalgia patients with low-dose cyclobenzaprine was safe and appears to be effective,\" says Seth Lederman, MD, president of TONIX Pharmaceuticals, which funded the study.\nTONIX is developing a lower-dose version and improving the formula, Lederman says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\n\nThis story does report that this pill has not been compared to other treatments for fibromyalgia. But it fails to put this approach of attempting to improve sleep into context with treatments that directly address the pain and other major symptoms of fibromyalgia. Also, as mentioned above, the story does not tell readers that some of the same researchers (and others) have previously reported the results of larger studies of other drugs intended to improve the sleep of people with fibromyalgia. Nor does this story mention any of the common (non-drug) steps people with fibromyalgia can take to improve their sleep.", "answer": 0}, {"article": "Feb. 1, 2012 -- A new drug appears to be effective for shrinking uterine fibroids and controlling the heavy menstrual bleeding they often cause, according to new research from Europe.\nIn one study, the drug ulipristal acetate proved to be much more effective than a placebo for shrinking the non-malignant uterine tumors.\nIf trials now under way in the U.S. prove positive, New Jersey-based Watson Pharmaceuticals Inc. and Swiss-based PregLem hope to market ulipristal acetate as a fibroid treatment under the trade name Esmya, says Watson spokesman Charlie Mayr.\nIn another, ulipristal acetate was found to be as effective as monthly injections of the drug Lupron for reducing heavy bleeding in women with uterine fibroids.\nUlipristal acetate is the active chemical in the emergency contraceptive sold in the U.S. as Ella, but the daily doses taken by the fibroid patients in the studies were much smaller than those in the contraceptive.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story ended with an important message about patient decision-making and with an expert quote that there are good alternatives to hysterectomy but many patients never hear about them.\u00a0 But then the story missed the golden opportunity of outlining what those alternatives are.", "answer": 0}, {"article": "In 37 years as a police officer, Edwin Michel coped with a plane crash, a sniper, wildfires and three bullet wounds.\n\nNothing much rattled him until he was diagnosed with prostate cancer in November 2016. His doctor said the cancer wouldn\u2019t kill him but Mr. Michel, now 76 years old, wasn\u2019t entirely reassured. He felt more confident after a genomics test later revealed his prostate cancer was very low risk. The test, known as Oncotype DX, takes a sample from a prostate biopsy and analyzes 17 genes in it to estimate how aggressive...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not provide any discussion of other risk assessment tools, such as the PSA test, Gleason score, biopsy results, and sometimes MRI scans.\u00a0 It would be helpful to know the independent contribution of the expensive new test to decision making after adjusting for the other known risks.", "answer": 0}, {"article": "Mumford, who's now 30, says he's never felt better.\nAlso, patients can get the treatment in about three weeks -- as opposed to six to eight for bone marrow from an adult donor, said Laughlin, founder and medical director of the Cleveland Cord Blood Center.\nCord blood stem cell transplants have the same risks as adult bone marrow transplants: the new blood rejecting the host, called graft-versus-host disease.\nIf collected and stored for private use, the procedure can cost as much as $2,000 or more, plus annual storage fees.\nThen, the stem cells are injected into the patient's body and travel to the bone marrow cavities, where they create new, healthy marrow.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions ways in which cord blood donation is superior to or no worse than adult bone marrow transplant. Overall it implies that cord blood donation is jumping the queue to become the preferred choice of the two, as a \"medical breakthrough that\u2019s saving lives.\". But the fact that bone marrow is still considered first for adults, and the reasons why, are not discussed.", "answer": 0}, {"article": "Imagine plopping six cups of coffee grounds on the heads of patients just before they are wheeled into the operating room to have nose or throat surgery?\n\"These are very delicate operations and a sophisticated image guidance system has been developed to help the surgeons, but they don't trust the system because sometimes it is spot on and other times it is off the mark,\" said Robert Webster, associate professor of mechanical engineering and otolaryngology, who is developing a surgical robot designed specifically for endonasal surgery.\n\"Actually, we do have a solution to this problem but it involves drilling and attaching the markers directly to the skull...which we don't like to do because it is painful and it's a step backwards from the majority of what we are doing,\" said Assistant Professor of Otolaryngology Paul Russell, who is collaborating with the engineers on the project.\n\"The basic assumption is that, after registration, the spatial relationships between the patient's head and the fiducial markers remains constant,\" said Patrick Wellborn, the graduate student who is making the presentation.\nIn essence, that is what a team of Vanderbilt University engineers are proposing in an effort to improve the reliability of the sophisticated \"GPS\" system that surgeons use for these delicate operations.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does discuss the use of stabilizing markers and points to their downside. Unfortunately, the release ignores the potential upside of the gold standard approach, greater precision in registration and greater precision of therapy.\nThe news release says researchers believe the cap will \u201ccontribute to improving the guidance system\u2019s accuracy\u201d by increasing the number of markers used to indicate head positioning as well as improving the stability of the markers. Currently, stabilizing markers would involve \u201cdrilling and attaching the markers directly to the skull\u2026which we don\u2019t like to do because it is painful and it\u2019s a step backwards from the majority of what we are doing,\u201d said assistant professor of otolaryngology Paul Russell, who is collaborating with the engineers on the project.", "answer": 1}, {"article": "The study had some limitations, the authors acknowledged.\nThe data are compelling evidence that statins are not detrimental for people with or at risk of Parkinson's disease, he said.\n\"Right now we don't have any good evidence that there is anything we can do to reduce the risk of developing Parkinson's disease, but research is ongoing,\" added Isaacson, also an associate professor of neurology at Florida International University's Herbert Wertheim College of Medicine in Miami.\nThe researchers can't say exactly how -- or even if -- statins reduce the risk of Parkinson's.\nFor example, only about 70 percent of people who were taking drugs to lower cholesterol were actually on statins at the study's start.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "At the moment there are no alternative strategies to reduce the risk of developing Parkinson\u2019s.\u00a0 Dr. Isaacson\u2019s comment, \u201cRight now we don\u2019t have any good evidence that there is anything we can do to reduce the risk of developing Parkinson\u2019s disease, but research is ongoing,\u201d says it all.", "answer": 1}, {"article": "\"The biological mechanism of labor initiation remains unknown, and a large percentage of preterm pregnancies do not respond well to current medications,\" said Ronghua Zhuge, Ph.D., associate professor within the University of Massachusetts Medical School's Department of Microbiology and Physiological Systems in Worcester, Massachusetts.\nOur mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.\nThe researchers first exposed the tissue to native hormones such as oxytocin and chemical compounds to make it contract, mimicking normal or premature labor.\nThis could be good news for those trying to prevent preterm labor: New research published online in The FASEB Journal suggests that exposing bitter taste receptors in the uterus to certain substances can stop many unwanted contractions that occur during premature labor.\nBy activating the bitter taste receptors in the uterus, the bitter substances relaxed the contracted uterine muscle tissue more completely than the current drugs used to prevent preterm labor in humans.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release only makes passing reference to the bitter substances being better than other treatments. It does not name the bitter substance used in the study or any alternatives.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061008/16healthwatch.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There were no options presented for either maintaining bone mineral density or for treating low bone density. The only treatment recommendation within the story was for balancing phosphoric acid consumption with calcium rich foods; it would be more useful to present this in a more readily understandable format for readers to act upon if they so desired.", "answer": 0}, {"article": "For more information, visit http://www.\n\"While all sedation medications and combination of medications are effective and safe in the hands of experienced providers, ketamine-alone is associated with the fewest serious adverse events and significant interventions, making it a logical choice for providing procedural sedation for children in emergency departments.\"\nThe results of the study show that choice of sedation medication had the biggest impact on the incidence of adverse events and need for significant interventions in response to those events.\nOTTAWA, ON - August 21, 2017 - Researchers at the Children's Hospital of Eastern Ontario (CHEO) looked at the incidence of and risk factors associated with sedation-related adverse events in pediatric emergency departments as part of a multi-centre observational study published today in JAMA Pediatrics.\n\"Although sedation-related serious adverse events occur infrequently, recognition and early intervention is necessary to ensure patient safety,\" said Dr. Maala Bhatt, lead author, director of pediatric emergency research at CHEO, and assistant professor at the University of Ottawa.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release names propofol and fentanyl as two alternatives to ketamine, among the six medications evaluated. We give it credit for providing this general comparison of sedation drugs:\n\u201cThe incidence of serious adverse events was lowest among patients sedated with ketamine-alone and highest among patients sedated with combination drugs ketamine plus propofol or fentanyl.\u201d", "answer": 1}, {"article": "\"Cardiovascular disease is the number one cause of death in the U.S., and while statins are very effective, a good proportion of people are not meeting their goals, and in this setting the shot could be a valuable addition,\" he said.\nThe study was funded by AMG145 manufacturer Amgen Inc.\n\nHigh cholesterol is a major risk factor for heart disease.\n\"There are still plenty of people who can't achieve adequate LDL levels with existing drugs, including statins,\" he noted.\n\"This new shot may provide a more long-lasting approach, especially if it could be given once a month,\" Sacco said.\nThe shot turned off a newly identified cholesterol regulator, PCSK9, which interferes with the liver's ability to clear bad cholesterol from the bloodstream.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions healthy lifestyle changes and statin drugs as\u00a0established\u00a0ways to lower cholesterol. It could have mentioned other approaches \u2014 such as nonstatin\u00a0cholesterol-lowering\u00a0drugs as well as\u00a0special margarines fortified with plant sterols \u2014 that are sometimes\u00a0used to lower cholesterol.", "answer": 1}, {"article": "In a related editorial, Drs.\nThe most common side effects in both groups were fatigue and depletion of white blood cells.\nThe study included 508 women who were given eribulin and 254 women who received treatment of the physician's choice, which was defined as: any single-agent chemotherapy, hormonal or biological treatment approved for cancer treatment; radiotherapy; or symptomatic treatment alone.\nDr. Javier Cortes, of the Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology in Barcelona, Spain, and colleagues published the findings in the March 3 online edition of The Lancet.\nCommenting on the study, Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City, said, \"The findings of this trial are exciting because they will propel eribulin into wider use.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The survival benefit for women who were treated with eribulin is clearly presented.\u00a0 The article also included the definition of the treatment of the physician\u2019s choice that was\u00a0used by the study authors.", "answer": 1}, {"article": "In years past, \"the message was that chocolate consumption might be associated with higher LDL [bad] cholesterol or perhaps higher incidence of cardiovascular disease,\" he said.\nFor one thing, it's possible that some factor other than chocolate could be helping lower the risk of stroke.\nBut the findings, based on a review of existing research, aren't conclusive, and they don't prove that chocolate is good for your heart.\nThe National Stroke Association has more on stroke.\nBoth are good for heart health,\" he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No explanation was given for the researcher\u2019s recommendation of dark chocolate over milk or white chocolate, and no reasons were given for why \"dark chocolate in particular\" \u2013 as the story states \u2013 may have health benefits. ", "answer": 0}, {"article": "This new way of testing fetal DNA seemed to have already become fairly common where Seitz used to live, in Washington, D.C.\nShe didn't want an invasive procedure like amniocentesis or chorionic villus sampling.Those are considered the gold standard for prenatal genetic testing, but doctors must put a needle into the womb to collect cells that contain fetal DNA, which means a small risk of miscarriage.\nFor example, here's one thing that might turn out to be a little more complicated than would-be parents might expect.\n\"There's at least some evidence that it's happening to a greater degree than I think many of us are comfortable with,\" she says.\nEven though the newer blood tests do look at fetal DNA, they can't give a definitive answer like an amniocentesis can because they're analyzing scraps of fetal DNA in the mother's blood that are all mixed up with her own DNA.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did compare and contrast the new prenatal screening tests to traditional diagnostic tests like\u00a0amniocentesis and chorionic villus sampling, which are more invasive.", "answer": 1}, {"article": "Epic Sciences is headquartered in San Diego.\nThis question weighs heavily on doctors and patients, but now, with the Oncotype DX AR-V7 test, we can provide them the confidence to know whether continuing with hormonal therapy or switching to chemotherapy will result in better survival outcomes,\" said Ryan Dittamore, chief of medical innovation at Epic Sciences and a co-author on the study.\nAbout the Oncotype DX\u00ae AR-V7 Nucleus Detect\u2122 Test\n\nDesigned by Epic Sciences and based on results from multiple studies led by Memorial Sloan Kettering Cancer Center, the Oncotype DX\u00ae AR-V7 Nucleus Detect\u2122 test is the first and only liquid biopsy test of its kind that can potentially prolong the lives of men with metastatic castration-resistant prostate cancer (mCRPC) by helping their physician identify the most effective treatment.\nNEW YORK and SAN DIEGO, June 28, 2018 /PRNewswire/ -- An international team of researchers from Memorial Sloan Kettering Cancer Center (MSK), Epic Sciences, The Institute of Cancer Research, UK, and London Health Sciences Centre, Canada, have shown that a blood test can identify patients with metastatic castration resistant prostate cancer (mCRPC) who may live longer if they switch from targeted androgen receptor-signaling inhibitor (ARSi) therapy, such as enzalutamide and abiraterone, to taxane-based chemotherapy.\nThe results were that patients positive for AR-V7 who were treated with taxane-based chemotherapy had superior overall survival (OS) relative to those treated with ARSI therapy (median OS, 14.3 vs. 7.3 months).\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does not mention other ways to determine that hormone therapy isn\u2019t working. There may not be any comparable alternatives.\nThere are ways to assess prognosis and these could be considered alternatives. The paper states: \u201cTo investigate confounding factors that might influence the decision to administer an ARS inhibitor or taxane, a risk score was developed based on a prognostic model developed from our training cohort22\u00a0and applied to the current cohort.\u201d This suggests the authors developed a comparator to their test. As such, it would have been reasonable to comment that there may be other ways to assess risk. The advantage of this one is that it targets what treatment should be given beyond the overall risk itself.", "answer": 2}, {"article": "\"But I would say it would be perhaps more helpful for primary care physicians in an outpatient setting, because that is where it's most challenging to identify heart failure.\n\"Every individual has a breath print that differentiates them from other people, depending on what's going on in their body,\" explained study lead author Dr. Raed Dweik, a staff physician in the department of pulmonary, allergy and critical care medicine with the Respiratory Institute at Cleveland Clinic.\nMONDAY, March 25, 2013 (HealthDay News) -- An experimental breath test, designed to quickly identify patients suffering from heart failure simply by analyzing the contents of a single exhaled breath, has demonstrated promise in early trials, a team of researchers says.\nA single breath sample was obtained from each of the patients within 24 hours of admission, as well as from an additional 36 patients with acute decompensated heart failure as an independent point of comparison.\nCurrently, a diagnosis of heart failure comes from a variety of factors, according to the U.S. National Heart, Lung, and Blood Institute.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does list some of the standard tests for heart failure. It also notes that the research is too preliminary to tell whether this sort of breath test would be any better. However, it is likely that readers will get the impression that the new test is an advance, even though there have not been any experiments done to compare different methods.\nThe story could have compared with the B-type Natriuretic Peptide (BNP) blood test (an inexpensive blood test).", "answer": 1}, {"article": "TUESDAY, Jan. 31, 2017 (HealthDay News) -- A breath test to detect stomach and esophageal cancers shows promise, researchers say.\nEach year, 1.4 million cases of cancer of the stomach and esophagus (the tube leading from the throat to the stomach) are diagnosed worldwide.\nThis study suggests that we may be able detect these differences and use a breath test to indicate which patients are likely to have cancer of the esophagus and stomach, and which do not,\" he explained.\n\"A breath test could be used as a noninvasive, first-line test to reduce the number of unnecessary endoscopies.\nThis method is expensive, invasive and has some risk of complications,\" study author Dr. Sheraz Markar said in an ECC news release.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story made it clear that this test is to help improve upon the current method of endoscopy:\u00a0\u201cA breath test could be used as a noninvasive, first-line test to reduce the number of unnecessary endoscopies.\u201d It could have been clearer that finding cancers \u201cearlier\u201d \u2014 especially in healthy-seeming people \u2014 would be a huge leap from what is demonstrated here.", "answer": 1}, {"article": "MS is an autoimmune neurodegenerative disorder that affects nearly 2.5 million people worldwide.\nThat myelin increases the speed of neural transmission is one of the most well-established concepts in neurobiology, and combined with the clear evidence from Chan's preclinical research showing that clemastine fumarate promotes myelin formation, myelin regeneration is the only plausible explanation for the VEP results, the authors said.\nThe drug tested in the trial, clemastine fumarate, was first identified as a candidate treatment for MS in 2013 by UCSF's Jonah R. Chan, PhD, Debbie and Andy Rachleff Distinguished Professor of Neurology, vice chief of the Division of Neuroinflammation and Glial Biology, and senior author of the new study.\nIn light of previous laboratory studies of the antihistamine compound at UCSF, the researchers said, the drug most likely exerted its effect by repairing damage MS had inflicted on myelin, an insulating membrane that speeds transmission of electrical signals in the nervous system.\nTo enhance the power of their study, the researchers used a \"crossover\" design: they divided the patient population in two and gave the drug, blinded to both participant and researcher, to one group, and a placebo to the other for 90 days; then they switched between the two groups, giving a placebo to the first group and the drug to the other for the next 60 days.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "As there is no cure for MS, treatment focuses on slowing its progression, managing its symptoms and speeding up recovery after attacks.\nThe release does note that current drugs work on the immune system, but there\u2019s more that could be said. To treat MS attacks, patients are given corticosteroids or plasma exchanges, in which their blood cells are mixed with a protein solution and put back into their bodies.\nDifferent drugs, such as beta interferons, are prescribed to delay MS progression and to alleviate symptoms. Patients may also undergo physical therapy and be given muscle relaxants to reduce muscle stiffness.\nThe news release doesn\u2019t mention any of these therapies, which is why we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "Sports medicine and pain doctors are also recommending them for problems like tennis elbow, Achilles tendinitis and overuse injuries and strains.\n\u201cSuddenly there were tons of folks who thought topical Nsaids were a good idea.\u201d\n\nDr. Roy D. Altman, a rheumatology professor at the David Geffen School of Medicine at the University of California, Los Angeles, said the drugs might be especially helpful for \u201cthe elderly or those taking multiple medications, who were not getting treated but who can now use topical Nsaids and get some benefit.\u201d\n\nAnother leading pain researcher, Dr. Roger Chou, an associate professor of medicine at Oregon Health and Science University, noted that the skin creams delivered \u201cvery high joint concentrations of the topical Nsaid, higher than with standard oral doses, with very low blood levels\u201d \u2014 less than 5 percent of those found with oral Nsaids.\nThe risks in the most vulnerable population \u2014 people with other illnesses, like liver disease, or those on blood thinners \u2014 are not known, because these patients are generally excluded from studies.\nStill, in one of the only head-to-head trials between topical and oral Nsaids, subjects taking the pills had a much higher rate of indigestion, diarrhea, abdominal pain, abnormal liver tests and anemia than those using the creams.\nBut a number of new controlled trials and meta-analyses like Dr. Moore\u2019s suggest that topical Nsaids are as effective as their oral counterparts for treating osteoarthritis in the knee and hand as well as musculoskeletal injuries like soreness and tendinitis.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe essence of this story is an attempt to compare topical NSAIDs with pills and other pain treatments. As noted above, though, the story does not mention that most people with minor pains feel better after awhile even if they don\u2019t take any pain relief medication. It also should have mentioned that the difference between placebo and active treatment groups in the clinical trials is often slim.", "answer": 1}, {"article": "TUESDAY, March 27, 2012 (HealthDay News) -- When taken as a supplement, unroasted -- or green -- coffee-bean extract can help people shed pounds, according to a small preliminary study.\nThe study was conducted in India and funded by Applied Food Sciences, the American manufacturer of two green-coffee-extract products.\nA follow-up study involving 60 patients is now in the planning stages.\nIn one section, study participants, who were all between the ages of 22 and 26, consumed a capsule filled with 700 milligrams of green coffee extract.\nAll the patients were instructed to maintain their usual dietary habits, while the study team monitored them for weight loss over a period of nearly six months.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not compare green coffee extract with other approaches to weight loss, such as dietary changes or drugs.", "answer": 0}, {"article": "A recent Canadian study looked at the issue, but the analysis had a caveat: Each of the more than 3,400 clinical trial patients received rivaroxaban the first five days after surgery.\nThe new U-M study suggests patients may be adequately protected if they take aspirin alone from day one.\nBased on the experience of 41,537 Michigan patients undergoing knee replacement, the study may further the debate about the routine use of aspirin for clot prevention.\nThe U-M study involved patients undergoing knee replacement surgery at any of the 29 Michigan hospitals in the surgical quality group.\nThese days, most patients have a generally low risk of blood clots after knee replacement for a number of reasons.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release highlights the comparison between alternatives for minimizing blood clot risk due to knee replacement surgery.", "answer": 1}, {"article": "High-risk tumors are more aggressive and thus more likely to eventually kill the patient.\nOf the almost 2,000 patients on anticoagulants in the study, 1,649 were taking aspirin, 428 warfarin, 287 clopidogrel (Plavix), 26 enoxaparin, and 408 a combination of blood thinners.\nIn looking at the records of more than 5,000 men with prostate cancer, 2,000 of whom were taking aspirin or another blood-thinning drug, researchers presenting at the annual meeting of the American Society for Radiation Oncology (ASTRO) in San Diego report that the risk of dying from the cancer was reduced by more than half.\nOf the blood thinners used in the study, aspirin was the one which seemed to account for most of the benefit, the researchers said\n\nThere has already been some evidence that cancer and the body's coagulation system might be linked in some way.\nMONDAY, Oct. 25, 2010 (HealthDay News) -- One of the world's most ubiquitous and pedestrian drugs -- aspirin -- may cut the risk of dying for men who have prostate cancer that has not yet spread beyond the gland, a new study suggests.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe researchers say it would be premature to recommend the use of anticoagulants in prostate cancer patients, because the benefits and risks have yet to be clearly identified\u2026 and so it is also premature to expect comparisons to alternatives.", "answer": 2}, {"article": "Flavonoids have been found to relax blood vessels and thereby improve blood flow, inhibit platelets from sticking together in the blood, and have a beneficial antioxidant effect. What still is not known is whether regularly eating dark chocolate, especially with its high sugar and fat content, eventually will lead to an unhealthy weight gain that would erase the beneficial effects of the flavonoids found in the cocoa.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\nThe report neglects to mention \u201ctreatments\u201d other than chocolate that might improve the endothelial function of these subjects. Among these is low-cost, fat-free, calorie-burning exercise.\n", "answer": 0}, {"article": "To resolve that possibility, a new trial is under way at 20 cancer centers, including M.D.\nIn all, the study enrolled 23 patients between 2005 and 2007.\nIt was only open to those with a particular protein \u2014 present in one-third to two-thirds of glioblastomas \u2014 and those who were tumor free after surgery and radiation.\nHassenbusch lived almost three years after his diagnosis.\n\"But two years later, I'm in good shape, living a normal life and still returning cancer-free scans every month, thanks to this trial.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This was a story about additional treatments that might be used in conjunction with currently utilized therapy.\u00a0 It was clear that surgery, radiation and standard chemotherapy are used.\u00a0 ", "answer": 1}, {"article": "SUNDAY, March 21, 2010 (HealthDay News) -- For the first time in humans, scientists have successfully used a gene-manipulation therapy to enter tumor cells and block the production of toxic proteins that are causing cancer, researchers report.\n\"This is one step away from getting into the actual DNA.\"\n\"This is something we've been waiting to see,\" he continued.\nThe precision of the process is crucial to limiting side effects, the researchers said.\nThe experiment proceeded just as planned, as biopsies later showed.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no discussion of other targeted therapy research \u2013 something the Reuters story at least briefly described. ", "answer": 0}, {"article": "Based on those results, an advisory panel to the F.D.A., meeting in March 2007, voted 13 to 4 that there was \"substantial evidence\" that the drug worked and 17-0 that the drug was safe.\nCancer vaccines of the type represented by Provenge, known as immunotherapy, are different from conventional vaccines in that they do not aim to prevent disease, but to enlist the body\u2019s defenses in attacking the disease after it occurs.\nThe only approved treatment for them now is the chemotherapy drug Taxotere, from Sanofi-Aventis, which extended median survival by about three months in trials.\nThe trial involved 512 patients whose cancer had spread beyond the prostate gland and who were no longer benefiting from therapies intended to deprive the tumors of testosterone.\nIn an earlier trial, men who received Provenge lived a median of 25.9 months, compared with 21.4 months for those who received a placebo.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says the only approved treatment for the cancers Provenge treats is Taxotere, which has been shown to extend life by three months. \nThis may be technically accurate as stated. But the American Cancer Society lists at least eight other chemotherapy agents used to treat advanced prostate cancer. ", "answer": 0}, {"article": "This study was supported by the Arthur R. Sekerak Cancer Research Fund a Yale Cancer Center philanthropic fund.\nThe booster strategy lowered the flu infection rate among patients to 6% versus an expected rate of 20%, and it improved protection against all flu strains covered by the vaccine in 66% of patients, said the study's first author Andrew Branagan, M.D., a postdoctoral associate in medicine (hematology).\nThe findings were presented Dec. 6 at the 57th annual meeting of the American Society of Hematology in Orlando, Florida.\nEven though patients with multiple myeloma and other plasma cell disorders may receive an annual flu vaccine, studies show that a one-time flu shot does not offer adequate immune response.\n\"Using an approved flu vaccine in a novel dosing schedule yielded promising results for a group patients at high risk for infection,\" Branagan said.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Although this study examines a novel approach, it is still necessary to compare it to existing protocols. At minimum, we would like to know how the booster strategy compared with the single vaccination. We\u2019re told the outcome is better with the novel strategy but we aren\u2019t provided any of the data.", "answer": 0}, {"article": "However this does not help them to overcome their fear in the long term.\nThe latest study, published in the British Dental Journal, looked at the characteristics of 130 patients (99 women and 31 men) attending a psychologist-led CBT service and the outcomes of their treatment.\nCBT provides a way of reducing the need for sedation in people with a phobia, but there will still be those who need sedation because they require urgent dental treatment or they are having particularly invasive treatments.\nA proportion of the patients surveyed were found to have other psychological conditions - 37% had high levels of general anxiety and 12% had clinically significant levels of depression.\nProfessor Tim Newton from the Dental Institute at King's College London and lead author of the study said: \"People with dental phobia are most commonly given sedation to allow them to become relaxed enough for a short period of time to have their dental treatment performed.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The primary alternative to CBT is sedation, which the release addresses.\nBut we expected the news release to go into more detail about the types of sedation and dental procedures the study authors were referring to. For example, prior to dental treatment \u2014 which can range from a basic cleaning or filling for a cavity, to more involved surgical procedures \u2014 patients might be given an anti-anxiety medication to make them more relaxed. In some cases, patients require intravenous sedation. Since the release doesn\u2019t describe what the authors mean by sedation, it\u2019s a very imprecise comparison.  ", "answer": 0}, {"article": "Ridker says the findings should clarify how doctors can optimize the way they treat their heart patients \u2014 about half of people who have had a heart attack tend to have high levels of inflammatory factors, while half have high cholesterol levels.\nThe bottom line is we now have clear evidence that lowering inflammation through this pathway lowers rates of heart attack and stroke with no change at all in cholesterol.\u201d\n\nAbout a quarter of people who have heart attacks will have another heart event even if they keep their cholesterol at recommended levels.\nIt\u2019s the reason doctors recommend low-dose aspirin to prevent recurrent heart attacks in people who have already had them, why they also prescribe statins, which lower both cholesterol and inflammation, and why they have started to measure inflammation levels in the blood.\n\u201cThis all makes sense to me.\u201d Studies have already shown, for example, that inflammation may be a factor in prostate cancer and colon cancer.\nThe cancer data is still preliminary, and needs to be confirmed with additional studies, but it\u2019s encouraging, says Dr. Otis Bradley, chief medical officer for the American Cancer Society, who was not involved in the study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does note that statin therapy also offers some anti-inflammatory effects that are possibly or probably responsible for prevention benefits in heart disease. But there are many effective and less expensive alternatives to secondary cardiac disease prevention that were not mentioned, such as smoking cessation, aspirin, statins, blood pressure control, etc.", "answer": 0}, {"article": "The differences over when to start regular screening reflect the growing concern that the benefits of mammograms may have been oversold, and that they don't outweigh the anxiety and potential harm caused by over-diagnosis and false positives from the tests.\nThe U.S. Preventive Services Task Force, an independent panel of experts whose members are appointed by the federal government, issued a final set of recommendations late Monday saying that women between the ages of 50 and 74 should get routine screening once every two years.\nFor women in their 40s, the likelihood of benefit is less and the potential harms are proportionally greater, it said.\n\"This means making sure that cost is not a deterrent to care,\" she said.\nThe controversy over when a woman should get mammograms is about to heat up again.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternatives in a story like this one are the recommendations from other organizations. And the story does explain varying recommendations from the USPSTF and two other groups: the American College of Obstetricians and Gynecologists, and the American Cancer Society.", "answer": 1}, {"article": "The screening phase of the trial lasted about seven years.\n\u201cThis indicates that the long-term benefits of screening in terms of deaths prevented are more than double those often quoted for short-term follow-up.\u201d\n\nThe new data adds to evidence on the long-term benefits of regular mammography screening.\nDr. Stamatia Destounis, a radiologist at Elizabeth Wende Breast Care in Rochester, New York, who was not involved in the study, said radiologists have been quoting results of the Swedish study for years and the new findings show breast cancer screening is \u201ceven more of a benefit than we understood.\u201d\n\nShe said sweeping changes in the U.S. screening guidelines two years ago that scaled back recommendations on breast cancer screening caused a lot of confusion among doctors and patients about the benefits of mammograms.\nThe guidelines contradicted years of messages about the need for routine breast cancer screening starting at age 40, eliciting protests from breast cancer experts and advocacy groups who argued the recommendation for fewer screenings would confuse women and result in more deaths from breast cancer.\nMany groups, including the American Cancer Society, have stuck by their long-standing recommendations of a yearly breast exam for women starting at age 40, stressing that the breast X-rays have been proven to save lives by spotting tumors early, when they are most easily treated.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story only briefly touches on the fact that \u201ceveryone must make up their own mind\u201d regarding mammography, but it\u2019s not explicit about the fact that women may choose not to have routine mammograms. In addition, the story indicates that the U.S. Preventive Services Task Force made their recommendations against routine screening in women 40-49 to avoid unnecessary biopsies and anxiety, but it should be mentioned that these recommendations were also implemented to minimize needless treatment, including surgery, chemotherapy and radiation therapy.", "answer": 0}, {"article": "The body mass index, or BMI, associated with the lowest risk of death has increased since the 1970s, a study finds, from 23.7, in the \"normal\" weight category, to 27, which is deemed \"overweight.\"\nI know you journalists always want that,\" Nordestgaard says.\n\"This is total speculation,\" Nordestgaard says.\nMore than 100,000 people were involved.\nSo he and his colleagues sliced and diced the data to see what could account for the shift.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 2}, {"article": "Conservative treatment options for herniated disks range from over-the-counter pain medications to injections of corticosteroids directly into the affected area of the spine.\nThe Society is based in Oak Brook, Ill. (RSNA.org)\n\nEditor's note: The data in these releases may differ from those in the published abstract and those actually presented at the meeting, as researchers continue to update their data right up until the meeting.\nThe results of the study are superior to those typically reported for usual care strategies and injections and may help a substantial number of patients with sciatic disk compression to avoid surgery, Dr. Napoli added.\n\"We learned that when pulsed radiofrequency is followed by steroid injection, the result is longer lasting and more efficacious than injection only,\" Dr. Napoli said.\nFor comparison, a group of 120 patients received one to three sessions of CT-guided steroid injection on the same anatomical target with no pRF.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release defines what alternatives are available for acute back pain with sciatica, including pain medications, cortisteroids and surgery. It details outcomes in patients treated with steroid injections compared with\u00a0pRF.", "answer": 1}, {"article": "New research analyzing more than 22,000 U.S. cases of aortic aneurysm repair is likely to hasten the trend toward more procedures being done with a device called a stent-graft instead of the typical surgery that requires up to eight weeks of recovery.\n\nThe study by doctors at Harvard Medical School and the federal Centers for Medicare and Medicaid Services found the death rate in surgery, 4.8%, was four times that of the 1.2% death rate in placing stent-grafts to seal off the aneurysm. Surgery tended to provide a more permanent...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not provide adequate information about treatment options.\u00a0 The story did not provide sufficient information about the risk of death from aortic aneurysms if left untreated in order for the reader to evaluate the relative benefit to be gained from the treatments discussed. Watchful waiting (or active monitoring) is an option, but it was not discussed. ", "answer": 0}, {"article": "All compared people taking at least 200 milligrams of Vitamin C each day with people taking placebos.\nIt did reduce the severity and duration of colds slightly, but the researchers say the difference was so slight it ended up being pretty meaningless, and not worth the effort or expense of taking all that vitamin C.\n\nPeople apparently protected from colds by vitamin C, Senay said, are those who subject their immune systems to extraordinary amounts of physical stress, such as people who run marathons, or do serious trekking in the winter.\nAnd the results, just published by The Cochrane Library, are likely to disappoint people who swear by vitamin C.\n\nAccording to their analysis, daily vitamin C basically had no effect on the incidence of the common cold in the general population, except for very specific groups of people, all of them small groups.\nFor the rest of us, the chances of vitamin C warding off colds is so slight, the lead researcher concludes it \"doesn't make sense to take vitamin C 365 days a year to lessen the chance of catching a cold.\"\nThe federal Centers for Disease Control and Prevention says the best bit of cold prevention involves not taking a pill, but doing simple, if boring, things such as washing your hands, thoroughly and often.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "When the discussion shifts to the importance of adequate intake of vitamin C, the physician-journalist fails to make sufficiently clear that the known benefits of vitamin C are from eating whole foods high in the vitamin.\u00a0Thus the viewer does not fully understand that eating these foods is a wise alternative to taking the supplements. \u00a0\nThe report ends nicely with the note that the only proven method of reducing colds risk is to wash hands. ", "answer": 0}, {"article": "Recent research indicates that vitamins C, E and zinc can help vision.\nCompared to coffee, soft drink and iced tea drinkers, study participants who consumed a cup or more of hot caffeinated tea daily had 74 percent lower odds of having glaucoma, the study authors report in the British Journal of Ophthalmology.\nThe research team found no associations between coffee, iced tea, decaffeinated tea or soft drink consumption and the likelihood of having glaucoma.\nThat includes more than three million Americans, only half of whom are aware they have the disease, according to the Glaucoma Research Foundation.\n(Reuters Health) - People who drink hot tea daily may be less likely than others to develop glaucoma symptoms, U.S. researchers say.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does make brief mention of lifestyle, environmental and diet interventions that may influence glaucoma, but could have made it more clear that none of these have been proven to prevent glaucoma.", "answer": 1}, {"article": "With his colleagues, he looked back at some 40,000 such surgeries done at dozens of academic medical centers in the U.S. \u2014 roughly 14,000 open procedures and 26,000 laparoscopic ones.\nWhen the appendix had burst, however, the open surgery racked up a considerably higher bill.\nFirst, it looks only at academic medical centers.\n\u201cOverall, this study shows benefit from laparoscopy on every aspect, including cost,\u201d he told Reuters Health.\nYet again, the patients who had laparoscopy fared much better than those who had conventional surgery.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The focus of the story was the comparison between two surgical approaches.", "answer": 1}, {"article": "Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival.\n\nThe test, developed by closely held Epic Sciences Inc., San Diego, detects a mutation associated with a poor response to two new drugs, Xtandi from Medivation Inc. and Astellas Pharma Inc. of Japan, and Zytiga from Johnson & Johnson.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does not explicitly describe whether there are other methods of detecting AR-V7, though it is implicit that AR-V7 has not been used clinically as a biomarker before, and two other companies developing a similar test are mentioned. The\u00a0story is based around whether using AR-V7 as a biomarker could lead to better outcomes than\u00a0current clinical standards, so the comparison to the \u201cstatus-quo\u201d alternative is thoroughly explored.", "answer": 1}, {"article": "This is the first to correct an inherited genetic mutation.\n\"New technologies such as gene and cell therapies hold out the potential to transform medicine,\" FDA Commissioner Dr. Scott Gottlieb said in a statement announcing the August approval of Kymriah, considered to be the first gene therapy to be approved for the US market.\n\"For a one-time therapy, like Luxturna, a non-traditional payment and distribution model is necessary to ensure needs of all parties -- patients, payers and providers -- are addressed,\" said Jennifer Luddy, a spokeswoman for Express Scripts.\n(CNN) A one-time treatment with Luxturna, the first US Food and Drug Administration-approved gene therapy for an inherited disorder, will cost $425,000 per eye.\nThe company believes the total \"population in the US, Europe and select additional markets in the Americas and Asia/Pacific is up to approximately 6,000 individuals\" who have the mutation targeted by Luxturna, explained Monique da Silva, a spokeswoman for Spark Therapeutics.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Effective alternative treatments for\u00a0RPE65 don\u2019t exist yet, and \u2014 while this may seem obvious to savvy readers who understand gene-editing technologies \u2014 the story should have clearly stated this for the vast majority of people who aren\u2019t familiar with the basics.", "answer": 0}, {"article": "Researchers recommend large-scale clinical trials to confirm that nighttime fasting results in favorable changes to biomarkers of glycemic control and breast cancer risk.\n\u201cNew evidence suggests that when and how often people eat can also play a role in cancer risk.\u201d\n\nWomen in the study reported eating five times per day with a mean nighttime fasting of 12 hours.\nNewswise \u2014 A decrease in the amount of time spent eating and an increase in overnight fasting reduces glucose levels and may reduce the risk of breast cancer among women, report University of California, San Diego School of Medicine researchers in the journal Cancer Epidemiology, Biomarkers & Prevention.\nIt may have a big impact on public health without requiring complicated counting of calories or nutrients.\u201d\n\nWomen who fasted for longer periods of time overnight had significantly better control over blood glucose concentrations.\nThe data shows that each three hour increase in nighttime fasting was associated with a 4 percent lower postprandial glucose level, regardless of how much women ate.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The researchers state that \u201climiting consumption of red meat, alcohol and refined grains while increasing plant-based foods\u201d reduce breast cancer risk, which is enough to earn the release a satisfactory rating. But we\u2019d note that obesity after menopause is another factor associated with increased risk, one that may be reduced through caloric moderation/restriction and maintenance of a healthy body weight. The release noted that participants who had longer fasting durations had a lower caloric intake, but it did not suggest that the lower calorie intake alone might be a factor in lowering breast cancer risk. That additional context would have been useful.", "answer": 1}, {"article": "But Cao doesn't think people should start taking aspirin to prevent cancer until more research is done.\nThe association of aspirin with reduced cancer risk was the same for women and men regardless of race, history of diabetes, family history of cancer, weight, smoking, regular use of other painkillers or taking multivitamins, the study authors added.\n\"The results of ongoing research to develop more tailored treatment based upon a personalized assessment of risks and benefits is critical before recommending aspirin for preventing cancer,\" she said.\nThe reduced risk was largely due to fewer cases of gastrointestinal cancers, including colon cancer, rectal cancer and esophageal cancer.\n\"People who are uncertain about whether they should be using aspirin should talk to their health care provider, who knows their personal medical history and can help weigh their individual risks and benefits,\" Jacobs said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not say what other interventions\u00a0have been shown or are under investigation to reduce the incidence of colorectal cancer. They include colonoscopy/polyp removal, increased activity, weight loss, cessation of cigarette smoking, and cutting back on excessive alcohol use.", "answer": 0}, {"article": "\u201cThat\u2019s the miracle.\u201d\n\u2022 New hope for young patients with rare genetic disease (\u201cCBS Evening News,\u201d 10/16/15)\n\u2022 Follow the Calliope Joy Foundation on Twitter, Facebook and Instagram\nShe can still smile and laugh.\nAnd it runs in families.\nIt could be years before any children with MLD will be allowed to receive the treatment in the United States.\nThere are seven of them, ages 2 to 11.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not discuss if there are alternatives under development.", "answer": 0}, {"article": "While the procedure may look straightforward, it's extremely delicate, said Linda Cormier, a sales representative for Cambridge Endo, whose headquarters is in Framingham, Mass.\nThe hook, grasper and scissors are on the ends of shafts less than one-fifth of an inch wide.\nThe recovery has been pain-free, and the cancer hasn't returned, he said.\nThat was what happened to Davis, who had gone to a hospital for a kidney stone.\nIf a rare mishap occurs, the doctor will have to resort to conventional surgery, requiring a much bigger incision.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story mentions open surgery, it does nothing to describe the pros and cons of the options.", "answer": 0}, {"article": "And what about colon cancer screening for the elderly?\nThe panel's reticence to choose one option over another may be at odds with the preference of many doctors, who often advise colonoscopy as the \"gold standard\" test.\nThe USPSTF notes that only one-third of eligible adults in the United States are screened for colon cancer, and more need to take advantage of this effective method of prevention.\nThis year about 134,000 people in the country will be diagnosed with the disease, and about 49,000 will die from it., the panel said\n\nThe USPSTF is an independent, volunteer panel of experts that makes recommendations about the effectiveness of specific preventive health services.\nWEDNESDAY, June 15, 2016 (HealthDay News) -- Reiterating a recommendation last made in 2008, an influential U.S. panel of health experts is advocating that regular colon cancer screening begin at age 50 and continue until at least age 75.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story lists all the screening techniques the USPSTF looked at. It notes that the report intentionally did not rank the techniques and includes a dissenting opinion from a physician who was not part of the task force.\nIt was also worth mentioning that an average risk person who is informed about the screening may chose not to be screened as a reasonable choice, but only as part of a shared decision making process with her/his doctor.", "answer": 1}, {"article": "Ten percent of study participants who had not had a hysterectomy showed precancerous changes in the lining of the uterus, and all of those resolved with weight loss.\n\"The study results demonstrate that there is a huge alteration, but I don't even know what to say about that, except it is really new and intriguing area to look at in the link between obesity and cancer.\nWhile the study speaks to the transformative effect bariatric surgery can have, Modesitt urged people to avoid gaining weight in the first place and for those seeking to lose weight to exercise and eat more healthily before turning to surgery.\nIt found that bariatric surgery:\n\u2022 produced a mean weight loss of more than 100 pounds\n\nCHARLOTTESVILLE, Va., Oct. 1, 2015 - A study evaluating the effects of bariatric surgery on obese women most at risk for cancer has found that the weight-loss surgery slashed participants' weight by a third and eliminated precancerous uterine growths in those that had them.\n\"There are lots of studies showing if you exercise, it improves your insulin, your glucose, all of those sorts of things that go along with the cancer-causing effect.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There is a nice admonition at the end of the release encouraging people to keep their eye on the main way to avoid complications from being overweight or obese: avoid eating too much and exercise more. The release says:\nWhile the study speaks to the transformative effect bariatric surgery can have, Modesitt urged people to avoid gaining weight in the first place and for those seeking to lose weight to exercise and eat more healthily before turning to surgery. \u201cWe really should be working on diet and exercise from the get-go in our entire society, starting with our children. And exercise does seem to be protective \u2014 even if you don\u2019t lose all the weight, it absolutely has beneficial effects,\u201d she said. \u201cThere are lots of studies showing if you exercise, it improves your insulin, your glucose, all of those sorts of things that go along with the cancer-causing effect. Almost everybody agrees adding exercise would be wonderful and improve health on many levels. But losing excess weight would also be good.\u201d", "answer": 1}, {"article": "\"Although it is not clear if bisphosphonates are the cause, these unusual femur fractures have been predominantly reported in patients taking bisphosphonates,\" the FDA says.\nAmid all the debate, many specialists are wondering if women on bisphosphonates should take a \"holiday\" from the drug from time to time.\nThe idea is that perhaps they'd get the osteoporosis benefit without the risks of osteonecrosis and unusual fractures.\nWomen who had taken the drugs for five years or longer had nearly a three times higher risk of suffering atypical fractures compared with women who had only transient exposure to such drugs.\nDrugs To Prevent Weak Bones Linked To Unusual Fractures In Women\n\nThere's fresh evidence pointing to a troubling link between commonly used osteoporosis drugs and a rare type of thighbone fracture.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "One strength of the story was its ending, with a discussion with a bone specialist about the option of taking a drug \u201choliday\u201d from time to time, and the question of whether women who stop taking it temporarily should start again.", "answer": 1}, {"article": "\u201cThis test looks very promising, but it is also very expensive,\u201d\n\nWhile there are risks attached to amniocentesis and CVS screens, these are minimized when the test is performed by a skilled obstetrician, she says.\nStill, he adds, \u201cit\u2019s an important step forward.\u201d\n\nThe technology is likely prohibitively expensive and time-consuming at this point, he says.\n\u201cIt\u2019s not ready for prime time, but researchers are actively working on methods to increase its efficiency,\u201d he says.\nFor now the test just looks for Down syndrome, but \u201ctechnology will advance to the point where noninvasive testing will encompass more of the less common genetic anomalies,\u201d she says.\nWhile the new screen only looks for Down syndrome, Sullivan says that some of the other trisomy birth defects can be more easily identified on an ultrasound exam.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story tries to do a good thing by explaining at the very end that the new test is not a diagnostic test, as amniocentesis and chorionic villus sampling are.\u00a0 Rather, it\u2019s a screening test.\u00a0 The distinction \u2013 and the significance of that \u2013 could have been made more clearly, but we give the story the benefit of the doubt.", "answer": 1}, {"article": "But researchers say the preliminary findings could one day lead to diabetes treatments.\nThe study was small, including just 10 patients who had the surgery and 11 patients who followed severely calorie-restricted diets.\n\u201cCertainly weight loss by any means improves type 2 diabetes, but there is something else going on with gastric bypass surgery,\u201d study researcher Blandine Laferrere, MD, of Columbia University\u2019s St. Luke\u2019s and Roosevelt Hospital Center, tells WebMD.\nWhen researchers compared patients who had gastric bypass surgery to those who lost the same amount of weight by dieting, they found that the surgery patients had lower levels of amino acids that have been linked to insulin resistance.\nAnd the patients in both groups had lost just a fraction of the weight they needed to lose at the time of the analysis.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story briefly mentioned the difference in short term improvement in diabetes in those having gastric bypass and those losing weight through caloric restriction.\u00a0 But it really didn\u2019t quantify the benefits and harms of the two alternative approaches.", "answer": 0}, {"article": "The 7 percent figure works out to about 18 pounds for someone who weighs 250.\nBut it's important to know that the weight loss that's typical for users of the drug -- 5 to 10 percent of total weight -- will be less than many dieters expect.\nMore than 100 studies involving some 30,000 patients have been conducted with Orlistat, according to GlaxoSmithKline (GSK) Consumer Healthcare, the maker of Orlistat, which has petitioned the FDA to permit OTC sales of the drug.\nIn the longest study of Orlistat, participants who took the drug in addition to eating fewer calories and increasing exercise shed up to 12 percent of their body weight the first year.\nAnd many consumers may be put off by the drug's significant gastrointestinal side effects, including flatulence, diarrhea and anal leakage.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Article presents \ninformation on weight loss results from xenical, diet, and exercise (7% of body weight) compared with diet and exercise (4% \nof body weight) over a 4 year period. The story did not mention sibutramine, another prescription weight loss drug. ", "answer": 1}, {"article": "A new report highlights a novel way for doctors to replace thinning hairlines: transplanting leg hair.\n\u201cHe had resorted to cropping his hair short to obscure the problem.\u201d\n\nWith the patients under local anesthesia, Dr. Umar used a device that creates microscopic wounds around hair follicles in the back of the leg; the follicles were then removed and transplanted to the hairline.\nIf you take that hair and use it in the hairline, it can end up looking harsh and pluggy, because the hair is too thick.\u201d\n\nDr. Umar was inspired to develop the procedure in part from personal experience.\nThe other patient, a 29-year-old man who had also undergone a traditional transplant, was likewise \u201cunhappy about his hairline, which he felt was too harsh and straight,\u201d Dr. Umar wrote.\nThe procedure has the potential to restore the hairlines of millions of men with male pattern baldness, the most common cause of hair loss and often an enormous source of stress.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does talk about how transplants are most often done, but it does not explain that there are a wide variety of techniques being used, many of which have very little in the way of peer reviewed evidence supporting them. After introducing the concept that hair loss creates \u201cenormous stress\u201d for men, the story might have talked with a researcher who has studied male self-esteem to find out whether cosmetic procedures can create their own anxiety because of exactly what this story describes: outcomes that \u201cend up looking harsh and pluggy\u201d. The story also does not mention that the men chosen for this surgery were men who the doctor describes as having hair thick enough on their legs to work for a transplant to the head. Not all men would be candidates.\nThe story also doesn\u2019t mention any of the alternative strategies used in hair transplant.\u00a0 In addition to transplanting hair from other areas of the scalp, chest, thigh, leg and pubic hair have been used.", "answer": 0}, {"article": "Zecuity, which is battery-operated, delivers 6.5 milligrams of sumatriptan over the course of about five hours and can relieve nausea, as well as reduce sensitivity to light and sound.\n\"I've had some patients where the nausea and vomiting was so bad they couldn't even swallow a pill,\" said Nancy Waltman, a nurse practitioner with the University of Nebraska Medical Center College of Nursing, Lincoln Division.\nThe most frequent side effects were pain at the site of application along with tingling, itching, warmth and discomfort.\nA nasal spray is available, as is an injection, but many patients aren't comfortable with these options, Khan and Waltman noted.\nThe patch is attached to the upper arm or thigh, and when the patient pushes a button the drug is delivered through the skin.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions alternative delivery systems for migraine medication, including pills, sprays, and injections (although as mentioned above, it doesn\u2019t compare the efficacy of these different approaches). The story could have also mentioned that there are a variety of non-triptan\u00a0drugs, including NSAID pain relievers, that can be\u00a0effective for treating acute migraine attacks.", "answer": 1}, {"article": "Decades later, it became popular as a psychedelic club drug.\n\"While the science is promising, ketamine is not ready for broad use in the clinic,\" Insel wrote in his blog a few months ago.\n\"It became clear to me that the future of psychiatry was going to include ketamine or derivatives of ketamine,\" says David Feifel, a professor of psychiatry at the University of California, San Diego, who began administering the drug to patients in 2010.\nAnd in 2006, a team from the National Institute of Mental Health published a landmark study showing that a single intravenous dose of ketamine produced \"robust and rapid antidepressant effects\" within a couple of hours.\nBut the studies of ketamine have produced results so dramatic that some doctors, including Feifel, are bypassing the usual protocols.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story seems to have two different standards for summarizing study evidence. Even as the story highlights the potential benefits and minimizes harms of ketamine, it dismisses conventional treatments saying a major study concluded \u201ccurrent antidepressants really aren\u2019t much better than a placebo.\u201d\u00a0For the severe depression mentioned in the story, there is evidence that antidepressants are quite a bit better than placebo.", "answer": 0}, {"article": "Such screening is increasingly used in research.\nThe largest analysis to date of amyloid plaques in people\u2019s brains confirms that the presence of the substance can help predict who will develop Alzheimer\u2019s and determine who has the disease.\n\u201cThe papers indicate that amyloid imaging is important to be sure that the drugs are being tested on people who have amyloid,\u201d said Dr. Roger Rosenberg, the director of the Alzheimer\u2019s Disease Center at the University of Texas Southwestern Medical Center at Dallas, who wrote an editorial about the studies.\nThe findings also confirm that amyloid screening, by PET scan or cerebral spinal fluid test, can help identify people for clinical trials of drugs to prevent Alzheimer\u2019s.\nTwo linked studies, published Tuesday in JAMA, also support the central early role in Alzheimer\u2019s of beta amyloid, the protein that creates plaques.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was mention of the two different screening methods used in these studies \u2014 PET and cerebral spinal fluid test \u2014 but no discussion of which method was more precise or if they yielded similar accuracy. In addition, it would have been helpful to know the accuracy of clinical diagnosis of\u00a0AD \u2014 it\u2019s given in one of the papers, for comparison.", "answer": 0}, {"article": "The U.S. Preventive Services Task Force (USPSTF) says there is no proof that the benefits of routine mammogram screening outweigh the risks for average-risk women in their 40s.\n\"What we are seeing is that women with mammogram -detected breast cancer require less treatment,\" Malmgren tells WebMD.\n\"If all those women were screened in their 40s, only 8,500 would die.\"\nThe finding comes from a careful study of nearly 2,000 women diagnosed with first-time breast cancer at age 40 to 49.\nFor women in their 50s and 60s, the benefits of getting regular mammograms clearly outweigh the risks.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Interesting this story never mentioned that the study was comparing breast cancer tumors detected by patient/doctor to those detected by mammograms.", "answer": 0}, {"article": "The research team was led by Hoon-Ki Sung of The Hospital for Sick Children in Ontario, Canada.\n\"Strikingly, these fasting-stimulated changes in the growth of vascular cells and subsequent immune alterations occur even after a single cycle of 24-hour fasting, and are completely reversed when mice start eating again,\" adds Yun Hye Kim.\nIntermittent fasting promotes adipose thermogenesis and metabolic homeostasis via VEGF-mediated alternative activation of macrophage, Cell Research DOI: 10.1038/cr.2017.126\n\nNote: Kyoung-Han Kim's current affiliation is the University of Ottawa Heart Institute, Canada.\nThe fasting regime helped lower fat build-up in the white fat by increasing the brown-like fat (involved in burning energy and producing body heat) of mice on the high fat diet.\nThis happens during periods of intermittent fasting because there is an increase in vascular growth factor (VEGF) that help form blood vessels and activate anti-inflammatory macrophage.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "While the release is written as if it could help inform human obesity treatment or prevention, there is no discussion of how obesity is treated or prevented now and the many alternatives available. These include changes in exercise and diet patterns and bariatric surgery.", "answer": 0}, {"article": "The procedure already has lost some popularity because of emerging evidence that popular drug-coated stents can raise the risk of blood clots months later.\nIt fixes only one blockage at a time whereas drugs affect all the arteries, experts said.\nAbout 1.2 million angioplasties are done in the United States each year.\nAlso, the clogs treated with angioplasty are not the really dangerous kind.\nHalf of these low-risk patients received stents and medication.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention medication as the alternative to stenting.", "answer": 1}, {"article": "In clinical trials, a plant-based diet lowers total cholesterol by 12.5 mg/dL.\nThe study authors hypothesize that the greater risk reduction for total, HDL, and LDL cholesterol levels observed in the longitudinal studies is likely due to long-term adherence to plant-based eating patterns and changes in body composition.\nThe authors predict the strong correlation between vegetarian diets and lower cholesterol levels may be due to the association a plant-based diet has with a lower body weight, a reduced intake of saturated fat, and an increased intake of plant foods, like vegetables, fruits, legumes, nuts, and whole grains, which are naturally rich in components such as soluble fiber, soy protein, and plant sterols.\n\"I no longer work for a living,\" notes Dr. Ross, who now resides in Westfir, Ore. \"I wake up every day eager to hear about how a plant-based diet and a healthful lifestyle is changing and saving lives in our community.\n\u2022 In observational studies, a plant-based vegetarian diet is associated with a 22.9 mg/dL reduction in LDL cholesterol and a 3.6 mg/dL reduction in HDL cholesterol, compared to control groups following an omnivorous diet.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This release compares the effects of several other diet types on cholesterol levels to a plant-based vegetarian diet. Readers learned that a plant-based vegetarian diet is associated with greater reductions in total, HDL, and LDL cholesterol levels than omnivorous (diets based on both animals and plants), low-fat, calorie-restricted, or conventional diabetes diets. However, the release lumps most of these alternative diets into one group to arrive at a comparison between vegetarian diets and the others. Since there are large differences in cholesterol levels between the plant-based vegetarian diet and each alternative diet type it would have been helpful to readers to break these comparisons down by individual diet.\nMore importantly, it could be argued that these benefits may also apply to a \u201cplant-based\u201d diet that\u2019s not vegetarian. Strong clinical trial evidence supports a Mediterranean style of eating that doesn\u2019t require completely cutting out meat.", "answer": 1}, {"article": "Doctors used MRI and mapping biopsies to locate the cancerous tissues.\nIn this study, after 12 months, it\u2019s a 9-in-10 chance.\u201d\n\nThe men in the study were aged 45 to 80 with medium- to high-risk cancer, and would likely have undergone surgery or radiotherapy down the line.\n\u201cFocal therapy of individual prostate-cancer lesions, regardless of whether they are multifocal or unifocal, leads to a low rate of genitourinary side-effects and an encouraging rate of early freedom from clinically significant prostate cancer,\u201d the authors concluded in the study.\nWhile the initial results were promising, they need to be replicated; HIFU also needs to be studied long-term and compared with other therapies.\nAhmed told Bloomberg that HIFU may also be cheaper than other standard treatments, noting that the cost of the MRI and mapping was an estimated $2,400, plus about $1,600 for HIFU; in comparison, removing the prostate costs about $7,100.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As noted in the \u201cEvidence\u201d criterion above, we feel the story allowed the researcher to get away with making comparative claims of superiority after a very preliminary study in just 41 men.\nAmong the other therapies to be mentioned would be active surveillance (deferring any active treatment until/unless there is evidence of cancer progression), which is an appropriate strategy for men with low-risk cancers (27% of the study group according to the Lancet article).\n\u00a0", "answer": 0}, {"article": "MONDAY, Feb. 22, 2010 (HealthDay News) -- Women who experience depression during pregnancy may have another treatment option, new research suggests.\nMany women are cautious about using medications during pregnancy, reports the study.\nInterpersonal psychotherapy is an option for women who are depressed during pregnancy, but this type of therapy isn't always available, according to the study.\n\"We found our acupuncture protocol was helpful, but that does not mean that any acupuncture for depression treatment will be effective.\nTo learn more about depression during and after pregnancy, visit the National Women's Health Information Center.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story appropriately discusses antidepressant medication and psychotherapy, two very important and helpful treatments for partum depression.", "answer": 1}, {"article": "\"Sometimes [the mother] is a bit uncomfortable, or sometimes Dad has to go on a business trip or Grandma wants to fly in,\" Lavin said.\nThe standard practice has been that doctors planning repeat C-sections do so between 36 and 40 weeks, when most fetuses have developed enough to survive outside the womb.\nThe tests the doctors perform to determine the extent of the fetus's development are often not sophisticated enough to determine subtle milestones for breathing and processing food independently, said Dr. John Thorp, a University of North Carolina-Chapel Hill obstetrician and one of the authors of the study.\n\"This happens to me every day,\" Lavin said.\nBreathing problems -- already a high risk because labor helps clear the baby's lungs of fluid -- happened four times as often in babies born at 37 weeks than those born at 39 weeks.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Clearly vaginal labor after C-section is the alternative to elective repeat C-section. The story could have done more to discuss the pros and cons of vaginal delivery after C-section.", "answer": 1}, {"article": "The study followed more than 1,600 people over the age of 60 for five years.\n\"What it tells us is that statins might not be effective in slowing the progression of disease, but they might ... prevent disease,\" said Mary Haan of the University of Michigan.\n\"It seems as though the statins because they lower cholesterol reduce production of these plaques,\" said Dr. Gayatri Devi.\nSince cholesterol is part of the tell-tale plaques on the brains of Alzheimer's patients, it made sense to think that statins might help.\nA patient calls you up and says \"I'm losing my memory a little, would you be tempted to put them on a statin, LaPook asked.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The segment does an excellent job of reporting on the established methods for reducing risk of dementia or Alzheimer\u2019s: physical and mental activity, a good diet and general heart-healthy behaviors. And it does a good job warning people away from the conclusion that based on this study they should take statins to reduce dementia risk. ", "answer": 1}, {"article": "And it needs to be strong enough and elastic enough that it actually affects the recoil of the skin.\u201d\n\nThat, he said, \u201cis the challenge I put to them.\u201d\n\nDr. Robert Langer, a biomedical engineer who is a professor at M.I.T.\n\u201cWe were looking for safety, spreadability, adherence, and the right kind of mechanical and optical properties.\u201d\n\nThe \u201cskin\u201d can last for more than a day.\nOne of the first applications, said Dr. Barbara A. Gilchrest, a dermatology professor who is part of the research team, was on undereye bags, a condition that plagues so many middle-aged and older people.\n\u201cWhen we move skin, it doesn\u2019t snap back to what it used to be.\u201d\n\nWhat if there was a way to restore the elastic nature of skin?\nThe skin still has to be able to breathe through this stuff.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll give the story credit in this rating\u00a0since it mentioned current practices in treating dry skin, one of the touted uses of this new product, and explains how those current practices are less than optimum. It doesn\u2019t however mention that surgery is the common approach to addressing undereye bags.", "answer": 1}, {"article": "\u201cBut it does give us hope.\u201d\nOn average, the score on a scale for ranking gastrointestinal symptoms dropped 82 percent from the beginning to the end of treatment, while average developmental age increased by 1.4 years, according to the release.\n\u201cWe have to be mindful of the placebo effect, and we have to take [the findings] with a grain of salt,\u201d Matthew Sullivan, an associate professor of microbiology at The Ohio State University, said in the release.\nThe study, which was published in the journal Microbiome, included 18 children with autism and moderate to severe gastrointestinal problems.\n\u201cTransplants are working for people with other gastrointestinal problems,\u201d lead study author Ann Gregory, a microbiology graduate student at The Ohio state University, said in a news release.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not include any information on other ways to manage gastrointestinal issues for children and teens with autism, which may include changes in diet. The story also does not mention cognitive behavioral therapies that are common for this diagnosis.\nJust to clarify, while some children with autism have gut problems, some do not. The diagnosis of autism may not include gut distress. Treating children for their gut symptoms may or may not have any influence on their behavior.", "answer": 0}, {"article": "The blood test that millions of men undergo each year to check for prostate cancer leads to so much unnecessary anxiety, surgery and complications that doctors should stop testing elderly men, and it remains unclear whether the screening is worthwhile for younger men, a federal task force concluded yesterday.\nBut it remains unclear whether that translates into a reduction in the death rate from the disease.\nEach year, prostate cancer is diagnosed in more than 218,000 U.S. men.\nAbout 28,000 die of it, making it the most common cancer and second-leading cancer killer among men.\nThe PSA test, which measures a protein in the blood produced by prostate tissue, has significantly increased the number of prostate cancer cases being diagnosed at very early stages.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story was about the new recommendation regarding routine screening of men older than 75 years of age with PSA test;\u00a0 the story presented arguments for and against the use of the test.", "answer": 1}, {"article": "For more information, please visit http://www.\nThe research, conducted at LA BioMed, found a reduction in the amount of low-attenuation plaque, or \"soft plaque,\" in the arteries of patients with metabolic syndrome who took Aged Garlic Extract.\n\"This study is another demonstration of the benefits of this supplement in reducing the accumulation of soft plaque and preventing the formation of new plaque in the arteries, which can cause heart disease,\" said Matthew J. Budoff, MD, an LA BioMed lead researcher.\n\"We have completed four randomized studies, and they have led us to conclude that Aged Garlic Extract can help slow the progression of atherosclerosis and reverse the early stages of heart disease.\"\nA follow-up screening conducted a year after the initial screening found those who had taken Aged Garlic Extract had slowed total plaque accumulation by 80%, reduced soft plaque and demonstrated regression (less plaque on follow-up) for low-attenuation plaque.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release only discusses the impact of a single commercial product, Aged Garlic Extract, which is produced by the company funding the research and one of the\u00a0supporters of the conference at which the research was presented. It does not provide any information on other similar products although there are many available on the market. In addition, there are other ways to prevent or reduce the risk of cardiovascular disease including, but not limited to, avoiding smoking, controlling blood pressure, cholesterol and weight and taking daily aspirin.", "answer": 0}, {"article": "\"The easier it is to detect CF, the earlier it can be diagnosed, and the better people's chances are at living a longer, healthier life\", says Joanna Valsamis, Chief Healthcare, Research and Advocacy Officer at Cystic Fibrosis Canada.\nThe test is commonly used in universal newborn disease-screening programs and measures the concentrations of salt.\n\"Sweat contains lots of information related to human health that researchers have not fully analyzed and we found some unexpected chemicals associated with CF,\" he says.\nBut life expectancy rates have risen dramatically in recent decades with the median age of survival now over 50 years, due to better treatments to improve lung function, better nutrition and lung transplants.\nThey identified several unknown chemicals beyond chloride that were consistently associated with babies who had CF, including two different drug and environmental compounds the infants secreted in sweat at much lower concentration levels.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does a good job of explaining the sweat chloride test, which is widely used to make a final diagnosis of CF in infants and children.", "answer": 1}, {"article": "Lona Sandon, a registered dietitian and assistant professor of clinical nutrition at the University of Texas Southwestern Dallas, reacted with cautious optimism to the findings.\n\"Fish oil may prevent loss of weight and muscle by interfering with some of the pathways that are altered in advanced cancer,\" study author Dr. Vera Mazurak, of the University of Alberta in Edmonton, Canada, said in a news release.\n\"But I would caution that the amount of pure concentrated fish oil supplement the people in this study were given is a lot,\" she added.\nThe authors concluded that fish oil supplementation appears to be a safe and effective way to prevent malnutrition among cancer patients, and may ultimately prove to be of benefit for other groups of people, such as elderly patients who also face a significant ongoing risk for muscle loss.\n\"This holds great promise, because currently there is no effective treatment for cancer-related malnutrition.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story quoted the researcher from a news release saying \u201cThis holds great promise, because currently there is no effective treatment for cancer-related malnutrition.\u201d\u00a0 But there was no discussion of any other research or any other approaches to cancer-related malnutrition.\u00a0 So this claim of novelty by the researcher was never explored or substantiated. This is NOT the only research in this field, and the story could have included at least a line about other work.", "answer": 0}, {"article": "P-Cure continues to develop advanced patient-centric solutions with a focus on adaptive therapy and real time motion management.\nIt may also deliver less collateral radiation to sensitive organs while enabling greater accuracy in proton beam delivery,\u201d said Michael Marash, Ph.D., founder and CEO of P-Cure.\nP-Cure (P-Cure, Ltd.), a leading provider of Patient-Centric solutions for proton therapy, has received U.S. Food and Drug Administration (FDA) approval for its patented upright imaging solution.\nBecause of the high capital costs, proton therapy is currently only available to less than one percent of patients who could potentially benefit from it.\nThe P-Cure team is committed to enabling all oncology centers and hospitals globally to establish cost-effective proton therapy services for the best possible care and cure,\u201d said Dr. Marash.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The device is being compared to existing devices used to deliver proton beam therapy. As such, there is a comparison. although it\u2019s a bit opaque. It points out that standard proton therapy may radiate healthy body parts inadvertently. It causes more discomfort. It costs too much. These statements could have been elucidated, preferably through quantification, to create a meaningful comparison for reporters and patients.", "answer": 1}, {"article": "Nevertheless, accumulating evidence has her urging patients to get their calcium from their diet, rather than reflexively telling them to take 1,200 milligrams of calcium a day.\nA recent meta-analysis done by the same group of researchers found a 27 to 31 percent increased risk of heart attacks in women taking calcium without vitamin D.\n\nMany older women take calcium supplements with or without vitamin D to keep their bones strong, especially since that has long been standard medical advice.\n\"The cautious way forward seems to be to encourage people to obtain their calcium from the diet, rather than from supplements, since food calcium has not been shown to carry this increased risk of heart disease,\" Reid added.\n\"There is a lack of consensus at the present time as to what recommendations should be regarding the use of calcium supplements,\" said study senior author Dr. Ian Reid, who fully expected that the new results will have a \"significant impact on recommendations.\"\n\"If women have good reason to take calcium because their bones are thin, then they should not be afraid of taking the calcium,\" said Houck, who is also a cardiologist with Scott & White in Temple, Texas.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not provide readers with any information about possible alternatives, saying only that women should be making sure that they get a maximum of 1,500 milligrams of calcium from both their diets and supplements combined. This isn\u2019t a very good guidepost for readers. We would have liked to have seen at least a sentence or two indicating what patients might be able to do for bone strength, if anything, were they to avoid calcium supplementation.\n", "answer": 0}, {"article": "Treatment usually involves replacing one of the steroids they are unable to produce - called cortisol - with a medication.\nIn a mouse study, the team showed that the effects of corticosterone on fat cells were reduced compared with cortisol.\nThe researchers say that, with further research, these findings may one-day lead to improved therapies for other conditions that respond to steroid treatment, including asthma and rheumatoid arthritis.\nThe new treatment - expected to have fewer side effects than existing therapies - could help people with disorders of the adrenal gland whose bodies are unable to produce a class of steroids called corticosteroids.\nThe team found that corticosterone was as effective as cortisol, but had reduced effects on fat cells compared with cortisol.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The text offers an extended comparison of\u00a0the side effects of the current use of cortisol and those of the possible new treatment.", "answer": 1}, {"article": "Alexander Technique is a series of posture lessons, devised by a 19th century Australian actor named F.M.\n\"The fact of having your arms up and carrying the weight of this instrument and pushing the instrument toward you and so you have this stress, this wall you're pushing against,\" says Rodriguez.\n\"We look at what you are doing that causes that problem in the first place, so how you sit at the computer or how you pick up your child or what you do when you're driving,\" says Gray.\n\"The people who had 24 lessons had gone down from about 21 days of pain that the usual care group reported to about 3 days in pain,\" says Little.\n\"The whole point is that you understand the process so that you can arrive there yourself,\" says Gray.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article mentioned that the jazz trumpeter featured in the piece had failed to improve after trying massage, chiropractic, and powerful painkillers. The implication in the article is that this treatment worked where other treatments didn\u2019t. However, the article did not discuss the benefits and risks of other potentially effective treatments for low back pain\u2014or how instruction in the Alexander Technique might fit into the larger universe of treatment choices.\u00a0 \u00a0", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/09/national/a005536S75.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No mention of other drugs that may have a similar effect. No mention of harms or disadvantages of taking the drug, even as a single-dose. Skin problems have been reported in people taking nevirapine in combination with other HIV drugs. Liver toxicity has also been reported, but only with long-term use. ", "answer": 0}, {"article": "PROVIDENCE, R.I. [Brown University] -- To the tantalizing delight of chocolate lovers everywhere, a number of recent studies employing various methods have suggested that compounds in cocoa called flavanols could benefit cardiovascular health.\nAll studies were small and of short duration, not all of the biomarkers tracked in these studies changed for the better, and none of the studies were designed to test directly whether cocoa flavanol consumption leads to reduced cases of heart attacks or type 2 diabetes.\nThe greatest effects were seen among trial volunteers who ate between 200 and 600 milligrams of flavanols a day (based on their cocoa consumption).\nIn addition to Lin and Liu, the study's other authors are Isabel Zhang, Alina Li from Brown University, JoAnn Manson, Howard Sesso and Lu Wang from Brigham and Women's Hospital.\nThose consuming higher doses saw some of the insulin resistance benefits and a drop in triglycerides, but not a significant increase in HDL.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There is no comparison of alternatives in the release. Are statins a much bigger factor, for example, in cardio health? What about omega-3 fatty acids? What about just eating a balanced diet overall?\nThe release would have been improved with a mention that modest weight loss and exercise are standard ways to improve metabolic markers for cardiovascular disease.", "answer": 0}, {"article": "The study also found other benefits.\nThe paper suggests that the drug may one day offer a nonsurgical alternative to \"vertical sleeve gastrectomies\" that have become popular in the battle against morbid obesity.\nThe drug contributed to development of brown fat, which helps burn calories, and relieves inflammation of cells in various tissues, which is the result of chronic obesity.\nIn the meantime, basic weight loss advice remains the same: fewer calories in, more calories expended by physical activity.\nBut Ronald Evans, director of the institute's Gene Expression Laboratory and lead author of the new study, said in an interview that if it shows the same promise in primate studies, clinical trials on humans could begin in a couple of years.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention surgical treatment of morbid obesity, but it prematurely suggests that the drug would be superior, despite an absence of evidence. A more suitable comparison may have been other medications for obesity and their mechanism of action.", "answer": 0}, {"article": "Propping open clogged arteries with a tiny wire-mesh tube called a stent is no better at reducing the risk of heart attack or death in patients with stable heart disease than treatment with medications, according to a large new study that challenges routine use of a procedure that rapidly became standard medical practice.\nAfter about five years, the number of patients who experienced a heart attack, were hospitalized or died because of their heart problems was virtually identical in the two groups, the researchers found.\nThe procedure costs about $50,000 and is considered safe, though it does carry some risks.\nBut Boden said that the study did include patients with moderate to severe heart disease and that many such patients undergo the procedure in the belief it will protect them against heart attacks.\nThose concerns had led doctors to curtail their use of the newer devices, and the new findings are expected to have a similar effect on angioplasty overall.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses lifestyle changes and medication as alternate treatment options, and these alternate options were directly compared to angioplasty in the study.\u00a0 ", "answer": 1}, {"article": "The George Institute is now looking at strategies to maximise uptake of the study results.\nThe Triple Pill, consisted of the blood pressure medications telmisartan (20 mg), amlodipine (2.5 mg), and chlorthalidone (12.5 mg).\nDr Ruth Webster, of The George Institute for Global Health, said this was a major advance by showing that the Triple Pill was not only more effective than standard care, it was also safe.\nCompared with patients receiving usual care, a significantly higher proportion of patients receiving the Triple Pill achieved their target blood pressure of 140/90 or less (with lower targets of 130/80 for patients with diabetes or chronic kidney disease).\nThe researchers tested an entirely new way of treating hypertension by giving patients three drugs, each at half dose, in a single pill for early treatment of high blood pressure.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release calls the pill \u201cinnovative\u201d and says it \u201ccould transform the way blood pressure is treated around the world\u201d \u2026 but it fails to mention that combination blood pressure-lowering medications have been around for decades. And, as mentioned above, there are some once-daily \u201ctriple pills\u201d already on the market.", "answer": 0}, {"article": "What is the effect of Topical Curcumin Gel for treating burns and scalds?\nThe process goes through a sequence of acute and chronic inflammatory events, during which there is redness, swelling, pain and then healing, often with scarring in the case of burns and scalds of the skin.\nThe author of the study believes that the effectiveness of curcumin gel on the skin - or topical curcumin - is related to its potent anti-inflammatory activity.\n\"Curcumin gel appears to work much better when used on the skin because the gel preparation allows curcumin to penetrate the skin, inhibit phosphorylase kinase and reduce inflammation,\" explains Dr Heng.\nIn this report, use of curcumin after burns and scalds were found to reduce the severity of the injury, lessen pain and inflammation, and improve healing with less than expected scarring, or even no scarring, of the affected skin.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Although the news release does mention the use of curcumin tablets, we wish it could have gone into depth about some conventional therapies used to minimize scarring after a burn.\nThere are various ways to treat burns, such as specialty wound dressings and antibiotics to prevent infection and to speed up healing. Careful monitoring for infection is critical. To minimize scarring, some doctors recommend wearing pressure garments, which are tight-fitting clothes to be worn over burned areas. These are worn 23 hours per day (taken off only for bathing) for up to\u00a02 years after the burn. If the burn area is very large, patients may undergo physical therapy. Deep burns could require plastic surgery or skin grafts.\nSince none of the more traditional burn treatments are discussed, we give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": "Natural remedies have an obvious appeal, but how do you know which ones to choose and whether the claims are backed by science?\nThe Risks: According to the National Institute of Allergy and Infectious Diseases, honey may be useful in relieving coughing, but it should never be given to children under a year of age because in rare cases it can cause infantile botulism.\nThe Science: For decades, parents looking for an over-the-counter medicine to cure a child\u2019s sickness and coughing have turned to syrupy medicines containing dextromethorphan, a popular cough suppressant found in products like Children\u2019s Dimetapp DM and Robitussin DM.\nIn one double-blind study published in The Archives of Pediatric and Adolescent Medicine, researchers recruited 105 children and teenagers who had coughs from upper-respiratory infections.\nThe subjects were randomly divided into three groups: one that received no treatment, another that received one or two teaspoons of buckwheat honey, and a third that received a dose of honey-flavored dextromethorphan.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job comparing and contrasting the different remedies. We wish it had provided real numbers, but, overall, it did a good job.", "answer": 1}, {"article": "LONDON -- Sanofi-Aventis SA's obesity drug Acomplia can improve blood-sugar levels and weight loss in diabetic patients, according to a study presented at the World Diabetes Congress in South Africa.\n\nThe findings from the clinical trial have shown newly diagnosed patients with type-two diabetes who weren't taking antidiabetic drugs had significantly improved blood-sugar levels and lost more weight with Acomplia, compared with a dummy pill over a period of six months. In addition, Acomplia -- also known as rimonabant -- helped...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story reported on the comparison of rimonabant as compared to placebo in a group of individuals with type-two diabetes whose sugar levels were not adequately controlled using diet alone.\u00a0 Although rimonabant may be the first in a new class of drugs that may someday be used in the treatment of diabetes, the story failed to mention the pharmacologic and lifestyle approaches currently used to treat diabetes.\u00a0 It did not mention the clear evidence that intensive behavioral counseling for weight loss is effective in improving health outcomes in obese adults, and improving blood sugar control in diabetic patients. ", "answer": 0}, {"article": "Most bills do allow parents to opt out, because the question remains: Where to make this decision - at the statehouse ... or your house.\nNot yet,\" Alexander says.\nKen Alexander understands.\n\"Even if you think you aren't at risk, you are,\" adds Audrey.\nBut is it something that we are in position to sort of ramrod down people's throats?\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention any alternatives, most notably, regular pap smears.", "answer": 0}, {"article": "\u201cToo often, parents fall victim to the false claims of charlatans who prey on desperate families.\nNevertheless, for parents of children with autism, even a modest reduction would be worthwhile.\u201d\n\nDr Max Davie, of the Royal College of Paediatrics and Child Health, said it offered \u201ca hugely cheering message for families\u201d, while Uta Frith, emeritus professor of cognitive development at University College London, called it \u201ca remarkably positive story, because the intervention itself was neither intensive nor invasive\u201d.\n\u201cThis is not a cure, in the sense that the children who demonstrated improvements will still show remaining symptoms to a variable extent, but it does suggest that working with parents to interact with their children in this way can lead to improvements in symptoms over the long term.\u201d\n\nThe trial involved 152 children aged two to four.\nThere are no drugs to treat the condition, which typically sets in around the age of two, and many families have tried intensive training of their children by therapists, with mixed results.\nThe absence of any hope, as well as the very sudden regression in children\u2019s behaviour, led many parents to believe in the discredited theory of Andrew Wakefield that the MMR (measles, mumps and rubella) vaccine was the cause of autism.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article noted that there are no cures or predictably effective treatments for severe autism, and that even a modest improvement in symptoms would be a boon. The training intervention is compared adequately to the traditional \u201cdirect therapist-child\u201d type of treatment.", "answer": 1}, {"article": "And our brains like rewards.\nIn the meantime, he says, the study has shown that it is possible to do neurofeedback research that involves a placebo.\nShe says it might have been because she and her son spent so much time going to all those sessions together, and had pizza together afterward.\nIn recent years, more people have been trying an alternative approach called neurofeedback, a type of therapy intended to teach the brain to stay calm and focused.\n\"There has been a need for some time to have the kind of carefully controlled study that would provide more definitive answers for parents and for the field,\" he says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story quotes a researcher who says that two other approaches \u2014 medication and behavior therapy \u2014 have a more extensive research base supporting their use for ADHD compared with neurofeedback.", "answer": 1}, {"article": "The paper \"Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening\" is available at: https:/\n\nTo request a copy of the study, please contact: Daniel Luzer\n\n daniel.luzer@oup.com\nThe HPV test captures the known cancer causing viruses, but there are gynecologists who believe that there may be unknown cancer causing viruses and so continue to do the Pap smear (plus HPV testing).\nAn HPV test, in which doctors test a cervicovaginal specimen for the presence of the nucleic acids of carcinogenic types of HPV, is more sensitive than the Pap test (a microscopic examination of exfoliated cells) for detection of precancers.\nThe accumulated evidence supports inclusion of HPV testing in screening; thus, the main choice moving forward is between cotesting and primary HPV testing alone.\nHPV-negative/ Pap test-positive results preceded only small fractions of cases of precancer (3.5%) and cancer (5.9%); these cancers were more likely to be regional or distant stage than other cases.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release is about comparing alternative screenings, either co-testing or HPV alone. The report does not address Pap alone (recommended for women under 30 years old).", "answer": 1}, {"article": "Dana-Farber/Boston Children's is a site in the multi-center Phase 1 trial.\n\"The stem cells' dependence on Ezh2 suggests they will be especially vulnerable to drugs that target the protein,\" Orkin remarks.\nThe findings, reported online today by the journal Cancer Discovery, raise the prospect that Ezh2 blockers, in combination with Gleevec and similar drugs, could eradicate the disease in some patients in relatively rapid fashion or could be an effective therapy for those who become resistant to Gleevec-like agents, the authors state.\n\"Our findings suggest inhibition of Ezh2 should be considered as a way to eradicate CML when used in combination with current targeted therapies.\nDana-Farber/Boston Children's Cancer and Blood Disorders Center -- the nation's top pediatric cancer center, according to U.S. News & World Report - brings together two internationally known research and teaching institutions that have provided comprehensive care for pediatric oncology and hematology patients since 1947.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Aside from\u00a0the current standard of care \u2014 imatinib-like drugs \u2014 the release only\u00a0vaguely references \u201csecond- and third-line targeted therapies\u201d that \u201ccan often return the disease to remission,\u201d yet doesn\u2019t name them.", "answer": 0}, {"article": "July 30, 2012 -- If it weren't for routine PSA prostate cancer screening, an extra 17,000 Americans each year would learn that they had the worst form of the disease, a new study suggests.\nThat kind of prostate cancer -- metastatic prostate cancer, in which the cancer spreads to the bone or other parts of the body -- is rapidly fatal, usually within two years or less.\nBut he would not yet have symptoms or detectable metastatic disease, so he'd be diagnosed with earlier-stage disease.\nThe new study seems to make a powerful argument in favor of PSA testing.\nIt finds that in the three years before widespread PSA testing (1983-1985), men getting their first diagnosis of prostate cancer were three times more likely to learn they had very late-stage cancer than men diagnosed in the most recent three years for which data is available (2006-2008).\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternative to PSA screening is the choice to decline screening, which is implicit in the discussion about the tradeoffs.", "answer": 1}, {"article": "Breast Cancer Patients Have Improved Immune And Neuroendocrine Functions Following Massage Therapy.\nThe immune changes included increased white blood cells knowns as natural killer (NK) cells, which provide rapid responses to viral-infected cells.ii\n\nAn additional randomized study found women with stage 1 and 2 breast cancer may benefit from massage therapy for enhancing dopamine and serotonin while also increasing NK cell number and lymphocytes.\nThe American Massage Therapy Association, the most respected name in massage therapy, is the largest non-profit, professional association serving massage therapists, massage students and massage schools.\n\"Researchers working with patients with compromised immune systems have found massage therapy can improve how the immune system functions,\" said Jeff Smoot, President of the American Massage Therapy Association (AMTA).\nAccording to research from Cedars-Sinai, participants in a Swedish massage group experienced significant changes in lymphocytes, which play a large role in defending the body from disease.i A lymphocyte is one of the three subtypes of white blood cells in the immune system.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release included no discussion of other alternatives to prevent the flu, common cold or other infectious diseases that are common in the fall and winter months. The Centers for Disease Control recommends an annual flu shot, washing hands and frequently cleaning touched surfaces and objects. England\u2019s National Health Service also recommends a healthy lifestyle, such as a wholesome diet, regular exercise and drinking plenty of warm fluids in the winter months.", "answer": 0}, {"article": "Previous laboratory research by Borrello and his colleagues showed that activated MILs could selectively target and kill myeloma cells taken from patients and grown in laboratory culture flasks.\nIn nonblood-based tumors, such as melanoma, only about one-half of patients have T cells in their tumors that can be harvested, and only about one-half of those harvested cells can be grown.\nOther Johns Hopkins scientists who contributed to the research include Carol Ann Huff, Janice Davis, M. Victor Lemas, Susan Fiorino, Jeffrey Bitzan, Anna Ferguson, Amy Emerling, Leo Luznik, William Matsui, Jonathan Powell, Ephraim Fuchs, Gary L. Rosner, C. Epstein, Lakshmi Rudraraju, Richard F. Ambinder, Richard J. Jones and Drew Pardoll.\nAdditionally, the scientists found that patients whose bone marrow before treatment contained a high number of certain immune cells, known as central memory cells, also had better response to MILs therapy.\nOther types of tumor-infiltrating cells can be used, but they are usually less plentiful in patients' tumors and may not grow as well outside the body, says Borrello.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does mention that other forms of this adoptive T cell therapy use different cells, suggesting that other approaches are possible. The release also notes, \u201cThree days before the injections of expanded MILs, patients received high doses of chemotherapy and a stem cell transplant, standard treatments for multiple myeloma.\u201d", "answer": 1}, {"article": "Participants in the higher seafood consumption group ate an average of two seafood meals per week.\n\"This study helps show that while cognitive abilities naturally decline as part of the normal aging process, there is something that we can do to mitigate this process,\" says Martha Clare Morris, ScD, a Rush nutritional epidemiologist and senior author of the paper.\nThe study did not find a significant difference in the rate of decline in episodic memory (recollection of personal experiences), working memory (short-term memory used in mental function in the immediate present) and visuospatial ability (comprehension of relationships between objects).\n(Chicago) - Eating a meal of seafood or other foods containing omega-3 fatty acids at least once a week may protect against age-related memory loss and thinking problems in older people, according to a team of researchers at Rush University Medical Center and Wageningen University in the Netherlands.\nThe results were the same after researchers adjusted for other factors that could affect memory and thinking skills, such as education, physical activity, smoking and participating in mentally stimulating activities.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The story says that \u201cresearchers adjusted for other factors that could affect memory and thinking skills, such as education, physical activity, smoking and participating in mentally stimulating activities.\u201d It doesn\u2019t tell us which are potentially good (and which are bad), but it\u2019s sufficient for a Satisfactory rating.\nThe release would have been stronger if it had addressed the question (probably on some on readers\u2019 minds) about whether fatty acid supplements could possibly have the same effect that the researchers observed with seafood consumption. These supplements are widely used, not to mention costly, so this may have been worth including.", "answer": 1}, {"article": "SAN DIEGO, July 14, 2015 /PRNewswire/ -- GenomeDx Biosciences today announced that a study featured on the cover of Urology demonstrates that Decipher\u00ae Prostate Cancer Classifier significantly influenced treatment recommendations following prostate surgery, reducing disagreement between urologists and radiation oncologists, and has the potential to enhance personalization of patient care.\nIn addition, the 19% of the patients with the highest risk based on Decipher had a nearly 10-fold higher risk of distant metastases by 5 years.\nThe Decipher results increased agreement in treatment recommendations between urologists and radiation oncologists, as the odds of a recommendation for adjuvant treatment by urologists vs radiation oncologists increased from 0.27 (95% CI, 0.17-0.44) to 0.46 (95% CI, 0.29-0.75) after results of the Decipher test were made available.\n\"Conflicting treatment recommendations by different specialists looking at the same disease can be highly confusing for patients and is a problem for the health care system in general,\" said Paul Nguyen, M.D., of Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School.\n\"It is notable that while the Decipher test significantly influenced treatment decisions, it did not increase the total number of people receiving adjuvant therapy, suggesting that it helped ensure that the ones selected for adjuvant therapy are the ones most likely to benefit from it,\" said Doug Dolginow, M.D., chief executive officer of GenomeDx.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "We\u2019re not told if there are any alternatives. Even if Decipher stands alone as a post-operative\u00a0test, that\u2019s critical information.\nIn the study itself, the authors did provide clinicians with information about risk groups,\u00a0PSA, and extensive information about the pathology of the cancer. Studies (and guidelines) have used\u00a0these parameters to guide treatment\u2013it would be useful to know whether the initial decisions followed accepted practice. If not, then clinician education might be a more (cost) effective intervention than providing results from an expensive test.", "answer": 0}, {"article": "Blood tests determined blood selenium, good cholesterol and bad cholesterol levels at the start of the study.\n\"There are various reasons for that, including the fact that in the U.S. you have a wheat belt that means there is quite a high amount of selenium in the bread staple, which is not the case in the U.K.\"\n\n\"So, we can't extrapolate our findings to the U.S.,\" Rayman said.\n\"Overall, the evidence is inadequate to establish a protective role of selenium in cardiovascular disease or to recommend selenium supplementation to improve cardiovascular health,\" he said.\n\"The issue is that there have been an awful lot of studies, about eight, that have looked at blood cholesterol, both good and bad, and have found an association with high blood selenium,\" said study author Margaret P. Rayman, a professor of nutritional medicine at the University of Surrey in Guildford, England.\n\"So we looked for whether selenium actually causes cholesterol to rise, and we definitively found that there wasn't an adverse effect,\" Rayman said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u00a0notes that\u00a0bread in the U.S. is a good source of selenium, and that U.S. consumers generally have no need to take a supplement. So, there\u2019s really no need to talk about alternatives. We\u2019ll rule it not applicable.", "answer": 2}, {"article": "or \"Have you taken your medications yet today?\nWhile there are more than 100,000 health-related apps on the market, the evidence to date is lacking as to whether many of those apps are safe or effective, according to Zubin Eapen, a cardiologist and assistant professor of medicine at Duke University School of Medicine.\nNot only does this research provide evidence that a text-based program can improve heart disease risk factors, but it also shows that a bunch of bells and whistles aren't required for successful health outcomes.\nIt can't tell us whether text messaging could eventually lead to fewer subsequent heart attacks among the patients receiving those messages or whether the positive health outcomes would continue past the six-month study window.\n\"We [as physicians] are always looking for evidence to make sure that we are recommending the right things for our patients, whether it's a drug, a device or a digital product, like an app,\" says Eapen, who is also medical director of the Duke Heart Failure Same-Day Access Clinic.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The focus of the story is not so much on how the text message intervention directly reduced heart disease risk, but on the extent to which it resulted in patients taking steps to reduce their own risk \u2014 such as by exercising more, smoking less, making dietary changes, or taking prescription drugs on a regular basis. The story does discuss other \u201cmobile health interventions,\u201d such as smartphone apps \u2014 but notes that there don\u2019t appear to be many mobile health projects that rely simply on text messages. The story also looks at how the text messages helped patients pursue lifestyle changes \u2014 like exercising more and smoking less \u2014 that reduced their risk.", "answer": 1}, {"article": "U.S. experts familiar with the study call it interesting but say the treatment needs more study and wonder if it would catch on in the U.S.\nDec. 13, 2010 -- Acupuncture treatments to treat one type of lazy eye proved as good as the traditional patching of the eye used to help the eyes work together, according to a new study.\n''These results suggest that the treatment effect of acupuncture is equivalent to that of patching for anisometropic amblyopia in older children,\" Lam writes.\nBut at 25 weeks, the resolution rates were similar in the two groups: 30% of the patched group and 42% of the acupuncture group.\nSo Dennis Lam, MD, a researcher at the Joint Shantou International Eye Center of Shantou University and Chinese University of Hong Kong, and his colleagues evaluated 88 children, ages 7 to 12, with the condition known as anisometropic amblyopia, in which there is a difference in the degree of nearsightedness or farsightedness between the two eyes.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story weighs some of the pros and cons of acupuncture compared with the traditional patch therapy. It notes that the patch has the advantage of being inexpensive and that it can be worn at home, making it more convenient.", "answer": 1}, {"article": "Loading up on fiber-fortified processed foods isn\u2019t likely a good way to increase the kind of fiber that benefits the gut.\n\u201cWe discovered that the patients who exhibited higher amounts of were the patients who had a very strong improvement in cholesterol, in glycemia, in waist to hip ratio and also a reduction in different parameters in both cardiovascular disease and risk factors.\u201d\n\nHigher levels of , the findings suggest, seem to have favorable effects on health.\nBoth groups of people lost the same amount of weight, but the high- group had a stronger decrease in visceral fat than the others, says study author Patrice D. Cani, PhD, professor and group leader of the Metabolism and Nutrition Research Group at Universit\u00e9 Catholique de Louvain in Belgium.\n\u201cOur diet and deteriorated microbiota are really a major piece of the puzzle in trying to understand why Western diseases are rising like crazy.\u201d\n\nSonnenburg says that when researchers try on mice what many of us do on a regular basis\u2014eat food depleted of dietary fiber\u2014their gut microbes behave erratically.\nIt\u2019s increasingly clear that the composition of your gut bacteria likely influences your risk for many health problems, from obesity and type-2 diabetes and even certain autoimmune diseases.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story was mostly about gut bacteria, but it does discuss the potential impact of A. muciniphila on cholesterol, glycemia (i.e., blood sugar levels), and other risk factors for cardiovascular disease. It would have been useful here to discuss other interventions, such as exercise, that can influence these risk factors.", "answer": 0}, {"article": "Others have such high cholesterol that taking statins alone is not enough.\nThe results, published in the Annals of Internal Medicine, also show that the drugs have a significant effect on reducing heart attacks and overall mortality.\nThese new drugs \"could be for someone who needs an addition to statin, or it could be instead of statin,\" Martin said.\n\"It seems that the group that takes them, compared to the group that doesn't, has half the rate of cardiovascular events and mortality as those that don't,\" Dr. Seth S. Martin of the Johns Hopkins School of Medicine told CBS News.\nOne in six American adults lives with high cholesterol, and millions have trouble getting it under control, according to the Centers for Disease Control and Prevention.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explains that millions of people take statins in order to lower their levels of a certain cholesterol. It positions these new drugs as alternatives to statins. While that\u2019s enough for a Satisfactory rating, the story does not point out that exercise and changes in diet are also known to lower levels of harmful cholesterol. There are also a number of other therapies available for patients with elevated lipids.", "answer": 1}, {"article": "It\u2019s a promising preliminary sign.\nBut they differ in a key way: Whereas the algorithm the NIH uses can predict if someone has a given genetic disorder, the Face2Gene algorithm spits out not diagnoses, but probabilities.\nTo continue to fix this problem, both the NIH and Face2Gene need help from more researchers who can upload more patients\u2019 faces \u2014 but that\u2019s easier said than done.\n(The program is funded by the NIH\u2019s Fogarty International Center; President Trump eliminated funding for the center in his 2018 \u201cskinny\u201d budget proposal announced in March.)\nIn addition to his work as a researcher, Muenke directs a program that brings health care professionals from developing countries to the US for a month-long crash course in medical genetics.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes clear that there is physician experience, as well as genetic tests, as alternatives. Because the software-makers insist this new tool is not to be used for diagnoses, we\u2019re still not sure what the benefit of this new technology would be, and why it\u2019s needed, though.", "answer": 1}, {"article": "A large, new study may be reassuring to women considering mastectomies because of a history of breast cancer in their families.\n\nStanford University researchers affirmed that women with mothers and sisters who carry one of the BRCA gene mutations but who aren't carriers themselves don't have an especially heightened risk of breast cancer.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There aren\u2019t really any alternatives to BRCA testing for women with a strong family history of breast cancer, so we\u2019ll rate this not applicable.\nHowever, in just another line or two, the story could have noted that there are other, less common\u00a0genetic mutations that also confer an increased risk of breast cancer. And it could have mentioned that there are other options available to help estimate a woman\u2019s risk of breast cancer (e.g. the Gail model, Claus model, etc). These are not genetically\u00a0based\u00a0but some do account for family history to help refine risk estimates.", "answer": 2}, {"article": "\u201cWhen it recognizes that it\u2019s gone inside the cell, it says OK, now it\u2019s time to disassemble and give off the RNA.\u201d\n\nIn a phase 1 clinical trial in patients with various types of tumors, the team gave doses of the targeted nanoparticles four times over 21 days in a 30-minute intravenous infusion.\nOther teams are using fats or lipids to deliver the therapy to the treatment target.\nThe finding, reported in the journal Nature on Sunday, offers early proof that a new treatment approach called RNA interference or RNAi might work in people.\nTumor samples taken from three people with melanoma showed the nanoparticles found their way inside tumor cells.\nDavis said that part of the study will be presented at the American Society of Clinical Oncology meeting in June.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story acknowledged that other research teams are exploring using fats or lipids to reach the target.\u00a0 ", "answer": 1}, {"article": "MONDAY, Dec. 13, 2010 (HealthDay News) -- Acupuncture may be an effective way to treat older children struggling with a certain form of lazy eye, new research from China suggests, although experts say more studies are needed.\nFor the latter group, doctors will often place a patch over the \"good\" eye temporarily in addition to eyeglasses, and treatment success is typically achieved in two-thirds of cases.\n\"However, I think it's worth considering or trying,\" Chang added, \"because nothing else seems to work very well for patients of that age, including patch therapy.\nHowever, while this approach is often successful in younger children (between the ages of 3 and 7), it is successful among only about a third of older children (between the ages of 7 and 12).\nChildren, however, often have trouble adhering to patch therapy, the treatment can bring emotional issues for some and a reverse form of lazy eye can also take root, the researchers said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that standard treatment for younger children with amblyopia involves eyeglasses or contact lens designed to correct problems with focus.\u00a0Patch therapy is\u00a0useful\u00a0for older children,\u00a0according to the story,\u00a0but may be tougher for children to adhere to and has potential adverse effects.", "answer": 1}, {"article": "The other trial had nearly identical results.\n\"The ability of these potential drugs to treat individuals with a single F508del mutation means that more people than ever before could benefit,\" said Dr. Michael Boyle, senior vice president for therapeutics at the foundation.\nThis is the first time, Rowe said, that CFTR modulator therapy has \"pushed the needle\" for patients with one F508del mutation.\nWhat's most exciting, they said, is that the triple-drug approach could open up new options to nearly all cystic fibrosis patients.\nTHURSDAY, Oct. 18, 2018 (HealthDay News) -- In what researchers are calling a \"breakthrough,\" two preliminary trials have found that either of two triple-drug regimens could potentially benefit 90 percent of people with cystic fibrosis.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions existing therapies to target the genetic mutations of cystic fibrosis patients. There are other approaches under study such as such gene editing and stem cell replacement, but those have a ways to go scientifically.", "answer": 2}, {"article": "The Penn-led team administered a once-daily dose of LDX for four weeks to 32 healthy, non-ADHD-diagnosed women between the ages of 45 and 60 experiencing difficulties with executive functions as a result of mid-life onset menopause, and as measured using the Brown Attention Deficit Disorder Scale (BADDS).\nThey work by promoting the release of dopamine, which is impaired in ADHD and other disorders characterized by executive function problems.\nAll participants served as their own controls by being randomly assigned to cross-over to a placebo for an additional four weeks.\nResults of the study are published online today in the journal Psychopharmacology.\nThe researchers found a 41 percent overall improvement in executive functions for women receiving LDX, compared to a 17 percent improvement when taking placebo medication.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release offers no mention or discussion of alternative treatments for menopause-related symptoms or cognitive dysfunction.", "answer": 0}, {"article": "Though CA125 is valuable to look for recurrence of cancer, it is not recommended for screening because it can surge, for example, during menstruation. However, guidelines from the American College of Obstetricians and Gynecologists and the National Comprehensive Cancer Network (NCCN) recommend a CA125 test plus vaginal ultrasound imaging for a woman with nonspecific symptoms that could signal ovarian cancer, such as bloating and pain. A CT or MRI scan may be added, although these are expensive. A biopsy is usually avoided because it could spread cancer cells.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes it clear that no effective early detection screening test exists. Existing strategies\u2014the CA125 blood test and vaginal ultrasound\u2014are mentioned and then discounted, in part via a personal narrative of a young woman who received a late diagnosis of cancer. While data-driven specifics aren\u2019t included on why standard methods aren\u2019t sufficient, this is enough to rate Satisfactory.\nA\u00a0direct comparison of\u00a0survival stemming from existing diagnostic tests relative to survival stemming from ROMA and OVA1 would have strengthened the story. If those numbers aren\u2019t available, that should have been pointed out.", "answer": 1}, {"article": "Still, even starting the trial could be a boost to Advanced Cell, which often makes headlines but has struggled to raise money.\nIt is likely to be several years before such a treatment can reach the market, if it works.\nIt sells one drug for a rare disease and has garnered hundreds of millions of dollars from licensing deals with big pharmaceutical companies.\nBut the drug works best when given every four weeks, which can be inconvenient for patients and doctors.\nThe hope is that the implanted cells will replace those injured by the disease.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Laser surgery and photodynamic therapy are other potential treatment options for wet AMD. The story did not mention them.", "answer": 0}, {"article": "For its part, the pediatricians group hopes the new recommendations will encourage more parents to circumcise their sons \u2014 and more insurance plans to pay for it.\n\"Those families who choose circumcision should have access to circumcision.\nThey liken the procedure to female genital mutilation.\nThe academy's task force spent seven years combing through the latest research, analyzing more than a thousand studies.\nIt also reduces the chances that men will spread HPV to their wives and girlfriends, protecting them from getting cervical cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternative is no circumcision and was presented in the article.", "answer": 1}, {"article": "Andersson will be available to the media in an embargoed web briefing on Tuesday, March 7, 2017, at 2 p.m.\nAlthough the results provide evidence that PDE5 inhibitors may benefit heart health, the retrospective study design makes it impossible to ascertain direct cause and effect, Andersson noted.\nThe ACC's Annual Scientific Session, which in 2017 will be March 17-19 in Washington, brings together cardiologists and cardiovascular specialists from around the world to share the newest discoveries in treatment and prevention.\nHowever, previous studies have associated the use of PDE5 inhibitors with a decreased blood pressure in the left ventricle, which reduces the amount of work required to pump blood and therefore could help explain why the drugs might benefit people with heart failure.\nThe researchers also were unable to account for socioeconomic status; as a next step, they are planning a larger study that will include more health records and complete information on marital status, educational level and disposable income.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The treatment of ED was not the focus of the research. Still, in a release suggesting the drug\u2019s safety and benefits in preventing future heart disease we\u2019d like to see some emphasis on how keeping a heart-healthy lifestyle through diet and exercise could be positive alternatives for risk reduction.", "answer": 0}, {"article": "?\nThe new research, presented last month at the North American Research Conference on Complementary and Alternative Medicine in Edmonton, Alberta, is scheduled to be published in the journal Menopause early next year, according to lead researcher Ann Vincent, an assistant professor of medicine at the Rochester, Minn., clinic.\nBeginning in 2002, WHI researchers reported that estrogen was beneficial in reducing hot flashes, but that the hormone, routinely prescribed to middle-aged women for years, also raised the risk of cancer, heart disease, stroke, dementia and other ailments.\nAs a result, federal health officials have recommended that women bothered by menopausal symptoms such as unpredictable sweats, sleep disturbances and vaginal dryness take the lowest dose of estrogen for the shortest possible time.\nThe 2,000-year-old treatment is widely used around the world, according to the National Center for Complementary and Alternative Medicine (NCCAM), part of the National Institutes of Health (NIH).\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Other options for dealing with menopausal hot flashes are reviewed, along with their shortcomings. However, this section was brief and could have discussed many other options which have known benefit. ", "answer": 1}, {"article": "But two days later, most patients were satisfied.\n\"Emergency nurses and doctors need a variety of pain-relieving options when treating patients, given the concerns around opioids such as morphine, which carry the risk of addiction when used long-term,\" Cohen said in a university news release.\nOverall, nearly 83 percent of acupuncture-only patients said they would probably or definitely repeat their treatment, compared with about 81 percent in the combined group, and 78 percent who took painkillers alone.\nMONDAY, June 19, 2017 (HealthDay News) -- Acupuncture is a safe and effective alternative to pain medications for some emergency room patients, a new study reports.\nThe study -- billed as the world's largest randomized, controlled trial of acupuncture in the emergency department -- included 528 patients.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explains that the study compared the result of using acupuncture versus the use of painkillers versus the use of both in tandem, so it is clear that there are alternatives available for analgesia.\nHowever, the three conditions\u2013acute low back pain, migraines or ankle sprains\u2013are all treated differently and have a host of known appropriate strategies. For example, rest for back pain, triptan medications for migraine, ice and elevation for sprain. We think this deserved a mention in the story.", "answer": 1}, {"article": "Dry eye in the Beaver Dam Offspring Study: prevalence, risk factors, and health-related quality of life.\nJerry St. Peter, Vice President and Head of Sun Ophthalmics, added: \"A key strategic imperative for our ophthalmic business is to participate in the rapidly growing, underserved, and dynamic Dry Eye market, which is expected to reach $5 billion by 2020.\nThe demonstration of efficacy by Seciera\u2122 at 12 weeks is earlier than other drugs approved for dry eye in the same class.\nBased on published data, the efficacy and safety endpoints in these trials compared favorably to other formulations of cyclosporine A with the advantage of early onset.\nNational Health and Wellness Survey: The Global Health and Wellness Report - 2014.http://www.kantarhealth.com/docs/ebooks/global-health-and-wellness-report.pdf.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does refer to \u201cother approved drugs in the category\u201d but it provides no information about what other approaches might be useful in dealing with dry eyes. The National Eye Institute, for example, offers several approaches to dealing with the problem including prescription and over-the-counter medications, as well as surgical procedures.", "answer": 0}, {"article": "But are they benefiting from acupuncture itself, or just getting a placebo effect?\nAfter all, the goal of what they call integrative medicine, which combines conventional and alternative treatments like acupuncture, is to harness the body\u2019s power to heal itself.\n\u201cThe thing that can\u2019t be argued in my study is the duration of the effect.\nWhen the German researchers tracked how much pain medicine the patients used, they detected a noticeable difference between real acupuncture and the sham treatment.\nRather than proving that acupuncture does not work, in other words, the study may suggest that it works even when administered poorly.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "      \n\n\n \n\n \nThe article mentions several alternative treatments for the three conditions discussed in the article\u2014and, in the online version at least, the study links can lead readers to further information.\n\u00a0\n ", "answer": 1}, {"article": "In an earlier study, Elkins and his Baylor colleagues showed that hypnosis dramatically reduced hot flash and night sweat frequency in breast cancer patients with treatment-related symptoms.\n\u201cThere is certainly a need for non-pharmacologic treatments for hot flashes and night sweats,\u201d says North American Menopause Society (NAMS) Executive Director Margery Gass, MD.\nThey are linked to declining estrogen levels, but it remains unclear just why the sudden lack of estrogen sends the body into thermal mayhem, and why some women are more affected than others.\nOnly hormone therapy, which many women can\u2019t take or want to avoid, is more effective for treating the most common symptom of menopause, says researcher Gary R. Elkins, PhD.\nThe women were also given a recording of the hypnotic induction, and they were asked to practice self-hypnosis at home daily.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions hormone therapy as an effective treatment with risks, but does not go further into detail. The researcher is quoted as saying in the article, \u201cOnly hormone therapy, which many women can\u2019t take or want to avoid, is more effective for treating the most common symptom of menopause.\u201d But how much more effective is hormone therapy? And what exactly are the risks? The researcher also adds that therapeutic hypnosis works \u201cas well or better\u201d than antidepressants or other non-hormonal therapies, but it would have helped if the story specifically described the non-hormonal alternatives.\nThe LA Times article gave a better description of the other complementary/alternative medicine treatments.", "answer": 0}, {"article": "\u201cTraining peer counselors to do phone counseling is an effective, low-cost and non-stigmatizing way for new moms to get the help they need.\u201d\n\nParticularly for first-time mothers, postpartum depression can be hard to distinguish from the stress and fatigue that come with caring for a new infant around the clock, Letourneau said.\nWhile all of the mothers were depressed at the start of the study, at mid-point only 32 percent were at risk for depression, and this declined to 15 percent at the end.\nOn average, the women spoke more than eight times and the calls typically lasted about 38 minutes, the researchers reported in the Journal of Advanced Nursing.\nEven though the small study had several women drop out and lacked a control group of moms who received different treatment, the results are consistent with previous research that has proven peer counseling works, said Dr. Ruta Nonacs, a psychiatrist at the Center for Women\u2019s Mental Health at Massachusetts General Hospital in Boston.\nFurthermore, at mid-point, 60 percent of the mothers had low depression scores; this percentage rose to 75 percent at end.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story implies that the major alternative for managing PPD is in-person counseling from a mental health professional. It also notes that many of the women had previously received treatment with medication, suggesting that this is an option for PPD.", "answer": 1}, {"article": "THURSDAY, May 9, 2013 (HealthDay News) -- Scientists report positive results in early testing of a wireless pacemaker that's placed in the heart instead of being connected to it via wires from the upper chest.\nIt's also not clear when the pacemaker may be publicly available, and its cost is unknown.\nIt's only been implanted in a few dozen people who were studied for a matter of months, limiting information about its long-term use and safety.\nStill, he said, the new device will probably be more expensive than other pacemakers, and may pose special risks of its own.\nIf the old device is left in place, it is not known what the long-term effects of this will be.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are other wireless pacing devices being developed, yet the story offered no information about these alternatives, or how this new device might compare.\u00a0 What sets it apart?\u00a0 Why is this newsworthy?", "answer": 0}, {"article": "Denver, CO. (February 17, 2016) - U.S. children are not consuming enough vegetables, resulting in an inadequate intake of key nutrients, including potassium and dietary fiber, which are important for growth, development and overall health.\nNutrient Density and the Cost of Vegetables from Elementary School Lunches.\nIn fact, a study of elementary school students demonstrated that students are not consuming the majority of vegetables offered to them in school lunches.\nToday, as the largest vegetable commodity board, the USPB is proud to be recognized as an innovator in the produce industry and dedicated to positioning potatoes as a nutrition powerhouse--truly, goodness unearthed.\nBased in Denver, Colorado, the USPB represents more than 2,500 potato growers and handlers across the country.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are many comparisons in the study but the release mentions none of the many other dietary sources of potassium and fiber.", "answer": 0}, {"article": "\"This smartphone reader has the potential to improve access and speed up healthcare delivery,\" said Li.\nThe smartphone reader, which includes a portable device, takes a photo of 96 sample wells at once and uses a computer program to carefully analyze color to determine positive or negative results.\nIf they send results off to a lab in a distant city, the doctors sometimes must wait for days -- by which time the infection may have become widespread.\nThe researchers tested the device, which is about the size of a hand, with 771 patient samples at Hospital of University of Pennsylvania and found that it provided false positives only about one percent of the time (was 97. to 99.9 percent accurate).\nThe work could lead to faster and lower-cost lab results for fast-moving viral and bacterial epidemics, especially in rural or lower-resource regions where laboratory equipment and medical personnel are sometimes not readily available.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "As noted above, this test was done by the device\u2019s developers under ideal lab conditions. The comparisons to existing devices and speculation about relative effectiveness should wait until field tests are done.", "answer": 0}, {"article": "\"These findings support increasing fruit and vegetable consumption as a means of preventing premature death,\" write researcher Chaoyang Li, MD, PhD, of the CDC and colleagues in the Archives of Internal Medicine.\nAlthough previous studies have suggested eating more fruits and vegetables is associated with a lower risk of disease, studies have not shown that taking beta-carotene supplements reduces the risk of dying from heart disease or cancer.\nResearchers found that people with the highest levels of the antioxidant alpha-carotene in their blood had a 39% lower risk of death from any cause, including heart disease and cancer, than those who had the lowest levels of the antioxidant during the 14-year study.\nThe study shows that eating foods rich in antioxidants, like vegetables and fruits, fights disease and may prolong life.\nAlpha-carotene is part of a group of antioxidants known as carotenoids, which also includes beta-carotene and lycopene.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nOther than saying that other studies failed to find benefits from beta-carotene supplements, the story fails to discuss what is known about how alpha-carotene might compare to other components of foods.", "answer": 0}, {"article": "For more information, visit www.uth.edu.\nLooking back, the experience was even better than I was expecting, and I hope to see nanoparticle therapy advance into an option for anyone diagnosed with prostate cancer in the future.\u201d\n\nThe gold nanoparticles were invented by Naomi Halas, the head of Rice University\u2019s Laboratory for Nanophotonics.\n\u201cThis therapy could be life-changing for men diagnosed with prostate cancer and I\u2019m honored to be among the first doctors the U.S. Food and Drug Administration approved to put it to the test,\u201d said Steven Canfield, M.D., chair of the division of urology at McGovern Medical School at UTHealth, who recognized the possibility of the nanoparticles to treat prostate cancer and helped developed the trial to test the theory.\nI am excited as we continue tracking the progress of this groundbreaking improvement to prostate cancer care.\u201d\n\nDoug Flewellen, the first patient in Texas to receive the new method of care, says for him, the procedure was a no-brainer.\nThe fusion of MRI and ultrasound imaging technology that we use to accurately identify and diagnose the cancer, combined with the extreme precision of the gold nanoshells in targeting the diseased cells, allows us to be incredibly accurate at obliterating them.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "We learn about other alternatives:\u00a0 \u201cTreatment options have traditionally included radical prostatectomy, which is the removal of the prostate gland and some of the tissue around it, radiation therapy and cryotherapy, among others. These methods carry the potential to have a negative impact on urinary function and sexual performance.\u201d\nand\n\u201cThe side effects of current prostate cancer treatments can be extremely traumatic. This new technology holds the potential to eliminate those life-altering effects, while still removing the cancer tissue and reducing hospital and recovery time.\u201d\nWhile this is useful information it is inadequate. Impotence and urinary incontinence are often the downstream consequences of prostate cancer treatment but how did the rates of these adverse effects compare to the gold nanoparticle treated group?\u00a0 We don\u2019t know.\nIn addition, the other treatment methods also carry the potential of curing cancers. We can\u2019t say the same for the new technology.", "answer": 0}, {"article": "Researchers report these findings in the journal Archives of General Psychiatry.\n\"What I tell people is: If they\u2019re worried about their thinking abilities, that they should make an appointment with a neuropsychology or a neurologist to get an evaluation,\" Brinkman says.\n\"The way we diagnose Alzheimer\u2019s disease is by evaluating the behavior and the risk factor medical profile, not by looking at biological markers at this point.\"\nThe results from the study suggest that beta-amyloid is a much earlier predictor of Alzheimer's disease than tau, which supports the hypothesis that beta-amyloid accumulation in the brain occurs first in the course of the disease.\nAs scientists gain more insight into predicting Alzheimer's, aging adults may struggle with the question of whether they want to know their risk, especially since there's still no cure.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "That independent expert added this important reminder:\n\u201cWhat I tell people is: If they\u2019re worried about their thinking abilities, that they should make an appointment with a neuropsychology or a neurologist to get an evaluation,\u201d Brinkman says. \u201cThe way we diagnose Alzheimer\u2019s disease is by evaluating the behavior and the risk factor medical profile, not by looking at biological markers at this point.\u201d", "answer": 1}, {"article": "Those who received fluorouracil and folinic acid chemotherapy had lived an average of 23 months.\nTUESDAY, Sept. 7, 2010 (HealthDay News) -- Pancreatic cancer patients undergoing chemotherapy after surgery don't see improved long-term survival with the drug gemcitabine, compared with patients receiving a chemotherapy regimen consisting of fluorouracil and folinic acid, new research suggests.\n\"Really in the scope of things following major surgery, both are fairly tolerable regimens, and this study doesn't necessarily change the pattern of use in terms of choosing post-operative therapy,\" Choti said.\n\"In conclusion, gemcitabine did not result in improved overall survival compared with fluorouracil plus folinic acid in patients with [surgically removed] pancreatic cancer,\" the authors concluded in their report.\n\"But the point is that pancreatic cancer is a terrible disease, and really just a minority of patients are candidates for surgery.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story details the comparison between two approaches. It wasn\u2019t exactly clear about whether either was \u201cnew\u201d vs \u201cexisting,\u201d but, in fact, they are both existing approaches, with the one positioned as the \u201cnewer\u201d approach, gemcitabine, currently the preferred agent according to the JAMA editorial. While we would have loved more clarity about the reason why the study compared these two approaches, overall, the comparative nature and tone of the story are clear and seem appropriate.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Tens of thousands of kids may benefit from cholesterol-lowering medication, but no one would know because screening guidelines exclude too many children, U.S. doctors said Monday.\nYet among the kids without heart disease in their family, the percentage of children who might benefit from treatment was closer to two percent than to one, meaning that family history didn\u2019t seem to make a difference.\n\u201cUnfortunately, there is no evidence that starting a ten-year-old on cholesterol-lowering drugs will prevent heart disease 40 years later,\u201d said Dr. Michael L. LeFevre, a member of the task force.\nFor example, the U.S. Preventive Services Task Force, a federal expert panel, currently doesn\u2019t recommend routine cholesterol screening in any children.\nNeal said treating youth with cholesterol-lowering drugs, the so-called statins, would curb the risk that they went on to develop heart problems in middle age.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story includes an expert who argues against universal cholesterol screening for children. It also points out that lifestyle changes would be part of the treatment considered for children who have elevated cholesterol.", "answer": 1}, {"article": "GALVESTON, Texas -Researchers from The University of Texas Medical Branch at Galveston found that testosterone replacement therapy may slow disease progression of chronic obstructive pulmonary disease.\n\"However, we are the first to conduct a large scale nationally representative study on this association.\"\nLow testosterone is common in men with COPD and may worsen their condition.\nThe paper is currently available in Chronic Respiratory Disease.\nThe goal of the study was to find out whether testosterone replacement therapy reduced the risk of respiratory hospitalizations in middle-aged and older men with COPD.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are a range of treatments for COPD, none of which are mentioned in this release.", "answer": 0}, {"article": "Newswise \u2014 Baltimore, Md.\n\u201cBy continuing to develop a comprehensive thermal oncology program, we are giving patients more effective treatment options and therefore another reason to hope for better outcomes.\u201d\n\n\u201cThe Maryland Proton Treatment Center has achieved another milestone by becoming the first center to offer both deep-thermal therapy and proton therapy,\u201d says E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs at UM Baltimore and the John Z. and Akiko K. Bowers Distinguished Professor and dean at UMSOM.\nThe acquisition of the deep-tissue thermal therapy system was made possible by donations from Jack and Emily Howell and the Middendorf Foundation, Inc.\n\n\u201cWithin the Department of Radiation Oncology and throughout our cancer center, we strive to make every available tool in the cancer-fighting toolbox available to our patients,\u201d says William F. Regine, MD, FACR, FACRO, the Isadore & Fannie Schneider Foxman Endowed Chair and Professor of radiation oncology at UMSOM and chair of radiation oncology at UMGCCC.\n\u201cWe are very pleased to be able to offer deep-tissue thermal therapy, which can be combined with standard radiation therapy as well as proton-beam therapy to enhance the cancer-killing effects of the radiation,\u201d says Zeljko Vujaskovic, MD, PhD, a professor of radiation oncology and director of the Division of Translational Radiation Sciences (DTRS) in the Department of Radiation Oncology at the University of Maryland School of Medicine (UMSOM).\n\u201cEarly research suggests that adding thermal therapy to proton-beam therapy may be associated with an even greater benefit than when combined with standard radiation therapy, and we are excited to be at the forefront of making this combination therapy available to cancer patients,\u201d says Dr. Vujaskovic, an internationally recognized expert in hyperthermic oncology.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "As mentioned above, a physician quoted in the news release states that the combined therapy might have an \u201ceven greater benefit\u201d than when proton therapy is combined with standard radiation therapy, but that is the only comparison made. The news release does not mention any more traditional methods of cancer treatment, such as surgery, chemotherapy or standard radiation alone nor how they compare to the new combination. ", "answer": 0}, {"article": "Compared with the 35 stroke patients who got clot-dissolving medicine alone, the 35 who got the two-pronged treatment were nearly twice as likely to regain some neurological function after three days. Imaging results revealed that for those who got both treatments, 100% of the brain tissue initially affected by a clot had blood flowing to it after 24 hours. Among the subjects who only got alteplase, the median level of restored blood flow was 37%.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job discussing the different methods of treatment for stroke, and the disparity in the results seen in various studies.", "answer": 1}, {"article": "\"Compared to childhood vaccines, people would [probably] think 55% is not too impressive, because many childhood vaccines are in the range of 80% to 90% [effective],\" says researcher Hung Fu Tseng, PhD, MPH, a research scientist at Kaiser Permanente Southern California.\nAnother new study, published in the American Journal of Preventive Medicine, finds that by 2008, less than 7% of U.S. adults aged 60 and older had gotten the vaccine, which has been available just since 2006.\nGetting the vaccine makes it less likely that adults will get the painful rash that can occur when the varicella zoster virus, which causes childhood chickenpox, reactivates to cause shingles.\nHowever, he tells WebMD, the 55% risk reduction ''is pretty high compared to other adult vaccines.\"\nThe associated pain can last months or even years.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nAs this story points out, less than 7 percent of people age 60 or older have gotten the shingles vaccine (while many more in that group have gotten flu, pneumonia and other vaccinations). The story should have addressed the reasons that so many primary care physicians and their older patients have decided that deferring vaccination against shingles is a reasonable option. The shared decision-making option of NOT\u00a0being vaccinated was not given a forum here.\u00a0 Instead, the line:\u00a0 \u201cOnce patients learn about it, most are agreeable.\u00a0 \u201cEverybody wants it, because they have heard all the horror stories,\u201d (said UCLA\u2019s Dr. Galler.)\u201d\n", "answer": 0}, {"article": "Dec. 2, 2011 (Chicago) -- An experimental approach in which penile nerve tissue is frozen to knock out overactive nerves helped men with premature ejaculation last three times longer.\nIts supporters say the technique, or a similar one involving heat therapy, could someday become a standard treatment for the condition.\nThe findings were presented here at the annual meeting of the Radiological Society of North America.\nAlso unknown: whether men would opt for the treatment.\nA time to ejaculation of more than two minutes is normal, he tells WebMD.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions antidepressants, anesthetic ointments and cream, and behavioral therapies as alternatives for PE.", "answer": 1}, {"article": "\u2022 Delayed surgery with long-course (25x2 Gy) radiotherapy followed by surgery after 4-8 weeks.\nThe study now presented in The Lancet Oncology is based on the claim that the adverse effects of rectal cancer treatment can be reduced by administering more but lower doses of radiation for a longer time, or by increasing the interval between radiotherapy and surgery.\n\"The results of the study will give rise to improved therapeutic strategies, fewer complications with a sustained low incidence of local recurrence, and better survival rates for rectal cancer patients,\" says Professor Martling.\nIt also showed that there is no difference between long-course and short-course radiotherapy other than that the former considerably lengthens the time for treatment.\n\"Back then we showed that preoperative radiotherapy reduces the risk of local recurrence by over 50 per cent for patients with rectal cancer,\" says principal investigator Anna Martling, senior consultant surgeon and professor at Karolinska Institutet's Department of Molecular Medicine and Surgery.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The purpose of this study was to compare the timing of existing standard\u00a0treatment modalities. Complementary and alternative treatments are beyond the scope of the news release.", "answer": 1}, {"article": "We know early intervention is extremely important.\nTUESDAY, Feb. 22, 2011 (HealthDay News) -- By analyzing patterns in the brain's electrical activity, researchers say they've been able to assess autism risk in children as young as 6 months of age.\nThe technology has been around for awhile -- developed in the late 1920s, it has been used for more than 60 years to detect seizures in epileptics.\n\"In this study, we have taken the first step in showing that there is definitive information in the electrical signals measured by EEG to distinguish normal controls from infants at high risk for developing autism,\" Bosl said.\n\"My hope is we would have a simple way of measuring brain activity in every child and see the patterns emerging that might track autism characteristics,\" Bosl said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "When reading this story, one starts to think that doctors have no idea how to diagnose autism, and yet autism diagnoses clearly are on the rise. (Prevalence being on the rise is a matter of debate.) How this diagnostic approach compares to existing methods or emerging methods, such as the MRI scan described in the December study, remain a mystery.\u00a0Even a brief mention of MRI or behaviors that parents and pediatricians might observe and refer for additional testing would have been helpful.", "answer": 0}, {"article": "Jan. 4, 2013 -- A new study from Australia may offer a new way of identifying people at risk of glaucoma years before vision loss happens.\nNone of the participants had glaucoma when they entered the study.\nCompared with the group as a whole, those people who were diagnosed with the eye disease during the following decade were older, had higher blood pressure, and were more likely to be female.\nIf caught early, though, there are medications and procedures that may help treat glaucoma.\nThe disease involves damage to the optic nerve, which relays images from the retina to the brain.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Again, we\u2019ll give the story the benefit of the doubt for at least nodding in the direction of other alternatives.\u00a0 For example:", "answer": 1}, {"article": "\"I think [men] would use it more than is realized,\" said Alukal, who was not involved in the new research.\nThis is the first time that a combination of testosterone and a synthetic progestin called Nestorone has been tested as a gel that could be applied topically.\nThe study, conducted in conjunction with the University of Washington, involved 56 men who were assigned to receive one of three types of gels: one gel containing both testosterone plus a gel containing one of two doses of the synthetic progestin; or a gel containing testosterone on its own plus a \"placebo\" gel with no progestin.\nAlthough men have sometimes received a bad rap for not being willing to assume responsibility for birth control, Dr. Joseph Alukal, an assistant professor of urology at NYU Langone Medical Center, in New York City, thinks this reputation may be somewhat undeserved.\nBecause the new study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions condoms and vasectomy as the other contraception options for men. It would have been nice to see some data on how effective these are at preventing unwanted pregnancy and a comparison with the gel tested here.", "answer": 1}, {"article": "Check out more than one clinic and make sure you know what it defines as a \u201csuccess\u2019\u2019 \u2014 a viable transferring of an egg leading to a baby, or just a safely thawed egg.\n\u25a0 After a woman\u2019s mid-30s, her eggs may not be of high enough quality to produce a baby.\n\u25a0 The \u201csuccess\u2019\u2019 rates of egg freezing may vary widely from one fertility center to another.\nDiscarding an unused embryo, which has the potential to develop into a baby, has weightier implications for many than discarding unused eggs.\n\u25a0 There may be significant religious and ethical advantages to freezing eggs as opposed to embryos.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Not applicable. The story didn\u2019t really compare egg freezing with other fertility approaches, but that\u2019s OK because it really focused on questions about the egg freezing trend. The story did touch on several advances \"nudging the use of egg-freezing forward\" and on several methods to test the genetic viability of both eggs and embryos. ", "answer": 2}, {"article": "The researchers noted that thousands of people in this final group were participants in the Women\u2019s Health Initiative, a long-term study sponsored by the National Heart, Lung and Blood Institute in the U.S. Earlier reports based on data gathered by the Women\u2019s Health Initiative found that calcium and vitamin D supplements were associated with a lower risk of fractures, but only for women who took hormone therapy after menopause. To get a clearer picture of the direct link (if any) between supplements and fracture risk, Zhao and his colleagues opted not to include data from women on hormone therapy.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story references getting calcium from one\u2019s diet and getting vitamin D from sun exposure.", "answer": 1}, {"article": "Simmons said the results did not mean all children with elevated cortisol levels would go on to develop behavioural problems or mental illness, with many other social, environmental and genetic factors also involved.\n\u201cLooking at hair tells us new things.\u201d\n\nThe research is part of the ongoing Murdoch Childrens Research Institute\u2019s Childhood to Adolescence Study following a cohort of 1,200 children in and around Melbourne and was published in the journal, Psychoneuroendocrinology.\n\u201cWhat\u2019s less commonly understood is that beyond poor mental health, it can also be associated with the development of other illnesses such as diabetes, obesity and cholesterol issues, because cortisol is also central to glucose availability, blood pressure and immune function, so identifying these children is important.\u201d\n\nWhile blood or saliva tests could be used to detect cortisol levels, these methods were sometimes problematic, especially in children, Simmons said.\n\u201cHowever, hair samples are not only easier to obtain, but provide us with a picture of total cortisol throughout the system across many months rather than just at a point in time,\u201d Simmons said.\nThe greater number of traumatic events a child had experienced, such as divorce, injury, moving house, severe illness or the death of a family member, the higher the hair cortisol concentrations were, the researchers found.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Alternatives to testing cortisol levels in hair were mentioned \u2014 as in saliva and blood.\u00a0Alternatives regarding ways to identify children at risk would seem to abound and likely explain much more than any lab test ever will. For example,\u00a0kids who come from homes where they aren\u2019t provided with adequate food, from parents with mental health problems, etc. (sociological/environmental variables). We\u2019ll give the benefit of the doubt here but it\u2019s really only a partial Satisfactory.", "answer": 1}, {"article": "ASTRO publishes three medical journals, International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment.\nOur trial confirms that SBRT may be preferable to other treatment approaches for newly-diagnosed cases of prostate cancer, including more aggressive disease.\u201d\n\nThe abstract, \u201cFive-Year Outcomes from a Multi-Center Trial of Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer,\u201d will be presented in detail during a scientific session at ASTRO\u2019s 58th Annual Meeting at 7:45 a.m. Eastern time on Monday, September 26, 2016.\nThe technique has become the standard of care for many non-surgical lung cancer patients, as it limits exposure to the heart and surrounding lungs.\nSpecifically in the low-risk group, the five-year RFS rate was 97.3 percent, which is superior to the 93 percent historical comparison DFS control rate (p = 0.014).\nAlthough prostate tumors generally respond well to radiation therapy (RT), the possibility of radiation exposure to healthy tissue in the genitourinary (GU) and gastrointestinal (GI) systems can be of concern.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Some of the men in the study had a low-risk form of prostate cancer, which might have made them eligible for active surveillance rather than surgery. That option is not discussed in the news release. As mentioned in the quantifying benefits section, the news release does mention that this type of radiotherapy was compared with standard radiotherapy, although it was not directly studied.", "answer": 0}, {"article": "This is the experience many women have.\nChanges like this can make a big difference, says Dr. William Camann, the director of obstetric anesthesiology at Brigham and Women's Hospital in Boston and one of the pioneers of the procedure in the U.S. At Brigham and Women's, their version of the family-centered cesarean is called the gentle cesarean.\nThe techniques are relatively easy and the main goals simple: Let moms see their babies being born if they want and put newborns immediately on the mother's chest for skin-to-skin contact.\n\"It is the first time we have really done anything innovative or creative with changing the C-section procedure in years,\" she says.\nFamily-centered cesareans are a relatively new idea in the U.S., and many doctors and hospitals have no experience with them.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The piece compared other alternatives to the family-centered cesarean \u2014 mainly, the vaginal delivery and the traditional C-section. It mentioned that in a typical C-section, a closed curtain shields the operating field and the baby is quickly whisked away after birth.", "answer": 1}, {"article": "Second induction for VYXEOS-treated patients was 100u/m2 on days 1 and 3 and the control arm was cytarabine 100mg/m2/day by continuous infusion for 5 days and daunorubicin 60mg/m2 on days 1 and 2 (5+2).\nFor a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Celator's Form 10-K for the year ended December 31, 2014, subsequent reports on Form 10-Q and 8-K, and other filings by the company with the U.S. Securities and Exchange Commission.\nThe Company estimates that nearly 70 percent of AML patients are over the age of 60, and approximately 75 percent are intermediate or high risk.\nThe percentage of patients alive 24 months after randomization was 31.1% on the VYXEOS arm compared to 12.3% on the 7+3 arm.\nThe hazard ratio (HR) was 0.69 (p=0.005) which represents a 31 percent reduction in the risk of death versus 7+3.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release gets a satisfactory rating for devoting plenty of space to describing the new drug\u2019s advantages in terms of survival advantage over the comparator, or current standard of care. Are there other treatments that are useful in treating high risk AML? \u00a0We never get that information. This would have been much stronger if a statement about\u00a0the studies of the non-liposomal formulation of the drug was given.", "answer": 1}, {"article": "\u201cWhat does it mean, to improve metabolic health?\n\u201cWe are filling a space by combining natural compounds with scientific validation.\u201d\n\nThe active ingredients in Basis are nicotinamide riboside, a substance that makes NAD and is found in traces in many foods such as milk, and pterostilbene, an antioxidant found in blueberries.\nMost of them have no scientific basis, and you don\u2019t know what you are getting.\u201d\n\nGuarente was involved in several other efforts to develop antiaging medicines that did not pan out.\nA leading biologist at the Massachusetts Institute of Technology, with backing from five scientists who are Nobel prize recipients, is wading into the murky world of dietary supplements with a new antiaging pill that is said to restore muscle tissue, improve brain function, and increase energy levels by improving \u201cmetabolic health.\u201d\n\nLeonard Guarente, one of the best-known antiaging researchers in the region, and the roster of eminent scientists have formed Elysium Health, which on Tuesday will debut its first product, a pill called Basis.\nIf Elysium Health were developing Basis as a drug, it would have to conduct clinical trials with humans to prove that it works, and the Food and Drug Administration would have to sign off on its scientific evidence before it could be sold as medicine.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We give the story credit for mentioning that each of the active ingredients in Basis are already available in separate pills. But since the story is about a company that claims to offer healthier aging in a pill, we thought it was especially important to mention non-chemical approaches that are also associated with healthy aging, such as a good diet and exercise. The story didn\u2019t do that.", "answer": 0}, {"article": "WASHINGTON (Jan. 11, 2015) -- Symptoms of mild to minimal depression were associated with early indicators of heart disease in a research letter published today in the Journal of the American College of Cardiology, but the study found regular exercise seems to reduce the adverse cardiovascular consequences of depression.\nIn addition, as many as 20 percent of people hospitalized with a heart attack report symptoms of depression, while patients with heart disease have three times the risk of developing depression compared to the general population.\nDepression has been linked to an increased risk of heart disease and other physical ailments, and depression is commonly associated with worse outcomes for patients with heart disease and other conditions.\nThe American College of Cardiology is a 49,000-member medical society that is the professional home for the entire cardiovascular care team.\nResearchers used questionnaires to evaluate patients for depression and levels of physical activity.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The study is not a traditional treatment-versus-control study, rather it studies possible interaction effects between physical activity and depression for different cardiovascular disease indicators. A discussion of alternative treatments is not particularly relevant.", "answer": 2}, {"article": "* Drug being developed by Pfizer, Elan and Johnson & Johnson\n\nLONDON, March 1 (Reuters) - New imaging technology suggests an experimental drug for Alzheimer\u2019s reduces clumps of plaque in the brain by around 25 percent, lifting hopes for a medicine that disappointed in clinical tests two years ago.\nThe treatment was generally well tolerated, although two patients on the highest dose had transient brain swelling.\nThe effect was similar with three different doses of the drug, they reported in the journal Lancet Neurology.\nBut a rival school blames toxic tangles caused by an abnormal build-up of the protein tau.\nThe new study, which only involved 28 patients, is modest fillip.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0There was no discussion of other approaches to treating Alzheimer\u2019s disease.", "answer": 0}, {"article": "The study appears online in the Journal of Clinical Investigation.\nIf studies show the same thing in humans, the heart hormone may hold the key to an effective weight loss treatment, says researcher Sheila Collins, PhD, of Sanford-Burnham Medical Research Institute in Orlando, Fla.\n\u201cThese hormones are involved in fluid regulation, but we showed in this study that they also play a role in breaking down fat,\u201d she says.\nAdults don\u2019t have much brown fat, but a new study suggests that hormones produced by the heart just might help them make more.\nFeb. 6, 2012 -- You may have heard about brown fat -- a unique type of fat that acts like a furnace in the body to burn calories instead of storing them as excess weight.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not discuss evidence-based strategies for weight loss, such as behavioral weight loss programs. It could also have mentioned other new research which shows, at least in mice, that exercise helps turn white fat brown.\n\u00a0", "answer": 0}, {"article": "The chemo failure was the latest in a string of personal setbacks.\n\"We took a disease where nothing really works for any length of time and we've given her a year of life, and hopefully much more, where she's been much better,\" Hyman, her oncologist, says.\nOur series is produced with member station WNYC, and with Ken Burns Presents: Cancer: The Emperor of All Maladies, which will air on PBS starting March 30.\nShe's been in the clinical trial for a year now, and continues to take Zelboraf (or vemurafenib generically) daily.\nCalled a basket trial, the study is designed to include people whose tumors have the same kind of genetic fingerprint regardless of where in the body the tumors are found.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "At least on one alternative is mentioned, e.g. \u201ctraditional chemotherapy\u201d (Temodar/temozolomide), so we\u2019ll rate the story satisfactory. However, it\u2019s important to note that radiation therapy is not discussed at all, and it is part of the standard of care alongside chemotherapy and surgery. There are other potential alternatives, too, including drugs that limit blood flow to cancerous tissue and immunotherapy techniques (aka \u201ccancer vaccines\u201d).", "answer": 1}, {"article": "Boutot and Bertone-Johnson suggest that more prospective studies of their findings are warranted, including studies that compare soy-based and non-soy vegetable proteins.\nFor a woman with a 2,000 calorie per day diet, the authors explain, this is equal to three to four servings of such foods as enriched pasta, breakfast cereal, tofu and nuts, or about 32.5 grams a day.\n\"A better understanding of how dietary vegetable protein intake is associated with ovarian aging may identify ways for women to modify their risk of early onset menopause and associated health conditions,\" write first author and then-graduate student Maegan Boutot, with her advisor, professor Elizabeth Bertone-Johnson.\nFew studies have evaluated how protein intake is associated with menopause timing, they add, and to their knowledge this is the first to look specifically at early menopause.\nBoutot and Bertone-Johnson add, \"Though relatively few women in our study consumed very high levels of vegetable protein and our power for analyses of more extreme intake levels was limited, women consuming 9 or more percent of their calories from vegetable protein had a hazard ratio of 0.41 (95 percent confidence interval = 0.19-0.88)\" compared to those eating less than 4 percent.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There don\u2019t seem to be any common strategies to prevent early menopause, but the news release could have delved into alternative potential causes such as autoimmune disease, genetics and cancer treatment.", "answer": 2}, {"article": "Svetsky cautioned that weight gain from eating large amounts of dark chocolate would counteract any benefits on blood pressure.\nVolunteers for the study ate just over six grams of dark chocolate daily for almost five months \u2014 one square from a German chocolate bar called Ritter Sport, equal to about 1\u00bd Hershey's Kisses.\nUniversity of Cologne researcher Dr. Dirk Taubert, the study's lead author, said the blood pressure reductions with dark chocolate were small but still substantial enough to potentially reduce cardiovascular disease risks, although study volunteers weren't followed long enough to measure that effect.\nChocolate-makers have embraced these findings and have developed new ways to satisfy the sweet tooth and curb the guilt by introducing more varieties of dark chocolates, fortifying them with vitamins and anti-oxidants, reports Miller.\n\"The nibs don't contain any sugar and are full of antioxidants.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This report did not mention other methods for obtaining comparable reductions in blood pressure such as adhering to the DASH diet http://dashdiet.org/, exercise http://www.nlm.nih.gov/medlineplus/ency/imagepages/19233.htm, or medications.", "answer": 0}, {"article": "WASHINGTON -- A new study shows patients taking the anticlotting drug Plavix along with a type of drug used to block stomach acid have an increased risk of a subsequent hospitalization for heart trouble.\n\nThe study, which is being published in this week's Journal of the American Medical Association, adds to other recent studies that suggest proton pump inhibitors like Aciphex, Nexium, Prevacid and Protonix reduce the effectiveness of Plavix, which is marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis SA.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned another class of medications, H2 inhibitors, that could be considered instead of proton pump inhibitors (PPI) for patients for whom guidelines strongly recommend the use of Plavix.\n\u00a0It is interesting to know that while several brand name PPI\u2019s were mentioned in the beginning of the story, omeprazole (Prilosec) was not listed. \u00a0And at the end of the story, only the brand names for H2 blockers were listed. \u00a0It would have been better to list both the brand and generic names.\u00a0\u00a0 We think that\u2019s a better practice in health journalism.\u00a0\u00a0 ", "answer": 1}, {"article": "\"Cluster headache is a rare, debilitating and difficult to treat disorder with few effective acute therapies,\" Dr. Stephen Silberstein, director of the headache center at Jefferson University in Philadelphia, said in a statement.\nThere aren\u2019t many specific treatments but they include the migraine drug sumatriptan, delivered via auto-injector, and inhaled oxygen.\nThe device is a vagus nerve stimulator and it\u2019s not entirely clear how it works.\nBoth approaches are limited \u2014 it\u2019s not safe to use the injection more than twice a day \u2014 and inconvenient.\nThe idea is to disrupt signals that run along the vagus nerve, a giant nerve that runs from the brain all the way to the colon.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article did mention that there are \u201ccommonly prescribed treatments,\u201d and it named some of them.", "answer": 1}, {"article": "He cites clinical data showing stroke and death rates of more than 10 percent within one year among those getting stents -- not much different from the results in the same study for surgery.\nMeanwhile, patient demand for stents is growing.\nDr. Alberts and some other doctors say that both procedures are done too often and that the advent of carotid stenting seems to be making the problem of over-treatment worse.\nEveryone agrees that clinical evidence about the relative risks in different types of patients is only beginning to emerge.\n\"My memory and energy levels are better now,\" she said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Mentions endarterectomy having \ncomparable outcome; single mention of medical treatment with no mention of outcome; no data for watchful waiting. Therefore, \nincomplete.", "answer": 0}, {"article": "The exams didn\u2019t become more embarrassing or less comfortable, either.\nThe new report shows that during the two years, those same people had increasing confidence in their skills, with no increase in embarrassment or discomfort.\n\u201cWe are now trying to see if people can learn, perform and have continuing confidence without the physician reinforcement,\u201d said Robinson.\n\u201cFor example, men can\u2019t see the top of their bald heads or the back of their necks or ears,\u201d Robinson said.\nAmong people who received the skin exam training, the researchers found a steep increase in their confidence at performing skin exams between the start of the study and four months later.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Early on in the news story, the writer mentions that without\u00a0a partner to assist in skin examinations, patients are told to use mirrors to check out hard-to-reach body parts.", "answer": 1}, {"article": "Drs.\n\"Our study suggests that bupropion is the best initial choice of antidepressant for the vast majority of Americans who have depression and are overweight or obese,\" said study leader David Arterburn, MD, MPH.\n\"We found that bupropion is the only antidepressant that tends to be linked to weight loss over two years,\" Dr. Arterburn said.\nResearch at Group Health points to bupropion (Wellbutrin) as first choice for overweight and obese patients with depression\n\nSEATTLE--Group Health researchers have found that bupropion (marketed as Wellbutrin) is the only antidepressant that tends to be linked to long-term modest weight loss.\nBut in some cases, an overweight or obese patient has reasons why bupropion is not for them--like a history of seizure disorder--and it would be better for them to choose a different treatment option.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "In essence, the purpose of this study was to compare alternatives and report their effect on weight gain or loss. The news release notes that fluoxetine was chosen as the \u201creference\u201d drug to compare with buproprion. The study suggests that in addition to fluoxetine, the researchers looked at data from patients assigned to a number of other drugs, too, but their data sets were incomplete.", "answer": 1}, {"article": "Amminger and colleagues warn against over-interpretation of their findings.\n\"The finding that treatment with a natural substance may prevent or at least delay the onset of psychotic disorder gives hope that there may be alternatives to antipsychotics for the prodromal phase [symptoms leading up to psychosis onset],\" Amminger and colleagues suggest.\nThe finding comes from a placebo-controlled clinical trial that enrolled 81 young people -- average age 16 -- teetering on the brink of psychosis.\nIt may be that fish oil works better in young people with pre-psychotic conditions than in older people with more established psychiatric disorders.\nThat's the same level of efficacy seen with antipsychotic medications, note study researcher G. Paul Amminger, MD, of the University of Vienna, Austria, and colleagues.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story briefly compares the efficacy of fish oil supplements to antipsychotic medications and \u201cother interventions.\u201d However, more specific information on this would have been useful.\u00a0 Additionally, it would have been helpful to know that participants in both groups received psychosocial and psychological interventions. ", "answer": 1}, {"article": "Chavarro and colleagues studied 926 men who had prostate cancer that hadn\u2019t spread.\nThey were more than 2.5 times as likely to die of their prostate cancer than patients eating the healthiest diet and they were more than one and a half times as likely to have died of anything over the 10 years, Chavarro\u2019s team reports in the journal Cancer Prevention Research.\n\u201cOur results suggest that the same dietary recommendations that are made to the general population primarily for the prevention of cardiovascular disease may also decrease the risk of dying from prostate cancer among men initially diagnosed with nonmetastatic disease (cancer that has not spread),\u201d said Dr. Jorge Chavarro of Brigham and Women\u2019s Hospital and Harvard Medical School, who led the study.\n\u201cBecause cardiovascular disease is one of the top causes of death among prostate cancer survivors, our findings regarding all-cause mortality are what we anticipated and closely align with the current knowledge of the role of diet on cardiovascular disease,\u201d he said in a statement.\nProstate cancer survivors who eat a typical American diet loaded with red meat, cheese and white bread are far more likely to see their cancer come back and kill them, and they\u2019re more likely to die sooner of any disease than patients who eat a healthier diet, researchers reported Monday.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t address anything, beyond diet, that prostate cancer survivors might do to reduce their risk of recurrence and death. But since there aren\u2019t necessarily any interventions that are proven to reduce recurrence, we\u2019ll give the story the benefit of the doubt here and call it Not Applicable. To meet this criterion, the story could have mentioned androgen deprivation therapy, which is used in some cases to prevent recurrence. Other lifestyle interventions that are associated with reduced risk for all-cause mortality (eg, exercise) also could have been mentioned.", "answer": 2}, {"article": "We're sorry, but we seem to have lost this page.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This should have been the entire point of the story, but there is really no comparison. Just broad statements made about MRIs being superior, etc.", "answer": 0}, {"article": "So for many of these women, these medications are life-saving and life-altering.\"\n\"The risk increase of taking antidepressants late in pregnancy, if present, is much more modest than previous studies have found,\" says Krista Huybrechts, Ph.D., an epidemiologist at Brigham and Women's Hospital.\nBOSTON -- In 2006, the FDA warned the public that the use of common antidepressants, like Prozac and Paxil, late in pregnancy could put a baby at risk for respiratory failure.\nDr. Economy warns patients about the potential risks like withdrawal in the newborn and a small risk of heart defects, but says for many women, the worst time to stop their medications is at the end of pregnancy when postpartum depression becomes a concern.\nBut now a new, large-scale study finds that the risk is negligible -- much lower than previously believed, reports CBS Boston's Dr. Mallika Marshall.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Two\u00a0choices are presented in this story for pregnant women who suffer from\u00a0depression:\u00a0take SSRIs or don\u2019t. But that leaves out a third possible choice, mentioned in the study, which is to take a non-SSRI antidepressant. The story could have earned a Satisfactory by mentioning that alternative, or at least providing more information about the complications pregnant women might face if they\u2019re depressed and not taking an antidepressant.", "answer": 0}, {"article": "\"It is very big.\n\"This new technology has the potential to facilitate an easy-to-administer, noninvasive blood test that would allow us to count tumor cells, and to characterize the biology of the cells,\" said Robert McCormack, Veridex's head of technology innovation and strategy.\n\"It is appropriate to view announcements such as the one today with enthusiasm, but recognize that we must temper that excitement with the realization that there is still much research to be done to determine the true impact of this test on the treatment of patients with cancer.\"\nDr. Mehmet Toner, director of the BioMicroElectroMechanical Systems Resource Center in Massachusetts General's Center for Engineering in Medicine, says while it will take at least five years before the test is on the market, it's another step toward personalized medicine and the implications for patients are significant.\n\"The challenging goal of sorting extremely rare circulating tumor cells from blood requires continuous technological, biological and clinical innovation to fully explore the utility of these precious cells in clinical oncology,\" Toner said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no meaningful discussion of any testing alternatives \u2013 only brief mention of another test from the same company making this new announcement \u2013 but without any details about how the two are different \u2013 much less anything about any other testing research.\u00a0 As Len Lichtenfeld of the American Cancer Society reminds readers:\u00a0\u201c\u2026we are seeing many tests that are being touted as important in answering various questions about the future behavior of an individual\u2019s cancer but we are not seeing the type of validation we need to know whether or not such claims are in fact clinically relevant.\u00a0 There are so many markers and genetic tests out there that even the most knowledgeable experts in the clinical treatment of patients with cancer are having a hard time separating the proverbial wheat from the chaff.\u201d\n\u00a0", "answer": 0}, {"article": "But Riddle soon heard that certain compounds in cannabis\u2014cannabinoids\u2014have been shown to induce cancer cell death.\n\u201cI\u2019m done with you guys bullying us.\u201d\n\nThen, she took out a bag and dumped the contents on the table: nine months of cancer drugs prescribed to her son, Landon, who was 4 at the time.\n\u201cHe also had elements of what I know a lot of folks would call \u2018chemo brain.\u2019 He would get very frustrated and very angry, all normal because his little body was just being invaded by this intense medication and rounds of chemotherapy treatment.\u201d Throughout that year, Riddle and her son traveled back and forth from Colorado to Utah, so he could continue chemo, but this time with the aid of cannabis, to make treatment more bearable.\nWhile cannabis is legal in many U.S. states, the drug is still classified by the Drug Enforcement Administration as a Schedule 1 narcotic (along with heroin and cocaine), which make it very difficult for scientists to conduct clinical trials on people.\nFirst, there would be several months of aggressive inpatient chemo and other therapies for what\u2019s known as \u201cremission reduction.\u201d After that, even when blood work showed the disease had entered remission, Landon would need years of chemo and monitoring\u2014called \u201cconsolidation\u201d\u2014to make sure his body wasn\u2019t harboring leukemia cells.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The problem here is that the story should have been more clear that one interpretation of the series of events is that the conventional treatment succeeded in putting the cancer into remission\u2026 and that the improvement in the patient\u2019s quality of life might be entirely due to the discontinuation of that treatment.\nBy repeatedly stating that the patient began to feel better after starting cannabis oil treatment, the story implies the oil caused the improvement and might be superior to the conventional treatment, rather than noting that the oil might not have anything to do with the patient feeling better, and that even in this single case, there cannot be any firm conclusions about the relative value of the treatment options.", "answer": 0}, {"article": "And, they say, it might not help cure many deadly prostate cancers because those cancers may have already spread outside the prostate, microscopically seeding other organs, long before a P.S.A.\n\u201cIt is not all pure data that is promoting aggressive screening.\u201d Dr. Andriole is directing a National Cancer Institute study of 76,000 men that failed to find a screening benefit after 10 years.\nBut even with this uncertainty, prostate cancer specialists say, most men who are treated would not have died of prostate cancer, and that is especially true for elderly men, in particular those who are frail and have a limited life expectancy.\nPathologists can distinguish between cancers that look particularly aggressive and those that do not, but there is a real possibility that even if tissue obtained at a biopsy has only less aggressive tumor cells, more aggressive cells might still be lurking in the prostate.\nBut if a man has been screened year after year, it can be hard to suggest he stop because he may not live much longer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story presented information about the impact of being tested for prostate cancer using the PSA test versus not having the test. \u00a0It was especially clear about the idea that a life expectancy of 10 years as a man thinks about potential benefit.\nBut, again, the option of not being screened wasn\u2019t reflected in the patients profiled in the piece.", "answer": 1}, {"article": "WASHINGTON -- A U.S. Food and Drug Administration panel of outside medical experts backed a Novartis AG drug, Exelon, for treatment of dementia in patients with Parkinson's disease.\n\nExelon is currently on the market to treat mild to moderate Alzheimer's disease. The FDA said it wasn't sure whether dementia associated with Parkinson's was much different than dementia associated with Alzheimer's. Dementia is a condition that typically first presents itself as memory loss greater than what would be expected as part of the normal...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention other treatment options, such as memantine. ", "answer": 0}, {"article": "It is sort of a window into the lung.\u201d\n\nCigarette smoke causes 90 percent of all cases of lung cancer, which kills 1.2 million people a year globally.\nThe researchers have patented their findings through the universities but Bild said myo-inositol supplements are cheap and freely available.\nAnd it can be found in the windpipes of smokers, meaning they do not need more dangerous and uncomfortable lung tests.\nBut only about 10 percent of smokers ever develop lung cancer, although they often die of other causes such as heart disease, stroke or emphysema.\nAnd the second group was taking the natural supplement, myo-inositol, to try to prevent lung cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "       \n \nThe story did not mention alternative approaches for detecting early stages of lung cancer, including chest x-rays or CT scan screening.\u00a0 \n\u00a0\n ", "answer": 0}, {"article": "Qi Sun of the Harvard School of Public Health and his colleagues analyzed data collected from 13.984 female nurses participating in the Nurses\u2019 Health Study, an ongoing study examining a variety of health issues.\nThe findings fit with current federal dietary guidelines, which recommend up to one drink per day for women and just to two drinks per day for men.\nNow, the researchers stressed that wasn\u2019t the case for women who consumed more than two drinks a day or four drinks or more at a time.\nThose who drank between one-third and 1 drink per day five to seven days a week were almost 50 percent more likely to be in good health when they got older compared with those who did not imbibe.\n\u201cThese data suggest that regular, moderate consumption of alcohol at midlife may be related to a modest increase in overall health status among women who survive to older ages,\u201d the researchers wrote.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study didn\u2019t mention any other factors that we know can promote healthy aging, including a healthy diet and physical activity. That could have been done in just another additional line.", "answer": 0}, {"article": "\u201cThere\u2019s a sizable demand, but the hype around efficacy far exceeds available evidence,\u201d notes Doraiswamy, adding that, for healthy young people such as Silicon Valley go-getters, \u201cit\u2019s a zero-sum game.\n\u201cThere\u2019s pretty conclusive evidence from animal studies that intermittent fasting is beneficial for brain function and resistance to aging from neurogenerative diseases,\u201d he says.\nUnfortunately, the drug ended up severely imbalancing his electrolytes, which can lead to dehydration, headaches, vision and cardiac problems, muscle contractions and, in extreme cases, seizures.\nBut while some studies have found short-term benefits, Doraiswamy says there is no evidence that what are commonly known as smart drugs \u2014 of any type \u2014 improve thinking or productivity over the long run.\nOne chief executive he treated, Ngo said, developed an unhealthy predilection for albuterol, because he felt the asthma inhaler medicine kept him alert and productive long after others had quit working.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t address proven strategies to improve mental skills such as good nutrition, adequate sleep, social engagement, cognitively challenging activities, and exercise.", "answer": 0}, {"article": "For the really Type A personality, here's a chance to measure how well you are relaxing. Makers of home biofeedback devices that monitor your heart rhythms say the devices teach you to combat emotional stress. Psychologists and psychiatrists say the gadgets appear to help their stressed-out patients but warn that there isn't yet strong scientific evidence that they work.\n\nBiofeedback has long been used to treat stress in psychologists' offices -- with an expert who leads the patient in relaxing breathing exercises and...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no mention of alternative treatment options. Deep breathing exercises are mentioned, but what other options are available? What are the advantages and disadvantages of this approach by comparison?", "answer": 0}, {"article": "\"These treatments really have the potential to transform people's lives,\" Vickery said, \"and I have seen it happen firsthand: the sense of relief [families] get when a child becomes desensitized.\"\n\"It's intuitive that that process would trigger some allergic symptoms in many patients,\" Vickery said.\nThe risk paid off: Two-thirds of the kids in the study were able to eat the equivalent of two peanuts without any symptoms after following the months-long experimental treatment regimen, the researchers found.\nSicherer said, \"The family that does this really, really, really has to be a rule follower.\n\"The purpose is not to get them to be no longer peanut allergic and allow them to eat whatever they want.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes clear that there is currently no approved treatment for peanut allergy.\u00a0 \nIn addition, the profiled patient is described as having to eat her school lunch at a peanut-free table, showing reader the practice of avoiding exposure \u2014 currently the only way to manage a peanut allergy.\u00a0\u00a0\nHowever, the story doesn\u2019t mention that AR101 is among at least four peanut immunotherapy products potentially entering the market.", "answer": 1}, {"article": "Injections of botulinum toxin, best known as a wrinkle treatment, are now being used increasingly to prevent chronic migraine sufferers. Scientific data are mixed, but two large recent studies show Botox can reduce the number of headache days in chronic sufferers.\n\nMigraine headache is a debilitating neurological condition that manifests itself as an intense throbbing pain on one or both sides of the head, according to the Migraine Research Foundation, a New York nonprofit. Some 14 million people experience migraine attacks...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article mentioned that other drugs are employed to treat migraines, but it didn\u2019t mention any by name.\nThe Wall Street Journal story never discussed non-pharmacologic therapies. Yet addressing triggers related to diet, stress, sleep deprivation, and medication side-effects are front-line preventive treatments for migraines. And they are certainly viable alternatives to Botox injections.\nAnd since Botox injections have never been compared to other standard treatments for chronic migraines in clinical trials, it is quite possible that those interventions could be superior to Botox injections.", "answer": 0}, {"article": "Amgen has partnered with Novartis AG to co-commercialize Aimovig in the United States, while Amgen has rights to the drug in Japan and Novartis has rights to commercialize in rest of world.\nThe drug, a monoclonal antibody, was given monthly by injection at a dose of 140 mg for the trial.\nReuter said the 17-point gap between the treatment and placebo groups was in line with previous Aimovig studies.\nThe 12-week trial, presented this week at the annual meeting of the American Academy of Neurology, involved 246 patients suffering four to 14 migraine headaches a month who had tried two to four preventive treatments that either did not work for them or had intolerable side effects.\nA decision by the FDA is due by May 17.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story alludes to the existence of other preventive therapies for migraines when it tells us that participants did not respond to other treatments. However, it doesn\u2019t say what those treatments are.", "answer": 0}, {"article": "Sleep-specific quality of life was examined with the Functional Outcomes of Sleep Questionnaire (FOSQ), which assesses the effect of sleep disorders and excessive daytime sleepiness on activities of daily living such as productivity and intimacy.\nThe study involved 2,027 patients with sleep apnea who began PAP therapy between Jan. 1, 2010, and Dec. 31, 2014.\nFor a copy of the study, \"Impact of Sleep-Disordered Breathing Treatment on Quality of Life Measures in a Large Clinic-Based Cohort,\" or to arrange an interview with a study author or an AASM spokesperson, please contact the AASM at 630-737-9700 or media@aasm.org.\nOne treatment option for sleep apnea is PAP therapy, which uses mild levels of air pressure, provided through a mask, to keep the throat open while you sleep.\nThe study is published in the Nov. 15 issue of the Journal of Clinical Sleep Medicine.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "While CPAP is a widely used and effective treatment for sleep apnea, it is not the only solution. Other treatments include dental appliances, surgery, and nerve stimulation. The news release did not make any mentions of these alternate treatments.", "answer": 0}, {"article": "Chronic rhinosinusitis (CRS) affects a sizable minority -- 14 percent to 16 percent -- of U.S. residents.\nThey should try medical therapy, and if medical therapy fails and the surgeon feels that part of the problem is anatomic, then surgery would be a good tool for them to use,\" Josephson said.\n\"It's a minimally invasive type of surgery performed with a telescope that goes into the nostril,\" then basically snips away abnormal and interfering tissue while leaving normal tissue behind, Smith explained.\n\"These were patients who have chronic sinusitis so, by definition, they have at least three months of symptoms and they have evidence of an ongoing inflammation or infection of their nose and sinuses on either a CT scan or an examination of the nose and sinuses,\" Smith said.\nThis second finding is probably explained by the fact that people going for second or further surgeries were probably sicker to begin with, Josephson said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story mentions that medical therapy can be an effective alternative to surgery, more information on the specific medications, including nasal steroids, oral decongestants and antihistamines,\u00a0would have helped readers. ", "answer": 1}, {"article": "Griffiths says his team's new study grew out of a decade of research at Johns Hopkins on the effects of psilocybin in healthy volunteers, which found that psilocybin can consistently produce positive changes in mood, behavior and spirituality when administered to carefully screened and prepared participants.\n\"Before beginning the study, it wasn't clear to me that this treatment would be helpful, since cancer patients may experience profound hopelessness in response to their diagnosis, which is often followed by multiple surgeries and prolonged chemotherapy,\" says Griffiths.\nTo measure the changes in attitudes, moods and behavior over time, the researchers administered a questionnaire that assessed negative or positive changes in attitudes about life, mood and behavior.\nIn the other session, participants received a capsule with what is considered a moderate or high dose (22 or 30 milligrams per 70 kilograms).\n\"A life-threatening cancer diagnosis can be psychologically challenging, with anxiety and depression as very common symptoms,\" says Griffiths.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Again, the release does a good job here. For example, the release cites a lead researcher from the Johns Hopkins team saying that \u201ctraditional psychotherapy offered to people with cancer, including behavioral therapy and antidepressants, can take weeks or even months, isn\u2019t always effective, and in the case of some drugs, such as benzodiazepines, may have addictive and other troubling side effects.\u201d Would a more detailed comparison be valuable? Yes. Do we think the language in the release is sufficiently meaningful to merit a satisfactory rating? Also yes.", "answer": 1}, {"article": "By middle age, Ms. Gallagher, 51, the owner of a pet-sitting business in Torrance, Calif., was avoiding mirrors and considering liposuction, but she worried about the effects of anesthesia and the recovery time.\nShe enrolled in a trial, and by the third treatment session, \u201cI noticed a dramatic difference,\u201d she said.\nThen she discovered another option: a series of fat-reducing injections intended to slim down a double chin.\nShe stood ramrod-straight, head held high, to make the bulge less apparent.\nAs an adult, she faithfully performed facial exercises purported to tighten the area under the chin.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story points out that liposuction is an alternative.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/01/17/national/a130050S19.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We rate this\nsatisfactory, although, in comparing treatment options, the possible harms of surgery could have been explored more fully.\nThe story does not mention specific potential surgical or post-operative complications. 22.3% of those who underwent surgery\n(this included those randomized to the surgery group or those from watchful waiting who crossed over into the surgery group)\nhad complications which included wound infections, urinary tract infections, and in a few cases, serious cardiovascular\nproblems requiring hospitalization.", "answer": 1}, {"article": "So, how best to reach these targets?\nThe researchers found that women who consumed high levels of fiber (28 grams per day, on average) had a 24 percent lower risk of developing breast cancer before menopause, compared with women who ate low levels of fiber (14 grams per day, on average).\nGiven the known benefits of high-fiber diets and the growing evidence that fiber may play a role in preventing disease, the government's Dietary Guidelines for Americans also say most people need to consume more.\nA Diet High In Fiber May Help Protect Against Breast Cancer\n\nIf the advice to eat more fiber seems easy to ignore, you're not alone.\nThey were in their 30s and 40 when asked, so there could be \"recall bias\" \u2014 the women's memories may be foggy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t discuss other risk factors for breast cancer at all, much less other lifestyle choices that can reduce risk, such as maintaining a healthy weight, exercising, limiting alcohol consumption or getting enough sleep.\u00a0Perspective is needed about ways we can stay healthy overall and reduce later cancer risk.", "answer": 0}, {"article": "itself the first clear and reproducible example of cancer immunotherapy, developed at Fred Hutch ?\nBecause it was the first study of this particular approach, the researchers focused on a high-risk group -- AML patients undergoing bone marrow transplant who had certain genetic or disease characteristics that decrease the chance of long-term transplant success -- \"a hard population of patients,\" Chapuis said, many of whom \"were horribly sick.\"\nThe findings in this group of trial participants contrast with the outcomes the researchers observed in a cohort of similar patients who received transplants around the same time but did not receive engineered T cells.\nThis is the team's first trial of this strategy, which was initially developed in the lab of Dr. Phil Greenberg, one of the study's leaders and the head of Fred Hutch's Program in Immunology.\nOf the 12 AML patients who received this experimental T-cell therapy after a transplant put their disease in remission, all are still in remission after a median follow-up of more than two years.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Without any information on the extent of the type of leukemia relapse risk that is the target of this research or any evidence that a reduction in relapse rates ultimately gives patients longer or better quality life, there is no way to make an informed comparison with existing treatments. Nevertheless, the release makes unsupported assertions that this treatment appears to be superior to conventional treatment. The release also leaves out any mention of similar experimental therapies.", "answer": 0}, {"article": "Find out more about bedwetting and its treatment at the Nemours Foundation.\n\"This study really underscores the fact that children who have other issues with sleep should be looked at for bedwetting because anything that depresses sleep at night can lead to bedwetting,\" said AUA spokesman Dr. Anthony Atala, a urologist at Wake Forest University in Winston-Salem, N.C.\n\n\"If a child has bedwetting, pay close attention to their sleep patterns, and observe them while they are asleep and you can see whether they are breathing at a regular pace, and if not, seek additional help,\" Atala said.\n\"There are several potential causes of bedwetting, and sleep apnea is clearly one of them,\" said Dr. Lane S. Palmer, chief of pediatric urology at the Cohen Children's Medical Center in New Hyde Park, N.Y.\n\n\"There are secondary positive effects of this tonsil- or adenoid-removing surgery, but I don't know that I would jump to have my child's tonsils or adenoids out as a primary treatment for bedwetting,\" he said.\nThe findings were to be presented Monday at the annual meeting of the American Urological Association (AUA), in Washington, D.C. Research presented at medical meetings should be viewed as preliminary until it has been published in a peer-reviewed medical journal.\n\"About 5 to 7 million children are bedwetters, and the causes fall into three main groups: bladder issues, sleep-related problems and the kidneys,\" he explained.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job talking about the different causes of bed wetting but not the potential treatments. \u201cThere are many other causes of bedwetting, Lakshmanan said. \u201cAbout 5 to 7 million children are bedwetters, and the causes fall into three main groups: bladder issues, sleep-related problems and the kidneys,\u201d he explained. \u201cThe children in this study wet the bed due to sleep-related problems.\u201d We would have particularly liked to hear an estimate for the number of children who resolve bedwetting (even \u201cabnormal\u201d bedwetting into grade school) on their own. From a healthcare perspective and a parenting perspective, do we really want to do operations on kids to end this annoyance?", "answer": 0}, {"article": "Reductions in pancreas, stomach and brain cancers were difficult to quantify because of smaller numbers of deaths.\nAspirin protected people against gastrointestinal cancers the most, the study found, with rates of death from these cancers around 54 percent lower after five years among those who took aspirin compared to those who did not.\n\u201cIt is further proof that aspirin is, by a long way, the most amazing drug in the world,\u201d he said.\nIn Rothwell\u2019s study, published in The Lancet, researchers found the 20-year risk of death was reduced by about 10 percent for prostate cancer, 30 percent for lung cancer, 40 percent for colorectal or bowel cancer and 60 percent for oesophageal cancer in those taking aspirin.\nHis suggestion was that healthy people could start taking a small 75 mg dose of aspirin every day from the age of about 40 or 45 and continue doing so until they reached around 70 to 75, when the risk of the aspirin causing stomach bleeding rises.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe story presents daily low-dose aspirin as the way to go\u2026 without any serious consideration of alternatives available to people concerned about their risk of dying from cancer.", "answer": 0}, {"article": "Surgeons sometimes fly blind when operating on hard-to-reach anatomical parts or hard-to-see conditions. For visual references inside the brain or body, they often rely on images and scans taken before an operation.\n\nA growing number of hospitals are equipping operating suites with magnetic resonance imaging, CT scanners and other technology that enables surgeons to scan a patient in real time, without having to move them from the operating table.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explains how, in theory, real-time imaging could significantly improve surgical outcomes. But the story does not actually offer any comparison of the outcomes of surgical procedures that use real-time imaging techniques versus surgical procedures that do not.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/29/national/w155455S59.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article mentions ongoing studies with the goal of improving the vaccine so that protection against bird flu could be accomplished with loser doses.", "answer": 1}, {"article": "\u201cLet\u2019s talk about your test results,\u201d my neurologist said.\n\nShe looked as if she had good news. Instead, it was shocking.\n\nThe carotid artery on the left side of my neck, one of the brain\u2019s two main sources of blood and oxygen, was clogged with fatty plaque, the doctor said. The artery was almost completely blocked.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes no mention of carotid artery stenting. This omission is surprising, since the reporter has covered this alternative on several occasions:\n(Full text versions of some stories are behind a paywall.)", "answer": 0}, {"article": "While nivolumab is approved for treating metastatic NSCLC, for example, that indication calls for using it if the disease continues to progress either during or after chemotherapy.\nWhen the scientists analyzed the tumors they had cut out, they found that in about half of the people treated with nivolumab, the growths showed significant destruction by immune cells, meaning that nivolumab had unmasked the tumors as foreign and allowed the immune system\u2019s killer cells to attack them.\nThe medications target a protein called PD-1, its related PD-L1, or CTLA-4, which protect the body\u2019s cells from being killed by immune cells; because tumors are normal cells growing out of control, they take advantage of this molecular security blanket to avoid getting detected by immune cells.\n\u201cTo give you some idea of how significant that is, with chemotherapy we normally see the same degree of response around 20% of the time.\u201d\n\nForde says that the strong response seen in people at the beginning of the disease could suggest that immunotherapies might be useful in re-training the immune system to fight cancer for long periods of time \u2014 possibly even a lifetime.\n\u201cThe Holy Grail is to have a relatively non-toxic therapy that could potentially use the body\u2019s own immune system to prevent recurrence,\u201d he says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions chemotherapy, which it says \u201ctherapy typically leads to only a 5% improvement in people\u2019s chances of living five years \u2014 but an up to 70% chance of being exposed to serious toxicities.\u201d (But, note that the story never provided information on immunotherapy\u2019s serious toxicities.)", "answer": 1}, {"article": "Still, the study stands as \"a major landmark in cancer immunotherapy,\" says Dr. Bernard Fox, president of the International Society for Biological Therapy of Cancer.\nAfter one year, the once palpable tumors were no longer detectable in diagnostic scans.\nAt first, the injections caused only side-effects: widespread itching, fatigue, and diarrhea.\n\"Some of the people are now out 44 months and still remain free of disease,\" Urba says.\nIf caught early, before cancer cells break off and spread, surgery can stop melanoma.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explained that \"Other drug companies are at work on competing versions of the immune-enhancing antibody therapy.\"", "answer": 1}, {"article": "WASHINGTON -- The Food and Drug Administration on Wednesday approved ImClone Systems Inc. and Bristol-Myers Squibb Co.'s Erbitux as a treatment for head and neck cancer, the agency said Wednesday.\n\nThe drug, which is designed to block proteins involved with cancer growth, was first approved in 2004 as a colon cancer treatment.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the author does mention radiation as the alternative and that the side effects of Erbitux plus radiation are similar to that of radiation alone, there is no mention of cisplatin and other newer chemotherapy drugs that are the current standard of care.", "answer": 0}, {"article": "\u201cHowever,\u201d she added, \u201cunlike a pill, which always has the same ingredients, acupuncture, like psychotherapy, varies from one provider to the other.\u201d\n\nSo while the specific regimen used in this study appeared effective, Manber said, \u201cI do not think we can say that our study proves that acupuncture is effective for depression during pregnancy.\u201d\n\nIt\u2019s estimated that 3 to 5 percent of pregnant women are diagnosed with depression, Manber and her colleagues note in their report.\nAnother 49 women received control acupuncture and 49 received massage.\nFourteen women who received depression-specific acupuncture reported pain during the needling, as did seven in the control-acupuncture group.\nAfter eight weeks, patients in the depression-specific acupuncture group had a higher rate of response to treatment.\n\u201cThe acupuncture protocol we have tested appears effective,\u201d lead researcher Dr. Rachel Manber, of Stanford University in California, told Reuters Health in an email.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 1}, {"article": "\u201cIf it\u2019s happening because of fear or the common reason I hear \u2013 \u2018I just want to be done with it\u2019 \u2013 that\u2019s a different situation.\u201d\n\nTuttle\u2019s study found 60 percent of women with breast cancer chose lumpectomies, which remove only the tumors, not the whole breasts.\nResearch has found this procedure is equally effective, particularly with smaller tumors and often when used in combination with radiation.\nBoth Leach and Tuttle are pursuing research studies to address the why question.\nThen the women can have genetic tests and assess their risks for follow-up cancers before deciding whether to have one or both breasts removed.\n\u201cIt\u2019s a survival thing,\u201d she said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article sufficiently compares bilateral and single mastectomy, and reports that the lumpectomy with radiation option is more common.\u00a0 \n\u00a0", "answer": 1}, {"article": "A flu drug \u2014 shown to reduce the duration of symptoms \u2014 could upend treatment in U.S.\n\nNext winter, there may be a new drug for people who contract influenza \u2014 one that appears to be able to shut down infection quickly and, unlike anything else on the market, can be taken as a single dose.\n\nThe Food and Drug Administration on Tuesday said that it would give the drug, baloxavir marboxil, a priority review, and approval has the potential to upend the way influenza is treated.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explains that the only other drug approved to treat the flu is Tamiflu, which is not widely used. The writer explains that both drugs need to be taken within 48 hours of symptom onset and that\u00a0baloxavir marboxil is a single one-time dose, while Tamiflu must be taken twice daily for five days.", "answer": 1}, {"article": "MONDAY, March 21, 2011 (HealthDay News) -- While the majority of morbidly obese patients who undergo gastric banding say they are generally satisfied years later, almost 40 percent are saddled with major complications, while about half have to have their bands removed, a small, new Belgian study reveals.\nThe finding comes on the heels of a recent study out of the University of California, San Francisco that suggested gastric bypass surgery is superior to alternative surgical methods (such as gastric banding) for promoting weight loss and/or eliminating type 2 diabetes.\nThe results: 12 years or more later, more than 60 percent of the banding patients said they were \"satisfied\" with their experience.\nMeanwhile, in a critique published alongside Himpens work, Dr. Clifford W. Deveney, a professor of surgery in the department of surgery at Oregon Health and Science University in Portland, concluded that the current study does \"not shed a favorable light on the use of LAGB\".\n\"So I think,\" he continued, \"that the patient should be made aware of these facts, and also that the weight loss is going to be less with the band than with a gastric bypass.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story relied on a critique published alongside the study from Dr. Clifford W. Deveney, a professor of surgery in the department of surgery at Oregon Health and Science University in Portland, to provide readers some good comparison information between\u00a0 gastric bypass surgery and gastric banding. We would have liked to have seen\u00a0a more detailed discussion of the evidence for both and also\u00a0at lesat some mention of diet and exercise.", "answer": 1}, {"article": "Senator Arlen Specter, a Pennsylvania Democrat and longtime advocate for cancer screening, said in an interview: \u201cAnd this Pap smear guideline is yet another cut back in screening?\nThere are 11,270 new cases of cervical cancer and 4,070 deaths per year in the United States.\nStill, the new recommendations for Pap tests are likely to feed a political debate in Washington over health care overhaul proposals.\nThe new guidelines say women 30 and older who have three consecutive Pap tests that were normal, and who have no history of seriously abnormal findings, can stretch the interval between screenings to three years.\nIn addition, women who have a total hysterectomy (which removes the uterus and cervix) for a noncancerous condition, and who had no severe abnormalities on previous Pap tests, can quit having the tests entirely.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story adequately compares the two guidelines. \nBut it failed to compare the options\u2013and consequences to patients\u2013of getting screened and not getting screened.\u00a0 ", "answer": 0}, {"article": "Cocaine use is widespread in the Western World.\nIn addition, 69% (11/16) patients) in the experimental group showed no relapse to cocaine use, whereas only 19% (3/16) patients) in the control group showed a similar positive result (the results are adjusted for patients who dropped out of the trial).\nThe results of this pilot study, published in the peer-reviewed journal European Neuropsychopharmacology, suggest that this may become an effective medical treatment for patients with cocaine addiction, although a larger trial is needed to confirm the initial findings.\nAt the end of the first 29 days of the experiment, the experimental group was given the option of continuing the treatment, whereas those in the control group were given the possibility of receiving the same rTMS treatment as the experimental group for 63 days.\nAs far as we know, this work represents the first clinical report indicating that rTMS treatment results in significant reduction in cocaine use.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release states, \u201cThere is no effective drug treatment for cocaine addiction, with behavioural therapies being the main element of any treatment regime.\u201d The medicinal drugs used on members of the control group were intended to treat accompanying symptoms brought on by cocaine use. In addition, addiction specialists have found that some drugs do offer some small benefits clinically, but they are not FDA approved for cocaine addiction treatment.", "answer": 1}, {"article": "\"Further studies are needed to address these questions.\"\n\"The purpose of our study was to investigate the effects of ketamine for TRD in younger patients for whom this indication for ketamine administration is not well studied,\" Mark Roback, a professor of pediatrics at the University of Minnesota, told Newsweek.\n\"Adolescence is a very important time for studying depression, first because depression often starts during these years, and second because it is an important time for brain development,\" Kathryn Cullen, from the Department of Psychiatry at UM, told Newsweek.\nResearchers from the University of Minnesota (UM) and the nonprofit Mayo Clinic found that ketamine caused an average decrease of 42 percent on the Children\u2019s Depression Rating Scale (CDRS)\u2014the most widely used rating scale in research trials for assessing the severity of depression and change in depressive symptoms among adolescents.\nThe study serves to point out the need for further, rigorous, study designed to answer the many questions that remain about ketamine for TRD, such as optimal dosing and route of administration, dosing interval and treatment length, and long-term effects\u2014just to name a few.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The nature of this study was to investigate the potential use of ketamine as an alternative to other drug treatments.\u00a0 Participants had to have tried at least two previous drug approaches without success before they could qualify for inclusion in this study.\u00a0 So therefore, there clearly were alternatives considered and the story mentioned them.\nThe story would have benefited from a wider discussion of the treatment of adolescent depression, including the role of psychotherapy.", "answer": 1}, {"article": "The timing of treatment also mattered.\nIf the device works in larger trials and becomes widely available for migraine patients, it might offer an alternative for people who can\u2019t tolerate migraine drugs or an option patients could try in addition to medication when they don\u2019t get enough pain relief from drugs alone, Schoenen said.\nEven though the study\u2019s participants were not told whether they were assigned active or placebo treatment, one limitation of the experiment is that participants often stopped placebo treatments before the recommended 20-minute course of stimulation was done, the authors note in Neurology.\nWhen researchers excluded the lowest pulse width, they found 64 percent of people in the other active treatment groups had at least a 50 percent pain reduction two hours after treatment, compared with 26 percent of people in the placebo group.\n\u201cThe percentage of attacks for which TENS is sufficient as sole treatment and allows sustained pain relief remains to be determined,\u201d Schoenen cautioned.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We only\u00a0get\u00a0a\u00a0passing\u00a0mention\u00a0of\u00a0drugs, and there are many available. Quickly fleshing out the efficacy of those drugs versus this TENS technique would have gone a long way in helping migraine sufferers who may be\u00a0desperate\u00a0to try the most effective, affordable, and least invasive treatment.", "answer": 0}, {"article": "Tens of thousands?\nThe way the study was done, he says, \"does not allow one to conclude\" that Provenge is working because it mobilizes the immune system specifically against prostate cancer.\nThe primary mystery is how Provenge extends life, since it doesn't shrink prostate tumors, as far as anyone can tell.\n\"Prolongation of survival without a measurable antitumor effect is surprising,\" writes Dr. Dan Longo of the National Institute on Aging in a NEJM editorial.\nLongo, the NEJM editorialist, says he'd be more convinced if the placebo patients had received infusions of white blood cells that had been exposed just to the general immune-stimulating part of the Provenge treatment, without the prostate antigen part.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says the drug performed \"better than the only other approved treatment for such advanced cancers\" and that \"Other immunotherapy approaches are in the pipeline, along with fancier versions of drugs to block the hormones that feed prostate cancer.\" ", "answer": 1}, {"article": "They showed a 21% reduction in the number of deaths caused by cancer among those who had taken aspirin, compared with people who had not.\nThe latest study confirms the earlier results and concludes that similar effects can be shown for other types of cancers.\nThe protective effect of taking low doses of aspirin varied according to the type of cancer and how long aspirin had been taken, the authors found.\nA previous study by the same authors showed that low doses of aspirin (75-300 milligrams) reduced the number of cases of colorectal cancer by a quarter and deaths caused by the disease by more than a third.\nThe fall in the risk of death broke down according to individual types of cancer: Reductions in pancreatic, stomach, and brain cancers were difficult to quantify because of smaller numbers of deaths, the authors say.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story does not present alternative ways of reducing cancer risk. Some other news reports specifically noted that avoiding smoking and obesity are both known to reduce cancer risk.", "answer": 0}, {"article": "The study of nearly 32,000 people in eight countries boosts hope that early detection by CAT scans may reduce the death toll of lung cancer, much as mammography has done for breast cancer.\nOnly 15 percent of people with the disease survive five years from the time it is diagnosed.\nMany of these lump-shaped masses were watched with further scans to see whether they grew; others were examined with other imaging devices.\nOf that group, 85 percent had small tumors that had not spread.\nI think we have enough data to move forward and apply this to a high-risk population.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions x-rays and no screening as alternatives to CT scanning.", "answer": 1}, {"article": "LOS ANGELES -- Researchers have demonstrated for the first time that the progression of Type-1 diabetes can be halted -- and possibly reversed -- by a stem cell transplant that preserves the body's diminishing ability to make insulin, according to a study published today.\nThe researchers also cautioned that the process is not without risk, with patients vulnerable to infection during part of the therapy.\nThe idea is to wipe out the faulty immune system and replace it .\nIn the interim, they were given antibiotics to protect against infections.\nOf the remaining 14 patients, 12 were able to stop taking insulin shortly after their transplants.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article discusses the alternate, standard thereapy for type 1 diabetics, which is insulin injections.\u00a0 ", "answer": 1}, {"article": "You can contact NPR science correspondent Richard Harris at rharris@npr.org.\nFor those patients (who weren't included in the Swiss analysis), the benefits are so clear \"it's almost mandatory to be on a statin drug,\" Grundy says.\n\"Some harms are mentioned, but it's entirely unclear how they were considered when coming up with the recommendations,\" says Milo Puhan, a physician and epidemiologist at the University of Zurich and senior author of the new study.\n\"I think for me, as a physician,\" says Ilana Richman, an internist at the Yale School of Medicine, \"this kind of data suggests that if we give more weight to the potential for adverse events, then maybe it's reasonable to hold off for lower-risk patients.\"\nYet both the new guidelines and the latest study agree on an important point: Doctors and patients should spend more time reviewing the benefits and risks of statins, with attention paid to each person's particular circumstances.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternative of not taking a statin was the key message here, and that\u2019s laudable. However, we have a couple of concerns.\nFirst, we learn that \u201csome statins were more effective than others, with atorvastatin (the generic name for Lipitor) being the best of the bunch.\u201d\u00a0 However, the story doesn\u2019t explain on what basis some statins are \u201cmore effective.\u201d In fact, some statins may be more effective at lower cholesterol, but the study found that no statin rises above others when it comes to the outcomes that counts most to patients \u2014 reducing cardiovascular deaths.\nAlso, the story doesn\u2019t mention lifestyle interventions \u2014 diet and exercise.", "answer": 0}, {"article": "Data suggest that the drug begins to affect sexual satisfaction after four weeks of continuous treatment.\nBut the difference was important to the women, says study researcher Michael L. Krychman, MD, medical director of sexual medicine at Hoag Hospital in Newport Beach, Calif.\n\n\"The absolute number of women who had remission of sexual distress was clinically significant, but equally important to them was how it improved their lives,\" Krychman tells WebMD.\nIn the 24-week \"Bouquet\" studies (each of the Boehringer Ingelheim-funded studies is named after a flower), there were few drug-related side effects.\nWhile HSDD is a controversial diagnosis -- some experts see it as the medicalization of what is for many women a relationship issue -- the 1,378 premenopausal women enrolled in the clinical trials were suffering distress over their lack of sexual desire.\nJust under a third of women taking flibanserin got over their sexual distress and/or lack of sexual desire (vs. about a fifth of women taking placebo pills).\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story indicates that\u00a0an alternative drug called the Intrinsa testosterone patch\u00a0is available in Europe, but not in the U.S.\u00a0The story also notes a difference between\u00a0these dugs; Intrinsa\u00a0is a hormonal treatment compared to flibanserin which is a non-hormonal.\u00a0", "answer": 1}, {"article": "For more information, go to http://www.\nThe study, published in the American Journal of Clinical Nutrition, was led by CHORI Senior Scientist Janet King, PhD.\nThis was a novel approach, different from the commonly used method of looking at zinc in the blood or using stunting and morbidity for assessing zinc status.\nZinc is ubiquitous in our body and facilitates many functions that are essential for preserving life.\nUCSF Benioff Children's Hospital Oakland (formerly Children's Hospital & Research Center Oakland) is a premier, not-for-profit medical center for children in Northern California, and is the only hospital in the East Bay 100% devoted to pediatrics.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The alternatives here are to eat more natural foods rich in zinc or to take dietary supplements. Some sources of zinc include oysters, red meat, poultry, beans, nuts, whole grains and breakfast cereals.\nSupplements contain several forms of zinc, including zinc gluconate, zinc sulfate and zinc acetate. According to the National Institutes of Health, research has not established whether differences exist among forms of zinc in absorption, bioavailability or tolerability. As we mentioned in the Costs section, a bottle of 100 zinc tablets is priced around $4 to $6.\nSince these alternatives are not discussed, we give the news release a Not Satisfactory rating.", "answer": 0}, {"article": "The subjects were divided into two groups.\nIn fact, most people try 8 to 10 times and this includes quit attempts with standard cessation medications like nicotine patch and gum and prescription drugs like varenicline,\" said Alan Levy, Ph.D., chairman and CEO of Chrono Therapeutics.\nThe Chrono Solution is designed to deliver the first dose of nicotine replacement therapy (NRT) shortly before a smoker wakes up and then creates a pattern of \"peaks and troughs\" of nicotine delivery throughout the rest of the day to assure the smoker has more nicotine support when cravings are predicted to be strongest.\nCravings were assessed via three different methods: the Questionnaire for Smoking Urges (QSU), the Mood and Physical Symptoms Scale (MPSS) and a single craving question, each of which is a validated tool to assess cravings.\nThe clinical trial was a randomized, double blinded study of 24 adult males who smoked 11 or more cigarettes per day, indicating a high level of nicotine dependence.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "We\u2019ll give the benefit of the doubt here. The news release does indeed compare this new device to nicotine patches, gum and prescription drugs, but it does so inaccurately. The issue being discussed here is craving control and this trial is moot regarding the control of smoking.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070805/13folate.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Other than a recommendation to keep folate intake to somewhere less than 1,000 micrograms per day, there were no treatment recommendations in this story, nor alternative treatment options presented.\u00a0 A treatment option for colorectal cancer prevention is removal of the precursor lesion, polyps via surveillance colonoscopy.", "answer": 0}, {"article": "The study's authors acknowledged that their preliminary data offers \"promise for the use of time-restricted feeding as a weight loss technique in obese adults, but longer-term, large-scale randomized controlled trials [are needed].\"\n\"There are also many studies that either report no overall effect or sometimes the opposite.\nFurther research is now needed to uncover whether 16:8 works better than other fasting diets in terms of weight loss and health benefits.\nIndividuals who ate between 10 a.m. and 6 p.m. consumed around 350 fewer calories, resulting in a loss of 3 percent body weight, and their blood pressure dropped by around 7mm Hg.\nWe observed that fewer participants dropped out of this study when compared to studies on other fasting diets,\u201d said Varady.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions other diets such as alternate-day fasting.", "answer": 1}, {"article": "The 80% by 2018 campaign from the National Colorectal Cancer Roundtable, for example, which aims to increase the rate of screening, emphasizes a suite of options.\nAnd colonoscopies are well-reimbursed for the physicians who perform them.\nThere\u2019s a small but real risk of harm, such as a perforation.\nThe group said that while some tests are backed by more evidence than others, it found no head-to-head studies suggesting any strategy \u2014 including colonoscopy \u2014 is better than another.\nMost people prefer to have sedation during the procedure, which means time off from work and finding a ride home.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Since this story is totally about the available alternatives for colorectal cancer screening, it easily gets a Satisfactory rating.\u00a0 \u00a0", "answer": 1}, {"article": "\"A lot of the time, people have quite painful and challenging experiences revisiting the trauma, and [MDMA] can help them do it without being overwhelmed or numbed out,\" he says.\nThe study, which appears in the Journal of Psychopharmacology, included 20 people with PTSD stemming from traumas such as sexual assault and combat stress.\nThis was the first clinical trial to explore the therapeutic potential of MDMA since the drug was outlawed in 1985, and the researchers required the permission of the National Institutes of Health, the Food and Drug Administration , and the Drug Enforcement Administration.\nThe drug MDMA\u2014better known by its street name, Ecstasy\u2014may be illegal, but a new study suggests that it\u2019s also a promising treatment for post-traumatic stress disorder.\nTwo months later, 10 of the 12 people who took MDMA had improved to the point where they no longer met the diagnostic criteria for PTSD, and three participants whose condition had prevented them from holding down a job were able to return to work.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says that \"MDMA is believed to raise levels of the feel-good brain chemical serotonin and the so-called \"bonding hormone,\" oxytocin.\" Existing anti-depressants and anti-anxiety drugs do the same thing, but none of these drugs are mentioned. Also, because these patients were talking to therapists, there should have been some control in the study design for the therapy itself. How do we know how much the drug was raising people\u2019s sense of euphoria and how much of the change was due to the therapy?", "answer": 0}, {"article": "Candace's treatment, Downing said, involved a one-size-fits-all approach to mental health that sees medications as a magic pill.\nDowning's family offers a powerful case study into the pros and cons of new guidelines recommending widespread screening of adolescents for mental disorders: Last month, the U.S. Preventive Services Task Force, a federal group that makes public health recommendations, said that all adolescents between ages 12 and 18 should be screened for major depression.\nThe treatment worked, she said, because \"getting all the stuff out of your head that you don't need there gives you more room for all the stuff you need to have in your head.\"\n\"Screening a child to find out what the root of the problem is can be useful,\" Downing said.\nThe very different experiences of the two sisters illustrate the paradox at the heart of screening recommendations: What matters is not whether screening is done but how it is done and how screening information gets used.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not clearly delineate the treatment options for managing major depressive disorder in adolescents. \u00a0It should have indicated that serotonin re-uptake inhibitors, psychotherapy, and a combination of the two are all currently recommended for this age group. \u00a0Omitting combination treatment is especially problematic.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Despite recent debate about how well antidepressants really work in people with only mild or moderate depression, a new analysis of drug studies suggests they may have some benefit across the board.\nSome of the study\u2019s authors have testified for or received funding from drug companies, though the report itself was funded by national health agencies.\nHowever, in the elderly the differences between the treatment and placebo groups were much smaller, and the researchers calculated that 17 older patients would have to be treated with Prozac for one to gain from it.\nWhat\u2019s more, one researcher not involved in the study said its findings still don\u2019t mean the drugs are any better than non-drug methods of treating depression, such as talk therapy and being more physically active.\nMost of those trials were funded and run by the pharmaceutical companies that manufacture Prozac and Effexor \u2014 Eli Lilly and Wyeth, respectively.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story at least noted alternatives including psychotherapy and exercise, but didn\u2019t give information about the effects, pros/cons of these options.", "answer": 0}, {"article": "Bone-health experts are making a new push to reduce rates of osteoporosis, with a particular focus on controlling the bone-wasting disease in men.\n\nAn important goal is to get greater numbers of men to be tested for osteoporosis when they come to a hospital or clinic with a fracture to the wrist, vertebrae or other bones that wasn\u2019t from a major accident or trauma. Doctors call this a fragility fracture\u2014one that results from a decrease in bone density.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Ideally, we\u2019d like to see some mention here of the option not to perform BMD testing, since there is no real evidence supporting this recommendation. But the story gets high marks for talking about a range of treatment options for osteoporosis and general bone health, and we applaud that. It\u2019s rare to see a story try to pack in so much treatment information into one story, which is why we often ding stories in this part of the review.", "answer": 1}, {"article": "The results are chronicled in Robison\u2019s new book, \u201cSwitched On: A Memoir of Brain Change and Emotional Awakening.\u201d\n\nIn a moving, often harrowing narrative reminiscent of \u201cAwakenings\u201d and other popular works by the late neurologist and writer Oliver Sacks, Robison writes of the transformations these sessions helped unlock, the welcome ones \u2014 and the not so welcome.\nRather, it may be best used to alleviate certain symptoms associated with spectrum disorder, including depression.\nHis second marriage, to a woman who herself suffered from chronic depression, came undone within a year of his initial TMS sessions.\nPeople close to him questioned whether the risk was worth it.\n\u201cNow translate that concept to emotions,\u201d he continues.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no discussion of alternatives\u2013either of alternative treatments the patient\u00a0received, or of general options\u00a0for people with autism.", "answer": 0}, {"article": "WEDNESDAY, June 1, 2016 (HealthDay News) -- If you find yourself hospitalized, you've got a one in five chance of needing a urinary catheter -- raising your risk for a urinary tract infection.\nFor the study, Saint and his colleagues tried the new program in 600 hospitals.\nVisit the U.S. Centers for Disease Control and Prevention for more on urinary tract infections.\nThe findings were published June 2 in the New England Journal of Medicine.\n\"Unfortunately, there are side effects with a catheter.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternative is the status quo,\u00a0which is discussed in terms of its problems.", "answer": 1}, {"article": "\u201cThe dogma is strong,\u201d he said.\nIt\u2019s hard for us as surgeons and medical oncologists and radiation oncologists to accept that you don\u2019t have to remove the nodes in the armpit.\u201d\n\nDr. Grant W. Carlson, a professor of surgery at the Winship Cancer Institute at , and the author of an editorial accompanying the study, said that by routinely taking out many nodes, \u201cI have a feeling we\u2019ve been doing a lot of harm.\u201d\n\nIndeed, women in the study who had the nodes taken out were far more likely (70 percent versus 25 percent) to have complications like infections, abnormal sensations and fluid collecting in the armpit.\nThe complications \u2014 and the fact that there was no proof that removing the nodes prolonged survival \u2014 inspired Dr. Giuliano to compare women with and without axillary dissection.\n\u201cIt\u2019s a little frustrating.\u201d\n\nEventually, he said, genetic testing of breast tumors might be enough to determine the need for treatment, and eliminate the need for many node biopsies.\nIt is not known whether the findings also apply to women who do not have radiation and chemotherapy, or to those who have only part of the breast irradiated.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a great job explaining the history of this form of treatment and how it has evolved over time. \u201cBut doctors have continued to think that even microscopic disease in the lymph nodes should be cut out to improve the odds of survival. And until recently, they counted cancerous lymph nodes to gauge the severity of the disease and choose chemotherapy. But now the number is not so often used to determine drug treatment, doctors say. What matters more is whether the disease has reached any nodes at all. If any are positive, the disease could become deadly. Chemotherapy is recommended, and the drugs are the same, no matter how many nodes are involved.\u201d The story goes on to do something that stories like this rarely do, it compares compares the harms from different forms of treatment, saying \u201cAfter armpit surgery, 20 percent to 30 percent of women develop lymphedema, Dr. Port said, and radiation may increase the rate to 40 percent to 50 percent. Physical therapy can help, but there is no cure.\u201d", "answer": 1}, {"article": "For more information, please see www.arthrokinex.com\nTypically, the treatment process is painless and just takes a few minutes and consists of one injection per week for three weeks, followed by quarterly injections, as needed.\nSignificantly better concentration, healing/pain reduction durability, faster production (just one hour), one-fifth the price, and chemical additive free, IRAPjoint\u2122 is now available in multiple physician practices throughout the United States.\nFinally, a U.S. based company has a solution for America's professional and weekend athletes as well as those struggling with aching or arthritic joints.\nThe cost of the USA-based IRAPjoint\u2122 treatment is $2,000 compared to the reported price of $10,000 for a foreign competitor.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release doesn\u2019t name any alternatives for joint pain. For patients with mild symptoms, over-the-counter oral medicines like ibuprofen and naproxen can help. For some, physical treatments can help strengthen muscles and can improve function of the joint. At the other end of the spectrum, for patients with very severe arthritis, joint replacement is an invasive but effective option. However, for many with moderate symptoms, there is a need for treatments than can control symptoms. Injections into affected joints with other medicines including steroids and hyaluronic acid have been available for a long time. These treatments can have short-term benefit for some individuals, but don\u2019t help everyone.\u00a0 ", "answer": 0}, {"article": "However, the findings do not apply to every stroke victim.\n\u201cI really cannot overstate the size of this effect.\u201d\n\nThe key finding is that there is often more time than doctors realized in which brain cells can still be rescued by a procedure to remove the clot.\n\u201cThese striking results will have an immediate impact and save people from lifelong disability or death,\u201d Dr. Walter J. Koroshetz, director of the National Institute of Neurological Disorders and Stroke, said in a statement.\nThe researchers used a special type of brain imaging to identify the patients who still had live brain tissue that could be saved if the blood supply was restored.\nOnly about half the patients who were screened qualified for treatment, known as thrombectomy, which uses a mechanical device to pull clots out of a blood vessel.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story didn\u2019t make it clear enough that patients in the non-surgery group still received standard medical treatment for stroke. What does that consist of, and how effective is it? We\u2019re not told.", "answer": 0}, {"article": "Doctors in Seattle cured a late-stage cancer patient after tinkering with his body's defenses against infection, leading to cautious optimism about treating late-stage melanoma, a deadly skin cancer.\n\nThe surprising result, published in this week's issue of the New England Journal of Medicine, is the latest hopeful finding from the 30-year-old field of \"adoptive immunotherapy,\" which theorizes that the body can be taught to fight off its own cancers.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that the person undergoing the new immunotherapy failed to improve with chemotherapy, though it does not mention tumor excision or radiation as other potential therapies. And one wonders whether the prior chemotherapy played a role in the one Seattle patient\u2019s remission.\u00a0 ", "answer": 0}, {"article": "To book an interview, please contact: \n\nTucker Wilson \n\nMedia Relations \n\nFaculty of Health Sciences \n\nMcMaster University \n\n(905) 525-9140, ext.\nIn a study, recently published in the journal Vaccine, the researchers show that a novel chlamydial antigen known as BD584 is a potential vaccine candidate for the most common species of chlamydia known as Chlamydia trachomatis.\nIn the research team's study, BD584 was able to reduce chlamydial shedding - a symptom of C. trachomatis - by 95 per cent.\nHamilton, ON July 19, 2016 -- The first steps towards developing a vaccine against an insidious sexual transmitted infection (STI) have been accomplished by researchers at McMaster University.\nThe results look very promising, said senior author James Mahony, a professor of Pathology and Molecular Medicine for McMaster's Michael G. DeGroote School of Medicine and a researcher at St. Joseph Healthcare Hamilton's Research Institute where the work was performed.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There is no other pharmacological treatment for preventing the chlamydia infection currently available so we rate this \u201cnot applicable.\u201d However, it might have been noted that most public health experts recommend condoms for preventing this and other sexually transmitted diseases.", "answer": 2}, {"article": "SUNDAY, April 14, 2013 (HealthDay News) -- A method designed to target, freeze and destroy a tumor's cellular function seems effective in combating lung tumors, a small ongoing study finds.\nFunding for their work was provided by Galil Medical, a medical device manufacturer based in Arden Hills, Minn.\n\nBecause this study was presented at a medical meeting, the conclusions should be considered preliminary until published in a peer-reviewed journal.\nFor his part, Dr. David Carbone, a professor and director of the James Thoracic Center at the Ohio State University Wexner Medical Center, said that the findings regarding cryoablation are \"not incredibly novel,\" given that the procedure has been around for years.\nThe study authors cautioned that while the initial findings are encouraging, the treatment should not be seen as a cure for this type of metastatic (spreading) lung disease.\nThe targeted tumors were less than 3.5 centimeters (about 1.4 inches), which Woodrum described as being \"small to medium in size.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Granted, as already noted, the \u201cindependent\u201d expert discussed \u201cmultiple different technologies for doing this kind of very localized approach.\u201d\u00a0 But he also stated his own preference for stereotactic radiosurgery and the story didn\u2019t include any data/evidence comparison to help readers. This represents a major flaw in the reporting.\u00a0 There are multiple approaches to treatment currently including surgery, chemotherapy, radiofrequency ablation, stereotatic and other forms of radiation and proton beam therapy.\u00a0 There are data on the success of each of these in improving survival in patients with metastatic disease.", "answer": 0}, {"article": "\"We think it will be a very important tool in the toolbag of surgeons and physicians treating obesity and its co-morbidities,\" said Gregory S. Lea, senior vice president and chief financial officer of EnteroMedics. \"When patients leave the diet, counseling and drug world and have nothing more, they turn to surgical procedures, and only 1% to 2% of patients who might be eligible for bariatric surgery are getting it.\"", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story references the other common treatments for obesity \u2014 bariatric surgery (the only other FDA-approved surgical intervention for obesity) and pharmacological treatments. The report also contains a brief discussion on how the device might compare cost-wise to gastric banding. However, the story does not discuss how the weight loss with this device compares with that of the other therapies. That information is crucial for readers to develop an informed opinion, and would have been easy to include.", "answer": 0}, {"article": "What's that like for Mason?\nMore research will be needed to try to establish whether they actually repair damage to the spinal cord.\n\"There was nothing we could have done to change that night,\" said Bob Gambuti.\nToday, the company sponsoring the trial reported four of the six patients experienced improvement in both motor strength and function.\nBut it's hard to know what would have happened without them.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no discussion of alternative therapies or avenues of research for spinal cord injuries.", "answer": 0}, {"article": "Whether you've been relatively inactive or fairly athletic, age is the enemy of one of the most important sets of muscles in the body: the group of four known as the rotator cuff that surround the ball of the shoulder joint.\n\nAbout 54% of adults older than 60 have a completely or partially torn rotator cuff, compared with just 4% of those between 40 and 60. But tears are most frequently caused by degeneration of the tendon due to age, rather than injury from sports or trauma. Studies show that tears can be managed without...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention that tears can be managed \u201cwithout surgery,\u201d but then it discredits this statistic by saying \u201cone\u2019s strength tends not to improve\u201d without surgery. It does not attribute that assessment, and readers may be left in confusion. Existing traditional surgery methods and non-surgical alternatives are not given the same weight in the story as new techniques. The Annals journal article referenced in the story stated: \u201cFuture studies of high quality are needed to explore the relative effectiveness of early vs. delayed surgery, nonoperative versus operative treatments.\u201d", "answer": 0}, {"article": "\"This study provides clinical proof of concept that CAM2038 will be an effective treatment for opioid use disorder,\" said Behshad Sheldon, President and CEO of Braeburn Pharmaceuticals, \"The current opioid crisis demands innovation, and CAM2038's novel technology is now one step closer to providing physicians and patients with a different approach to treating this deadly chronic disease.\"\nA key objective of medication-assisted treatment for opioid use disorder is to reduce or eliminate the use of illicit opioids.\nDuring this period, four challenge sessions were conducted with a randomized hydromorphone dose to determine subjective 'liking' score based on a visual analogue scale.\nThe ability of CAM2038 to produce a long-lasting and robust blockade of hydromorphone-induced Drug Liking is especially encouraging,\" said Sandra D. Comer, Ph.D, Professor of Neurobiology, Columbia University.\nThe CAM2038 products are designed for administration by healthcare personnel to ensure proper delivery that minimizes the risks of diversion, abuse, misuse, and accidental exposure.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The FDA approved buprenorphine in 2002. According to SAMHSA, medication-assisted treatments like buprenorphine should be given in combination with counseling and behavioral therapies. No mention is made of whether the subjects in the experiment were given those supplementary therapies. Nor was any mention made of alternative drug treatments to buprenorphine. One of the most common ones is methadone.", "answer": 0}, {"article": "But this is not the case for those getting cortisone shots, he wrote; they \u201ctend to lag behind significantly at those time frames.\u201d In other words, in some way, the cortisone shots impede full recovery, and compared with those adopting a wait-and-see policy, those getting the shots \u201care worse off.\u201d Those people receiving multiple injections may be at particularly high risk for continuing damage.\nThe shots were quite effective, providing rapid relief of pain.\nThe fibers within the tendons fray.\nIt had such a magical, immediate effect against pain.\nSome people, including physicians, may decide that the answer remains yes.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\nThe article mentioned multiple treatment alternatives.\n", "answer": 1}, {"article": "In the study, published in the Annals of Internal Medicine, researchers reviewed 83 studies on the two methods.\n\"Based on currently available evidence, it appears reasonable to substitute core needle biopsy procedures for open surgical biopsy given the comparable sensitivity and lower complication rates,\" write researcher Wendy Bruening, PhD, of the ECRI Institute Evidence-Based Practices Center in Plymouth Meeting, Pa., and colleagues.\nIn addition, the study showed women initially diagnosed with breast cancer with needle biopsy were more likely to be treated with a single breast cancer surgery than those initially diagnosed by open surgical biopsy.\nResearchers say needle biopsy has fewer complications and a shorter recovery time than open surgical biopsy, but some women and doctors may have concerns about the accuracy of the procedure compared with traditional open surgery methods of breast cancer diagnosis.\nThe results showed that core needle biopsies were about as accurate as open surgery at detecting cancerous vs. noncancerous breast lesions.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The focus of the story is a recent meta-analysis that adds to a body of evidence sugesting core needle biopsies are as accurate and less risky compared with surgical open biopsies for diagnosing\u00a0 breast cancer.\u00a0 Since the focus of the story was less invasive methods of biopsy,\u00a0 it would have been good to describe the different kinds of core needle biopsies, as well as fine needle aspiration, which is even less invasive than the core biopsy and can be used for palpable masses. Nonethless, we\u2019ll give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "For more information visit http://www.\nIt provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease.\nAfter one year of the study, 36 per cent of patients treated with nivolumab were still alive compared with 17 per cent for the comparator arm.\nThis phase III clinical trial expands the repertoire of nivolumab even further, showing that it is the first treatment to have significant benefits in relapsed head and neck cancer.\nProfessor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:\n\n\"Nivolumab is one of a new wave of immunotherapies that are beginning to have an impact across cancer treatment.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The study at issue was for patients who were seeing cancer progression despite the use of conventional chemotherapy treatments. In other words, as the release makes clear, the alternatives had been tried already.", "answer": 1}, {"article": "And there's another potential problem with existing treatments.\nThe greater possibility of a cure and fewer side effects, in turn, will lead more people who think they have hepatitis C to \"come out of the woodwork,\" said Schiff, who's familiar with the study findings.\nThe side effects, particularly of the treatment component known as interferon, can be \"pretty hard to deal with,\" said Nicholas A. Meanwell, a co-author of the study and a researcher with the Bristol-Myers Squibb pharmaceutical company.\nFor now, much of the attention in the world of liver disease is on two drugs -- telaprevir and boceprevir -- that Schiff expects will become available within the next year and a half.\nIt's too early to tell if the drug actually works, and it will be years before it's ready to seek federal approval to be prescribed to patients.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story gives an inaccurate portrait of how the\u00a0treatment approach with the new antiviral drugs will differ from the current standard regimen. The story suggests\u00a0that the new drugs will replace existing treatments, but\u00a0studies of newer antivirals have used the drugs\u00a0in combination with standard therapy not in replacement of it.\u00a0The story should have clarified that\u00a0the newer agents will, at least initially, be used\u00a0as an\u00a0adjunct to\u00a0existing therapies if and when they receive FDA approval.\u00a0\u00a0", "answer": 0}, {"article": "But given the 2013 research suggesting \u201ctoxicity of high coffee doses\u201d in some people, he said, \u201cto me the most reasonable approach would be to keep coffee intake to two to three cups most days.\u201d\n\nSecond Take: STAT knows better than to get between coffee lovers and their cup o\u2019 joe, so if you want to take this study as permission to keep beating a path to your Keurig, we\u2019re not going to slow you down.\nOverall, the conclusions have been pro-coffee.\nTakeaway: Observational studies that associate coffee drinking with health benefits are strongly suggestive but not definitive.\nis enough to make STAT cross-eyed.\nEven the 5-plus\u2019s had 12 percent lower mortality.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We thought that a comparison of alternatives to coffee was beyond the scope of the story.", "answer": 2}, {"article": "Kalluri and his colleagues examined serum samples from 190 patients with pancreatic cancer, 32 patients with breast cancer and 100 healthy volunteers.\nIt now needs to be taken over by some diagnostic corporation before it can launch into something for widespread use.\u201d\n\nWhat needs to be determined is \u201cwhat the sensitivity and specificity would be in a screening population of 100,000 people,\u201d said Dr. Brian Wolpin, of the Dana Farber Cancer Institute.\nBut, he said, \u201cthis is just a speculation based on the current strength of the study.\u201d\n\nHad such a test been available, it might have save the life of Dr. Teresa Flippo-Morton, a prominent breast surgeon from Charlotte, N.C.\n\n\u201cShe was an expert in oncology,\u201d said Dr. Derek Raghavan, a colleague and president of the Levine Cancer Institute where Flippo-Morton worked.\n\u201cSomething like this could potentially flatten that curve and change the epidemiology of pancreatic cancer.\u201d\n\nStill, Donahue said, the method needs to be \u201cheavily vetted and validated.\n\u201cIt kills people and it kills them quickly.\u201d\n\nA screening test could have a huge effect, said Dr. Timothy Donahue, an associate professor of surgery and molecular and medical pharmacology and chief of pancreas and gastrointestinal surgery at the University of California, Los Angeles.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no mention of alternatives in this story or whether other research has gone in this direction and failed to yield a marketable test. While\u00a0there really aren\u2019t any good screening tests, there is another tumor marker (CA 19-9) that has been used for screening, but it does not readily detect the early-stage cancers. The study actually compared the new test with CA 19-9.", "answer": 0}, {"article": "A man whose P.S.A.\n\u201cThere\u2019s a strong case that they should be exempted from screening.\u201d\n\nThe advice is less clear for men with scores between 1.0 and 2.0 at the age of 60.\nThe long-term risk of dying from prostate cancer ranged from about 1 percent to 3 percent for these men, and the decision to screen may depend on their personal views and family histories, Dr. Vickers said.\n\u201cWe need to screen fewer people, screen the right people, and we don\u2019t have to treat every cancer we catch.\u201d\n\nA version of this article appeared in print on September 28, 2010, on page D1 of the New York edition of The Times.\nThe findings also suggest that at least half of men who are now screened after age 60 don\u2019t need to be, the study authors said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0The story focused on the possibility of reducing the number of PSA tests a man might undergo in his lifetime to screen for prostate cancer if at age 60 his PSA level is found to be less than 1. \u00a0SInce the test is run on a blood sample collected as part of the blood collected for various other types of screening and testing, the story did not make clear why reducing the number of PSA tests a man has is of importance. \u00a0It goes beyond the cost of the test itself and includes the costs for biopsies and cancer treatments which would not be done. \u00a0The story should have been clearer that beyond costs, reducing the number of tests may be a benefit because not only is testing itself stressful, but the more you test, the more likely you are to get an abnormal result. \u00a0Even if this elevated PSA level is addressed by just repeating the test, treating a urinary infection, etc \u2013 it still adds stress and cost.", "answer": 0}, {"article": "In dark suits and blue shirts, with serious expressions on their round faces, they walked to stand next to their mother in a very beige room outside Washington, D.C.\nJust because a drug doesn\u2019t measure up in that way, he says, \u201cdoesn\u2019t mean the drug is not effective.\u201d\n\nBut even if the FDA agrees to overlook some of the negative data about ataluren, insurers may not.\nIn an e-mailed statement, FDA spokesperson Sandy Walsh confirmed that the FDA\u2019s decisions are all \u201cbased on an assessment of the available data and whether the benefits of the drug outweigh its risks.\u201d That data can include the experience of patients like Max, Rowan and Charlie.\nThe drug, called Exondys 51 or eteplirsen, allows the genetic machinery that produces the protein to skip over the mutated part to make something that will work better.\nThe brothers, ages 6 through 11, suffer from a debilitating and deadly genetic condition called Duchenne muscular dystrophy (DMD).\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no known cure for Duchenne muscular dystrophy.\u00a0 The story does devote some space to another drug, Exondys 51, which has been approved by the FDA, but the text is clear that the type of DMD that afflicts the three boys is not responsive to that drug.", "answer": 1}, {"article": "MONDAY, March 22, 2010 (HealthDay News) -- The anti-clotting drug Plavix is of modest benefit in cutting the odds of death in patients with heart failure and heart attack who don't undergo angioplasty, a new study finds.\nThe study appears online March 23 and in the March 30 print issue of the Journal of the American College of Cardiology.\nDanish researchers analyzed data from more than 31,000 patients hospitalized with heart attack between 2000 and 2005 and divided the patients into four groups: two groups with heart failure (one that received Plavix and one that did not) and two groups without heart failure (one that received Plavix and one that did not).\nA randomized study comparing conventional heart failure therapy with and without Plavix \"is needed urgently,\" the editorial writer concluded.\nThe mean follow-up was 18 months for both heart failure groups and just over two years for both non-heart failure groups.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0There was no discussion about the impact other medications in the same class as Plavix have in the populations studied.", "answer": 0}, {"article": "May 12, 2010 (Baltimore) -- The powerful sleeping medication Xyrem can help relieve the hallmark symptom of pain in people with fibromyalgia, suggests a study that pitted the drug against a placebo.\nXyrem, which is approved by the FDA for the treatment of narcolepsy, corrects the same disturbed sleep patterns that studies have shown are common in fibromyalgia patients, Jones says.\nThe National Fibromyalgia Association estimates that about 10 million Americans, mostly women, have fibromyalgia, an unexplained condition characterized by chronic pain and fatigue.\nMore than half of people who took Xyrem reported at least a 30% improvement in pain, says Kim Dupree Jones, PhD, of Oregon Health & Science University in Portland.\nAlso, small, preliminary studies suggested the drug can reduce pain and fatigue in people with fibromyalgia.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story describes the 3 other medications currently indicated to treat fibromyalgia, noting that Xyrem has a unique mechanism of action. Readers would have also benefited from a discussion of the non-drug treatments for fibromyalgia, as well.\u00a0", "answer": 1}, {"article": "A video in which Professor Probert explains how the machine works can be found here\n'The use of a gas chromatography (GC)-sensor system combined with advanced statistical methods towards the diagnosis of urological malignancies', published today in the Journal of Breath Research, describes a diagnostic test using a special tool to 'smell' the cancer in men's urine.\nProfessor Norman Ratcliffe said, \"There is currently no accurate test for prostate cancer, the vagaries of the PSA test indicators can sometimes result in unnecessary biopsies, resulting in psychological toll, risk of infection from the procedure and even sometimes missing cancer cases.\nThe results of the pilot study using the GC sensor system indicate that it is able to successfully identify different patterns of volatile compounds that allow classification of urine samples from patients with urological cancers.\nWith help from industry partners we will be able to further develop the Odoreader, which will enable it to be used where it is needed most; at a patient's bedside, in a doctor's surgery, in a clinic or Walk In Centre, providing fast, inexpensive, accurate results.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The story goes into some detail about how this test might compare with the PSA test and gives a brief mention of biopsies. The lead author states:\u00a0 \u201cThere is currently no accurate test for prostate cancer, the vagaries of the PSA test indicators can sometimes result in unnecessary biopsies, resulting in psychological toll, risk of infection from the procedure and even sometimes missing cancer cases.does indicate that the PSA test is problelmatic for false positives.\u201d", "answer": 1}, {"article": "The surgery worked.\nWatson says we don't know for sure, but it's possible the body begins to adapt to those changes, which is why the weight loss is reversed over time.\nIf the stomach pouch has stretched, new sutures are put in place to once again reduce the size of the stomach.\n\"It was the first time in my life that I've ever lost a lot of weight and was able to maintain it.\"\nThe problem is that over the years the stomach stretches, and when that happens, Watson says, \"Patients are able to eat more at one sitting and they feel hungrier more often.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We are told the there are other procedures available to help maintain the benefits of bariatric surgery, but they are not described. \u00a0And while the story states that the patient is recommitting herself to lifestyle changes, exercise and diet after receiving the TORe procedure, it would have been useful to describe the role of these measures in preventing the initial weight regain. The authors of the research stated; \u201cTORe is one approach to avoid weight regain; a longitudinal multidisciplinary approach with dietary counseling and behavioral changes are required for long term results.\u201d", "answer": 0}, {"article": "For the study, a former associate professor of Dermatology and Pathology at Yale University, Rossitza Lazova, M.D., collaborated with a national and international team of researchers to determine whether atypical moles could be more accurately diagnosed as either benign or cancerous (melanoma) using imaging mass spectrometry (IMS) \u2014 a technology that enables pathologists to focus in on individual proteins within sampled skin cells.\nThe test, which analyzes proteins in cells, could provide more reliable results for clinicians with patients who might be at risk for this deadly cancer.\nFor centuries pathologists have relied on the microscopic examination of tumors to distinguish between atypical moles and melanoma.\nThe researchers found that in nearly all cases, the IMS analysis was a more accurate predictor, both of benign lesions and melanomas, than standard microscopic examination.\nIn a prior study, the researchers used IMS to identify a molecular signature comprised of five proteins to differentiate between one type of benign mole and melanoma.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release mentions the current standard of practice but does not offer a data-based comparison, as we note in the \u201cquality of evidence section.\u201d", "answer": 1}, {"article": "For more information about the AACR, visit http://www.\nIn addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers.\nIn an interview, Sakoda said, \"Metformin use was not associated with lung cancer risk when we looked at all patients with diabetes.\nHowever, our results suggest that risk might differ by smoking history, with metformin decreasing risk among nonsmokers and increasing risk among current smokers.\nMetformin use was not associated with lower lung cancer risk overall; however, the risk was 43 percent lower among diabetic patients who had never smoked, and the risk appeared to decrease with longer use.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release investigates the possibility that metformin may decrease the risk of lung cancer in people who never smoked. This would have been an opportune place to add that not smoking \u2014 or quitting smoking, if you are a smoker \u2014 is probably the most important thing one can do to reduce the risk of lung cancer.", "answer": 0}, {"article": "A week later, under no medication, participants returned to repeat the experiment.\nThis is called 'reconsolidation', and we now plan to test the effect of doxycycline on reconsolidation of fear memories.\nTo treat such diseases, we already have clinically approved drugs that block these enzymes, including the antibiotic doxycycline, so we wanted to see if they could help to prevent fear memories from forming in the brain.\nThe fear memory response was calculated by subtracting the baseline startle response -- the response to the sound on the 'good' colour - from the response to the sound when the 'bad' colour was showing.\n\"We have demonstrated a proof-of-principle for an entirely new treatment strategy for PTSD,\" explains Professor Bach.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release doesn\u2019t mention any of the other treatment strategies for PTSD or show how this drug might compare with them.\nOne other drug that\u2019s been studied for its use in the blocking of learning conditioned fear is the beta blocking blood pressure drug propanolol. ", "answer": 0}, {"article": "Feb. 15, 2011 -- Taking zinc, either as a syrup or lozenge, through the first few days of a cold may shorten the misery of an upper respiratory infection, a new research review shows.\n\u201cWe really don\u2019t have interventions for colds that work.\u201d\n\nThe review of 15 studies with 1,360 participants was published by the Cochrane group, an international collaboration of researchers that reviews evidence behind therapeutic interventions.\n\u201cThe evidence from the recent trials does support the use of zinc lozenges in treatment of common cold,\u201d says study researcher Meenu Singh, MD, a pediatric pulmonologist at the Post Graduate Institute of Medical Research in Chandigarh, India.\nThe review also found that zinc cut the number of days that kids missed school because of being sick and reduced the use of antibiotics by cold sufferers.\n\u201cThis is great news,\u201d says Kay Dickersin, PhD, an epidemiologist with the Johns Hopkins School of Public Health and director of the U.S. Cochrane Center.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes a brief mentoin of only one alternative to zinc: antibiotics. It says, \u201cThe review also found that zinc cut the number of days that kids missed school because of being sick and reduced the use of antibiotics by cold sufferers.\u201d What? Most doctors will tell you that antibiotics are ineffective against the common cold, and that they are mainly given as a placebo to make patients feel like they are taking action. Raising the issue of antibiotics without explaining that they don\u2019t really work is a disservice to readers.\u00a0We would have liked to have seen some comment on the best ways to protect yourself and your family from getting a cold besides zinc products. A few words about hand hygiene and keeping your hands away from your eyes, mouth and nose would have been helpful to the readers.", "answer": 0}, {"article": "Tens of thousands of patients a year undergo the procedure \"off-label,\" however, paying around $5,000 out-of-pocket, based on the claims of doctors who say it can cure everything from Alzheimer's to autism.\nThe taxpayer-funded study tested whether a controversial alternative therapy, called chelation, could reduce heart attacks and other cardiovascular problems in people who had already survived a heart attack.\nFurther analysis showed the benefits were limited to those with diabetes, rather than for patients overall.\nAn investigation by the federal Office for Human Research Subject Protections, which is charged with protecting patients, found that patients may not have been properly informed of chelation's risks.\nYet some doctors say the study was far from rigorously performed, and so badly run that its marginally positive results are meaningless.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that there are\u00a0medications and\u00a0lifestyle changes that clearly have been shown to reduce heart disease. That\u2019s good enough.", "answer": 1}, {"article": "Carissa Cascio, an assistant professor of psychiatry from Vanderbilt University School of Medicine, who specializes in autism and neuro-imaging, believes these study results are important.\nCurrently there's no biologic test for autism, so pediatricians look to see if a child is meeting certain developmental milestones as well as signs and symptoms of autism.\n(The advocacy group Autism Speaks has posted videos to help parents see the signs of autism)\n\nThe earlier a child has been identified as having autism, the earlier behavioral therapies can be applied to lessen the impact of the disorder later in life.\nThe study included only males between the ages of 7 and 28 because they were part of a bigger research project at the University of Utah, which is following males with autism for a longer period.\nWhile previous studies using different types of scans have been able to identify people with autism, Lange says, \"no one has looked at it [the brain] the way we have and no one has gotten these type of results.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Unlike the Reuters story, this one actually pointed out that there are other ways to detect autism beyond brain scans. \u201cCurrently there\u2019s no biologic test for autism, so pediatricians look to see if a child is meeting certain developmental\u00a0milestones as well as\u00a0signs and symptoms of autism. (The advocacy group Autism Speaks has posted\u00a0videos to help parents see the signs of autism)\u201d\u00a0We would have liked to have seen a couple of additional comments about the current testing modes, their limitations and the degree of accuracy provided by them.", "answer": 1}, {"article": "For more information on hospital patient services, visit muschealth.org.\nThis is because the accuracy of the device simplifies the decision made by emergency personnel about where to take patients first, according to Raymond D. Turner, M.D., professor of neurosurgery and chief of the Neuroscience Integrated Center of Clinical Excellence at MUSC.\nIt is also not clear how the device would work for patients with cranial implants, as metal interferes with the device's operating radio frequencies.\nIn contrast, a standard physical examination achieved only 40 to 89 percent accuracy in identifying patients with large-vessel occlusion who could benefit from endovascular therapy.\nCompared to the neurologists' diagnoses, the device displayed 92 percent specificity -- the ability to detect the difference between patients with severe stroke and those with other conditions such as mild stroke or healthy participants with no brain pathology.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The study compares this device to a clinical diagnosis by neurologists and the release states that the device showed \u201c92 percent specificity\u201d which we are told is above the \u201cstandard physical examination tools used by emergency personnel that display specificity scores between 40 and 89 percent.\u201d\nBut as noted above, the better comparison would be comparing this device to CT scans given that mobile CT scanners are increasingly being used in ambulances.", "answer": 0}, {"article": "What's the point of a runny nose?]\n\u201cIt's almost symbiotic,\u201d Navarro said, \u201cbecause in order for it to survive and thrive, it needs its host to be happy and healthy.\u201d\n\nPerhaps the adaptations that help the parasites stay hidden also benefit their host by reining in overactive immune systems.\nAnd because of the risks associated with parasites, going around infecting people isn't a viable treatment option.\nThe study is the latest from a surprising field of research into the potentially positive sides of parasites, one of the most maligned groups in the animal kingdom.\nThis suggests that AIP-2 might also help humans, since dendritic cells have the same function in us that they do in mice.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the article talks about 235 million asthma sufferers across the world, it provides no description of the challenges they face or the limitations of current treatment options. It\u2019s not clear, therefore, why or for what types of people an alternative treatment is needed and what this treatment might have to offer over the status quo.", "answer": 0}, {"article": "This new development represents a big step forward in personalised medicine.\nWe are excited that CURATE.AI could ultimately enhance patient accessibility to important new combination therapies, saving lives in the process,\" said Prof Ho, who is also from the Biomedical Engineering and Pharmacology departments at NUS, as well as a member of the Biomedical Institute for Global Health Research and Technology (BIGHEART) at NUS.\nRemarkably, CURATE.AI subsequently identified a ZEN-3694 dose that was 50 per cent lower than the patient's starting dose of the drug prior to CURATE.AI analysis.\n\"No two patients' profiles are alike, and as a patient's body and the cancer itself evolve during treatment, the CURATE.AI profile evolves as well, enabling the clinical and engineering teams to optimise care for the entire duration of treatment, an unprecedented advance for combination therapy,\" Prof Ho explained.\n\"The implementation of CURATE.AI represents a game-changing shift in the way that combination therapy can be optimised at the single patient level, and we have shown that N-of-1 medicine can be a reality.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "CURATE.AI is far from the only AI tool that has been considered for use in cancer treatment. For example, HealthNewsReview.org wrote last year about a (failed) attempt to incorporate IBM\u2019s Watson system into cancer treatment at M.D. Anderson Cancer Center. And there are hundreds of papers that address various attempts to use AI, machine learning, or artificial neural networks in the context of cancer treatment. Here\u2019s a review paper from 2006 that addresses 396 related papers that had already been published at that time. The release on CURATE.AI does not make clear how this new AI tool is different from or similar to the body of work in the field.\u00a0 We don\u2019t expect a news release to offer a detailed overview of how the new work differs from what came before it, but we do expect a release to provide at least a broad idea of what sets the new work apart.", "answer": 0}, {"article": "For pain, they were randomly assigned to take acetaminophen along with a non-opioid \u2014 ibuprofen \u2014 or with one of three commonly prescribed opioids: oxycodone, hydrocodone or codeine.\nData on pain came from the participants' ratings; no information on side effects was collected.\nAdults with arm or leg pain caused by a sprain, strain or fracture.\nThe study did not assess longer-term pain reduction.\nMight non-opioid painkillers work just as well as these addictive drugs?\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story (and the study itself) are focused on the comparison of alternatives.", "answer": 1}, {"article": "The American Academy of Family Physicians has more about cholesterol-lowering drugs.\n\"Of note is the reduction in the number of myalgias (muscle pains) for patients compared to the number of myalgias experienced by people taking statins.\n\"The most interesting aspect of this study is use of a novel approach using monoclonal antibodies -- a subtype of antibodies -- in the management of elevated LDL cholesterol,\" said Dr. Kenneth Ong, acting chief of cardiology at the Brooklyn Hospital Center.\nThe 12-week, phase 2 clinical trial was conducted at 33 international sites and included adults who suffered muscle problems when taking statins, a class of cholesterol-lowering drugs that includes Crestor and Lipitor.\nThe study was published online Nov. 5 in the Journal of the American Medical Association, to coincide with a planned presentation at the American Heart Association's annual meeting in Los Angeles.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does make clear that this drug is intended to offer an alternative to patients who have problems with standard statin drug treatment. It also reports that reductions in LDL cholesterol levels were comparable to those seen with statin treatment. However, as noted above, the story fails to point out that while statin treatment has been shown to reduce health risks for patients with heart disease neither this trial nor any others have yet shown meaningful health benefits for these patients.", "answer": 1}, {"article": "Parkinson's disease is a degenerative condition that affects the central nervous system.\nThe study findings should be interpreted cautiously because the participants were mostly white professionals, and the results might not apply to other ethnic groups.\nBut, he added, it's important for people to realize that this research isn't applicable to people who already have the disease.\nFor women, however, a reduction in risk was only seen when they ate at least several servings of berries a week, according to the study.\nThere are no harmful effects from berry consumption, and they lower the risk of hypertension too,\" Gao added.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There aren\u2019t really any effective alternatives for preventing Parkinson\u2019s disease, so we\u2019ll rule this not applicable.", "answer": 2}, {"article": "Depression risk was assessed using the Edinburgh Postnatal Depression Scale (EPDS) six weeks after childbirth.\n\u201cWe found that certain women who experience good pain relief from epidural analgesia are less likely to exhibit depressive symptoms in the postpartum period.\u201d\n\nThe researchers controlled for factors already known to increase the risk for postpartum depression, including pre-existing depression and anxiety, as well as post-delivery pain caused by tissue trauma during childbirth.\n\u201cPostpartum depression can develop from a number of things including hormonal changes, psychological adjustment to motherhood, social support, and a history of psychiatric disorders.\u201d\n\nLabor pain may be more problematic for some women than others, the authors note.\nIt may be psychologically harmful for some women and play a significant role in the development of postpartum depression,\u201d said Grace Lim, M.D., director of obstetric anesthesiology at Magee Women\u2019s Hospital of the University of Pittsburgh Medical Center and lead investigator on the study.\nNewswise \u2014 CHICAGO \u2013 Epidural anesthesia may do more than relieve pain during labor; in some women it may decrease the likelihood of postpartum depression, suggests a preliminary study presented at the ANESTHESIOLOGY\u00ae 2016 annual meeting.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The best comparison we get to alternatives is a bit of minor scaremongering. This release really should have brought more to bear on births where women choose to not to use an anesthetic, also called \u201cnatural\u201d birthing. It should also be noted that nitrous oxide is increasingly being offered as an alternative in hospitals around the US. That\u2019s worth noting.", "answer": 0}, {"article": "A 33-year-old Queens woman who was treated by Batzofin last week fits that bill. Married for two years, she failed to get pregnant through intercourse, with and without drugs. When Batzofin told her about his new procedure, she said, \"Let's go for it.\"", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story focuses on a comparison of IVF v. IVM.\u00a0 Other methods to increase fertility are not discussed.\u00a0 Women with subfertility and PCO may try less dramatic means to enhance their likelihood of conceiving with modest weight loss and conventional medications as needed.\u00a0 ", "answer": 0}, {"article": "Allergan Inc. said that two large human tests of its Botox drug, best known for smoothing wrinkles, showed that periodic injections prevent headaches in adults who suffer from chronic migraines.\n\nEven though details of the study weren't released, the announcement, which surprised many physicians and investors, sent Allergan's shares soaring 11%, or $5.95, to $60.53 at 4 p.m. in New York Stock Exchange composite trading. Botox has been used to treat severe headaches for many years, but some researchers have long been skeptical...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention alternative treatments for migraines, of which there are many.", "answer": 0}, {"article": "DOI: 10.1016/j.ajog.2017.11.570.\nThese questions addressed in a new study by researchers from Charit\u00e9 - Universit\u00e4tsmedizin Berlin, the results of which have been published in the American Journal of Obstetrics and Gynecology*.\nSo far, research into the clinical effectiveness of apps has been limited, and only a few have been tested using randomized controlled trials,\" says Dr. Daniel Pach of the Institute of Social Medicine, Epidemiology and Health Economics.\nHowever, the women who were involved during the planning stages, all of whom were affected by menstrual pain, wanted an app,\" reports the study's principal investigator, Prof. Dr. Claudia Witt of the Institute of Social Medicine, Epidemiology and Health Economics.\n\"We were surprised to see that, after six months, two thirds of participants continued to use self-acupressure.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes that the trial aimed to evaluate whether women achieved greater reduction from acupuncture as an add-on treatment than from \u201cusual care alone.\u201d Usual care was described as pain medication and hormonal contraceptives.\nThe release would have been improved had it made it explicit that the study participants continued to use other pain relief therapies while doing acupressure and that the acupressure study was designed to test the technique\u2019s value as an adjunct therapy.", "answer": 1}, {"article": "The testing is done under medical supervision.\n\"We found that 14 percent of the patients challenged had mild or moderate allergic reactions,\" explains study author Carla Davis, an allergist and director of the Food Allergy Program at Texas Children's Hospital.\nA new study published in the Annals of Allergy, Asthma & Immunology illuminates just how many people come to find out they can eat foods they've long avoided.\nAs we've reported, people sometimes misinterpret the symptoms of a condition such as lactose intolerance for a food allergy.\nBut the only way to confirm that it was safe for Jula to eat egg was to take the food challenge test.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "In one sense, the only alternative to having an oral food challenge is not having an oral food challenge, and possibly not discovering that a child has grown out of an allergy. That issue is covered in this story. Another important point is that skin prick tests have been found to produce misleading results in a large proportion of patients. There is a growing conviction among researchers and practitioners that the only way to confirm beyond doubt that an individual has a food allergy is to conduct a food challenge. That alternative was mentioned in the story, but more emphasis would have presented a fuller picture of the significance of the study findings.", "answer": 1}, {"article": "Such shared and informed decision making might enhance treatment adherence which is one of the main challenges of treating major depressive disorder,\" said Gerald Gartlehner, M.D., associate director of the RTI-UNC Evidence-based Practice Center, who was the principal investigator of the evidence review, which was also published today by AHRQ.\nThey found that symptom improvement and rate of remission were similar between the two options, whether used alone or in combination with each other.\n\"Our findings indicate that both options should be considered effective initial treatment strategies.\"\nPatients also sometimes express concerns about becoming addicted to medications and therefore prefer psychotherapy.\nA recent evidence review of several alternatives to medication found that using cognitive behavioral therapy as the first treatment for depression can be equally effective as using a second generation antidepressant.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "While the release is about comparative trials it didn\u2019t delve into what improvement means.", "answer": 1}, {"article": "The page may no longer exist or may have moved to another web address. Try again to locate what you want by choosing a section from the navigation menu at left, viewing our Site Map or using the search box below.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a thorough job in comparing alternatives. It mentions the effectiveness and side effects of hormone replacement therapy and even cites the results of the Women\u2019s Health Initiative. It also talks about other medications used to treat hot flashes and other alternative therapies, such as yoga, acupuncture, qi gong and meditation. However, the effectiveness of the other alternative therapies is not proven (beyond small, short term, and often un-blinded studies).", "answer": 1}, {"article": "Nov. 12, 2012 -- A drug used outside the U.S. to treat osteoporosis may not only lessen the everyday pain associated with knee osteoarthritis, but may even slow down the progression of osteoarthritis, researchers say.\nAnd nearly 19% of women and 14% of men age 45 and older have joint pain, stiffness, and other symptoms of knee osteoarthritis, according to a large 2007 study.\nThe function of cartilage is to reduce friction in the joints and serve as a \"shock absorber.\"\nIn a three-year study of more than 1,300 people with knee osteoarthritis, digital X-rays revealed substantially less loss of cartilage in the joint space in those who took strontium ranelate every day compared with people who took a placebo daily.\nThe wearing away of cartilage leads to pain and other symptoms.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that there are no\u00a0drugs currently available that can\u00a0delay the progression of knee osteoarthritis, and that current osteoarthritis treatments, such as medication and physical therapy, are aimed at improving symptoms.", "answer": 1}, {"article": "\u201cSo in our study we wanted to expand that and look at all-cause mortality and be able to see whether optimism improves other health behaviors that then affects mortality, or whether there\u2019s an independent effect of optimism on mortality.\u201d\n\nFor the study, the researchers analyzed data on from 2004 to 2012 on 70,000 women who participated in the Nurses\u2019 Health Study, a long-running research project tracking women\u2019s health via surveys every two years.\nHaving an optimistic outlook on life may do more than just boost your mood.\nThey suggested a number of steps people can take to improve their level of optimism.\nChan School of Public Health.\n\u201cSo it could be that optimism directly impacts our biological functioning,\u201d Hagan said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does discuss healthy dietary choices and exercise.", "answer": 1}, {"article": "(Reporting by Susan Kelly, editing by Dave Zimmerman)\nIn the study, patients on pump therapy saw a reduction in average A1C levels of 0.8 percent, compared with a 0.2 percent average reduction for those who received multiple injections.\n\u201cWhat we\u2019ve been able to show is that by combining this technology, you can lower the A1C, which reduces your risk of complications, and you can do it safely without increasing your rate of hypoglycemia,\u201d said study author Dr. Richard Bergenstal, executive director of the International Diabetes Center at Park Nicollet Health Services in Minneapolis.\nAdult and pediatric patients using the pump and continuous glucose monitoring device saw reductions in levels of A1C, a commonly used measure of blood sugar, that were four times greater than those who received regular insulin injections in the study of 485 patients ranging from age 7 to 70.\nPatients in the study, which was presented at a meeting of the American Diabetes Association in Orlando, Florida, and sponsored by Medtronic, achieved better glucose control over a one-year period without an increase in hypoglycemia, or dangerously low blood sugar.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n \nAlthough the story does mention that people with diabetes can manage blood glucose levels with multiple daily injections of insulin, without a pump, it leaves out a critical piece of information. Patients who could successfully manage their blood sugar levels without a pump were excluded from the study. Readers should be told how often people with diabetes can achieve treatment targets without using a pump. This story does not make clear that the trial results apply only to people who are unable to achieve treatment goals by using multiple daily insulin injections.\n", "answer": 0}, {"article": "For more information, visit www.aao.org.\nIn addition, the non-invasive nature of the device and its relatively large surface area make this technology a potential candidate for delivering multiple ocular drugs at once, further reducing the burden of self-administration on patients.\n\"In making effective treatments easier for patients, the hope is that we can reduce vision loss from glaucoma, and possibly other diseases,\" said study author James D. Brandt, M.D., director of the UC Davis Medical Center Glaucoma Service.\nThe authors noted the device could also be used for non-glaucoma medications, with potential applications for dry eye, allergies and inflammation.\nFor more information on glaucoma, visit the American Academy of Ophthalmology's EyeSmart\u00ae public information website, www.aao.org/eye-health.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does not compare the ring with existing approaches to help patients adhere to treatment plans, such as better physician-patient communication and simplified drug regimens. It also gives a quote from a study author saying, \u201cWhat is exciting is that this is just one of several sustained-release drug delivery methods designed to help patients who have trouble taking daily eye drops.\u201d But there\u2019s no elaboration to explain what these other methods are or whether they have been studied or approved for use in glaucoma patients.", "answer": 0}, {"article": "Before the introduction of whooping cough vaccine in the 1940s, more than 200,000 cases a year were reported in the U.S. By 1965, that number plummeted to fewer than 10,000 a year. But the disease made a comeback in the 1990s, as the newer \"acellular\" vaccine \u2014 containing only cellular material but not whole cells \u2014 was phased in. While it is safer and has fewer side effects than the old version, studies have found that its protective effects wane more quickly than originally expected.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternative would be not getting a Tdap vaccine as a pregnant mother, so we\u2019ll rate this N/A.", "answer": 2}, {"article": "\"We're trying to provide an alternative material, an alternative therapy,\" he said, because the current method involves the dentist removing all of the infected pulp tissue, \"scraping it out, and it can be very painful.\"\nThe process works by stimulating native stem cells inside teeth, triggering repair and regeneration of pulp tissues.\nInstead of the current dental materials used on fillings, which are toxic to cells, the new approach harnesses stem cells instead.\nThey're developing a new treatment strategy that could someday help heal a damaged tooth using the patient's own stem cells.\nIt's a barrier between enamel and the soft tissue that contains all the blood vessels and cells,\" Celiz explained.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that root canals are the current standard of therapy.", "answer": 1}, {"article": "The study did not follow people over time.\nDr. Fiore, who has reported receiving payments from drug makers, said that \u201cthere are millions of smokers out there desperate to quit, and it would be a tragedy if they felt, because of one study, that this option is ineffective.\u201d\n\nIn the new study, conducted in , the researchers followed a representative sample of 1,916 adults, including 787 people who said at the start of the study that they had recently quit smoking.\n\u201cSome studies have questioned these treatments, but the bulk of clinical trials have unequivocally endorsed them,\u201d said Dr. Michael Fiore, director of the \u2019s Center for Tobacco Research and Intervention and the chairman of the panel that wrote the guidelines.\nMotivation matters a lot; so does a person\u2019s social environment, the amount of support from friends and family, and the rules enforced at the workplace.\nThe use of replacement products made no difference, whether they were taken for the recommended two-month period (they usually were not), or with the guidance of a cessation counselor.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story lists a range of alternative factors for successful smoking cessation at the end of the piece: \u201cMotivation matters a lot; so does a person\u2019s social environment, the amount of support from friends and family, and the rules enforced at the workplace. Media campaigns, increased tobacco taxes and tightening of smoking laws have all had an effect as well.\u201d This isn\u2019t quite a comparison with nicotine products, but we give the story credit for covering some of this territory.", "answer": 1}, {"article": "This is relatively new thinking.\nThe authors of the just-published study reviewed all of the available evidence on the topic and included 146 studies in their final analysis.\nNot so long ago, in 2000, the American Academy of Pediatrics recommended that allergenic foods be kept away from infants until they were at least a year old, and often older.\nEarly introduction didn\u2019t seem to make a difference for autoimmune diseases, at least according to the available evidence; eating gluten young wasn\u2019t associated with the risk of developing celiac disease.\nMore research is necessary to figure out the ideal amounts of these allergens, the optimum times of introduction and the reasons behind the link.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story does not seem to require comparison of alternatives, since it isn\u2019t about treatments.", "answer": 2}, {"article": "Both are reasonable options.\u201d\nBotox injections are also used, often in cases where the medicine does not work.\nThe most common treatment for urinary incontinence is a daily dose of an anticholinergic medicine that alters the action of certain nerves.\n\u201cThis gives patients the information to make an informed decision.\nSignificantly, those who took Botox were more likely to have their symptoms completely disappear.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not detail other available alternatives, such as muscle strengthening exercises, surgery, or other medications.", "answer": 0}, {"article": "How miserable is combing a child's hair, lock by lock, to pick off head lice? So miserable that some parents are buying $30 shampoos and other washes that promise to ward off the tiny, grayish bugs.\n\nThe parents get peace of mind that they are doing something. Conveniently for the product makers, there's no way to tell if they kept lice at bay, or if children wouldn't have gotten lice anyway. Makers say sales are growing fast.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story includes the question of whether the lice control products are any more effective than regular shampoos and conditioners. It also mentions that girls can keep wear their hair \u201cup and tight.\u201d", "answer": 1}, {"article": "The Ache: Common cholesterol-lowering drugs called statins can have unpleasant side effects, including muscle aches and weakness.\n\nThe Claim: An extract from a bitter, fragrant citrus fruit called bergamot, commonly known as a flavoring in Earl Grey tea, can lower cholesterol with minimal side effects, some scientists say. It also boosts good cholesterol, reduces fatty deposits in the liver and lowers blood sugar, they add.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Because of the included quote about statins, we\u2019ll award a satisfactory rating. The story could have mentioned how bergamot compares to other supplements that claim to lower cholesterol, and provided general information about a diet low in saturated fats and high in plant sources of foods.", "answer": 1}, {"article": "You've probably heard about it \u2014 maybe you even remember seeing it once \u2014 but you're not really sure what it is or even where to find it.\n\nThe female condom (FC2), or internal condom, is a non-hormonal barrier method of birth control. But instead of going on a penis, it goes in a vagina, which is why it's also sometimes referred to as an internal condom. For more information, BuzzFeed Health spoke with two experts who could demystify this lesser-known contraceptive:\n\n* Dr. Harry Fisch, clinical professor of urology and reproductive medicine at Weill Cornell Medical College, and chief corporate officer of Veru Healthcare, which distributes FC2\n\n* Dr. Lauren Streicher, associate clinical professor of obstetrics and gynecology at Northwestern University\u2019s Feinberg School of Medicine", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job of talking about many alternatives that couples have for birth control.", "answer": 1}, {"article": "\u201cAnd it might be of some help.\u201d\nHe said more research was needed, but for now, \u201cI think the market is running way out in front of the science.\u201d\n\nScientists agree that DHA, naturally transmitted to a fetus through the placenta in the last half of pregnancy, is important, probably to visual and brain development.\nDr. Jatinder Bhatia, a neonatologist heading the nutrition committee of the American Academy of Pediatrics, said that unless further studies showed no benefit as children got older, he would continue recommending DHA, now in many prenatal vitamins, because \u201cI\u2019m not convinced at this time that we should reverse course.\u201d\n\nMuch about DHA is unknown.\nThe lead researcher, Dr. Maria Makrides of the University of Adelaide in Australia, said this suggested that full-term babies already get enough DHA in the womb, and that \u201cthere\u2019s no extra boost\u201d from getting more.\nSeveral studies indicate that babies born prematurely receive too little DHA, and some studies have found that premature babies fed DHA after birth show better cognitive performance or visual coordination later on than preemies who aren\u2019t given DHA.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was only a brief mention of alternatives on the postpartum depression issue \u2013 and that in the very last line: \"\u201cThere\u2019s no harm that we know of at all, in contrast to many antidepressants\"\u00a0\u2013 according to one doctor.\u00a0 But that is insufficient context and comparison. \nDitto for this issue:\u00a0 \"Some studies, including the new report, suggest DHA supplementation in pregnancy reduces the likelihood of premature birth.\"\u00a0 But how does this evidence (no data given in the story) compare with other attemtps to do the same thing?\u00a0", "answer": 0}, {"article": "\"In Europe, we have been reluctant to recommend that all men get PSA testing as we have felt that there has been a lack of knowledge,\" agreed lead researcher Dr. Jonas Hugosson, a professor of urology at the University of Gothenburg.\nThe men were between 50 and 65 at the start of the study.\n\"When we see patients with low-risk disease we don't treat them, we observe them,\" he said.\nAmbivalence over the test hasn't been confined to the United States.\nOf the men in the screened group diagnosed with prostate cancer, nearly 79 percent were diagnosed because they took part in the study, the researchers noted.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0The entire story was about whether PSA screening is better than no screening. ", "answer": 1}, {"article": "And the chunky monkeys?\nThe important thing is that we passed a milestone where we can now make drugs based on this knowledge and we can potentially slow down aging itself,\" Sinclair explains.\nAsked if he's suggesting that it's some kind of a rejuvenation drug that would turn a 70-year-old into a 35-year-old, Westphal tells Safer, \"That might be pretty hard to do.\n\"When I Googled this resveratrol, I was shocked to find that red wine was the top hit,\" Sinclair remembers.\n\"If the promise holds true, I think this has the chance to change healthcare,\" Dr. Christoph Westphal tells\n\nDr. Westphal says we all may soon be taking a drug that just might beat the clock, a simple pill that could delay the inevitable.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions calorie restriction as the other way to prevent aging and mentions exercise. The story should have done more to discuss these options. Instead, it practically dismisses them as difficult and ineffective.\u00a0 Story excerpt:\u00a0 \"But if the scientists at Sirtris are on the right track, it could mean forget dieting, forget the sweaty business of working out \u2013 just pop a pill and you are in guilt-free couch potato paradise.\"", "answer": 0}, {"article": "\"Think of pasta as a canvas from which you can add nutrient-dense, fiber-rich foods like fresh vegetables, fruits, cheese, lean meats and legumes, when creating meals for your family.\"\nPasta pleases even the pickiest of young eaters.\nNPA is the leading trade association for the U.S. pasta industry.\n\"Good nutrition is critical to the developing minds and bodies of children and adolescents.\nThe data review did not look at any health outcomes associated with pasta consumption except for the ones specified below.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not discuss alternative diets that might provide the shortfall nutrients identified by the USDA.", "answer": 0}, {"article": "Abbott Laboratories is betting heart patients will benefit from a new type of arterial stent that dissolves away when it is no longer needed.\n\nStents are scaffold-like devices used to prop open clogged heart arteries. Most stents are made of metal. But Abbott's new device, called Absorb, is made from a plastic-like material called polylactide that is commonly used in surgical sutures. The Absorb scaffold\u2014Abbott doesn't call it a stent\u2014is designed to completely fade away in two years and to cease supporting arteries at six...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We would have liked to have a comment or two on the parallel developments ongoing in this field. Coronary artery disease is more than a singe blockage. It is a systemic disease that is progressive unless systemic interventions are employed. Aggressive medical therapy is now viewed as an essential element to ongoing care and should have been included for completeness", "answer": 0}, {"article": "A response was considered a 30% reduction in the Yale-Brown Obsessive Compulsive Scale (YBOCS) score, which is used to measure the severity of OCD symptoms.\nThe procedure is noninvasive and doesn't require anesthesia, and the pulses are delivered via an electromagnetic device or coil that is placed or worn on the head.\nOverall, 38% of the people with the real device responded to the treatment compared with 11% of those with the sham device.\nThe Food and Drug Administration made the announcement on Friday, expanding the use of a technology that has been around for decades.\nThe approval was based on a clinical trial of 100 people with obsessive-compulsive disorder, where roughly half received treatment with TMS and the other half had a sham treatment that didn't deliver the electromagnetic pulses.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the article mentions alternative treatments (psychotherapy and medications), it doesn\u2019t compare them to outcomes claimed for TMS.", "answer": 0}, {"article": "That's according to a study just published in the journal CANCER.\nThe new study discrediting the test, coupled with persistent questions about how useful prostate screening is for most men anyway, add up to a whole lot of discussion points patients should take to their doctors.\nBefore treatment recommendations are made, doctors put most prostate tumors through other tests, too, like the Gleason score, and they look at the percentage of biopsies that are positive for cancer cells.\nThey say what's really needed is a set of tests that classify prostate tumors by what genes are turned on or off in the cells.\nIt includes criteria like whether the doctor can feel a nodule through rectal examination, and whether a tumor is detected through a test called trans-rectal ultrasound.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story included one expert\u2019s perspective that the new study questioning the value of clinical staging \u201cmay not make much difference in the real world\u201d because other tests are used like the Gleason score and the percentage of biopsies that are positive for cancer cells.\u00a0 So some attempt was made to put this into the context of other tests that are used.", "answer": 1}, {"article": "Current treatments target the immune cells involved in the disease and none are specific for FLS.\n\"Here, we investigated whether this venom component, called iberiotoxin, would be able to specifically block the FLS potassium channel and reduce the severity of the rheumatoid arthritis in rat models of the disease.\"\n\"We think that this venom component, iberiotoxin, can become the basis for developing a new treatment for rheumatoid arthritis in the future.\"\nIn some cases they reversed the signs of established disease, meaning that the animals had better joint mobility and less inflammation in their joints.\nScorpion venom may lead to improved treatments for rheumatoid arthritis\n\n\"Scorpion venom has hundreds of different components.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does the bare minimum here, stating, \u201cCurrent treatments target the immune cells involved in the disease and none are specific for FLS.\u201d", "answer": 1}, {"article": "Why has it taken so long for hip arthroscopy to catch up to its shoulder and knee counterparts?\nThis is a marked uptick from a decade ago, when Ochiai said the single course in hip arthroscopy was nearly canceled due to lack of interest.\nIn the past 10 to 15 years, doctors have discovered one specific cause of hip pain: a tear in the acetabular labrum, a condition in which the cartilage that lines the hip socket is damaged.\nWhile that is still done, restorative techniques have been introduced that allow for the preservation of the labrum instead of its removal.\nWith the hip, however, doctors using arthroscopes discovered a host of conditions, including labrum tears and FAI, that had not been recognized.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\n \nThe story briefly mentions rest and physical therapy, and implies that they do not work, but it is hardly a balanced discussion. Also, the story does not mention open surgical procedures, the historical \u201cgold standard,\u201d which can also restore the normal clearance that separates the femur and hip socket. There is no discussion of the relative benefits of the newer procedure compared with the options\u2013and no mention that there do not appear to be any clinical studies comparing treatments. ", "answer": 0}, {"article": "(CNN) A new blood test may be as accurate as a test requiring a painful spinal tap for differentiating Parkinson's disease from similar disorders, according to a study published Wednesday in Neurology, the medical journal of the American Academy of Neurology.\nAn accurate blood test, then, would be good news in these situations.\nInstead, the cause is multiple system atrophy, a neurodegenerative disease.\n\"Disease-specific therapies are now in trials, so accurate diagnosis is essential in determining if these new treatments work,\" he said.\nFor early-stage study participants, generally, sensitivity was 70% and specificity was 80%.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u00a0discusses the alternative\u2013a spinal tap test.", "answer": 1}, {"article": "Paul J.D.\n\u201cThis new technology may also provide physicians with a safer, more controllable option for treating patients.\u201d\n\nThe team co-authored the paper, \u201cUltrasonic modulation of tissue optical properties in ex vivo porcine skin to improve transmitted transdermal laser intensity,\u201d which recently was accepted for publication by the society\u2019s journal, Lasers in Surgery and Medicine.\n\u201c\u2018Sonoillumination\u2019 will be extremely beneficial for clinicians and the ASLMS presentation allowed us to demonstrate the system to the people who actually will be using the technology once it\u2019s commercialized.\u201d\n\nNicholas Golda, associate professor of dermatology and director of dermatology surgery at the MU School of Medicine, echoed the merits of the sonoillumination system and the effect it will have on dermatology.\n\u201cWe\u2019ve named the technique \u2018sonoillumination,\u2019 and we\u2019re hopeful that the procedure will be available widely in the near future.\u201d\n\nWhiteside and his team, including adviser, Heather K. Hunt, an assistant professor of bioengineering in the MU College of Engineering, tested the sonoillumination system on porcine skin tissue samples.\nIn 2016, the Office of Technology Management and Industry Relations reported that Mizzou received $14.9 million in revenue from more than 40 technology licenses.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Although the release does include claims that this experimental device is better than existing dermatological lasers, there are no details about how, or how much, better it might be. What\u2019s more, the release fails to mention other methods, including applying glycerol or mechanical vibration to improve laser light transmission through skin. The draft journal article cites other research into using ultrasound, but this somewhat similar technique was not mentioned in the news release.\nThe confusing mishmash of references to \u201copen-air transmission\u201d and sonoillumination is not useful to readers who don\u2019t dig into the conference or patent application materials.", "answer": 0}, {"article": "Johnston says the fight against obesity needs creative solutions that help people manage their weight, appetite and hunger by offering socially acceptable food choices.\nThe researchers conclude that afterschool programs and schools can replace energy dense, unhealthy snacks with peanuts to provide a healthier alternative for children (researchers in the study ensured students did not suffer from nut allergies).\nThe 12-week study was conducted by researchers at the University of Houston Department of Health and Human Performance (HHP), Baylor College of Medicine and Texas Woman's University.\nAt the end of the period, those students who received the snack more regularly experienced a decrease in their overall BMI (-.7kg/m2) compared to those who did not receive the regular peanut snack (-.3kg/m2).\n\"We'd like to think it's preventable, but from where I sit right now, there hasn't been a lot shown to be very effective on a large scale.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release quotes a researcher who says \u201cthere hasn\u2019t been a lot shown to be very effective on a large scale\u201d for childhood obesity. That\u2019s true enough, but we thought the release needed to go a little bit further to earn a Satisfactory rating. This is a very active area of study, and the release could have given a few examples of what \u2014 besides peanuts \u2014 has been tried and what the results have been.", "answer": 0}, {"article": "Asthma on the Rise in U.S.\nThere is no cure, but most people can control their symptoms, reduce the severity of their disease, and prevent asthma attacks by avoiding asthma triggers and correctly using prescribed medicines, such as steroid inhalers, the CDC says.\nOf those, 52 were given standard treatment (typically an inhaled steroid and a bronchodilator), and 226 were treated with kampo herbs.\nYoshiteru Shimoide, MD, head of the Yoshiteru Shimoide Clinic of Internal Medicine in Kagoshima City, Japan, presented the results here at the annual meeting of the American Academy of Allergy, Asthma, & Immunology (AAAAI).\nThere's much room for improvement, Shimoide says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story was based on a comparison of kampo herbs and standard drug treatment.\u00a0 The story also mentioned that asthma can usually be controlled by avoiding asthma triggers and correctly using prescribed medications.", "answer": 1}, {"article": "APA's membership includes more than 122,500 researchers, educators, clinicians, consultants and students.\nThe study was too short to reveal any long-term effects so the researchers plan to follow the participants as they age to provide additional evidence of whether college studies may reduce the risk or delay the onset of dementia.\nThe researchers suspect that campus study may provide greater benefits in boosting cognitive capacity because of social interaction with professors and fellow students, but the study didn't analyze any differences between on-campus or online courses.\nThe participants who took college classes volunteered for the study so they probably had a greater interest in continuing education that the general senior population, the journal article noted.\nParticipants were reassessed annually for three years following their studies.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release refers to other studies including those that have utilized other methods not involving formal education.", "answer": 1}, {"article": "The other new drug, ipilimumab (pronounced ip-ee-LIM-yoo-mab), when combined with dacarbazine, extended median survival to 11.2 months compared with 9.1 months for those who received dacarbazine alone.\nThe drug, which is taken orally twice a day, would be used only by the roughly half of melanoma patients whose tumors have this mutation.\nAfter three years, 20.8 percent of those who got that new drug were alive, compared with 12.2 percent of those in the control group.\nIn the latest trial, a big one was liver damage.\nBecause of that, researchers do not yet know the median survival.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story adequately explained the comparisons between both new drugs and the older dacarbazine chemo drug.", "answer": 1}, {"article": "\"Parents often say that their biggest concern is, 'When is my child going to be back to normal again?'\nIf the experimental test pans out, \"a pediatrician could collect saliva with a swab, send it off to the lab and then be able to call the family the next day,\" says Steven Hicks, an assistant professor of pediatrics at Penn State Hershey.\nA reliable test would help overcome a major obstacle in assessing and treating concussions, which affect more than one million children and adolescents in the U.S. each year.\nAnd, right now, there's no way to know which kids are going to have long-term problems, he says.\nSpit Test May Reveal The Severity Of A Child's Concussion\n\nA little spit may help predict whether a child's concussion symptoms will subside in days or persist for weeks.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does compare the spit test to a widely used concussion survey. However, many readers and listeners are likely to be confused about the basis of the comparison, and incorrectly believe that the researchers compared how well the tests guide patient care, when actually the new study looked only at the ability to predict reports of symptoms.", "answer": 1}, {"article": "WATCH: The naked mole rat might help us cure cancer\nThe research, led by Richard Wilson of Harvard University, revealed that in more than 500 US counties, mammography screening programs were linked with more diagnoses of smaller breast cancers \u2014 but not with fewer deaths or with fewer larger breast cancers (which theoretically would be prevented by finding the disease early through screening).\nIn a related commentary in the journal, a pair of doctors from the University of Washington School of Medicine note that the estimates of overdiagnosis of breast cancer are \"frustratingly broad\" \u2014 from less than 10 percent to 50 percent or more of women who get screened.\nThe trouble with overdiagnosis is that while the cancers doctors find wouldn't have harmed their patients, the treatment and stress that result from the diagnosis probably will.\nWe have to find a better way to screen women for breast cancer\n\nThe medical community has known about overdiagnosis and overtreatment for years, documenting the problem in a range of cancers \u2014 in breast, prostate, lung, and thyroid (which you can see in the chart above).\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternative to mammography is not getting screened. The story suggests this is an option, especially for women who are under the age of 50. \u201cWomen with no risk factors for breast cancer should also know that they can wait until age 50 for their first screening,\u201d the story says.", "answer": 1}, {"article": "New research from BYU exercise science professors finds that pro-inflammatory molecules actually go down in the knee joint after running.\nRunning may also slow the process that leads to osteoarthritis\n\nWe all know that running causes a bit of inflammation and soreness, and that's just the price you pay for cardiovascular health.\nThe researchers found that the specific markers they were looking for in the extracted synovial fluid--two cytokines named GM-CSF and IL-15--decreased in concentration in the subjects after 30 minutes of running.\n\"What we now know is that for young, healthy individuals, exercise creates an anti-inflammatory environment that may be beneficial in terms of long-term joint health,\" said study lead author Robert Hyldahl, BYU assistant professor of exercise science.\nIn a study recently published in the European Journal of Applied Physiology, Seeley and a group of BYU colleagues, as well as Dr. Eric Robinson from Intermountain Healthcare, measured inflammation markers in the knee joint fluid of several healthy men and women aged 18-35, both before and after running.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There is no mention of any alternatives. Many runners are told to switch to other forms of exercise as they get older to avoid joint pain. Do other forms of exercise produce the same benefits on inflammation?", "answer": 0}, {"article": "The study, \"The Impact of Preoperative Statin Therapy on Open and Endovascular Abdominal Aortic Aneurysm Repair Outcomes,\" recently was published in Vascular, the official publication of the International Society for Vascular Surgery.\nIn an effort to prevent cardiovascular disease they take statin medications.\nWe wanted to understand the impact statin use has on surgical outcomes when repairing this type of aneurysm.\"\nThe MU School of Medicine has improved health, education and research in Missouri and beyond for more than 165 years.\nThese cholesterol-lowering medications protect blood vessels from plaque formation and stress, and in some cases can even slow the progression of aortic aneurysms.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release compares surgery outcomes with or without statins.", "answer": 1}, {"article": "\"Our results demonstrate that [Opdivo] is more effective in treating patients with stage III and IV melanoma, cutting the risk of relapse by a third,\" lead researcher Dr. Jeffrey Weber, professor of medicine at NYU School of Medicine, said in a university news release.\n\"It is amazing that there is now an alternative that is superior to conventional chemotherapy for advanced metastatic disease,\" Green said after reviewing the new study findings.\nThe study found that patients taking Opdivo had fewer severe side effects than those taking Yervoy, at 14 percent versus 45 percent.\nThe international study was funded by Opdivo's maker, Bristol-Myers Squibb, and included more than 900 patients with stage III and stage IV melanoma.\nAfter a year of treatment, 71 percent of patients in the Opdivo group were alive without any recurrence of the disease, compared with 61 percent of those treated with Yervoy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story clearly compares the use of Opdivo to the use of Yervoy, and cites an independent source as noting that Opdivo \u201cis superior to conventional chemotherapy for advanced metastatic disease.\u201d", "answer": 1}, {"article": "However, they also say that women should talk to their doctors about risk factors that could lead them to start breast cancer screening earlier.\nBut the review of female patients between the ages of 40 and 44 found that 50 percent had an above-average risk for breast cancer, and therefore would be eligible to begin screening mammography at age 40, said lead researcher Dr. Jennifer Plichta.\nThat includes 39 percent who met the ACS criteria for above-average risk for breast cancer, and an additional 11 percent who met the American Society of Breast Surgeons' criteria.\nThe study also found a significant percentage of women would qualify for other breast screening methods, including breast MRI and genetic testing, Plichta said.\nFifty percent of these women met either the ACS or the ASBS requirements for early mammography, Plichta said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No other alternatives were discussed in the story besides the breast cancer risk assessment. But it seems like there likely are none\u2013you either have the risk assessment or none, so we\u2019ll rate this N/A.", "answer": 2}, {"article": "\u201cPRP is probably the best treatment for chronic refractory lateral epicondylitis if it is used after classical types of treatment like rest, braces, nonsteroidal anti inflammatory drugs, cortisone injections or physiotherapy have all failed,\u201d Thanasas said.\nAnalogous blood injections, in which the patient\u2019s own blood is taken and then injected into a specific area of the body, is used to help harness the healing power of blood to treat the degeneration of tendons.\nNEW YORK (Reuters) - Blood injections, especially of platelet-rich blood, into the affected area help relieve the pain associated with \u201ctennis elbow\u201d where other treatment methods have failed, according to a Greek study.\nThanasas added that further studies are needed to see how and when the PRP therapy is most effective, adding that he and his colleagues are about to start trials of PRP therapy in which different concentrations of white blood cells are used to see how this affects the regeneration of tendons.\n\u201cThere is now a solution for patients suffering from unrelenting \u2018tennis elbow,\u2019\u201d said Christos Thanasas from Henry Dunant Hospital, Athens, who led the study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions alternatives, which is why we give it credit here. It could have done a better job explaining why all other treatment methods should be exhausted, short of surgery, before turning to plasma injections.", "answer": 1}, {"article": "\"F.E.S.\nSo when the implant is turned on, it electrically stimulates the nerves in order to cause the muscles to move in motions, for example, to open and close the hands.\n\"This is a multi-channel implantable device,\" Peckham explains.\nIt was the lowest point of Annette's life; the woman who once trained dogs to assist the disabled would now be relying on one herself.\nWith the touch of a button, Annette turns on a device much like a pacemaker that's implanted in her chest.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention any alternative treatment options, such as physical and occupational therapy. It isn\u2019t clear what additional benefit the device has provided beyond standard physical and occupational therapy. Time also can have a helpful effect. It isn\u2019t clear what is the relative contribution of this new device versus standard care. ", "answer": 0}, {"article": "Molecular Psychiatry; 18 Oct 2016; DOI: 10.1038/mp.2016.167\nBy looking at additional beneficial side-effects of the treatments, the researchers were able to show that there was a significant antidepressant effect from the drugs compared to a placebo based on a meta-analysis of seven randomised controlled trials.\nAll currently available antidepressants target a particular type of neurotransmitter, but a third of patients do not respond to these drugs.\nDr Golam Khandaker, who led the study, says: \"It's becoming increasingly clear to us that inflammation plays a role in depression, at least for some individuals, and now our review suggests that it may be possible to treat these individuals using some anti-inflammatory drugs.\nThe research was mainly funded by the Wellcome Trust, with further support from the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release make clear that these drugs would be aimed at patients currently not helped by any existing drugs, so a comparison with those other medications would not be very helpful here. The release could have included some non-pharmaceutical alternatives.", "answer": 2}, {"article": "\"The truth is that quit smoking programs, like other programs that treat addictions, often have fairly low success rates. But that doesn't mean they're not worthwhile or that you should be discouraged. Your own success in quitting and staying that way is what really counts, and you have some control over that. Even if you don't succeed the first few times, keep trying. You can learn from your mistakes so that you'll be ready for those pitfalls next time.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study is comparing two alternatives when quitting smoking\u2013either cold turkey or gradually. The story discusses these options, along with the use of nicotine replacement in both scenarios. That\u2019s enough to qualify as Satisfactory.\nHowever, another alternative the author didn\u2019t mention was medications that can help with cravings\u2013such as bupropion. What does the research say (if anything) about how those medications might augment quitting? That\u2019s important to discuss.", "answer": 1}, {"article": "Utian is now an independent consultant and was a co-author of one of the studies.\nIn one study, the number of daily hot flashes experienced by postmenopausal women taking 1,800 milligrams of the drug per day declined from around 10 to around 2.\nHormone therapy is the only FDA-approved treatment for hot flashes related to menopause, but many women are reluctant to undergo hormone therapy because its long-term use has been linked to an increased risk for breast cancer and stroke .\nBut a similar reduction in hot flashes was seen in women who took placebo pills instead of the slow-release gabapentin.\n\u201cThese side effects, when they did occur, tended to occur early in treatment and disappear within a few weeks,\u201d Sweeney says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions low-dose hormone replacement therapy, which is one option for particularly bothersome hot flashes. It could have also\u00a0mentioned\u00a0lifestyle changes such as keeping cool and avoiding dietary triggers, which are useful approaches for some\u00a0women. The story also notes that almost half the women in the placebo arm of one of the trials reported improvement. It would have been helpful to readers to highlight that fact and put the drug results in context with the fact that women feel better after a few weeks even without any treatment. On balance, the story does enough to fulfill the criterion.", "answer": 1}, {"article": "Will it help avoid back surgeries, for example, that may or may not have great outcomes?\nThe study, \"Real-World Massage Therapy Produces Meaningful Effectiveness Signal for Primary Care Patients with Chronic Low Back Pain: Results of a Repeated Measures Cohort Study,\" was published online March 14 in the journal Pain Medicine.\n\"The study can give primary care providers the confidence to tell patients with chronic low back pain to try massage, if the patients can afford to do so,\" Munk said.\nThe massage therapist designed and provided a series of 10 massages -- at no cost to the patient -- in a clinical treatment environment, mimicking the experience of people who choose to seek massage therapy in the real world.\nPatients who were taking opioids experienced improvements in their pain from disability in some cases but were two times less likely to experience clinically meaningful change compared to those who were not taking opioids.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "We would like to give the release credit for mentioning that back pain is very complex, and that surgery is sometimes an option. However, we think the release falls short in not acknowledging that there has been extensive research on a variety of complementary approaches before this study including yoga, massage, acupuncture and exercise. The release could have provided that information about alternatives, as well as make some effort to tell us how massage compares with other non-invasive physical treatments.\nThe complexity of the problem, the option for surgery and the nature of chronic treatment are all relevant, as the release notes, but that\u2019s no substitute for mentioning other treatment alternatives, some of which, like physical therapy, are covered by insurance.", "answer": 0}, {"article": "We already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.\u201d\n\nUltimately, the researchers hope that the drug \u201ccould likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms \u2013 making it a \u2018game changer\u2019 for future treatment,\u201d said Brightling.\nThe Lancet Respiratory Medicine, 2016.\n\u201cMost treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all the types of tests.\nWhen asthma symptoms occur, the number of white blood cells rises, and this measurement is used to define how severe the condition is.\n\u201cA unique feature of this study was how it included measurements of symptoms, lung function using breathing tests, sampling of the airway wall and CT scans of the chest to give a complete picture of how the new drug works,\u201d said Brightling in the press release.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Current treatment options for asthma aren\u2019t mentioned.", "answer": 0}, {"article": "\"We wouldn't want to be encouraging people to drink that much [coffee], without people considering the other risks factors,\" Hashibe says.\nCoffee did not decrease the risk of a third type of oral cancer \u2013 laryngeal cancer.\nResearchers found that regular coffee drinkers \u2013 those who drank more than four cups of coffee a day \u2013 had a 39 percent decreased risk of two types of head and neck cancer: oral cavity and pharynx cancers.\nWe encourage you to focus your comments on those medical and health topics and we appreciate your input.\nThey looked at nine existing studies and analyzed how much coffee was consumed by more than 5,000 cancer patients and about 9,000 healthy people.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story didn\u2019t comment \u2013 as the WebMD story did \u2013 on other factors analyzed in the study such as tea, fruits and vegetables. ", "answer": 0}, {"article": "\"Previous patients got sick, but it wasn't clear at the time whether it was due to the T cells or an infection,\" said pediatric oncologist Stephan Grupp, who oversaw Emily's care at Children's Hospital of Philadelphia. \"Now we know the main reason they were sick was the cells. But now we can intervene. She taught us.\"", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions chemotherapy and bone marrow transplants as treatment options for leukemia.", "answer": 1}, {"article": "Zee and her fellow researchers had 13 adults ages 60 and older spend two nights in a sleep lab.\n\u201cThat\u2019s very much tied to what part of the slow wave the stimulus is hitting on.\u201d\n\nThat doesn\u2019t mean there aren\u2019t benefits to other soothing background sounds.\nA small new study published in suggests that one easy way for older adults to get deeper sleep and stronger memories is to listen to a certain soothing sound called \u201cpink noise\u201d\u2014a mix of high and low frequencies that sounds more balanced and natural than its better-known cousin, \u201cwhite noise.\u201d\n\nIt may sound strange, but previous studies have found that playing so-called pink noise during sleep improves the memory of younger adults.\n\u201cIt\u2019s just noticeable enough that the brain realizes it\u2019s there, but not enough to disturb sleep.\u201d The sounds were timed to match their slow-wave oscillations.\n\u201cWe wanted to see if it would work in older people, too,\u201d says senior author Dr. Phyllis Zee, professor of neurology at Northwestern University Feinberg School of Medicine.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does mention some other soothing sounds that might help people sleep better, such as music, nature sounds, or white noise apps. It would have been helpful to include some other strategies for improved sleep as well such as over-the-counter sleep aids, sleep hygiene (exercise, limiting naps, restricting certain foods before bedtime), and cognitive behavioral therapy.", "answer": 1}, {"article": "This new approach to drug discovery is a promising technology that is rapidly moving in the translational research space , .\nAmong these, the abstract \"Tivanisiran a new treatment for Dry Eye Disease, that improved signs and symptoms in clinical trials\" (Posterboard number: 925 - B0103) is highlighted, the compound improving the ocular inflammatory parameters, tear quality and a reduction in ocular pain associated with dry eye disease is also underlined1.\nTivanisiran is a product under development for the treatment of signs and symptoms related to dry eye syndrome and has the potential to be developed for other pathologies that cause ocular pain (corneal lesions, refractive surgery, etc.)\nDry eye can be treated with cyclosporin drops or autologous serum, but there is as yet no specific product for chronic treatment of the ocular pain related to dry eye syndrome; oral analgesics or anaesthetics are used in general.\nThe therapeutic application of targeted siRNAs is booming given the specificity of gene silencing for a particular protein in a given tissue and the lack of side effects.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions alternatives to tivanisiran:\n\u201cDry eye can be treated with cyclosporin drops or autologous serum, but there is as yet no specific product for chronic treatment of the ocular pain related to dry eye syndrome; oral analgesics or anaesthetics are used in general. However, the main treatment consists of artificial tears, in the form of drops, gel or creams. Preservative-free eye drops have generally been found to offer the best long-term response.\u201d\nThe American Optometric Association publishes a patient pamphlet that provides additional management options.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Botox injections may provide some relief from arm tremors caused by multiple sclerosis, according to a small study published Monday.\n\u201cSo practitioners will have to be up to speed,\u201d LaRocca said.\n\u201cThis study is fairly preliminary, and it had a small number of patients,\u201d LaRocca said.\nBut there\u2019s still a lot to be learned, he cautioned in an interview.\nPhysical therapy and exercise have been studied, but are usually not very effective, said LaRocca, who was not involved in the new study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "A VP at the National MS Society said \u201cRight now there\u2019s no good way to treat MS arm tremors.\u201d", "answer": 1}, {"article": "The earliest trials with patients who developed POCD were performed after the 1950s.\n\"With regard to the use of dexamethasone, more research is needed to confirm our finding, preferably in multicenter trials, but there are strong indications that it can be beneficial in many cases.\"\n\"The results reinforce recent evidence of the importance of avoiding deep anesthesia,\" Carmona said.\n\"The causes of and risk factors for POCD are still being discussed,\" she said.\nThe good news, according to a Brazilian study published by the journal PLoS One, is that two relatively simple measures can help to reduce the incidence of POCD: administering a small dose of the anti-inflammatory drug dexamethasone immediately before an operation and avoiding profound anesthesia during the operation.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Frankly, there\u2019s not a lot of research out there on steps to pro-actively reduce rates of cognitive dysfunction after anesthesia, and we\u2019re not aware of alternative interventions designed to do so.", "answer": 1}, {"article": "Diseases like Alzheimer\u2019s start years, even decades, before the first symptoms of memory loss shows up.\n\u201cBut what\u2019s nice about it is that it\u2019s a nice non-cognitive, motor factor so it\u2019s looking at another aspect of brain function.\u201d\n\nMORE: This Alzheimer\u2019s Breakthrough Could Be a Game Changer\n\nPetersen suggests that every physician should get this information on their patients at age 65; that way, they can have a baseline against which to compare any changes as their patients age.\nAnd with rates of those diseases rising, experts say that more primary care physicians\u2014not neurology experts\u2014will have the task of identifying these patients early so they can take advantage of whatever early interventions might be available.\nCurrently, the only way to truly separate out those on the road to Alzheimer\u2019s is to conduct expensive imaging tests of the brain, or to do a spinal tap, an invasive procedure that extracts spinal fluid for signs of the amyloid protein that builds up in the disease.\nIn the next phase they studied the results of the patient\u2019s basic mental exam as well as of a psychiatric evaluation, because depression and anxiety have been connected to Alzheimer\u2019s.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story points out that other methods of testing are available for Alzheimer\u2019s disease including sophisticated scanning and genetic testing. We\u2019ll award a satisfactory rating on that basis. However, we\u2019d note that the story does not point out that many of the tests used in the study are currently used to diagnose mild cognitive impairment and are already used by primary care physicians and others.", "answer": 1}, {"article": "Research on a bacterial toxin first discovered in Adelaide has led to the development a new blood test for the early diagnosis of ovarian cancer - a disease which kills over 1000 Australian women and 150,000 globally each year.\nThe team has now engineered a harmless portion of the toxin to enhance its specificity for the cancer glycan and used this to detect it in blood samples from women with ovarian cancer.\nThe new blood test has the potential to dramatically improve early detection of the disease, although it will require further testing before it is available for clinicians.\nThe team is currently seeking scientific and commercial partners to further test the technology with larger numbers of patient samples and to adapt it for mass screening.\nOur new test is therefore a potential game changer,\" says Professor James Paton, Director of the University of Adelaide's Research Centre for Infectious Diseases.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "No other alternative tests are mentioned.\u00a0\u00a0Cancer antigen 125, or CA-125, a test for screening for ovarian cancer, is recommended when there is high clinical suspicion (when the patient is having particular symptoms to suggest the presence of cancer).\nMentioning this test, and its pros and cons, would have provided useful context for readers wondering about how these preliminary results stack up against our current screening tests.\nThe release should also have noted that the US Preventive Services Task Force recommends against screening for ovarian cancer in asymptomatic women. The American College of Obstetricians and Gynecologists does not support screening.\n\u00a0\n\u00a0", "answer": 0}, {"article": "\u201cWe would hope that it would work just as well ... there is no reason why not.\u201d\n\nThe ability to base a diagnosis on an objective biological test, rather than having to rely on personality traits, should mean patients get treatment more quickly, he added.\nAutism spectrum disorders are diagnosed in one percent of the population in Britain and the United States, and the condition affects four times as many boys as girls.\nExperts not involved in the research applauded the research but cautioned further study was still needed.\nCognitive behavioral therapy and educational treatment can be highly effective for some patients and the impact of a more certain prognosis would be especially beneficial for children.\nAutism is a complex brain disorder characterized by difficulties in social interaction and communication, ranging from mild to profound impairment.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that autism is currently diagnosed via interviews and patient observation. \u00a0", "answer": 1}, {"article": "The average age of the participants was 11.\n\"This receptor has several effects, but one of them may be to modulate the calcium inside and outside the neuron, which is very much related to the excitability of nerve cells,\" he explained.\nOne child remained seizure-free, but 12 of the initial participants dropped out of the study because the cannabidiol didn't seem to do them any good.\n\"This was a very, very treatment-resistant group, and the response was very promising,\" Devinsky said.\n\"There is a fairly active and vocal group of families in Colorado who are using cannabidiol oils that are made artisanally,\" she said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The interest in marijuana constituents as possible treatments arose because existing alternatives\u2014anti-seizure drugs\u2014do not work with some patients. So a premise of this story is that existing alternatives are unsuccessful in this group of paitents.", "answer": 1}, {"article": "To automatically receive news releases from UT Southwestern via email, subscribe at http://www.\n\"The high cure rate is striking when compared to the reported five-year cure rates from other approaches like surgery or conventional radiation, which range between 80 to 90 percent, while the side effects of this treatment are comparable to other types of treatment,\" said Dr. Raquibul Hannan, Assistant Professor of Radiation Oncology and lead author for the study.\nIn contrast, the SBRT therapy we used allows the delivery of highly focused radiation in only five treatments, allowing patients to return to their normal lives more quickly,\" said senior author Dr. Robert Timmerman, Director of the Annette Simmons Stereotactic Treatment Center at UT Southwestern, and Professor and Vice Chairman of the Department of Radiation Oncology.\n\"Our hope is that the high potency of this form of treatment will significantly improve treatment of these patients,\" says Dr. Hannan, the principal investigator of the high-risk prostate SBRT trial.\nThe study - the first trial to publish five-year results from SBRT treatment for prostate cancer - found a 98.6 percent cure rate with SBRT, a noninvasive form of radiation treatment that involves high-dose radiation beams entering the body through various angles and intersecting at the desired target.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release gives us some information about this treatment vs. traditional radiation and lists other important alternatives including prostatectomy (surgical removal of the prostate gland), brachytherapy (the implantation of small radioactive seeds), and external beam radiation. One alternative not mentioned \u2014 which is appropriate for low-risk cancers \u2014 is active surveillance (monitoring the patient and deferring active treatment).", "answer": 1}, {"article": "That study enrolled just 62 people, but the results were significant enough for NIH to fund new research _ at Pennsylvania, the University of Texas in Houston, Boston University and other sites _ enrolling about 650 cocaine users to see if modafinil really does work.\nThe main side effect so far: insomnia, not surprising as modafinil is sold today to help narcolepsy patients fend off that neurologic disease's sudden sleep attacks.\nIn addition to blunting cocaine's notorious cravings, modafinil might also counter the damage that cocaine wreaks on users' brain circuits _ damage that in turn fuels the cycle of addiction.\nThe prospect of that double-whammy has the National Institutes of Health spending $10.8 million researching modafinil as a potential cocaine treatment.\nResults from the first of three key clinical trials could arrive by year's end.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t mention any other pharmacological, psychosocial or behavioral interventions, although cognitive behavioral therapy was part of the treatment for both the placebo and treatment groups in the pilot study conducted by Dr. Dackis and mentioned in the article. ", "answer": 0}, {"article": "\u201cIf this is the case, dosage shouldn\u2019t matter.\nBut the fact that the fewest recurrences were seen in men who took the highest statin doses is compelling, says senior investigator Stephen J. Freedland, MD, of the Duke Prostate Center.\n\u201cStatin users may see their doctors more often and may be more health conscious in general, and it has been suggested that this could explain the observed reduction in risk,\u201d Freedland tells WebMD.\nIn a new study from Duke University Medical Center, men who took statins for their hearts were 30% less likely to have their cancers come back after their prostates were removed than men who did not take the drugs.\nThose who took the highest doses saw their recurrence risk drop by half.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is a brief mention of radiation, but that is merely in passing. There really is nothing in the story about what a typical treatment regimen might be for these patients and what it might be like if statins became the go-to treatment. There also isn\u2019t anything in the story that offers any theory about what might be causing this. It seems as if the authors don\u2019t really know and are just excited about this potential connection that they have made. If they, or someone else in the field, were pressed to offer a theory, some of the holes in the evidence might begin to show.", "answer": 0}, {"article": "\"This result suggests that adequate pain management should be an important goal of care, even after minor outpatient surgery, and that more effective pharmacologic and nonpharmacologic strategies should be explored,\" writes Dr. Naveen Poonai, Clinician Scientist, Lawson Health Research Institute, and Associate Professor, Emergency Medicine, Department of Paediatrics, Schulich School of Medicine & Dentistry, Western University, with coauthors.\nPain scores for children in both the oral morphine and ibuprofen groups were similar, but the children receiving oral morphine reported more adverse effects, such as nausea, vomiting, drowsiness, dizziness and constipation.\n\"Oral morphine versus ibuprofen administered at home for postoperative orthopedic pain in children: a randomized controlled trial\" is published October 10, 2017.\nOral morphine use at home has not been previously studied in children who have had minor surgery nor has it been compared with ibuprofen.\nIn the first 24 hours, more than 80% of the children in the study needed pain relief at home.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This news release reports the results of a randomized superiority trial designed to specifically compare two alternatives. So the release scores well on this criterion.", "answer": 1}, {"article": "\"I hope that people will respect the rigorous methodology used in this blinded, randomized, controlled trial and accept the result,\" study researcher Deirdre Lyell, MD, assistant professor of obstetrics and gynecology at Stanford University School of Medicine, says in a news release.\nMany pregnant women who have symptoms of depression worry that taking antidepressants might harm their unborn babies -- so they stop taking their medications, say researchers at the Stanford University School of Medicine.\nAll of the women received therapy for eight weeks and were interviewed at the four- and eight-week marks by someone who did not know which treatment they were getting.\nSome received depression-specific acupuncture treatments, others had needles inserted in acupuncture points not known to relieve depression, and a third group received massage therapy.\nAcupuncture might be a useful alternative, they say, because a study of pregnant women shows that the procedure works in reducing depressive symptoms better than other non-pharmacological techniques.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\nWhile the story discussed antidepressants, there was no mention of how acupuncture compares to psychotherapy, another non-drug\u00a0alternative that does not put the fetus at any direct risk. \n\u00a0", "answer": 0}, {"article": "AstraZeneca PLC's cholesterol drug Crestor sharply lowered risk of heart attacks among apparently healthy patients in a major study that challenges longstanding heart-disease prevention strategies. The findings could substantially broaden the market for statins, the world's best-selling class of medicines.\n\nHeart experts said the findings, presented Sunday at the annual scientific meeting of the American Heart Association in New Orleans, could reshape cholesterol-treatment guidelines used for more than a decade to fight cardiovascular...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The two main issues in the study reported on was the use of CRP to identify candidates who could benefit from lipid lowering \u00a0and then the use of Crestor to lower lipids in these individuals to lower cardiovascular disease risk. \u00a0In terms of treatment options,the story indicated the uncertainty about whether the outcomes observed were the result of the specific drug study or could be obtained with the use of any in the statin class of drugs. \u00a0It also mentioned that the reduction in CRP was not associated with the decrease in LDL levels seen in the study participants. \u00a0There was no discussion, however, about what, if any, other means for lowering CRP were available.\nThe story did mention that there was little known about what the long term impact of maintaining very low levels of LDL cholesterol.", "answer": 1}, {"article": "A drug-coated stent made by Abbott Laboratories that is awaiting U.S. regulatory approval is as safe as, and potentially more effective than, the market-leading version of the heart device made by Boston Scientific Corp., according to findings presented Tuesday at the EuroPCR conference in Barcelona.\n\nClinical-trial data analyzed by Abbott two years after its Xience V stents were implanted in patients are likely to reassure investors and regulators about the product's long-term safety and could restore some investor confidence...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not even provide a clear picture of what would be involved in treatment using the medical device highlighted, let alone outline the other options available for those with cardiovascular disease.\u00a0 ", "answer": 0}, {"article": "This story has been updated with additional information.\nThe early results are \u201cpromising and exciting,\u201d said Dr. Allison Baker, a psychiatrist at Massachusetts General Hospital\u2019s Center for Women\u2019s Mental Health, but \u201cwe need to see replication of this data over a much wider range in terms of numbers.\u201d\n\nThe study is small and has not been peer-reviewed; Sage disclosed the results in a press release.\nIn cases of severe depression, that equilibrium gets out of whack, and Sage\u2019s drug is meant to restore it, modulating those GABA receptors to allow NMDA to do its job.\nThe company has not submitted study data to federal regulators and isn\u2019t at this point seeking approval of the drug, known as SAGE-547, for postpartum depression.\nThe drug has a \u201cvery, very short half-life\u201d in the body, Jonas said, meaning that it can be metabolized quickly.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This is a barely passing satisfactory as the story does briefly acknowledge alternatives. The only reference to conventional antidepressant treatment is that it doesn\u2019t work as quickly as this experimental drug appears to. Talk therapy is mentioned, but there is no mention of its effectiveness. While it is true that antidepressants can take weeks, they and mood stabilizing drugs for women with bipolar disorder do treat postpartum depression. In women with a history of this highly recurrent condition, antidepressant treatment may be started or maintained\u00a0during pregnancy.", "answer": 1}, {"article": "Panel Says Aspirin Lowers Heart Attack Risk For Some\n\nMillions of Americans take baby aspirin every day to prevent a heart attack or stroke.\nIf they are at high risk of heart disease, they're doing the right thing, according to draft recommendations issued Monday by the U.S. Preventive Services Task Force.\n\"With all the good therapies, better blood pressure control, better cholesterol control, all the things we do in modern medicine,\" he says, \"over the last couple of decades, we've had nearly a 50 percent reduction in the rate of cardiovascular disease.\"\n\"It's just not prudent or safe,\" he says, noting that bleeding in the abdomen or brain is extremely dangerous and can be fatal.\n\"Because heart attacks are caused by clots in the arteries of the heart, aspirin can help prevent heart attack and it can also help prevent strokes that are caused by blood clots,\" Owens says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The main point of the story is a recommendation to modify existing aspirin use habits. \u00a0So it nicely sets up a comparison between current practice and recommended behavior. The story also nods to other approaches and medications (e.g. cholesterol and blood pressure drugs).", "answer": 1}, {"article": "The significance of that is not clear.\n\u201cBut,\u201d she added, \u201cit should be noted that yoga controlled the blood sugar levels which otherwise rose in the control group.\u201d\n\nIn addition to that, the study found, signs of so-called oxidative stress declined in the yoga group.\nThe findings, reported in the journal Diabetes Care, do not suggest that yoga should replace other forms of exercise for people with type 2 diabetes \u2014 a disease commonly associated with obesity.\nThe study, of 123 middle-aged and older adults, found that those who added yoga classes to standard diabetes care shed a handful of pounds over three months.\nTo really lose weight and rein in blood sugar, more-vigorous exercise would work better, according to Shreelaxmi V. Hegde of the Srinivas Institute of Medical Science and Research Center in Mangalore, India.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no discusion about how adding other lifestyle changes in addition to the other management strategies in place affect the health of those with type II diabetes. For example, prior studies have examined the benefits of regular light exercise. A discussion of exercise alternatives and their relative benefits would have helped the readers judge the benefit of yoga in context.", "answer": 0}, {"article": "Raji presented the findings here at the annual meeting of the Radiological Society of North America.\nIn a new study, imaging scans showed that regular fish-eaters were less likely to have brain cells die off in the area of the brain responsible for short-term memory -- recalling a phone number that was just heard, for example.\n\"The new study is the first to establish a direct relationship between fish consumption, brain structure, and Alzheimer's risk,\" Raji says.\nThis benefit is thought to come from the omega-3 fatty acids in fish, although studies of fish oil supplements have produced disappointing results in people who already have Alzheimer's.\nAnd people who ate baked or broiled fish at least weekly and didn't lose brain cells were much less likely to develop Alzheimer's disease or mild mental impairment, says Cyrus Raji, MD, PhD, of the University of Pittsburgh School of Medicine.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story at least hinted at \u201cother risk factors for memory loss that could affect the results, including age, gender, education, obesity and physical activity.\u201d\n ", "answer": 1}, {"article": "\u2018\u2018There is no chance that for these patients, that chemotherapy would have any benefit.\u2019\u2019\n\nDr. Karen Beckerman, a New York City obstetrician diagnosed with breast cancer in 2011, said she was advised to have chemo but feared complications.\nThe new study is the first to assign women treatments based on their scores and track recurrence rates.\nAfter five years, about 99 percent had not relapsed, and 98 percent were alive.\nOthers besides Oncotype DX also are on the market, and Hudis said he hopes the new study will encourage more, to compete on price and accuracy.\nEach year, more than 100,000 women in the United States alone are diagnosed with this.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story describes the usual course of treatment, which is surgery followed by years of a hormone-blocking drug, as well as chemotherapy.", "answer": 1}, {"article": "Your cells might be aging faster than you are, and new tests purport to help you find out.\n\nA few companies are offering mail-order testing to measure the length of people\u2019s telomeres, the protective caps of DNA on the ends of chromosomes that have been likened to the plastic tips that prevent shoelaces from fraying. Telomeres gradually shorten as people age and eventually may disappear, leaving cells vulnerable to disease and death.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Most people over the age of 50 would be vastly better off following prudent health advice and visiting their doctor to discuss whether they should to be screened for specific treatable conditions such as high blood pressure, diabetes, breast cancer, high cholesterol, hypothyroidism or colorectal cancer, to name a few. The story doesn\u2019t mention that.", "answer": 0}, {"article": "Moscona said tests were needed that would show the drug actually helped reduce disease symptoms in animals.\n\u201cDevelopment of effective antiviral drugs and vaccines for human parainfluenza virus has lagged far behind influenza, despite the recognized impact of these diseases in children\u201d and adults, \u201cparticularly the elderly, immunocompromised and patients with underlying airway disease.\u201d\n\nParainfluenza viruses are not closely related to flu but belong to another family of viruses called paramyxoviruses.\nThe researchers said that means patients with flu-like symptoms could get the drug without the need for a test to show whether their infection was caused by influenza or parainfluenza.\nBecause Fludase affects the human cells that viruses infect, not the virus itself, it is less likely to cause the virus to develop resistance, the company believes.\nAdding parainfluenza to its approved indications would provide a unique and potentially large market for San Diego-based NexBio.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "       \n \nThe story points out that there are no existing alternatives for preventing parainfluenza virus infections. In addition, the story briefly mentions other vaccines that have developed resistance to the flu virus.\n ", "answer": 1}, {"article": "-- Practice good sleep hygiene.\nIf your teen has to get up at, say, 6:30 to be at school by 7:30, that means bedtime's at 9:15 or 9:30 p.m.)\n\nVorona says he'd like to delve deeper into the sleep-obesity question.\nAnd alcohol, which Aziz says \"can make us go to sleep, but it's not the deep sleep\" that we need to produce growth hormone (which in turn helps regulate insulin).\nOn the other hand, Vorona says, \"The last thing I want readers to think is that Dr. Vorona thinks we're facing this obesity epidemic because we're sleep deprived.\nIf sleep extension could have a salutary effect on helping people lose weight,\" he says, we'd have another tool in the fight against obesity.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are no data presented on sleep extension and related approaches as\u00a0interventions for weight loss. Thus it\u2019s impossible to compare them to other interventions for weight loss. However, we give it a strike for one reason.\nThe story attempts to put sleep into some kind of context in the overall mechanism of obesity by ending on the sleep researcher\u2019s caveat that he doesn\u2019t believe sleep deprivation is the root cause of the obesity epidemic. But he suspects it\u2019s \"part of the picture, along with lack of exercise and dietary indiscretion.\" The story cites no evidence or study to support his suspicion. We have no idea\u00a0how big or how small a part sleep makes up in that picture. No doubt, Vorona doesn\u2019t know either. But he is still suggesting that sleep deprivation has a role in obesity. The vague point, without evidence or relative qualification, will for some readers\u00a0elevate the role of sleep deprivation relative to the other contributing factors.\u00a0\nIt\u2019s relevant because each factor is associated with a weight loss intervention, and diet and exercise interventions have a warehouse of studies behind them. A brief discussion about the roles of calorie restriction and exercise for long-term weight loss and maintenance would have put the role of sleep interventions in perspective for readers.", "answer": 0}, {"article": "In a twist in the debate about the safety of menopause hormones, new research suggests the real problem may not be the hormone itself, but the fact that it's typically swallowed as a pill.\n\nThis week, the medical journal Circulation offers some of the strongest evidence yet that the risks of hormones are dramatically reduced when the drugs are absorbed through the skin in patches and gels rather than taken as pills. The study by French researchers showed that one of the most serious risks associated with hormone use -- blood...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions\u00a0estrogen in the form of pills, patches, rings and gels. ", "answer": 1}, {"article": "In an interview last spring with Psych Congress Network, an Internet news site for mental health professionals, Dr. Timothy Wilens, chief of child and adolescent psychiatry at Massachusetts General Hospital, said \u201cwe have enough data to say they\u2019re actually neuroprotective.\u201d The pills, he said, help \u201cnormalize\u201d the function and structure of brains in children with A.D.H.D., so that, \u201cover years, they turn out to look more like non-A.D.H.D.\nIf the pills can truly produce long-lasting benefits, more parents might be encouraged to start their children on these medications early and continue them for longer.\nFor most people with A.D.H.D., stimulants can temporarily boost focus, motivation and self-control by increasing the availability of these chemical messengers.\nOne peer-reviewed 2013 study co-authored by Dr. Swanson suggested that the stimulants may change the brain over time so as to undermine the long-term response to the medication and even exacerbate symptoms when people aren\u2019t taking them.\nOne possible reason, as the report noted, was that many children refuse to continue taking medication after a year or so, something most parentsof such children well know.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While the story seems open to the possibility that ADHD can be treated without drugs, it doesn\u2019t specify any alternative approaches or how they compare with drug treatment.", "answer": 0}, {"article": "In another 12%, tumors stopped growing for at least six months.\n\"This is the first study looking at women who have failed so many other treatments,\" Krop tells WebMD.\nDec. 15, 2009 (San Antonio) -- A new targeted cancer drug has been shown to shrink tumors in women with metastatic breast cancer after an average of seven other drugs, including Herceptin, failed.\n\"But we think these results are as good as we've ever seen is such a refractory [sick] population,\" he says.\nIt's a Trojan horse approach, where Herceptin homes in on cancer cells and delivers the cancer-killing agent directly to its target.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This topic is not addressed directly. The nature of the study design implies that perhaps there are no alternatives, given that subjects are described as having \"refractory\" breast cancers, and given that there are baseline data regarding a median of 7 other therapies for metastatic disease. However, the abstract states that the range of prior therapies was as low as 1, so the role of possible alternatives is not clear. Because the end of the article mentions other trials that are comparing T-DM1 to other therapies, it would seem that a more explicit discussion of alternatives \u2014 or that there were no alternatives for these subjects \u2014 would clarify the potential treatment role of T-DM1.", "answer": 2}, {"article": "They did so to offer support, but also to spread awareness, because they say too often life and death for someone having a cardiac arrest comes down to chance. If a bystander performs CPR while medics are on their way, survival rates more than double, doctors say.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are no exact alternatives to bystander CPR, but the bystander use of AEDs has been shown to vastly improve survival rates after cardiac arrest if used quickly. Obviously they are not widely available outdoors, but they are increasingly placed in airports, office buildings, schools, recreational and sports venues, and even department stores. Some mention of AEDs would have been\u00a0welcome.", "answer": 0}, {"article": "But conventional germicidal lamps aren\u2019t safe for humans to be around.\n\u201cThink about doctor\u2019s waiting rooms, schools, airports and airplanes\u2014any place where there\u2019s a likelihood for airborne viruses.\u201d And unlike the flu vaccine, he says, far-UVC light is likely to be effective against all airborne microbes, including newly emerging virus strains.\n\u201cIf you have a lamp over the surgical site that can sterilize the air, you can prevent the bacteria from floating down and contaminating the wound.\u201d\n\nBrenner can\u2019t predict how long it might take for these lamps to be commercially available, but he says he\u2019s \u201cextremely optimistic\u201d about the technology.\n\u201cYou can sterilize a hospital room, but not when anyone\u2019s inside.\u201d\n\nAbout five years ago, Brenner says, the Columbia team came up with a potential solution.\nFor that reason, UV devices are often used for sterilization \u2014 for medical equipment in hospitals, for example, or drinking water for backcountry campers.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No mention is made that there is no cure for any of the strains of influenza virus and, therefore, most interventions focus solely on prevention and symptom management.\nThis is important information to include when both your opening and closing paragraphs imply the far-UVC light studied might prevent the spread of the flu in public places.", "answer": 0}, {"article": "\u201cIt\u2019s reasonable to screen for something that\u2019s common, dangerous and has a treatment that\u2019s effective and safe.\u201d\n\nDr. William Cooper, a pediatrics and preventive medicine professor at Vanderbilt University, called it \u201can innovative approach\u201d that finds not just kids at risk but also parents while they\u2019re still young enough to benefit from preventive treatment, such as cholesterol-lowering statin drugs.\nIf a child was found with the disorder, parents were tested.\nexpert panel.\nResults were published Wednesday by the New England Journal of Medicine.\nThat\u2019s nearly twice as many as most studies in the past have suggested.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternative here is no screening in early childhood.", "answer": 2}, {"article": "But light was associated with better driving.\n\u201cSleep deprivation makes this worse of course, and together with the clock, this conspires to impair our ability to sustain attention to task (e.g., driving), and avoid distraction, and react quickly to external stimuli like traffic lights, brake lights in front of you, road signs, etc,\u201d Mistlberger added by email.\n\u201cThere is evidence that the use of bright light at the office (or even at home directly prior to beginning the work shift) may be beneficial in preventing sleep deprivation-related motor vehicle collisions,\u201d said Russell Griffin, a researcher at the University of Alabama at Birmingham who wasn\u2019t involved in the study.\n\u201cWe experience severe sleepiness toward the end of the night shift, and this may overlap with our commute time,\u201d said senior study author Dr. Ralph Mistlberger of Simon Fraser University in British Columbia, Canada.\nThe proven way to avoid the effects of sleepiness on the road is to consistently get enough sleep, said Dr. Flaura Koplin Winston, a researcher at the University of Pennsylvania and the Children\u2019s Hospital of Philadelphia who wasn\u2019t involved in the study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "An\u00a0independent source notes that the only \u201cproven\u201d way to avoid the effects of drowsiness when driving is \u201cto consistently get enough sleep.\u201d\u00a0 Other strategies for remaining alert behind the wheel are also mentioned.", "answer": 1}, {"article": "Why smokers are more susceptible is not known for sure, but some scientists believe it has to do with smoking-caused damage that allows the bacteria to more easily attach to the lungs and windpipe, said Dr. Pekka Nuorti, a medical epidemiologist with the Centers for Disease Control and Prevention.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The original AP story discussed the inefficacy of the vaccine in younger people and mentions that there is no booster available, even though protection drops off after 5-10 years.\u00a0 But the NY Daily News deleted that section.\u00a0 The story does not mention how smoking cessation counseling will be administered with vaccine.\u00a0 The story also mentions deaths from pneumonia in those over 65, but we are not told how pneumonia is typically treated in this population and in younger people, or in smokers in particular.\u00a0 We don\u2019t know how many smokers need to be vaccinated to prevent one case of invasive infection; we don\u2019t know how many cases will be prevented by adopting this new strategy. This uncertainty is not made clear in this article.\u00a0 \n\u00a0", "answer": 0}, {"article": "Coleman disclosed receiving speaker fees from Novartis; the researchers also received academic grant funding from the drug maker.\nIn addition, there were some troubling side effects among women taking Zometa, including 17 cases of osteonecrosis of the jaw (a severe bone disease that can result in death of the jawbone).\nIn the trial, known as AZURE (Adjuvant Treatment with Zoledronic Acid in State II/III Breast Cancer), Coleman and his colleagues evaluated 3,360 breast cancer patients from 174 participating centers, all with stage II or III cancers but no evidence of metastases (cancer that has spread beyond the original site).\n\"The role of bisphosphonates in preventing cancer recurrence has been less clear,\" she said, noting that multiple studies have had conflicting findings.\n\"As a whole, the study is negative,\" study author Dr. Robert Coleman, a professor of medical oncology at the University of Sheffield in England, said during a Thursday news conference on the findings.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did point out that the women in this trial did receive standard therapy (and it did so more clearly than the other story we reviewed), though it did not specifically say what that treatment entails. We will give the story a satisfactory rating since it is not clear that there is a proven alternative that would provide the type of recurrence and survival benefits seen in a previous study of zoledronic acid for early stage breast cancer.", "answer": 1}, {"article": "But Carlson says she believes finding purpose and civic engagement may forestall some of the damage of aging on the brain.\nThe men who were enrolled in Experience Corps, however, showed a .7 percent to 1.6 percent increase in brain volumes over the course of two years.\nThe control arm of the study, those not involved in Experience Corps, exhibited age-related shrinkage in brain volumes.\n\"We're embedding complexity and novelty into their daily lives, something that tends to disappear once people retire.\nThey engage in problem solving and they socialize in ways they wouldn't have if they stayed at home.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "While this study suggests that social activity (in a special program) may be nourishing to brain health, it does not compare or mention other research into possible methods for preserving brain mass and preventing cognitive decline. For instance, a healthy diet, exercise, not smoking, drug therapy, etc.", "answer": 0}, {"article": "\"It's clear that these medications are beneficial,\" said Wadden, who has been a paid consultant to pharmaceutical companies as well as Weight Watchers. \"Unfortunately, there's a sense that they must not work if you have to take them indefinitely. But I think obesity medications should be used on a long-term basis for chronic weight management, just as I take a [cholesterol-lowering] statin and a blood-pressure medication for the long term.\"", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compares alternative strategies for weight loss, although not in great detail.", "answer": 1}, {"article": "Obese children who cut sugar from their diets saw improvements in markers of heart disease after just nine days, a study in Atherosclerosis found.\nAfter nine days, the researchers found a 33 percent drop in triglycerides, a type of fat tied to heart disease; a 49 percent reduction in a protein called apoC-III that is tied to high triglyceride levels; and large reductions in small, dense LDL cholesterol, a risk factor for heart disease.\nFor the study, researchers evaluated 37 children ages 9 to 18 who were obese and at high risk for heart disease and Type 2 diabetes.\nThough this study is small and short-term, it builds on this group\u2019s previous research implicating added sugars as a contributor to metabolic disorders and heart disease.\nThe only change was their sugar intake: The researchers swapped foods high in added sugars, like pastries and sweetened yogurts, for options like bagels and pizza.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes no mention of other strategies typically employed to reduce markers of heart disease, including other types of dietary changes, exercise and drugs such as statins (which are typically reserved for adults). The UCSF\u00a0news\u00a0release did include this type of information.", "answer": 0}, {"article": "With the FDA's announcement, drugs like pembrolizumab have also begun to change the way that physicians, patients and government regulators think of cancer. No longer will they see all cancers of the lung, breast, colon, brain, liver, pancreas and prostate as distinct from one another. Instead, they will look for the common genetic mutations that give rise to cancers no matter where they're found. And they'll treat those cancers with a drug that uses that common signature as a homing beacon, either for the immune system or for targeted cancer drugs to attack.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story strongly implies that pembrolizumab is better than existing cancer treatments for patients with the relevant genetic marker, but that is a claim that has yet to be tested, since none of the trials included any direct comparisons between the new drug and existing treatments.", "answer": 0}, {"article": "The review identified a handful of drugs that \u201care probably effective and should be considered for migraine prevention.\u201d These include the antidepressants amitriptyline (Elavil, Endep or Vanatrip) and venlafaxine (Effexor); the beta blockers atenolol (Senormin or Tenormin) and nadolol (Corgard); and for menstrual migraines, naratriptan (Amerge) and zolmitriptan (Zomig).\nIn a summary of the guidelines written for patients and their families, this is how migraines are described:\n\nPreventive treatment involves taking a seizure drug and a beta-blocker every day to reduce the frequency, severity and duration of migraines.\nNeurologists estimate that about 38% of people who suffer from migraines stand to benefit with such a regimen, and studies suggest that as many as half of migraines can be prevented with drugs, according to Dr. Stephen D. Silberstein, a neurologist at the Jefferson Headache Center at Thomas Jefferson University in Philadelphia.\nThe authors also noted that frovatriptan (Frova), which is used to treat migraine symptoms, can also help prevent menstrual migraines.\nIn addition, an herbal remedy derived from a family of plants called Petasites or butterbur was found to be effective, according to the review.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Unlike the USA Today story we reviewed, non-drug approaches were not mentioned.\u00a0 Despite the fact that the story was based on a set of guidelines for drug treatments, we would have liked to have seen a few words on non-pharmacologic approaches including stress reduction, diet, etc.", "answer": 0}, {"article": "Hendricks says psychedelics can possibly help patients shift their priorities, or lead to drastic changes in perspective or even spiritual experiences that will help them improve their mental states.\nAdditionally, the effects of psychedelics on the developing brain are still largely unknown, meaning they could pose a threat to people with a predisposition to schizophrenia.\nIn 2011, individuals with advanced-stage cancer were given single doses of psilocybin and were found to have reduced long-term incidences of depression and anxiety.\nThe study, published recently in the Journal of Pharmacology, analyzed data from an annual survey conducted by the National Survey on Drug Use and Health that measures substance abuse in relation to mental illness.\nThe results showed that those who had taken these substances in their lifetime had a 19% less likelihood of exhibiting psychological distress in the past month, and their reports of suicidal thoughts in the past year were likely to be 14% lower.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story should have explained that antidepressant medicines and psychotherapy are effective for treatment of depression. Providing this context can help normalize and reduce stigma surrounding depression treatment.", "answer": 0}, {"article": "The findings were published today in the Journal of Bone and Mineral Research.\n\"Our compound only locks the collagen -degrading CatK activity, preventing the unregulated breakdown of collagen in bones without any other negative impacts.\"\nUsing a compound derived from red sage, UBC researchers have found a way to selectively block an enzyme called Cathepsin K (CatK), which plays a major role in the breakdown of collagen in bones during osteoporosis.\nOsteoporosis is a global health problem that will affect one out of three women and one of out five men worldwide, with a multi-billion-dollar pharmaceutical industry dedicated to finding treatments to stop its progression.\nThey found that it prevented bone loss and increased the bone mineral density of the mice treated with the compound by 35 per cent, when compared with the control group.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Existing treatments for osteoporosis including prescription drugs such as alendronate, risedronate, zoledronic acid and denosumab, as well as exercise and dietary changes, were not mentioned. The news release mentions \u201ca multi-billion-dollar pharmaceutical industry dedicated to finding treatments to stop its progression,\u201d implying that red sage could constitute a cost-effective alternative, but it doesn\u2019t delve into the effectiveness of current treatment options.", "answer": 0}, {"article": "MONDAY, Feb. 15, 2010 (HealthDay News) -- People with high-functioning autism or Asperger's syndrome were better able to \"catch\" social cues after inhaling the hormone oxytocin, new research shows.\n\"In the absence of intellectual deficits, the areas where they have the greatest struggle is around social communication and social connectedness,\" she continued.\nWhile there are drugs for the secondary symptoms of autism, such as irritability and aggression, doctors have nothing yet for the core symptoms in the areas of language, social interaction and intellectual deficits.\nWhen observed playing a virtual ball game, individuals who had inhaled oxytocin were able to interact better with their virtual partners compared to untreated participants.\nI don't know whether this is a realistic therapy as we have it now but, potentially, in the future it could really help these people whose primary autistic symptoms are having to do with reduction in social activity.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does discuss the treatment of autism and that no drug therapies are currently available for the social dysfunction observed in people with Asperger syndrome and other forms of autism.", "answer": 1}, {"article": "The paper\u2019s authors, in addition to Small, are Prabha Siddarth, Dr. Zhaoping Li, Karen Miller, Linda Ercoli, Natacha Emerson, Jacqueline Martinez, Koon-Pong Wong, Jie Liu, Dr. David Merrill, Dr. Stephen Chen, Susanne Henning, Nagichettiar Satyamurthy, Sung-Cheng Huang, Dr. David Heber and Jorge Barrio, all of UCLA.\nThe amygdala and hypothalamus are regions of the brain that control several memory and emotional functions.\nThat study will include some people with mild depression so the scientists can explore whether curcumin also has antidepressant effects.\nThe researchers plan to conduct a follow-up study with a larger number of people.\nParticipants were randomly assigned to receive either a placebo or 90 milligrams of curcumin twice daily for 18 months.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There is no discussion of other therapies used in addressing memory or mood problems.", "answer": 0}, {"article": "A recent study has found evidence suggesting text messages could reduce one\u2019s odds of a second heart attack.\n\nA six-month clinical trial in Australia found that patients recovering from a heart attack were more likely to maintain lower blood pressure, less body fat and lower cholesterol levels than a control group when the patients received text messages asking and giving suggestions about their health routines. Patients receiving the texts also were more likely to be active and to quit smoking than the patients in the control...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does\u00a0mention some other interventions used to prevent heart attacks, such as\u00a0typical medications taken to lower blood pressure or cholesterol.", "answer": 1}, {"article": "Revenues from pharmaceutical and device corporations are available at http://www.\nEvery second counts, in the current standard of care, patients who experience stroke-like symptoms and call 9-1-1 arriving to the hospital by ambulance are assessed by clinical examination and imaging (CT or MRI scan) in the Emergency Department.\nHOUSTON, Feb. 23, 2017 - stroke patients receiving clot-busting medications before arriving at the hospital have a lower risk for disability afterward, according to research presented at the American Stroke Association's International Stroke Conference 2017.\nPast research showed the sooner that a clot-busting tPA drug is given after an ischemic stroke - one in which a clot is blocking blood flow - the better patients fare.\n\"Time is brain in acute stroke after vascular collaterals fail, and faster treatment yields better outcomes,\" said May Nour, M.D., Ph.D., lead researcher, interventional neurologist and director of UCLA's Mobile Stroke Rescue Program.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does an OK job discussing how the approach being studied compares with the standard of care. It says:\n\u201cEvery second counts, in the current standard of care, patients who experience stroke-like symptoms and call 9-1-1 arriving to the hospital by ambulance are assessed by clinical examination and imaging (CT or MRI scan) in the Emergency Department. This takes a certain amount of time from the patient\u2019s symptom onset which prompted the 9-1-1 call.\u201d", "answer": 1}, {"article": "His research group is making plans to try the technique on patients with advanced ovarian cancer and sarcomas \u2014 rare tumors that arise from connective tissue in bones and muscle.\nThe key is to identify specific cancer-fighting cells already circulating in the blood of patients and make thousands of copies of them in the lab.\nIn one of those patients, the treatment resulted in complete remission of his metastatic melanoma and evidence that his immune system stands ready to fight any return of the cancer after three years.\nThe study, published Monday in the Proceedings of the National Academies of Science, contributes to hopes that a tumor-fighting strategy called immunotherapy can slow, halt or even reverse the growth of a range of cancers \u2014 and do so with fewer dangerous side effects.\n\"Each article that shows clinical activity is giving us a piece of the puzzle\" that will make it safer and more effective, he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Brief reference was made to one patient having had 6 years of chemotherapy \u201conly to have his melanoma return.\u201d And Rosenberg\u2019s comments at the end note a competing immunotherapy approach.\u00a0 But the story didn\u2019t give readers a clear context of melanoma treatments, or of why and for whom immunotherapy would be tried, etc.", "answer": 0}, {"article": "For more information about ColonaryConcepts, LLC, please visit http://www.\n\"We are very pleased with the efficacy and safety results of this study, which clearly support advancing this product to a Phase 3 trial,\" said Corey A. Siegel, M.D., M.S., a co-founder of ColonaryConcepts, and Director of the Inflammatory Bowel Disease Center at the Dartmouth-Hitchcock Medical Center and Associate Professor of Medicine at The Geisel School of Medicine at Dartmouth.\n\"The ECP approach allows patients to eat solid food bars and drink palatable low-volume beverages, a patient-friendly design that participants in the study clearly favored over conventional preps,\" comments Dr. Siegel.\nThe study tested six formulations of ECP, using different doses of the active ingredients integrated within different meal kit menus, randomized against two U.S. Food and Drug Administration-approved active comparators.\n\"Approximately 40% of those who ought to have a colonoscopy avoid the procedure, and the top reason cited for their avoidance is the prep,\" said Dr. Rex.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The clinical trial compares the outcomes of this colonoscopy prep to that of two existing, FDA-approved preps. But we\u2019re never told what those preps were. There are many approved preparations including combining Gatorade with polyethylene glycol, tablets and laxatives.\nThe release also could have mentioned that while colonoscopy is considered by some to be the gold standard, some groups, like the US Preventive Services Task Force, recognize other screening approaches including fecal occult blood screening and sigmoidoscopy. However, sometimes these procedures must be followed by a colonoscopy in the event of a positive screen.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070715/23knee.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article fails to mention that the pain and functional limitations caused by knee osteoarthritis occasionally improve on their own or often respond to nonsurgical treatments (e.g. strengthening and exercise, weight loss, medications, injections, bracing, in-shoe orthotics) and smaller operations (e.g. osteotomy). (A sidebar on a motion analysis laboratory mentions braces and physical therapy). For younger surgical candidates, this is important information, because knee replacements have a limited life and young patients concerned about the need for a second operation later in life often prefer to wait as long as possible before having their first.", "answer": 0}, {"article": "Routledge added that current evidence shows that not smoking, only consuming alcohol within recommended limits, staying active, monitoring cholesterol levels and eating a balanced diet can all help with the health of the heart and brain.\nThere is currently no cure for dementia, though medication can be used to temporarily treat its symptoms.\nBut he added that focus should also be paid to dementia sufferers after their diagnosis, saying: \"The elephant in the room is the lack of support for people and their families once they get a diagnosis of dementia.\"\nVascular dementia is directly caused by reduced blood flow to the brain, and this can also play a role in the development of Alzheimer's disease, studies have found.\nA group of almost 3,200 patients, aged 58-74, had ultrasounds on their necks in 2002, before having their cognitive functions monitored for up to 14 years, from 2002 to 2016.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explains that researchers are attempting to see if the test should be added as part of \u201croutine screening\u201d for risk factors. It would have been helpful to briefly explain what is currently included in routing screening.", "answer": 1}, {"article": "These studies have been done with people, but other promising research has only been done with lab animals so far. In one 2009 study in the Journal of Medicinal Food, tart cherries helped fat rats. Not our favorite role models perhaps, but the obese beasties' risk of Type 2 diabetes and heart disease were reduced significantly, and parallel studies are now in the works with members of our own species, says lead author E. Mitchell Seymour: \"There are some interesting and potentially exciting results on the horizon. Stay tuned.\"", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "In just an additional line or so, the story could have included something about alternatives for inflammatory osteoarthritis. It also could have mentioned other foods that are rich in anti-inflammatory and anti-oxidant compounds.", "answer": 0}, {"article": "\"They did show a higher recurrence or progression rate with endometrial cancer than with AEH and that is consistent with other data,\" said Bakkum-Gamez, who added that the IUD method would not be appropriate for later-stage cancers, which tend to be more aggressive.\nNine of the women in the study successfully delivered babies.\nThe majority of these women have not yet had children, according to background information in the article.\nThe IUD was removed at the end of the year if there was no evidence of cancer.\nNo adverse effects from treatment were noted, according to the researchers, who declared no conflicts of interest.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compares the progestin IUD with systemic hormones and hysterectomy", "answer": 1}, {"article": "Toenail fungus causes nails to become thick, yellow and brittle in a way that looks pretty ugly and can be painful.\nCompared with oral medication, he says, \u201cthe odds of success are better with the laser; plus, there\u2019s no side effects.\u201d\n\nThe most common oral treatment, Lamisil, works for about two out of three patients, according to Lamisil\u2019s FDA-approved prescribing information, but it has been associated with rare cases of serious liver problems.\n\u201cI\u2019ve had patients come in who have had laser procedures and not seen long-term success.\u201d\n\nFirestone also says that over-the-counter antifungal nail creams and ointments rarely work because they can\u2019t penetrate the nail root.\nIn this case, there is a chance.\u201d\n\nEven John Strisower, the founder of PinPointe USA, says patients should expect at least a minimal reinfection within five years after laser treatment.\nIn one small study about laser treatment for toenail fungus, which appeared last year in the Journal of the American Podiatric Medical Association, \u201c26 eligible toes (ten mild, seven moderate, and nine severe)\u201d were treated with a laser produced by Nomir Medical Technologies, which is still seeking FDA approval.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention multiple alternatives, but it also knocks each one of them down. Lamisil \u201chas been associated with rare cases of serious liver problems\u201d and other \u201cpotential side effects include diarrhea, headache, rashes and changes in taste.\u201d Then the story quotes a podiatrist who does not use lasers but never says what he does use. Instead, he lists a litany of treatments that don\u2019t work. \u201cFirestone also says that over-the-counter antifungal nail creams and ointments rarely work because they can\u2019t penetrate the nail root. Home remedies such as tea tree oil, bleach and vinegar also don\u2019t work, he says.\u201d Then we are introduced to Richard, the first-name-only guy with foot fungus. He is presented as a success story for laser treatments. The story says, \u201chis nails were fully cleared of the yellowed, thickened look after a year.\u201d We think that, on balance, the story did not fairly compare the new approach with existing alternatives. Instead, it stacked the deck against these alternatives, leading readers to conclude that lasers would be the best choice.", "answer": 0}, {"article": "Portions of this study were supported by National Institutes of Health grants (CA140933, CA104825, CA109298, P50CA083639, U54CA151688, U54CA96300, U54CA96297, and CA016672), an Ovarian Cancer Research Fund program Project Development Grant, the Department of Defense (grants OC073399, W81XWJ-10-0158, and OC100237), the Betty Ann Asche Murray Distinguished Professorship, the RGK Foundation, the Gilder Foundation, the Blanton-Davis Ovarian Cancer Research Program, and a Gynecologic Cancer Foundation-St. Louis Ovarian Cancer Awareness grant.\nAll these factors were associated with decreased survival, yet those who received beta-blockers had either equivalent or improved overall survival.\nThere are currently two clinical trials, one led by MD Anderson, evaluating the combination of chemotherapy and propranolol (a type of NSBB) on cancer biology and on stress modulators in patients with newly diagnosed EOC.\nIt showed that stress hormones fuel progression of ovarian and other cancers, and that beta-blockers - among the most proven drugs in cardiovascular medicine - might be a new way to stifle that effect.\nAccording to The University of Texas MD Anderson Cancer Center investigators, the drugs block the effects of stress pathways involved in tumor growth and spread.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The relevant research is based on evaluating the use of beta blockers in conjunction with conventional chemotherapy, not as an alternative to chemotherapy or other courses of treatment. As such, we\u2019ll rate \u201cCompare Alternatives\u201d as not applicable.", "answer": 2}, {"article": "Leone-Bay said that cancer studies have been conducted on Afrezza in rats.\n\"They have done the required safety studies and come out clean, but it's only been tested for six months, so long-term isn't known,\" said Sanjoy Dutta, director of the insulin initiative at the Juvenile Diabetes Research Foundation.\nThe new drug, Afrezza, which is awaiting approval from the U.S. Food and Drug Administration, works faster, keeps blood sugar levels at a closer to normal level and has less risk of causing low blood sugar levels (hypoglycemia) than currently available injectable insulins, researchers say.\nTUESDAY, March 23, 2010 (HealthDay News) -- A new form of inhaled insulin appears to help people with diabetes who must use insulin, with fewer potential risks than an earlier form of inhaled insulin that is no longer on the market.\n\"Afrezza is an ultra-rapid-acting insulin, and clinical studies have shown us that it has the potential to change diabetes therapy, because in the body, Afrezza looks like the insulin that's normally in a person's body,\" said Andrea Leone-Bay, vice president of pharmaceutical development for MannKind Corp., manufacturer of Afreeza.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does compare Afrezza to available injectable insulin. However, there are a number of different short-acting injectable insulins available, and it\u2019s not clear what is being compared here. The claim of its superiority \u2014 it \"keeps blood sugar levels at a closer to normal level\u2026than currently available injectible insulin\" \u2014 is entirely unsubstantiated. We can\u2019t rate it Satisfactory for making this critical comparison in an unclear, unsupported fashion.\nWhile it also compares Afrezza to Exubera, Exubera is no longer an available alternative. The main issue here is that Afrezza needs to be compared to short-acting, injectable insulin designed for preprandial use, not a medication that has been discontinued.", "answer": 0}, {"article": "Does it cross her mind what would have happened if she didn't have the ultrasound?\nAnd it's an important story, because about half of women under the age of 50 are found to have dense breast tissue when they get their mammograms.\nBut this study - the most definitive so far - may encourage more doctors to consider ultrasound, which is easier and less expensive.\nIn today's study of about 2,809 women with dense tissue and other risk factors, mammography alone found only half of the cancers.\n\"This could have gone on for years before anybody found it, and it could have been a whole different story,\" she said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned MRI as a supplemental screening method for women at very high risk of breast cancer or recurrence due to a variety of risk factors, including dense breast tissue.\u00a0 The story also mentions breast biospy if there is a suspicion of cancer.\u00a0 Importantly, the story mentioned that screening may need to be tailored to a woman\u2019s individual risk profile, as well as her prefered screening schedule based on risks and benefits. ", "answer": 1}, {"article": "To learn more about DOs and the osteopathic approach to medicine, visit http://www.\nThe osteopathic philosophy of medicine takes a whole person approach to prevention, diagnosis and treatment, giving its practitioners a distinct model for clinical problem solving and patient education.\nHis team's research on the role of autoantibodies explains that:\n\u2022 All humans possess thousands of autoantibodies in their blood;\n\u2022 These autoantibodies specifically bind to blood-borne cellular debris generated by organs and tissues all over the body;\n\u2022 An individual's autoantibody profile is strongly influenced by age, gender and the presence of specific diseases or injuries; and\n\u2022 Diseases cause characteristic changes in autoantibody profiles that, when detected, can serve as biomarkers that reveal the presence of the disease.\n\"There are significant benefits to early disease detection because we now know that many of the same conditions that lead to vascular disease are also significant risk factors for Alzheimer's.\nWe also know that many people tune out messages about nutrition and exercise until a health crisis gets their attention,\" said Jennifer Caudle, DO, assistant professor of family medicine at Rowan University.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "If you simply looked\u00a0on our website, searching for past news about supposedly imminent Alzheimer\u2019s tests, you\u00a0would\u00a0get dizzy going down the trail of past promises. \u00a0Much less if you did a literature search.\nThis story provides no context about other work in the field, while providing no\u00a0information about\u00a0how the performance of this test sets its apart from others.", "answer": 0}, {"article": "This, sadly, is expected; more than 178 million doses of Gardasil have been given worldwide, and given that huge number it\u2019s a statistical certainty that some young people will die not long after getting them.\nAll the evidence shows Gardasil to be safe and to be effective against a virus that causes horrific illnesses.\nWhen it comes to health issues, especially ones tied to sexuality, reason goes out the window and emotions take over.\nIt\u2019s like Bizarro world, where everything is backward.\nIt also shows that the claims made by anti-vaxxers are wrong, and that people fighting the vaccine because of their own sexual biases are making things far worse.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that abstinence, if it worked, could obviate the need for the vaccine.", "answer": 1}, {"article": "IRE uses strong electric fields that cause cells to die without exposing the tissue to radiation or heat.\nThere were no IRE-related complications and toxicity was extremely low: 27 patients reported a transient reduction of erectile function (EF) (resolved after 6-8m), 15 a permanent reduction and 2 a permanent loss of EF.\nInitial tumor control was achieved in all patients, and during the follow-up period of up to 4 years, the recurrence rates were 0/55 (Gleason <7), 3/117 (Gleason 7) and 10/67 (Gleason >7).\n\"The patients we have treated at The Prostata Center have had their cancers destroyed without the need for surgery, with a low incidence of side effects and in most cases have been back on their feet the next day,\" said Dr. Michael K. Stehling, an internationally recognized expert on image guided tumor ablation treatments and primary author of the study.\nFor the study, Dr. Stehling and his team of researchers evaluated data from 265 patients with primary (stages T1-T4) and recurrent PCa after surgery, radiation therapy and HIFU.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "We would have liked to see the release outline the typical alternatives for a patient presenting with prostate cancer, and explain how this image-guided IRE therapy compares to other therapies.\nThe release states: \u201cUnlike other treatment procedures for prostate cancer therapy, image guided or IRE only destroys cells; vital tissue structures are not affected.\u201d But it doesn\u2019t outline side-by-side the alternatives for patients.\nCurrently, cryotherapy or other local therapies are not recommended as therapy for primary or\u00a0recurrent\u00a0prostate cancer due to lack of long-term data comparing these treatments with radiation and surgery, according to the  National Comprehensive Cancer Network (NCCN). For patients with recurrent cancer,\u00a0the typical treatments include hormone therapy, chemotherapy, immunotherapy, and radiopharmaceutical therapy. \u00a0Treatment choice for recurrent cancer would depend upon the initial stage and whether \u201crecurrence\u201d meant biochemical progression (PSA increase) or clinical evidence of progressive or metastatic cancer.\nIn this release, the group studied was not described well enough to know which alternative therapies would have been appropriate.\nA common problem with early-stage primary cancers is overtreatment. \u00a0An appropriate option for many men with low-risk cancers is \u201cactive surveillance\u201d \u2014 not receiving any active treatment because there is no evidence for benefit. \u00a0We do not know how many of the study subjects had low-risk cancers.", "answer": 0}, {"article": "Such an analysis is months away.\n\u201cThe challenge now shifts from proving the efficacy of the method to developing the proper quality standards, infrastructure and guidelines to bring this needed benefit to those at high risk for the disease \u2014 now,\u201d Ms. Fenton said.\nThere is just tremendous potential.\u201d\n\nBut Dr. Edward F. Patz Jr., professor of radiology at Duke who helped devise the study, said he was far from convinced that a thorough analysis would show that widespread CT screening would prove beneficial in preventing most lung cancer deaths.\nThe study, called the National Lung Screening Trial, was conducted by the American College of Radiology Imaging Network and the cancer institute.\nPatients wishing to get a CT lung screen will most likely have to pay the roughly $300 charge themselves, since few insurers pay for such scans unless an illness is suspected.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe story reports that no other screening method (including chest x-rays) has been shown to reduce lung cancer death rates among current and former smokers. However, many health experts are concerned that lung cancer screening could lull smokers into a false sense of safety. This story fails to mention quitting smoking as a way to reduce the risk of death. Nonethless, we\u2019ll give the story the benefit of the doubt on this criterion.\n", "answer": 1}, {"article": "CHICAGO\u2014For patients facing a choice between bypass surgery and a popular, less-invasive procedure to treat heart blockages, surgery improves chances of long-term survival, researchers said Tuesday.\n\nIn a study that analyzed data on nearly 190,000 Medicare patients treated between 2003 and 2007, 16.4% of surgery patients had died after four years, compared with 20.8% treated with angioplasty and a stent to prop open diseased vessels.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study itself was about comparing two treatments, and this story was superior to the NPR story and the Associated Press story we reviewed in making those comparisons clear.\nStill, we would have liked to have seen some comments on the third alternative available to people with coronary artery disease, medical treatment.\u00a0 Without some mention, people with coronary artery disease may be led to believe that there are only interventional options. For many this is not the case.", "answer": 1}, {"article": "\"Our idea was to ask, 'What are the most important proteins we could find in Alzheimer's patients?'\nThe test has also shown promise in predicting which patients with mild memory loss are at high risk of developing the dreaded syndrome, which each year kills 66,000 Americans and inflicts incalculable heartache on the families of its victims.\nAlthough the studies were small in scale, researchers said the experiment proved that the concept of screening for chemical signals was promising and that the first Alzheimer's blood test might be within reach after further large scale studies.\n\"I do see great potential in this technology,\" said UCSF professor Dr. Lennart Mucke, director of the Gladstone Institute of Neurological Disease.\nIn one experiment using stored blood samples, the test was positive for Alzheimer's disease in 38 out of 42 patients who had been independently diagnosed by clinicians as having the disease - a 90 percent accuracy rate.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u00a0made reference to\u00a0several other tests which are currently being explored for use in detecting Alzheimer\u2019s disease.\u00a0 While it did mention MRI, the story did not mention current approaches to diagnosis (i.e. eliminating other possible diagnoses).", "answer": 0}, {"article": "\u201cAnd when stimulation arrived in a good state, the average was about 15 to 20 percent worse than usual.\u201d\n\nDr. Doris Greenblatt, a psychiatrist who participated in the trial at Emory, said she sought the surgery because her epilepsy had long caused memory problems.\n\u201cIt was a little humiliating, to be honest,\u201d she said of the testing.\nMany of the electrodes sit in or near memory areas, and the wait can take weeks in the hospital.\n\u201cEach seizure I had tore at the fabric of memory, and it was as if my memories weren\u2019t attached to anything,\u201d Dr. Greenblatt said.\n\u201cThe average enhancement effect was about 12 to 13 percent,\u201d Dr. Kahana said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Since there are really no alternatives as far as treatment goes, we\u2019ll rate this N/A.", "answer": 2}, {"article": "The researchers then cross-referenced this information with health department death records.\nRelated: Severe childhood obesity is on the rise in the U.S.\n\nIt\u2019s recommended that people get 150 minutes (or two and half hours) of exercise each week, based on guidelines from the American Heart Association, the U.S. Centers for Disease Control and Prevention and other medical authorities.\nThese weekend warriors cram the recommended amount of exercise into one or two days, while the rest of us faithfully head to the gym multiple times a week for a half-hour hamster run on the treadmill.\nHowever, experts caution that it is possible to overdo it, and more exercise than two and a half hours a week can actually be unhelpful and even harmful.\n\u201cI would be more concerned about what\u2019s happening at the point of exercise\u2014not the long-term benefits,\u201d says Dr. Howard Andrew Selinger, chair of family medicine at Quinnipiac University.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the focus of the story was the \u201cweekend warrior,\u201d several comments were included suggesting alternative exercise strategies, including: \u201cThis could be something as simple as a brisk walk\u00a0or other low-impact options for vigorous exercise about 20 minutes a day. \u00a0\u201cIn theory, someone who did one bout of 150 minutes of moderate exercise is a weekend warrior,\u201d says O\u2019Donovan.\u00a0This study shows that it doesn\u2019t matter how you decide to split up the recommended weekly amount of exercise. You just need to do it.\u201d", "answer": 1}, {"article": "Researchers conducted a systematic review of existing peer-reviewed research evaluating infusion care for several conditions, including cystic fibrosis, antibiotics following orthopedic surgery and several cancers requiring infused chemotherapies.\nHome infusion services are a rapidly growing delivery model in the health care system with rising rates of chronic and acute conditions that require intravenous therapy.\nThe research showed that patients receiving intravenous therapy at home had as good or better clinical outcomes as those patients who received the same therapy in a traditional health care setting.\nThis unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs.\nDespite this, clinical outcomes and quality of care have not previously been systematically evaluated.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release explains the alternatives of clinic or hospital infusion compared to home infusion.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070603/11back.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The news story mentions common treatment options for sciatica, but says little about options other than surgery for degenerative spondylolisthesis (DS). In the new DS study, these included epidural injections and physical therapy.", "answer": 0}, {"article": "In 2012, a federally funded panel of experts on preventive care concluded there are more risks than benefits to screening American men for prostate cancer with the PSA test. And in April 2017, the U.S. Preventive Services Task Force dumped the decision squarely into the laps of patients and their doctors. Some men between 55 and 69 years of age might well decide to get their PSA checked, the task force said. After hearing the ledger of pros and cons, however, others in that age bracket might just as reasonably skip the screening test, the panel concluded.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is all about the comparison of screening to not screening.", "answer": 1}, {"article": "And for now, the research is preliminary, so it's too early to know for sure if the treatment is appropriate to be used for any kind of depression.\nAfter two years, of the 12 patients still in the study, seven patients (58 percent) were in remission.\nMost of the patients continued to receive the treatment over two years, although researchers temporarily turned it off in three of them as part of the study before realizing that doing so caused their depression to return.\nIf patients are interested in deep brain stimulation treatment, they should try to get into the study that's ongoing, Mayberg said.\nThe level of stimulation is controlled by a pacemaker-like device implanted in the chest.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story alludes to other treatment options, including medications and electroconvulsive therapy, and it quotes an outside expert saying that these are preferable.", "answer": 1}, {"article": "Researchers around the world are seeking ways to regenerate damaged hearts, spines and skin with stem cells. At an operating table here recently, Kotaro Yoshimura leaned over a 51-year-old woman and put stem cells to use for a different purpose: cosmetic breast surgery.\n\nDr. Yoshimura jabbed the underside of the woman's left...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that this procedure is largely for cosmetic purposes, but it has been used as a reconstructive technique. Fat transfer has been used without stem cells for reconstruction for about 10 years.\u00a0 The story also notes the more common silicone and saline implants as options for breast reconstrution and augmentation. ", "answer": 1}, {"article": "For more information about our products and the organization, visit http://www.\nOctober 26, 2017 - For younger patients with severe damage to the rotator cuff muscles, a \"reverse\" shoulder replacement provides lasting improvement in shoulder function, according to a study in The Journal of Bone & Joint Surgery.\nThe RTSA technique--using an implant in which the natural locations of the shoulder \"ball and socket\" are reversed--uses other muscles to move the shoulder, providing an alternative when the rotator cuff is severely damaged or destroyed.\nAbout The Journal of Bone & Joint Surgery\n\nThe Journal of Bone & Joint Surgery (JBJS) has been the most valued source of information for orthopaedic surgeons and researchers for over 125 years and is the gold standard in peer-reviewed scientific information in the field.\nThe average Constant score--a standard assessment accounting for shoulder motion, strength, daily activities, and pain--at the time of final-follow-up improved from 24 to 59 (out of a possible 100).\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There\u2019s no mention of any alternatives to this surgery in this release. This is surely something that should have been discussed. Alternative treatments such as superior capsular reconstruction should be considered prior to RSA, particularly for the patients with massive tears of the rotator cuff without signs of shoulder arthritis. Failures of RSA in a younger individual can be devastating, at times leaving individuals with no good options when the implant fails and the patient has lost a significant amount of bone related to the implantation of the prosthesis and destruction of bone that sometimes occurs with failure of the implant.", "answer": 0}, {"article": "A Harvard researcher hopes an old arthritis drug, which he read about in a 19th century German medical journal, could be a cheap new treatment for diabetes.\n\nIn the late 1990s, Steven Shoelson's research suggested that the drug, called salsalate, might also help diabetics. The idea sent him into the basement stacks of a Harvard library to see whether anyone else had pursued the notion.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Other than a mention in passing about \u2018costly medications\u2019, the story did not contain information about means of treatment currently available for individuals with type 2 diabetes. \u00a0While this drug was framed as an inexpensive, generic option, there are actually many low cost generic options that people with type 2 diabetes can use to keep their sugar level in check. \u00a0There was no mention of this in the article.", "answer": 0}, {"article": "\u2022 Keep up to date with Tenovus Cancer Care by following them on Twitter @tenovuscancer or Liking their page on Facebook http://www.\nFollowing on from this research, Tenovus Cancer Care is launching a two year study looking in more depth at the longitudinal effect of choir singing over several months.\nSinging in a choir for just one hour boosts levels of immune proteins in people affected by cancer, reduces stress and improves mood, which in turn could have a positive impact on overall health, a new study by Tenovus Cancer Care and the Royal College of Music published today in ecancermedicalscience has found.\nRosie Dow, Head of Sing with Us at Tenovus Cancer Care and co-author of the research, added: \"This research is so exciting, as it echoes everything all our choir members tell us about how singing has helped them.\nDr Daisy Fancourt, Research Associate at the Centre for Performance Science, a partnership between the Royal College of Music and Imperial College London and co-author of the research, said: \"Many people affected by cancer can experience psychological difficulties such as stress, anxiety and depression.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Many studies have given cancer patients access to meditation, massage and other forms of stress-reduction in order to influence their immune systems. Choir singing should be compared to those existing results to show us \u2014 does it lower cortisol as much as meditation, for example? This comparison would have helped make the release much better.\nPatients who do not already belong to a choir or sing regularly may in fact benefit more from other types of interventions to improve emotional well-being.", "answer": 0}, {"article": "The majority of cases are caught at around 66.\nThe next steps should be to understand how this research can be developed into tests that could identify men who might be more likely to develop aggressive cancers, and how this could be rolled out to patients.\u201d\n\nDr. Iain Frame, the director of research at the charity Prostate Cancer UK, highlighted that men with a family history of prostate cancer are two-and-a-half times more likely to be diagnosed with the disease compared to a man with no family history.\nThe resulting test hones in on these and the existing 100 known markers to pinpoint the 1 percent of men who are at six times greater risk of developing the condition, and the 10 percent of men who have a threefold greater risk of developing the disease, a study author told The Guardian.\nAlthough prostate cancer is the second leading cause of cancer death in the U.S. after lung, few risk factors have been found, and it is difficult to accurately diagnose.\nThe new method is being trialed on 300 men in doctors' offices across London, and is due to be expanded to 5,000 next year, according to BBC News.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned family history as one way to flag men at greater risk of developing prostate cancer.\nIt mentioned PSA tests, rectal exams and biopsies as ways to test for the disease.", "answer": 1}, {"article": "The NYU Langone researchers believe that obesity may contribute to the risk for development of psoriasis and psoriatic arthritis through fat tissue-driven systemic inflammation.\nIt is estimated that as many as 20 percent of individuals with moderate to severe psoriasis develop psoriatic arthritis in their lifetime.\nResults were even more pronounced in those with severe disease activity, with scores falling from 7.7 before surgery to 5.7 after for patients with severe psoriasis, and from 8.2 to 4.8 after surgery for patients with severe psoriatic arthritis.\nAccording to the study's authors, the findings suggest that losing excess weight may improve symptoms in people who have these lifelong conditions.\nPatients who saw the most improvements had more severe disease at the time of surgery and were of an older age at diagnosis.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "It would have been nice to know how other patients losing weight in the conventional sense compared to these patients. Alternatives to bariatric surgery exist and should have been mentioned. Two alternatives to bariatric surgery for reduction of psoriasis symptoms \u2014\u00a0 conventional weight loss and other treatments for psoriasis (topical agents, medications, and UV treatment) \u2014 that would reduce symptoms at least as much as surgery should have been discussed here. Presumably patients who lost weight through non-surgical means would have also benefited from having their psoriasis symptoms reduced.", "answer": 0}, {"article": "UW-Madison radiology professor Weibo Cai is also a senior author on the study.\nThat existing unit, \"Maestro,\" approved by the Food and Drug Administration in 2015, administers high-frequency zaps to the vagus nerve to shut down all communication between the brain and stomach.\n\"One potential advantage of the new device over existing vagus nerve stimulators is that it does not require external battery charging, which is a significant advantage when you consider the inconvenience that patients experience when having to charge a battery multiple times a week for an hour or so.\"\n\"Our expectation is that the device will be more effective and convenient to use than other technologies,\" says Wang.\nThat ongoing maintenance can be a big barrier to use, says Luke Funk, a surgery professor in UW-Madison's Division of Minimally Invasive, Foregut and Bariatric Surgery.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does report that there is an existing FDA-approved device for weight loss that uses a similar vagus nerve stimulation method. However, as mentioned above, the release improperly makes claims of superiority that have yet to be tested.\nBesides implantable devices there are, of course, a whole hosts of non-invasive means of losing weight, including the newer drug liraglutide which may lead to losses greater than those seen with implantable devices.", "answer": 1}, {"article": "The findings are mixed on substance abuse.\n\u201cIt\u2019s a shift from having our mental health defined by the content of our thoughts,\u201d Dr. Hayes said, \u201cto having it defined by our relationship to that content \u2014 and changing that relationship by sitting with, noticing and becoming disentangled from our definition of ourselves.\u201d\n\nFor all these hopeful signs, the science behind mindfulness is in its infancy.\nA recent review by Canadian researchers, focusing specifically on mindfulness meditation, concluded that it did \u201cnot have a reliable effect on depression and anxiety.\u201d\n\nTherapists who incorporate mindfulness practices do not agree when the meditation is most useful, either.\nWith Dr. Kabat-Zinn, they wrote a popular book, \u201cThe Mindful Way Through Depression.\u201d Psychotherapists\u2019 curiosity about mindfulness, once tentative, turned into \u201cthis feeding frenzy, of sorts, that we have going on now,\u201d Dr. Kabat-Zinn said.\nYet so far, the evidence that mindfulness meditation helps relieve psychiatric symptoms is thin, and in some cases, it may make people worse, some studies suggest.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does an excellent job describing the practice of mindfulness mediation, as well as the utility and purpose of mindfulness therapies in a clinical setting. The notes that mindfulness is typically compared with\u00a0 traditional cognitive therapy, another treatment option. The sidebar listing meditative therapies and evidence of their relative benefit is an excellent addition to the article. ", "answer": 1}, {"article": "The finding is another in a series suggesting that early detection of cancer might not always lead to better outcomes for patients.\nDr. Andrew Berchuck, director of gynecologic oncology at , said that while \u201cit\u2019s the American way, sort of, to be aggressive\u201d and treat early, some doctors and patients even now did not start chemotherapy when CA125 rises.\n\u201cBut there are also people who wouldn\u2019t want to go back on chemo unless they absolutely have to.\u201d\n\nDiane Paul, an ovarian cancer survivor and patient advocate in , said that when she was getting the CA125 test, she asked her doctors not to tell her the results, to reduce her anxiety.\nThe new study, done in and nine other countries, compared 265 women who began chemotherapy after their CA125 levels began to rise with 264 women who waited to begin chemotherapy until they had symptoms, like or pain.\n\u201cThis makes me feel in control of this disease,\u201d said Carol Tawney of Shawnee, Kan., a seven-year survivor who has her CA125 tested every two months.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Clearly no testing is the alternative to CA-125. The story could have also mentioned regular imaging tests as a way to monitor for recurrent cancer.", "answer": 1}, {"article": "Also unknown: Will insurers pay for the expensive test without evidence it leads to better care or saves lives?\nA new genetic test to gauge the aggressiveness of prostate cancer may help tens of thousands of men each year decide whether they need to treat their cancer right away or can safely monitor it.\nThe results suggest the test could triple the number of men thought to be at such low risk for aggressive disease that monitoring is a clearly safe option.\nIndependent experts say such a test is desperately needed but that it's unclear how much information this one adds or whether it will be enough to persuade men with low-risk tumors to forgo treatment, and treat it only if it gets worse.\n\"We're not giving patients enough information to make their decision,\" said Dr. Peter Carroll, chairman of urology at the University of California, San Francisco.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll give the story the benefit of the doubt on this one.\u00a0 It covered a lot of ground and we don\u2019t want to ding it for what it might have done a bit better.\nIt at least gave data comparing one of the new tests with \u201cone current method.\u201d\nIt at least said the new test is \u201csimilar to tests used now for certain breast and colon cancers.\u201d\nAnd it at least reported that \u201cDoctors now base risk estimates on factors such as a man\u2019s age and how aggressive cells look from biopsies that give 12 to 14 tissue samples. But tumors often are spread out and vary from one spot to the other.\u201d", "answer": 1}, {"article": "Results of the regenerative medicine study published in the journal Nature Nanotechnology.\nWe have shown that skin is a fertile land where we can grow the elements of any organ that is declining,\" said Dr. Chandan Sen, director of Ohio State's Center for Regenerative Medicine & Cell Based Therapies, who co-led the study with L. James Lee, professor of chemical and biomolecular engineering with Ohio State's College of Engineering in collaboration with Ohio State's Nanoscale Science and Engineering Center.\nOur technology keeps the cells in the body under immune surveillance, so immune suppression is not necessary,\" said Sen, who also is executive director of Ohio State's Comprehensive Wound Center.\nResearchers at The Ohio State University Wexner Medical Center and Ohio State's College of Engineering have developed a new technology, Tissue Nanotransfection (TNT), that can generate any cell type of interest for treatment within the patient's own body.\nIn lab tests, this technology was also shown to reprogram skin cells in the live body into nerve cells that were injected into brain-injured mice to help them recover from stroke.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release doesn\u2019t mention any alternatives or reference previous experimental attempts to use this technology. However, the release claims that multiple conditions could be treated with the technology, so it would be difficult to mention the array of alternatives that might be applicable. If this technology becomes a realistic alternative in people then alternatives would be important to describe.", "answer": 2}, {"article": "It hopes setting such a standard would also help prevent teenagers who experiment with tobacco from becoming addicted.\nThe FDA estimates that setting such a standard would help 5 million smokers quit within a year and prevent more than 33 million teens and young adults from becoming regular smokers by the year 2100.\nWASHINGTON (Reuters) - The U.S. Food and Drug Administration took a fresh step on Thursday towards setting a maximum nicotine level for tobacco products in a bid to lower tobacco-related deaths across the country, saying it would collect public comment and scientific research over the next three months.\nThe FDA will continue to take enforcement actions against companies that inappropriately target children, including through the promotion of e-cigarettes, Gottlieb said.\nThe comment period will be open through mid-June, said Mitch Zeller, director of FDA\u2019s Center for Tobacco Products.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned e-cigarettes in passing and mentioned the FDA\u2019s efforts to tackle smoking in general. However, there are a host of ways that federal policy might tackle smoking rates in this country that were not raised, including outlawing menthol cigarettes, placing further restrictions on advertising, and adding stronger language or graphic warnings on cigarette packaging.", "answer": 0}, {"article": "CHICAGO -- Acupuncture gets a thumbs-up for helping relieve pain from chronic headaches, backaches and arthritis in a review of more than two dozen studies -- the latest analysis of an often-studied therapy that has as many fans as critics.\n\"Perhaps a more productive strategy at this point would be to provide whatever benefits we can for our patients, while we continue to explore more carefully all mechanisms of healing,\" he wrote.\nThe federal government's National Center for Complementary and Alternative Medicine paid for most of the study, along with a small grant from the Samueli Institute, a non-profit group that supports research on alternative healing.\nThat makes the conclusion more robust, said Dr. Andrew Avins, author of an Archives commentary and a physician and researcher with the University of California at San Francisco and Kaiser-Permanente.\nThe military has used it to help treat pain from war wounds, and California recently passed legislation that would include acupuncture among treatments recommended for coverage under provisions of the nation's new health care law.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story briefly mentions that standard treatments for chronic pain include medications and\u00a0physical therapy. Close call, but good enough. We would have appreciated a comment about the relative value of these \u201cmainstream\u201d treatments.", "answer": 1}, {"article": "(Boston)--Despite the continued controversy surrounding the use of testosterone in men who have testosterone deficiency (hypogonadism), a new study has found that long-term use of testosterone therapy not only improves vigor and vitality, but may reduce the risk of death due to cardiovascular (CV) disease.\nDr. Ahmad Haider has received partial compensation for data entry from Bayer Pharma.\nDr. Gheorghe Doros has received payment for statistical analysis from Bayer Pharma.\nIn addition, T is essential for overall health and well-being and for the prevention of osteoporosis.\nInsufficient levels of circulating T in men, contributes to frailty and bone loss.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "No other options are discussed.", "answer": 0}, {"article": "WEDNESDAY, Aug. 18, 2010 (HealthDay News) -- Fibromyalgia sufferers may find relief from the chronic pain condition by doing tai chi, new research finds.\nMost patients, according to background information in the article, remain in pain years after the diagnosis, are aerobically unfit, have poor muscle strength and flexibility, and need medications to control symptoms.\nThe controlled breathing and movements may promote \"mental tranquility,\" according to the study, which could help with pain.\n\"This could represent an ideal exercise for fibromyalgia sufferers.\nAbout 10 million Americans have fibromyalgia, and about 75 percent to 90 percent of them are women, according to estimates from the National Fibromyalgia Association.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0Very brief mention is given to existing alternatives, such as exercise, sleep techniques and medication, but no discussion of the track record of how well the alternative methods work.\u00a0", "answer": 0}, {"article": "Visit the Mayo Clinic News Network.\nWhile twice-daily injections of low-molecular-weight heparin has been the traditional treatment of choice for cancer patients who suffer a venous clot, Dr. McBane notes that there are numerous limitations to this therapy.\n\"As a class, these drugs have a number of advantages, including oral delivery, lack of interactions with foods or other medications, and the lack of a need for monitoring drug levels.\"\nThe drug was associated with fewer major bleeding events and fewer recurrent blood clots, compared to low-molecular- weight heparin.\n\"Clotting events can be deadly with pulmonary embolism being the second most common cause of death in cancer patients.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release compares apixaban to low molecular weight heparin (LMWH), although as mentioned above it does not discuss any harms of apixaban or quantify any of the health benefits with numbers. It does do a good job, however, of discussing possible problems with LMWH and why apixaban might be a good alternative medication.", "answer": 1}, {"article": "For those with early stage breast cancer, \"lumpectomy is just as effective if not more effective than mastectomy,\" said researcher Dr. Shelley Hwang, chief of breast surgery at Duke Cancer Institute in Durham, N.C.\n\n\"There are lots of women who think the more [treatment] they do, the better they will do,\" she said.\nIn this procedure, just the tumor and some healthy tissue are removed, sparing the rest of the breast.\nOver the entire follow-up, those who underwent lumpectomy were more likely to survive the breast cancer.\nThis means their cancer depends on estrogen to grow.\nAges ranged from 39 to 80.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story didn\u2019t say anything about adjuvant chemotherapy or hormone therapy.", "answer": 0}, {"article": "Research presented at meetings should be considered preliminary until published in a peer-reviewed journal.\nThe potential for Clostridium novyi-NT to prompt an immune response against cancer is intriguing, said Sacha Gnjatic, who is associate director of the Human Immune Monitoring Center at Mount Sinai in New York City.\n\"If that happens, it actually helps to increase the presence of tumor-specific antigens, which are proteins that make a tumor more obvious to the immune system,\" Janku said.\n\"Classic immunotherapy which is now approved or being heavily investigated doesn't seem to be working for a majority of sarcomas,\" Janku explained.\nResearchers have moved on to the next phase, in which patients taking the immunotherapy drug pembrolizumab (Keytruda) will also be treated with a single injection of Clostridium novyi-NT, Janku said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned \u201cclassic immunotherapy\u201d as not seeming to work for most sarcomas, which are cancers that arise in connective tissue such as fat, muscle, and bone. However, it did not mention other treatment options such as radiation, surgery, or chemotherapy.\nAs a side note, most immunotherapies are very new\u2013with still-emerging side effects and unknown long-term benefits\u2013so we take issue with framing immunotherapy as \u201cclassic.\u201d Standard is perhaps a more accurate word.", "answer": 0}, {"article": "Tucatinib is a small molecule inhibitor of the HER2 growth factor receptor.\nThe fact that it is a small molecule means the drug is able to pass through the blood-brain barrier to act against brain metastases of the disease.\nThe drug works by targeting the HER2 \"tyrosine kinase\" - a link in the chain of communication that allows HER2 receptors to signal the growth of the cell.\nThere are women who are alive today because of this drug,\" says Virginia Borges, MD, MMSc, director of the Breast Cancer Research Program and Young Women's Breast Cancer Translational Program at the University of Colorado Cancer Center.\nBecause the drug is taken in pill form and has a very favorable side effect profile, Borges points out that it is relatively patient-friendly, allowing women to avoid treatments in infusion centers and also many of the side-effects associated with chemotherapies.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release quotes researcher Virginia Borges, MD, MMSc, director of the university\u2019s Breast Cancer Research Program saying that trials of other drugs have been \u201clackluster\u201d in their effects on breast cancers positive for both HER2 and estrogen receptors. Borges further suggests that tucatinib is more effective than other drugs in preventing brain metastases. The release notes that because tucatinib is a \u201csmall molecule,\u201d it can pass through the blood-brain barrier to interfere with brain metastasis, which is more common in HER2-positive breast cancers. However, there is no specific comparison of this ability with other drugs currently in use.", "answer": 0}, {"article": "Saline \u2014 salt dissolved in water \u2014 has been the most widely used fluid in the U.S. for more than a century even as evidence has emerged that it can harm kidneys, especially when used a lot.\nThe shortage has eased, but some supply issues remain.\nIVs are one of the most common things in health care.\nFederal grants helped pay for the work.\nOther IV solutions called balanced fluids include saline but also contain potassium and other things that make them more like plasma, the clear part of blood.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "A discussion of other fluid replacement strategies is not germane given the subject of this study.", "answer": 2}, {"article": "Good clinical studies are few, however, and although I and other physicians tell our patients to drink green tea, there hasn't been any definitive proof of the value of that advice.\nThere's a growing body of research to suggest that both are probably good for you.\nWe've heard a lot about the health benefits of tea, especially green tea.\nIt is high in polyphenols--compounds with strong antioxidant activity that in test-tube and animal models show anticancer and heart-protective effects.\nThat's why I was so interested in a report last week in the Journal of the American...\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article did not mention other ways to decrease cardiovascular mortality risk.", "answer": 0}, {"article": "Although these trials showed a small reduction in the average number of night-time urinations with Noctiva compared to placebo, more patients treated with Noctiva were able to at least halve their number of night-time urinations, and patients treated with Noctiva had more nights with one or fewer night-time urinations.\nAlthough there are other FDA-approved medications that also contain desmopressin, none of those medications are approved to treat nocturia.\nThe lower Noctiva dose is recommended as the starting dose for those who may be at risk for hyponatremia, such as the elderly.\nIt works by increasing the absorption of water through the kidneys, which leads to less urine production.\nThe Agency also is responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There\u2019s no mention of other treatments for nocturnal polyuria including behavioral strategies such as fluid restriction and medications including the generic form of desmopressin (see the section on novelty).", "answer": 0}, {"article": "The findings were published in the journal Nature Materials.\nBut Dr. Grazia Pertile, director of ophthalmology at the Sacred Heart Don Calabria in Negrar, Italy and one of the Italian researchers, said in a written statement that her team's device could be \u201ca turning point in the treatment of extremely debilitating retinal diseases.\u201d\n\nShe\u2019s not alone in that assessment.\nThese promise that patients could become more independent.\u201d\n\nWhen healthy, retinal cells transmit visual information to the brain.\nThe new prosthesis is designed to be implanted onto the back wall of the eye, where it absorbs light and transforms it into an electrical signal that stimulates the still-active retinal cells to restore vision.\nThe researchers were unable to determine how well the rats were able to see, if at all, but they noted that the animals\u2019 eyes continued to react to light more than six months after the implant was installed.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u00a0mentions current therapies for age-related macular degeneration, such as \u201cvitamins, laser surgery, stem cell treatments, and implantable miniature telescopes.\u201d The reader learns that these treatment slow the degenerative process but are not a cure. The story\u00a0also mentions a currently available artificial retina.\nIt also could have mentioned that many patients with AMD will not need any interventions as the process is slow for most.", "answer": 1}, {"article": "Doctors numbed the lower half of O'Brien's body.\nThe new surgery simply moves them to the side in order to fit the knee with titanium and plastic caps \u2014 creating a knee joint free of pain and arthritis.\nScar tissue from previous surgeries and arthritis were removed before she was fitted with the prostheses which will act as her new knee.\n\"With this kind of surgery we don't cut into the muscle at all,\" Dr. Bergersaid.\nFive hours after surgery she said she was feeling great.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Other than categorizing traditional knee replacement as requiring \u2018a long and painful recovery period\u2019 there was no mention of other treatment options for osteoarthritis of the knee.", "answer": 0}, {"article": "And the experimental combined system itself was not fully automated.\nIndeed, even if device makers are able to develop fully automated prototypes of combination systems, they are likely to face regulatory hurdles, analysts said, and would have to factor in product liability concerns.\n\u201cThe significance is in showing that the existing devices, which are available commercially, can be combined to create the first version of an artificial pancreas,\u201d said Dr. Roman Hovorka, the lead author of the study.\nThe study not only indicated that the algorithm system prevented very low glucose overnight, Dr. Hovorka said, but it also indicated that the experimental system was better able to keep blood glucose in an acceptable range.\n\u201cThis is something that companies have been striving to do for years, and as computer chip technology evolves, it gets closer,\u201d said Rick Wise, an analyst at Leerink Swann, a health care investment bank.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story describes currently available technology for glucose monitoring and insulin infusion. It describes the limitations of current approaches for managing insulin, especially during the overnight period. The story is a bit misleading in that it leaves the impression that all type 1 diabetics are currently using pumps at night.\u00a0 This is not actually the case.\u00a0 Most people are doing self monitoring of blood glucose and making judgement calls on whether and how much insulin to administer.\u00a0However, the story does enough for a satisfactory in our view.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070107/15downs.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention amniocentesis, chorionic villus sampling and the quadruple screen as alternatives. The story should have also pointed out that no screening remains a viable option. News stories should include the perspective of someone who chose to forego testing. \u00a0 ", "answer": 1}, {"article": "\"Where's the money going to come from?\n\"I can certainly understand why people are concerned about linking these -- it's clear we're going to have to carve billions out of the health-care system,\" said Thomas Herzog, chairman of gynecologic oncology at Columbia University New York Presbyterian Hospital, speaking on behalf of ACOG.\n\"We really felt that the downsides of more frequent screening outweighed any benefits,\" said Alan G. Waxman, a professor of obstetrics and gynecology at the University of New Mexico who led the revision of the guidelines.\nThe Obama administration distanced itself from the breast exam guidelines announced Monday by a federal task force, saying the panel does not set government policy or determine what services are covered by the government.\n\"More testing is not always more intelligent testing.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story describes the new guidelines in layman\u2019s terms, and briefly describes the old ones. It makes it difficult for the reader to find and digest this information, however.\u00a0 \nIt should have indicated the risks of not getting screened at all.\u00a0 ", "answer": 0}, {"article": "An FDA advisory panel is scheduled to review Qnexa again on Feb. 22.\nAnd the fact that there isn't ... medical treatments for obesity, including pharmaceuticals, really is a challenge, considering how big the problem is in this country.\"\n\"There's been a long history with obesity drugs that we've had to take off the market.\n\"We have two-thirds of all Americans who are overweight or obese, and the costs are nearing $150 billion a year,\" says Christine Ferguson, a health policy professor at George Washington University.\nPart of what's going on is that the FDA has gotten a lot more cautious about approving new drugs in general after some serious drug-safety problems, such as heart problems linked to the painkiller Vioxx.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "One source quoted captured some of the dilemma regarding alternatives:\u00a0 \u201c\u201dWe go from Weight Watchers to bariatric surgery. And the fact that there isn\u2019t \u2026 medical treatments for obesity, including pharmaceuticals, really is a challenge, considering how big the problem is in this country.\u201d", "answer": 1}, {"article": "ISI Group analyst Mark Schoenebaum said although the vemurafenib results look the most encouraging, the findings are unlikely to make a difference for current sales estimates, since virtually all eligible patients will be treated with both drugs, either in sequence or in combination.\nAbout half of all melanomas have the genetic aberration.\nSide effects included skin rashes and joint pain.\nMeanwhile, doctors are already working out treatment strategies.\nAbout 18 percent of patients developed a low-grade skin cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story adequately described the comparison data reported in the two studies.", "answer": 1}, {"article": "The study's third co-author is Julie-Andr\u00e9e Marinier, from the Centre de recherche interdisciplinaire en r\u00e9adaptation du Montr\u00e9al m\u00e9tropolitain and \u00c9cole d'optom\u00e9trie at the Universit\u00e9 de Montr\u00e9al.\n\u201cThis cost saving can be both to the individual, and if appropriate, to the insurance companies that may provide individuals with assistive devices.\u201d\n\nPartners in research: This work was supported in part by the Vision Health Research Network, the Fonds de recherche du Qu\u00e9b\u00e9c - Sant\u00e9, the Antoine Turmel Foundation, CRIR, and the MAB-Mackay Foundation.\n\u201cTablet computers offer many of the same benefits while being socially acceptable,\u201d says Aaron Johnson, the study\u2019s senior author, and an associate professor in the psychology department, and a member of the Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal (CRIR).\n\u201cWhat was interesting to note was that it didn\u2019t matter what technology was used to do the magnification: an iPad worked just as well as a traditional device like a closed circuit television system (CCTV),\u201d he says.\nBut there were no significant differences in the reading rates of participants who had previous experience using the CCTV, compared to the reading rates of first-time CCTV users.\u201d\n\nAnother benefit is that many older adults feel stigmatized by using the traditional devices, because they identify them as having an impairment or disability.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release compares using a widely available consumer device to using more traditional and more expensive devices. We\u2019ll give them a Satisfactory for naming the CCTV device but we\u2019re never told what the other alternative magnification device was, although the release often refers to two traditional alternatives. We also would have liked some comparative prices and inclusion of other brands besides the Apple brand.", "answer": 1}, {"article": "Actinic keratoses are typically red, scaly skin lesions that can over time develop into a type of skin cancer.\nBy contrast, only 4% and 5%, respectively, of the people who received the placebo had complete clearance.\nBecause the new gel is only used for a few days, any irritation is usually short-lived.\nThis has long been used as a folk remedy for skin lesions.\nCryotherapy, or freezing the affected skin area, is also used but can sometimes leave a scar.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As noted above, no data were provided comparing the performance of the new gel and previously available topical treatments.", "answer": 0}, {"article": "\u201cThis isn\u2019t a magic bullet.\nThat kind of approach could be risky.\u201d\n\nNutt said the results showed that psilocybin \u201cis safe and fast acting, so may - if administered carefully - have value for these patients.\u201d\nWe\u2019re just learning how to do this treatment.\u201d\n\nMagic mushrooms grow worldwide and have been used since ancient times, both for recreation and for religious rites.\nThe World Health Organization estimates that some 350 million people worldwide are affected by depression, a common mental disorder characterized by sadness, loss of interest or pleasure, tiredness, feelings of guilt or low self-worth, disturbed sleep and appetite, and poor concentration.\nBlood pressure, heart rate and the self-reported intensity of the effects of psilocybin were monitored during each session, and the patients were seen by a psychiatrist the next day and one, two, three and five weeks after the second dose.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The text is clear that there are few alternatives if antidepressants and therapy don\u2019t work. The story would have been stronger if it had mentioned atypical antidepressants and electroconvulsive therapy as alternatives.", "answer": 1}, {"article": "A growing number of doctors are offering an expensive laser procedure they say zaps away a common fungus that causes ugly, discolored nails. Published data on laser treatment for nail fungus is scant, but early results suggest it is a reasonable option for people who don't want the side effects of oral medications.\n\nOnychomycosis, or fungal infection of nails\u2014most often on the toes\u2014affects about 12% of Americans, according to the American Academy of Dermatology. Some people are genetically prone to it. Others, including swimmers...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story offered good comparisons in its broad-ranging discussion of treatment options.\u00a0 We only wish there had been a more direct discussion of not being treated, perhaps profiling someone who chose to forego treatment. And it did not mention the host of topical and oral drug treatments currently under study.", "answer": 1}, {"article": "Last Wednesday, the F.D.A.\n\u201cThere are very few treatments in all of cardiovascular medicine that could claim that \u2014 I can think of heart transplant, and that\u2019s it.\u201d\n\nThe results were even more notable, he said, because the early versions of the devices were clunky, stiff and difficult to use.\nThe consensus of the group, he said, was that \u201cnot every one of the 1,150 cardiac surgery programs or the 1,600 cath labs in the U.S. should be able to do it.\u201d\n\nIn June 2014, after another company, Medtronic, did similar studies, its device was approved, too, for high-risk patients.\nThe result was a requirement that a hospital should be doing at least 50 surgical aortic valve replacements a year to have access to the technology.\nMedtronic also has a new version of its valve that cardiologists expect will soon be approved.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does explain that surgery is the alternative, but it would have been helpful to provide more concrete numbers (outcomes, cost) to show how patients fare with surgery vs TAVR. The story would have been better if also told readers about drug treatment for milder cases and that some valves can be repaired, rather than replaced.", "answer": 1}, {"article": "Renal vein surgery can often be managed with minimally invasive laparoscopic techniques, but this is not typically advisable for an IVC thrombus (a fibrous clot), which is surgically far more complex with potentially fatal complications that can occur in the course of removing the thrombus and reconstructing the IVC.\n\"Using robotic nephrectomy, our complication rate and lack of mortalities compare reasonably with open series with no grade III to V complications, according to the Clavien system, in any patient, including no deaths.\"\nNone of the operations was converted to open surgery and all but two patients were ambulatory on the day of or day after surgery.\nEight patients had node positive disease and seven patients had distant recurrence 15 months later including four of those with node positive disease.\nPatient age ranged from 43 to 80 years.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release did provide\u00a0a few comments about open surgery, the standard surgical approach. However, it provides only the associated complication rate. \u00a0A true comparison would have provided more supportive evidence.", "answer": 0}, {"article": "The DAWN trial included trial locations in the United States, Spain, France, Australia and Canada.\nThe international multi-center clinical study, known as the DAWN trial, randomly assigned 206 stroke victims who arrived at the hospital within six to 24 hours to either endovascular clot removal therapy, known as thrombectomy, or to standard medical therapy.\n\"These findings could impact countless stroke patients all over the world who often arrive at the hospital after the current six-hour treatment window has closed,\" says co-principal investigator Raul Nogueira, MD, professor of neurology, neurosurgery and radiology at Emory University School of Medicine and director of neuroendovascular service at the Marcus Stroke & Neuroscience Center at Grady Memorial Hospital.\n\"Our research and clinical teams are immensely proud of these breakthrough findings, which are so profound they will likely result in a paradigm shift that will not be seen again for many years in the field of stroke therapeutics,\" says Michael Frankel, MD, professor of neurology, Emory University School of Medicine, chief of neurology and director of the Marcus Stroke and Neuroscience Center for the Grady Health System.\n\"Looking at the physiological state of the brain and evaluating the extent of tissue damage and other clinical factors seems to be a better way to decide if thrombectomy will benefit patients as opposed to adhering to a rigid time window,\" says Nogueira.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Readers of the release will get a general and adequate idea of the relative lack of options open to stroke victims who arrive at a hospital after the six-hour window considered optimal for mechanical clot removal. The alternative is not doing the procedure for late arrivals which is fairly clear from the release.", "answer": 1}, {"article": "To learn more about NAMS, visit http://www.\n\"This study shows that, for women who need or choose to avoid medications, electro-acupuncture may be an option because it has minimal risks, but blinded controlled trials are needed,\" says Dr. JoAnn Pinkerton, NAMS executive director.\nAlthough it is not exactly understood how acupuncture affects sleep, it has been shown to affect a number of neurotransmitters associated with sleep, such as serotonin and melatonin.\nCLEVELAND, Ohio (November 28, 2016)--It's somewhat of a little-known adverse effect of having breast cancer, but studies suggest that approximately 30% to 40% of women with breast cancer report persistent hot flashes.\nThe study showed electro-acupuncture to be comparable to, if not better than, gabapentin in helping to reduce hot flash severity and frequency and improving overall sleep quality (including falling asleep faster and fewer sleep disruptions).\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release points out that electro-acupuncture was compared with the drug gabapentin. But there are numerous other alternatives to both a fairly powerful drug with its own side effects and electro-acupuncture.\u00a0 There are many other ways to help one sleep while experiencing hot flashes such as non-hormonal medications and lifestyle changes \u2014 dressing in layers, lowering the thermostat, staying away from caffeine \u2014 to name a few.", "answer": 0}, {"article": "+3582944 54542\n\nIntake of fermented and nonfermented dairy products and risk of incident CHD: the Kuopio Ischaemic Heart Disease Risk Factor Study Timo T. Koskinen, Heli E. K. Virtanen, Sari Voutilainen, Tomi-Pekka Tuomainen, Jaakko Mursu, Jyrki K. Virtanen.\nFor instance, the consumption of milk and sour milk have declined, while many fermented dairy products, such as yoghurt, quark and cheeses, have gained in popularity,\" Adjunct Professor Jyrki Virtanen from the University of Eastern Finland says.\nWhen the study participants were divided into four groups on the basis of their consumption of fermented dairy products with less than 3.5% fat, the risk of incident coronary heart disease was 26% lower in the highest consumption group compared to the lowest consumption group.\nThe study participants were divided into groups on the basis of how much they ate different dairy products, and the researchers compared the groups with the highest and lowest consumption, while also taking various lifestyle and nutrition factors into consideration.\nThe new study provides further evidence on the health benefits that fermented dairy products may have over non-fermented ones.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The headline suggests fermented dairy products may protect against heart attacks, but does not mention any other common sense steps that may be protective.\nExercise, not smoking, and a prudent plant-based diet are other habits known to be associated with lower risk.", "answer": 0}, {"article": "Her mother, aunt and grandmother died of cancer.\n\u201cProphylactic removal of ovaries and fallopian tubes is strongly recommended in women before age 40 in BRCA1 and BRCA2 mutation carriers,\u201d said Dr. Susan Domchek, executive director of the University of Pennsylvania\u2019s Basser Research Center, which specializes in BRCA mutations.\n\u201cThere is no effective screening for ovarian cancer and too many women with advanced stage ovarian cancer die of their disease.\u201d\n\nWriting for The New York Times\u2019s Op-Ed page, Ms. Jolie Pitt, 39, said she had expected to have her ovaries and fallopian tubes removed, a procedure called a laparoscopic bilateral salpingo-oophorectomy, but that a cancer scare made her decide to undergo the procedure sooner.\nBRCA mutations cause about 5 to 10 percent of breast cancers and 10 to 15 percent of ovarian cancers among white women in the United States.\nCancer experts said Tuesday that the actress and filmmaker Angelina Jolie Pitt was wise to have had her ovaries and fallopian tubes removed last week because she carries a genetic mutation, BRCA1, that significantly increases the risk of ovarian cancer, a disease so difficult to detect that it is often found only at an advanced, untreatable stage.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a very good job in highlighting the different approaches and the relative advantages and disadvantages of each including surveillance with CA-125 measurements. But while observation is not an ideal option for women at increased risk of ovarian cancer, the story could have explained that the risk is not as high for ovarian cancer as it is for breast cancer. For the BRCA1 mutation, risk of ovarian cancer is about 40%, but for BRCA2 there is a 10% to 17% lifetime risk of ovarian cancer.", "answer": 1}, {"article": "The essential tremor research has been supported by InSightec, the Focused Ultrasound Foundation and the BIRD (US-Israel Binational Industry Research and Development) Foundation.\nNot only did the researchers determine that the procedure was safe and effective, they found that it offered a lasting benefit, reducing shaking for trial participants throughout the 12-month study period.\nThe most commonly reported side effects were gait disturbances and numbness in the hand or face; in most instances, these side effects were temporary but some were permanent.\nThe device focuses sound waves inside the brain to create heat, much like a magnifying glass focuses light.\nFDA Approved Based on the clinical trial led by Elias, the federal Food and Drug Administration has approved the focused ultrasound device, manufactured by InSightec Inc., for the treatment of essential tremor.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release never mentions the current alternative approaches used to treat essential tremors, either the pharmacological approach with drugs such as propranolol or primidone, or the neurosurgical approach of deep-brain stimulation.", "answer": 0}, {"article": "But study author Dong Wang, a graduate student with the departments of nutrition and epidemiology at Harvard T.H.\nDr. Sonia Anand, a professor of medicine and epidemiology at McMaster University in Hamilton, Canada, praised the study, saying it's \"reasonable\" to link changes in diet to death rates in this way.\nFor more about healthy eating, visit the U.S. Centers for Disease Control and Prevention.\nAs a result, she said, it's crucial to look at a variety of studies and see if trends hold up.\nOne option, he said, is to increase the number of farmers markets that accept food stamps.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t discuss anything besides healthier diets that might have contributed to increased longevity during the study period. More widespread use of effective medications (e.g. statin drugs)? Lower smoking rates? More regular physical activity? A line or two would about other relevant trends would have been welcome.", "answer": 0}, {"article": "Kale and oranges are high in vitamin C, another antioxidant.\nBut the majority of those studies have focused on adults, and it\u2019s becoming clear that many of cancer\u2019s drivers start early in life, with genes and even with childhood exposures to potential carcinogens.\n\u201cWe recommend whole fruit and not fruit juice,\u201d says Farvid, \u201cbecause maybe one of the most important ways that fruit decreases risk of breast cancer is through fiber, and even natural fruit juice often has no fiber in it.\u201d\n\nIn another study also published in the , a separate group of researchers found that among 22,000 Danish women, those who added two alcoholic drinks a day on average increased their risk of developing breast cancer by 30% over five years.\n\u201cThis study also has an important message for schools and the need to provide students with the opportunity to consume more fruits and vegetables as part of the school meal program.\u201d\n\nFarvid wasn\u2019t able to document a strong relationship between vegetables and lower breast cancer risk, but says that may be because the study wasn\u2019t powered enough to detect an effect.\nThe findings are among the first to look at how diet during adolescence can affect health later, and highlights the importance of establishing healthy habits from a young age, especially since many of the chronic diseases occur over many years and get rooted early in life.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This one squeaks by, because it also addresses risk factors such as alcohol and red-meat consumption. However, it would have been better to place the work into a broader context of lifestyle factors that influence risk, such as exercise, maintaining a health weight and avoiding tobacco use.", "answer": 1}, {"article": "There is also a dramatic price difference between the two diagnostic tests.\nIntroduced a decade ago, IGRAs have high specificity, producing few false positives, but require blood samples and complicated lab work, which has limited their widespread use.\n\u2022 Among participants with HIV, the ability of all three tests to detect TB infection was diminished, though the C-Tb appeared more robust in HIV-infected participants with low CD4 T cell counts.\nThese phase III trial results demonstrate that C-Tb is safe, has comparable diagnostic performance to QFT-GIT and addresses the problem of false positive TST results in BCG vaccinated persons.\n\u2022 The specificity of C-Tb, unlike the TST, was not impacted by the BCG vaccine, the partially effective vaccine that many residents in the developing world receive.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Since the release is showing results of comparisons between existing tests for tuberculosis and the new C-Tb test, there clearly are alternatives, so we\u2019ll give it a satisfactory grade in this category.", "answer": 1}, {"article": "While the new study results do seem to advocate for testosterone replacement therapy, Barua stresses the need for \"appropriate screening, selection, dosing, and follow-up of patients to maximize the benefit of testosterone therapy.\"\n\"Patients who failed to achieve the therapeutic range after testosterone replacement therapy did not see a reduction in [heart attack] or stroke and had significantly less benefit on mortality.\"\nThe authors also caution that \"off-label\" use remains a concern.\nTestosterone isn't prescribed with the goal of improving heart health, but that is a consideration in many cases.\nExamples of these conditions include failure of the testicles to produce testosterone because of reasons such as genetic problems or chemotherapy.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Information about other ways to reduce mortality from heart attacks or stroke \u2014 whether lifestyle changes or other types of drugs \u2014 is not mentioned.", "answer": 0}, {"article": "The frequency of screening mammograms -- and the appropriate age to begin them -- has been debated since the U.S. Preventive Services Task Force in 2009 recommended that women routinely get screening mammograms every other year starting at age 50.\nInformation about the women and their mammograms came from the Breast Cancer Surveillance Consortium, funded by the National Cancer Institute.\nThey found a small but not significant increase in the chance that women diagnosed with breast cancer had a more advanced case if they underwent screening every other year instead of every year.\nThose false-positives may cause inconvenience and anxiety, and biopsies can cause pain and scarring, the researchers note.\nAfter 10 years of annual screening, more than half of women will be called back at least once for another mammogram.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did an adequate job comparing \u2013 at a very high level \u2013 annual screening versus biennial screening.", "answer": 1}, {"article": "In late July, Sen. David Vitter, R-Louisiana, wrote a letter to the FDA saying that there are no new safety concerns and that \"the [FDA advisory] committee's concerns appear to have been based on cost-effectiveness.\"\nWhen they cost more, \"I'm spending more and more time justifying even treatments that do have regulatory approval.\"\n\"There was a delay in progression of the tumor, but it had no effect on quality of life, or survival,\" Visco says.\nIn AVADO, it improved by just 24 days.\nFor 15 years, she's been fighting breast cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story briefly discusses radiation and other chemotherapy treatments for metastatic breast cancer; however, there are many other treatments that could have been mentioned.\u00a0 It would take just a few more words.\u00a0 ", "answer": 0}, {"article": "\u201cIn contrast, if CPR is not initiated before the arrival of the emergency medical services, only 1 in 30 people survive a cardiac arrest.\u201d\n\nFor the current study, researchers looked at 30-day survival for patients who had cardiac arrests outside of a hospital between 2005 and 2011.\nAfter 13 minutes, patients who got CPR at the scene continued to have better survival odds but the difference was no longer statistically meaningful.\nUnlike a heart attack, which happens when blood flow to a portion of the heart is blocked, cardiac arrest occurs when the heart\u2019s electrical system malfunctions, often due to irregular heart rhythms.\nFor ambulance arrival times up to ten minutes, 6.7 percent in the CPR group and 2.2 percent of the other patients survived.\nIf the ambulance took more than 13 minutes, the survival rate was 3.7 percent in the CPR group and 1.5 percent for the others - a difference that wasn\u2019t statistically meaningful.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "In a way this story is all about the alternative to bystander CPR: doing nothing until the ambulance arrives. There really isn\u2019t another alternative that could have been discussed.", "answer": 1}, {"article": "Ingber says some scientists are interested in using the chips to conduct research that would be unethical if performed on people, such as studying the effects of gamma radiation on the human body.\nIt takes up to 15 years and $5 billion for a new drug to make it through testing and earn approval from the U.S. Food and Drug Administration (FDA).\n\u201cYou can go forward with a candidate drug with greater assurance and confidence that it will have the desired effect on humans,\u201d says Tagle.\nThe sophisticated architecture of these organs-on-chips\u2014which are about the size of a thumb drive\u2014has also earned the Wyss Institute recognition in the art world with a Design of the Year award from the Design Museum and placement in the Museum of Modern Art\u2019s permanent collection.\n\u201cThe real power of this approach is that you have a window to the inner workings of life,\u201d says Don Ingber, founding director of the Wyss Institute and a professor of Vascular Biology and of Bioengineering at Harvard University.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The report describes laboratory testing on animal models, like mice and monkeys, and says chemicals are metabolized at a different rate in animals. We think that\u2019s enough for a Satisfactory rating here.", "answer": 1}, {"article": "Two classic laboratory measures of inflammation are sedimentation rate \u2014 the ability of red blood cells to clump together, which isn't a factor in ME/CFS \u2014 and C-reactive protein, which reflects levels of a single cytokine that wasn't one of those linked to severity in this study.\nThat typically happens to people with the mysterious illness commonly known as chronic fatigue syndrome.\nThis is significant because symptoms in these patients and findings from other studies also suggest that chronic inflammation plays a major role in the illness.\n\"Inflammation is much more complicated than two imperfect old measures,\" Montoya says.\nThe link to gradation in severity, rather than simply seeking a positive versus negative result, represents a new approach to the search for biological markers for the illness.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story reports some of the possible explanations for the failure of existing tests to accurately diagnose chronic fatigue.", "answer": 1}, {"article": "\"We would therefore recommend that a future prospective study should be performed to further assess the impact of alcohol consumption on rheumatoid arthritis, a study recording alcohol consumption at the time rather than asking about it later.\"\nAlcohol consumption may also protect people who already have the autoimmune disease from developing a more debilitating form.\nThe association was seen in both men and women, though it was stronger in males.\nThe teetotalers had quadruple the risk of having rheumatoid arthritis compared with those who drank in the highest category.\nThis finding is slightly different than what is reported in the current study (that the severity of the disease decreased with more alcohol).\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Not even a word about other approaches to treating rheumatoid arthritis.\u00a0 Even a line may have satisfied this criterion. ", "answer": 0}, {"article": "Guyuron, chair of plastic surgery at University Hospitals Case Medical Center in Cleveland, went on to identify four common \"trigger sites\" and publish studies showing that, in selected patients, surgical decompression of nerves in one or more of these sites provides lasting migraine relief. He has also taught 250 plastic surgeons around the world (none in the Philadelphia area) to perform the outpatient operation, which costs an average of $10,000 and is not covered by many insurers.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not present a meaningful comparison of alternative treatments to surgery. But it does list a variety of treatments. \u201cThe first line of treatment is an ever-growing arsenal of pharmaceuticals \u2013 most not approved for migraine \u2013 including over-the-counter and prescription analgesics, triptans, ergotamines, antiseizure drugs, antidepressants, cardiovascular drugs, and opioid painkillers.\u00a0For migraines that are focused at the back of the head, newer treatments include shots to numb the occipital nerves at the nape of the neck, or an implantable device that stimulates those nerves.\u00a0Botox, given every three months, is injected into neck and forehead muscles.\u201d We wish that the story had helped readers sort through this list to understand which treatments tend to provide the biggest relief. Instead, it goes straight to another patient whose only credentials appear to be a \u201cmigraine odyssey\u201d that \u201cinspired an educational book and her website, helpforheadaches.com.\u201d\nJust listing the alternatives isn\u2019t the same thing as comparing them. This treatment hasn\u2019t been adequately compared to others that are listed as being used in these patients.", "answer": 0}, {"article": "And on a Tuesday evening earlier this summer, the company partnered with a women\u2019s group to host a conversation about \u201cproactive steps you can take today to reach your future family building goals.\u201d Appetizers, wine, and beer were served \u2014 and, in a gesture to the crowd full of women with pregnancy on their minds, non-alcoholic beverages were on the menu, too.\nPetrozza said he worries that women might wrongly interpret a long litany of genetic risks to mean that their hopes to start a family are \u201cdoomed.\u201d He also said he sees the test as \u201cvery costly for what it\u2019s trying to do \u2014 and not really giving, at least at this point, what I would consider meaningful information.\u201d\n\nThe Fertilome test was eight years in the making.\nThe Fertilome test can help you decide if it is right for you.\u201d\n\nThe company\u2019s website also features testimonials from women who say they have used Fertilome to help guide their decisions.\n\u201cIt will help save a lot of heartache and time if we could know from the very beginning that [a given patient] is at risk for a uterine factor, or if it\u2019s more her eggs,\u201d said Dr. Angie Beltsos, a reproductive endocrinologist in private practice in Chicago who ordered the Fertilome test for one of her patients for the first time last month.\nThe Fertilome test, which must be ordered by a doctor, analyzes a woman\u2019s DNA for 49 genetic variants that have been linked to various conditions that can sometimes cause fertility problems.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story would have been stronger had it provided more information about traditional diagnostic efforts. However, there was a useful comparative effort that was anecdotal, at the end of the story. A woman struggling with infertility, offered the test, asked her physician if the test\u2019s results would change the treatment strategy.\u00a0 The answer was \u201cno.\u201d", "answer": 1}, {"article": "April 9, 2012 -- Taking soy to relieve hot flashes has received mixed reviews over the years.\n\"For many women with symptoms and especially with concerns about hormone replacement therapy, trying soy for six to 12 weeks to see if it relieves their symptoms could be a first line of treatment,\" says Melissa Melby, PhD, a professor of medical anthropology at the University of Delaware.\n\"What this study shows is that ingesting soy isoflavones will help you,\" she says.\nThe study is published in Menopause: The Journal of The North American Menopause Society.\nNow, researchers who took another look at 19 published studies find that soy supplements may help, at least over time.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story only stated, \u201cSoy has been touted as an alternative treatment to hormone replacement therapy after HRT was linked to an increased risk of breast cancer.\u201d\nBut there\u2019s still a decision to be made by women \u2013 taking both harms and benefits into account.\u00a0 As already noted in the \u201cBenefits\u201d criterion comment above, the story never delivers specific data on the absolute benefit seen in the soy vs. placebo meta-analysis. So it paints HRT as risky, and then promotes soy\u2019s benefits with its definitive headline \u201cSoy supplements can cool hot flashes\u201d and other language in the story \u2013 without ever clearly defining the scope of the benefit.\nWhat was the size of the benefit?\u00a0 What was the size of the tradeoff of potential harms?\u00a0 The story didn\u2019t deliver that information \u2013 so a meaningful discussion of alternatives was not provided.\u00a0 One could imagine a very helpful infographic being created to explain this.\nTo make matters worse, both the subhead and the body copy allow a researcher to go beyond the evidence of the study \u2013 which was about soy supplements \u2013 and to offer her opinion, \u201cI personally think foods containing soy are better.\u201d", "answer": 0}, {"article": "What does that mean?\n\"Although it's promising, we really have to see the benefit long-term to justify the cost,\" she added.\n\"The experimental therapy, focusing on functionality, not using pain as a reliable symptom, and not as a guideline to adapt movements or activities, leads to better treatment outcomes,\" Malfliet said.\n\"These positive effects were found until the last follow-up measurement at one year after treatment,\" Malfliet said.\nThey should \"learn to put pain into the right perspective, should remain active or increase their activity levels gradually, and should avoid fear of moving,\" said Malfliet, of Vrije University Brussel in Belgium.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll give this a just-passing rating. There are several brief statements about alternatives.\u00a0Relevant statements include, \u201cPeople with chronic back pain often try painkillers and other treatments without success\u201d and \u201cThey assigned another 25 men and 35 women to standard care \u2014 exercise, and back and neck education.\u201d", "answer": 1}, {"article": "It is the first shingles vaccine to combine a non-live antigen with a specifically designed adjuvant.\nMany vaccines are made from a weakened form of the virus, but Shingrix is made from just a single protein--known as glycoprotein E--that comes from the outer shell of the herpes zoster virus.\n\"The efficacy is approximately 90% for all age groups--even for those over 70 years of age.\nA new study has shown how the body's immune system responds to the new shingles vaccine, Shingrix, making it more than 90% effective at protecting against the virus.\n\"Our research shows that the vaccine stimulates your immune system to produce more antibodies and it generates a 24-fold increase in T cells.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release states:\nShingrix is different from most other vaccines. Many vaccines are made from a weakened form of the virus, but Shingrix is made from just a single protein\u2013known as glycoprotein E\u2013that comes from the outer shell of the herpes zoster virus.\nAs noted above, it would have been helpful if the release had stated how the established vaccine compared in the rate of effectiveness.", "answer": 1}, {"article": "The study\u2019s conclusions contrast with those of a report last year by the United States Preventive Services Task Force, an independent group that issues guidelines on cancer screening, questioning the benefit of screening women younger than 50.\nThe new study took advantage of circumstances in Sweden, where since 1986 some counties have offered mammograms to women in their 40s and others have not, according to the lead author, Hakan Jonsson, professor of cancer epidemiology at Umea University in Sweden.\nResearchers reported Wednesday that mammograms can cut the breast cancer death rate by 26 percent for women in their 40s.\nBut their results were greeted with skepticism by some experts who say they may have overestimated the benefit.\nTheir paper is published online in the journal Cancer and will be presented on Friday at a meeting sponsored by the American Society for Clinical Oncology and five other organizations.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nAlthough not discussed in detail, the story does mention that the United States Preventive Services Task Force has questioned the value of screening mammograms for women younger than 50, thus implying that not being screened is an option to consider.", "answer": 1}, {"article": "Cancer cells remain elusive and tough to locate, but a new crop of nuclear-imaging tests promises to lead to more accurate prognosis and treatment.\n\nThe tests use imaging agents that combine radioactive isotopes with targeted molecules that can spot cancer at the cellular level. The ability to accurately locate the cancers helps physicians make better and earlier diagnoses\u2014and may eventually make possible targeted nuclear-medicine therapies that identify and kill cancer cells, but not the surrounding healthy cells.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does a pretty decent job of talking about PSA screening, conventional (PET) nuclear imaging, and genetic testing, and ultimately defines the new nuclear tests as \u201ccomplementary\u201d by quoting an independent sources.\nHowever, the story ideally also would have discussed alternatives for staging and determining recurrence, such as bone scans, CT scans and MRI.", "answer": 1}, {"article": "Overall, the study found, measures of spasticity dropped an average of three points \u2014about 30 percent \u2014 on a 24-point scale when patients smoked marijuana, but didn\u2019t change after they smoked the placebo.\nBut the evidence that pot smoking actually helps with spasticity has been anecdotal.\nBut another limitation, she pointed out, is that the study looked at the effects, and side effects, of marijuana over only a few days.\nEach patient smoked marijuana once a day for three days and used the placebo cigarette once a day on three separate days.\n\u201cBut smoking marijuana does not appear to be a long-term solution, because of the cognitive effects,\u201d he told Reuters Health.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explained that the marijuana was used in subjects who had failed to get better with standard medication.", "answer": 1}, {"article": "\"This is outside the box. I've never used it this far out,\" Metz said. \"My radar is up if I see [such an injury] again. As we get more follow-up from David, it will be important to publish this case so people will be aware.\"", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article mentioned physical therapy and pain medication as standard treatment for delayed radiation effects on muscles and joints. It did a good job describing how challenging it can be to manage.", "answer": 1}, {"article": "Schneider\u2019s team found no evidence of HIV anywhere.\n\u201cIt is possibly a cure, that\u2019s for sure, you won\u2019t know for absolute sure until the person dies and undergoes extreme PCR (genetic) analysis of post-mortem tissue.\u201d\n\nThe mutation affects a receptor, a cellular doorway, called CCR5, that the AIDS virus uses to get into the cells it infects.\n\u201cIt\u2019s not practical and it can kill people,\u201d said Dr. Robert Gallo of the Institute of Human Virology at the University of Maryland, who helped discover the human immunodeficiency virus that causes AIDS.\nWASHINGTON (Reuters) - German researchers who used a bone marrow transplant to treat a cancer patient with the AIDS virus, have declared him cured of the virus \u2014 a stunning claim in a field where the word \u201ccure\u201d is barely whispered.\nAll these places are suspected \u201creservoirs\u201d where HIV can hide out for years, to rebound in patients who stop taking drugs that suppress the infection.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The last sentence in the story reads \u201cCocktails of strong drugs can suppress the virus, keeping patients healthy and reducing the chance they will infect others, but there is no vaccine.\u201d We would have liked to have seen a little more on this point. The fact is, HIV infection is becoming more and more like a chronic disease because of the success of antiretroviral (ARV) therapies. The death rate from AIDS has plummeted, even in developing countries, over the past two decades. This means that, while a vaccine or another therapy that eliminated the virus post-infection would be a boon for humankind, it is not the only approach worth hailing. We would like to see more ink devoted to innovative attempts to stop the spread of HIV and to broadly apply ARVs in countries that already have a high concentration of infected adults and less attention given to one offs like this study.\u00a0We would have rated this as satisfactory if the story did not mention the vaccine issue. That expands the criterion into prevention and therefore into public health measures as comparators.", "answer": 0}, {"article": "[But] Kalydeco controls CF at the basic defect, so I'm OK with the other 'c' word, control, because I'm living it and I've never felt better in my life.\"\nThe time from gene discovery to successful drug may be shortening, but there are only a handful of successful drugs so far, and for a while at least, the appearance of new ones will be slow.\nThe only way to fix that would be gene therapy, where a healthy form of the gene would supplant the damaged one.\n\"But it wasn't until 20 years later that we were able to find drugs that directly target the underlying cause of cystic fibrosis,\" says Fred Van Goor, who led the team at what is now Vertex Pharmaceuticals that developed Kalydeco.\nThe announcement was supposed to be made in conjunction with three papers in the Sept. 8 issue of Science, but a reporter for Reuters got hold of the story early.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There\u2019s no mention of what people typically do to treat cystic fibrosis and what advantage, if any, this drug brings. The mention of the clinical trial says that a patient was given a placebo and then the drug. But have tests been done comparing existing treatments to this new treatment?\nA Wall Street Journal story on the drug last February at least mentioned that until now patients took \u201cmedicines that only tackled the symptoms of the disease, such as antibiotics to treat the infections. Patients typically spent a few hours each day wearing vibrating vests to dislodge mucus build-up.\u201d", "answer": 0}, {"article": "So it really is extraordinarily helpful for people.\u201d\n\u201cIt would take my heart away when I was trying to eat and I\u2019d look up and they were looking at me.\u201d\n\nSamuels, 72, has essential tremor, a movement disorder characterized by uncontrollable shaking mostly in the hands or legs.\nIt has been shaking for years and they look at it as though, \u2018Hmm, is this really my hand?\u2019 It\u2019s really a remarkable moment.\u201d\n\nFor Samuels, who underwent the procedure on June 29, the recovery has been surprising.\nThe therapy, called focused ultrasound thalamotomy, uses the energy generated by sound waves to burn off certain cells in the thalamus, a region of the brain where the essential tremor is thought to originate.\nI can eat like a normal person, doing things that I couldn\u2019t do before.\u201d\n\nIn July, the Food and Drug Administration approved the device being used in the trial.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story states, \u201cDoctors usually treat essential tremor with medication, but the drugs don\u2019t work well for all patients.\u201d That\u2019s true, and so we\u2019ll give this a Satisfactory rating for at least mentioning alternatives.\nBut it should be noted that other procedural treatment options were not compared or even mentioned in the story and received only a brief mention in one of the videos.\nThe current standard for tremor patients who don\u2019t respond to medication is deep-brain stimulation, in which a probe connected to a pacemaker is implanted in the thalamus to suppress the tremors. Gamma Knife thalamotomy, which delivers precise doses of radiation to the thalamus, is also considered to be a safe and effective therapy for patients who don\u2019t respond to medication.\nAlso, some patients have mild symptoms that can be treated with relaxation techniques and the avoidance of triggers such as caffeine.", "answer": 1}, {"article": "Griffith said a German study recently found that donated corneas cost about $2,500.\n\"We were pleasantly surprised that in six patients, vision improved from about 20/400 to 20/100, meaning that these patients could see objects four times farther away than before the operation,\" said Griffith, director of the Integrative Regenerative Medicine Center at Linkoping University in Sweden.\nAn estimated 5 million people in the world have an eye disease called trachoma that affects the cornea, and another 1.5 million to 2 million are thought to have developed cornea-related blindness through other diseases or trauma.\nThe next step in research, Griffith said, is to create a \"new generation\" of cornea implants and test them on a wider variety of patients.\nThe shortage means trouble for many of those whose corneas -- the clear surface at the front of the eye -- have been injured or damaged by illness.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does compare the treatment to human corneal transplants. It could have talked about plastic corneas, too. Dr. Mark J. Mannis, the one independent source in the story refers to a \"repertoire of corneal transplant surgeons.\" What else is in that repertoire? It would\u00a0be nice to know, and it would be even nicer to know how this procedure stacks up against the other options in terms of costs and benefits.\u00a0", "answer": 1}, {"article": "Sexual health charity the FPA, Fertility UK, and the Faculty of Sexual and Reproductive Health of the Royal College of Obstetricians and Gynaecologists are jointly calling for more large-scale independent trials to ensure that evidence for such apps is on a par with other rigorously tested methods of contraception.\nAnd if the app gives you a \"red day\" \u2013 meaning you could be fertile \u2013 you have to abstain from sex, or use another method of protection such as condoms.\nSo if you could reliably know when you've ovulated as a woman, and then you give that egg two or three days to die, any time after that in the cycle you will not get pregnant because there's no egg to fertilise,\" Dr Susan Walker, a senior lecturer in sexual health at Anglia Ruskin University, told BuzzFeed News.\nAt first she starts to use the app to prevent pregnancy, and when she's ready [to get pregnant] she switches to plan, and usually she gets pregnant quite quickly, because the app already knows her body and cycle.\"\nThe app was approved as a class IIb medical device by T\u00fcv S\u00fcd, a notified body in Sweden where it is based.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article makes reference to other forms of birth control and their advantages and disadvantages with relationship to the Natural Cycles app. \u00a0This information helps the reader put the new information into greater context.\nThe writer also mentioned other apps that track a woman\u2019s monthly cycle, based on user data for when a period begins and ends.", "answer": 1}, {"article": "But the limit is tricky to impose.\nSher's ethics board said OK.\n\n\"And she went ahead and had a baby at 57 years of age without any problems whatsoever,\" Sher says.\n\"I guess there's a big assumption that most women that need to do this [are] career, successful, rich women,\" she says.\n\"My best friend and I made a pact together that at age 38, if we were both still single, we were going to have a child on our own,\" says Robyn Ross.\n\"There should be guidelines, I think, that are more clearly defined,\" says Dr. Geoffrey Sher, who heads the Sher Institutes for Reproductive Medicine and is based in Las Vegas.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No head to head data are provided. The story doesn\u2019t say how different outcomes are for embryo vs. oocyte freezing, and could have included more information (less dramatically) about natural changes in fecundability and pregnancy outcomes with age. ASRM has identified the \u201cbest practice\u201d as encouraging women to consider pregnancy whenever possible within the optimal timeframe rather for hoping for a technology fix.", "answer": 0}, {"article": "For older people who fracture a hip, the prognosis is grim: a third or more die within a year and only about 1 in 5 return to their pre-injury level of function.\n\nA new approach to care could mean it doesn\u2019t have to be that way.\n\nMore hospitals are putting hip fracture patients on a fast track from the emergency room to the operating room,...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story is a comparison of alternatives, comparing established methods with newer methods.", "answer": 1}, {"article": "They think I am crazy, even a [Defeat Autism Now doctor] we once saw,\" said a message posted by a parent on the AutismWeb.com bulletin board in March\n\nParents \"research anything they can get their hands on and there are so many things saying 'Try this or try that' that aren't necessarily safe.\nHis findings are complicated, but basically blood tests show 70 percent of his autistic patients have zinc deficiencies (pointing to problems with processing heavy metals), and the vast majority also have immune system problems of varying kinds.\nThe 106-year-old Children's Institute (formerly called the Rehabilitation Institute) plans to fund the room through the $30 million capital campaign it launched in 2005, after buying out its Shady Avenue site from the University of Pittsburgh Medical Center.\nBut we wonder -- we speculate -- that it's possible if we have children living in a unique environment that has not [previously] been created scientifically that we can make a difference.\nNo cause for autism has been found, and debates rage as to whether the brain development disorder is purely genetic or caused in part by environmental factors, including air and food-borne chemicals.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This article gives brief mention (one sentence) to traditional treatments\u00a0including educational, physical, speech, and behavioral therapies.\u00a0 There is no mention of psychotropic medications which are also commonly used.", "answer": 0}, {"article": "\"I think it has the potential to increase business for Covidien,\" Garcia, chief of interventional cardiology and vascular interventions at St. Elizabeth's Medical Center in Boston, said Thursday.\n\"This particular product plays very strongly into where we see the market going,\" he said.\nHe said he has no financial stake in the company.\nThe company says this is a major step forward in treating PAD because, unlike stents, atherectomy \"leaves no metal behind.\"\nIt occurs when arteries in the legs become narrowed or blocked by plaque.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There were company comments about qualitative differences among alternative approaches, but no real substantive discussion about comparative outcomes.", "answer": 0}, {"article": "While the value of CT scans for screening remains the focus of debate, no one questions the value of the tests for allowing doctors to quickly diagnose a wide variety of health problems, including head injuries, heart problems, cancer, appendicitis, fractures and gallstones.\nThe use of CT scans is expected to continue to rise as possible new applications, such as for lung and colon cancer screening, become more widespread.\nThe upsurge in CT use has fueled a big jump in the annual amount of radiation that each American is receiving from medical procedures of all kinds.\nDefensive medicine also plays a role, with some doctors ordering the tests to stave off accusations that they withheld the most cutting-edge technology from their patients.\nA CT chest scan, for example, exposes a patient to more than 150 times more radiation than a standard chest X-ray.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions other kinds of tests, such as blood tests, MRIs or\u00a0ultrasound.", "answer": 1}, {"article": "Abraham is a consultant for the company.\nThe research team tested the safety and effectiveness of a transvenous phrenic nerve stimulator made by Respicardia Inc. Much like a pacemaker, it sends a regular signal telling the diaphragm to breathe during sleep.\n\"Not only did we see this reduction in events per hour, the patients also rated themselves better on the Epworth Sleepiness Scale (meaning they were less sleepy during the day) and on a global assessment of their overall quality of life,\" Abraham said.\nUnlike the more common obstructive sleep apnea, in which the airway partially collapses and causes pauses in breathing, central sleep apnea (CSA) occurs when the brain fails to control breathing during sleep.\n\"This tells us the effects of neurostimulation are clinically relevant and this could be a promising therapy for those with central sleep apnea.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "We give this a borderline satisfactory rating. The release gives brief mention to a common treatment for sleep apnea \u2014 continuous \u201cpositive airway pressure,\u201d or CPAP devices \u2014\u00a0 but it provides little context other than to say \u201cmany patients don\u2019t tolerate them well and a recent study showed them to be harmful.\u201d\nThe release could have included more context to help a reader evaluate the traditional treatment compared to the surgical implant, or weigh risks vs. benefits of having the implant.", "answer": 1}, {"article": "In this study, researchers randomly assigned half of 263 healthy Swedish full-term newborns to have their cords clamped more than three minutes after birth.\nWhen separated by sex, only the boys showed statistically significant improvement.\nFour years later, the children underwent a series of assessments for IQ, motor skills, social skills, problem-solving, communication skills and behavior.\nRabe's editorial accompanied the study published Tuesday in the journal JAMA Pediatrics.\nJaundice is treated with blue light therapy and rarely has serious complications.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There\u2019s either early or late clamping, and the article describes both methods.", "answer": 1}, {"article": "What does a heart attack look like in women?\nThe study can't say specifically what about the berries seemed to result in a lower risk of heart attack among these women, or that there was a direct cause-and-effect link between eating the berries and lowered heart attack risk.\nMONDAY, Jan. 14, 2013 (HealthDay News) -- Eating three or more servings of blueberries and strawberries each week may help reduce a woman's risk of heart attack, a large new study suggests.\nAlthough more research is needed to confirm these benefits, \"these data are important from a public health perspective because these fruits can be readily incorporated into the habitual diet,\" the study concluded.\n\"These substances, called anthocyanins -- a flavonoid -- are naturally present in red- and blue-colored fruits and vegetables, so they are also found in high amounts in cherries, grapes, eggplant, black currants, plums and other berries.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No alternatives are mentioned. To prevent heart attacks, patients can either take medications, such as blood-thinning and cholesterol-lowering drugs, or make lifestyle changes, like maintaining a healthy weight, exercising and not smoking.", "answer": 0}, {"article": "Antioxidants can also provide some protection but there has been controversy over the effectiveness of such food supplements, he said: \u201cPersonally, I think it is much better to eat lots of vegetables and fruit rather than taking any supplements.\u201d\n\nDr Richard Russell, a consultant respiratory physician in the NHS and medical advisor to the British Lung Foundation, who was not involved in the research, said the inhaler was both credible and promising: \u201cEctoine is a beautifully elegant molecule and it clearly works by helping water to stabilise, giving you a film of water in times of stress.\u201d\n\n\u201cThe work that has been published thus far, in credible, internationally recognised journals, show that this stuff has positive properties, protecting against triggered inflammation,\u201d he told the Guardian.\nI was in New York last week, and the air was also not very clean.\u201d\n\nThe protective effect of ectoine was discovered by Prof Jean Krutmann and colleagues at the Leibniz Research Institute for Environmental Medicine, while investigating whether the molecule could protect skin against sun damage.\nBut on the other hand we have to be realistic and in many countries you cannot just switch traffic overnight to electric cars and do other drastic things.\u201d\n\n\u201cIt will take many more years, especially in countries like China, and I think there is an ethical need to provide something to the general population to protect them,\u201d he said.\nThe perfect situation is that the patient inhales in the morning and evening at home.\u201d\n\nThe inhaler has been tested in three small groups of patients particularly at risk from air pollution, due to asthma, COPD and bronchitis, with the positive results due to be published soon, Bilstein said.\nThis means large clinical trials are not required for official approval and the inhaler could be on sale soon, at an estimated cost of \u00a317 a month, after Bitop selects a marketing partner.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does provide at least one alternative strategy, though it wasn\u2019t explained clearly:\n\u201cAntioxidants can also provide some protection but there has been controversy over the effectiveness of such food supplements, he said: \u2018Personally, I think it is much better to eat lots of vegetables and fruit rather than taking any supplements.'\u201d\nIt also mentioned the need to reduce harmful vehicle emissions, though it said more short-term solutions were needed.", "answer": 1}, {"article": "For men with advanced prostate cancer, the news for decades has been mostly bleak. Until recently, only two treatments had been shown to prolong survival.\n\nResearchers reported Monday that the drug abiraterone, being developed by Johnson & Johnson, extended survival by an average of 3.9 months among men with cancer that has spread beyond the prostate and for whom other treatments have failed. Among men, prostate cancer is the second-leading cancer killer, behind only lung cancer.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe story highlights two other drugs that were recently approved to treat patients similar to those included in this trial.", "answer": 1}, {"article": "What are the limitations of IVM?\nAlthough ICSI is safe and effective, the bigger concern is if a patient going through IVM doesn\u2019t use ICSI, Shastri said.\nAlthough IVF is still considered the gold standard, there\u2019s an infertility treatment available that is offering hope \u2014 in vitro maturation (IVM).\nFor starters, since there is less time involved with IVM, women who are undergoing chemotherapy, radiation or plan to have surgery may be good candidates.\nAlthough IVM may eventually become more common, IVF still remains the standard of care and the most effective way for women to get pregnant.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This is a difficult call. Although it\u2019s possible that the story could have mentioned other assisted reproductive technologies beyond standard IVF and IVM, we think that discussion would be highly technical and probably beyond the scope of this article. We\u2019ll award a Satisfactory here.", "answer": 1}, {"article": "Celgene\u2019s drug Abraxane prolonged the lives of patients with advanced pancreatic cancer by almost two months in a clinical trial, researchers reported Tuesday, signifying an advance in treating a notoriously difficult disease but not as big a leap as some doctors and investors had hoped.\n\n\u201cIt was not the breakthrough we were anticipating,\u201d said Dr. Andrea Wang-Gillam, an assistant professor and pancreatic cancer specialist at Washington University in St. Louis, who was not involved in the trial.\n\nStill, Dr. Wang-Gillam and others said any progress was welcome against metastatic pancreatic cancer, which has defied most treatments, with patients tending to live only about six months after diagnosis.\n\nPancreatic cancer is the fourth most common cause of cancer death, with 38,000 Americans expected to die this year, almost as many deaths as from breast cancer, according to the American Cancer Society. Yet there are only 45,000 new cases of pancreatic cancer a year compared with more than 230,000 new breast cancer cases.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Excellent comparison of alternatives.\u00a0 Excerpts:\n\u201cA big impediment to future Abraxane sales in pancreatic cancer could be that its median survival was almost three months less than that of Folfirinox, a combination of four generic cancer drugs.\nResults of a clinical trial published in 2011 showed that pancreatic cancer patients getting Folfirinox had a median survival of 11.1 months compared with 6.8 months for those getting gemcitabine.\nExperts cautioned that it was difficult to draw conclusions since Abraxane and Folfirinox were not compared directly in the same trial. Nonetheless, doctors are going to make treatment decisions based on the separate results.\u201d\nAnd:\n\u201cIn 2005 the Food and Drug Administration approved Tarceva, now sold by Roche and Astellas, to treat pancreatic cancer. In a clinical trial, those who got Tarceva plus gemcitabine had a median survival only 12 days longer than those who received a placebo plus gemcitabine.\u201d", "answer": 1}, {"article": "Feb. 17, 2011 (Orlando, Fla.) -- Taking a pomegranate pill a day may help slow the progression of prostate cancer, preliminary research suggests.\nHowever, men who took three pills daily were more likely to suffer mild to moderate diarrhea: 14% vs. 2% of those who took one pill.\nAfter six months of taking the capsules, it took 19 months for their PSA levels to double.\nThe new study involved 92 men with cancer that had not spread beyond the prostate and rising PSA levels.\nAt the start of the study, the men's PSA levels were doubling every 12 months.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story could have at least included a line about other research exploring other ways to prevent prostate cancer or slow its progression. It also could have provided information about active surveillance.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070506/14healthwatch.lede.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story does mention Fosomax and Actonel, this is not sufficient information on the alternatives and the advantages and disadvantages of the different approaches. The story should have also mentioned calcium supplements, physical activity, estrogens, and smoking and alcohol cessation as alternatives.", "answer": 0}, {"article": "\"The first importance of the trial is that it shows hepatic [liver] targeting of hormonal action,\" Ladenson said.\nAnd though statins are widely used and most often successful, an alternative to them would be welcome, Ladenson said.\nIf eprotirome does pass all the anticipated tests successfully, its use at first probably would be in combination with a statin, Angelin said.\nAt best, results would not be available for \"at least two to three years,\" Angelin said.\n\"The effects on LDL cholesterol and lipoproteins are pretty exciting,\" Califf said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Since results were not quantified in the story, we really don\u2019t even learn how the drug compared with statins alone. ", "answer": 0}, {"article": "Recipients were at most seven years older or younger than the donors.\nItalian researchers retrospectively studied 647 kidney transplants, grouping the donors according to whether they were in their 50s, 60s, 70s or 80s.\nA new study has found a kidney transplanted from a deceased 79-year-old can be as effective as one from a person 30 years younger.\nIn an average follow-up of five years, they found that the rate of unusable donor kidneys and the long-term outcomes of recipients varied little among the first three age groups \u2014 around 18 percent of the organs had to be discarded, and the five-year survival was about 88 percent\nThe study is in the Clinical Journal of the American Society of Nephrology.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is a complicated measuring of risk and benefit for patients facing kidney transplants. Transplants are usually better than dialysis for patients, but transplants carry their own risks of infection, just to give one example. This\u00a0post did not include any context about the risk equation and how it might be changed if more organs from older donors were available.", "answer": 0}, {"article": "Investigators conducted a randomized controlled trial in the pediatric Emergency Department at The Mount Sinai Hospital comparing lung ultrasound to chest X-ray in 191 children from birth to 21 years of age.\nThe Mount Sinai Hospital is ranked as one of the nation's top 10 hospitals in Geriatrics, Cardiology/Heart Surgery, and Gastroenterology, and is in the top 25 in five other specialties in the 2014-2015 \"Best Hospitals\" issue of U.S. News & World Report.\nFurthermore, the reduction in chest X-rays in the investigational arm resulted in an overall cost savings of $9,200, and length of stay in the Emergency Department was decreased by 26 minutes.\nThe research team was led by James Tsung, MD, MPH, Associate Professor in the Department of Emergency Medicine and Department of Pediatrics at the Icahn School of Medicine at Mount Sinai, and former clinical fellow Brittany Pardue Jones, MD, who's currently Assistant Professor in the Department of Pediatrics at Vanderbilt University School of Medicine.\nTo watch study author discuss this research, click this link: https:/\n\nPneumonia is the leading cause of death in children worldwide, according to the World Health Organization (WHO).\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release adequately explains that chest X-rays are the diagnostic method of choice for determining cases of pneumonia, according to the World Health Organization. The study\u2019s primary goal was to determine if chest ultrasounds were an adequate alternative to chest X-rays. A non-imaging method used to diagnose pneumonia is a physical examination. ", "answer": 1}, {"article": "COLUMBIA, Mo.\nNow, a University of Missouri School of Medicine researcher has found that a complex procedure to remove the prostate achieves excellent long-term survival for men after radiation therapy has failed.\nIf the cancer is localized, a highly skilled surgeon can remove the gland and surrounding tissue using a robotic minimally invasive technique or through an open surgery.\nThe procedure is challenging because tissue that surrounds the prostate is scarred during radiation treatment, making it difficult for the surgeon to identify and cut out tissue that needs to be removed.\n\"Because radical prostatectomy is a complex surgery, there can be a reluctance to undergo the procedure,\" Pokala said.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release did not include information on what alternatives patients may have chosen who suffered recurrence after radiation, but did not elect to have the prostatectomy. However, we\u2019ll give them the benefit of a doubt since there are no clinical trials comparing options such as cryotherapy, surgery and brachytherapy.", "answer": 1}, {"article": "The report concluded that both are necessary for bone health but that as for preventing cancer, heart disease, diabetes and autoiummune disorders, the evidence was \u201cinconsistent, inconclusive as to causality, and insufficient to inform nutritional requirements.\u201d Even so, the committee recommended that children and adults up to age 70 get 600 IU of vitamin D daily \u2014 from food and, if necessary, supplements \u2014 and that adults age 71 and older get 800 IU.\nSome studies have found no ill effects from taking far higher amounts, and many of the prospective but not proven benefits against cancer and other diseases are believed to require doses ranging from 2,000 to 5,000 IU.\nThese studies are as consistent as we have ever seen with any nutrient.\u201d\n\nBut, he adds, \u201cthose studies do not prove cause and effect.\nThe so-called D2d study, which will run for four years, is seeking to enroll 2,382 people older than 30 who are at high risk of developing diabetes due to weight or blood-sugar levels but who have not yet been diagnosed with the disease.\nThere is such controversy now that the only way to convince people who sit on those sides of the equation is to complete rigorous, randomized trials.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternative here is to obtain vitamin D from foods, or not to supplement at all. The study covers both these options when it outlines the Institute of Medicine recommendations.", "answer": 1}, {"article": "Hofer coined the term \"hidden regulators\" that pass between mother and baby.\nIt's not just that mother and baby are together, Gray says, but also that the mother is in some way \"programming the baby, the breathing, temperature and heart rate.\"\nThis was a \"serendipitous magical finding,\" says Gray, suggesting that skin-to-skin contact acted something like a \"natural incubator.\"\nHe found that when healthy newborns had kangaroo care, there was less facial grimacing and crying suggesting pain, compared to babies who had been swaddled and had the procedure in their bassinets, \"sort of alone.\"\n\"The baby gets landed in a trusting environment,\" he says, reassuring them that life outside the womb can also be \"soft, comfortable and warm.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is a very brief, indirect discussion of what happens if\u00a0kangaroo care is not in place, which is that the newborn baby is placed in a bassinet or incubator, \u201csort of alone.\u201d That\u2019s just barely enough to rate satisfactory.", "answer": 1}, {"article": "Bochner teamed up with Northwestern oncologist Dr. Leo Gordon and colleagues to test if this BTK inhibitor could shut down an enzyme inside cells that is involved when you have an allergic reaction.\nWhile the study was small - only two patients qualified out of about 35 that were screened for allergies - the implications are much larger for later phases of this study.\nCurrently, the study is being expanded to adults with food allergy to see if their skin test and basophil activation test responses show a similar reduction with just a few doses of ibrutinib and how long such benefits might last.\n\"The hope is that drugs like BTK inhibitors will protect people with food allergies from having anaphylaxis, or at least increase how much of that food they can eat without reacting,\" Bochner said.\nThe cancer patients who were allergic to allergens such as cat dander and ragweed saw their allergic skin test reactivity reduced by 80 to 90 percent in one week, and this persisted with continued use of the drug for at least one to two months.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not compare this approach to existing allergies treatments. There are numerous over-the-counter and prescription medications available, along with air filters and masks for airborne allergens.", "answer": 0}, {"article": "Until today, researchers were not sure that fixing the mitral valve would do much to help these patients.\nIn the new trial, 614 patients with severe heart failure in the United States and Canada were randomly assigned to receive a MitraClip along with standard medical treatment or to continue with standard care alone.\nIn the new study, a device called the MitraClip was used to repair the mitral valve by clipping its two flaps together in the middle.\nThe leaky mitral valve makes the heart enlarge even more, as it tries to compensate, and heart failure worsens.\nBut that research included many patients with less severe valve problems, the procedure was not performed as adeptly, and the patients\u2019 medications were not as well optimized as in the new study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story stated, \u201cUntil now, there has been little doctors can do\u201d for people with heart failure, aside from drugs to control symptoms. This is perhaps a little pessimistic as there are a number of different medications that have been shown to improve outcomes in heart failure patients.", "answer": 1}, {"article": "Additional information about clinical trials, including information for potential participants and financial supporters, is available at http://www.\nInitial clinical trial results, published in a 2012 PLOS One paper, reported that two doses of BCG spaced four weeks apart led to reductions in autoreactive T cells, an increase in Tregs and what turned out to be a transient increase in insulin production.\nThe study from a Massachusetts General Hospital (MGH) research team - published in npj Vaccines - also reports that the effects of BCG vaccine on blood sugar control appear to depend on a totally novel metabolic mechanism that increases cellular consumption of glucose.\nMihai G. Netea, PhD, professor in the Department of Internal Medicine at Radboud University Medical Center in the Netherlands, says of this study, \"The clinical effects and the proposed mechanism demonstrated are exciting and add to the emerging consensus that the BCG vaccine can have a lasting and valuable impact on the immune system.\nThe lead author of the npj Vaccines paper is Willem M. K\u00fchtreiber, PhD, MGH Immunobiology Laboratories.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are no known alternatives to insulin so we\u2019ll rate this Not Applicable. People with type I diabetes are dependent on insulin to manage their disease because their bodies to not produce insulin. It is the only established treatment other than pancreas transplant with other interventions \u2014 like diet and exercise \u2014 being secondary to the insulin replacement.\nTo date, their are no established forms of therapy based solely on an autoimmune mechanism to lower blood sugars as BCG is claimed to do by the study authors.", "answer": 2}, {"article": "Neither Hologic nor Rovers had input into the research design, analysis or interpretation of results.\nFor the study, researchers mailed at-home, self-collection kits to low-income women in North Carolina who were overdue for screening by national guidelines.\n\"This is a proof-in-principle study that we used to determine whether home self-collection is highly effective for detecting high-grade disease,\" Smith said.\nThey reported this screening approach detected high-risk HPV in all of the cases of women who were found to have high-grade, abnormal cervical precancerous growths, showing that self-collection at home for HPV may be a viable method to identify women at high-risk for cervical cancer.\nIn the journal Obstetrics & Gynecology, researchers published the results of mailing at-home, HPV self-collection kits to 193 low-income women in North Carolina who were overdue for screening according to national guidelines.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release compares screening test results across three scenarios, including the standard screening protocol of on-site, clinician-collected sampling.", "answer": 1}, {"article": "The researchers focused on blueberries and strawberries because these are the most widely consumed varieties in the U.S.\nThe effect remained even after the researchers adjusted for other things that can influence heart-disease risk, such as obesity, high blood pressure, smoking, low levels of physical activity and a family history of heart disease.\nWhen we\u2019re making choices in our 20s, we may think that a burger and fries is great, but the message is that there are alternatives that make a difference for the rest of your life.\nThe women who ate more berries also tended to eat healthier overall, consuming more vegetables and fruits than those who didn\u2019t eat as many berries; but when the scientists broke down the women\u2019s diets, they found that the highest consumers of berries even had a lower risk of heart attack compared with women who still ate plenty of fruits and vegetables but fewer berries.\nThat means that regular consumption of berries might be a relatively easy way to lower a woman\u2019s risk of having a heart attack later in life, possibly even insulating her from heart problems.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Like the other two stories, no alternatives are mentioned. To prevent heart attacks, patients can either take medications, such as blood-thinning and cholesterol-lowering drugs, or make lifestyle changes, like maintaining a healthy weight, exercising and not smoking.", "answer": 0}, {"article": "A widely anticipated study suggests that hormone therapy started soon after menopause can ease depression, anxiety, hot flashes and other adverse symptoms that many women face, without increasing risks for cardiovascular disease.\n\nThere was no increase in breast cancer, stroke, heart attack or blood clots, but the study's researchers said the sample size was too small and the study time too short to draw firm conclusions.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not detail the traditional treatment plan, or existing alternatives, for symptoms of menopause.", "answer": 0}, {"article": "Scientists say they have created a new drug that can attack ovarian and lung cancers in patients for whom other treatments have failed.\nThe cocktail also stopped the cancer growing for almost six months, which is unexpected for patients with advanced-stage cancers who were unresponsive to currently available treatments, including chemotherapy, the authors said.\nConfirmatory studies will be essential and if positive would broaden our armamentarium for fighting this cancer.\u201d\n\nThis article has been updated with comment from Professor Udai Banerji\u200b.\nDr. Susana Banerjee, consultant medical oncologist at The Royal Marsden NHS Foundation Trust and team leader in gynecological cancers at ICR, who is leading the phase II trial, commented in a statement: \u201cEffective treatment options for women with relapsed ovarian cancer are limited, so these results are very encouraging.\nThe U.K.-based researchers used a new drug along with chemotherapy medication known as paclitaxel on 25 women with high-grade, serous ovarian cancer, and 40 participants with squamous non-small cell lung cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story correctly mentions that treatment options for ovarian cancer are limited, but doesn\u2019t spell out what is available. In addition to chemotherapy, surgery is commonly performed to remove ovarian tumors, and other targeted therapies are under study.", "answer": 0}, {"article": "But this is where it gets more complicated.\nThis is an evolving field, and our goal is to better discern who is at high and low risk of breast cancer and develop a greater range of prevention strategies.\u201d\n\nAn individual risk analysis should prompt conversation between doctor and patient about the potential benefits and the risk of the therapy.\nAt that point, the panel said, women \u201care likely to have more benefit than harm from using tamoxifen or raloxifene.\u201d\n\nASCO\u2019s lower cutoff worries some experts.\nKenneth Lin, a family physician at Georgetown University who worked on developing the task force\u2019s SERM guidelines, notes that while SERMs may have reduced new cases, they \u201chave not been shown to reduce breast cancer mortality in any study or meta-analysis.\u201d One possible explanation, he says, is that \u201cthese drugs are effective at preventing nonlethal cancers rather than the more serious ones.\u201d\n\nNot used enough?\n\u201cAt the 1.67 percent high-risk threshold,\u201d Georgetown\u2019s Lin says, \u201cevery woman age 62 and older would be [considered] high-risk.\u201d That might lead to a situation in which millions of women would be encouraged, unnecessarily,to consider this therapy, along with its potential harmful effects.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story spends most of its time on drugs for prevention, but wisely does point out lifestyle alternative behaviors known to lower risk.\n\u201cMost important, become familiar with your family history, know your risk factors and discuss them with your primary-care physician. Age and family history cannot be controlled, but lifestyle changes \u2014 including eating a healthful diet, exercising, not smoking and not over consuming alcohol \u2014 are eminently doable and can reduce your risk. These basic tenets of\u00a0leading a healthy lifestyle\u00a0have been shown to be important factors in breast cancer prevention.\u201d\nIt would have been interesting to hear about the comparative effectiveness of instituting lifestyle changes vs. drugs for reducing cancer risk.", "answer": 1}, {"article": "Two new just-released studies offer fresh insights into the best way to lose weight and keep it off. Jennifer Corbett Dooren has details on The News Hub. Photo: Bloomberg\n\nA diet based on healthy carbohydrates\u2014rather than a low-fat or low-carbohydrate diet\u2014offers the best chance of keeping weight off without bringing unwanted side effects, a study published Tuesday in the Journal of the American Medical Association suggests.\n\nStudy participants following a low-glycemic-index diet, which is similar to a Mediterranean diet and focuses on fish, fruit, vegetables, nuts and whole grains, also saw improved cholesterol levels and other important markers that lower the risks of developing heart disease...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The focus of the story was on different dietary approaches to weight loss.", "answer": 1}, {"article": "But in Vertex\u2019s trial, about 70 percent of those who achieved an effective cure were able to do so in 24 weeks, or about six months.\nBut experts hope that eventually several of the pills now in development could be used together, much as AIDS is treated, doing away with the need for interferon.\nThat shorter time line, plus a higher chance of success, could entice more people to be treated, experts say.\nThe existing treatment is a combination of alpha interferon, which is injected, and ribavirin, an oral drug.\nAnd numerous other companies, from pharmaceutical giants to small start-ups, are in hot pursuit.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The comparison could have been more detailed, but, you do get the picture that this new drug will simply be an add on to existing therapies, albeit with the potential for cutting down the treatment time considerably. ", "answer": 1}, {"article": "Insulin helps glucose (sugar) enter cells to provide fuel for those cells.\n\"This was an impressive study showing how GHRH can have a positive effect on cognitive function,\" Zonszein said.\n\"It stimulates a whole cascade of hormones in the body and brain; it stimulates normal function of a system that was working at a younger age so that cells can do what they were programmed to do at birth.\"\n\"Growth hormone-releasing hormone doesn't target one specific area in the body and brain,\" said study lead author Laura Baker, an associate professor of psychiatry and behavioral science at the University of Washington School of Medicine, in Seattle.\nIt promotes all kinds of growth in the body and brain, but if you have excess IGF1, it may put you at risk for cancer,\" said Baker, who added that people with Alzheimer's disease tend to have low levels of IGF1.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There wasn\u2019t the kind of clear context and background as provided in the Reuters story:\n\u201c\u2026researchers have failed so far to come up wiht effective drugs to treat mild cognitive impairment, just as there is no known treatment to stave off the normal memory decline that comes with age.\u201d", "answer": 0}, {"article": "Christian\u2019s team studied 676 school-age children whose mothers had been in a clinical trial in which some got iron and folic acid supplements and other nutrients while they were pregnant.\nIron and folic acid deficiency are very common,\u201d she said.\n\u201cThese results speak to a large swath of people residing in that part of the world.\nThe World Health Organization estimates that in developing countries, every other pregnant woman is anemic and about 40 percent of preschool children are anemic.\nAbout 80 percent of the children \u2014 aged 7 to 9 \u2014 were enrolled in school.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not compare the approach used in the study with any other approach.", "answer": 0}, {"article": "A variation of a drug commonly given to cancer patients with bone damage appears to be an effective tool for preventing repeat hip fractures in elderly patients, according to a study in the New England Journal of Medicine.\n\nThe study results, which were to be presented yesterday in Hawaii, have potentially big implications because hip fractures are a common and debilitating injury for older people. Most of the 300,000 hip fractures each year in the U.S. are related to osteoporosis in older people, as well as falls, according...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned that the study demonstrated that there could be benefit from the treatment of elderly hip-fracture patients with this drug or another bisphosphonate.", "answer": 1}, {"article": "Each received a book detailing her prescribed diet.\nThe latest findings add to a growing body of evidence that the high-protein Atkins diet does not cause the harmful heart and artery effects long feared by many researchers.\nThe study by Stanford University researchers compared the Atkins approach with three others: the standard low-fat, reduced-calorie regimen long recommended by many physicians and weight-loss experts; the Zone, a reduced-carbohydrate approach developed by author Barry Sears; and the very low-fat, high-carbohydrate regimen created by Dean Ornish.\nAs for weight loss, the goal that concerns dieters the most, none of the groups managed to shed the large numbers of pounds touted by weight-loss programs and television shows such as \"The Biggest Loser.\"\nThe findings confirm, he said, that reducing carbohydrates, \"especially those with refined starch and sugar like that found in the U.S. diet, has metabolic benefits.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story reported on weight loss outcomes comparing four different methods for altering food consumption to result in weight loss.\u00a0 However additional treatment options were not even mentioned, such as balancing caloric intake with exercise, and weight loss surgery for the morbidly obese.", "answer": 0}, {"article": "What if we told you that a guy with no background in science or medicine - not even a college degree - has come up with what may be one of the most promising breakthroughs in cancer research in years?\nIt was the worst kind of luck that gave Kanzius the idea to use radio waves to kill cancer cells: six years ago, he was diagnosed with terminal leukemia and since then has undergone 36 rounds of toxic chemotherapy.\nIt's not something that a layman like me should be in, it should be left to doctors and research people,\" he told Stahl.\nHere's the important part: if clinical trials pan out - and there's still a long way to go - the Kanzius machine will zap cancer cells all through your body without the need for drugs or surgery and without side effects.\nHis name is John Kanzius, and as correspondent Lesley Stahl first reported last April, he's a former businessman and radio technician who built a radio wave machine that has cancer researchers so enthusiastic about its potential they're pouring money and effort into testing it out.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The segment mentions other treatment options only in a glancing way and in the most negative light\u2013and without indicating that many cancers are treatable, and sent into remission, with current techniques. ", "answer": 0}, {"article": "Researchers have found strong evidence that adenotonsillectomy \u2014 the surgery to remove the tonsils and adenoids \u2014 can help relieve childhood behavioral or attention problems, including attention-deficit hyperactivity disorder, or A.D.H.D.\nAlthough the surgery has become less common with antibiotics, more than 400,000 children under 15 have their tonsils, adenoids or both removed every year, according to estimates by the Metropolitan Insurance Company.\nThe rest have the operation to relieve breathing difficulty or nighttime sleep apnea, a serious disorder in which the sleeping child briefly stops breathing during the night.\nAccording to the paper, which was published yesterday in Pediatrics, it has been known that children with sleep disorders often have behavior problems.\nTwenty-two of the adenotonsillectomy patients, but only 2 of the controls, had a diagnosis of attention-deficit hyperactivity disorder.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "In the story, there is no mention of other treatment options for ADHD or for sleep apnea. For example, CPAP machines should have been mentioned as a non-surgical alternative to adenotonsillectomy for sleep apnea.", "answer": 0}, {"article": "I'm proof.\"\nIf an AAA is found, doctors sometimes use a stent to repair the aorta, but it doesn't always work since the aneurysms are often in places where a stent can\u2019t fit.\n\"The use of 3-D printing to personalize aortic repair is fascinating,\" said Dr. Ramesh Gowda, director of interventional cardiology at Mount Sinai Beth Israel.\nWhen they would open me up [the aorta] could just blow.\u201d\n\nThe bulge in the large artery that carries blood away from the heart can be immediately life-threatening if it grows large enough to rupture.\n\u201cI\u2019m unsure where the technology will go but it is a very fascinating discovery.\u201d\n\nAfter her surgery, Berg is now back to back to enjoying her life.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story isn\u2019t always clear about whether it\u2019s comparing the 3D technique with open surgery or with stent procedures that do not use the technology. In any case, there\u2019s no data to make the safety and effectiveness distinctions clear.\nThe story says \u201cdoctors sometimes use a stent to repair the aorta, but it doesn\u2019t always work since the aneurysms are often in places where a stent can\u2019t fit. And even if the stent does fit, patients often undergo a long, painful recovery.\u201d It says, \u201cUsing a minimally invasive endoscopic vascular surgical technique, patient recovery times are quicker.\u201d\nThe story also does not make it clear that not every case requires surgery. According to the Mayo Clinic, \u201cDepending on the size and the rate at which your abdominal aortic aneurysm is growing, treatment may vary from watchful waiting to emergency surgery. Once an abdominal aortic aneurysm is found, doctors will closely monitor it so that surgery can be planned if it\u2019s necessary. Emergency surgery for a ruptured abdominal aortic aneurysm can be risky.\u201d", "answer": 0}, {"article": "Study author Dr. Kang Zhang, the chief of ophthalmic genetics at UC San Diego's Shiley Eye Institute, told CBS News, \"Unlike [the] current way of cataract surgery, which destroys over half of lens stem cells and requires implantation of a plastic intranet ocular lens, we devised a new surgery to make a very small opening at the side of a cataractous lens bag, remove [the] cataract inside, allow the opening to heal, and promote dormant lens stem cells to regrow an entirely new lens with vision.\"\nIn cataract surgery, which has been around for several decades, eye surgeons make an incision in the front of the eye and remove the lens from its supporting capsule.\nThe experimental procedure was done in 12 infants who were born with a congenital cataract condition.\nMany children also later go on to suffer from glaucoma.\nThe new procedure described in Nature involves making a slim incision at the side of the lens capsule, removing the entire lens, yet preserving the empty capsule bag or \"scaffold.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job of\u00a0describing conventional cataract surgery as the main alternative to this new procedure.", "answer": 1}, {"article": "The ancient art of applying suction cups to the body has gotten a boost from several new studies that show it helps relieve a variety of painful conditions. But scientists say larger, more rigorous studies are needed.\n\nCupping, as the practice is called, was performed traditionally in China and other countries, and is now available from acupuncturists, and some chiropractors and massage therapists in the U.S. In the traditional method, called fire cupping, a ball of burning cotton is briefly placed inside a glass cup to heat...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention any alternatives. What are the traditional treatments for knee arthritis pain and chronic neck pain? Or for pain management in general? A few words about over the counter analgesics, massage, or other proven therapies would have been helpful.", "answer": 0}, {"article": "\"Amazing,\" said Campbell with a smile.\n(CNN) -- As a thick, gray haze began to descend over the words in her schoolbooks, and eventually the faces of loved ones, Barbara Campbell barely grasped that she was going blind.\n\"This is really the first step toward a really bionic eye,\" said Aries Arditi, a senior fellow in vision science at Lighthouse International, a nonprofit advocacy group for the blind and one of the study sites for the artificial retina.\nThe shape is communicated to the brain -- the idea being that Campbell might one day perceive some semblance of a shape of that tree.\n\"Being able to repair, in some way, a function that has been lost is a very exciting thing,\" Del Priore said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story fails to compare this artificial retina with similar products in clincial testing, or to other approaches to restoring vision that are in development. \nIt also fails to indicate what standard care is for patients with retinitis pigmentosa, and whether treatments exist to stablize or slow the progress of the disease. ", "answer": 0}, {"article": "\u201cI had terrible pangs of sadness and despondency.\nI was missing my husband so badly.\u201d\n\nEven after seeing a therapist, which helped, she suffered from nightmares and couldn\u2019t bear to hear arias from their favorite operas.\n\u201cI had many interests.\u201d She traveled and even tried dating again.\n\u201cI volunteered, to get myself out and doing things, to fill the gaps,\u201d she said.\n\u201cBut I wasn\u2019t really doing well,\u201d said Ms. Schomaker, 73.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story spends time talking about ordinary vs. complicated grief, but it doesn\u2019t describe what might be the alternative ways of a person coping with dysfunction years after a loss. Is treatment for depression sometimes effective? What are the alternatives to the label of \u201ccomplicated grief?\u201d\nWe also found the description of the special therapy too brief. These few words were all we could find to define this new form: \u201cfocuses specifically on bereavement symptoms, and incorporates memories, photographs and recordings.\u201d We hoped for more detail about how this therapy might differ from more traditional forms of psychotherapy.", "answer": 0}, {"article": "\u201cThis is still investigational and requires more research.\nThe medical device maker said it completed an initial feasibility study of 30 men, average age of 60, who suffered from erectile dysfunction (ED).\nThere are an estimated 30 million men in the United States who have ED and 300 million worldwide.\nIt is the inception of an entirely new way of treating ED that has never been seen before,\u201d he said.\nThe stent \u2014 a tiny wire mesh tube similar to those used to prop open heart arteries \u2014 was placed in the internal pudendal artery, which supplies blood to the penis.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Some comparison was made with drug therapy for erectile dysfunction.\u00a0 But there was no mention of a very safe and often effective alternative \u2013 the penile vacuum pump. Penile implants are also effective, though require surgical procedures. It would have required only an additional line to give this backgrounding context.\u00a0 Even business story readers and investors would want this reminder.", "answer": 0}, {"article": "As this Lancet study points out, because annual flu shots were recommended for the elderly since the 1960s, it has been unethical to conduct high-quality randomized controlled trials where you give only one group the shot in order to compare it with another group that didn't get the vaccine.\nIn February, the World Health Organization offers a prediction \u2014 based on surveillance and laboratory and clinical studies \u2014 and then each country uses that prediction to approve vaccines in its jurisdiction.\nThe meta-analyses found no evidence of serious side effects beyond the odd case of soreness at the injection site.\nFor children under age 2, the benefits are less clear; the evidence, the researchers found, was scant, and of the research that was available, it seemed the efficacy of the shot was similar to placebo.\nThe potential for error here can dramatically alter the effectiveness of the flu shot in a given season.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention the meager alternatives to influenza vaccination \u2014 that is, proper hand washing hygiene and the isolation of flu patients from those free of the disease.", "answer": 1}, {"article": "He and his colleagues are now planning a multicenter trial of fish oil for the prevention of psychotic illness in 320 at-risk people.\nThe researchers included people who met at least one of the following three criteria: having low-level psychotic symptoms; having transient psychotic symptoms; or having a schizophrenia-like personality disorder or a close relative with schizophrenia, along with a sharp decline in mental function within the past year.\nThe effect of fish oil capsules, Amminger noted, was similar to that seen in two trials of antipsychotic drugs in at-risk individuals.\nFurthermore, only about a third of people at high risk for psychotic disorders will go on to develop full-fledged mental illness in a given year.\nThere\u2019s considerable evidence that abnormal fatty acid metabolism may contribute to the development of schizophrenia, Amminger and his team note in the Archives of General Psychiatry.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story does compare treatment with fish oil/omega-3 PUFA\u00a0supplements to\u00a0an alternative treatment with antipsychotic medications.\u00a0\u00a0 In addition, the story reports on potential harms of treatment with antipsychotic medication.", "answer": 1}, {"article": "\u2018What insanity is that?\u2019 Hundreds of NC children are being killed or injured by guns.\n\nDid you realize that in the past five years, hundreds of teens and youth have been killed or hurt by gunfire in North Carolina? Here\u2019s what some say you can do about it.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not state whether there are any intrinsic advantages or disadvantages to the \u201cnew\u201d vaccine. It also fails to note that FluMist is not approved for use in high-risk patients. Nor does it describe other actions people can take to prevent the flu. In addition to vaccination, the Centers for Disease Control and Prevention recommend several measures (http://www.cdc.gov/flu/protect/habits.htm).", "answer": 0}, {"article": "Dr. Louis Jacques, director of the coverage and analysis group at the Centers for Medicare and Medicaid Services, said cost was not a factor and that the agency had reviewed products approved by the F.D.A.\n\u201cThere\u2019s really no precedent for another drug that does this,\u201d said Dr. Matthew R. Smith, a prostate cancer specialist at the Massachusetts General Hospital.\nAnother investigator in the trial, Dr. David C. Smith of the University of Michigan, said he could not believe it when the bone scan of one patient, who previously had widespread cancer in his bones, came back completely clean.\n\u201cI thought they had scanned the wrong person,\u201d said Dr. Smith, who is not related to the doctor in Massachusetts.\nThe drug was approved by the Food and Drug Administration in April after a clinical trial showed that those getting the drug had a median survival of about 26 months, four months longer than those in a control group.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did an inadequate job of explaining the target group of men who would be appropriate candidates to consider Provenge or for the study of XL184. And while mentioning that Taxotere, a drug currently used to treat advanced prostate cancer, has not been shown to have much affect on bone scans, the story could have seized the opportunity to explain that the benefits seen with Taxotere have not yet been demonstrated for XL184. \u00a0The story went on to add that drugs like Zometa and denosumab, used to treat bone lesions in men with advanced prostate cancer, haven\u2019t been shown to fight cancer itself. \u00a0In fact \u2013 neither has XL184. \u00a0At this point \u2013 what we know is that after 6 weeks of treatment XL184 improves the picture seen on bone scan. \u00a0But we do not yet know whether it changes the course of the cancer itself \u2013 i.e. do men live longer?", "answer": 0}, {"article": "To learn more about the Society and the field of endocrinology, visit our site at http://www.\n\u2022 Smoking cessation, weight loss (if indicated), limiting or avoiding alcohol, maintaining adequate levels of vitamin D and calcium, eating a healthy diet, and regular physical activity are suggested for all women with prior breast cancer\n\u2022 Non-pharmacologic therapies for VMS such as cognitive behavioral therapy, hypnosis, and acupuncture may be helpful as are vaginal lubricants and moisturizers\n\u2022 Several emerging approaches such as selective estrogen receptor modulators (SERMs), Tissue selective estrogen complex (TSECs), estetrol, and neurokinin B inhibitors show promise as useful agents to expand options for symptom relief with less breast cancer risk but have not yet been tested to confirm safety in women with prior breast cancer\n\nOther authors of the study include: Cynthia A. Stuenkel of the University of California, San Diego in La Jolla, Calif.; Susan R. Davis of the School of Public Health and Preventative Medicine, Monash University in Australia; JoAnn V. Pinkerton of the University of Virginia in Charlottesville, Va.; Ann Gompel of Paris Descartes University in France; and Mary Ann Lumsden of the University of Glasgow School of Medicine, Dentistry, and Nursing in Scotland.\n\"Following breast cancer, women should generally not be treated with menopausal hormone therapy but should instead focus on lifestyle modifications such as smoking cessation, weight loss, and regular physical activity,\" said the study's first author, Richard J. Santen, M.D., of the University of Virginia Health System in Charlottesville, Va. \"Pharmacologic agents are also available to treat women with severe symptoms.\nMenopause is a normal part of a woman's aging process but pre-menopausal women treated with chemotherapy can also develop premature menopause, and consequently, severe menopausal symptoms including sleep disorders, vulvovaginal atrophy (VVA), vasomotor symptoms (VMS), mood changes, depressive symptoms, cardiovascular disease, osteopenia, and osteoporosis.\nEndocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release lists things women should do to help relieve menopausal symptoms, but there are no comparisons of which ones may be more beneficial. Knowing which ones offered the strongest benefits would help women decide on which approaches to follow. It\u2019s unrealistic to suggest that all women would be willing or able to make all of the modifications recommended. We\u2019ve all heard these messages throughout our lives. A cancer diagnosis may be the incentive needed to make changes but women deserve to know which changes have the potential for the greatest\u00a0 benefit.", "answer": 0}, {"article": "\"More than 30 years since the discovery of the antidepressant effects of sleep deprivation, we still do not have an effective grasp on precisely how effective the treatment is and how to achieve the best clinical results,\" said study senior author Philip Gehrman, PhD, an associate professor of Psychiatry and member of the Penn Sleep Center, who also treats patients at the Cpl.\nThe findings of this meta-analysis hope to provide relief for the estimated 16.1 million adults who experienced a major depressive episode in 2014.\n\"Regardless of how the response was quantified, how the sleep deprivation was delivered, or the type of depression the subject was experiencing, we found a nearly equivalent response rate.\"\nAlso, future studies are needed to include a more comprehensive assessment of potential predictors of treatment outcome to identify those patients most likely to benefit from sleep deprivation.\nSuch drugs typically take weeks or longer to experience results, yet 16.7 percent of 242 million U.S. adults filled one or more prescriptions for psychiatric drugs in 2013.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions that depression is most typically treated with anti-depressant drugs. We would have liked a little more context for readers on other non-drug treatments such as exercise and cognitive behavioral therapy.", "answer": 1}, {"article": "San Francisco--A new study, presented today at the Society of NeuroInterventional Surgery's (SNIS) 15th Annual Meeting, found that new stroke imaging technology could decrease delays in care by up to 60 minutes, giving patients a better chance at making a full recovery.\nThe time required to transfer a patient from their CT scan to the operating room could delay EVT by as long as 60 minutes.\n\"By using this technology in the angiosuite, hospitals can reduce intra-facility transfer delays and hence the time of stroke symptom onset to treatment, which will significantly reduce brain damage and improve outcomes for patients,\" said Nicole Cancelliere, lead author of the study and an interventional clinical research technologist at Toronto Western Hospital.\nThe lead PI on this study, Professor Vitor Mendes Pereira, concluded by saying, \"By reducing intra-facility transfer times, patients can receive EVT treatment sooner, which can significantly impact patient outcomes\".\nThe imaging allows accurate detection of hemorrhage, occlusion site, ischemic core, and tissue at risk, suggesting that baseline imaging can be performed in the angiosuite using cone beam imaging.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release briefly discusses alternatives in this sentence: \u201cPreliminary results show that the cone beam imaging software compares favorably with baseline and follow-up CT scans.\u201d It would have been helpful to note if the software compared favorably in terms of speed, accuracy, or both. What sort of testing was done? What were the results? How does that compare with baseline and follow-up CT scans?\nThe release also says that \u201cThis study suggests that in the future, stroke patients can bypass the CT scan or emergency department and go directly to the angiosuite for imaging and proper care.\u201d Thus the comparison is mentioned but it could have been made clearer.\u00a0 It also could have noted that medicine-based treatment (clot busting drugs) is an alternative to the procedure described here.", "answer": 1}, {"article": "She worked with a group of mice that are genetically bred to have healthy ratios of omega 3 fatty acids.\nThe study, presented at the American Society of Reproductive Medicine annual meeting, was in mice, so more research needs to be completed before omega 3 foods or supplements become part of treatment for infertility.\nWhat she found: The mice with the higher levels of omega 3 fatty acids seemed to have more precursors to egg cells than control mice with lower levels of the fat, meaning they had a larger reserve of eggs-to-be.\n(Some people who are predisposed to bleeding problems may be at higher risk of hemorrhages with high doses of omega 3s, but those cases are relatively rare.)\nMore studies need to replicate and confirm the role that omega 3 fatty acids might play in fertility, but for now, Skaznik-Wikiel says that there isn\u2019t much harm in consuming more omega 3 fats.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no discussion of any other steps women might take to increase their odds of becoming pregnant when they are ready to start a family.", "answer": 0}, {"article": "\"Dislocation is a common reason for a total hip replacement to fail, and when it happens, sufferers can experience significant pain and require another surgery to fix the problem,\" explains lead study author Jonathan Vigdorchik, MD, an assistant professor of orthopedic surgery at NYU School of Medicine and associate fellowship director of the Division of Adult Reconstructive Surgery at NYU Langone Orthopedic Hospital.\nThese findings represent a six-fold decrease in the rate of dislocation in the high-risk group.\nMore than 310,000 hip replacements are performed in the United States each year, and an estimated 2.5 million Americans are currently living with hip replacements.\nNYU Langone research presented at last year's AAOS Annual Meeting showed that spinal deformity was a significant risk factor for dislocation and subsequent revision surgery.\nAll 192 patients underwent a total hip replacement through the high-risk algorithm, with dual mobility implants being used in 143 of the cases.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Since we\u2019re not aware of alternatives to this tool we\u2019ll rate this criteria Not Applicable.  ", "answer": 2}, {"article": "MONDAY, July 6, 2015 (HealthDay News) -- A scan of calcium deposits inside your arteries can help doctors deduce how long you're likely to live, a new study has found.\n\"This is not a new test, but these results emphasize the importance of looking at this marker in addition to the traditional risk factors,\" said Dr. William Zoghbi, past president of the American College of Cardiology and head of cardiovascular imaging for Houston Methodist Hospital.\nThe test, called a coronary calcium scan, uses a regular CT scan to look for calcium deposits in the three major arteries that carry blood away from the heart, said lead author Leslee Shaw, a professor of cardiology at Emory University in Atlanta.\n\"Calcium scoring really is the earliest marker in the development of hardening of the arteries in people who have no symptoms,\" he said.\nThe results of a calcium scan can be reassuring for people with few or no calcium deposits, and can provide people with high calcium levels with added impetus to take better care of themselves, Shaw said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions the importance of eating right, exercising, and taking medication to treat heart risk factors for improving heart health \u2014 which is important to reiterate. However, treatment of heart disease was not the primary point of the study. One of the main reasons for doing this study was to compare the predictive power of CAC tests to some other risk factor assessments, and the story does not mention those other methods.", "answer": 0}, {"article": "Foods to avoid\n\n Dairy: Milk, ice cream, yogurt, cottage and ricotta cheeses (except for lactose-free versions)\n\n Fruits: Apples, peaches, pears, watermelon, cherries, figs\n\n Vegetables: Garlic, onions, leeks, asparagus, cauliflower or large servings (more than \u00bd cup) of broccoli and Brussels sprouts\n\n Grains: Wheat (except in sourdough bread), rye, barley\n\n Legumes and nuts: Cashews, kidney beans, soy beans and soy milk\n\n Sweeteners: Honey, fructose, xylitol, agave syrup\n\nFoods to include \n\n Dairy and dairy substitutes: Kefir, almond milk, coconut milk\n\n Fruits: Bananas, blueberries, grapes, oranges, strawberries\n\n Vegetables: Carrots, green beans, bell peppers, potatoes, tomatoes\n\n Grains: Rice, oats, gluten-free bread (but check labels for high-FODMAP ingredients)\n\n Legumes and nuts: Peanuts, pecans, walnuts\n\n Sweeteners: Cane sugar, aspartame, stevia\n\u201cBut I think it\u2019s a reasonable thing to try.\u201d\n\nThe largest study so far, with 92 patients, was conducted at University of Michigan.\nThe theory is that FODMAPs, found in many fruits, vegetables, grains, dairy foods and sweeteners, are poorly digested by susceptible people.\nIt\u2019s not known if the diet leads to any nutritional deficiencies or keeps working in the long run \u2014 especially for patients who get little support from doctors or dietitians.\nIt found that 52% of low-FODMAP patients and 41% of patients on a less-restrictive diet reported \u201cadequate relief.\u201d The difference was not statistically significant, says study co-author William Chey, a professor of gastroenterology.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions a number of alternatives, including other existing diets that seem to compete favorably with the low-FODMAP diet, such as medication, probiotics, and fiber supplements. The story notes that these other strategies \u201cstill have roles in treating IBS\u201d.", "answer": 1}, {"article": "The U.S. Food and Drug Administration today approved Nuplazid (pimavanserin) tablets, the first drug approved to treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson\u2019s disease.\nBreakthrough therapy designation is a program designed to expedite the development and review of drugs that are intended to treat a serious condition and where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint.\nThe neurological disorder typically occurs in people over age 60, when cells in the brain that produce a chemical called dopamine become impaired or die.\nIn clinical trials, the most common side effects reported by participants taking Nuplazid were: swelling, usually of the ankles, legs, and feet due to the accumulation of excessive fluid in the tissue (peripheral edema); nausea; and abnormal state of mind (confused state).\n\u201cHallucinations and delusions can be profoundly disturbing and disabling,\u201d said Mitchell Mathis, M.D., director of the Division of Psychiatry Products in the FDA\u2019s Center for Drug Evaluation and Research.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The only alternative mentioned in the news release is the placebo used for comparison in the clinical trial. What about other treatment methods? According to patient advocacy groups, other government websites and review articles, there are numerous alternatives in use for treating PD-related hallucinations and delusions. Among them, according to the University of Florida College of Medicine:", "answer": 0}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.\nTo determine an alternate but effective therapy, the researchers enrolled 100 patients age 45-78 with significant stroke risk and coupled with diligent pulse monitoring -- manually or by using a smartphone - twice a day with \"as needed\" anticoagulants for the treatment of AF.\n\"It is extremely common for patients with AF to seek treatment that does not involve the use of chronic oral anticoagulants therapy, as there are other risks associated with their long term use,\" said co-author Francis E. Marchlinski, MD, FHRS, director of Electrophysiology for the University of Pennsylvania Health System and Richard T. and Angela Clark President's Distinguished Professor in the Perelman School of Medicine at the University of Pennsylvania.\nHowever, a new study shows the use of novel anticoagulants for AF prescribed on an \"as-needed basis\" guided by diligent pulse monitoring, can be a safe and effective alternative to lowering overall risk of stroke.\nPHILADELPHIA - Patients with atrial fibrillation (AF), a rapid irregular heartbeat caused by pooling blood in the heart which can lead to heart failure and stroke, are often treated with an ablation, a minimally invasive procedure used to remove the tissue which causes the pooled blood.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release presents \u201cas-needed anticoagulation\u201d drug therapy as an alternative to \u201clong-term, daily oral anticoagulation medications.\u201d The problem is that we\u2019re not sure what to do \u2013 take no medicine, daily medicine or this \u201cas needed\u201d medicine. We aren\u2019t told if the comparator is a daily anti-coagulation (such as warfarin, the standard treatment) or no anti-coagulation. It isn\u2019t clear and it is important.", "answer": 0}, {"article": "Her research group led both studies.\nFor example, a poor test grade or bad performance evaluation might lead to feelings of \"I'm not good enough,\" but the lessons encourage more positive thinking about \"how many exams have you passed, to put this failure in a more accurate light,\" Guille said.\nThe research involved about 200 medical interns \u2014 residents in their first post-graduate year, which is often one of the most intense periods of doctor training.\nGuille said medical students and residents tend to be high-achieving perfectionists, but that they need to learn \"you can't always be perfect in medicine, you have to figure out how to deal with failure.\"\nAn earlier study of 740 interns found that suicidal thoughts increased almost four-fold during the first three months of residency, said Dr. Constance Guille of the Medical University of South Carolina in Charleston.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study in question compared access to a web based therapy plan to emailed reminders of available resources. \u00a0We would like to have seen some comment on the relative value of traditional individualized \u201ctalk\u201d therapy to compare to the web based program.", "answer": 0}, {"article": "For more information, visit http://www.\nSSIs are the most common hospital-acquired infection and the leading cause of hospital readmission following an operation.1,2,3 Due to the prevalence off SSIs, the WiSOR research team decided to see if postoperative wound monitoring could be effectively achieved by having patients upload photos through the WoundCare app and answer a few brief questions to gather information not easily captured through images.\nPatients gave universally positive feedback about the app's ease of use and the ability to have wounds monitored\n\nCHICAGO (Jan. 19, 2018): A new smartphone app called WoundCare is successfully enabling patients to remotely send images of their surgical wounds for monitoring by nurses.\nStudy authors note that the success and sustainability of a post-discharge wound-monitoring protocol requires a dedicated transitional care program and not simply adding a task to the current staff workload.\n\"This drawback leads to the common and frustrating scenario where patients present to a routine, scheduled clinic appointment with an advanced wound complication that requires readmission, with or without reoperation.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The study mentions patients whose infections are detected during routine follow-up exams, but doesn\u2019t describe what steps are currently taken to catch post-operative infections. Do hospitals educate patients to recognize infections? Do staff follow up in any way, perhaps with phone calls? Those questions aren\u2019t answered.", "answer": 0}, {"article": "SUNDAY, March 1, 2015 (HealthDay News) -- A procedure that delivers the anesthetic lidocaine (Xylocaine) directly to nerves in the back of the nasal cavity appears to offer significant relief to migraine sufferers, preliminary research indicates.\nAnd, he said, the hope was that lidocaine would essentially short-circuit that bundle's headache-causing pathway.\n\"When a body gets used to having a chronic headache suppressor, the patient can experience a rebound in the absence of that suppressor.\nThe day after the procedure, average migraine pain levels had dropped from about 8 to just over 4.\nThe participants all underwent a session of \"image-guided therapy,\" in which a spaghetti-sized catheter was inserted through a nostril and into the nasal passage to deliver a dose of lidocaine to a nerve center known as the sphenopalatine ganglion.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article mentioned that the new procedure was a \u201cclear simple alternative to standard migraine treatments,\u201d but it did not detail what those treatments were. And what\u2019s simple about image-guided therapy and a spaghetti-sized catheter? The story could have added that a whole range of medications exist to treat migraines, such as pain relievers like aspirin, to preventative medications like anti-seizure drugs, to Botox.", "answer": 0}, {"article": "For more information or to arrange an interview with Dr. Vuksan, please contact:\n\"The findings are most important for populations at high risk for cardiovascular disease, such as Type 2 diabetics, who have normal levels of LDL cholesterol, but elevated levels of non-HDL or apo B,\" said Dr. Vladimir Vuksan, research scientist and associate director of the Risk Factor Modification Centre of St. Michael's.\nThe review also indicated that barley had similar cholesterol-lowering effects as oats, which is often the go-to grain for health benefits.\nIt is the first study to look at the effects of barley and barley products on both LDL and non-HDL cholesterol in addition to apolipoprotein B, or apoB, a lipoprotein that carries bad cholesterol through the blood.\n\"After looking at the evidence, we can also say that barley is comparably effective as oats in reducing overall risk of cardiovascular disease\" said Dr. Vuksan.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release makes brief mention of barley in comparison to oats. It states that \u201cbarley is higher in fibre, has twice the protein and almost half the calories of oats, which are important considerations for those with weight or dietary concerns,\u201d\u00a0 We aren\u2019t provided any quantification of the claim.\nThe release also skipped over some of the other common ways there are to lower cholesterol including medications, exercise, other foods and dietary supplements, and weight loss.", "answer": 0}, {"article": "The new awards provide up to $600,000 each over three years to support the work of collab...\n\nUW to test using MDMA to treat PTSD\n\nThe Department of Family Medicine and Community Health of the UW School of Medicine and Public Health will take part in a multisite Food and Drug Administration-approved Phase III trial investigating MDMA as an adjunct to psychotherapy for the tre...\nThe search committee for the Science and Medicine Graduate Research Scholars (SciMed) program director position enthusiastically announces four finalists who have been invited to give public presentations.\nRyan Coller wins federal challenge for app to help children with complex care needs\n\nA team of researchers at the University of Wisconsin School of Medicine and Public Health and the College of Engineering have won a share of a $100,000 award to develop technology for families caring at home for children with complex medical needs...\nThomas Mackie to lead new joint innovation initiative between UW Health and School of Medicine and Public Health\n\nUW Health has selected Thomas \u201cRock\u201d Mackie to be the inaugural leader of the health system\u2019s innovation initiative, which it is pursuing in partnership with the UW School of Medicine and Public Health.\nThe Wisconsin Partnership Program is pleased to present its 2019-2024 Five-Year Plan, which was approved by the UW System Board of Regents in December, 2018 and goes into effect March, 2019.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release notes that\u00a0\u201cThis is the first time any therapy has been shown to stabilize memory loss over a year.\u201d That\u2019s all well and good, but how do the results compare with other FDA approved treatments for Alzheimer\u2019s disease or others that may be on the horizon? The release doesn\u2019t address this issue.", "answer": 0}, {"article": "Former NASA astronaut Mark Kelly announced that he is running for John McCain's Senate seat in Arizona in the 2020 election.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u00a0notes that\u00a0other asthma treatments aren\u2019t \"game-changers\" for patients who aren\u2019t responding to medical therapy, the implication being that thermoplasty is. But we don\u2019t really know whether thermoplasty represents a big improvement over medical therapy just yet. \nThat being said, the story did emphasize that this treatment is only being considered for patients whose asthma isn\u2019t being controlled by existing treatments. By providing this important context, the story\u00a0does enough to satisfy the criteria.", "answer": 1}, {"article": "\u201cDoctors and patients need to think about the cancer risk when ordering this test.\u201d\n\nThe study, published in the new edition of Archives of Internal Medicine, found a small but real risk from the average radiation \u2014 for every 100,000 men between 45 and 75 undergoing the test every five years, there would be 42 cancers; for every 100,000 women ages 55 to 75, there would be 62.\nThey say the test's value is limited because it doesn't identify which plaque are stable and which could rupture and cause a heart attack.\nOne Houston doctor said that there was just one scanner in Houston in the mid-'90s, and now the $1 million machines are all over the city.\nIt eventually attracted attention in cardiology circles, where the scans' costs and benefits are the subject of much debate.\nThe legislation was introduced in 2007 and passed quietly this year.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nAlthough this story points out that alternative screening techniques are available and it makes reference to cholesterol, it does not include any details about the alternatives.", "answer": 0}, {"article": "\"The arthritis was so bad that I could barely step down without severe pain.\u201d\n\nBecause she wasn\u2019t eligible for a knee replacement she tried cortisone injections, physical therapy, medications \u2014 nothing relieved her pain.\n\"I thought I was going to limp for the rest of my life,\" she said.\nRecovery time is minimal, with most patients walking immediately after the procedure and resuming normal activities in a day or two.\nInstead, doctors use specialized needles that emit radio frequencywaves into the knee.\nThe cost of the treatment is between $2,000 and $4,000.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The text mentions treatment options and compares the radio frequency procedure with one of them.", "answer": 1}, {"article": "An ongoing study will evaluate the product over two years.\nIf it appears to have a positive effect, then it may be something that could benefit patients even before definitive symptoms of Alzheimer's appear, Wurtman said.\n\"I don't think it has any effect on the fundamental diseases process, but we'll see,\" he said.\n\"There isn't a clear diet that prevents you from getting Alzheimer's disease or improves your memory,\" Thies said.\nThe new drink, called Souvenaid, may actually stimulate the growth of new synapses, said the drink's inventor, Massachusetts Institute of Technology scientist Dr. Richard Wurtman.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no discussion of any other research in the field of memory boosting. A brief nod to what is known (exercise, stimulation such as puzzles, etc.) about reducing cognitive decline would have been appreciated.", "answer": 0}, {"article": "Related: Is Your Medication Helping or Hurting?\n\"It gave us an answer \u2014 that this was her physiology and her genetics and not something in her head.\u201d\n\nThe Avera Institute for Human Genetics (AIHG) in Sioux Falls, South Dakota is among several institutions exploring the role of pharmacogenomics \u2014 the science of how our inheritance and genetic makeup influences the way we metabolize medications.\n\u201cOnce the genetic testing became available it provided Sarah with more than just physical relief,\" says Dr. Matthew B. Stanley of the Avera Medical Group in Sioux Falls, South Dakota.\nShe was also prescribed selective serotonin reuptake inhibitors (SSRIs) \u2014 a class of drugs including Prozac which are used to treat anxiety and depression \u2014 but they \"made me feel like I was losing my mind,\" Ellis told NBC News.\nDNA Tests May Be a Guide\n\n'One piece of the puzzle'\n\nAIHG\u2019s pharmacogenomics research has led to the development of Genefolio, a genetic test that uses an individual\u2019s unique DNA to predict how that individual will respond to medications.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article mentions that other organizations are \u201cexploring the role of pharmacogenomics,\u201d and it mentions one other specific test, GeneSight Psychotropic, which it describes as \u201csimilar to many used in hospitals.\u201d This is enough to merit a marginal Satisfactory score.\nIt does not say how similar the Genesight Psychotropic test is to the Genefolio test developed by the Avera Institute for Human Genetics, as we note above in the quantified benefits criterion. Thus, the article provides no data whatsoever about the clinical utility of Genefolio or of any other genetic tests other than GeneSight Psychotropic; instead, it focuses on the anecdotal story of how the Genefolio test helped a patient\u2019s doctor decide to prescribe for her a lower dose of an older antidepressant and on the positive results that produced.", "answer": 1}, {"article": "The researchers also made a secondary discovery.\nAt the conclusion of the two-year study, the researchers found that increasing levels of omega-3 in the blood were associated with reduced breast density\u2014but only in women with a body mass index above 29, bordering on obesity.\nAlthough Lovaza contains both of the fatty acids DHA -- 375 milligrams -- and EPA -- 465 milligrams, only DHA blood levels were associated with breast density reduction.\nThe protection likely comes from the fatty acids' anti-inflammatory effects, said Dr. Andrea Manni, professor and division chief of endocrinology, diabetes and metabolism, Penn State College of Medicine.\nOther investigators on this project were Narinder Sandhu and Carina Signori, Department of Medicine; Susann E. Schetter, Department of Radiology; Jason Liao and Ana Calcagnotto, Department of Public Health Sciences; John P. Richie, Bogdan Prokopczyk and Neil Trushin, Department of Pharmacology; Cynthia DuBrock, Penn State Hershey Cancer Institute; Christopher Hamilton and Laurence M. Demers, Department of Pathology; Cesar Aliaga and Karam El-Bayoumy, Department of Biochemistry and Molecular Biology, all at Penn State Milton S. Hershey Medical Center; Terryl J. Hartman, Emory University; and John McGinley and Henry J. Thompson, Colorado State University.Susan G. Komen for the Cure and Penn State Hershey Cancer Institute funded this research.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release makes no mention of any other approaches to reducing the potential risk of developing breast cancer although some preventative actions are readily known and could have been included. These include limiting alcohol, not smoking, controlling weight, breast-feeding and exercising.\nSince the focus of the research was on reducing risk by reducing breast density the most obvious alternative to taking omega-3 supplements is losing weight through diet.", "answer": 0}, {"article": "A type of sleeping pill that several major pharmaceutical companies are racing to develop received good news yesterday when Swiss biotech company Actelion Ltd. reported positive clinical data.\n\nSleep experts say the drug class needs further study but could potentially offer some benefits beyond Ambien, the top-selling drug in the $3.8 billion global market for sleeping pills. While Ambien and similar drugs, called nonbenzodiazepine drugs, are effective and easily tolerated by most people, some insomniacs don't respond to the...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While the\u00a0story mentioned one other category of drug used in the treatment of insomnia, it did not mention that a range of treatment options exist including lifestyle changes that may be of benefit.", "answer": 0}, {"article": "As part of the new study, published online Monday in the journal Lancet, researchers examined the cancer death rates of 25,570 patients who had participated in eight different randomized controlled trials of aspirin that ended up to 20 years earlier.\nThe specific dose of aspirin taken did not seem to matter \u2014 most trials gave out low doses of 75 to 100 milligrams \u2014 but the participants in the longest lasting trials had the most drastic reductions in cancer death years later.\nThe risk of lung cancer death was 30 percent lower, the risk of colorectal cancer death was 40 percent lower and the risk of esophageal cancer death was 60 percent lower, the study reported.\nMany Americans take aspirin to lower their risk of heart disease, but a new study suggests a remarkable added benefit, reporting that patients who took aspirin regularly for a period of several years were 21 percent less likely decades later to die of solid tumor cancers, including cancers of the stomach, esophagus and lung.\n\u201cThere\u2019s been a lot of work over the years showing that certain compounds can increase the risk of cancer, but it\u2019s not been shown before that we can reduce the risk with something as simple as aspirin.\u201d\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story does not present alternative ways of reducing cancer risk. Some other news reports specifically noted that avoiding smoking and obesity are both known to reduce cancer risk.", "answer": 0}, {"article": "The CDC says the next step is to fully review all the data and begin to develop guidelines for the use of these drugs in heterosexual men and women here in the U.S.\nThe risk of infection was reduced 63% overall, but for participants who actually got the drugs, that risk decreased by 78%.\nThe study, called TDF2, followed 1,200 uninfected heterosexual men and women between the ages of 18 and 39 years in Botswana, Africa.\n\u201ciPrEx provided the first proof of an important new method of HIV prevention that can help slow the global toll of 2.6 million new HIV infections each year.\n\"It is clear we are not going to find one magic pill to solve the issue of HIV but by combining this approach with others we are beginning to get a better handle on combination packages.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions several other approaches that are effective for preventing HIV transmission, including microbicides, vaginal gels, clean needles, medical male circumcision, early treatment, counseling, testing, condoms and suppressive therapy for pregnant women.", "answer": 1}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\nOAK BROOK, Ill. - An MRI breast imaging technique that requires no contrast agent, combined with sophisticated data analysis, could reduce the number of unnecessary breast biopsies, according to a new study appearing online in the journal Radiology.\nThe new approach is not intended to replace current contrast-enhanced breast MRI protocols in general, Dr. Bickelhaupt emphasized, but to expand the spectrum of options available for answering specific clinical questions.\n\"Diffusion kurtosis imaging has been introduced in DWI to provide important information on tissue structures at a microscopic level,\" said study lead author Sebastian Bickelhaupt, M.D., from the German Cancer Research Center in Heidelberg, Germany.\nShould the results hold in larger trials, the model has potential advantages in the clinic beyond its ability to reduce unnecessary biopsies in women with BI-RADS 4 lesions.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The lead researcher is quoted explaining that the new approach is not being presented as a substitute for current MRI protocols that use contrast imaging to detect malignancies. Diffusion kurtosis imaging simply adds to the spectrum of diagnostic tools. A statement detailing why the software algorithm might be superior to use of\u00a0gadolinium-based contrast agents that need to be injected intravenously would have made the comparison clearer.", "answer": 1}, {"article": "For more information, visit http://www.aaojournal.org.\n\u201cWhile we cannot totally avoid developing cataracts, we may be able to delay their onset and keep them from worsening significantly by eating a diet rich in vitamin C.\u201d \u201cGenetic and Dietary Factors Influencing the Progression of Nuclear Cataract,\u201d Yonova-Doing, et al.\nDespite the advent of modern cataract removal surgery, cataracts remain the leading cause of blindness globally.1 Researchers at King\u2019s College London looked at whether certain nutrients from food or supplements could help prevent cataract progression.\nAbout OphthalmologyOphthalmology, the official journal of the American Academy of Ophthalmology, publishes original, peer-reviewed, clinically-applicable research.\n\u201cThe most important finding was that vitamin C intake from food seemed to protect against cataract progression,\u201d said study author Christopher Hammond, M.D., FRCOphth, professor of ophthalmology at King\u2019s College London.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "In the study (as opposed to the news release) the authors say that they \u201calso found dietary manganese to be protective against cross-sectional nuclear cataract independent of vitamin C,\u201d but found no association between dietary magnesium and nuclear cataract progression and the lack of a dose response.\u201d\nThat muddies the waters a bit, but would have been nice to include \u2014 if only to underscore the fact that much about science is not clear. And we never learn from the release that other interventions, like reducing cigarette smoking and ultraviolet light exposure, may prevent or delay the development of cataract, or that diabetes and overweight are risk factors, too. The study itself underscored these points.", "answer": 0}, {"article": "The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3, in combination with chemotherapy.\nIn the trial, patients who received Rydapt in combination with chemotherapy lived longer than patients who received chemotherapy alone, although a specific median survival rate could not be reliably estimated.\nIn addition, patients who received Rydapt in combination with chemotherapy in the trial went longer (median 8.2 months) without certain complications (failure to achieve complete remission within 60 days of starting treatment, progression of leukemia or death) than patients who received chemotherapy alone (median three months).\nPatients who experience signs or symptoms of lung damage (pulmonary toxicity) should stop using Rydapt.\nThe agency also is responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The new medication was used in combination with standard chemotherapy. That tells us the alternative was standard chemotherapy alone, an important comparison.", "answer": 1}, {"article": "MUSC operates a 700-bed medical center, which includes a nationally recognized children's hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), Hollings Cancer Center (a National Cancer Institute-designated center), Level I Trauma Center, Institute of Psychiatry, and the state's only transplant center.\nBecause evidence suggests that SUDs and PTSD share overlapping neurobiological pathways, Sudie E. Back, Ph.D., lead author on the article, hypothesized that NAC treatment with CBT would be a novel approach to treat co-occurring PTSD and SUD.\nN-acetylcysteine reduced PTSD symptoms, cravings, and depression in veterans with PTSD and substance use disorder in a randomized controlled pilot trial conducted at the Medical University of South Carolina and the Ralph H. Johnson VA Medical Center\n\nN-acetylcysteine, when combined with group cognitive behavioral therapy (CBT), reduced symptoms of posttraumatic stress disorder (PTSD), cravings, and depression significantly more than CBT alone in veterans with co-occurring PTSD and substance use disorder, a particularly difficult-to-treat population, according to the findings of a randomized controlled pilot trial conducted by researchers at the Medical University of South Carolina (MUSC) and the Ralph H. Johnson VA Medical Center.\nAlthough these early, promising findings show that NAC reduced PTSD symptoms, craving, and depression, NAC should not be used as a monotherapy or substitute for evidence-based behavioral treatment, but instead be seen as an adjunct therapy that enhances it.\n\"Addiction goes along with virtually every psychiatric disorder at a higher percentage than it does in the general population\" said Peter W. Kalivas, Ph.D. the senior author on the article and chair of the Department of Neuroscience at MUSC.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release mentions other treatments for PTSD (such as SSRI antidepressants) even though we don\u2019t learn how effective those treatments are compared to N-acetylcysteine. The lead researcher very helpfully mentions that the drug should not be used without cognitive behavioral therapy or other forms of psychological counseling.\nThe news release places the results of the study in a positive light noting, \u201cCurrently, there are no well-explored pharmacological treatments for patients with co-occurring PTSD/SUD. Although selective serotonin reuptake inhibitors have been approved by the FDA for treatment of PTSD, pharmacological treatments for co-occurring PTSD/SUD have yielded suboptimal results.\u201d\nWhile SSRI\u2019s have been the most studied to date, other drugs that have been studied in preliminary trials could have been mentioned, including prozosin, prazosin, guanfacine, atomoxetine, topiramate, memantine, acamprosate, and ketamine. A 2014 article in Addictive Behaviors journal describes some of these: \u201cPharmacological treatment of comorbid PTSD and substance use disorder: recent progress.\u201d (Addictive behaviors\u00a039.2 (2014): 428-433.)", "answer": 1}, {"article": "But she refused to discuss a timetable.\nThis summer, a critical review of existing research in BMJ, The British Medical Journal, \u201ccast doubt over the size of the effect of these medications\u201d for the general population, said Dr. Roger Harrison, an author of the paper, \u201cbut still suggested that they might benefit some people as a treatment.\u201d\n\nDr. Harrison said he believed that people should generally increase their intake of omega-3 acids, best done by eating more fish.\n\u201cIn other countries, uptake may be harder because doctors think of it as just a dietary intervention.\u201d\n\nIn the largest study of fish oil \u2014 conducted more than a decade ago \u2014 Italian researchers from the Gissi Group (Gruppo Italiano per lo Studio della Sopravvivenza nell\u2019Infarto), gave 11,000 patients one gram of prescription fish oil a day after heart attacks.\nThere was a great need, the authors concluded, to \u201cimprove awareness of this important advice.\u201d\n\nThe fact that fish oil is also sold as a nutritional supplement has made it harder for some doctors to regard it as a powerful drug, experts said.\nThe American College of Cardiology now advises patients with coronary artery disease to increase their consumption of omega-3 acids to one gram a day, but it does not specify if this should be achieved by eating fish or by taking capsules.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story made scanty reference to consumption of fish as a method of increasing omega-3 intake as well as the use of over-the-counter preparations of fish oil as means of increasing intake of omega-3 fatty acids. However. the story focused disproportionately on the fish oil product with FDA approval for one application. There was too much discussion of a single product, when many products exist. The story needed to give more information on diet and risks of mercury exposure.", "answer": 0}, {"article": "Guadecitabine works to reverse a so-called epigenetic change in cancer cells known as methylation, which may alter genetic activity in cells in a way that can block the action of tumor-suppressing genes, pushing cells to become cancerous and resistant to therapy.\nThe current study was based on previous studies in the laboratory of Nita Ahuja, M.D., director of the Sarcoma and Peritoneal Surface Malignancy Program and professor of surgery at the Johns Hopkins University School of Medicine, which showed that guadecitabine limited the growth of colorectal cancer cell lines when combined with irinotecan, says Azad.\nAlthough the study's main purpose was to test the safety rather than the effectiveness of guadecitabine doses, \"we were very happy to see some patients who benefited from the combination of the therapies for many months to more than a year,\" says Nilofer Azad, M.D., professor of oncology at the Johns Hopkins University School of Medicine.\n\"We did see that giving a higher dose of the drug seemed to produce a better methylation response among patients,\" says Valerie Lee, M.D., a fellow at the Johns Hopkins Kimmel Cancer Center.\nAmong the side effects of the combined treatment, 16 patients experienced neutropenia, a low count of the infection-fighting white blood cells called neutrophils; five patients with neutropenia had fevers; three patients became anemic; and two patients developed thrombocytopenia, a lowered count of blood-clotting platelets.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are a lot of drugs, and drug combinations, that are approved for use in colorectal cancer chemotherapy. Given that the release explicitly states that the study was not done to assess the potential benefits of guadecitabine, we don\u2019t expect it to compare the drug\u2019s performance to those other drugs.", "answer": 2}, {"article": "MARLBOROUGH, Mass., April 26, 2016 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced that study results published today in a research letter in JAMA conclude that breast tomosynthesis (Hologic's Genius\u2122 3D MAMMOGRAPHY\u2122) exams reduce recall rates, and increase invasive cancer detection in women with both dense and nondense breasts.\nThe Company's core business units focus on diagnostics, breast health, GYN surgical and skeletal health.\nThe latter two groups are considered dense; however, the vast majority of women whose mammograms are considered dense have heterogeneously dense breast tissue.\nIn addition, there can be no assurance that the systems will achieve any expected level of sales or market share.\nBreast cancer screening using tomosynthesis in combination with digital mammography.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The purpose of study compared\u00a0digital mammography alone with digital mammography with the addition of 3D mammography.", "answer": 1}, {"article": "Two new devices\u2014one that deflates fat cells, one that destroys them\u2014have just been cleared for \"body contouring\" in doctors' offices by the Food and Drug Administration.\n\nZeltiq grabs onto love handles and belly pouches and freezes the fat cells inside, causing them to self-destruct over several months. Zerona...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0There was no comparison of the circumference reduction obtained with the devices either to each other or to other protocols.", "answer": 0}, {"article": "Japanese drug regulators could approve the drug for use in Japan by early March, the Journal reported.\nThe drugmaker plans to apply for approval in the U.S. this summer; however, the drug likely wouldn't be available here until next year.\nIn a clinical trial, a single dose of the drug made by the pharmaceutical company eliminated the virus from people's bodies in a median time of 24 hours, The Wall Street Journal reported.\nA Japanese drug company is offering up a big claim: Shionogi & Co. says it has an experimental pill that can kill the flu virus within a single day, according to news reports.\nOnce inside a cell, it hijacks the cell's machinery, forcing the cell to make copies of the virus.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although, as noted above, the article compares the claims for the new drug to Tamiflu with respect to mode and speed of action, it doesn\u2019t mention vaccination or other symptomatic treatment, nor does it give any quantitative information that would enable accurate comparisons of cost, safety or effectiveness.", "answer": 0}, {"article": "Streicher, an associate professor of clinical obstetrics and gynecology at the Northwestern University Feinberg School of Medicine, said the study drew \"erroneous conclusions.\"\nAccording to the FDA, which looked at three clinical trials of Addyi that included about 2,400 women, about 10% more patients treated with Addyi reported meaningful improvements in satisfying sexual events, sexual desire, or reduced distress compared to women taking a placebo.\nDr. Lauren Streicher, medical director of the Center for Sexual Medicine at Northwestern Memorial Hospital in Chicago, said the results cited in the Dutch study are averages, and while Addyi doesn't work for everyone, many of her patients have benefited from it.\nThe International Society for the Study of Women's Sexual Health went even further, calling the study \"a great disservice to the millions of pre-menopausal women suffering from (hypoactive sexual desire disorder).\"\nThey said for women using the drug, the number of additional \"satisfying sexual events\" averaged out to about 0.5 per month.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The \u2018alternative\u2019 in the clinical studies was, presumably, a placebo, yet as some commentators have noted, the drug has never been tested against a more holistic approach that acknowledges the complexity of female sexuality and which address physical, psychological, and social factors.", "answer": 0}, {"article": "Strengthening gamma oscillations appeared to switch the microglia back into a productive state.\nEd Mann, an associate professor of neuroscience at the University of Oxford, said: \u201cI was surprised, and it\u2019s exciting, that such a simple stimulus can target a molecular pathway and have such an effect in an hour.\u201d\n\nQuestions remain, however, about whether boosting gamma oscillations and sweeping amyloid plaques out of the visual brain region would help with memory, which is centred in the hippocampus, or broader cognitive abilities.\nDavid Reynolds, chief scientific officer at Alzheimer\u2019s Research UK, said: \u201cIt is conceivable that changing brain cell rhythms could be a future target for therapies, but researchers will need to explore how light flickering approaches could not only reduce amyloid in the visual area of the brain but in those areas more commonly affected in Alzheimer\u2019s.\u201d\n\nThe authors suggest that it may be possible to take a multi-sensory approach, using a combination of flashing lights and vibrating chairs.\n\u201cIf humans behave similarly to mice in response to this treatment, I would say the potential is just enormous, because it\u2019s so non-invasive, and it\u2019s so accessible,\u201d said Li-Huei Tsai, director of the Picower Institute for Learning and Memory at MIT, and the paper\u2019s senior author.\nThe study, published on Wednesday in the journal Nature, hinges on the observation that Alzheimer\u2019s patients show a loss of synchronised brain activity, known as gamma oscillations, which is linked to attention and memory.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Overall, this story feels inappropriately weighted in several ways, and a lack of background information about the state of the science in treatment for Alzheimer\u2019s disease is one of them. The recently failed Eli Lilly trial is mentioned, but there\u2019s no explanation of other prevention and treatment approaches (some of which are based on an entirely different model of the disease) that are currently under investigation.\nThere\u2019s also no sense of just how little can be done for Alzheimer\u2019s patients at this point in time, nor indeed how devastating the condition is for victims and their families. That kind of information would have provided a much-needed context for the results of the study.", "answer": 0}, {"article": "\"The positive effects of bariatric surgery on health outcomes -- such as diabetes and cardiovascular disease -- are reasonably well-studied, but less is known about the effects on pregnancy and [post-delivery] outcomes,\" Johansson pointed out.\nWhile various techniques may be used, the surgery restricts the amount of food the stomach can hold and/or reduces the intestines' absorption of calories and nutrients from food.\nThe investigators didn't examine what might have caused smaller babies among bariatric surgery recipients, or higher stillbirths.\nHe also noted that some experts advise women who undergo weight-loss surgery before pregnancy to delay conceiving until 12 to 24 months after the procedure, the period when the most rapid weight loss occurs.\nBut Caughey, who wrote an editorial accompanying the new research, said women considering weight-loss surgery should make the decision based on the long-term health benefits of the procedure -- not on potential pregnancy-related benefits.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not mention alternative weight loss techniques (e.g. counseling on diet and exercise, medication, etc) for women prior to surgery, or the potential benefits for obese women of minimizing weight gain during pregnancy.", "answer": 0}, {"article": "Stanford\u2019s Department of Medicine also supported the work.\nThree of the 10 top-selling drugs in the United States in dollar sales \u2014 adalimumab, etanercept and infliximab \u2014 are biologics prescribed for psoriatic arthritis as well as for the more common rheumatoid arthritis.\nAlthough the ultimate cause of the disease remains unknown, there was a good clinical rationale for hoping it might be responsive to ixekizumab.\nFor example, psoriatic arthritis manifests most often in the lower extremities and is associated with the autoimmune skin condition called psoriasis, in which raised red, scaly patches appear on the skin.\nThe drug, an injectable monoclonal antibody, is already commercially available for the treatment of psoriasis, for which it has been remarkably effective, said Genovese.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There was a good explanation about the alternatives \u2014 drugs\u00a0like the TNF inhibitors already on the market such as adalimumab, etanercept and infliximab \u2014 but that\u00a0\u201conly about half of psoriatic arthritis patients who are given TNF inhibitors get better.\u201d We also learn that \u201canother approved monoclonal-antibody that targets IL-17, secukinumab, was approved in 2016 for psoriatic arthritis.\u201d", "answer": 1}, {"article": "The study appears in the September issue of the journal PLoS Medicine.\n\"It would certainly be premature to suggest taking statins to prevent rheumatoid arthritis ,\" he tells WebMD.\nThe analysis revealed that patients who took statins for at least eight years during the decade-long study period were roughly 40% less likely to develop rheumatoid arthritis than people who did not take statins at all or who took them less persistently.\nThere is also a suggestion that statins reduce systemic inflammation and may be protective against RA and other chronic inflammatory diseases.\nIn the newly published study, Chodick and colleagues examined data on 1.8 million members of Israel's Maccabi Healthcare Services HMO.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe story does not mention any alternative approaches to reducing the risk of rheumatoid arthritis. There are a number of risks factors associated with the development of rheumatoid arthritis. Of the four, only smoking is modifiable. The others are female gender (women get RA about twice as often as men), family history and age (most people with RA develop it between 40 and 50 years of age). A complete story would have provided a bit more background for the reader.", "answer": 0}, {"article": "\u201cThere\u2019s definitely a major need for a permanent, total artificial heart,\u201d Laman A.\nImplanted in the patient\u2019s chest after the diseased heart is removed, it uses information gleaned from sensors to mimic the activity of the natural organ.\nIt is operated by a microcontroller and powered by electromagnetic induction through the skin or through a plug implanted behind the patient\u2019s ear.\nThe device, made of both synthetic and animal tissue, is driven by two miniature electric motors.\nIts device, powered by a small air compressor that can be carried in a backpack, has been implanted in more than 800 patients as a bridge before transplant.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Barely satisfactory.\u00a0 No real comparison was made, but at least other devices that are approved or in development were noted. ", "answer": 1}, {"article": "This abstract can be found at sirmeeting.org.\nOne month later, researchers followed the progress of eight patients and found that GAE significantly decreased pain (-58 mm on the Visual Analog Scale), reduced stiffness and increased physical function (-36.3 on the Western Ontario and McMaster University Osteoarthritis Index).\nLOS ANGELES (March 19, 2018)--A nonsurgical treatment could improve quality of life for patients with knee pain due to osteoarthritis, according to new research presented today at the Society of Interventional Radiology's 2018 Annual Scientific Meeting.\n\"A majority of our patients with osteoarthritis of the knee saw significant pain reduction, not only just a few days after the procedure, but a month after as well, making this an accessible treatment for patients looking to improve their quality of life without surgery,\" said Sandeep Bagla, M.D., director of interventional radiology at the Vascular Institute of Virginia and lead author of the study.\nBut GAE provides another option for patients struggling with pain and may even allow patients to avoid the painful recovery of knee surgery and the need for the kind of opioid pain medications associated with the dangerous epidemic in the United States.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions medications and specifically opioids as one treatment for knee OA. According to the American Academy of Orthopaedic Surgeons, alternatives also include exercise, over-the-counter anti-inflammatory medications such as ibuprofen and naproxen sodium, and corticosteroid injections.", "answer": 1}, {"article": "Colitis, inflammation of the colon, is the second most common side effect from ICIs, occurring in up to 40 percent of patients, explained Wang.\n\u201cIf the patient is a good responder to immunotherapy, that means you\u2019ve taken their effective treatment away,\u201d said Wang.\nThe current data further suggests there is the potential for many molecular studies to better understand the role of the microbiome in driving ICI-colitis and immunotherapy response more broadly.\nAdditionally, distinct new populations of bacterial species were evident in these patients following FMT compared to pre-treatment samples, including several species known to be protective or reduce inflammation.\n\u201cThe resolution of colitis in these patients can be confirmed clinically and endoscopically after FMT treatment,\u201d said Wang.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The text explains that traditional treatment of severe gastrointestinal symptoms involves steroids and drugs that may suppress the efficacy of immunotherapy and suppress an individual\u2019s immune system, while generating their own unpleasant side effects.", "answer": 1}, {"article": "A rare malignancy known as squamous cell carcinoma of the anal canal (SCCA) is on the increase, and now researchers have reported results of the first-ever phase II clinical trial results for treatment with the immunotherapy drug nivolumab.\nThe phase II study, for which findings are being presented at this week's American Association for Cancer Research's annual meeting in New Orleans, was designed and led by researchers at The University of Texas MD Anderson Cancer Center's Human Papillomavirus-Related (HPV) Cancers Moon Shot Program.\nStudy team members for the correlative analysis included Armeen Mahvash, M.D., Interventional Radiology; Luis Vence, Ph.D., Jorge Blando, D.V.M., and James Allison, Ph.D., all of Immunology; Robert Wolff, Cancer Medicine; Aki Ohinata, GI Medical Oncology; Chimela Ohaji, Investigational Cancer Therapeutics; and Padmanee Sharma, M.D., Ph.D., Genitourinary Medical Oncology.\nOf note, patients who scored as responders had higher frequency of CD8 T-cells and PD-L1 CD45 immune cells in pre-treatment samples.\n\"This study demonstrated responses in five of 18 patients treated at MD Anderson, and many of the patients had significant reductions in their tumor size.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Immunotherapy may offer a less toxic alternative to traditional chemotherapy, but there is no mention of that here. In fact, there is no attempt to describe the relative advantages and disadvantages of nivolmab versus the traditional treatment protocol. The release also neglects to mention that human papillomavirus (HPV) vaccine has been proven to prevent anal precancerous lesions and has the potential to make this tumor even more rare.", "answer": 0}, {"article": "Dr. Jae Jung, a dermatologist at City of Hope cancer center in Duarte, California, agreed.\nIt doesn't involve any high-priced new pharmaceuticals -- the key may be an over-the-counter vitamin supplement that costs less than $10 a month.\n\"It's safe, it's almost obscenely inexpensive, and it's already widely commercially available,\" Dr. Diona Damian, the senior author of the study and a professor of dermatology at the University of Sydney, told HealthDay.\nThe two most common forms of the disease, basal cell carcinoma and squamous cell carcinoma, can usually be treated successfully.\nFor the study, researchers in Australia looked at nearly 400 people who had had at least two non-melanoma skin cancers.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Tried-and-true skin cancer prevention methods \u2014 e.g. limiting exposure, using shade, and applying sunscreen \u2014 aren\u2019t mentioned. We\u2019re also told that basal and squamous skin cancers are typically treatable, but not how. It would have helped this article to mention cryogenic freezing, radiation, and surgical removal as ways to treat those cancers.", "answer": 0}, {"article": "Pancreatic cancer is currently very difficult to detect while it is still resectable.\n\"Our test can detect pancreatic cancer with 96% accuracy at stage I and II, while there is still the possibility of successful surgical intervention.\nSince the immune system is the first to respond to threats like complex diseases, such as cancer, autoimmune diseases and infections, the microarray was designed to mirror this early response.\nIn the future, the screening method could be used to screen people who are at a higher risk of developing pancreatic cancer, such as those with a hereditary risk, newly onset diabetes patients and patients with chronic inflammation of the pancreas.\nThere is currently no cure and few treatment options for advanced pancreatic cancer, which is the late stage when pancreatic cancer is usually diagnosed\", explains Carl Borrebaeck, professor at the department of Immunotechnology at Lund University.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release doesn\u2019t mention how pancreatic cancer is currently diagnosed \u2014 CT scan, biopsy, carbohydrate antigen (CA) 19-9\u00a0blood test that measures the CA 19-9 level in the blood \u2014 and how this test might compare.", "answer": 0}, {"article": "More About: The Study\n\nNathalie Scheers had looked at parvalbumin before in another context.\nParvalbumin is a cause of fish allergies, so we knew that it passed over to the blood, and that this form of parvalbumin is specific for fish\"\n\nShe joined forces with Pernilla Wittung-Stafshede, and together they took the idea forward.\nPernilla Wittung-Stafshede stresses the importance of finding ways to combat these neurological conditions in the future:\n\n\"These diseases come with age, and people are living longer and longer.\nWe already knew that they can meet in the gut, the blood, or the brain,\" explains Pernilla Wittung-Stafshede.\nParvalbumin effectively 'scavenges' the alpha-synuclein proteins, using them for its own purposes, thus preventing them from forming their own potentially harmful amyloids later on.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "No alternatives to preventing Parkinson\u2019s and other neurodegenerative diseases are mentioned. On the surface this omission may seem justified since there are none.\nBut perhaps it would help readers to tell them this up front. The following is our suggested wording:\n\u201cPlease note there are no interventions of any kind proven to prevent any neurodegenerative disease. Furthermore, no cause and effect relationship between amyloid (of any kind) and these diseases have ever been established. Finally, this is an in vitro study, so no conclusions regarding clinical efficacy in humans can be made.\u201d", "answer": 0}, {"article": "\u201cModels are models,\u201d Lin said.\nThe finding that assigned-to-screening men were no more likely to avoid death from prostate cancer might therefore have been because their screening behavior wasn\u2019t different enough from the \u201cunscreened\u201d (but in fact partly screened) men\u2019s, not because PSA screening doesn\u2019t save lives.\nIn April, however, the task force proposed instead that men aged 55 to 69 discuss PSA\u2019s pros and cons with their doctor and then decide what to do, factoring in that if 1,000 men get regular PSA screening for a decade it will save about one life.\nSome experts in cancer screening and statistics said its novel approach was \u201con shaky ground\u201d and used a \u201ccompletely unverifiable\u201d methodology that they had \u201cnever seen before,\u201d but others praised its \u201cintriguing and innovative approach.\u201d There was one area of agreement, however: \u201cI imagine it\u2019s going to generate some buzz,\u201d said biostatistician Ted Karrison of the University of Chicago.\nAmong other drawbacks, the tests lead to overdiagnosis (meaning a biopsy finds malignant cells but they are so innocuous they would never harm, let alone kill, the man) as well as incontinence and impotence from treatment (including of harmless cancers).\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This research is specifically about comparing the value of screening for prostate cancer vs not screening. New biomarkers and variations on the PSA test itself, along with other screening modalities, such as digital rectal exam, are not mentioned and were not addressed in the studies that are described.", "answer": 1}, {"article": "The petitioners filed the results of that study in October.\nIt all has to do with nixtamalization, the process by which tough corn kernels are softened by soaking in an alkaline solution, usually of slaked lime.\nThe rates are highest among Hispanics: Latina women are roughly 20 percent more likely to have a baby with a neural tube defect compared to non-Latina white women.\n\"The story of folic acid is one of the great public health stories of \u2014 ever,\" says Dr. R.J. Berry, who works with the Division of Birth Defects and Developmental Disabilities of the Centers for Disease Control and Prevention in Atlanta.\nInstead, they were consuming corn masa flour products, because that was the staple grain in that diet,\" says Cynthia Pellegrini, senior vice president of public policy and government affairs at the March of Dimes.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story never really discusses the alternative of taking vitamin supplements.\nStandard preventive advice for women of childbearing age who are considering pregnancy is to take a multivitamin in order to have enough folic acid for any future pregnancy. But this advice may be unheeded, vitamins may be too expensive, or pregnancy may be unintended.", "answer": 0}, {"article": "This is one of the first few studies that suggests a different mechanism.\nAs a result, doctors are looking for additional treatments to help these patients, referred to as \u201cnonresponders.\u201d\n\nModern antidepressants essentially work by building up concentrations of neurotransmitters, which amplifies their effect on the brain.\n\u201cIt provides clues to new treatments, and it provides clues to understanding what causes depression as well as what goes on biochemically when people get better from depression.\u201d\n\nThe researchers studied the use of SAMe or a placebo in 73 adults with depression who were not responding to prescription antidepressant treatment.\nIt\u2019s a medication that works differently than everything else.\u201d\n\nThe study was funded by a grant from the National Institutes of Mental Health, but the SAMe pills and placebo pills were provided by the dietary supplement maker Pharmavite.\nThat\u2019s probably the best hypothesis.\u201d\n\nOther studies have suggested that SAMe can relieve symptoms of depression.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The piece tells us that more than half of patients with depression are nonresponders and doctors are looking for additional treatments to help them. But it doesn\u2019t tell us what is currently done to treat nonresponders, nor does it point out that we are unable to compare the results for adjunctive SAMe to those for other strategies \u2014 adjunctive or otherwise \u2014 for managing nonresponders.\u00a0When someone doesn\u2019t respond to an SSRI, as with the nonresponders in this study, are other SSRIs tried or other classes?\u00a0It goes to the preliminary nature of this evidence that is glossed over. Other options, indeed, include:\u00a0 changing antidepressants, adding an antidepressant or another psychotropic drug, adding psychotherapy, electroconvulsive therapy and the approved (but less supported by evidence) transcranial magnetic stimulation, and vagal nerve stimulation.\u00a0 None of these options is mentioned. ", "answer": 0}, {"article": "The Australian team believe theirs would be the first to detect melanoma.\nAntibodies \"are easily accessible in the blood, so it provides a fantastic test to identify an early-stage cancer,\" said project lead Professor Mel Ziman, leader of the university's Melanoma Research Group on Monday.\nDr. Jodie Moffat, head of early diagnosis at Cancer Research UK, agreed that a test which finds melanoma earlier could help reduce deaths from the disease, adding that \"melanoma can be more than skin deep, and it's much harder to treat when diagnosed at a late stage after it has spread.\"\nThe problem is particularly serious in Australia, where melanomas were the fourth most commonly diagnosed cancer in 2017 and cause about 1,700 deaths a year, according to the university.\nIn the study , published Tuesday in the journal Oncotarget, Ziman's team screened 245 blood samples from both melanoma patients and healthy volunteers.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job in providing the current diagnostic methods.\nThe story seemed to give mixed messages about the value of screening with the new blood test. An investigator is quoted as noting that\u00a0current methods of melanoma detection are expensive and invasive, involving a trip to a clinician, who must biopsy the lesion to discover whether it is cancerous. \u00a0Elsewhere, the release notes that you still need a biopsy to evaluate a positive blood test. \u00a0Clearly, a clinician visit and biopsy will always be required to diagnosis a cancer.\nAside from self-examination, having a clinician perform a skin exam during routine examinations is another alternative to the blood test\u2013but is not addressed in the story.", "answer": 1}, {"article": "It\u2019s easy to get into the habit of popping a pill to have a good night\u2019s sleep. Insomnia, which affects a third of adults, becomes more common as we age.\n\nBut as evidence has mounted about the risks of drugging the brain to induce or maintain slumber, more doctors are steering patients away from sleep aids, including over-the-counter medications, and are offering innovative behavioral-change solutions.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The primary focus of this story is explaining why cognitive behavioral therapy is the better alternative for treating insomnia due to the negative side effects of insomnia drugs. The story also includes a great deal of practical information about \u201csleep hygiene,\u201d as well.", "answer": 1}, {"article": "Dr. P. Murali Doraiswamy, a biological psychiatrist at Duke who had helped recruit patients for the study, called the results among \u201c the most highly anticipated data from the entire meeting.\u201d\n\nTo compare the scans with autopsy results, the company scanned the brains of 35 people in hospices who were expected to die within six months.\nIn 34 of the 35 patients, the PET scan, the pathologists\u2019 report and the computerized pathology report agreed.\nIn one patient who had Alzheimer\u2019s, the pathologist and the radiologist analyzing the scan did not see much plaque, but the computerized analysis of the scan and the two autopsy reports did.\nAlthough the scans looked promising, the companies needed to show that what they revealed was the same as what a pathologist would see on autopsy.\nSome had Alzheimer\u2019s and others did not.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0There was no discussion about other sorts of approaches currently under study for early and accurate identification of Alzheimer\u2019s disease.", "answer": 0}, {"article": "Lona Sandon, a registered dietitian and assistant professor of clinical nutrition at the University of Texas Southwestern Medical Center at Dallas, agreed.\n\"The question was to see if more weight loss could be achieved if we provided decent quality lifestyle intervention, mostly dietary counseling, along with this medication,\" said study lead author Dr. Kishore Gadde, director of the Obesity Clinical Trials Program at Duke University Medical Center in Durham, N.C.\n\n\"And the answer was yes,\" Gadde said.\n\"The important thing to keep in mind is that although we diagnose obesity on the basis of a mathematical formula -- a BMI of 30 and up -- the basis for obesity may differ from one individual to another.\"\nMONDAY, Oct. 15, 2012 (HealthDay News) -- A prescription medication originally developed to treat epilepsy may help obese adults shed weight when combined with routine nutritional counseling, researchers say.\n\"But for about a third [of patients], biological issues are at play, such as not easily experiencing satiety signals from the gut to the brain, which senses what your energy intake has been,\" he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention the other drugs offered to treat obesity, but it does not make a clear comparison. It says, \u201cJust a few prescription medications are approved in the United States for long-term treatment of obesity, including orlistat (brand name Xenical) and lorcaserin hydrochloride (Belviq).\u201d It does, though, explain how the drug stacked up against diet alone, saying, \u201cPatients who took 400 milligrams of the anti-seizure drug zonisamide daily for a year lost nearly 7.5 pounds more on average than those assigned to dietary and lifestyle changes alone, the new study found.\u201d\nThe story could have discussed costs and compared side effects and weight loss to the other two drugs. It wouldn\u2019t take much time, space, or words to do so.", "answer": 0}, {"article": "The syndrome is present when someone has three of those five risk factors.\nAside from helping to prevent the metabolic syndrome\u2013 a cluster of risk factors for heart disease and diabetes- a new study in the Journal of the American College of Cardiology says, the diet can have positive global effects on the individual risk factors: low HDL (\"good\") cholesterol, high triglycerides, high blood pressure and a high blood sugar rate, as seen by your doctor through a blood test.\nBut it's not only in the U.S.\n\n\"This is a global epidemic,\" Eckel emphasized.\nIn addition, waist size is a risk factor- a waist more than 35 inches for women and 40 inches for men is of concern.\nFor children, the numbers are also sobering: 20 million kids under age 5 are overweight.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not include information about how this dietary approach to cardiovascular disease and diabetes risk management compared with the use of medication or other dietary approaches. Other studies have compared the Mediterranean diet with a lower carb diet and others, and looked at intermediate endpoints that go along with the metabolic syndrome. This could have been addressed easily in just another line or two.", "answer": 0}, {"article": "Also, can we distinguish autism from other forms of developmental delay?\"\n\"It is during the toddler/preschool years that autism typically presents and needs to be diagnosed,\" he explained.\n\"What we can measure are signals in the brain, in a specific language area, that are depressed in autistic children and normal in typical children,\" she said.\nTo further test this screening approach, another group of 27 autistic children, aged 5 to 17, underwent fMRI and the researchers were able to identify 26 of them as autistic.\nWhile the children were undergoing the fMRI, the researchers played recordings of their parents talking to them and watched for brain activity in areas of the brain responsible for hearing and understanding language.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not go into much detail about the alternatives to MRI\u00a0screening, but it does say that most chlidren are diagnosed by a clinician, not through any biological screening or brain scan.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a180226S32.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Story explains why researchers thought adding clopidogrel to aspirin might be helpful in a broader group of people.", "answer": 1}, {"article": "To find out more about the activities of EULAR, visit: http://www.\nFor further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR congress \n\nPress Office in Room 5B of Fiera Roma during EULAR 2015 or on: \n\nEmail: eularpressoffice@cohnwolfe.com \n\nOnsite tel: +44 (0) 7738 890 799 / +44 (0) 20 7331 5442 \n\nTwitter: @EULAR_Press \n\nYoutube: Eular Pressoffice\n\nThe European League Against Rheumatism (EULAR) is an umbrella organisation which represents scientific societies, health professional associations and organisations for people with rheumatic diseases throughout Europe.\n\"The optimal management of RA involves achieving the lowest possible disease activity - ideally remission, and then maintaining this level of control,\" said lead author, Dr. James Galloway, Department of Rheumatology, King's College Hospital NHS Foundation Trust, UK.\nReducing the TNFi dose by two-thirds resulted in more flares (exacerbations of symptoms and signs) but these subsided when the higher dose of TNFi was restarted, and did not adversely affect subsequent progression of any disability.\nOver the course of the congress there will be some 300 oral and just under 2,000 poster abstract presentations, more than 150 sessions, 400 lectures, 40 poster tours and 350 invited speakers.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes that conventional synthetic disease-modifying anti-rheumatic drugs such as methotrexate can prevent joint damage and loss of function. It adds that biologic therapy \u2014 usually a tissue necrosis factor inhibitor \u2014 is reserved for those who either don\u2019t respond, or respond inadequately.", "answer": 1}, {"article": "The Claim: Red palm oil, a deep orange fat pressed from the palm tree fruit, is a superfood\u2014packed with healthy antioxidants and good for the heart, say companies who sell it.\n\nThe Verdict: The colorful oil is rich in tocotrienols, nutrients in the vitamin E family, and carotenoids, which the body converts into vitamin A. Several studies suggest possible benefits in stroke and liver disease from vitamin extracts made from the oil, but so far there isn\u2019t proof that consuming the oil can ward off disease, scientists say.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story does not provide detailed comparisons of red palm oil to other oils\u2026 or other ways of getting health benefits for the heart or other organs\u2026 there are some specifics about how various processing methods affect the oil and some brief references to other types of cooking oils. And again, the overall message is that there is not enough evidence to support claims that red palm oil has any special health benefits, which implies that it is not better than alternatives.", "answer": 1}, {"article": "When planning a day at the beach, should you add Polypodium leucotomos to your picnic basket? The company that sells the natural fern extract says a daily dose can help protect against sunburn, sun-related aging and even genetic mutations that cause skin cancer. Dermatologists say preliminary evidence suggests the extract does protect against the sun -- but don't throw away your sunscreen yet.\n\nEvery year, 36% of U.S. adults get at least one sunburn, according to the federal Centers for Disease Control and Prevention....", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story does mention the obvious alternative \u2013 sunscreen, it does not mention protective clothing, umbrellas, hats, or just staying out of the sun period.", "answer": 0}, {"article": "Despite popular lore, agency won't allow labels to say drink is good for consumers' hearts\n\nWASHINGTON - There is no credible scientific evidence that drinking green tea reduces the risk of heart disease, federal regulators said last week in rejecting a petition that sought to allow tea labels to make that claim.\nUnlike black and oolong tea, it is made from unfermented tea leaves.\nA health claim, in the language of the FDA, characterizes the relationship between a substance and a reduction in the risk of contracting a particular disease.\nThe Food and Drug Administration said it reviewed 105 articles and other publications submitted as part of the petition but could find no evidence to support claims of the beverage's health benefits.\nGreen tea is brewed from Camellia sinensis, also known as Thea sinensis.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no mention of lifestyle or dietary approaches or drugs for decreasing heart disease risk.", "answer": 0}, {"article": "(Reuters) - Details of a large heart safety study presented on Monday appear to give Merck and Co\u2019s diabetes drug Januvia a clean bill of health, possibly setting the stage for a return to sales growth for the drugmaker\u2019s biggest product.\nThe detailed results also showed no increase in hospitalization for heart failure, which had been a particular concern with DPP-4 inhibitors, the class to which Januvia belongs.\nThere were 228 such hospitalizations for Januvia and 229 in the placebo group, according to data also published in the New England Journal of Medicine.\nJanuvia, an oral medication known chemically as sitagliptin that helps lower blood sugar levels, had sales of about $4 billion in 2014, plus another $1.8 billion for the related combination product Janumet\n\nOn the study\u2019s main focus, after about three years 11.4 percent of Januvia patients had experienced cardiovascular death, non-fatal heart attack, non-fatal stroke or hospitalization for unstable angina versus 11.6 percent in the placebo group.\nThere was also no significant difference between Januvia and placebo in infections, cancer, kidney failure or severe hypoglycemia, which is dangerously low blood sugar, researchers reported.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not compare the drug to any alternatives, only to a placebo. It does not point out that the medications the subjects were already taking seemed to be just as effective without adding the new drug.", "answer": 0}, {"article": "Studies Say Meditation May Help\n\n\u201cThe main finding [of our research] is that, added on top of usual medical care, intervention with a mind-body technique \u2014 transcendental meditation \u2014 can have a major effect on cardiovascular events,\u201d says Robert Schneider, lead author on the study published in Circulation: Cardiovascular Quality and Outcomes and a professor at the Maharishi University of Management, an institution in Iowa that was founded by the creator of transcendental meditation.\nIn the past, these benefits have been hard to test scientifically, largely because study participants who volunteered for meditation programs may have been biased to see them succeed.\nBut while the magnitude of those results is remarkable, the study involved a relatively small number of participants, and did not reveal how meditation may be lowering heart disease risk.\nAnd while the participants in both groups exercised more and cut back on alcohol during the study, they did so at similar rates, making these changes unlikely to be responsible for the differences in health outcomes either.\nThe meditating group enjoyed an average drop of 4.9 mm Hg in systolic blood pressure compared to the control group and also reported less stress and less anger.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions \u201cheart-friendly diet and exercise\u201d and \u201cmedication\u201d as elements of cardiovascular care. We\u2019ll call it good enough.", "answer": 1}, {"article": "We can't find the page you're looking for. Try one of these options.\n\nAre you sure this is the right web address? Let us know.", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does not touch upon other hair loss therapies, including how they compare to the new cooling cap.\nTo treat hair loss doctors can recommend drugs, such as minoxidil (better known as Rogaine), which is an over-the-counter liquid or foam that patients can rub into their scalps to regrow hair and to prevent further hair loss. Physicians can also suggest hair transplant or restoration surgery to treat permanent hair loss.\nIn laser therapy, a low-level laser device is used to treat men and women with pattern baldness.\nIf patients don\u2019t respond to the above treatments, they can try wearing hairpieces and wigs, whose costs may be covered by insurance. It\u2019s also important to note that hair loss from chemotherapy is temporary for many women so more information about the duration of benefit may lead some women to conclude that short-term hair loss is an acceptable alternative.", "answer": 0}, {"article": "She cited a 2010 review estimating that 11 million to 12 million women a year will suffer from a UTI, accounting for 1.6 billion antibiotic prescriptions a year.\n\"It is the urine output which is of course the key factor leading to the effect seen in the study,\" said Wessells, chair of the department of urology at the University of Washington School of Medicine in Seattle.\nWhat's more, the amount of time that passed before a woman's next UTI and between recurrent infections was longer in the water group than in the control group.\nThe study, conducted in Bulgaria, involved 140 healthy premenopausal women who had at least three UTIs in the past year.\nWhether the advice would benefit women with normal urine output, however, is unclear, Wessells noted.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not discuss alternatives to drinking extra water but there may not be any. According to the National Institute of Diabetes and Digestive and Kidney Disease, \u201cExperts don\u2019t think eating, diet, and nutrition play a role in preventing or treating bladder infections.\u201d\nChanges in hygiene habits \u2014 such as emptying the bladder after sex \u2014 can reduce the frequency of UTIs.", "answer": 2}, {"article": "First published on September 5, 2007 at 12:00 am\nEven though they cost, on average, $1.5 million, the robot systems are gaining popularity.\nFinding satisfied patients is probably the easiest aspect of robotic surgery.\nMy hands and feet move in a way that's totally intuitive.\nInstead, he has used the machine to do hundreds of heart valve repairs.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article indicates that conventional bypass and stenting are alternatives to the robot-assisted surgery. ", "answer": 1}, {"article": "Bianchi said one study had estimated the blood test costs about 255 pounds in the UK (about $413), all included.\nSome European hospitals already rely on the method, called cell-free fetal DNA, although it\u2019s not available from doctors in the U.S.\n\n\u201cWhat they are finding in England is that many women are not going on to have the invasive tests,\u201d Bianchi told Reuters Health.\n\u201cRemember, gender is not a disease.\u201d\n\nThe test looks for small pieces of the male sex chromosome in the mother\u2019s blood, which would mean she is carrying a baby boy.\nIn those procedures, doctors either extract a small amount of the fluid that surrounds the fetus (amniocentesis) or they take a sample of the placenta (chorionic villus sampling).\nBecause such disorders mostly strike boys, knowing that the baby is a girl could spare the mother diagnostic procedures, such as amniocentesis, that carry a small risk of miscarriage.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story explains the existing alternatives \u2013 ultrasound and more invasive sampling methods. But it doesn\u2019t do as good a job as the competing NY Times story in describing other types of tests (urine tests) that have been developed.", "answer": 0}, {"article": "Bleier said the device, which consists of a lead wire and a neurostimulator the size of a stopwatch, is implanted on top of a buttock muscle. Patients don't feel it when they sit down and you can't see its imprint under a tight pair of pants. Patients can try the stimulation for two weeks with the pacemaker outside the body before deciding whether to have it implanted, an outpatient procedure. Medicare pays about $21,500 for the device and treatment.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story provided an overview (albeit sometimes brief) of dietary changes, Kegel exercises, biofeedback, surgery to repair the sphincter, Solesta and InterStim.\nOur non-journalist reviewer (HD) thought this should be graded unsatisfactory.\u00a0 He wrote: \u201cWhile the story did a reasonable job in providing the reader with treatment options, it really centered on a Medtronic device that is only useful in certain types of patients.\u00a0 There are other forms of the disorder and other more effective treatment options for select patients.\u00a0 Readers are provided with a limited view of the disorder and its many treatments.\u201d\nThe journalist reviewer (GS), while acknowledging that the discussion of treatment options was limited, still felt it was more inclusive than many such stories we review.\n\u00a0", "answer": 1}, {"article": "Several of Cook's co-researchers work for the company.\nThere are plenty of questions left, said Dr. Ashesh Mehta, director of epilepsy surgery at the North Shore-LIJ Comprehensive Epilepsy Care Center in Great Neck, N.Y.\n\n\"This study is an important first step,\" said Mehta, who was not involved in the research.\nThe prospect of being able to predict seizures is \"very exciting,\" he said, in part because it's the uncertainty of the disorder that can dim people's quality of life.\n\"We just wanted to see if this is feasible, and this study shows that it is,\" said lead researcher Dr. Mark Cook, of the University of Melbourne and St. Vincent's Hospital in Australia.\nTHURSDAY, May 2, 2013 (HealthDay News) -- An implanted device that monitors brain activity may offer a way to predict seizures in people with uncontrolled epilepsy, a small pilot study suggests.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We were pleased that the story briefly mentioned, \u201cEpilepsy is usually managed with medication, but for 30 percent to 40 percent of people with the condition, drugs don\u2019t keep seizures at bay. The new study included 15 people who were having at least two to 12 \u201cdisabling\u201d seizures a month that were resistant to drug therapy.\u201d But, we would have liked to have seen a comment or two about Vagal Nerve Stimulation (see http://www.epilepsy.com/epilepsy/vns ) as an additional piece of information.", "answer": 1}, {"article": "The medical approach to treating tonsil infections has evolved over recent decades.\nThe study results showed \"there may be new evidence that supports expanding the criteria and opening up the procedure to more individuals,\" said Dr. Alyssa Hackett, an otolaryngologist with the New York Eye and Ear Infirmary of Mount Sinai in New York City.\nThe researchers decided to review whether the throat infection guidelines are too stringent, ruling out patients who potentially could benefit but don't meet the high threshold of recurring infections, Chinnadurai said.\n\"Though a tonsillectomy is low-risk, it is not risk-free, and those risks need to be weighed against the benefits for each individual child,\" Chinnadurai said.\n\"In the right child with the right indications, these are really wonderful procedures that can be life-changing for both the child and the family,\" said Hackett, who wasn't involved with the new research.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is about a comparison between tonsillectomies and watchful waiting, the primary two alternatives in dealing with either recurrent sore throats and obstructive breathing.\nThe published studies note that watchful waiting includes antibiotic therapy.\u00a0 ", "answer": 1}, {"article": "This study will be presented at a medical conference.\nThe results showed that men who ate the most foods rich in flavonoids had a 35% lower risk of Parkinson\u2019s disease compared with those who ate the least.\nBut when researchers looked at specific sub-groups of flavonoids, they found both men and women who ate the most foods rich in anthocyanins, which are found primarily in berries and apples, had a 22% lower risk of Parkinson\u2019s disease compared to those who ate the least.\nA new study shows men who ate the most foods rich in a group of antioxidants known as flavonoids were 35% less likely to develop Parkinson\u2019s disease than those who ate the least.\nThe study doesn\u2019t prove that berries (or flavonoids in any other food) prevent Parkinson\u2019s disease.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There\u2019s not even a line about other research looking at other factors to lower Parkinson\u2019s risk.\u00a0 There\u2019s also no discussion of other research looking at potential benefits of flavonoids.", "answer": 0}, {"article": "In five weeks of trying the diet, Pelsser says, parents will know if their child is responding or not; if not, they can move on to other treatments.\nU.S. experts had some caveats, saying that the results of the study, which included 100 children, should be repeated in other populations to see if the findings hold up.\nThe diet studied, known as the restricted elimination diet (RED), can work, the researchers say, because they believe ADHD symptoms in some children might be affected by eating specific foods.\n''I am of the opinion that every child deserves this diagnostic intervention,\" researcher Lidy Pelsser, PhD, of the ADHD Research Centre in Eindhoven, the Netherlands, tells WebMD.\nIn the study, published in The Lancet, 78% of children who stuck with the diet did respond by having fewer symptoms.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned other therapies in passing. \u201cBesides dietary restriction, medication and behavior therapy are used to treat children with ADHD.\u201d But, given that existing therapies have been around for decades, we think the story does not meet our bar, which requires \u201csome assessment of their relative performance.\u201d", "answer": 0}, {"article": "Botox's manufacturer, Allergan, thinks those older studies are more credible.\nA big reason Botox and its cousins, such as Myobloc, were OK'd was that preclinical testing showed that after being injected, they did not travel along the body's highways\u2014nerve cells\u2014to the brain and spinal cord.\nThat stands in contrast to the findings of earlier studies, which suggested that the neurotoxin is completely broken down at the injection site into innocuous compounds and does not migrate beyond it\u2014or if it does, only into the bloodstream or lymph system.\nThe FDA didn't do much in response, but since then it has been getting new reports of serious adverse reactions in people receiving Botox, and launched a safety review.\nThe reason countless lab animals have given their lives during the testing of experimental drugs is to allow manufacturers and regulators to see that a compound might be toxic, even deadly, before millions of people use it.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story really did not provide much insight into the uses of this compound other than its use with wrinkles. It did not include any information about treatment options for wrinkle management or treatment options for the other conditions which botulinum toxin is used to treat.", "answer": 0}, {"article": "Tamoxifen, a generic drug, is already approved for reducing the risk of breast cancer.\nAs for the data on vaginal and vulvar cancer prevention, they came from combining data from three trials used to test the ability of the vaccine, Gardasil, made by Merck & Company, to prevent cervical cancer.\nWhile both drugs reduced cases of breast cancer by about half from what would have been expected for the women in the study, raloxifene caused fewer cases of blood clots, cataracts and uterine cancers, making it initially appear the winner.\nDr. Patricia A. Ganz of the University of California, Los Angeles, who presented the quality-of-life data here, said decisions should be made based on each woman's circumstances.\nThe editorial in the journal said the new data \"still may not be enough to convince primary care physicians to be more aggressive than they have been to date in breast cancer chemoprevention.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "It\u2019s not clear from the article whether women have other options for lowering breast cancer risk. Explaining how few options there are would have helped readers to understand why these findings are important. ", "answer": 0}, {"article": "MONDAY, June 27, 2011 (HealthDay News) -- Brilinta, an experimental anti-clotting medication currently awaiting U.S. Food and Drug Administration approval, performed better than the industry standard, Plavix, when used in tandem with low-dose aspirin, a new study finds.\nThe data and conclusions of the research should be viewed as preliminary until published in a peer-reviewed journal.\nThe findings were reported Monday in an American Heart Association online conference.\nHowever, patients who took Brilinta with higher doses of aspirin (more than 300 milligrams) had worse outcomes than those who took Plavix plus high-dose aspirin, the investigators reported.\nA study author agreed that for most patients, using the drug with a lower dose of aspirin is usually warranted.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The main PLATO study was a comparison of an experimental drug (ticagrelor) to an approved one (clopidogrel).", "answer": 1}, {"article": "It involves extracting white blood cells called T cells \u2014 the foot soldiers of the immune system \u2014 from a patient\u2019s blood, freezing them and sending them to Novartis\u2019s sprawling manufacturing plant in Morris Plains, N.J.\n\u201cThe efficacy takes care of itself, but safety takes a lot of attention.\u201d\n\nOne of the most common side effects is called cytokine release syndrome, which causes high fever and flulike symptoms that in some cases can be so dangerous that the patient ends up in intensive care.\n\u201cNobody was hoping for zero cancer.\u201d\n\nThe pioneering therapy administered to Ludwig and a few other adults at the University of Pennsylvania hospital paved the way for clinical trials with children.\n\u201cI said, \u2018Surely, this has been tried on kids somewhere else in the world,\u2019 \u201d recalled her father, Thomas Whitehead of Philipsburg, Pa. \u201cBut Steve said, \u2018Nope, some adults got it, but that was a different kind of leukemia.\u2019 \u201d\n\nAfter she received the therapy, Emily\u2019s fever soared, her blood pressure plummeted, and she ended up in a coma and on a ventilator for two weeks in the hospital\u2019s intensive care unit.\nThe CAR T-cell treatment, manufactured by the drug company Novartis, initially would be available only for the small number of children and young adults whose leukemia does not respond to standard care.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "First of all, the story makes clear that CAR T-cell treatment \u2014 if approved \u2014 would be available only to those for whom conventional treatments have not worked. That\u2019s a key point. Second, the story does articulate the difference between this form of immunotherapy (which is customized to the patient) and other immunotherapy techniques, which are so-called \u201ccheckpoint inhibitors\u201d and are not individualized. As mentioned earlier, we would have liked to have seen more data on the success rates of standard treatment vs these treatments.", "answer": 1}, {"article": "For the study, researchers looked at data on 27,347 women ages 50 to 79 who joined two WHI trials between 1993 and 1998 and were followed through 2014.\nOne limitation of the study is that the WHI didn\u2019t look at different dosages of hormone pills, and the findings may be different for other dosages or different types of therapy such as gels or creams or skin patches.\nAs the ovaries curb production of the hormones estrogen and progesterone in the years leading up to menopause and afterward, women can experience symptoms ranging from irregular periods and vaginal dryness to mood swings and insomnia.\nWith additional years of follow-up, it also appears that the increased heart attack risk associated with HRT in the initial results from the WHI trials is limited to older women, McNeil added.\nAfter 18 years, including both the treatment period and a decade or more of follow-up, women\u2019s age when they joined the study no longer appeared to significantly influence death rates.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is about alternatives, on its face, about the alternative of taking or not taking hormone replacement therapy. We wish there had been a sentence or two more on how\u00a0other methods are available to women to ease symptoms.", "answer": 1}, {"article": "\"So many people say `how can cancer screening be harmful?'\n\"They're identifying a group of guys who don't need to be screened, or need to be screened less often,\" said Dr. Otis Brawley, the cancer society's chief medical officer.\nThe results are \"provocative,\" but this type of study can't prove that screening prevents deaths, said Dr. Matthew R. Smith of the Massachusetts General Hospital Cancer Center.\n\"The answer is, it could hurt a lot,\" said Dr. Allen Lichter, chief executive of the American Society of Clinical Oncology.\nBut HPV is \"the common cold\" of the nether regions \u2014 most sexually active young people have been exposed to it, said Debbie Saslow, the American Cancer Society's director of breast and gynecologic cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Alternative screening strategies for cervical cancer were discussed. \nThe option of not being screened for prostate cancer came through in this quote:\u201dThey\u2019re identifying a group of guys who don\u2019t need to be screened, or need to be screened less often,\u201d said Dr. Otis Brawley, the cancer society\u2019s chief medical officer.\nFor ovarian cancer the story emphasized that the study in question was \u201ca warning to people who get screening tests that aren\u2019t recommended, or who question whether screening can ever hurt.\u201d", "answer": 1}, {"article": "Participants who slept for six hours each night did only slightly better -- they were 4.2 times more likely to develop a cold than the seven-hour-a-night folks.\n\"Sleep is part of our own nature's defense against illness,\" says Dr. M. Safwan Badr, former president of the American Academy of Sleep Medicine and chief of the division of pulmonary, critical care and sleep medicine at Wayne State University School of Medicine in Detroit.\nThe study provides more evidence of the link between healthy sleeping habits \u2014 which experts say means at least seven hours of sleep each night \u2014 and overall good health.\n\"It's almost alarming how strong the effects are,\" says Aric Prather, an assistant professor in the department of psychiatry at the University of California, San Francisco and lead author of the study, published Monday in the journal Sleep.\nTo conduct the study, the researchers asked 164 healthy participants with an average age of 30 to wear a wrist actigraph \u2014 a device that monitors sleep \u2014 for one week to establish their baseline sleep habits.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not provide any meaningful discussion of possible alternatives to reducing colds such as frequent hand-washing. As noted above, the benefit of more sleep = less colds comes at a cost of having less awake time to do things. Some people might be better off having more colds! That makes alternatives potentially important.", "answer": 0}, {"article": "This randomised trial (phase 2a) recruited 28 patients with Dupuytren's disease who were scheduled to have surgery in Edinburgh to remove diseased tissue in their hand.\nThe researchers are continuing to investigate the use of this drug to treat Dupuytren's disease in a phase 2b trial called the RIDD trial, which is currently running in Oxford and Edinburgh.\nThere is currently no NICE approved treatment for early disease and typically people are told to return to their GP once their fingers become so bent that their hand function is impaired.\n\"We are delighted to have received further funding from the Wellcome Trust and Department of Health to test whether adalimumab will work for patients with early stage Dupuytren's disease,\" said Professor Sir Marc Feldmann, co-author and former director of the Kennedy Institute.\n\"Our data have shown that a concentrated formulation of adalimumab injected directly into the diseased tissue may be effective in targeting the cells responsible for Dupuytren's disease,\" said Jagdeep Nanchahal, MD, PhD, University of Oxford Professor of Hand, Plastic and Reconstructive Surgery, who led the study.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Surgery is the only other therapy mentioned in this news release.\nIt does not mention two other common treatments: needling and enzyme injections (physical and chemical attempts to break up contractures, respectively).", "answer": 0}, {"article": "He is a neuroscientist at the University of South Florida's College of Pharmacy and Byrd Alzheimer's Institute in Tampa.\nIn the study, blood levels of caffeine were more than 50% lower among people with MCI who developed Alzheimer's during follow-up, when compared with their counterparts who did not worsen.\nThere may even be a reason to start for people in their late 30s and up, he says.\nJune 7, 2012 -- Drinking three cups of coffee per day may help turn the tide against Alzheimer's disease among older adults who are already showing signs of memory problems, a new study shows.\nAccording to the findings, people older than 65 who had higher blood levels of caffeine developed Alzheimer's disease two to four years later than their counterparts with lower caffeine levels.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There aren\u2019t any proven strategies to reduce Alzheimer\u2019s risk. However, there are a number of lifestyle factors \u2014 exercise, healthy diet, etc.\u2013 that have at least as much evidence to support them as coffee. The story could have mentioned these.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2009/11/02/financial/f035110S68.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story compared boceprevir with another investigational drug called telaprevir. A discussion of other treatments for hepatitis C is not warranted given that this subset of patients did not respond to the standard drug therapies. However, the story failed to make it clear that boceprevir is used in conjuction with two standard drugs. ", "answer": 1}, {"article": "WEDNESDAY, May 11, 2011 (HealthDay News) -- It may be possible to assess a man's fertility by checking his \"anogenital distance,\" the gap between his scrotum and anus, a new study suggests.\nThey measured the scrotum-anus distance as well as the penis length of 117 infertile and 56 fertile men visiting an andrology clinic.\nOne expert who's done her own research in this area applauded the study.\n\"First, this could represent a noninvasive way to test testicular function and reproductive potential in adult men,\" he said in a Baylor news release.\n\"And second, it suggests that gestational exposures and development may impact adult testicular function.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No comparison is made with any other method of testing testicular function or reproductive potential in adult men.", "answer": 0}, {"article": "But that may be changing.\n\"You need to be monitored by your surgeon during that period of time.\u201d\n\nOne downside: the implants aren\u2019t covered by insurance or Medicare, says Hamilton, adding \u201cthe cost is around $4,000 to $5,000.\u201d\n\nThere are other risks with the procedure, but they are rare, according to clinical trials.\nIt\u2019s functioning in your day-to-day life.\u201d\n\nEkstadt has the privilege of being the first person in the nation to get the Raindrop outside of a clinical trial.\n\u201cAnd an infection in the cornea can cause scarring that can affect your vision.\u201d\n\nHamilton suggests that people wanting to have an implant find an experienced eye surgeon, one who does both cataract surgery and refractive surgery, which includes LASIK.\n\u201cSo the other eye needs to have good distance vision without glasses,\u201d Hamilton says, adding that sometimes people have laser surgery to improve the distance vision in the eye that won\u2019t be getting an implant to improve vision close-up.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We weren\u2019t satisfied with the story weighing the risks vs. benefits of these two surgical implants, Raindrop and KAMRA. The story did not compare the two of them to give people any idea of how they differ. Many patients who are candidates for vision correction for near vision may use glasses to correct it. The implant surgery carries risks, which include worsening vision, according to an FDA announcement\u00a0on the Raindrop device.", "answer": 0}, {"article": "Featherstone came up with a comprehensive way of measuring a person's risk for caries, or tooth decay.\nIf you pay out of pocket, a varnish treatment costs from $23 to $55, compared with a filling, which ranges from $86 to $606, according to the American Dental Association.\nAt this point, Featherstone says, two-thirds of dental schools in the U.S. teach some kind of disease management model based on a thorough risk assessment.\nIt includes testing the level of bacteria in the mouth, and looking at dietary habits, medical conditions, medications, saliva flow and history of tooth decay.\nBut if you catch decay early, Featherstone says, it can be reversed using fluoride treatments like varnish and concentrated toothpaste and gels.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not quantify the benefits of these new preventive treatments, or similar approaches, so it fails to give readers a useful comparison with standard dental care or advice for most adults\u2013such as\u00a0fluoride toothpastes, community water fluoridation, flossing, and mouthwashes.", "answer": 0}, {"article": "Devenish manufactures pre-mix and special feed for pigs, poultry, cattle, sheep, equine, game, companion animals and aquaculture.\nThe study showed that consuming omega-3 enriched chicken and eggs resulted in a halving of the number of subjects with such a high-risk omega-3 Index.\n\"International guidelines recommend eating oily fish at least once per week, however, many people do not eat fish at all and less than 20% of the world's population have optimal omega-3 PUFA levels.\n\"Omega-3 enriched chicken and eggs offer consumers an attractive alternative to eating oily fish or to the lifelong taking of supplements, with the potential for substantial health benefits,\" Professor Stanton said.\nThe 161 subjects involved in the study consumed at least three portions of chicken and eggs per week, that were naturally enriched with omega-3 Polyunsaturated Fatty Acids (PUFA), the same nutrients found in oily fish.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "We\u2019ll give this category a Satisfactory since the alternative to this new, supposedly enhanced feed is regular chicken feed now on the market.\u00a0 The story also mentions that the primary source of omega-3 fatty acids is oily fish and/or dietary supplements.", "answer": 1}, {"article": "In the Atlas trial, it appears that roughly 40 percent of the patients assigned to take tamoxifen for the additional five years stopped prematurely.\nOther doctors were not so sure.\nThere was virtually no difference in death and recurrence between the two groups during the five years of extra tamoxifen.\nThey came from about three dozen countries.\n\u201cIf it can keep the cancer away, I\u2019m all for it,\u201d said Ms. Behrend, 39, a single mother in Tomball, Tex.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This comparison was brief but adequate.", "answer": 1}, {"article": "Bardwell hasn't worked since November because his condition, inherited, makes breathing so difficult.\nThe hope is that such stimulation will modulate nervous system responses, such as toning down the release of hormones that typically occur at times of stress and increasing the flow of blood.\n\"Despite the development of drugs that treat heart failure, patients continue to deteriorate,\" said Dr. Guillermo Torre-Amione, a Methodist heart failure specialist and leader of the effort.\nNew pathway to the heart\n\nElectrical stimulation of the spinal column may ease cardiac problems without drugs\n\nIn a possible new way to treat heart failure, Houston surgeons implanted a device and wire in a Pearland man Monday that will electrically stimulate portions of his spinal cord.\nThere is considerable data showing connections between the brain, nervous system and heart, said Torre, but until now, no one has attempted to take advantage of the relationship therapeutically.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says heart failure\u00a0is currently treated by oral medications, almost all of which lower blood pressure, and it adds that Mr. Bardwell is on the heart transplant list \u2014 another option for advanced heart failure patients. It could\u00a0have mentioned the availability of the left ventricular assist device, or LVAD, which also can play a role.", "answer": 1}, {"article": "For the study, the researchers followed 57,872 women in B.C.\nThe study, published today in the British Medical Journal Open, found that low-income pregnant women who receive care from a midwife compared to a physician are less likely to go into early labour, to have a baby with a low birth weight, or to have a small-for-gestational age birth, meaning a fetus or infant that is smaller or less developed than normal for the number of weeks in pregnancy.\nMidwives, general practitioners (GPs) and obstetricians (OBs) are all qualified to provide safe prenatal care for women during their pregnancy, labour and birth, but each offer a different style of care that matches different women's preferences and needs.\nAfter controlling for differences such as age, previous pregnancies, where they lived and pre-existing medical conditions, the researchers found that low-income women who were receiving prenatal care from a midwife had 29 per cent lower odds of a small-for-gestational age birth compared to women who received care from a GP.\nMcRae said the findings add new evidence in support of midwifery care, and support the development of policies to ensure midwives are available and accessible, especially for low-income women.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release met our threshold here by saying midwives, general practitioners, and obstetricians \u201care all qualified to provide safe prenatal care for women during their pregnancy, labour and birth, but each offer a different style of care that matches different women\u2019s preferences and needs.\u201d", "answer": 1}, {"article": "The benefits were still seen after a year.\n\"Both acupuncture and traditional medicine have a place in treating fibromyalgia,\" said Dr. Alexander Rances, an acupuncturist, pain management specialist and attending physician at North Shore University Hospital in Manhasset, N.Y.\n\n\"A combination of Western as well as traditional Chinese medicine probably offers these patients the best possible therapy,\" he said.\nFibromyalgia treatment usually starts with medications such as the nerve pain medication Lyrica (pregabalin), and if that fails or is only partly effective, doctors might add acupuncture to the mix, Rances said.\nAccording to the study authors, nine out of 10 patients try some form of alternative therapy, such as massage or acupuncture, in addition to their regular pain medication.\n\"Individualized acupuncture is a safe and good therapeutic option for the treatment of patients with fibromyalgia,\" said lead researcher Dr. Jorge Vas, of the pain treatment unit at Dona Mercedes Primary Health Center in Seville, Spain.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Acupuncture is considered to be an alternative, or complement, to traditional western medicine. The story mentions that most fibromyalgia patients take medications for pain, depression,\u00a0and other symptoms, and that they may also receive other alternative therapies, such as massage.", "answer": 1}, {"article": "Botox is now being used by men, some of whom did not even run for President. The number of men in the U.S. who paid to get a series of tiny injections in their face nearly tripled from 2001 to 2007--to 300,000, or about 7% of the total Botoxed population. And despite the recession, those numbers aren't going down yet; one of the many things the laid-off cannot afford is to look their age.\n\nMen usually get Botox to remove those two vertical lines between their eyebrows that make them look angry and confused and thus, one could argue, masculine. They...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Well, the story does mention that an alternative to Botox, a product called Reloxin, may be approved by the FDA soon. \nThe story implies that getting no treatment for wrinkles is a reasonable alternative.\u00a0 \nIt would have been useful, however, to hear about other cosmetic treatments\u2013fillers, laser treatments, creams, and so on\u2013that are used on wrinkles, whether they are shown to \"work\" or not.\u00a0 ", "answer": 1}, {"article": "\"I\u2019m hoping this will help the women who need it.\u2019\u2019\n\nOne expert, Andrew Goldstein who runs the Sexual Wellness Center in Annapolis, Md., described a \"huge\u2019\u2019 unmet need for a medical treatment.\nThe drug, which is being developed by the giant German drug maker Boehringer Ingelheim, could become the first treatment approved by U.S. regulators for women who suffer from hypoactive sexual desire disorder.\nThe issue of a woman\u2019s libido is more complicated than the dysfunction treated by the well-known little blue pill, according to women\u2019s sexual health experts.\n\"To the extent that the drug may act as an incentive to bring the subject up, that will be a good opportunity,\u2019\u2019 he said.\n\"There\u2019s a huge economic cost to divorce, and this is often cited as one of the main reasons for a divorce,\u2019\u2019 Goldstein said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story correctly indicates that there are no drugs currently approved to to treat acquired hypoactive sexual desire disorder in pre-menopausal women.\u00a0 The story does acknowledge that hyposexual desire disorder is multi-factorial and that a drug would not\u00a0address other\u00a0contributing factors.\u00a0", "answer": 1}, {"article": "For more information, visit www.idri.org.\n\"While previous attempts have used vaccines primarily developed for other diseases, this is the first totally defined vaccine candidate developed specifically for leprosy, using the latest technologies and offering no less than those exposed to leprosy deserve,\" said Steven Reed, Ph.D., IDRI President, CEO & Founder.\n\"We are thrilled that after 15 years and an investment of over $5.1 million, made possible by our faithful donors and partners, a leprosy-specific vaccine is beginning a Phase I clinical trial,\" says Bill Simmons, President and CEO of American Leprosy Missions.\nIn addition to IDRI and American Leprosy Missions, a variety of partners are taking part in efforts to eliminate leprosy, including Novartis and the Novartis Foundation.\n\"We believe this may be the most exciting breakthrough in leprosy treatment since multi-drug therapy, the current treatment for leprosy, was launched in the 1980s.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release states that there are no other leprosy vaccine candidates, despite the fact that multiple countries (including India and Brazil) already use a leprosy vaccine (though the effectiveness of that vaccine is widely debated). The release would have been stronger if it had noted this vaccine and articulated how LepVax aims to improve on it.\nThe release notes that drug therapies do exist for leprosy, though it focuses on the drawbacks associated with treatment rather than the extent to which the treatment is effective. The release also refers to \u201cprevious attempts\u201d \u2014 presumably at developing a vaccine \u2014 \u201cthat have used vaccines primarily developed for other diseases.\u201d But it doesn\u2019t discuss how effective these \u201cprevious attempts\u201d have been. For example, a 1996 paper in The Lancet reported that a modified vaccination regime involving the so-called BCG vaccine, which is also used to vaccinate against tuberculosis, gave at least 50 percent protection against leprosy.\nPresumably the goal of LepVax is to improve the efficacy of leprosy vaccination, but the release would have been stronger if it had addressed this and provided the relevant context. Again, the idea that it increased humoral and cellular responses to those already exposed requires further explanation (this was noted in the description on clinical trials.gov).", "answer": 0}, {"article": "Migraines are throbbing, one-sided headaches that can be accompanied by nausea as well as sensitivity to light, sound, smell, and movement.\nAnd while Botox seemed to decrease my migraines by one or two per month, it wasn't enough to bother fighting about it with a new insurance company.\n\"There's a big hole to fill, both in prevention and acute therapies,\" says Alexander Mauskop, director of the New York Headache Center in New York City.\nAccording to one recent survey by the Centers for Disease Control and Prevention, about 10 percent of men and 20 percent of women in the U.S. reported having had a migraine in the last three months.\nNot only do these bypass the liver to block CGRP, but one injection appears to be effective for up to three months with almost no noticeable side effects.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story gives plenty of details:\nA number of people prescribed medications for depression, high blood pressure and epilepsy discovered migraine relief, too. Now, many of those drugs, including propranolol and topiramate, have been tested and approved for migraine. But no one drug works for everyone, and side effects can prove intolerable or downright unpleasant.\nThe writer also describes her own quest for relief:\nSince that day more than 17 years ago, I have tried six preventive prescription medications. Not one helped. I alternated among four different, neurologist-recommended supplements, all to no avail. I received bi-monthly injections of magnesium and participated in one of the first clinical trials of Botox. And while Botox seemed to decrease my migraines by one or two per month, it wasn\u2019t enough to bother fighting about it with a new insurance company. I exercised regularly. I experimented with an elimination diet that left me eating nothing but broccoli and white rice, but still the migraines came. I averaged about 15 to 20 each month.", "answer": 1}, {"article": "\u201cThe potential for a nutritional lifestyle intervention to counter obesity driven by high-carbohydrate food, though we don\u2019t know yet how significantly, is fascinating,\u201d Arciero says\u2014especially when it\u2019s as simple and delicious as reheating your pasta.\n\u201cCooking the carbohydrate starch alters the chemical bonds in the food,\u201d Arciero explains.\nThere, they\u2019re fermented and turned into short-chain fatty acids, which the body burns as energy.\nProducts made from these foods, including bean flour, potato starch, tapioca starch and brown rice flour, also count.\nThese kinds of carbs bypass the small intestine (where most food is digested) and head to the large intestine (also known as the colon) to be metabolized.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions different types of carbs and lists a variety of foods that contain resistant starches.", "answer": 1}, {"article": "Bethany, who manages occupational therapists for a nursing-home chain, and Jay, a rural mail carrier, shuttled between the Twin Cities visiting their daughters.\nIt is also far from clear that such a personalized approach \u2014 possibly costing hundreds of thousands of dollars \u2014 is economically viable on a large scale or will produce the lasting remissions that everyone hopes to see.\n\u201cThen suddenly it\u2019s over.\u201d\n\nIf his daughter\u2019s cancer returns yet again, \u201cI have no idea what we\u2019ll do,\u201d Jay said.\n\u201cNo matter what you do, you feel like a bad mom.\u201d\n\nA year or so after treatment began, Ava relapsed.\nIt\u2019s too soon.\u201d\n\nScientists have wanted for decades to marshal the immune system to vanquish cancer, but their attempts have mostly been frustrated.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes a point of noting that, at present, CAR T-cell therapy is used only when all other courses of action \u2014 chemotherapy, bone marrow transplants, etc. \u2014 have failed.", "answer": 1}, {"article": "Oct. 28, 2010 -- A University of Manchester, England, engineering professor has invented a portable breast scanner that could lead to more accurate tests for younger women without the need for X-rays.\nWhile mammography works on breast density, radiofrequency looks at contrasts between normal and diseased breast tissues.\nThe breast is placed in a scanner cup and an image appears on screen.\nThis group, the team says, accounts for 20% of all breast cancer cases.\nCosts are reduced and the electronics fit into a case the size of a lunchbox.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 0}, {"article": "The World Health Organization estimates that more than 300 million people suffer from clinical depression world-wide. But cost, time, stigma, distance to travel, language barriers and other factors prevent many from seeking help.\n\nNow, a growing group of health-care providers are betting that technology\u2014from web-based courses to mobile apps that send prompts via text\u2014can help bridge that gap.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The piece discusses several interventions, and offers a graphic representation of recovery rates for individuals in Great Britain across five therapeutic modalities. But, there is no mention of psychiatric medications. Since those are frequently helpful in short-term situations and at least for moderate depression, they should have been included in the comparisons.", "answer": 0}, {"article": "She said primary care physicians, gynecologists and women \u201cneed to be more aware that these tests exist.\u201d\n\nDr. Sandhya Pruthi, a breast cancer expert at the Mayo Clinic in Rochester, Minnesota, who counsels women with BRCA mutations, said the study adds more evidence that the surgery can help save lives, but the choice is never easy.\n\u201cAnd you can save the majority of women who would have died of their breast cancer,\u201d she added.\nThose with the BRCA1 mutation also have a 36 to 63 percent higher risk of ovarian cancer and those with the BRCA2 mutation have a 10 to 27 percent higher risk of ovarian cancer.\n\u201cIt\u2019s not a decision made on a single visit,\u201d she said.\nWomen with mutations in the BRCA1 or BRCA2 genes have a 56 to 84 percent higher risk of developing breast cancer during their lifetimes.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story does not discuss the alternatives available to women.", "answer": 0}, {"article": "For that reason, the finding that marijuana may actually help improve patients\u2019 sleep, she said, is \u201cparticularly noteworthy.\u201d\n\nThe cannabinoid family, which includes marijuana, is \u201cemerging as an interesting new class of drugs for pain management,\u201d Ware said.\nBut, \u201cwe also know that treating chronic pain of any kind requires more than just (drugs),\u201d he said.\nThe condition is treated with a range of different medications, including drugs usually intended for people with depression and epilepsy.\n\u201cThis offers another potential tool in the tool box for treating chronic neuropathic pain,\u201d Dr. Mark Ware, a neuroscientist at the McGill University Health Center in Montreal and the study\u2019s lead author, told Reuters Health.\nMost patients did not report feeling \u201chigh\u201d at any point during the study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story talks about a range of treatment options and even has the study\u2019s lead author suggesting, that \"these patients should also be getting behavioral and physical therapy.\"", "answer": 1}, {"article": "Cholesterol production by the tumour will not be the only reason why ER-positive breast cancers recur, but campaigners are excited by the possibilities for a treatment if further research corroborates these findings.\nThe scientists grew cancer cells in the lab in the absence of oestrogen and found they produced an alternative fuel, in the form of the cholesterol molecule.\nThis discovery may, in future, help reduce these concerns for some patients, by allowing doctors to test if their cancer is likely to return, and tailor treatment accordingly.\u201d\nFar too many women have to deal with the potentially devastating consequences of their breast cancer coming back and this research presents an important opportunity to improve the effectiveness of today\u2019s most commonly used treatments.\nThe scientists say the findings are boosted by two studies which found the over-activation of certain genes linked to cholesterol production were linked with a poorer response to the anti-cancer drugs.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Some discussion of other avenues of research into hormone therapy resistance would have been helpful, especially other therapies that are further along in human clinical trials.", "answer": 0}, {"article": "Building upon previous research, the study challenges the widely held belief that recovery from a TBI is limited to two years after an injury.\nThe findings, published in Brain and Behavior, further suggest that changes in cortical thickness and neural network connectivity may prove an effective way to quantitatively measure treatment efficacy, an ability that has not existed until now.\nA recent study from the Center for BrainHealth at The University of Texas at Dallas shows that a certain type of instructor-led brain training protocol can stimulate structural changes in the brain and neural connections even years after a traumatic brain injury (TBI).\nThese brain changes can interfere with brain network communication and the cognitive functions those networks support,\" said Dr. Kihwan Han, research scientist at the Center for BrainHealth and lead author of the study.\nPrevious studies have shown that cortical thickness and rsFC can be potential markers for training-induced brain changes.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release compares strategy-based training against knowledge-based training. But the release neglected to mention other approaches to treating TBI. Since the focus here is on cognitive impairments, the release might have mentioned some common treatments such cognitive behavior therapy and occupational therapy.", "answer": 1}, {"article": "Watch Sanjay Gupta MD Saturday at 4:30pm and Sunday at 7:30am ET.\n(CNN) -- Most heart attacks strike with no warning, but doctors now have a clearer picture than ever before of who is most likely to have one, says Dr. Arthur Agatston, a Miami cardiologist and author of the best-selling South Beach diet books.\nOne large federally funded study found the coronary calcium score a better predictor of coronary events like a heart attack than the traditional Framingham Risk Score, which considers age, cigarette smoking, blood pressure, total cholesterol and HDL, the \"good\" cholesterol.\n\"There is a large group in the middle called intermediate risk, which may be as much as 50% of the population,\" said Dr. Erin Michos, a cardiologist at the Ciccarone Center for the Prevention of Heart Disease at Johns Hopkins University\n\nA good candidate for a coronary calcium scan, she says, would be a 50-year-old man with slightly elevated cholesterol and a father who had a heart attack.\n\"Do you put this 50-year-old who has this family history on a statin medication with potential expense (and) side effects for the next four decades of his life, or do you further refine how far at risk he is?\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The premise of this story is that screening tests can make a dramatic difference in heart disease. In reality, the tests may offer an incremental improvement in predicting risk among certain people who fall into a gray middle zone of risk based on conventional methods. There is a reference to the use of these tests in people with intermedicate risk, but the broad claims at the beginning and end of this story overwhelm any reasonable comparison between the touted tests and established alternatives. The story mentions diet and lifestyle changes only in the context of a claim that these tests \u201cgive patients a chance to make major changes in their diet and lifestyle.\u201d The story fails to note that people routinely stick to bad habits even when told they have a high risk of health problems or that since improving diet and lifestyle has benefits for everyone, an alternative approach would be to focus more effort and attention on effective strategies for changing behavior.", "answer": 0}, {"article": "Scarmeas' previous research has shown that the Mediterranean diet may reduce the risk of Alzheimer's disease.\n\"We've got these diseases of aging that cause disability, cost a ton of money to treat and manage, and wreck people's lives,\" said Dr. Gregory Cole, a professor of medicine and neurology at the University of California, Los Angeles, who was not involved in this new study.\nKnown as brain infarcts, they're involved in vascular dementia, the second most common form of dementia, after Alzheimer's disease.\nIt is possible that the diet protects the brain vessels themselves, irrespective of other problems such as high blood pressure, Scarmeas said.\nFor example, other research has found that higher adherence to the diet seems to protect against hypertension, also associated with these brain problems.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story could have at least briefly mentioned other approaches to risk reduction.\u00a0 For example, control of hypertension and use of daily aspirin to reduce risk of vascular disease in the brain.\u00a0 It doesn\u2019t require many words in a story to put one area of research into context of other research in the field. ", "answer": 0}, {"article": "The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about diabetes medicines.\nShe noted that glitazones -- a separate class of newer drugs such as Rezulin, Avandia and Actos that also target insulin resistance -- have all shown initial promise in clinical trials before worrisome side effects began to surface in users (due to concerns around heart risks, Avandia remains on the U.S. market but under limited distribution).\nShe said that, \"though this study includes a small sample size followed for a short period of time, the results are promising in that TAK-875 appears to be effective for glycemic [blood sugar] control without significant risk for hypoglycemia or weight gain.\nDr. Minisha Sood, endocrinologist at Lenox Hill Hospital in New York City stressed that, \"given the rising global incidence of type 2 diabetes, the medical community is eagerly awaiting the development of novel agents to add to our existing armamentarium of anti-diabetic agents.\"\nSUNDAY, Feb. 26, 2012 (HealthDay News) -- An experimental drug improves patients' blood sugar control without increasing the risk of low blood sugar (hypoglycemia) in patients with type 2 diabetes, according to the results of a phase 2 clinical trial.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not directly compare alternatives, but it puts the experimental drug in the right context through comments from Dr. Loren Wissner Greene. \u201cShe noted that glitazones \u2014 a separate class of newer drugs such as Rezulin, Avandia and Actos that also target insulin resistance \u2014 have all shown initial promise in clinical trials before worrisome side effects began to surface in users (Avandia was recently withdrawn from the U.S. market due to heart risks).\u201d", "answer": 1}, {"article": "But widely prescribed sleep medications such as Ambien (zolpidem) and Lunesta (eszopiclone) can leave people feeling hung over and inattentive the next day.\nThe appeal of orexin antagonists, said Dr. Michael Thorpy, director of the Sleep-Wake Disorders Center at Montefiore Medical Center in New York City, is that they \"target a system that's more specific for sleep.\"\nThese new medications -- known as dual orexin receptor antagonists (DORA) -- target a more specific region of the brain than popular sleep drugs such as Ambien and Lunesta, promoting sleep without affecting learning and memory (also called \"cognition\"), according to the new research.\nLunesta and Ambien affect GABA receptors, which are found throughout the brain and are associated with side effects, including thinking disturbances, and deficits in attention and memory, explained Uslaner.\nThis area of the brain releases orexins during the day to keep us awake and lowers levels at night so we can sleep.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story focuses on the use of drugs to help people with sleep disorders.\u00a0 While popular, other approaches including cognitive behavioral therapy have been shown to be far more beneficial in the long run that simple drug therapy. And there is no mention of the many non-drug approaches to dealing with sleep problems.", "answer": 0}, {"article": "Doctors and patients\u2019 advocates urged women considering the procedure to go for counseling and take their time before making a decision, noting that other risk-reducing options were available, like tamoxifen therapy for estrogen receptor-positive breast cancer and the use of more sensitive magnetic resonance imaging screening for earlier detection.\n\u201cFewer women are having just one breast removed.\u201d\n\nYounger women, white women and women with a previous cancer diagnosis were more likely to opt for a contralateral prophylactic mastectomy, the study found, as were women who had lobular histology, meaning the cancer started in the lobules or milk-making glands of the breast.\nThough all women with breast cancer are at risk of developing a second cancer in the uninvolved breast, the risk is slightly greater with lobular histology, Dr. Tuttle said, and white women may be more likely to carry genetic mutations associated with an increased risk of developing cancer in the contralateral breast.\nThough the researchers had limited information about the patients, Dr. Tuttle suggested that younger women might be choosing the procedure because their cancers tended to be very aggressive, and they had more years ahead of them in which a second cancer might develop.\n\u201cFor the vast majority of our patients, this does not impact the chances of dying of breast cancer, and that\u2019s the key thing here,\u201d said Dr. Julie R. Gralow, the chairwoman of the communications committee of the American Society of Clinical Oncology and an associate professor of medical oncology at the University of Washington and the Fred Hutchinson Cancer Research Center in Seattle.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes surgical treatment options for women with early stage breast cancer. However, the story does not mention radiation with lumpectomy. Forgoing radiation due to preferences to avoid side effects\u00a0 may play into a woman\u2019s decision to undergo a mastectomy or bilateral mastectomy. The story cites breast cancer experts who note that there is little difference between these surgical treatments in terms of dying from breast cancer.\u00a0 The story lists other non-surgical options for prevention for women at high risk of developing breast cancer, or having a recurrence. The story also didn\u2019t mention that some reconstruction procedures (e.g. tram flaps) can only be done once, so women considering those may have double and do both at once. \n\n", "answer": 0}, {"article": "\u201cThe big questions we still haven\u2019t answered are precisely how it works and how it can be harnessed to treat disorders.\u201d\n\nRussell A. Barkley, a professor of psychiatry at the Medical University of South Carolina and a leading authority on attention problems, has long dismissed claims that neurofeedback can help.\nIn an interview in the summer, the study\u2019s director, Dr. L. Eugene Arnold, an emeritus professor of psychiatry at Ohio State, noted that there had been \u201cquite a bit of improvement\u201d in many of the children\u2019s behavior, as reported by parents and teachers.\n(He adds that his system, as distinct from \u201cclinical\u201d neurofeedback, aims not to change brain waves but rather to put the user in an \u201cattentive state\u201d that makes it easier to learn skills.)\nDr. Arnold said that if the results bore out that neurofeedback was making the difference, he would seek financing for a broader study, with as many as 100 subjects.\nThe findings prompted a boomlet of interest in which clinicians of varying degrees of respectability jumped into the field, making many unsupported claims about seeming miracle cures and tainting the treatment\u2019s reputation among academic experts.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story includes one comment refering to proven treatments, readers are short-changed by the lack of detail or any discussion of the weight of evidence backing alternatives as comapred to the vague and scarcely studied claims of benefit from neurofeedback.", "answer": 0}, {"article": "2008;1214:177-187.\n\"It's an important trial,\" says Dr. Steven Hirsh, director of clinical research for Life Extension in Fort Lauderdale, Fla. \"The findings are very noteworthy and support further study in randomized controlled trials with larger sample sizes and durations.\n\"We are excited that the benefits observed in the early pilot and preclinical research extended to this larger trial,\" says Luke G. Huber, ND, MBA, vice president of product innovation and scientific development at Life Extension.\nThe team of researchers, led by Dr. Rafael de la Torre, program director of IMIM Hospital del Mar Medical Research Institute and study co-principal investigator, and Dr. Mara Dierssen, group leader at Center for Genomic Regulation, Barcelona, Spain, and study co-principal investigator, proposed that EGCG might have conferred these benefits by inhibiting an enzyme called DYRK1A, which has been implicated in Down syndrome and neurodegenerative conditions including Alzheimer disease.\nIn acknowledging the novelty of their findings and calling for more research, the Spanish research team noted that \"\u2026this study is the first well-powered trial that shows improvement in adaptive behavior (functional academics) and brain-related changes in young adults with Down's syndrome.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Researchers point out in their journal article that there is no approved intervention to improve cognitive deficits in individuals with Down\u2019s syndrome. General treatment approaches include early intervention and educational, physical, speech-language, occupational and emotional/behavioral therapies, according to the National Institutes of Health. Regarding drugs and supplements, the agency adds, \u201cNo controlled clinical studies of these medications for Down syndrome have demonstrated their safety and efficacy, however.\u201d\nBut the release contains none of this context and makes no mention of potential treatment alternatives, which is why we rate it Not Satisfactory here.", "answer": 0}, {"article": "LONDON (Reuters) - Scientists have developed an eye implant that allowed three blind patients to see shapes and objects within days of treatment in a trial and say the device could become routine for some kinds of blindness in five years.\nThe implant device, which sits completely within the eye, is a tiny plate, measuring just 3 mm squared and a 10th of a millimeter thick, which has around 1,500 tiny light sensors connected to amplifiers and electrodes.\n\u201cTo go from being completely blind for many years, to being able to read a few letters and see shapes is an amazing step.\u201d\n\nRetinitis pigmentosa in a genetic eye condition that leads to blindness and affects about 1 in 4,000 people worldwide.\nThe device \u2014 known as a sub-retinal implant \u2014 sits underneath the retina and works by directly replacing light receptors that are lost as a result of the disease.\nOther types of retinal implants, known as epiretinal implants, sit outside the retina and because they bypass the intact light-sensitive structures in the eyes they require the patient to wear an external camera and processor unit.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that there are other implants, saying, \u201cOther types of retinal implants, known as epiretinal implants, sit outside the retina and because they bypass the intact light-sensitive structures in the eyes they require the patient to wear an external camera and processor unit.\u201d But that\u2019s not a true comparison, nor does it provide readers with the true picture of how much R&D is happening right now in this field. As is often the case in medicine, surgical options and devices are not the only solution. Lowly old Vitamin A is often the first step for treating retinitis pigmentosa.", "answer": 0}, {"article": "But for now this category is useful only to researchers.\nRather, the goal in creating this category is to see if scientists can define when the disease starts, and track it through biomarker tests, brain imaging, or other yet-to-be-invented tests.\nAlzheimer's Redefined, But Changes Mean Little For Patients\n\nThe definition of Alzheimer's disease just got wider and deeper, but the expansion won't change how the vast majority of people are diagnosed.\nAnd it does leave one wondering if a lot more worry will be generated by the notion of \"preclinical Alzheimer's,\" when science and medicine can't offer anything to ease those fears.\nThe guidelines say, for instance, that newly developed \"biomarker\" tests, such as assays for proteins in spinal fluid, and some specialized brain scans can be used for early diagnosis of Alzheimer's.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThis story gives readers a sense that putting off evaluation for signs of early Alzheimer\u2019s disease is a reasonable alternative, since not only are lab tests and brain scans not ready for regular clinical use, but there is limited value in getting a diagnosis since there are no treatments that can change the course of the disease.", "answer": 1}, {"article": "No significant side-effects remained after two years.\n\u201cThis is truly a huge leap forward.\u201d\n\nThe treatment, called vascular-targeted photodynamic therapy or VTP, was developed by scientists at the Weizmann Institute of Science in Israel in collaboration with the privately-owned STEBA Biotech.\nResults of a trial in 413 patients showed that the drug, which is activated with a laser to destroy tumor tissue in the prostate, was so effective that half the patients went into remission, compared with 13.5 percent in a control group.\n\u201cThe fact that the treatment was performed so successfully by non-specialist centers in various health systems is really remarkable,\u201d Emberton said.\n\u201cThese results are excellent news for men with early localized prostate cancer, offering a treatment that can kill cancer without removing or destroying the prostate,\u201d said Mark Emberton, a University College London consultant urologist who led the trial.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story addresses the current standard of care for low-risk prostate cancers, active surveillance, along with treatments for more aggressive disease. But as noted above, we don\u2019t think the description of active surveillance is accurate, the description of radical therapy is excessively gloomy, and the story doesn\u2019t warn that people treated with VTP will likely need to follow the same protocol involved with active surveillance. For these reasons we think the comparison is Not Satisfactory.", "answer": 0}, {"article": "Non-smokers without symptoms generally are not screened for lung cancer in the U.S.\nMost of the tumors found via CT scans were small, whereas those found through X-ray screening or in patients with symptoms were more often further advanced, according to the findings published in the journal Lung Cancer.\nWhile doctors ruled out cancer, those patients would have undergone further tests, sometimes including biopsies, which can cause complications including infection and bleeding.\nThere and in Canada, the lung cancer debate has centered around how often to screen smokers, and until what age screening should be done, Roberts said.\nAnd screening comes with an inherent risk of false-positives \u2014 scans which suggest a lung cancer that turns out not to be there.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The focus of the story was a comparison of lung CT versus x-rays or physician followup of patient symptoms.", "answer": 1}, {"article": "\"If you are a patient and someone says, 'There is an 85% chance of you spending $120,000 on a drug, and spending four months of your life being sick, with no benefit,' you're not going to be so excited.\"\nNone of the new drugs works for everyone.\nThe woman died a year later.\nA few years ago, that would have been a very short list.\nFor the first time, however, patients such as Herry have options.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The entire story was an overview of competing alternative therapies.", "answer": 1}, {"article": "Ankle replacement has been around for three decades, but it has been slow to catch on.\nStill, Dr. Deland said, \u201cwe\u2019re getting fewer and fewer failures.\u201d\n\nThe new models require that less bone be removed, so the bone to which the device is affixed is stronger.\n\u201cBut I can\u2019t tell you how many patients come in, and I mention this option they don\u2019t even know exists.\u201d (Dr. Radnay, who says he has performed more than 100 ankle replacements using an Inbone device from Wright Medical Group of Arlington, Tenn., is now a paid consultant to the company, helping to gather data on long-term success rates.)\nUntil lately, such patients have had only one surgical option: ankle fusion surgery, in which the worn-out part of the joint is removed and the bones are permanently locked together with screws and plates.\nThe bodies of many older Americans are practically bionic: more than 770,000 hip and knee replacements are performed each year in the United States.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This article correctly indicates that ankle fusion is the only surgical option to joint replacement.\u00a0 Many experts consider ankle fusion to be a highly successful procedure that relieves pain for many patients despite some loss ankle flexibility.\u00a0 A more detailed comparison of the procedures would have been informative to the readers. In addition, the story\u00a0should have indicated that non-surgical options such as medication, physical therapy and orthotics, are the more common treatment approaches.\n", "answer": 0}, {"article": "Back in April the WSJ wrote about the race to develop ways of detecting Alzheimer\u2019s disease using a brain scan. Currently only a post-mortem sampling of brain tissue can provide a definitive diagnosis. But the hope is that a technology that could be used in living patients could help rule out Alzheimer\u2019s in some patients and for those that have the disease, allow its \u2026", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0This story mentions that this compound is among a group of compounds being studied for their ability to accurately identify Alzheimer\u2019s disease prior to post mortem examination of the brain. \u00a0It is unfortunate that this story (not whatever was reported in April) failed to discuss how the compound in the study, florbetavir differs from the other compounds under study.\nBecause PET tracers must be produced in a cyclotron and used quickly. \u00a0This limits the use of PET scans to those center that have a cyclotron or are located near a commercial supplier. \u00a0Florbetavir has a longer interval that other tracers under study and may well be the most notable attribute of the drug.\nWe\u2019ll give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "WASHINGTON (Reuters) - Statin drugs may lower the risk of colon cancer by as much as 12 percent, U.S. researchers reported on Monday.\nStatins are not risk-free.\nSamadder\u2019s team did what is known as a meta-analysis, combining the findings of 22 scientific studies with more than 2.5 million volunteers.\nIn May, British researchers reported that patients taking them have a higher risks of liver dysfunction, kidney failure, muscle weakness and cataracts.\nThe longer people took the highly popular cholesterol-lowering pills, the lower their risk of later developing colon cancer, the researchers told a meeting of the American College of Gastroenterology.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0The story did not provide any information about other approaches to reducing risk of colon cancer. It would take a line to do so. ", "answer": 0}, {"article": "July 7, 2010 -- The FDA says it has approved the use of micro-sized implantable telescopes to improve vision in patients with end-stage, age-related macular degeneration.\nThe tiny device, called an Implantable Miniature Telescope (IMT), is designed to replace the natural lens.\nIt provides an image that has been magnified more than two times, the FDA says in a news release.\nIt damages the center of the retina, or macula, and results in a loss of vision in the center of the visual field.\nIt is designed to magnify and project images onto a healthy portion of the afflicted person's retina.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explained that \"Despite advancements in therapies for macular degeneration, \u2018retina specialists still did not have a treatment for the many wet and dry AMD patients who progressed to end-stage disease.\u2019 \"", "answer": 1}, {"article": "There are substantial risks.\nIn addition, the researchers are planning to try the approach on children with brain cancer, as well as other types of cancer, including melanoma and breast cancer.\nThe modified virus retains the ability to infect and kill brain tumor cells, and also appears to trigger the patient's own immune system cells to attack the tumors, the researchers say.\nThe scientists removed one of the virus's genes to prevent it from causing polio and replaced that gene with one from a harmless virus known as a rhinovirus, which ordinarily causes the common cold.\n\"Those that have survived more than two years are in remission, and we expect them to continue to be long-term survivors.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned standard treatment without getting specifics, and also mentioned plans to combine this treatment with chemotherapy and other drugs. It could have also mentioned other studies that are attempting to find a cure for glioblastoma.", "answer": 1}, {"article": "Lee is a professor of medicine and director of the electrophysiology laboratories and clinics at UCSF.\n\"Therefore,\" he said, \"we need to be extremely aggressive in treating atrial fibrillation patients with anticoagulants [blood thinners] when indicated.\nAlthough the study looked at patients taking warfarin (Coumadin), newer drugs -- including rivaroxaban (Xarelto) and apixaban (Eliquis) -- should reduce the risk of dementia even more, Bunch said.\nFRIDAY, May 12, 2017 (HealthDay News) -- Blood thinners are often prescribed to prevent strokes in people with the abnormal heart rhythm known as atrial fibrillation.\nThe researchers said that the key is to start blood thinners, such as warfarin, soon after atrial fibrillation is diagnosed.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions\u00a0use of aspirin and\u00a0notes that \u201caspirin\u2019s benefit in cutting the risk of dementia is limited.\u201d\nHowever, aspirin is not really recommended as an alternative to blood thinners (guidelines don\u2019t recommend this anymore, so we were\u00a0surprised to see it mentioned). But beyond this, there aren\u2019t any real alternatives.", "answer": 1}, {"article": "WEDNESDAY, Aug. 31, 2016 (HealthDay News) -- Weight-loss surgery helps people drop a significant amount of weight, and now a new study confirms that much of the weight appears to stay off for at least 10 years.\nThe average age of the men and women studied was about 52, and three-quarters were men.\nAnother possible limitation was the loss of patients during the follow-up, which could have affected the results, the researchers noted.\nThe new finding, he added, validates his belief that the gastric bypass could be a \"durable procedure.\"\n\"These results may not generalize to everyone,\" he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This is another strong point of the story. The study compared the longer term weight-loss outcomes of the three primary bariatric surgical procedures.", "answer": 1}, {"article": "I thought this is so minimal, it\u2019s stupid.\u201d\n\nAfter a few weeks, she said she began to feel better, and after 12 weeks \u201cthe pain had diminished 90 percent.\u201d She has continued tai chi, lost 50 pounds and can walk three to seven miles a day.\nBut not all of these reports have been conclusive, and tai chi is hard to study because there are many styles and approaches.\n\u201cThere was no joy to life,\u201d she said.\nIt\u2019s defined by what the patient tells you,\u201d he added.\n\u201cFibromyalgia is so common, and we have such a difficult time treating it effectively.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0The story talks about how the study compared different alternatives, and it mentions, at least in passing, several other therapies.", "answer": 1}, {"article": "\u201cOver the next couple of years, we will find out what it means.\u201d\n\nOn Oct. 23, 2008, Avid and two other companies, and , that are developing fluorine 18-based dyes for amyloid scans, got a pointed question from an advisory committee to the F.D.A.\nOther tests are being studied \u2014 ones that look for amyloid in cerebrospinal fluid that bathes the brain; scans that look for shrinkage of the brain in areas needed for memory and reasoning; PET scans that look for uptake of glucose, a cellular fuel, to show areas where the brain was active and where it was not.\n\u201cSomething bad happens, and now something good happens.\u201d\n\nLate last year, Avid saw the initial results of its hospice study \u2014 data from the first six patients.\nThe type of scans used in this study, PET scans, are expensive and patients have to go to a scanning center, get injected with a radioactive dye, wait for the dye to reach their brain and then have a scan.\nMost of the time, the scans were as expected \u2014 those with Alzheimer\u2019s had lots of plaque, those with normal memories had little if any and those with mild memory impairment were in between.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As mentioned above, there should have been some attempt here to explain why this scan would be better than a doctor talking with her patient. Nonetheless it does mention the existing diagnostic approaches along with the difficulties in making the diagnosis, so we\u2019ll give it the benefit of the doubt on this criterion.", "answer": 1}, {"article": "[Why it's so hard to find a mental health professional ]\n\nLam and his colleagues followed 122 patients and evaluated whether light therapy improved their mood when it was used both with and without fluoxetine, or Prozac, a commonly prescribed antidepressant.\nAlthough the light therapy helped many patients, it provided the most benefit to those who were also taking the antidepressant.\nSome participants were instead given placebo pills and placebo devices.\nBut now a study has found that light therapy also works in treating non-seasonal depression.\nAbout 60 percent of those using light therapy with the antidepressant reported feeling almost back to normal, Lam said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Even in a short word count, this story did convey that there are alternatives, including antidepressants and psychotherapy.", "answer": 1}, {"article": "Elizabeth Williams, from the School of Biomedical Sciences at Queensland University of Technology, tells Newsweek the two studies \u201cdescribe tantalizing complementary and consistent results in Phase 1 trials in melanoma patients using vaccines.\"\n\u201cThe data shows that it is a safe and well tolerated strategy that stimulates relevant anti-tumor immune responses.\u201d\n\nHowever, the treatment has its downsides: \u201cAs the vaccine therapies are designed and generated specifically for each individual there is a lag time from enrollment to commencement of treatment\u2014approximately four months\u2014which may be too long from some patients with advanced cancer.\nAdditional clinical trials will be required to determine the utility of these individualised neoepitope vaccines.\u201d\n\nCatherine Pickworth, science communication officer at Cancer Research UK said: \u201cThe promising results from these two small, early-stage studies show that personalized cancer vaccines designed to treat skin cancer are safe to use, and that for some patients, they can successfully harness the power of the body\u2019s own immune system to kill cancer cells.\nBut working out the unique mutations of each person\u2019s cancer, a time-consuming and complicated process, must first be identified before a vaccine can be developed for them.\nCancer vaccines that are personalized to the patient\u2014designed to help the immune system identify tumors as foreign bodies and destroy them\u2014have been considered as a potential treatment for a number of years.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0\nThe story doesn\u2019t mention any other treatment options for melanoma by name but states that additional research is needed to determine the effectiveness of these vaccines in comparison to existing options.\nThe story could have been improved by including information about the prevalence of cancer recurrence among cancer patients using existing treatment options such as surgery and chemotherapy.\nOne of the trials described was conducted in people who had had surgery and no other treatment options. It would have been helpful to include the length of time to tumor recurrence in people who had not received any other interventions.", "answer": 0}, {"article": "In a first, U.S. trial to test Cuban lung-cancer vaccine\nHe said the results established the double-immunotherapy combination as a first-line treatment for patients with a high \u201ctumor mutational burden,\u201d but that it was too early to know whether the treatment leads to longer survival.\nBut the disease is so lethal that many patients don\u2019t survive long enough to try second- or third-line treatments, so researchers are trying to develop and use more effective approaches earlier.\nThe estimated proportion of patients in the combination therapy group who were alive and whose disease had not gotten worse at a year was about 34 percent, about double the proportion for the chemo-only group.\nThe American Cancer Society estimates that 234,000 people will be diagnosed with the disease this year, and 154,050 will die of it.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story states that most patients diagnosed with advanced lung cancer \u201cinitially receive chemotherapy, which provides only marginal benefit\u201d and \u201cresearchers are trying to develop and use more effective approaches earlier.\u201d", "answer": 1}, {"article": "Russo says, \"One of our main findings is that there was no overall relationship between most types of physical activity and the likelihood of becoming pregnant for women who had already had one or two pregnancy losses, except for walking, which was associated with higher likelihood of becoming pregnant among women who were overweight or obese.\"\nThe researchers conclude that \"these findings provide positive evidence for the benefits of physical activity in women attempting pregnancy, especially for walking among those with higher BMI.\n- Results of a recent study to better understand modifiable factors such as physical activity that may affect a woman's ability to conceive a child suggest that walking may help women to improve their chances of becoming pregnant.\nFor the 1,214 women in the study, the association of walking with the ability to become pregnant, known as fecundability, varied significantly by body mass index, the authors report.\nWhitcomb, whose research on the determinants of fertility and pregnancy outcomes usually involves studying biomarkers at the molecular level, adds, \"Lifestyle is definitely relevant to these outcomes because it can have an effect at the molecular level.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "What other types of physical activity were measured? Many women might be left wondering if other forms of exercise are just as good as walking. It might have helped to clarify this (and if the study did not address this, then make that clear to readers). It would also help readers to note what the \u201cdose\u201d of exercise was that was associated with a positive effect on fertility.\nThere is a statement included from the lead author that could confuse people:\nOne of our main findings is that there was no overall relationship between most types of physical activity and the likelihood of becoming pregnant for women who had already had one or two pregnancy losses [except for walking, which was associated with higher likelihood of becoming pregnant among women who were overweight and obese.\nThat\u2019s a lot of caveats! And many women \u2014 overweight or not, with previous miscarriages or not \u2014 might be left wondering if their form of exercise helps or hinders their chances at conception.", "answer": 0}, {"article": "Savient expects Krystexxa to be available by prescription later this year.\nKrystexxa, which is made by Savient Pharmaceuticals Inc. of East Brunswick, N.J., is an enzyme that lowers uric acid levels by metabolizing it into a chemical that does not cause bodily damage and is then passed through the urine.\nSept. 17, 2010 -- The FDA has approved Krystexxa (pegloticase) for the treatment of gout.\nThe condition is associated with obesity, high blood pressure, high cholesterol, and diabetes.\nThe drug is administered to patients every two weeks as an intravenous infusion.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The company president may say that \"Krystexxa is the first-ever and only treatment approved by the FDA for adult patients who suffer with chronic gout that is refractory to conventional therapy\" but a good news story would explain:\u00a0", "answer": 0}, {"article": "Newswise \u2014 SEATTLE (March 24, 2017) \u2013 The U.S. Food and Drug Administration yesterday granted accelerated approval to the checkpoint inhibitor Bavencio (avelumab) for the treatment of patients with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy.\nBy early 2015, the disease had nearly killed him, despite surgery, radiation and chemotherapy.\nThe approval as a first- and second-line therapy \u201cis a really big deal,\u201d said Nghiem.\nHe is a consultant for EMD Serono Inc. and receives funding from Bristol-Myers Squibb to perform biomarker studies in MCC clinical trials.\nThen he enrolled in a clinical trial and received his first of many infusions of the new immunotherapy drug \u2013 avelumab.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release makes no mentions of, or comparisons to, other therapies.\nStandard therapies include surgery, radiation and chemotherapy.", "answer": 0}, {"article": "In the new study of 24 patients, scores on a standard test measuring the disturbances of memory, language, attention, and other cognitive skills that are hallmark symptoms of Alzheimer's disease dropped an average of slightly more than five points in those treated with IVIG.\nApril 14, 2010 (Toronto) -- A decades-old drug made from human plasma appears to slow the decline of mental skills in people with Alzheimer's disease, suggest results from a small preliminary study.\nResearchers believe the drug can replenish a depleted pool of natural antibodies against beta-amyloid protein, which forms the sticky plaques that riddle Alzheimer's patients' brains.\nThat compares with a 15-point decline in patients who initially received placebo and switched to IVIG, says Norman Relkin, MD, of Cornell Weill College of Medicine in New York City.\nIt's a form of intravenous immunoglobulin, or IVIG, drugs that are usually used to treat immune system disorders.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no comparison between these results and other Alzheimer\u2019s research, except for the Mayo expert\u2019s reminder that \"In the past few years alone, several Alzheimer\u2019s drugs that made it to this stage failed to pan out in further testing.\"\u00a0 However, because of the importance of that reminder at the very end of the story, we\u2019ll give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "Volunteers had the doctored lotion slathered onto one arm and regular moisturizer on the other.\n\u201cIt does open a window for a potential new treatment.\u201d\n\nHealthy skin harbors a different mix of bacteria than skin damaged by disorders such as atopic dermatitis, the most common form of eczema.\nIn lab tests and on the surface of animal skin, those substances could selectively kill Staph aureus, and even a drug-resistant strain known as MRSA, without killing neighboring bacteria like regular antibiotics do, the team reported in the journal Science Translational Medicine.\nThe study couldn\u2019t address the bigger question of whether exposure to the right mix of protective bacteria might improve atopic dermatitis itself, cautioned Mount Sinai\u2019s Guttman-Yassky.\nThis community \u2014 what scientists call the microbiome \u2014 plays critical roles in whether we stay healthy or become more vulnerable to various diseases.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story gives a tiny mention to the alternative for skin infections\u2013antibiotics. This is a barely passing satisfactory:\n\u201cIn lab tests and on the surface of animal skin, those substances could selectively kill Staph aureus, and even a drug-resistant strain known as MRSA, without killing neighboring bacteria like regular antibiotics do, the team reported in the journal Science Translational Medicine.\u201d", "answer": 1}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\nLed by scientists at the Phoenix Epidemiology and Clinical Research Branch, part of NIH\u2019s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the team studied a total of nine men and women with obesity who resided in the Branch\u2019s metabolic ward on two separate visits, each for eight days.\nBut the five people who got inactive stimulation on the first visit, and active tDCS at the brain target on the second visit, consumed an average of 700 fewer calories and lost an average of 0.8 pounds on the second visit.\nThe NIDDK, a component of the NIH, conducts and supports research on diabetes and other endocrine and metabolic diseases; digestive diseases, nutrition and obesity; and kidney, urologic and hematologic diseases.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The story does not compare alternatives. It does state that this new therapy of brain stimulation would be combined with existing known treatments for obesity, such as exercise. The first line of the release states \u201c\u2026 when combined with diet and exercise.\u201d This was a lost opportunity later in the story to discuss intensive behavior changes interventions and surgical treatment for severe obesity with known efficacy.", "answer": 0}, {"article": "\"More often than not, the damage is due to benign (noncancerous) conditions such as enlarged prostate\" -- a condition called benign prostatic hyperplasia or BPH, Groskopf tells WebMD.\nIt showed that the test accurately predicts whether a prostate biopsy will reveal cancer in high-risk men.\nIf a man has any type of damage to the prostate, his PSA level can go up.\nThe PSA test detects prostate-specific antigen, a protein given off by all prostate cells.\nThis often triggers unnecessary biopsies and, sometimes, unnecessary surgery.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0There was no discussion of the myriad of molecules that are currently being investigated for their potential to provide better information for detecting the bad prostate cancers. ", "answer": 0}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\nThe approach has shown promise in studies focusing on short-term observations, but information is lacking on long-term outcomes.\nThe present study now documents the prognostic importance of the comprehensive assessment provided by hybrid imaging.\"\n\"The strategy of direct referral to invasive coronary angiography without noninvasive imaging is obsolete,\" Dr. Kaufmann said.\nCardiac hybrid imaging combines coronary computed tomography angiography (CCTA) and myocardial perfusion imaging with single photon emission tomography (SPECT) to provide information on both stenosis and perfusion.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release is clear that the study is testing an alternative to the standard approach for evaluating cardiovasular\u00a0risk in patients with suspected coronary artery disease.", "answer": 1}, {"article": "The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $800 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.\nThe cognitive effects of proton therapy - primarily affecting verbal comprehension and processing speed - were also less serious than what has been reported with photon radiotherapy, and those effects were primarily seen in children who were under the age of 8 when treated.\nIn July 2015, MGH returned into the number one spot on the 2015-16 U.S. News & World Report list of \"America's Best Hospitals.\"\nThe neuroendocrine effects of proton therapy - deficits in any hormone level were seen in 63 percent of participants seven years after treatment - were similar to what has been reported with photon therapy.\nThe paper from a team led by Massachusetts General Hospital (MGH) investigators describes patient outcomes an average of seven years after proton therapy for medulloblastoma, a fast-growing tumor that develops in the cerebellum at the base of the brain.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does make multiple comparisons to studies of other therapies. We do not feel that this was framed properly in the release, but we address this in the quality of evidence section.", "answer": 1}, {"article": "The all-Achillion regimen could hit the U.S. market by 2020 in a conservative scenario, Deutsche Bank\u2019s Alethia Young estimated.\nThe main goal is to achieve a cure, or sustained virological response, 12 weeks after the completion of therapy.\nThe question then becomes whether ACH-3422 plus ACH-3102 - a weaker nuke and a stronger NS5A inhibitor - could be a good enough doublet as Harvoni, William Blair\u2019s Katherine Xu said.\nThe new-generation hepatitis C regimens use a two- to three-drug combination \u2013 a nucleotide analog inhibitor or \u201cnuke\u201d and a NS5A inhibitor in Gilead\u2019s case \u2013 to achieves a cure in about eight to 12 weeks, making them faster and more effective than older treatment options.\nLaunched in October, its sales touched $2.11 billion in the quarter ended Dec. 31.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention several drug regimens that are available for treatment of hepatitis C and notes that they appear to take longer to achieve a response than the new drug. We\u2019ll call this good enough for a satisfactory, but we\u2019d note that there are other treatments for hepatitis C that have a long and detailed history in the medical literature. A good hepatitis C expert could have provided a nice summary for readers.", "answer": 1}, {"article": "LONDON (Reuters) - Scientists in Canada and Sweden have used laboratory-made biosynthetic corneas to restore vision to patients in a small human trial, and shown for the first time that they can help to repair damaged eye tissue.\nThe researchers found that, eventually, the cells and nerves from nine of the 10 patients regrew completely and packed themselves into the implant, resulting in a kind of \u201cregenerated\u201d cornea that looked and functioned like normal, healthy eye tissue.\n\u201cThe results were pretty encouraging and there is great potential here,\u201d Fagerholm said in a telephone interview.\nAlthough the fragile film is easily destroyed by trauma or infection, replacement human corneas can be used to restore vision, although this depends on a steady supply of donors.\nAfter the patients were also fitted with contact lenses, which is common after corneal transplants, their vision was comparable with that of patients who undergo regular human corneal tissue transplants.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does compare the treatment to human tissue transplants. It could have pointed out that the study was not designed as a direct comparison with people who received a human cornea transplant.", "answer": 1}, {"article": "The AHA further breaks down the unsaturated-fat advice by suggesting that people devote about 5% to 10% of their daily calories to foods containing linoleic acid.\nFor decades, the message about fats has been relatively simple \u2014 reduce the amount of oils and fats you eat from animal and dairy products (less red meat and cheese) and substitute them with healthier fats from plants or fish (olive oil, omega-3 fatty acids).\nThen, over the ensuing decades, it became clear as science progressed that there were multiple types of polyunsaturated fats, and these compounds potentially have distinct biochemical and health effects.\u201d\n\nThere has been some evidence to suggest that omega-6 fatty acids, for example, may trigger inflammation, a condition that is linked to an increased risk of heart problems, while omega-3 fatty acids, found in deepwater fish like salmon, tend to inhibit inflammatory reactions.\nThe difference came down to the specific type of fats that make up these foods \u2014 animal and dairy fats tend to be saturated, which means all of the free bonds available in a chain of carbon atoms are bound to hydrogen atoms, while plant fats are unsaturated, meaning some of carbon atoms have double bonds with each other.\nBut in the latest study on fats published in the BMJ, researchers found convincing evidence that not all plant fats are created equal and that linoleic acid, or omega-6 fatty acids, may be associated with a higher risk of early death from any cause, as well as increased risk of heart disease and death from heart-related conditions.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Even a brief mention of other approaches to reduce cardiovascular risk, such as other lifestyle changes (e.g. quitting smoking), drug therapy, and surgery, would have earned a satisfactory here.\u00a0 It would have required only a few more words to do so.", "answer": 0}, {"article": "The World Health Organization estimates that 8 million people develop active TB each year and nearly 2 million die.\nThe test costs about $63 in Europe, but the company has agreed to provide it for less than half that in poor countries, said John Bishop, Cepheid's chief executive officer, as quoted in a story by the Associated Press.\nThe test, known as the \"Xpert MTB/RIF\" test for Mycobacterium tuberculosis and resistance to rifampin (RIF), appears to be more than 97 percent accurate and is even able to diagnose drug-resistant TB, researchers said.\nFor the study, a research team led by Dr. Catharina C. Boehme, of the Foundation for Innovative New Diagnostics in Geneva, Switzerland, used the Xpert MTB/RIF test on 1,730 patients suspected of having drug-sensitive or multidrug-resistant pulmonary tuberculosis.\n\"The test also indicates rapidly whether difficult-to-treat, drug-resistant forms are present,\" he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that\u00a0current testing for tuberculosis (TB) involves looking at\u00a0respiratory mucus under a microscope. However, it didn\u2019t mention the fact that there are several\u00a0other rapid nucleic acid tests for diagnosing TB that are similar to the test covered in the story. These alternative tests are not as simple to conduct and can\u2019t be deployed on a wide scale with very high accuracy. Nevertheless, making mention of these tests would have added some of the context that we felt was generally lacking in this story.", "answer": 0}, {"article": "\"How bulging is the eardrum?\nIf many children in prior studies didn't really have ear infections, then it's not surprising the antibiotics didn't work for them, says Dr. Jerome Klein of Boston University, who wrote an editorial that accompanies the new studies.\nBut here's the rub \u2013 diagnosing ear infections in very young children, who tend to squirm, is not easy.\nBut Spiro thinks \"the pendulum will swing the other way\" \u2013 that is, toward immediate antibiotic treatment \u2013 because of the new studies.\nTo do a correct diagnosis, says Dr. Alejandro Hoberman of the University of Pittsburgh, the doctor needs to be able to see the child's eardrum, which may mean cleaning out earwax first.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "By talking with the experts, such as Dr. Jerome Klein of Boston University and Dr. David Spiro of Oregon Health Sciences, the blog post does a great job comparing the wait-and-see approach with the antibiotic approach. It also\u00a0notes that the American Academy of Pediatrics endorses the wait and see approach and specifically speaks to the issue of correct diagnosis. We would have liked to have seen some definition of wait and see. And we\u00a0wish the story had provided more data to back up some of the assertions made by the doctors.", "answer": 1}, {"article": "So far, Freedman noted, the only hot-flash treatment that has consistently worked in studies is hormone replacement therapy (HRT).\nTheir exact cause is unknown, but hormonal regulation of body temperature is thought to be involved.\nBut no one knows if altering serotonin levels actually does affect women\u2019s hot flashes.\nHot flashes often need no drug treatment at all, though.\nIt remained there at week eight.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article mentions at the very end other remedies for treating hot flashes besides prescription drugs.", "answer": 1}, {"article": "The findings were published online today in Pediatrics.\nHowever, recent research suggests colic may linked to an immature immune system struggling with bacterial imbalances in the gastrointestinal tract, and that high levels of E. coli bacteria in particular may contribute to colic symptoms.\nResearchers from the University of Turin, Italy, found that a few daily drops of Lactobacillus reuteri, a bacterium that can help improve digestion, significantly reduced crying among infants with colic.\nTo test this theory, the Italian researchers compared 25 healthy infants who were randomly assigned to receive drops of Lactobacillus reuteri to 21 healthy infants randomly assigned to receive placebo drops.\nAug. 16, 2010 -- A probiotic supplement may be an option for parents trying to soothe a colicky baby, according to a new study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that there is no known cause or cure for infant colic. However,\u00a0the story should have noted that colic\u00a0goes away on it\u2019s own after several weeks, and is not a \"disease\", therefore may not need treatment. A close call, but satisfactory.", "answer": 1}, {"article": "Total hip replacement surgery is increasingly common, with more than 300,000 procedures done every year in the U.S.\nAccording to research done by the American Academy of Orthopaedic Surgeons, there are no significant differences between either approach in recovery outcomes six months after surgery.\nAnd to be quite honest, if the pain is controlled and the patient is healthy and medically completely stable there is no reason for them to be in the hospital.\n\"While I recognize there is no place like home, should there be the need for urgent or medical care the question is will that be available to the patient when they're in the setting of their own home,\" Padgett said.\nDuring the surgery, Davidovitch uses a short-acting spinal anesthetic that lasts about 2 \u00bd hours, and when closing the wound he injects \"a cocktail of medications\" to help with the inflammation and pain.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As noted above, the story exaggerates the differences between hip replacements billed as \u201csame-day\u201d and those that give patients more conservative timelines.", "answer": 0}, {"article": "\"There is a growing sense that VE [vasogenic edema] or ARIA [amyloid-related imaging abnormalities] is a manageable side effect and may actually be a sign that the drug is clearing amyloid from the brain and the blood vessels,\" said Salloway.\nThe other study, which involved looking at more than 2,000 MRI scans from 262 patients, found 36 cases of amyloid-related imaging abnormalities (ARIA) may have been linked to the bapineuzumab.\n\"I think it is too early to tell from the data from this small Phase 2 safety trial,\" said Ian Murray, an assistant professor of neuroscience and experimental therapeutics at Texas A&M Health Science Center College of Medicine in College Station.\nBut only 8 of those 36 cases involved symptoms, and they were more likely to be found in patients with APOE-e4 who were taking higher doses of the drug.\nThe researchers, who said monitoring of bapineuzumab will continue, are now awaiting the results of a larger Phase III trial on the drug.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story failed to explain how patients taking\u00a0bapineuzumab compared with those who did not take the drug. \u00a0Without this information, it is impossible to evaluate the value this medication may have to patients. The story also should have put the findings seen with bapineuzumab in context with those of the other approved drugs (Aricept, etc) that have limited efficacy or perhaps mentioned the other drugs that are in testing.", "answer": 0}, {"article": "\"But the [overall] rate of invasive breast cancer diagnosis was no different with or without CAD,\" Fenton said.\nFor one thing, computer-aided detection (CAD) increases the amount of diagnostic testing among women who turn out not to have breast cancer.\nAlthough it has rapidly become part of mammogram screening, Fenton said there is limited and conflicting research on its effect.\nSome of the very early cancers diagnosed in older women, he noted, may not have caused them a problem during their lifetime.\nThe CAD software looks for areas that may indicate cancer so the radiologist can then look more closely at the mammogram.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "By explaining the limitations & benefits of adding CAD to standard mammography readings, the article informs readers about both methods.", "answer": 1}, {"article": "The requested document is forbidden. Please try your operation again .", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned different approaches to the removal of the prostate as well as complete list of the treatment options for early stage prostate cancer.", "answer": 1}, {"article": "The 1,788 who continued statins up to the day of surgery had a risk of death within 30 days of 1.7 percent, compared with 2.9 percent for 452 who stopped one to three days before surgery, and 3.8 percent for 781 who did not take statins or stopped more than 72 hours before their operations.\nUnless you have some other reason to stop them, you should take statins right up to the morning of surgery.\u201d\nResearchers looked at 3,021 heart surgery patients, most of whom were taking cholesterol-lowering statins.\n\u201cBut there\u2019s never before been data saying how harmful stopping shortly before surgery can be.\nThe scientists had no data on how long patients had been taking statins, but only on when they stopped.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Because there likely are no alternatives to a statin that would be recommended, we\u2019ll rate this N/A.", "answer": 2}, {"article": "After a systematic review of medical research on the subject, experts reported that adding an aromatase inhibitor -- a drug that reduces the amount of estrogen produced in the body -- has clearly been shown to reduce the number of tumor recurrences in postmenopausal women compared with the standard drug tamoxifen, which works by blocking the action of estrogen on cancer tumors that are estrogen-receptor positive.\n\"Are [aromatase inhibitors] better than tamoxifen?\nThe drugs can also cause side effects that need to be taken into account when prescribing.\n\"Aromatase inhibitors are clearly associated with osteoporosis and with bone and joint [conditions].\nBut the [financial] costs are much more expensive.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 1}, {"article": "[On average] \"22 grams (about .78 ounces) of new heart tissue grew,\" which he says is quite remarkable considering this had never been done before and the average weight of the part of the heart that is responsible for pumping the blood through the body is about 150 grams (about 5.3 ounces).\nNot only did this show that the procedure was safe, it also showed that the cells can help reduce scarring and even cause new heart muscle to grow.\n\"By preventing the consequences of a heart attack you may be able to prevent further down the heart failure that happens in [many of these] patients.\"\nA total of 25 patients participated in the clinical trial, which was designed to determine if it was safe to have cells grown from one's own heart tissue injected back into the heart.\nThe damaged area also doesn't conduct electric current as well, leading to an abnormal heart rhythm, which can cause more problems.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no discussion of alternatives in this story. One might think that the only option for heart attack patients is to wait around until stem cell treatments become available. Even an additional line about alternatives would have been appreciated.\n\u00a0", "answer": 0}, {"article": "Premature birth can lead to a long list of medical problems and puts babies at risk of dying.\nThe test isn't ready for prime time, however, and it's not foolproof: a study found that it misses some premature births and incorrectly predicts others.\nStill, the test \"should be an important tool for an obstetrician who currently has no clue\" if premature birth is a possibility until it happens, said Brigham Young University (BYU) chemistry professor Steven W. Graves.\nOne option is to provide drugs that dampen the immune system so the baby's lungs develop faster, said Dr. Jennifer Wu, an obstetrician-gynecologist at Lenox Hill Hospital in New York City.\nThe researchers developed a screening method that looked for so-called peptide biomarkers in the blood that -- in tandem with several other proteins -- predicted 80 percent to 90 percent of the premature births at 28 weeks of gestation.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story didn\u2019t comment on any other research in this field \u2013 nothing on any other investigations into what can be done to better predict prematurity.\u00a0 So this one study on this one approach is reported in isolation.\nThe big gap that is unaddressed is that we don\u2019t have any treatments even if we know someone is at high risk. In effect, we would be \u201calarming\u201d lots of patients to no particular end at this point; unless they have had a prior preterm birth and are eligible for progesterone treatment but use of that preventive intervention starts at 16 to 22 weeks and is not relevant to the new test.", "answer": 0}, {"article": "Available from: http://www.\nILC 2017: The study evaluated the use of a direct-acting antiviral treatment in children aged 6 to 11, for whom the standard of care has been pegylated interferon plus ribavirin\n\nApril 21, 2017, Amsterdam, The Netherlands: A study presented today that evaluated an investigational dosage of once-daily ledipasvir 45 mg/sofosbuvir 200 mg (LDV/SOF) in children aged six to 11 years infected with the Hepatitis C virus (HCV), found that 99% of children (n=89/90) had undetectable levels of HCV-RNA 12 weeks after treatment.\n\"This study is a breakthrough for the management of children aged six to 11 years old with Hepatitis C, demonstrating that the new DAA regimen is highly efficacious and, more importantly, safe in this group of HCV-infected children\", said Prof Frank Tacke, University Hospital Aachen, Germany, and EASL Governing Board Member.\n\"These data establish the use of the oral direct-acting antivirals as an important treatment option in HCV-infected children aged six to 11 years old.\"\nAbout The European Association for the Study of the Liver (EASL)\n\nSince its foundation in 1966, this not-for-profit organisation has grown to over 4,000 members from all over the world, including many of the leading hepatologists in Europe and beyond.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release offers a comparison with the current standard of care: \u201cWhile direct-acting antivirals have been used to treat and cure adult patients with HCV,4-7 until now children have been mainly treated for 24 to 48 weeks with pegylated interferon plus ribavirin (RBV), an older treatment which causes severe side effects.\u201d", "answer": 1}, {"article": "Dr. Arie Kaufman of SUNY Stony Brook demonstrated the virtual colonoscopy for CBS New York's Dr. Max Gomez.\nSuch highly specific screening may allow doctors to detect more abnormal growths, called polyps, when they are as small as .10 mm, so they can be removed before they become full-blown cancer tumors.\nThis next step in virtual colonoscopy, called \"immersive colonoscopy,\" projects 3D images of the colon large enough to fill the walls of a room.\nThe CDC says colonoscopy may also be recommended for people experiencing stomach pain, aches or cramps that don't go away, unexplained weight loss and blood in the stool.\nMore routine DNA tests and stool sampling, which show signs of bleeding caused by irregular growths, can also help detect colon polyps and indicate that the need for a full colonoscopy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The American Cancer Society provides a comprehensive listing of screening methods for colon cancer based on the level of risk of an individual. The story mentions a standard colonoscopy as an alternative as well as DNA tests and stool sampling.", "answer": 1}, {"article": "Doctors tell patients who are at risk of developing stones to drink lots of water and avoid foods rich in oxalate, such as rhubarb, okra, spinach and almonds.\nThe work offers the first evidence that the compound hydroxycitrate (HCA) is an effective inhibitor of calcium oxalate crystal growth that, under certain conditions, is actually able to dissolve these crystals.\nHCA was also tested in human subjects, as seven people took the supplement for three days, allowing researchers to determine that HCA is excreted through urine, a requirement for the supplement to work as a treatment.\nThe head-to-head studies of CA and HCA determined that while both compounds inhibit the growth of calcium oxalate crystals, HCA was more potent and displayed unique qualities that are advantageous for the development of new therapies.\nIn addition to Rimer and Asplin, authors on the paper include Giannis Mpourmpakis and his graduate student, Michael G. Taylor, of the University of Pittsburgh; Ignacio Granja of Litholink Corporation, and Jihae Chung, a UH graduate student working in Rimer's lab.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release provides a brief summary of common advice for kidney stone prevention, including drinking lots of water, avoiding certain foods, and often recommending citrate. The release does not discuss medical treatments for serious kidney stones, but then hydroxycitrate is being proposed only as an additional preventive treatment.", "answer": 1}, {"article": "Safety, tolerability and response were assessed every eight weeks for the first six months and every 12 weeks thereafter.\nDr. Mehnert, who is also a medical oncologist in the Melanoma and Soft Tissue Oncology Program at Rutgers Cancer Institute, shares more about the research:\n\nQ: How was the study structured?A: At the time our abstract was submitted, 22 patients with a diagnosis of advanced or metastatic papillary or follicular thyroid cancer who failed prior standard therapy were accrued from multiple international sites.\nMost thyroid cancers can be treated successfully, but advanced cases can be difficult to treat, especially if they do not respond to radioactive iodine (RAI) therapy.\nQ: How are immunotherapy drugs changing the landscape of cancer treatment?A: Although many patients treated do not respond, when immunotherapy does induce responses in patients with advanced cancers, these responses may be very long lasting in terms of disease control.\nJanice M. Mehnert, MD, director of the Phase I and Developmental Therapeutics Program at Rutgers Cancer Institute of New Jersey, is the lead author of research highlighting the immunotherapy drug pembrolizumab and its effect on advanced thyroid cancer.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not mention or compare any of the alternatives. According to Cancer.Net, approved treatments (depending on the type and stage of the thyroid cancer) include surgery, hormone treatment, radioactive iodine, external-beam radiation, chemotherapy and other therapies that target the immune system.", "answer": 0}, {"article": "In a study published in the journal Aging, Bredesen and colleagues showed how 10 patients who were experiencing age-related memory decline showed brain scan improvements after following an approach called metabolic enhancement for neurodegeneration (MEND), a 36-point individualized regimen of diet, exercise, brain stimulation, sleep improvements, medication and vitamins and other specific protocols for five to 24 months.\n\"Not all things from the approach have a lot of scientific support behind them,\" Galvin told CBS News.\n\"If you told me that your mother is 86 and living in a home, I would say that I'd want to treat you,\" he said.\n\"It's important to be excited about this approach,\" he told CBS News.\nFor example, an MRI of one patient showed hippocampal volume at the 17th percentile for his age range prior to MEND.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention alternatives. But many interventions, including drugs, have been tried to reverse memory loss and none have been found to work, so we\u2019ll rate this as N/A.", "answer": 2}, {"article": "The disorder is estimated to affect about one in 500 people and causes extremely high cholesterol.\nThe trial, presented here at the annual scientific meeting of the American Heart Association, included 168 patients with heterozygous familial hypercholesterolemia, in which a defective gene inherited from one parent impairs the ability to properly metabolize LDL.\nThe Phase II trial found that after 12 weeks, patients treated with a low dose of AMG145 had a 43 percent reduction in LDL, while those given a higher dose had a drop of 55 percent.\nThe new drug, given by injection every four weeks, is part of a promising new class of biotech medicines known as PCSK9 inhibitors designed to target a protein that prevents the body from removing artery blocking LDL cholesterol from the bloodstream.\nThe most common side effects seen in the trial were injection-site reactions, cold-like symptoms and headache.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While the story mentions statin treatment for high cholesterol, it fails to tell readers that this trial does not provide evidence that would allow people to compare meaningful harms and benefits of this experimental drug to those of statins.", "answer": 0}, {"article": "As Albert, a pseudonym for an AA member in Georgia, previously told me, \u201cThere\u2019s just not a lot of widely advertised options available.\u201d AA and 12-step treatment are \u201cthe most well-known and most recommended option, so that\u2019s kind of where you tend to go.\u201d\n\nZemore\u2019s study begins to peel away at this problem.\nPresumably, you could get those by participating in alternatives to AA.\u201d\n\nIn other words, these alternatives could help the one-third to two-thirds of people who don\u2019t get anything or much out of AA.\nThis is a big part of the 12 steps, with the final step even invoking \u201ca spiritual awakening.\u201d For people who aren\u2019t religious or spiritual, this can be a big turn-off; that\u2019s one reason SMART and LifeRing exist to begin with \u2014 they\u2019re meant to be secular alternatives to the 12 steps.\nThe study, in short, looked at how people\u2019s self-reported outcomes with AA and 12-step programs compare with the three biggest alternative mutual help groups \u2014 Women for Sobriety, SMART Recovery, and LifeRing.\nThere\u2019s good research into how AA works, but it\u2019d be good to figure out if SMART, LifeRing, and Women for Sobriety work in a similar way.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u2019s main focus is to compare popular 12-step programs with their alternatives. And it explains why alternatives are necessary, since many people object to the spiritual component of AA. It would have been useful to also include outcomes associated with medication for alcohol use disorder, as well as outcomes when there is no formal treatment.", "answer": 1}, {"article": "\u201c[PRP] works, and the results have been amazing,\u2019\u2019 says John Ferrell, the sports medicine physician who treated me.\nThe centrifuges already are licensed, and the procedure uses a patient\u2019s own blood, which is regarded as safe.\nThe researchers call the results \u201cclinically relevant,\u2019\u2019 despite the study\u2019s small size, and say the next step should be a larger, controlled clinical trial.\nThe orthopedist wouldn\u2019t let me drive for six weeks, or run, swim or lift weights for three months.\nThis meant that the tear was causing my problems, and fixing it probably would restore strength and function to my shoulder and end my pain.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is basically touting a possible new therapy as an alternative to traditional rotator cuff surgery, but it does a poor job of comparing them in an evidence-based manner.", "answer": 0}, {"article": "At 14, MS-13 was his family.\nNewsday's coverage of the Class of 2019, led by Mariano Rivera and Mike Mussina.\nA hijab, a turban, a beard: What aren\u2019t you seeing?\nA former gang member recently recalled when he decided to join the gang.\nOver 24,000 employees at 116 LI companies were polled on what makes their employers great.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Ideas about exercise modalities (dance, treadmills) are presented, but information about medications or devices used in the treatment of Parkinson\u2019s is lacking", "answer": 0}, {"article": "So his team designed a randomized controlled clinical trial to see if short-term use of a curcumin supplement could reduce inflammation in people with metabolic syndrome, a cluster of risk factors for heart disease.\nThe researchers didn\u2019t examine the effect of curcumin on any diseases, and it was a fairly brief study, so it\u2019s not clear what the long-term implications may be they caution in their report.\nThey found that the people who took curcumin had improved blood levels of all three biomarkers as well as reduced fasting blood sugar and hemoglobin A1c, a measure of long-term blood sugar levels.\nThe study team also analyzed data from eight previous studies and confirmed that curcumin had shown a significant reduction of CRP concentrations in a total of 281 patients.\n\u201cTwo key effects of curcumin that account for most of the therapeutic effects of this compound are its strong antioxidant and anti-inflammatory properties,\u201d said Sahebkar researcher at the Mashhad University of Medical Sciences in Iran, in an email.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention any other medical interventions that can be used to reduce inflammation, such as corticosteroids or over-the-counter anti-inflammatories (e.g., ibuprofen). Statin drugs also reduce certain inflammation markers and are proven to reduce the risk of heart disease. However, these drugs weren\u2019t mentioned.", "answer": 0}, {"article": "A study of a proposed diabetes drug, Januvia, from Merck & Co. showed it lowered a key measure of blood sugar when taken in combination with another common diabetes drug.\n\nThe study, due to be presented Thursday at the European Association for the Study of Diabetes in Copenhagen, involved 1,056 patients diagnosed with Type 2 diabetes who hadn't previously been treated with diabetes medications.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention some other medications to lower blood sugar, such as sufonylureas and insulin. However, lifestyle interventions are very important for controlling blood sugar (as well as blood pressure and cholesterol) and are not mentioned at all. This is an important treatment area that should not be overlooked in diabetes. ", "answer": 0}, {"article": "Saturated fats can remain a part of a healthy diet, in limited amounts \u2013 but there are two easy ways to help:\n\u2022 Saturated fats should make up 10 percent of total caloric intake daily.\nIn fact, the study found that the lower the cholesterol, the greater the risk of death.\nBut even when their cholesterol levels were lowered by the switch from saturated fats, there was no longevity benefit.\nAll that is known is the participants had a normal cholesterol levels and normal blood pressure.\nWhether statins have additional properties to reduce risk, in addition to lowering serum cholesterol remain under study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job of talking about the complicated recommendations regarding diet, as well as medications, specifically statins.", "answer": 1}, {"article": "But therapies have been improving steadily.\nThe therapy is exciting, AIDS specialists say, even though it is at least three years from market, because it could offer a completely new tool to combat a 25-year-old foe.\n``The proof of the pudding is always what happens when you give it to people and look at what the potency of the antiviral effect is,\" said Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.\nThat hints at the opportunity to use bevirimat in potent combination with existing drugs, said Dr. Daniel R. Kuritzkes, director of AIDS research at Brigham and Women's Hospital and an associate professor of medicine at Harvard Medical School.\nIf approved by the Food and Drug Administration, bevirimat, developed by Panacos Pharmaceuticals Inc., would represent the first in a new class of drugs that uses an unusual approach to block maturation of the virus that causes AIDS.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that this drug would be taken in combination with current antiretroviral therapies. The story places this new drug in the context of a discussion of new drugs that interrupt the replication of HIV; however, bevirimat is still in the midst of clinical trials. ", "answer": 1}, {"article": "\"Far-UVC light has a very limited range and cannot penetrate through the outer dead-cell layer of human skin or the tear layer in the eye, so it's not a human health hazard,\" said Brenner, who directs Columbia's Center for Radiological Research.\nBut he believes \"the use of overhead, low-level far-UVC light in public locations would be a safe and efficient method for limiting the transmission and spread of airborne-mediated microbial diseases, such as influenza and tuberculosis.\"\nIt appears that low-dose far-UV light is safe and effective, and has the advantage of inactivating a wide range of disease-causing viruses.\"\nBut this type of light can cause skin cancer and cataracts, so it's not used in public spaces.\nIt could offer a new, inexpensive way to eliminate airborne flu viruses in indoor public spaces such as hospitals, doctors' offices, schools, airports and aircraft, said the team from Columbia University Medical Center in New York City.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does well to quote one independent source who reminds readers that hand-washing, immunization, and antiviral medications remain important in protecting against the flu.", "answer": 1}, {"article": "\"This is the earliest phase, and you now have to show that it actually breaks down the gluten peptides that trigger a response in the stomach at a speed that will protect the human,\" said Dr. Joseph Murray, a professor of medicine in the division of gastroenterology and the department of immunology at the Mayo Clinic, in Rochester, Minn. \"Let's see how it goes with a whole slice of bread.\"\nThe next step is to show that the enzyme is not toxic and functions as designed in animals.\nThey say these are less likely to trigger the autoimmune response that can create a wide range of painful and irritating symptoms.\nThe re-engineered enzyme, named KumaMax, appears to be highly effective, at least in a test tube.\n\"We did the engineering to change the genes and sent that into standard microorganisms to create the protein,\" Siegel said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "A gluten-free diet is the only effective alternative for celiac disease. The story makes this clear.", "answer": 1}, {"article": "A new study offers a fresh strategy for treating patients suffering from both coronary artery disease and heart failure, afflictions linked to poor quality of life and high risk of death that affect as many as two million Americans.\n\nThe 1,212-patient study calls into question the need for immediate bypass surgery in these patients\u2014an approach commonly recommended by doctors. The study, called Stich, found benefits in treating people with medication only, and in treating people with a combination of bypass surgery and medication....", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a great job showing how the standard interventions for heart disease stacked up against each other in this study. We wish that some mention had been made of diet and exercise and that at least a sentence had been included about whether there might be differences in outcomes seen as a result of different medication patterns. The story doesn\u2019t make it clear what exactly the patients were taking.", "answer": 1}, {"article": "Or are these symptoms merely the consequence of the violence of the shock, of which will ultimately only leave a bump behind?\nToday, the only reliable diagnosis is the CT Scan, which is only available in some hospitals and, in addition to being expensive, exposes patients to radiations.\n\"We wondered if it was possible to isolate certain proteins whose presence in the blood increases in the event of mild traumatic brain injury,\u00bb explains Jean-Charles Sanchez, professor at the Department of Internal Medicine of Specialties and the Biomarkers Centre of the Faculty of Medicine of the UNIGE.\nHis team has developed a rapid diagnostic test (POCT) called TBIcheck, inspired by the principle of pregnancy testing: by placing a single drop of blood on the well of a small 5cm plastic case, the patient knows within 10 minutes whether there is a risk of mild trauma, namely whether or not his H-FABP level is higher than 2.5 nanograms per millilitre of blood.\nResearchers from the University of Geneva (UNIGE), in collaboration with the Hospitals of Barcelona, Madrid and Seville, have developed a small device - Point-of-Care Test (POCT) - that analyses the level of proteins in the blood and allows, using a single drop of blood, to diagnose the possibility of a mild traumatic brain injury.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release stated that the \u201conly reliable diagnosis is the CT Scan, which is only available in some hospitals and, in addition to being expensive, exposes patients to radiations.\u201d\nThis is misleading. In fact, diagnosing a concussion is complicated. Patients are usually assessed by a doctor using the Glasgow Coma Scale\u2014a series of physical tests for determining the level of consciousness. A CT scan can also be used in order to detect severe brain injury such as bleeding and swelling. However, patients suspected of having a concussion don\u2019t always show signs of brain damage when scanned.", "answer": 0}, {"article": "Additional training in the therapy for behavioral health providers in all branches of the military is needed, he said.\n\"The online program can also be done from home rather than at a military behavioral health clinic, which some service members may avoid due to concerns about stigma,\" said Pruiksma, an assistant professor of psychiatry at the University of Texas Health Science Center at San Antonio (UT Health San Antonio).\nFor military personnel, internet-delivered cognitive behavioral therapy appears to be an effective alternative to meeting regularly with a therapist, although it is about half as effective as traditional methods, according to results of a study conducted by Daniel Taylor, University of North Texas professor of psychology and director of UNT's Sleep Health Research Laboratory.\nIn a previous study of civilians with insomnia, Taylor and his research team discovered that cognitive behavioral therapy led to significant improvements in sleep efficiency, with the research subjects' use of sleep medication declining from 87.5 percent before therapy to 54 percent afterward, although the subjects weren't required to stop taking their medication.\nBoth the in-person and Internet therapy had the exact same content, with the Internet lessons presented as audio recordings accompanied by visual graphics and animations.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release describes how two types of CBTi (online and in-person) compared. It mentions medications are used as a therapy for about 10 percent of the deployed military but that they can leave people groggy and with slow cognitive processing and reaction times \u2014 which are dangerous in conflict zones.", "answer": 1}, {"article": "These findings suggest the pills may help protect against death in patients with pneumonia.\n\u201cGiven the potential low number needed to treat to prevent a death suggested by this study, we believe that a strong case exists for randomized trials of statins in people with serious infection to determine if a simple and practical intervention at the point of diagnosis of pneumonia has a beneficial effect.\u201d\n\nDouglas\u2019s team, whose research was published in the British Medical Journal, used data from computerized medical records of doctors\u2019 practices in Britain to identify statin users.\nPatients with a record of pneumonia were followed for six months to see if they died, and the researchers found that 13 percent (109 out of 847) of statin users died compared with 20 percent (578 out of 2,927) of non-statin users.\n\u201cStatins are safe, cheap, and an easy intervention in terms of delivery,\u201d said Ian Douglas, a lecturer in epidemiology at the LSHTM who led the research.\nDouglas noted that since this study looked at patients who were already taking statins when they developed pneumonia, a full randomized clinical trial was needed to find out whether starting a statin at the time of diagnosis has a similar effect.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t really give us much context on pneumonia or why statins might be beneficial. It says that lower cholesterol levels might help the immune system fight infections, but most researchers ascribe the potential benefits of statins to other effects, such\u00a0as reduced inflammation. There\u2019s no word on\u00a0any other\u00a0approaches that might be helpful for reducing pneumonia deaths, such as increasing flu vaccination rates. And it would have required only a few more words to address this.", "answer": 0}, {"article": "Liver cancer is the second-leading primary cause of cancer-related deaths worldwide.\nThe success of this trial opens the field for testing drugs in third-line treatment of HCC and provides a rationale to test regorafenib as a first-line treatment or in combination with therapies administered directly into the tumor or diseased liver in patients in an earlier stage of HCC, according to Dr. Llovet.\nIn January, Bayer announced that the U.S. Food and Drug Administration (FDA) had granted priority review status for Stivarga (regorafenib) as a second-line systemic treatment for patients with hepatocellular carcinoma.\n\"This study represents a breakthrough in the management of hepatocellular carcinoma, since it provides evidence for clinical benefits in an area that was an unmet medical need,\" said Josep M. Llovet, MD, founder and Director of the Liver Cancer Program and Professor of Medicine and Liver Diseases at the Icahn School of Medicine at Mount Sinai.\nThis trial provides evidence that regorafenib is the first systemic treatment for patients whose HCC progressed during treatment with sorafenib, the only other drug with proven clinical benefit.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes that patients in the study had already been treated with sorafenib, and that sorafenib is the \u201conly other drug with proven clinical benefit\u201d in treating HCC. That\u2019s enough to earn it a satisfactory rating here. However, it would have been stronger if it had mentioned other elements of treatment, such as surgery, chemotherapy and radiation therapy. In addition, hospice or palliative care programs for patients who had run out of treatment options might result in improvement in outcomes.", "answer": 1}, {"article": "Hamilton, ON August 11, 2016 - A study led by McMaster University researchers has found that, contrary to recent reports, flu nasal sprays provide similar protection against influenza as standard flu shots.\nPublished today in the scientific journal Annals of Internal Medicine, the study shows that the nose spray had a similar effect to the standard flu shot.\nThis study was funded by the Canadian Institutes for Health Research.\nThen, subsequently, it was no longer preferred and now not recommended at all.\nOur study challenges previous studies because our results show conclusively that the vaccines show similar protection when both direct and indirect effects are taken into account.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Since the study looked a two forms of influenza vaccine administration, it obviously addresses the question of comparing alternatives.", "answer": 1}, {"article": "But diabetics are hopeful they'll some day be free of a lifetime of pinpricks and injections.\nOne patient was as young as 14.\nThey look impressive,\" said Dr. Gordon Weir of Joslin Diabetes Center in Boston.\nIt is less common than Type 2 diabetes, which is associated with obesity.\n\"It's the threshold of a very promising time for the field,\" said Dr. Jay Skyler of the Diabetes Research Institute at the University of Miami.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The current standard therapy for type 1 diabetics is briefly discussed, e.g. daily insulin injections.\u00a0 ", "answer": 1}, {"article": "Thousands of breast cancer patients at risk of developing aggressive secondary tumours could benefit from a potential new genetic test.\nProfessor Coleman said: \"If the test is negative for this gene, then they can be offered this bone strengthening treatment, which can give them a better chance of surviving their cancer.\u201d\n\nA test for the gene, known as MAFTest, has been developed by a Spanish medical company called Inbiomotion following work conducted at the Institute for Research in Biomedicine (IRB) in Barcelona.\n\u201cIt only seems to be effective in some patients, particularly older women, while others show no response and in some younger women it may even be harmful.\u201d\n\nThe new study, which is published in the journal Lancet Oncology, has shown it may be possible to identify women who will benefit from bisphosphonates by using a test that looks for a gene known as MAF.\nThe new study, which is published in the journal Lancet Oncology, was part of an international phase 3 clinical trial involving 3,360 women with stage II or III breast cancer.\n\u201cThe discovery made at IRB Barcelona and tested in the current study could be of great use to clinicians and would avoid unnecessary treatment of patients who would not benefit or could be harmed by the treatment,\" added Professor Roger Gomis, leader of the growth control and cancer metastasis group at IRB Barcelona, who was a co-author on the study.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release doesn\u2019t name any alternatives for preventing metastasis in women with breast cancer.\u00a0 It would have been helpful to note in the news release that the drug was given in addition to \u201cstandard\u00a0adjuvant systemic therapy, \u201d according to the journal article, which presumably would include chemotherapy and hormone therapy.", "answer": 0}, {"article": "The ACC leads in the formation of health policy, standards and guidelines.\nThe study, \"Digital Mammography: Screening for Coronary Artery Disease?,\" will be presented on April 3, 2016, at 9:45 a.m. CT/10:45 a.m. ET/3:45 p.m. UTC at the American College of Cardiology's 65th Annual Scientific Session in Chicago.\nIt's a freebie and provides critical information that could be lifesaving for some women,\" Hecht said, adding he hopes these findings will prompt clinicians, who rarely report breast arterial calcification, to routinely report not just the presence or absence of breast arterial calcifications but also to estimate and note the amount.\nBecause the study involved women who received both mammography and CT scan for clinical indications, these women may have been more likely than the average woman to have coexisting conditions, although Hecht said these were unrelated to heart disease.\nLaurie Margolies, M.D., associate professor of radiology at the Icahn School of Medicine at Mount Sinai, and co-author of the study will be available to the media in an embargoed web briefing on Tuesday, March 22, 2016, at 2 p.m. ET/1 p.m. CT/6 p.m. UTC.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions alternatives, the standard risk assessment tools, as the Framingham Risk Score and the 2013 Cholesterol Guidelines Pooled Cohort Equations. Although it\u2019s questionable, as noted above, if there is an accurate comparison.", "answer": 1}, {"article": "The researchers from Harvard's T.H.\n\"The results of this study emphasize the role of an early life high-fiber diet on prevention of breast cancer in later life.\nThe findings showed that breast cancer risk was 12 to 19 percent lower among women who ate more dietary fiber in their youth, depending on how much more they ate.\n\"The sexy headline is eat this and you'll have a lower risk of breast cancer, but I'd shift the focus to, eat more fiber because it's better for you and you'll be a healthier person and you're less likely to be obese and have chronic inflammation and other things that will reduce your risk for heart disease and cancer along the way,\" said Attai.\nOne weakness she pointed out in the study is that the women were asked to recall details about their adolescent diet when they were in their 30s and 40s.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does note that increasing dietary fiber consumption \u201cis just one mechanism by which we can reduce risk,\u201d but it doesn\u2019t mention any of the other mechanisms. Exercise, maintaining a healthy weight, getting sufficient sleep and limiting alcohol consumption can also help reduce breast cancer risk.", "answer": 0}, {"article": "Parkinson's is a disease that affects nerve cells in the brain that control the movement of muscles.\nThe exact cause is unknown, but experts believe it's a combination of genetic and environmental factors.\nThe findings came from an analysis of data on 136,474 people who did not have Parkinson's at the start of the study.\nThose who took the largest doses of ibuprofen were less likely to have developed Parkinson's than were those who took smaller amounts of the drug, the study found.\nBut in the meantime, Tagliati said, he would \"definitely discuss ibuprofen use\" with his patients because, if it works to protect against the disease, it could very well benefit those who already have it.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story mentioned that levodopa is the current standard treatment for Parkinson\u2019s, there was no discussion of any other research into prevention of Parkinson\u2019s Disease. ", "answer": 0}, {"article": "Geoffrey A. Fowler discusses the headset with Yvonne Felix, a blind artist and supporter of the technology.\nLeaps in augmented-reality technology are being used to help people with severely low vision gain back enough sight to function, and then some.\nBut when the Toronto-based artist and mother puts on a new kind of camera-equipped headgear, she looks at me like no one has before.\nPhoto/Video: Emily Prapuolenis/The Wall Street Journal\n\nYvonne Felix\u2019s eyes don\u2019t work well enough on their own for her to read, recognize faces or cross the street without help.\nThe visor that allows legally blind people to see is no longer Star Trek fiction.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story walks through the iteration of wearable screens for those with low vision, and it also mentions two competing models aside from the eSight 3. We also get a passing mention of an unnamed \u201csurgical procedure.\u201d\nStargardt disease has no treatment, according to the National Eye Institute, though other \u201clow vision\u201d conditions can be treated with retinal implants, and some are responsive to other types of surgery. However, since there are many diseases or conditions that can lead to low vision and legal blindness, and news stories aren\u2019t supposed to be encyclopedic entries, we\u2019ll mark this one satisfactory.", "answer": 1}, {"article": "PHILADELPHIA - In a finding that suggests the potential for practice change that would reduce the use of antibiotics in dermatology, researchers in the Perelman School of Medicine at the University of Pennsylvania have found the diuretic drug spironolactone may be just as effective as antibiotics for the treatment of women's acne.\nThe study, published this month in the Journal of Drugs and Dermatology, found patients who were originally prescribed spironolactone changed to a different drug within one year at almost the same rate as those who were prescribed antibiotics.\nWithin a year, 14.4 percent of spironolactone patients and 13.4 percent of antibiotic patients had switched to alternative treatments, suggesting each treatment was working at almost the same rate, despite the fact that tetracycline-class antibiotics are prescribed five times as frequently.\nThe prescription change is a proxy for ineffectiveness, since switching is often the result of treatment failure due to lack of efficacy, side effects, cost, or other factors.\nMore than 50 percent of women in the United States are treated for acne between the ages of 20 and 29, while more than 35 percent are treated between the ages of 30 and 39.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release is comparing two alternatives. It would have been helpful to mention that there are other ways of dealing with acne besides just these two methods. There are a number of prudent approaches to treating acne before turning to prescription medications.", "answer": 1}, {"article": "For more information, visit http://www.\n\"The existing totality of evidence suggests an urgent need to increase the use of varenicline in the general population as well as in those with serious mental illness who on average die about 20 years earlier than the general population, in part, because their smoking rates may be as high as 75 percent,\" said Hennekens.\nTo further FAU's commitment to increase much needed medical residency positions in Palm Beach County and to ensure that the region will continue to have an adequate and well-trained physician workforce, the FAU Charles E. Schmidt College of Medicine Consortium for Graduate Medical Education (GME) was formed in fall 2011 with five leading hospitals in Palm Beach County.\nWith more than 70 full and part-time faculty and more than 1,300 affiliate faculty, the college matriculates 64 medical students each year and has been nationally recognized for its innovative curriculum.\nNonetheless, since then, there has been a 76 percent decline in the number of prescriptions dispensed from a peak of about 2 million in the last quarter of 2007 to about 531,000 in the first quarter of 2014.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release states that patients assigned to Chantix in the EAGLES trial \u201cachieved significantly higher abstinence rates at 12 weeks than those assigned to placebo, nicotine patch or bupropion.\u201d We give the release credit for naming some common alternatives for smoking cessation that were evaluated alongside Chantix in the trial but wish it had defined the comparison more concretely.", "answer": 1}, {"article": "Scientists from the University of Gothenburg\u2019s Sahlgrenska Academy have developed a portable pocket-sized vestibular, or balance, stimulation device in a bid to improve the lives of Parkinson\u2019s sufferers.\nThe effectiveness of oral levodopa reduces as Parkinson\u2019s disease progresses in the patient and can lead to involuntary movements, or dyskinesia.\nHe also said they were working on the hypothesis that other diseases which affect the dopamine system, such as ADHD (Attention Deficit Hyperactivity Disorder), could also benefit from this kind of treatment.\nThe plan is now for the device to be tested in a longer-term study, where patients will be using it at home.\nThe difference is that we use a particular current profile which you can stimulate the balance organs with without creating a balance disturbance.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says that levodopa is commonly used to treat the symptoms associated with Parkinson\u2019s, and notes that the drug\u2019s efficacy tends to wane over time.", "answer": 1}, {"article": "\"CMS made the right decision,\" said John Petrini, a Santa Barbara, Calif., gastroenterologist who heads the American Society for Gastrointestinal Endoscopy.\nCurrently about half of Americans over 50 are screened for the disease; some shun traditional colonoscopy, which is the only way to remove polyps, because of its invasive nature.\nInitially regarded as a high-tech novelty, the new procedure has in recent months received key endorsements as a first-line screening test from influential medical groups, notably the American Cancer Society, after several large studies found it to be effective at finding large polyps.\nThe prospects for significant expansion of the procedure, which is covered by a growing number of insurance companies, have collided with a large and unexpected roadblock.\n\"This is a really good test that's going to find way more cancer than optical colonoscopy,\" said Mark Klein of Washington Radiology Associates, who has performed more than 1,200 virtual colonoscopies since 2002, Rowe's among them.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions standard colonoscopy as the alternative to virtual colonoscopy. The story could have also mentioned some of the other screening tests that are available, such as stool tests, sigmoidoscopy or barium enema.", "answer": 1}, {"article": "So who wouldn't want a pill to fight the doldrums caused by skipping too many time zones too fast?\nIn a statement, Dr. Lesley Russell, Cephalon's chief medical officer, said:\n\nThe most common side effects for Nuvigil, include diarrhea, headache, insomnia and nausea, according to Cephalon.\nIn March, the FDA turned down Cephalon's jet-lag application and questioned how good the data supporting it really were.\nBut the regulators weren't buying the evidence put forward by the company to prove the medicine's benefits in treating travelers' \"excessive sleepiness\" outweighed its risks.\nThe regulators just gave a second thumbs down to drugmaker Cephalon's application to sell Nuvigil as a remedy for jet lag.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Not applicable.\u00a0 There was no discussion of other approaches to jet lag.\u00a0 But we acknowledge that this short blog piece was written to address the news of the day \u2013 the new regulatory review.\u00a0 So this news \u2013 in this news format \u2013 need not try to do it all. As stated above, we appreciate how it gave context and history even with its tight 250-word space.", "answer": 2}, {"article": "Peer-reviewed clinical studies show that the Proove Opioid Risk\u00ae profile accurately identifies patient risk for opioid abuse.\nThis study, entitled \"Evaluation of a Predictive Algorithm that Detects Aberrant Use of Opioids in an Addiction Treatment Centre\", is published in the peer-reviewed Journal of Addiction Research and Therapy (Impact Factor: 1.4).\nDistinguished Fellow American Society of Addiction Medicine (ASAM), Diplomate American Board of Addiction Medicine and Fellow American College of Preventive Medicine, J. Ramsay Farah, MD, MPH, MRO, CPE, led a research team that showed Proove Opioid Risk\u00ae identifies patients at risk for Opioid Use Disorder (OUD) with nearly 97% accuracy.\nProove Opioid Risk\u00ae is a proprietary precision medicine profile consisting of an algorithm which analyzes 17 variables (11 genetic and 6 lifestyle and behavioral factors) individually supported by over 30 peer-reviewed publications.\nDr. Ashley Brenton, Associate Director of R&D for Proove states, \"This validation study builds on the peer-reviewed evidence supporting Proove Opioid Risk\u00ae and its components as an optimal model to predict opioid abuse risk.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release mentions no alternatives to the use of this algorithm. Most doctors already ask patients about their substance use and abuse history and other important lifestyle and environmental factors before prescribing opioids to them. In addition, in March 2016, the CDC issued a \u201cGuideline for Prescribing Opioids for Chronic Pain,\u201d intended to help doctors decide which of their patients truly need opioids and when to use alternative treatments to manage patients\u2019 pain.\nAnother company, Canterbury Healthcare, is marketing a similar genetic test for opioid addiction susceptibility.", "answer": 0}, {"article": "London, England (CNN) -- Researchers hope a new treatment developed in the United Kingdom will prove vital in controlling future flu pandemics such as H1N1 (swine) flu, bird flu as well as ending the need for annual flu jabs.\n\"With this type of vaccine, you would at least be able to start using the vaccine as soon as you knew a new pandemic was starting.\nYou could stockpile the vaccine and wouldn't have this wait to make a new pandemic-specific vaccine,\" she said.\nThe vaccine would be an important step in treating seasonal flu, not just pandemics.\nNormally it's the very old or very young that die from flu, but every year there are deaths from influenza A,\" said Gilbert.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 0}, {"article": "Doctors say it has given them a new weapon in the battle against sleep apnea, and many patients who struggled with C.P.A.P.\nFor decades, the standard treatment has been \u201ccontinuous positive airway pressure.\u201d A mask worn at night pushes air into the nasal passages, enabling easier breathing.\n\u201cAll sleep apnea is not created equal.\u201d\n\nSome people, for example, breathe through the mouth at night, not the nostrils.\nThe device contains two pinhole-size valves, one over each nostril.\nBut not everyone finds that Provent alleviates their apnea.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does compare the Provent patch to the standard treatment, known as continuous positive airway pressure, but it does not explain that there are indeed other approaches including exercise and weight loss, oral appliances and surgery. One additional line in the story could have addressed this.", "answer": 0}, {"article": "But there are dangers to this approach.\n\u201cThe challenge for the next few years is to find out the limitations, the boundaries, the real mechanisms.\u201d\n\nStill, whatever the role of inflammation in epilepsy, Elisa Moller says that anti-inflammatories were a miracle intervention for her son.\n\u201cIt was not known that inflammation was a common feature of different types of epilepsy.\u201d\n\nNormal brain function is regulated by the glial cells, which protect neurons and induce an inflammatory response if the brain is injured.\nBut this response also can contribute to seizures, some experts believe, either because components of the immune system stimulate neurons or because the glial cells\u2019 capacity to regulate the brain is diminished when they become \u201cdistracted\u201d by an injury.\n\u201cOver time, both of them may feed off each other.\u201d\n\nAbout 50 million people worldwide, including more than 2.7 million people in the United States, are struggling with epilepsy in some form.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not do a good job comparing alternatives. For example, it mentions in passing that the same child who is being used as proof of a \u201cmiracle intervention\u201d with anti-inflammatories is also on a restrictive diet, without providing any information about the proof \u2014 if any \u2014 of the efficacy of these types of diets.", "answer": 0}, {"article": "There are probably a few reasons for this, including cost, if not covered by insurance, and a perception that these agents are not safe in light of the history with weight loss agents.\u201d\n\nIn fact, a 2017 report that examined the medical records of 2.2 million patients found that fewer than one in 50 patients who were eligible for a diet pill prescription received one.\nBut within a couple of years some patients began to develop very scary side effects: damage to heart valves that could lead to heart failure and a kind of high blood pressure, pulmonary hypertension, that proved to be fatal in some cases.\n\u201cThe process of weight gain makes it hard to lose weight,\u201d he explained, adding that in certain areas of the brain nerve cells are actually damaged and sometimes die.\nAnd even when we starve ourselves thin, we often can\u2019t reverse those alterations.\nBack in the early '90s, doctors thought they had struck gold with a combination of drugs, fenfluramine and phentermine, or fen-phen, that seemed to magically melt fat away.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did mention diet and exercise, but did not mention weight-loss surgery and didn\u2019t explain how weight-loss drugs stack up against other interventions.", "answer": 0}, {"article": "With 25 years of specializing in natural phospholipid research, development and production, Lipogen guarantees its customers ingredient systems that are supported by the highest level of scientific data, technical quality and safety to meet the growing demand for natural cognitive health solutions.\nAt the end of the 2-month study, out of 220 women under the age of 40 who consumed the product regularly, 23 women (10.45%) reported that they noticed relief of premenstrual syndromes.\nThe previously unrecognized PMS/PMDD benefit of PS Plus came about when 2,000 volunteers received and consumed Lipogen's PS Plus for brain health and stress management.\nAccording to the Medical University of South Carolina, current available treatments include SSRIs and other drug treatments that treat side effects and can cost from US$60.00 - US$535.00 per month.\nMore than 200 different symptoms have been associated with PMS, including emotional symptoms such as: stress, anxiety, insomnia, fatigue, mood swings, emotional sensitivity and/or changes in libido.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Other than mentioning anti-depressants, which are not routinely prescribed for PMS, the release does not discuss any of the many other alternatives to managing PMS/PMDD symptom relief. Many interventions have been studied, from exercising (from which there is insufficient evidence) to other CAM therapies. According to a review published in American Family Physician journal, \u201cA 2009 systematic review found 62 studies of herbal supplements, vitamins, and minerals with published claims for PMS symptom relief, only 10 of which were [randomized controlled trials] RCTs.\u201d The review found that data are insufficient to evaluate the effectiveness of ginkgo, saffron, St. John\u2019s wort, soy, or vitamin E, because only one study existed for each. However, results suggested that chasteberry and vitamin B6 may reduce PMS symptoms.\u201d \u00a0Other pharmacologic interventions include: SSRIs, oral-contraceptives, GnRH agonists, and anxyolitics.\nThe release might have been strengthened somewhat if there had been some acknowledgement of some other non-pharmalogical interventions.", "answer": 0}, {"article": "Get to know how you can help save and improve kids' lives at http://www.\n\"We looked at all of these metabolites in concussed male adolescent patients and in non-concussed male adolescent patients and it turns out that the spectrum is really different,\" explains Daley, who is also Western's Associate Vice-President (Research) and a principal investigator at Western's renowned Brain & Mind Institute.\nThis new method, fully funded by the Children's Health Foundation and conducted by the Western Concussion Study Group, is unique in that previous attempts have looked unsuccessfully for a single highly accurate protein biomarker that can distinguish concussed from non-concussed adolescent patients.\n\"This novel approach, to use blood testing of metabolites as a diagnostic tool for concussions, was exploratory and we were extremely pleased with the robustness of our initial results,\" says Dr. Fraser, also an Associate Professor in Western's Departments of Paediatrics, Physiology & Pharmacology and Clinical Neurological Sciences at the Schulich School of Medicine & Dentistry.\n\"This relatively quick and inexpensive blood test for concussion is by far the most accurate reported with tremendous potential for clinical management and commercialization,\" says Kirk Brown, Manager of Business Development for Lawson.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release mentions that there are other ways to diagnose a concussion. It notes:\n\u201cDiagnosis of a clinically significant concussion, or a mild traumatic brain injury, can be difficult as it currently relies on a combination of patient symptom assessment and clinician judgement.\u201d\n\u201cThis new method\u2026is unique in that previous attempts have looked unsuccessfully for a single highly accurate protein biomarker that can distinguish concussed from non-concussed adolescent patients\u201d\nWe\u2019ll rate it borderline satisfactory for giving a nod to alternative tests. However, the release would have been more informative if it had included some actual numbers comparing the potential test with traditional tests and other blood tests in development.", "answer": 1}, {"article": "This study was presented at a medical conference.\n\"A key question now is to work out which patients will benefit from the drug -- clearly, some patients do and some don't,\" Johann de Bono, MD, PhD, of the U.K.'s Royal Marsden NHS Foundation Trust, says in a news release.\nAnd while the average patient survived only four months longer than those on standard chemotherapy -- 14.8 months vs. 10.9 months -- some patients did much better.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\nIt appears that abiraterone is able to shut down androgen production not only in the testes, but also from the adrenal gland and from within prostate tumors themselves.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no meaningful comparison with other approaches. \nOne last time, let\u2019s look at how the competing Wall Street Journal story tried to give such context:\u00a0\n\"When you have drugs that act in different ways and each is giving some measurable benefit, that is significant progress in a field where new agents have come along very rarely in the past,\" says Steve K. Clinton, director of prostate and genitourinary oncology at Ohio State University\u2019s James Cancer Hospital and Research Institute, Columbus. Dr. Clinton wasn\u2019t involved in the current study and doesn\u2019t have consulting relationships with the companies.\u00a0\nThat\u2019s an example of the kind of context \u2013 the kind of comparison \u2013 we look for in such stories. ", "answer": 0}, {"article": "He reviewed the study but was not involved in it.\nIn their study, published in the Feb. 23 issue of the Journal of the American Medical Association, Miglioretti and her colleagues found that false positives and interval cancers were both higher in women with a history of breast cancer than in those without such history.\nThe researchers evaluated 12 years of data from 58,870 screening mammograms in 19,078 women with early-stage breast cancer and an equal number of mammograms in another 55,315 women who had never had breast cancer.\n\"But they also need to remain vigilant because they are at increased risk of cancers not detected on mammography that show up between mammograms.\"\nIt points to the need, she said, for women to remain vigilant about screening after their breast cancer treatment -- and to report any symptoms to their doctor immediately.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Satisfactory mostly because of the inclusion of the comments by Dr Audeh about MRI, which is really the only acceptable alternative to mammography for followup of breast cancer survivors, and it is still unclear how MRI and mammography should be used in concert.", "answer": 1}, {"article": "(Reuters) - Asterias Biotherapeutics Inc said initial data from a small study showed that its lead stem cell therapy could improve mobility in patients paralyzed by a spinal cord injury.\nData showed that the severity of the spinal injury was reduced in the first patient and two other patients were able to resume their rehabilitation programs soon after being injected with the stem cells.\n\u201cBut we do expect the patients to have significant improvements in mobility.\u201d\n\nNearly 30,000 Asterias\u2019s shares were traded by 12:30 p.m.\nAsterias is looking to show recovery of mobility in four out of every 10 patients treated with OPC-1, compared with two out of 10 achieving the same level of improvement without any treatment, Chief Executive Pedro Lichtinger told Reuters in early August.\nIn an early-stage study conducted by Geron, the therapy showed potential in repairing spinal injury in four of the five patients tested, without any adverse events.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Severe spinal cord damage is unfortunately irreversible, but treatments to improve nerve function exist. These include medications, such as intravenous methylprednisolone for acute spinal cord injuries, and surgery to remove foreign objects that are compressing the spine. Rehabilitation nurses and physical therapists could also work with patients to maintain and strengthen muscle function.\nSince the article does not mention any of these alternatives, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "For more information, visit http://www.\nAfter six months of treatment, more than 93 percent of 901 respondents reported their pain dropped from a median of eight to four on a 10-point scale.\nThe researchers in the study also include, Ran Abuhasira, a BGU Ph.D. candidate working in the Soroka Clinical Research Center, Lihi Bar-Lev Schleider of \"Tikun Olam,\" and Prof. Raphael Mechoulam of Hebrew University.\nThe new study, published in The European Journal of Internal Medicine, found cannabis therapy is safe and efficacious for elderly patients who are seeking to address cancer symptoms, Parkinson's disease, post-traumatic stress disorder, ulcerative colitis, Crohn's disease, multiple sclerosis, and other medical issues.\nAfter six months, more than 18 percent of patients surveyed had stopped using opioid analgesics or had reduced their dosage.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are a large number of treatment options for patients with pain due to various conditions but none are mentioned here except for the misleading assertion in the headline that cannabis was compared with opioids. As mentioned earlier, the release doesn\u2019t acknowledge that there was no comparison to other therapies in this observational study. Rather, the release tends to dismiss them in terms of side effects using opioids as an example. There are other medicinal and non-medicinal therapies that could be used.", "answer": 0}, {"article": "Evivo has commenced rigorous clinical trials with the prototype to demonstrate the results from infant stool samples.\nThe liquid will remain pink if a sample has low levels of acetate and lactate, indicating that Bifidobacterium is missing and that key nutrients from breast milk, human milk oligosaccharides (HMO), are being wasted.\nIdentifying a Disappearing, Yet Critical Piece of Gut Health\n\nDr. Henrick's previously published findings, which are the basis for the Evivo test, show an inverse correlation between rising infant fecal pH, reduced acetate and lactate, and lower levels of beneficial Bifidobacterium, proving that the infant gut microbiome has been rapidly changing over the last three generations.\nPoint-of-Care Diagnostic Expert Turns Focus to the Infant Gut\n\nThe development of the prototype is led by Dr. Bethany Henrick, Ph.D., Director of Immunology and Diagnostics for Evivo.\n\"Currently there is no way to easily determine whether a baby is colonized with healthy bacteria,\" said Mark Underwood, M.D., Chief of Neonatology at UC Davis Medical Center.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "No alternatives to a test discovering low levels of Bifidobacterium are noted \u2014\u00a0that is, other than using Evivo probiotic products to raise them. One option not mentioned is to ignore the test entirely and not use any medical product like Evivo probiotics (or similar), since studies that the release links to say long-term research is required to suss out any definitive link between low or high levels of Bifidobacterium\u00a0in a baby\u2019s gut and\u00a0their health later in life.\nAdditionally, people could avoid antibiotics (the primary cause of shifts in the microbiome) and feed their children a variety of foods which probably results in healthy colonization.", "answer": 0}, {"article": "\"Sure.\nBut we were surprised by how healthy he seemed seven months later, in August 2008, when we visited with him and his wife Marianne at their home in Erie, Pa.\n\n\"I must say you look like a completely different person to me.\nSo even though he had been feeling good for awhile, he admitted there was always fear his disease could take a turn for the worse.\nWhen 60 Minutes met him back then, he showed Stahl how the radio waves - transmitted across a small field - created enough energy to light up a fluorescent bulb.\n60 Minutes decided to keep track of Kanzius and his invention, so we followed him for over a year, as he pushed to speed up the research on his machine and fought to slow down his own cancer, which was killing him.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\n \nNot only does this story fail to discuss the range of treatment options available to patients with leukemia and other cancers, it broadcasts an egregious misrepresentation of the chemotherapy regimen given to John Kanzius by emphasizing the \u201chorrible side effects\u201d while failing to give standard treatment credit for Kanzius\u2019s temporary remission.\n The story also failed to mention that there are multitudes of experimental and proven cancer treatments that use targeted approaches that are conceptually similar to the Kanzius approach.", "answer": 0}, {"article": "(Reuters) - The U.S. Food and Drug Administration (FDA) on Friday expanded the use of Novartis AG\u2019s relapsing multiple sclerosis (MS) drug Gilenya to treat children and adolescents.\n\nMS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body and is among the most common causes of neurological disability in young adults.\n\nGilenya is the first FDA-approved drug to treat pediatric patients suffering from relapsing MS, the U.S. health regulator said.\n\nIn a clinical trial 86 percent of patients receiving Gilenya remained relapse-free after 24 months of treatment, compared to 46 percent of those who were administered another MS drug.\n\nGilenya was first approved by the FDA to treat adults with relapsing MS.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned that Gilenya was compared with another drug, but it doesn\u2019t go into specifics. It also doesn\u2019t mention that corticosteroid medications can be used to reduce inflammation.", "answer": 0}, {"article": "Funding for the study was provided by the Wake Forest Translational Science Institute and Center for Integrative Medicine and the Claude Pepper Older Americans Independence Center of Wake Forest Baptist.\nAt the beginning of this pilot study, the research team found that more than half of the participants had insufficient concentrations of vitamin D in the blood (less than 20 ng/ml), while less than a quarter had concentrations in the optimal range (30 ng/ml or more).\n\"Falls in homebound older people often lead to disability and placement in a nursing home,\" said Denise Houston, Ph.D., R.D., associate professor of gerontology and geriatric medicine at Wake Forest Baptist and lead author of the study.\nThe study included the participants' history of falls and their fear of falling, blood tests at the beginning and at end of the trial to measure 25-hydroxyvitamin D (biomarker for vitamin D in blood), and a monthly diary recording falls during the trial period.\nWINSTON-SALEM, N.C. - Aug. 17, 2015 - Every year falls affect approximately one in three older adults living at home, with approximately one in 10 falls resulting in serious injury.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Neither the news release nor the study makes any mention of other possible interventions that might result in fewer or less-serious falls. For example,\u00a0balance programs such as Tai Chi are known to decrease fall risk. Other steps that may help include the installation of hand rails, the use of carpeting on steps, the use of bright-colored tape on steps to increase depth perception, etc.", "answer": 0}, {"article": "Aging is never easy, particularly during menopause. But for 30 years women could at least depend on estrogen and progestin supplements, a comforting hormonal hand to hold that would not only ease the uncomfortable symptoms of getting older but also keep skin supple and hair lustrous. Doctors even encouraged women well into their 70s to take the treatments, on the basis of studies showing that they protected against heart disease and cushioned bones against osteoporosis-related fractures.\n\nIt seemed almost too easy--and it was. In 2002 the quick pharmaceutical fix was all but snatched away when a large government study found that...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention the various supplements, such as black cohosh, that are used to treat menopausal symptoms.", "answer": 0}, {"article": "Cut It Out (Surgically)\n\nAt 32, it just didn't make sense that Daniel Sheiner was exhausted literally from the moment he woke up.\nThen, there's surgery to remove blockage in the nasal passage.\nHe's exercising at the gym three times a week, lifting weights.\nHe had energy, an ability to focus and get things done.\nHe is also starting to experiment with recipes and cooking, something he had absolutely no energy or interest in doing before the surgery.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Gold stars for NPR finding someone to talk knowledgeably about the alternatives and risks.", "answer": 1}, {"article": "For the second time, the U.S. Food and Drug Administration has approved a drug that, instead of targeting tumors by location\u2014breast cancer, prostate cancer, lung cancer\u2014attacks cancers according to specific genetic structures, known as biomarkers.\n\"This is especially true when it comes to pediatric cancers.\nThe search for a cancer cure goes on, but in the meantime, there is hope for more effective treatments.\nFor example, immunotherapy drugs can now tag cancer cells so that it's easier for a patient's own immune system to identify and attack them.\n\"This new site-agnostic oncology therapy isn\u2019t specific to a cancer arising in a particular body organ, such as breast or colon cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no discussion of how this treatment compares to alternatives. Readers are not told that such comparisons have not yet been studied.", "answer": 0}, {"article": "The state's most comprehensive health sciences university, LSU Health New Orleans includes a School of Medicine, the state's only School of Dentistry, Louisiana's only public School of Public Health, and Schools of Allied Health Professions, Nursing, and Graduate Studies.\nIn all patients, only one reduction technique was performed per patient.\nThis relationship strengthens the researchers' hypothesis that the lower pole ligaments stretch at a significantly slower rate than the upper pole ligaments.\nThis occurs when breast tissue drops to the lower portion of the breast independent of nipple position.\n\"Breast reduction is one of the most commonly performed plastic surgery procedures.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The research compared specific anatomic differences seen with two recognized surgical approaches to reduction mammaplasty.", "answer": 1}, {"article": "Dr Fabiansen , the main author of the paper appearing in PLOS Medicine today, underscores the importance of the findings:\n\n\"Previous studies of nutritional supplements have mainly looked at the effect on weight gain.\nThe results of the study can be used directly both in the treatment and prevention of acute malnutrition.\nPrevious research has focused on treatment of severe acute malnutrition.\nMore than 30% of children in the world have chronic malnutrition.\nAcute malnutrition is more life-threatening than chronic.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The study is all about comparing widely used alternatives about which there have been long standing questions of relative benefit.", "answer": 1}, {"article": "She's skeptical about the Lancet study, pointing out that patients improved only moderately, and not much more than those who were counseled about pacing themselves.\nA study published this year in the Lancet found that a form of talk therapy, as well as exercise, offered relief for some patients.\nThe therapy and the exercise group improved the most, reporting less fatigue, insomnia and anxiety.\nIts cause is still unknown, but over the years, researchers have identified various brain, immune system and energy metabolism irregularities involved.\nSome patients describe the syndrome as feeling like an \"unrelenting, unremitting flu.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not compare this approach to any alternatives; other options include antidepressant medications (in fact about 1/3 of patients were on an antidepressant).", "answer": 0}, {"article": "* Anorexia among most common psychiatric disorders in girls\n\nLONDON, March 7 (Reuters) - Scientists have for the first time reported successful use of a brain-stimulating implant to help patients with severe anorexia whose condition had not improved with other treatments.\nThe patients, all women, were aged between 24 and 57 and had had anorexia for between four and 37 years.\nHe also said the improvements in mood and anxiety even in patients who were still underweight were \u201cespecially striking\u201d given that severely anorexic patients did not respond well to conventional medicines or psychotherapies.\nThe devices were activated 10 days later and researchers measured changes in the patients\u2019 mood and anxiety to help find the correct level of stimulation.\nTreatment usually focuses on changing behaviour, but experts say up to 20 percent of patients get no benefit from such treatments and are at risk of dying prematurely.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story stated:\n\u201cTreatment usually focuses on changing behaviour, but experts say up to 20 percent of patients get no benefit from such treatments and are at risk of dying prematurely.\u201d", "answer": 1}, {"article": "(Reuters Health) - Complementary and alternative medicine options may help men manage premature ejaculation, according to a new review of existing research.\n\u201cThere are a range of treatments available for premature ejaculation, including drug treatments, behavioral techniques and counseling, however, some men may not want to visit the doctor, take drugs long-term or be on a long wait list for counseling,\u201d said lead author Katy Cooper of the University of Sheffield in the UK.\nSome studies suggest that between 20 and 30 percent of men report early ejaculation concerns, but the International Society for Sexual Medicine estimates that about 4 percent of men have a lifelong condition.\n\u201cThere are no approved treatments for premature ejaculation,\u201d said Donald Patrick, vice chair for research at the University of Washington in Seattle.\nThe improvements were small, and the studies were of varying quality, but preliminary evidence suggests that acupuncture, Chinese herbal medicine, Ayurvedic herbal medicine and a Korean topical cream may all have desirable effects, researchers conclude in the journal Sexual Medicine.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study noted that the various alternatives were compared against placebo or alternative treatments. It would have been useful to know how the various herbal remedies compared against what is considered by many physicians to be a reference standard\u2013the off-label use of an SSRI antidepressant, such as paroxetine.", "answer": 1}, {"article": "SUNDAY, Sept. 19, 2010 (HealthDay News) -- For asthma patients whose condition is not controlled with standard inhaled steroids, the addition of Spiriva -- a medication already approved for lung disease -- appears to improve breathing, a new study finds.\nThese drugs carry a note on their labels warning of the possibility of severe adverse events, including death, he noted.\nSome people will respond to some medications, some respond to others,\" he said.\nFor more information on asthma, visit the U.S. National Library of Medicine.\nThese included: Spiriva plus an inhaled steroid; a double dose of the inhaled steroid; and an inhaled steroid plus Serevent, a long-acting beta agonist that relaxes the muscles in the airway.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "By the nature of the study, an unapproved therapy was compared to existing alternatives.\u00a0", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Women who take bone drugs for several years have a slightly increased chance of suffering an unusual type of thigh fracture, according to a large Canadian study.\nThe majority are postmenopausal women.\nThere are several alternative ways to treat osteoporosis, including hormone treatment for women.\nSo far, however, the cheap and effective bisphosphonate bone drugs remain the most popular treatment option.\nThe risk of a thighbone fracture differed depending on how long the women had been taking the medicine.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does briefly mention alternatives, including hormone therapy.", "answer": 1}, {"article": "THURSDAY, May 24, 2018 (HealthDay News) -- Because vertigo can have many causes, treating it can be difficult, but researchers have identified a new type that may be effectively treated with medication.\nThe others' outcomes were not revealed.\nOthers had them two to three times a week.\nAfterwards, a video recorded the patients' eye movements.\nThirty-five study participants had this form of vertigo.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story describes a proposed new diagnosis so suggesting alternatives doesn\u2019t apply.", "answer": 2}, {"article": "The requested URL was not found on this server. That\u2019s all we know.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses other flu treatments, specifically Tamiflu and the experimental drug, peramivir, so we\u2019ll give it a satisfactory grade on this criterion.\u00a0 But it could have mentioned other treatments in the hospital that also affect mortality, including type of ventilation, antibiotics for secondary infection and extracorporeal membrane oxygenation.\u00a0\u00a0 ", "answer": 1}, {"article": "The calculator used in this study is a simplified version of that model.\n\u201cThat\u2019s the hope.\u201d\n\nHe said he thinks electronic health records will be key to putting individualized guidelines into practice.\nThe problem with the old-fashioned way, he told Reuters Health in an email, is that there are many pieces of information about a patient to consider.\nIf, on the other hand, the number of heart attacks and strokes prevented were kept the same, the individualized guidelines would accomplish that result at a 67 percent cost savings versus the national guidelines.\n\u201cThe general theme is that we can do better, and we may have an opportunity to improve patients\u2019 health outcomes,\u201d Owens said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The entire focus of the story was a comparison of a \u201ctailored medicine\u201d approach to existing guidelines for treatment of high blood pressure.\nIt would have been interesting to explore whether this is the only model for tailoring clinical information to arrive at better clinical outcomes or whether there are other models available for this purpose.", "answer": 1}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.\nIn a study of 195 asymptomatic women with dense breast tissue who had a negative mammogram within the previous 11 months, AB-MR detected five additional cancers after a negative screening mammography, according to preliminary findings from a Penn Medicine team presented this week at the Radiological Society of North America meeting in Chicago.\n\"Having dense breast tissue makes it more difficult to detect a cancer on a mammogram,\" said the study's lead author, Susan Weinstein, MD, an associate professor of Radiology and the director of breast MRI at Penn Medicine.\n\"Based on the literature and our results, women with dense breast tissue who desire supplemental screening, these results suggest that AB-MR may be a better option than other supplemental screening tests such as whole breast ultrasound.\nCHICAGO -- Among women with dense breast tissue, for whom traditional mammograms are less effective at detecting cancer, who request additional screening after a negative mammogram, abbreviated breast MRI (AB-MR) may be a valuable cancer detection tool.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release compares the cancer detection rates of abbreviated breast MRI with mammography and digital tomosynthesis (DBT), or 3D mammography. However, it didn\u2019t compare it with the most common screening alternative for these types of breasts \u2014 whole breast screening ultrasound \u2014 since as the release said, ultrasound carries \u201chigher rates of false positives.\u201d\nAs noted above, we wish the release would have noted the rate of false positives associated with abbreviated MRI screening.", "answer": 1}, {"article": "With this in mind, researchers developed a probiotic supplement aimed at reducing inflammation caused by microbial imbalances in the gut.\nThe results showed that the group receiving the probiotic supplement, on average, didn't return to the hospital as quickly and required less in-patient treatment time compared to the placebo group.\nAnd a new study from Baltimore's Sheppard Pratt Health System, conducted by a research team led by Faith Dickerson, finds that a probiotic supplement may reduce inflammation of the gut, which is known to exacerbate bipolar disorder.\nThere is also mounting evidence linking imbalances in the microbial species that make up the gut microbiome to a number of health problems including allergies, autoimmune disorders, and psychiatric mood disorders.\nCurrently, the standard treatment includes a combination of psychotherapy and prescription medications such as mood stabilizers and antipsychotics.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release mentions the standard treatments for bipolar disorder:\n\u201cCurrently, the standard treatment (of bipolar illness) includes a combination of psychotherapy and prescription medications such as mood stabilizers and antipsychotics.\u201d", "answer": 1}, {"article": "\u201cOur analysis firmly establishes that controlling LDL over time translates to fewer deaths in this population.\u201d\n\nProfessor Sir Nilesh Samani, medical director at the British Heart Foundation, said: \u201cThis research further demonstrates the benefits of statins for people who have high levels of cholesterol in their blood.\nThere was also an 18% reduced risk of dying from any cause over the 20-year period.\nThe 20-year project examined data from 2,560 men taking part in a randomised clinical trial to test the effects of statins versus a placebo.\n\u201cThe role of cholesterol in causing heart disease has been disputed by some, but this paper provides yet more evidence of the link, and the benefits of statins to prevent heart disease.\u201d\nThey found that compared with the placebo, there was a 27% reduced risk of coronary heart disease, a 28% reduced risk of dying from coronary heart disease, and a 25% reduced risk of coronary \u201cevents\u201d such as a heart attack.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This is not adequately explained. While a 20-year study sounds impressive, we\u2019re not told about other similar treatments and lifestyle changes.", "answer": 0}, {"article": "Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance.\n\"The Oncotype DX DCIS Score result was validated in two studies including nearly 900 patients and is the only genomic test for patients with pre-invasive breast cancer,\" said Phil Febbo, M.D., chief medical officer, Genomic Health.\nNOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.\nThe Oncotype DX DCIS Score result provides patients with an individualized estimate of local (in the same breast) recurrence, which could be either invasive breast cancer or DCIS.\nThe results showed that physician treatment recommendations changed for 31 percent of patients after receiving the DCIS Score result, reducing the number of patients receiving a radiotherapy recommendation by approximately one-third.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not discuss alternatives to the Oncotype DX DCIS Score, except for the absence of such testing. But since there are no other commercially available tumor genomic tests for DCIS, we\u2019ll rate the story Not Applicable here.", "answer": 2}, {"article": "WEDNESDAY, Nov. 30, 2011 (HealthDay News) -- Eating baked or broiled fish as little as once a week may boost brain health and lower the risk for mild cognitive impairment and Alzheimer's disease, new brain scan research suggests.\nFor now, the connection must be viewed as an association, rather than a cause-and-effect.\n\"They had larger brain cells in areas of the brain responsible for memory and learning.\n\"And that would be a very small lifestyle change that can affect disease risk a long time down the line.\"\nFor more on brain health, visit the Society for Neuroscience.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The competing WebMD story much more explicitly stated \u201cother risk factors for memory loss.\u201d\n ", "answer": 0}, {"article": "Some doctors are raising concerns about a new cancer-treatment device that uses electrical jolts to zap tumors but that hasn't been through a large clinical trial to prove it's safe and effective in people.\n\nThe device, called NanoKnife, is currently being used in about 13 U.S. hospitals including Baptist Health Medical Center in Little Rock, Ark., University of Louisville, and Shands Hospital/University of Florida in Gainesville, Fla. Each machine costs as much as $300,000. Some of the hospitals are aggressively promoting...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not do a very good job of contrasting this treatment with other treatments. This is disappointing because one of the claims made by the manufacturer\u2019s CEO is: \"We think this is a very promising technology for treating cancer that is otherwise untreatable.\" Some specifics about those cancers and how they are otherwise treated would have been nice. Because the NanoKnife has not been compared to a more traditional surgical approach, the benefits of the new technology are hard to\u00a0define. Unfortunately the story relies on a biased statement by the CEO of the manufacturer as its sole comparator.", "answer": 0}, {"article": "Because the prostate is small and tiny shifts in position can make accurately targeting tumors difficult, OU Physicians has software and a real-time machine that allow doctors to place the seeds exactly where they are needed.\nAlthough long-term data are unavailable, results have been positive.\nThe procedure requires a hospital stay, at the end of which the needles and pellets are removed.\nIn the balloon-catheter method, also known as Mammosite, a doctor inflates a balloon in the tumor cavity, and a catheter delivers the radioactive pellet.\nBrachytherapy also has fewer side effects such as radiation burns.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article describes the most common alternative, external beam radiation. \n\u00a0", "answer": 1}, {"article": "\"Studies comparing stage of disease with outcome following surgery suggest that death rates frompancreatic cancer would be reduced if the disease were diagnosed at an earlier stage,\" said Dr. Raghu Kalluri, chair of cancer biology at M.D.\nThe researchers found that the presence of the protein could distinguish with 100 percent accuracy whether patients had early stage pancreatic cancer or chronic pancreatitis, a major risk factor for the cancer.\nThe pancreas is located deep within the body, so early tumors cannot be seen or felt during routine physical exams.\nIf such a test were developed, it would likely be used first to test patients at high risk for pancreatic cancer.\n\"This presents an unprecedented opportunity for informative early detection of pancreatic cancer and in designing potential curative surgical options.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article refers to \u201cvarious markers\u201d that are used to detect pancreatic cancer in a blood test but calls them too unreliable for widespread screening. The article is consistent with others in stating there currently is no reliable test available.", "answer": 1}, {"article": "Cardinal says older adults need to realize that exercise can greatly improve their quality of life by maximizing function as long as possible.\nThat belief \"is pervasive among older adults,\" he says, even though for many of them, meeting the minimum requirements \"is doable.\"\n\"It's the secret ingredient to successful aging in terms of quality of life.\"\nPrevious findings from the same study showed that the exercise program lowered the risk of becoming disabled in the first place; this one showed that it sped recovery from an episode of disability and lowered the risk of subsequent episodes.\nAccording to statistics from the Centers for Disease Control and Prevention, just 28 percent of those 75 and up meet the recommendation for aerobic activity, and only 8 percent also did the suggested amount of strength training.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The most likely alternative is a rehab program that would incorporate many of the same elements as the study protocol.", "answer": 2}, {"article": "In devising their models, the researchers updated assumptions that have cast doubt on the relevance of existing breast-cancer risk calculators, which relied on the experiences of women who got an earlier generation of screening mammograms and were more likely to die of breast cancer than is currently the case. Here, teams of modelers from Erasmus University in the Netherlands, Albert Einstein College of Medicine in New York and Harvard Pilgrim Healthcare assumed that women were getting digital mammograms, which offer improved cancer detection rates at lower radiation dosages than earlier mammographic methods. They took into account improved rates of breast cancer treatment effectiveness, and changing causes of mortality for women older than 50. They also took account of the fact that breast density decreases in older women.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article explains the current guidelines, and the variations in recommendations that are based on previous calculations of risk. Implicit in the story is the fact that these are \u201cguidelines,\u201d and not prescriptive rules; and that there must always be interpretations and exceptions to them.", "answer": 1}, {"article": "Saxon and her team reported their observations in the Nov. 22 online edition of Circulation.\nThe finding is based on an analysis of nearly 186,000 patients outfitted with either an implantable cardioverter defibrillator (ICD), a cardiac resynchronization therapy device (CRT), or a defibrillator combined with a CRT device (a CRT-D).\nThe poorer prognosis for CRT-only patients was attributed to their older average age (76 years), and the fact that they may be relatively sicker overall.\nThe study authors noted that the observation is somewhat surprising, given that some of the patients not enrolled in structured studies have already experienced a cardiac event and are therefore prescribed such devices to prevent a recurrence.\n\"It's highly likely the reason these patients did better is that they were receiving earlier diagnoses, and they were also empowered to take charge of their own health care more,\" Saxon said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story fails to provide the reader with sufficient information on the differences between the devices in the study and the rationale for one over another in patients with heart failure. The study sought to answer 4 questions, only one of which was highlighted in the story. As a result a comparison between the various devices and remote monitoring is muddled to say the least.", "answer": 0}, {"article": "Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.\nThis approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.\n\"TrueTear\u2122 represents a technological breakthrough for eye care professionals as it delivers an effective, non-invasive and drug-free way to temporarily increase tear production,\" said David Nicholson, Chief R&D Officer, at Allergan.\nWARNINGS \n\nDo not apply stimulation around electronic monitoring equipment (eg, cardiac monitors, ECG alarms), in the bath/shower, while driving, operating machinery, during activity in which sneezing/watery eyes may cause risk, areas other than the nose, within 3 feet of shortwave or microwave therapy equipment, around flammable anesthetics mixture (air, oxygen or nitrous oxygen).\nThere have been two clinical studies showing positive safety and effectiveness of the device in the increase of tear production completed with 145 aqueous deficient dry eye adult patients.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release includes quotes calling the device a breakthrough and touting its superiority to other dry eye treatments, without clearly noting that neither of the studies mentioned in the release compared the device to other treatments.\nIt also doesn\u2019t name any alternative treatments now in use, including artificial tears, and immunosuppresant drugs and tear duct plugs.", "answer": 0}, {"article": "There\u2019s ample reason for caution.\nInflammation is a sign of damage from cholesterol.\nAll were taking statins to lower LDL cholesterol.\nThe study was sponsored by Merck, the drug\u2019s manufacturer.\nThe first patients will be enrolled in April, according to Dr. Rory Collins of Oxford University, where the research will be overseen.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The lead sentence of this story portrays the experimental drug as a potential complement to lifestyle changes and statin treatment. ", "answer": 1}, {"article": "Any opinions, findings, conclusion, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the view of the U.S. Dept.\nIn addition, there were differences in the measured absolute amounts of exercise performed when comparing objective activity monitoring using a wearable \"device\" and self-report of physical activity.\nThere was a continuous, graded effect with the greatest benefits seen in the participants who engaged in at least 48 minutes of physical activity per week.\nThe content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.\nFor the LIFE study, the researchers analyzed data from 1,635 men and women age 70-89 over an average of 2.6 years.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release doesn\u2019t mention any alternatives to walking as a physical exercise. Multiple studies have shown benefits to the elderly from resistance training, cardiovascular endurance training, balance and flexibility training.", "answer": 0}, {"article": "Funding came from the National Institutes of Health and the American Heart Association.\nTo reap the most benefit, the exercise regimen should begin by late middle age (before age 65), when the heart apparently retains some plasticity and ability to remodel itself, according to the findings by researchers at the Institute for Exercise and Environmental Medicine (IEEM), which is a collaboration between UT Southwestern Medical Center and Texas Health Presbyterian Hospital Dallas.\nIn the current study, researchers wanted to know if exercise can restore the heart's elasticity in previously sedentary individuals - especially if begun in late middle age.\nAt the end of the two-year study, those who had exercised showed an 18 percent improvement in their maximum oxygen intake during exercise and a more than 25 percent improvement in compliance, or elasticity, of the left ventricular muscle of the heart, Dr. Levine noted.\nThe more than 50 participants in the study were divided into two groups, one of which received two years of supervised exercise training and the other group, a control group, which participated in yoga and balance training.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "It\u2019s not clear if there are any viable alternatives to exercise for the outcomes addressed in this study. The subjects selected for this study \u2014 if they, indeed, have less flexible left ventricles \u2014 are potentially comparable to patients with what is called \u2018heart failure with a preserved ejection fraction (or, HFpEF; with ejection fracture being a way to measure the efficiency of the heart as a pump). The paper mentions the medication, spironolactone, as \u2018the only treatment strategy recommended (class II recommendation) to counteract the debilitating effects of HFpEF.\u201d The news release could have mentioned this alternative, but we won\u2019t dock points for not doing so. We\u2019ll rate it not applicable.", "answer": 2}, {"article": "So, the investigators asked, could a scan identify those whose actual risk is lower than what was calculated?\nBut if that person has a calcium score of zero, the actual risk turned out to be 4 percent, below the 7.5 percent threshold for recommending a statin according to the guidelines and below the 5 percent risk for considering a statin.\nFor example, a person who, according to the current risk calculator, has a 12 percent risk of a heart attack in the next decade should take a statin, the guidelines say.\nDr. Krumholz and Dr. Khurram Nasir, a preventive cardiologist at Baptist Health South Florida, who conceived the new study, reasoned that research on heart scans had not been designed to help doctors make treatment decisions they face today.\nAccording to today\u2019s guidelines, half had risk scores high enough that a statin would be recommended or should be considered.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no mention of alternative risk calculators that include lifestyle and other factors, which people on the fence can use to help clarify their thinking about statin treatment. It also does not clearly point out that people who are uncertain about statin treatment can try the drug to see if they experience bothersome side effects. In other words, there are alternative ways for people to gather information that could help them decide about statin treatment.", "answer": 0}, {"article": "Both types are thought to be beneficial.\nThe MRIs showed higher white matter hyperintensity volume, tiny lesions in the brain, raising the risk for death, stroke and dementia for the low omega-3 fatty acids group.\n\u201cThis is an important new finding that supports omega-3 for brain health and brain size,\u201d said Dr. Majid Fotuhi, chairman of the Neurology Institute for Brain Health and Fitness and assistant professor of neurology at Johns Hopkins University School of Medicine.\nThe typical American diet doesn't contain enough of either.\nThey controlled for such risk factors as age, smoking, gender, body mass index, physical activity and APOE, the one known gene linked to dementia risk.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions alternative sources of omega-3 fatty acids and recommends the MyPlate government dietary guide. Other alternatives for dementia prevention such as exercise and mental stimulation could have been mentioned as well.\n\u00a0", "answer": 1}, {"article": "Kaiser funded the study.\n\"Even after the rash has healed, the pain can last for months or even years,\" said lead study author HungFu Tseng, a research scientist at the Kaiser Permanente Division of Research and Evaluation in Pasadena, Calif.\n\nZostavax, as the vaccine is called, was approved in 2006, based on the results of clinical trials.\n\"I think it's a very good vaccine, and it's a safe vaccine, but obviously there needs to be continuing surveillance of usage of the vaccine to make sure there are no adverse effects that are seen in one in a 100 million cases versus one in five or 10,000 people,\" said Sumaya, also a member of CDC's Advisory Committee on Immunization Practices.\nIn vaccinated individuals, the rate of shingles was 6.4 cases per 1,000 people in a year while it was twice that -- 13 per 1,000 -- in the unvaccinated population, the investigators found.\nEven though the vaccine is only about 55 percent effective, \"it's better than nothing,\" she said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\n\nWhile it may seem that the decision to vaccinate is a simple yes or no matter, this story does a nice job of expanding the question to include other vaccination priorities. It includes comments that point out that shingles, while terribly painful, is not contagious or life-threatening\u2026 and that considering the high cost of the shingles vaccine, it may be reasonable to place a higher priority on other vaccinations. The story does readers a service by addressing some of the real world choices people face, rather than merely considering a single intervention in a vacuum.", "answer": 1}, {"article": "The U.S. drugmaker on Monday said patients taking the approved 2 milligram dosage of Keytruda and those taking an experimental 10 milligram dose had longer overall survival compared with those taking docetaxel, a standard treatment for non small cell lung cancer (NSCLC), the most common form of lung cancer.\nMore detailed data from the study will be provided soon, Merck said, adding that it will ask the U.S. Food and Drug Administration later this year to add the new data to the drug\u2019s package insert label.\nThose whose tumors expressed PD-L1, but not at high levels, did not show such a statistically significant benefit in progression-free survival.\nKeytruda and a similar treatment from Bristol-Myers Squibb Co called Opdivo are antibodies designed to block the interaction between PD-L1 and another protein, PD-1, whose natural function is to put checks on the immune system.\nThe approval was contingent on the company providing more detailed data in the future on Keytruda\u2019s safety and effectiveness.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does make clear that Keytruda was being compared to docetaxel, so we\u2019ll award a Satisfactory here. Again, however, it would have been very good to know how well Keytruda compared to docetaxel. Was the improvement in overall survival time, and in postponing progression for patients with high-expressing PD-L1 cancers, a meaningful one? Even if Merck declined to provide that information, the story could say that. Are they still crunching the numbers? Or the story could have included input from independent experts on what a \u201cmeaningful\u201d improvement might look like; reasons to be optimistic; reasons to be cautious.", "answer": 1}, {"article": "\"There are 150,000 new cases of colon cancer each year in the United States, treated at an estimated cost of $14 billion,\" noted Dr. David A. Ahlquist, professor of medicine and a consultant in gastroenterology at the Mayo Clinic in Rochester, Minn.\n\n\"The dream is to eradicate colon cancer altogether and the most realistic approach to getting there is screening,\" he said.\nIn two other presentations at the meeting, researchers have linked key gene variants to the risk for colon cancer and also to the prognosis of the disease.\n\"Obviously, these findings need to be replicated on a larger scale,\" he said.\nIf a DNA abnormality is found, a colonoscopy would still be needed to confirm the results, just as happens now after a positive fecal occult blood test (FOBT) result.\nThe search for a highly accurate, noninvasive alternative to invasive screens such as colonoscopy or sigmoidoscopy is a \"Holy Grail\" of colon cancer research.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not compare the new approach with other similar approaches now in development, and did not give adequate data-driven comparisons with other screening methods that are now used.", "answer": 0}, {"article": "Craig Horswill, clinical associate professor of kinesiology and nutrition at the University of Illinois at Chicago, says the study adds to the growing body of evidence that suggests strategies for increasing non-exercise active thermogenesis \u2014 defined as spontaneous activity unrelated to a fitness routine \u2014 are needed to help overcome the detrimental effects of prolonged sitting.\nThe device, which is commercially available, was a movable footrest, suspended from the underside of the desk, which enabled the feet to swing, twist or teeter.\n\u201cThis is more evidence that NEAT, something everyone can do throughout the day, may be an important strategy for improving health, and even reducing early death,\u201d said Horswill.\nThe findings are published in WORK, a journal affiliated with the Canadian Association of Occupational Therapists and endorsed by the International Ergonomics Association.\n\u201cThese results suggest that non-exercise active thermogenesis, which we call NEAT, can increase movement and calorie burning, and may have the potential to impact health,\u201d said Horswill, the senior author on the study.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "No other alternative devices that promote leg movement while seated were mentioned. But in fact there are a ton of other options to stimulate movement while seated \u2014 from balance balls to leg and arm peddlers (and some are also significantly less expensive).", "answer": 0}, {"article": "PARIS (Reuters) - Sanofi-Aventis\u2019 cabazitaxel candidate prostate cancer drug combined with prednisone reduced the risk of death by 28 percent compared with another treatment, the outcome of a final-stage trial showed.\nThis compared with 1.9 percent using mitoxantrone.\nThe primary endpoint of the so-called Tropic trial was overall survival.\nFiling for approval in the EU has been completed.\nThe FDA\u2019s review should happen in the third quarter, Sanofi said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0There was no comparison with other approaches other than the single other treatment in the study. \u00a0This is an inadequate representation of the options for men managing advanced prostate cancer.", "answer": 0}, {"article": "Control subjects were recruited from volunteers at the locations where the study was being conducted.\n\"This is the first paper demonstrating an objective method of diagnosing mTBI that relies on physiologic parameters,\" said Hoffer, who is professor of otolaryngology at the University of Miami Miller School of Medicine.\nAnother benefit for this research was that \"this next generation test has the considerable advantage of not requiring baseline testing,\" said study co-author Carey Balaban, Ph.D., of the University of Pittsburgh.\nThe goal was to identify OVRT performance metrics that differentiated between mTBI and control groups and to create a model that could accurately evaluate mTBI neurologic status in patients.\n\"It is not inconceivable that in the near future you will see the I-Portal goggle used on every sideline in America,\" Hoffer said.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release says that mild traumatic brain injury is usually diagnosed through physical exam findings. One of the study authors adds the goggle does not require baseline testing \u2014 which includes assessments to gauge reaction time, memory capacity, speed of mental processing, and executive functioning of the brain, according to the Sports Concussion Institute.\nIt would have been interesting to compare the sensitivity/specificity numbers of the goggle to those of the physical exam (with baseline testing). Sure, 95 percent specificity sounds pretty good itself, but what accuracy can physicians achieve the traditional way (aka through the physical exam)?\nAlthough the news release doesn\u2019t address this, we feel it did a Satisfactory job here by mentioning the alternative.", "answer": 1}, {"article": "A new study confirms that long-acting forms of contraception such as intrauterine devices and implants are better than birth control pills and patches at preventing pregnancies, giving doctors new ammunition to recommend these methods.\n\nThe study, to be published Thursday in the New England Journal of Medicine, involved about 7,500 women in a project promoting long-acting birth control to reduce unintended pregnancies. There are an estimated three million unplanned pregnancies a year in the U.S., often because of incorrect or...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Mixed bag:\nThe story does a good job of comparing alternatives from the standpoint of effectiveness.\u00a0 However it neglects any consideration of how they compare in terms of side effects and cost.\n\u00a0", "answer": 0}, {"article": "Why Biogen is breathing a sigh of relief with the latest Alzheimer\u2019s data\n\nWe already know Eli Lilly\u2019s big bet on Alzheimer\u2019s disease didn\u2019t work. But a deep dive into just how it failed has provided a bit of encouragement to Biogen and the many companies still hoping to succeed where their rival fell short.\n\nLilly\u2019s treatment, solanezumab, had no significant effect on the buildup of toxic brain plaques believed by many to be responsible for Alzheimer\u2019s neuron-destroying effects. The company had already disclosed that the treatment failed to improve patients\u2019 cognition and function, but the new data, released Thursday night, shed some important light on the underlying biology.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story adequately compares alternatives and discusses the overall lack of any effective medication for Alzheimer\u2019s disease.\nAs noted above, however, a discussion of competing hypotheses about the origins of the disease, along with related potential treatment strategies, would have been useful to include.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/15/national/a141001S34.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No mention made of other approaches to bone loss such as engaging in weight bearing exercise, or prescription medications to enhance bone building or inhibit bone resorption.", "answer": 0}, {"article": "http://www.\nAmsterdam, July 3, 2017 - Doctors should consider radiosurgery earlier for patients with severe facial pain, according to a new study in the International Journal of Radiation Oncology*Biology*Physics (the \"Red Journal\") - the official journal of the American Society for Radiation Oncology (ASTRO).\nWhile this can reduce the pain, it makes patients drowsy and tired, and they report feeling drunk.\nThe article is \"Stereotactic Radiosurgery for Trigeminal Neuralgia Improves Patient-Reported Quality-of-Life and Reduces Depression,\" by Rupesh Kotecha, Jacob A. Miller, Sujith Modugula, Gene H. Barnett, Erin S. Murphy, Chandana A. Reddy, John H. Suh, Gennady Neyman, Andre Machado, and Sean Nagel.\nAccording to the new study, radiosurgery, which is normally a second line treatment to be used following the medication, helps improve quality of life and reduce depression in patients with TN.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Although the release comments on medicines used for treating trigeminal neuralgia, their mention focuses on very severe side effects. However, no information is provided about the use of these medicines in the patients participating in this study. Only by directly comparing different forms of treatment can one determine their relative benefits. It is also worth mentioning that some patients will have spontaneous improvement, so it isn\u2019t clear if it was the radiation treatment, or just the passage of time that helped.", "answer": 0}, {"article": "NEW YORK (Reuters Health) \u2014 Could one hour be all you need to quit smoking, without cravings or side effects?\nThe lack of any drugs involved in laser therapy \u201cwould be the beauty of this,\u201d he said.\nThose in the three treatment group, in turn, had better success rates than a control group that was given fake laser treatments.\nIn response, Laser Therapeutics is designing another study to address those comments, he said.\nThe UK study found that the side effects of the treatment were similar to some withdrawal symptoms, and the FDA has classified the laser as a \u201cnonsignificant risk\u201d device.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a great job placing the therapy into the larger context of interventions to help people quit smoking, particularly acupuncture.", "answer": 1}, {"article": "The scientists published details of their work online Thursday in the journal Science Translational Medicine.\nThe success represents an advance that is \"absolutely critical in terms of making prosthetics useful,\" says Mike McLoughlin, an engineer at the Johns Hopkins University Applied Physics Laboratory.\n\"But we're really not at the point where we could, say, get him to feel the difference between silk and burlap,\" Gaunt says.\nStill, the ability to receive touch sensation from a robotic arm has the potential to help not only thousands of people who are paralyzed, but also people with a wide range of physical disabilities, McLoughlin says.\n\"Without sensory feedback, somebody would have to actually have to look at the prosthetic, look at the cup, start to close the hand, (and) visually see the cup is starting to deform,\" he says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not give readers any sense of what else is out there for an amputee, including other prosthetics such as one from 2014 that provides \u201csensory\u201d info without need of a brain implant. (The electrodes are implanted in the patient\u2019s arm.)\nIt also does not provide context that many people with upper limb amputations choose to use less-high-tech prosthetics because these last longer and are more durable or because they cost less.", "answer": 0}, {"article": "The pill is his blood pressure medication.\nIt occurs when something blocks or reduces the flow of blood to brain cells.\nHe also keeps his blood pressure down by exercising and paying attention to his weight and diet.\nThe evidence is clearest for a type of dementia called vascular dementia.\nAnd he says other people with high blood pressure should follow his lead.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story indirectly discusses alternatives\u2013such as exercise and diet.", "answer": 1}, {"article": "THURSDAY, July 20, 2017 (HealthDay News) -- A laser treatment can reduce spots in people's vision known as \"floaters,\" a new study finds.\nThey explained that, currently, there are three management options for floaters: patient education and observation; surgery; and a laser procedure known as YAG vitreolysis.\nFor her part, Goldberg said that although \"there was significant improvement in patients' symptoms following treatment, and no significant complication was seen,\" these findings are early and \"it is difficult to predict the long-term safety of this laser procedure.\"\n\"Floaters often arise as the vitreous -- a gel-like substance that fills the eye -- contracts and pulls away from the back of the eye,\" explained ophthalmologist Dr. Naomi Goldberg, who reviewed the new research.\n\"Greater confidence in these outcomes may result from larger confirmatory studies of longer duration,\" the study authors wrote.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes clear that there are alternatives to the YAG laser treatments:\u00a0 \u201cThere are three management options for floaters: patient education and observation; surgery; and a laser procedure known as YAG vitreolysis.\u201d Some discussion of the effectiveness of surgery and education would have been useful, however.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070520/28diet.b.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The news story neglected to mention other safe methods of controlling weight in postmenopausal women. These include calorie-watching and exercise.", "answer": 0}, {"article": "Thus, we foresee an exciting, long term relationship that will benefit cancer patients and cancer research.\u201d\n\nIn December 2007, Hitachi was the first company in the U.S. to clear FDA Premarket Notification Special 510(k) for the \u201cPROBEAT\u201d system with its spot scanning irradiation technology.\nToshiaki Higashihara, President & COO of Hitachi, Ltd. stated that, \u201cWe are greatly honored that Johns Hopkins selected Hitachi as their proton partner.\nThree primary benefits are: (1) more accurate irradiation which reduces the side effects to healthy tissues surrounding the tumor compared with irradiation from conventional double scattering irradiation; (2) patient-specific collimators and boluses become obsolete, shortening set up times for patients; and (3) high proton beam usage factor reducing unnecessary secondary radiation.\nThis collaboration, which includes a 10-year maintenance service, marks the first multi-room PBT application in the nation\u2019s capital.\nUnlike conventional scattering technology, spot scanning technology delivers narrow beams to the tumor and the complex tumor shape can be irradiated through repetitive beam delivery with quick position change.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does not mention the alternatives to PBT. The more widely available alternative to proton therapy is photon radiotherapy. The hardware costs for a proton center are approximately twice that of a photon facility.", "answer": 0}, {"article": "Here's the scientific proof.\nWith the widespread availability of marijuana in recent years thanks to its legalization in a growing number of states, there has been increasing concern about the long-term health consequences on teens who might be able to get easier access to it illegally.\nOne major limitation of the study is that it ends when the men are in their 30s \"which may be too early for decrements in health to emerge,\" the authors acknowledge.\nHowever, the reanalysis regarding psychotic disorders contradicted the earlier conclusions -- that there indeed appeared to be a higher risk of psychotic disorders among marijuana users in the study versus non-users that approached statistical significance when using a more liberal test.\nUpdate: The study's findings generated significant controversy along with requests for supplemental analysis, according to the editors of the Psychology of Addictive Behaviors.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This is not an\u00a0applicable category for this story topic. However, it is interesting to consider whether teens who use marijuana are not\u00a0using alcohol, and whether that may lower their risk of harms from alcohol use.", "answer": 2}, {"article": "\"We know there is decreased utilization of PSA testing in some institutions and health systems, but has the number of incident cases per month changed substantially since the draft guideline was issued?\"\nWhile it may reduce the risk of over diagnosis and overtreatment, the reduction in intermediate and high risk cancer diagnoses raises concern because of the potential for delayed diagnoses of important cancers in men who may benefit from treatment, according to investigators reporting in The Journal of Urology\u00ae.\nThe study showed that 12 months after the draft guidelines were published diagnoses of new low risk cancers had fallen by 37.9%, and continued to fall more rapidly than other disease risk strata, suggesting that, in this regard, the USPSTF recommendation had its intended effect,.\nSimilarly, new diagnoses had fallen by 23.0-29.3% among men over age 70 and by 26.0% among infirm men, populations at risk for harms of treatment but unlikely to live long enough to benefit from early detection.\n\"Our study was designed to assess the impact of the USPSTF recommendation on screening practices among urologists and primary care providers and the incidence of prostate cancer,\" explained lead investigator Daniel A. Barocas, MD, MPH, of the Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The alternatives are to screen (or at least screen more selectively) vs. not to screen. Although the story at least raises the comparison, the only way to truly compare the alternatives is to look at mortality outcomes, ideally with randomized trials. We have data from the ERSPC (European Randomised Study of Screening for Prostate Cancer) showing that screening reduces mortality by about 1/1000; the US PLCO (Prostate, Lung, Colorectal, and Ovarian) Cancer Screening Trials was negative. A key message is that men need to make informed decisions and be aware that a potential trade off with not screening is that the risk of dying from prostate cancer might be slightly increased. However, the current study is unable to provide data to quantitate that risk.", "answer": 1}, {"article": "March 7, 2011 -- Traditional Chinese acupuncture may be useful in reducing the severity of hot flashes and other symptoms of menopause, a new study suggests.\nLevels of estrogen and other hormones were measured before the study and after the first and last acupuncture sessions in both those receiving real and sham treatments.\nHalf of them received traditional acupuncture treatment.\nThose in the comparison group were treated with shams needles at the same acupuncture points.\nThe rest were treated with \u201csham\u201d acupuncture needles that were blunted and did not penetrate the skin.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No discussion of other research in this field, including lots on acupuncture.", "answer": 0}, {"article": "Megan L. Kavanaugh, a senior research scientist at the Guttmacher Institute, which studies reproductive health, said in an interview that \u201call new insurance plans obtained through the act\u2019s exchanges fully cover all contraceptive methods without any co-payments or other out-of-pocket costs.\u201d Title X family planning clinics and Planned Parenthood clinics are more likely than other sources to offer LARC methods, she said.\nIn real-world use, these methods are associated with a one-year pregnancy rate of less than one per 100 women.\nThe latter is also associated with some cramping at the time of insertion.\nThe risk of an unwanted pregnancy with these other methods was especially high among women under 21, whose rate of unintended pregnancy was nearly double that among older women.\nWith both implants and IUDs, fertility returns quickly as soon as the devices are removed.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story did a great job of outlining many different alternative methods of contraception and their effectiveness.", "answer": 1}, {"article": "He studied the extract puerarin.\nMay 17, 2012 -- An extract from the Chinese herb kudzu may help drinkers cut down on drinking, according to a new pilot study.\n\"It didn't stop the drinking,\" says researcher David M. Penetar, PhD, assistant professor of psychology at McLean Hospital and Harvard Medical School.\nIt is one of the substances known as isoflavones found in kudzu.\nThe study is published in Drug and Alcohol Dependence.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that there are other medications approved for treating alcohol abuse and dependence, but they don\u2019t work for everyone. Some additional detail about these medications wouldn\u2019t have been out of place, but we\u2019ll call it good enough for a satisfactory.", "answer": 1}, {"article": "But after controlling for those risk factors, \"the difference [in brain aging] is still there so we conclude that omega-3 fatty acids likely explain them,\" Tan said.\nThe study, published in the Feb. 28 issue of the journal Neurology, did not prove that omega-3 fatty acids prevent mental decline, merely that there may be an association between consumption of fatty acids and brain health.\nThe researchers found that those with the lowest levels of omega-3s had worse scores on tests of visual memory, attention and abstract thinking than people who ranked in the top 75 percent for fatty-acid levels.\nBut in the current work, researchers could estimate the amount of omega-3s that participants had consumed in the past several months by looking at how much had built up in their red blood cells.\nAnother possibility is that the slight mental decline that the people in the older brain group were experiencing caused them to eat less healthy omega-3-rich foods, instead of vice versa.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no discussion of other habits or behaviors, such as exercise and mental stimulation, that are associated with maintenance of cognitive function with age. The story also did not mention other potential sources of omega-3 fatty acids, as CNN did.", "answer": 0}, {"article": "Awair is the first smart air quality device that monitors, analyzes and provides feedback to improve the air you breathe.\nAs soon as you see other colored (amber and red) dots show up on top of the green dots, your environment is getting off the healthy ranges whether it being temperature, humidity, CO2, VOCs, and dust,\u201d Ronald Ro, the CEO and co-founder of Bitfinder Inc., the makers of Awair, told FoxNews.com.\n\u201cLow dry humidity in the winter can make asthma worse and children who have dried mucosa can acquire some nasal infections easier,\u201d Dr. Robert G. Lahita, chairman of medicine at Newark Beth Israel Medical Center in New Jersey, told FoxNews.com.\nEvery room in your house could be susceptive to some form of an air pollutant, but now there is a new device and app that says it can help you breathe easier by tracking air quality.\nThe device collects data such as indoor temperature, humidity, carbon dioxide, fine dust particles and VOCs.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not talk about any of the other air quality monitoring devices that are on the market, at all. And there are a lot of them. We\u2019ll come back to this under \u201cNovelty.\u201d", "answer": 0}, {"article": "Study Limitations: Imbalances caused by matching groups of obese patients for comparison based on age, sex, body mass index and diagnoses of diabetes.\nBecause researchers are not intervening for purposes of the study they cannot control for all the natural differences that could explain study findings.\nWhy The Research Is Interesting: Much is known about the short-term outcomes of bariatric surgery for weight loss but relatively little is known about its long-term effects.\nSome previous research has been limited by a number of factors, including the lack of a comparison group of obese patients who did not undergo bariatric surgery.\nLink will be live at the embargo time http://jamanetwork.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The nonsurgical alternatives to treating obesity are not clearly explained in this news release.", "answer": 0}, {"article": "\"Although autism is still principally a clinical diagnosis, this study ... may allow for a new approach to classifying children with autism and may even assist in the early identification of affected children at a younger age,\" said Dr. Andrew Adesman, chief of developmental and behavioral pediatrics at the Steven & Alexandra Cohen Children's Medical Center of New York in New Hyde Park, NY.\n\"What was unique about this study is the very large number of children studied,\" Dawson noted.\nShe said the findings are important because, \"they help us understand why individuals with autism have difficulty with complex behaviors, such as social interaction and language.\nThe use of EEG-based testing may help diagnose autism in children and may improve early detection in infants, leading to more effective treatments and coping strategies, the researchers said.\nThe children with autism also had increased connectivity between brain regions that were farther apart, which might be a mechanism developed to compensate for reduced short range connectivity, the researchers said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention that autism is a clinical diagnosis (and though this research study was not about diagnosis, it deals with better understanding the brain activity behind the behaviors which lead to the diagnosis). It would be hard for the writer to do much more than that.", "answer": 1}, {"article": "\u201cThe study suggests there is little advantage of choosing Eylea or Lucentis over Avastin when a patient\u2019s loss of visual acuity from macular edema is mild, meaning a visual acuity of 20/40 or better.\nLaser treatment alone was the standard treatment for DME until widespread adoption of anti-VEGF drugs a few years ago.\nSubsequently, injections were resumed if DME worsened.\nThe macula is the area of the retina used when looking straight ahead.\nMacular edema can arise during any stage of diabetic retinopathy and is the most common cause of diabetes-related vision loss.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Corrective laser surgery is named as the alternative therapy to drugs.", "answer": 1}, {"article": "Media Advisory: To contact corresponding author Susan L. McElroy, M.D., call Jennifer Pierson at 513-536-0316 or email jennifer.pierson@lindnercenter.org\nThis study was supported by Shire Development, LLC, including funding to Scientific Communications & Information and Complete Healthcare Communications, Inc., for support in writing and editing the manuscript.\nThe study included 259 and 255 adults with BED in safety and intention-to-treat analyses, respectively.\nConfirmation of these findings in ongoing clinical trials may results in improved pharmacologic treatment for moderate to severe BED,\" the study concludes.\nConsequently, many patients with BED are undertreated despite having functional impairments and difficulties in their social and personal lives.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release\u00a0identifies cognitive behavior therapy and psychotherapy as alternatives, but offers no comparison in outcomes other than to make the point that few health care providers use the behavioral alternatives.", "answer": 1}, {"article": "If a pill could prevent teenagers from taking dangerous risks, would you consider it for your children?\n\nI\u2019d be tempted. My skateboard- and bicycle-riding son was hit by a car\u2014twice\u2014when he was a teenager. I would have welcomed anything that could have averted those dreadful phone calls from the emergency room.\n\nWhile some bumps and scares...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no mention of alternatives in the piece, but there are several.", "answer": 0}, {"article": "UnitedHealthcare's medical policy for TMS says it is unproven for treating depression.\n\"We had several patients who were headed toward the hospital, who had this treatment and were able to avoid that,\" said Dr. Scott West, a psychiatrist who pioneered the treatment in Nashville 2 and one-half years ago.\n\"When this large magnet pulses repetitively, it causes an electromagnetic field which then passes through the skull and stimulates the brain tissue itself,\" said West, explaining a cascading effect that results in the interior nerve fibers connecting better.\nIt's an alternative to electroconvulsive therapy \u2014 shock treatments \u2014 for patients who have not responded to drugs or psychotherapy.\n\"I have a room in my house in which I had stacked boxes from when we moved 10 years ago that I wanted to get to, but I couldn't do it,\" the Centerville woman said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does provide some insight into the alternative approaches including drug therapy and electroconvulsive therapy. No useful information is provided about ECT, Vagal nerve stimulation or magnetic seizure therapy. \u00a0 The comparisons however are provided by devotees of the technology and no references are provided.", "answer": 0}, {"article": "The day after the article was released, the Mayo Clinic removed the headline, replacing it with the still misleading statement that smokeless tobacco was \u201cnot a safe product.\u201d\n\n\u201cPeople can only make as good a decision as the information available to them allows,\u201d said Sweanor, an adjunct professor in the University of Ottawa\u2019s Faculty of Law who has spearheaded the development of world-leading tobacco control initiatives in Canada since the early 1980s.\n\u201cThe public is dramatically misinformed about the relative risks of substitutable tobacco and nicotine products.\n\u201cIt would be scandalous, even criminal, to keep such facts from consumers,\u201d the researchers write.\nThe risk differentials are huge, but this is simply not known by a vast majority of those whose lives are at risk,\u201d adds Sweanor.\nIt is as if tobacco consumers were blindfolded and not allowed to see dramatic differences in harm from different products.\u201d\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Smokeless tobacco products are clearly the comparable product here and the topic of the release.", "answer": 1}, {"article": "The U.S. Physicians Health Study II included nearly 50,000 male doctors aged 50 and older and spanned more than 10 years.\nThe protective effect of the daily pill was described as \u201cmodest\u201d by the trial investigators who emphasized that the primary use of vitamins was to prevent nutritional deficiencies.\n\u201cOur trial took a very commonly used multivitamin that has basically low levels of all the different essential vitamins and minerals.\u201d\n\nThe findings suggest that the biggest health benefit may come from a broad combination of dietary supplements, he said.\nThe findings were published in the Journal of the American Medical Association and presented on Wednesday at a meeting of the American Association for Cancer Research in Anaheim, California.\nExcluding prostate cancer, researchers found about a 12 percent reduction in overall cancer occurrence and said the protective effect seemed to be greater in people who had previously battled cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story doesn\u2019t\u00a0compare multivitamins with\u00a0other steps\u00a0that may be helpful for preventing cancer, such as a healthy diet, exercise, and not smoking. The AP made these comparisons.", "answer": 0}, {"article": "Probably not.\nBut the numbers came out this way: People who drink more than four cups of coffee each day have 39% lower odds of getting mouth or throat cancer, compared to people who don't drink coffee.\nThough there weren't enough data on decaf drinkers to draw conclusions, drinking tea -- even massive quantities -- was not protective.\nThat's probably not what University of Milan researchers Carlotta Galeone, ScD, PhD, and colleagues thought they'd find when they analyzed nine studies comparing 5,139 people with head and neck cancer to 9,028 people without cancer.\nThe protection was seen for oral and pharyngeal cancer, but not for cancer of the larynx.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was some discussion of whether the association could be attributable to caffeine or fruit and vegetable consumption, and what was seen in tea drinkers.\u00a0 We\u2019ll give the story the benefit of the doubt for mentioning these other factors, although, again, inappropriate \"protective\" or \"effect\" language was used in this discussion. \n", "answer": 1}, {"article": "Please visit http://www.\n\"We put the 2012 UCSF clinical study into the real world and showed it works,\" said lead author Peter Rechmann, DMD, PhD, professor of preventive and restorative dental sciences in the UCSF School of Dentistry.\nThe authors said now that this has been shown to be effective in a non-academic clinical setting, there also is potential for insurance companies to reimburse CAMBRA and other preventive therapies for adults, thereby lowering patient costs while increasing profits for dental practices.\nThe findings, which support earlier research demonstrating positive results of the assessment and treatment method in a university setting, have the potential to transform dental care for high-risk patients at a lower cost to both patients and dental clinics and practices.\nAmong 242 patients (137 intervention, 105 control) initially identified as high risk for caries, only a quarter of the patients remained at high risk in the CAMBRA group at 24 months, while just over half (54 percent) of the control group did.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "In the strictest possible way, the release does not directly talk about all the different ways of preventing dental caries. But we were glad that the release discussed the improvements that happened for some patients in the control group who received fewer products. We are glad the release talks about possibly following up on this, in case the lesser products could still benefit many patients.\nExcerpt:\nThe researchers said the risk reduction among the control group may have been caused by the fluoride toothpaste enhancing tooth repair, as well as the mouth rinse enhancing saliva flow and having bactericidal effects. While not as significant as the CAMBRA group in this study, the risk level of these patients dropped more dramatically over time than for those in the 2012 UCSF CAMBRA study.\nIt was surprising to see the benefits gained by the control group,\u201d Rechmann said. \u201cMore research is needed to see if the products and treatment administered to this group function in the way we speculate, and if so, they might be made easily available to dental patients. Doing so can change the whole picture of caries control.", "answer": 1}, {"article": "Master said each participant was asked to carry an accelerometer to record movements and an iPod Touch loaded with an app that would ping them prompts at intervals during each day to report any symptoms they were feeling. They also completed activity questionnaires and summaries. In addition, they wore a device called an ActiGraph to monitor sleep.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Rest is the standard recommended care for concussion.\nIn terms of alternatives for tracking concussion symptoms, there does seem to be a plethora of apps available, which the story didn\u2019t mention.", "answer": 2}, {"article": "You've seen high-definition televisions. Now some medical centers are marketing their high-definitioncolonoscopes, which they say will detect more pre-cancerous polyps. Several recent studies have found a small benefit to high-definition colonoscopy over the standard variety, but gastroenterologists say physician technique is more important in detecting polyps than equipment.\n\nColonoscopy, a screening test doctors recommend for most people starting at age 50, allows doctors to remove pre-cancerous growths before they become...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As mentioned above, the story discusses several options and ends with two good graphs that actually rely on the lead doctor in the most recent study to show the benefits of high-def colonscopy, a doctor who \"receives research funding from Olympus Corp., a manufacturer of HD\u00a0scopes.\" He\u00a0helps\u00a0emphasize the importance of colonscopy\u00a0technique and\u00a0provides specifics that could help patients\u00a0ask tough questions of their own physicians. \nThe last graph in the story is about a cheaper alternative that is described as a \"reasonable alternative\" that has to be performed with more frequency. But why no mention of fecal occult blood stool tests? FOBT is the only screening test for colon cancer showed by randomized clinical trial to decrease colon cancer mortality and incidence.\u00a0 As good as the story may have been on other points, this story joins many journalistic efforts that don\u2019t seem to give FOBT its due. And for that we must rule this criterion unsatisfactory. ", "answer": 0}, {"article": "NEW YORK (Reuters Health) - When symptom-free people have heart scans to look for clogged arteries, they can end up with overtreatment and side effects, researchers said Monday.\n\u201cOverdiagnosis is threatening to become an increasingly important public health problem because of the enthusiasm for and proliferation of unproven screening tests,\u201d Lauer writes.\nBy contrast, it\u2019s well known that the scans expose patients to a high dose of X-rays, which can increase their likelihood of developing cancer.\nThe researchers expected that if the extra drugs and procedures were actually helpful, the treated people would have a lower rate of serious heart problems in the future.\nCurrently, whether a patient gets statin or aspirin is based on risk factors such as their age, and how much cholesterol is in their blood.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story ends with the researcher saying \u201cdoctors should focus on patients\u2019 lifestyle and traditional risk factors such as smoking and obesity.\u201d", "answer": 1}, {"article": "Though the study was small, the results were striking: Subjects lost an average of 17.5 pounds in 22 weeks and reduced their overall body weight by 10.5%.\nThe trial was conducted in India and paid for by Applied Food Sciences Inc. of Austin, Tex., a manufacturer of green coffee bean extract.\nSubjects did not change their calorie intake over the course of the trial.\nWhen roasted at 475 degrees, coffee beans are sometimes described as rich and full-bodied.\nIn fact, it is already available as a naturopathic medicine and antioxidant.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not compare green coffee extract with other approaches to weight loss, such as dietary changes or drugs.", "answer": 0}, {"article": "Current evidence definitely supports screening, he said.\nThe researchers note that a percentage of the patients presenting at screening had early symptoms, like a persistent cough, so the rate of cancer detection in patients who showed no indication of disease was 2.2 percent, still double the rates of previous studies.\nThe higher rates, coupled with the majority of cases being found in early, treatable stages, point toward the need for ongoing, accessible free screening in high-risk populations and underserved regions, say researchers at the Georgia Cancer Center at Augusta University.\nThe combination technology is often used to visualize other tumor types throughout the body and many patients require an injection of sugar dye, which will be taken up by the tumor but must first circulate for about an hour before the scan is done.\nThe screening of 264 high-risk individuals within a 150-mile radius of Augusta found 3 percent had lung cancer and 75 percent of those were caught early, said Dr. Carsten Schroeder, thoracic oncology surgeon at the Georgia Cancer Center and Medical College of Georgia at AU.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The focus appears to be on getting lung cancer screenings or not getting them \u2014 rather than on the virtues of any particular diagnostic technique (though there is one reference to the use of low-dose computed tomography (LDCT) technology rather than conventional chest X-rays). As such, we\u2019ll rate this not applicable.", "answer": 2}, {"article": "The brain controls how long we live.\n\u201cHowever, if the mechanism is fundamental, you might expect to see effects when an intervention is based on it.\u201d\n\nPrevious experiments had already hinted that the hypothalamus, an almond-sized part of the brain in humans, played some role in the ageing process, but what it was remained unclear.\nThe work, described as a tour de force and a breakthrough by one leading expert, suggests that ageing across the body is controlled by stem cells that are found in the hypothalamus region of the brain in youth, but which steadily die off until they are almost completely absent in middle age.\nTo test whether the decline in stem cells was causing ageing, and not itself a result of old age, the researchers injected mice with a toxin that wiped out 70% of their neural stem cells.\nImplants of stem cells that make fresh neurons in the brain were found to put the brakes on ageing in older mice, keeping them more physically and mentally fit for months, and extending their lives by 10-15% compared to untreated animals.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is all about basic research that suggests an approach that one day might slow, or possibly reverse, the aging process.\u00a0 There are no real alternatives available now to affect the aging process beyond lifestyle choices that might be healthier and appropriate treatments for illnesses that might otherwise shorten lifespans.", "answer": 2}, {"article": "Jan. 13, 2010 (Coronado, Calif.) -- A blood test under study to help diagnose lung cancer looks promising, researchers reported Tuesday at a cancer meeting in California.\nIf perfected, the test could help spare patients the need to undergo invasive procedures such as biopsies when lung cancer is suspected, they predict.\nAccording to Dubinett, about one in 500 chest X-rays shows a lung nodule of ''indeterminant significance.\"\nWhen that occurs, the next step is to examine the suspicious area, with the physician ordering a biopsy or inserting a scope into the lungs to evaluate further.\n''Currently, 20% to 25% of surgeries done for suspected lung cancer turn out to be benign diagnoses,\" says Steven Dubinett, MD, professor of medicine and pathology and director of the Lung Cancer Research Program at the Jonsson Comprehensive Cancer Center at the David Geffen School of Medicine, University of California, Los Angeles.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article describes the challenges with existing techniques, proceeding to invasive procedures following X-rays, and the outside source mentions CT scans. ", "answer": 1}, {"article": "The study was was paid for by Cytograft Tissue Engineering.\nThe vessels failed in three of the patients, which experts said was not surprising in patients so seriously ill. One other patient withdrew from the study and another died of unrelated causes.\n\"This technology is very, very promising,\" said Vladimir Mironov of the Medical University of South Carolina, who co-wrote an accompanying commentary in the Lancet that praised the study as \"a revolutionary milestone.\"\nSome experts said the results suggested that doctors might one day be able to custom-produce blood vessels for patients with circulatory problems in their hearts or legs.\nBut because dialysis is done so regularly, kidney patients often run out of healthy vessels and need an artificial one, often made out of gortex.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story makes clear that tissue-engineered blood vessel grafts are still far from clinical use, it says that at least for some patients in this study, the experimental grafts performed better than standard approaches. However, the study did not make any direct comparisons to standard approaches, so there is no evidence to support claims of superiority.", "answer": 0}, {"article": "Less Fat.\u201d\n\nMeanwhile, Erchonia Medical, based in McKinney, Tex., has aggressively marketed its Zerona laser as \u201cthe first non-invasive body contouring procedure to effectively remove excess fat\u201d even though it has yet to receive F.D.A.\nIf you\u2019re sedentary and not eating healthy food, he said, then once fat is leaked after Zerona treatments, \u201cyour body will just store it again.\u201d\n\nHow the body rids itself of fat, and how quickly, after any noninvasive body slimming procedure is unclear, said Dr. Lawrence S. Bass, a plastic surgeon in Manhattan who started using a Zeltiq device last July.\nIt has cleared the Zerona laser for pain reduction 24 hours after breast augmentation or as a way to decrease the pain associated with recovering from liposuction.\nThe low-level laser causes \u201cfat to seep out of a cell, almost like a balloon being struck by a needle,\u201d said Ryan Maloney, medical director for Erchonia Medical.\n\u201cI still have three more sessions,\u201d Ms. Bonvouloir wrote in an e-mail message.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article could have devoted more space to comparing these procedures to the process, benefits, and risks of liposuction. It could have distinguished between the two new treatments and the existing heat treatments and topical creams also sold by some of the same dermatologists, chiropractors, plastic surgeons and web infomercials that support Zeltic and Zerona. It does get points, however, for mentioning two new ultrasound products about to enter the market. \u00a0 ", "answer": 0}, {"article": "(\u201cEnjoyed\u201d?\nBut in the human studies, it wasn\u2019t always clear whether active mothers who have active children simply raised their kids to exercise a lot or whether there might have been a genetic predisposition to physical activity.\nIf that feels a little onerous, consider new findings out of Baylor College of Medicine in Houston suggesting that love of physical activity may start in the womb.\nIf expectant mothers know that exercise is not only good for them but also may offer lifelong benefits for their babies, I think they will be more motivated to get moving.\u201d\nThe offspring of those mothers turned out to be about 50 percent more physically active than those born to mothers that hadn\u2019t had the exercise wheel option.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story refers repeatedly to \u201cexercise,\u201d the only physical activity studied here was mice running on an exercise wheel, and not other forms of vigorous activity. That\u2019s the limitations of mouse research, and why these sorts of stories should be reported on sparingly.", "answer": 0}, {"article": "He divided a group of rats into galantamine and donepezil cohorts.\n\"At the doses shown to reduce nicotine self-administration, the AChEIs did not make our animals sick,\" Schmidt said.\n\"We know from the literature that upward of 30 percent of patients will report nausea and vomiting [when taking these drugs], and this will limit their compliance,\" he said.\nThere's no data to suggest that a clinician treating a smoker should prescribe one of these AChEIs now.\n\"We're very interested in screening potential efficacy of anti-addiction medications in our models,\" said Schmidt, a professor in Penn's School of Nursing and Perelman School of Medicine.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release nods briefly to the existence of other medications for smoking cessation and how galantamine would differ.\n\u201cOur goal in investigating these different repurposed medications is not to replace the medications that are already available,\u201d she said. \u201cWe know that they\u2019re effective. Our goal is to target different populations of smokers who may be more likely to experience these cognitive deficits.\u201d\nAlthough it doesn\u2019t specifically mention any other smoking cessation tools and techniques by name or discuss how successful galantamine might be in comparison, we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "After several trips to the doctor, the Mullins received the worst possible news.\n\"It's wonderful to go and talk to a parent, whose child has just diagnosed with an advanced neuroblastoma and say the odds of being cured has increased dramatically,\" said Dr. M. Fevzi Ozkaynak with the Maria Fareri Children's Hospital at the Westchester Medical Center in New York.\n\"I've been through it, it was the past, time to move on,\" he said.\nBut then his doctor offered an additional step: an experimental treatment called immunotherapy, in which antibodies that target the cancer are injected into the bloodstream and attach to the tumor cell.\n\"They tested it on me and it was a success, so I hope it works on all other kids,\" Brian said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story offered a list of treatments that the featured youngster had undergone. \u00a0While mentioning that the study results discussed came from a clinical trial, there was no discussion about whether there were other modalities currently under investigation for treatment or management of neuroblastoma.\u00a0 ", "answer": 0}, {"article": "Breaking the diet with so much as a few cookies can cause seizures to flare up.\nThough its exact mechanism is uncertain, the diet appears to work by throwing the body into ketosis, forcing it to burn fat rather than sugar for energy.\nFor the British trial, the researchers enrolled 145 children ages 2 to 16 who had never tried the diet, who were having at least seven seizures a week and who had failed to respond to at least two anticonvulsant drugs.\nAs the first randomized trial of the diet, the new study lends legitimacy to a treatment that has been used since the 1920s but has until recently been dismissed by many doctors as a marginal alternative therapy.\n\u201cThis is the first time that we\u2019ve really got Class 1 evidence that this diet works for treatment of epilepsy,\u201d said Dr. J. Helen Cross, professor of pediatric neurology at University College London and Great Ormond Street Hospital.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story reported that the children in the particular study reported on had failed to respond to at least two antiseizure medications, the story did not provide information about treatment options for children with epilepsy or whether the diet would typically be used instead of or in addition to other treatments for epilepsy. \u00a0", "answer": 1}, {"article": "\"We found that the combination of two anticytokines containing extra-low doses of antibodies against TNF\u03b1 and IFN?\nFor example, rheumatoid arthritis is associated with dysfunction of the blood vessel lining (called endothelium), which leads to lipid accumulation in the artery wall, plaque formation and atherosclerosis.\nIn patients with highly active disease, the standard biologics are better at preventing severe complications such as progressive joint destruction and/or systemic manifestations (vasculitis, uveitis, involvement of internal organs).\nFlorence, Italy - 9 July 2016: Immunotherapy reduces cardiovascular risk in patients with rheumatoid arthritis, according to research presented today at Frontiers in CardioVascular Biology (FCVB) 2016 by Professor Aida Babaeva, head of the Department of Internal Medicine, Volgograd State Medical University, Volgograd, Russia.1 The combination of two extra-low dose anticytokine drugs reduced rheumatoid arthritis disease activity and cardiovascular events.\nPatients taking the combination of anticytokines had a lower rheumatoid arthritis disease activity score, as measured by the DAS28,2 and more dramatic decreases in IL-1, IL-6 and TNF\u03b1 than the group on standard therapy alone.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are a range of alternatives (statins, antihypertensives, anticoagulants) that can help reduce cardiovascular risk in patients but none of these alternatives are mentioned in the context of the study. Even one line acknowledging the existence of these alternatives would have rendered this a much more satisfactory release.", "answer": 0}, {"article": "Philip Gehrman, a Penn clinical psychologist who was senior author, said the study proves that rapid treatment of depression is possible. But more research is needed to figure out why sleep deprivation works. His team is now conducting its own study. He's not hoping to use sleep deprivation as a treatment but thinks that pinpointing what it does to the brain will help doctors develop other, more sustained treatments.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story briefly hints at the other common treatments: drugs (notably antidepressants) and talk therapies like cognitive behavioral therapy.", "answer": 1}, {"article": "The research was funded by the National Institute for Health Research Imperial Biomedical Research Centre and the Biotechnology and Biological Sciences Research Council\nThese areas, called the caudate and the nucleus accumbens, found in the centre of the brain, have previously been linked to food cravings and the motivation to want a food.\nIn a previous research study by the same team, published in 2013, they found that overweight volunteers who added the inulin-propionate ester supplement to their food every day, gained less weight over six months compared to volunteers who added only inulin to their meals.\nThese show that altering how the gut works can change not only appetite in general, but also change how the brain responds when they see high-calorie foods, and how appealing they find the foods to be.\"\nThis study illustrates very nicely that signals produced by the gut microbiota are important for appetite regulation and food choice.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes that eating the amount of fiber to produce the same effects on the gut biome as the experimental supplement would be difficult, and notes that the average amount of daily fiber intake in the UK is just 15 grams, compared to the 60 grams that would be needed. As noted in the summary above, an alternative inulin-based product is already on the market. That would have been a useful addition to the release.", "answer": 1}, {"article": "One major trial was carried out at Queen Mary University of London (QMUL) in the United Kingdom and published in the journal Hypertension.\nDuring the 4 weeks in which they were taking the juice, patients in the active supplement group, whose beetroot juice contained inorganic nitrate, experienced a reduction in blood pressure of 8/4 millimeters of mercury (mmHg).\nBeetroot contains high levels of dietary nitrate (NO3), which the body converts into biologically active nitrite (NO2) and nitric oxide (NO).\nThe first figure is systolic pressure, generated when the heart is pumping, and the second figure is diastolic pressure, created when the heart is relaxing and filling with blood.\nThe patients in the active supplement group also experienced a 20 percent or so improvement in blood vessel dilation capacity, and their artery stiffness reduced by around 10 percent.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does make\u00a0the\u00a0point (through a quote borrowed directly from a news release) that for some high blood pressure patients, complying with daily doses of drugs to combat their condition, \u201cwhen they feel ok,\u201d presents a major problem, and therefore, obtaining the same therapeutic outcome though eating specific foods would be \u201chugely beneficial.\u201d The story also notes that there are other sources of dietary nitrate other than beet juice, including leafy greens\u00a0such as lettuce and cabbage.\nWe\u2019ll award a satisfactory here, but we note that the story could have mentioned several other dietary approaches that are also associated with lowering of blood pressure. The best known are lowering sodium intake and the related \u201cDASH diet.\u201d Weight loss and exercise are also among the range of blood pressure-lowering alternatives.", "answer": 1}, {"article": "Ingelfinger, who wrote an editorial published with the study, echoed Montgomery's cautious optimism.\n\"The desensitization protocols now in use are time-consuming, and they don't always work,\" she said, noting that they can leave dangerous antibodies behind.\nWEDNESDAY, Aug. 2, 2017 (HealthDay News) -- A new treatment might open the door for more patients with advanced kidney disease to get a transplant, a preliminary study suggests.\nBut the findings mark another step forward for patients like these, according to Jordan, who is medical director of the kidney transplant program at Cedars-Sinai, in Los Angeles.\nThe enzyme is derived from a strain of Streptococcus bacteria, and it essentially chops up the antibodies that would attack the organ.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions the existence of other desensitization efforts. But it could have done a much better job of comparing such efforts and their likely impact to programs designed to increase the supply of tissue matched organs and to suppress rejection of donor organs.", "answer": 1}, {"article": "Six months after treatment, the YAG group reported significantly greater improvement in self-reported floater-related visual disturbance (54 percent) compared with sham controls (9 percent).\nChirag P. Shah, M.D., M.P.H., and Jeffrey S. Heier, M.D., of the Ophthalmic Consultants of Boston, randomly assigned 52 patients (52 eyes) to receive YAG laser vitreolysis (n = 36) in one session or a sham (placebo) laser treatment (control; n = 16).\nThree management options exist for floaters: patient education and observation; surgery; and the laser procedure, YAG vitreolysis, of which there are limited published studies on its effectiveness for treating floaters.\nEMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, JULY 20, 2017\n\nThe commentary, \u201cYAG Laser Vitreolysis\u2014Is It as Clear as It Seems?,\u201d by Jennifer I. Lim, M.D., of the University of Illinois at Chicago; and Editor, JAMA Ophthalmology, also is available at the For The Media website.\n\u201cGreater confidence in these outcomes may result from larger confirmatory studies of longer duration,\u201d the authors write.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions three treatment options for eye floaters \u2014 patient education and observation, surgery, and laser treatment \u2014 but didn\u2019t comment on how these treatments compared in effectiveness. That\u2019s probably because the study did not compare laser surgery against other treatments for eye floaters.\nThe American Association of Opthalmology, as of 2015, viewed the evidence for laser treatment benefits as too limited to offer its official support.", "answer": 1}, {"article": "Risk reduction [was] probably in the range of 80 to 95 percent,\" said researcher Timothy Rebbeck, an epidemiologist at the University of Pennsylvania.\nA new study in the Journal of the American Medical Association shows the clearest evidence yet that women carrying the BRCA1 and BRCA2 genes should consider preventive surgery because they are at a very high risk for breast and ovarian cancers.\nOnly 3 percent of those who had surgery died, compared with 10 percent of those who did not, during the follow-up period.\nIt confirms what smaller studies have suggested in the past: Women who have a family history of breast cancer can greatly reduce their chances of getting the disease by having a double mastectomy.\n\"A lot of times I see these women having had a very preventable type of breast cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nAlthough the story mentions that women who have BRCA1/2 mutations may opt for intensive monitoring to catch disease early, it portrays that option as unreasonable. ", "answer": 0}, {"article": "Warren says he wishes the solution were as simple as just taking folic acid.\nThe Norwegian study is the largest to date on the benefits of folic acid for autism prevention, and marks one of the first tangible things a woman can do to reduce her risk of giving birth to a child with the disorder.\n\"This is pretty exciting,\" said Alycia Halladay, senior director for environmental and clinical sciences for Autism Speaks, an autism advocacy group.\n\"It is possible that folic acid ... might provide protection against other neurodevelopmental disorders like autism,\" said Zachary Warren, director of the Treatment and Research Institute for Autism Spectrum Disorders at Vanderbilt University, who was also not involved in the study.\nAmerican Congress of Obstetricians and Gynecologists (ACOG) guidelines call for all women of child-bearing age - not just those who plan to get pregnant - to take 400 micrograms of folic acid daily to prevent birth defects.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There aren\u2019t any proven strategies to reduce autism risk, although research suggests a link to maternal smoking, the father\u2019s age at conception (older than 40 = higher risk), and exposure to air pollution and pesticides. The story could have mentioned these, but we won\u2019t ding it for not doing so. The best we can rule it is Not Applicable.", "answer": 2}, {"article": "Whether it is encouraging people to eat right or to exercise, they said, the hardest part is not getting them to start doing the right things but getting them to keep doing the right things.\nThe study did not indicate that mental training can hold off all cognitive decline permanently.\nThe study tracked 2,802 healthy adults from diverse backgrounds who were, on average, 73 years old.\nA third group was taught memory skills, which involved remembering word lists and using visualizations and associations as memory aids.\nThe participants in the study ranged from age 65 to their early 90s, but Marsiske said the findings apply to people in their 50s or even younger.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not mention other sorts of lifestyle interventions that have been postulated to help individuals age successfully.", "answer": 0}, {"article": "Adding Victoza to insulin therapy quickly eliminated these peaks and dips in blood sugar.\nAt the annual meeting of the Endocrine Society in Boston, Dandona reported the results of a study in which 14 adults, whose type 1 diabetes was well controlled with insulin given via an insulin pump, received once-daily Victoza for either one week or 24 weeks.\n\"Some patients have now been treated for up to a year, and the effect is as good as it was at the beginning,\" Dandona said at a news conference webcast from Boston.\nJune 7, 2011 - People with well-controlled type 1 diabetes had even better sugar control, used less insulin, and lost an average of 10 pounds in six months when taking the type 2 diabetes drug Victoza in a small clinical study.\nThis appeared to be due to reduced appetite and food intake.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that another drug in the same class as Victoza might have similar benefits in type 1 diabetes. The\u00a0story\u00a0might have included more information\u00a0about the importance of testing blood sugars, frequent insulin changes, and careful dietary monitoring in improving control of diabetes.", "answer": 1}, {"article": "Editor's note: Tune in as Dr. Sanjay Gupta explores the signs, tests and lifestyle changes that could make cardiac problems a thing of the past on \"The Last Heart Attack,\" Saturday, August 27, 8 and 11 p.m.\nTo put the diet to the real-world test, participants received a one-hour counseling session with a dietitian and an illustrated study booklet at the outset and, later, received a 30-40 minute follow up session.\nThe 351 participants in the study suffered from high cholesterol but were not on a cholesterol-lowering statin medication.\nA control group advised to eat a vegetarian, low-saturated diet but not with the cholesterol-lowering foods a saw a slight dip in total cholesterol, from 249 to 246, and in LDL, from 167 to 161.\n\"The question one had to address was how does this play out with people in the real world,\" Jenkins said in a telephone interview.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not clearly explain that the control group in this study was eating the \u201cstandard\u201d diet recommended to reduce risk of heart disease \u2014 an important detail. It also does not discuss how the results compare with those of statin drugs.", "answer": 0}, {"article": "\u201cDr.\n\u201cHere at Valley, we are proud to offer this option for our patients and are excited about its potential for vastly improving patient care for women with breast cancer.\u201d The technique involves placing tissue expanders (interim implants) under the skin on top of a woman\u2019s pectoralis muscles after her breast tissue has been removed.\n\u201cIt is very rewarding as a reconstructive surgeon to continuously refine these procedures for our patients.\u201d\n\nMs. Burt chose the Valley breast surgery team after carefully researching her treatment options for DCIS (ductal carcinoma in situ), a diagnosis that is often debated among clinicians as to whether it should be classified as breast cancer at all.\n\u201cIt\u2019s important to listen to each woman\u2019s needs and then to decide together what is the best approach to treatment, so that in the end the cancer will be gone and the woman can move on with her life,\u201d says Dr. Wilson.\nIn addition to exceptional cosmetic results, the technique is likely to improve clinical outcomes as evidenced by ongoing research that shows women who undergo this procedure experience less pain and a shorter recovery period.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Options for reconstructive breast surgeries are as numerous as they are nuanced, depending on the needs of the patient. However, none of them \u2014 one-stage implant surgeries, muscle flap surgeries, etc. \u2014 get even a passing mention.\nIn the context of this procedure, it would have been helpful to clear up the alternatives, including the more-common procedure of getting an implant beneath the chest muscle (where it\u2019s less likely to cause complications).\nIt should always be stressed that there is no one-size-fits-all approach to breast cancer reconstruction. Factors taken into account include the patient\u2019s constitution, other medical problems, location of the cancer in the breast, type of cancer, need for preoperative or postoperative chemotherapy, need for radiation therapy, and patient preferences for cosmetic outcome. In addition, extensive discussion needs to be held regarding the potential complications of each reconstructive approach.", "answer": 0}, {"article": "Writing in the British Journal of General Practice, Bailey and colleagues report how they examined data from almost 50,000 individuals aged 40 or over who had been given a blood test by their GP.\nThe patients were selected at random from a national database.\nIn the general population about 1% of individuals over the age of 40 develop cancer each year.\nIn total, over 31,000 patients found to have a raised platelet count, and nearly 8,000 without, were included in the analysis.\nBut it remained unclear whether the condition could signal an increased risk of all cancers, and how it ties in with factors such as age and sex.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are no relevant alternatives to discuss.", "answer": 2}, {"article": "Researchers then analyzed health status information collected after the women turned 70.\nFor example, compared to nondrinkers, women who drank up to one alcoholic drink per day were 20% more likely to be disease-free at age 70 than nondrinkers.\nA new study shows women who drank the equivalent of a beer or small glass of wine each day were less likely to develop chronic diseases like heart disease, cancer, and diabetes as they got older compared to nondrinkers or those who drink four or more drinks at one time.\nThe women filled out questionnaires about what they ate and drank at midlife, about age 58.\nIn the study, researchers looked at the effects of drinking alcohol at midlife on the risk of diseases commonly associated with aging in a group of 13,894 women enrolled in the Nurses' Health Study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Again, an expert could have put these results in perspective with other factors known to promote healthy aging, such as a healthy diet and regular physical activity,\u00a0which were not mentioned in the story.", "answer": 0}, {"article": "While the mechanism behind the vision-cognition relationship isn\u2019t well understood, Zheng said, worsening vision can discourage people from brain-stimulating activities like doing crosswords and engaging with other people.\n(Reuters Health) - Waning eyesight may hasten the pace of cognitive decline in older people, suggests a U.S. study.\nPoor eyesight and weakening mental function are common in older people and related to one another, but the question of whether vision influences cognition, or vice versa, has not been clear, the study team writes in JAMA Ophthalmology.\nWhile mental function at one check-up was also related to vision at the following exam, the effect of vision on subsequent mental function was significantly stronger.\n\u201cIf you\u2019re aging without good vision, not only are you giving your brain less stimulation, you might be altering your brain at a structural level,\u201d she said in a phone interview.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions several approaches to maintaining eyesight. Mentioning other possible approaches to preventing cognitive decline (diet, exercise, etc.) would\u2019ve been a bonus.", "answer": 1}, {"article": "Of the patients with insomnia, the average age was 45 and nine were women.\nThe most effective treatment is cognitive behavior therapy, which involves changes such as avoiding cigarettes, alcohol and caffeine before bed, and getting plenty of bright light in the morning but turning off the TV, computer and dimming the lights during a wind-down period, among other techniques for improving \"sleep hygiene.\"\n\"The theoretical concept is correct, in that we do know from many previous studies that as the body core temperature cools, our sleep improves, and with warming of the core temperature, we have more restless sleep,\" Kohler said.\nPrevious research has shown that the brains of people with insomnia are \"hyperaroused\" and have a higher brain metabolism in the frontal lobes, which helps explain why they have trouble drifting off to sleep and staying asleep, said study co-author Dr. Daniel Buysse, a professor of psychiatry and clinical and translational science at University of Pittsburgh School of Medicine.\nWhile wearing the cooling cap, it took insomnia patients an average of 13 minutes to fall asleep and they spent 89 percent of their time in bed actually sleeping, about the same as controls who didn't have insomnia (the latter group averaged 16 minutes to fall asleep and 89 percent of the time in bed sleeping) .\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story included some good context:\n\u201cMedications can help, although many people complain of side effects, Kohler said. The most effective treatment is cognitive behavior therapy, which involves changes such as avoiding cigarettes, alcohol and caffeine before bed, and getting plenty of bright light in the morning but turning off the TV, computer and dimming the lights during a wind-down period, among other techniques for improving \u201csleep hygiene.\u201d", "answer": 1}, {"article": "He hopes to make periodontal treatment a standard part of treating prostate disease, much like cardiac patients are often encouraged to visit their dentist before undergoing heart procedures and a dental checkup is advised for women who are pregnant or considering pregnancy.\nBut even without prostate treatment, 21 of the 27 men showed decreased levels of PSA.\nResearchers found 21 of the 27 participants had no or mild inflammation, but 15 had biopsy-confirmed malignancies.\nThose with the highest levels of inflammation benefited the most from the periodontal treatment.\nThe men also had to have at least 18 teeth and were examined for signs of gum disease, such as increased levels of inflammation and bleeding and/or loose teeth due to attachment and bone loss.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "How is prostatitis currently treated? How do the results reported here compare with those treatments? The release doesn\u2019t say.", "answer": 0}, {"article": "For more information about Wolters Kluwer's solutions and organization, visit http://www.\nJanuary 2, 2018 - In addition to reducing headache frequency and severity, surgical treatment for migraine leads to significant improvements in everyday functioning and coping ability, according to a study in the January issue of Plastic and Reconstructive Surgery\u00ae, the official medical journal of the American Society of Plastic Surgeons (ASPS).\n\"It seems that migraine surgery patients can recover function and ability to cope with pain very well after surgery, in stark contrast to what has been shown in other pain conditions,\" Dr. Austen and coauthors write.\n\"Pain questionnaires used in the evaluation of better-understood and more common pain syndromes have not been applied to migraine surgery,\" Dr. Austen and coauthors write.\nThat was much higher than in studies of patients with other types of chronic pain: for example, an average 19 percent improvement after nonsurgical treatment for low back pain.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This is another important criterion which the news release did not meet. And even though the published study did not address alternatives either, we still encourage news release writers to include this background for interested readers \u2014 both patients and journalists.\nPresumably, patients who turn to surgery have been resistant to the usual interventions and if so, this should be clarified in the news release.\nThere are many alternatives to migraine treatment, from prophylactic daily medications to Botox injections. In fact, Botox injections operate on the same mechanism that the migraine surgery does: the botulinum toxin is injected into facial nerves to paralyze them and release pressure on the nerves surrounding the face. Botox injections for migraines have been well-studied and proven to be effective; the procedure was approved by the FDA in 2010. Unlike the surgery however, the Botox injections are not permanent \u2014 though they also appear to carry fewer side effects. It would make the most sense to compare the surgery to Botox injections, but neither the researchers nor the news release did this. Nor did they compare the migraine surgery to any other migraine treatments. Instead, they compared results from the patient questionnaire to patients that suffered other chronic pain ailments, such as lower back pain. They said that migraine patients reported greater improvement than lower back pain patients, but this tells us very little because the two conditions are so different.", "answer": 0}, {"article": "Age-related macular degeneration affects upward of 15 million Americans.\n\u201cThough additional pre-clinical data is needed, our institute is close to a time when we can offer adult stem cells as a promising source for personalized therapies for this and other human diseases.\u201d\n\nNext steps include testing the efficacy and safety of the stem cell injection in preclinical animal studies to provide information for applying for an investigational new drug.\n\u201cThis is the first study to show preservation of vision after a single injection of adult-derived human cells into a rat model with age-related macular degeneration,\u201d said Shaomei Wang, MD, PhD, lead author of the study published in the journal STEM CELLS and a research scientist in the Eye Program at the Cedars-Sinai Board of Governors Regenerative Medicine Institute.\nCedars-Sinai researchers in the Induced Pluripotent Stem Cell (iPSC) Core, directed by Dhruv Sareen, PhD, with support from the David and Janet Polak Foundation Stem Cell Core Laboratory, first converted adult human skin cells into powerful induced pluripotent stem cells (iPSC), which can be expanded indefinitely and then made into any cell of the human body.\nNewswise \u2014 LOS ANGELES (EMBARGOED UNTIL 7 A.M. EDT on APRIL 14, 2015) \u2013 An injection of stem cells into the eye may soon slow or reverse the effects of early-stage age-related macular degeneration, according to new research from scientists at Cedars-Sinai.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release included no discussion of alternative approaches or other research being done on age-related macular degeneration.\nThere\u00a0are ongoing early clinical trials of stem cells in the treatment of AMD using cells differently derived than the ones reported here. So there are \u201calternatives\u201d to this particular type of stem cell therapy that also may show promise.\u00a0There are a few reports from Japan and elsewhere suggesting that there are alternatives to \u201cbolus injections\u201d of stem cells that may pose risks.\nIn addition, some current federal clinical trials have found that some vitamin and mineral supplements appear to reduce the risk of late-onset of the disease by as much as 25 percent.\nSo this is not the only work being done in this field, as the news release might suggest to some journalists or to the general public. \u00a0Even a brief mention of other research would have been important context to improve\u00a0public comprehension.", "answer": 0}, {"article": "Each patient completed standardized behavioral rating scales and participated in a semi-structured interview answering five open-ended questions to stimulate conversation, such as \"Do you have hope?\"\nThe study is published in the journal Suicide and Life-Threatening Behavior, a leading journal for suicide research.\nThese results provide strong evidence for using advanced technology as a decision-support tool to help clinicians and caregivers identify and prevent suicidal behavior, says John Pestian, PhD, professor in the divisions of Biomedical Informatics and Psychiatry at Cincinnati Children's Hospital Medical Center and the study's lead author.\n\"These computational approaches provide novel opportunities to apply technological innovations in suicide care and prevention, and it surely is needed,\" says Dr. Pestian.\nCINCINNATI -- Using a person's spoken or written words, new computer tools can identify with great accuracy whether that person is suicidal, mentally ill but not suicidal, or neither.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes standardized behavioral rating scales, and the fact that clinicians and caregivers are involved in screening patients for suicide risk. But it lacks details on what those screenings are called, how and when they are done, and what qualitative and health record-related risks they look for (e.g. mental health conditions,\u00a0acute\u00a0stress, history of suicide attempts, behavior changes, and more). Having at least a basic description of how patients are typically screened for suicide risk and subsequent observation would have made this release a lot stronger.", "answer": 0}, {"article": "The quality of life survey measured overall functioning (physical, emotional, cognitive, etc.\nThe study is titled \u201cQuality of Life in Patients Undergoing Pleurectomy and Decortication for Malignant Pleural Mesothelioma.\u201d The surgeries were performed by Dr. Vigneswaran at University of Chicago Medicine, where he practiced before recently joining Loyola.\nPrior to surgery, 31 percent of the patients had a performance status score of 0 (fully functional); 65 percent had a performance status score of 1 (able to do light house work or office work); and 4 percent had a performance status of 2 (ambulatory and capable of self-care, but unable to work).\nBut a study led by a Loyola Medicine thoracic surgeon has found just the opposite: Patients who underwent an operation called pleurectomy and decortication (PD) generally reported their quality of life improved after surgery.\n\u201cThe net benefit of pleurectomy and decortication justifies the procedure in the majority of patients with malignant pleural mesothelioma,\u201d Dr. Vigneswaran concluded.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does not compare other treatments to pleurectomy and decortication. Although no cure is available, there are other types of surgeries to help treat mesothelioma. These include procedures to decrease fluid build-up (pleurodesis), to remove as much cancer as possible (debulking) and to remove a lung and surrounding tissue. Patients could also undergo chemotherapy or radiation therapy to kill cancer cells. \nSince none of these options are discussed in the news release, we give it a \u201cNot Satisfactory\u201d rating here.", "answer": 0}, {"article": "Polio viruses are attracted to nerve cells \u2014 that\u2019s why they cause paralysis.\n\u201cThe most important thing is, it sets up a secondary immune response and really destroys the distant tumor cells.\u201d\n\nThe very first patient was Stephanie Hopper, who was diagnosed with a glioblastoma when she was just 20.\n\u201cThere is currently no effective therapy.\u201d\n\nStandard treatment of brain tumors includes surgery if the tumor is somewhere reachable; chemotherapy; and radiation.\nThe medical team used polio viruses already weakened and altered for use in polio vaccines, and genetically engineered them to carry parts of a common cold virus, called a rhinovirus, known to be attracted to glioma cells.\n\u201cThe virus infection causes a very potent inflammation response and that response causes brain swelling.\u201d\n\nThe cancer drug Avastin is used in low doses to control the swelling, the team said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned standard treatment for glioblastoma can include surgery, chemotherapy, and radiation.\nHowever, the story would have been stronger if had mentioned that there are other experimental viral treatments under study for glioblastoma.", "answer": 1}, {"article": "But a 2012 Cochrane review of randomized clinical trials found there's no evidence that removing wisdom teeth will prevent or reduce crowding of other teeth down the line.\nFor most people, they start to grow in between ages 17 and 25.\nThat's because the tooth is easier to remove if its roots aren't fully developed.\nHere's what you need to know to figure that out.\nSo the question comes down to which side of the fence medical professionals fall on, and what works best for their patients.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story adequately weighs the benefits of both approaches \u2014 early removal or waiting to see if complications develop later on.", "answer": 1}, {"article": "[11]\n\nEVZIO (naloxone HCl injection) Auto-injector is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.\nAdditionally, there are nearly two times the number of prescription opioid-related deaths as compared to heroin-related deaths.1 On average, 3,300 children five years old and younger are admitted to emergency departments each year due to accidental opioid exposure.\nFor example, taking high doses of opioids, taking an opioid in combination with other drugs (e.g., benzodiazepines) or alcohol, or if there is a history of certain medical conditions (e.g., COPD, severe asthma) places individuals at significantly higher risk for life-threatening OIRD.\n\"The Cabell-Huntington Health Department is pleased to have EVZIO in our community,\" said Dr. Michael Kilkenny, Physician Director of the Cabell-Huntington Health Department in Huntington, West Virginia.\n\"People at an overdose scene may be very emotional, so it really helps that EVZIO has audio instructions on how to administer this potentially life-saving medication,\" said Laurie Fugitt, RN, BSN, co-founder of Georgia Overdose Prevention.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "No alternatives were offered. Besides the injectable forms of naloxone, a Narcan nasal spray is also on the market.\nThe National Institute of Allergy and Infectious Disease provides a listing of diffferent forms of naloxone.", "answer": 0}, {"article": "What would that look / sound / smell like?\nLed by Dr Linda Solbrig from the School of Psychology, the research involved 141 participants, who were allocated either to FIT or Motivational Interviewing (MI) - a technique that sees a counsellor support someone to develop, highlight and verbalise their need or motivation for change, and their reasons for wanting to change.\nThe full study, entitled Functional Imagery Training versus Motivational Interviewing for Weight Loss: A randomised controlled trial of brief individual interventions for overweight and obesity is available to view in the International Journal of Obesity (doi: 10.1038/s41366-018-0122-1).\nProfessor Jackie Andrade, Professor in Psychology at the University of Plymouth, is one of the co-creators of FIT, and she explains: \"FIT is based on two decades of research showing that mental imagery is more strongly emotionally charged than other types of thought.\n\"As well as being delighted by the success of the study in the short term, there are very few studies that document weight loss past the end of treatment, so to see that people continued to lose weight despite not having any support shows the sustainability and effectiveness of this intervention.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release addresses this, sort of, when it states: \u201cMost people agree that in order to lose weight, you need to eat less and exercise more, but in many cases, people simply aren\u2019t motivated enough to heed this advice \u2013 however much they might agree with it. So FIT comes in with the key aim of encouraging someone to come up with their own imagery of what change might look and feel like to them, how it might be achieved and kept up, even when challenges arise.\u201d That\u2019s enough to earn it a satisfactory ranking, particularly since it is consistent with the underlying study. However, it would be more valuable to see how effective FIT is when used in conjunction with proven weight loss techniques.", "answer": 1}, {"article": "Physical function of their knee also improved, based on an index used to judge the effects of osteoarthritis, Bagla added.\n\"This therapy is very well-targeted to that particular mechanism, and certainly it should be investigated further,\" said Vedantham, who wasn't involved with the study.\nOnly 13 had undergone the procedure by the time of Monday's annual meeting, and only eight had made it to the one-month follow-up, Bagla said.\nThe small pilot study -- the first U.S. clinical trial of this procedure -- involved 20 patients with moderate to severe arthritis pain.\n\"Perhaps we can demonstrate and prove patients do not need to be on these medications and can alternatively go through a minimally invasive procedure like this to reduce their knee pain,\" Bagla said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions joint replacement and medications to reduce knee pain. However, it doesn\u2019t mention steroids, hyaluronic acid, plasma protein derivatives, physical therapy and less invasive surgical procedures. The point is that there are a number of options, none particularly good, but readers should be aware that they exist and are used.", "answer": 0}, {"article": "Esketamine Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Major Depressive Disorder with Imminent Risk for Suicide.\nTo put this into context, an analysis of placebo-controlled data from three prior studies conducted by Duru and Fantino determined that a minimum change in MADRS of 1.9 was clinically meaningful.2 In addition, the average difference is between 2-3 points for currently approved antidepressants vs. placebo.3\n\nSafety results were consistent with previous studies of esketamine in younger adult populations.\nEsketamine received Breakthrough Therapy Designations from the U.S. FDA in November 2013 for treatment-resistant depression and in August 2016 for the indication of major depressive disorder with imminent risk for suicide.4\n\nAbout Major Depressive Disorder\n\nMajor depressive disorder affects nearly 300 million people of all ages globally and is the leading cause of disability worldwide.5 Individuals with depression, including major depressive disorder, experience continuous suffering from a serious, biologically based disease which has a significant negative impact on all aspects of life, including quality of life and function.5 Although currently available antidepressants are effective for many patients, about one third of patients do not respond to treatment and are thought to have treatment-resistant depression.6\n\nAbout the Janssen Pharmaceutical Companies of Johnson & Johnson\n\nAt the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease.\nThe most common treatment-emergent adverse events (>10%) reported in the esketamine group were metallic taste, nausea, vertigo, dizziness, headache, drowsiness, dissociation, blurred vision, paraesthesia (tingling sensation) and anxiety.\nThe results from these studies will inform regulatory filings for esketamine nasal spray in treatment-resistant depression, for which Janssen has received Breakthrough Therapy Designations from the U.S. FDA.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The trials at issue here are specifically aimed at patients for whom two or more antidepressants did not work. However, there are some additional alternatives for treatment-resistant depression which could have been included in the release, such as electroconvulsive therapy and atypical antidepressants. Many people with depression are given selective serotonin reuptake inhibitor, or SSRI (Prozac, Lexapro, Zoloft and others) or similar medications by their primary care doctor, and if that fails, are given another medication in the same class or in the serotonin and norepinephrine reuptake inhibitors (SNRI) class of medications. Psychiatrists have a larger arsenal of medications and therapies to try.", "answer": 0}, {"article": "MONDAY, Feb. 21, 2011 (HealthDay News) -- When it comes to shedding pounds and improving or eliminating type 2 diabetes, gastric bypass surgery may be better than other surgical weight-loss procedures, two new studies find.\nIn the bypass group, patients lost an average of 64 percent of their excess weight, vs. 36 percent for those in the lap-banding group.\nAll patients were morbidly obese (with a body-mass index higher than 40), and 34 in each group had type 2 diabetes.\nLater complications may include malnutrition, hernias and a tendency in about one in 10 people to regain much of the weight they lost as a result of the procedure.\nBut obese patients should be careful to choose surgeons who have performed a high volume of these procedures before committing, said Dr. Guilherme M. Campos, lead author of one of two papers appearing in the February issue of the Archives of Surgery.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As with the LA Times, there was no mention of the effectiveness of diet or lifestyle interventions for weight loss. Even a line would have helped.", "answer": 0}, {"article": "To learn more about the Society and the field of endocrinology, visit our site at http://www.\nWashington, DC--For years after it was administered, growth hormone continued to reduce the risk of fractures and helped maintain bone density in postmenopausal women who had osteoporosis, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.\nMore than 10 million American adults have osteoporosis, and 80 percent of the people being treated for the condition nationwide are women, according to the Society's Endocrine Facts and Figures Report.\nDuring an 18-month-long randomized, double-blind trial, 80 postmenopausal women with osteoporosis received daily injections of either placebo, a single unit of growth hormone or a 2.5-unit dose of growth hormone.\n\"The findings indicate the beneficial effects of growth hormone remained long after the treatment ceased,\" Krantz said.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not mention other osteoporosis treatment options \u2014 such as bisphosphonates, fall prevention interventions, etc. \u2014 at all, making it impossible for readers to determine how the growth hormone therapy performed relative to other courses of action.", "answer": 0}, {"article": "[Added June 10] So Gokhale studied findings from anthropologists, such as Noelle Perez-Christiaens, who analyzed postures of indigenous populations.\nIf you look at an American's spine from the side, or profile, it's shaped like the letter S. It curves at the top and then back again at the bottom.\nNow she's sharing their secrets with back pain sufferers across the U.S.\n\nAbout two decades ago, Esther Gokhale started to struggle with her own back after she had her first child.\nIt's what goes into making the J-shaped spine that matters: \"You have to use muscle strength to get your spine to look like a J shape,\" he says.\nIn fact, if you look at drawings from Leonardo da Vinci \u2014 or a Gray's Anatomy book from 1901 \u2014 the spine isn't shaped like a sharp, curvy S. It's much flatter, all the way down the back.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does stress that having good core muscle strength is important to reducing or preventing back pain, regardless of whether one uses the Gokhale Method. And it discusses approaches other than Gokhale to achieve that strength. However, it would have been good to note that there are multiple factors that can contribute significantly to back pain, including arthritis, osteoporosis, and injury. With any sort of nerve impingement (e.g. herniated disc pinching nerve), exercise alone will not work. And if there are degenerative changes, often more treatment is required, and that is very common. Finally, not all back pain is benign, and one would need to rule out things like metastatic cancer if pain is ongoing. The story would have been stronger if it had noted that sometimes exercise isn\u2019t enough \u2014 and sometimes other treatment options are required so that a patient can manage the pain well enough to begin an exercise regime.", "answer": 1}, {"article": "\"If you have chest pains and you needed a test,\" Douglas said, \"and if I said to you: 'Either one of these two tests will be equally effective in preventing heart attack or death, but this one will have less chance of going to the cath lab if you don\u2019t have blockages,' which one would you pick?\"\nFindings also were published the New England Journal of Medicine.\nUntil this study, doctors have been \"guessing\" which form of those two diagnostic tests is best, Douglas said.\n\"And I wonder if it's worth doing those tests when rates of cardiac events are so low.\"\n(He did not want his last name published).\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The whole point of the study was to compare a newer and an older approach to diagnosing heart problems.", "answer": 1}, {"article": "But definitively proving these benefits is challenging, requiring years of costly research.\n\u201cBy opposing one group of muscles against another, it stimulates osteocytes, the bone-making cells.\u201d\n\nMost experts argue that it\u2019s difficult, perhaps impossible, for adults to gain significant bone mass.\nAt the time the study was submitted for publication, \u201cwith more than 90,000 hours of yoga practiced largely by people with osteoporosis or osteopenia, there have been no reported or X-ray detected fractures or serious injuries of any kind related to the practice of yoga in any of the 741 participants,\u201d Dr. Fishman and his colleagues wrote.\nThe findings, as reported last month in Topics of Geriatric Rehabilitation, showed improved bone density in the spine and femur of the 227 participants who were moderately or fully compliant with the assigned yoga exercises.\nIf you don\u2019t fall, you greatly reduce your risk of a serious fracture.\u201d\n\nFor more fitness, food and wellness news, follow us on Facebook and Twitter, or sign up for our newsletter.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article mentions the tolerability of osteoporosis drugs, though the study wasn\u2019t a comparison between the two. \u00a0While the study didn\u2019t examine this, comparing yoga\u2019s effects against alternative\u00a0weight-bearing exercise forms (running, walking) might merit a mention.", "answer": 1}, {"article": "Trying to diagnose prostate cancer is one of the most maddening tasks a doctor has.\nIf you had precursors such as high grade PIN (prostatic intraepithelial neoplasia) your score was about 38 to 40 and men who had cancer scored about 50 to 55.\u201d\n\nThe test had a specificity of 78 percent, meaning that 78 percent of the men who had cancer indicated by the test actually did.\nIt is a string of RNA that does not appear to have any function but that is overexpressed, or overactive, in prostate cancer.\nThis is far less sensitive than PSA, which catches 87 percent of tumors, but if the two tests are used together they can help rule out the need for unnecessary surgery or radiation.\nThis compares to just 21 percent for PSA alone, the researchers told a meeting of the American Urological Association in San Francisco.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0The outcomes from this test were compared to that of the PSA test. \u00a0There could have been at least a line, however, about the many other tests currently being tested for their ability to diagnose and predict the future course of prostate cancer. For example, on the same day this study was presented at the American Urological Association meeting, at least one other study about another prostate test looking for increased levels of genetic material was presented at the same meeting.\u00a0 ", "answer": 0}, {"article": "Smoking was defined as having had one or more cigarettes in the last week.\nThe authors believe that future trials of vitamin C supplementation in pregnant smokers should determine whether the benefits are greater if the supplementation starts earlier and continues postnatally in the babies themselves.\nAt the time they enrolled in the study, the women had lower levels of ascorbic acid than have been reported among women who do not smoke.\n\u201cAlthough vitamin C supplementation may protect to some extent the lungs of babies born to mothers who smoke during pregnancy, those children will still be at greater risk for obesity, behavioral disorders and other serious health issues,\u201d she said.\nIn the current study, 251 pregnant women who smoked were randomly assigned at 13 to 23 weeks of gestation to either receive vitamin C (125 women) or a placebo (126 women).\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "We were glad to see this important caveat relating to an alternative intervention included:\n\u201cHelping mothers quit smoking should remain the primary goal for health professionals and public health officials.\u201d", "answer": 1}, {"article": "So are lycopene packed tomatoes really the magic fruit?\n\"It's a compelling study and it fits with other data that we have about risk of stroke and vegetable and fruit consumption,\" explains Dr. Daniel Labovitz, director of the Stern Stroke Center at Montefiore Medical Center in New York.\nThough the study looks promising, experts say that we can't necessarily give all of the credit to lycopene.\n\"Eating tomatoes is a good thing, but we don't know if there is really anything unique about tomatoes apart from other fruits and vegetables that reduce stroke risk,\" explains Dr. Walter Willett, chair of the Department of Nutrition at Harvard School of Public Health in Boston, Massachusetts.\n\"This study adds to the evidence that a diet high in fruits and vegetables is associated with a lower risk of stroke,\" says study author Jouni Karppi, of the University of Eastern Finland in Kuopio.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story suggests that we consume a mix of fruits and vegetables every day, because, as one expert put it: \u201c\u2026we don\u2019t know if there is really anything unique about tomatoes apart from other fruits and vegetables that reduce stroke risk.\u201d\nThe story could have mentioned other controllable factors associated with stroke risk, including tobacco use, obesity, and heavy alcohol consumption.", "answer": 1}, {"article": "\"It does.\nWhat's happening now is that the vast majority, about 70 percent, are done the old-fashioned way, with a large surgical incision, lots of pain, and a six-to-eight-week recovery.\n\"If patients really know that they have options when it comes to hysterectomy, we will start seeing some of the changes that I feel need to happen,\" Warren said.\nIt's all over in about an hour, and patients are usually home within a day and back to normal within a week or two.\n\"You would think in today's age and the way that we've improved in so many areas of medicine, women would begin questioning this, but we're finding that they're not,\" said Beth Cahill of the National Womens Health Resource Center.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention any of the highly effective treatment\u00a0alternatives to hysterectomy. Fibroids and abnormal bleeding are the two most common reasons why women undergo elective hysterectomy. The story makes it seem as though the only option is between abdominal and laparoscopic hysterectomy, when in reality a woman has a choice among lots of options, such as vaginal hysterectomy, myomectomy, ablation, uterine artery embolization, and\u00a0medical management.", "answer": 0}, {"article": "When left untreated, however, B.P.H.\nBut for patients who have trouble getting back to sleep, \u201cthere are many effective options, and patients almost always end up with less bothersome symptoms once they choose to do something,\u201d he said.\nThat is because after age 50 many men face an embarrassing problem called B.P.H., for benign prostatic hyperplasia.\nThis slowly progressive enlargement of the prostate can make urination difficult or painful and send men trudging to the bathroom many times during the day and night.\nSurprisingly, his case is not unique.\u201d\n\nMany doctors are now urging men to become proactive earlier to prevent chronic problems in the future.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story provided a pretty extensive laundry list of approaches that can be taken to manage benign prostatic hyperplasia from not doing anything to surgery.\u00a0", "answer": 1}, {"article": "About 100,000 men and women age 45 and up took part in the studies.\n\u201cIn my mind, if you have diabetes or multiple risk factors for heart disease \u2014 such as smoking or obesity \u2014 it is reasonable to take aspirin.\u201d\n\nIn addition, working to eliminate those risk factors by other means will not only slash the risk of heart disease, but also a host of other health problems.\n\u201cI don\u2019t think this paper is inconsistent with previous work.\u201d\n\nNichols, who was not involved in the study, said aspirin is clearly beneficial for people who\u2019ve already had heart disease, and that it also seems to help those at high risk.\nOn the other hand, that analysis also found aspirin increased the rate of bleeding from 0.7 to 1 per 1,000 people per year, making the authors conclude the drug was of \u201cuncertain net value.\u201d\n\nHeart disease is the leading killer worldwide and accounts for more than a third of deaths in the U.S., according to the American Heart Association.\nIn the current study, published in the American Journal of Cardiology, the researchers also report small decreases in stroke and death risks with aspirin, although those changes might have been due to chance.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Embedded in the analysis was at least a nod to other approaches.\u00a0 For example, the story stated:\n\u201cThere is not universal agreement on what is high risk,\u201d he told Reuters Health. \u201cIn my mind, if you have diabetes or multiple risk factors for heart disease \u2014 such as smoking or obesity \u2014 it is reasonable to take aspirin.\u201d In addition, working to eliminate those risk factors by other means will not only slash the risk of heart disease, but also a host of other health problems.\u201d", "answer": 1}, {"article": "The results of the Women's Health Initiative (WHI)--the largest, most scientifically rigorous study of older women's medical issues ever conducted--continue to startle researchers, confuse the public and frustrate headline writers. Case in point: last week's report that taking estrogen for seven years does not increase the risk of breast cancer for many women. There is a lot of good news in that finding, as well as some important caveats.\n\nIn many ways, the story began four years ago when researchers halted a different part of the WHI--one that looked at the long-term health effects of taking the hormone combination estrogen and progestin...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Other options for managing menopause symptoms are not noted.", "answer": 0}, {"article": "For more information, visit http://www.\nThe study results showed that there was a higher number of callbacks among women ages 40-49 compared to women ages 50-59 (17% compared with 12.5%) and to women ages 60-69 (17% compared with 10.2%).\nWith educational activities representing the entire spectrum of radiology, ARRS will host leading radiologists from around the world at the ARRS 2018 Annual Meeting, April 22-27, at the Marriott Wardman Park Hotel in Washington, DC.\nBy adding the women ages 40-49 to the screening population of 50 and over, the overall callback rate increased 1.5%, the biopsy rate increased 0.1% and 19.3% more cancers were detected.\nThe study to be presented by Abid Irshad of the Medical University of South Carolina examined the effectiveness of screening mammography between ages 40-49 in comparison to age groups 50-59 and 60-69.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release didn\u2019t discuss breast MRIs or other ways of detecting cancer in younger women. While there are other procedures, such as ultrasounds, that can detect breast cancer, mammograms remain the gold standard of breast cancer screening.", "answer": 0}, {"article": "They conclude that using assisted reproductive technology \u2013 such as storing eggs before chemo, is \u201cthe most effective option for fertility preservation.\u201d\nThe researchers followed the women for one year after they had finished chemotherapy.\nThe results are published in the Journal of the American Medical Association.\nAmong the women who had not received triptorelin, the rate of early menopause was 25.9%.\nBreast cancer treatments that have shown the best results for for disease free survival include chemotherapy, hormonal therapy, or both.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article did a satisfactory job of mentioning one major alternative to the reviewed procedure.", "answer": 1}, {"article": "The Ache: In cold and flu season, pathogens spread when people are crammed into close quarters, such as airplanes and cars.\n\nThe Claim: Personal air purifiers worn around the neck clean the air in the wearer\u2019s breathing zone of viruses and bacteria as well as allergens, say companies that sell them.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions no alternatives to the use of these devices.\u00a0 It does mention in passing that touching contaminated surfaces is an alternative route of infection to that of inhalation. But what about frequent hand washing? And in a story focusing on the lengths people will go to in order to lower their risk of catching the flu, it\u2019d be nice to see some acknowledgment of the value of the flu vaccine.", "answer": 0}, {"article": "DBS has been used to treat tremors associated with Parkinson\u2019s disease, but Machado said the new approach, if successful, will achieve something novel.\nSomeone has a stroke in the United States every 40 seconds, and it has become the leading cause of serious long-term disability among Americans.\n\u201cThe big difference is that when we are treating the motor symptoms of Parkinson\u2019s disease, we\u2019re trying to make the symptom, like a tremor, go away,\u201d he said.\nClose to 800,000 Americans have a stroke each year and estimates suggest about half of those people will be disabled from it.\nWith physical therapy, many people regain some motor function, but the brain damage cannot be reversed and many still have profound movement problems.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does point out that the standard treatment for stroke victims who suffer a disability is physical therapy. However,\u00a0clot busting drugs and other early intervention methods are also being tried as means to improve stroke outcomes.", "answer": 1}, {"article": "\"If a cell phone company told you they tested all the models and their model came out the best, would you believe it?\nOne of the most prominent claims, that POM can decrease arterial plaque by 30 percent, was taken from a single pilot study that included just 19 people and was funded by the makers of POM.\nAccording to a study by the FTC, this halo effect can even lead people to overlook warning statements -- about the high sodium content of a product, for example.\nThat's the paradox of products such as POM, Silverglade says: The health claims on these products strain the imagination, yet studies have repeatedly shown that health claims sell food.\nThis phenomenon is known as a \"health halo,\" an aura of healthfulness attached to a product based on labels like \"low-fat\" \"all-natural\" or \"made with whole grains\" that seduces consumers into overeating.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The\u00a0purported health benefits of POM and other\u00a0health drinks are based on their supposedly high content of antioxidant compounds.\u00a0People can obtain similarly high levels of antioxidants, at much lower cost,\u00a0just by eating a healthy diet with lots of regular fruits and vegetables, which are also rich in antioxidants. In fact, it\u2019s probably better to rely on a variety of different foods to make sure you get enough of everything and not too much of any specific compound. The story should have pointed this out.", "answer": 0}, {"article": "Though randomized controlled clinical trials of bright light are difficult to do properly \u2014 one expert is fond of saying that it is difficult to \u201cblind\u201d studies of bright light \u2014 the American Psychiatric Association considers bright-light therapy an effective low-risk treatment for both S.A.D.\n\u201cStudies have also shown that light influences serotonin and epinephrine pathways in the brain, the same neurotransmitter systems known to be affected in people with general depression.\u201d\n\nBut while part of the appeal of light therapy is that it can be self-prescribed, using a light box is not as simple as it may appear.\n\u201cIf you can fix the drift, you can fix the depression.\u201d\n\nLight therapy may even help with major nonseasonal depression, experts say, and with sleep disorders.\nNo one knows exactly how light treatment works, but most experts seem to agree that the body has a master biological clock that responds to or is \u201cset\u201d by natural light fluctuations.\n\u201cThe hormone melatonin, which is secreted at night, can be suppressed by light,\u201d Dr. Rosenthal said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention the existing use of anti-depressant drugs for seasonal depression, but does not compare in detail the price or length of drug therapy vs. light therapy. This comparison would have been very helpful to consumers. Other alternatives \u2013 including cognitive behavioral therapy, psychotherapy or exercise \u2013 were not mentioned.", "answer": 0}, {"article": "And Medicare has established a registry to see how well large-scale screening works.\nResearchers call it \u201ccompeting mortality.\u201d Finding lung cancer is a hollow victory if patients endure testing and treatment, then die of another illness before the cancer would have killed them.\nAmong the 65- to 74-year-olds getting CT scans in the national trial, moreover, many had other serious health problems \u2014 heart disease, diabetes, hypertension, pulmonary disease \u2014 which probably contributed to only 55 percent surviving five years, compared with 64 percent among those under age 65.\nThe post-surgical death rate in the national trial was just 1 percent, but that involved major medical centers with specialized radiologists and surgeons \u2014 the ideal setting.\nBut it is worth remembering that however effective it is, screening can\u2019t ward off disease.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The single study discussed in this story\u2014the National Lung Screening Trial\u2014compared low-dose CT scans with more traditional X-ray diagnoses. But in reality, the comparison is between low- dose CT and not doing one at all. No one is recommending a regular x-ray of the chest.", "answer": 1}, {"article": "The population studied was relatively homogenous, and \"the [body mass] findings were not the object of the study (wheezing or asthma in children was the primary objective), growth was a secondary finding,\" Rabin explained.\nThough these children are larger, they do not have increased rates of obesity,\" Wu added.\n\"The use of fish oil in the latter part of the pregnancy has an impact on bone and muscle mass.\nHowever, the findings only showed an association and did not prove that fish oil pills caused healthier growth in children.\nThe American Academy of Pediatrics has more on healthy growth.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Since there is little existing research in this area, the inclusion of another alternative would be difficult.", "answer": 2}, {"article": "The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives in a future epidemic of the deadly disease.\n\nThe research, by doctors from the U.S. and Liberian governments and elsewhere, was published Wednesday in the New England Journal of Medicine. The study looked at 1,500 patients in Liberia, and took place amid and after the outbreak of Ebola in Liberia from 2014 into 2015.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll give story a not applicable in this category since there currently is no proven successful treatment against Ebola.", "answer": 2}, {"article": "This version has been corrected.\nThat has left only two ways to determine whether the abnormality is cancerous: inserting a needle through the chest wall and into the tumor, or surgically opening a patient's chest to find it (and remove it if necessary).\nHe called the technology \"a canary in the coal mine\" for lung cancer, which kills about 160,000 people in the United States each year.\nBut now, according to a study published Sunday in the New England Journal of Medicine, there appears to be a new, much less invasive way of determining whether a growth is malignant.\nWith the vast majority of lung cancer victims being smokers, the epithelial cells show changes that could be tracked once the technology became available, he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does a good job of describing current tests and what they can and cannot do. And it notes that although there are serious efforts to develop blood tests\u00a0that can predict response to treatment and even early cases of lung cancer, these are likely years away from clinical use.", "answer": 1}, {"article": "The drug, known chemically as denosumab, is widely considered to be Amgen\u2019s most important future growth driver and the FDA decision comes nearly two months ahead of the agency\u2019s expected action date of July 25.\nAmgen said the drug will be available within the next two weeks and cost $825 per 60 milligram injection based on wholesale acquisition cost.\n\u201cMost of us certainly expected this drug to be approved,\u201d said Cowen and Co analyst Eric Schmidt, adding it was \u201ca surprise that it happened before\u201d July 25.\nHe estimates U.S. annual peak sales of $750 million to $1 billion in osteoporosis.\n\u201cIt\u2019s also superior to Zometa in its ability to delay subsequent events,\u201d Perlmutter said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 0}, {"article": "The robot-surgeon team might not have outperformed the surgeon alone because the procedure was a relatively simple one.\nBut all I need to do is add 5 and 5.\u201d\n\nEspecially in a time of concern over rising medical costs, \u201cwe should not simply use the highly sophisticated technology just because it\u2019s there,\u201d Falcone said.\nWith the surgeon alone, \u201cthe incision is smaller (and) the manipulations are more controlled,\u201d Dr. Ceana Nezhat, an author on the study and the chair of Obstetrics & Gynecology at Northside Hospital in Atlanta, told Reuters Health.\n\u201cWe were surprised that (surgery with the robot) did not have better outcomes than (the surgeon alone), as we have always believed if you can see more and see better you can do more and do better,\u201d the authors write.\nNEW YORK (Reuters Health) - Robots may not help doctors do a better job on some surgeries, according to a new study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This was the entire point of the study and the point of the story. At least a mention of non-surgical treatments of endometriosis would have been nice, especially since the majority of cases can be treated nonsurgically. ", "answer": 0}, {"article": "Holick and others say there is little or no downside to ingesting even high levels of vitamin D.\n\n\"I've been treating patients with 50,000 units of vitamin D once a week for eight weeks followed by 50,00 every other week for over a decade, and I've not seen any untoward toxicity,\" Holick says.\nSun exposure is key for vitamin D, known as the sunshine vitamin.\nA decade ago, Medicare payments were only about $1 million.\nNot so fast, other experts say.\nNeither study subjects nor investigators will know until the end which regimen they are on.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned a variety of sources for obtaining vitamin D.\u00a0 ", "answer": 1}, {"article": "HIFs activate programs that promote the development of blood vessels, facilitate oxygen delivery and promote efficient nutrient utilization.\nResearchers surprisingly found a subset of tumors that do not respond to the drug, but were able to identify biomarkers that, once verified, would help determine which patients are more likely to benefit from HIF-2 therapies.\n\"The approaches we have taken pave the way for identifying drug candidates for other proteins that have traditionally been considered undruggable.\"\nThe findings show that HIF-2 is a promising target to combat kidney cancer, said Dr. Brugarolas, senior author and a Virginia Murchison Linthicum Scholar in Medical Research at UT Southwestern.\nIn a previous report, Dr. Kevin Courtney, Assistant Professor of Internal Medicine and a coauthor of the current study, reported at the American Association of Clinical Oncology annual meeting that HIF-2 inhibitors were safe in patients and had activity even in heavily pretreated patients.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "While the treatment was compared to another kidney cancer drug,\u00a0sunitinib, we don\u2019t really learn what other alternative treatments outside of sunitinib or PT2399 are used to treat kidney cancer.", "answer": 0}, {"article": "But the triggers are different for different people.\nShe has far fewer headaches and when she does have them, they're far less severe.\nPeople who go to the doctor for headaches are increasingly likely to be sent for advanced testing and treatment, a study finds.\nToday there are a lot more advanced diagnostic machines than there were a decade ago, and more patients are asking to be tested.\nIt's estimated that every year 12 million Americans go to the doctor seeking help for headaches.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions alternatives to medical or surgical treatment in the last two paragraphs of the story but it does not explain the relative benefits or harms of any approach.", "answer": 0}, {"article": "The research will be highlighted by study authors during a special press conference to be moderated by Tobias S. K\u00f6hler, MD, MPH, FACS, AUA spokesperson and associate professor of Surgery at Southern Illinois University on May 8, 2016 at 7:30 a.m. PT in the San Diego Convention Center.\nFollowing a 13-week efficacy phase, men continued to receive their assigned treatment for up to 52 weeks.\nOf the 315 men, 210 were randomized to LPCN 1021 and 105 were randomized to active control.\nIt is often administered as a gel, patch, injection or implant (pellet).\nTestosterone therapy is used to treat men with clinically diagnosed testosterone deficiency (serum T levels <300 ng/dL), also known as hypogonadism.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release states that this oral form of testosterone was compared with T gel. It also names other delivery forms including a patch, injection or implant (pellet) ", "answer": 1}, {"article": "The requested URL /2011-08-30/business/29945941_1_mark-kris-cancer-cases-lung was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\nThe story appears to imply that standard treatments don\u2019t work for patients with tumors that have this specific gene variant. However, cancer treatment statistics indicate that these patients are just as likely as other patients to respond to first-line treatment. The new drug is intended to be used when those standard treatments aren\u2019t enough. Then the tumor gene test is needed, because giving this new drug does not appear to do any good for the overwhelming majority of patients, it is to be used only in that subset of patients with tumors that might be susceptible. Also, the story should have been clearer about explaining that neither of the preliminary trials included any comparison to standard treatment.\n", "answer": 0}, {"article": "Fighting bacteria with drugs designed to kill them helps fuel the problem of antibiotic resistance if stronger bacteria can survive and evolve to become \u201csuperbugs.\u201d\n\n\u201cBut instead of always setting a bomb off to kill an infection, there are situations where using an anti-virulence method may be just as effective, while also helping to restore balance to the health of the patient,\u201d said Quave.\nThe medicines include antibiotics, which act on bacteria, as well as drugs to fight fungal, viral or parasitic infections.\nThe plant extracts didn't harm the skin tissues or the normal, healthy bacteria found on skin.\nPlants have been used repeatedly in traditional medicine over the centuries, and knowledge about their use is passed down from generation to generation, which points to their efficacy, she said.\nThe woody plant has long been a staple in Brazilian traditional medicine.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternatives are antibiotics and other infection-fighting drugs, and the story discusses how those have become less effective in recent years.", "answer": 1}, {"article": "Palliative Care Consults for Patients with Advanced Cancers Reduces Hospitalization and Improves Quality of Care\n\nIntegration of Palliative Care Improves Many Measures of Quality\n\nNewswise \u2014 (NEW YORK \u2014 March 15, 2017/Embargoed until March 17, 4:00 pm ET) Cancer patients admitted to the hospital with advanced stages of disease who were referred early to palliative care had decreased health care utilization and increased use of support services following discharge, according to a new study led by researchers at the Icahn School of Medicine at Mount Sinai.\nThe integration of palliative care improves symptom control and decreases unwanted health care use, yet many patients are never offered these services.\nSuch interventions drive escalating costs and are often directly in conflict with patients\u2019 prior stated wishes,\u201d said Dr. Smith.\n15 nationally in the 2016-2017 \u201cBest Hospitals\u201d issue of U.S. News & World Report.\nPatients with advanced cancers often have significant symptoms that affect their emotional status, quality of life, and functional ability.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Alternatives to palliative care for late-stage cancer patients are described clearly.", "answer": 1}, {"article": "Once a woman hits puberty the number drops to 300,000 and by age 30 the amount decreases by 90 percent.\n\u201cIt's a question of having the knowledge and awareness of keeping your options open.\u201d\n\nThe test is a simple blood analysis that usually costs less than $100.\nFor years, it\u2019s been a staple in fertility clinics; it\u2019s officially called the Anti-M\u00fcllerian hormone (AMH) test.\n\u201cIf I had waited until I met my husband and we were trying now to have a child it would be a very different story.\u201d\n\n\u201cEven the best AMH level in the world is not a guarantee for someone going forward or even right now but they are good indicators for fertility,\u201d said Hurwitz.\n\u201cI took the AMH test and I'm glad I did because the results were not what I was hoping them to be,\u201d said Gold.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There were no alternatives\u2013or the lack thereof\u2013mentioned in the story. Readers should be informed: How do other long-term fertility-detection methods compare to this one?", "answer": 0}, {"article": "See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.\n\"Based on establishment of safety of the CaverStem\u2122 procedure in a formal university-based clinical trial, and independent confirmation of efficacy in an European clinical trial1, we have launched commercialization for the CaverStem\u2122 procedure,\" said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings.\nAccording to the National Institutes of Health, approximately 30 million men in the United States suffer from Erectile Dysfunction2, of which 9 million do not respond to pharmacological treatments such as Viagra, Levitra and Cialis.\nThe trial, sponsored by Creative Medical Technology Holdings, was conducted at the University of California Los Angeles Harbor Hospital/LA Biomed under Institutional Review Board (IRB) approval.\n\"The CaverStem\u2122 procedure involves obtaining a small amount of bone marrow from the patient, purifying the stem cells using a closed system device that is FDA cleared, and then administering these cells in the same procedure into the patient's penis,\" said Thomas Ichim, Ph.D, Chief Scientific Officer and Co-Founder of the Company.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release said that 9 million men affected by ED don\u2019t respond to standard\u00a0pharmacological treatments such as Viagra, Levitra and Cialis. However, it didn\u2019t make any mention of other types of treatments, such as lifestyle changes (quitting smoking and drinking), psychological counseling, vacuum erection devices or surgery. There are a number of other treatments available for ED that is unresponsive to standard medications. None of these other treatments including devices, injections or surgical implants are ideal, so the search for new treatment options is warranted. But the unstated implication that stem cell therapy should be the next choice after a medicine trial is problematic.", "answer": 0}, {"article": "For more information, visit http://www.\nThe PSMA-inhibiting theranostic agent, called PSMA-617, is still in its initial stages, but it could be ideal for the treatment of patients with hormone-refractory prostate cancers, which are notoriously difficult to control and linked to poor prognosis.\nThe current clinical methods are not sensitive enough for detecting disease beyond the prostate, but we are convinced that this novel theranostic radiotracer represents a significant step forward that could have a major impact on the future of prostate cancer care.\"\n\"Prostate cancer still represents one of the main causes for cancer-related deaths among men,\" said Matthias Eder, PhD, co-author of the study and a researcher in the division of radiopharmaceutical chemistry at the German Cancer Research Center in Heidelberg, Germany.\nTo be clear, other PSMA-based theranostics have reached the research bench, but previous contenders had too many limitations in terms of instability in live subjects, a lack of imaging contrast between targeted tissue and background signal and increased PSMA-associated binding to normal organs such as the kidneys.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Other attempts at creating this type of imaging/therapy drug are mentioned, and the fact that metastatic prostate cancer is currently difficult to control and has a poor prognosis implies that there are few successful alternatives. We\u2019ll award a Satisfactory, although the release could have made it clearer that targeted therapies are only a subset of treatments for metastatic cancer \u2014 which also includes various chemotherapies and the Provenge vaccine.", "answer": 1}, {"article": "And we were thrilled to see such a huge impact.\nIt shows that palliative care and cancer care aren\u2019t mutually exclusive.\u201d\n\nDr. Atul Gawande, a Harvard Medical School surgeon and writer who just published a long article in The New Yorker about hospitalized patients\u2019 suffering before death, called the study \u201camazing.\u201d\n\n\u201cThe field was crying out for a randomized trial,\u201d he added.\n\u201cBut I couldn\u2019t have completed the program without the psychosocial support.\u201d\n\nPalliative care experts now want to study patients with other cancers, heart disease, stroke, dementia and emphysema.\nSaying the study was \u201cof critical importance,\u201d Dr. R. Sean Morrison, president of the American Academy of Hospice and Palliative Medicine, said it was the \u201cfirst concrete evidence of what a lot of us have seen in our practices \u2014 when you control pain and other symptoms, people not only feel better, they live longer.\u201d\n\nThere is sometimes tension between medical specialties, since surgeons and oncologists often view cancer as a battle, while palliative care specialists are seen as \u201cgiving up.\u201d\n\nPalliative care typically begins with a long conversation about what the patient with a terminal diagnosis wants out of his remaining life.\nAlthough the study could not determine why the patients lived longer, the authors and other experts had several theories: depression is known to shorten life, and patients whose pain is treated often sleep better, eat better and talk more with relatives.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As noted in the competing reviews, the point of the study was to compare early palliative care with existing standard cancer treatment. However, this story, like the others, could have provided more information about what standard cancer treatment \u2014 the current \"existing alternative\" \u2014 entails.\u00a0", "answer": 1}, {"article": "Wine rounds out the list of of 10 \"brain healthy\" food groups that help protect against Alzheimer's: green leafy vegetables, other vegetables, nuts, berries, beans, whole grains, fish, poultry, olive oil and wine.\nNow here are the five food groups it says you should avoid to reduce your risk of developing dementia...\n\nYou already know they're not so good for your waistline, and it turns out pastries and other sweets could have a negative effect on brain health as well.\nThe study, published in the journal Alzheimer's & Dementia, looked at more than 900 people between the ages of 58 and 98 who filled out food questionnaires and underwent repeated neurological testing.\nThe Mediterranean and DASH diets do not specifically recommend these types of vegetables, but the MIND diet study found that including greens in addition to other veggies made a difference in reducing the risk of Alzheimer's.\nDiet appears to be just one of \"many factors that play into who gets the disease,\" said nutritional epidemiologist Martha Clare Morris, PhD, the lead author of the MIND diet study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story compares two of the alternatives to the MIND diet, the DASH diet and the Mediterranean diet, so we\u2019ll give it a pass here. However, it is unclear from the story what these diets are being compared to and one might assume it is a standard American diet, but it is really a low-fat control diet.\u00a0 The story does not make this clear. The story could have discussed the scoring system used in the study, which was clearly described in the scientific article. In addition, the story goes into quite a bit of detail about what might be okay for people to do with their diet, beyond what the scientific study actually stated.", "answer": 1}, {"article": "Sorry. The page you requested is not available", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article states that six other drugs, all with shortcomings, are available to treat relapsing-remitting MS.", "answer": 1}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\nOf the 60 cancers detected in the study group over the observation period (7,007 screening rounds), 59 were found only using MRI, one was found also by mammography, and none by mammography or ultrasound alone.\n\"This suggests that MRI finds breast cancers that also mammography would find, but MRI detects them earlier, and it finds the cancers which, if MRI had not been done, would have progressed to interval cancers.\"\nAccording to Dr. Kuhl, the results suggest that MRI can serve as a useful supplemental screening tool for women at average risk, especially those with dense mammographic tissue, and that MRI is superior to supplemental ultrasound for this purpose.\nMRI screening has not been considered necessary for women at average risk, and there has been resistance to expansion of MRI into this population due, in part, to concern over higher costs.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release includes a comparison with breast ultrasound. It found that supplemental MRI screening\u00a0is useful for women with average risk of cancer who exhibit a range of breast densities and that it is superior to the alternative of breast ultrasound\u00a0for this purpose.", "answer": 1}, {"article": "For decades, researchers have searched unsuccessfully for ways to automatically coordinate insulin delivery with real-time changes in blood sugar to essentially create an artificial pancreas that maintains target blood sugar levels with minimal effort.\n\"This is hugely promising and very significant research,\" he tells WebMD.\nNow new technology is making this possible, and new research shows that an experimental system can improve nighttime blood sugar control.\n\"Nighttime is the time of day that strikes fear into patients and parents of children with diabetes.\"\nThe system proved better than a conventional insulin pump for maintaining optimal blood sugar levels during the night in a study from the U.K.'s University of Cambridge.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a slightly better job than the Reuters piece of explaining how type 1 diabetes is currently managed and why nighttime hypoglycemia can be a problem. Barely enough for a satisfactory rating", "answer": 1}, {"article": "It is very healthy.\nI was meeting with a cardiologist recently, and he said he doesn\u2019t advise (coconut oil) for any clients.\u201d\n\nThe fat issue is complicated by the types of fatty acids found in coconut, versus other saturated fats.\nIt\u2019s simple all the way around.\u201d\n\nOne tablespoon of coconut oil contains 120 calories and 14 grams of fat, 12.5 grams of which is saturated.\n\u201cA lot of rehydrating beverages have additives, whereas the coconut water \u2014 it\u2019s super clean.\u201d\n\nCoconut oil and milk, though, are receiving mixed reviews.\n\u201cIf they want to make more, they just build more factories.\u201d\n\nCraven describes the race to turn coconut water into a big market, like iced tea or energy drinks, as something akin to a gold rush.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The only comparisons we saw in this story were between coconut oil and butter. That was one line in a box that ran with the story and not enough to provide any meaningful comparisons to existing alternatives. Overall, readers are not given the information they would need to make informed comparisons between coconut-based products and other foods and drinks.", "answer": 0}, {"article": "LONDON -- GlaxoSmithKline PLC said it has produced an effective bird-flu vaccine for humans and could begin producing the shots at year's end, leaving it to governments to decide whether to begin ordering the shots.\n\nGlaxo, the world's second-biggest drug maker by sales behind Pfizer Inc., called the findings a breakthrough but said it needs to gather additional data before it can answer several important questions, including how much of the vaccine it will be able to manufacture.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention any alternatives.", "answer": 0}, {"article": "Specifically, seizure frequency dropped in the CBD-treated group by 39 percent from a median of nearly 12 convulsive seizures per month before the study to about six; three patients' seizures stopped entirely.\nThe study included a liquid pharmaceutical formulation of CBD, called Epidiolex, which is manufactured by GW Pharmaceuticals and has not been approved by the U.S. Food and Drug Administration.\nThe difference in the degree of seizure reduction between the CBD group and the placebo group was both statistically significant and clinically consistent.\nIn that program, both the researchers and patient's families knew they were receiving CBD, which may have introduced a bias into the results.\nFuture research will look at whether safety and tolerability might be improved and whether efficacy of CBD can be maintained at lower doses.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "In the trial, patients in the experimental group had Epidiolex \u201cadded to their existing treatment over a 14-week period,\u201d so it is obvious that other treatments are available. But these standard medications are not alternatives to cannabidiol. Instead, cannabidiol is an add-on treatment, not an alternative to existing drugs. The release could have named those standard medications and noted that other cannabidiol compounds are being studied in people with epilepsy.", "answer": 0}, {"article": "The most common adverse reactions were vaginal discharge and abnormal Pap smear.\nThe U.S. Food and Drug Administration approved Intrarosa (prasterone) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.\nIntrarosa is the first FDA approved product containing the active ingredient prasterone, which is also known as dehydroepiandrosterone (DHEA).\n\"Pain during sexual intercourse is one of the most frequent symptoms of VVA reported by postmenopausal women,\" said Audrey Gassman, M.D., deputy director of the Division of Bone, Reproductive, and Urologic Products (DBRUP) in the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research (CDER).\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There is no discussion of alternatives in this short news release. There are many interventions available now for vulvar and vaginal atrophy (VVA), including hormonal and non-hormonal therapies.\nOver-the-counter treatments include non-hormonal vaginal moisturizers for VVA symptoms, as well as lubricants to alleviate pain during sexual intercourse. Water-based vaginal moisturizers are available as liquids, gels or ovules and are inserted every few days. Silicone or water-based vaginal lubricants are shorter acting than moisturizers and are applied right before sexual activity.\nPostmenopausal women can also opt for low-dose vaginal estrogen preparations in the form of creams, rings or tablets to treat their VVA.\nSince none of these options are mentioned in the news release, we give it an Not Satisfactory rating here.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070513/21sunscreen.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story fails to note other measures sun-lovers can take to protect themselves from UV rays. These include the use of protective clothing and avoiding midday sun. (Dermatol Clin. 2002 Oct;20(4):601-6.)", "answer": 0}, {"article": "Co-authors are Erinn M. Hade, Ph.D.; Tracie C. Collins, M.D., M.P.H., M.H.C.D.S.\n\u2022 Available multimedia including photos and an audio interview are on the right column of the release link - https:/\n\u2022 Story on previous JAHA study (June 21, 2018): Breastfeeding may reduce a mother's heart attack and stroke risk\n\u2022 For updates and new science from JAHA, follow @JAHA_AHA\n\nStatements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position.\nThe study was also limited by the relatively small number of strokes that occurred during the follow-up period (just 3.4 percent of the women experienced a stroke during the study period and 1.6 percent reported having had a stroke prior to the study) and by the Women's Health Initiative's exclusion of women who had already had severe strokes at the time of recruitment.\nDALLAS, Aug. 22, 2018 -- Breastfeeding is not only good for babies, there is growing evidence it may also reduce the risk for stroke in post-menopausal women who reported breastfeeding at least one child, according to new research in Journal of the American Heart Association, the Open Access Journal of the American Heart Association/American Stroke Association.\nRecent findings point to the benefits of breastfeeding on heart disease and other specific cardiovascular risk factors,\" said Lisette T. Jacobson, Ph.D., M.P.A., M.A., lead author of the study and assistant professor in the department of preventive medicine and public health at the University of Kansas School of Medicine-Wichita.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does a nice job here, stating: \u201cBreastfeeding is only one of many factors that could potentially protect against stroke. Others include getting adequate exercise, choosing healthy foods, not smoking and seeking treatment if needed to keep your blood pressure, cholesterol and blood sugar in the normal range.\u201d\nNot all of the alternatives have been proven to protect against stroke but listing them is a worthwhile reminder that lifestyle changes might reduce their risk.", "answer": 1}, {"article": "\"Of concern is that complication rates are still higher than desirable for this procedure, and there was suboptimal use of stroke-preventing anticoagulation [anti-clotting] therapy after the procedure,\" added Fonarow, who was not involved with the study.\nAccording to Dr. Hugh Calkins, \"Atrial fibrillation ablation is a well-established procedure that has imperfect results.\"\nBut the procedure can have complications, which should be considered carefully by doctors and patients, said Arbelo, a senior specialist in the Cardiovascular Institute at the Hospital Clinic of Barcelona in Spain.\n\"Catheter ablation is a valid alternative for the management of atrial fibrillation with a satisfactory success rate,\" said study lead researcher Dr. Elena Arbelo.\nIn addition, 45 percent of patients who had a successful procedure were still taking antiarrhythmia drugs 12 months later.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story explains\u00a0that medication is the first-line treatment: \u201cFor those whose atrial fibrillation can\u2019t be controlled with medications, catheter ablation may be recommended.\u201d\nWe do wish the story had made it clear that few people with atrial fibrillation fall into the group needing ablation.", "answer": 1}, {"article": "(CNN) -- The use of mammograms has dipped since a medical task force made controversial recommendations that women in their 40s may not need to get breast cancer screenings every year, according to one of three small studies to be presented Monday.\nAlthough the task force concluded that the net benefit of mammography in the 40s is small, Hardesty said: \"If you're the one person we find your cancer, it's the world to you.\"\n\"The data that we have suggests that 1 in a thousand will benefit from mammograms in the 40-49 age,\" she said.\nAs a result, some women experience false positives, anxiety and unnecessary biopsies because of mammograms, according to data.\nThe studies suggest that fewer physicians are recommending annual mammograms for women in their 40s, fewer patients in that age group are getting screened and that tumors found through routine mammography are more likely to be detected in early stages of cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was a far more balanced discussion of harms and benefits in this story, although the use of personal opinion and recommendations, and the ending resulted in an imbalance in the piece.\u00a0 Excerpts that demonstrate this imbalance:\nWouldn\u2019t a more balanced way to end the piece \u2013 focusing on the shared decision-making element so important in this issue \u2013 have been to end with this:\nNonethless, all of this was in the piece, so we\u2019ll give it the benefit of the doubt.", "answer": 1}, {"article": "\"If [Livia] gets more women to know about TENS, then great,\" she said.\nGunter's main question about Livia is whether it will be significantly different from the already available and effective TENS devices, which usually cost around $35.\nWhen the frequency from the device hits the brain faster than the pain, the brain takes that signal first and is distracted from the menstrual aches, the company claims.\nNow there's Livia, a medical device that's being marketed as the \"off switch for menstrual pain.\"\nIts conclusion: \"High-frequency nerve stimulation may help relieve painful menstrual cramps.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The\u00a0story notes\u00a0that oral contraceptives and analgesics are also used, and that\u00a0traditional TENS units are also widely available.", "answer": 1}, {"article": "Researchers say metabolic abnormalities that eventually lead to type 2 diabetes can be present years before diabetes is diagnosed.\n\"These findings could provide insight into metabolic pathways that are altered very early in the process leading to diabetes,\" says researcher Thomas Wang, MD, of Massachusetts General Hospital's Cardiovascular Research Center, in a news release.\nFor example, insulin resistance, where the body does not use insulin effectively, occurs long before blood sugars reach the level seen in type 2 diabetes.\n\"They also raise the possibility that, in selected individuals, these measurements could identify those at highest risk of developing diabetes so that early preventive measures could be instituted.\"\nMarch 20, 2011 -- Elevated levels of a group of five amino acids may predict the development of diabetes years before any noticeable symptoms occur, according to a new study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There\u2019s no new approach yet, but, the story does\u00a0present this research as a step toward a new type of screening. The headline says, \u201cBlood Test May Predict Risk of Diabetes.\u201d With that in mind, we think important contextual informatoin was missed. There should have been some comparison to other biometric models that are in the literature and used to identify patients at high risk for developing diabetes. Also, it would have been good to put this new evidence in context with what doctors already know. Many biomarkers are known to be predictors of diabetes. What you would like to know is once these other factors have been taken into consideration, how did this amino acid screen improve on those techniques?", "answer": 0}, {"article": "A capsule of Probiotic Immunity from New Chapter Inc., based in Brattleboro, Vt., contains 1 billion each of 10 different organisms, including Streptococcus salivarius subsp. thermophilus and Lactobacillus acidophilus, two species of bacteria often found in yogurt. Other ingredients include herbs such as cumin, ginger and spinach. Users are instructed to take two capsules each day, preferably one in the morning and one in the evening, on an empty stomach. You can buy a bottle of 90 capsules for about $20 at many health food stores.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u2019s second paragraph briefly mentions some options:\n\u201cAvoiding germs entirely would require something like solitary confinement or a head-to-toe application of Purell. As an alternative, many people try to do what they can to strengthen their immune systems. Vitamin C is old news, and echinacea and other herbs haven\u2019t really panned out. \u201c", "answer": 1}, {"article": "A surgically implanted electrical device that stimulates the sacral nerve can calm an overactive bladder, according to a company that sells it. Physicians say sacral neural stimulation works well for many patients, but a test period with an external device is recommended first.\n\nMillions of Americans suffer from \"urge incontinence,\" accidents caused by a strong, sudden need to get to the bathroom, or overly frequent urination, defined as eight or more times a day. Quality of life is affected, as sufferers must...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions exercises, biofeedback and medications as alternatives to the device, and is careful to point out that these should be considered first-line treatment options before the device is considered. The story could have done more to describe the pros and cons of the alternatives.", "answer": 1}, {"article": "For more information about Pitt Public Health, visit the school's Web site at http://www.\nThe analysis, published today in the journal Stroke, determined that resuming anticoagulation therapy after a person suffers a major bleeding event was associated with a higher likelihood of stroke-free survival than discontinuing anticoagulation.\n\"If a patient who is on an anticoagulant to avoid a stroke has a major bleeding event, doctors are faced with a catch-22: Discontinue the anticoagulant to avoid future bleeding, but again place their patient at increased risk of stroke; or resume the anticoagulant to continue avoiding a stroke, but then have to worry about another bleeding event,\" said lead author Inmaculada Hernandez, Pharm.D., Ph.D., an assistant professor in Pitt's School of Pharmacy, who completed this work as a doctoral student at Pitt's Graduate School of Public Health.\nThe risk of dying from any cause or having a stroke was 23 to 34 percent higher in patients who discontinued anticoagulation therapy compared to those who resumed it.\n\"Our results should encourage clinicians to seriously consider resuming anticoagulation among patients who survived a major bleeding event, particularly if the source of bleeding was identified and addressed,\" said senior author Samir Saba, M.D., associate professor of medicine and associate chief of cardiology at UPMC Heart and Vascular Institute.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release focuses on the potential for superior outcomes with a new anticoagulant compared with warfarin, the traditional medication. However, there are other new anticoagulants on the market and they were not mentioned.", "answer": 0}, {"article": "She and her colleagues found no evidence that taking NSAIDs had any effect on risk of developing the deadly skin cancer.\n\u201cI think the jury is still out.\u201d\n\nThere\u2019s reason to hope NSAIDs might offer some protection against this type of cancer, however - earlier this year, a review found that people who use painkillers such as ibuprofen on a regular basis may be less likely to get bladder cancer.\nThe findings are interesting, but should not lead people to conclude that popping a few painkillers will reduce their risk of skin cancer, cautioned Dr. Maryam Asgari of Kaiser Permanente Northern California and the University of California San Francisco, who co-authored the 2008 study.\nFor one, you have to get the comparison right, she noted; there\u2019s always a concern that people without cancer who agree to participate in the study may be more health conscious to begin with, and it\u2019s this that protects them from cancer, not their use of NSAIDs.\nAs a result, \u201cI wouldn\u2019t recommend (taking NSAIDs to reduce melanoma) just based on this\u201d new study, Asgari noted.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "It\u2019s curious that the story never mentioned that the study also looked at statins and found \u201cno significant protective effect was observed with statin exposure.\u201d\u00a0 Why wasn\u2019t that mentioned? Negative findings deserve publicity as well.", "answer": 0}, {"article": "\u201cRadiation dose reduction resulted in significantly improved swallowing and nutritional status,\u201d she said.\nThe study, published in the December 26 issue of the Journal of Clinical Oncology, showed that patients treated with reduced radiation had less difficulty swallowing solids (40 percent versus 89 percent of patients treated with standard doses of radiation) or impaired nutrition (10 percent versus 44 percent of patients treated with regular doses of radiation).\nWe want to help improve our patients\u2019 quality of life.\u201d\n\nThe study included 80 patients from 16 ECOG-ACRIN Cancer Research Group sites who had stage three or four HPV-positive squamous cell carcinoma of the oropharynx, and were candidates for surgery.\n\u201cWe found there are some patients have very high cure rates with reduced doses of radiation,\u201d said Barbara Burtness, MD, Professor of Medicine (Medical Oncology), Yale Cancer Center, Disease Research Team Leader for the Head and Neck Cancers Program at Smilow Cancer Hospital, and the chair of the ECOG-ACRIN head and neck committee.\n\u201cToday, many younger patients are presenting with HPV-associated squamous cell carcinoma of the oropharynx,\u201d said Dr. Burtness.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The\u00a0release summarizes a study that compares low dose and high dose radiation, and notes that\u00a0chemotherapy was also part of the treatment regimen for the patients. It\u00a0states that all of the patient volunteers were candidates for surgery, which is another\u00a0alternative or adjunct therapy for these types of cancers.", "answer": 1}, {"article": "Epilepsy is a neurological disorder that disrupts electrical communication between neurons in the brain.\n\"No one study decides an issue; the sample size is still relatively small (because this is a rare syndrome and so hard to study large numbers of cases) and the duration of treatment so far has been relatively short,\" Hall, who was not involved in the research, wrote in an email.\n\"After 3,800 years of cannabis use for epilepsy ... we finally have solid evidence,\" said Dr. Orrin Devinsky, lead author of the study and director of NYU Langone's Comprehensive Epilepsy Center.\n\"Interestingly, it looks similar to our other seizure medications in terms of efficacy and tolerability,\" Porter said.\nThe Epilepsy Foundation's Fureman said, \"before publication of this trial, much of the clinical evidence about CBD's effects on people's seizures was uncontrolled and anecdotal.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is not a deep comparison of alternatives in this piece, but we give it credit for quoting an independent expert saying, \u201cInterestingly, it looks similar to our other seizure medications in terms of efficacy and tolerability. \u2026 So, sadly, not a home run for most patients but another tool in our treatment regimen.\u201d", "answer": 1}, {"article": "Tim Barham, the vice president of HBB, the maker of Lazy Cakes, said, \u201cWe look at the brownie as a supplement.\u201d\n\nNews reports have classified Lazy Cakes as dietary supplements, but last month, Douglas Karas, an F.D.A.\nIt also warned that women who are pregnant or trying to conceive should avoid melatonin \u201cbased on possible hormonal effects.\u201d (Drank\u2019s bottle now say it is a dietary supplement.)\nFor me, it\u2019s to get a good night\u2019s sleep.\u201d\n\nYet the products, intended for adults only, are being marketed as a novel way to relax in a stressed-out, wired world.\n\u201cIt should not be permitted by the F.D.A.\u201d\n\nTechnically, it is not.\n\u201cA hangover effect has been reported\u201d with large doses, said Anna Rouse Dulaney, a toxicologist with the Carolinas Poison Center.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Not applicable.\u00a0 It isn\u2019t possible to compare existing alternatives to these products because there is no information documenting efficacy of the products.", "answer": 2}, {"article": "For more information, visit http://www.\nThus, higher cognitive control regions will stay active even while the brain is processing salient emotional stimuli, giving the individual the capacity to shift their mindfulness and attention so that they are not perseverating,\" said Dr. Iacoviello.\nThe underlying mechanism for MDD that the intervention targets involves an imbalance in the activity of specific brain regions: individuals with MDD show hyperactivity of neural systems involved in emotion processing, such as the amygdala, coupled with decreased activity of systems involved in cognitive control and emotion regulation, such as the prefrontal cortex.\nErik Lium, PhD, Senior Vice President at MSIP, said, \"We strongly believed in the potential of this technology based on early trials at Mount Sinai, and are pleased with our commercial partnership with Click Therapeutics.\nThis treatment was developed at the Icahn School of Medicine at Mount Sinai by Brian Iacoviello, PhD, an Assistant Professor of Psychiatry who is Director of Scientific Affairs for Click Therapeutics, and Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean and Professor of Psychiatry, Neuroscience, and Pharmacological Sciences.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Many other therapies for major depression have been developed, and some of them use technological approaches. Besides these, there are also drugs, psychotherapy and exercise with known benefits. The release would have been stronger if it had listed some of what is already known to work, and explained how the new therapy fit into that context. Is it cheaper? More effective? Easier for rural patients to access?", "answer": 0}, {"article": "It was funded by Arena Pharmaceuticals, Inc., which developed lorcaserin.\nThe drug lorcaserin works on the serotonin receptor -- the same appetite-controlling hormone targeted by the notorious drug fenfluramine, the \"fen\" component of combination medication fen-phen.\nBut lorcaserin is far more selective than the drug fenfluramine and much safer, its manufacturer says, because it specifically targets the serotonin receptor associated with hunger while having no impact on the heart.\nJuly 14, 2010 -- An experimental weight loss drug that targets the brain\u2019s hunger center was shown to be safe and effective for helping dieters shed pounds in a two-year study, researchers say.\nDiet Drug Users Lost Twice as Much Weight The study included about 3,200 obese or overweight adults who were randomly assigned to take 10 milligrams of the diet drug or placebo, twice a day for a year.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story misses one huge point. How does this drug do when compared to diet and exercise? The story mentions that the drug is not as effective as two existing drugs, but doesn\u2019t compare it to other weight loss treatments. If people walked 30 minutes a day and ate a balanced diet, would they lose more than 12 pounds on average in a year\u2019s time? (Ask that Subway pitchman.)", "answer": 0}, {"article": "Eteplirsen, which Sarepta says has shown no side effects so far, is vying with a similar drug being developed by GlaxoSmithKline to become the first medicine that works by directly countering the cause of the disease.\nMr. Garabedian said Sarepta did not have the money or the manufacturing capacity to make the drug available outside of clinical trials.\nEteplirsen could also be the first drug to reach the market for Sarepta since it was founded 32 years ago.\nAnd the stock had already roughly quadrupled since July, when Sarepta announced some interim results from the study.\nThose with the disease make barely any dystrophin, a protein necessary for muscles to function.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story noted that there is at least one other drug in development and that there is a rather ineffective treatment available in the form of steroids.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - A large waistline more than doubles the risk that people in their 40s will develop precancerous cells in the colon, according to Korean researchers.\nThere are cheaper methods such as testing stool for blood, Dr. Michael L. LeFevre, of the University of Missouri in Columbia, told Reuters Health.\n\u201cBut attempts to draw those conclusions now is a bit premature, because most colorectal polyps don\u2019t become cancers.\u201d\n\nThe Korean researchers, at Konkuk University in Seoul, examined more than 1,700 men and women, aged 40 to 59, who had no signs of colon cancer and no family history for the disease.\n\u201cYou want to make sure that the advantages are going to outweigh the harms,\u201d said the American Cancer Society\u2019s Smith.\n\u201cThe idea that you\u2019re tailoring screening to age and some combination of risk factors is entirely reasonable,\u201d said Robert Smith, the director of cancer screening at the American Cancer Society.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story very briefly mentions one alternative to colonoscopy, the stool test for blood. While this is the most widely-available alternative, there are other alternatives, including CT Colography, sigmoidoscopy, barium enema, and the choice to not have screening at all.", "answer": 1}, {"article": "The new research paper also demonstrates how the plant-based chemicals work together.\n\"After screening a natural compound library, we developed an unbiased look at combinations of nutrients that have a better effect on prostate cancer than existing drugs,\" says corresponding author Stefano Tiziani, assistant professor in the Department of Nutritional Sciences and Dell Pediatric Research Institute at UT Austin.\nThe most promising active ingredients were then tested on model animals: ursolic acid, a waxy natural chemical found in apple peels and rosemary; curcumin, the bright yellow plant compound in turmeric; and resveratrol, a natural compound common to red grapes or berries.\nNew research from The University of Texas at Austin identifies several natural compounds found in food, including turmeric, apple peels and red grapes, as key ingredients that could thwart the growth of prostate cancer, the most common cancer afflicting U.S. men.\nThe experiment was designed, analyzed and written up with coauthors Alessia Lodi, John DiGiovanni and Achinto Saha, all of UT Austin.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "While there\u2019s no proven strategy to prevent prostate cancer, there is general advice for reducing overall cancer risk such as quitting smoking, maintaining a healthy weight, exercising, and eating a variety of plant foods. Current treatment options include watchful waiting, active surveillance, hormone therapy, chemotherapy, radiation therapy and surgery. These aren\u2019t mentioned.\nSpeaking of prevention and treatment in the same release really oversimplifies the issues. There are studies showing that chemoprevention with 5-alpha reductase inhibitors can reduce the risk of prostate cancer, although the FDA will not allow manufacturers to suggest these compounds prevent cancer because these agents were associated with an increased risk for high-grade cancers. Treatment options completely depend upon the stage of the cancer\u2013thus range from conservative management to aggressive attempts at curative therapy to palliative care. The role of these substances in any of these settings is obviously completely unknown.", "answer": 0}, {"article": "MONDAY, July 11, 2011 (HealthDay News) -- Teens who have high levels of folic acid appear to do better in school than those with lower levels, Swedish researchers report.\nInsufficient folic acid is a cause of certain birth defects of the spine and brain, including spina bifida.\nIt's not going to do us any harm and it might do us some good,\" he said.\nIn fact, folate deficiencies may be involved in the development of autism, he added.\nIn previous studies, folic acid levels have been linked to mental ability; however, until now this had not been linked with improved school performance, the study authors said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story did a very nice job of indicating food sources of folic acid as well as those foods that are good sources of folic acid by virtue of food supply supplementation.", "answer": 1}, {"article": "For more information, go to http://www.\nThe power of nutrient-rich, properly formulated food-based supplements, such as the CHORI-bar, to move dysregulated metabolism in a healthy direction may help reverse obesity-associated conditions, and thereby reduce the risk of future chronic diseases.\nImproved metabolism resulting from eating the bar is also associated with a number of reports of feeling better (though this observation has not yet been formally tested), which the CHORI team predicts will help people transition to improved lifestyle habits.\nThe CHORI-bar is intended as a non-traditional means to positively impact the obesity epidemic by initiating a healthier metabolism without requiring sudden drastic behavioral changes.\nWhile poor diets contain much that is not healthy (e.g., too much salt, sugar), they also are missing or deficient in a number of important components (e.g., vitamins/minerals, omega-3 fatty acids, fiber) necessary for healthy metabolism.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The story notes, \u201cConventional approaches that encourage weight loss by improving dietary habits, reducing caloric intake and modifying activity can be successful, but prove difficult for many to initiate and sustain.\u201d We\u2019ll call that sufficient for a Satisfactory rating here.", "answer": 1}, {"article": "There are some points we need to note about this study.\nWhile current medications are useful, they are better at targeting mania symptoms (the 'up' phase), leaving a lack of effective treatment for people experiencing depressive episodes.\n\"If we can confirm these results, then it's good news for people with Bipolar Disorder, as there is a great need for better treatments for the depressive phase of Bipolar Disorder\" said lead researcher Melanie Ashton of Deakin University in Australia.\nBipolar Disorder (which used to be called 'manic depression') is characterised by episodes of mood swings, between being very up or very down with periods in between the two extremes.\nA total of 133 participants were randomly assigned to take a combination of nutraceuticals (compounds derived from foods such as vitamins or minerals that treat or prevent a disease or disorder) including the anti-inflammatory amino acid n-acetylcysteine (NAC), or NAC alone, or a placebo (a dummy pill) for 16 weeks.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Bipolar disorder is fairly well-defined in the release, and it\u2019s mentioned \u201cthere is a great need for better treatments for the depressive phase.\u201d However, current alternative treatments such as medications, light therapy or electroconvulsive therapy (ETC) in severe cases are not mentioned.", "answer": 0}, {"article": "Ohio\u2019s roads stink. Here are 5 options to fix them\n\nNobody likes paying more. But it turns out, if we want our roads to improve, we might have to.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story reports that women who take hormones for severe menopausal symptoms should do so at the lowest dose for the shortest time possible. \nIt should have briefly mentioned that other interventions are available to treat the conditions for which the hormones were widely prescribed, including heart disease and osteoporosis.\u00a0\u00a0 ", "answer": 0}, {"article": "This news-agency article is no longer available on nytimes.com.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We will give the story a satisfactory rating on this criterion because it does discuss existing methods for monitoring medication adherence and it makes clear that the apps mentioned still need to be studied. However, the overall tone of the story implies confidence that the apps will prove themselves to be more efficient than current methods, which is a proposition that has yet to be adequately tested.", "answer": 1}, {"article": "So far, the FDA is erring on the side of caution.\nDr. Mina Fazel, child psychiatrist at the Oxford University Children\u2019s Hospital, says, \u201cIt\u2019s complicated, because you\u2019re giving antidepressants when you\u2019re very worried about that young person\u2019s mood.\u201d Essentially, the moment when it seems most necessary to prescribe the drugs may also be the moment when the patient is most at risk of suicide.\n\u201cFor antidepressants in adolescents, this equation will rarely favor prescribing; in younger children, almost never.\u201d\n\nTo be clear, Jureidini believes there is almost never a justification for prescribing antidepressants to children or adolescents.\n\u201cThey\u2019re not better than nothing,\u201d he said, \u201cand there\u2019s quite clear evidence that they\u2019re more dangerous than nothing.\u201d He arrived at this conclusion after applying the customary dose of skepticism doctors are taught to apply when translating research findings to clinical practice.\nThe Oxford paper notes that 3 percent of children ages 6-12 and nearly 6 percent of teenagers ages 13-18 suffered from major depressive disorder, the psychiatric term for what is colloquially known as depression.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses cognitive behavioral therapy, which it says is recommended by guidelines from the psychiatric associations in most countries and \u201chas been shown to work, at least by participants\u2019 own assessment of their depression levels.\u201d It also mentions the high cost of cognitive behavioral therapy and the fact that it \u201cmay not always be readily available,\u201d which could explain the growing reliance on antidepressant drugs.\nHowever, the story is incorrect when it states Prozac is the only drug approved to treat depression in people under 18. Escitalopram (Lexapro) is also approved by the FDA to treat adolescents for depression.\nIt also offers up conflicting information.\u00a0In the last sentence, it\u00a0links to a Cochrane meta-analysis and says\u00a0\u201ctherapy and medication are more effective together than in isolation.\u201d But that\u2019s not what the analysis concluded. Instead, it said: \u201cWe do not know whether psychological therapy, antidepressant medication or a combination of the two is most effective to treat depressive disorders in children and adolescents.\u201d", "answer": 0}, {"article": "Aug. 12, 2012 -- Daily aspirin use, long recommended for people at high risk of heart attack, may also reduce the risk of dying from cancer, according to new research.\n\"In our analysis, daily aspirin use was associated with about a 16% lower risk of dying from cancer overall,\" Jacobs says.\nHe describes that reduction as modest.\nThe benefit, however, may not be as great as believed, says researcher Eric Jacobs, PhD, of the American Cancer Society.\nEven so, he says, \"our results provide additional support for the potential benefit of daily aspirin for [reducing] cancer mortality.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "At least the story included this line:\u00a0 \u201cMany other strategies will also reduce the risk of cancer.\u00a0 Among them:\u00a0 engaging in regular physical activity, maintaining a healthy diet and not smoking cigarettes.\u201d", "answer": 1}, {"article": "MIT scientists find evidence that Alzheimer\u2019s \u2018lost memories\u2019 may one day be recoverable\n\n\u2019Siri, I want to commit suicide\u2019 and other statements likely to yield unhelpful responses from your phone\n\nRoots of Napoleon complex may be justified: Study finds short men get short of end stick in life.\nThe study did caution that 30 of the 103, or about one-third, of the participants in the meditation group reported an \"adverse event,\" most often an increase in pain due to yoga.\nThe study looks at adults with chronic low back pain, one of the leading cause of disabilities in the United States and one reason why more and more people are addicted to painkillers.\nThe two wrote that despite this and other unknowns, the study provides \"a compelling argument for ensuring that an evidence-based health care system should provide access to affordable mind-body therapies.\"\nLed by Daniel C. Cherkin of Group Health Research Institute in Seattle, the experiment involved randomly assigning 342 adults with the condition to meditate, talk with a psychologist or continue with their normal techniques for addressing the pain, such as medication.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is effectively all about comparing alternatives, though\u2013again\u2013it should have made clear that MBSR and CBT were used in conjunction with conventional medical treatment, and it left out discussion of other well-known non-medication treatment methods, such as exercise.", "answer": 1}, {"article": "TUHS neither provides nor controls the provision of health care.\n\"We show that we can intervene after disease is established and pharmacologically rescue mice that have tau-induced memory deficits,\" explained senior investigator Domenico Pratic\u00f2, MD, Scott Richards North Star Foundation Chair for Alzheimer's Research, Professor in the Departments of Pharmacology and Microbiology, and Director of the Alzheimer's Center at Temple at LKSOM.\nTo recapitulate the clinical situation of dementia in humans, in which patients are already symptomatic by the time they are diagnosed, Dr. Pratic\u00f2 and colleagues used specially engineered tau transgenic mice, which develop tau pathology - characterized by neurofibrillary tangles, disrupted synapses (the junctions between neurons that allow them to communicate with one another), and declines in memory and learning ability - as they age.\n\"At the onset of dementia, leukotrienes attempt to protect nerve cells, but over the long term, they cause damage,\" Dr. Pratic\u00f2 said.\nThey show, for the first time in an animal model, that tau pathology - the second-most important lesion in the brain in patients with Alzheimer's disease - can be reversed by a drug.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release would have been improved if it had acknowledged the multiple failures over many decades of other once promising drugs for dementia tested in animals. The take-home message should be that these disorders, and brain chemistry in general, are complicated, and although research may bring hope, it has yet to bring effective treatments.", "answer": 0}, {"article": "Depression affects about 20 percent of people at some point in their lives.\nAn imbalance in serotonin levels is believed to be linked to depression.\nThey were later assessed by experts for their depression levels and the group that received genuine electroacupuncture was found to be a lot happier.\nThe electroacupuncture was given in addition to medication that the patients were already taking and meant to augment their treatment, Zhang told a news conference.\n\u201cWhen the acupoints are stimulated, some brain centres responsible for producing serotonin are stimulated,\u201d explained Ng, a consultant at the department of psychiatry at the Kowloon Hospital in Hong Kong.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No meaningful comparison was given with any other approach to depression.", "answer": 0}, {"article": "Merck & Co. and Schering-Plough Corp. said a long-awaited trial showed their cholesterol drug Vytorin failed to slow progression of heart disease better than a cheaper drug, threatening the companies' $5 billion-a-year cholesterol-fighting franchise.\n\nSchering-Plough's shares fell 8% to $25.52 and Merck declined 1.3% to $59.78 at 4 p.m. in New York Stock Exchange composite trading.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This was story about the failure of one combination therapy to outperform the single, simpler, less expensive therapy. \u00a0It did not, however, provide information about other means of lowering risks from cardiovascular disease. \u00a0These should have been mentioned in order to put the results of the ENHANCE study into perspective.", "answer": 0}, {"article": "PhD candidate Alexandra Wade says the new MedDairy diet challenges popular perceptions of what is considered healthy.\n\u201cThis study shows that the new MedDairy works better than a generic low-fat diet, ensuring better health outcomes for people at risk of cardiovascular disease.\u201d\n\nImportantly, the MedDairy diet also meets additional calcium requirements recommended by Australia\u2019s national health bodies.\nIt also includes 1-2 servings of dairy foods (700-820mg calcium), which is less than half the dairy recommended by the Australian National Health and Medical Research Council (NHMRC) for older Australians.\n\u201cThe new MedDairy diet allows for three to four servings with dairy, which means Australians can more sustainably meet their recommended daily nutrient intakes while also maintaining the significant health benefits offered through the MedDiet.\nThe results show that the dairy-supplemented MedDiet (MedDairy) significantly improved blood pressure, heart rate, cholesterol, mood and cognitive function.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There\u2019s no discussion about how the effectiveness of a dairy-supplemented Mediterranean diet might compare to a traditional Mediterranean diet as it relates to heart disease risk. The release claims a\u00a0dairy-supplemented Mediterranean diet \u201cis more effective\u201d than a low-fat diet but offers no data to back up the claim.", "answer": 0}, {"article": "That\u2019s the good news.\nIn an editorial accompanying the study, Emily Jungheim and Graham Colditz of Washington University School of Medicine in St. Louis wrote that the findings indicate that while there \u201cmay still be a role for short-term use of unopposed estrogen for treating some women with menopausal symptoms ... this role may be vanishing as existing and emerging data continue to be better understood.\u201d\n\nRowan Chlebowski, one of the researchers who worked on the analysis, stressed that the study only looked at women who were taking estrogen alone.\nA new analysis of the landmark Women\u2019s Health Initiative, the federal study that discovered the health risks, indicates that women who stopped using estrogen after the dangers were uncovered are no longer at increased risk for strokes and blood clots about 10 years after they stopped.\nIn the new analysis, researchers analyzed data collected from 7,645 women who were in the part of the study examining the effects of taking estrogen alone an average of 10.7 years, after the study was halted because of the evidence the drugs were harming women.\nThe bad news is that there is no benefit of being less likely to develop heart disease, and any reduction in the risk of hip bone fractures evaporates with time, according to a report in the latest issue of the Journal of the American Medical Association.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although not as thorough as the NY Times on this point, the story at least stated:\n\n\u201cIn an editorial accompanying the study, Emily Jungheim and Graham Colditz of Washington University School of Medicine in St. Louis wrote that the findings indicate that while there \u201cmay still be a role for short-term use of unopposed estrogen for treating some women with menopausal symptoms \u2026 this role may be vanishing as existing and emerging data continue to be better understood.\u201d\nRowan Chlebowski, one of the researchers who worked on the analysis, stressed that the study only looked at women who were taking estrogen alone. Women who took a combination of estrogen and progestin face increased risk for breast cancer, previous studies have shown, Chlebowski said.\u201d\nWe\u2019ll give it a satisfactory score on this, but for reader comprehension, we think the Times piece was much better.\n\u00a0", "answer": 1}, {"article": "The fact that recognizing and acknowledging a familiar person is such...\nYou must then summon the speech centers in your frontal lobes, which recruit your breath and muscles and at last allow you to utter the words Hi, Mom.\nA little bit of current may calm the tremors of Parkinson\ufffds disease, ease depression and epilepsy, and awaken those with terrible injuries.\nFrom there it is relayed to your memory center, where it is identified by comparison with every other face you've ever seen.\nA lateral X-Ray of the head of a 38-year-old man shows two Deep Brain Stimulation (DBS) leads with four electrodes attached to each implanted in the subcortical area of the brain called the thalamus.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story stated that \"Twenty percent of miminally conscious patients recover well enough to return to the community and resume their lives\" and that those suffering from traumatic brain injury have few options.\u00a0 However \u2013 it did not provide any insight as to what the treatment options are.\u00a0 ", "answer": 0}, {"article": "The muscle into which needles deliver vaccine is not nearly as active immunologically.\nFlu patch may take sting out of your fears\n\nIn what would be a boon for needle-phobes of all ages, researchers have developed a skin patch that vaccinates against the flu and could be available in five years.\n\"It's a technological approach that makes a lot of sense,\" said Dr. Jan Drutz, a general pediatrician at Texas Children's Hospital who calls needle-phobia common in both kids and adults.\n\"We've now demonstrated a technology that can enable painless, self-administered flu vaccination,\" said Mark Prausnitz, a professor in the Georgia Tech School of Chemical and Biomolecular Engineering and leader in the research.\nIn the study, one group of mice received the influenza vaccine from traditional hypodermic needles; another group received the vaccine through the dissolving microneedles; and a control group received the microneedle patches not containing any vaccine.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Like the AP competition, the story fails to mention\u00a0the availability of\u00a0options to reduce vaccine pain. These include\u00a0the Flumist nasal spray and topical creams that can be used to anesthetize the site of the needle stick.", "answer": 0}, {"article": "[1]\n\nWriting in a linked Comment, Dr Nahid Bhadelia from Boston University School of Medicine and Boston Medical Center, Boston, USA says, \"[This study] validates the accuracy of the ReEBOV RDT in patients who are well into their illness...suggesting it could be used to triage this subset of patients if RT-PCR is not available, particularly in those with a high index of clinical suspicion for a differential diagnosis...the data presented provide crucial information about the point of-care function of this rapid diagnostic test, such as ease of use, quality of samples taken at the bedside, and the concordance with venous samples...the results raise caution regarding the performance of the widely used altona RT-PCR assay, which the authors suggest might have underperformed because of laboratory specific technical and performance factors.\"\nA new test can accurately predict within minutes if an individual has Ebola Virus Disease (EVD), according to new research published in The Lancet.\nThe altona RT-PCR assay failed to detect a small number of EVD cases that tested positive by both RDT and by an alternative RT-PCR test (Trombley), all with relatively low amounts of virus.\n106 suspected Ebola patients admitted to two treatment centres in Sierra Leone (run by the Ministry of Health and Sanitation of Sierra Leone and supported by the non-governmental organisation Partners In Health) during February 2015 were tested by both RDT (performed on a fingerstick blood sample at the point-of-care) and by standard RT-PCR (performed on plasma in the laboratory).\nThe study is the first to show that a point-of-care EVD test (ReEBOV Antigen Rapid Test; Corgenix) is faster than and as sensitive as a conventional laboratory-based molecular method used for clinical testing during the recent outbreak in Sierra Leone.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This is\u00a0definitely a strong part of the release\u00a0\u2014 the new test is compared to two manufacturers\u2019 versions of the standard RT-PCR test.\u00a0But the release doesn\u2019t mention\u00a0other diagnostic tests, including virus isolation and ELISA.", "answer": 1}, {"article": "\u201cMore often than not, it\u2019s not clear-cut which way to go,\u201d explained Barry Rosenstein, professor of radiation oncology at Mt.\n\u201cIf a man has five or six, it increases his chances quite a bit.\u201d\n\nThe research is still in the early stages, so doctors aren\u2019t likely to be using the genetic markers to determine treatment any time soon.\n\u201cAnd if we can do that, then there\u2019ll be enough confidence to put it into use in the clinic.\u201d\n\nEven better, he suggested, it may one day be possible to use drugs to target the SNiPs, or the biological processes they influence, as a way to prevent damage from therapy.\nWhile Derweesh agreed with Rosenstein that such a technique will take time to validate, and be used to steer patients toward a particular therapy -- something he called the \"holy grail\" -- he suggested that in the nearer term, such markers might be used as a trigger to pre-emptively begin erectile rehabilitation or to take measures that might lessen the potential damage.\nIf you see a radiation oncologist he\u2019ll say oncology.\u201d\n\nDetermining what type of treatment a man should receive is only part of the dilemma of prostate cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Alternative treatment approaches are not discussed. Presumably all subjects have cancer confined to the prostate and are eligible for attempted curative therapy (surgery or radiation). \u00a0However, a substantial proportion of early-stage cancers are low-risk\u2013and do not necessarily even require treatment. \u00a0These men face no risk for treatment-related erectile dysfunction. \u00a0The alternative active treatment\u2013surgery\u2013is actually much more likely than radiation therapy to cause erectile dysfunction. \u00a0The other major issue regarding treatment alternatives is whether patients would achieve better cancer control\u2013a potentially more important outcome for patients than the complication risks.", "answer": 0}, {"article": "Jason Dragoo\u2019s Stanford University research team gets 100 to 200 inquiries every day from people interested in joining its clinical trial studying the use of stem cells to treat knee injuries.\n\nThe interest highlights a growing demand for the use of stem cells derived from a person\u2019s own bone marrow or fat to treat orthopedic injuries. Osteoarthritis, a degenerative joint disease where the protective tissue or cartilage around a joint wears down, is a particular focus of inquiry.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Non-surgical and drug alternatives for treating pain from osteoarthritis of the knee were not discussed. Also, the story starts out by saying \u201cKnee osteoarthritis, or arthritis of the knees, is a difficult-to-treat and painful condition affecting millions of people.\u201d Many patients have mild symptoms that are well controlled with medicine, exercise, physical therapy and other simpler and less expensive treatments than discussed here. The article should have mentioned these and said that the treatments discussed are considered for those not responding to these other, first-line therapies.", "answer": 0}, {"article": "Overweight people could be given help with the discovery that a drug used for sleep disorder could also reduce the impulse for food\n\nOverweight people could be given help with the discovery that a drug used for sleep disorder could also reduce the impulse for food.\nThere are many factors that cause obesity but there is a growing weight of evidence that shows obesity is not just caused by a behavioural disorder, such as a lack of self-control, but that many overweight people are physically addicted to foods rich in fat and sugar.\nThere is mounting evidence to show that there is a substantial number of obese people who are food addicts because they have an inability to control their impulsive actions and this drug has shown it can give them more control, which will help overweight people lose weight and so improve their health.\nWhen we eat food that tastes good we get a powerful release of dopamine in the pleasure/reward section of the brain, but food addicts have been found to have a deficiency in a certain type of dopamine so that their sense of reward and pleasure is diminished, thus they have to eat more to reach the same level of pleasure as anybody else.\nIn the paper Pharmacological manipulation of impulsivity: A randomized controlled trial published in Personality and Individual Differences, the scientists conducted a series of trials on 60 men aged between 19 and 32, with 20 taking a placebo, 20 Atomoxetine and 20 Modafinil.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There is no mention of alternatives to the use of the narcolepsy drugs studied as a means of weight control. The release could have acknowledged there are numerous appetite-control drugs, countless diets and exercise strategies available for to help change eating patterns.", "answer": 0}, {"article": "Screening patients for heart disease with a heart-imaging test prompted greater follow-up care but had little to no effect on the number of heart attacks and other cardiovascular events in those patients, a new study found.\n\nResearchers at Johns Hopkins Hospital in Baltimore led the study, which was published online Monday in the Archives of Internal Medicine.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story indicated that the CCTA was a possible non-invasive alternative to a cardiac catheterization. \u00a0While this may be true in certain circumstances, neither test is recommended for the population of individuals who were in the study. That point could have been emphasized more clearly.\nThe story could have reported on the fact that the researchers did not report the effect of coronary calcium scores (information that the researchers collected but did not feed back to patients and providers); that is the test most often touted for coronary heart disease screening in asymptomatic people.", "answer": 0}, {"article": "Servan-Schreiber offered more words of wisdom to LaPook -- words he says doctors rarely impart to their patients -- and LaPook discussed with co-anchor Harry Smith on The Early Show Friday why he thinks it is that cancer survivors aren't offered more guidance by the medical establishment:\n\nServan-Schreiber appears in the joint CBS, NBC, ABC special \"Standing Up To Cancer\" Friday night.\n\"There's tremendous evidence that physical exercise helps prevent cancer, and also helps people who already have cancer prevent a recurrence,\" he says.\nHe has penned the best-selling book, \"Anti-Cancer: A New Way of Life,\" about his past and on-going battle, and offers suggestions to fellow cancer patients.\n\"\n\nServan-Schreiber did what he knew best -- he hit the books, and was surprised to find studies on how nutrition and exercise might help the body fight cancer -- information doctors never told him.\nA conventionally trained physician, Servan-Schreiber says surgery and chemotherapy saved his life, but when he asked how he could change his lifestyle to help beat the cancer for good, he came up empty.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions a grab-bag of \"lifestyle changes\" but does not do anything to describe what they involve (do you have to do them all?)\u00a0or the pros and cons of the different options.", "answer": 0}, {"article": "Medical researchers are well aware that the dummy pills used in clinical trials often provide as much relief as the actual drugs being tested. This is what's known as the placebo effect, and it's quite common in people with Parkinson's, a movement disorder that causes tremors, stiffness and balance problems. A 2008 meta-analysis found that placebos used in clinical trials of Parkinson's treatments improved symptoms by an average of 16%.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study itself was a comparison of two different placebos \u2014 one cheap, the other expensive. The story makes this clear.", "answer": 1}, {"article": "For more information about the AACR, visit http://www.\nAmong the 36 patients with hormone receptor-positive breast cancer, 11 had a partial response, with four of the 11 responders having continued prior endocrine therapy, and an additional 18 patients had stable disease.\nFor example, abemaciclib has greater selectivity for CDK4 compared with palbociclib, which may explain why it does not affect white blood cell counts as severely, allowing it to be taken on a continuous schedule without treatment holidays, he said.\nAuthor Comment: \"These data show that abemaciclib is an oral drug that can be taken on a continuous schedule and achieve durable clinical activity against multiple tumors including breast and lung cancers,\" said Shapiro.\nThree of the 17 patients with glioblastoma had stable disease, with two of them continuing to receive treatment without disease progression for 19 and 23 cycles, respectively.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release spells out some specific features of abemaciclib that explain why researchers think it has potential advantages over a similar drug that is already FDA-approved. However, this comparison puts the new drug in an entirely positive light, which it has yet to demonstrate it deserves. We\u2019ll dock points for that concern here. Since the comparison with the competing drug also speaks to abemaciclib\u2019s novelty, we\u2019ll award a Satisfactory for that criterion (see below) so as not to double-ding the release. ", "answer": 0}, {"article": "But investors had been anticipating a bigger effect.\nThe Victoza trial, known as Leader, had been designed to show Novo\u2019s drug did not increase heart risk, so its superiority is welcome news for the company, especially as Sanofi\u2019s (SASY.PA) rival Lyxumia failed to show heart benefits in an earlier test.\nThe findings, which involved following 9,340 patients for a median 3.8 years, were also published online in the New England Journal of Medicine.\nMads Krogsgaard Thomsen, Novo\u2019s chief science officer, said the results should encourage doctors to use Victoza earlier, since they could now see it offered \u201clife-expanding\u201d treatment.\nNovo, the world\u2019s biggest diabetes company, had said in March that Victoza cut heart risks \u201csignificantly\u201d in the study but the scale of the benefit was only disclosed on Monday.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "How Victoza performs in reducing severe cardiovascular events compared to rival drugs is mentioned numerous times. It is worth noting that there was no mention that the drug is given by injection. For individuals with diabetes reading the article, this oversight is important in that it may make them more inclined to oral medicines that are easier to take.", "answer": 1}, {"article": "No doubt you have heard that yogurt is teeming with bacteria--and no doubt you try not to think about that as you dig into a cup of the stuff. Yes, they're supposed to be good bacteria, ones that not only don't make you sick but actually improve your health. Still, a spoonful of critters with unlovely names like Lactobacillus reuteri, Lactobacillus rhamnosus and Bifidus regularis will never sound like a palate pleaser to even the most dedicated health nut.\n\nWhether or not you've ever developed a taste--or even a tolerance--for living things in your lunch, more are on the way. Food...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story missed the mark by failing to compare and contrast probiotic availability from the foods they are naturally found in with foods specifically fortified with probiotics. \u00a0Is there really any difference between eating Activia or Dannon yogurt? \u00a0And if the point of the story was to educate viewers about allergies and bowel regulation, it should have mentioned generally accepted treatment options for these.", "answer": 0}, {"article": "Nov. 5, 2012 (Los Angeles) -- An IV infusion of \"good\" HDL cholesterol seems to rapidly remove cholesterol out of plaque-clogged arteries following a heart attack, a small, early study suggests.\nIn the year after a heart attack, about 12% of people have a second heart attack or stroke.\nHDL removes cholesterol from artery walls, but current HDL-boosting drugs, such as niacin and fibrates, take years to work, according to Gille.\nStandard heart attack medications, such as aspirin and anti-clotting drugs, prevent clotting but don\u2019t eliminate an underlying factor: cholesterol that has built up on artery walls, he says.\nAnd half of them happen in the first month, says researcher Andreas Gille, MD, PhD.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Barely satisfactory, as the story at least nodded in the direction of other HDL-boosting drugs.", "answer": 1}, {"article": "And after they did, olive oil was still linked to a lower stroke risk.\nPeople who said they used olive oil for both cooking and as a dressing were considered \u201cintensive users.\u201d\n\nOver the next five to six years, those intensive users suffered strokes at a rate of 0.3 percent per year.\nThe findings, according to Scarmeas, argue for more research into olive oil\u2019s potential benefits against not only heart disease, but stroke and other neurological diseases as well.\nThese latest findings support the general advice that people replace dubious dietary fats \u2014 namely, saturated fats and \u201ctrans\u201d fats \u2014 with olive oil and other unsaturated fats, according to an expert not involved in the study.\nThe one-third of participants with the highest oleic acid levels were 73 percent less likely to suffer a stroke than the one-third with the lowest levels.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story at least mentioned other factors that could be at play \u2013 \u201cno single food is consumed in isolation, he points out in his editorial. Olive oil is one part of the Mediterranean diet that has been tied to heart benefits. The diet also boasts plenty of fruits and vegetables, legumes, whole grains, fish and moderate amounts of red wine.\u201d", "answer": 1}, {"article": "DUARTE, Calif. -- A City of Hope-led study found that the use of low-dose aspirin (81mg) reduces the risk of breast cancer in women who are part of the California's Teacher's Study.\nThis study differed from other studies that have looked at aspirin and cancer risk because it focused on the dose levels of the aspirin women had taken and tracked the frequency of the use of low-dose aspirin as opposed to regular aspirin.\nIn the ensuing years before 2013, 1,457 of these participants developed invasive breast cancer.\nOther collaborating authors include Alison J. Canchola, M.S., and Lisa M. Moy, M.P.H., from the Cancer Prevention Institute of California, and Susan L. Neuhausen, Ph.D., The Morris & Horowitz Families Professor in Cancer Etiology & Outcomes Research, Nadia T. Chung, M.P.H., and James V. Lacey Jr., Ph.D., M.P.H., from City of Hope.\nThe content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are a host of things that women can do to reduce their risk of breast cancer. However, none of these things are mutually exclusive. One can be physically active and limit alcohol intake, for example. None of these other ways to reduce breast cancer risk are mentioned.", "answer": 0}, {"article": "And for this, patients should do their part.\n\u201cTherefore, it is important to study the factors associated with the diagnosis of colon cancer occurring after colonoscopy.\u201d\n\nDuring a colonoscopy, a flexible camera is passed through the colon in search of abnormal growths known as polyps and other warning signs of early tumors.\n\u201cThis is very different from a population undergoing screening.\u201d\n\nColonoscopy would probably miss a smaller percentage of cancers in such a large population, Lieberman said, because the rate would be lower.\nThe US Preventive Services Task Force, an independent panel of medical experts appointed by the federal government, recommends screening people aged 50 to 75 for the disease, but does not specify which test is best.\n\u201cThe key to maximizing protection against colorectal cancer after colonoscopy is performance by an operator with excellent examination\u201d and growth-removal technique, \u201cin a well-prepped colon,\u201d Kahi told Reuters Health by e-mail.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says, \"Another less expensive test is fecal occult blood testing, which involves taking stool specimens at home and mailing them to the doctor\u2019s office or medical lab. The US Preventive Services Task Force, an independent panel of medical experts appointed by the federal government, recommends screening people aged 50 to 75 for the disease, but does not specify which test is best.\" There could have been some mention of how effective fecal occult blood testing is and whether similar studies have been done on that type of screening.", "answer": 1}, {"article": "Of those taking an inert pill, or placebo, 91 percent did.\nPut another way, the risk of cancer returning in the original or the opposite breast was 34 percent lower in women on 10 years of letrozole compared with those who stopped after five.\nThe trial included 1,918 postmenopausal women who had what\u2019s called hormone-receptor positive breast cancer, in which the hormones estrogen or progesterone fuel the proliferation of cells.\nStill, said Dr. Richard Schilsky, who serves as the chief medical officer of ASCO and who was not involved in the study, \u201cthere\u2019s a substantial benefit\u201d to continuing aromatase inhibitors out to 10 years to lower the chance of cancer developing in the other breast.\nFor any individual woman, the odds of developing \u201ccontralateral\u201d breast cancer \u2014 that is, in the opposite breast \u2014 are still lower than 200-to-1 per year.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Continuing aromatase inhibitor was compared to not continuing it. There was a brief mention that study participants had taken another drug, tamoxifen, before starting letrozole. However, we\u2019d have liked to have seen details on what other long-term alternatives women have for preventing recurrence.", "answer": 0}, {"article": "An experimental drug designed by Roche Holding AG's Genentech unit against a new cancer target yielded encouraging results against two rare tumors, researchers said, potentially opening up a new front in the battle against the disease.\n\nIn a small study, the drug, known as GDC-0449, shrank tumors in 18 of 33 patients, or 55%, with an advanced form of a skin cancer called basal cell carcinoma. In addition, the drug had a dramatic, though temporary, effect on a 26-year-old patient who had undergone multiple surgeries, chemotherapy...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story briefly mentions chemotherapy, surgery and radiation as treatment options for cancer.\u00a0 ", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070723/23healytip.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not comment on other means for lowering LDL cholesterol; this was not, however relevant to the main topic of the story, namely \u2013 the potential for increased incidence of cancer seen in individuals who lower their cholesterol.", "answer": 2}, {"article": "Whitaker said that while it could be around five years before the results of this study are translated into a test for doctors to use in clinics, she hoped it would then also help them to determine which patients have aggressive tumors.\n\u201cThe protein is easy to detect because it is found in urine and would potentially be a very simple test to carry out on men to identify those most at risk of developing the disease,\u201d said Hayley Whitaker of the Cambridge institute, who led the study.\nLONDON (Reuters) - A protein in urine could be a strong indicator of prostate cancer risk, according to British scientists who say their findings could one day be developed into a quick and simple test for the disease.\n\u201cAt the moment, PSA testing is the best method we have to detect prostate cancer but it has significant limitations, so there is an urgent need to find new biomarkers such as MSMB that could be used in screening and diagnosis,\u201d said Rosalind Eeles of the ICR and The Royal Marsden Hospital, who also worked on the study.\nScientists from the Cancer Research UK Cambridge Research Institute and the Institute of Cancer Research (ICR) said the protein, called microseminoprotein-beta or MSMB, is found at reduced levels in men diagnosed with the disease and are also lower in men with more aggressive forms of the cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0The story indicated that the current laboratory screening test for prostate cancer (PSA) has low specificity and that because it doesn\u2019t distinguish aggressive disease from that which is less aggressive, it leads to unnecessary treatment. \u00a0The story was strongly suggestive that the test reported on had the potential to reduce both of these.\u00a0 But it didn\u2019t offer any data-driven comparison \u2013 limited though that possibility may have been given the early stage of this research.\u00a0 But it also didn\u2019t compare this test with other urine tests trying to do the same thing. ", "answer": 0}, {"article": "\"Are they normal variations?\nIn the most complete test of its kind, the institute is using both an electrocardiogram and limited echocardiogram to see the rhythm and structure of the heart.\nFor decades pediatricians and family physicians have sought a more effective way to identify young athletes at risk of dying while playing the sports they love.\nBut the Children's Hospital study is showing more than twice that rate and a higher rate for more minor abnormalities as well, perhaps because of better technology, Grenier says.\nApproval is generally granted to teens with little to no family history of heart problems and a physical exam devoid of medical red flags.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no discussion of the relative value or effectiveness of standard physical examinations and health histories for identifying potential risks of sports participation.", "answer": 0}, {"article": "The study is preliminary and doesn't prove cause and effect.\nIn a study of 232 people taking medication for psoriasis, those who also took statins had fewer of the thick, red, scaly, itchy patches that are the hallmark sign of psoriasis, compared with people who didn't take the cholesterol-lowering drugs.\nBut the findings, presented at the American Academy of Dermatology annual meeting, raise an interesting possibility worthy of further study, experts agree.\nMarch 8, 2010 (Miami Beach, Fla.) -- Once again, cholesterol-lowering statin drugs have been shown to be good for more than the heart.\n\"There was a trend toward less severe psoriasis severity in people taking statins,\" says researcher Adam Perry, a fourth-year medical student at Emory University in Atlanta.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0This story was about the possibility that statin medications have a role for improving psoriasis. \u00a0The story did mention that examining whether statins improve psoriasis in the absence of high cholesterol was one area to be explored. \u00a0There was no discussion of other medications or medication combinations that may be under study to treat psoriasis and there was no mention of the lack of controls in the retrospective study reported on.", "answer": 0}, {"article": "\u201cWhen drugs don\u2019t work, what else is there?\u201d\n\u201cIt quickly becomes clear that \u2018weird\u2019 is going to be just fine if it replaces the pain.\u201d\n\nChronic pain is a particularly difficult problem to understand and solve.\nIn September, the journal Pain published the largest-ever clinical trial of spinal cord stimulators, comparing their use with conventional pain therapies, including drugs, nerve blocks and physical therapy.\nThe implants cost about $20,000, and the procedure, hospital care and follow-up can bring the total bill to about $40,000.\nThe condition, complex regional pain syndrome, or C.R.P.S., typically develops after a medical procedure or an accident.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The news story mentions several alternatives to spinal stimulators\u2014bed rest, drugs, nerve blocks, and physical therapy. However, it neglects to point out the consensus view among pain experts that this is a treatment of last resort\u2014to be used only after everything else has failed, including surgery.", "answer": 1}, {"article": "For Patients and the General Public:", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "No alternatives are mentioned for treatment of either HER2-positive or triple negative breast cancer. This is a major oversight given that a variety of treatments, such as Herceptin, are available for HER2-positive breast cancer.", "answer": 0}, {"article": "Neck pain was assessed by the Northwick Park Questionnaire (NPQ) at 3, 6, and 12 months.\nBoth acupuncture and Alexander Technique prove effective for long-term relief of chronic neck pain\n\nIn a randomized, controlled trial, both acupuncture and the Alexander Technique led to long-term significant reductions in neck pain and associated disability compared with usual care alone.\nAcupuncture is a procedure in which patients have thin needles inserted into specific points on the body to relieve pain and the Alexander Technique is an educational process that teaches people how to avoid unnecessary muscular and mental tension in everyday activities.\nTo speak with the lead author, Dr. Hugh MacPherson, please contact David Garner at david.garner@york.ac.uk or +44 (0) 1904 322153.\nIn addition, persons with chronic neck pain often seek complimentary care to manage their condition, such as acupuncture or the Alexander Technique.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The goal\u00a0of the news release is in fact to accomplish this very criterion. The release accurately states, \u201cUsual care for neck pain generally consists of prescribed medications and visits to physical therapists and other health care professionals.\u201d", "answer": 1}, {"article": "It has been 51 years since the first birth-control pill became available in the U.S., bringing dozens of contraceptive options for women in its wake. There are currently two options on the market for men\u2014vasectomy or a condom.\n\nThe research pipeline is full of possibilities, though. Scientists at Columbia University Medical Center have halted sperm production and started it again in mice with no apparent side effects, using a drug that blocks receptors for vitamin A. An injectable synthetic substance, in Phase 3 clinical trials...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The entire column was a comparison of methods.\u00a0 Very nice wrapup.", "answer": 1}, {"article": "For more information, visit http://www.\nIn addition, the product's proprietary formulation contains unique combinations and concentrations of cleaning agents that weaken the core of the plaque structure to help the subject visualize and more effectively remove the plaque.\nThese results, published today online ahead of print in the American Journal of Medicine, with an accompanying editorial by the editor-in-chief, show that Plaque HD\u00ae, produced statistically significant reductions in dental plaque and inflammation throughout the body as measured by hs-CRP.\nThe results released today from a randomized trial of a novel plaque identifying toothpaste, (Plaque HD\u00ae), show statistically significant reductions in dental plaque and inflammation throughout the body.\nThe original research from the landmark Physician's Health Study, in which Hennekens was the founding principal investigator, was the first to demonstrate that hs-CRP predicted future heart attacks and strokes.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not mention the availability of inexpensive plaque-disclosing tablets. Consumers would want to know if such tablets might be an alternative to the very pricey Plaque HD toothpaste, an important point that the study did not explore. The release also does not discuss the potential effect of brushing frequency or duration.", "answer": 0}, {"article": "\u201cSo this is a possible fringe benefit.\u201d\n\nResearchers studied 2,447 men over 12 years, examining them every other year.\nThe study, published online by The American Journal of Epidemiology, had limited data on dosage, but scientists believe that even low doses of anti-inflammatory drugs reduce the risk of urological problems.\nMoreover, they had a 48 percent reduced risk of having an elevated level of prostate-specific antigen, or P.S.A., the protein measured in a common blood test for prostate cancer.\nOther nonsteroidal anti-inflammatory drugs, or Nsaids, like naproxen (Aleve) or ibuprofen (Advil or Motrin), have the same effect.\nTaking aspirin every day may lower the risk for prostate enlargement, a new study has found.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does not discuss any other treatment options, including watchful waiting (no active treatment), medications like 5-alpha reductase inhibitors or alpha blockers, minimally invasive therapies, and surgery. ", "answer": 0}, {"article": "\u201cThis is a very important claim for us to allow to be incorporated into food labels,\u201d said Dr. Scott Gottlieb, the commissioner of the F.D.A.\nThe product, called Hello, Peanut, can be mixed into pur\u00e9ed baby food to expose infants to peanuts starting around five months old.\nA new powdered peanut product is the first food item allowed to claim it may reduce peanut allergies in infants, though parents of susceptible babies are urged to consult a doctor before trying it.\nWhile many foods like whole grains, nuts and supplements carry qualified health claims stating that they may reduce the risk of diseases like cancer or heart disease, this is the first time a food product label will be allowed to make a qualified claim that it reduces the risk of an allergy, officials said.\n\u201cThe guidelines for how to approach allergens in children are changing, the science is changing, and it\u2019s important for parents to know.\u201d\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that peanut butter can be diluted with water to make a soupy, infant-friendly, peanut-containing food at less cost than the packaged powder product.", "answer": 1}, {"article": "The trial was funded by Pfizer.\nSome 67 per cent of the 347 women in the palbociclib plus fulvestrant group showed clinical benefit - either a reduction in tumour size or control of disease for at least six months - compared with 40 per cent of the 174 women in the placebo plus fulvestrant group.\nThe research showed that using 'liquid biopsies' that measure cancer DNA circulating in the blood to detect PIK3CA, and tests for blood hormone levels, the palbociclib combination worked in all types of hormone-receptor positive, HER2 negative breast cancer.\nThe combination - of a first-in-class targeted drug called palbociclib, and the hormone drug fulvestrant - slowed cancer growth in around two thirds of women with advanced forms of the most common type of breast cancer.\nIt provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Throughout the news release, comparison between the drug combination is made with the alternative of taking only one of the drugs, fulvestrant, plus placebo. Several clinical endpoints are reported, all showing the clear advantage of the drug combination.", "answer": 1}, {"article": "Manuka is proving to be a moneymaker for many companies that market it online as \"nature's miracle\" and \"nature's greatest secret,\" claiming it can relieve everything from stomach ulcers to bedsores and sinus infections.\nAll honey is medicinal to some extent.\nThe dressings should be available this fall.\nThe picture has not always been so bright for manuka, or its manufacturers.\nAfter four weeks, seven of those 10 wounds no longer showed the bacteria's presence.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention other types of wound dressings and antibiotics as alternatives.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070408/16healy.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no mention of other options for reducing coronary heart disease risk or of\u00a0other treatments for menopausal symptoms, since no one is proposing that HRT be used for reducing coronary disease risk.", "answer": 0}, {"article": "SpermCheck, which is approved by the U.S. Food and Drug Administration, assesses sperm count with 98% accuracy in 10 minutes and does away with the unpleasantness of conjuring up a sperm sample in a doctor\u2019s office.\nThese tests can be expensive (costing hundreds of dollars and not typically covered by insurance), inconvenient and are often embarrassing.\u201d\n\nMORE: \u2018Sonicated\u2019 Sperm: Could Ultrasound Be the Next Male Contraceptive?\n\u201cThis at-home test was created to meet the needs of couples who are considering and just planning on starting a family, those currently having trouble conceiving,\u201d says Herr, and \u201ceven those men who are just curious about their sperm count.\u201d\n\nWould-be virile men \u201cjust curious\u201d about their sperm count?\nThe test reveals whether sperm count appears normal, at 20 million or more sperm per ml; lower than that indicates a trip to the doctor is pretty much unavoidable.\nMORE: The Sperm Bike: Cycling to Drum Up Sperm Donations\n\nIt relies on scrutiny of a particular protein found only in the head of mature sperm; the protein was discovered by John Herr, director of the Center of Cell Biology at the University of Virginia and the chairman of SpermCheck.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story quotes the company\u2019s website:\u00a0 a \u201ctrip\u00a0to a fertility clinic for a semen analysis is not for everyone. These tests can be expensive (costing hundreds of dollars and not typically covered by insurance), inconvenient and are often embarrassing.\u201d As we noted earlier, this test is not a replacement for the standard test that would be performed if the man visited the physician.\u00a0 Sperm count alone does not tell the complete story.\nWhy not interview an independent fertility specialist about the alternatives?", "answer": 0}, {"article": "The study was funded by the Celladon Corp. of La Jolla, Calif.\n\"This is the first time gene therapy has been tested and shown to improve outcomes for patients with advanced heart failure,\" study lead author Dr. Donna Mancini, professor of medicine and the Sudhir Choudhrie professor of cardiology at Columbia University College of Physicians and Surgeons in New York City, said in a university news release.\n\"There are a lot of treatments for heart failure but at some point patients stop responding and then the prognosis is poor,\" said Dr. Rita Redberg, AHA spokeswoman and professor of medicine at the University of California, San Francisco.\n\"The therapy works by replenishing levels of an enzyme necessary for the heart to pump more efficiently by introducing the gene for SERCA2a, which is depressed in these patients.\nThe study authors hope that, if replicated in larger trials, the gene-therapy treatment could actually delay or obviate the need for heart transplants in patients with heart failure.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Other than saying that one goal of this line of research is to provide an alternative to heart transplants, the story does not describe the alternative treatments available to people with heart failure. For example, even when drug therapy loses its effectiveness, some heart failure patients are receiving heart assist pumps for long-term use\u2026 so there are approved alternatives to a heart transplant for some patients like those in this trial. The story should have included that fact. ", "answer": 0}, {"article": "New research now shows that resistance training may protect the nervous system and thus slow the progression of the disease.\nThis is the main finding of a study conducted by a research partnership between Aarhus University, Aarhus University Hospital, the University of Southern Denmark and the University Medical Center Hamburg-Eppendorf, that has just been published in Multiple Sclerosis Journal.\n\"Over the past six years, we have been pursuing the idea that physical training has effects on more than just the symptoms, and this study provides the first indications that physical exercise may protect the nervous system against the disease,\" says one of the researchers behind the study, Associate Professor Ulrik Dalgas from the Department of Public Health at Aarhus University.\n\"For the past 15 years, we have known that physical exercise does not harm people with multiple sclerosis, but instead often has a positive impact on, for example, their ability to walk, their levels of fatigue, their muscle strength and their aerobic capacity, which has otherwise often deteriorated.\nNew research shows that resistance training protects the brain in persons with multiple sclerosis, which may delay the development of the disease\n\nIn the past, multiple sclerosis patients were advised not to exercise for fear of exacerbating the illness.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release mentions drugs as a treatment option for patients with MS. These include immunosuppressants, like corticosteroids to reduce nerve inflammation and beta interferons to reduce the frequency and severity of relapses. Plasma exchanges can also help patients who haven\u2019t responded to steroids and whose symptoms are new and severe.\nOther treatments options include physical therapy and muscle relaxants to help relieve MS signs and symptoms.\nAlthough we would have liked more detail on established therapies, we feel the mention of medication was good enough for a Satisfactory rating here.", "answer": 1}, {"article": "\"We do need something,\" he said.\n\"This is probably not going to be used for wide-scale screening but it could be used for children who we have some sense that they have autism and want to gather more information,\" said David Amaral, president of the International Society for Autism Research and research director of the University of California Davis MIND Institute.\n\"We're focusing on this earliest time period, when the brain is still developing and still changing,\" explained study author Lisa Eyler, an assistant professor of psychiatry at the University of California, San Diego.\nIn the youngest children, the activation was about equal in both the right and left hemisphere, while in the older children, activity became more pronounced on the left side, which is similar to adult patterns and to be expected, Eyler explained.\nThey have a long way to go before they're actually able to implement a test like this,\" said Keith Young, vice chairman of research in psychiatry and behavioral science at the Texas A&M Health Science Center College of Medicine in Temple.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The reader would have benefited from a brief discussion on the current gold standard approach to the disgnosis of autism.\u00a0 While structural and functional diagnostic studies are used in research, they are not commonly applied in routine clinical care.\u00a0 The failure to compare existing methods to the study method does not allow the reader to appreciate how far from the norm the testing procedure is.\u00a0 There could have been more discussion of other diagnostic techniques that are in experimental trials or past techniques that have been tried and discarded.", "answer": 0}, {"article": "\"That's huge,\" said lead author Fran Weaver, a researcher with the Hines VA Hospital in Hines, Ill.\n\nShe said the best drugs provide only one to two hours of added improvement, or \"on time.\"\nUp to 15% of Parkinson's patients are good candidates for the therapy, but only 2% get it, he said.\nAt times, she said, she felt incredibly fidgety.\nHer medication use has dropped dramatically and \"my body has calmed down,\" she said.\n\"(But) we used aspirin long before we knew how it worked.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes it clear that the alternative to surgery is a cocktail of medications, which have their limitations.", "answer": 1}, {"article": "\"What we look for are shelves of books that have gone missing, which represent a missing fragment of a chromosome, or extra fragments of chromosome, that could contain genes related to autism.\"\nThe study appeared online March 15 and will be published in the April print issue of Pediatrics.\nStill, there is much geneticists can't tell parents.\nIf a parent is also found to have the abnormality, geneticists conclude that the couple is at higher risk of having a child with autism.\nThe U.S. National Institute of Neurological Disorders and Stroke has more on autism.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story provided data comparing the two standard genetic tests to the newer CMA test. ", "answer": 1}, {"article": "THURSDAY, Feb. 3, 2011 (HealthDay News) -- A special restrictive diet may significantly reduce symptoms of attention-deficit hyperactivity disorder (ADHD) in young children, a new study suggests.\n\"If parents have noticed that a child's behavior seems to get worse with certain foods, it may be worth considering,\" said Ghuman, who is an associate professor of psychiatry and pediatrics at the University of Arizona in Tucson.\nSince some children have negative physical reactions to certain foods -- such as eczema, asthma and gastrointestinal problems -- that affect different organ systems, it has been suggested that foods may also affect the brain in a way that results in adverse behavior, according to information in the study.\n\"We think that dietary intervention should be considered in all children with ADHD, provided parents are willing to follow a diagnostic restricted elimination diet for a five-week period, and provided expert supervision is available,\" they concluded.\nParents have long suspected that sugary foods might be a culprit in inducing symptoms, but there's not a lot of evidence to support this theory, according to the NIMH.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Neither story we reviewed (neither this one nor WebMD) did a good job in this area. Some discussion of the success rate of the two standards\u00a0of care \u00a0\u2014 behavioral therapy and medication \u2014 would have strengthened the story.", "answer": 0}, {"article": "The end point also shifts the paradigm from palliation to cure,\" remarked Dr. Scher.\nThe results suggest that some men who have previously been considered incurable can possibly be cured; investigators also establish a new paradigm for testing various drug combinations in conjunction with local treatment of the prostate to determine which is the best approach (ie, has the highest undetectable disease rate).\nHowever, none achieved the primary end point of undetectable PSA with testosterone recovery at 20 months after initiation of therapy with ADT alone, although one patient had a PSA of Of the 15 patients with bone metastases, 14 (93%) reached an undetectable PSA when ADT, surgery, and radiation were used.\nWhile the study is only a first step, one-fifth of the patients treated had no detectable disease, with an undetectable prostate-specific-androgen (PSA) and normal blood testosterone, after 20 months.\nAccording to lead investigator Howard I. Scher, MD, Chief of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center in New York City, \"The sequential use of the three different modalities helped illustrate the role and importance of each in achieving the undetectable PSA with normal testosterone level end point, which represents a 'no-evidence of disease' status.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes that the results of the three-pronged treatment approach were better than would have been achieved with any of the treatment options on their own. However, it doesn\u2019t provide evidence for this statement. Because the treatment was offered to a small, highly-selected group of patients and the study did not have a control group, the validity of this claim is uncertain.", "answer": 0}, {"article": "With knee-replacement surgery on the rise, more patients with two bad knees are opting for a controversial procedure that replaces both at the same time.\n\nSimultaneous bilateral knee replacement, as the surgery is known, is a subject of debate among orthopedic surgeons, with conflicting evidence about the risks and benefits. Proponents say it eliminates the need for a second hospital stay and grueling rehabilitation period, reduces time spent under anesthesia and costs less.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is, in effect, all about comparing alternatives \u2014 bilateral versus staged knee replacement. One thing that\u2019s not made clear anywhere in the story is whether the knee replacements in question for any or all of the studies were total knee replacements, partial knee replacements, or both. Are there differences in cost? Benefits? Risks? That would have been useful to include.", "answer": 1}, {"article": "The sprawling research team, led by Dr. John M. Kane, chairman of the psychiatry department at Hofstra North Shore-LIJ School of Medicine, randomly assigned 34 community care clinics in 21 states to provide either treatment as usual, or the combined package.\nThe team recruited 404 people with first-episode psychosis, mostly diagnosed in their late teens or 20s.\nThe team trained staff members at the selected clinics to deliver that package, and it included three elements in addition to the medication.\nThe group that started on the combined treatment scored, on average, more poorly on both measures at the beginning of the trial.\nAbout half got the combined approach and half received treatment as usual.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There were good explanations of the two alternatives being compared by the research itself \u2014 the drug-focused standard and the more comprehensive integrated care.", "answer": 1}, {"article": "Accessed October 2013 from http://www.hcup-us.ahrq.gov/reports/statbriefs/sb23.jsp [5] Flum, D. R., et al.\n\u201cThis combination of lifestyle modification and balloon therapy provides a new low risk option for patients struggling with obesity.\u201d\n\nThe Obalon 6-Month Balloon System, a swallowable, gas-filled intragastric balloon for weight loss in adults with obesity for whom diet and exercise has failed, was approved in September by the U.S. Food and Drug Administration (FDA).\n\u201cThe balloon and other technologies may help to fill the therapeutic gaps between diet and exercise and medical therapy, and medical therapy and surgery, where the gaps are quite large.\u201d\n\nPeople with obesity and severe obesity have higher rates of heart disease, diabetes, some cancers, arthritis, sleep apnea, high blood pressure and dozens of other diseases and conditions.\n\u201cThere is no magic pill for obesity, but this swallowable balloon and other intragastric balloons may offer new hope to people who otherwise would not seek treatment or not have as good a result with diet and exercise alone,\u201d said Raul J. Rosenthal, MD, ASMBS President and Chairman, Department of General Surgery, Cleveland Clinic Florida, who was not involved in the study.\n\u201cThe significant weight loss achieved with the Obalon 6-Month Balloon System is maintained at 12 months,\u201d said Aurora Pryor, MD, study co-author and Chief Bariatric, Foregut and Advanced GI Surgery, Stony Brook University.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release tells readers that the trial results indicate the balloon and counseling were more effective than lifestyle counseling alone. It also says that bariatric surgery is the most effective obesity treatment and it does refer to \u201cother intragastric balloons.\u201d However, these vague references to alternatives do not provide readers meaningful information, especially since the release never specifically notes that the trial did not compare this balloon to other similar devices.\nIt\u2019s worth noting that behavioral weight management programs generally result in 5-10 percent weight losses at 6 months to 1 year. When comparing Look AHEAD\u2019s (a lifestyle intervention program) one year data, average weight loss was greater than achieved with Obalon at 8.6 percent.", "answer": 0}, {"article": "[It] can hurt,\" D'Amico said.\nIn October 2010, the U.S. Food and Drug Administration asked manufacturers to add a warning that certain drugs used in hormone therapy (including the one used in the study) were linked to a small but increased risk of diabetes, heart attack, stroke and sudden death in men.\n\"This study, in conjunction with what we know about hormonal therapy, really nails home the conclusion that hormonal therapy should not be used in men with low-risk disease because the risks outweigh any conceivable benefit,\" commented Dr. Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston and author of an accompanying journal editorial.\n\"We can give 15 to 20 percent higher doses of radiation now than we could then, and we can do it more safely and more accurately,\" he said.\nThese findings are good news for some men, since the effects of short term of hormone therapy are reversible, D'Amico said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was some discussion about how current radiation therapy differs from that received by the men in the study reported on. \u00a0However there was no mention of some of the other forms of radiation therapy that are often used for men with low-risk prostate cancer such as brachytherapy.\nThere was no discussion of alternative approaches to prostate cancer such as surgery or delay of invasive treatment called active surveillance.", "answer": 0}, {"article": "The best moment in Rene\u00e9 Ford's life came the day her son Chase, then 2, tried to kick his doctor. It was July 2005, and that angry gesture marked the first time the boy had moved below the neck in more than a month.\n\nThese days when you look at Chase, you don't at first notice any sign of what happened to him that year--not the fall he took while jumping on the couch nor the paralyzing blow to the neck as he hit the wooden armrest. More and more, Chase can do the kinds of things any other 4-year-old can...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention any treatment alternatives. Although there is a brief mention of \"traditional therapy,\" the story does not place locomotor therapy in the context of current care options.", "answer": 0}, {"article": "But another finding from that study sheds an interesting light on one of 5-Hour Energy\u2019s central claims \u2014 that the energy shot, unlike competitors\u2019, produces \u201cNo Crash Later.\u201d\n\nAccording to the study, 24 percent of test participants who received 5-Hour Energy had reactions similar to a \u201cmoderately severe crash that left them extremely tired and in need of rest, another drink or some other action,\u201d lawsuit filings show.\nWhatever the case, the energy drink boom has come full circle in Asia, the region where it started.\nAsked whether consumers mistakenly believe that the shot does not produce a caffeine-related crash, Ms. Lutz said that the use of the special mark and its explanation were clear.\nShe added that another study showing the benefits of 5-Hour Energy was undergoing \u201cpeer review\u201d for possible publication in a scientific journal.\nThe study found that test subjects given 5-Hour Energy experienced \u201cenergy\u201d for about 40 minutes longer than when given Red Bull or Monster Energy, though it was not clear from court papers whether that difference reflected the energy shot\u2019s higher levels of caffeine.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Aside from caffeine, we\u2019re not sure that there are any other legal means of increasing alertness. We\u2019ll rate this as not applicable.", "answer": 2}, {"article": "Though the findings are correlational, walnuts are uniquely high in omega-3 and omega-6 fatty acids, which may be of particular value in Type 2 diabetes prevention.\n\u201cThis is the first on walnuts and diabetes.\n\u201cThere\u2019s been a lot of research on nuts in general in relation to cardiovascular health,\u201d said the senior author, Dr. Frank B. Hu, a professor of medicine at Harvard.\nThe scientists, writing in the April issue of The Journal of Nutrition, used dietary and health data on 138,000 women participating in a large continuing study of women\u2019s health.\nPrevious studies have suggested an inverse relationship between tree nut consumption and diabetes.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Again, you can turn to the comments left after the story online to see what readers would have liked to have seen.\u00a0 Excerpts of the comments:", "answer": 0}, {"article": "Three trials had used zinc acetate lozenges and found that colds were shortened on average by 40%.\nIf that outlier trial was excluded, the difference between the three zinc acetate and the three zinc gluconate trials shrinked to just 2%, i.e., a 40% vs. 38% reduction in common cold duration.\nNevertheless, he also considers that \"the current evidence of efficacy for zinc lozenges is so strong that common cold patients should be encouraged to try them for treating their colds, but the patients should ascertain that the lozenges do not contain citric acid or its salt citrate.\"\nAlthough the binding difference between zinc acetate and zinc gluconate is a fact, it is not evident whether that causes significant differences at the clinical level for treating the common cold.\nAccording to Dr. Hemil\u00e4, there is no justification for the popular phrase that \"there is no cure for the common cold\" because of the strong evidence that zinc lozenges can shorten common cold duration by over 30%.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release doesn\u2019t mention alternative sources of zinc and alternative treatments for cold symptoms. Zinc is available in a number of common foods \u2014 beef, lamb, cashews, and chocolate among others.", "answer": 0}, {"article": "In addition to retaining its first place ranking for the best hospital in the Twin Cities and second in the State of Minnesota in the U.S. News & World Report's 2016-17 best hospital rankings, Abbott Northwestern has received nursing magnet certification, a recognition earned by only five percent of hospitals nationwide.\nHow to treat patients who have microinvasive breast cancer - tumors that are 1 mm or less in size (the thickness of a dime) -- is somewhat controversial.\nOnly 1.5 percent had positive lymph nodes - indicating the rare possibility of metastatic cancer.\nThe Virginia Piper Cancer Institute\u00ae, part of Allina Health, provides comprehensive care through all aspects of cancer prevention, early detection and treatment to help individuals maintain quality of life and find ways to live with and beyond cancer.\n\"These findings allow surgeons to select which patients with microinvasive tumors may actually benefit from lymph node sampling, while sparing other patients from this procedure,\" said Tamera Lillemoe, M.D, pathologist and a study co-author.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are no radiologic or other non-surgical diagnostic alternatives for evaluating the spread of microinvasive breast cancer to the axillary lymph nodes, so we rate this Not Applicable.", "answer": 2}, {"article": "The results were published in January in Nature Medicine.\nCurrently, people who do not have HIV but are at substantial risk of getting it--because they have multiple sexual partners, for example, or an HIV-infected partner--can receive antiviral medications to prevent disease, a strategy called pre-exposure prophylaxis (PrEP).\nBut just like the antiviral medications used to treat infection, PrEP can have severe side effects and must be taken daily to be effective, which poses significant challenges to adequate compliance.\n\"Based on our findings we think these types of antibodies could be a viable substitute for the drugs currently used in PrEP,\" says Caskey.\nIn an effort to accomplish this, the investigators are looking into modified variants of the antibodies with prolonged activity, so that they would need to be given less often in the PrEP setting.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions that broadly neutralizing antibodies may eventually be an alternative to currently available antiviral therapy as well as pre-exposure prophylaxis, PrEP, (a lower dose of antiviral therapy taken as prevention). The current study doesn\u2019t look at clinical outcomes so the comparison may be premature, although it\u2019s presented in a pretty general way.", "answer": 1}, {"article": "The research, supported by the European Research Council and titled Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells, is published by PNAS.\nThis can lead to a wide-range of side-effects from renal failure to neurotoxicity, ototoxicity, nausea and vomiting.\u201d\n\n\u201cExisting platinum-based cancer treatments often become less effective after the first course, as cancer cells learn how they are being attacked, but our new osmium compound with its different mechanism of action, remains active against cancer cells that have become resistant to drugs such as Cisplatin\u201d.\nThe research could also lead to substantial improvements in cancer survival rates, suggests co-researcher Dr Isolda Romero-Canelon:\n\n\u201cCurrent statistics indicate that one in every two people will develop some kind of cancer during their life time, with approximately one woman dying of ovarian cancer every two hours in the UK according to Cancer Research UK and two deaths every hour from bowel cancer.\nCommenting on the drug\u2019s benefits when compared to existing platinum-based drugs, such as Cisplatin, Professor Sadler says:\n\n\u201cPlatinum-based drugs are used in nearly 50% of all chemotherapeutic regimens and exert their activity by damaging DNA and cannot select between cancerous and non-cancerous cells.\nThe researchers argue that the drug could be cheaper to produce, less harmful to healthy cells than existing treatments and has been shown to be active against cancer cells which have become resistant to platinum-based drugs.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "One researcher does talk about a comparison with existing treatments and why new therapies are needed.\n\u201cExisting platinum-based cancer treatments often become less effective after the first course, as cancer cells learn how they are being attacked, but our new osmium compound with its different mechanism of action, remains active against cancer cells that have become resistant to drugs such as Cisplatin\u201d.", "answer": 1}, {"article": "Bottom Line: For adults coming to the emergency department for arm or leg pain due to sprain, strain, or fracture, there was no difference in pain reduction after 2 hours with ibuprofen-acetaminophen vs three comparison opioid-acetaminophen (paracetamol) combinations.\nFor more details and to read the full study, please visit the For The Media website.\nThe combination of ibuprofen and acetaminophen may represent an effective non-opioid alternative.\nWhy The Research Is Interesting: The United States is facing an opioid epidemic with almost 500,000 individuals dying from opioid overdoses since 2000.\nAbout 1 in 5 patients required additional medication to control their pain.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The entire release (and the study it is discussing) are based on the comparison of alternatives for addressing acute pain in an emergency room environment.", "answer": 1}, {"article": "Amid a dry spell for breakthrough cancer drugs, recent U.S. approval of Eisai Co.'s Halaven represents some vindication for a small group of researchers who believe, contrary to recent pharmaceutical fashion, that molecules from nature hold promise against hard-to-treat diseases.\n\nThe Food and Drug Administration's approval of Halaven in November for treating late-stage breast cancer was a triumph of chemistry and tenacious research. Its path, extending nearly three decades from the first studies, demonstrates not only potential...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 1}, {"article": "TUESDAY, Feb. 28, 2012 (HealthDay News) -- Menstrual cramps are the bane of many women, but new research suggests that a form of vitamin D may one day be added to the meager list of pain relievers for the sometimes disabling condition.\nAfter two months, average pain scores dropped 41 percent for women assigned vitamin D treatment, while no difference in pain was reported in the placebo group.\nThe vitamin is also known to have anti-inflammatory effects, Rabin added.\nThe Italian study participants all had blood levels of vitamin D measuring in the lowest 25 percent of normal at the study's outset, although the researchers didn't report the womens' blood levels afterward.\nAnd since the study period lasted only two months, there was no way to tell whether such a high dose produced any toxic long-term effects.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article did talk about NSAIDs and birth control pills as other alternatives to help alleviate menstrual cramps.", "answer": 1}, {"article": "But if the beta-amyloid plaques that are the disorder's key physical hallmark could be detected before memory loss and cognitive troubles were evident to all, would you want to know?\nIt's an early test for those who already have cognitive concerns and who wonder whether Alzheimer's disease may be the cause.\nWith growing understanding that the changes of Alzheimer's disease may be decades in the making, the value of early detection is gaining adherents, said Weiner.\nThe \"real game-changer,\" he says, will be when one of the many experimental therapies under study for Alzheimer's disease succeeds in blocking or reversing its progress.\nUntil recently, the diagnosis of Alzheimer's disease could be made only after a patient's death, when a pathologist could find physical evidence of amyloid plaques and neurofibrillary tangles.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions the existence of at least one similar agent that is being tested as a diagnostic aid. Other approaches, such as testing for biomarkers of Alzheimer\u2019s disease in spinal fluid, are also in the works.", "answer": 1}, {"article": "ASTHMA According to conventional wisdom, asthma and other allergic diseases like hay fever are made worse by dirty environments. Recent evidence has suggested, however, that children exposed to dirt and germs early in life may have a lower risk of developing asthma and other allergies. Studies have found that the children of farmers -- who presumably are exposed to a ... (Full article: 838 words)", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although two of the lifestyle recommendations for management of pre-hypertension (i.e. low-salt diet and regular exercise) were mentioned, the article relied on the New England Journal of Medicine article for estimates for the efficacy of lifestyle interventions to reduce hypertension instead of studies of these (and other lifestyle) interventions. Individuals receiving either the drug or placebo in this trial also received printed materals about lifestyle modifications and review and reinforcement of diet and exercise at all visits. This means that the study was really about the potential benefit of the drug in addition to usual lifestyle recommendations. That should have been made clear. ", "answer": 0}, {"article": "Male infertility has a range of root causes, from low or abnormal sperm production to blockages to illness.\nThough the system is in the prototyping stage, it could eventually shake up the world of fertility testing by allowing men to evaluate their sperm in their own homes and helping health centers with fewer resources offer easy, cheap testing.\nSeveral other home-based tests are already on the market, but Boston researchers say their version can analyze additional aspects of the sample, checking how well the sperm move (known as motility) as well as their concentration.\nThe app is similar to a fitness tracker, in a sense, in that it stores any history of previous semen samples as well.\nThough it\u2019s as common as female infertility, it often goes unrecognized due to factors like cultural stigma, the high cost and time required for testing, and access to laboratory facilities.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Readers are not given any details on the obvious alternative\u2013going to a clinic for testing, or using one of the other already-available at-home devices. These and other details aren\u2019t addressed, and they\u2019re important in establishing the significance of the new prototype device.", "answer": 0}, {"article": "And this creates economic issues.\nFor this reason, new techniques are adapted slowly with extreme care, and in some cases, not at all.\u201d\n\nUnger adds that surgeons are naturally cautious and typically wait to see results from many studies before they switch methods.\nHe says that while he\u2019s heard about the benefits of the anterior approach, he\u2019s \u201cnot aware of a randomized, controlled trial comparing the posterior and anterior approach that shows a definite superiority of one over the other.\u201d What\u2019s key is that \u201csurgeons need to do the approach they\u2019re most comfortable with to get the best outcomes.\u201d\n\nA study by Unger in the Journal of Bone and Joint Surgery in 2011 found that with the anterior procedure, there was less muscle damage and inflammation both in the immediate postoperative period and two days later than with the posterior approach.\nWith the anterior approach, Bollinger says, \u201cwe can take\n\nX-rays during the operation, to see if the new hip is placed correctly and adjust it, when necessary.\u201d Many surgeons use a special operating table that makes this possible.\nIf they\u2019ve had the posterior procedure, even if they don\u2019t consciously feel weak, they tend to shift their weight onto one foot and teeter like [Charlie] Chaplin.\u201d\n\nGiven benefits such as these, why haven\u2019t more surgeons switched methods?\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does compare the two alternatives on several different fronts. But it always felt like an uneven playing field.\u00a0 The evidence wasn\u2019t quantified. And so the story may oversimplify the debate between anterior and posterior approaches. Less invasive posterior techniques have been developed and are employed by many surgeons. It would have been helpful for the story to have surgeons comment on the relative benefits perceived between the anterior approach and less invasive posterior techniques. It may not be just an anterior vs. posterior issue.", "answer": 0}, {"article": "Aug. 10, 2011 -- Two of three patients dying of chronic lymphocytic leukemia (CLL) appear cured and a third is in partial remission after infusions of genetically engineered T cells.\n\"Here's this guy, the handwriting is on the wall, any hematologist will tell you he is a goner -- this guy was essentially cured,\" Galipeau tells WebMD.\nMoreover, the signal does not call down the deadly all-out immune attack -- the feared \"cytokine storm\" -- that can do more harm than good.\n\"I think it is a big deal,\" says Jacque Galipeau, MD, professor of hematology and medical oncology at Emory University Winship Cancer Center.\n\"Within three weeks, the tumors had been blown away, in a way that was much more violent than we ever expected,\"June says in a news release.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story talked about bone marrow transplants, while the Reuters story made no mention of them. This was an important comparison for readers. \u201cCure is possible, but it requires a risky bone marrow transplant. About 20% of patients don\u2019t survive this treatment \u2014 and even when they do, there\u2019s only a 50-50 chance of a cure.\u201d", "answer": 1}, {"article": "Cook's primary-care doctor, Sujay Pathak, an internist in Baltimore, first saw her in February.\nThe extra oxygen appears to trigger the healing of brain cells, and switches on genes specifically related to brain repair.\nDuring each treatment, they sit or lie inside a hyperbaric chamber, which varies in size from a person-size tube to a large room that can hold several patients.\nThe man had also suffered a traumatic brain injury several years earlier, which left him unable to speak more than a few words.\nPatients typically receive between 40 and 60 hour-long hyperbaric treatments spread over two to three months.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "It\u2019s mentioned that post-concussion syndrome has proven difficult to treat, with existing therapies having varied success at targeting symptoms, but not addressing the cause.", "answer": 1}, {"article": "Ideally, the order goes the other way around: We test the idea, and then we implement.\u201d\n\nThese states have the fattest pets \u2014 and they might surprise you\n\nLong before they conquered the Internet, cats took over the world\n\nA kitten nursery saves tiny lives in a city aiming to become \u2018no kill\u2019\n\nBear breaks into house, plays the piano but not very well\nIn 2012, the Department of Veterans Affairs said it would not cover costs of service dogs for veterans with post-traumatic stress disorder, citing \u201ca lack of evidence to support a finding of mental health service dog efficacy.\u201d The department is now in the midst of a multiyear study on the topic, which could lead to government funding for these pooches.\nStill, they cautioned that \u201cthis study does not answer whether pet dogs have direct effects on children\u2019s mental health or whether other factors associated with acquisition of a pet dog benefit their mental health.\u201d\n\nIt was a classic case of conflating correlation and causation, which Herzog says is common.\nAnd that\u2019s just as important.\u201d\n\nFocusing too much on scientific support sometimes feels like a form of \u201cphysics envy,\u201d Beck added, \u201cwhere you try to quantify everything without appreciating it.\u201d\n\nBut there are good reasons for rigorous research on animals and mental health.\nThe study was designed to avoid some of the pitfalls that Crossman has seen elsewhere, which is why some of the 78 young participants got to play only with a fuzzy blanket \u2014 because tactile stimulation is known to reduce stress \u2014 and why others simply waited for the 15 minutes.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "It\u2019s not clear what the direct alternatives would be here, so we\u2019ll rate this as not applicable. However, the story could have talked first-line treatments such as medications and traditional talk therapy. Therapy animals are meant to extend those mainstream treatments, not replace them.", "answer": 2}, {"article": "The procedure is not yet recommended by professional medical societies, said Dr. Sara Brubaker, a specialist in maternal and fetal medicine at N.Y.U.\n\u201cJust understanding that it\u2019s possible is exciting.\u201d\n\nBut it will take further studies following C-section babies for many years to know to what degree, if any, the method protects them from immune and metabolic problems, he said.\nBut the first to reach an infant born by cesarean section come mostly from the environment \u2014 particularly bacteria from inaccessible or less-scrubbed areas like lamps and walls, and skin cells from everyone else in the delivery room.\nA mother\u2019s vaginal fluids \u2014 loaded with one such essential bacterium, lactobacillus, that helps digest human milk \u2014 are collected before surgery and swabbed all over the infant a minute or two after birth.\nThe results show the complexity of labor, said Dr. Alexander Khoruts, a microbial expert and associate professor of medicine at the University of Minnesota.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We\u2019ll rate this as Not Applicable. There is an outstanding hypothesis that colonization of the newborn with \u2018friendly\u201d bacteria from the mother\u2019s vaginal secretions confers some advantages. This study merely test the ability to colonize a newborn delivered by cesarean delivery artificially. There aren\u2019t really any alternatives to discuss here.", "answer": 2}, {"article": "The Cochrane reviewers selected 15 studies that enrolled a combined 1,360 participants.\n\u201cBut there still needs to be consensus about the dose.\u201d\n\nZinc experts say that many over-the-counter zinc products may not be as effective as those studied by researchers because commercial lozenges and syrups often are made with different formulations of zinc and various flavors and binders that can alter the effectiveness of the treatment.\nWhile it\u2019s not certain how the mineral curbs colds, it appears to have antiviral properties that prevent the cold virus from replicating or attaching to nasal membranes.\nAlthough a majority of trials have shown some benefit from zinc, many of them have been criticized for failing to \u201cmask\u201d the treatment, meaning the participants most likely knew they were using zinc, which may have skewed the results.\nThe review found that not only did zinc reduce the duration and severity of common cold symptoms, but regular zinc use also worked to prevent colds, leading to fewer school absences and less antibiotic use in children.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While the review only includes trials comparing zinc to a placebo, the story could have briefly discussed the efficacy of other types of over-the-counter cold remedies. Furthermore, we would have liked to have seen some comment on the best ways to protect yourself and your family from getting a cold besides zinc products. A few words about hand hygiene and keeping your hands away from your eyes, mouth, and nose would have been helpful to readers.\u00a0\n\u00a0", "answer": 0}, {"article": "The fact that even with this bias we see no large benefit \u2014 indeed, seemingly no benefit at all \u2014 to running more rather than running less reinforces the value of moderate running.\nThe way researchers do this is with a measurement known as MET \u2014 metabolic equivalent of task \u2014 which gives a numeric value to various activities depending on their energy intensity.\nA hazard rate of 0.48 \u2014 compared with a sedentary group \u2014 suggests a much larger reduction in the risk of death than a hazard rate of 0.90.\nTo be more concrete: In most of these studies, the more intense runners are healthier (for example: less likely to smoke and thinner) than the less-intense runners.\nAt least in this article, I won\u2019t say anything about other kinds of exercise \u2014 no yoga or SoulCycle \u2014 though these have their own MET measures.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes clear early on that it is not looking at other forms of exercise, but explains the concept of \u201cmetabolic equivalent of task\u201d measurements (or METS) which can be used to determine the \u201cenergy intensity\u201d of various activities. It does mention a few other activities, such as yoga and cycle spinning, that may also be associated with mortality benefits. Presumably, one could use the METs associated with other exercises \u2014 such as bicycling, swimming or rowing \u2014 to find which exercises/paces are comparable to jogging 5-7 mph. However, that would take some homework, because while the story explains what METs are, it doesn\u2019t tell readers how many METs are associated with the \u201coptimal\u201d moderate jogging pace.", "answer": 1}, {"article": "\"With my technique, there is a much more limited scar and it limits the scarring in the fold of the breast, which is usually the most uncomfortable. By the third day, most women are up and around and doing most of their activities.\"", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story quotes a specialist saying that women with macromastia who do not have surgery can wear special reinforced bras, sports bras or even two bras, and can treat pain with analgesics and rashes with ointments. ", "answer": 1}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\nThe NIAID group continues to adapt the RT-QuIC assay to detect additional types of neurological diseases with greater accuracy using the least invasive patient sample possible \u2014 whether that is blood, skin, nasal brushings, or other samples.\nThe group, led by NIH\u2019s National Institute of Allergy and Infectious Diseases (NIAID), tested 60 cerebral spinal fluid samples, including 12 from people with Parkinson\u2019s disease, 17 from people with dementia with Lewy bodies, and 31 controls, including 16 of whom had Alzheimer\u2019s disease.\nThe group conducted the tests using Real-Time Quaking-Induced Conversion (RT-QuIC), an assay developed and refined over the past decade at NIAID\u2019s Rocky Mountain Laboratories.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release says \u201ctest results were available within two days, compared to related assays that require up to 13 days.\u201d\nHowever, it doesn\u2019t say how the faster test compares in terms of accuracy. The study says early detection is helpful in part because \u201cthe accuracy of diagnoses based on other clinical indices is poorest in the earlier phases of disease.\u201d", "answer": 1}, {"article": "But she said it\u2019s more convenient and less time-consuming to administer.\nThe subjects, ranging in age from 55 to 95, were classified in three groups based on cognitive abilities: normal, mild cognitive impairment and impaired.\nThe 10-minute, non\u00adinvasive examination can detect subtle lapses in the brain\u2019s perceptual ability that may signal the early stages of mental decline caused by dementia.\nThe task becomes more difficult, especially for people with early stages of dementia, as the dots move around, changing their direction, speed and intensity.\nThe test, which has been around since 1975, offers only a broad indication of cognitive abilities and fails to pick up borderline problems, she said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job in providing the reader with other testing methods and a bit about their complexity and time requirements.\u00a0 We are told that the new approach is as good if not better that existing instruments.\u00a0 So, we are giving the story a Satisfactory rating.\u00a0 But again, we are never given any data supporting that viewpoint.", "answer": 1}, {"article": "Total energy intake was within the normal range.\n\u2022 The Study is named (FATFUNC) and was performed by researchers at the KG Jebsen center for diabetes research, Department of Clinical Science at the University of Bergen.\n\"These results indicate that most healthy people probably tolerate a high intake of saturated fat well, as long as the fat quality is good and total energy intake is not too high.\nA new Norwegian diet intervention study (FATFUNC), performed by researchers at the KG Jebsen center for diabetes research at the University of Bergen, raises questions regarding the validity of a diet hypothesis that has dominated for more than half a century: that dietary fat and particularly saturated fat is unhealthy for most people.\n\"We here looked at effects of total and saturated fat in the context of a healthy diet rich in fresh, lowly processed and nutritious foods, including high amounts of vegetables and rice instead of flour-based products,\" says PhD candidate Vivian Veum.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release is about comparing two diets \u2014 one high in \u201clowly\u201d processed fats (butter, cream and cold-pressed oils) and another high in carbohydrates.\nThe release does not give us details of the diets (what to consume and how much) so it\u2019s almost impossible to compare them.", "answer": 0}, {"article": "The most surprising new finding relates to breast cancer.\nDr. Chlebowski previously led research that showed cancer risks associated with combination hormone therapy, but he says the new data on estrogen alone show that in certain women, estrogen use to relieve menopausal symptoms is a \u201cgood choice.\u201d\n\n\u201cWhen you look at the debate, people are saying hormones are good or not good \u2014 it\u2019s been all or nothing.\nI hope it gets across to women, because we are not reversing ourselves.\u201d\n\nIndeed, the investigators emphasized that the results do not change recommendations concerning combination hormone therapy for the two-thirds of menopausal women who still have a uterus.\nAn accompanying editorial in the journal was skeptical about the results, arguing that the design of the initiative, which is skewed toward older women and stopped all forms of hormone treatment after several years of use, does not match the way doctors typically prescribe treatment to women in their 50s at the onset of menopause.\nA major caveat in interpreting the new estrogen data is that the study used conjugated equine estrogens, which are estrogen compounds derived from the urine of pregnant mares and marketed by Wyeth Pharmaceuticals under the brand Premarin.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story delivered important information on how not all hormone replacement therapy is the same.\u00a0 For example:\n\u201cA major caveat in interpreting the new estrogen data is that the study used conjugated equine estrogens, which are estrogen compounds derived from the urine of pregnant mares and marketed by Wyeth Pharmaceuticals under the brand Premarin. The brand has fallen out of favor with many women who are choosing treatments that contain estradiol, which is chemically similar to a woman\u2019s natural estrogen. It is not known whether the benefits of estrogen shown in the Women\u2019s Health Initiative would be replicated using a different type of estrogen.\u201d\nand\n\u201d\nDr. Chlebowski previously led research that showed cancer risks associated with combination hormone therapy, but he says the new data on estrogen alone show that in certain women, estrogen use to relieve menopausal symptoms is a \u201cgood choice.\u201d\n \n\u201cWhen you look at the debate, people are saying hormones are good or not good \u2014 it\u2019s been all or nothing. This calls attention to the fact that there are differences,\u201d said Dr. Chlebowski. \u201cI hope that separation will become clearer now.\u201d\n\u00a0", "answer": 1}, {"article": "Aug. 4, 2010 -- The plant extract resveratrol, found in the skin of red grapes, appears to suppress inflammation and may fight aging in humans, according to a new study.\nResults showed that resveratrol suppressed the generation of \u201cfree radicals\u201d -- unstable molecules known to cause oxidative stress and release pro-inflammatory substances into the blood, resulting in damage to the blood vessel lining.\nPeople taking resveratrol also showed suppression of the inflammatory protein tumor necrosis factor, or TNF, and other compounds that increase blood vessel inflammation and interfere with insulin action, causing insulin resistance and the risk of developing diabetes.\nThe researchers signed up 20 people and put them at random into two groups, one receiving a placebo and the other a supplement containing 40 milligrams of resveratrol.\nStudy author Husam Ghanim, PhD, of the University of Buffalo says the popular plant extract has been shown to prolong life and reduce the rate of aging in roundworms, fruit flies, and yeast, apparently because resveratrol affects a gene associated with longevity.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Since the story framed this primarily as an anti-aging therapy \u2013 with possible impact on heart disease, stroke and type 2 diabetes thrown in \u2013 it would have been helpful for readers to be reminded about proven approaches to any of these conditions.\u00a0 But the story gave no such comparisons. ", "answer": 0}, {"article": "When it made its recommendation, the Academy of Pediatrics admitted \u201cit is clear that additional research is needed to further document the effects of changes in school start times over time.\u201d\n\nWell, there\u2019s some new (but still incomplete) evidence that later start times do help teens get more sleep.\nWhen your body clock is off from society\u2019s, scientists call it \u201csocial jet lag.\u201d And like the jet lag from a long journey, it messes with your body.\nBut that has consequences: Around 69 percent of high school students get less than eight hours of sleep on a school night, according to the Centers for Disease Control and Prevention, which puts these teens at risk of negative impacts on health.\nIn 2014, the Academy of Pediatrics wrote that \u201cthe urgency and the magnitude of the problem of sleep loss in adolescents\u201d warranted big changes in school start times.\nFor one, teens need more sleep than adults: about eight or nine hours a night, compared with about the six or seven their parents require.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are alternative public health measures that might get teens to sleep more (for example, a public education campaign). This context would have been helpful: What are the other options, and how effective might they be?", "answer": 0}, {"article": "A drug derived from this bushy sea creature showed modest, preliminary promise as an Alzheimer's treatment.\n\nIn small Alzheimer\u2019s study, hints of modest benefit from unusual drug\n\nA little-known drug company announced modestly encouraging results for its experimental Alzheimer\u2019s drug on Monday, a rare but still preliminary glimmer of hope in a field that has been battered by failure after failure.\n\nA mid-stage study by a tiny company wouldn\u2019t usually attract much attention, but the results unveiled by Neurotrope BioScience have been eagerly anticipated because its drug \u2014 derived from a bushy, hermaphroditic sea creature \u2014 takes a novel approach.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions FDA approved drugs: \u201cThere are four FDA-approved drugs for Alzheimer\u2019s, which affects 5.5 million people in the US: donepezil (sold as Aricept), galantamine (Razadyne), rivastigmine (Exelon), and memantine (Namenda). But none is a cure, and none affects the destruction of neurons and synapses, which causes the disease\u2019s memory loss and cognitive catastrophe.\u201d It also highlights that this new agent works in a different way from existing medications.", "answer": 1}, {"article": "Appeared or available on-line: May 4, 2016\n\nThis study, scheduled to be published later this year in a special cardiovascular issue of Cell Transplantation, is currently freely available on-line as an unedited early e-pub at: http://www.\nIn addition, there was a significant reduction in the time to first hospitalization in cell-treated patients, with a trend toward reduction in mortality as well.\n\"There are an increasing number of patients with advanced coronary artery disease that are not amenable to surgical or percutaneous revascularization,\" said study co-author Dr. Timothy D. Henry of the Cedars-Sinai Heart Institute.\n\"The results of our study are even more provocative given that the outcomes represent the effect of a single treatment,\" wrote the researchers.\nAccording to the researchers, the study demonstrated that CD34+ cells have the ability to restore the microcirculation and improve myocardial tissue perfusion.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "In order to fully appreciate any new or emerging treatment, it\u2019s important to compare it to existing techniques that address the same problem. The release does mention \u201cconventional medical treatments\u201d and \u201crevascularization\u201d but doesn\u2019t explain what those things are nor does it offer any comparisons with this developing therapy. There are a host of other treatments out there, from surgical interventions to pharmaceutical treatments.", "answer": 0}, {"article": "Australian researchers have completed the world's first randomised control trial (RCT) assessing the efficacy and safety of ketamine as a treatment for depression in elderly patients.\n\"Not only was ketamine well-tolerated by participants, with none experiencing severe or problematic side effects, but giving the treatment by a simple subcutaneous injection (a small injection under the skin) was also shown to be an acceptable method for administering the drug in a safe and effective way.\"\n\"These results are a promising early piece of the puzzle, but the risks of ketamine use are still not wholly understood.\nThe results, published in the latest American Journal of Geriatric Psychiatry, provide preliminary evidence suggesting ketamine's effectiveness as an antidepressant when delivered in repeated intravenous doses.\n\"Our results indicate a dose-titration method may be particularly useful for older patients, as the best dose was selected for each individual person to maximise ketamine's benefits while minimising its adverse side effects.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This is the one area where more information was greatly needed. The release notes that ketamine therapy is intended for treatment-resistant patients, but we learn nothing about about the effectiveness of other therapies, like anti-depressants, electroconvulsive therapy (ECT), cognitive behavioral therapy, etc.", "answer": 0}, {"article": "The drugs are thought to counter cancer growth by suppressing inflammatory pathways and stimulating tumors\u2019 ability to expand and develop blood supplies.\n\u201cAlso, this potential cancer-protective effect should be taken into account when discussing benefits and harms of NSAID use.\u201d\n\nAlice Park is a writer at TIME.\n(One COX-2 inhibitor, Vioxx, was voluntarily pulled from the market by its maker in 2004 after it was linked to an increased risk of heart disease.)\n\u201cWe hope that the potential cancer-protective effect of NSAIDs will inspire more research on skin cancer prevention,\u201d Johannesdottir said in a statement.\nOver the study period, people who filled more than two prescriptions for aspirin, NSAIDS or COX-2 inhibitors had a 13% lower risk of melanoma and a 15% lower risk of squamous cell carcinoma than those who filled fewer prescriptions, the researchers found.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There were no direct references to alternative methods for preventing skin cancer \u2014 like using sunscreen, avoiding midday sun, etc.\u00a0 Even an additional line could have satisfied this criterion.", "answer": 0}, {"article": "It also has a very low rate of false positives - it is 98% accurate at ruling out RA.'\nWhile tests for individual proteins usually have a relatively low diagnostic sensitivity, a more general test called CCP, that detects synthetic citrullinated peptides, identifies a lot more RA cases.\nThe Kennedy Institute's Professor Kim Midwood said: 'What is particularly exciting is that when we looked at samples taken from people before their arthritis began, we could see these antibodies to cTNC up to 16 years before the disease occurred - on average the antibodies could be found seven years before the disease appeared.\nWe decided to see if it could be citrullinated and, if so, whether it was a target for the autoantibodies that attack the body in RA.\nThese altered forms can prompt an immune response from the body, which can see it turning antibodies on itself - causing rheumatoid arthritis.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release provides some information about the cyclic citrullinated peptide (CCP) test, the standard test used, and states that the new blood test appears to be more accurate and reliable in comparison. The true alternative is actually to wait until symptoms develop.", "answer": 1}, {"article": "Carl Dieffenbach, AIDS chief at the National Institute of Allergy and Infectious Diseases, agreed.\n\"For the first time, people are beginning to think about a cure\" as a real possibility, said Dr. John Zaia, head of the government panel that oversees gene therapy experiments.\n\"The cells are engrafting - they're staying in the bloodstream, they're expanding over time,\" said Lalezari, who has no personal financial ties to Sangamo, the study's sponsor.\nEven if the new approach doesn't get rid of HIV completely, it may repair patients' immune systems enough that they can control the virus and not need AIDS medicines - \"what is called a functional cure,\" he said.\n\"We're hopeful that this is sufficient to give the level of immune reconstitution similar to what was seen with the patient from Germany,\" he said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Within the realm of other gene therapy attempts, the story explained, \u201cThis is the first time researchers have permanently deleted a human gene and infused the altered cells back into patients. Other gene therapy attempts tried to add a gene or muffle the activity of one, and have not worked against HIV\u201d", "answer": 1}, {"article": "The vaccine trains T-cells in the body to go after cervical cells with potentially cancerous genes embedded in them.\nBut in some people HPV leads to genital warts and cancers \u2013 notably, cervical cancer.\nHPV causes about 5% of cancers globally.\nKissing is not known to deliver this STD.\nMen up to age 26 are also eligible for Gardasil to protect against HPV.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was some discussion of alternative approaches \u2013\u00a0 Gardasil and Cervarix.", "answer": 1}, {"article": "The new study included slightly more than 1,000 men from Finland aged 46 to 65.\n\u201cThe results support the recommendation that people get more than five servings of fruits and vegetables a day, which would likely lead to a major reduction in the number of strokes worldwide, according to previous research.\u201d\n\nOther studies have shown that high lycopene levels may be linked to a reduced risk of certain cancers.\n\u201cThis study adds to the evidence that a diet high in fruits and vegetables is associated with a lower risk of stroke,\u201d says researcher Jouni Karppi, PhD, of the University of Eastern Finland in Kuopio.\nOct. 8, 2012 -- Men who eat lots of tomatoes and tomato-based products may have a lower risk for stroke, a new study suggests.\nMen who had the highest lycopene levels were 59% less likely to have this kind of stroke than men with the lowest levels.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that tomatoes aren\u2019t the only sources of lycopene. It also included a recommendation for a diet rich in fruits and vegetables, adequate exercise, and quitting smoking, as steps that may be beneficial for stroke prevention.", "answer": 1}, {"article": "For those who have resolved to get fit in the New Year, O\u2019Donovan recommends to start with moderate exercise, such as brisk walking, and then to set realistic, incremental goals to boost confidence without running the risk of setbacks due to injury.\nNearly 9,000 of the study participants died in the period.\nBut the weekend warriors also saw substantial health benefits if they met the physical activity target too.\nIn the study, those who exercised a little had a 29% lower risk of death than those who did no exercise at all.\nThere are doing a large proportion of vigorous exercise and that makes you fitter than moderate exercise,\u201d said O\u2019Donovan.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses the impact of different activity levels on early death risk.", "answer": 1}, {"article": "\u2022 The demonstration of a fully automated calculation quantifying retinal autofluorescence that showed a 2.1-fold increase in patients with Alzheimer's, compared with controls.\nOur goal is to develop a product that is easy to use, affordable and widely accessible.\nThe article provides new insights into the disease's manifestations in the retina and information on the optical imaging system.\nAmong key findings, the researchers report a 4.7-fold increase in retinal plaque burden in patients with Alzheimer's, compared to controls, and they provide observations regarding geometric distribution and layer location of amyloid pathology in the retina.\nWe look forward to the potential of retinal imaging playing a vital role in solving the problem of Alzheimer's, both in identifying and monitoring those who may be affected by the disease.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "As noted, there is a passing reference to other types of diagnostic tools but no true comparisons.", "answer": 0}, {"article": "\"Why is a higher adherence to the MedDiet related to slowing down the rate of cognitive decline?\nTwo of the included studies focused on younger adults and they both found improvements in cognition using computerized assessments.\nIn total, 18 out of the 135 articles met their strict inclusion criteria.\nSo regardless of being located outside of what is considered the Mediterranean region, the positive cognitive effects of a higher adherence to a MedDiet were similar in all evaluated papers;\" he said.\nBy sticking to the Mediterranean diet the study showed that people had slowed rates of cognitive decline, reduced conversion to Alzheimer's, and improved cognitive function.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Other lifestyle or medical interventions are not mentioned in the release. The published review article itself cited other lifestyle interventions.", "answer": 0}, {"article": "The experimental treatment, a decades-old generic vaccine for tuberculosis called bacillus Calmette-Gu\u00e9rin (BCG), seems to alter both cellular metabolism and the immune system, said Dr. Denise Faustman of Massachusetts General Hospital, senior author of the study published Thursday in npj Vaccines.\n(The standard of care is a continuous glucose monitor, in which a probe is inserted into the abdomen, plus an insulin pump.)\nPatients in the trial, whose blood sugar levels have remained near normal for five to eight years, take about one-third less insulin than they did before, reducing their risk of hypoglycemia, in which insulin lowers blood sugar to dangerously low levels.\nIt alters the immune system so as to increase levels of T regulatory cells; T regs keep other immune cells in check, including those that attack the pancreas\u2019s insulin-making cells \u2014 the root cause of type 1 diabetes.\nThe new paper describes how the BCG vaccine, which has been used for nearly 100 years against tuberculosis and is considered extremely safe, might affect diabetes.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The only alternative is insulin, and the story makes clear that even with the vaccine, patients still need to take it, but in smaller doses.", "answer": 2}, {"article": "\u201cWe think this is the first (study) to show this.\u201d\n\nMoss said women have often been overlooked in studies of heart disease, which until recently were dominated by men.\n\u201cThis was far greater than expected.\nCurrently, 42 million American women are living with heart disease.\nBut it also suggested that women benefited more from resynchronization therapy than men.\nIn the MADIT-CRT trial, women were more likely to suffer heart failure caused by a viral infection of the heart, whereas in men, the condition is more often caused by blocked heart arteries, Moss said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no discussion about alternatives.", "answer": 0}, {"article": "The average age of people in both groups was 73.\nOther assessments, such as PET scans for plaques of Alzheimer's proteins in the brain, are good at detecting early signs of Alzheimer's disease, but available to few patients.\n\"Diffusion tensor imaging is a way of measuring the movement of water molecules along white matter tracts,\" Raji said.\nThey used a technique called diffusion tensor imaging to assess the health of the brain's white matter, which encompasses the cables that enable different parts of the brain to talk to one another.\nNeurologists can get a ballpark estimate of a patient's risk of Alzheimer's dementia using the Mini-Mental State Examination questionnaire, or by testing for the high-risk form of the gene ApoE, which increases a person's risk of Alzheimer's by up to 12-fold.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Mentioned were the Mini-Mental State Examination questionnaire, testing for the high-risk form of the gene ApoE, and PET scans to look for plaques of Alzheimer\u2019s proteins in the brain.", "answer": 1}, {"article": "For more information, visit http://www.\nThe current study, based on data from a nationwide flu surveillance network including 14 states, focused on pregnant women hospitalized with laboratory-confirmed flu over four recent flu seasons, from 2010 to 2014.\nEditor's Note: The study authors' and editorial commentary authors' affiliations, acknowledgments, and disclosures of financial support and potential conflicts of interests are available in the study and the commentary, which are embargoed until 12:01 a.m. EST on Thursday, Feb. 4.\nAmong pregnant women with severe flu illness who were treated early -- within two days of the start of symptoms -- the median length of stay was about five days shorter compared to hospitalized pregnant women with severe flu illness who were treated later (2.2 days vs. 7.8 days).\n\"Overall, considering the accumulating evidence of fetal benefit and safety, influenza vaccination of pregnant and postpartum women should be a public health priority in accordance with national recommendations,\" the commentary authors wrote.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Oseltamivir is one of two FDA approved antivirals for treating influenza. The other is zanamivir. The\u00a0 FDA has taken a very murky approach to recommending these drugs during pregnancy. The FDA website states, \u201cBoth drugs are designated \u201cPregnancy Category C,\u201d\u00a0which means that they have not been studied in pregnant women. However, Pregnancy Category C does NOT mean the drug cannot be used\u00a0in pregnant women. \u00a0Pregnant women can and should receive a category C drug when the possible benefits of using the drug are more likely than the possible risk of harm to the woman or her baby.\u201d\nThe release could have acknowledged the existence of zanamivir and whether similar observations were made about its effectiveness.", "answer": 0}, {"article": "\u201cAnd what\u2019s happened with gonorrhea?\nThe research, conducted in New Zealand, found that the gonorrhea rate among teens and young adults there who had received a meningitis B vaccine during an emergency campaign in the early 2000s was significantly lower than the rate seen in people of the same age who weren\u2019t vaccinated.\n\u201cGonorrhea rates have been going down in the vaccine group whereas in the non-vaccine group it\u2019s following the rest of the province.\u201d\n\nIt is not clear how long the protection \u2014 if it\u2019s real \u2014 will actually last.\nBut the same component is one of several in the Bexsero vaccine, which was used in Quebec when the government decided to vaccinate against meningococcal B disease in a part of the province with a high relative rate of cases a few years ago.\n\u201cMathematical modeling has shown that even a vaccine of moderate efficacy and duration could have a substantial effect on the transmission and prevalence of gonorrhea, if coverage in the population is high and protection lasts during the highest risk period,\u201d Kate Seib, of Australia\u2019s Institute for Glycomics, wrote in a commentary that accompanied the study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There\u2019s no discussion of other strategies to address the spread of gonorrhea. The CDC has urged the development of new treatments for gonorrhea. Public health education, including condom use, can prevent new cases. A report sponsored by health agencies in the U.S. and the United Kingdom highlighted the need for strong data-driven public health surveillance to better understand how resistant strains evolve and get transmitted, as well as point-of-care diagnostic testing to identify resistant strains. At least a line or two discussing these alternatives would have informed readers that the vaccine isn\u2019t the only solution.", "answer": 1}, {"article": "THURSDAY, Jan. 5, 2012 (HealthDay News) -- Preliminary findings suggest a drug used to treat another disease might also reduce painful flare-ups in gout patients starting new medication regimens.\nThe researchers wanted to learn if rilonacept could lower this short-term risk for by neutralizing a specific target protein -- interleukin 1 or IL-1 -- before it initiates inflammation.\nAbout half were also given an initial double-dose injection of rilonacept (320 milligrams) followed by a single dose for 16 weeks.\n\"So for this population of patients who can't tolerate cheaper medications, rilonacept may be a necessary indication.\"\nHowever, he cautioned that the high cost of rilonacept will most likely curtail its use.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are at least other 6 drugs under development for gout at the moment. The story didn\u2019t mention anything about any of them.", "answer": 0}, {"article": "In this study, the average age was about 59 years old - six years younger than the age at which the U.S. Preventive Services Task Force, a government-backed panel, recommends all women begin being screened for osteoporosis.\nThat may spare the patients from additional testing and additional costs.\nThe researchers then found that their ability to accurately diagnose those same patients with osteoporosis from a CT scan depended on what threshold for bone density they used.\nThe disease affects over 12 million Americans over 50.\nAt the lower threshold, the researchers found 9 percent of those diagnosed with osteoporosis were misdiagnosed.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The entire frame of the story was a comparison of DXA tests to CT scans.", "answer": 1}, {"article": "\u201cOnce again pregnant women are being told it\u2019s O.K.\nDr. Malden C. Nesheim, chairman of the institute\u2019s committee and a provost emeritus at Cornell, said, \u201cWe are quite cautious because the studies we looked at are not controlled for all the variables, and we can\u2019t distinguish between the effects from omega-3\u2019s or replacement of other foods in the diet.\u201d\n\nThe National Oceanic & Atmospheric Administration had requested the institute\u2019s report because it said consumers were confused about how much and what kind of fish they should eat.\n\u201cAccording to NOAA\u2019s own statistics, per capita consumption of seafood has risen from 14.8 pounds in 2001 to 16.6 pounds in 2004.\u201d\n\nJane Houlihan, the research director of the Environmental Working Group, another advocacy group, said, \u201cThe Harvard study reads like an advertisement for the seafood industry.\u201d\n\nBoth studies reinforce advice from the Food and Drug Administration and the Environmental Protection Agency in 2004, to eat about six ounces of fish a week, preferably high in omega-3\u2019s, with a caveat for women of childbearing age and children under 12 not to eat swordfish, shark, tile fish or king mackerel and to limit their intake of albacore (white meat) tuna to six ounces a week to avoid mercury.\nDr. Mozaffarian agreed that, because the evidence is based on observational studies and clinical trial data, it is not definitive, but he added, \u201cIt\u2019s the best evidence we have.\u201d As for the study\u2019s finding that total mortality could be cut by 17 percent, he said, \u201cWhile one can argue over the precise size of benefits, even if the benefit is only one-half or one-quarter as large, it still greatly outweighs the risk.\u201d\n\nThe report from the Institute of Medicine tells the government that much more research is needed.\n\u201cFortunately, Environmental Defense and Monterey Bay Aquarium, who specialize in both health and environmental fish issues, provide advisory cards for choosing fish, and no one can manage this without one.\u201d\n\nThe Environmental Defense list is at oceansalive.org and the Monterey Bay Aquarium\u2019s is at mbayaq.org/cr/seafoodwatch.asp.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article nicely summarizes the potential advantages and disadvantages of fish consumption. However, it does not compare the reported protective effect of fish either to other potentially cardioprotective foods or to established medical therapies (e.g. aspirin) for cardiovascular disease. Eating fish is only one piece of a healthy lifestyle for minimizing risk of cardiovascular disease and overall mortality.", "answer": 0}, {"article": "Researchers compared 136 women with rheumatoid arthritis with 544 healthy women of similar age.\n\u201cBut even if you breast-feed for a month or two, it makes a difference.\u201d\n\nAlthough the mechanism is not clear, the scientists write that the protective effect may come from long-term changes in the mother\u2019s immune system induced by breast-feeding.\n\u201cBreast-feeding for an entire year is difficult for many women,\u201d said Dr. Mitra Pikwer, the lead author and an intern at Malmo University Hospital in Malmo, Sweden.\nAfter controlling for factors including smoking and education level, they found that women who breast-fed for 1 to 12 months reduced their risk of arthritis by 25 percent, and that those who breast-fed for more than a year cut their risk in half.\nThe community-based approach and the fact that data on breast-feeding was collected before the onset of disease give the study strength.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\nThe story does not mention whether other factors (e.g. behavioral, environmental, genetic) might also reduce the risk of RA. For example, one of the purposes of the Swedish study was to see whether oral contraceptives\u2014containing hormones that rise during pregnancy\u2014protect women against rheumatoid arthritis. The study concluded that they do not.\n", "answer": 0}, {"article": "Together, stomach and oesophageal cancer account for around 1.4 million new cancer diagnoses each year worldwide [2].\nThis means that not only was the breath test good at picking up those who had cancer (sensitivity), it was also good at correctly identifying who did not have cancer (specificity).\nBoth tend to be diagnosed late, because the symptoms are ambiguous, meaning the five-year survival rate for these two types of cancer is only 15%.\nAmsterdam, The Netherlands: A test that measures the levels of five chemicals in the breath has shown promising results for the detection of cancers of the oesophagus and stomach in a large patient trial presented at the European Cancer Congress 2017 [1].\nThe team is also working on breath tests for other types of cancer, such as colorectal and pancreatic, which could be used as first-line tests in general practice surgeries.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release seems to be favorably comparing this breath test, which is a screening test, to conventional diagnostic methods, including endoscopy, even though there is not yet any evidence to support comparisons.\nThe release would have been improved with a more careful distinction of who the screening test is geared for \u2014 is it a screening tool for healthy people to help rule out cancer or is it only for those with cancer symptoms? ", "answer": 0}, {"article": "He contended that kratom does not act on the brain's opioid receptors the way prescription painkillers and heroin do. But back in 2016, the Journal of the American Chemical Society reported that kratom indeed works this way. Last month, an FDA study found that 22 of the 25 of the most prevalent compounds in kratom do bind to opioid receptors, and so should be considered an opioid. The study also said most deaths did occur in people who used kratom in addition to other drugs, though in one case, only kratom was detected.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that there are effective existing treatments for opioid withdrawal.\nScientific studies have indicated that the most effective treatment for opioid withdrawal includes the\u00a0medically supervised use of opioid medications such as methadone.", "answer": 1}, {"article": "JACC is ranked No.\n\"It may not only be the cardiovascular health information from the program that is helpful but also the cognitive stimulation from and exposure to positive adult role models, which in turn influence personality traits critical for health behavior and habits,\" Bhatt said.\nIntroducing healthy lifestyle behaviors to children in preschool improves their knowledge, attitude and habits toward healthy diet and exercise and can lead to reduced levels of body fat, according to a study published today in the Journal of the American College of Cardiology.\nThe Journal of the American College of Cardiology, which publishes peer-reviewed research on all aspects of cardiovascular disease, is the most widely read cardiovascular journal worldwide.\n\"There is a need for a complete change in the timing of when we deliver care,\" said Valentin Fuster, M.D., Ph.D., senior author of the paper.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The use of education for preschool-aged children to prevent cardiovascular disease appears novel, and we are not aware of a direct alternative \u201ceducation\u201d that exists. We\u2019ll rule this one Not Applicable.", "answer": 2}, {"article": "Nine rode exercise bikes in a gym to compare the sweat patches\u2019 performance with the decidedly lower-tech method of sweat-testing used today \u2014 taping on absorbent pads and carting the resulting wet samples to a laboratory.\nBy simply looking at a color change, \u201csuch a patch allows people to now have an opportunity to understand their health and how it changes depending on activities.\u201d\n\nIt\u2019s a growing field: Other research groups around the country, including some of Bao\u2019s colleagues, are pursuing wearable biosensors.\nFor simple fitness purposes, it could give an early warning that it\u2019s time to replenish electrolytes before someone starts to feel dehydrated.\n\u201cSweat has biochemical components within it that tell us a lot about physiological health,\u201d said John A. Rogers, who directs Northwestern University\u2019s Center for Bio-Integrated Electronics and led the new research.\nThe patches stayed in place and worked even in the challenging outdoor race, and the patches\u2019 biochemical test results agreed with the indoor bikers\u2019 conventional sweat tests, the researchers reported in the journal Science Translational Medicine.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does state that the patch was shown in the study to be just as good as a pad sent to a laboratory for analysis in terms of collecting sweat samples. But there\u2019s no comparison with other alternatives for monitoring health measures such as blood tests, and in the case of dehydration, good old-fashioned thirst.", "answer": 0}, {"article": "Type 2 diabetes is caused by the body\u2019s in ability to break down sugars from the diet.\n\u201cIt isn\u2019t an irreversible, inexorable condition that you can never escape from \u2014 at the moment, people are told that.\u201d\n\nPrevious studies have suggested that lifestyle changes, including diet and exercise, can be powerful ways to lose weight and combat diabetes.\nThe diet, which was designed to help people lose up to 30 pounds, involved three to five months of a strict low-calorie liquid formula diet averaging no more than 850 calories a day, followed by two to eight weeks of reintroducing food, along with nutritional education and cognitive behavioral therapy to help people stick with the new eating plan.\nIf more people can benefit from losing weight alone, then that would mean less cost to the health care system, as fewer people will suffer the serious complications of advanced disease, which can include heart problems, neuropathy, vision issues and even amputations.\nBut in a paper published in the , researchers in the UK describe a landmark study in which people with diabetes went into remission\u2014just by losing weight.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions gastric bypass surgery as another method to dramatic weight loss and that has been shown to reverse diabetes. It also mentioned the high cost of and risk of complications from gastric bypass. Unfortunately, readers cannot compare the cost and harms of the managed diet approach, as the story omits their mention.", "answer": 1}, {"article": "To learn more about NAMS, visit http://www.\nThe results of this small, retrospective, non-sham-controlled study demonstrated that this type of laser surgery was particularly effective in reducing the intensity of dyspareunia (painful sex) and dryness.\n\"Until more data are available, all treatment options, including lubricants, vaginal moisturizers, and FDA-approved vaginal and systemic hormone therapies, should be discussed with women who suffer from GSM to determine the best treatment option for them.\"\nCollectively known as the genitourinary syndrome of menopause (GSM), the various genital and urinary problems associated with menopause have created a market for new therapies and treatments to help women regain sexual function and bladder control.\nIts multidisciplinary membership of 2,000 leaders in the field--including clinical and basic science experts from medicine, nursing, sociology, psychology, nutrition, anthropology, epidemiology, pharmacy, and education--makes NAMS uniquely qualified to serve as the definitive resource for health professionals and the public for accurate, unbiased information about menopause and healthy aging.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release names some of the many treatments available for managing menopause symptoms through this quote from the executive director of NAMS:\nUntil more data are available, all treatment options, including lubricants, vaginal moisturizers, and FDA-approved vaginal and systemic hormone therapies, should be discussed with women who suffer from GSM to determine the best treatment option for them.", "answer": 1}, {"article": "These initial findings are interesting, but, as with all areas of mental health, there is still more research to be done.\u201d\n\nMental health problems, including depression, are estimated to cost \u00a3105bn a year in England.\nCurrently it is impossible to establish who should or should not be given antidepressants, or combinations of them.\nResearchers focused on two independent clinical groups of depressed patients on two biological markers that measure inflammation of the blood, as heightened levels are associated with poor response to antidepressants.\nPatients who have blood inflammation above a certain threshold could be directed towards earlier access to more assertive antidepressant strategies, including the addition of other antidepressants or anti-inflammatory drugs,\u201d Pariante added.\nAbout half of all patients with depression get no benefit from antidepressants the first time they take them and they never work for one in three people.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Given the main focus of the story is\u00a0blood tests, the apparent alternative would be no blood tests.", "answer": 2}, {"article": "Current ACS prostate screening cancer guidelines recommend that men make an informed decision with their doctor about whether to be tested for prostate cancer.\nThe thought was that since high PSA levels are correlated with prostate cancer, rapidly rising levels of PSA, called \"PSA velocity,\" from one year to another would also be an indicator of prostate cancer.\nThe whole issue of prostate cancer screening -- including the PSA test, the digital rectal exam and PSA velocity -- has been controversial, said Dr. Otis Brawley, chief medical officer of the American Cancer Society (ACS).\n\"We found there was no strong association between PSA velocity and prostate cancer, and virtually none with aggressive prostate cancer,\" said study author Andrew Vickers, of Memorial Sloan-Kettering Cancer Center in New York City.\nBut the National Comprehensive Cancer Network and American Urological Association guidelines do recommend biopsies based on high PSA velocities, even in the absence of an elevated PSA or a suspicious digital rectal exam, according to background information in the study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0The story contrasted using change in PSA level versus simply the PSA level for their impact on prostate biopsy recommendations and subsequent diagnosis of prostate cancer.\nMore importantly, much more explicity than the competing AP story, this story (through the words of Dr. Otis Brawley of the American Cancer Society) addressed the option of not being screened at all.\u00a0 Excerpts:\n", "answer": 1}, {"article": "Half got standard care: a session of nutrition counseling with a registered dietitian and written materials.\nWhile the Weight Management Center has a high success rate at helping patients lose weight to fight diabetes, many people with the condition don't live near a specialized program and need help that's readily available.\nLeft uncontrolled, the condition can damage blood vessels and nerves, putting people at risk of having a heart attack or stroke.\nO'Neil said because Weight Watchers has centers all over the country, including sites in small towns with limited or no medical facilities, its program could help meet this need if combined with diabetes-specific counseling.\nThe MUSC Health Weight Management Center takes a scientific approach to weight loss, focusing on changes in activity levels, behavior, thinking, diet and support systems.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release offers some comparison of the intervention group vs the standard of care group, but does not mention other possible approaches to weight loss such as competing meal replacement plans, liquid supplement diets, exercise-based programs, bariatric surgery and primary prevention in the form of nutritional education among high risk groups.\nWe already know that intensive interventions for exercise and diet are needed for weight management. It would be useful to know how Weight Watchers compares to these other intensive interventions in terms of cost and effectiveness. In its assessment of a review of comparable meal control programs, the American Academy of Family Physicians found that:\n\u201cAt 12 months, Weight Watchers participants achieved at least 2.6 percent greater weight loss than the control group, and Jenny Craig users saw at least 4.9 percent greater weight loss than the control group.\u201d\n\u201cOther programs, including NutriSystem, showed comparable weight-loss results in the short term, but the study said additional research is needed to determine their long-term results.\u201d", "answer": 0}, {"article": "And if patients are given a choice of catheterization sites, what factors should they consider?\nThe approach allows patients to sit up immediately afterward and even walk, an impossibility in femoral procedures, which require that they lie flat on their backs for several hours to prevent severe bleeding.\nThe radial artery is thinner and offers a much more circuitous path, more like driving on a two-lane mountain road with frequent switchbacks.\nSome recent studies have found the approach has a lower rate of complications, including severe bleeding, than femoral procedures.\nBut in Europe, Canada and Japan, about 50 percent of catheterizations are performed using the technique devised in the early 1990s.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While there was no discussion about the appropriate use of cardiac catheterization in general, the story included information about the two arterial routes that may be used for the procedure.", "answer": 1}, {"article": "Treatment typically involves the use of inhaled steroids and bronchodilators to open airways and make breathing easier.\nCOPD is the umbrella term for chronic lung diseases, including chronic bronchitis and emphysema.\nThe study showed that acupuncture may improve stomach function, making it easier for people with COPD to eat a healthy diet and maintain a normal weight.\nOthers got a sham acupuncture treatment, in which the needles did not enter their skin.\nIt is often marked by a chronic cough and shortness of breath.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not address any other alternative treatments for COPD, except acupuncture. The implication is that one can use standard meds or those meds plus acupuncture. There are other non-medicine treatments for COPD. If the mechanism for action is relaxation, there are also other forms of relaxation.", "answer": 0}, {"article": "Sept. 28, 2010 -- Intrauterine devices (IUDs) -- used to prevent pregnancy -- may also be an effective treatment for some patients with early-stage uterine cancer who want to preserve their fertility.\n\nIn a small, early study, carefully selected patients with cancer that had not spread beyond the inner lining of the uterus were treated with IUDs that released the hormone progesterone.\n\nThe treatment was found to be as effective as oral hormone therapy, which is the most widely used nonsurgical, fertility-sparing treatment for the cancer.\n\n\u201cOur results show promise for the treatment of younger endometrial cancer patients with early disease who desire pregnancy in the future,\u201d gynecologic oncologist Lucas Minig tells WebMD. \u201cBut patients must be screened very carefully to make sure their disease has not spread.\u201d", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions hysterectomy as the primary alternative.", "answer": 1}, {"article": "Predefined analyses showed significant differences between active and control study groups for hippocampal and whole-brain atrophy, and favourable effects for CDR Sum of Boxes and episodic memory (both were most pronounced in patients with high baseline cognition with regular intake).\n\u2022 Academy of Sciences of the - Institute of Physiology\n\nFor further information on the European LipiDiDiet study and consortium, visit: http://www.lipididiet.eu\n\u2022 A Clinical Trial investigating the effects of Fortasyn Connect (Souvenaid) in Prodromal Alzheimer's Disease: Results of the LipiDiDiet study H. Soininen, , M. Kivipelto, T. Hartmann for the LipiDiDiet study group (2016), presentation held at 14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy,\n\u2022 The World Alzheimer Report 2015: 'The Global Impact of Dementia'.\n\"This is exciting because it shows that in the absence of effective drug options, we really have found something that can help slow down some of the most distressing symptoms in very early AD (pre-dementia); especially in those who started the intervention early.\nProfessor Hilkka Soininen, Professor in Neurology MD, PhD from the University of Eastern Finland, who headed the clinical trial as part of the LipiDiDiet project, said: \"Today's results are extremely valuable as they bring us closer to understanding the impact of nutritional interventions on very early AD (pre-dementia) which we are now better at diagnosing but unable to treat due to a lack of approved pharmaceutical options.\nExtensive preclinical investigation, which took place as part the LipiDiDiet project, indicated that the nutrient combination in Fortasyn Connect has effects on multiple biological pathways that contribute to an overall neuroprotective effect.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "While the release makes it clear \u2014 and accurately so \u2014 that there are no pharmaceutical treatments for dementia, it also states \u201cWe have known for a while that diet can reduce the risk of developing dementia.\u201d We disagree. No diet has ever been shown to reduce the risk of dementia. The best we\u2019ve got are epidemiological studies that show an association between diet and dementia risk. That\u2019s not the same as reducing risk. The release also says that \u201csingle nutrients simply aren\u2019t powerful enough to fight a disease like Alzheimer\u2019s alone.\u201d That\u2019s a gross oversimplification that could lead people to think that more is better when it comes to vitamins and dementia.", "answer": 0}, {"article": "American veterans coping with PTSD are traveling to lodges in the Amazon that offer ayahuasca, a hallucinogenic brew. Some say it has helped them manage emotional trauma from war, but others say it\u2019s not worth the journey. Photo: Ryan Dube/WSJ\n\nAfter surviving firefights and a roadside bomb in Afghanistan, U.S. Army veteran Asa Barrett tried antidepressant drugs and therapy to overcome depression and bouts of anger. Nothing worked.\n\nBut then, like many other foreigners, he journeyed to Peru\u2019s remote Amazonian jungle to drink ayahuasca, a centuries-old, sacred indigenous brew that some Western scientists think can help to heal psychological traumas.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story could have done a better job of explaining what treatments users of ayahuasca tried before taking the extreme step of traveling to the Amazon. The lead describes one U.S. Army vet who \u201ctried antidepressant drugs and therapy to overcome depression and bouts of anger. Nothing worked.\u201d\u00a0 But there\u2019s no indication that the reporter attempted to contact a clinician who treated the vet, or one who treats vets with similar conditions, to find out what specific therapies are used and their rate of efficacy.", "answer": 0}, {"article": "All patients were also given physiotherapy, and had their motor skills tested at the start of the trial and on day 90.\nSignificantly greater improvements in motor function were recorded after three months in patients taking Prozac, where the average test score improved by 34.0 points, than in the placebo group, where the average improvement was 24.3 points.\n\u201cThe positive effect of the drug on motor function... suggests that the neuronal ... action of SSRIs provides a new pathway that should be explored further,\u201d said Francois Chollet of Toulouse University Hospital, who led this research.\nThe cost of caring for its victims, who often have motor function difficulties like paralysis or weakness on one side, puts a heavy burden on already stretched healthcare systems.\nHemiplegia \u2014 paralysis to one side of the body \u2014 and hemiparesis \u2014 weakness on one side of the body \u2014 are the most common disabilities after stroke and scientists believe SSRIs might help improve movement by increasing the level of the brain chemical serotonin in the central nervous system.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Again, the story reported only what was in the study but fell short on context. It notes that all subjects in the study received physiotherapy, which means Prozac was compared to physiotherapy alone. But it didn\u2019t describe the established medications routinely used in patients after a stroke, thereby making Prozac and SSRIs were the only drugs to be considered. ", "answer": 0}, {"article": "NEW YORK (Reuters Health) - There may be a seed of truth amidst the many health claims for pomegranate juice, researchers from Israel said Thursday, at least for kidney patients on dialysis.\n\u201cMuch higher than red wine, for instance.\u201d\n\nThe researchers figured an antioxidant-rich diet might help patients with kidney failure, because the level of free radicals in their blood increases as the blood circulates through the dialysis device.\n\u201cThe effects of juice were compared to a placebo, not to any other kind of juice that might have exactly the same effect.\u201d\n\n\u201cThe pomegranate people are spending millions to prove what I could have told them in the first place,\u201d she added.\nThe findings were presented at the American Society of Nephrology\u2019s meeting in Denver \u2014 aka Renal Week \u2014 and have not yet been vetted by independent experts.\n\u201cI certainly don\u2019t know of anything else that would have such a profound effect,\u201d he told Reuters Health, cautioning at the same time that the study needed to be replicated by other centers.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Again, the Marion Nestle concluding quote was key:\u00a0 \u201cPomegranate juices \u2014 like most if not all fruit and vegetable juices \u2014 have antioxidant activity. Does this make pomegranates better than any other fruit? Investigators have yet to show this.\u201d", "answer": 1}, {"article": "While a positive test result is highly suggestive of IBS, only 44 percent of patients with IBS tested positive, meaning that many people who test negative could in fact still have the condition.\nShe got the new blood test to confirm her diagnosis, and when it came back positive, she said she felt a sense of relief knowing IBS wasn't all in her head.\nThe tests, which measure antibodies in the blood, were based on research suggesting that IBS may develop after infection from a bacterial toxin found in food poisoning.\nMaking it worse for many patients, there hasn't been a conclusive test to diagnose what's wrong with them.\n\"We now have a test to say, you have a disease,\" Pimentel told CBS News.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Even a mention of an alternative (such as how IBS is currently diagnosed) would have merited a satisfactory, but there is no mention of alternatives.", "answer": 0}, {"article": "But serious side effects were more common among the briakinumab users.\nBriakinumab works by dampening the immune system response that causes psoriasis, said Bruce Bebo, director of research and medical programs for the National Psoriasis Foundation, based in Portland, Ore.\n\nMore serious infections were seen in people taking briakinumab (2.6 percent) vs. those taking methotrexate (1.8 percent).\nThe drug briakinumab reduced psoriasis symptoms by at least 75 percent in nearly 82 percent of those taking it, compared to just 40 percent of those on methotrexate.\nAfter six months, nearly 82 percent of those in the briakinumab group had at least a 75 percent improvement in the psoriasis area-and-severity index (PASI), a commonly used measurement to assess the severity of psoriasis.\n\"Very high levels of response\" were observed and maintained throughout the study period, said lead researcher Dr. Kristian Reich, a professor of dermatology at the University of Gottingen and a managing partner at Dermatologikum Hamburg, both in Germany.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As with the \u201cnovelty\u201d criterion above, on this point, WebMD\u2019s version of the story was better because it at least reminded readers that \u201ca similar drug, Stelara\u2026was approved by the FDA in 2009.\u201d Neither story wrapped this research into the broader context of other approaches to psoriasis \u2013 including non-drug therapies.", "answer": 0}, {"article": "While the American Cancer Society, the American College of Physicians and other gastroenterology experts recommend virtual screening every five years, the U.S. Preventive Services Task Force, a congressionally mandated but non-federal, independent group of medical experts, concluded the evidence wasn\u2019t strong enough to justify Medicare coverage of the service.\nBut according to Dr. Marc Gollub, director of CT and gastrointestinal radiology at Memorial Sloan-Kettering Cancer Center, \u201cthe radiation is much lower than a regular CT scan and has not been proven to be of any risk.\nBut in spite of those challenges, Megan McHugh at the Health Research and Educational Trust in Chicago and her team report that about 17% of hospitals in the U.S. now offer the screening test, up from 13% in 2005.\nOr, the images can be combined to generate a 3D view of the colon, allowing the doctors to \u201cfly through\u201d the organ looking for any suspicious growths or protrusions.\nThe images can be viewed as two dimensional CT scans, which display any possible abnormalities protruding from the lining of the colon.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story creates a false dichotomy \u2013 as if screening is a choice between regular colonoscopy or CT colonoscopy.\u00a0 And it inaccurately states that \u201cthe American Cancer Society, the American College of Physicians and other gastroenterology experts recommend virtual screening every five years.\u201d\u00a0 That is not, for example, what the American Cancer Society recommends.\nOn the ACS website, a range of choices are presented \u2013 not just virtual colonoscopy \u2013 making the story\u2019s statement misleading at best.\u00a0 The ACS website states:\nBeginning at age 50, both men and women should follow one of these testing schedules:\nAnd it\u2019s odd that the story never mentioned a new statement by the American College of Obstetricians and Gynecologists reminding women that they have a range of screening options including high-sensitivity guaiac fecal occult blood test or fecal immunochemical test. ", "answer": 0}, {"article": "That protein is known as an epidermal growth factor receptor (EGFR) kinase.\nThe scientists say non-small cell lung cancers that had become invulnerable to the chemotherapy drugs Iressa and Tarceva were stymied in a study by a compound designed and formulated in the Dana-Farber laboratory.\nThe scientists say in the news release that not only did they find that a compound called WZ4002 can slow tumor growth, but that it is possible to \"selectively target the drug-resistant mutant EGFR in tumors, with relatively less effect on the normal EGFR in health tissues.\"\nIt's early to discuss the use of such compounds in patients, the scientists say, but one of the researchers, Michael J. Eck, MD, PhD, also of Dana-Farber, says he's optimistic their approach \"will lead to an effective treatment for the thousands of non-small cell lung cancer patients worldwide who develop resistance to Iressa and Tarceva every year.\"\nThe researchers say the framework of the new compound is different from that of other cancer drugs and acts against a protein that carries a structural defect, according to a news release.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article mentions that the compound is being developed for NSCLCs that are resistant to 2 other drugs. However, it does not mention whether those 2 drugs are the only available treatment approaches for patients who might conceivably receive the new compound.", "answer": 0}, {"article": "Mallory attended the Brain Balance Achievement Center three times a week after school for three months at a time, starting in November 2014.\n\u201cThe easiest way to get their brain to become coordinated is by making their body coordinated, so a large part of what we're doing is this sensory motor interaction, building their muscle tone, building their strength, building their body spatial awareness.\u201d\n\nThe program also incorporates what Melillo calls \u201cbionutritional\u201d guidelines to make sure children are getting the proper nutrition for optimal learning.\n\u201cWe tried some medication therapies that ended up being really a nightmare for us, and making matters worse.\u201d\n\nMedication is often the first line of defense in conventional medicine for kids with ADD and ADHD, with doctors prescribing everything from stimulants to antipsychotics and even antidepressants to help control the symptoms.\n\u201cShe couldn't do anything to stop it, and I really began to realize that her brain wouldn't let her, even if she wanted to be good, her brain wasn't allowing her to.\u201d\n\nMallory\u2019s oppositional behavior reached a fever pitch when the family moved from their home in Hoboken, N.J. to the suburb of Glen Rock, N.J. in 2014.\n\u201cAnd if [kids] have poor coordination in their body, they often have poor coordination in their brain -- poor coordination between their networks -- so they can't bring all these networks together to learn in the most optimal way.\u201d\n\nThe program uses a combination of sensory motor (physical) exercises and academic learning to help stimulate and strengthen the parts of the brain responsible for certain disorders.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions drugs that are often prescribed for children with behavioral disorders. But it does not offer any evidence-based comparison of approaches.\u00a0While offering the Brain Balance system as a superior treatment,\u00a0the story\u00a0does not provide the context that some of the elements of the Brain center\u2019s treatment are also offered in traditional therapeutic centers.\nThis line in the story \u2013 \u201cwith doctors prescribing everything from stimulants to antipsychotics and even antidepressants to help control the symptoms\u201d \u2013 also demands some further explanation. \u00a0This statement makes the use of antipsychotics and antidepressants sound commonplace. \u00a0It would be the rare and controversial practice to use these.", "answer": 0}, {"article": "The other is that, for tens of thousands of years, parasites and other infections unusual in modern society were a major problem in humans. The body developed a defense mechanism - inflammation - to fight them. Now, there aren't as many of these infectious diseases for our bodies to deal with, but we still have this defense mechanism. It has begun to target other things, such as allergens in the environment. Immunotherapy helps teach the body to better tolerate these harmless parts of our environment.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does a pretty good job of explaining alternatives to the relatively new immunotherapies, as well as some treatment cost comparisons. As stated earlier, the discussion was weighted toward immunotherapy and not OTC and prescription medications.", "answer": 1}, {"article": "At the top of the list?\nThis means that a single 200-calorie sugary drink may be OK for a person who typically consumes a 2,000 calorie-per-day diet.\n\"The good news is that we now understand which foods we need to target to prevent Americans from dying prematurely from cardiometabolic diseases,\" says lead study author Renata Micha, a public health nutritionist and epidemiologist at the Friedman School at Tufts University.\nBut, here's the flip side: The researchers also found there's a significant risk in eating too little of certain healthy foods.\nEating More \u2014 Or Less \u2014 Of 10 Foods May Cut Risk Of Early Death\n\nAbout half of all U.S. deaths from heart disease, stroke and Type 2 diabetes are linked to poor diets, according to a new study published in the Journal of the American Medical Association.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses exercise as another lifestyle factor that might be associated with reduced risk of death. Smoking could also have been mentioned.\nAs well, stress\u00a0management and solid social connections are believed to be important lifestyle factors affecting health, yet unlikely to be captured in those nutrition-related questionnaires.", "answer": 1}, {"article": "Knee surgery for a torn meniscus is done about half a million times each year in the U.S.\nThe new federally funded study compared surgery with a less drastic option.\nAfter six months, both groups had similar rates of functional improvement.\nResults were published online by the New England Journal of Medicine.\nHe still does the recommended exercises several times a week.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The focus of the story was a study comparing alternative treatment approaches.", "answer": 1}, {"article": "It may also prevent infections and exacerbations of Chronic Obstructive Pulmonary Disease (COPD) like emphysema.\nHe cautioned that the study is not definitive proof that vitamin D can prevent ARI but it suggests that it can and at little risk to the patient.\nBut Ginde said the primary finding that vitamin D can reduce ARI is a major step forward in treating these dangerous infections.\nAt the same time, Ginde found that those who received higher doses of vitamin D also saw an increase in falls.\nThose with higher doses saw ARIs cut nearly in half.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release says that there are not enough good options for preventing ARIs, but it does not adequately explain the options.", "answer": 0}, {"article": "March 31, 2010 -- A widely prescribed drug used to shrink enlarged prostates appears to reduce the incidence of prostate cancer in men with an increased risk for the disease.\nThe drugs work by blocking the conversion of testosterone into a key hormone associated with prostate growth.\nA total of 8,231 men between the ages of 50 and 75 took part in the study, published in the New England Journal of Medicine.\nAll of the men had elevated blood levels of prostate specific antigen (PSA), which indicated an increased risk for prostate cancer.\n\"But we don't have studies saying that they decrease the risk of death from prostate cancer.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions finasteride as the primary alternative to Avodart for chemoprevention of prostate cancer.", "answer": 1}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nSteroids improve survival and reduce the chances of certain birth defects for extremely premature infants, even if the treatment course is not finished before delivery, according to a study funded by the National Institutes of Health (NIH).\nThe study team also found evidence that the better outcomes likely were due to lower rates of bleeding in the brain and of a brain injury called cystic periventricular leukomalacia.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\nThe study followed the infants from birth to 18 to 22 months of age and measured survival and brain and nervous system outcomes.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Alternative therapies are not discussed in the news release. For women who are more likely to deliver prematurely, they may receive a progesterone shot \u2014 the most common being the 17-OHPC shot \u2014 to prevent preterm birth. Other medications, such as tocolytics, which include ritodrine, magnesium sulfate, calcium channel blockers and indomethacin, can be administered to delay delivery. Additionally, women in preterm labor usually are given antibiotics, as some studies have suggested that antibiotics may prolong pregnancy and reduce problems in the newborn.\nSince none of these alternatives are mentioned, we give the news release a Not Satisfactory rating.", "answer": 0}, {"article": "Cowen & Co estimates that use of DNA blood tests for cancer screening will exceed $10 billion a year by the end of the decade.\n\u201cIf we are relying on a test that can only detect cancer after it has formed, we miss a huge opportunity to intervene,\u201d said Dr. Scott Kopetz of the University of Texas MD Anderson Cancer Center.\n\u201cFor any given test, the rate of false positives causing unnecessary alarm and false negatives that provide false security should be known,\u201d said Dr. Keith Stewart, an oncologist who heads Mayo Clinic\u2019s Center for Individualized Medicine.\n\u201cWe do expect to detect cancer DNA when the tumors are small - much sooner than stage three or four,\u201d Plante said.\nBut the move by Pathway, a privately owned maker of genetic tests ranging from cancer risk and heart health to drug response, underscores a growing debate over how much genetic information should be made available to healthy people if it is not yet clear how it can improve their health.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The true alternative to these tests is routine cancer screening using proven screening methods recommended by the US Preventive Services Task Force. In fact, the whole name \u201cliquid biopsies\u201d is wrong. These are not biopsies at all, they are screening tests for healthy people that look for biomarkers of cancer in the blood. But we don\u2019t know what kind of clinical significance they have or if they will lead to better outcomes. Neither story gave a full explanation of the alternative screening approaches, although this story did mention colonoscopies (which are one such screening method) as well as screening tests for prostate cancer. We\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "These included 1 percent who had blood clots and 1 percent who suffered bleeding.\n\"The practical implication is the possibility to incorporate Avastin with any chemotherapy regimen in the frontline therapy of metastatic non-squamous lung cancer,\" he added.\nThe efficacy of the drug has been proven previously, he noted, but this study provides an in-depth analysis of Avastin's safety profile under \"real life\" conditions, he added.\nFor the study, Crino's team studied Avastin in more than 2,200 patients with advanced or recurrent non-squamous non-small-cell lung cancer.\n\"Today we have a new option to treat non-squamous lung cancer, incorporating Avastin in chemotherapy regimens and in maintenance therapy,\" said lead researcher Dr. Lucio Crino, director of medical oncology at S. Maria della Misericordia Hospital in Perugia, Italy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0There was no discussion about whether there are other drugs that may be used in conjunction with the standard treatment for metastatic non-squamous non-small cell lung cancer to improve patient outcomes. \u00a0And since the story did not discuss how the use of Avastin changes outcomes, it failed to report on how this new approach compared with existing treatment.", "answer": 0}, {"article": "WASHINGTON\u2014The Food and Drug Administration questioned the clinical benefit of using GlaxoSmithKline PLC's Avodart to cut the risk of prostate cancer.\n\nAvodart is currently approved to treat benign enlargement of the prostate. The company is seeking FDA approval to market the drug to certain men to reduce the risk of prostate cancer. The drug will be reviewed by an FDA advisory panel on Wednesday along with Merck & Co.'s Proscar, a drug similar to Avodart.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are no proven ways to\u00a0prevent prostate cancer (although supplements such as vitamin E and selenium have been found to be ineffective),\u00a0so we can\u2019t\u00a0fault this article for not mentioning any.\u00a0We\u2019ll call it not applicable.", "answer": 2}, {"article": "For more information about featured studies, as well as a schedule of availability for featured researchers, please visit http://www.\nThe team also reported that endoscopic sleeve gastroplasty patients customarily left the hospital on the same day of treatment, while laparoscopic sleeve gastrectomy patients stayed for about three days and laparoscopic banding patients for a day and a half.\nPatients who underwent ESG -- a procedure performed through the mouth with an endoscope to \"accordion\" the stomach by suturing pleats to reduce its size -- achieved greater weight loss than laparoscopic banding, but less weight loss than laparoscopic sleeve gastrectomy surgery.\nAt one-year follow-up, patients who chose laparoscopic sleeve gastrectomy surgery achieved the greatest percent total body weight loss at 29.28 percent, compared to 17.57 percent for endoscopic sleeve gastroplasty patients and 14.46 percent for laparoscopic banding patients.\n\"For years, patients seeking weight-loss interventions had limited options because they could not tolerate or did not want surgery, or it was not even an option for them,\" added Dr. Sharaiha.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does compare the most common types of medical weight loss interventions that involve making changes to the stomach. However, there is no real discussion of alternatives, such as pharmaceutical interventions, attending counseling or support groups, and lifestyle changes involving diet and exercise. This is an important oversight given that, even with a surgical or endoscopic procedure, these other interventions are likely to play an important role in helping patients keep off any weight that they lose. What would the outcome be for\u00a0patients who only\u00a0went to a \u201ccenter of excellence\u201d weight loss facility for a full year?", "answer": 0}, {"article": "\"Research has shown that subtle markers of autism are identifiable in the first year of life,\" explained Dr. Ron Marino, associate chair of pediatrics at Winthrop-University Hospital in Mineola, N.Y. \"Video feedback seems like a natural and potentially very potent extension of intervention when it can be most effective,\" he added.\nThe goal of the therapy -- delivered over five months while the infants were ages 7 to 10 months -- was to improve the infant's attention, communication, early language development, and social engagement.\nThose studies \"will need to include a larger, more diverse sample population and need to look at developmental outcomes over a much longer period of time.\"\nSome of the families were assigned to a therapy program in which a therapist used video feedback to help parents understand and respond to their infant's individual communication style.\n\"But our findings suggest that targeting the earliest risk markers of autism -- such as lack of attention or reduced social interest or engagement -- during the first year of life may lessen the development of these symptoms later on.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention any of the other therapies for treating children with ASD, which include behavioral modification therapies and medications, or the pros and cons or costs of these different therapies.", "answer": 0}, {"article": "In its marketing campaign, Cyberonics notes that VNS treatment does not cause the weight gain associated with antidepressants and the confusion and memory loss common after electroconvulsive therapy (ECT), psychiatry's term for shock treatments.\nBecause that study lacked a control group and because patients received other depression treatments after the device was implanted, there is no way to know whether the device was responsible.\nThe generator emits regular pulses of electricity that are supposed to stimulate serotonin and other brain chemicals believed to regulate mood, according to Cyberonics.\nThat study involved 235 patients, all of whom received the device, which was turned on in only half the group.\nWorsening depression and suicide attempts were reported by one-third of patients in one study funded by Cyberonics, according to data presented to the FDA.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is mention of psychotherapy, electroconvulsive therapy and antidepressants but few details are given about these options. ", "answer": 1}, {"article": "The report, he added, might quell the craze.\nIn general, most people are not getting enough vitamin D from their diets, but they have enough of the vitamin in their blood, probably because they are also making it naturally after being out in the sun and storing it in their bodies.\nAs for vitamin D, some prominent doctors have said that most people need supplements or they will be at increased risk for a wide variety of illnesses, including heart disease, and autoimmune diseases.\nAt the same time, vitamin D sales have soared, growing faster than those of any supplement, according to The Nutrition Business Journal.\nNow it is easy to find pills, even in places like , with 5,000 international units.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Not\u00a0applicable for this story. The approaches discussed are not new, and there\u2019s not\u00a0really any alternative to getting adequate amounts\u00a0of these essential nutrients.", "answer": 2}, {"article": "New research in The FASEB Journal suggests the potential of tendon stem cells to improve healing and treatment for acute tendon injuries and chronic tendon disease\n\nNew research published online in The FASEB Journal suggests that tendon stem (TSCs) may be able to significantly improve tendon healing by regulating inflammation, which contributes to scar-like tendon healing and chronic matrix degradation.\nOur mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.\nThis has implications for the treatment of acute tendon injuries and chronic tendon disease.\nConnective tissue growth factor (CTGF) was used in both models to stimulate the anti-inflammatory roles of TSCs.\nDetails: Solaiman Tarafder, Esther Chen, Yena Jun, Kristy Kao, Kun Hee Sim, Jungho Back, Francis Y. Lee, and Chang H. Lee.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Alternatives to the use of stem cells for treating inflamed tendons get no space in this text. Standard therapies including physical therapy and anti-inflammatory medicines are not mentioned.", "answer": 0}, {"article": "Potluri cautioned, however, that this study can't prove that statins actually extended life in cancer patients.\n\"We cannot, however, recommend statins for cancer prevention without a positive clinical trial.\"\nThe database includes information on cancer and other medical conditions, including high cholesterol.\n\"People with high cholesterol should be taking statins to lower their cholesterol and reduce their cardiovascular risk,\" he said.\nAfter adjusting for factors that might play a role in dying, such as age, gender, ethnicity and common causes of death, the researchers found those taking statins lived longer than those who were not taking them.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is only about the concept of prevention, and not about a specific therapy regimen that is being suggested. In light of that, we can call it \u201cnot applicable.\u201d", "answer": 2}, {"article": "Elder's team found the right amount of sleep and stress reduction at the start of the trial predicted successful weight loss.\nTUESDAY, March 29, 2011 (HealthDay News) -- If you're looking to lose those extra pounds, you should probably add reducing stress and getting the right amount of sleep to the list, say researchers from Kaiser Permanente's Center for Health Research in Portland.\nAnd the factors that promote health -- eating well, being active, not smoking, sleeping enough, controlling stress, to name a few --promote all aspects of health,\" he added.\nIn fact, although diet and exercise are the usual prescription for dropping pounds, high stress and too little sleep (or too much of it) can hinder weight loss even when people are on a diet, the researchers report.\n\"If sustained, the dietary choices made by people undergoing short sleep could predispose them to obesity and increased risk of cardiovascular disease,\" the researchers wrote in an American Heart Association news release.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "One of the strengths of this story in comparison with its shorter LA Times competition is the context it provided, much of it from an independent expert who said:\n\u201cPeople who are healthy and vital tend to be healthy and vital not because of any one factor, but because of many. And the factors that promote health \u2014 eating well, being active, not smoking, sleeping enough, controlling stress, to name a few \u2013promote all aspects of health. \u2026The important message is that weight loss should not be looked at with tunnel vision. \u2026 This study encourages weight loss in a more holistic context.\u201d", "answer": 1}, {"article": "Nivolumab has been approved by the U.S. Food and Drug Administration for advanced melanoma, lung cancer, kidney cancer and Hodgkin lymphoma.\n\"The response rate is better than we've seen for other potential second-line treatments and nivolumab is really well-tolerated, which is important because bladder cancer patients are a fragile group after frontline treatment with platinum chemotherapy,\" said Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology at MD Anderson.\nAt a median follow up of 213 days, 33.3 percent remained on treatment, and 45.6 percent of patients survived for at least one year, which Sharma noted \"is better than anything we've seen in the past.\"\n\"We can get good results without choosing to treat patients based on PD-L1 status,\" said Sharma, who also is scientific director of MD Anderson's immunotherapy platform and an investigator with the Parker Institute for Cancer Immunotherapy at MD Anderson.\nThe study found no significant difference in response rates between those with little to no PD-L1 on their tumors (26 percent) and those with greater PD-L1 expression (24 percent).\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes that the only drug currently approved \u201cfor second-line treatment of metastatic bladder cancer\u201d is a competing drug: atezolizumab. This would have been better if it had explained what \u201csecond-line treatment\u201d means \u2014 since many readers are not going to know.", "answer": 1}, {"article": "But then a few years later she started noticing something interesting.\nYou can find a practitioner through the National Certification Commission for Acupuncture and Oriental Medicine, or if you prefer a medical doctor, visit the website of the American College for Advancement in Medicine, where you can put in your ZIP code and find a doctor who specializes in integrative medicine.\nIn 2008, a survey of more than 30,000 U.S. women in the journal Obstetrics & Gynecology found that nearly 40 percent reported that they'd had a sexual problem at some point in their lives, most often a lack of desire.\nHere's more information on ginkgo, including its sexual effects, from the National Center for Complementary and Alternative Medicine at the National Institutes of Health.\n(CNN) -- Losing interest in sex would be unfortunate for most people, but for Linda Poelzl it was a professional hazard.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Before rushing out to try maca root supplements or herbal combinations, women might want to\u00a0explore whether\u00a0there\u2019s an alternate explanation for their\u00a0symptoms, whether it\u2019s a relationship problem, a physical health issue\u00a0(e.g. thyroid disorder, depression, sleep deprivation), or perhaps\u00a0the side effect from a\u00a0medication. This story didn\u2019t mention any of these possibilities or how they might be treated. \u00a0\u00a0\u00a0", "answer": 0}, {"article": "That\u2019s not to mention cost: The drug\u2019s price is listed at $850 per month.\nBut doctors have also found that the rate of retrograde menstruation is about the same in women with and without endometriosis, so they think additional factors spur the disorder in some.\nBecause the extra tissue has no way to exit the body (it can\u2019t go through the vagina since it\u2019s not growing in the uterus), it builds up and becomes trapped, leading to pain and, in some cases, infertility.\nThe three main ways it manifests are through pelvic pain, infertility, and pelvic masses such as cysts, scar tissue, and fibroids.\nMany women in the trial experienced the symptoms of menopause \u2014 hot flashes, headache, insomnia \u2014 and researchers have also found the drug causes bone loss.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "A number of existing pain-reduction alternatives are mentioned, from hormonal treatments to surgery, and their debits discussed. It would have been helpful to try and articulate how many women find the current alternatives insufficient.", "answer": 1}, {"article": "Medical-device makers, venture capitalists and surgeons are racing to turn a once-controversial weight-loss procedure into the next big thing in elective surgery.\n\nOnce dismissed by some surgeons as a gimmick, gastric banding -- in which a silicone band is wrapped around the upper stomach to restrict food intake -- is now the focus of a fierce competition pitting consumer-products giant Johnson & Johnson against Botox maker Allergan Inc. Venture-capital-backed outpatient centers are popping up to implant the bands. Growing...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story included a pretty comprehensive comparison between gastric banding and gastric bypass, another type of weight loss surgery. It only mentioned diet and exercise in passing and failed to mention medication that can be used for weight loss.\u00a0 ", "answer": 1}, {"article": "The study enrolled 119 participants.\nGUMC was one of 21 participating medical centers across the U.S.\n\nFurther studies, including analysis of frozen blood and cerebrospinal fluid taken from patients, are underway to test possible drug mechanisms.\nThe biggest risk factor for developing Alzheimer's is aging, and studies with animals found that most age-related diseases--including Alzheimer's--can be prevented or delayed by long-term caloric restriction (consuming two-thirds the normal caloric intake).\nWASHINGTON (Sept. 11, 2015) -- The largest nationwide clinical trial to study high-dose resveratrol long-term in people with mild to moderate Alzheimer's disease found that a biomarker that declines when the disease progresses was stabilized in people who took the purified form of resveratrol.\nThe Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization, which accounts for the majority of externally funded research at GUMC including a Clinical and Translational Science Award from the National Institutes of Health.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "It would have been helpful to know what standard treatments for Alzheimer\u2019s are and how resveratrol could compare with these drugs in the future. According to the National Institute on Aging, several other drugs on the market \u2013 like Donepezil (Aricept\u00ae), rivastigmine (Exelon\u00ae), and galantamine (Razadyne\u00ae) \u2013 may help slow down cognitive decline, but do not change the underlying disease process.\u00a0The release could have discussed the lack of great treatments, further supporting the importance of this work.", "answer": 0}, {"article": "New blood tests will speed up diagnosis for the most common GI disorder\n\nLOS ANGELES (May 14, 2015) - Millions of people afflicted by irritable bowel syndrome can now be diagnosed quickly and accurately with two simple blood tests developed by a Cedars-Sinai gastroenterologist.\nPimentel will also present the research on Sunday, May 17th, at Digestive Disease Week 2015 in Washington, D.C.\n\nPimentel and fellow researchers studied nearly 3,000 people, comparing IBS patients to those diagnosed with inflammatory bowel disease, celiac disease and those with no GI disease.\nIBS is the most common gastroenterological disorder in the United States, affecting nearly 40 million people.\nThe blood tests identified the two antibodies associated with IBS -- anti-Cdtb and anti-vinculin -- with greater than 90 percent certainty.\nFor more information on IBS and the new blood test for the disorder, watch this video:\n\nFirst Ever Blood Test for IBS\n\nCedars-Sinai has entered into an exclusive license agreement with Commonwealth Laboratories for several patent applications covering the blood tests, developed by Pimentel to detect both anti-CdtB and anti-vinculin antibodies in the diagnosis of irritable bowel syndrome and inflammatory bowel disease.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release says that IBS has been \u201cnearly impossible to diagnose until now.\u201d But the release also says IBS \u201cis the most common gastroenterological disorder in the United States.\u201d There\u2019s a clear disconnect between these two statements. IBS may not be easy to diagnose, but it is diagnosed. Often, an IBS diagnosis is reached after other conditions have been ruled out. A diagnosis may also come after extensive additional testing. In other words, the new blood tests would be a significantly quicker and easier way to reach diagnosis. But the release should have simply said that.", "answer": 0}, {"article": "Broccoli has been linked to a growing list of health benefits, such as a reduced risk of cancer and osteoporosis. New research suggests consuming broccoli could also slow or reverse blood-vessel damage and atherosclerosis due to high cholesterol.\n\nThe study, in Experimental Biology and Medicine, found that a high-cholesterol diet combined with supplements containing sulforaphane, a natural compound in cruciferous vegetables such as broccoli and Brussels sprouts, significantly reduced levels of LDL, the so-called bad cholesterol,...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no discussion of alternate strategies for minimizing either the accumulation of arterial plaques specifically or heart disease generally.", "answer": 0}, {"article": "\"Sixty to 80 percent [success] for something that somebody's not going to get guaranteed pain relief -- in my mind, it's not something I would go for,\" Duggal says.\n-- Icing the bottom of the foot, sometimes using ice to massage the heel area\n\n-- Using cups made of gel in shoes to cushion the heel (and many orthopedic surgeons say expensive custom-made orthotics are not necessary)\n\n-- Wearing a night splint, a simple brace that holds the foot in a flexed position to keep the plantar fascia stretched during sleep\n\n-- Physical therapy, though some studies indicate that some PT practices such as ultrasound and whirlpool are not helpful\n\n-- Use of NSAID (non-steroidal anti-inflammatory) drugs such as ibuprofen and naproxen\n\n-- Corticosteroid injections into the heel, though this is controversial and should not be used repeatedly\n\n-- Backing off activities like running until the pain goes away, and then reinitiating them gradually\n\nAbout 90 percent of sufferers will get better with time.\nIt's the same technology used since the 1980s to blast kidney stones, an application called lithotripsy, but for foot problems doctors use less intense shock waves.\nIn high-impact activities like running, the forces even exceed the actual weight because it's so concentrated in a narrow spot where the fascia attaches to the heel bone.\nShock-wave therapy for plantar fasciitis is beginning to catch on around the U.S., partly since this stubborn type of foot pain is so common -- and so difficult to treat.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The discussion of alternatives is a real strength of this piece. Instead of relegating this coverage\u00a0to a throwaway line at the end of the piece as\u00a0many stories\u00a0do, this story\u00a0mentioned\u00a010 low-tech treatments that patients are advised to try before considering shockwave therapy. In addition,\u00a0the story\u00a0explained that nearly all\u00a0patients with heel pain eventually get better regardless of what kind of treatment they\u00a0receive.\u00a0\u00a0\u00a0", "answer": 1}]